<SEC-DOCUMENT>0001171843-15-002688.txt : 20150508
<SEC-HEADER>0001171843-15-002688.hdr.sgml : 20150508
<ACCEPTANCE-DATETIME>20150508151603
ACCESSION NUMBER:		0001171843-15-002688
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20150331
FILED AS OF DATE:		20150508
DATE AS OF CHANGE:		20150508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		15846291

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q_050815.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html>
<head>
    <title>f10q_050815.htm</title>
    <!--Licensed to: Nasdaqomx-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Washington, D.C. 20549</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="45%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="45%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 10-Q</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="45%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td width="10%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: left">&#160;</td>
<td width="45%" style="PADDING-BOTTOM: 2px">&#160;</td>
</tr></table>
</div>

<div>&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Quarterly Report Pursuant to Section&#160;13 or 15(d)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the quarterly period ended March&#160;31, 2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commission File Number 000-23186</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="45%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td width="10%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: left">&#160;</td>
<td width="45%" style="PADDING-BOTTOM: 2px">&#160;</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 24pt; FONT-WEIGHT: bold">BIOCRYST PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="45%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td width="10%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: left">&#160;</td>
<td width="45%" style="PADDING-BOTTOM: 2px">&#160;</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DELAWARE</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">62-1413174</font></div>
</td>
</tr><tr>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(State of other jurisdiction of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">incorporation or organization)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(I.R.S. Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Identification No.)</font></div>
</td>
</tr><tr>
<td valign="middle" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="middle" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4505 Emperor Blvd., Suite&#160;200</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Durham, North Carolina</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">27703</font></div>
</td>
</tr><tr>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Address of principal executive offices)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(919) 859-1302</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Registrant&#8217;s telephone number, including area code)</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="45%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td width="10%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: left">&#160;</td>
<td width="45%" style="PADDING-BOTTOM: 2px">&#160;</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">x</font> &#160;&#160;&#160;&#160;No&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">x</font> &#160;&#160;&#160;&#160;No&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non- accelerated filer or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&#160;12b-2 of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="24%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large&#160;accelerated&#160;filer</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">x</font></div>
</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="24%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated&#160;filer</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">&#168;</font></div>
</td>
</tr><tr>
<td valign="middle" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="middle" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="middle" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-accelerated filer</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font> &#160;&#160;(Do not check if a smaller reporting company)</font></div>
</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="24%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller&#160;reporting&#160;company</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">&#168;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font> &#160;&#160;&#160;&#160;No&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The number of shares of Common Stock, par value $0.01, of the Registrant outstanding as of April&#160;30, 2015 was 72,520,545.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BIOCRYST PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->&#160;INDEX</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Page&#160;No.</font></div>
</td>
</tr><tr>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Part I. Financial Information</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#p1i1">Item&#160;1. Financial Statements:</a></font></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#p1i1">3</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#bs"><font style="DISPLAY: inline">Consolidated Balance Sheets &#8212; March&#160;31, 2015 and December&#160;31, 201</font>4</a></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#bs">3</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#cl"><font style="DISPLAY: inline">Consolidated Statements of Comprehensive Loss &#8212; Three Months Ended March&#160;31, 2015 and 201</font>4</a></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#cl">4</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#cf"><font style="DISPLAY: inline">Consolidated Statements of Cash Flows &#8212; Three Months Ended March&#160;31, 2015 and 201</font>4</a></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#cf">5</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#notes">Notes to Consolidated Financial Statements</a></font></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#notes">6</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#p1i2">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></font></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#p1i2">18</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#p1i3">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></font></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#p1i3">27</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#p1i4">Item&#160;4. Controls and Procedures</a></font></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#p1i4">28</a></font></div>
</td>
</tr><tr>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Part II. Other Information</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#p2i1a">Item&#160;1A. Risk Factors</a></font></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#p2i1a">29</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#p2i6">Item&#160;6. Exhibits</a></font></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#p2i6">44</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#sign">Signatures</a></font></font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#sign">45</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EX-10.1</font></div>
</td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EX-10.2</font></div>
</td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EX-31.1</font></div>
</td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EX-31.2</font></div>
</td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EX-32.1</font></div>
</td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EX-32.2</font></div>
</td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><!--EFPlaceholder--><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I. FINANCIAL INFORMATION<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->&#160;<a name="p1i1">Item&#160;</a>1. Financial Statements<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->&#160;<a name="bs">BIOCRYST </a>PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED BALANCE SHEETS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2015 and December&#160;31, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(In thousands, except per share data)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Note 1)</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assets</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,367</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54,54<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted cash</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,637</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Investments</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,160</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,232</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Receivables from collaborations</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,594</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,849</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Receivables from product sales</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,641</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventory</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,21<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">683</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,322</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,172</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred collaboration expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">81,366</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">89,343</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Investments</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41,116</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41,116</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture and equipment, net</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">727</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">207</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred collaboration expense</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">163</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">177</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,495</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,031</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">129,867</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">136,874</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liabilities and Stockholders&#8217; Equity</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,307</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,849</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,291</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,329</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest payable</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,241</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,029</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred collaboration revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,490</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,481</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred product sales revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,533</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,605</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-recourse notes payable</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,00<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,000</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,862</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,293</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred collaboration revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,256</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,552</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred rent</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">378</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">394</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217; equity:</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 72,474 in 2015 and 71,955 in 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">725</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">72<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid-in capital</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">546,698</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">542,943</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated other comprehensive income (loss)</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated deficit</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(483,062</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(467,898</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">64,371</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">75,635</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities and stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">129,867</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">136,874</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><!--EFPlaceholder--><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="cl">BIOCRYST </a>PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March&#160;31, 2015 and 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(In thousands, except per share data-Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenues</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product sales, net</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">537</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Royalty revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,518</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,821</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Collaborative and other research and development</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,771</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,637</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total revenues</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,826</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,458</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cost of products sold</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,12<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,183</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,061</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,588</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Royalty</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">73</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,256</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,844</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss from operations</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(14,43<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,386</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest and other income</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">117</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,315</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,242</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain (loss) on foreign currency derivative</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">464</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,526</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15,164</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,137</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic and diluted net loss per common share</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(0.21</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(0.17</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted average shares outstanding</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">72,341</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">59,589</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unrealized gain (loss) on available for sale investments</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Comprehensive loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15,024</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,139</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><!--EFPlaceholder--><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="cf">BIOCRYST </a>PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March&#160;31, 2015 and 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(In thousands-Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Operating activities</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15,164</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,137</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation and amortization</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">45</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation expense</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,259</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,610</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of debt issuance costs</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">110</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value of foreign currency derivative</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(464</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,526</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in operating assets and liabilities:</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Receivables</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,896</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,165</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventory</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(527</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,848</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">892</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred collaboration expense</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,404</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,252</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest payable</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,212</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">685</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(359</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(296</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net cash used in operating activities</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(3,726</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(8,959</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acquisitions of furniture and equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(565</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in restricted cash</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,487</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchases of investments</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,378</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,367</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sales and maturities of investments</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,482</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,350</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net cash used in investing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(3,948</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(1,023</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sale of common stock, net</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,175</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise of stock options</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">155</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,804</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employee stock purchase plan sales</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">171</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">128</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payment of foreign currency derivative collateral</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,530</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net cash provided by financing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1,501</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2,402</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Decrease in cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(6,173</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(7,580</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents at beginning of period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54,540</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,164</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and cash equivalents at end of period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">48,367</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">13,584</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="notes">BIOCRYST </a>PHARMACEUTICALS, INC.<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(In thousands, except per share amounts)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 1 &#8212; Significant Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Company</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $111,280, to continue its planned operations through the middle of 2016. The Company&#8217;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond the middle of 2016 it will need to: (1)&#160;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&#160;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&#160;raise additional capital through equity or debt financings or from other sources; (4)&#160;obtain product candidate regulatory approvals, which would generate revenue and cash flow; (5)&#160;reduce spending on one or more research and development programs; and/or (6)&#160;restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.&#160;&#160;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November&#160;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basis of Presentation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;). Royalty Sub was formed in connection with a $30,000&#160;financing transaction the Company completed on March&#160;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These financial statements should be read in conjunction with the financial statements for the year ended December&#160;31, 2014 and the notes thereto included in the Company&#8217;s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&#160;31, 2014 has been derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form 10-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reclassifications</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and Cash Equivalents</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Restricted Cash</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Restricted cash as of March&#160;31, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $1,087 in royalty revenue paid by Shionogi&#160;&amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,400 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company has not realized any significant losses from its investments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At March&#160;31, 2015, the Company believes that the costs of its investments are recoverable in all material respects.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair value of the Company&#8217;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<!--EFPlaceholder--></font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="18" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2015</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amortized</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gains</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Losses</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair&#160;Value</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="50%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obligations of U.S. Government and its agencies</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,302</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,345</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Corporate debt securities</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,139</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">144</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,297</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificates of deposit</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,625</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,634</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,066</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">201</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(27</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,276</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="20" nowrap valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="18" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, 2014</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amortized</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gains</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Losses</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair&#160;Value</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="50%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obligations of U.S. Government and its agencies</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,307</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,306</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="50%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Corporate debt securities</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,152</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">151</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,261</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificates of deposit</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,838</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(63</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,781</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,297</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">179</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(133</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,348</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes the scheduled maturity for the Company&#8217;s investments at March&#160;31, 2015 and December&#160;31, 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<!--EFPlaceholder--></font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing in one year or less</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,16<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,232</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing after one year through two years</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,656</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,459</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing after two years</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,46<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,657</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,276</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,348</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Receivables from Collaborations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services or royalty receivables from Shionogi&#160;&amp; Co. Ltd. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At March 31, 2015 and December&#160;31, 2014, the Company had the following receivables.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2015</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Billed</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unbilled</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="55%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi&#160;&amp; Co. Ltd.</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="55%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total receivables</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,594</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="12" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="white">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, 2014</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Billed</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unbilled</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="55%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi&#160;&amp; Co. Ltd.</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="55%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total receivables</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,849</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Receivables from Product Sales</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font>. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventory</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At March 31, 2015 and December 31, 2014, the Company&#8217;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#8220;FIFO&#8221;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2014, in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div style="TEXT-INDENT: 27pt">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div style="TEXT-INDENT: 27pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s inventory consisted of the following at March&#160;31, 2015 and December&#160;31, 2014:</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Work in process</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">267</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Finished Goods</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,210</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">416</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net inventories</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,210</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">683</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Patents and Licenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued Expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to investigative sites in connection with clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&#160;and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">professional fees.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of March 31, 2015 and December 31, 2014, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accumulated Other Comprehensive (Loss) Income</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accumulated other comprehensive (loss) income is comprised of unrealized gains and losses on investments available-for-sale and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified from accumulated other comprehensive (loss) income are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the three months ended March 31, 2015, realized gains of $8 were reclassified out of accumulated other comprehensive (loss) income. No reclassifications out of accumulated other comprehensive (loss) income were recorded during the three months ended March&#160;31, 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue Recognition</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recognizes revenues from collaborative and other research and development arrangements and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&#160;persuasive evidence of an arrangement exists; (ii)&#160;delivery has occurred or services have been rendered; (iii)&#160;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&#160;collectability is reasonably assured.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Collaborative and Other Research and Development Arrangements and Royalties</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables, the Company evaluates whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Under certain of our license agreements, the Company receives royalty payments based upon our licensees&#8217; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Event payments are recognized as revenue upon the achievement of specified events if (1)&#160;the event is substantive in nature and the achievement of the event was not reasonably assured at the inception of the agreement and (2)&#160;the fees are non-refundable and non-creditable. Any event payments received prior to satisfying these criteria are recorded as deferred revenue. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><!--EFPlaceholder--><font style="FONT-STYLE: italic; DISPLAY: inline">Product Sales</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</font></font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and requires it to use information from external sources.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Rebates and Chargebacks</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#8217;s selling price.&#160;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#8217;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from the Company&#8217;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Discounts and Sales Incentives</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with the Company&#8217;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Product Returns</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Advertising</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recorded the following revenues for the three months ended March&#160;31, 2015 and 2014:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<!--EFPlaceholder--></font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product sales, net</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">537</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Royalty revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,518</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,821</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Collaborative and other research and development revenues:</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,475</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,341</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 0.5pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi (Japan)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 0.5pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">296</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 0.5pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">296</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total collaborative and other research and development revenues</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,771</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,637</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total revenues</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,826</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,458</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s on-going review of the level of services actually performed.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deferred collaboration expenses represent sub-license payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-Based Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; has occurred.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest Expense and Deferred Financing Costs</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interest expense for the three months ended March&#160;31, 2015 and 2014 was $1,315 and $1,242, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended March&#160;31, 2015 and 2014.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Currency Hedge Agreement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&#160;31, 2015 and 2014 resulted in a gain of $464 and a loss of $1,526, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of March&#160;31, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss Per Share</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#8217;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended March&#160;31, 2015 and 2014 does not include 3,458 and 5,206, respectively, of such potential common shares, as their impact would be anti-dilutive.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Use of Estimates</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Significant Customers and Other Risks</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#8217;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s primary source of revenue that has an underlying cash flow stream is the reimbursement of peramivir and BCX4430 development expenses, which was earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its peramivir and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#8217;s collaborative and other research and development revenues. The completion, as with the June 30, 2014 BARDA/HHS peramivir development contract, or termination of the NIAID/HHS and BARDA/HHS BCX4430 programs/collaboration could negatively impact the Company&#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA; however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. The Company&#8217;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Risks from Third Party Manufacturing and Distribution Concentration</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company relies on single source manufacturers for API and finished product manufacturing of RAPIVAB. Additionally, the Company relies upon a single third party to provide warehousing and distribution services for RAPIVAB. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Credit Risk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale receivables discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Accounting Pronouncements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In April 2015, the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">Financial Accounting Standards Board</font> (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2015-03, <font style="FONT-STYLE: italic">Simplifying the Presentation of Debt Issuance Costs</font>. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">The Company does not expect this ASU will have a material impact on its consolidated financial statements.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2014, the FASB issued ASU 2014-09 &#8211; <font style="FONT-STYLE: italic; DISPLAY: inline">Revenue from Contracts with Customers</font> , which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This ASU is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2016. Early adoption is not permitted and companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 2 &#8212; Stock-Based Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March&#160;31, 2015, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&#8220;Incentive Plan&#8221;) and the Employee Stock Purchase Plan (&#8220;ESPP&#8221;), both which were amended and restated in March 2014 and approved by the Company&#8217;s stockholders in May 2014. Stock-based compensation expense of $2,259 ($2,165 of expense related to the Incentive Plan and $94 of expense related to the ESPP) was recognized during the first three months of 2015, while $1,610 ($1,558 of expense related to the Incentive Plan and $52 of expense related to the ESPP) was recognized during the first three months of 2014.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There was approximately $14,621 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of March&#160;31, 2015. That cost is expected to be recognized as follows: $4,006 during the remainder of 2015, $4,528 in 2016, $4,064 in 2017, $1,990 in 2018 and $33 in 2019. In addition, the Company has outstanding performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; has occurred and the award vests. At the time of vesting, compensation expense will be recognized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock Incentive Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Commencing March&#160;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of March 31, 2015, 50% of the August 2013 grants have vested based upon achievement of two milestones: (1) successful completion of the OPuS-1 clinical trial for which vesting occurred in the second quarter of 2014, and (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014. Thus, as of March&#160;31, 2015, 50% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&#160;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Related activity under the Incentive Plan is as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<!--EFPlaceholder--></font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Awards</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Available</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Price</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="55%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance December&#160;31, 2014</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,362</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,605</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.21</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="55%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted stock unit awards granted</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(133</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="55%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted stock unit awards cancelled</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="55%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock option awards granted</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(917</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">917</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11.83</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="55%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock option awards exercised</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(240</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.07</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock option awards cancelled</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(28</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9.05</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="55%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance March&#160;31, 2015</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,341</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,254</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.78</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For stock option awards granted under the Incentive Plan during the first three months of 2015 and 2014, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the first three months of 2015 and 2014 was $8.11 and $8.28, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the first three months of 2015 and 2014. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#8217;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted Average Assumptions for Stock Option Awards Granted to</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employees and Directors under the Incentive Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected Life in Years</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.5</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.5</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected Volatility</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">87</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected Dividend Yield</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk-Free Interest Rate</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.5</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.6</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Employee Stock Purchase Plan</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 519 shares remain available for purchase at March&#160;31, 2015. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 20 shares during the first three months of 2015 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing model.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 3 &#8212; Collaborative and Other Research and Development Contracts</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">U.S.&#160;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;).</font> In January 2007, BARDA/HHS awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February&#160;24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding to support the filing of a NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014 according to its terms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 31, 2015, we announced that the Biomedical Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response (&#8220;ASPR&#8221;) awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&#160;&#160;This BARDA/HHS contract includes a base contract of $12,134 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $34,989.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;).</font> In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of March 31, 2015 could be up to $29,147, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous i.v. and i.m. BCX4430 for the treatment of Marburg virus disease, to conduct an initial Phase 1 human clinical trial and to study BCX4430 as a treatment for Ebola virus disease. As of March 31, 2015, a total of $25,021 has been awarded under exercised options within the contract. BCX4430 is the lead compound in the Company&#8217;s BSAV research program.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&#8217;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Shionogi&#160;&amp; Co., Ltd. (&#8220;Shionogi&#8221;).</font> In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan and to provide rights for Shionogi to perform a Phase&#160;3 clinical trial in Hong Kong. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Green Cross Corporation (&#8220;Green Cross&#8221;).</font> In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;).</font> In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor, for use in oncology (the &#8220;Original Agreement&#8221;). Under the terms of the license agreement, as amended, Mundipharma obtained worldwide rights to forodesine.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively).</font> In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000&#160;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&#160;days advance notice or in the event of material uncured breach by the Licensors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&#160;any milestone payments the Company may receive in the future under its license agreement dated February&#160;1, 2006 with Mundipharma and (ii)&#160;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company&#8217;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On November&#160;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On June&#160;19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&#8217;s common stock, or in a combination of cash and shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited (&#8220;CIRL&#8221;), formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#8220;VUW&#8221;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property are in the process of being transferred to VUW or its wholly owned subsidiaries, including the contracts to which BioCryst is a party. Except for a substitution of parties, the terms and conditions of the contracts are expected to remain unchanged.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The University of Alabama at Birmingham (&#8220;UAB&#8221;).</font> The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon three months notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 4 &#8212; Royalty Monetization</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March&#160;9, 2011, the Company completed a $30,000&#160;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&#160;from the transaction after transaction costs of $4,309&#160;and the establishment of a $3,000&#160;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&#160;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&#160;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&#160;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was not impacted as a result of this transaction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Non-Recourse Notes Payable</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March&#160;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&#160;9, 2011 (the &#8220;Indenture&#8221;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&#160;per annum, payable annually in arrears on September&#160;1st of each year (the &#8220;Payment Date&#8221;). The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Royalty Sub&#8217;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September&#160;1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&#8217;s future results of operations or cash flows.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March&#160;31, 2015, the aggregate fair value of the PhaRMA Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Foreign Currency Hedge</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2015 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&#160;will be required if, on May&#160;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#8217;s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&#160;31, 2015 and 2014 resulted in a gain of $464 and a loss of $1,526, respectively. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of March 31, 2015 and December&#160;31, 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of March 31, 2015, the maximum amount of hedge collateral the Company may be required to post is $11.7 million.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 5 &#8212; Stockholders&#8217; Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On November&#160;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration.<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="p1i2">Item&#160;</a>2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Quarterly Report on Form 10-Q contains statements of a forward-looking nature relating to future events or the future financial performance of BioCryst. Such statements are only predictions and the actual events or results may differ materially from the results discussed in the forward-looking statements. Factors that could cause or contribute to such differences include those discussed below and elsewhere in this report, as well as those discussed in other filings made by the Company with the Securities and Exchange Commission, including the Company&#8217;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See &#8220;Information Regarding Forward-Looking Statements.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cautionary Statement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The discussion herein contains forward-looking statements within the meaning of Section&#160;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created in Section&#160;21E. Forward looking statements regarding our financial condition and our results of operations that are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted within the United States (&#8220;U.S. GAAP&#8221;), as well as projections for the future. The preparation of these financial statements requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We operate in a highly competitive environment that involves a number of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical companies, including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty of regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights, the need for future capital, competition associated with products, potential competition associated with our products and product candidates and retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or our collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will have sufficient funding to meet our future capital requirements. Statements contained in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute, forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ materially from expected results. The most significant known risks are discussed in the section entitled &#8220;Risk Factors.&#8221; Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.&#160;We caution you not to place undue reliance on any forward-looking statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our revenues are difficult to predict and depend on numerous factors, including the prevalence and severity of influenza in regions for which peramivir has received regulatory approval, seasonality of influenza, ongoing discussions with government agencies regarding future RAPIVAB and/or BCX4430 development and stockpiling procurement, as well as entering into, or modifying, licensing agreements for our product candidates. Furthermore, revenues related to our collaborative development activities are dependent upon the progress toward and the achievement of developmental milestones by us or our collaborative partners.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our operating expenses are also difficult to predict and depend on several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts), drug manufacturing, and clinical research activities, the ongoing requirements of our development programs, and the availability of capital and direction from regulatory agencies, which are difficult to predict. Management may be able to control the timing and level of research and development and general and administrative expenses, but many of these expenditures will occur irrespective of our actions due to contractually committed activities and/or payments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a result of these factors, we believe that period to period comparisons are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event, the prevailing market price of our common stock could be materially adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Overview</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. We focus on the treatment of rare diseases in which significant unmet medical needs exist and align with our capabilities and expertise. We integrate the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies and Estimates</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Corporate Highlights</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RAPIVAB (peramivir injection)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">RAPIVAB was approved by the FDA on December 19, 2014 for the treatment of acute uncomplicated influenza in adult patients who have been symptomatic for no more than two days. We have elected the &#8220;Sell-Through&#8221; revenue recognition methodology and recognized approximately $537,000 of RAPIVAB product sales in the first quarter of 2015. With the approval and commercial availability of RAPIVAB, we have moved our focus to obtaining a stock-piling procurement contract with the U.S. Government to realize the strategic value of this program.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">HAE Program</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BCX4161</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 18, 2014, we announced the dosing of the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered BCX4161 in patients with HAE. OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety of two doses of BCX4161, 300 mg and 500 mg, administered three-times daily compared with placebo. This trial is being conducted in the U.S. as well as other countries and is expected to enroll approximately 100 HAE patients. The primary efficacy endpoint for the trial is the mean angioedema attack rate for each BCX4161 dose group compared to placebo. BCX4161 has Orphan Drug designation in the U.S. and Europe and has Fast Track designation for the treatment of HAE in the U.S.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BCX7353 and other 2nd generation HAE compounds</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In January 2015, we selected BCX7353, one of two advanced stage, preclinical, optimized, plasma kallikrein inhibitors, to advance into Phase 1 development as a once-daily, oral prophylactic HAE treatment. BXC7353 is structurally different from BCX4161, but has a similar mechanism of action targeting plasma kallikrein. BCX7353 has completed all toxicology requirements necessary for testing in healthy human volunteers and we expect it to enter Phase 1 clinical development in the second quarter of 2015. In addition to BCX7353, we continue to work on multiple other second generation molecules that are at an earlier stage of preclinical development.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BCX4430</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 15, 2014, we announced the dosing of the first subject in a randomized, placebo-controlled Phase 1 clinical trial to evaluate i.m. administration of BCX4430 in healthy volunteers. The main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430 administered via i.m. injection in healthy subjects.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 23, 2014, we announced results from a successful proof-of-concept study of BCX4430 for the treatment of experimental Ebola virus infection in Rhesus macaques, conducted at USAMRIID. The primary goal of the study was to assess the effect of BCX4430 treatment on survival through Day 41 in animals infected with Ebola virus. Dosing of&#160;placebo or BCX4430 by i.m. injection was initiated 30-120 minutes after virus challenge and continued twice a day for 14 days. The overall survival rate for BCX4430 treated animals at day 41 was 10 of 12 (83%, p &lt; 0.001 compared to controls). Preliminary evaluation of the quantity of virus in the blood showed an approximate 3-log reduction in Ebola virus RNA copies/mL of plasma, compared with control animals. This Rhesus macaques study was conducted following the completion, in November 2014, of a dose-ranging study of BCX4430 for the treatment of cynomolgus macaques infected with Ebola virus. The cynomolgus macaques study was designed to evaluate whether BCX4430 showed a meaningful benefit for survival in Ebola virus NHP disease models. In this study, BCX4430 demonstrated a statistically significant prolongation of survival for the animals at the highest dose regimen tested, but no animals survived beyond 21 days.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 12, 2015, NIAID/HHS exercised an additional option under our BCX4430 development contract which provides an additional $2.7 million to us for i.v. development and submission of an IND. Exercise of this option yields $25.0 million of obligated option funding under the $29.1 million contact.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2015, the Biomedical Advanced Research and Development Authority (&#8220;BARDA/HHS&#8221;) within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response (&#8220;ASPR&#8221;) awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&#160;&#160;This BARDA/HHS contract includes a base contract of $12.1 million to support BCX4430 drug manufacturing as well as $22.9 million in additional development options that can be exercised, bringing the potential value of the contract to $35.0 million.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations (three months ended March&#160;31, 2015 compared to the three months ended March&#160;31, 2014)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March&#160;31, 2015, total revenues were $6.8 million as compared to $3.5 million for the three months ended March&#160;31, 2014. Revenues in the first quarter of 2015 included $1.5 million of royalty revenue from Shionogi and Green Cross associated with sales of peramivir in Japan and Korea, $4.5 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of BCX4430 and i.v. peramivir and $0.3 million associated with collaborative revenue amortization from other corporate partnerships. In addition, we recorded approximately $0.5 million of RAPIVAB revenue under the &#8220;Sell-Through&#8221; revenue recognition methodology. The increase in revenue in the first quarter of 2015, as compared to 2014, resulted primarily from higher collaborative revenue associated with BCX4430 under NIAID/HHS and BARDA/HHS contracts. Revenues in the first quarter of 2014 included $1.8 million of royalty revenue from Shionogi and Green Cross associated with sales of peramivir in Japan and Korea, $1.3 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of BCX4430 and i.v. peramivir and $0.3 million associated with collaborative revenue amortization from other corporate partnerships.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development (&#8220;R&amp;D&#8221;) expenses increased to $17.1 million for the first quarter of 2015 from $9.2 million in 2014. The increase in 2015 R&amp;D expenses, as compared to 2014, reflect increased spending on our HAE program, and to a lesser extent, our BCX4430 program.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes our R&amp;D expenses for the periods indicated (amounts are in thousands).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<!--EFPlaceholder--></font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="6" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;Ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font></div>
</td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">R&amp;D expenses by program:</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4161</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,246</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,335</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,674</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2nd generation HAE compounds</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,881</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,360</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Peramivir</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,146</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">695</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other research, preclinical and development costs</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,173</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,043</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total R&amp;D expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,120</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,183</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">General and administrative expenses increased to $4.1 million for the first quarter of 2015 as compared to $1.6&#160;million in 2014. The increase of $2.5 million is primarily due to RAPIVAB administrative, distribution and marketing expenses as well as unrestricted grants awarded to the U.S. and International HAE patient advocacy groups. Although we do not have plans to incur substantial commercial expenses to promote RAPIVAB in the U.S. in the future, we do expect our G&amp;A expenses to be higher than in previous quarters associated with RAPIVAB distribution expenses and other increases in administrative expenses associated with corporate growth in preparation for future NDA and other regulatory filings and for product commercialization.&#160;&#160;Marketing and distribution expenses for RAPIVAB will likely be seasonal, occurring in advance of and during the influenza season.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interest expense related to the non-recourse notes issued in conjunction with the non-dilutive peramivir royalty monetization transaction in March 2011 was $1.3&#160;million in the first quarter of 2015, compared to $1.2 million in the first quarter of 2014. In addition, a mark-to-market gain of $0.5 million was recognized in the first quarter of 2015 related to our foreign currency hedge, compared to a mark-to-market loss of $1.5 million in the same quarter in the prior year, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash expenditures have exceeded revenues since our inception and we expect our 2015 operating expenses to exceed our 2015 revenues. Our operations have principally been funded through public offerings and private placements of equity securities; cash from collaborative and other research and development agreements, including U.S. Government contracts for peramivir and BCX4430; and to a lesser extent, the PhaRMA Notes financing. To date, we have been awarded a BARDA/HHS peramivir development contract totaling $234.8 million, which expired on June 30, 2014, a NIAID/HHS BCX4430 development contract totaling $29.1 million, which is ongoing, and a BARDA/HHS BCX4430 development contract totaling $35.0 million. The total amount of NIAID/HHS and BARDA/HHS funding obligated under awarded options in the active contracts is $25.0&#160;million and $12.1 million, respectively. Most recently, we completed a successful public offering in June 2014 of 11.5 million shares of common stock at a price of $10.00 per share following the release of our OPuS-1 clinical trial results, which provided net proceeds to us of approximately $107.8 million. This financing provides us liquidity through the middle of 2016. We retain the ability to offer for sale approximately $160.0 million of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from effective shelf registration statements, which we filed with the Securities and Exchange Commission. In addition to the above, we have received funding from other sources, including other collaborative and other research and development agreements; government grants; equipment lease financing; facility leases; research grants; and interest income on our investments.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 31, 2015, we had net working capital of $19.5 million, a decrease of approximately $12.6 million from $32.1 million at December&#160;31, 2014. The decrease in working capital was principally due to our normal operating expenses associated with the development of our product candidates. Our principal sources of liquidity at March&#160;31, 2015 were approximately $48.4 million in cash and cash equivalents; approximately $60.3 million in investments considered available-for-sale; and approximately $5.6 million in U.S. Government receivables. We anticipate our cash and investments will fund our operations through the middle of fiscal 2016.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We intend to contain costs and reduce cash flow requirements by closely managing our third party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain research and development projects and using consultants. We expect to incur additional expenses, potentially resulting in significant losses, as we continue to pursue our research and development activities, primarily related to our clinical trial activity. We may incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement of patent and other intellectual property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our investments.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We extended or executed additional lease obligations in 2015 for our Birmingham, Alabama operations, which increases the obligation by $5.6 million and extends these new obligations through 2026. These operating lease obligations encompass future rental obligations of our Birmingham operating facilities.</font></font></div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We plan to finance our needs principally from the following:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">lease or loan financing and future public or private equity financing;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our existing capital resources and interest earned on that capital;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">payments under existing and executing new contracts with the U.S. Government; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">payments under collaborative and licensing agreements with corporate partners.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As our programs continue to advance, our costs will increase. Our current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements and additional personnel resources and testing required for the continuing development of our product candidates will consume significant capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for peramivir and BCX4430, the amount of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for the development and or commercialization of our product candidates, the progress and results of our current and proposed clinical trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates and the progression of our other programs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">With the funds available at March&#160;31, 2015, we believe these resources will be sufficient to fund our operations through the middle of fiscal 2016. Our future liquidity needs, and ability to address those needs, will largely be determined by the success of our product candidates and key development and regulatory events in the future. In order to continue our operations substantially beyond the middle of fiscal 2016, we will need to: (1)&#160;successfully secure or increase U.S. Government funding of our programs, including procurement contracts; (2)&#160;out-license rights to certain of our products or product candidates, pursuant to which we would receive cash milestones; (3)&#160;raise additional capital through equity or debt financings or from other sources; (4)&#160;obtain product candidate regulatory approvals, which would generate revenue and cash flow; (5)&#160;reduce spending on one or more research and development programs; and/or (6)&#160;restructure operations. We retain the ability to offer for sale approximately $160.0 million of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from our effective shelf S-3 registration statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our long-term capital requirements and the adequacy of our available funds will depend upon many factors, including:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our ability to perform under our government contracts and receive reimbursement, and receive stockpiling procurement contracts;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the magnitude of work under our government contracts;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the progress and magnitude of our research, drug discovery and development programs;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">changes in existing collaborative relationships or government contracts;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our ability to negotiate favorable development and marketing strategic alliances for certain product candidates or a decision to build or expand internal development and commercial capabilities;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">successful commercialization of marketed products by either us or a partner;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our ability to engage sites and enroll subjects in our clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">increases in personnel and related costs to support the development and commercialization of our product candidates;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the scope of manufacturing of our drug substance and product candidates required for future NDA filings;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">competitive and technological advances;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the time and costs involved in obtaining regulatory approvals;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">post-approval commitments for RAPIVAB and other products that receive regulatory approval; and</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We expect that we will be required to raise additional capital to complete the development and commercialization of our current product candidates and we may seek to raise capital in the near future. Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate partners or from other sources, including governmental agencies in general and existing government contracts specifically, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale back or eliminate certain of our research and development programs. Our future working capital requirements, including the need for additional working capital, will be largely determined by the advancement of our portfolio of product candidates as well as rate of reimbursement by U.S. Government agencies of our peramivir and BCX4430 expenses and any future decisions regarding the future of the peramivir and BCX4430 programs, including those relating to stockpiling procurement. More specifically, our working capital requirements will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates; obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing processes developed on our behalf by third parties; and the level of required administrative support for our daily operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financial Outlook for 2015</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based upon our development plans, expected operations and our awarded government contracts, we expect 2015 operating cash usage to be in the range of $65 to $80 million, and expect our total 2015 operating expenses to be in the range of $75 to $95 million. Our operating expense range excludes equity-based compensation expense due to the difficulty in accurately projecting this expense as it is significantly impacted by the volatility and price of the Company&#8217;s stock, as well as vesting of the Company&#8217;s outstanding performance-based stock options. Our operating cash forecast excludes any impact of our royalty monetization, hedge collateral posted or returned, and any other non-routine cash outflows or inflows. Our ability to remain within our operating expense and operating cash target ranges is subject to multiple factors, including unanticipated or additional general development and administrative costs and other factors described under the Risk Factors located elsewhere in this report.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off-Balance Sheet Arrangements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March&#160;31, 2015, we do not have any unconsolidated entities or off-balance sheet arrangements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have established various accounting policies that govern the application of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities. Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which could have a material impact on the carrying values of assets and liabilities and the results of operations.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">While our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements included in our 2014 Annual Report on Form&#160;10-K for the year ended December&#160;31, 2014, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventory</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our inventories consist of RAPIVAB finished goods and work in process, which are valued at the lower of cost or market using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor, overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires us to utilize significant judgment. In connection with the FDA approval of RAPIVAB in December 2014, the Company began capitalizing costs associated with the production of RAPIVAB commercial inventories.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued Expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We enter into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to investigative sites in connection with clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and product candidates;&#160;and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">professional fees.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue Recognition</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recognize revenues from collaborative and other research and development arrangements and product sales. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&#160;persuasive evidence of an arrangement exists; (ii)&#160;delivery has occurred or services have been rendered; (iii)&#160;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&#160;collectability is reasonably assured.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Collaborative and Other Research and Development Arrangements and Royalties</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing performance obligations or we have completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables, we evaluate whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under certain of our license agreements, we receive royalty payments based upon our licensees&#8217; net sales of covered products. We recognize royalty revenues when we can reliably estimate such amounts and collectability is reasonably assured. Royalty revenue paid by Shionogi on their product sales is subject to returns.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. Event payments are recognized as revenue upon the achievement of specified events if (1)&#160;the event is substantive in nature and the achievement of the event was not reasonably assured at the inception of the agreement and (2)&#160;the fees are non-refundable and non-creditable. Any event payments received prior to satisfying these criteria are recorded as deferred revenue. Under our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Product Sales</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recognize revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, we sell RAPIVAB to specialty distributors, who, in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions to revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We utilize data from external sources to help estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. External sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and sell-through to customers, and information from third-party suppliers of market research data to the pharmaceutical industry.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and requires it to use information from external sources.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Rebates and Chargebacks</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#8217;s selling price.&#160;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, we maintain reserves for amounts payable under these programs relating to RAPIVAB sales.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of our product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. We acquire prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. We update our estimates and assumptions each period and record any necessary adjustments to reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates and chargebacks differ from our estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Discounts and Sales Incentives</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with our specialty distributors, we provide an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in our individual contracts. We track sales to our specialty distributors each period and accrue a liability relating to the unpaid portion of these fees by applying contractual rates to such sales.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Product Returns</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not record a product return allowance as we do not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our research and development costs are charged to expense when incurred. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additionally, we have license agreements with third parties, such as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. We expense maintenance payments as incurred.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deferred collaboration expenses represent sub-license payments paid to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We group our R&amp;D expenses into two major categories: direct external expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by program. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. These costs apply to work on our clinical and preclinical candidates as well as our discovery research efforts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-Based Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; has occurred. Significant management judgment is also required in determining estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future changes in estimates, may differ substantially from our current estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Foreign Currency Hedge</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with our issuance of the PhaRMA Notes, we entered into a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S.&#160;dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which we may be required to pay a premium in each year from 2015 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $2.0&#160;million will be required if, on May&#160;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement. In conjunction with establishing the Currency Hedge Agreement, we will be required to post collateral to the counterparty, which may cause us to experience additional quarterly volatility in our financial results. We will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreements. In establishing the hedge, we provided initial funds of approximately $2.0&#160;million to support our potential hedge obligations. As of March 31, 2015, the maximum amount of hedge collateral we may be required to post is $11.7 million.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Currency Hedge Agreement does not qualify for hedge accounting treatment and therefore mark-to-market adjustments will be recognized in our Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&#160;31, 2015 resulted in a $0.5 million gain. Mark-to-market adjustments are determined by quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted accounting principles. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of March&#160;31, 2015, no collateral was posted under the agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Tax</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We account for uncertain tax positions in accordance with accounting principles generally accepted in the U.S. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against all potential tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Information Regarding Forward-Looking Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This filing contains forward-looking statements within the meaning of Section&#160;21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#8220;safe harbor&#8221; created in Section&#160;21E. All statements other than statements of historical facts contained in this filing are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking statements are principally contained in &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as any amendments we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements about:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the initiation, timing, progress and results of our preclinical testing, clinical trials, and other research and development efforts;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the potential funding from our contracts with BARDA/HHS for the development and support of the NDA filing for RAPIVAB and the potential funding from our contracts with NIAID/HHS and BARDA/HHS for the development of BCX4430;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the potential for a government stockpiling order or profit from commercial sales of RAPIVAB;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the potential use of RAPIVAB as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the further preclinical or clinical development and commercialization of our product candidates, including our HAE program, RAPIVAB, BCX4430, early stage discovery programs, forodesine, and other PNP inhibitor development programs;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the implementation of our business model, strategic plans for our business, product candidates and technology;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our ability to establish and maintain collaborations or out-license rights to our drug candidates;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">plans, programs, progress and potential success of our collaborations, including Mundipharma for forodesine and Shionogi and Green Cross for peramivir in their territories;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Royalty Sub&#8217;s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the foreign currency hedge agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our ability to operate our business without infringing the intellectual property rights of others;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">estimates of our expenses, revenues, capital requirements and our needs for additional financing;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the timing or likelihood of regulatory filings and approvals;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our ability to raise additional capital to fund our operations;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our financial performance;&#160;and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">competitive companies, technologies and our industry.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#8220;Risk Factors.&#8221; Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->&#160;<a name="p1i3">Item&#160;</a>3. Quantitative and Qualitative Disclosures about Market Risk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interest Rate Risk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are subject to interest rate risk on our investment portfolio and borrowings under our PhaRMA Notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We invest in marketable securities in accordance with our investment policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our investment exposure to market risk for changes in interest rates relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses. Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure portfolio liquidity. A hypothetical 100 basis point drop in interest rates along the entire interest rate yield curve would not significantly affect the fair value of our interest sensitive financial instruments. We generally have the ability to hold our fixed-income investments to maturity and therefore do not expect that our operating results, financial position or cash flows will be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#8217; issuers. To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant losses from our investments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">27</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not use interest rate derivative instruments to manage exposure to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk and reinvestment risk. We reduce default risk by investing in investment grade securities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Foreign Currency Risk</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The majority of our transactions occur in U.S. dollars and we do not have operating subsidiaries or investments in foreign countries. Therefore, we are not subject to significant foreign currency exchange risk in our normal operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the issuance by Royalty Sub of the PhaRMA Notes, we entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, we are required to post collateral based on our potential obligations under the Currency Hedge Agreement as determined by periodic mark-to-market adjustments. Provided the Currency Hedge Agreement remains in effect, we may be required to pay an annual premium in the amount of $2.0&#160;million from May&#160;2015 through May&#160;2020. Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined in accordance with the Currency Hedge Agreement) is such that the U.S. dollar is worth 100 yen or less.<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->&#160;<a name="p1i4">Item&#160;</a>4. Controls and Procedures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We maintain a set of disclosure controls and procedures that are designed to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed in our periodic filings under the Exchange Act is recorded, processed, summarized and reported in a timely manner under the Exchange Act. We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of March&#160;31, 2015, the Company&#8217;s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by it under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company&#8217;s management, including the Chief Executive Officer and Chief Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There have been no changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2015 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">28</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II. OTHER INFORMATION<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><!--EFPlaceholder--><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;<a name="p2i1a">ITEM&#160;</a>1A.</font> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">RISK FACTORS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An investment in our stock involves risks. You should carefully read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial condition or results of operations, along with all of the other information included in our other filings with the Securities and Exchange Commission, before deciding to buy our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Relating to Our Business</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">We have incurred losses since our inception, expect to continue to incur such losses, and may never be profitable.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since our inception, we have not achieved profitability. We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development efforts progress. We expect that such losses will fluctuate from quarter to quarter and losses and fluctuations may be substantial.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To become profitable, we, or our collaborative partners, must successfully manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable agreements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future license agreements or revenues directly from product sales.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Because of the numerous risks and uncertainties associated with developing our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our success depends upon our ability to advance our products through the various stages of development, especially through the clinical trial process.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To receive the regulatory approvals necessary for the sale of our product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate is safe and effective. The development process is complex and uncertain. Because of the cost and duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show good results in the clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have a reasonable commercial potential. We may suffer significant setbacks in pivotal pre-clinical studies and clinical trials (e.g. BCX4430, BCX4161 and our second generation HAE product candidates), even after earlier clinical trials show promising results. Clinical trials may not be adequately designed or executed, which could affect the potential outcome and analysis of study results. Any of our product candidates may produce undesirable side effects in humans. These side effects could cause us or regulatory authorities to interrupt, delay or halt clinical trials of a product candidate. These side effects could also result in the FDA or foreign regulatory authorities refusing to approve the product candidate for any targeted indications. We, our partners, the FDA or foreign regulatory authorities may suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks. Clinical trials may fail to demonstrate that our product candidates are safe or effective and have acceptable commercial viability. Regulatory authorities may interrupt, delay or halt clinical trials for a product candidate for any number of reasons.</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our ability to successfully complete clinical trials is dependent upon many factors, including but not limited to:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our ability to find suitable clinical sites and investigators to enroll patients;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the availability of and willingness of patients to participate in our clinical trials;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the ability to maintain contact with patients to provide complete data after treatment;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our product candidates may not prove to be either safe or effective;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">manufacturing or quality control problems could affect the supply of product candidates for our trials; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">delays or changes in requirements by governmental agencies.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Clinical trials are lengthy and expensive. We or our partners incur substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that the tests and trials will ever result in the commercial sale of a product. For example, clinical trials require adequate supplies of drug and sufficient patient enrollment. Lack of adequate drug supply or delays in patient enrollment, including in our planned clinical trials for HAE, can result in increased costs and longer development times. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners might not file the required regulatory submissions in a timely manner and may not receive regulatory approval for the product candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">29</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our clinical trials may not adequately show that our product candidates are safe or effective.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Progression of our product candidates through the clinical development process is dependent upon our trials indicating our product candidates have adequate safety and efficacy in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols. Failure to achieve either of these in any of our programs, including BCX4161 and our second generation HAE product candidates, could result in delays in our trials or require the performance of additional unplanned trials. This could result in delays in the development of our product candidates and could result in significant unexpected costs or the termination of programs.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If we are unable or fail to meet payment obligations, performance milestones relating to the timing of regulatory filings, or development and commercial diligence obligations, are unable or fail to make milestone payments or material data use payments in accordance with applicable provisions, or fail to pay the minimum annual payments under our respective licenses, our licensors may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate or commercialization of the product would cease.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to obtain additional financing or acceptable partnership arrangements, we may be unable to complete the development and commercialization of our product candidates or continue operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As our programs advance, our costs are likely to increase. Our current and planned discovery, pre-clinical and clinical trials plus the related development, manufacturing, regulatory approval process requirements, and additional personnel resources and testing required for supporting the development of our product candidates will consume significant capital resources. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including: our ability to raise additional capital; the development progress of our collaborative agreements for our product candidates; the amount of funding we receive from NIAID/HHS and BARDA/HHS for BCX4430 or from other new partnerships with third parties for the development of our product candidates, including BCX4161 and our second generation HAE product candidates; the amount or profitability of any orders for RAPIVAB (peramivir injection) or BCX4430 by any government agency or other party; the progress and results of our current and proposed clinical trials for our most advanced product candidates, including BCX4161, BCX7353 and our other second generation HAE product candidates; the progress made in the manufacture of our lead products and the progression of our other programs. We expect that we will be required to enter into one or more acceptable partnership arrangements in order to complete the development of ulodesine for the treatment of gout.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We expect that we will be required to raise additional capital to complete the development and commercialization of our current product candidates and we may seek to raise capital at any time. Additional funding, whether through additional sales of securities or collaborative or other arrangements with corporate partners or from other sources, including governmental agencies in general and from any BARDA/HHS or NIAID/HHS contract specifically, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds or lack of an acceptable partnership may require us to delay, scale-back or eliminate certain of our research and development programs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In order to continue future operations and continue our drug development programs, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government funding, we may decide to access the equity or debt markets or seek other sources to meet liquidity needs. Our ability to raise additional capital may be limited and may greatly depend upon the success of ongoing development related to our current drug development programs, including post approval studies for peramivir,&#160;the progress, timeline and ultimate outcome of&#160;the OPuS-2 clinical trial, progress of our second generation HAE compounds, funding for and continued successful development of BCX4430, and progress of our early discovery programs. In addition, constriction and volatility in the equity and debt markets may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners (which include investors, licensing partners, and the U.S. Government) which may be unstable or may become unstable in the current economic and political environment. Any such instability may impact these parties&#8217; ability to fulfill contractual obligations to us or they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions could place severe downward pressure on the stock and credit markets, which could reduce the return available on invested corporate cash, which if severe and sustained could have a material and adverse impact on our results of operations and cash flows and limit our ability to continue development of our product candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">30</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">If BARDA/HHS or NIAID/HHS were to eliminate, reduce or delay funding from our contracts, this would have a significant negative impact on our revenues and cash flows.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our projections of revenues and incoming cash flows are substantially dependent upon BARDA/HHS and NIAID/HHS reimbursement for the costs related to our BCX4430 program. If BARDA/HHS or NIAID/HHS were to eliminate, reduce or delay the funding for these programs or disallow some of our incurred costs, we would have to obtain additional funding for continued development or regulatory registration for these product candidates or significantly reduce or stop the development effort.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Further, BARDA/HHS and NIAID/HHS may challenge actions that we have taken or may take under our contracts with them, which could negatively impact our operating results and cash flows.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In contracting with BARDA/HHS and NIAID/HHS, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or if we are found to be in violation could result in contract termination. U.S. Government contracts typically contain extraordinary provisions that would not typically be found in commercial contracts. For instance, government contracts permit unilateral modification by the government, interpretation of relevant regulations (i.e., federal acquisition regulation clauses), and the ability to terminate without cause. In addition, U.S. Government contracts are subject to an in-process review, where the U.S. Government will review the project and its options under the contract. As such, we may be at a disadvantage as compared to other commercial contracts. U.S. Government contracts are subject to audit and modification by the government at its sole discretion. If the U.S. Government terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our government contracts with BARDA/HHS and NIAID/HHS have special contracting requirements, which create additional risks of reduction or loss of funding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have recently completed work under a contract with BARDA/HHS for the development of our neuraminidase inhibitor, peramivir. We also have entered into contracts with BARDA/HHS and NIAID/HHS for the development of BCX4430 as a treatment for diseases caused by RNA pathogens, including Marburg virus disease and Ebola virus disease, respectively. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found to be in violation, could result in contract termination. U.S. Government contracts typically contain extraordinary provisions that would not typically be found in commercial contracts. For instance, government contracts permit unilateral modification by the government, interpretation of relevant regulations (i.e., federal acquisition regulation clauses), and the ability to terminate without cause. In addition, U.S. Government contracts are subject to the in-process review described above. As such, we may be at a disadvantage as compared to competitors that do not rely on U.S. Government contracts.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">U.S. Government contracts typically contain unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion, each of which subjects us to additional risks. These risks include the ability of the U.S. Government to unilaterally:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">terminate or reduce the scope of our contract; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">audit and object to our contract-related costs and fees, including allocated indirect costs.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The U.S. Government may terminate its contracts with us either for its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further, if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a U.S. Government contractor, we are required to comply with applicable laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, estimating, compensation and management information systems. Audits conducted by the U.S. Government for the completed BARDA/HHS contract have been performed and concluded through fiscal 2009; all subsequent fiscal years are still open and auditable. Audits under the active BARDA/HHS and NIAID/HHS contracts may occur at the election of the U.S. Government. Based on the results of its audits, the U.S. Government may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector commercial companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">31</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to successfully commercialize or establish collaborative relationships to commercialize certain of our product candidates or if any partner terminates or fails to perform its obligations under agreements with us, potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our business strategy is to increase the asset value of our product candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with third parties as appropriate. As needed, potential third-party alliances could include preclinical development, clinical development, regulatory approval, marketing, sales and distribution of our product candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Currently, we have established collaborative relationships with Mundipharma for the development and commercialization of forodesine and with each of Shionogi and Green Cross for the development and commercialization of peramivir, in Japan, Taiwan and South Korea. The process of establishing and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, a change in business strategy, a change of control or other reasons;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our contracts for collaborative arrangements may expire;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our partners may choose to pursue alternative technologies, including those of our competitors;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">we may have disputes with a partner that could lead to litigation or arbitration;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">we do not have day to day control over the activities of our partners and have limited control over their decisions;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our partners may not devote sufficient capital or resources towards our product candidates; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our partners may not comply with applicable government regulatory requirements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If we or our partners fail to fulfill our responsibilities in a timely manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further development of one or more of our product candidates, undertake commercialization activities at our own expense or find alternative sources of funding. Any delay in the development or commercialization of our product candidates would severely affect our business, because if our product candidates do not progress through the development process or reach the market in a timely manner, or at all, we may not receive additional future event payments and may never receive milestone, product sales or royalty payments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">We do not have a great deal of experience in commercializing our products or technologies, and our future revenue generation is uncertain.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not have a great deal of experience in commercializing our products or technologies. We currently have limited marketing capability, no direct or third-party sales force and limited distribution capabilities. We may be unable to establish or sufficiently increase these capabilities for products we are, or plan to, commercialize. In addition, our revenue from collaborative agreements may be dependent upon the status of our preclinical and clinical programs. If we fail to advance these programs to the point of being able to enter into successful collaborations, we will not receive any potential future event or other collaborative payments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">32</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our ability to receive revenue from products we commercialize presents several risks, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">we or our collaborators may fail to successfully complete clinical trials sufficient to obtain FDA marketing approval;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">reimbursement is constantly changing, which could greatly affect usage of our products; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market and commercialize our approved drugs.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If our development collaborations with third parties, such as our development partners and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We rely heavily upon other parties for many important stages of our product candidate development, including but not limited to:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">discovery of compounds that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">licensing or designing of enzyme inhibitors for development as product candidates;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">execution of some preclinical studies and late-stage development for our compounds and product candidates;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">management of our clinical trials, including medical monitoring and data management;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">execution of additional toxicology studies that may be required to obtain approval for our product candidates; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our failure to engage in successful collaborations at any one of these stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies, manufacture our starting materials, drug substance and product candidates or manage our regulatory function breached their obligations to us or perform their services inconsistent with industry standards and not in accordance with the required regulations, this would delay or prevent both the development of our product candidates and the availability of any potential commercial product.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices (&#8220;cGLP&#8221;), current Good Manufacturing Practices (&#8220;cGMP&#8221;) and current Good Clinical Practices (&#8220;cGCP&#8221;), and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates could be delayed, and our business, financial condition and results of operations could be materially adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commercialization of RAPIVAB is subject to the potential commercialization risks described herein and numerous additional risks. Any potential revenue benefits to us are highly speculative.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">33</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commercialization success of RAPIVAB is uncertain and is subject to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition, commercialization of RAPIVAB is subject to further risks and commercialization may be negatively impacted by a number of factors, including, but not limited to, the following:</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">RAPIVAB may not prove to be adequately safe and effective for market approval in markets other than the United States;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">necessary funding for post marketing commitments and further development of RAPIVAB may not be available timely, at all, or in sufficient amounts;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for RAPIVAB;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">regulatory authorities may not make needed accommodations to accelerate the drug testing and approval process for RAPIVAB outside the United States;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a limited number of governmental entities are expected to be the primary potential stockpiling customers for RAPIVAB and if we are not successful at marketing RAPIVAB to these entities for any reason, we will not receive substantial revenues from stockpiling orders;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">government and third party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for RAPIVAB;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">we may not be able to maintain sufficient and acceptable commercial manufacturing ourselves or through third-party manufacturers;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the commercial demand and acceptance for RAPIVAB by healthcare providers and by patients may not be sufficient to result in substantial revenues of RAPIVAB;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">effectiveness of our marketing efforts, especially since we have no sales force for RAPIVAB and we have devoted limited resources to its commercialization;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">market satisfaction with existing alternative therapies;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">perceived efficacy relative to other available therapies;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">disease prevalence;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">cost of treatment;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">pricing and availability of alternative products;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">marketing and sales activities of competitors;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">shifts in the medical community to new treatment paradigms or standards of care; and</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">relative convenience and ease of administration.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If any or all of these and other risk factors occur, we will not attain significant revenues or gross margins from RAPIVAB and our stock price and or cash flows may be adversely affected.</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are subject to various federal and state laws regulating the marketing of RAPIVAB and, if we do not comply with these regulations, we could face substantial penalties.</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our sales, promotion and other activities related to RAPIVAB, or any of our other products under development following their regulatory approval, are subject to regulatory and law enforcement authorities in addition to the FDA, including the Federal Trade Commission, the Department of Justice, and state and local governments. We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including both federal and state anti-kickback laws. Although we seek to comply with these statutes, it is possible that our practices, or those of our distributors, might be challenged under anti-kickback or similar laws. Violations of fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">34</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have a number of outstanding post-marketing commitments to the FDA, which we may not complete successfully or on time for any number of reasons, including but not limited to lack of funds to complete the studies or insufficient interest by appropriate sites, investigators or study subjects. For example, as a condition of the approval of RAPIVAB, we are required to complete a pediatric patient study of RAPIVAB and to submit the final results of this clinical trial to the FDA. Depending on the outcome of this clinical trial, we may be unable to expand the indication for RAPIVAB or we may be required to include specific warnings or limitations on dosing this product, which could negatively impact our sales of RAPIVAB. We may be subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products could be subject to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies. Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, RAPIVAB, and any other future product candidates&#8217; approval, may contain requirements for costly post-marketing testing and surveillance to monitor its safety or efficacy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our advertising and promotion are subject to stringent FDA rules and oversight. In particular, the claims in our promotional materials and activities must be consistent with the FDA approvals for our products, and must be appropriately substantiated and fairly balanced with information on the safety risks and limitations of the products. We must review adverse event information concerning our products and make expedited and periodic adverse event reports to the FDA and other regulatory authorities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, the research, manufacturing, distribution, sale and promotion of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If our operations are found to be in violation of any of the healthcare fraud and abuse laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance with all applicable federal and state fraud and abuse laws may be costly.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance and adversely affect our ability to market our products, obtain collaborators and raise capital.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2010, the President signed the Patient Protection and Affordable Care Act, or PPACA, which makes extensive changes to the delivery of health care in the U.S. The PPACA includes numerous provisions that affect pharmaceutical companies, some of which became effective immediately and others of which will be taking effect over the next several years. For example, the PPACA seeks to expand health care coverage to the uninsured through private health insurance reforms and an expansion of Medicaid. The PPACA will also impose substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on all manufacturers of brand prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical discounts to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that could reduce reimbursement levels for health care items and services generally, including pharmaceuticals. It also will require reporting and public disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals. We cannot predict what effect the PPACA or other healthcare reform initiatives that may be adopted in the future will have on our business. Further, it remains unclear whether there will be any changes made to provisions of the PPACA or other health care laws through acts of Congress in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care could result in decreased net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers will also be required to report and disclose investment interests held by physicians and their immediate family members during the preceding calendar year. &#160;Failure to submit required information may result in civil monetary penalties for payments, transfers of value or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar provisions is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, there have been a number of other legislative and regulatory proposals aimed at changing the pharmaceutical industry. In particular, legislation has been enacted in certain states and proposed at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could fact a material adverse effect on our business, financial condition, results of operations and growth prospects.&#160; As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">35</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Managed care organizations are increasingly challenging the prices charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many managed care organizations negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the managed care organization&#8217;s patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of RAPIVAB or any other product we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial condition and results of operations.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">There are risks related to the potential government use or sale of RAPIVAB.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Government use or sale of RAPIVAB in emergency situations, or otherwise, may result in the use of RAPIVAB which is outside of its approved use. To the extent that RAPIVAB is used as a treatment for influenza by any government entity, there can be no assurance that it will prove to be generally safe, well-tolerated and effective. Such government use of RAPIVAB may create certain liabilities for us. There is no assurance that we or our manufacturers will be able to fully meet the demand for RAPIVAB in the event of additional orders. Further, we may not achieve a favorable price for additional orders of RAPIVAB in the United States or in any other country. Our competitors may develop products that could compete with or replace RAPIVAB. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully enforce our intellectual property rights.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There is no assurance that the non-U.S. partnerships that we have entered into for RAPIVAB will result in any order for RAPIVAB in those countries. There is no assurance that RAPIVAB will be approved for any use or will achieve market approval in additional countries. In the event that any emergency use or market approval is granted, there is no assurance that any order by any non-U.S. partnership or commercialization of RAPIVAB in other countries will be substantial or will be profitable to us. The sale of RAPIVAB, emergency use or other use of RAPIVAB in any country may create certain liabilities for us.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Because we have limited manufacturing experience, we depend on third-party manufacturers to manufacture our product, product candidates and the materials for our product candidates. If we cannot rely on third-party manufacturers, we will be required to incur significant costs and potential delays in finding new third-party manufacturers.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have limited manufacturing experience and only a small scale manufacturing facility. We currently rely upon third-party manufacturers to manufacture the materials required for our product, product candidates and most of the preclinical and clinical quantities of our product candidates. We depend on these third-party manufacturers to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party manufacturers may encounter difficulties with meeting our requirements, especially for RAPIVAB and BCX4161, including but not limited to problems involving:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">inconsistent production yields;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">product liability claims;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">difficulties in scaling production to commercial and validation sizes;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">interruption of the delivery of materials required for the manufacturing process;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">scheduling of plant time with other vendors or unexpected equipment failure;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">potential catastrophes that could strike their facilities or have an effect on infrastructure;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">poor quality control and assurance or inadequate process controls; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies, particularly associated with RAPIVAB and planned studies for BCX4161, BCX7353 and BCX4430.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">36</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For example, our product manufacturer for RAPIVAB has been issued a Warning Letter and a Form 483 from the FDA. Failure to adequately address the observations made in the Form 483 and subsequent, timely satisfactory inspections and other necessary FDA processes may result in issues with future supply of RAPIVAB.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These contract manufacturers may not be able to manufacture the materials required for our product candidates at a cost or in quantities necessary to make them commercially viable. We also have no control over whether third-party manufacturers breach their agreements with us or whether they may terminate or decline to renew agreements with us. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue to do so. Furthermore, changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change of a third-party manufacturer (including RAPIVAB), may require prior review and approval in accordance with the FDA&#8217;s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or similar foreign regulatory agencies at any time may also implement new standards, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they may be subject to regulatory action, civil actions or penalties.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If we are unable to maintain current manufacturing or other contract relationships, or enter into new agreements with additional manufacturers on commercially reasonable terms, or if there is poor manufacturing performance or failure to comply with any regulatory agency on the part of any of our third-party manufacturers, we may not be able to complete development of, seek timely approval of, or market, our product candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our raw materials, drug substances, and product candidates are manufactured by a limited group of suppliers and some at a single facility. If any of these suppliers were unable to produce these items, this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Royalties and milestone payments from Shionogi under the Company&#8217;s license agreement with Shionogi (the &#8220;Shionogi Agreement&#8221;) will be required to be used by Royalty Sub to service its obligations under its PhaRMA Notes, and generally will not be available to us for other purposes until Royalty Sub has repaid in full its obligations under the PhaRMA Notes.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0 million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and, if approved for commercial sale, Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar foreign currency hedge arrangement put into place by us in connection with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest in Royalty Sub. Payments from Shionogi to us under the Shionogi Agreement will generally not be available to us for other purposes until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds will be required to be dedicated to Royalty Sub&#8217;s debt service and not available to us for product development or other purposes. As of September 1, 2014, the payments from Shionogi were insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in an event of default with respect to the PhaRMA Notes. As a result of this event of default, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may&#160;exercise other remedies available to them under the indenture or other documents related to&#160;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&#160;and we might otherwise be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because an event of default has occurred under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub, in which case we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Royalty Sub&#8217;s ability to service its payment obligations in respect of the PhaRMA Notes, and our ability to benefit from our equity interest in Royalty Sub, is subject to numerous risks. Peramivir was first approved for marketing and manufacturing in Japan in October 2009 and has been offered for sale in Japan only since January 2010. As a result, there is limited sales history for peramivir in Japan, and there can be no assurance that peramivir will gain market acceptance in the Japanese market. In addition, Shionogi&#8217;s sales of peramivir are expected to be highly seasonal and vary significantly from year to year, and the market for products to treat or prevent influenza is highly competitive. Under our license agreement with Shionogi, Shionogi has control over the commercial process for peramivir in Japan and Taiwan. Royalty Sub&#8217;s ability to service the PhaRMA Notes may be adversely affected by, among other things, changes in or any termination of our relationship with Shionogi, reimbursement, regulatory, manufacturing and/or intellectual property issues, product returns, product recalls, product liability claims and allegations of safety issues, as well as other factors. As Royalty Sub has been unable to service its obligations under the PhaRMA Notes and an event of default has occurred under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may&#160;exercise other remedies available to them under the indenture&#160;or other documents related to&#160;the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs&#160;and we might otherwise be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">37</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shionogi&#8217;s failure to successfully market and commercialize peramivir in Japan would have a material adverse effect on Royalty Sub&#8217;s ability to service its obligations on the PhaRMA Notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The successful commercialization of peramivir in Japan depends on the efforts of Shionogi and is beyond the control of us or Royalty Sub. Sales by Shionogi depend on many factors, including the incidence and severity of seasonal influenza in Japan each year (both of which can vary very significantly from year to year), the perceived and actual efficacy and safety of peramivir, the experience of physicians and patients with peramivir, continued market acceptance, continued availability of supply, competition, sales and marketing efforts, governmental regulation, and pricing and reimbursement in Japan. Shionogi is responsible for the marketing and sale of peramivir in Japan, including with respect to the pricing of peramivir in that market. There are no minimum royalties, sales levels or other performance measures required of Shionogi under the Shionogi Agreement and Shionogi could in its sole discretion reduce or cease its sale efforts of peramivir in Japan, subject to its covenant in the Shionogi Agreement to use diligent efforts to commercialize peramivir in Japan. If Shionogi is unable to, or fails to, successfully market and commercialize peramivir, it would have a material adverse effect on Royalty Sub&#8217;s ability to service its obligations under the PhaRMA Notes and our ability to benefit from our equity interest in Royalty Sub. To date, Shionogi royalties have been insufficient for Royalty Sub to service annual interest obligations from the PhaRMA Notes and the PhaRMA Notes are in default.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may be required to pay significant premiums under the foreign currency hedge arrangement entered into by us in connection with the issuance of the PhaRMA Notes. In addition, because our potential obligations under the foreign currency hedge are marked to market, we may experience additional quarterly volatility in our operating results and cash flows attributable to the foreign currency hedge arrangement.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the issuance by Royalty Sub of the PhaRMA Notes, we entered into a foreign currency hedge arrangement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the foreign currency hedge agreement, we may be required to pay an annual premium in the amount of $2.0 million in each May, provided the foreign currency hedge arrangement remains in effect, continuing through May 2020. Such payment will be required if, in May of the relevant year, the spot rate of exchange for Japanese yen-U.S. dollars (determined in accordance with the foreign currency hedge arrangement) is such that the U.S. dollar is worth 100 yen or less. We will be required to mark-to-market our potential obligations under the currency hedge and post cash collateral, which may cause us to experience additional quarterly volatility in our operating results and cash flows as a result. Additionally, we may be required to pay significant premiums or a termination fee under the foreign currency hedge agreement entered into by us in connection with the issuance of the PhaRMA Notes. The Company is required to maintain a foreign currency hedge at 100 yen per dollar under the agreements governing the PhaRMA Notes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">If we or our partners do not obtain and maintain governmental approvals for our product candidates under development, we or our partners will not be able to sell these potential products, which would significantly harm our business because we will receive no revenue.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We or our partners must obtain regulatory approval before marketing or selling our future product candidates. If we or our partners are unable to receive regulatory approval and do not market or sell our future product candidates, we will never receive any revenue from such product sales. In the United States, we or our partners must obtain FDA approval for product candidates that we intend to commercialize. The process of preparing for and obtaining FDA approval may be lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign government regulation and export laws of the United States. Because of the risks and uncertainties in biopharmaceutical development, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. If the FDA delays regulatory approval of our product candidates, our management&#8217;s credibility, our value and our operating results may suffer. Even if the FDA or foreign regulatory agencies approve a product candidate, the approval may limit the indicated uses for a product candidate and/or may require post-approval studies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The FDA regulates, among other things, the record keeping and storage of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs damage, or if our vendor data systems fail, suffer damage or are destroyed. If we receive approval to market our potential products, whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements are wide ranging and govern, among other things:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">adverse drug experience reporting regulations;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">product promotion;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">38</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">product manufacturing, including good manufacturing practice requirements;&#160;and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">product changes or modifications.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our failure to comply with existing or future regulatory requirements, or our loss of, or changes to, previously obtained approvals, could have a material adverse effect on our business because we will not receive product or royalty revenues if we or our partners do not receive approval of our products for marketing.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We face intense competition, and if we are unable to compete effectively, the demand for our products, if any, may be reduced.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The biotechnology and pharmaceutical industries are highly competitive and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications that we are working on. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing of desirable disease targets, licensing of desirable product candidates, and development and marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Competition may also arise from, among other things:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">other drug development technologies;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">methods of preventing or reducing the incidence of disease, including vaccines;&#160;and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">new small molecule or other classes of therapeutic agents.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Developments by others may render our product candidates or technologies obsolete or noncompetitive.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We and our partners are performing research on or developing products for the treatment of several disorders including HAE, recurrent/refractory peripheral T-cell lymphoma and broad spectrum antivirals which may be developed as medical countermeasures. We expect to encounter significant competition for any of the pharmaceutical products we plan to develop. Companies that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive advantage. Such is the case with Eisai Co. Ltd.&#8217;s TARGRETIN&#174; for cutaneous T-cell lymphoma and the current neuraminidase inhibitors marketed by GSK and Roche for influenza and CINRYZE&#174; and FIRAZYR&#174; for HAE, marketed by Shire Pharmaceuticals, Inc., and KALBITOR&#174; for HAE, marketed by Dyax Corporation. Therapeutic products with potentially promising data to treat Ebola include Tekmira Pharmaceutical s Corporation&#8217;s TKM-Ebola (RNAi interference based) and Mapp Biopharmaceutical, Inc.&#8217;s ZMapp (antibody-based) both of which have been used in Ebola infected patients. Further, several pharmaceutical and biotechnology firms, including major pharmaceutical companies and specialized structure-based drug design companies, have announced efforts in the field of structure-based drug design and molecules in development in the fields of HAE and in other therapeutic areas where we have discovery and development efforts ongoing. If one or more of our competitors&#8217; products or programs are successful, the market for our products may be reduced or eliminated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Compared to us, many of our competitors and potential competitors have substantially greater:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">capital resources;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">research and development resources, including personnel and technology;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">regulatory experience;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">preclinical study and clinical testing experience;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">manufacturing and marketing experience;&#160;and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">production facilities.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any of these competitive factors could impede our funding efforts, render technology and product candidates non-competitive or eliminate or reduce demand for our product candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">39</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our success will depend in part on our ability and the abilities of our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad. The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#8220;USPTO&#8221;), the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions. The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We also rely on trade secrets to protect technology in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our ability to receive patent protection or protect our proprietary information may be imperiled.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our success depends in part on avoiding the infringement of other parties&#8217; patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors, we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If we or our partners are unable or fail to adequately initiate, protect, defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions. We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed certain trademark and trade name applications worldwide. We cannot assure you as to:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the degree and range of protection any patents will afford against competitors with similar products;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">if and when patents will issue;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">if patents do issue we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents;&#160;or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the USPTO or other foreign patent office upholds patents issued to others or if the USPTO grants patent applications filed by others, we may have to:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">obtain licenses or redesign our products or processes to avoid infringement;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">stop using the subject matter claimed in those patents;&#160;or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">40</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">pay damages.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We may initiate, or others may bring against us, litigation or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any such proceeding may be substantial whether or not we are successful.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our success is also dependent upon the skills, knowledge and experience, none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates and any such events would significantly impair the value of such product candidates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">We face an inherent risk of liability in the event that the use or misuse of our products results in personal injury or death and our product liability insurance coverage may be insufficient.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the use or misuse of RAPIVAB or any other FDA-approved products we may sell in the future harms people, we may be subject to costly and damaging product liability claims brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product candidates in clinical trials could also expose us to product liability claims. We cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product candidates and, therefore, the amount of insurance coverage we currently may not be adequate to cover all liabilities or defense costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity could be harmful to our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us of our product candidates. We have product liability insurance covering our commercial sale of RAPIVAB and our clinical trials. Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">withdrawal of clinical trial volunteers or patients;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">damage to our reputation and the reputation of our products, resulting in lower sales;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">regulatory investigations that could require costly recalls or product modifications;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">litigation costs;&#160;and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the diversion of management&#8217;s attention from managing our business.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Insurance coverage is increasingly more costly and difficult to obtain or maintain.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">While we currently have insurance for our business, property, directors and officers, and our products insurance is increasingly more costly and narrower in scope, and we may be required to assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain or maintain insurance coverage at reasonable costs or at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">41</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If our facility incurs damage or power is lost for a significant length of time, our business will suffer.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We store clinical and stability samples at our facility that could be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant delays in our drug development process.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, we store most of our preclinical and clinical data at our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug development process and any system failure could harm our business and operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">A significant disruption in our information technology systems or a cyber-security breach could adversely affect our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are increasingly dependent on information technology systems to operate our business. Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information technology systems could negatively impact operations.&#160; If our systems are damaged, fail to function properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and any such events could adversely affect our business.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates and commercialization of our products and the related expansion of our business will be delayed or stopped.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are highly dependent upon our senior management and scientific team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. Competition for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm our business because we rely upon these personnel for many critical functions of our business.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If because of our use of hazardous materials, we violate any environmental controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our research and development involves the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these materials could occur. In the event of an accident, we could be liable for any damages that result and any liabilities could exceed our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks relating to investing in our common stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Several of our stockholders own greater than 5% of our outstanding common stock. Our top five stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations based upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters requiring approval of the stockholders, including the election of our directors and other corporate actions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our stock price has been, and is likely to continue to be, highly volatile, which could result in the value of your investment in our common stock to decline significantly.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently, and these fluctuations are often not related to our financial results. For the twelve months ended March 31, 2015, the 52-week range of the market price of our stock was from $7.29 to $14.62 per share. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common stock:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">announcements of technological innovations or new products by us or our competitors;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">developments or disputes concerning patents or proprietary rights;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">additional dilution through sales of our common stock or other derivative securities;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">status of new or existing licensing or collaborative agreements and government contracts;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">announcements relating to the status of our programs;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">developments and announcements regarding new and virulent strains of influenza;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">we or our partners achieving or failing to achieve development milestones;</font></div>
</td>
</tr></table>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">42</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">publicity regarding certain public health concerns for which we are or may be developing treatments;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">regulatory developments in both the United States and foreign countries;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">public concern as to the safety of pharmaceutical products;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">actual or anticipated fluctuations in our operating results;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">changes in financial estimates or recommendations by securities analysts;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">changes in the structure of healthcare payment systems, including developments in price control legislation;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">additions or departures of key personnel or members of our board of directors;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">economic and other external factors or other disasters or crises; and</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">period-to-period fluctuations in our financial results.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Future sales and issuances of securities may dilute the ownership interests of our current stockholders and cause our stock price to decline.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Future sales of our common stock by current stockholders into the public market could cause the market price of our stock to fall. As of April&#160;30, 2015, there were 72,520,545 shares of our common stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of April&#160;30, 2015, there were 10,920,129 stock options and restricted stock units outstanding, 1,327,593 shares available for issuance under our Amended and Restated Stock Incentive Plan, and 518,511 shares available for issuance under our Employee Stock Purchase Plan. In addition, we could also make equity compensation grants outside of our Stock Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.</font></div>

<div>&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If some or all of such shares are sold or otherwise issued into the public market over a short period of time, our current stockholders&#8217; ownership interests may be diluted and the value of all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices. Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable, or at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you do not agree.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our board of directors has the authority to issue up to 4,800,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third parties to acquire a majority of our outstanding voting stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, our certificate of incorporation provides for staggered terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors and prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have never paid cash dividends on our stock. We currently intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash dividends on our common stock in the foreseeable future.<!--EFPlaceholder--></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">43</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->&#160;<a name="p2i6">Item&#160;</a>6. Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See the Exhibit&#160;Index attached to this quarterly report and incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">44</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="sign">SIGNATURES</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 8<font style="DISPLAY: inline; FONT-SIZE: 10pt">th</font> day of May, 2015.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BIOCRYST PHARMACEUTICALS, INC.</font></div>
</td>
</tr><tr>
<td valign="middle" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="62%" style="PADDING-BOTTOM: 0.75pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="38%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Jon P. Stonehouse</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jon P. Stonehouse</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="62%"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Executive Officer)</font></div>
</td>
</tr><tr>
<td valign="middle" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="62%" style="PADDING-BOTTOM: 0.75pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="38%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Thomas R. Staab, II</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thomas R. Staab, II</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="62%"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Senior Vice President, Chief Financial Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and Treasurer</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="62%"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Financial and Principal Accounting Officer)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">45</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="exh">INDEX </a>TO EXHIBITS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<!--EFPlaceholder--></font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="83%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number</font></div>
</td>
<td valign="bottom" width="83%" style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;&#160;</font>3.1</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Form&#160;8-K filed December&#160;22, 2006.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;&#160;</font>3.2</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Form&#160;8-K filed July&#160;24, 2007.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;&#160;</font>3.3</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificate of Increase of Authorized Number of Shares of Series&#160;B Junior Participating Preferred Stock. Incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Form&#160;8-K filed November&#160;4, 2008.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;&#160;</font>3.4</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Form&#160;8-K filed May&#160;8, 2014.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;&#160;</font>3.5</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificate of Increase of Authorized Number of Shares of Series&#160;B Junior Participating Preferred Stock. Incorporated by reference to Exhibit&#160;3.2 to the Company&#8217;s Form&#160;8-K filed May&#160;8, 2014.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;&#160;</font>3.6</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amended and Restated Bylaws of Registrant effective October&#160;29, 2008. Incorporated by reference to Exhibit&#160;3.2 to the Company&#8217;s Form&#160;8-K filed November&#160;4, 2008.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.1</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fifth Amendment to Lease Agreement dated January 15, 2015, by and between Riverchase Capital LLC, a Florida limited liability company, Stow Riverchase, LLC, a Florida limited liability company, as successor landlord to RBP, LLC and the Company. Incorporated by reference to Exhibit 10.42 to the Company&#8217;s Form 10-K filed March 2, 2015.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10.2)&#8224;</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, dated March 27, 2015.&#160;&#160;(Portions omitted pursuant to request for confidential treatment.)</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(31.1)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(31.2)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(32.1)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(32.2)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div>
</td>
</tr><tr>
<td valign="middle" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="87%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(101)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financial statements from the Quarterly Report on Form 10-Q of BioCryst Pharmaceuticals, Inc. for the three months ended March 31, 2015, formatted in XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="5%" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="45%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="25%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(&#160;&#160;)</font></div>
</td>
<td align="left" valign="top" width="97%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Filed or furnished herewith.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8224;</font></div>
</td>
<td align="left" valign="top" width="97%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Confidential treatment requested.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><!--EFPlaceholder--><!--EFPlaceholder--><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>exh_102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
<head>
    <title>exh_102.htm</title>
    <!--Licensed to: Nasdaqomx-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff">
<div style="TEXT-ALIGN: right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 10.2</font></div>

<div style="TEXT-ALIGN: right">&#160;</div>

<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></div>
</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" valign="middle" width="32%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-TOP: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AWARD/CONTRACT</font></font></div>
</td>
<td colspan="3" width="43%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">1. THIS CONTRACT IS A RATED ORDER </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">UNDER DPAS (15 CFR 350)</font></font></div>
</td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">RATING</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">PAGE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;&#160;&#160;&#160; 1</div>
</td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-TOP: black 1.5pt solid">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">OF PAGES</font></div>

<div>&#160;&#160;&#160;&#160;&#160; 55</div>
</td>
</tr><tr>
<td colspan="2" width="32%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">2. CONTRACT <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(Proc.</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Inst.</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> Ident.)</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font>NO.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">HHSO100201500007C</font></font></div>
</div>
</td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">3. EFFECTIVE DATE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31, 2015</font></font></div>
</div>
</td>
<td width="18%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td colspan="4" width="38%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">4. REQUISITION/PURCHASE REQUEST/PROJECT NO.</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OS150001</font></font></div>
</div>
</td>
</tr><tr>
<td width="18%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">5. ISSUED BY</font></font></div>
</td>
<td width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CODE</font></font></div>
</td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td colspan="2" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">6. ADMINISTERED BY <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(If</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">other</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">than</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> Item</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">6)</font></font></font></font></div>
</td>
<td width="12%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CODE</font></font></div>
</td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="3" width="44%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Office of Acquisitions Management, Contracts, and Grants </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(AMCG)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">330 Independence Ave., S.W. Room G640</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Washington, D.C. 20201</font></font></div>
</td>
<td colspan="2" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">See Block 5.</font></font></div>
</td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="5" valign="top" width="75%" style="BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">7. NAME AND ADDRESS OF CONTRACTOR <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(No.</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">street,</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> county,</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">state</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">and</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">ZIP</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Code)</font></font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BioCryst Pharmaceuticals </font></font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nottingham Hall</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4505 Emperor Blvd., Suite 200</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Durham, NC 27703</font></font></font></div>
</div>
</td>
<td colspan="3" valign="top" width="25%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">8. DELIVERY</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">See Schedule.</font></font></div>
</div>
</td>
</tr><tr>
<td colspan="5" width="75%" style="BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CAGE: 4GBX7</font></font></div>
</td>
<td colspan="3" width="25%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9/ DISCOUNT FOR PROMPT PAYMENT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></font></div>
</td>
</tr><tr>
<td colspan="2" width="32%" style="BORDER-BOTTOM: black 1.1pt solid">&#160;</td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid">&#160;</td>
<td width="18%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="12%" style="BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10. SUBMIT INVOICES</font></font></div>
</td>
<td colspan="2" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">ITEM</font></font></div>
</td>
</tr><tr>
<td colspan="2" width="32%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CODE DUNS No. 618194609</font></font></div>
</td>
<td colspan="3" width="43%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">FACILITY CODE</font></font></div>
</td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">ADDRESS SHOWN IN: F.3</font></font></div>
</td>
<td colspan="2" width="13%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See Section G<font style="DISPLAY: inline; FONT-SIZE: 10pt">.</font></font></font></div>
</td>
</tr><tr>
<td width="18%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">11. SHIP TO/MARK FOR</font></font></div>
</td>
<td width="14%">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CODE&#160;&#160;&#160;&#160; </font></font></div>
</td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">N/A</font></font></div>
</td>
<td colspan="2" width="12%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">12. PAYMENT WILL BE MADE BY</font></font></div>
</td>
<td width="12%" style="TEXT-ALIGN: right; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CODE&#160;&#160;&#160;&#160;&#160;&#160; </font></font></div>
</td>
<td colspan="2" width="13%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">N/A</font></font></td>
</tr><tr>
<td width="18%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="14%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="12%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="18%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="12%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="8%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="18%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See Block 5</font></font></div>
</td>
<td width="14%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="12%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="12%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See Block 5</font></font></div>
</td>
<td width="12%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="8%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></td>
<td width="14%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="18%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="3" width="44%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">13. AUTHORITY FOR USING OTHER FULL AND OPEN COMPETITION: <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold">N/A</font></font></font></font></div>
</td>
<td colspan="5" width="12%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">14. ACCOUNTING AND APPROPRIATION DATA</font></font></div>
</td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10 U.S.C. 2304(c)(&#160;&#160;&#160;&#160;)</font></font></div>
</td>
<td colspan="2" width="26%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41 U.S.C. 253(c)(&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;)</font></font></font></font></td>
<td colspan="5" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Object Class - 25103</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CAN# - 1990500</font></font></div>
</td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">15A. ITEM NO.</font></font></div>
</td>
<td colspan="2" width="14%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">15B. SUPPLIES/SERVICES</font></font></div>
</td>
<td width="18%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">15C. UNIT PRICE</font></font></div>
</td>
<td width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">15D. AMOUNT</font></font></div>
</td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">15E. UNIT PRICE</font></font></div>
</td>
<td colspan="2" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">15F. AMOUNT</font></font></div>
</td>
</tr><tr>
<td colspan="3" valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Title: BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies</font></font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(See Schedule)</font></font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(See Schedule)</font></font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(See Schedule)</font></font></div>
</td>
<td colspan="2" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(See Schedule)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td colspan="5" width="18%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">15G. TOTAL AMOUNT OF CONTRACT</font></font></div>
</td>
<td width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">&#8250;</font></font></td>
<td colspan="2" width="5%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$12,133,606</font></font></div>
</td>
</tr><tr>
<td colspan="8" width="18%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16. TABLE OF CONTENTS</font></td>
</tr></table>
</div>

<div align="center">
<table bgcolor="white" cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 7pt">&#160;(<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#252;</font>)</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 7pt">SEC.</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 7pt">DESCRIPTION</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 7pt">PAGE(S)</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 7pt">&#160;(<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#252;</font>)</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 7pt">SEC.</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 7pt">DESCRIPTION</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 7pt">PAGE(S)</font></td>
</tr><tr>
<td colspan="4" width="50%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">PART I - THE SCHEDULE</font></font></div>
</td>
<td colspan="4" width="50%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">PART II <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">-</font> CONTRACT CLAUSES</font></font></div>
</td>
</tr><tr>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">A</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">SOLICITATION/CONTRACT FORM</font></font></div>
</td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">01</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">I</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CONTRACT CLAUSES</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">47</font></td>
</tr><tr>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">B</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">SUPPLIES OR SERVICES AND PRICE/COST</font></font></div>
</td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">03</font></td>
<td colspan="4" width="4%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACH.</font></font></div>
</td>
</tr><tr>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">C</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">DESCRIPTION / SPECS / WORK STATEMENT</font></font></div>
</td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">10</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">J</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">LIST OF ATTACHMENTS</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">54</font></td>
</tr><tr>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">D</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">PACKAGING AND MARKING</font></font></div>
</td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">11</font></td>
<td colspan="4" width="4%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">PART IV - REPRESENTATIONS AND INSTRUCTIONS</font></font></div>
</td>
</tr><tr>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">E</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">INSPECTION AND ACCEPTANCE</font></font></div>
</td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">11</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">K</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">REPRESENTATIONS, CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">55</font></td>
</tr><tr>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">F</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">DELIVERIES OR PERFORMANCE</font></font></div>
</td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">12</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
</tr><tr>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">G</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">CONTRACT ADMINISTRATION DATA</font></font></div>
</td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">22</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left; BORDER-LEFT: medium none; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
</tr><tr>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">H</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">SPECIAL CONTRACT REQUIREMENTS</font></font></div>
</td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">29</font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></td>
<td width="4%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="34%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-RIGHT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="8%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div align="center">
<table bgcolor="white" cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="6" width="90%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CONTRACTING OFFICER WILL COMPLETE ITEM 17 OR 18 AS APPLICABLE</font></font></div>
</td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid">&#160;</td>
</tr><tr>
<td colspan="3" valign="top" width="51%" style="BORDER-BOTTOM: black 1.1pt solid">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.</font><font style="FONT-FAMILY: times new roman; FONT-SIZE: 12pt">X</font> CONTRACTOR&#8217;S NEGOTIATED AGREEMENT </font>(<font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Contractor</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">is</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">required</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">to</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">sign</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">this</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">document</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">and</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">return</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="TEXT-DECORATION: underline">&#160; 2&#160;&#160;</font></font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">copies</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">to</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">issuing</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">office.)</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">Contractor</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">agrees</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">to</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">furnish</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">and</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">deliver</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">all</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">items</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">or</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">perform</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">all</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">the</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">services</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">set</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">forth</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">or</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">otherwise</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">identified</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">above</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">and</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">on</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">any</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">continuation</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">sheets</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">for</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">the</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">consideration</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">stated</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">herein.</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">The</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">rights</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">and</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">obligations</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">of</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">the</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">parties</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">to</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">this</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">contract</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">shall</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">be</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">subject</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">to</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">and</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">governed</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">by</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">the</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">following</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">documents:</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(a)</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">this</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">award/contract,</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(b)</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">the</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">solicitation,</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">if</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">any,</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">and</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(c)</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">such</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">provisions,</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">representations,</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">certifications,</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">and</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">specifications,</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">as</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">are</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">attached</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">or</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">incorporated</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">by</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">reference</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">herein.</font><font size="3" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(Attachments</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">are</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">listed</font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"> </font><font size="3" style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">herein.)</font></font></font></font></div>
</td>
<td colspan="4" valign="top" width="49%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18.</font><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 12pt">o</font> <font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">AWARD</font> (Contractor is not required to sign this document.) Your offer on Solicitation Number __________________, including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as to the items listed above and on any continuation sheets. This award consummates the contract which consists of the following documents: (a) the Government&#8217;s solicitation and your offer, and (b) this award/contract. No further contractual document is necessary.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td width="24%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">19A. NAME AND TITLE OF SIGNER <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(Type</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">or</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">print)</font></font></font></font></div>
</td>
<td width="1%">&#160;</td>
<td width="13%">&#160;</td>
<td colspan="4" width="36%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">20A. NAME OF CONTRACTING OFFICER</font></font></div>
</td>
</tr><tr>
<td valign="top" width="24%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Jon P. Stonehouse</font></td>
<td width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="13%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="36%" style="BORDER-BOTTOM: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thomas P. Hastings</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td width="1%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="24%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">19B. NAME OF CONTRACTOR</font></font></div>
</td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="13%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">19C. DATE SIGNED</font></font></div>
</td>
<td colspan="2" width="36%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">20B. UNITED STATES OF AMERICA</font></font></div>
</td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="10%" style="BORDER-LEFT: black 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">20C. DATE SIGNED</font></font></div>
</td>
</tr><tr>
<td width="24%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="13%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="2%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="36%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="10%" style="BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
</tr><tr>
<td width="24%" style="BORDER-BOTTOM: black 1.1pt solid">&#160;</td>
<td width="1%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="13%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px">&#160;</td>
<td width="2%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">BY</font></td>
<td width="36%" style="BORDER-BOTTOM: black 1.1pt solid">&#160;</td>
<td width="1%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="10%" style="BORDER-LEFT: black 1.1pt solid; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr>
<td width="24%" style="BORDER-BOTTOM: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(Signature of person authorized to sign)</font></font></div>
</td>
<td width="1%" style="BORDER-BOTTOM: black 1.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="13%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="2%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 8pt">&#160;</font></td>
<td width="36%" style="BORDER-BOTTOM: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 8pt">(Signature of person authorized to sign)</font></font></div>
</td>
<td width="1%" style="BORDER-BOTTOM: black 1.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="10%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.1pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>
</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>
</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Contents</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="92%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="95%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I &#8211; THE SCHEDULE</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION B &#8211; SUPPLIES OR SERVICES AND PRICES/COSTS</font></div>
</td>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT</font></div>
</td>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION D &#8211; PACKAGING, MARKING AND SHIPPING</font></div>
</td>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">11</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION E &#8211; INSPECTION AND ACCEPTANCE</font></div>
</td>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">11</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION F &#8211; DELIVERIES OR PERFORMANCE</font></div>
</td>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">12</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION G - CONTRACT ADMINISTRATION DATA</font></div>
</td>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">22</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION H - SPECIAL CONTRACT REQUIREMENTS</font></div>
</td>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">29</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="92%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="95%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II - CONTRACT CLAUSES</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION I - CONTRACT CLAUSES</font></div>
</td>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">47</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="92%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="95%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION J - LIST OF ATTACHMENTS</font></div>
</td>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">54</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="92%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="95%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART IV - REPRESENTATIONS AND INSTRUCTIONS</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION K - REPRESENTATIONS AND CERTIFICATIONS</font></div>
</td>
<td align="right" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">55</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">PART I &#8211; THE SCHEDULE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION B &#8211; SUPPLIES OR SERVICES AND PRICES/COSTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are currently no medical countermeasures (MCMs) available for the prophylaxis or treatment of infection with Ebola virus, a high priority agent for the PHEMCE Implementation Plan.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 15.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BioCryst&#8217;s proposal focuses on BCX4430, a novel small molecule nucleoside with broad spectrum antiviral activity being developed for diseases caused by RNA pathogens. BCX4430, an inhibitor of viral RNA &#8211; dependent RNA polymerase (RdRp), is the lead compound in BioCryst&#8217;s broad spectrum antiviral program to meet the need for an effective and broad-spectrum parenteral direct- acting antiviral medical countermeasure (MCM). The proposed activities take into account the Ebola virus disease (EVD) outbreak in West Africa while advancing the development of BCX4430 toward an NDA filing. The tasks include manufacturing process development activities, manufacturing of Drug substance (DS) and drug product (DP) and clinical trial material, and the nonclinical development activities to advance the intra-muscular and intravenous formulation</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">through NDA-enabling toxicology studies including </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * * </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">toxicology and </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * * </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">toxicology in </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Advanced Research and Development effort will progress in specific stages that cover the base work segment and the four (4) option work segments. Work performed during the base segment and in the four (4) option segments each constitutes an independent, non-severable discrete work segment that cannot be subdivided for separate performance. Work specified in each work segment is <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> and each are necessary to support the development of BCX 4430 as an MCM. Each of the non-severable, discreet work segments contains multiple activities that when reviewed in total shall satisfy a defined end-product for each segment. The Government has determined that it has a Bona Fide Need for each non-severable discrete work segment. That need will be met upon the completion of the defined task(s) listed in the Work Breakdown Statement (WBS) in the Statement of Work (SoW) for each work segment (See Section J- Attachment 1), the completion of the Milestones in the Contract and submission of the deliverables required in the Contract (See Section J&#8211;Attachment 2.). Each work segment provides independent merit and value to the Government. Each work segment will be fully funded from an appropriation source that is current at the time the contract is awarded (Base Work Segment) and at the time the Government exercises each option.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE B.2. BASE PERIOD (March 31, 2015 through September 30, 2016)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The total estimated cost of the base period of the contract excluding fee is</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">$</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;* * *&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The total fixed fee for the base period of performance is <font style="DISPLAY: inline; FONT-WEIGHT: bold">$ * * *</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">c.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fixed fee for the base period of performance (CLIN 0001) and any exercised cost- reimbursement contract options shall be paid at a rate equal to *&#160;*&#160;*&#160;% of actual costs incurred per invoicing period, with the balance of fee payable upon successful completion of all work under each CLIN, subject to the following limitations:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 63pt">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 36pt">
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The government shall withhold the payment of a portion of the fee to protect the government&#8217;s interest as set forth in Federal Acquisition Regulation (FAR) 52.216-8, Fixed Fee (June 2011). The government shall withhold 15 percent of the total fixed fee or $100,000, whichever is less, until after government review and acceptance of the Final Technical Progress Report.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">d.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The total estimated cost of the base period of the contract, CLIN 0001, represented by the sum of the total estimated cost plus fixed fee is <font style="DISPLAY: inline; FONT-WEIGHT: bold">$12,133,606</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> The government will not be responsible for any Contractor-incurred costs that exceed this amount unless a modification to the contract is signed by the Contracting Officer which expressly increases this amount.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: right; WIDTH: 63pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">e.&#160;&#160;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall maintain records of all contract costs and such records shall be subject to FAR 52.215-2 (Oct 2010), Audit and Records-Negotiation, and Health and Human Services Acquisition Regulation (HHSAR) 352.242-74, Final Decisions on Audit&#160;&#160;Findings, incorporated by reference into this contract in SECTION I.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CLIN</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.2pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated Period of Performance</font></div>
</td>
<td align="left" valign="top" width="16%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplies/Services</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 8.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Estimated Cost</font></div>
</td>
<td valign="top" width="2%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-TOP: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fixed Fee</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 25.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Estimated Cost Plus Fixed Fee</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0001</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">03/31/2015 &#8211;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">09/30/2016</font></div>
</td>
<td align="left" valign="top" width="16%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 24pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture of Clinical Trial Material and Process Improvements</font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="2%" style="BORDER-BOTTOM: black 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$12,133,606</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE B.3. OPTION PRICES</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 47pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to FAR 52.217-9, Option to Extend the Term of the Contract (Mar 2000), set forth in full in ARTICLE I.3 of this contract, the government may, by unilateral contract modification, require the Contractor to perform discrete portions of additional work as specified in the Statement of Work.</font></div>

<div align="left">&#160;</div>

<div align="left">Unless the government exercises one or more optional CLINs, the contract consists <font style="DISPLAY: inline; TEXT-DECORATION: underline">only</font><font style="DISPLAY: inline; TEXT-DECORATION: underline"> </font>of the base work specified in the Statement of Work as defined in SECTIONS C and F, with estimated costs set forth in ARTICLE B.2 of the contract.</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 0.6pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CLIN</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 0.6pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Option</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 0.6pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated Period of Performa nce</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 0.6pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplies/ Services</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 0.6pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Estimated Cost</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 0.6pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fixed Fee</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 0.6pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Estimated Cost Plus Fixed Fee</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0002</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">***</font></td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Commercial Scale-up and NDA</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Registration batches</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0003</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">***</font></td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nonclinical NDA-</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">enabling Toxicology IM</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0004</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">***</font></td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In Vitro Experiments</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0005</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">***</font></td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nonclinical NDA-</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">enabling Toxicology IV</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ ***</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE B.4. LIMITATIONS APPLICABLE TO DIRECT COSTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Items Unallowable Unless Otherwise Provided</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 62.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notwithstanding the clause FAR 52.216-7, Allowable Cost and Payment, incorporated in this&#160;&#160;contract, <font style="DISPLAY: inline; TEXT-DECORATION: underline">unless</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">authorized</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">in</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">writing</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font>by the Contracting Officer in the form of a Contracting&#160;&#160;Officer Authorization (COA), the costs of the following items or activities shall be <font style="DISPLAY: inline; TEXT-DECORATION: underline">unallowable </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font>as direct costs:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Acquisition, by purchase or lease, of any interest in real property;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Special rearrangement or alteration of facilities;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Purchase or lease of any item of general purpose office furniture or office equipment regardless of dollar value. (General purpose equipment is defined as any items of personal property which are usable for purposes other than research, such as office&#160;&#160;equipment and furnishings, pocket calculators, etc.);</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Travel to attend general scientific meetings, subject to limitation under Article B.4.b.1;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Foreign travel;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subcontractor and/or Consultant costs;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Patient care costs;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accountable government property (defined as both real and personal property with an acquisition cost of $1,000 or more and a life expectancy of more than two years) and &#8220;sensitive items&#8221; regardless of acquisition value (Section J, Attachment 6).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Printing Costs (as defined in the government Printing and Binding Regulations).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Light Refreshment and Meal Expenditures are not authorized.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Costs for meeting room or conference space used for face to face meetings with United&#160;&#160;States government (USG) staff in the performance of this contract at Government or Contractor facilities are not authorized.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Travel Costs</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Total expenditures for all travel (transportation, lodging, subsistence, and incidental expenses) incurred by the Prime Contractor in direct performance of this contract during the base period shall not exceed <font style="DISPLAY: inline; FONT-WEIGHT: bold">$40,000</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>without the prior written approval of the Contracting Officer. Cost must be consistent with FAR 52.247-63 &#8211; Preference for U.S. <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Flag Air Carriers.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contactor shall invoice and be reimbursed for all travel costs in accordance with F A R&#160;&#160;31<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> 20 5 <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> 4 6,&#160;&#160;T r a v el&#160;&#160;C os t s&#160;&#160;a nd&#160;&#160;GSA Per Diem Rates (www.gsa.gov/perdiem).</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Requests for foreign travel must be submitted at least four weeks in advance and shall contain the following:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">meeting(s) and place(s) to be visited, with costs and dates;</font></font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">names(s) and title(s) of Contractor personnel to travel and their functions in the contract project;</font></font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt">(iii) <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">contract purpose to be served by the travel;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(iv)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">how travel of Contractor personnel will benefit and contribute to accomplishing the contract project, or will otherwise justify the expenditure of AMCG contract funds;</font></font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(v)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">how such advantages justify the costs for travel and absence from the project of more than one person if such are suggested; and</font></font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(vi)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">what additional functions may be performed by the travelers to accomplish other purpose of the contact and thus further benefit the project.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE B.5. ADVANCE UNDERSTANDINGS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Subcontracts</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Prior written consent from the Contracting Officer in the form of a Contracting Officer&#160;&#160;Authorization (COA) is required for any subcontract that:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Is of the cost-reimbursement type or Time-and-Materials (T&amp;M);</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 32.3pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Is Fixed-Price and exceeds $150,000 or 5% of the&#160;&#160;total estimated cost of the Contract, whichever value is greater.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 23.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contracting Officer shall request appropriate supporting documentation in order to&#160;&#160;review and determine authorization, pursuant with FAR Clause 52.244-2, Subcontracts (Alternate I). After receiving written consent of the subcontract by the Contracting Officer, a copy of the signed, executed subcontract and consulting agreement shall be provided to the Contracting Officer within ten (10) calendar days.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 80.95pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Note: Consulting services are treated as subcontracts and subject to the &#8216;consent to&#160;&#160;subcontract&#8217; provisions set forth in this Article.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;* * * </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">as major subcontractor under the Contract</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 11.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The services under the Contract will include certain chemical manufacturing&#160;&#160;services. It is anticipated that, a large portion of the chemical manufacturing services </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">will be subcontracted to </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * * </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">by the Contractor. Accordingly, </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * * </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">is expected to </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">be a material subcontractor under the Contract and COA approval is hereby granted.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c.&#160; &#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Services Performed under Contract with NIAID</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 15.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain development services have been funded under by HHS/NIAID under&#160;&#160;contract number HHS27220130017C (the &#8220;NIAID Contract&#8221;). The focus of the NIAID Contract were certain IND enabling studies as well as certain contract manufacturing transfer and scale up services and certain Phase 1 studies. The parties recognize that certain work under this Contract is not expected to begin until certain related services (&#8220;Related Services&#8221;) are completed under the NIAID Contract. Such&#160;&#160;services include but are not limited to the technology transfer and scale up chemical </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">manufacturing services at </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * * </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The parties agree that if for any reason the Related </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Services are delayed or unable to be completed under the NIAID Contract, Contractor shall be relieved of its obligations to continue performance under this Contract.</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Security</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 33.2pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A Security Plan is required for this effort. A security waiver may be requested. In the event a security waiver cannot successfully be attained, the Government will notify the Contractor who will subsequently be required to deliver a security plan to the Government, conforming with the following paragraphs.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 21.4pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The work to be performed under this contract will involve access to sensitive Biomedical Advanced Research and Development Authority [BARDA] program information. Upon contract award, the Program Protection Officer (PPO) will request submission of and review the Draft Security Plan in detail and submit comments within ten (10) business days to the CO to be forwarded to the Contractor. The Contractor shall review the Draft Security Plan comments, and if changes are required, submit a Final Security Plan to the U.S. Government within thirty (30) calendar days after receipt of the Program Protection Officer&#8217;s (PPO) comments. The Final Security Plan shall include a timeline for compliance of all&#160;&#160;the required security measures. Upon completion of initiating all security measures, the Contractor shall supply to the CO and Contracting Officer&#8217;s Representative (COR) a letter certifying compliance to the elements outlined in the Final Security Plan. The execution of&#160;&#160;the work under this contract shall be in accordance with the approved Final Security Plan. As outlined above, the content of the Final Security Plan shall be considered as part of the Contractor&#8217;s Technical Proposal. The Contractor shall ensure that the storage, generation, transmission&#160;&#160;or exchanging of BARDA sensitive information has the appropriate security controls in place. At a minimum, the Final Security Plan shall address the following items:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 32.3pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Personnel Security Policies and Procedures including, but not limited to: Recruitment of new employees; Interview process; Personnel background checks; Suitability/adjudication policy; Access determination; Rules of behavior/conduct;&#160;&#160;Termination procedures; Non-disclosure agreements.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Physical Security Policies and Procedures including but not limited to: Internal/external&#160;&#160;access control; Identification/badge requirements; Facility visitor access; Parking areas and access; Barriers/perimeter fencing; Shipping, receiving and transport (on and off-&#160;&#160;site); Security lighting; Restricted areas; Signage; Intrusion detection systems; Closed circuit television; Other control measures.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 80.95pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Information Security Policies and Procedures including but not limited to: Identification of sensitive information; Access control/determination; Secured storage infrastructure; Document control; Retention/destruction requirements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Information Technology Security Policies and Procedures including but not limited to: Intrusion detection and prevention systems; firewalls, Encryption systems; Identification of&#160;&#160;sensitive information/media; Passwords; Removable media; Laptop policy; Media access control/determination; Secure storage; System document control; System backup;&#160;&#160;System disaster recovery.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Security Reporting Requirement <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Violations of established security protocols shall be&#160;&#160;reported to the CO and COR within 24 hours of the contractor&#8217;s discovery of any compromise, intrusion, loss or interference of its security processes and procedures. The&#160;&#160;Contractor shall ensure that all software components that are not required for the operation and maintenance of the database/control system have been removed and/or&#160;&#160;disabled. The Contractor shall provide to the CO and the COR information appropriate to&#160;&#160;Information and Information Technology software and service updates and/or workarounds to mitigate all vulnerabilities associated with the data and shall maintain the required level of system security.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 30pt" align="left"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 30pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor will investigate violations to determine the cause, extent, loss or compromise of sensitive program information, and corrective actions taken to prevent&#160;&#160;future violations. The CO in coordination with BARDA will determine the severity of the violation. Any contractual actions resulting from the violation will be determined by the Contracting Officer.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">e.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Confidential Treatment of Sensitive Information</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall, to the extent permitted by law, guarantee strict confidentiality of&#160;&#160;sensitive/confidential information/data that is provided by the USG during the&#160;&#160;performance of the contract. The USG has determined that certain information/data that the Contractor will be provided during the performance of the contract is of a sensitive nature.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Disclosure of confidential/sensitive information/data, in whole or in part, by the Contractor&#160;&#160;can only be made after the Contractor receives prior written approval from the Contracting Officer. Whenever the Contractor is uncertain with regard to the proper&#160;&#160;handling of information/data under the contract, the Contractor shall obtain a written&#160;&#160;determination from the Contracting Officer.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notwithstanding the foregoing, such information/data shall not be deemed of a sensitive&#160;&#160;or confidential nature with respect to the Contractor for purposes of this contract if such&#160;&#160;information/data: (a) was already known to the Contractor other than by prior disclosure by the USG or discovered through work under a prior&#160;&#160;USG contract; (b) was generally available or&#160;&#160;known, or was otherwise part of the public domain, at the time of its disclosure to the Contractor; (c) became generally available or known, or otherwise became part of the public domain, after its disclosure to, or, with respect to the information/data by, the&#160;&#160;Contractor through&#160;&#160;no fault of the Contractor; (d) was disclosed to the Contractor, other&#160;&#160;than under an obligation of confidentiality or non-use, by a third party who had no obligation to the USG that controls such information/data not to disclose such&#160;&#160;&#160;&#160;&#160;information/data to others; or (e) was independently discovered or developed by the Contractor, as evidenced by its written records, without the use of information/data belonging to the USG.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 26.65pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor may disclose information/data of a sensitive nature provided by the USG&#160;&#160;to the extent that such disclosure is: (a) made in response to a valid order of a court of competent jurisdiction (b) otherwise required by law or regulation, (c) made by the Contractor to the Regulatory Authorities as required in connection with any filing, application or request for Regulatory Approval; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information/data.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">f.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sharing of contract deliverables within United States Government (USG)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In an effort to build a robust medical countermeasure pipeline through increased collaboration, BARDA may share technical deliverables with USG entities responsible for Medical Countermeasure Development. In accordance with recommendations from the Public Health Emergency Medical Countermeasure Enterprise Review<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> agreements established in the Integrated Portfolio Advisory Committee (PAC) Charter, and agreements between BARDA and the Department of Defense and the National Institutes of Health, BARDA may share technical deliverables and data created in the performance of this contract with colleagues within the Integrated Portfolio. This advance understanding does not authorize BARDA to share financial information outside of the United States Government. The Contractor is advised to review the terms of FAR 52.227-14, Rights in Data &#8211; General, regarding the government&#8217;s rights to deliverables submitted during</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><br>
&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 80.95pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">performance as well as the government&#8217;s rights to data contained within&#160;&#160;those deliverables.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">g.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Approval of Protocols</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall submit all protocols as referenced under this Contract to the COR f o r review and approval. The Government requires no fewer than eight (8) business days to perform a review. The Contractor shall take this review time into account and submit protocols as early as possible to avoid delays. The Government&#8217;s comments and&#160;&#160;feedback shall be addressed prior to approval. The COR will review and provide approval of protocols.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">h.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Rights in Data</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contract will incorporate the Alternate II to FAR Clause 52.227-14, Rights in Data&#8212;general, pursuant to FAR Clause 52.227-14 (g)(3). In the event that the&#160;</font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">U.S. Government requires the delivery of pre-existing privately funded data, BioCryst will identify that specific pre-existing privately funded data and that data will be marked with the limited rights notice specified under FAR Clause 52.227-14 (g)(3)(a).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 15.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><a name="bookmark0"><!--EFPlaceholder--></a>SECTION C <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> DESCRIPTION/SPECIFICATIONS/WORK STATEMENT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE C.1. STATEMENT OF WORK</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 15.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Independently and not as an agent of the government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities not otherwise provided by the government as needed to perform the Statement of Work dated March 27, 2015, set forth in SECTION J <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> List of Attachments, attached hereto and made a part of the contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE C.2. REPORTING REQUIREMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Refer to ARTICLE F.2 for specific instructions regarding Reporting Requirements.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE C.3. EARNED VALUE MANAGEMENT SYSTEM (EVMS) IMPLEMENTATION REQUIREMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 15.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor and BARDA agree that the EVMS implementation requirements that are&#160;&#160;contained in the contract are limited to the implementation requirements outlined by the 7&#160;&#160;Principles of Earned Value Management Tier 3 System Implementation Intent Guide contained in&#160;&#160;the Attachments (Section J.) of the contract. The total amount of this contract reflects the use of&#160;&#160;the 7 Principles of EVMS Implementation.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Refer to Article F.2. for specifics on EVMS deliverables.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE C.4. PROJECT MEETING CONFERENCE CALLS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A conference call between the Contracting Officer&#8217;s Representative and designees and the&#160;&#160;Contractor&#8217;s Project Leader/delegate and designees shall occur bi-weekly or as otherwise mutually agreed upon by the USG and the Contractor or determined by the Contracting Officer.&#160;&#160;During this call the Contractor&#8217;s Project Leader/delegate&#160;&#160;and designees will discuss the activities&#160;&#160;since the last call, any problems that have arisen and the activities planned until the next call takes place. The Contractor&#8217;s Project Leader/delegate may choose to include other key personnel&#160;&#160;on the conference call to give detailed updates on specific projects or this may be requested by&#160;&#160;the Contracting Officer&#8217;s Representative. Electronic copy of conference call meeting&#160;&#160;minutes/summaries shall be provided via e-mail to the CO, COR, and uploaded in e-room by the Contractor within five (5) business days after the conference call is held.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE C.5. OTHER PROJECT MEETINGS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Kickoff Meeting</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 6.2pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor and USG shall conduct a kickoff meeting within 30 calendar days after contract award. Contractor shall provide an itinerary/agenda no later than 5 business days before&#160;&#160;meeting. Minutes from the kickoff meeting must be provided within 10 business days of&#160;&#160;the event.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quarterly and Ad-Hoc Meetings</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 11.2pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall participate in Project Meetings to coordinate the performance of the&#160;&#160;contract, as requested by the Contracting Officer&#8217;s Representative. These meetings may include face-to-face meetings with AMCG and BARDA in Washington, D.C. and at work sites of the Contractor and subcontractors. Such meetings may include, but are not limited to, meetings of the Contractor to discuss study designs, site visits to the Contractor&#8217;s facilities, and meetings&#160;&#160;with the Contractor and HHS officials to discuss the technical, regulatory, and ethical aspects of the program. Subject to the data rights provisions in this contract, the Contractor will provide data, reports, and presentations to groups of outside experts and USG personnel as required by the Contracting Officer&#8217;s Representative in order to facilitate review of contract activities. Contractor shall provide itinerary/agenda at least 5&#160;&#160;business days&#160;&#160;in advance of face-to-face meeting.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F<font style="DISPLAY: inline; FONT-WEIGHT: bold">ace-to-Face</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Project</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Review</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Meetings</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 12.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall, at a time to be determined later, present a comprehensive review of contract progress to date in a face-to-face meeting in Washington, DC. The contractor will be responsible for updating BARDA program on technical progress under the Statement of Work.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Presentation must be delivered seven (7) business days prior to the scheduled meeting.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><a name="bookmark1"><!--EFPlaceholder--></a>SECTION D &#8211; PACKAGING, MARKING AND SHIPPING</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 12.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All deliverables required under this contract shall be packaged, marked and shipped in&#160;&#160;accordance with USG specifications. At a minimum, all deliverables shall be marked with the contract number and Contractor name. The Contractor shall guarantee that all required materials&#160;&#160;shall be delivered in immediate usable and acceptable condition</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unless otherwise specified by the Contracting Officer, delivery of reports to be furnished to the USG under this contract (including invoices) shall be delivered to AMCG and BARDA electronically along with a concurrent email notification to the Contracting Officer, Contract Specialist, and COR (as defined in SECTION F.3. ELECTRONIC SUBMISSION) summarizing the electronic delivery.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><a name="bookmark2"><!--EFPlaceholder--></a>SECTION E &#8211; INSPECTION AND ACCEPTANCE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE E.1. FAR 52.252-2, CLAUSES INCORPORATED BY REFERENCE (FEBRUARY 1998)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This contract incorporates the following clauses by reference, with the same force and effect as if&#160;&#160;they were given in full text. Upon request, the Contracting Officer will make their full text available.&#160;&#160;Also, the full text of a clause may be accessed electronically at these addresses: <font style="DISPLAY: inline; TEXT-DECORATION: underline">https://www.acquisition.gov/FAR/</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font>&#160;HHSAR&#160;Clauses at: <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.hhs.gov/policies/hhsar/subpart352.html</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">FAR<font style="DISPLAY: inline; TEXT-DECORATION: underline"> </font></font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Clause</font> </font></font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Title<font style="DISPLAY: inline; TEXT-DECORATION: underline"> </font></font><font style="DISPLAY: inline; TEXT-DECORATION: underline">and</font><font style="DISPLAY: inline; TEXT-DECORATION: underline"> </font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Date</font> </font></font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.246-9</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Inspection of Research and Development (Short Form) (Apr 1984)</font></td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="ARTICLEE.2.DESIGNATIONOFGOVERNMENTP"><!--EFPlaceholder--></a>ARTICLE E.2. DESIGNATION OF GOVERNMENT PERSONNEL</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 16.2pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the purpose of this SECTION E, the designated Contracting Officer&#8217;s Representative (COR)&#160;&#160;is the authorized representative of the Contracting Officer. The COR will assist in resolving&#160;&#160;technical issues that arise during performance. The COR however is not authorized to change&#160;&#160;any contract terms or authorize any changes in the Statement of Work or modify or extend the period of performance, or authorize reimbursement of any costs incurred during performance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="ARTICLEE.3.INSPECTION,ACCEPTANCEAND"><!--EFPlaceholder--></a>ARTICLE E.3. INSPECTION, ACCEPTANCE AND CONTRACT MONITORING</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 12.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Inspectionandacceptanceofthemateria"><!--EFPlaceholder--></a>Inspection and acceptance of the materials services and documentation called for herein shall be accomplished by the Contracting Officer or a duly authorized representative.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Inspectionandacceptancewillbeperfor"><!--EFPlaceholder--></a>Inspection and acceptance will be performed at:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 58.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="OfficeofAcquisitionManagement,Contra"><!--EFPlaceholder--></a>Office of Acquisition Management, Contracts, and Grants (AMCG) Office of the Assistant Secretary for Preparedness and Response</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 34.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services 330 Independence Avenue, S.W., Room G640 Washington, D.C. 20201</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Site Visits and Inspections</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 21.65pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At the discretion of the USG and independent of activities conducted by the Contractor,&#160;&#160;with 48 hours&#8217; notice to the contractor, the USG reserves the right to conduct site visits&#160;&#160;and inspections on an as needed basis, including collection of product samples and intermediates held at the location of the contractor, or subcontractor. All costs reasonably incurred by the Contractor and subcontractor for such visit and/or inspection shall be allowable costs subject to the Allowable cost requirements in FAR Subpart 31.2. The Contractor shall coordinate these visits and shall have the opportunity to accompany the USG on any such visits. Under time-sensitive or critical situations, the USG reserves&#160;&#160;the right to suspend the 48 hour notice to the Contractor. The areas included under the site visit could include, but are not limited to: security, regulatory and quality systems, manufacturing processes and&#160;&#160;cGMP/GLP/GCP&#160;&#160;compliance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 12.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the USG, Contractor, or other party identifies any issues during an audit, the Contractor&#160;&#160;shall capture the issues, identify potential solutions, and provide a report to the USG for review and acceptance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If issues are identified during the audit, the Contractor shall submit a report to the&#160;&#160;CO and COR within five (5) business days detailing the finding and corrective action(s) of the audit.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">COR and CO will review the report and provide a response to the Contractor within ten (10) business days.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Once corrective action is completed, the Contractor will provide a final report to&#160;&#160;the CO and COR.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><a name="bookmark3"><!--EFPlaceholder--></a>SECTION F &#8211; DELIVERIES OR PERFORMANCE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE F.1. PERIOD OF PERFORMANCE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Base Period</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 20pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under CLIN 0001, the estimated period of performance for the base performance segment of this contract shall be from March 31, 2015 through September 30, 2016 (18 months).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Option CLINs</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CLIN</font></div>
</td>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Option</font></div>
</td>
<td valign="top" width="34%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated Period of Performance</font></font></div>
</td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplies/Services</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0002</font></div>
</td>
<td valign="top" width="5%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</td>
<td valign="top" width="34%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; * * *</font></td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 26.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Commercial Scale-up and NDA Registration batches</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0003</font></div>
</td>
<td valign="top" width="5%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>
</td>
<td valign="top" width="34%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; * * *</font></td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 52.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nonclinical NDA-enabling Toxicology IM</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0004</font></div>
</td>
<td valign="top" width="5%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</td>
<td valign="top" width="34%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; * * *</font></td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In Vitro Experiments</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0004</font></div>
</td>
<td valign="top" width="5%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</td>
<td valign="top" width="34%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; * * *</font></td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 52.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nonclinical NDA-enabling Toxicology IV</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE: Base period and all option periods (if exercised in accordance with FAR clause FAR&#160;&#160;clause 52.217-09,</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Option to Extend the Term of the Contract (Mar 2000), shall not exceed </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * * </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">months.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE F.2. DELIVERABLES</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 23.95pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Successful performance of the final contract shall be deemed to occur upon completion of performance of the work set forth in the Statement of Work dated March 27, 2015, set forth in SECTION J <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> List of Attachments of this contract and upon delivery and acceptance, as required by the Statement of Work, by the Contracting</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Officer, of each of the deliverables described in&#160;&#160;SECTION C, SECTION F, and SECTION J, Attachment 2, &#8220;Contract WBS Milestones and Related Deliverables&#8221;.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 19.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All deliverables and reporting documents listed within this section shall be delivered electronically&#160;&#160;(as defined in SECTION F.3. ELECTRONIC SUBMISSION) to the CO, CS, and the COR unless otherwise specified by the Contracting Officer.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Summary of Contract Deliverables</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 7.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unless otherwise specified by the Contracting Officer, the deliverables identified in this&#160;&#160;SECTION F shall also be delivered electronically to the designated eRoom along with a concurrent email notification sent to the Contracting Officer, Contract Specialist, COR,&#160;&#160;and Alternate COR stating delivery has been made.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 7.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All paper/hardcopy documents/reports submitted under this contract shall be printed or copied, double- sided, on at least 30 percent post-consumer fiber paper, whenever practicable, in accordance with FAR 4.302(b). Hard copies of deliverables and reports furnished to the USG under the resultant Contract (including invoices) shall be addressed as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 34.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">HHS/ASPR/AMCG</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ATTN: Thomas P. Hastings, Contracting Officer 330 Independence Avenue, S.W., Room G640 </font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, DC 20201</font></div>

<div align="left">* * *</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 34.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">HHS/ASPR/BARDA</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ATTN: Kimberly Sciarretta, Contracting Officer&#8217;s Representative 330 Independence Avenue, S.W., Room G640</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, DC 20201</font></div>

<div align="left">* * *</div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="4" valign="top" width="78%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Technical Reports</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deliverable</font></div>
</td>
<td align="left" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deliverable Schedule</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Once Monthly Teleconference and Meeting Minutes</font></div>
</td>
<td align="left" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 5.25pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Contractor shall prepare minutes of all &#8220;Project Meetings and &#8220;Project Meeting Conference Calls&#8221; as defined in Article C. of this contract. In preparation for the monthly calls, briefing materials, including the agenda and documents and information to be discussed will be prepared as needed.</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor shall provide teleconference agenda and related materials twenty-four (24) hours in advance of the call.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 31.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor provides meeting minutes to COR within five (5) business days of the meeting. COR reviews, comments, and approves minutes within 15 business days of receipt.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 15pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Draft Security Plan</font></div>
</td>
<td align="left" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.5pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Draft Security Plan as detailed in Article B.5.d.</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 13.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Within 10<font style="DISPLAY: inline; FONT-SIZE: 10pt">th</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>calendar days following the effective date of the contract</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 26.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Monthly Technical Progress Report and Invoice</font></div>
</td>
<td align="left" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 10.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Monthly Progress report shall address the progress occurring over the corresponding period of time. See below, ARTICLE F.2.(b), &#8220;Detailed Description of Select Contract Deliverables,&#8221; for detailed instructions. Additionally, submission of the Monthly Technical Progress Report will contain the invoice for actual costs incurred during the previous month that work was performed under the contract. The costs incurred in the invoice will be justified in a summary report contained within the Monthly Technical Progress Report.</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The 15<font style="DISPLAY: inline; FONT-SIZE: 10pt">th</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>calendar day of each month following the first full month of the contract award. The Monthly Progress Report will not be&#160;&#160;required in months when an Annual or Final Technical Progress Report is due.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 35.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Annual Progress Report</font></div>
</td>
<td align="left" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 20.55pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Annual Progress report shall address the progress occurring over the corresponding period of time. See below, Article F.2.(b), &#8220;Detailed Description of Select Contract Deliverables,&#8221; for detailed instruction.</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.25pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The 15<font style="DISPLAY: inline; FONT-SIZE: 10pt">th</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>calendar day of the month following the end of each 12- month performance period. The Monthly Progress Report will not be required in months when an Annual Progress report is due</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 20.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In-Process Review (GO/NO GO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 10pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Decision Gate) Presentation</font></div>
</td>
<td align="left" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 10.15pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In preparation for the IPR, the Contractor shall prepare a presentation demonstrating the technical progress made towards completion of the tasks under each work segment. The presentation shall demonstrate the status or completion of the milestones and deliverables as specified under Section F.</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 27.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The presentation must be submitted to the CO/COR thirty</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.95pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(30) business days prior to the IPR IPR for BARDA review and comment. Subsequently, a revised/final presentation will be required ten (10) business days prior to the IPR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 10.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The CO will provide a written response within ten (10) business days on the decision to exercise or not exercise an option.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></div>
</td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 14.6pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Earned Value Management Report</font></div>
</td>
<td align="left" colspan="2" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As described in Article C.3.</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The 15<font style="DISPLAY: inline; FONT-SIZE: 10pt">th</font><font style="DISPLAY: inline; FONT-SIZE: 10pt"> </font>calendar day of each month following the first full month of the contract award.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7</font></div>
</td>
<td align="left" colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 29.55pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Draft Final Technical Progress Report</font></div>
</td>
<td align="left" colspan="2" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 17.95pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A draft Final Report containing a summation of the work performed under each task and subtask and the results obtained for the entire contract Period of Performance (PoP). The draft report shall be duly marked as &#8220;Draft.&#8221; BARDA will provide comments that the Contractor shall incorporate into the Final Technical Progress Report.</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forty-five (45) calendar days before the completion date of the contract.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8</font></div>
</td>
<td align="left" colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 8.95pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Final Technical Progress Report</font></div>
</td>
<td align="left" colspan="2" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 18.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A Final Report containing a summation of the work performed and the results obtained for the entire contract Period of Performance (PoP).</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 16.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thirty (30) calendar days after the technical period of performance.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></div>
</td>
<td align="left" colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 9.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Summary of Salient Results</font></div>
</td>
<td align="left" colspan="2" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 24.85pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor shall submit, with the Final Report, a summary (not to exceed 200 words) of salient results achieved during the performance of the contract.</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 14pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On or before the expiration date of the contract.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></div>
</td>
<td align="left" colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 9.55pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deviation Notification. Changes to Execution of Planned Tasks and Mitigation Strategy</font></div>
</td>
<td align="left" colspan="2" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 13.15pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In order to process for changing tasks, including activities associated with task content, cost and schedule per IMP/Gantt baseline, the Contractor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 8.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">s h al l notify the Government of significant changes, justification, and rationale for proposed alternative in writing. Cost reallocation and reconciliation of the budget should be included. Contractor shall provide a high-level management strategy for risk mitigation and update the Risk Management Plan</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 18.55pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Notice due within 1 week after discovery or need for changes to product development plan per Gantt identified.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 8.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor shall revise the IMP/Gantt within thirty (30) calendar days, update monthly s part of the Monthly Progress Report, and update the Risk Management Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 29.15pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor must address, in writing, all concerns raised by BARDA and re-submit a IMP/GANTT that reflects or addresses BARDA<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#8217;</font>s concerns.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11</font></div>
</td>
<td align="left" colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 19.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development Report</font></div>
</td>
<td align="left" colspan="2" valign="top" width="31%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 16.55pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Final Reports detailing the parameters and capacity of upstream and downstream conditions.</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Upon successful completion.</font></div>
</td>
</tr><tr>
<td colspan="6" valign="top" width="78%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other Technical Reports</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item</font></div>
</td>
<td align="left" colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deliverable</font></div>
</td>
<td align="left" colspan="2" valign="top" width="53%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deliverable Schedule</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12</font></div>
</td>
<td align="left" colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Audit Reports</font></div>
</td>
<td align="left" colspan="2" valign="top" width="53%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Within fifteen (15) calendar days of the audit</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13</font></div>
</td>
<td align="left" colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 4.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FDA/Regulatory Agency</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Correspond. &amp; Meeting Summaries</font></div>
</td>
<td align="left" colspan="2" valign="top" width="53%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 24.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Within five (5) business days of each meeting for Contractor&#8217;s minutes and upon receipt of minutes from FDA/regulatory agency.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 4.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FDA/Regulatory Agency Submissions</font></div>
</td>
<td valign="top" width="53%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.9pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BARDA shall provide comment within five (5) business days after receipt. BARDA reserves the right to request more than 5 business days for review of any regulatory submission that is of significant length.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 29.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Contractor shall inform BARDA of the anticipated submission length so BARDA can make a determination if more than 5 business days will be needed to complete its review of the document.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 14.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Supplemental Technical Documents</font></div>
</td>
<td align="left" valign="top" width="53%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 27.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Upon request. Contractor shall provide CO and COR with deliverables from the following contract funded activities: Process Development Reports; Stability Assay Reports; Assay Qualification Plan/Report; Assay Validation Plan/Report; Assay Technology Transfer Report; Batch Records; Contractor/</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 20.55pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subcontractor Standard Operating Procedures (SOPs); Master Production Records; Certificate of Analysis; Clinical Studies Data or Reports. The CO and COR reserve the right to request within the PoP a nonproprietary technical document for distribution within the USG.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 8.85pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor shall provide technical document within 5 business days of CO or COR request.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor can request additional time on an as-needed basis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 10.2pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*If corrective action is recommended, the Contractor must address, in writing, concerns raised by BARDA.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 34.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Invention Report</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 32.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Annual Utilization Report</font></div>
</td>
<td align="left" valign="top" width="53%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 37.85pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Due on or before the 30<font style="DISPLAY: inline; FONT-SIZE: 10pt">th</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>of the month following each 12-month period of performance.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Final Invention Report</font></div>
</td>
<td align="left" valign="top" width="53%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Due on or before the completion date of the contract.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kickoff Meeting</font></div>
</td>
<td align="left" valign="top" width="53%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Within thirty (30) calendar days of contract award.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Detailed Description of Select Contract Deliverables</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Monthly Progress Report</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 108pt; MARGIN-RIGHT: 6.3pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This report shall include a description of the activities during the reporting&#160;&#160;period, and the activities planned for the ensuing reporting period. The first reporting period consists of the first full month of performance plus any fractional part of the initial month. Thereafter, the reporting period shall consist&#160;&#160;of each calendar month.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 107.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall submit a Monthly Progress Report on or before the 15th calendar day following the last day of each reporting period and shall include&#160;&#160;the following:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 108pt; MARGIN-RIGHT: 6.3pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A cover page that includes the contract number and title; the type of report and period that it covers; the Contractor's name, address, telephone number, fax number, and e-mail address; and the date of submission;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 97.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION I <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> An introduction covering the purpose and scope of the contract effort; SECTION II &#8211; PROGRESS</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION II Part A: OVERALL PROGRESS <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> A description of overall progress;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> A</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 15.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">description of all meetings, conference calls, etc. that have taken place during the reporting period. Include progress on administration and management issues (e.g. evaluating and managing subcontractor performance and personnel changes);</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 15.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION II Part C: TECHNICAL PROGRESS <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> For each activity related to the Gantt chart, document the results of work completed and costs incurred during the period covered in relation to proposed progress, effort and budget. The report shall be in sufficient detail to explain comprehensively the results achieved. The description shall include pertinent data and/or graphs in sufficient detail to explain any significant results achieved and preliminary conclusions resulting from analysis and scientific evaluation of data&#160;&#160;accumulated to date under the contract. Include progress or status updates for all SOW tasks in each of the monthly technical progress reports for which there is activity ongoing in that SOW task area(s) as well as data for completed&#160;&#160;studies in any SOW task. The report shall also include a description of problems encountered and proposed corrective action; differences between planned and actual progress, why the differences have occurred and what corrective actions are planned; preliminary conclusions resulting from analysis&#160;&#160;and scientific evaluation of data accumulated to date under the project.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 98pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION II Part D: PROPOSED WORK <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> A summary of work proposed for the next reporting period and preprints/reprints of papers and abstracts, and a&#160;&#160;current/updated Gantt chart.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 7.65pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION II Part E: Outstanding Issues/Anticipated Areas of Concern <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> a list of any existing contractual concerns that impact the technical scope of work, schedule, or cost, as well as a list of potential or anticipated areas of concern that may be encountered in the future months.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 7.65pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 98pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A Monthly Progress Report will not be required in the same month that the Annual or Final Technical Progress Reports are submitted.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 99pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Annual Progress Reporting Requirement</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 10.3pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This report shall include a summation of the activities during the reporting&#160;&#160;period, and the activities planned for the ensuing reporting period. The first reporting period consists of the&#160;&#160;first full year of performance plus any fractional part of the initial year. Thereafter, the reporting period shall consist of each&#160;&#160;calendar year.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 6.2pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall submit an Annual Progress Report on or before the 15th calendar day following the last day of each reporting period and shall include&#160;&#160;the following:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 15.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A cover page that includes the contract number and title; the type of report and period that it covers; the Contractor's name, address, telephone number, fax number, and e-mail address; and the date of submission;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 98pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION I-EXECUTIVE SUMMARY <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> A brief overview of the work completed and major accomplishments achieved during the reporting period.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION&#160;&#160;II-PROGRESS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 12.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION II Part A: OVERALL PROGRESS <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> A description of overall progress highlighting the </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 12.5pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 12.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">significant accomplishments in the past year;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> A </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">description of all meetings, conference calls, etc. that have taken place during </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the reporting period. Include progress on administration and management issues (e.g. evaluating and managing subcontractor performance and personnel changes);</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 12.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION II Part C: TECHNICAL PROGRESS <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> For each activity, document the results of work completed and cost incurred during the period covered in&#160;&#160;relation to proposed progress, effort and budget. The report shall be in sufficient detail to explain comprehensively the results achieved. The description shall include pertinent data and/or graphs in sufficient detail to explain any significant results achieved and preliminary conclusions resulting from analysis and scientific evaluation of data accumulated to date under the&#160;&#160;contract. The report shall include a description of problems encountered and proposed corrective action; differences between planned and actual progress, why the differences have occurred and what corrective actions are planned; preliminary conclusions resulting from analysis and scientific evaluation of data accumulated to date under the project. The report should summarize progress made under each SOW task.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 98pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION II Part D: PROPOSED WORK <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> A summary of work proposed for the next reporting period; and preprints/reprints of papers, abstracts and a current Gantt chart.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 2.35pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A Monthly and Annual Progress Report will not be required for the period when the Final Technical Progress Report is due and a Monthly Progress Report will not be required in the same month that the Annual Progress Report is submitted.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Draft Final Technical Progress Report and Final Technical Progress Report</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 14.4pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These reports are to include a summation of the work performed and results obtained for the entire contract period of performance, detailing accomplishments for each task. This report shall be in sufficient detail to describe comprehensively the results achieved. The Draft Final Report and Final Report shall be submitted in accordance with the DELIVERIES Article in SECTION F of the contract. The Draft Final Technical Progress Report shall be submitted forty-five (45) calendar days before completion date of the contract and the Final Technical Progress Report shall be submitted 30 Calendar days post technical period of performance. The report shall conform to the following format:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 12.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cover page to include the contract number, contract title, performance period covered, Contractor's name and address, telephone number, fax number, e- mail address and submission date;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 7.85pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION I: EXECUTIVE SUMMARY <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Summarize the purpose and scope of the contract effort including a summary of the major accomplishments relative to the specific activities set forth in the Statement of Work.;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 12.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECTION II: RESULTS <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> A detailed description of the work performed related to the Gantt chart, the results obtained, and the impact of the results on the scientific and/or public health community, including a listing of all manuscripts (published and in preparation) and abstracts presented during the entire period&#160;&#160;of performance, and a summary of all inventions.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Draft</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Final</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Technical</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Progress</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Report</font>: The Contractor is required to submit the Draft Final Technical Progress Report to the Contracting Officer's Representative and Contracting Officer. This report is due forty-five (45) calendar days before the completion date of the contract. The Contracting Officer's Representative and Contracting Officer will review the Draft Final</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 98pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Technical Progress Report and provide the Contractor with comments within fifteen (15) calendar days after receipt.</font></div>

<div align="left">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 14.35pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Final</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Technical</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Progress</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Report</font>: The contractor shall incorporate all BARDA comments into the Final Technical Progress Report. The Contractor will deliver the final version of the Final Technical Progress Report 30 Calendar days post technical period of performance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 99pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Summary of Salient Results</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 15.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On or before the expiration of the contract the Contractor shall submit, with the Final Technical Progress Report, a summary (not to exceed 200 words) of salient results achieved during the performance of the contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 99pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Audit Reports</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 15.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Within fifteen (15) calendar days of an audit related to conformance to FDA regulations and guidance, including adherence to GLP, GMP, GCP guidelines,&#160;&#160;the Contractor shall provide copies of the audit report (so long as received from the FDA) and a plan for addressing areas of nonconformance to FDA regulations and guidelines for GLP, GMP, or GCP guidelines as identified in the&#160;&#160;final audit report.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 99pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Copies of FDA/Regulatory Agency Correspondence and Meeting Summaries</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Within five business days of any formal meeting with the FDA or other&#160;&#160;regulatory agency, the contractor shall forward the initial draft minutes to BARDA. The contractor shall forward final draft minutes when available.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Within five business days of any informal meeting with the FDA or other&#160;&#160;regulatory agency, the contractor shall forward the final draft minutes to BARDA.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall forward the dates and times of any meeting with the FDA and other regulatory agencies to BARDA and make arrangements for appropriate BARDA staff to attend the meetings.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide BARDA the opportunity to review and comment upon any documents to be submitted to the FDA or other regulatory agency. The contractor shall provide BARDA with five (5) business days in which to review and provide comments back to the contractor prior to the contractor&#8217;s submission to the FDA.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall forward Standard Operating Procedures (SOPs) upon request from Project Officer/Contracting Officer.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide upon request animal study and/or other technology packages developed under this contract. Packages shall include complete protocols and critical reagents for animal models developed and/or improved with contract funding.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide upon request raw data and/or specific analysis of data generated with USG funds.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 99pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other&#160;&#160;Reports/Deliverables</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Government Rights in Data and Inventions</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 6.2pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Technology packages developed under the contract that include complete protocols and critical reagents developed and/or improved with contract funding must be submitted at the request of the Contracting Officer&#8217;s Representative.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Institutional Biosafety Approval</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 5.9pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 5.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall provide documentation of materials submitted for Institutional Biosafety Committee Review and documentation of approval of&#160;&#160;experiments at the request of the Contracting Officer&#8217;s Representative.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Experimental Protocols</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall submit all study/experiment/test plans, designs, and protocols.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Data</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 7.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall provide data and/or specific analysis of data generated with contract funding at the request of the Contracting Officer&#8217;s Representative.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Earned Value Management (EVM) Deliverables</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">i.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Earned Value Management (EVM) / Contract Performance Report (CPR)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 7.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor will provide a monthly CPR at an agreed upon reporting level using WBS and Variance Analysis report formats agreed upon by ASPR after EVM is implemented. The supplemental monthly Control Account Plan (CAP) report shall contain, at the work package level, time phased budget (budgeted cost of work scheduled), earned value (budgeted cost of work performed), and actual costs of work performed as captured in Contractor&#8217;s EVM systems. The Contractor shall provide a rationale in the package of its use of % complete as EVMS methodology, or identity if any other EVMS methodology is being used.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor shall provide EVM/CPR as part of the Monthly Progress Report (this requirement begins only as set forth in the Contract Milestones &amp; Related Deliverables table)</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor shall provide top level or key changes in baseline cost as a result of anticipated cost savings or risks</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In accordance with FAR 52.215-2, Audit and Records-Negotiation (Oct 2010), the USG may request, on a monthly or ad hoc basis that the Contractor provide raw data at a reporting level or lower level as ASPR deems necessary.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor must address, in writing, all concerns raised by the USG.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Reporting will commence after the EVM system has been implemented but no later than six (6) months after start of base period.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 99pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ii.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Integrated Master Plan (IMP)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall provide an IMP including WBS, critical path milestones, and Earned Value Management Plan</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor shall provide the draft IMP within 180 days of contract award with final due 8 months after award and updated monthly as part of the Monthly Progress Report</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor must address, in writing, all concerns raised by the USG.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iii.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Performance Measurement Baseline Review (PMBR)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 7.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">PMBR Report shall address each of the items listed below and be cross- referenced to the IMP, WBS, SOW, and Risk Management Plan.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor provides baseline proposal</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Responsibility Assignment Matrix</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A description of the work scope through control account Work Authorization Documents and/or WBS Dictionary down to the agreed upon control account level.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Template for work packages</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Integrated Master Schedule (IMS) with the inclusion of agreed major milestones and control account plans for all control accounts</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Baseline revision documentation and program log(s) risk management plan</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">PMBR is due within one year of contract award</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor shall provide baseline proposal .ppt briefing 10 business days prior to meeting</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor provides agenda to COR 2 business days in advance of meeting</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">COR approves (with CO concurrence) and distributes agenda</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">COR approves (with CO concurrence) all meeting material</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contactor provides minutes with 2 business days of the meeting</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">COR reviews and approves (with CO concurrence) minutes</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASPR will review documentation and provide written comments and questions to Contractor</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor shall address BARDA&#8217;s comments and resubmit PMBR report for BARDA approval within 10 business days.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iv.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risk Management Plan</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 10.3pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall provide a Risk Management Plan that outlines the impacts of each risk in relation to the cost, schedule, and performance objectives. The plan shall include risk mitigation strategies. Each risk mitigation strategy will capture how the corrective action will reduce impacts on cost, schedule and performance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">&#167;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; Due within 180 days of contract award</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: right; WIDTH: 126pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">&#167;</font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; Contractor provides updated Risk Management Plan in Monthly Progress Report</font></div>
</td>
</tr></table>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">&#167;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; ASPR shall provide Contractor with a written list of concerns in response plan submitted</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">&#167;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; Contractor must address, in writing, all concerns raised by ASPR within 20 business days of Contractor&#8217;s receipt of ASPR&#8217;s concerns.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">v.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Requirement for Notification of Deviation and Mitigation Strategy</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 15.95pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Process for changing IMS activities associated with cost and schedule as baselined at the PMBR. Contractor shall notify ASPR of significant changes to&#160;&#160;the IMS defined as increases in cost above 10% for Go/No Go Milestones or schedule slippage of more than 180 days, which would require an extension to&#160;&#160;the period of performance. Contractor shall provide a high level management strategy for risk mitigation. Notice due within one (1) business day after discovery.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE F.3. ELECTRONIC SUBMISSION</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 10.3pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For electronic delivery, the Contractor shall upload documents to the appropriate folder on https://eroom.bardatools.hhs.gov/eRoom (&#8220;eRoom&#8221;) which is the designated USG file sharing&#160;&#160;system. The USG shall provide two contractor representatives authorized log in access to the file&#160;&#160;share program. Each representative must complete a mandatory training provided by the USG&#160;&#160;prior to gaining user access. A notification email should be sent to the CO and COR upon electronic delivery of any documents.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE F.4. SUBJECT INVENTION REPORTING REQUIREMENT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 15.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All reports and documentation required by FAR Clause 52.227-11, Patent Rights-Ownership by the Contractor, including, but not limited to, the invention disclosure report, the confirmatory&#160;&#160;license, and the government support certification, one copy of an annual utilization report, and a&#160;&#160;copy of the final invention statement, shall be submitted to the Contracting Officer. A final invention statement (see FAR 27.303 (b)(2)(ii)) shall be submitted to the Contracting Officer on&#160;&#160;the expiration date of the contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Reports and documentation submitted to the Contracting Officer shall be sent to the address set&#160;&#160;forth in SECTION G &#8211; CONTRACT ADMINISTRATION DATA.</font></div>

<div align="left">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 6.2pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If no invention is disclosed or no activity has occurred on a previously disclosed invention during&#160;&#160;the applicable reporting period, a negative report shall be submitted to the Contracting Officer at the address listed above.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><a name="bookmark4"><!--EFPlaceholder--></a>SECTION G <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> CONTRACT ADMINISTRATION DATA</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE G.1. CONTRACTING OFFICER</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 88.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following Contracting Officer (CO) will represent the USG for&#160;&#160;the purpose of this contract: </font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 88.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Thomas P. Hastings</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contracting Officer </font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">DHHS/OS/ASPR/AMCG</font></div>

<div align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">330 Independence Avenue, S.W. Room G644 Washington, D.C. 20201 </font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(571) 221-2978</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * *</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 97.6pt" align="left"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contracting Officer (CO) is the only individual who can legally commit the USG to the expenditure of public funds. No person other than the Contracting Officer can make any changes to the terms, conditions, general provisions, or other stipulations of this contract.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contracting Officer is the only person with the authority to act as agent of the USG under this contract. Only the Contracting Officer has authority to (1) direct or negotiate any changes in the statement of work; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize reimbursement to the Contractor of any costs incurred during the performance of this contract; (5) otherwise change any terms and conditions of this&#160;&#160;contract.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No information other than that which may be contained in an authorized modification to this&#160;&#160;contract, duly issued by the Contracting Officer, which may be received from any person employed by the US government, other otherwise, shall be considered grounds for deviation from any stipulation of this contract.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The USG may unilaterally change the CO or CS designation.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE G.2. CONTRACTING OFFICER'S REPRESENTATIVE (COR) and ALTERNATE CONTRACTING OFFICER'S REPRESENTATIVE (COR)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 88.95pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following COR and Alternate COR will represent the government for the&#160;&#160;purpose of this contract: </font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 88.95pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">COR:</font></div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kimberly Sciarretta</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Biomedical Advanced Research and Development Authority (BARDA) Office of the </font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Assistant Secretary for Preparedness and Response Department of Health and Human Services</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Email:* * *</font></div>

<div align="left">* * *</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 88.95pt">&#160;</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Alternate COR:</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chia-Wei Tsai</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Biomedical Advanced Research and Development Authority (BARDA) Office of the </font></font></font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Assistant Secretary for Preparedness and Response Department of Health and Human Services</font></font></font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * *</font></font></font></div>

<div align="left">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * *</font></font></font></font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
</tr></table>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mailing Address:</font></div>

<div align="left">&#160;</div>

<div align="left">330 Independence Avenue, SW G644 Washington, D.C. 20201 The COR is responsible for:</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><font size="2"><br>
The COR is responsible for:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Recommending to the Contracting Officer changes in requirements;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Assisting the Contracting Officer in interpreting the statement of work and any other technical&#160;&#160;performance requirements;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Performing technical evaluation as required;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Performing technical inspections and acceptances required by this contract; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Assisting in the resolution of technical problems encountered during performance. The USG&#160;&#160;may unilaterally change the COR designation.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE G.3. KEY PERSONNEL</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The key personnel specified in this contract are considered to be essential to work performance.&#160;&#160;At least 30 days prior to diverting any of the specified individuals to other programs or contracts (or as soon as possible, if an individual must be replaced, for example, as a result of leaving the employ of the Contractor), the Contractor shall notify the Contracting Officer and shall submit comprehensive justification for the diversion or replacement&#160;&#160;request (including proposed&#160;&#160;substitutions for key personnel) to permit evaluation by the USG of the impact on performance under this contract. The Contractor shall not divert or otherwise replace any key personnel without the written consent of the Contracting Officer. The USG may modify the contract to add or delete key personnel at the request of the Contractor or USG.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following individuals are considered to be essential to the work being performed hereunder:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="gainsboro">
<td align="left" valign="top" width="18%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name</font></div>
</td>
<td align="left" valign="top" width="47%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="18%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">William Sheridan</font></div>
</td>
<td align="left" valign="top" width="47%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SVP and Chief Medical Officer and Principal Investigator</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="18%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Ray Taylor</font></div>
</td>
<td align="left" valign="top" width="47%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">VP Project Management and Project Team Leader</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="18%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Elliott Berger</font></div>
</td>
<td align="left" valign="top" width="47%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SVP Regulatory Affairs</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE G.4. CONTRACT FINANCIAL REPORT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: right; WIDTH: 54pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.&#160;&#160; </font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financial reports on the attached Financial Report of Individual Project/Contract shall be submitted by the Contractor to the CO with a copy to the COR in accordance with the instructions for completing this form, which accompany the form, in an original and one electronic copy, not later than the 30th business day after the close of the reporting period. The line entries for subdivisions of work and elements of cost (expenditure categories), which shall be reported within the total contract, are discussed in paragraph e., below. Subsequent changes and/or additions in the line entries shall be made in writing.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unless otherwise stated in the instructions for completing this form, all columns A through J, shall be completed for each report submitted.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The first financial report shall cover the period consisting of the first full three calendar months following the date of the contract, in addition to any fractional part of the initial month. Thereafter, reports will be on a quarterly basis.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contracting Officer may require the Contractor to submit detailed support for costs contained in one or more interim financial reports. This clause does not supersede the record retention requirements in FAR Part 4.7.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">e.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The listing of expenditure categories to be reported is incorporated as a part of this contract and can be found under SECTION J Attachment 4 entitled, "Financial Report of Individual Project/Contract,".</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">f.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The USG may unilaterally revise the &#8220;Financial Report of Individual Project/Contract&#8221; to&#160;&#160;reflect the allotment of additional funds.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE G.5. INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORTING</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Include Program Support Center (PSC) in Receipt of Invoices:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 39.4pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Documents shall be delivered electronically to the Contracting Officer (CO), the Contracting Specialist (CS), the Contracting Officer&#8217;s Representative (COR) and PSC. Unless otherwise specified by the Contracting Officer all deliverables and reports furnished to the Government under the resultant contract (including invoices) shall be addressed as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 53.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thomas P. Hastings Contracting Officer HHS/ASPR/AMCG</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 4.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">330 Independence Ave., S.W., Room G640</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 40.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Washington, DC 20201 Email:<font id="TAB1" style="MARGIN-LEFT: 12pt"></font>* * *</font></div>
</td>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 80.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kimberly Sciarretta Contracting Officer Representative HHS/ASPR/BARDA</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 5.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">330 Independence Ave., S.W., Room G640 Washington, DC 20201 Email:<font id="TAB1" style="MARGIN-LEFT: 12pt"></font>* * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-RIGHT: #000000 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 16.15pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor invoices/financial reports shall conform to the form, format, and content requirements of the instructions for Invoice/Financing requests and Contract Financial&#160;&#160;Reporting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Monthly invoices must include the cumulative total expenses to date, adjusted (as applicable) to show any amounts suspended by the USG.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor agrees to immediately notify the CO in writing if there is an anticipated overrun (any amount) or unexpended balance (greater than 10 percent) of&#160;&#160;the estimated costs for the base period or any option period(s) (See estimated costs under Articles B.2) and the reasons for the variance. These requirements are in addition&#160;&#160;to the specified requirements of FAR Clause 52.232-20, Limitation of Cost</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 53pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">that is incorporated by reference under Article I.1 which states; </font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Limitation of Cost (Apr 1984)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(a) </font></div>
</td>
<td width="1790">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The parties estimate that performance of this contract, exclusive of any fee, will not cost the Government more than (1) the estimated cost specified in the Schedule or, (2) if this is a cost-sharing contract, the Government&#8217;s share of the estimated cost specified in the Schedule. The Contractor agrees to use its best efforts to perform the work specified in the Schedule and all obligations under this contract within the estimated cost, which, if this is a cost-sharing contract, includes both the Government&#8217;s and the Contractor&#8217;s share of the cost.</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font><font size="2">&#160;</font></div>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(b)</font></div>
</td>
<td width="1790">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Contractor shall notify the Contracting Officer in writing whenever it has reason to&#160;&#160;believe that&#8212;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) </font></div>
</td>
<td width="1790">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The costs the Contractor expects to incur under this contract in the next 60 days, when added to all costs previously incurred, will exceed 75 percent of the estimated cost specified in the Schedule; or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) </font></div>
</td>
<td width="1790">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The total cost for the performance of this contract, exclusive of any fee, will be either greater or substantially less than had been previously estimated.</font></div>
</td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(c) </font></div>
</td>
<td width="1790">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As part of the notification, the Contractor shall provide the Contracting Officer a revised estimate of the total cost of performing this contract.</font></div>
</td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(d) </font></div>
</td>
<td width="1790">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Except as required by other provisions of this contract, specifically citing and stated to be an exception to this clause&#8212;</font></div>
</td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) </font></div>
</td>
<td width="1790">The Government is not obligated to reimburse the Contractor for costs incurred in excess of (i) the estimated cost specified in the Schedule or, (ii) if this is a cost-sharing contract, the estimated cost to the Government specified in the Schedule; and</td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td width="1790">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Contractor is not obligated to continue performance under this contract (including actions under the Termination clause of this contract) or otherwise incur costs in excess of the estimated cost specified in the Schedule, until the Contracting Officer (i) notifies the Contractor in writing that the estimated cost has been increased and (ii) provides a revised estimated total cost of performing this contract. If this is a cost-sharing contract, the increase shall be allocated in accordance with the formula specified in the Schedule.</font></div>
</td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(e)</font></div>
</td>
<td width="1790">No notice, communication, or representation in any form other than that specified in paragraph (d)(2) of this clause, or from any person other than the Contracting Officer, shall affect this contract&#8217;s estimated cost to the Government. In the absence of the specified notice, the Government is not obligated to reimburse the Contractor for any costs in excess of the estimated cost or, if this is a cost- sharing contract, for any costs in excess of the estimated cost to the Government specified in the Schedule, whether those excess costs were incurred during the course of the contract or as a result of termination.</td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(f)</font></div>
</td>
<td width="1790">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If the estimated cost specified in the Schedule is increased, any costs the Contractor incurs before the increase that are in excess of the previously estimated cost shall be allowable to the same extent as if incurred afterward, unless the Contracting Officer issues a termination or other notice directing that the increase is solely to cover termination or other specified expenses.</font></div>
</td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div>
<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(g) </font></div>
</td>
<td width="1790">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change orders shall not be considered an authorization to exceed the estimated cost to the Government specified in the Schedule, unless they contain a statement increasing the estimated cost.</font></div>
</td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div>
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 71px">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 24px">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(h) </font></div>
</td>
<td width="1790">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">If this contract is terminated or the estimated cost is not increased, the Government and the Contractor shall negotiate an equitable distribution of all property produced or purchased under the contract, based upon the share of costs incurred by each.</font></div>
</td>
</tr></table>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt">
<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2">&#160;</font></div>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall submit an electronic copy of the payment request to the approving official instead of a paper copy. The payment request shall be transmitted as an attachment via e-mail to the address listed above in one of the following formats: MSWord, MS Excel, or Adobe Portable Document Format (PDF). Only one payment request shall be submitted per e-mail and the subject line of the e-mail shall include the Contractor's name, contract number, and unique invoice number.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">e.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An electronic copy of the payment request shall be uploaded into the designated eRoom (as defined in SECTION F.3 ELECTRONIC SUBMISSION) and an e-mail notification of the upload will be provided to the CO and COR.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">f.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All invoice submissions shall be in accordance with FAR Clause 52.232-25, Prompt Payment (Oct 2008).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">g.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Invoices <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Cost and Personnel Reporting, and Variances from the Negotiated&#160;&#160;Budget</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor agrees to provide a detailed breakdown on invoices of the following cost&#160;&#160;categories:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Direct Labor <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> List individuals by name, title/position, hourly/annual rate, level&#160;&#160;of effort (actual hours or % of effort), and amount claimed.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fringe Benefits <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Cite rate and amount</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Overhead <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Cite rate and amount</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Materials &amp; Supplies <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Include detailed breakdown when total amount is over $1,000.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 108pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">e.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Travel <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Identify travelers, dates, destination, purpose of trip, and total&#160;&#160;breaking out amounts for transportation (plane, car etc), lodging, M&amp;IE. Cite&#160;&#160;COA, if appropriate. List separately, domestic travel, general scientific meeting travel, and foreign travel.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">f.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consultant Fees <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Identify individuals, amounts and activities. Cite appropriate COA</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">g.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subcontracts <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Attach subcontractor invoice(s). Cite appropriate COA</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">h.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Equipment <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Cite authorization and amount. Cite appropriate COA</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">i.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other Direct Costs <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Include detailed breakdown when total amount is over $1,000.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 108pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">j.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">G&amp;A <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> Cite rate and amount.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">k.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Total Cost</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">l.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fee</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">m.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Total Cost Plus Fixed Fee</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 16.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Monthly invoices must include the cumulative total expenses to date, adjusted (as applicable) to show any amounts suspended by the USG. Nothing in this section discharges the contractor&#8217;s responsibility to comply with any applicable FAR Parts 30 or 31 clauses&#8217; relating to cost reimbursement subcontracts. In order to verify allowability, further breakdown of costs may be requested at the USG&#8217;s discretion. The Contractor shall subcontract with Firm Fixed Price Contracts to the maximum extent practicable.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 16.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additional instructions and an invoice template are provided in Attachment 3, Invoice/Financing Request Instructions and Contract Financial Reporting Instructions for&#160;&#160;Cost-Reimbursement Type Contracts. All invoices must be signed by a representative of&#160;&#160;the contractor authorized to certify listed charges are accurate and comply with government regulations. Invoices should be submitted electronically (in accordance with ARTICLE F.4., (ELECTRONIC SUBMISSION) and in hard copy with original signature.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE G.6. INDIRECT COST RATES</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 34px">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td width="1851">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following contractor established provisional billing rates are incorporated into the contract, and will be utilized for billing purposes during both the base and contract option periods pending the establishment of final indirect cost rates for each fiscal year or until revised by the contracting officer in accordance with the provisions of FAR 42.705-1. See FAR Clause 52.216-7.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="4" valign="top" width="68%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BioCryst Pharmaceuticals</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-TOP: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="28%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Rate Type</font></div>
</td>
<td colspan="3" valign="top" width="1%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Rate</font></td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Allocation Base</font></font></td>
</tr><tr>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fringe Benefits</font></div>
</td>
<td colspan="3" valign="top" width="1%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * %</font></td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; * * *</font></td>
</tr><tr>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Overhead</font></div>
</td>
<td colspan="3" valign="top" width="1%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *&#160;%</font></td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; * * *</font></td>
</tr><tr>
<td align="left" valign="top" width="28%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">G&amp;A</font></div>
</td>
<td colspan="3" valign="top" width="1%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * %</font></td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; * * *</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Use of the above provisional rates does not change any cost ceilings, contract obligations, or specific allowance or disallowance provided for in the contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 32.15pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor must notify the contracting officer promptly for an adjustment of the provisional rates if it becomes evident that the rates would cause substantial overpayment or underpayment of indirect expenses to BioCryst Pharmaceuticals.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The final billing rates for each fiscal year will be based on the incurred cost submission subject to Government audit determination. Indirect costs rate proposals must be submitted to the cognizant agency&#8217;s Contracting Officer within 6 months subsequent to each of the contractor&#8217;s fiscal year ends. (See also FAR Clause 52.216-7(d) (2) incorporated herein). Copies of the indirect cost submission for each fiscal year must also be submitted to the AMCG contracting officer, and the AMCG auditor identified as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Director, Acquisition Program Support</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Office of Acquisition Management, Contracts and Grants (AMCG)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Office of the Assistant Secretary for Preparedness and Response (ASPR) US Department of Health and Human Services (DHHS)</font></font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">300 Independence Avenue, SW, Room G644 Washington, DC 20201</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE G.7. REIMBURSEMENT OF COST</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The USG shall reimburse the Contractor those costs determined by the Contracting Officer to be allowable (hereinafter referred to as allowable cost) in accordance with FAR 52.216-7, Allowable Cost and Payment and FAR Subpart 31.2. Examples of allowable costs include, but&#160;&#160;are not limited to, the following:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All direct materials and supplies that are used in the performing of the work provided for under the contract, including those purchased for subcontracts and purchase orders.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All direct labor, including supervisory, that is properly chargeable directly to the contract, plus fringe benefits.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All other items of cost budgeted for and accepted in the negotiation of this basic contract or modifications thereto.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Travel costs including per diem or actual subsistence for personnel while in an actual travel status in direct performance of the work and services required under this contract subject to the restrictions under Article B.4. b. and the following:</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 27</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">i.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Air travel shall be by the most direct route using &#8220;air coach&#8221; or &#8220;air tourist&#8221; (less than first class) unless it is clearly unreasonable or impractical (e.g.,&#160;&#160;not available for reasons other than avoidable delay in making reservations, would require circuitous routing or entail additional expense offsetting the savings on fare, or would not make necessary connections) and must comply with the Fly America Act (49 U.S.C. 40118).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ii.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Rail travel shall be by the most direct route, first class with lower berth or nearest equivalent.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iii.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Costs incurred for lodging, meals, and incidental expenses shall be considered reasonable and allowable to the extent that they do not exceed on a daily basis the per diem rates set forth in the Federal Travel Regulation (FTR).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iv.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Travel via privately owned automobile shall be reimbursed at not more than the current General Services Administration (GSA) FTR established&#160;&#160;mileage rate.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE G.8. POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contractor Performance Evaluations</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interim and final evaluations of Contractor performance will be prepared on this contract in accordance with FAR Subpart 42.1502. The final performance evaluation will be prepared at the time of completion of work. In addition to the final evaluation, an interim evaluation shall be submitted at least once during the contract period of performance. The interim evaluation is expected to be submitted on December 23, 2015.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interim and final evaluations will be provided to the Contractor as soon as practicable after completion of the evaluation. The Contractor will be permitted thirty days to review the document and to submit additional information or a rebutting statement. If agreement cannot be reached between the parties, the matter will be referred to an individual one level above the Contracting Officer whose decision will be final.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Copies of the evaluations, Contractor responses, and review comments, if any, will be retained as part of the contract file, and may be used to support future award decisions.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Electronic Access to Contractor Performance Evaluations</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The USG website for Contractor Performance Assessment Reporting System (CPARS) </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">is <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.cpars.gov.</font><font style="DISPLAY: inline; TEXT-DECORATION: underline"> </font>Through this website Contractors may access evaluations through a secure website for review and comment by completing the online registration form. </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The registration process requires the Contractor to identify an individual that will serve as a primary contact and who will be authorized access to the evaluation for review and comment. In addition, the Contractor will be required to identify an alternate contact that will be responsible for notifying the cognizant contracting official in the event the primary contact is unavailable to process the evaluation within the required 30-day time frame.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE G.9. CONTRACT COMMUNICATIONS/CORRESPONDENCE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall identify all correspondence, reports, and other data pertinent to this contract by imprinting the contract number HHSO100201500007C from Page 1 of the contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 28</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE G.10. OVERTIME COMPENSATION</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No overtime (premium) compensation is authorized under this contract. Billing of actual hours should be limited to total working hours in a month.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><a name="bookmark5"><!--EFPlaceholder--></a>SECTION H <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> SPECIAL CONTRACT REQUIREMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 32.15pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor, depending upon the nature of the work, is responsible for following the provisions below in conducting its own work under this Contract. The Contractor also is responsible for incorporating these provisions into any subcontract awarded, if applicable to the specific nature of the work in the subcontract. Accordingly, those provisions shall be flowed- down as applicable.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.1 CLINICAL AND NON-CLINICAL TERMS OF AWARD</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BARDA has a responsibility to obtain documentation concerning mechanisms and procedures that are in place to protect the safety of participants and animals in BARDA funded clinical trials and non-clinical studies. Therefore, the Contractor shall develop a protocol for each clinical trial <font style="FONT-STYLE: italic; DISPLAY: inline">and</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>non-clinical study funded under this contract and submit all such protocols and protocol amendments to the Contracting Officer&#8217;s Representative (COR) for evaluation and comment. </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Approval by the COR is required before work under a protocol may begin. The COR comments will be forwarded to the Contractor within ten (10) business days. The Contractor must address, in writing, all concerns (<font style="FONT-STYLE: italic; DISPLAY: inline">e.g.</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>study design, safety, regulatory, ethical, and conflict of interest) noted&#160;&#160;by the COR.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the draft protocols are to be submitted to the FDA, BARDA review shall occur before submission, pursuant to the terms set forth by ARTICLE F.2 of this contract. The Contractor shall consider revising their protocols to address BARDA&#8217;s concerns and recommendations prior to FDA submission. The Contractor must provide BARDA with a copy of FDA submissions, within the time frame set forth by ARTICLE F.2 of this contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Execution</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">of</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">clinical</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">and</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">non-clinical</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">studies</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">requires</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">written</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">authorization</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">from</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">the</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">government.</font> The USG will provide written authorization to the Contractor upon either 1) receiving documentation in which all COR comments have been satisfactorily addressed; or 2) receiving documentation that the FDA has reviewed and commented on the protocol.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The government shall have rights to all protocols, data resulting from execution of these protocols, and final reports funded by BARDA under this contract, as set forth in PART II of this contract and defined in the FAR. The government reserves the right to request that the Contractor provide any contract deliverable in a non-proprietary form to ensure the government has the ability to review and distribute the deliverables as the government deems necessary.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Important information regarding performing human subject research is available at&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www3.niaid.nih.gov/healthscience/clinicalstudies/</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any updates to technical reports are to be addressed in the Monthly and Annual Progress Reports. The Contractor shall advise the Contracting Officer&#8217;s Representative or designee in writing and via electronic communication in a timely manner of any issues potentially affecting contract performance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 29</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Non-Clinical Terms of Award</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These Non-Clinical Terms of Award detail an agreement between the Biomedical Advanced Research and Development Authority (BARDA) and the Contractor; they apply to all grants and contracts that involve non-clinical research.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Safety and Monitoring Issues</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">i.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PHS Policy on Humane Care and use of Laboratory Animals</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Before award and then with the annual progress report, the Contractor must submit to BARDA a copy of the current Institutional Animal Care and Use Committees (IACUC) documentation of continuing review and approval and the Office of Laboratory Animal Welfare (OLAW) federal wide assurance number for the institution or site.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If other institutions are involved in the research (e.g., a multicenter trial or study), each institution&#8217;s IACUC must review and approve the protocol. They must also provide BARDA initial and annual documentation of continuing review and approval and federal wide assurance number.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor must ensure that the application, as well as all protocols, are reviewed by the performing institution&#8217;s IACUC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 24.9pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To help ensure the safety of animals used in BARDA-funded studies, the Contractor must provide BARDA copies of documents related to all major changes in the status of ongoing protocols, including the following:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All amendments or changes to the protocol, identified by protocol version number, date, or both and date it is valid.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All material changes in IACUC policies and procedures, identified by version number, date, and all required signatories (if applicable).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Termination or temporary suspension of the study(ies) for regulatory issues.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Termination or temporary suspension of the protocol.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any change that is made in the specific IACUC approval for the indicated study(ies).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any other problems or issues that could affect the scientific integrity of the study(ies), i.e., fraud, misrepresentation, misappropriation of funds, etc.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor must notify BARDA of any of the above changes within five (5) working days from the time the Contractor becomes aware of such changes by email or fax, followed by a letter signed by the institutional business official, detailing notification of the change of status to the local IACUC and a copy of any responses from the IACUC.</font></div>

<div align="left">&#160;</div>

<div align="left">If a non-clinical protocol has been reviewed by an institutional biosafety committee (IBC) or the NIH Recombinant DNA Advisory Committee (RAC), the Contractor must provide information about the initial and</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 30</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 116pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ongoing review and approval, if any. See the NIH Guidelines for Research Involving Recombinant DNA Molecules.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ii. Non-Clinical Data and Safety Monitoring Requirements</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 26.65pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BARDA strongly recommends continued safety monitoring for all non- clinical studies of investigational drugs, devices, or biologics. FDA expects non-clinical studies to include safety in addition to efficacy. The&#160;&#160;Contractor should consider evaluation of clinical relevant safety markers in the pivotal&#160;&#160;and non-pivotal, non-clinical studies. In preparation for clinical trials of licensed or not yet licensed products, it is imperative that BARDA- sponsored studies of any type measure the risk and safety parameters that are elicited and provide a safety profile from the studies for future human risk assessment.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 29.1pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A risk is minimal where the probability and magnitude of harm or discomfort anticipated in the proposed research are not greater than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. For example, the risk of drawing a small amount of blood from a healthy subject for research purposes is no greater than the risk of doing so as part of a routine physical examination (45 CFR 46.102(i)).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 24.85pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BARDA will work with the Contractor on decisions regarding the type and extent of safety data accrual to be employed before the start of efficacy or safety studies.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall inform BARDA of any upcoming site visits and/or audits of CRO facilities funded under this effort. BARDA reserves the right to accompany the Contractor on site visits and/or audits of CRO&#8217;s as BARDA deems necessary.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BARDA Review Process before Non-Clinical study Execution Begins</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BARDA is under the same policy-driven assurances as NIH in that it has a responsibility to ensure that mechanisms and procedures are in place to protect the safety and welfare of animals used in BARDA-funded non-clinical trials.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 36.75pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 79.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Therefore, before study execution, the Contractor must provide the following (as applicable) for review and comment by BARDA:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">IACUC approved (signed) non-clinical research protocol identified by version&#160;&#160;number, date, or both, including details of study design, euthanasia criteria, proposed interventions, and exclusion criteria.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For non-pivotal mouse studies, the Contractor will provide an annual animal care and use protocol.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Documentation of IACUC approval, including OLAW federal wide number, IACUC registration number, and IACUC name.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor should reduce the number of animals required for a study using power of statistics.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Plans for the management of side effects, rules for interventions and euthanasia criteria.</font></div>
</td>
</tr></table>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 31</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Procedures for assessing and collecting safety data were appropriate.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If a study is contracted through Contract Research Organizations (CROs), work orders and service agreements the Contractor shall assure an integrated safety documentation plan is in place for the study site, pharmacy service records on the dosing material to be used and excipients, and laboratory services (including histopathology).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Documentation that the Contractor and all required staff responsible for the conduct of the research have received training in the protection and handling&#160;&#160;of animals, or that the CRO has the required documentation.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Purchasing of animals and/or other supplies for non-clinical studies funded in part or in whole by BARDA requires written approval by the Contracting Officer in accordance with the contract. The Contractor must have the ability to return/re-sell animals, at purchase price, to distributor or a third part, in the event that the Contracting Officer Authorization is not granted.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Provide justification for whether studies require good laboratory practice (GLP) conditions.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 162pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Provide justification for whether studies will be classified as non- pivotal or&#160;&#160;pivotal studies.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Documentation of each of the above items shall be submitted to BARDA for evaluation and comment in conjunction with the protocol. Execution of non- clinical studies requires written authorization from the Contracting Officer in accordance with this section of the contract.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 99pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">c.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">References</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 62.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Public Health Service Policy on Humane Care and Use of Laboratory Animals:&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">http://grants.nih.gov/grants/olaw/InvestigatorsNeed2Know.pdf</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 80pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">USDA Animal Welfare Act:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 24.9pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">http://awic.nal.usda.gov/nal_display/index.php?info_center=3&amp;tax_level=3&amp;tax_su</font>&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">bject=182&amp;topic_id=1118&amp;level3_id=6735&amp;level4_id=0&amp;level5_id=0&amp;placement_d</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">e</font>&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">fault=0</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 32</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Clinical Terms of Award</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 41.2pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These Clinical Terms of Award detail an agreement between the government and the Contractor; they apply to all grants and contracts that involve clinical research.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 99pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">i.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Safety and Monitoring Issues</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 108pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Institutional Review Board or Independent Ethics Committee Approval</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Before award and then with the annual progress report, the Contractor must submit to BARDA a copy of the current IRB-or IEC-approved informed consent document, documentation of continuing review and approval and the OHRP federal wide assurance number for the institution or site.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If other institutions are involved in the research (e.g., a multicenter clinical trial or study), each institution&#8217;s IRB or IEC must review and approve the protocol. They must also provide BARDA initial and annual documentation of continuing review and approval, including the current approved informed consent document and federal wide number.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor must ensure that the application as well as all protocols are reviewed by their IRB or IEC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To help ensure the safety of participants enrolled in BARDA-funded studies, the Contractor must provide BARDA copies of documents related to all major changes in the status of ongoing protocols, including the following:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All amendments or changes to the protocol, identified by protocol version number, date, or both and dates it is valid.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All changes in informed consent documents, identified by version number, dates, or both and dates it is valid.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Termination or temporary suspension of patient accrual.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Termination or temporary suspension of the protocol.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any change in IRB approval.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any other problems or issues that could affect the participants in the studies.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 29.05pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor must notify BARDA through the COR and CO of any of the above changes within five (5) working days by email or fax, followed by a letter signed by the institutional business official, detailing notification of the change of status to the local IRB and a copy of any responses from the IRB or IEC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If a clinical protocol has been reviewed by an institutional biosafety committee (IBC) or the NIH Recombinant DNA Advisory Committee (RAC), the Contractor must provide information about the initial and ongoing review and approval, if any. See the NIH Guidelines for Research Involving Recombinant DNA Molecules.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 33</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Data and Safety Monitoring Requirements</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BARDA strongly recommends independent safety monitoring for clinical trials of investigational drugs, devices, or biologics; clinical trial of licensed products; and clinical research of any type involving more than minimal risk to volunteers. </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Independent monitoring can take a variety of forms. Phase III clinical trials must be reviewed by an independent data and safety monitoring board (DSMB); other trials may require DSMB oversight as well. The Contractor shall inform BARDA of any upcoming site visits and/or audits of CRO facilities funded under this effort.</font></font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BARDA reserves the right to accompany the Contractor on site visits and/or audits of CROs as BARDA deems necessary.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A risk is minimal where the probability and magnitude of harm or discomfort anticipated in the proposed research and not greater than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. For examples, the risk of drawing a small amount of blood from a healthy individual for research purposes is no greater than the risk of doing so as part of a routine physical examination (45 CFR 46.102I).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Final decisions regarding the type of monitoring to be used must be made jointly by BARDA and the Contractor before enrollment starts. Discussions with the responsible BARDA Project Officer regarding appropriate safety monitoring and approval of the final monitoring plan by BARDA must occur before patient enrollment begins and may include discussions about the appointment of one of the following.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Independent</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Safety</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Monitor</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>&#8211; a physician or other appropriate expert who is independent of the study and available in real time to review and recommend appropriate action regarding adverse events and other safety issues.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Independent</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Monitoring</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Committee</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">(IMC)</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">or</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Safety</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Monitoring</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Committee</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">(SMC)</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>&#8211; a small group of independent investigators and biostatisticians who review data from a particular study.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Data</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">and</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Safety</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Monitoring</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Board</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>&#8211; an independent committee charged with reviewing safety and trial progress and providing advice with respect to study continuation, modification, and termination. The Contractor may be required to use an established BARDA DSMB or to organize an independent DSMB. All phase III clinical trials must be reviewed by a DSMB; other trials may require DSMB oversight as&#160;&#160;well. Please refer to: NIAID Principles for Use of a Data and Safety Monitoring Board (DSMB) For Oversight of Clinical Trials Policy</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">When a monitor or monitoring board is organized, a description of it, its charter or&#160;&#160;operating procedures (including a proposed meeting schedule and plan for review of adverse events), and roster and <font style="FONT-STYLE: italic; DISPLAY: inline">curriculum</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">vitae</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>from all members must be submitted to and approved by BARDA before enrollment starts. The Contractor will also ensure that the monitors and board members report any conflicts of interest and the Contractor will maintain a record of this. The Contractor will share conflict of interest reports with BARDA.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additionally, the Contractor must submit written summaries of all reviews conducted by the monitoring group to the BARDA within thirty (30) days of reviews or meetings.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 34</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ii.</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">BARDA</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Protocol</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Review</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Process</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Before</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Patient</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Enrollment</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Begins</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>BARDA has a responsibility to ensure that mechanisms and procedures are in place to protect the safety of participants in BARDA-supported clinical trials. Therefore, before patient accrual or participant enrollment, the Contractor must ensure the following (as applicable) are in place at each participating institution,&#160;&#160;prior to patient accrual or enrollment:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">IRB- or IEC-approved clinical research protocol identified by version number, date, or both, including details of study design, proposed interventions, patient eligibility, and exclusion criteria.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Documentation of IRB or IEC approval, including OHRP federal wide number, IRB or IEC registration number, and IRB and IEC name.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">IRB- or IEC- approved informed consent document, identified by version number, date, or both and dates it is valid.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Plans for the management of side effects.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Procedures for assessing and reporting adverse events.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Plans for data and safety monitoring (see above) and monitoring of the clinical study site, pharmacy, and laboratory.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 126pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Documentation that the Contractor and all study staff responsible for the design or conduct of the research have received training in the protection of human subjects.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 26.65pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Documentation to demonstrate that each of the above items are in place shall be submitted to the BARDA) for evaluation and comment in conjunction with the protocol. Execution of clinical studies requires written authorization from BARDA in accordance with this section of this contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">iii Investigational New drug or Investigational Device Exemption Requirements</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 27.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food&#160;&#160;and Drug Administration (FDA) investigational new drug (IND) or&#160;&#160;&#160;&#160;investigational device exemption (IDE).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 27.85pt" align="left"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 88.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exceptions must be granted in writing by FDA. If the proposed clinical trial will be performed under an IND or IDE, the Contractor must provide BARDA with the name and institution of the IND or IDE sponsor, the date the IND or IDE was&#160;&#160;filed with FDA, the FDA IND or IDE number, any written comments from FDA, and the written responses to those comments.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unless FDA notifies Contractor otherwise, The Contractor must wait thirty (30) calendar days from FDA receipt of an initial IND or IDE application before initiating a clinical trial.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 24.9pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor must notify BARDA if the FDA places the study on clinical hold and provide BARDA any written comments from FDA, written responses to the comments, and documentation in writing that the hold has been lifted.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 29.1pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor must not use grant or contract funds during a clinical hold to fund clinical studies that are on hold. The Contractor must not enter into any new financial obligations related to clinical activities for the clinical trial on clinical hold.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 35</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">v.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Required Time-Sensitive Notification</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under an IND or IDE, the sponsor must provide FDA safety reports of serious adverse events. Under these Clinical Terms of Award, the Contractor must submit copies to the responsible Contracting Officer&#8217;s Representative (COR) as follows:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ii.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expedited safety report of unexpected or life-threatening experience or death:</font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A copy of any report of unexpected or life-threatening experience or death associated with the use of an IND drug, which must be reported to FDA by telephone or fax as soon as possible but no later than seven (7) days after the IND sponsor&#8217;s receipt of the information, must be submitted to the COR within</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">24 hours of FDA notification.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iii.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expedited safety reports of serious and unexpected adverse experiences:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A copy of any report of unexpected and serious adverse experience associated with use of an IND drug or any finding from tests in laboratory animals that suggests a significant risk for human subjects, which must be reported in writing to FDA as soon as possible but no later than 15 day after the IND sponsor&#8217;s receipt of the information, must be submitted to the COR within 24 hours of FDA notification.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iv.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">IDE reports of unanticipated adverse device effect:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 135pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A copy of any reports of unanticipated adverse device effect submitted to FDA must be submitted to the COR within 24 hours of FDA notification.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">v.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expedited safety reports:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 135pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sent to the COR concurrently with the report to FDA.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">vi.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other adverse events documented during the course of the trial should be included in the annual IND or IDE report and reported to BARDA annually.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 89pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In case of problems or issues, the Contracting Officer&#8217;s Representative will contact the Contractor within ten (10) working days by email or fax, followed within thirty (30) calendar days by an official letter to the Contractor&#8217;s Project Manager, with a copy to the institutions&#8217; office of sponsored programs, listing issues and appropriate actions to be discussed.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 135pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">vii.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Safety reporting for research not performed under an IND or IDE.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 24.8pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Final decisions regarding ongoing safety reporting requirements for research not performed under an IND or IDE must be made jointly by the Contracting Officer&#8217;s Representative and the Contractor.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.2. CARE OF LIVE VERTEBRATE ANIMALS, HHSAR 352.270-5 (October 2009)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Before undertaking performance of any contract involving animal-related activities where the species is regulated by USDA, the Contractor shall register with the Secretary of Agriculture of the United States in accordance with 7 U.S.C. 2136 and 9 CFR sections 2.25 through</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.28. The Contractor shall furnish evidence of the registration to the Contracting Officer.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 36</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall acquire vertebrate animals used in research from a dealer licensed by the Secretary of Agriculture under 7 U.S.C. 2133 and 9 CFR Sections 2.1-2.11, or from a source that is exempt from licensing under those sections.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor agrees that the care, use and intended use of any live vertebrate animals in the performance of this contract shall conform with the Public Health Service (PHS) Policy on Humane Care of Use of Laboratory Animals (PHS Policy), the current Animal Welfare Assurance (Assurance), the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC) and the pertinent laws and regulations of the United&#160;&#160;States Department of Agriculture (see 7 U.S.C. 2131 et seq. and 9 CFR Subchapter A, Parts 1-4). In case of conflict between standards, the more stringent standard shall govern.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If at any time during performance of this contract, the Contracting Officer determines, in consultation with the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health (NIH), that the Contractor is not in compliance with any of the requirements and standards stated in paragraphs (a) through (c) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under this contract until the Contractor corrects the noncompliance. Notice of the suspension may be communicated by telephone and confirmed in writing. If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer's written notice of suspension, the Contracting Officer may, in consultation with OLAW, NIH, terminate this contract in whole or in part, and the Contractor's name may be removed from the list of those contractors with approved&#160;&#160;Assurances.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 37.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Note: The Contractor may request registration of its facility and a current listing of licensed dealers from the Regional Office of the Animal and Plant Health Inspection Service (APHIS), USDA, for the region in which its research facility is located. The location of the appropriate APHIS Regional Office, as well as information concerning this program may be obtained by contacting the Animal Care Staff, USDA/APHIS, 4700 River Road, Riverdale, Maryland 20737 (E-mail: <font style="DISPLAY: inline; TEXT-DECORATION: underline">ace@aphis.usda.gov</font>;W eb site: (<font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.aphis.usda.gov/animal_welfare</font>).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.3. ANIMAL WELFARE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All research involving live, vertebrate animals shall be conducted in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals. This policy may be accessed at:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">http://grants1.nih.gov/grants/olaw/references/phspol.htm</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.4. INFORMATION ON COMPLIANCE WITH ANIMAL CARE REQUIREMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Registration with the U. S. Dept. of Agriculture (USDA) is required to use regulated species of animals for biomedical purposes. USDA is responsible for the enforcement of the Animal Welfare Act (7 U.S.C. 2131 et. seq.), <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.nal.usda.gov/awic/legislat/awa.htm</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 32.15pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Public Health Service (PHS) Policy is administered by the Office of Laboratory Animal Welfare (OLAW) <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://grants2.nih.gov/grants/olaw/olaw.htm</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> An essential requirement of the PHS Policy <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://grants2.nih.gov/grants/olaw/references/phspol.htm</font><font style="DISPLAY: inline; TEXT-DECORATION: underline"> </font>is that every institution using live vertebrate animals must obtain an approved assurance from OLAW before they can receive funding from any component of the U. S. Public Health Service.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The PHS Policy requires that Assured institutions base their programs of animal care and use on the Guide for the Care and Use of Laboratory</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Animals <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.nap.edu/readingroom/books/labrats/</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font>and&#160;that&#160;they&#160;comply&#160;with&#160;the</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 37</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">regulations (9 CFR, Subchapter A)<font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.nal.usda.gov/awic/legislat/usdaleg1.htm</font><font style="DISPLAY: inline; TEXT-DECORATION: underline"> </font>issued by the U.S. Department of Agriculture (USDA) under the Animal Welfare Act. The Guide may differ from USDA regulations in some respects. Compliance with the USDA regulations is an absolute requirement of this Policy.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.aaalac.org</font><font style="DISPLAY: inline; TEXT-DECORATION: underline"> </font>is a professional organization that inspects and evaluates programs of animal care for institutions at their request. Those that meet the high standards are given the accredited status. As of the 2002 revision of the PHS Policy, the only accrediting body recognized by PHS is the AAALAC. While AAALAC Accreditation is not required to conduct biomedical research, it is highly desirable. AAALAC uses the Guide as their primary evaluation tool. They also use the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching. It is published by the Federated of Animal Science</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Societies <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.fass.org</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.5. REQUIREMENTS FOR ADEQUATE ASSURANCE OF PROTECTION OF VERTEBRATE ANIMAL SUBJECTS</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The PHS Policy on Humane Care and Use of Laboratory Animals requires that applicant organizations proposing to use vertebrate animals file a written Animal Welfare Assurance with the Office for Laboratory Animal Welfare (OLAW), establishing appropriate policies and procedures to ensure the humane care and use of live vertebrate animals involved in research activities supported by the PHS. The PHS Policy stipulates that an applicant organization, whether domestic or foreign, bears responsibility for the humane care and use of animals in</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">PHS- supported research activities. Also, the PHS policy defines &#8220;animal&#8221; as &#8220;any live, vertebrate animal used, or intended for use, in research, research training, experimentation, biological testing or for related purposes.&#8221; This Policy implements and supplements the U.S. government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training, and requires that institutions use the Guide for the Care and Use of&#160;&#160;Laboratory Animals as a basis for developing and implementing an institutional animal care and use program. This Policy does not affect applicable State or local laws or regulations that </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">impose more stringent standards for the care and use of laboratory animals. All institutions are required to comply, as applicable, with the Animal Welfare Act as amended (7 USC 2131 et. seq.) and other Federal statutes and regulations relating to animals. These documents are available from the Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD 20892, (301) 496-7163. See <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://grants.nih.gov/grants/olaw/olaw.htm</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 34.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No PHS supported work for research involving vertebrate animals will be conducted by an organization, unless that organization is operating in accordance with an approved Animal Welfare Assurance and provides verification that the Institutional Animal Care and Use Committee (IACUC) has reviewed and approved the proposed activity in accordance with the PHS policy. Applications may be referred by the PHS back to the institution for further review in the case of apparent or potential violations of the PHS Policy. No award to an individual will be made unless that individual is affiliated with an assured organization that accepts responsibility for compliance with the PHS Policy. Foreign applicant organizations applying for PHS awards for activities involving vertebrate animals are required to comply with PHS Policy or provide evidence that acceptable standards for the humane care and use of animals will be met. Foreign applicant organizations are not required to submit IACUC approval, but should provide information that is satisfactory to the USG to provide assurances for the humane care of such animals.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.6. APPROVAL OF REQUIRED ASSURANCE BY OLAW</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under governing regulations, federal funds which are administered by the Department of Health and Human Services, Office of Biomedical Advanced Research and Development Authority (BARDA) shall not be expended by the Contractor for research involving live vertebrate animals,</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 38</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30.4pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">nor shall live vertebrate animals be involved in research activities by the Contractor under this award unless a satisfactory assurance of compliance with 7 U.S.C. 2316 and 9 CFR Sections 2.25-2.28 is submitted within 30 days of the date of this award and approved by the Office of Laboratory Animal Welfare (OLAW). Each performance site (if any) must also assure compliance with 7 U.S.C. 2316 and 9 CFR Sections 2.25-2.28 with the following restriction: Only activities which do not directly involve live vertebrate animals (i.e. are clearly severable and independent from those activities that do involve live vertebrate animals) may be conducted by the Contractor or individual performance sites pending OLAW approval of their respective assurance of compliance with 7 U.S.C. 2316 and 9 CFR Sections 2.25-2.28. Additional information regarding OLAW may be obtained via the Internet</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">at <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://grants2.nih.gov/grants/olaw/references/phspol.htm</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.7. REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25.8pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Anyone who becomes aware of the existence or apparent existence of fraud, waste and abuse in BARDA funded programs should report such matters to the HHS Inspector General's Office in writing or on the Inspector General's Hotline. The toll free number is 1-800-HHS-TIPS (1-800- 447-8477). All telephone calls will be handled confidentially. The e-mail address</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">is <font style="DISPLAY: inline; TEXT-DECORATION: underline">Htips@os.dhhs.gov</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font>and&#160;the&#160;mailing&#160;address&#160;is:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Office of Inspector General</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Department of Health and Human Services TIPS HOTLINE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">P.O. Box 23489 Washington, D.C. 20026</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.8. PROHIBITION ON CONTRACTOR INVOLVEMENT WITH TERRORIST ACTIVITIES</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor acknowledges that U.S. Executive Orders and Laws, including but not limited to</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">E.O. 13224 and P.L. 107-56, prohibit transactions with, and the provision of resources and support to, individuals and organizations associated with terrorism. It is the legal responsibility of the Contractor to ensure compliance with these Executive Orders and Laws. This clause must be included in all subcontracts issued under this contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.9. IDENTIFICATION AND DISPOSITION OF DATA</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor will be required to provide certain data generated under this contract to the Department of Health and Human Services (DHHS). DHHS reserves the right to review any other data determined by DHHS to be relevant to this contract. The contractor shall keep copies of all data required by the Food and Drug Administration (FDA) relevant to this contract for the time specified by the FDA.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.10. EXPORT CONTROL NOTIFICATION</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractors are responsible for ensuring compliance with all export control laws and regulations that may be applicable to the export of and foreign access to their proposed technologies.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 32.3pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractors may consult with the Department of State with any questions regarding the International Traffic in Arms Regulation (ITAR) (22 CRF Parts 120-130) and /or the Department of Commerce regarding the Export Administration Regulations (15 CRF Parts 730-774).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.11. CONFLICT OF INTEREST</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 28.1pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor represents and warrants that, to the best of the Contractor's knowledge and belief, there are no relevant facts or circumstances which could give rise to an organizational conflict of interest, as defined in FAR 2.101 and Subpart 9.5, or that the Contractor has disclosed all such relevant information. Prior to commencement of any work, the Contractor agrees to notify the Contracting Officer promptly that, to the best of its knowledge and belief, no actual or potential conflict of interest exists or to identify to the Contracting Officer any actual or potential</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 39</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 26.6pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">conflict of&#160;&#160;interest the firm may have. In emergency situations, however, work may begin but notification shall be made within five (5) working days. The Contractor agrees that if an actual or potential&#160;&#160;organizational conflict of interest is identified during performance, the Contractor shall promptly&#160;&#160;make a full disclosure in writing to the Contracting Officer. This disclosure shall include a&#160;&#160;description of actions which the Contractor has taken or proposes to take, after consultation with&#160;&#160;the Contracting Officer, to avoid, mitigate, or neutralize the actual or potential conflict of interest.&#160;&#160;The Contractor shall continue performance until notified by the Contracting Officer of any contrary&#160;&#160;action to be taken. Remedies include termination of this contract for convenience, in whole or in&#160;&#160;part, if the Contracting Officer deems such termination necessary to avoid an organizational&#160;&#160;conflict of interest. If the Contractor was aware of a potential organizational conflict of interest prior to award or discovered an actual or potential conflict after award and did not disclose it or&#160;&#160;misrepresented relevant information to the Contracting Officer, the USG may terminate the&#160;&#160;contract for default, debar the Contractor from USG contracting, or pursue such other remedies as&#160;&#160;may be permitted by law or this contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.12. INSTITUTIONAL RESPONSIBILITY REGARDING INVESTIGATOR FINANCIAL CONFLICTS OF INTEREST</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall comply with the requirements of 45 CFR Part 94, Responsible Prospective Contractors, which promotes objectivity in research by establishing standards to ensure that Investigators (defined as&#160;&#160;the project director or principal Investigator and any other person, regardless of title or position,&#160;&#160;who is responsible for the design, conduct, or reporting of research funded under BARDA&#160;&#160;contracts, or proposed for such funding, which may include, for example, collaborators or consultants) will not be biased by any Investigator financial conflicts of interest.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the failure of an Investigator to comply with an Institution's financial conflicts of interest policy or a&#160;&#160;financial conflict of interest management plan appears to have biased the design, conduct, or reporting of the BARDA-funded research, the Contractor must promptly notify the Contracting Officer of the corrective action taken or to be taken. The Contracting Officer will consider the situation and, as necessary, take appropriate action or refer the matter to the Contractor for further&#160;&#160;action, which may include directions to the Contractor on how to maintain appropriate objectivity in the BARDA-funded research project.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 28.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contracting Officer and/or HHS may inquire at any time before, during, or after award into any Investigator disclosure of financial interests, and the Contractor&#8217;s review of, and response to, such disclosure, regardless of whether the disclosure resulted in the Contractor&#8217;s determination of&#160;&#160;a financial conflict of interests. The Contracting Officer may require submission of the records&#160;&#160;&#160;&#160;&#160;or&#160;&#160;review them on site. On the basis of this review of records or other information that may be available, the Contracting Officer may decide that a particular financial conflict of interest will bias the objectivity of the BARDA-funded research to such an extent that further corrective action is needed or that the Institution has not managed the financial conflict of interest in accordance with&#160; <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4 5&#160; <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">C F R&#160; <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Part 94. The issuance of a Stop Work Order by the Contracting Officer may be necessary until the matter is resolved.</font></font></font></font></font></div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 32.15pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the Contracting Officer determines that BARDA-funded clinical research, whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment, has been designed, conducted, or reported by an Investigator with a financial conflict of interest that was not disclosed managed or&#160;&#160;reported the Contractor shall require the Investigator involved to disclose the financial&#160;&#160;conflict of interest in each public presentation of the results of the research and to request an&#160;&#160;addendum to previously published presentations.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.13. NEEDLE DISTRIBUTION</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall not use contract funds to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 40</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.14. RESTRICTION ON ABORTIONS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall not use contract funds for any abortion.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.15. CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 32.15pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall not use contract funds for (1) the creation of a human embryo or embryos&#160;&#160;&#160;for&#160;&#160;research purposes; or (2) research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death greater than that allowed for research on fetuses in utero under 45 CFR 46.204(b) and Section 498(b) of the Public Health Service Act (42 U.S.C. 289g(b)). The term "human embryo or embryos" includes any organism, not protected </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">as a human subject under 45 CFR 46 as of the date of the enactment of this Act, that is derived by fertilization, parthenogenesis, cloning, or any other means from one or more human gametes or human diploid cells.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additionally, in accordance with a March 4, 1997 Presidential Memorandum, Federal funds may not be used for cloning of human beings.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.16. DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall not use contract funds to disseminate information that is deliberately false or misleading.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.17. CONFIDENTIALITY OF INFORMATION</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Confidential information, as used in this article, means information or data of a personal nature about an individual or proprietary information or data submitted by or pertaining to an institution or organization.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the USG will furnish to the Contractor or that the Contractor is expected to generate which is confidential and providing further that the government is not entitled to unlimited rights to that information pursuant to FAR 52.227-14. Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract. Failure to agree will be settled pursuant to the "Disputes" clause.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">e.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Whenever the Contractor is uncertain with regard to the proper handling of material under&#160;&#160;the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor should obtain a written&#160;&#160;determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">f.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 41</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.18. ACCESS TO DOCUMENTATION/DATA</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The USG shall have physical and electronic access to all documentation and data generated under this contract, including: all data documenting Contractor performance; all data generated; all communications and correspondence with regulatory agencies and bodies to include all audit observations, inspection reports, milestone completion documents, and all Offeror commitments and responses. Contractor shall provide the USG with an electronic copy of all correspondence with the FDA within 5 business days of receipt. The USG shall acquire unlimited rights to all data funded under this contract in accordance with FAR Subpart 27.4 and FAR Clause 52.227-14.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.19. EPA ENERGY STAR REQUIREMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In compliance with Executive Order 12845 (requiring Agencies to purchase energy efficient computer equipment), all microcomputers, including personal computers, monitors, and printers that are purchased using USG funds in performance of a contract shall be equipped with or meet the energy efficient low-power standby feature as defined by the EPA Energy Star program unless the equipment always meets EPA Energy Star efficiency levels. The microcomputer, as configured with all components, must be Energy Star compliant.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This low-power feature must already be activated when the computer equipment is delivered to the agency and be of equivalent functionality of similar power managed models. If the equipment will be used on a local area network, the vendor must provide equipment that is fully compatible with the network environment. In addition, the equipment will run commercial off-the-shelf software both before and after recovery from its energy conservation mode.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.20. ACKNOWLEDGMENT OF FEDERAL FUNDING</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 28.45pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Section 507 of P.L. 104-208 mandates that Contractors funded with Federal dollars, in whole or in&#160;&#160;part, acknowledge Federal funding when issuing statements, press releases, requests for proposals, bid solicitations and other documents. This requirement is in addition to the continuing requirement to provide an acknowledgment of support and disclaimer on any publication&#160;&#160;reporting&#160;&#160;the results of a contract funded activity.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 28.45pt" align="left"><font size="2"><br>
&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">A.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Publication and Publicity</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No information related to data obtained under this contract shall be released or publicized without providing BARDA with at least thirty (30) days advanced notice and an opportunity to review the proposed release or publication.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to the requirements set forth in HHSAR Clause 352.227-70, Publications and Publicity incorporated by reference in SECTION I of this contract, Section 507 of <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">P.L. 104-208 mandates that Contractors funded with Federal dollars, in whole or in part, acknowledge Federal funding when issuing statements, press releases, requests for proposals, bid solicitations and other documents. Contractors are required to state:</font></font></div>
</td>
</tr></table>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160; </font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the percentage and dollar amounts of the total program or project costs financed with Federal money and;</font></font></div>
</div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the percentage and dollar amount of the total costs financed by nongovernmental sources</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For purposes of this contract "publication" is defined as an issue of printed material&#160;&#160;offered for distribution or any communication or oral presentation of information, including any manuscript or scientific meeting abstract. Any publication containing data&#160;&#160;generated under this contract must be submitted for BARDA review no less than thirty </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(30) calendar days for manuscripts and fifteen (15) calendar days for abstracts before</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 42</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">submission for public presentation or publication. Contract support shall be acknowledged in all such publications substantially as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">"This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201500007C.&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">B.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Press Releases</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 32.15pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Misrepresenting contract results or releasing information that is injurious to the integrity of BARDA may be construed as improper conduct. Press releases shall be considered to include the public release of information to any medium, excluding peer-reviewed scientific publications. The contractor shall ensure that the COR has received an advance copy of any press release related to the contract not less than six (6) business days prior to the issuance of the press release.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall acknowledge the support of the Department of Health and Human Service, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, whenever publicizing the work under this contract in any media by including an acknowledgment substantially as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">"This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">HHSO100201500003C.&#8221;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.21. IN-PROCESS REVIEW</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In Process Reviews (IPR) will be conducted at the discretion of the USG to discuss the progression of the milestones. The USG reserves the right to revise the milestones and budget pending the development of the project. Deliverables such as an overall project summary report and/or slides will be required when the IPRs are conducted. The Contractor&#8217;s success in completing the required tasks under each work segment must be demonstrated through the Deliverables and Milestones specified under SECTION F. Those deliverables will constitute the basis for the USG&#8217;s decision, at its sole discretion, to proceed with the work segment, or institute changes to the work segment, or terminate the work segment.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">IPRs may be scheduled at the discretion of the USG to discuss progression of the contract. The Contractor shall provide a presentation following a prescribed template which will be provided by the USG at least 30 business days prior to the IPR. Subsequently, the contractor will be requested to provide a revised/final presentation to the Contracting Officer at least 10 business days prior to the IPR.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.22. PROHIBITION ON THE USE OF APPROPRIATED FUNDS FOR LOBBYING ACTIVITIES AND HHSAR 352.203-70 ANTI-LOBBYING (March 2012))</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor is hereby notified of the restrictions on the use of Department of Health and Human Service's funding for lobbying of Federal, State and Local legislative bodies.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 29.1pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Section 1352 of Title 10, United Stated Code (Public Law 101-121, effective 12/23/89), among other things, prohibits a recipient (and their subcontractors) of a Federal contract, grant, loan, or cooperative agreement from using appropriated funds (other than profits from a federal contract) to pay any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 43</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Congress in connection with any of the following covered Federal actions; the awarding of any Federal contract; the making of any Federal grant; the making of any Federal loan; the entering </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">into of any cooperative agreement; or the modification of any Federal contract, grant, loan, or cooperative agreement. For additional information of prohibitions against lobbying activities, see FAR Subpart 3.8 and FAR Clause 52.203-12.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 29.1pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, as set forth in HHSAR 352.203-70 &#8220;Anti-Lobbying&#8221; (March 2012)), the current Department of Health and Human Services Appropriations Act provides that no part of any appropriation contained in this Act shall be used, other than for normal and recognized executive- legislative relationships, for publicity or propaganda purposes, for the preparation, distribution, or use of any kit, pamphlet, booklet, publication, radio, television, or video presentation designed to support, or defeat legislation pending before the Congress, or any State or Local legislature except in presentation to the Congress, or any State or Local legislative body itself.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The current Department of Health and Human Services Appropriations Act also provides that no part of any appropriation contained in this Act shall be used to pay the salary or expenses of any contract or grant recipient, or agent acting for such recipient, related to any activity designed to influence legislation or appropriations pending before the Congress, or any State or Local legislature.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.23. PRIVACY ACT APPLICABILITY</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notification is hereby given that the Contractor and its employees are subject to criminal penalties for violation of the Privacy Act to the same extent as employees of the USG. The Contractor shall assure that each of its employees knows the prescribed rules of conduct and that each is aware that he or she can be subjected to criminal penalty for violation of the Act.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 129.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A copy of 45 CFR Part 5b, Privacy Act Regulations, may be obtained at&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.gpoaccess.gov/cfr/index.html</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Project Officer is hereby designated as the official who is responsible for monitoring contractor compliance with the Privacy Act.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall follow the Privacy Act guidance as contained in the Privacy Act System of Records number 09-25-0200. This document may be obtained at the following link: <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://oma.od.nih.gov/ms/privacy/pa-files/0200.htm</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.24. LABORATORY LICENSE REQUIREMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall comply with all applicable requirements of Section 353 of the Public Health Service Act (Clinical Laboratory Improvement Act as amended) (42 U.S.C. 263a and 42 CFR Part 493). This requirement shall also be included in any subcontract for services under the contract.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.25. QUALITY ASSURANCE (QA) AUDIT REPORTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BARDA reserves the right to participate in QA audits. Upon completion of the audit/site visit the Contractor shall provide a report capturing the findings, results and next steps in proceeding with the subcontractor. If action is requested of the subcontractor, detailed concerns for addressing areas of non-conformance to FDA regulations for GLP, GMP, or GCP guidelines, as identified in the audit report, must be provided to BARDA. The Contractor shall provide responses from the subcontractors to address these concerns and plans for corrective action execution.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor shall notify CO and COR of upcoming, ongoing, or recent audits/site visits of subcontractors as part of weekly communications</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor shall notify the COR and CO within 5 business days of report completion.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 44</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.26. BARDA AUDITS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor shall accommodate periodic or ad hoc site visits by the USG. If the USG, the Contractor, or other parties identifies any issues during an audit, the Contractor shall capture the issues, identify potential solutions, and provide a report to the USG.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If issues are identified during the audit, Contractor shall submit a report to the CO and COR detailing the finding and corrective action(s) within 10 business days of the audit.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">COR and CO will review the report and provide a response to the Contractor with 10 business days.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Once corrective action is completed, the Contractor will provide a final report to the CO and COR.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.27. SECURITY REPORTING REQUIREMENT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Violations of established security protocols shall be reported to the Contracting Officer (CO) and Contracting Officer&#8217;s Representative (COR) upon discovery and within 24 hours of any compromise, intrusion, loss or interference of its security processes and procedures. The Contractor shall ensure that all software components that are not required for the operation and maintenance of the database/control system has been removed and/or disabled. The Contractor shall provide to the CO and the COR information appropriate to Information and Information Technology software and service updates and/or workarounds to mitigate all vulnerabilities associated with the data and shall maintain the required level of system security.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor will investigate violations to determine the cause, extent, loss or compromise of sensitive program information, and corrective actions taken to prevent future violations. The Contracting Officer in coordination with BARDA will determine the severity of the violation. Any contractual actions resulting from the violation will be determined by the Contracting Officer.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.28. RESTRICTION ON EMPLOYMENT OF UNAUTHORIZED ALIEN WORKERS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall not use contract funds to employ workers described in section 274A (h) (3) of the Immigration and National Act, which reads as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;(3) Definition of unauthorized alien &#8211; As used in this section, the term &#8216;unauthorized alien&#8217; with respect to the employment of an alien at a particular time, that the alien is not at that time either </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(A)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">an alien lawfully admitted for permanent residence, or (B) authorized to be so employed by this Act or by the Attorney General.&#8221;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.29. NOTIFICATION OF CRITICAL PROGRAMMATIC CONCERNS, RISKS, OR POTENTIAL RISKS</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 36.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If any action occurs that creates a cause for critical programmatic concern, risk, or potential risk to BARDA or the Contractor and Incident Report shall be delivered to BARDA.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Within 48 hours of activity or incident or within 24 hours for a security related activity or incident, Contractor must notify BARDA.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additional updates due to COR and CO within 48 hours of additional developments.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractor shall submit within 5 business days a Corrective Action Plan (if deemed necessary by either party) to address any potential issues.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If corrective action is deemed necessary, Contractor must address in writing, its consideration of concerns raised by BARDA within 5 business days.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 45</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.30. PUBLIC READINESS AND EMERGENCY PREPARDENESS ACT (&#8220;PREP ACT&#8221;)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective December 3, 2014 the Secretary of the Department of Health and Human Services has issued a declaration pursuant to section 319F-3 of the Public Health Service Act (42 U.S.C. </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">247d-&#160;&#160;6d) to provide liability protection for activities related to Ebola Virus Disease Vaccines consistent&#160;&#160;with the terms of the declaration. GlaxoSmithKline (GSK Code Name&#160;&#160;&#160;GSK3390107A) &#8220;Recombinant Replication Deficient Chimpanzee Adenovirus Type 3-Vectored Ebola Zaire&#160;&#160;Vaccine&#8221;, is named in the declaration as a covered countermeasure, and as such&#160;&#160;the Government shall provide liability protection for activities related to GSK3390107A, consistent with the terms of the declaration.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE H.31. PERSON IN PLANT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">With seven (7) business days advance notice to the Contractor in writing from the Contracting Officer, the USG may place a person-in-plant in the Contractor&#8217;s or&#160;&#160;subcontractor&#8217;s facility, who shall be subject to the Contractor&#8217;s or subcontractor&#8217;s&#160;&#160;policies and procedures regarding security and facility access at all times while in the facility.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An article substantially similar to this Person-in-Plant article shall be incorporated into any <a name="bookmark6"><!--EFPlaceholder--></a>subcontract for experimental or manufacturing work.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 46</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><a name="PARTII-CONTRACTCLAUSES"><!--EFPlaceholder--></a>PART II <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> CONTRACT CLAUSES</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="SECTIONI-CONTRACTCLAUSES"><!--EFPlaceholder--></a><a name="bookmark7"><!--EFPlaceholder--></a>SECTION I - CONTRACT CLAUSES</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE I.1. FAR 52.252-2, CLAUSES INCORPORATED BY REFERENCE (FEBRUARY 1998)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 76.4pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This contract incorporates the following clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 165.35pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Also, the full text of a clause may be accessed electronically at these addresses: <font style="DISPLAY: inline; TEXT-DECORATION: underline">https://www.acquisition.gov/FAR/</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font>&#160;HHSAR&#160;Clauses</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">at:&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.hhs.gov/policies/hhsar/subpart352.html</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FEDERAL ACQUISIITON REGULATION (48 CFR CHAPTER 1) CLAUSE:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">52.242-15,</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Stop</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Work</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Order</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(August 1989)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Clauses</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">for</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Cost-Reimbursement</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Research</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">and</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Development</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Contract</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(1)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 29.85pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FAR <font style="DISPLAY: inline">CL</font> <font style="DISPLAY: inline">AUSE</font></font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">DATE</font></font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">CLAUSE</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline">TITLE</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.202-1</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nov 2013</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Definitions</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.203-3</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 1984</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gratuities</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.203-5</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Covenant Against Contingent Fees</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.203-6</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sep 2006</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restrictions on Subcontractor Sales to the government</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.203-7</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anti-Kickback Procedures</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.203-8</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 38.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.203-10</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Price or Fee Adjustment for Illegal or Improper Activity</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.203-12</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 2010</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Limitation on Payments to Influence Certain Federal Transactions</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.203-13</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 2010</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor Code of Business Ethics and Conduct</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.203-17</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 37.15pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor Employee Whistleblower Rights and Requirements to Inform Employees of Whistleblower rights</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.204-4</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2011</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Printed or Copied Double-Sided on Recycled Paper</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.204-7</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 2013</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">System for Award Management</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.204-10</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 2013</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reporting Executive Compensation and First-Tier Subcontract Awards</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.204-13</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 2013</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">System for Award Management Maintenance</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 47</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.209-6</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aug 2013</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 13.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Protecting the government&#8217;s Interests When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.209-9</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 2013</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Updates of Publicly Available Information Regarding Responsibility Matters</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.210-1</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 2011</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Market Research</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.215-2</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 2010</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Audit and Records &#8211; Negotiation</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.215-8</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 1997</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Order of Precedence - Uniform Contract Format</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.215-10</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aug 2011</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Price Reduction for Defective Certified Cost or Pricing Data</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.215-12</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 2010</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subcontractor Certified Cost or Pricing Data</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.215-15</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 2010</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pension Adjustments and Asset Reversions</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.215-17</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 1997</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Facilities Capital Cost of Money</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.215-18</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 2005</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 22.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reversion or Adjustment of Plans for Post-Retirement Benefits (PRB) other than Pensions</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.215-19</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 1997</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Notification of Ownership Changes</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.215-21</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 2010</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 48.2pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Requirements for Certified Cost or Pricing Data and Data Other Than Certified Cost or Pricing Data &#8211; Modifications</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.215-23</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 2009</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Limitations on Pass-Through Charges</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.216-7</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jun 2013</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Allowable Cost and Payment</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.216-8</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jun 2011</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fixed Fee</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.217-8</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nov 1999</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option to Extend Services</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.219-8</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Utilization of Small Business Concerns</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.222-2</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2011</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payment for Overtime Premiums</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.222-3</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jun 2003</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convict Labor</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.222-21</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Feb 1999</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prohibition of Segregated Facilities</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.222-26</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mar 2007</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equal Opportunity</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.222-35</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equal Opportunity for Veterans</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.222-36</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equal Opportunities for Workers with Disabilities</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.222-37</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employment Reports on Veterans</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.222-40</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dec 2010</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Notification of Employee Rights Under the National Labor Relations Act</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.222-50</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Feb 2009</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Combating Trafficking in Persons</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.222-54</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aug 2013</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employment Eligibility Verification</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.223-6</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2001</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug-Free Workplace</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.223-18</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aug 2011</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Encouraging Contractor Policies to Ban Text Messaging While Driving</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 48</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.224-1</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 1984</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Privacy Act Notification</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.224-2</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 1984</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Privacy Act</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.225-13</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jun 2008</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restrictions on Certain Foreign Purchases</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.227-1</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dec 2007</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Authorization and Consent, Alternate I</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.227-2</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dec 2007</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Notice and Assistance Regarding Patent and Copyright Infringement</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.227-3</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 1984</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Patent Indemnity</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.227-11</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 19.55pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Patent Rights - Ownership by the Contractor (Note: In accordance with FAR 27.303(b)(2), paragraph (e) is modified to include the requirements in FAR 27.303(b)(2)(i) through (iv). The frequency of reporting in (i) is annual.)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.227-14</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Rights in Data &#8211; General</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.227-16</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jun 1987</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional Data Requirements</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.232-9</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 1984</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Limitation on Withholding of Payments</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.232-17</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.232-20</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 1984</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Limitation of Cost</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.232-23</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Assignment of Claims</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.232-25</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jun 2013</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prompt Payment Alternate I (Feb 2002)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.232-33</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 2013</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payment by Electronic Funds Transfer--System for Award Management</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.233-1</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 2002</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Disputes</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.233-3</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aug 1996</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Protest After Award, Alternate I (June 1985)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.233-4</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 2004</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Applicable Law for Breach of Contract Claim</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.242-1</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 1984</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Notice of Intent to Disallow Costs</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.242-3</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Penalties for Unallowable Costs</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.242-4</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 1997</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Final Indirect Costs</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.242-13</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jul 1995</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bankruptcy</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.243-2</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aug 1987</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes - Cost Reimbursement, Alternate V (Apr 1984)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.244-2</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 2010</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subcontracts, Alternate I (Jun 2007)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.244-5</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dec 1996</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Competition in Subcontracting</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.244-6</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oct 2014</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subcontracts for Commercial Items</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.245-1</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 2012</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Government Property</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.245-9</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 2012</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Use and Charges</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.246-9</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2001</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inspection of Research and Development (Short Form)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 49</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.246-23</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Feb 1997</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Limitation of Liability</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.246-25</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Feb 1997</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Limitation of Liability &#8211; Services</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.247-63</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jun 2003</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preference for U.S.-Flag Air Carriers</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.247-67</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Feb 2006</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Submission of Transportation Documents for Audit</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.249-6</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">May 2004</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Termination&#160;&#160;(Cost-Reimbursement)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52-249-14</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 1984</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Excusable Delays</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.251-1</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 2012</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Government Supply Sources</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52.253-1</font></div>
</td>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 1991</font></div>
</td>
<td align="left" valign="top" width="59%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Computer Generated Forms</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(2)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CFR CHAPTER 3) CLAUSES:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 16.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">HHSAR <font style="DISPLAY: inline">CLA</font> <font style="DISPLAY: inline">USE</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline">NO.</font></font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">DATE</font></font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">TITLE</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.201-70</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2006</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paperwork Reduction Act</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.202-1</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2006</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Definitions, with Alternate paragraph (h)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.203-70</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mar 2012</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anti-Lobbying</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.216-70</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2006</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional Cost Principles</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.222-70</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2010</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor Cooperation in Equal Employment Opportunity Investigations</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.223-70</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2006</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Safety and Health</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.224-70</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2006</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Privacy Act</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.227-70</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2006</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Publications and Publicity</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.228-7</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dec 1991</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-TOP: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Insurance - Liability to Third Persons</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.231-70</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aug 2012</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Salary Rate Limitation</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.231-71</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2001</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pricing of Adjustments</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.233-71</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2006</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Litigation and Claims</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.242-70</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2006</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Key Personnel</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.242-73</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2006</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Withholding of Contract Payments</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.242-74</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Apr 1984</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Final Decisions on Audit Findings</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">352.270-4</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jan 2006</font></div>
</td>
<td align="left" valign="top" width="58%" style="BORDER-BOTTOM: black 0.6pt solid; BORDER-LEFT: #000000 0.6pt solid; BORDER-RIGHT: #000000 0.6pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Protection of Human Subjects</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 50</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE I.2. ADDITIONAL CONTRACT CLAUSES</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This contract incorporates the following clauses by reference, with the same force and effect, as if they were given in full text. Upon request, the Contracting Officer will make their full text available.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ARTICLE I.3. ADDITIONAL FAR CLAUSES INCLUDED IN FULL TEXT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FAR 52.217-9 Option to Extend the Term of the Contract</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">O<font style="DISPLAY: inline; FONT-SIZE: 10pt">PTION</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">TO</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>E<font style="DISPLAY: inline; FONT-SIZE: 10pt">XTEND</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">THE</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>T<font style="DISPLAY: inline; FONT-SIZE: 10pt">ERM</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">OF</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">THE</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>C<font style="DISPLAY: inline; FONT-SIZE: 10pt">ONTRACT</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>(M<font style="DISPLAY: inline; FONT-SIZE: 10pt">AR</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>2000)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; MARGIN-LEFT: 18pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The government may extend the term of this contract by written notice to the Contractor within 15 days of the date the contract expires; provided that the government gives the Contractor a preliminary written notice of&#160;&#160;its intent to extend at least 60 days before the contract expires. The preliminary notice does not&#160;&#160;commit the government to an extension.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 36pt; MARGIN-LEFT: 18pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the government exercises this option, the extended contract shall be considered to include this option clause.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; MARGIN-LEFT: 18pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The total duration of this contract, including base contract and the exercise of any options under this clause, shall not exceed twenty-eight (28) months.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FAR 52.219-1 Small Business Program Representations</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">S<font style="DISPLAY: inline; FONT-SIZE: 10pt">MALL</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>B<font style="DISPLAY: inline; FONT-SIZE: 10pt">USINESS</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>P<font style="DISPLAY: inline; FONT-SIZE: 10pt">ROGRAM</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>R<font style="DISPLAY: inline; FONT-SIZE: 10pt">EPRESENTATIONS</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>(O<font style="DISPLAY: inline; FONT-SIZE: 10pt">CT</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>2014)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1) The North American Industry Classification System (NAICS) code for this acquisition is <font style="DISPLAY: inline; TEXT-DECORATION: underline">541711</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline"><font size="2"><font style="FONT-STYLE: italic"><font style="FONT-STYLE: normal"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font><font id="TAB2" style="FONT-STYLE: normal; LETTER-SPACING: 9pt; COLOR: black"> </font><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The small business size standard is <font style="FONT-STYLE: normal; DISPLAY: inline; TEXT-DECORATION: underline">500</font><font style="FONT-STYLE: normal; DISPLAY: inline; TEXT-DECORATION: underline"> </font>employees.</font></font></font></font></font></div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">(3)<font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black"> </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The small business size standard for a concern which submits an offer in its own name, other than on a construction or service contract, but which proposes to furnish a product which it did not itself manufacture, is 500 employees.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 70px">
<div><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;</font></div>
</td>
<td width="1815">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Representations</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The offeror represents as part of its offer that it [X] is, [ ] is not a small business concern.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The offeror represents as part of its offer that it [ ] is, [X] is not, a small disadvantaged&#160;&#160;business concern as defined in 13 CFR 124.1002.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The offeror represents as part of its offer that it [ ] is, [X] is not a woman-owned small business concern.</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 51</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FAR 52.219-28, Post-Award Small Business Program Representation</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">P<font style="DISPLAY: inline; FONT-SIZE: 10pt">OST</font>-A<font style="DISPLAY: inline; FONT-SIZE: 10pt">WARD</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>S<font style="DISPLAY: inline; FONT-SIZE: 10pt">MALL</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>B<font style="DISPLAY: inline; FONT-SIZE: 10pt">USINESS</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>P<font style="DISPLAY: inline; FONT-SIZE: 10pt">ROGRAM</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>R<font style="DISPLAY: inline; FONT-SIZE: 10pt">EPRESENTATION</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>(J<font style="DISPLAY: inline; FONT-SIZE: 10pt">UL</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>2013)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Definitions</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> As used in this clause--</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Long-term</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">contract</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>means a contract of more than five years in duration, including options. However, the term does not include contracts that exceed five years in duration because the period of performance has been extended for a cumulative period not to exceed six months under the clause at 52.217-8, Option to Extend Services, or other appropriate authority.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 27.2pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Small</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">business</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">concern</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>means a concern, including its affiliates, which is independently owned and operated, not dominant in the field of operation in which it is bidding on government contracts, and qualified as a small business under the criteria in 13 CFR part 121 and the size standard in paragraph (c) of this clause. Such a concern is "not dominant in its field of operation" when it does not exercise a controlling or major influence on a national basis in a kind of business activity in which a number of business concerns are primarily engaged. In determining whether dominance exists, consideration shall be given to all appropriate factors, including volume of business, number of employees, financial resources, competitive status or position, ownership or control of materials, processes, patents, license agreements, facilities, sales territory, and nature of business activity.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the Contractor represented that it was a small business concern prior to award of this contract, the Contractor shall represent its size status according to paragraph (e) of this clause or, if applicable, paragraph (g) of this clause, upon the occurrence of any of the following:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 90pt; MARGIN-LEFT: 90pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Within 30 days after execution of a novation agreement or within 30 days after modification of the contract to include this clause, if the novation agreement was executed prior to inclusion of this clause in the contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 90pt; MARGIN-LEFT: 90pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Within 30 days after a merger or acquisition that does not require a novation or within 30 days after modification of the contract to include this clause, if the merger or acquisition occurred prior to inclusion of this clause in the contract.</font></font></div>

<div style="TEXT-INDENT: 90pt; MARGIN-LEFT: 90pt">&#160;</div>

<div style="TEXT-INDENT: 90pt; MARGIN-LEFT: 90pt">(3) <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For long-term contracts--</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160; </font></div>
</div>

<div style="TEXT-INDENT: 90pt; MARGIN-LEFT: 90pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Within 60 to 120 days prior to the end of the fifth year of the contract; and</font></font></div>

<div style="TEXT-INDENT: 90pt; MARGIN-LEFT: 90pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(ii)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Within 60 to 120 days prior to the date specified in the contract for exercising any option thereafter.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contractor shall represent its size status in accordance with the size standard in effect at the time of this representation that corresponds to the North American Industry Classification System (NAICS) code assigned to this contract. The small business size standard corresponding to this NAICS code can be found</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">at <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.sba.gov/contractingopportunities/officials/size/index.html</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The small business size standard for a Contractor providing a product which it does not manufacture itself, for a contract other than a construction or service contract, is 500 employees.</font></font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt">&#160;</div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt">(e)&#160; <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Except as provided in paragraph (g) of this clause, the Contractor shall make the representation required by paragraph (b) of this clause by validating or updating all its representations in the Online Representations and Certifications Application and its data in the Central Contractor Registration, as necessary, to ensure that they reflect the Contractor's current status. The Contractor shall notify the contracting office in writing within the timeframes specified in paragraph (b) of this clause that the data have been validated or updated, and provide the date of the validation or update.</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 52</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 30pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the Contractor represented that it was other than a small business concern prior to award of this contract, the Contractor may, but is not required to, take the actions required by paragraphs (e) or (g) of this clause.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(g)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the Contractor does not have representations and certifications in ORCA, or does not have a representation in ORCA for the NAICS code applicable to this contract, the Contractor is required to complete the following representation and submit it to the contracting office, along with the contract number and the date on which the representation was completed:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Contractor represents that it [] is, [X] is not a small business concern under NAICS Code <font style="DISPLAY: inline; TEXT-DECORATION: underline">541711</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font>assigned to contract number <font style="DISPLAY: inline; TEXT-DECORATION: underline">HHSO100201500007C</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 35pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FAR 52.232-40, Providing Accelerated Payment to Small Business Subcontractors</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS (DEC 2013)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Upon receipt of accelerated payments from the government, the contractor shall make accelerated payments to its small business subcontractors under this contract, to the maximum extent practicable and prior to when such payment is otherwise required under the applicable contract or subcontract after receipt of a proper invoice and all other required documentation from the small business subcontractor.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The acceleration of payments under this clause does not provide any new rights under the Prompt Payment Act.</font></font></div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt">&#160;</div>

<div style="TEXT-INDENT: 54pt; MARGIN-LEFT: 54pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Include the substance of this clause, including this paragraph (c), in all subcontracts with small business concerns, including subcontracts with small business concerns for the acquisition of commercial items.</font></font></div>

<div style="TEXT-INDENT: 63pt; MARGIN-LEFT: 54pt"><font size="2">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 53</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><a name="PARTIII-LISTOFDOCUMENTS,EXHIBITSA"><!--EFPlaceholder--></a><a name="bookmark8"><!--EFPlaceholder--></a>PART III <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="SECTIONJ-LISTOFATTACHMENTS"><!--EFPlaceholder--></a><a name="bookmark9"><!--EFPlaceholder--></a>SECTION J <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> LIST OF ATTACHMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following documents are attached and incorporated in this contract:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Statement of Work, dated March 27, 2015 (16 pages).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Milestones and Deliverables Chart (4 pages)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Manufacturing Chart (1 page)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">High-level Gantt Chart (2 pages)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Invoice/Financing Request Instructions and Contract Financial Reporting Instructions for Cost-Reimbursement Type Contracts (5 pages).</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financial Report of Individual Project/Contract (1 page)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Instructions for Completing Financial Report of Individual Project/Contract (3 pages)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of Earned Value Management Tier 2 System Implementation Intent Guide (26 pages)</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 54</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><a name="PARTIV-REPRESENTATIONSANDINSTRUCTIO"><!--EFPlaceholder--></a><a name="bookmark10"><!--EFPlaceholder--></a>PART IV <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> REPRESENTATIONS AND INSTRUCTIONS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="bookmark11"><!--EFPlaceholder--></a>SECTION K <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> REPRESENTATIONS AND CERTIFICATIONS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following documents are incorporated by reference in this contract:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: right; WIDTH: 36pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160; </font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Annual Representations and Certifications completed and located at the System for Award&#160; Management website (SAM.gov).</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: right; WIDTH: 36pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160; </font></div>
</td>
<td align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Animal Welfare Assurance &#8211; No Animal Studies will be conducted at BioCryst facilities. Animal Welfare Assurance Numbers will be procured from any subcontractors.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 126pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">End of Contract No. HHSO100201500007C</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 55</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ATTACHMENT 1</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 362.15pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Statement of Work HHSO100201500007C</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">March 27, 2015</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PREAMBLE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work submitted in response to the BARDA Broad Agency Announcement (BAA) CBRN-BAA-10-100-SOL-00013.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Government reserves the right to modify the milestones, progress, schedule, budget, or deliverables to add or delete deliverables, process, or schedules if the need arises. Because of the nature of this research and development (R&amp;D) contract and the complexities inherent in this and prior programs, at designated milestones the Government will evaluate whether work should be redirected, removed, or whether schedule or budget adjustments should be made.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">OVERALL OBJECTIVES AND SCOPE</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The overall objective of this contract is to advance the development of BCX4430, a novel small molecule nucleoside with broad spectrum antiviral activity being developed for diseases caused by RNA pathogens. BCX4430, an inhibitor of viral RNA &#8211; dependent RNA polymerase (RdRp), is the lead compound in our broad- spectrum antiviral program to meet the need for a parenteral, direct-acting antiviral medical countermeasure (MCM) having efficacy across multiple viruses. The scope of work for this contract includes preclinical and manufacturing development activities that fall into the following areas: manufacturing of clinical trial material, manufacturing process improvements and development, non-clinical toxicology studies; and all associated regulatory, quality assurance, management, and administrative activities. The proposed activities take into account the Ebola virus disease (EVD) outbreak in West Africa. The R&amp;D effort will contribute toward an NDA filing for BCX4430. Overall, this Statement of Work (SOW) focuses on:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Drug substance (DS) and drug product (DP) manufacturing process development activities that will be conducted at US based facilities, which will result in the ability to consistently produce high quality, cGMP compliant material and deliver drug supply that could be available for deployment as a medical countermeasure during the Ebola crisis and support future clinical and non-clinical studies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 63pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Nonclinical development activities to advance the intramuscular (IM) and intravenous (IV) formulation through NDA-enabling toxicology including * * * and * * * studies in the * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 56</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BASE: MANUFACTURE OF CLINICAL TRIAL MATERIAL</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Duration: 18 months</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.45pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Drug Substance and Drug Product cGMP manufacturing by US suppliers to support non-clinical and clinical activities. Drug Substance will be produced following an * * * starting with * * *, which will be used as the GMP starting material to produce BCX4430.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The primary objectives will be to</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Produce * * * batches of BCX4430 drug substance following * * *.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Conduct drug product process improvements that will be focused on validation of analytical methods, stress testing, stability studies, and process design space optimization</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Procurement of Starting Materials</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.45pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall procure the starting materials to produce * * * of the current manufacturing process of BCX4430. The key starting materials to be procured are * * * and * * *.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.1.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Procurement of Starting Materials to produce * * * batches of * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.45pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall procure * * * and * * * for the manufacture of * * * of * * * to support a * * * campaign (WBS 1.4.1 and 1.4.2) and a * * * batch of BCX4430 (Clinical Trial Material Batch * * * WBS1.7.1)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Further Process Improvements of * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.45pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct further process improvements that may be identified focused on improving the existing plant-scale processes following generally the same * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 58px">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.2.1&#160;&#160;</font></div>
</td>
<td width="1827">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct Process Improvements</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct the process improvements with existing plant-scale processes.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 60px">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.2.2&#160;&#160;</font></div>
</td>
<td width="1825">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Determination that Process is Sufficient to move to Commercial Scale up</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.45pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall evaluate the processes developed and provide sufficient information through a deliverable that will enable BARDA to determine that the processes are sufficient to move to commercial scale &#8211;up activities.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of * * * at * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.45pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce * * * of * * * will be utilized as the starting material for the manufacture of BCX4430 in accordance with cGMP guidance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.3.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of * * * of&#160;&#160;* * * (Batch * * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce * * * of * * * using the existing process at * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.3.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of * * * of&#160;&#160;* * * (Batch * * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce * * * of * * * using the existing process at * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacturing Campaign of BCX4430</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce * * * of BCX4430 at * * * in compliance with cGMP.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 57</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.4.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacturing of * * * of cGMP BCX4430 (DS Batch&#160;&#160;* * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce and release * * * of cGMP BCX4430 * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.4.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacturing of * * *&#160;&#160;of cGMP BCX4430 (DS Batch&#160;&#160;* * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce and release * * * of cGMP BCX4430 * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.4.3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Prepare a Campaign Summary Report</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall prepare a campaign summary report of the manufacture and release of DS Batches * * * .</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.4.4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Drug Substance Stability Studies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall place samples from DS Batch&#160;&#160;* * * of BCX4430 on a * * * stability program at&#160;&#160;* * * and a</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * * accelerated stability study at&#160;&#160;* * * .</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Table 1. BCX4430 Drug Substance Stability Study Sampling Points</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td rowspan="2" valign="top" width="6%" bgcolor="blue" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Test</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ID</font></div>
</td>
<td colspan="10" valign="top" width="65%" bgcolor="blue" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Months</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">0</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">9</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">12</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">24</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">48</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">60</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">C</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">D</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">E</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
</tr><tr>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">G</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 188.65pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE: BARDA will only cover stability activities for&#160;&#160;* * * . Table 2. BCX4430 Drug Substance Stability Tests</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 188.65pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="mediumblue">
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid; BORDER-TOP: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Test ID</font></div>
</td>
<td valign="top" width="48%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid; BORDER-TOP: #00007f 1.1pt solid; BORDER-RIGHT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Test</font></div>
</td>
</tr><tr>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.05pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A</font></div>
</td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid; BORDER-RIGHT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.05pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B</font></div>
</td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid; BORDER-RIGHT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">C</font></div>
</td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid; BORDER-RIGHT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">D</font></div>
</td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid; BORDER-RIGHT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.05pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">E</font></div>
</td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid; BORDER-RIGHT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F</font></div>
</td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid; BORDER-RIGHT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.05pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">G</font></div>
</td>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #00007f 1.1pt solid; BORDER-RIGHT: #00007f 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.5.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Drug Product Development</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 7.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct drug product process improvements that will be focused on validation of analytical methods, stress testing, stability studies, and process design space optimization.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 7.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct formulation development activities and produce a sterile, parenteral formulation containing&#160;&#160;* * * of the active compound per unit in compliance with cGMP guidance. Initial development efforts will be focused on delivering a * * * that tolerates terminal sterilization and provides an acceptable stability profile to support a&#160;&#160;* * * shelf life. Additionally, studies to include:&#160;&#160;* * * will be conducted to evaluate the feasibility of&#160;&#160;* * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 58</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.5.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stress Conditions Studies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 3.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct a series of experiments under conditions outlined in ICH guidance to evaluate the stability of the drug product made from available drug substance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.5.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Design Space Studies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct studies to evaluate and define the design space of the formulation process.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.5.3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Analytical Method Validation</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct analytical methods validation or qualification as listed in the table below.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Table 3. BCX4430 Drug Product Methods that will be Validated or Qualified</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="mediumblue">
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font color="white" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Te</font><font color="white" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">st</font></font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Method and Objective</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.5.4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Prepare Process Development Report for DP</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 3.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall prepare a process development report summarizing the experiments and results of the studies conducted to define the process and evaluate the formulation.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.5.5.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pre-formulation and Physicochemical Properties Studies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 3.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct studies to determine the physicochemical properties of the drug substance and identify potential formulations and primary packaging for an IM injection based on stability and ability to be produced on manufacturing lines.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.5.6.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Feasibility Runs</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct small-scale, nonGMP manufacturing runs of potential formulations and formats.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.5.7.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Extractable/Leachable Study</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 3.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct studies to determine drug product stability in primary packaging and of syringe types that will be used for delivery.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.5.8.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Excipient Compatibility Studies for IV Formulation from IM</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 3.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct studies to evaluate the compatibility of the IM formulation added to various standard IV fluids.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.6.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacturing of Drug Product to Support Clinical Trials</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 2.65pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce * * * batches of approximately * * * of drug product suitable for clinical trial use. The drug product will produced from the * * * cGMP DS Batches * * * (WBS 1.4.1 and 1.4.2)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 59</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.6.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of Clinical Trial Material (CTM Batch * * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce approximately * * * per cGMP for use in clinical trials.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.6.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of Clinical Trial Material (CTM Batch * * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce approximately * * * per cGMP for use in clinical trials.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.6.3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Prepare a Campaign Summary Reports</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall prepare a campaign summary report of the manufacture and release of CTM * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.6.4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Drug Product Stability Studies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall place drug product on stability based on the following conditions:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Table 4. BCX4430 Drug Product Stability Testing Conditions and Sampling</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="mediumblue">
<td align="left" valign="top" width="23%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stability Conditions</font></div>
</td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Configuration</font></div>
</td>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Test Points</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="23%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="23%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="23%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="33%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 196.25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE: BARDA will only cover stability activities for * * * </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 196.25pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 196.25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Table 5. BCX4430 Drug Product Stability Tests</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 196.25pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="mediumblue">
<td valign="top" width="48%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Test</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.6.5.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comparability Study</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 2.65pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct comparability studies evaluating drug substance produced by * * * and * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> and the subsequently produced drug product, will be conduct per FDA Guidance. These studies will evaluate: in- process checks, impurity profiles, release testing results, and stability profiles at standard and accelerated conditions to ensure the material produced by both manufacturers is substantially comparable.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 60</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.7.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of Additional Supply</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">That contractor shall produce * * * of BCX4430 based on * * * facility and subsequently produce * * * of drug product at * * * suitable for clinical trial use.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.7.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacturing of * * * cGMP BCX4430 (DS Batch * * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce * * * of cGMP BCX4430 from * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.7.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Prepare a Campaign Summary Report</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall prepare a campaign summary report of the manufacture and release of * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.7.3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacturing of approximately * * * (CTM Batch * * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce approximately * * * of cGMP BCX4430 drug product using drug substance from the * * * cGMP BCX4430 (DS Batch * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> WBS 1.7.1).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.7.4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Prepare a Campaign Summary Report</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall prepare a campaign summary report of the manufacture and release of CTM Batches * * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.7.5.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stability Studies for DS and DP</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct drug substance and drug product stabilities for the DS and DP manufactured in from the * * * of cGMP BCX4430 drug substance based on * * * (WBS 1.6).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE: BARDA will only cover stability activities for * * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.7.6.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comparability Studies</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct comparability studies evaluating drug substance produced by * * * and both process at * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> and the subsequently produced drug product, will be conduct per FDA Guidance. These studies will evaluate: in-process checks, impurity profiles, release testing results, and stability profiles at standard and accelerated conditions to ensure the material produced by both manufacturers and both * * * process are substantially comparable.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 61</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">2&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">OPTION 1: COMMERCIAL SCALE UP AND NDA REGISTRATION BATCHES</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Duration: * * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Go/No Go Criteria to Initiate: WBS 1.2.2 BARDA approval of process developed</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Through optimization of manufacturing processes, BARDA will evaluate and determine what process should be sufficient to initiate commercial scale up activities in this Option. This Option will add value to the project through conducting manufacturing regulatory activities that will be needed for future product approval with the FDA.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Decision Criteria:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;* * *</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;* * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The objective is to produce DS registration batches from the qualified process, * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> This will be determined upon the conclusion of the DS development effort being undertaken by BioCryst and funded by NIAID that is scheduled to conclude in December 2015. Additionally during this stage, the DP manufacturing process would be finalized for the commercial presentation and registration batches produced.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Procurement</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall procure the * * * starting materials needed to produce BCX4430.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.1.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Procurement of * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall qualify a vendor(s) to produce the * * * and procure enough material to support the manufacture of * * * batches of BCX4430 drug substance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.1.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Procurement of * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall qualify a vendor(s) to produce the * * * and procure enough material to support the manufacture of * * * batches of BCX4430 drug substance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Drug Substance Process Scale-up</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct process development work targeting a * * * that can be scaled to plant equipment. This work will include: development of a * * * through lab scale studies, process hazard evaluation including RC-1 and digital scanning calorimetry, lab scale qualification runs, pilot plant scale-up technical batches, necessary modifications to analytical methods based on the * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> and plant-scale registration runs.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.2.1&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Further Process Improvements of Final Route</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct further process improvements that may be identified focused on improving the * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">to be scaled up. The * * * will be based either * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.2.2&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Process Hazard Evaluation</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct process hazard evaluation studies needed for the scale-up of the optimized process into the plant.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.2.3&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Scale-up Technical Run</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct a nonGMP manufacturing run at plant-scale to ensure the safety and output of the optimized process.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 62</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.2.4&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Analytical Method Development and Qualification</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall modify, add to, revalidate, or requalify the analytical methods.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.2.5&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Prepare Process Development Report</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 4.6pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall prepare a process development report describing the experiments and results leading to the selection of the optimized manufacturing process</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.3&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of cGMP Drug Substance Registration Batches</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 4.6pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce * * * cGMP batches of BCX4430 following the * * * at a scale comparable to the estimated commercial scale.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.3.1&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of DS Batch (DS Batch&#160;&#160;* * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall manufacture a batch of cGMP BCX4430 at plant scale.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.3.2&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of DS Batch (DS Batch&#160;&#160;* * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall manufacture a batch of cGMP BCX4430 at plant scale.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.3.3&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of DS Batch (DS Batch&#160;&#160;* * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall manufacture a batch of cGMP BCX4430 at plant scale.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.3.4&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Prepare Campaign Summary Report</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 4.6pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall prepare a report summarizing the conduct, observations, and results of the manufacturing of DS Batches * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.4&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Drug Product Registration Batches</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall produce * * * drug product lots at * * * that will be used as the NDA registration batches.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.4.1&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of DP Registration (DPR Batch * * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall manufacture a NDA registration batch of cGMP BCX4430 drug product at a scale at least</font></font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * the estimated commercial scale.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.4.2&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of DP Registration (DPR Batch * * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall manufacture a NDA registration batch of cGMP BCX4430 drug product at a scale at least</font></font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * the estimated commercial scale.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.4.3&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacture of DP Registration (DPR Batch * * * )</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall manufacture a NDA registration batch of cGMP BCX4430 drug product at a scale at least</font></font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* * the estimated commercial scale.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.4.4&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Prepare campaign summary report</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 4.6pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall prepare a report summarizing the conduct, observations, and results of the manufacturing of DPR Batches * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 63</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.5&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stability studies for DS and DP</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct drug substance and drug product stabilities as described in Table 2 and Table 3 <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOTE:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">BARDA</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">will</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">only</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">cover</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">stability</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">activities</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">for</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>* * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font size="2">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.6&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comparability study</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall conduct comparability studies evaluating drug substance produced for clinical trials in the base period versus the NDA registration batches manufactured via * * * in Option 1, and the subsequently produced drug product, will be conduct per FDA Guidance. These studies will evaluate: in-process checks, impurity profiles, release testing results, and stability profiles at standard and accelerated conditions to ensure the material produced by both processes is substantially comparable.</font></font></div>
</div>
</div>

<div><font size="2">&#160;</font></div>

<div><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 64</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">3&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">OPTION 2: NONCLINICAL NDA-ENABLING TOXICOLOGY <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> IM</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Duration: * * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Go/No Go Criteria to Initiate: WBS 1.4.1 Completion of Manufacture cGMP BCX4430 ( * * * campaign DS Batch * * * )</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Through completion of manufacturing of this Drug substance Batch * * * <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> then there will be material to conduct further regulatory activities such as the IM non-clinical NDA-enabling toxicology studies in this option. This Option will add value to the project through conducting additional non-clinical activities that will support a potential future NDA.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Decision Criterion:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;* * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;* * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall perform nonclinical GLP studies of IM BCX4430 to characterize * * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GLP * * * Toxicology &#8211; IM</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall for each toxicology study develop the protocol, select and qualify the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Studies include:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.1.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct GLP * * * IM toxicology study <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.1.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct GLP * * * IM general toxicology study <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">* * * toxicology <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> IM</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall for each * * * study segment develop the protocol, select and qualify the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Studies include:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.2.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct * * * assessment in * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.2.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct * * * Dose Range Finding Studies in the * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.2.3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct Definitive * * * toxicology in the * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.2.4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct * * * toxicology * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nonclinical ADME <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> IM</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall procure radiolabeled BCX4430. In addition for each ADME study, the contractor shall develop the protocol, select and qualify the vendor, conduct the study and analyze study data resulting in a final study report. Studies include:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 65</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.3.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct Radiolabeled ADME study <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.3.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct Radiolabeled ADME &#8211; * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 5.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A listing of the proposed studies for the nonclinical NDA-enabling toxicology studies for the IM formulation is provided.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Table 6 Nonclinical NDA-enabling Toxicology Studies for an IM formulation</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="mediumblue">
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study #</font></div>
</td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Description</font></div>
</td>
<td valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Objective(s)</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 9.9pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Species (N)</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 24.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">GLP * * * IM general toxicology</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 24.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">GLP * * * IM general toxicology</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * <font style="DISPLAY: inline; FONT-SIZE: 10pt">assessment</font></font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 34.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * <font style="DISPLAY: inline; FONT-SIZE: 10pt">Dose</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Range</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Finding</font></font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 34.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * <font style="DISPLAY: inline; FONT-SIZE: 10pt">Dose</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Range</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Finding</font></font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Definitive</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>* * *</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">toxicology</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Definitive</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>* * *</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">toxicology</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * <font style="DISPLAY: inline; FONT-SIZE: 10pt">toxicology</font></font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Radiolabeled ADME</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 22.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Determine the absorption, distribution, metabolism and excretion of the test article following IM dosing</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Radiolabeled ADME</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 15.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Determine the absorption, metabolism and excretion of the test article following IM dosing</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div><font size="2">&#160;</font></div>

<div><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 66</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">4&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">OPTION 3: <font style="FONT-STYLE: italic; DISPLAY: inline">IN</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">VITRO</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>EXPERIMENTS &#8211; IV</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Duration: * * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 8.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Go/No Go to Initiate: WBS 1.5.8 Completion of Excipient compatibility studies for IV formulation Through completion of IV formulation studies, it will be determined what excipients are appropriate for IV</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 5.25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">formulation to then continue with toxicology studies of the IV formulation under this Option. This Option will add value to determine if there is any identified toxicology in <font style="FONT-STYLE: italic; DISPLAY: inline">in</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">vitro</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>assays before moving to animal studies in Option 4.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Decision Criterion:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;* * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;* * * &#8211; IV</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 8.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall develop the protocol, select and qualify the vendor, conduct the experiments and analyze the data resulting in a study report.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4.2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Conduct * * * Test &#8211; IV</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 8.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall develop the protocol, select and qualify the vendor, conduct the experiment and analyze the data resulting in a study report.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 7.6pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A listing of the proposed experiments for the <font style="FONT-STYLE: italic; DISPLAY: inline">in</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">vitro</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>experiments to be conducted in advance of the nonclinical NDA-enabling toxicology studies for the IV formulation is provided <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">Table</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">7</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Table 7 In vitro Experiments <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> IV</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="mediumblue">
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study #</font></div>
</td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Description</font></div>
</td>
<td valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Objective(s)</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 9.9pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Species (N)</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study Report on all in vitro assays</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 8.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall submit a summarized study report with data and conclusions from all in vitro experiments conducted in table 7 to determine whether there is any toxicology before advancing into non-clinical NDA enabling toxicology studies (Option 5).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 67</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">5&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">OPTION 4: NONCLINICAL NDA-ENABLING TOXICOLOGY <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> IV</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Duration: * * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Go/No Go Criteria to Initiate: WBS 4.3 Study Report on all <font style="FONT-STYLE: italic; DISPLAY: inline">in</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">vitro</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>assays</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Through completion of the IV <font style="FONT-STYLE: italic; DISPLAY: inline">in</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">vitro</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>toxicology studies with the IV formulation conducted in Option 3 and summarized in WBS 4.3, it will be determined if the IV formulation is safe to move into non-clinical toxicology animal studies in this Option. This Option will add value to the project through conducting additional non- clinical activities that will support a potential future NDA.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Decision Criterion:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;* * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;* * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GLP * * * Toxicology &#8211; IV</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall for each toxicology study develop the protocol, select and qualify the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report. Studies include:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.1.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct GLP * * * IV general toxicology study <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.1.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct GLP * * * IV toxicology study <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">* * * toxicology <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">-</font> IV</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall for each&#160;*** study segment develop the protocol, select and qualify the vendor, conduct in life and recovery phases and analyze study data resulting in a final study report. Studies include:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.2.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct * * * assessment in * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.2.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct * * * Dose Range Finding Studies in the * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.2.3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct Definitive * * * toxicology in the * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.2.4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conduct * * * Developmental toxicology * * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 1.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A listing of the proposed studies for the nonclinical NDA-enabling toxicology studies for the IV formulation is provided in <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">Table</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;</font>8</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Table 8. Nonclinical NDA-enabling Toxicology Studies for an IV Formulation</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="mediumblue">
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study #</font></div>
</td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Description</font></div>
</td>
<td valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Objective(s)</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 9.9pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Species (N)</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 23.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">GLP * * * IV general toxicology</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 23.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">GLP * * * IV general toxicology</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * <font style="DISPLAY: inline; FONT-SIZE: 10pt">assessment</font></font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 34.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * <font style="DISPLAY: inline; FONT-SIZE: 10pt">Dose</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Range</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Finding</font></font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 34.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * <font style="DISPLAY: inline; FONT-SIZE: 10pt">Dose</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Range</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Finding</font></font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 68</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Definitive</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>* * *</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">toxicology</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-TOP: #000080 0.85pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Definitive</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>* * *</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">toxicology</font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 23.55pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * <font style="DISPLAY: inline; FONT-SIZE: 10pt">Developmental</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">toxicology</font></font></div>
</td>
<td align="left" valign="top" width="42%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000080 1.1pt solid; BORDER-RIGHT: #000080 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 69</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">6&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">PROGRAM MANAGEMENT</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.95pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide all expertise needed for the implementation of the activities to be performed under this contract, including: research, manufacturing, regulatory, clinical, statistical analyses, management and administrative activities.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Technical and Project Management Support</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.95pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall appoint a Principal Investigator (PI) who will be responsible for all aspects of project performance and communication with the BARDA.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.95pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide project management that will ensure day-to-day monitoring and tracking of progress and timelines, the coordination of project activities and costs incurred.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.95pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide all managerial and administrative functions necessary for overall planning, monitoring, and implementing activities for the completion of the strategic product development plan.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.1pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide for all necessary legal affairs required to ensure the timely acquisition of all proprietary rights, including intellectual property rights and all materials needed to perform the project, as well as reporting to the Government all inventions made in the performance of the project.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subcontractor Management</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.95pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide for tracking, coordination and oversight of subcontractor efforts and manage communications with subcontractors.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risk Management</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.95pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall identify project risks, develop risk management strategies and implement mitigation actions.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Earned Value Management (EVM)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide EVM information.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.5.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Project Communications</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.95pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide for project communications including communications with BARDA and external experts.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall provide planning and steps required for the conduct of contract review meetings.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 70</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">7&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">REGULATORY</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall ensure adherence to FDA regulations and guidance, including requirements for the conduct of animal studies and assays under GLP, the manufacturing of the therapeutic product under cGMP, and the conduct of clinical trials under GCP standards.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7.1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Regulatory Authority Interactions</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall prepare and submit documentation and correspondence to regulatory authorities as required. The contractor shall request and conduct meetings with regulatory authorities to ensure the development program is conducted in accordance with regulatory guidelines and expectations.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7.2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quality Assurance</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall maintain quality assurance documentation. The contractor shall arrange for audits of subcontractor facilities to ensure all planned procedures comply with the FDA regulations and guidance that are required to meet GLP, cGMP and GCP standards. In addition, the contractor shall ensure that all contractor and/or subcontractor records and staff are available for site visits or audits.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7.3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Expert Collaborations</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 1.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contractor shall collaborate with experts in the field in the design of experiments and studies that support the advancement of the development program.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 71</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ATTACHMENT 2</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 276.25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MILESTONE AND DELIVERABLES CHART MARCH 27, 2015</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">HHSO100201500007C</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="royalblue">
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">WBS</font></div>
</td>
<td align="left" colspan="2" valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestone</font></div>
</td>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deliverable</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 19.7pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Success Criteria</font></div>
</td>
<td align="left" valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Timing</font></div>
</td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.3pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Go/No-Go for initiation</font></div>
</td>
</tr><tr>
<td colspan="7" valign="top" width="79%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CLIN 0001 - MANUFACTURE OF CLINICAL TRIAL MATERIAL</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.2.1</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Process Improvements Report</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Report on Process </font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Process Developed</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.2.2</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Determination of Sufficient Process for Commercial Scale up</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Evaluation report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BARDA</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">approval of developed process</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.3.2</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture * * * (Batch * * *)</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.4.1</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture cGMP BCX4430 (* * *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">campaign DS Batch *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* *)</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 DS</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA,</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.4.2</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture cGMP BCX4430 (* * *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">campaign DS Batch *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* *)</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 DS</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA,</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.4.3</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepare a Campaign Summary Reports</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Campaign Reports (DS Batches * * *)</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Completion of DS Campaigns</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.4.4</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug substance stability study</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Initial Report on stability activities</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stability data</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.5</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug Product Development</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DP Process Development </font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Report (WBS 1.5.4)</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-formulation and </font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Physicochemical Report (WBS1.5.5)</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Extractable/Leachable Report (WBS 1.5.7)</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Completion of Studies</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.5.8</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Excipient Compatibility Report for IV Formulation</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Compatibility Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">IV formulation completed</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.6.1</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture cGMP DP (CTM Batch * * *)</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 DP</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA,</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accepted GMP DS</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.6.2</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture cGMP DP (CTM Batch * * *)</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 DP</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA,</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accepted GMP DS</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.6.3</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepare a Campaign Summary Reports</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Campaign Reports (CTM Batches * * *)</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Completion of DP Campaigns</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 72</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table cellpadding="0" cellspacing="0" width="100%" style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.6.4</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug Product stability study</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Initial Report on stability activities</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stability Data</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.6.5</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Comparability Study</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Comparability Protocol and Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Completion of DS and DP Campaigns</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.7.1</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture cGMP BCX4340 (* * *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">campaign DS Batch *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * )</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 DS</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable DS process</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.7.2</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepare a Campaign Summary Report</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Campaign Reports (DS Batch* * *)</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Completion of DS Campaign</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.7.2</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture cGMP DP (CTM Batch * * *)</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 DP</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA,</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accepted GMP DS</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.7.4</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepare a Campaign Summary Report</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Campaign Report (CTM Batches * * *)</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Completion of DS Campaigns</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.7.5</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug Substance and Drug Product stability study</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Initial report on stability activities</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stability Data</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture of 1.7.1 drug substance and 1.7.2 drug product</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.7.6</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Comparability Study</font></div>
</td>
<td colspan="2" valign="top" width="21%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Comparability Protocol and Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Comparable DS and DP profiles</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td colspan="7" valign="top" width="79%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CLIN 0002 &#8211; COMMERCIAL SCALE UP AND NDA REGISTRATION BATCHES</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Go/No Go Criteria to Initiate: WBS 1.2.2 BARDA approval of process developed</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.2</font></div>
</td>
<td colspan="2" valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug Substance Process Scale-up</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Process Development Report (WBS 2.2.4)</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selection of the optimized manufacturing process</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * process</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.3.1</font></div>
</td>
<td colspan="2" valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture BCX4340 DS (DS Registration Batch * * *)</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 Registration DS</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * process</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.3.2</font></div>
</td>
<td colspan="2" valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture BCX4340 DS (DS Registration Batch * * *)</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 Registration DS</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA,</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * process</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.3.3</font></div>
</td>
<td colspan="2" valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture BCX4340 DS (DS Registration Batch * * *)</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 Registration DS</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA,</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * process</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.3.4</font></div>
</td>
<td colspan="2" valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepare a Campaign Summary Report</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Campaign Reports (DS Batches * * *)</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Completion of DS Campaign</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.4.1</font></div>
</td>
<td colspan="2" valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture BCX4430 DP (DP Registration Batch * * *)</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 DP</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA,</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accepted GMP DS</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.4.2</font></div>
</td>
<td colspan="2" valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture BCX4430 DP (DP Registration Batch * * *)</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 DP</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA,</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accepted GMP DS</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 73</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table cellpadding="0" cellspacing="0" width="100%" style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.4.3</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Manufacture BCX4430 DP (DP Registration Batch * * *)</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BCX4430 DP</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CofA,</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable quality and yield</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accepted GMP DS</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.4.4</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepare a Campaign Summary Report</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Campaign Report (CTM Registration Batches * *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*)</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Completion of DS Campaigns</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.5</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug substance and Drug Product stability study</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Report on stability activities</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stability Data</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.6</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Comparability Study</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Comparability Protocol and Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Comparable DS and DP profiles</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accepted GMP DS</font></div>
</td>
</tr><tr>
<td colspan="6" valign="top" width="79%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CLIN 0003 &#8211; NONCLINICAL NDA-ENABLING TOXICOLOGY - IM</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Go/No</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Go</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Criteria</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> to </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initiate:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">WBS </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.4.1</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Completion </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> Manufacture</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">cGMP BCX4430</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">(</font>* * *<font style="DISPLAY: inline; FONT-WEIGHT: bold">campaign DS</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Batch </font>*</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* *<font style="DISPLAY: inline; FONT-WEIGHT: bold">)</font></font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.1.1</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Complete GLP * * * IM Tox Study - * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Established NOAEL</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug Substance confirming to release criteria</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.1.2</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Complete GLP * * * IM Tox Study - * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Established NOAEL</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug Substance confirming to release criteria</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.2.1</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct * * * assessment in * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No significant findings</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.2.2</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct * * * Dose Range Finding Studies in the * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No significant findings</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.2.3</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct Definitive * * * toxicology in the * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No significant findings</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.2.4</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct * * * toxicology * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No significant findings</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.3.1</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct Radiolabeled ADME study - * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Characterize drug disposition</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable Radiolabel Material</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.3.2</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct Radiolabeled ADME &#8211; * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Characterize drug disposition</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acceptable Radiolabel Material</font></div>
</td>
</tr><tr>
<td colspan="6" valign="top" width="79%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CLIN 0004 &#8211; IN VITRO EXPERIMENTS &#8211; IV</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Go/No Go to Initiate: WBS 1.5.8 Completion of Excipient compatibility studies for IV formulation</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.1.</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct * * * Test &#8211; IV</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No effect on *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* *</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">IV</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">formulation WBS 1.5.8</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.2.</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct * * * Test &#8211; IV</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No effect on *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* *</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.3</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * * IV experiments</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study report on all * *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*assays with recommendation to proceed CLIN0005</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No toxicology *</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* *</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td colspan="6" valign="top" width="79%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CLIN 0005 &#8211; NONCLINICAL NDA-ENABLING TOXICOLOGY &#8211; IV</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Go/No</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Go</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">to</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Initiate: WBS 4.3</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Completion </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of </font>* * * <font style="DISPLAY: inline; FONT-WEIGHT: bold">IV</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> toxicology studies</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 74</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table cellpadding="0" cellspacing="0" width="100%" style="TEXT-ALIGN: center; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr style="TEXT-ALIGN: center;">
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.1.1</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Complete GLP * * *IV Tox Study - * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Established NOAEL</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; BORDER-TOP: #000000 1.1pt solid; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug Substance confirming to release criteria</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.1.2</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Complete GLP * * * IV Tox Study - * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Established NOAEL</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Drug Substance confirming to release criteria</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.2.1</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct * * * assessment in * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No significant findings</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.2.2</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct * * * Dose Range Finding Studies in the * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No significant findings</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.2.3</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct Definitive * * * toxicology in the * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No significant findings</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.2.4</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conduct * * * toxicology * * *</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Study Report</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No significant findings</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1.1pt solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">N/A</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 75</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ATTACHMENT 3</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 289.6pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BCX4430 MANUFACTURING SUMMARY MARCH 2 <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">,</font> 2015</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 9.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Starting Material</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Campaign</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CMO</font></div>
</td>
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 9.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DS Process Desc</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Timing</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DP</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Campaign</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DP</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Timing</font></div>
</td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Use</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-TOP: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Funding</font></div>
</td>
</tr><tr>
<td align="left" rowspan="2" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" rowspan="2" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" colspan="2" valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" rowspan="6" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" colspan="2" valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" colspan="2" valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" rowspan="2" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" colspan="2" valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" rowspan="3" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" rowspan="3" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="11%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="10%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="9%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
<td align="left" valign="top" width="7%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr><tr>
<td align="left" colspan="9" valign="top" width="80%" style="BORDER-BOTTOM: black 1.1pt solid; BORDER-LEFT: #000000 1.1pt solid; BORDER-RIGHT: #000000 1.1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* * *</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 76</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ATTACHMENT 4</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 302.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">HIGH-LEVEL GANTT CHART MARCH 27, 2015</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.05pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">* * *</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.15pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All activities covered under this BioCryst contract will provide merit and value to the Government by ensuring that funding supported under the Base period results in progress towards several activities to ensure moving the BioCryst BCX4430 compound through the development pipeline for future FDA approval. This activities include manufacturing clinical trial material to be used in clinical trials as an urgent need to the Ebola epidemic in west Africa (Base), commercial scale up and manufacturing of registration batches, a regulatory approval requirement (Option 1), non-clinical toxicology studies of the IM formulation to support NDA regulatory requirements (Option 2) and non-clinical toxicology studies of the IV formulation first in vitro (Option 3) and then in animals (Option 4) to support NDA regulatory requirements. BioCryst&#8217;s ability to complete three critical GO/NO GO contract milestones in the Base period will determine whether to exercise any follow-on option phases to continue supporting development of the compound.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are 4 decision points which will trigger advancement to Options.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Trigger 1 (for start of Option 1): Further optimization processes for manufacturing will be developed under the WBS 1.2.1 and then BioCryst will evaluate the processes developed and provide sufficient information through deliverable WBS 1.2.2 that will enable BARDA to determine that the processes are sufficient to move to commercial scale &#8211;up activities (milestone WBS1.2.2, July 2015), and then Option 1 can begin. In Option 1, the process developed in WBS 1.2 and other processes being developed to manufacture the BCX4430 compound will be evaluated, such that BioCryst can select a process of most value to the Government to generate * * * drug substance registration batches that will then be used to make * * * drug product registration batches at a scale at least * * * the estimated commercial scale which is a regulatory requirement for qualifying a GMP process for manufacturing.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Trigger 2 (for start of Option 3): In preparation for manufacturing clinical trial (drug product)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 77</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 9.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">material from the drug substance manufactured in the Base, the contractor will conduct formulation activities for both Intramuscular (IM) and intravenous (IV) administration. These formulations will then be applied to the generation of drug product (clinical trial material) in the remainder of the base.&#160;&#160;However, once an IV formulation is determined as compatible (WBS 1.5.8, July 2015) then preliminary toxicology studies <font style="FONT-STYLE: italic; DISPLAY: inline">in</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">vitro</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>of this formulation can be initiated in Option 3 (in Vitro experiments- IV) before moving in to animal toxicology studies (Option 4).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Trigger 3 (for start of Option 2): In order to conduct further regulatory activities to support NDA activities, toxicology experiments will need to be conducted with the IM formulation in</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 9.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">animals. However, drug product is needed for these studies. As soon as some of the drug substance material is manufactured in the base period (WBS 1.4.1,January 2016), then some of this material can be utilized for conducting these non-clinical animal toxicology studies in Option 2, a NDA regulatory requirement.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Trigger 4 (for start of Option 4): In order to proceed with conducting further regulatory activities to support NDA activities for the IV formulation, toxicology experiments will need to be conducted in animals. However, this can only proceed if the preliminary toxicology studies performed <font style="FONT-STYLE: italic; DISPLAY: inline">in</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">vitro,</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>as evaluated in the <font style="FONT-STYLE: italic; DISPLAY: inline">in</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">vitro</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>study report (WBS 4.3, March 2016), demonstrate that the IV formulation is safe.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 78</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ATTACHMENT 5</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">INVOICE/FINANCING</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">REQUEST</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">AND</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">CONTRACT</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">FINANCIAL</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 117pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">REPORTING</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">INSTRUCTIONS</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">FOR</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">COST-REIMBURSEMENT</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">TYPE</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">CONTRACTS</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 15.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Format:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Payment requests shall be submitted on the Contractor&#8217;s self-generated form in the manner and format prescribed herein and as illustrated in the Sample Invoice/Financing Request. Standard Form 1034, Public Voucher for Purchases and Services Other Than Personal, may be used in lieu of the Contractor&#8217;s self-generated form provided it contains all of the information shown on the Sample Invoice/Financing Request. DO NOT include a cover letter with the payment request.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 15.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Number</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Copies:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Payment requests shall be submitted in the quantity specified in the Invoice Submission Instructions in Section B of the Contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 15.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Frequency:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Payment requests should not be submitted more frequently than once every two weeks in accordance with the Allowable Cost and Payment Clause incorporated into this contract unless otherwise instructed by the Contract Officer. Small business concerns may submit invoices/financing requests more frequently than every two weeks when authorized by the Contracting Officer.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 15.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cost</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Incurrence</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Period:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Costs incurred must be within the contract performance period or covered by previously established pre contract cost provisions.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 15.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Billing</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Costs</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Incurred:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>If billed costs include (1) costs of a prior billing period, but not previously billed, or (2) costs incurred during the contract period and claimed after the contract period has expired, the Contractor shall cite the amount(s) and month(s) in which it incurred such costs.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 15.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Contractor's</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fiscal</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Year:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Payment requests shall be prepared in such a manner that the Government can identify costs claimed with the Contractor's fiscal year.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 5.6pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Currency:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>All contracts are expressed in United States dollars. When the Government pays in a currency other than United States dollars, billings shall be expressed, and payment by the Government shall be made, in that other currency at amounts coincident with actual costs incurred. Currency fluctuations may not be a basis of gain or loss to the Contractor. <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notwithstanding the above, the total of all invoices paid under this contract may not exceed the United States dollars authorized.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 15.55pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 15.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Costs</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Requiring</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Prior</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Approval:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Costs requiring the Contracting Officer's approval, which are not set forth in an Advance Understanding in the contract, shall be identified and reference the Contracting Officer's Authorization (COA) Number. In addition, the Contractor shall show any cost set forth in an Advance Understanding as a separate line item on the payment request.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Invoice/Financing</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Request</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Identification:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Each payment request shall be identified as either:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Interim</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Invoice/Contract</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Financing</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Request:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>These are interim payment requests submitted during the contract performance period.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Completion</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Invoice:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>The completion invoice shall be submitted promptly upon completion of the work, but no later than one year from the contract completion date, or within 120 days after settlement of the final indirect cost rates covering the year in which the contract is physically complete (whichever date is later). The Contractor shall submit the completion invoice when all costs have been assigned to the contract and it completes all performance provisions.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Final</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Invoice:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>A final invoice may be required after the amounts owed have been settled between the Government and the Contractor (e.g., resolution of all suspensions and audit exceptions).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Preparation</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">and</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Itemization</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">the</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Invoice/Financing</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Request:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>The Contractor shall furnish the information set forth in the instructions below. The instructions are keyed to the entries on the Sample Invoice/Financing Request.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Designated</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Billing</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Office</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Name</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">and</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Address:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Enter the designated billing office name and address, as identified in the Invoice Submission Instructions in Section B and F of the Contract Schedule.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Contractor's</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Name,</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Address,</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Point</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Contact,</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">VIN,</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">and</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">DUNS</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">or</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">DUNS+4</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Number:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Show the Contractor's name and address exactly as they appear in the contract, along with the name, title, phone number, and e-mail address of the person to notify in the event of an improper invoice or, in the case of payment by method other than Electronic Funds</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 79</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 10.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Transfer, to whom payment is to be sent. Provide the Contractor&#8217;s Vendor Identification Number (VIN), and Data Universal Numbering System (DUNS) number or DUNS+4. The DUNS number must identify the Contractor&#8217;s name and address exactly as stated on the face page of the contract. When an approved assignment has been made by the Contractor, or a different payee has been designated, provide the same information for the payee as is required for the Contractor (i.e., name, address, point of contact, VIN, and DUNS).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Invoice/Financing</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Request</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Number:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the appropriate serial number of the payment request.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Date</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Invoice/Financing</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Request</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Prepared:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the date the payment request is prepared.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(e)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Contract</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Number</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">and</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Order</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Number</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">(if</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">applicable):</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the contract number and order number (if applicable).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(f)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Effective</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Date:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the effective date of the contract or if billing under an order, the effective date of the order.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(g)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Total</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Estimated</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cost</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Contract/Order:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the total estimated cost of the contract, exclusive of fixed-fee. If billing under an order, insert the total estimated cost of the order, exclusive of fixed-fee.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(h)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Total</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fixed-Fee:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the total fixed-fee (where applicable).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(i)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Two-Way/Three-Way</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Match:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Identify payment to be made using a three-way match.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(j)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Office</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Acquisitions:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the name of the Office of Acquisitions, as identified in Section G of the Contract Schedule.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(k)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Central</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Point</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Distribution:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the Central Point of Distribution, as identified in the Invoice Submission Instructions in Section G of the Contract Schedule.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(l)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Billing</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Period:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the beginning and ending dates (month, day, and year) of the period in which costs were incurred and for which reimbursement is claimed.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(m)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Amount</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Billed</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Current</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Period:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the amount claimed for the current billing period by major cost element, including any adjustments and fixed-fee. If the Contract Schedule contains separately priced line items, identify the contract line item(s) on the payment request and include a separate breakdown (by major cost element) for each line item.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(n)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Amount</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Billed</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cumulative:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the cumulative amounts claimed by major cost element, including any adjustments and fixed-fee. If the Contract Schedule contains separately priced line items, identify the contract line item(s) on the payment request and include a separate breakdown (by major cost element) for each line item.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(o)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Direct</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Costs:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the major cost elements. For each element, consider the application of the paragraph entitled "Costs Requiring Prior Approval" on page 1 of these instructions.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="TEXT-ALIGN: left; WIDTH: 54pt">
<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1) </font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Direct</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Labor:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include salaries and wages paid (or accrued) for direct performance of the contract.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 10.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For Level of Effort contracts only, the Contractor shall provide the following information on a separate sheet of paper attached to the payment request:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 81pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">hours or percentage of effort and cost by labor category (as specified in the Level of Effort Article in Section F of the contract) for the current billing period, and</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 81pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">hours or percentage of effort and cost by labor category from contract inception through the current billing period. (NOTE: The Contracting Officer may require the Contractor to provide additional breakdown for direct labor, such as position title, employee name, and salary or hourly rate.)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fringe</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Benefits:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>List any fringe benefits applicable to direct labor and billed as a direct cost. Do not include in this category fringe benefits that are included in indirect costs.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(4)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Accountable</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Personal</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Property:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include permanent research equipment and general purpose equipment having a unit acquisition cost of $1,000 or more, with a life expectancy of more than two years, and sensitive property regardless of cost (see the HHS <font style="FONT-STYLE: italic; DISPLAY: inline">Contractor's</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Guide</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">for</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Control</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">of</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Government</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Property</font>). Show permanent research equipment separate from general purpose equipment.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 80</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 7.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On a separate sheet of paper attached to the payment request, list each item for which reimbursement is requested. An asterisk (*) shall precede the item if the equipment is below the $1,000 approval level. Include reference to the following (as applicable):</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">item number for the specific piece of equipment listed in the Property Schedule, and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">COA number, if the equipment is not covered by the Property Schedule.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 7.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Contracting Officer may require the Contractor to provide further itemization of property having specific limitations set forth in the contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(5)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Materials</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">and</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Supplies:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include equipment with unit costs of less than $1,000 or an expected service life of two years or less, and consumable material and supplies regardless of amount.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(6)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Premium</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pay:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>List remuneration in excess of the basic hourly rate.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(7)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Consultant</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fee:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>List fees paid to consultants. Identify consultant by name or category as set forth in the contract or COA, as well as the effort (i.e., number of hours, days, etc.) and rate billed.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(8)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Travel:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include domestic and foreign travel. Foreign travel is travel outside of Canada, the United States and its territories and possessions. However, for an organization located outside Canada, the United States and its territories and possessions, foreign travel means travel outside that country. Foreign travel must be billed separately from domestic travel.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(9)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Subcontract</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Costs:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>List subcontractor(s) by name and amount billed. Cite applicable COA or notification.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(10)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Other:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>List all other direct costs in total unless exceeding $1,000 in amount. If over $1,000, list cost elements and dollar amounts separately. If the contract contains restrictions on any cost element, that cost element must be listed separately.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(p)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cost</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Money</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">(COM):</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Cite the COM factor and base in effect during the time the cost was incurred and for which reimbursement is claimed.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(q)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Indirect</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Costs:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Identify the indirect cost base (IDC), indirect cost rate, and amount billed for each indirect cost category.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(r)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fixed-Fee:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Cite the formula or method of computation for fixed-fee, if applicable. The fixed-fee must be claimed as provided for by the contract.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(s)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Total</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Amounts</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Claimed:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Insert the total amounts claimed for the current and cumulative periods.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(t)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Adjustments:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include amounts conceded by the Contractor, outstanding suspensions, and/or disapprovals subject to appeal.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(u)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Grand Totals</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(v)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Certification</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Salary</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Rate</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Limitation:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>If required by the contract (see Invoice Submission Instructions in Section G of the Contract Schedule), the Contractor shall include the following certification at the bottom of the payment request:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 7.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;I hereby certify that the salaries billed in this payment request are in compliance with the Salary Rate Limitation Provisions in Section H of the contract.&#8221;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(w)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Signature</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 5.2pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Contracting Officer may require the Contractor to submit detailed support for costs claimed on one or more interim payment requests.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">FINANCIAL</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">REPORTING</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">INSTRUCTIONS</font>:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These instructions are keyed to the Columns on the sample invoice/financing request.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">A</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Expenditure</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Category:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Enter the expenditure categories required by the contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 81</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.9pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">B</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cumulative</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Percentage</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Effort/Hrs.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Negotiated:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Enter the percentage of effort or number of hours agreed to for each employee or labor category listed in Column A.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">C</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cumulative</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Percentage</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Effort/Hrs.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Actual:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Enter the percentage of effort or number of hours worked by each employee or labor category listed in Column A.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">D</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Amount</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Billed</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Current:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Enter amounts billed during the current period.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">E</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Amount</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Billed</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cumulative:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Enter the cumulative amounts to date.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column<font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">F</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cost</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">at</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Completion: <font style="FONT-WEIGHT: normal">Enter data only when the Contractor estimates that a particular expenditure category will vary from the amount negotiated. Realistic estimates are essential.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160; </font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160; Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">G</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Contract</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> Amount:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Enter the costs agreed to for all expenditure categories listed in Column A. </font></font>

<div align="left"><font size="2">&#160;</font></div>

<div align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160; Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">H</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold">-</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Variance</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">(Over</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">or</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Under):</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font>Show the difference between the estimated costs at completion (Column F) and negotiated costs (Column G) when entries have been made in Column F. This column need not be filled in when Column F is blank. When a line item varies by plus or minus 10 percent, i.e., the percentage arrived at by dividing Column F by Column G, an explanation of the variance should be submitted. In the case of an overrun (net negative variance), this submission shall not be deemed as notice under the Limitation of Cost (Funds) Clause of the contract.</font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Modifications:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Any modification in the amount negotiated for an item since the preceding report should be listed in the appropriate cost category.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 12.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Expenditures</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Not</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Negotiated:</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>An expenditure for an item for which no amount was negotiated (e.g., at the discretion of the Contractor in performance of its contract) should be listed in the appropriate cost category and all columns filled in, except for</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">G. Column H will of course show a 100 percent variance and will be explained along with those identified under H above.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 82</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SAMPLE INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORT</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="8%" style="BORDER-BOTTOM: black 2.75pt solid; BORDER-LEFT: #000000 2.5pt solid; BORDER-TOP: #000000 2.75pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(a)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(b)</font></div>
</td>
<td align="left" colspan="3" valign="top" width="37%" style="BORDER-BOTTOM: black 2.75pt solid; BORDER-TOP: #000000 2.75pt solid">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Designated Billing Office Name and Address:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DHHS/OS/ASPR/BARDA</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attn: Contracting Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 81.55pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">330 Independence Ave., S.W. Room G644</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Washington, D.C. 20201</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 19.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractor&#8217;s Name, Address, Point of Contact, VIN, and DUNS or DUNS+4 Number:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ABC CORPORATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 106.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100 Main Street Anywhere, USA Zip Code</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 10pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name, Title, Phone Number, and E-mail Address of person to notify in the event of an improper invoice or, in the case of payment by method other than Electronic Funds Transfer, to whom payment is to be sent.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">VIN:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DUNS or DUNS+4:</font></div>
</td>
<td align="left" valign="top" width="5%" style="BORDER-BOTTOM: black 2.75pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-TOP: #000000 2.75pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="5" valign="top" width="50%" style="BORDER-BOTTOM: black 2.75pt solid; BORDER-TOP: #000000 2.75pt solid; BORDER-RIGHT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 133.2pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(c)&#160; &#160;Invoice/Financing Request No.: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 133.2pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 133.2pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(d)&#160; &#160;Date Invoice Prepared:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 133.2pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(e)&#160; &#160;Contract No. and Order No. (if applicable): </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(f)&#160;&#160; &#160;</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effective Date:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left">(g)&#160;&#160; <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Estimated Cost of Contract/Order: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(h)&#160;&#160; Total Fixed-Fee (if applicable):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;&#160;&#160;&#160;&#160;&#160; [&#160; ]&#160; <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Two-Way Match: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; [&#160; ]&#160; Three-Way Match:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 144.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(i)&#160;&#160;&#160; Office of Acquisitions: </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 144.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 144.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(j)&#160;&#160;&#160;&#160; Central Point of Distribution:</font></div>
</td>
</tr><tr>
<td align="left" colspan="10" valign="top" width="84%" style="BORDER-BOTTOM: black 2.75pt solid; BORDER-LEFT: #000000 2.5pt solid; BORDER-RIGHT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(l) This invoice/financing request represents reimbursable costs for the period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</font></div>
</td>
</tr><tr>
<td colspan="2" rowspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9632;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expenditure Category*</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A</font></div>
</td>
<td align="left" colspan="2" valign="top" width="31%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 6.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cumulative Percentage of Effort/Hrs.</font></div>
</td>
<td colspan="3" valign="top" width="23%" style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount Billed</font></div>
</td>
<td rowspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 6.3pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cost at </font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 6.3pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Completion </font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 6.3pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F</font></div>
</td>
<td rowspan="2" valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contract </font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount </font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">G</font></div>
</td>
<td rowspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 9.9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Variance </font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 9.9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">H</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 9.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Negotiated </font></div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 9.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B</font></div>
</td>
<td align="left" valign="bottom" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 11.95pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actual </font></div>

<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 11.95pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">C</font></div>
</td>
<td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.3pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(m) </font></div>

<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.3pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current </font></div>

<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 12.3pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">D</font></div>
</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 1pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.95pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(n) </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.95pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cumulative </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 10.95pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">E</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(o) Direct Costs:</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) Direct Labor</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) Fringe Benefits</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3) Accountable Property</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4) Materials &amp; Supplies</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5) Premium Pay</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6) Consultant Fees</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7) Travel</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8) Subcontracts</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9) Other</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Direct Costs</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(p) Cost of Money</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(q) Indirect Costs</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(r) Fixed Fee</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(s) Total Amount Claimed</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(t) Adjustments</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 2.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(u) Grand Totals</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="19%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-RIGHT: #000000 2.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="10" valign="top" width="84%" style="BORDER-BOTTOM: black 2.5pt solid; BORDER-LEFT: #000000 2.5pt solid; BORDER-RIGHT: #000000 2.5pt solid">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I certify that all payments are for appropriate purposes and in accordance with the contract.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: arial, sans-serif; FONT-SIZE: 1pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Name of Official)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Title)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">* Attach details as specified in the contract</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 83</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 162pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 162pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 162pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 104.4pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="ATTACHMENT6"><!--EFPlaceholder--></a>ATTACHMENT 6</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="4" rowspan="2" valign="top" width="42%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-TOP: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 41.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FINANCIAL REPORT OF INDIVIDUAL PROJECT/CONTRACT</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 81pt; MARGIN-RIGHT: 48.15pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Note: Complete this Form in Accordance with Accompanying Instructions.</font></div>
</td>
<td align="left" colspan="3" valign="top" width="26%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid; BORDER-TOP: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Project Task:</font></div>
</td>
<td align="left" colspan="3" valign="top" width="25%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid; BORDER-TOP: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contract No.:</font></div>
</td>
<td align="left" colspan="2" valign="top" width="15%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid; BORDER-TOP: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date of Report:</font></div>
</td>
<td align="left" colspan="2" valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid; BORDER-TOP: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">0990-0134</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">0990-0131</font></div>
</td>
</tr><tr>
<td align="left" colspan="3" valign="top" width="37%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reporting Period:</font></div>
</td>
<td align="left" colspan="7" valign="top" width="56%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contractor Name and Address:</font></div>
</td>
</tr><tr>
<td align="left" rowspan="2" valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Expenditure Category</font></div>
</td>
<td align="left" colspan="2" valign="top" width="17%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 24.85pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Percentage of Effort/Hours</font></div>
</td>
<td colspan="2" rowspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 6.4pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cumulative </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 6.4pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Incurred Cost </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 6.4pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">at End of Prior </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 6.4pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Period</font></div>
</td>
<td rowspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 15.35pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Incurred Cost-- </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 15.35pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 15.35pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Period</font></div>
</td>
<td colspan="2" rowspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.15pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cumulative </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.15pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost to Date </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.15pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(D + E)</font></div>
</td>
<td rowspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost to </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 14.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Complete</font></div>
</td>
<td colspan="2" rowspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated Cost at Completion</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(F + G)</font></div>
</td>
<td colspan="2" rowspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.65pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Negotiated Contract Amount</font></div>
</td>
<td rowspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.1pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Variance (Over or Under) (I - H)</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="20%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Negotiated</font></div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; TEXT-ALIGN: center; BORDER-LEFT: #000000 0.85pt solid; BORDER-RIGHT: #000000 0.85pt solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actual</font></div>
</td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">A</font></div>
</td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.05pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">B</font></div>
</td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.05pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">C</font></div>
</td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.05pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">D</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">E</font></div>
</td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">F</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">G</font></div>
</td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.05pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">H</font></div>
</td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.05pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">I</font></div>
</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">J</font></div>
</td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="14%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="13%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 0.85pt solid; BORDER-LEFT: #000000 0.85pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 84</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ATTACHMENT 7</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 135.4pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INSTRUCTIONS FOR COMPLETING</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 135.4pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">"FINANCIAL REPORT OF INDIVIDUAL PROJECT/CONTRACT"</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GENERAL&#160;&#160;INFORMATION</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 5.85pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Purpose</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> This Quarterly Financial Report is designed to: (1) provide a management tool for use by be BARDA in monitoring the application of financial and personnel resources to the BARDA contracts; (2) provide contractors with financial and personnel management data which is usable in their management processes; (3) promptly indicate potential areas of contract underruns or overruns by making possible comparisons of actual performance and projections with prior estimates on individual elements of cost and personnel; and (4) obtain contractor's analyses of cause and effect of significant variations between actual and prior estimates of financial and personnel performance.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORTING&#160;&#160;REQUIREMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 14.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Scope.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>The specific cost and personnel elements to be reported shall be established by mutual agreement prior to award. The Government may require the contractor to provide detailed documentation to support any element(s) on one or more financial reports.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 14.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Number</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Copies</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">and</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Mailing</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Address.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>An original and two (2) copies of the report(s) shall be sent to the contracting officer at the address shown on the face page of the contract, no later than 30 working days after the end of the period reported. However, the contract may provide for one of the copies to be sent directly to the Contracting Officer&#8217;s Technical Representative.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORTING&#160;&#160;STATISTICS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 9.25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A modification which extends the period of performance of an existing contract will not require reporting on a separate quarterly report, except where it is determined by the contracting officer that separate reporting is necessary. Furthermore,&#160;&#160;when incrementally funded contracts are involved, each separate allotment is not considered a separate contract entity (only a funding action). Therefore, the statistics under incrementally funded contracts should be reported cumulatively from the inception of the contract through completion.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 14.5pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Definitions</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">and</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Instructions</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">for</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Completing</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">the</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Quarterly</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Report</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> For the purpose of establishing expenditure categories in Column A, the following definitions and instructions will be utilized. Each contract will specify the categories to be reported.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Key</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Personnel.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include key personnel regardless of annual salary rates. All such individuals should be listed by names and job titles on a separate line including those whose salary is not directly charged to the contract but whose effort is directly associated with the contract. The listing must be kept up to date.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Personnel--Other.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>List as one amount unless otherwise required by the contract.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fringe</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Benefits.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include allowances and services provided by the contractor to employees as compensation in addition to regular salaries and wages. If a fringe benefit rate(s) has been established, identify the base, rate, and amount billed for each category. If a rate has not been established, the various fringe benefit costs may be required to be shown separately. Fringe benefits which are included in the indirect cost rate should not be shown here.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(4)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Accountable</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Personal</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Property.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include nonexpendable personal property with an acquisition cost of $1,000 or more and with an expected useful life of two or more years, and sensitive items regardless of cost. Form HHS 565, "Report of Accountable Property," must accompany the contractor's public voucher (SF 1034/SF 1035) or this report if not previously submitted. See "Contractor's Guide for Control of Government Property."</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(5)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Supplies.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include the cost of supplies and material and equipment charged directly to the contract, but excludes the cost of nonexpendable equipment as defined in (4) above.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(6)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Inpatient</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Care.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include costs associated with a subject while occupying a bed in a patient care setting. It normally includes both routine and ancillary costs.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(7)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Outpatient</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Care.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include costs associated with a subject while not occupying a bed. It normally includes ancillary costs only.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(8)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Travel.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include all direct costs of travel, including transportation, subsistence and miscellaneous expenses. Travel for staff and consultants shall be shown separately. Identify foreign and domestic travel separately. If required by the contract, the following information shall be submitted: (i) Name of traveler and purpose of trip; (ii)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 85</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Place of departure,&#160;&#160;destination and return, including time and dates; and (iii) Total cost of trip.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(9)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Consultant</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fee.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include fees paid to consultant(s). Identify each consultant with effort expended, billing rate, and&#160;&#160;amount billed.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(10)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Premium</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pay.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include the amount of salaries and wages over and above the basic rate of pay.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(11)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Subcontracts.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>List each subcontract by name and amount billed.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(12)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Other</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Costs.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Include any expenditure categories for which the Government does not require individual line item&#160;&#160;reporting. It may include some of the above categories.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(13)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Overhead/Indirect</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Costs.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Identify the cost base, indirect cost rate, and amount billed for each indirect cost category.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(14)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">General</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">and</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Administrative</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Expense.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Cite the rate and the base. In the case of nonprofit organizations, this item will&#160;&#160;usually be included in the indirect cost.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(15)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fee.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Cite the fee earned, if any.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 49px">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(16)&#160;&#160;</font></div>
</td>
<td width="1836">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Costs to the Government. </font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; PREPARATION INSTRUCTIONS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These instructions are keyed to the Columns on the Quarterly Report.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">A--Expenditure</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Category</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> Enter the expenditure categories required by the contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">B--Percentage</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Effort/Hours</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Negotiated</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> Enter the percentage of effort or number of hours agreed to during contract negotiations for each labor category listed in Column A.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">C--Percentage</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Effort/Hours-Actual</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> Enter the cumulative percentage of effort or number of hours worked by&#160;&#160;each employee or group of employees listed in Column A.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 8.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">D--Cumulative</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Incurred</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cost</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">at</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">End</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">of</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Prior</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Period</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> Enter the cumulative incurred costs up to the end of the prior&#160;&#160;reporting period. This column will be blank at the time of the submission of the initial report.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">E--Incurred</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cost-Current</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Period</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> Enter the costs which were incurred during the current period.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">F--Cumulative</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Incurred</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cost</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">to</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Date</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> Enter the combined total of Columns D and E.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160; </font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">G--Estimated</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cost</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">to</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Complete</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> Make entries only when the contractor estimates that a particular expenditure&#160;&#160;category will vary from the amount negotiated. Realistic estimates are essential.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">H--Estimated</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Costs</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">at</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Completion</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> Complete only if an entry is made in Column G.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 48.1pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">I--Negotiated</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Contract</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Amount</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> Enter in this column the costs agreed to during contract negotiations for all&#160;&#160;expenditure categories listed in Column A.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 18pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Column</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">J--Variance</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">(Over</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">or</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Under)</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font> Complete only if an entry is made in Column H. When entries have been made in&#160;&#160;Column H, this column should show the difference between the estimated costs at completion (Column H) and negotiated&#160;&#160;costs (Column I). When a line item varies by plus or minus 10 percent, i.e., the percentage arrived at by dividing Column J by&#160;&#160;Column I, an explanation of the variance should be submitted. In the case of an overrun (net negative variance), this submission shall not be deemed as notice under the Limitation of Cost (Funds) Clause of the contract.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 8.75pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Modifications.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>List any modification in the amount negotiated for an item since the preceding report in the appropriate cost&#160;&#160;category.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 86</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 5.35pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 5.35pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Expenditures</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Not</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Negotiated.</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>List any expenditure for an item for which no amount was negotiated (e.g., at the discretion&#160;&#160;of the contractor in performance of its contract) in the appropriate cost category and complete all columns except for I.&#160;&#160;Column J will of course show a 100 percent variance and will be explained along with those identified under J above.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: right; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Page 87</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 133.3pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Department of Health &amp; Human Services HHS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 73.15pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="OfficeoftheAssistantSecretaryforPr"><!--EFPlaceholder--></a>Office of the Assistant Secretary for Preparedness and Readiness ASPR</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 73.15pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="BiomedicalAdvancedResearchandDevelop"><!--EFPlaceholder--></a>Biomedical Advanced Research and Development Authority BARDA</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 73.2pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 24pt">7 Principles of Earned Value Management</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 133.3pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 24pt">Tier 3</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 73.15pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 24pt">System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.8pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">01 October 2011</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><img src="seal.jpg" alt=""></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3pt" align="center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3pt" align="center"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 3pt" align="center"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TABLE OF CONTENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><br>
</font></div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">OVERVIEW</font></font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">1</font></font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><!--efplaceholder--><font style="DISPLAY: inline; FONT-WEIGHT: bold">EVM IMPLEMENTATION TIERS</font></font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">3</font></font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SEVEN PRINCIPLES OF EVM&#160;</font></font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">4</font></font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="principle1:planallworkscope4princ"><!--efplaceholder--></a>Principle 1: Plan all Work Scope</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principle 2: Break Work into Finite Pieces and Define Person/Organization Responsible for <font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Work </font></font></font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principle 3a: Integrate Scope, Schedule and Budget into a Performance Measurement Baseline</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principle 3b: Control Changes to the Baseline </font></font></font></div>
</td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principle 4: Use Actual Costs Incurred and Recorded in Accomplishing the Work Performed</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principle 5: Objectively Assess Accomplishments at the Work Performance Level</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principle 6a: Analyze Significant Variances From the Plan</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principle 6b: Prepare an Estimate at Completion Based on Performance to Date and Work to be Performed</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principle 7: Use EVMS Information in the Company&#8217;s Management Processes</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">10</font></font></td>
</tr><tr>
<td colspan="2" width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<a name="appendices10"><!--efplaceholder--></a><a name="appendix1:glossaryofterms10appendi"><!--efplaceholder--></a><font style="DISPLAY: inline; FONT-WEIGHT: bold">APPENDICES</font></font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">APPENDIX 1: Glossary of Terms</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Appendix 2 Supplemental EVM Implementation Guideline</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20</font></td>
</tr><tr>
<td width="3%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Appendix 3 Sample EVM Documents</font></td>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23</font></td>
</tr></table>
</div>

<div><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160; </font></font>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OVERVIEW</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="EarnedValueManagement(EVM)isaprogr"><!--EFPlaceholder--></a>Earned Value Management (EVM) is a program management tool, technique, and discipline that facilitates systematic planning for and monitoring of, high value, complex projects. It integrates a project&#8217;s scope of work with the related budget and schedule to permit detailed assessment of overall performance during the life of the project.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Severalgovernment-wideguidancedocumen"><!--EFPlaceholder--></a>Several government-wide guidance documents govern the definition and use of EVM systems. Guidelines outlining the qualities and characteristics of an EVM system are set forth in the American National Standards Institute/Electronic Industries Alliance (ANSI/EIA) Standard-748 (most current version). More detailed and specific guidance and direction is contained in OMB Circular A-11, <font style="FONT-STYLE: italic; DISPLAY: inline">Preparation,</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Submission </font><font style="FONT-STYLE: italic; DISPLAY: inline">and</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Execution</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">of</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">the</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Budget</font>, specifically in Part 7 of that Circular A-11, <font style="FONT-STYLE: italic; DISPLAY: inline">Planning,</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Budgeting,</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Acquisition,</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">and</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Management</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">of Capital</font><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">Assets</font>, and its supplement, the Capital Programming Guide.&#160;&#160;Based on this collective OMB guidance, EVMS is intended to be used on those parts of acquisitions that will involve developmental effort. This would include not only those acquisitions designated by the agency as major systems but also those acquisitions that include significant developmental, modification, or upgrade during the operational or steady-state phase of a program.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="TheFARruleonEVMSbecameeffectiveon"><!--EFPlaceholder--></a>The FAR rule on EVMS became effective on July 5, 2006.&#160;&#160;Its purpose is to implement EVMS policy in accordance with OMB Circular A-11. Because the new FAR coverage applies throughout the executive branch and to agencies with disparate definitions of and processes and procedures for major systems acquisitions, the FAR Council decided against a &#8220;one-size-fits all&#8221; approach and left several significant aspects of the detailed implementation up to the discretion of each covered agency.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 29.1pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="TheFARandHealthandHumanServicesAc"><!--EFPlaceholder--></a>The FAR and Health and Human Services Acquisition Regulations (HHSAR) language for EVMS will be utilized for all construction or Information Technology (IT) projects. Since most of the acquisitions at the Biomedical Advanced Research and Development Agency (BARDA) are unique in that most acquisitions are not Information Technology projects or construction projects, BARDA is developing EVM language that incorporates the 7 Principles of Earned Value Management. These principles allow flexibility to an EVM system structure but still meet the spirit of the ANSI/EIA Standard-748. It also incorporates discipline in implementation and operations and also provides the same reporting data outlined by OMB.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="TheSevenPrinciplesofEarnedValueMan"><!--EFPlaceholder--></a>The Seven Principles of Earned Value Management are as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="1.Planallworkscopetocompletion"><!--EFPlaceholder--></a>Plan all work scope to completion</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="2.Breakdowntheprogramworkscopeint"><!--EFPlaceholder--></a>Break down the program work scope into finite pieces that can be assigned to a responsible person or organization for control of technical, schedule and cost objectives</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="3.Integrateprogramworkscope,schedul"><!--EFPlaceholder--></a>Integrate program work scope, schedule, and cost objectives into a performance measurement baseline plan against which accomplishments can be measured. Control changes to the baseline.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="4.Useactualcostsincurredandrecorde"><!--EFPlaceholder--></a>Use actual costs incurred and recorded in accomplishing the work performed.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 73.15pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="5.Objectivelyassessaccomplishmentsat"><!--EFPlaceholder--></a>Objectively assess accomplishments at the work performance level.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="6.Analyzesignificantvariancesfromth"><!--EFPlaceholder--></a>Analyze significant variances from the plan, forecast impacts, and prepare an estimate at completion based on performance to date and work to be performed.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="7.Useearnedvalueinformationinthec"><!--EFPlaceholder--></a>Use earned value information in the company&#8217;s management processes.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160; </font></div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 81pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="EVMIMPLEMENTATIONTIERS"><!--EFPlaceholder--></a>EVM IMPLEMENTATION TIERS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 16.45pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="BARDAwillbeimplementingatieredappr"><!--EFPlaceholder--></a>BARDA will be implementing a tiered approach to EVM based on the type of acquisition, size of the acquisition and the technical readiness level. There are three tiers and they are as follows:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="TIER1"><!--EFPlaceholder--></a>TIER 1</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 28pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="ForallconstructioncontractsandITco"><!--EFPlaceholder--></a>For all construction contracts and IT contracts the ANSI/EIA-748 Standard for Earned Value Management Systems will apply and all relevant FAR/HHSAR clauses pertaining to EVMS will be incorporated in the contract. The National Defense Industrial Association (NDIA) Program Management Systems Committee (PMSC) ANSI/EIA-748 Standard for Earned Value Management Systems Intent Guide should be used as guidance.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TIER 2</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 26.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For countermeasure research and development contracts that have a total acquisition costs greater than or equal to $25 million and have a Technical Readiness Level (TRL) of less than 7 will apply EVM principles for tracking cost, schedule and technical performance that comply with the 7 Principles of EVM Implementation.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TIER 3</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Forcountermeasureresearchanddevelopm"><!--EFPlaceholder--></a>For countermeasure research and development contracts that have total acquisition costs less than </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">$25 million but greater than $10 million will apply EVM principles for tracking cost, schedule and technical performance that are consistent with the 7 Principles of EVM Implementation.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="ThisGuideisanexplanationoftheinte"><!--EFPlaceholder--></a>This Guide is an explanation of the intent of what is expected for a Tier 2 system implementation of the 7 Principles of EVM.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160; </font></div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 81pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="SEVENPRINCIPLESOFEVM"><!--EFPlaceholder--></a>SEVEN PRINCIPLES OF EVM</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Principle1:PlanallWorkScope"><!--EFPlaceholder--></a><a name="Inaperformancemeasurementsystemimpl"><!--EFPlaceholder--></a>Principle 1: Plan all Work Scope</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.4pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In a performance measurement system implementation the Statement of Work (SOW) should reflect all work that is to be performed. In a 7 Principles implementation a Work Breakdown Structure (WBS) shall be developed to include all elements of the SOW. The level of the WBS may not be as detailed as in a Tier 1 implementation. It would be developed at a higher level, such as level three or four, however, the government may expand specific technical legs to lower&#160;&#160;than level four and it may retract some non-technical legs to higher than 3.&#160;&#160;It is beneficial and </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">required to develop a WBS dictionary that explains what work is going to be performed in each WBS in detail. This will ensure that the contractor has identified all work scope and left no major work undefined. It is recommended that the work packages descriptions are clear and detailed so that there is an understanding of the work that is to be performed in the work packages. For the 7 Principles implementation programs it would be acceptable for the WBS Dictionary be expanded to include information that would normally be kept on a Work Authorization Document, such as charge numbers associated with the work, period of performance, the manager who is responsible for the work, and budget associated with the WBS. The additional &#8220;WAD info&#8221; would only be added to the lowest level (i.e. level 3 or 4) of the WBS. The roll up level WBS would only include scope. By doing this documentation is limited to one document instead of two.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="BydevelopingaWBSandaWBSDictionary"><!--EFPlaceholder--></a>By developing a WBS and a WBS Dictionary/Work Authorization Document the work scope has been defined but the documentation is greatly reduced and the costs associated with developing and updating the documentation is reduced. The intent of the combination document is not to reduce the level of information provided to the government but to reduce the amount of documents that need to be produced. An example of a WBS dictionary and Work Authorization document and what is expected on the document(s) is provided.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="InaTier3implementationitisnotnec"><!--EFPlaceholder--></a>In a Tier 3 implementation it is not necessary to provide a WBS Dictionary or a Work Authorization Document but it is important to develop a WBS and define a scope of work for each level of the WBS at the reporting level (usually level 3 or 2).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Principle2:BreakWorkintoFinitePiec"><!--EFPlaceholder--></a>Principle 2: Break Work into Finite Pieces and Define Person/Organization Responsible for Work</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 28.3pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Ina7PrinciplesTier2implementation"><!--EFPlaceholder--></a>In a 7 Principles Tier 2 implementation it is recommended that the work be broken into finite pieces in the schedule tool. It is recommended to plan the work by the lowest level WBS. The lowest level WBS (level 3 or 4) should be the control account and the activities would act as the work packages. Most of the normal functions accomplished when scheduling will be required on a 7 Principles Tier 3 implementation. These normal functions include, network scheduling, horizontal and vertical traceability, forecasting schedule start and completion dates, and running critical path analysis. As part of vertical traceability it is expected that all contract milestones will be listed on the schedule.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 99.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Thescheduleshouldincludebutisnotl"><!--EFPlaceholder--></a>The schedule should include but is not limited to include the following fields:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 99.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">WBS number</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="ControlAccountnumberWorkpackagenumb"><!--EFPlaceholder--></a>Control Account number</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Work package number</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 364.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="TasknameDuration"><!--EFPlaceholder--></a>Task name </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 364.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Duration</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 364.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Baseline Start and Finish Dates</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 364.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actual Start and Finish Dates </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 364.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Forecast Start and Finish Dates</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 364.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Predecessor/Successors </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 364.85pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Activity Percent Complete</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Alltheworkscheduledatthelowestlev"><!--EFPlaceholder--></a>All the work scheduled at the lowest level WBS should be identified by a single responsible manager. This manager, known as a Control Account Manager should be identified in the schedule tool and/or in a cost tool. In a 7 Principles implementation, only individuals at the lowest level WBS need be identified and there is no requirement for the costs to roll up by organization, although if it is not cost intensive or tool restricted then developing the OBS is recommended. In many cases, BARDA will provide the top three levels of the WBS for the contractor to use.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Principle3a:IntegrateScope,Schedule"><!--EFPlaceholder--></a>Principle 3a: Integrate Scope, Schedule and Budget into a Performance Measurement Baseline</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 26.05pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Thisprincipleintegratestheworkscope"><!--EFPlaceholder--></a>This principle integrates the work scope, the schedule and the budget into a performance measurement baseline. Since we discussed work scope and schedule the focus of this principle is the incorporation of the budget in a time-phased manner. The budget must be integrated with the scope of work and the schedule into a Performance Measurement Baseline (PMB). The budget is made up of both direct and indirect dollars. An accepted way of incorporating the budget and integrating with the scope and schedule is to resource load the Microsoft Project (or other scheduling tool) schedule. This is done by loading the individual people and their loaded rate&#160;&#160;into the tool. This budget data will be input at the work package level with a rate that includes&#160;&#160;the indirect costs. The budget will have to have the capability to be rolled up to the control account level and will need to be reported in a way that provides the responsible manager (Control Account Manager) with information needed to manage the program. Resource loading of the schedule is not the only way to incorporate the budget. As long as the budget in the budget/EV tool is linked to the schedule activities and it is flexible to change when schedule baseline dates change, then loading the budget in the Budget/EV tool is an acceptable way to integrate the cost and schedule baselines. The budget information will be displayed on the time- phased Control Account Plan reports. These reports should have the flexibility to report the dollars both in total dollars, as well as, direct and indirect broken out separately. Also the report&#160;&#160;is generally required as a deliverable on most contracts and must have the capability to include earned value or Budgeted Cost of Work Performed (BCWP) and actual costs or Actual Costs of Work Performed (ACWP).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Budgetingofsubcontractoreffortwillv"><!--EFPlaceholder--></a>Budgeting of subcontractor effort will vary depending on whether or not the subcontractor is a cost plus or fixed price subcontract. If it is cost plus then the expectation is that there will be monthly billing of costs from the subcontractor to the prime contractor and therefore budget must be planned in accordance with the work completed and billed. If it is fixed price then the budget should be planned with work execution or milestones completed and budget should only be planned in those months where work is expected to be completed.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 26.65pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Itisrecommendedthatmanagementreserv"><!--EFPlaceholder--></a>It is recommended that management reserve and undistributed budget be utilized in the budgeting process. Undistributed budget is budget that has not yet been distributed to a control account and it requires additional time to plan the work and distribute the budget to a control account. It is a temporary holding account and budget should only stay in Undistributed Budget for one or two months. If the work scope is easily identified to all the control accounts then the use of Undistributed Budget may not be necessary.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 29.1pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="ManagementReserveisbudgetthatisset"><!--EFPlaceholder--></a>Management Reserve is budget that is set aside, normally by the Program Manager, to be used to budget future but currently unknown tasks. It is associated with risk issues and is to be used to mitigate risk. It is not part of the Performance Measurement Baseline and it should not be used for out of scope work and to cover overruns.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Principle3b:ControlChangestotheBas"><!--EFPlaceholder--></a>Principle 3b: Control Changes to the Baseline</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.55pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="AproperlycontrolledPMBiscrucialto"><!--EFPlaceholder--></a>A properly controlled PMB is crucial to effective program management. The timely and accurate incorporation of contractual changes ensures that the information generated from the execution of the baseline plan provides an accurate picture of progress and facilitates correct management actions and decisions. The accurate and timely incorporation of authorized and negotiated changes into the PMB ensures that valid performance measurement information is generated for&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the new scope being executed.&#160;&#160;Near term new scope effort should be planned and have budget in control accounts. Far term new scope effort that cannot be reasonably planned in the near term can either be put in planning packages in the control account or left in Undistributed Budget if the control account has not been identified. The timely and accurate incorporation of authorized and negotiated changes into the PMB ensures that valid performance measurement information is generated for the new scope being executed. Budget revisions are made when work is added to the contract and are traceable from authorized contract target costs to the control account budgets&#160;&#160;or from management reserve. Management reserve may be used for future work when additional in- scope work has been identified.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Retroactivechangestothebaselinemay"><!--EFPlaceholder--></a>Retroactive changes to the baseline may mask variance trends and prevent the use of performance data to project estimates of cost and schedule at completion. Controlling retroactive adjustments, which should only be made in the current period, if possible, is imperative because they could arbitrarily eliminate existing cost and schedule variances.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 15.7pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Theuseofprogrambudgetlogsshouldbe"><!--EFPlaceholder--></a>The use of program budget logs should be used to track and log all budget changes. The ability to track budget values for both the internal and external changes will help in the maintenance of the performance measurement baseline from program start to completion. Contractor is expected to utilize baseline change documentation facilitating the change. It should provide the rationale/justification, approval process, work scope additions or deletions, dollars, changes to schedules, estimate at completion, etc. It should also include contractual change documents for external changes, such as a contract modification, letter to proceed, not to exceed letter, change order, etc., that transmit and authorize the change or addition to work, budget, and schedule. </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other documents that should change if a change of scope has been authorized is: Statement of Work, WBS (changes if applicable); WBS Dictionary (additions or deletions to scope); work authorization documents authorizing new scope, schedule and budget; schedules.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Principle4:UseActualCostsIncurreda"><!--EFPlaceholder--></a>Principle 4: Use Actual Costs Incurred and Recorded in Accomplishing the Work Performed</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 26.4pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="SomeofthenewacquisitionsatBARDAwi"><!--EFPlaceholder--></a>Some of the new acquisitions at BARDA will be required to be compliant with the Cost Accounting Standards. For Tier 3 implementation contractors must utilize a work order/job order/task code charge number structure that uniquely identifies costs at the control account level, which may be as high as the reporting level of the WBS. This will allow for accumulation and summarization of costs to higher levels of the work breakdown structure. Actual costs are accumulated in the formal accounting system in a manner consistent with the way the related work is planned and budgeted. Actual costs reported in the performance reports agrees with the costs recorded in the accounting system or can be explained as timing differences. The contractor will have to be able to incorporate and reconcile to the accounting system actual costs on their Contract Performance Reports (CPR) to the customer.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Dependingontheamountofmaterialand"><!--EFPlaceholder--></a>Depending on the amount of material and subcontractors on the program, it may be necessary for reporting purposes, to include accruals, or estimated actuals, for these costs. Since material and subcontractor invoices are not paid and recorded in the accounting system for up to several </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">months after the work has been planned, performance data will be skewed. Accruing or estimating actual costs based on receipt (for material) and expended hours for subcontractors will&#160;&#160;alleviate this issue. The use of accrual/estimated actuals should be reviewed on a case by case&#160;&#160;basis depending on the size of program, the amount of material or subcontractor budget and costs.&#160;&#160;If&#160;&#160;&#160;the material and subcontract effort on the project is minimal (represents less than 5% of the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">project budget) then the time and effort needed to manage the accruals would outweigh the benefit of having the costs accrued since the performance data would only be minimally affected. </font></font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although actual costs are generally reported to the USG in total dollars the system must be able to differentiate and report direct costs and indirect costs if requested.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 17.2pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Ifthesubcontractorhasafixedpricec"><!--EFPlaceholder--></a>If the subcontractor has a fixed price contract the prime contractor, then the prime contractor must report actual costs in accordance with the work that is accomplished. This is acheived by&#160;&#160;recording the actual costs equal to the work that was performed in the EVM system and on the CPR. If the subcontractor is a cost plus contract its imperative the costs the prime reports is in accordance with the costs incurred in that month. This is necessary to ensure that the data&#160;&#160;reported is not skewed. With this premise, fixed price subcontractors cost variances should not&#160;&#160;exist or be reported on the CPR whereas the cost reported for cost plus subcontractors should be&#160;&#160;based on what was incurred and not what has been invoiced to date, which may be months behind.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Principle5:ObjectivelyAssessAccompli"><!--EFPlaceholder--></a><a name="InordertomeetthisPrinciple,thesch"><!--EFPlaceholder--></a>Principle 5: Objectively Assess Accomplishments at the Work Performance Level</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In order to meet this Principle, the scheduling of the scope of work in work packages or activities need to incorporate measurable units or milestones in order to objectively assess accomplishments or obtain what we call &#8220;earned value&#8221;. These units or milestones are given a value based on labor resources needed to accomplish the work (which becomes the Budgeted Cost of Work Scheduled or BCWS). When they are accomplished (known as Budgeted Cost of Work Performed or BCWP) they receive the value associated with the budget which measures progress.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160; </font></div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Schedule status to measure progress needs to be on at least on a monthly basis although it is preferred on a bi-weekly basis. As part of the status process progress dates, such as actual start/complete and forecast start/complete need to be updated.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.15pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since Microsoft Project seems to be the schedule tool of choice by most contractors, there are four types of earned value methodologies utilized by Microsoft Project of which two assess progress by the completion of milestones and they are the 50/50 and 0/100 methodologies. In both cases, progress is reported for completion milestones and in the 50/50 methodology fifty percent of the value of the work package/activity is credited for starting the work. The other two earned value methodologies are assessed percent complete (also know as Supervisor&#8217;s Estimate) and level of effort (LOE). All four methodologies are legitimate earn value measurement techniques.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.1pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additional earned value methodologies, such as the weighted milestone methodology and percent complete with milestone gates may be utilized. The weighted milestone method allows value to be earned based on the resource value in each month, which eliminates artificial schedule variances.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.1pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For subcontractors that have a fixed price contract with the prime contractor, the expectation is that there will be no cost variance. The ACWP reported on the CPR will equal the BCWP earned, regardless of the payment schedule with subcontractor.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Principle6a:AnalyzeSignificantVarian"><!--EFPlaceholder--></a>Principle 6a: Analyze Significant Variances From the Plan</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.4pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Thepurposeofthisprincipleistoensu"><!--EFPlaceholder--></a>The purpose of this principle is to ensure that the earned value data is analyzed by the contractor and reported to the customer. The 7 Principles programs should be able to calculate the cost variance (BCWP minus Actual Cost of Work Performed (ACWP) and the schedule variance (BCWP minus BCWS) at least on a cumulative basis. It is recommended that variances be calculated on a current month basis also. The EVM system should also provide both monthly and cumulative Cost Performance Index (BCWP divided by ACWP) and Schedule Performance Index (BCWP divided by the BCWS). This data should be provided at the control account level&#160;&#160;and at the roll up levels and it needs to be in a format for Control Account Managers and program management to be able to utilize in managing the work.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 16.9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">It is also recommended that the To-Complete Performance Index (TCPI) be included in the Control Account Manager performance report. The TCPI is a valuable index that calculates the cost performance the control account needs to perform at in order to complete the work within the current reported EAC. When the TCPI is compared against the cumulative CPI it gives a good indication whether or not the current EAC is reasonable. For example, if a cumulative CPI is .85 and the TCPI calculates to equal 1.15 that is the performance factor that work would need to perform at in order to meet the current EAC. If the cumulative CPI is .85 then it can be determined that the current EAC might not be reasonable. It allows management and Project Controls the opportunity to question the Control Account Manager as to the validity of the current EAC. As a rule in thumb if the deviation between the CPI and the TCPI is greater than .2&#160;&#160;then&#160;&#160;the CAM should reassess the control account EAC.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These reports, which should be provided monthly, should also include the current Budget at Completion (BAC) and the current Estimate at Completion (EAC). In addition, it would be a</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="plusiftheCAMcouldseeareportwith"><!--EFPlaceholder--></a>plus if the CAM could see a report with their time-phased spread of hours and dollars for their budget plan (BCWS), work accomplished (BCWP) and actual costs (ACWP).</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For all variances that exceed the contractual variance threshold will include a description of what caused the variance, impact to the control account and the program, and a corrective action.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Principle6b:PrepareanEstimateatCom"><!--EFPlaceholder--></a>Principle 6b: Prepare an Estimate at Completion Based on Performance to Date and Work to be Performed</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.25pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Providing an updated EAC is a prime concern of the customer and the contractor. Therefore a robust EAC process should be in place whether the program is ANSI compliant or not.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.15pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on the performance to date the Estimates at Completion can be updated on a monthly basis by the Control Account Manager in the scheduling tool during the status process or in the cost/EVM tool at the end of the month&#8217;s process prior to submittal of the EVM report. The EAC is an element of the performance measurement system that needs to accurately reflect the contractor&#8217;s best estimate of what it will cost to complete the project.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.15pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Program management should be able to validate control account manager&#8217;s EACs by looking at performance indices, such as the To-Complete Performance Index, as well as independent statistical EACs.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Principle7:UseEVMSInformationinthe"><!--EFPlaceholder--></a>Principle 7: Use EVMS Information in the Company&#8217;s Management Processes</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17.3pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">One of the key areas that concerns government Program Management Offices (PMO) is the level of importance that contractor&#8217;s place on EVM as a management tool. During a site visit, such as conducting an Integrated Baseline Review, the PMO gauges what the interest, knowledge, and most importantly, the usage of the performance measurement data in managing the program. <font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">They want to know that the managers on the program, including the program manager, have received some earned value training. The level of involvement and use of the EVM data to manage their schedule, cost and technical issues is ascertained by questions. The PMO can also tell by how robust the EACs are and if the variance narratives are being written with impacts to the program and corrective actions being monitored by the contractor. It is important that the contractor&#8217;s management team, including the Program Manager, utilize the data from the performance measurement system as a management tool. They should be knowledgeable and understand the data. They should know what is causing the variances and ensure that the variance narratives are written properly and answer what the issues, impacts and corrective actions are. They should be able to demonstrate that they use the information to assist them in the management decision process.</font></font> </font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt">9</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="APPENDICES"><!--EFPlaceholder--></a>APPENDICES</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Thefollowingappendicesprovidefurther"><!--EFPlaceholder--></a>The following appendices provide further support in understanding the meaning and intent of properly implementing the 7 Principles of EVM.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Appendix1isaglossaryofthetermsus"><!--EFPlaceholder--></a>Appendix 1 is a glossary of the terms used in the Intent Guide.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Appendix2issupplementalguidanceonE"><!--EFPlaceholder--></a>Appendix 2 is supplemental guidance on EVM implementation. It provides some guidelines on what is expected in the implementation, required documents needed for the Performance Measurement Baseline Review, expected EVM implementation costs, EVM engines functionality needs, explains what is expected in the monthly EVM facilitation, discusses what EVM consultants need to know, and what the expected costs of EVM to BARDA.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Appendix3areexamplesofsomeoftheE"><!--EFPlaceholder--></a>Appendix 3 are examples of some of the EVM documents that are needed in an EVM system. There are three documents and they mostly apply to Tier 2 EVM implementations. These documents are samples and are not a reflection of the specific way the document must look.&#160;&#160;It&#8217;s included to provide contractors with an understanding of the type of information that is expected on these forms.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="APPENDIX1:GlossaryofTerms"><!--EFPlaceholder--></a>APPENDIX 1: Glossary of Terms</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="24%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 40.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actual Cost of Work Performed (ACWP)</font></div>
</td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 23.5pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The costs actually applied and recorded in accomplishing the work performed within a specified period.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="24%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Actual Direct Cost</font></div>
</td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 11.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Those costs identified specifically with a contract, based upon the contractor's cost identification and accumulation system as accepted by the cognizant DCAA representatives. (See Direct Costs).</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="24%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Advance Agreement (AA)</font></div>
</td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30.5pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">An agreement between the contractor and the Contract Administration Office concerning the application of an approved earned value management system to contracts within the affected facility.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="24%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Authorized Work</font></div>
</td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 13.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">That effort which has been authorized and is on contract, or that for which authorized contract costs have not been agreed to but for which written authorization has been received.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160; </font>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Baseline</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(See Performance Measurement Baseline).</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Budget at Completion (BAC)</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 23.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The sum of all budgets (BCWS) allocated to the contract. Synonymous with the term Performance Measurement Baseline.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 31.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Budgeted Cost for Work Performed (BCWP)</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 19.25pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The sum of the budgets for completed Work Packages and completed portions of open Work Packages, plus the appropriate portion of the budgets for level of effort and apportioned effort (Also see Earned Value).</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 31.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Budgeted Cost for Work Scheduled (BCWP)</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 18.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The sum of the budgets for completed Work Packages, planning packages, etc., scheduled to be accomplished (including in-process Work Packages), plus the amount of level of effort and apportioned effort scheduled to be accomplished within a given time period.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change Order (CO)</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 11.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A formal authorization by the Procuring Contracting Officer for a change of scope to an existing contract</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contract Modification</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 13.5pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A written and binding authorization to proceed created after change proposal negotiations.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contract Budget Base (CBB)</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 37.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The negotiated contract cost plus the estimated cost of authorized unpriced work, where:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 11.75pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) Negotiated Contract Cost is that cost on which contractual agreement has been reached. For an incentive contract, it is the definitized contract target cost plus/minus the value of changes which have been priced and incorporated into the contract through contract change order or supplemental agreement. For fixed-fee contracts, it is the negotiated estimated cost. Changes to the estimated cost will consist only of the formal contract modifications or change orders or change in the contract statement of work, not for cost growth, and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt">11</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) Estimated cost of authorized, unpriced work is the estimated cost (excluding fee or profit) for that work for which written authorization has been received, but for which definitized contract prices have not been incorporated into the contract through supplemental agreement.</font></font></td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Control Account</font></div>
</td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 15.5pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A management control point at which actual costs can be accumulated and compared to budgeted cost for work performed. A control account is a natural control point for cost/schedule planning and control since it represents the work assigned to one responsible organizational element on one contract work breakdown structure (CWBS) element.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 24.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Control Account Manager (CAM)</font></div>
</td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 17.85pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A member of a functional organization responsible for task performance detailed in a Control Account and for managing the resources authorized to accomplish the tasks.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 12.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Control Account Plan (CAP) Report</font></div>
</td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 19.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A CAP report is a timephased report which reflects all the work and effort to be performed in a control account. The CAP report will reflect the hours and dollars by element of cost (labor, subcontract, ODC, etc) and may also include milestone information.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 10.3pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contract Performance Report (CPR)</font></div>
</td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 13.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The monthly report submitted to the customer showing the current, cumulative and at completion status, the performance measurement baseline, manpower loading, and a narrative explanation of significant program variances.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contract Target Cost</font></div>
</td>
<td align="left" valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 12.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The dollar value (excluding fee or profit) negotiated in the original contract plus the cumulative cost (excluding fee or profit) applicable to all definitized changes to the contract. It consists of the estimated cost negotiated for a cost plus&#160;&#160;fixed fee contract and the definitized target cost for an incentive contract. The contract target cost does not include the value of authorized/un-negotiated work, and is thus equal to the contract budget base only when all authorized work has been negotiated/definitized.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt">12</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font><br>
</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cost Performance Index (CPI)</font></div>
</td>
<td align="left" valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 14.95pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">An efficiency rating reflecting a project's budget performance - either over or under. Measured as a ratio of the budgeted value of work accomplished versus the actual costs expended for a given project time period. The formula for CPI is BCWP/ACWP.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Discrete Effort</font></div>
</td>
<td align="left" valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 34.2pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Program effort that has a measurable output, product or service.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Direct Costs</font></div>
</td>
<td align="left" valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.95pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Those costs (labor, material, etc.) that can be reasonably and consistently related directly to service performed on a unit of work, and are charged directly to the contract, without distribution to an overhead unit.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Earned Value</font></div>
</td>
<td align="left" valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See Budgeted Cost for Work Performed (BCWP)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 22.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Earned Value Management System (EVMS)</font></div>
</td>
<td align="left" valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A project management system utilized for measuring project progress in an objective manner. Combines measurements of scope, schedule, and cost in a single integrated system.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Estimate at Completion (EAC)</font></div>
</td>
<td align="left" valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 11.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A value (expressed in dollars and/or hours) developed to represent a realistic appraisal of the final cost of tasks when accomplished. It&#8217;s the sum of direct &amp; indirect costs to date plus the estimate of costs for all authorized Work remaining. The EAC = ACWP + the Estimate-to-Complete.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Estimate to Completion (ETC)</font></div>
</td>
<td align="left" valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 29.35pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A value (expressed in dollar and/or hours) developed to represent a realistic appraisal of the cost of the work still required to be accomplished in completing a task.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Indirect Costs</font></div>
</td>
<td align="left" valign="top" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 43pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Represents those costs, because they are incurred for common or joint objectives, are not readily subject to</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt">13</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;treatment as direct costs. (See overhead).</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 18.3pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Integrated Baseline Review (IBR)</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 11.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">An Integrated Baseline Review (IBR) also known as Performance Measurement Baseline Review (PMBR) is a formal review led by the Government Program Manager and Technical Support Staff. An IBR is conducted jointly with the Government and their Contractor counterparts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 17.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The purpose of an IBR is to: verify the technical content of the Performance Measurement Baseline (PMB); assess the accuracy of the related resources (budgets) and schedules; identify potential risks.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Integrated Master Plan (IMP)</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 27.2pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The overall program plan including the work definition, technical approach, performance criteria, and completion criteria.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 19pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Integrated Master Schedule (IMS)</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 26.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The IMS expands the IMP to the work planning level. It defines the tasks, their durations, milestones, milestone dates which relate to the IMP completion criteria, and interdependencies required to complete the program. The IMP and IMS are used to track and execute the program.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Integrated Product Team (IPT)</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 27.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A grouping of project personnel along project objective lines rather than along organizational lines. Integrated Product Teams are work teams that represent a transition from a functional organization structure to a multi- functional project objective arrangement.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Internal Replanning</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 11.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Replanning actions performed by the program for remaining effort within the recognized total allocated budget.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level of Effort (LOE)</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 16.15pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Work that does not result in a final product, e. g., liaison, coordination, follow-up, or other support activities, and which cannot be effectively associated with a definable end</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt">14</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;product process result. It is measured only in terms of resources actually consumed within a given time period.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management Reserve (MR)</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.2pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">An amount of the total Contract Budget Base (CBB) withheld for management control purposes rather than designated for the accomplishment of a specific task or set of tasks. It is not a part of the Performance Measurement Baseline.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 16.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Negotiated Contract Target Cost</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 23.2pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The estimated cost negotiated in a Cost Plus Award Fee (CPAF), Cost Plus Fixed Fee (CPFF), Cost Plus Incentive Fee (CPIF) or Fixed Price Incentive Fee (FPIF) contract.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Original Budget</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The budget established at, or near, the time the contract was signed, based on the negotiated contract cost.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Overhead</font></div>
</td>
<td valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 16.8pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Indirect labor and material, supplies and services costs and other charges, which cannot be consistently identified with individual programs.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other Direct Costs</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 21.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A group of accounting elements which can be isolated to specific tasks, other than labor and material. Included in ODC are such items as travel, computer time, and services</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 17.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Performance Measurement Baseline (PMB)</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 12.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The time-phased budget plan against which contract performance is measured. It is formed by the budgets assigned to scheduled Control Accounts and the allocation of overhead costs. For future effort, not planned to the Control Account level, the performance measurement baseline also includes budgets assigned to higher level WBS elements, and undistributed budgets. It equals the total assigned budget less management reserve.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Performing Organization</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 11.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A defined unit within the program organization structure, which applies the resources to performs the authorized scope</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt">15</font></font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></font></font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;of work.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Planning Package</font></div>
</td>
<td valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160; A logical aggregation of far term work within a Control Account that can be identified and budgeted but not yet defined into Work Packages.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reprogramming</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160; Replanning of the effort remaining in the contract, resulting in a new budget allocation which exceeds the contract budget base. The resulting baseline is called an Over Target Baseline (OTB).</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Responsible Organization</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;A defined unit within program&#8217;s organization structure that is assigned responsibility for accomplishing specific tasks.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk Register</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 22.5pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Is a tool commonly used in project planning and organizational risk assessments. It is often referred to as a Risk Log. It is used for identifying, analyzing and managing risks.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 11.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Schedule Performance Index (SPI)</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 11.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">An efficiency rating reflecting how quickly or slowly project work is progressing. Measured as a ratio of work accomplished versus work planned for a given period of time. The formula for SPI is BCWP/BCWS.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Significant Variances</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 13.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Those differences between planned and actual cost and schedule performance which require further review, analysis, or action. Appropriate thresholds are established as to the magnitude of variances which will require variance analysis.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 43.3pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Statistical Estimate at Completion</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 18.4pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Is a single point estimate that can be quickly prepared and used to test the reasonableness of the current cost estimates and budget and to indicate when a comprehensive EAC should be prepared</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt">16</font></font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font size="2"><font size="2"><br>
</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><!--efplaceholder-->Time-Phased S/P/A Report</font></div>
</td>
<td valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Provides the timphased budget, performance (earned value) <font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and actual costs at a specific level. It may be at the reporting level, control account, and/or work package level. In all cases the report will also provide the data at the total project level.</font></font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">To-Complete Performance Index (TCPI)</font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="anefficiencyratingthatprovidesapro"><!--efplaceholder--></a>An efficiency rating that provides a projection of the anticipated performance required to achieve the EAC. TCPI indicates the future required cost efficiency needed to achieve a target EAC (Estimate At Complete). Any significant difference between TCPI and the CPI needed to meet the EAC should be accounted for by management in their forecast of the final cost.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Allocated Budget (TAB) </font></div>
</td>
<td align="left" valign="top" width="65%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The sum of all budgets allocated to the contract. Total <font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">allocated budget consists of the performance measurement baseline and all management reserve. The total allocated budget will reconcile directly to the Contract Budget Base (CBB). Any differences will be documented as to quantity and cause.</font></font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <a name="undistributedbudget(ub)budgetapplica"><!--efplaceholder--></a>Undistributed Budget (UB)</font></td>
<td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Budget applicable to contract effort which has not yet been <font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">identified to WBS elements at or below the lowest level of reporting to the Government.</font></font></font></td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Variance Analysis Report (VAR)</font></font></font></td>
<td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The internal report completed by the Control Account Manager and submitted, through the Intermediate Manager, to the program manager for those Control Accounts which have variances in excess of established thresholds.</font></td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<a name="variances(seesignificantvariances)."><!--efplaceholder--></a>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Variances</font></td>
<td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; (See Significant Variances).<a name="aformusedtoformallyauthorizeandbu"><!--efplaceholder--></a></font></td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="65%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<a name="workauthorizationdocument(wad)"><!--efplaceholder--></a>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Work Authorization Document (WAD)</font></td>
<td valign="top" width="65%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; A form used to formally authorize and budget work to the Control Account Manager. This document must include, as a minimum, the Control Account number, Statement of Work, scheduled start and finish dates, budget, and </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt">17</font></font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></font></font></div>
</div>
</div>

<font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="65%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160; the <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">identity of the CAM. It must be approved by Intermediate Manager, and be agreed to by the Control Account Manager.</font></font></td>
</tr><tr>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="65%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Work Breakdown Structure (WBS)</font></div>
</td>
<td valign="top" width="65%" style="TEXT-ALIGN: left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A product-oriented, family-tree composed of hardware, software, services, data and facilities which results from system engineering efforts. A work breakdown structure displays and defines the product(s) to be developed and/ or produced and relates the elements of work to be accomplished to each other and to the end product.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Program WBS.&#160;&#160;The work breakdown structure that covers the acquisition of a specific defense material item and is related to contractual effort. A program work breakdown structure includes all applicable elements consisting of at least the first three levels of the work breakdown structure and extended by the program manager and /or contractor(s). A program work breakdown structure has uniform element terminology, definition, and placement in the family tree structure.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contract WBS (CWBS) The complete WBS for a contract, developed and used by a contractor within the guidelines of MIL-Handbook 881 (latest revision) or NASA WBS Handbook (insert reference) or other customer guidelines and according to the contract work statement.&#160;&#160;It includes the approved work breakdown structure for reporting purposes and its discretionary extension to the lower levels by the contractor, in accordance with MIL- Handbook 881 and the contract work statement. It includes all the elements for the products (hardware, software, data, or services) which are the responsibility of the contractor.</font></div>
</td>
</tr><tr>
<td valign="top" width="35%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="65%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="35%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Work Packages</font></div>
</td>
<td valign="top" width="65%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Detailed short-span jobs, or material items, identified by the contractor for accomplishing work required to complete the contract. A Work Package has the following characteristics.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160; </font>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt">18</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="35%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="65%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160; 1.</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black"> </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="1.itrepresentsunitsofworkatlevels"><!--efplaceholder--></a>It represents units of work at levels where work is performed.</font></font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160; 2.</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black"> </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="2.itisclearlydistinguishablefromal"><!--efplaceholder--></a>It is clearly distinguishable from all other work packages.</font></font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3. <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">It is assignable to a single organizational element.</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4.</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black"> </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="4.ithasscheduledstartandfinishdat"><!--efplaceholder--></a>It has scheduled start and finish dates and, as applicable, interim milestones, all of which are representative of physical accomplishment.</font></font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; 5.</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black"> </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="5.ithasabudgetorassignedvalueexp"><!--efplaceholder--></a>It has a budget or assigned value expressed in terms of dollars, man-hours or other measurable units.</font></font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; 6.</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black"> </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="6.itsdurationislimitedtoarelative"><!--efplaceholder--></a>Its duration is limited to a relatively short span of time or it is subdivided by discrete value milestones to facilitate the objective measurement of work performed.</font></font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; 7. <font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">It</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt">is</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt">integrated</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt">with </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">detailed </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">engineering,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt"> </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">manufacturing,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt"> </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">or</font><font style="DISPLAY: inline; FONT-SIZE: 10pt"> </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">other schedules</font>.</font></font></font></div>
</td>
</tr><tr>
<td valign="top" width="35%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="65%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="35%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Work Package Budgets</font></div>
</td>
<td valign="top" width="65%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160; Resources which are formally assigned by the CAM to <font size="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">accomplish a Work Package, expressed in dollars and/or hours.</font></font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt">19</font></font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Appendix2SupplementalEVMImplementati"><!--EFPlaceholder--></a>Appendix 2 Supplemental EVM Implementation Guideline</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 36.05pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Implementationofa7PrinciplesofEVM"><!--EFPlaceholder--></a>Implementation of a 7 Principles of EVM system should be less expensive than if there was an ANSI/EIA-748. There is no need for the system to have to go through an EVM compliance review, plus the level of documentation should be streamlined.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Theimplementationshouldinclude:"><!--EFPlaceholder--></a>The implementation should include:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;EVMProcessflowsthatreflecthowac"><!--EFPlaceholder--></a>EVM Process flows that reflect how a company will build and maintain the EVM system. (EVM Procedures may also be included if the cost associated with them is reasonable)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;EVMenginetoolandascheduletool.I"><!--EFPlaceholder--></a>EVM engine tool and a schedule tool. It is not necessary to load the schedule tool, such as Microsoft Project, with resources. This adds an extra strep, additional costs and little to&#160;&#160;no value. It is recommended that all resource information be loaded in the EVM engine and leave the schedule tool to what it does best, measure progress through time (duration).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;TheEVMEngineneedstobeintegrated"><!--EFPlaceholder--></a>The EVM Engine needs to be integrated with the company&#8217;s accounting system.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="DocumentationneededforthePerformance"><!--EFPlaceholder--></a>Documentation needed for the Performance Measurement Baseline Review (PMBR)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;WBSDictionary/ControlAccountWorkAu"><!--EFPlaceholder--></a>WBS Dictionary/Control Account Work Authorization Documentation</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;IntegratedMasterSchedule"><!--EFPlaceholder--></a>Integrated Master Schedule</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;ResponsibilityAssignmentMatrix"><!--EFPlaceholder--></a>Responsibility Assignment Matrix</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;ControlAccountPlans"><!--EFPlaceholder--></a>Control Account Plans</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;PMBLog"><!--EFPlaceholder--></a>PMB Log</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;BaselineRevisionDocuments"><!--EFPlaceholder--></a>Baseline Revision Documents</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;RiskRegister"><!--EFPlaceholder--></a>Risk Register</font></div>
</td>
</tr></table>

<font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="EVMIMPLEMENTATIONCOSTS"><!--EFPlaceholder--></a>EVM IMPLEMENTATION COSTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Thecostforanimplementationdependso"><!--EFPlaceholder--></a>The cost for an implementation depends on the size of the contract and the tier level of EVM.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Tier2(projectsgreaterthan$25M)"><!--EFPlaceholder--></a><a name="Implementationcostsshouldrange$75K-$"><!--EFPlaceholder--></a>Tier 2 (projects greater than $25M)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Implementation costs should range $75K-$125K</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Tier3(projectslessthan$25M)"><!--EFPlaceholder--></a>Tier 3 (projects less than $25M)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Implementation costs should range ($50K - $100K)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="EVMENGINES/TOOLS"><!--EFPlaceholder--></a>EVM ENGINES/TOOLS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 14.9pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Dependingonthesizeofthecontractwo"><!--EFPlaceholder--></a>Depending on the size of the contract would predicate the level of functionality that would be needed. For Tier 2 contracts a larger, more robust EVM engine would be needed. For the Tier 3 small contracts MS Project or the MSP wrap-around would probably suffice although the more robust EVM engines can be used also.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Tier2"><!--EFPlaceholder--></a><a name="Itisrecommendedthatoneofthelarger"><!--EFPlaceholder--></a>Tier 2</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">It is recommended that one of the larger and flexible EVM engines be utilized. The tool should have the flexibility to be able to download data from MS Project and be able to upload or input budget data to provide time-phased budget information down to the work package level. It should be able to incorporate the companies Organization Breakdown Structure. It should be able</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 29pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="tomaintainbaseline,actualcosts,fore"><!--EFPlaceholder--></a>to maintain baseline, actual costs, forecast and performance periodic data. It should be able to forecast Estimate to Complete with the ability to set up different rate tables if necessary.&#160;&#160;It should have the capability to use all earned value methodologies. It should be able to print many types of EVM reports that can provide information to the Control Account Managers (CAM) and Program Managers (PM), as well as, the Contract Performance Report (CPR) and the Control Account Plans (CAP) that are contract deliverables.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Tier3"><!--EFPlaceholder--></a>Tier 3</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="ForTier3projects,acompanycancerta"><!--EFPlaceholder--></a>For Tier 3 projects, a company can certainly utilize an EVM engine as listed above or a less robust, less expensive EVM engine that provides the CPR and timephased S/P/A report. It may also use the Microsoft Project wrap-around tools of which there are several on the market. These tools also will provide the CPR and timephased S/P/A report for contract deliverable purposes.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="EVMFACILITATION"><!--EFPlaceholder--></a>EVM FACILITATION</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="EVMfacilitationpertainstothemonthly"><!--EFPlaceholder--></a>EVM facilitation pertains to the monthly process to include:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160; </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;ScheduleStatus"><!--EFPlaceholder--></a>Schedule Status</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;IntegrationofaccountingdataintoEV"><!--EFPlaceholder--></a>Integration of accounting data into EVM engine</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;RunmonthlyreportsforControlAccoun"><!--EFPlaceholder--></a>Run monthly reports for Control Account Managers (Tier 2 only)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;PreparethemonthlyContractPerforman"><!--EFPlaceholder--></a>Prepare the monthly Contract Performance Report (CPR) Formats 1 and 5</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;RunthemonthlytimephasedS/P/Aforb"><!--EFPlaceholder--></a>Run the monthly timephased S/P/A for both internal and external (contract requirement)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 90pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font>&#160;&#160;</div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="&#61623;PMBChangeControl"><!--EFPlaceholder--></a>PMB Change Control</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Dependingonthesizeofcontract,acon"><!--EFPlaceholder--></a>Depending on the size of contract, a contractor should have an EVM/cost analyst and schedule analyst for a Tier 2 contract and one combined cost/schedule analyst for a Tier 3 contract. The costs for a schedule analyst on a yearly basis for an employee hire should be equal to or less than </font></font><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">$125K. For a cost analyst it should be equal to or less than $110K. If a company is bringing in a contractor to provide staff implementation the costs should be up to $125/hr for a schedule analyst and $110/hr for an EVM/cost analyst.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="EVMCONSULTANTS"><!--EFPlaceholder--></a>EVM CONSULTANTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 27.8pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="Theremaybetheneedtobringinconsul"><!--EFPlaceholder--></a>There may be the need to bring in consultants to help set up your EVM system and perhaps provide EVM staff augmentation to provide the monthly facilitation. Make sure that you shop around and get several quotes. Also make sure that the consultants understand the statement of work pertaining to the BARDA EVM requirements. Most EVM consultants are used to working with companies that have a requirement to implement an ANSI/748 compliant EVM system per the DoD requirements and it is important that they have an understanding of what is required in a 7 Principles EVM implementation so that they don&#8217;t propose much more complex EVM system than is needed. Please be advised that the government will only accept reasonable costs associated with implementing a 7 Principles of EVM system.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="COSTOFEVM"><!--EFPlaceholder--></a>COST OF EVM</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 25pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BARDA is working diligently to keep the costs of EVM implementation and facilitation at a reasonable level.&#160;&#160;Since the goal at BARDA <font style="DISPLAY: inline; FONT-SIZE: 10pt">is to </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">provide an</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">integrated,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">systematic</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">approach</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">to the</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">development </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">and</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">purchase</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">of</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">the</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">necessary</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">vaccines,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">drugs,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">therapies,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">and</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">diagnostic</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">tools </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">for</font><font style="DISPLAY: inline; FONT-SIZE: 10pt"> public health</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">medical</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">emergencies</font>, it is imperative that the funds for product development are used for that such purpose.&#160;&#160;BARDA expects the costs for implementation and facilitation of EVM to range 1%-2% of development budget. This is ratified by the white paper by Dr. Christenson titled &#8220;The Costs and Benefits of the Earned Value Management Process&#8221;.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="Appendix3SampleEVMDocuments"><!--EFPlaceholder--></a>Appendix 3 Sample EVM Documents</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">WBS 1.4.1.x Cardiac (QTc) Safety</font></font><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Description</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 30pt" align="left"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="StudyTitle:&#8220;APhase1studytoassess"><!--EFPlaceholder--></a><font style="DISPLAY: inline; TEXT-DECORATION: underline">Study</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">Title:</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font>&#8220;A Phase 1 study to assess the cardiovascular safety of intravenous (IV) Panaceomycin in volunteers&#8221; (Thorough QT Study)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 17pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We will conduct a thorough evaluation of the cardiac effect of Panaceomycin Injection via a randomized, double-blind crossover study. A total of 100 participants (18-22 per arm) will randomize to one of five study arms to receive in a double-blind fashion a single IV infusion of either Panaceomycin Injection 10 mg/kg, Panaceomycin Injection at a supra-therapeutic dose, ciprofloxacin (positive control), or placebo. 12-Lead digital ECGs will be collected in triplicate via Holter monitor from each participant during dosing. Seven days after dosing, participants will be re-randomized to receive another treatment. ECGs will be collected and analyzed. A full statistical analysis and expert ECG report will be generated. Serum PK samples will also be collected at ECG collection time points and analyzed to confirm exposure.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 5.65pt" align="center"><font size="2"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="SampleWBSScopeDescription"><!--EFPlaceholder--></a>Sample WBS Scope Description</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-SIZE: 10pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked " * * * " and has been filed</font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission.</font></font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><font size="2"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7 Principles of EVM Tier 2 System Implementation Intent Guide</font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font size="2"><img src="timephased.jpg" alt=""></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 150.7pt" align="center"><font size="2"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="SampleTimephasedS/P/AReport"><!--EFPlaceholder--></a>Sample Timephased S/P/A Report</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">24 </font>

<div>
<hr style="COLOR: black" align="left" noshade size="4" width="100%">
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font size="2">&#160;</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title>exh_311.htm</title>
    <!--Licensed to: NASDAQ-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 31.1<a name="FIS_CERTIFICATION"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATIONS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Jon P. Stonehouse, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="49%">&#160;</td>
<td valign="bottom" width="2%">&#160;</td>
<td valign="middle" width="45%">&#160;</td>
</tr><tr>
<td align="left" valign="bottom" width="49%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May 8, 2015</font></div>
</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td valign="bottom" width="45%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ JON P. STONEHOUSE</font></div>
</div>
</td>
</tr><tr>
<td valign="top" width="49%">&#160;</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td align="left" valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jon P. Stonehouse</font></div>
</td>
</tr><tr>
<td valign="top" width="49%">&#160;</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td align="left" valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="eolPage44"><!--EFPlaceholder--></a><a name="D715544DEX312_HTM"><!--EFPlaceholder--></a><a name="FIS_EXHIBIT_31_2"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
    <title>exh_312.htm</title>
    <!--Licensed to: NASDAQ-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 31.2<a name="FIS_CERTIFICATION_2"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATIONS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Thomas R. Staab, II, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a.</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b.</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c.</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d.</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a.</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="8%">&#160;</td>
<td align="left" valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b.</font></div>
</td>
<td align="left" valign="top" width="83%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="49%">&#160;</td>
<td valign="bottom" width="2%">&#160;</td>
<td valign="middle" width="45%">&#160;</td>
</tr><tr>
<td align="left" valign="bottom" width="49%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May 8, 2015</font></div>
</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td valign="bottom" width="45%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ THOMAS R. STAAB, II</font></div>
</div>
</td>
</tr><tr>
<td valign="top" width="49%">&#160;</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td align="left" valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thomas R. Staab, II</font></div>
</td>
</tr><tr>
<td valign="top" width="49%">&#160;</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td align="left" valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Senior Vice President, Chief Financial Officer and Treasurer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="eolPage45"><!--EFPlaceholder--></a><a name="D715544DEX321_HTM"><!--EFPlaceholder--></a><a name="FIS_EXHIBIT_32"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exh_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title>exh_321.htm</title>
    <!--Licensed to: Nasdaqomx-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 32.1<a name="FIS_CERTIFICATION_3"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%">&#160;</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td valign="top" width="88%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font size="2">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="22%">&#160;</td>
<td valign="middle" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="22%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Jon P. Stonehouse</font></div>
</td>
<td align="left" valign="top" width="78%" style="PADDING-BOTTOM: 0.75pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jon P. Stonehouse</font></div>
</td>
<td align="left" valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="22%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and Chief Executive Officer</font></div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May 8, 2015</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exh_322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
<head>
    <title>exh_322.htm</title>
    <!--Licensed to: Nasdaqomx-->
    <!--Document Created using EDGARizerAgent 5.4.6.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit&#160;32.2<a name="FIS_CERTIFICATION_4"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March&#160;31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Thomas R. Staab, II, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="38%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Thomas R. Staab, II</font></div>
</div>
</td>
<td valign="bottom" width="62%" style="PADDING-BOTTOM: 0.75pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thomas R. Staab, II</font></div>
</td>
<td align="left" valign="top" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Senior Vice President, Chief Financial Officer and Treasurer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May&#160;8, 2015</font></div>
</td>
</tr></table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>bcrx-20150331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Fri May 08 17:32:20 UTC 2015 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:bcrx="http://www.biocryst.com/20150331" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:compsci="http://compsciresources.com" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="bcrx-20150331.xsd"/>
  <context id="c0_AsOf31Mar2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c1_AsOf31Dec2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c2_AsOf31Mar2015_CollaborationReceivablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c3_AsOf31Dec2014_CollaborationReceivablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c4_AsOf31Dec2014_TradeAccountsReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c5_AsOf31Mar2015_DeferredCollaborativeRevenueMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredCollaborativeRevenueMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c6_AsOf31Dec2014_DeferredCollaborativeRevenueMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredCollaborativeRevenueMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c7_AsOf31Mar2015_DeferredProductSalesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredProductSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31Dec2014_DeferredProductSalesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">bcrx:DeferredProductSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c9_From1Jan2015To31Mar2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c10_From1Jan2014To31Mar2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c11_AsOf31Dec2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="c12_AsOf31Mar2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="c13_AsOf30Apr2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <instant>2015-04-30</instant>
    </period>
  </context>
  <context id="c14_From1Nov2013To6Nov2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <startDate>2013-11-01</startDate>
      <endDate>2013-11-06</endDate>
    </period>
  </context>
  <context id="c15_AsOf9Mar2011_JPRRoyaltySubLLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-03-09</instant>
    </period>
  </context>
  <context id="c16_AsOf31Mar2015_CertificatesOfDepositMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c17_AsOf31Mar2015_RoyaltyReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c18_AsOf31Mar2015_CollateralForCreditMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c19_From1Jan2015To31Mar2015_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c20_From1Jan2015To31Mar2015_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c21_From1Jan2015To31Mar2015_PhaRMANotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c22_From1Jan2014To31Mar2014_PhaRMANotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c23_From1Jan2015To31Mar2015_SalesRevenueProductLineMember_CustomerConcentrationRiskMember_RAPIVABMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c24_AsOf31Mar2015_USGovernmentAgenciesDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c25_From1Jan2015To31Mar2015_USGovernmentAgenciesDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c26_AsOf31Mar2015_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c27_From1Jan2015To31Mar2015_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c28_AsOf31Mar2015_CommercialPaperMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c29_From1Jan2015To31Mar2015_CommercialPaperMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c30_AsOf31Dec2014_USGovernmentAgenciesDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c31_From1Jan2014To31Dec2014_USGovernmentAgenciesDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="c32_AsOf31Dec2014_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c33_From1Jan2014To31Dec2014_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="c34_AsOf31Dec2014_CommercialPaperMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c35_From1Jan2014To31Dec2014_CommercialPaperMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="c36_From1Jan2014To31Dec2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="c37_AsOf31Mar2015_UnbilledRevenuesMember_USDepartmentOfHealthAndHumanServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c38_AsOf31Mar2015_USDepartmentOfHealthAndHumanServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c39_AsOf31Mar2015_BilledRevenuesMember_ShionogiAndCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c40_AsOf31Mar2015_ShionogiAndCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c41_AsOf31Mar2015_BilledRevenuesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c42_AsOf31Mar2015_UnbilledRevenuesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c43_AsOf31Dec2014_UnbilledRevenuesMember_USDepartmentOfHealthAndHumanServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c44_AsOf31Dec2014_USDepartmentOfHealthAndHumanServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c45_AsOf31Dec2014_BilledRevenuesMember_ShionogiAndCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c46_AsOf31Dec2014_ShionogiAndCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c47_AsOf31Dec2014_BilledRevenuesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c48_AsOf31Dec2014_UnbilledRevenuesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c49_From1Jan2015To31Mar2015_USDepartmentOfHealthAndHumanServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c50_From1Jan2014To31Mar2014_USDepartmentOfHealthAndHumanServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c51_From1Jan2015To31Mar2015_ShionogiAndCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c52_From1Jan2014To31Mar2014_ShionogiAndCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c53_From1Jan2015To31Mar2015_IncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c54_From1Jan2015To31Mar2015_EmployeeStockPurchasePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c55_From1Jan2014To31Mar2014_IncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c56_From1Jan2014To31Mar2014_EmployeeStockPurchasePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c57_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_GrantsCommencingMarch12011Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:GrantsCommencingMarch12011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c58_From1Jan2015To31Mar2015_StockOptionsAndRestrictedStockMember_IncentivePlanMember_RetentionGrantsMadeInJanuary2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:StockOptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:RetentionGrantsMadeInJanuary2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c59_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_PerformanceBasedGrantsMadeInAugust2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:PerformanceBasedGrantsMadeInAugust2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c60_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c61_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_PerformancedBasedGrantsMadeinDecember2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:PerformancedBasedGrantsMadeinDecember2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c62_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_Non-employeeDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">bcrx:Non-employeeDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c63_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c64_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c65_AsOf31Mar2015_EmployeeStockPurchasePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c66_From1Jan2007To31Jan2007_USDepartmentOfHealthAndHumanServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-01-31</endDate>
    </period>
  </context>
  <context id="c67_From1Sep2009To30Sep2009_USDepartmentOfHealthAndHumanServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-09-01</startDate>
      <endDate>2009-09-30</endDate>
    </period>
  </context>
  <context id="c68_From1Feb2011To24Feb2011_USDepartmentOfHealthAndHumanServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-02-01</startDate>
      <endDate>2011-02-24</endDate>
    </period>
  </context>
  <context id="c69_From1Jan2007To24Feb2011_USDepartmentOfHealthAndHumanServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2011-02-24</endDate>
    </period>
  </context>
  <context id="c70_AsOf31Mar2015_BaseContractMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c71_AsOf31Mar2015_AdditionalDevelopmentOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c72_AsOf31Mar2015_ASPRBARDAContractMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c73_From1Sep2013To30Sep2013_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-09-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c74_From1Jan2015To31Mar2015_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c75_From1Jan2006To30Jun2006_GreenCrossCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-06-30</endDate>
    </period>
  </context>
  <context id="c76_From1Jan2015To31Mar2015_AECOMAndIRLMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c77_From1Jun2000To30Jun2000_AECOMAndIRLMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2000-06-01</startDate>
      <endDate>2000-06-30</endDate>
    </period>
  </context>
  <context id="c78_From1May2010To31May2010_AECOMAndIRLMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-05-01</startDate>
      <endDate>2010-05-31</endDate>
    </period>
  </context>
  <context id="c79_From1Jan2015To31Mar2015_UABMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c80_AsOf9Mar2011_JPRRoyaltySubLLCMember_RoyaltyMonetizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-03-09</instant>
    </period>
  </context>
  <context id="c81_From1Mar2011To9Mar2011_JPRRoyaltySubLLCMember_RoyaltyMonetizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-03-01</startDate>
      <endDate>2011-03-09</endDate>
    </period>
  </context>
  <context id="c82_From1Mar2011To9Mar2011_JPRRoyaltySubLLCMember_PhaRMANotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-03-01</startDate>
      <endDate>2011-03-09</endDate>
    </period>
  </context>
  <context id="c83_AsOf9Mar2011_JPRRoyaltySubLLCMember_PhaRMANotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-03-09</instant>
    </period>
  </context>
  <context id="c84_AsOf31Mar2015_PhaRMANotesMember_JPRRoyaltySubLLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c85_AsOf31Mar2015_JPY_PhaRMANotesMember_CurrencyHedgeAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c86_From1Jan2014To31Dec2014_PhaRMANotesMember_CurrencyHedgeAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="c87_AsOf31Dec2014_PhaRMANotesMember_CurrencyHedgeAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c88_From1Jan2015To31Mar2015_JPRRoyaltySubLLCMember_PhaRMANotesMember_CurrencyHedgeAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="c89_From1Jan2014To31Dec2014_JPRRoyaltySubLLCMember_PhaRMANotesMember_CurrencyHedgeAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="c90_AsOf31Mar2015_JPRRoyaltySubLLCMember_PhaRMANotesMember_CurrencyHedgeAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="c91_AsOf3Mar2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <instant>2015-03-03</instant>
    </period>
  </context>
  <context id="c92_AsOf6Nov2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
    </entity>
    <period>
      <instant>2013-11-06</instant>
    </period>
  </context>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="jpy">
    <measure>iso4217:JPY</measure>
  </unit>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">48367000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">54540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">2637000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">150000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">19160000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">18232000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" contextRef="c2_AsOf31Mar2015_CollaborationReceivablesMember" decimals="-3">5594000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" contextRef="c3_AsOf31Dec2014_CollaborationReceivablesMember" decimals="-3">3849000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" contextRef="c4_AsOf31Dec2014_TradeAccountsReceivableMember" decimals="-3">5641000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:InventoryNet unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">1210000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">683000</us-gaap:InventoryNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">4322000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">6172000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:DeferredCostsCurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">76000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">76000</us-gaap:DeferredCostsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">81366000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">89343000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">41116000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">41116000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">727000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">207000</us-gaap:PropertyPlantAndEquipmentNet>
  <bcrx:DeferredCollaborationExpenseAssets unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">163000</bcrx:DeferredCollaborationExpenseAssets>
  <bcrx:DeferredCollaborationExpenseAssets unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">177000</bcrx:DeferredCollaborationExpenseAssets>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">6495000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">6031000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">129867000</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">136874000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">5307000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">2849000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">12291000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">11329000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:InterestPayableCurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">7241000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">6029000</us-gaap:InterestPayableCurrent>
  <us-gaap:DeferredRevenueCurrent unitRef="usd" contextRef="c5_AsOf31Mar2015_DeferredCollaborativeRevenueMember" decimals="-3">1490000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent unitRef="usd" contextRef="c6_AsOf31Dec2014_DeferredCollaborativeRevenueMember" decimals="-3">1481000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent unitRef="usd" contextRef="c7_AsOf31Mar2015_DeferredProductSalesMember" decimals="-3">5533000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent unitRef="usd" contextRef="c8_AsOf31Dec2014_DeferredProductSalesMember" decimals="-3">5605000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LongTermNotesPayable unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">30000000</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">30000000</us-gaap:LongTermNotesPayable>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">61862000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">57293000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueNoncurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">3256000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">3552000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">378000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">394000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">0</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">725000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">720000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">546698000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">542943000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">-130000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">-483062000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">-467898000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">64371000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">75635000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">129867000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">136874000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c0_AsOf31Mar2015" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c1_AsOf31Dec2014" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c0_AsOf31Mar2015" decimals="-3">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c1_AsOf31Dec2014" decimals="-3">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c0_AsOf31Mar2015" decimals="-3">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Dec2014" decimals="-3">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c0_AsOf31Mar2015" decimals="-3">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c1_AsOf31Dec2014" decimals="-3">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c0_AsOf31Mar2015" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c1_AsOf31Dec2014" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c0_AsOf31Mar2015" decimals="-3">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c1_AsOf31Dec2014" decimals="-3">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c0_AsOf31Mar2015" decimals="-3">72474000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c1_AsOf31Dec2014" decimals="-3">71955000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c0_AsOf31Mar2015" decimals="-3">72474000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Dec2014" decimals="-3">71955000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:SalesRevenueGoodsNet unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">537000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:RoyaltyRevenue unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">1518000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">1821000</us-gaap:RoyaltyRevenue>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">4771000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">1637000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <us-gaap:SalesRevenueNet unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">6826000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">3458000</us-gaap:SalesRevenueNet>
  <us-gaap:CostOfGoodsSold unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">15000</us-gaap:CostOfGoodsSold>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">17120000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">9183000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">4061000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">1588000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:RoyaltyExpense unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">60000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">73000</us-gaap:RoyaltyExpense>
  <us-gaap:CostsAndExpenses unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">21256000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">10844000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">-14430000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-7386000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestAndOtherIncome unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">117000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">17000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">1315000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">1242000</us-gaap:InterestExpense>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">464000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-1526000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">-15164000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-10137000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c9_From1Jan2015To31Mar2015" decimals="2">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c10_From1Jan2014To31Mar2014" decimals="2">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">72341000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">59589000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">140000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">-15024000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-10139000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">45000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">53000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">2259000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">1610000</us-gaap:ShareBasedCompensation>
  <us-gaap:AmortizationOfFinancingCosts unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">110000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">110000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:IncreaseDecreaseInDerivativeAssets unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">464000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInDerivativeAssets unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-1526000</us-gaap:IncreaseDecreaseInDerivativeAssets>
  <us-gaap:IncreaseDecreaseInReceivables unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">-3896000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">1165000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInInventories unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">527000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">-1848000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-892000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">-14000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-15000</bcrx:DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">3404000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-2252000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInInterestPayableNet unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">1212000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInterestPayableNet unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">685000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">-359000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-296000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">-3726000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-8959000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquireProductiveAssets unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">565000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">7000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:IncreaseDecreaseInRestrictedCash unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">2487000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-1000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">3378000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">9367000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">2482000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">8350000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">-3948000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-1023000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">1175000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">155000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">3804000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockPlans unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">171000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">128000</us-gaap:ProceedsFromStockPlans>
  <bcrx:ReceiptPaymentOfForeignCurrencyDerivativeCollateral unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-1530000</bcrx:ReceiptPaymentOfForeignCurrencyDerivativeCollateral>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">1501000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">2402000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">-6173000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">-7580000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c11_AsOf31Dec2013" decimals="-3">21164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c12_AsOf31Mar2014" decimals="-3">13584000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <dei:EntityRegistrantName contextRef="c9_From1Jan2015To31Mar2015">BIOCRYST PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:DocumentType contextRef="c9_From1Jan2015To31Mar2015">10-Q</dei:DocumentType>
  <dei:CurrentFiscalYearEndDate contextRef="c9_From1Jan2015To31Mar2015">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c13_AsOf30Apr2015" decimals="INF">72520545</dei:EntityCommonStockSharesOutstanding>
  <dei:AmendmentFlag contextRef="c9_From1Jan2015To31Mar2015">false</dei:AmendmentFlag>
  <dei:EntityCentralIndexKey contextRef="c9_From1Jan2015To31Mar2015">0000882796</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c9_From1Jan2015To31Mar2015">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers contextRef="c9_From1Jan2015To31Mar2015">No</dei:EntityVoluntaryFilers>
  <dei:EntityFilerCategory contextRef="c9_From1Jan2015To31Mar2015">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c9_From1Jan2015To31Mar2015">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:DocumentFiscalYearFocus contextRef="c9_From1Jan2015To31Mar2015">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="c9_From1Jan2015To31Mar2015">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentPeriodEndDate contextRef="c9_From1Jan2015To31Mar2015">2015-03-31</dei:DocumentPeriodEndDate>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Note 1 &amp;#8212; Significant Accounting Policies&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;The Company&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $111,280, to continue its planned operations through the middle of 2016. The Company&amp;#8217;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond the middle of 2016 it will need to: (1)&amp;#160;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&amp;#160;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&amp;#160;raise additional capital through equity or debt financings or from other sources; (4)&amp;#160;obtain product candidate regulatory approvals, which would generate
      revenue and cash flow; (5)&amp;#160;reduce spending on one or more research and development programs; and/or (6)&amp;#160;restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.&amp;#160;&amp;#160;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November&amp;#160;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Basis of Presentation&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&amp;#8220;Royalty Sub&amp;#8221;). Royalty Sub was formed in connection with a $30,000&amp;#160;financing transaction the Company completed on March&amp;#160;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&amp;#8217;s opinion, necessary to present fairly, in all material respects, the Company&amp;#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;These financial statements should be read in conjunction with the financial statements for the year ended December&amp;#160;31, 2014 and the notes thereto included in the Company&amp;#8217;s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&amp;#160;31, 2014 has been derived from the audited consolidated financial statements included in the Company&amp;#8217;s most recent Annual Report on Form 10-K.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Reclassifications&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Cash and Cash Equivalents&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Restricted Cash&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Restricted cash as of March&amp;#160;31, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $1,087 in royalty revenue paid by Shionogi&amp;#160;&amp;amp; Co., Ltd. (&amp;#8220;Shionogi&amp;#8221;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,400 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Investments&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#8217;s investment policy requires it to purchase high-quality
      marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#8217;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities
      at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At March&amp;#160;31, 2015, the Company believes that the costs of its investments are recoverable in all material respects.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The following tables summarize the fair value of the Company&amp;#8217;s investments by type. The estimated fair value of the Company&amp;#8217;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;18&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;March&amp;#160;31, 2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Amortized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Cost&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Accrued&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Interest&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gains&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Losses&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Estimated&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Fair&amp;#160;Value&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Obligations of U.S. Government and its agencies&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20,302&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;42&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(2&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20,345&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Corporate debt securities&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;28,139&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;144&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(13&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;28,297&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Certificates of deposit&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,625&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;15&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(12&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,634&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total investments&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;60,066&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;201&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;36&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(27&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;60,276&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;20&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;18&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December&amp;#160;31, 2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Amortized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Cost&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Accrued&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Interest&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gains&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Losses&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Estimated&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Fair&amp;#160;Value&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Obligations of U.S. Government and its agencies&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20,307&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;22&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(23&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;23,306&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Corporate debt securities&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,152&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;151&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(47&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,261&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Certificates of deposit&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,838&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(63&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,781&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total investments&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,297&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;179&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(133&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,348&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The following table summarizes the scheduled maturity for the Company&amp;#8217;s investments at March&amp;#160;31, 2015 and December&amp;#160;31, 2014.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Maturing in one year or less&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;19,16&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;0&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;18,232&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Maturing after one year through two years&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;29,656&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;25,459&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Maturing after two years&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,46&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;0&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;15,657&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total investments&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;60,276&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,348&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&lt;!--EFPlaceholder--&gt;Receivables from Collaborations&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services or royalty receivables from Shionogi&amp;#160;&amp;amp; Co. Ltd. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At March 31, 2015 and December&amp;#160;31, 2014, the Company had the following receivables.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;10&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;March&amp;#160;31, 2015&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Billed&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unbilled&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Total&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;U.S. Department of Health and Human Services&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,087&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,087&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Shionogi&amp;#160;&amp;amp; Co. Ltd.&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,507&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,507&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total receivables&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,507&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,087&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5,594&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td valign=&quot;bottom&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;12&quot; valign=&quot;bottom&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
        &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;10&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December&amp;#160;31, 2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Billed&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unbilled&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Total&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;U.S. Department of Health and Human Services&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,778&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,778&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Shionogi&amp;#160;&amp;amp; Co. Ltd.&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,071&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,071&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total receivables&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,071&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,778&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3,849&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Receivables from Product Sales&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB&lt;font style=&quot;DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top&quot;&gt;TM&lt;/font&gt;. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Inventory&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;At March 31, 2015 and December 31, 2014, the Company&amp;#8217;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&amp;#8220;FIFO&amp;#8221;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;During 2014, in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s inventory consisted of the following at March&amp;#160;31, 2015 and December&amp;#160;31, 2014:&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Work in process&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;267&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Finished Goods&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,210&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;416&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net inventories&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,210&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;683&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Patents and Licenses&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Accrued Expenses&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services
      performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;5%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;2%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8226;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;88%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;fees paid to Clinical Research Organizations (&amp;#8220;CROs&amp;#8221;) in connection with preclinical and toxicology studies and clinical trials;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;5%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;2%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8226;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;88%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;fees paid to investigative sites in connection with clinical trials;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;5%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;2%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8226;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;88%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&amp;#160;and&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;5%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;2%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8226;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;88%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;professional fees.&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of March 31, 2015 and December 31, 2014, the carrying value of
      accrued expenses approximates their fair value due to their short-term settlement.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Income Taxes&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The liability method is used in the Company&amp;#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Accumulated Other Comprehensive (Loss) Income&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Accumulated other comprehensive (loss) income is comprised of unrealized gains and losses on investments available-for-sale and is disclosed as a separate component of stockholders&amp;#8217; equity. Amounts reclassified from accumulated other comprehensive (loss) income are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the three months ended March 31, 2015, realized gains of $8 were reclassified out of accumulated other comprehensive (loss) income. No reclassifications out of accumulated other comprehensive (loss) income were recorded during the three months ended March&amp;#160;31, 2014.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Revenue Recognition&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company recognizes revenues from collaborative and other research and development arrangements and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;#160;persuasive evidence of an arrangement exists; (ii)&amp;#160;delivery has occurred or services have been rendered; (iii)&amp;#160;the seller&amp;#8217;s price to the buyer is fixed or determinable; and (iv)&amp;#160;collectability is reasonably assured.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables, the Company evaluates whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;Under certain of our license agreements, the Company receives royalty payments based upon our licensees&amp;#8217; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Event payments are recognized as revenue upon the achievement of specified events if (1)&amp;#160;the event is substantive in nature and the achievement of the event was not reasonably assured at the inception of the agreement and (2)&amp;#160;the fees are non-refundable and non-creditable. Any event payments received prior to satisfying these criteria are recorded as deferred revenue. Under the Company&amp;#8217;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#8221;BARDA/HHS&amp;#8221;) and the National Institute of Allergy and Infectious Diseases (&amp;#8220;NIAID/HHS&amp;#8221;), revenue is recognized as reimbursable
      direct and indirect costs are incurred.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&lt;!--EFPlaceholder--&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Product Sales&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and requires it to use information from external sources.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Rebates and Chargebacks&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#8217;s selling price.&amp;#160;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#8217;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates
      and chargebacks differ from the Company&amp;#8217;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Discounts and Sales Incentives&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#8220;IMA&amp;#8221;) Fees. Per contractual agreements with the Company&amp;#8217;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Product Returns&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Advertising&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company recorded the following revenues for the three months ended March&amp;#160;31, 2015 and 2014:&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Product sales, net&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;537&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Royalty revenue&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,518&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,821&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Collaborative and other research and development revenues:&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;U.S. Department of Health and Human Services&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,475&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,341&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Shionogi (Japan)&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;296&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;296&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total collaborative and other research and development revenues&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,771&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,637&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total revenues&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6,826&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3,458&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Research and Development Expenses&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#8217;s manufacturing and clinical and preclinical studies are
      performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#8217;s on-going review of the level of services actually performed.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#8220;AECOM&amp;#8221;), Industrial Research, Ltd. (&amp;#8220;IRL&amp;#8221;), and the University of Alabama at Birmingham (&amp;#8220;UAB&amp;#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Stock-Based Compensation&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#8220;performance&amp;#8221; has occurred.&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Interest Expense and Deferred Financing Costs&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Interest expense for the three months ended March&amp;#160;31, 2015 and 2014 was $1,315 and $1,242, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended March&amp;#160;31, 2015 and 2014.&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Currency Hedge Agreement&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&amp;#160;31, 2015 and 2014 resulted in a gain of $464 and a loss of $1,526, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also
      required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of March&amp;#160;31, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Net Loss Per Share&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&amp;#8217;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended March&amp;#160;31, 2015 and 2014 does not include 3,458 and 5,206, respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Use of Estimates&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;Significant Customers and Other Risks&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&amp;#8217;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s primary source of revenue that has an underlying cash flow stream is the reimbursement of peramivir and BCX4430 development expenses, which was earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its peramivir and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#8217;s collaborative and other research and development revenues. The completion, as with the June 30, 2014 BARDA/HHS peramivir development contract, or termination of the NIAID/HHS and BARDA/HHS BCX4430 programs/collaboration could negatively impact the Company&amp;#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA;
      however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&amp;#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. The Company&amp;#8217;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#8217;s ability to complete its drug development activities.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company relies on single source manufacturers for API and finished product manufacturing of RAPIVAB. Additionally, the Company relies upon a single third party to provide warehousing and distribution services for RAPIVAB. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Credit Risk&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale receivables discussed above, the majority of the Company&amp;#8217;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Recent Accounting Pronouncements&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In April 2015, the &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman&quot;&gt;Financial Accounting Standards Board&lt;/font&gt; (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2015-03, &lt;font style=&quot;FONT-STYLE: italic&quot;&gt;Simplifying the Presentation of Debt Issuance Costs&lt;/font&gt;. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman&quot;&gt;The Company does not expect this ASU will have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In May 2014, the FASB issued ASU 2014-09 &amp;#8211; &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Revenue from Contracts with Customers&lt;/font&gt; , which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This ASU is effective for annual periods, and
        interim periods within those annual periods, beginning after December 15, 2016. Early adoption is not permitted and companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;The Company&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;BioCryst Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $111,280, to continue its planned operations through the middle of 2016. The Company&amp;#8217;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond the middle of 2016 it will need to: (1)&amp;#160;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&amp;#160;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&amp;#160;raise additional capital through equity or debt financings or from other sources; (4)&amp;#160;obtain product candidate regulatory approvals, which would generate
      revenue and cash flow; (5)&amp;#160;reduce spending on one or more research and development programs; and/or (6)&amp;#160;restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.&amp;#160;&amp;#160;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November&amp;#160;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.&lt;/font&gt;&lt;/div&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
  <us-gaap:InvestmentsAndCash unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">111280000</us-gaap:InvestmentsAndCash>
  <bcrx:SecuritiesOffered unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">150000000</bcrx:SecuritiesOffered>
  <bcrx:SecuritiesOffered unitRef="usd" contextRef="c14_From1Nov2013To6Nov2013" decimals="-3">10000000</bcrx:SecuritiesOffered>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Basis of Presentation&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&amp;#8220;Royalty Sub&amp;#8221;). Royalty Sub was formed in connection with a $30,000&amp;#160;financing transaction the Company completed on March&amp;#160;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&amp;#8217;s opinion, necessary to present fairly, in all material respects, the Company&amp;#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;These financial statements should be read in conjunction with the financial statements for the year ended December&amp;#160;31, 2014 and the notes thereto included in the Company&amp;#8217;s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&amp;#160;31, 2014 has been derived from the audited consolidated financial statements included in the Company&amp;#8217;s most recent Annual Report on Form 10-K.&lt;/font&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized unitRef="usd" contextRef="c15_AsOf9Mar2011_JPRRoyaltySubLLCMember" decimals="-3">30000000</bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Reclassifications&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.&lt;/font&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Cash and Cash Equivalents&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/font&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Restricted Cash&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Restricted cash as of March&amp;#160;31, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $1,087 in royalty revenue paid by Shionogi&amp;#160;&amp;amp; Co., Ltd. (&amp;#8220;Shionogi&amp;#8221;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,400 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/font&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c16_AsOf31Mar2015_CertificatesOfDepositMember" decimals="-3">150000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c17_AsOf31Mar2015_RoyaltyReceivableMember" decimals="-3">1087000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalents unitRef="usd" contextRef="c18_AsOf31Mar2015_CollateralForCreditMember" decimals="-3">1400000</us-gaap:RestrictedCashAndCashEquivalents>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqIaiEUguwqkWGa4cpv416hMMHjZG8xE46xL+mr4cf8Tq9b70MVwJzKgr6HCfYcFXZs/8eE/WbBTxrVDMgYuQntYWFD0E/pnX5XPvNTZUuRQpNVkusoa+c494MTAEv8KuXfbHWCH1lOJcQA3ctTEoDUIdP5GHFBF0gC+D9Yie2bdD3sKj9IR+JUyquyfDyqJut] CSR-->
  <us-gaap:InvestmentPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Investments&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&amp;#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&amp;#8217;s investment policy requires it to purchase high-quality
      marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&amp;#8217;s investments are not collateralized. The Company has not realized any significant losses from its investments.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities
      at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At March&amp;#160;31, 2015, the Company believes that the costs of its investments are recoverable in all material respects.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The following tables summarize the fair value of the Company&amp;#8217;s investments by type. The estimated fair value of the Company&amp;#8217;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;18&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;March&amp;#160;31, 2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Amortized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Cost&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Accrued&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Interest&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gains&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Losses&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Estimated&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Fair&amp;#160;Value&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Obligations of U.S. Government and its agencies&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20,302&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;42&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(2&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20,345&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Corporate debt securities&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;28,139&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;144&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(13&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;28,297&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Certificates of deposit&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,625&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;15&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(12&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,634&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total investments&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;60,066&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;201&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;36&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(27&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;60,276&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;20&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;18&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December&amp;#160;31, 2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Amortized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Cost&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Accrued&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Interest&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gains&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Losses&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Estimated&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Fair&amp;#160;Value&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Obligations of U.S. Government and its agencies&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20,307&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;22&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(23&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;23,306&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Corporate debt securities&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,152&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;151&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(47&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,261&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Certificates of deposit&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,838&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(63&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,781&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total investments&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,297&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;179&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(133&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,348&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The following table summarizes the scheduled maturity for the Company&amp;#8217;s investments at March&amp;#160;31, 2015 and December&amp;#160;31, 2014.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Maturing in one year or less&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;19,16&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;0&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;18,232&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Maturing after one year through two years&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;29,656&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;25,459&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Maturing after two years&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,46&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;0&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;15,657&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total investments&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;60,276&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,348&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentPolicyTextBlock>
  <bcrx:MaturityPeriodOfHighQualityMarketableSecurities contextRef="c19_From1Jan2015To31Mar2015_MaximumMember">P3Y</bcrx:MaturityPeriodOfHighQualityMarketableSecurities>
  <bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities contextRef="c19_From1Jan2015To31Mar2015_MaximumMember">P18M</bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities>
  <bcrx:MaturityPeriodOfShortTermInvestment contextRef="c20_From1Jan2015To31Mar2015_MinimumMember">P3M</bcrx:MaturityPeriodOfShortTermInvestment>
  <bcrx:MaturityPeriodOfShortTermInvestment contextRef="c19_From1Jan2015To31Mar2015_MaximumMember">P12M</bcrx:MaturityPeriodOfShortTermInvestment>
  <bcrx:LongTermInvestmentMaturityMinimum contextRef="c20_From1Jan2015To31Mar2015_MinimumMember">P12M</bcrx:LongTermInvestmentMaturityMinimum>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Receivables from Collaborations&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services or royalty receivables from Shionogi&amp;#160;&amp;amp; Co. Ltd. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At March 31, 2015 and December&amp;#160;31, 2014, the Company had the following receivables.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;10&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;March&amp;#160;31, 2015&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Billed&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unbilled&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Total&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;U.S. Department of Health and Human Services&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,087&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,087&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Shionogi&amp;#160;&amp;amp; Co. Ltd.&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,507&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,507&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total receivables&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,507&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,087&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5,594&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td valign=&quot;bottom&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;12&quot; valign=&quot;bottom&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
        &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;10&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December&amp;#160;31, 2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Billed&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unbilled&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Total&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;U.S. Department of Health and Human Services&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,778&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,778&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Shionogi&amp;#160;&amp;amp; Co. Ltd.&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,071&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,071&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total receivables&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,071&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,778&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3,849&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&amp;#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Receivables from Product Sales&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB&lt;font style=&quot;DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top&quot;&gt;TM&lt;/font&gt;. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:InventoryPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Inventory&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;At March 31, 2015 and December 31, 2014, the Company&amp;#8217;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&amp;#8220;FIFO&amp;#8221;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;During 2014, in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s inventory consisted of the following at March&amp;#160;31, 2015 and December&amp;#160;31, 2014:&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Work in process&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;267&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Finished Goods&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,210&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;416&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net inventories&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,210&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;683&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Patents and Licenses&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/font&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <bcrx:AccruedExpensesPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Accrued Expenses&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services
      performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;5%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;2%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8226;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;88%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;fees paid to Clinical Research Organizations (&amp;#8220;CROs&amp;#8221;) in connection with preclinical and toxicology studies and clinical trials;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;5%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;2%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8226;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;88%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;fees paid to investigative sites in connection with clinical trials;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;5%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;2%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8226;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;88%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&amp;#160;and&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;5%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;2%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8226;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;top&quot; width=&quot;88%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;professional fees.&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&amp;#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of March 31, 2015 and December 31, 2014, the carrying value of
      accrued expenses approximates their fair value due to their short-term settlement.&lt;/font&gt;&lt;/div&gt;</bcrx:AccruedExpensesPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Income Taxes&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The liability method is used in the Company&amp;#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/font&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <bcrx:AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Accumulated Other Comprehensive (Loss) Income&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Accumulated other comprehensive (loss) income is comprised of unrealized gains and losses on investments available-for-sale and is disclosed as a separate component of stockholders&amp;#8217; equity. Amounts reclassified from accumulated other comprehensive (loss) income are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the three months ended March 31, 2015, realized gains of $8 were reclassified out of accumulated other comprehensive (loss) income. No reclassifications out of accumulated other comprehensive (loss) income were recorded during the three months ended March&amp;#160;31, 2014.&lt;/font&gt;&lt;/div&gt;</bcrx:AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">8000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="0">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Revenue Recognition&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company recognizes revenues from collaborative and other research and development arrangements and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&amp;#160;persuasive evidence of an arrangement exists; (ii)&amp;#160;delivery has occurred or services have been rendered; (iii)&amp;#160;the seller&amp;#8217;s price to the buyer is fixed or determinable; and (iv)&amp;#160;collectability is reasonably assured.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables, the Company evaluates whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;Under certain of our license agreements, the Company receives royalty payments based upon our licensees&amp;#8217; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Event payments are recognized as revenue upon the achievement of specified events if (1)&amp;#160;the event is substantive in nature and the achievement of the event was not reasonably assured at the inception of the agreement and (2)&amp;#160;the fees are non-refundable and non-creditable. Any event payments received prior to satisfying these criteria are recorded as deferred revenue. Under the Company&amp;#8217;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&amp;#8221;BARDA/HHS&amp;#8221;) and the National Institute of Allergy and Infectious Diseases (&amp;#8220;NIAID/HHS&amp;#8221;), revenue is recognized as reimbursable
      direct and indirect costs are incurred.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&lt;!--EFPlaceholder--&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Product Sales&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and requires it to use information from external sources.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Rebates and Chargebacks&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&amp;#8217;s selling price.&amp;#160;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&amp;#8217;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates
      and chargebacks differ from the Company&amp;#8217;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Discounts and Sales Incentives&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Discounts and other sales incentives primarily consist of Inventory Management Agreement (&amp;#8220;IMA&amp;#8221;) Fees. Per contractual agreements with the Company&amp;#8217;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Product Returns&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Advertising&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company recorded the following revenues for the three months ended March&amp;#160;31, 2015 and 2014:&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Product sales, net&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;537&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Royalty revenue&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,518&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,821&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Collaborative and other research and development revenues:&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;U.S. Department of Health and Human Services&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,475&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,341&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Shionogi (Japan)&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;296&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;296&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total collaborative and other research and development revenues&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,771&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,637&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total revenues&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6,826&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3,458&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Research and Development Expenses&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&amp;#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&amp;#8217;s manufacturing and clinical and preclinical studies are
      performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&amp;#8217;s on-going review of the level of services actually performed.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&amp;#8220;AECOM&amp;#8221;), Industrial Research, Ltd. (&amp;#8220;IRL&amp;#8221;), and the University of Alabama at Birmingham (&amp;#8220;UAB&amp;#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&amp;#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&amp;#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/font&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Stock-Based Compensation&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&amp;#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &amp;#8220;performance&amp;#8221; has occurred.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Interest Expense and Deferred Financing Costs&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Interest expense for the three months ended March&amp;#160;31, 2015 and 2014 was $1,315 and $1,242, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended March&amp;#160;31, 2015 and 2014.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c21_From1Jan2015To31Mar2015_PhaRMANotesMember" decimals="-3">1315000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c22_From1Jan2014To31Mar2014_PhaRMANotesMember" decimals="-3">1242000</us-gaap:InterestExpense>
  <bcrx:CurrencyHedgeAgreementPolicyTextBlock contextRef="c10_From1Jan2014To31Mar2014">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Currency Hedge Agreement&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&amp;#160;31, 2015 and 2014 resulted in a gain of $464 and a loss of $1,526, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also
      required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of March&amp;#160;31, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.&lt;/font&gt;&lt;/div&gt;</bcrx:CurrencyHedgeAgreementPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Net Loss Per Share&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&amp;#8217;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended March&amp;#160;31, 2015 and 2014 does not include 3,458 and 5,206, respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/font&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">3458000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">5206000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:UseOfEstimates contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Use of Estimates&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;Significant Customers and Other Risks&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&amp;#8217;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s primary source of revenue that has an underlying cash flow stream is the reimbursement of peramivir and BCX4430 development expenses, which was earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its peramivir and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&amp;#8217;s collaborative and other research and development revenues. The completion, as with the June 30, 2014 BARDA/HHS peramivir development contract, or termination of the NIAID/HHS and BARDA/HHS BCX4430 programs/collaboration could negatively impact the Company&amp;#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA;
      however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&amp;#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. The Company&amp;#8217;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&amp;#8217;s ability to complete its drug development activities.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company relies on single source manufacturers for API and finished product manufacturing of RAPIVAB. Additionally, the Company relies upon a single third party to provide warehousing and distribution services for RAPIVAB. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.&lt;/font&gt;&lt;/div&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c23_From1Jan2015To31Mar2015_SalesRevenueProductLineMember_CustomerConcentrationRiskMember_RAPIVABMember" decimals="2">0.90</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Credit Risk&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale receivables discussed above, the majority of the Company&amp;#8217;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.&lt;/font&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <bcrx:AverageMaturityForPortfolioInvestments contextRef="c19_From1Jan2015To31Mar2015_MaximumMember">P18M</bcrx:AverageMaturityForPortfolioInvestments>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Recent Accounting Pronouncements&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In April 2015, the &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman&quot;&gt;Financial Accounting Standards Board&lt;/font&gt; (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2015-03, &lt;font style=&quot;FONT-STYLE: italic&quot;&gt;Simplifying the Presentation of Debt Issuance Costs&lt;/font&gt;. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman&quot;&gt;The Company does not expect this ASU will have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In May 2014, the FASB issued ASU 2014-09 &amp;#8211; &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Revenue from Contracts with Customers&lt;/font&gt; , which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This ASU is effective for annual periods, and
        interim periods within those annual periods, beginning after December 15, 2016. Early adoption is not permitted and companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;18&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;March&amp;#160;31, 2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Amortized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Cost&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Accrued&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Interest&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gains&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Losses&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Estimated&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Fair&amp;#160;Value&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Obligations of U.S. Government and its agencies&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20,302&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;42&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(2&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20,345&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Corporate debt securities&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;28,139&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;144&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(13&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;28,297&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Certificates of deposit&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,625&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;15&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(12&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,634&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total investments&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;60,066&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;201&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;36&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(27&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;60,276&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;20&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;18&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December&amp;#160;31, 2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Amortized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Cost&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Accrued&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Interest&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gains&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Gross&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unrealized&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Losses&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Estimated&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Fair&amp;#160;Value&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Obligations of U.S. Government and its agencies&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20,307&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;22&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(23&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;23,306&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Corporate debt securities&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,152&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;151&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(47&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,261&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Certificates of deposit&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,838&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(63&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,781&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;50%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;7%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;50%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total investments&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,297&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;179&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(133&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;7%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,348&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost unitRef="usd" contextRef="c24_AsOf31Mar2015_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3">20302000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest unitRef="usd" contextRef="c24_AsOf31Mar2015_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3">42000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains unitRef="usd" contextRef="c25_From1Jan2015To31Mar2015_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3">3000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss unitRef="usd" contextRef="c25_From1Jan2015To31Mar2015_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3">2000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss>
  <us-gaap:AvailableForSaleSecurities unitRef="usd" contextRef="c24_AsOf31Mar2015_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3">20345000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost unitRef="usd" contextRef="c26_AsOf31Mar2015_CorporateDebtSecuritiesMember" decimals="-3">28139000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest unitRef="usd" contextRef="c26_AsOf31Mar2015_CorporateDebtSecuritiesMember" decimals="-3">144000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains unitRef="usd" contextRef="c27_From1Jan2015To31Mar2015_CorporateDebtSecuritiesMember" decimals="-3">27000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss unitRef="usd" contextRef="c27_From1Jan2015To31Mar2015_CorporateDebtSecuritiesMember" decimals="-3">13000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss>
  <us-gaap:AvailableForSaleSecurities unitRef="usd" contextRef="c26_AsOf31Mar2015_CorporateDebtSecuritiesMember" decimals="-3">28297000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost unitRef="usd" contextRef="c28_AsOf31Mar2015_CommercialPaperMember" decimals="-3">11625000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest unitRef="usd" contextRef="c28_AsOf31Mar2015_CommercialPaperMember" decimals="-3">15000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains unitRef="usd" contextRef="c29_From1Jan2015To31Mar2015_CommercialPaperMember" decimals="-3">6000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss unitRef="usd" contextRef="c29_From1Jan2015To31Mar2015_CommercialPaperMember" decimals="-3">12000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss>
  <us-gaap:AvailableForSaleSecurities unitRef="usd" contextRef="c28_AsOf31Mar2015_CommercialPaperMember" decimals="-3">11634000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">60066000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">201000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">36000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">27000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss>
  <us-gaap:AvailableForSaleSecurities unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">60276000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:NuclearFuelNetOfAmortization unitRef="usd" contextRef="c0_AsOf31Mar2015" xs:nil="true"/>
  <us-gaap:SpentNuclearFuelObligationNoncurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" xs:nil="true"/>
  <us-gaap:PaymentsForNuclearFuel unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" xs:nil="true"/>
  <us-gaap:ProceedsFromNuclearFuel unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" xs:nil="true"/>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost unitRef="usd" contextRef="c30_AsOf31Dec2014_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3">20307000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest unitRef="usd" contextRef="c30_AsOf31Dec2014_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3">22000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss unitRef="usd" contextRef="c31_From1Jan2014To31Dec2014_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3">23000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss>
  <us-gaap:AvailableForSaleSecurities unitRef="usd" contextRef="c30_AsOf31Dec2014_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3">23306000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost unitRef="usd" contextRef="c32_AsOf31Dec2014_CorporateDebtSecuritiesMember" decimals="-3">27152000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest unitRef="usd" contextRef="c32_AsOf31Dec2014_CorporateDebtSecuritiesMember" decimals="-3">151000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains unitRef="usd" contextRef="c33_From1Jan2014To31Dec2014_CorporateDebtSecuritiesMember" decimals="-3">5000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss unitRef="usd" contextRef="c33_From1Jan2014To31Dec2014_CorporateDebtSecuritiesMember" decimals="-3">47000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss>
  <us-gaap:AvailableForSaleSecurities unitRef="usd" contextRef="c32_AsOf31Dec2014_CorporateDebtSecuritiesMember" decimals="-3">27261000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost unitRef="usd" contextRef="c34_AsOf31Dec2014_CommercialPaperMember" decimals="-3">11838000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest unitRef="usd" contextRef="c34_AsOf31Dec2014_CommercialPaperMember" decimals="-3">6000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss unitRef="usd" contextRef="c35_From1Jan2014To31Dec2014_CommercialPaperMember" decimals="-3">63000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss>
  <us-gaap:AvailableForSaleSecurities unitRef="usd" contextRef="c34_AsOf31Dec2014_CommercialPaperMember" decimals="-3">11781000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">59297000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <bcrx:AvailableForSaleSecuritiesAccruedInterest unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">179000</bcrx:AvailableForSaleSecuritiesAccruedInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains unitRef="usd" contextRef="c36_From1Jan2014To31Dec2014" decimals="-3">5000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss unitRef="usd" contextRef="c36_From1Jan2014To31Dec2014" decimals="-3">133000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss>
  <us-gaap:AvailableForSaleSecurities unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">59348000</us-gaap:AvailableForSaleSecurities>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Maturing in one year or less&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;19,16&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;0&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;18,232&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Maturing after one year through two years&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;29,656&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;25,459&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Maturing after two years&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11,46&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;0&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;15,657&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total investments&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;60,276&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,348&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;</bcrx:AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">19160000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">18232000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">29656000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">25459000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">11460000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">15657000</bcrx:AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears>
  <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;10&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;March&amp;#160;31, 2015&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Billed&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unbilled&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Total&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;U.S. Department of Health and Human Services&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,087&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,087&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Shionogi&amp;#160;&amp;amp; Co. Ltd.&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,507&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,507&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total receivables&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,507&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,087&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5,594&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
              &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
              &lt;/div&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr&gt;
            &lt;td valign=&quot;bottom&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
            &lt;td colspan=&quot;12&quot; valign=&quot;bottom&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
            &lt;/td&gt;
          &lt;/tr&gt;
        &lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;10&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December&amp;#160;31, 2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Billed&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Unbilled&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Total&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;U.S. Department of Health and Human Services&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,778&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,778&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Shionogi&amp;#160;&amp;amp; Co. Ltd.&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,071&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,071&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total receivables&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,071&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,778&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3,849&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;</bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c37_AsOf31Mar2015_UnbilledRevenuesMember_USDepartmentOfHealthAndHumanServicesMember" decimals="-3">4087000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c38_AsOf31Mar2015_USDepartmentOfHealthAndHumanServicesMember" decimals="-3">4087000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c39_AsOf31Mar2015_BilledRevenuesMember_ShionogiAndCoLtdMember" decimals="-3">1507000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c40_AsOf31Mar2015_ShionogiAndCoLtdMember" decimals="-3">1507000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c41_AsOf31Mar2015_BilledRevenuesMember" decimals="-3">1507000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c42_AsOf31Mar2015_UnbilledRevenuesMember" decimals="-3">4087000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">5594000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c43_AsOf31Dec2014_UnbilledRevenuesMember_USDepartmentOfHealthAndHumanServicesMember" decimals="-3">2778000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c44_AsOf31Dec2014_USDepartmentOfHealthAndHumanServicesMember" decimals="-3">2778000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c45_AsOf31Dec2014_BilledRevenuesMember_ShionogiAndCoLtdMember" decimals="-3">1071000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c46_AsOf31Dec2014_ShionogiAndCoLtdMember" decimals="-3">1071000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c47_AsOf31Dec2014_BilledRevenuesMember" decimals="-3">1071000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c48_AsOf31Dec2014_UnbilledRevenuesMember" decimals="-3">2778000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">3849000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Work in process&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;267&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Finished Goods&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,210&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;416&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net inventories&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,210&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;683&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:InventoryWorkInProcessNetOfReserves unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">267000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">1210000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves unitRef="usd" contextRef="c1_AsOf31Dec2014" decimals="-3">416000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Product sales, net&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;537&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Royalty revenue&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,518&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,821&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Collaborative and other research and development revenues:&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;U.S. Department of Health and Human Services&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,475&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,341&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Shionogi (Japan)&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;296&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 0.5pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;296&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total collaborative and other research and development revenues&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4,771&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,637&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total revenues&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6,826&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3,458&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;</bcrx:ScheduleOfRevenuesFromCollaborationsTableTextBlock>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment unitRef="usd" contextRef="c49_From1Jan2015To31Mar2015_USDepartmentOfHealthAndHumanServicesMember" decimals="-3">4475000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment unitRef="usd" contextRef="c50_From1Jan2014To31Mar2014_USDepartmentOfHealthAndHumanServicesMember" decimals="-3">1341000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment unitRef="usd" contextRef="c51_From1Jan2015To31Mar2015_ShionogiAndCoLtdMember" decimals="-3">296000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <bcrx:CollaborativeAndOtherResearchAndDevelopment unitRef="usd" contextRef="c52_From1Jan2014To31Mar2014_ShionogiAndCoLtdMember" decimals="-3">296000</bcrx:CollaborativeAndOtherResearchAndDevelopment>
  <us-gaap:Revenues unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">6826000</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">3458000</us-gaap:Revenues>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Note 2 &amp;#8212; Stock-Based Compensation&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;As of March&amp;#160;31, 2015, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&amp;#8220;Incentive Plan&amp;#8221;) and the Employee Stock Purchase Plan (&amp;#8220;ESPP&amp;#8221;), both which were amended and restated in March 2014 and approved by the Company&amp;#8217;s stockholders in May 2014. Stock-based compensation expense of $2,259 ($2,165 of expense related to the Incentive Plan and $94 of expense related to the ESPP) was recognized during the first three months of 2015, while $1,610 ($1,558 of expense related to the Incentive Plan and $52 of expense related to the ESPP) was recognized during the first three months of 2014.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;There was approximately $14,621 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of March&amp;#160;31, 2015. That cost is expected to be recognized as follows: $4,006 during the remainder of 2015, $4,528 in 2016, $4,064 in 2017, $1,990 in 2018 and $33 in 2019. In addition, the Company has outstanding performance-based stock options for which no compensation expense is recognized until &amp;#8220;performance&amp;#8221; has occurred and the award vests. At the time of vesting, compensation expense will be recognized.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Stock Incentive Plan&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&amp;#8217;s stock at the date of grant. Commencing March&amp;#160;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of March 31, 2015, 50% of the August 2013 grants have vested based upon achievement of two milestones: (1)
      successful completion of the OPuS-1 clinical trial for which vesting occurred in the second quarter of 2014, and (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014. Thus, as of March&amp;#160;31, 2015, 50% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&amp;#160;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Related activity under the Incentive Plan is as follows:&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Awards&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Available&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Options&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Outstanding&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Weighted&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Average&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Exercise&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Price&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Balance December&amp;#160;31, 2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,362&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;9,605&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6.21&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Restricted stock unit awards granted&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(133&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Restricted stock unit awards cancelled&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Stock option awards granted&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(917&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;917&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11.83&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Stock option awards exercised&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(240&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3.07&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Stock option awards cancelled&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;28&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(28&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;9.05&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Balance March&amp;#160;31, 2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,341&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;10,254&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6.78&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;For stock option awards granted under the Incentive Plan during the first three months of 2015 and 2014, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the first three months of 2015 and 2014 was $8.11 and $8.28, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the first three months of 2015 and 2014. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised
      at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&amp;#8217;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.&lt;!--EFPlaceholder--&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Weighted Average Assumptions for Stock Option Awards Granted to&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Employees and Directors under the Incentive Plan&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected Life in Years&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5.5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5.5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected Volatility&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;83&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;87&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected Dividend Yield&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.0&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.0&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Risk-Free Interest Rate&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1.5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1.6&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 519 shares remain available for purchase at March&amp;#160;31, 2015. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 20 shares during the first three months of 2015 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &amp;#8220;look-back&amp;#8221; option were determined using a Black-Scholes option pricing model.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <bcrx:NumberOfStockBasedCompensationPlans unitRef="pure" contextRef="c9_From1Jan2015To31Mar2015" decimals="0">2</bcrx:NumberOfStockBasedCompensationPlans>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">2259000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c53_From1Jan2015To31Mar2015_IncentivePlanMember" decimals="-3">2165000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c54_From1Jan2015To31Mar2015_EmployeeStockPurchasePlanMember" decimals="0">94</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c10_From1Jan2014To31Mar2014" decimals="-3">1610000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c55_From1Jan2014To31Mar2014_IncentivePlanMember" decimals="-3">1558000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c56_From1Jan2014To31Mar2014_EmployeeStockPurchasePlanMember" decimals="-3">52000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">14621000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">4006000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">4528000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">4064000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="-3">1990000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
  <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive unitRef="usd" contextRef="c0_AsOf31Mar2015" decimals="0">33</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage unitRef="pure" contextRef="c57_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_GrantsCommencingMarch12011Member" decimals="2">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c57_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_GrantsCommencingMarch12011Member">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage unitRef="pure" contextRef="c58_From1Jan2015To31Mar2015_StockOptionsAndRestrictedStockMember_IncentivePlanMember_RetentionGrantsMadeInJanuary2013Member" decimals="2">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c58_From1Jan2015To31Mar2015_StockOptionsAndRestrictedStockMember_IncentivePlanMember_RetentionGrantsMadeInJanuary2013Member">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c59_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_PerformanceBasedGrantsMadeInAugust2013Member" decimals="-3">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c60_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember" decimals="-3">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage unitRef="pure" contextRef="c59_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_PerformanceBasedGrantsMadeInAugust2013Member" decimals="2">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <bcrx:NumberOfMilestonesAchieved unitRef="pure" contextRef="c59_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_PerformanceBasedGrantsMadeInAugust2013Member" decimals="0">2</bcrx:NumberOfMilestonesAchieved>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage unitRef="pure" contextRef="c59_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_PerformanceBasedGrantsMadeInAugust2013Member" decimals="2">0.50</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage unitRef="pure" contextRef="c61_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_PerformancedBasedGrantsMadeinDecember2014Member" decimals="2">1.00</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate contextRef="c62_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_Non-employeeDirectorsMember">P1Y</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c63_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c64_From1Jan2015To31Mar2015_EmployeeStockOptionMember_IncentivePlanMember_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c53_From1Jan2015To31Mar2015_IncentivePlanMember" decimals="2">8.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c55_From1Jan2014To31Mar2014_IncentivePlanMember" decimals="2">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized unitRef="shares" contextRef="c65_AsOf31Mar2015_EmployeeStockPurchasePlanMember" decimals="-3">1475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant unitRef="shares" contextRef="c65_AsOf31Mar2015_EmployeeStockPurchasePlanMember" decimals="-3">519000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum unitRef="pure" contextRef="c54_From1Jan2015To31Mar2015_EmployeeStockPurchasePlanMember" decimals="2">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
  <bcrx:PercentageOfCommonStockSharesBeginning unitRef="pure" contextRef="c54_From1Jan2015To31Mar2015_EmployeeStockPurchasePlanMember" decimals="2">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
  <bcrx:PercentageOfCommonStockSharesEnding unitRef="pure" contextRef="c54_From1Jan2015To31Mar2015_EmployeeStockPurchasePlanMember" decimals="2">0.85</bcrx:PercentageOfCommonStockSharesEnding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee unitRef="shares" contextRef="c54_From1Jan2015To31Mar2015_EmployeeStockPurchasePlanMember" decimals="-3">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount unitRef="usd" contextRef="c65_AsOf31Mar2015_EmployeeStockPurchasePlanMember" decimals="-3">25000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans unitRef="shares" contextRef="c54_From1Jan2015To31Mar2015_EmployeeStockPurchasePlanMember" decimals="-3">20000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Awards&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Available&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Options&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Outstanding&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Weighted&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Average&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Exercise&lt;/font&gt;
            &lt;/div&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Price&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Balance December&amp;#160;31, 2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2,362&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;9,605&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6.21&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Restricted stock unit awards granted&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(133&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Restricted stock unit awards cancelled&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Stock option awards granted&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(917&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;917&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;11.83&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Stock option awards exercised&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(240&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3.07&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Stock option awards cancelled&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;28&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(28&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 1.1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman&quot;&gt;)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;9.05&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;55%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;55%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Balance March&amp;#160;31, 2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,341&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;10,254&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2.75pt double&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6.78&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant unitRef="shares" contextRef="c1_AsOf31Dec2014" decimals="-3">2362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c1_AsOf31Dec2014" decimals="-3">9605000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c1_AsOf31Dec2014" decimals="2">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod unitRef="shares" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod unitRef="shares" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable unitRef="shares" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">917000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod unitRef="shares" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">917000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c9_From1Jan2015To31Mar2015" decimals="2">11.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">240000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c9_From1Jan2015To31Mar2015" decimals="2">3.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable unitRef="shares" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">28000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c9_From1Jan2015To31Mar2015" decimals="-3">28000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c9_From1Jan2015To31Mar2015" decimals="2">9.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant unitRef="shares" contextRef="c0_AsOf31Mar2015" decimals="-3">1341000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c0_AsOf31Mar2015" decimals="-3">10254000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_AsOf31Mar2015" decimals="2">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2015&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 1pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt&quot; align=&quot;center&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2014&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 1pt solid&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected Life in Years&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5.5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5.5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected Volatility&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;83&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;87&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected Dividend Yield&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.0&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.0&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;70%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Risk-Free Interest Rate&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1.5&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
          &lt;/td&gt;
          &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;right&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1.6&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
          &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
            &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
            &lt;/div&gt;
          &lt;/td&gt;
        &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c9_From1Jan2015To31Mar2015">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c10_From1Jan2014To31Mar2014">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c9_From1Jan2015To31Mar2015" decimals="2">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c10_From1Jan2014To31Mar2014" decimals="2">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c9_From1Jan2015To31Mar2015" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c10_From1Jan2014To31Mar2014" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c9_From1Jan2015To31Mar2015" decimals="3">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c10_From1Jan2014To31Mar2014" decimals="3">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Note 3 &amp;#8212; Collaborative and Other Research and Development Contracts&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;U.S.&amp;#160;Department of Health and Human Services (&amp;#8220;BARDA/HHS&amp;#8221;).&lt;/font&gt; In January 2007, BARDA/HHS awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February&amp;#160;24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding
        to support the filing of a NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014 according to its terms.&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On March 31, 2015, we announced that the Biomedical Research and Development Authority within the U.S. Department of Health and Human Services&amp;#8217; Office of the Assistant Secretary for Preparedness and Response (&amp;#8220;ASPR&amp;#8221;) awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&amp;#160;&amp;#160;This BARDA/HHS contract includes a base contract of $12,134 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $34,989.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;National Institute of Allergy and Infectious Diseases (&amp;#8220;NIAID/HHS&amp;#8221;).&lt;/font&gt; In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of March 31, 2015 could be up to $29,147, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous i.v. and i.m. BCX4430 for the treatment of Marburg virus disease, to conduct an initial Phase 1 human clinical trial and to study BCX4430 as a treatment for Ebola virus disease. As of March 31, 2015, a total of $25,021 has been awarded under exercised options within the contract. BCX4430 is
      the lead compound in the Company&amp;#8217;s BSAV research program.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&amp;#8217;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Shionogi&amp;#160;&amp;amp; Co., Ltd. (&amp;#8220;Shionogi&amp;#8221;).&lt;/font&gt; In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan and to provide rights for Shionogi to perform a Phase&amp;#160;3 clinical trial in Hong Kong. Shionogi has commercially launched peramivir under the
      commercial name RAPIACTA in Japan.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Green Cross Corporation (&amp;#8220;Green Cross&amp;#8221;).&lt;/font&gt; In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Mundipharma International Holdings Limited (&amp;#8220;Mundipharma&amp;#8221;).&lt;/font&gt; In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&amp;#8220;PNP&amp;#8221;) inhibitor, for use in oncology (the &amp;#8220;Original Agreement&amp;#8221;). Under the terms of the license agreement, as amended, Mundipharma obtained worldwide rights to forodesine.&lt;font style=&quot;DISPLAY: inline; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&amp;#8220;AECOM&amp;#8221; and &amp;#8220;IRL&amp;#8221; respectively).&lt;/font&gt; In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &amp;#8220;Licensors&amp;#8221;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each
      licensed product (which range in the aggregate from $1,400 to almost $4,000&amp;#160;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&amp;#160;days advance notice or in the event of material uncured breach by the Licensors.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&amp;#160;any milestone payments the Company may receive in the future under its license agreement dated February&amp;#160;1, 2006 with Mundipharma and (ii)&amp;#160;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales
      of any resulting product made by the Company remains unchanged.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company&amp;#8217;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On November&amp;#160;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On June&amp;#160;19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&amp;#8217;s common stock, or in a combination of cash and shares.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited (&amp;#8220;CIRL&amp;#8221;), formerly Industrial Research Limited, transferred to Victoria University of Wellington (&amp;#8220;VUW&amp;#8221;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property are in the process of being transferred to VUW or its wholly owned subsidiaries, including the contracts to which BioCryst is a party. Except for a substitution of parties, the terms and conditions of the contracts are expected to remain unchanged.&lt;/font&gt;&lt;/font&gt;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;The University of Alabama at Birmingham (&amp;#8220;UAB&amp;#8221;).&lt;/font&gt; The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon
      three months notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&amp;#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <bcrx:CollaborativeAgreementContractValue unitRef="usd" contextRef="c66_From1Jan2007To31Jan2007_USDepartmentOfHealthAndHumanServicesMember" decimals="-3">102661000</bcrx:CollaborativeAgreementContractValue>
  <bcrx:CollaborativeAgreementAdditionalContractValue unitRef="usd" contextRef="c67_From1Sep2009To30Sep2009_USDepartmentOfHealthAndHumanServicesMember" decimals="-3">77191000</bcrx:CollaborativeAgreementAdditionalContractValue>
  <bcrx:CollaborativeAgreementAdditionalContractValue unitRef="usd" contextRef="c68_From1Feb2011To24Feb2011_USDepartmentOfHealthAndHumanServicesMember" decimals="-3">55000000</bcrx:CollaborativeAgreementAdditionalContractValue>
  <bcrx:CollaborativeAgreementAdjustedContractValue unitRef="usd" contextRef="c69_From1Jan2007To24Feb2011_USDepartmentOfHealthAndHumanServicesMember" decimals="-3">234852000</bcrx:CollaborativeAgreementAdjustedContractValue>
  <us-gaap:GovernmentContractReceivable unitRef="usd" contextRef="c70_AsOf31Mar2015_BaseContractMember" decimals="-6">12134000000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable unitRef="usd" contextRef="c71_AsOf31Mar2015_AdditionalDevelopmentOptionsMember" decimals="-6">22855000000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable unitRef="usd" contextRef="c72_AsOf31Mar2015_ASPRBARDAContractMember" decimals="-6">34989000000</us-gaap:GovernmentContractReceivable>
  <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts unitRef="usd" contextRef="c73_From1Sep2013To30Sep2013_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3">5000000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts unitRef="usd" contextRef="c74_From1Jan2015To31Mar2015_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3">29147000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
  <bcrx:CollaborativeAgreementPeriodOfContract contextRef="c74_From1Jan2015To31Mar2015_NationalInstituteOfAllergyAndInfectiousDiseasesMember">P5Y</bcrx:CollaborativeAgreementPeriodOfContract>
  <bcrx:CollaborationAgreementAdditionalPaymentsReceived unitRef="usd" contextRef="c74_From1Jan2015To31Mar2015_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-3">25021000</bcrx:CollaborationAgreementAdditionalPaymentsReceived>
  <us-gaap:ProceedsFromLicenseFeesReceived unitRef="usd" contextRef="c75_From1Jan2006To30Jun2006_GreenCrossCorporationMember" decimals="-3">250000</us-gaap:ProceedsFromLicenseFeesReceived>
  <bcrx:MilestonePaymentMinimum unitRef="usd" contextRef="c76_From1Jan2015To31Mar2015_AECOMAndIRLMember" decimals="-3">1400000</bcrx:MilestonePaymentMinimum>
  <bcrx:MilestonePaymentMaximum unitRef="usd" contextRef="c76_From1Jan2015To31Mar2015_AECOMAndIRLMember" decimals="-3">4000000</bcrx:MilestonePaymentMaximum>
  <bcrx:AnnualLicenseFeeMinimum unitRef="usd" contextRef="c76_From1Jan2015To31Mar2015_AECOMAndIRLMember" decimals="-3">150000</bcrx:AnnualLicenseFeeMinimum>
  <bcrx:AnnualLicenseFeeMaximum unitRef="usd" contextRef="c76_From1Jan2015To31Mar2015_AECOMAndIRLMember" decimals="-3">500000</bcrx:AnnualLicenseFeeMaximum>
  <bcrx:AdvanceNoticePeriodForTerminationOfAgreement contextRef="c77_From1Jun2000To30Jun2000_AECOMAndIRLMember">P60D</bcrx:AdvanceNoticePeriodForTerminationOfAgreement>
  <bcrx:StockIssuedDuringPeriodValueForModificationOfLicenseAgreement unitRef="usd" contextRef="c78_From1May2010To31May2010_AECOMAndIRLMember" decimals="-3">5911000</bcrx:StockIssuedDuringPeriodValueForModificationOfLicenseAgreement>
  <bcrx:PaymentsForModificationOfLicenseAgreement unitRef="usd" contextRef="c78_From1May2010To31May2010_AECOMAndIRLMember" decimals="-3">90000</bcrx:PaymentsForModificationOfLicenseAgreement>
  <bcrx:RenewablePeriodOfAgreement contextRef="c79_From1Jan2015To31Mar2015_UABMember">P5Y</bcrx:RenewablePeriodOfAgreement>
  <bcrx:PeriodOfAgreement contextRef="c79_From1Jan2015To31Mar2015_UABMember">P25Y</bcrx:PeriodOfAgreement>
  <bcrx:RoyaltyMonetizationTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Note 4 &amp;#8212; Royalty Monetization&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Overview&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On March&amp;#160;9, 2011, the Company completed a $30,000&amp;#160;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&amp;#160;from the transaction after transaction costs of $4,309&amp;#160;and the establishment of a $3,000&amp;#160;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&amp;#160;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&amp;#160;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&amp;#160;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &amp;#8220;Currency Hedge Agreement&amp;#8221;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&amp;#8217;s collaboration with Shionogi was not impacted as a result of this transaction.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Non-Recourse Notes Payable&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On March&amp;#160;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &amp;#8220;PhaRMA Notes&amp;#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&amp;#160;9, 2011 (the &amp;#8220;Indenture&amp;#8221;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&amp;#160;per annum, payable annually in arrears on September&amp;#160;1st of each year (the &amp;#8220;Payment Date&amp;#8221;). The Company remains entitled to receive any royalties and
      milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Royalty Sub&amp;#8217;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&amp;#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On September&amp;#160;1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to
      the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&amp;#8217;s future results of operations or cash flows.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;As of March&amp;#160;31, 2015, the aggregate fair value of the PhaRMA Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&amp;#160;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Foreign Currency Hedge&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2015 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&amp;#160;will be required if, on May&amp;#160;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&amp;#8217;s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&amp;#160;31, 2015 and 2014 resulted in a gain of $464 and a loss of $1,526, respectively. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of March 31, 2015 and December&amp;#160;31, 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of March 31, 2015, the maximum amount of hedge collateral the Company may be required to post is $11.7 million.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;</bcrx:RoyaltyMonetizationTextBlock>
  <bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized unitRef="usd" contextRef="c80_AsOf9Mar2011_JPRRoyaltySubLLCMember_RoyaltyMonetizationMember" decimals="-3">30000000</bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized>
  <bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet unitRef="usd" contextRef="c81_From1Mar2011To9Mar2011_JPRRoyaltySubLLCMember_RoyaltyMonetizationMember" decimals="-3">22691000</bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet>
  <bcrx:TransactionCosts unitRef="usd" contextRef="c81_From1Mar2011To9Mar2011_JPRRoyaltySubLLCMember_RoyaltyMonetizationMember" decimals="-3">4309000</bcrx:TransactionCosts>
  <bcrx:InterestReserve unitRef="usd" contextRef="c81_From1Mar2011To9Mar2011_JPRRoyaltySubLLCMember_RoyaltyMonetizationMember" decimals="-3">3000000</bcrx:InterestReserve>
  <bcrx:PrivatePlacementOfSeniorSecuredNotes unitRef="usd" contextRef="c82_From1Mar2011To9Mar2011_JPRRoyaltySubLLCMember_PhaRMANotesMember" decimals="-3">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage unitRef="pure" contextRef="c83_AsOf9Mar2011_JPRRoyaltySubLLCMember_PhaRMANotesMember" decimals="3">0.140</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:LongTermNotesPayable unitRef="usd" contextRef="c84_AsOf31Mar2015_PhaRMANotesMember_JPRRoyaltySubLLCMember" decimals="-3">30000000</us-gaap:LongTermNotesPayable>
  <us-gaap:DerivativeForwardExchangeRate1 unitRef="pure" contextRef="c85_AsOf31Mar2015_JPY_PhaRMANotesMember_CurrencyHedgeAgreementMember" decimals="0">100</us-gaap:DerivativeForwardExchangeRate1>
  <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities unitRef="usd" contextRef="c86_From1Jan2014To31Dec2014_PhaRMANotesMember_CurrencyHedgeAgreementMember" decimals="-3">1950000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
  <bcrx:RequiredForeignCurrencyHedgePerDollar unitRef="jpy" contextRef="c87_AsOf31Dec2014_PhaRMANotesMember_CurrencyHedgeAgreementMember" decimals="0">100</bcrx:RequiredForeignCurrencyHedgePerDollar>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments unitRef="usd" contextRef="c88_From1Jan2015To31Mar2015_JPRRoyaltySubLLCMember_PhaRMANotesMember_CurrencyHedgeAgreementMember" decimals="-3">464000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments unitRef="usd" contextRef="c89_From1Jan2014To31Dec2014_JPRRoyaltySubLLCMember_PhaRMANotesMember_CurrencyHedgeAgreementMember" decimals="-3">1526000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
  <bcrx:MaximumAmountOfCollateralRequiredToPost unitRef="usd" contextRef="c90_AsOf31Mar2015_JPRRoyaltySubLLCMember_PhaRMANotesMember_CurrencyHedgeAgreementMember" decimals="-5">11700000</bcrx:MaximumAmountOfCollateralRequiredToPost>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c9_From1Jan2015To31Mar2015">&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Note 5 &amp;#8212; Stockholders&amp;#8217; Equity&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On November&amp;#160;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration.&lt;!--EFPlaceholder--&gt;&lt;/font&gt;
    &lt;/div&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <bcrx:MaximumAggregateOfferingPrice unitRef="usd" contextRef="c91_AsOf3Mar2015" decimals="-3">150000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:MaximumAggregateOfferingPrice unitRef="usd" contextRef="c92_AsOf6Nov2013" decimals="-3">125000000</bcrx:MaximumAggregateOfferingPrice>
  <bcrx:RemainingAggregateOfferingPrice unitRef="usd" contextRef="c92_AsOf6Nov2013" decimals="-3">10000000</bcrx:RemainingAggregateOfferingPrice>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bcrx-20150331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Fri May 08 17:32:20 UTC 2015 -->
<xs:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://www.biocryst.com/20150331" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" elementFormDefault="qualified" xmlns:bcrx="http://www.biocryst.com/20150331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="bcrx-20150331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bcrx-20150331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bcrx-20150331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="bcrx-20150331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheet" id="bcrx_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheet_Parentheticals" id="bcrx_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/ConsolidatedIncomeStatement" id="bcrx_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/ConsolidatedCashFlow" id="bcrx_r_ConsolidatedCashFlow">
        <link:definition>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note1SignificantAccountingPolicies" id="bcrx_r_Note1SignificantAccountingPolicies">
        <link:definition>005 - Disclosure - Note 1 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note2StockBasedCompensation" id="bcrx_r_Note2StockBasedCompensation">
        <link:definition>006 - Disclosure - Note 2 - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContracts" id="bcrx_r_Note3CollaborativeandOtherResearchandDevelopmentContracts">
        <link:definition>007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note4RoyaltyMonetization" id="bcrx_r_Note4RoyaltyMonetization">
        <link:definition>008 - Disclosure - Note 4- Royalty Monetization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note5StockholdersEquity" id="bcrx_r_Note5StockholdersEquity">
        <link:definition>009 - Disclosure - Note 5 - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/AccountingPoliciesByPolicy" id="bcrx_r_AccountingPoliciesByPolicy">
        <link:definition>010 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note1SignificantAccountingPoliciesTables" id="bcrx_r_Note1SignificantAccountingPoliciesTables">
        <link:definition>011 - Disclosure - Note 1 - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note2StockBasedCompensationTables" id="bcrx_r_Note2StockBasedCompensationTables">
        <link:definition>012 - Disclosure - Note 2 - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note1SignificantAccountingPoliciesDetails" id="bcrx_r_Note1SignificantAccountingPoliciesDetails">
        <link:definition>013 - Disclosure - Note 1 - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/FairValueoftheCompanysInvestmentsbyTypeTable" id="bcrx_r_FairValueoftheCompanysInvestmentsbyTypeTable">
        <link:definition>014 - Disclosure - Note 1 - Significant Accounting Policies (Details) - Fair Value of the Company&#8217;s Investments by Type</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/ScheduledMaturityfortheCompanysInvestmentsTable" id="bcrx_r_ScheduledMaturityfortheCompanysInvestmentsTable">
        <link:definition>015 - Disclosure - Note 1 - Significant Accounting Policies (Details) - Scheduled Maturity for the Company&#8217;s Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/SummaryofReceivablesTable" id="bcrx_r_SummaryofReceivablesTable">
        <link:definition>016 - Disclosure - Note 1 - Significant Accounting Policies (Details) - Summary of Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/InventoryTable" id="bcrx_r_InventoryTable">
        <link:definition>017 - Disclosure - Note 1 - Significant Accounting Policies (Details) - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/SummaryofRevenuesTable" id="bcrx_r_SummaryofRevenuesTable">
        <link:definition>018 - Disclosure - Note 1 - Significant Accounting Policies (Details) - Summary of Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note2StockBasedCompensationDetails" id="bcrx_r_Note2StockBasedCompensationDetails">
        <link:definition>019 - Disclosure - Note 2 - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/StockIncentivePlanActivitiesTable" id="bcrx_r_StockIncentivePlanActivitiesTable">
        <link:definition>020 - Disclosure - Note 2 - Stock-Based Compensation (Details) - Stock Incentive Plan Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/WeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsundertheIncentivePlanTable" id="bcrx_r_WeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsundertheIncentivePlanTable">
        <link:definition>021 - Disclosure - Note 2 - Stock-Based Compensation (Details) - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContractsDetails" id="bcrx_r_Note3CollaborativeandOtherResearchandDevelopmentContractsDetails">
        <link:definition>022 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/Note4RoyaltyMonetizationDetails" id="bcrx_r_Note4RoyaltyMonetizationDetails">
        <link:definition>023 - Disclosure - Note 4- Royalty Monetization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqIaiEUguwqkWGa4cpv416hMMHjZG8xE46xL+mr4cf8Tq9b70MVwJzKgr6HCfYcFXZs/8eE/WbBTxrVDMgYuQntYWFD0E/pnX5XPvNTZUuRQpNVkusoa+c494MTAEv8KuXfbHWCH1lOJcQA3ctTEoDUIdP5GHFBF0gC+D9Yie2bdAZFTY8AnPWRJkdtpasB4JG] CSR-->
      <link:roleType roleURI="http://www.biocryst.com/role/Note5StockholdersEquityDetails" id="bcrx_r_Note5StockholdersEquityDetails">
        <link:definition>024 - Disclosure - Note 5 - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biocryst.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Disclosure - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:element name="FairValueOfTheCompanySInvestmentsByTypeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_FairValueOfTheCompanySInvestmentsByTypeAbstract"/>
  <xs:element name="ScheduledMaturityForTheCompanySInvestmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract"/>
  <xs:element name="SummaryOfReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_SummaryOfReceivablesAbstract"/>
  <xs:element name="InventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_InventoryAbstract"/>
  <xs:element name="SummaryOfRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_SummaryOfRevenuesAbstract"/>
  <xs:element name="StockIncentivePlanActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_StockIncentivePlanActivitiesAbstract"/>
  <xs:element name="WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract"/>
  <xs:element name="RoyaltyMonetizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RoyaltyMonetizationAbstract"/>
  <xs:element name="ExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ExpensesAbstract"/>
  <xs:element name="OperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_OperatingActivitiesAbstract"/>
  <xs:element name="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
  <xs:element name="ChangesInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
  <xs:element name="InvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_InvestingActivitiesAbstract"/>
  <xs:element name="FinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_FinancingActivitiesAbstract"/>
  <xs:element name="CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract"/>
  <xs:element name="DeferredCollaborationExpenseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_DeferredCollaborationExpenseAssets"/>
  <xs:element name="CollaborativeAndOtherResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CollaborativeAndOtherResearchAndDevelopment"/>
  <xs:element name="DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities"/>
  <xs:element name="ReceiptPaymentOfForeignCurrencyDerivativeCollateral" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral"/>
  <xs:element name="RoyaltyMonetizationTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RoyaltyMonetizationTextBlock"/>
  <xs:element name="DescriptionOfCompanyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_DescriptionOfCompanyPolicyTextBlock"/>
  <xs:element name="AccruedExpensesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AccruedExpensesPolicyTextBlock"/>
  <xs:element name="AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock"/>
  <xs:element name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock"/>
  <xs:element name="CurrencyHedgeAgreementPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CurrencyHedgeAgreementPolicyTextBlock"/>
  <xs:element name="ConcentrationOfMarketRiskPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock"/>
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock"/>
  <xs:element name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock"/>
  <xs:element name="ScheduleOfRevenuesFromCollaborationsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock"/>
  <xs:element name="AvailableForSaleSecuritiesAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AvailableForSaleSecuritiesAccruedInterest"/>
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears"/>
  <xs:element name="Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable"/>
  <xs:element name="Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems"/>
  <xs:element name="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable"/>
  <xs:element name="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable"/>
  <xs:element name="Note1SignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bcrx_Note1SignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="Note1SignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="SecuritiesOffered" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_SecuritiesOffered"/>
  <xs:element name="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized"/>
  <xs:element name="MaturityPeriodOfHighQualityMarketableSecurities" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_MaturityPeriodOfHighQualityMarketableSecurities"/>
  <xs:element name="AverageMaturityPeriodOfHighQualityMarketableSecurities" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities"/>
  <xs:element name="MaturityPeriodOfShortTermInvestment" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_MaturityPeriodOfShortTermInvestment"/>
  <xs:element name="LongTermInvestmentMaturityMinimum" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_LongTermInvestmentMaturityMinimum"/>
  <xs:element name="AverageMaturityForPortfolioInvestments" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AverageMaturityForPortfolioInvestments"/>
  <xs:element name="Note2StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bcrx_Note2StockBasedCompensationDetailsTable"/>
  <xs:element name="Note2StockBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_Note2StockBasedCompensationDetailsLineItems"/>
  <xs:element name="NumberOfStockBasedCompensationPlans" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_NumberOfStockBasedCompensationPlans"/>
  <xs:element name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear"/>
  <xs:element name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo"/>
  <xs:element name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree"/>
  <xs:element name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour"/>
  <xs:element name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive"/>
  <xs:element name="NumberOfMilestonesAchieved" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_NumberOfMilestonesAchieved"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate"/>
  <xs:element name="PercentageOfSalaryToPurchaseCommonStockMaximum" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum"/>
  <xs:element name="PercentageOfCommonStockSharesBeginning" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_PercentageOfCommonStockSharesBeginning"/>
  <xs:element name="PercentageOfCommonStockSharesEnding" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_PercentageOfCommonStockSharesEnding"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount"/>
  <xs:element name="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable"/>
  <xs:element name="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems"/>
  <xs:element name="CollaborativeAgreementContractValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CollaborativeAgreementContractValue"/>
  <xs:element name="CollaborativeAgreementAdditionalContractValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CollaborativeAgreementAdditionalContractValue"/>
  <xs:element name="CollaborativeAgreementAdjustedContractValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CollaborativeAgreementAdjustedContractValue"/>
  <xs:element name="ProceedsFromAwardsForResearchAndDevelopmentContracts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts"/>
  <xs:element name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts"/>
  <xs:element name="CollaborativeAgreementPeriodOfContract" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CollaborativeAgreementPeriodOfContract"/>
  <xs:element name="CollaborationAgreementAdditionalPaymentsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CollaborationAgreementAdditionalPaymentsReceived"/>
  <xs:element name="MilestonePaymentMinimum" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_MilestonePaymentMinimum"/>
  <xs:element name="MilestonePaymentMaximum" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_MilestonePaymentMaximum"/>
  <xs:element name="AnnualLicenseFeeMinimum" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AnnualLicenseFeeMinimum"/>
  <xs:element name="AnnualLicenseFeeMaximum" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AnnualLicenseFeeMaximum"/>
  <xs:element name="AdvanceNoticePeriodForTerminationOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AdvanceNoticePeriodForTerminationOfAgreement"/>
  <xs:element name="StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement"/>
  <xs:element name="PaymentsForModificationOfLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_PaymentsForModificationOfLicenseAgreement"/>
  <xs:element name="RenewablePeriodOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RenewablePeriodOfAgreement"/>
  <xs:element name="PeriodOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_PeriodOfAgreement"/>
  <xs:element name="Note4RoyaltyMonetizationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="bcrx_Note4RoyaltyMonetizationDetailsTable"/>
  <xs:element name="Note4RoyaltyMonetizationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_Note4RoyaltyMonetizationDetailsLineItems"/>
  <xs:element name="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet"/>
  <xs:element name="TransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_TransactionCosts"/>
  <xs:element name="InterestReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_InterestReserve"/>
  <xs:element name="PrivatePlacementOfSeniorSecuredNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_PrivatePlacementOfSeniorSecuredNotes"/>
  <xs:element name="RequiredForeignCurrencyHedgePerDollar" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RequiredForeignCurrencyHedgePerDollar"/>
  <xs:element name="MaximumAmountOfCollateralRequiredToPost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_MaximumAmountOfCollateralRequiredToPost"/>
  <xs:element name="MaximumAggregateOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_MaximumAggregateOfferingPrice"/>
  <xs:element name="RemainingAggregateOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RemainingAggregateOfferingPrice"/>
  <xs:element name="AECOMAndIRLMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AECOMAndIRLMember"/>
  <xs:element name="ASPRBARDAContractMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ASPRBARDAContractMember"/>
  <xs:element name="AdditionalDevelopmentOptionsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_AdditionalDevelopmentOptionsMember"/>
  <xs:element name="BaseContractMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_BaseContractMember"/>
  <xs:element name="ClinicalTrial2007Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ClinicalTrial2007Member"/>
  <xs:element name="CollaborationReceivablesMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CollaborationReceivablesMember"/>
  <xs:element name="CollateralForCreditMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CollateralForCreditMember"/>
  <xs:element name="CurrencyHedgeAgreementMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_CurrencyHedgeAgreementMember"/>
  <xs:element name="DeferredCollaborativeRevenueMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_DeferredCollaborativeRevenueMember"/>
  <xs:element name="DeferredProductSalesMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_DeferredProductSalesMember"/>
  <xs:element name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_EmployeeStockPurchasePlanMember"/>
  <xs:element name="GrantsCommencingMarch12011Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_GrantsCommencingMarch12011Member"/>
  <xs:element name="GrantsCommensingPriorToMarch12011Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_GrantsCommensingPriorToMarch12011Member"/>
  <xs:element name="GreenCrossCorporationMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_GreenCrossCorporationMember"/>
  <xs:element name="IncentivePlanMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_IncentivePlanMember"/>
  <xs:element name="InducementGrantMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_InducementGrantMember"/>
  <xs:element name="JPRRoyaltySubLLCMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_JPRRoyaltySubLLCMember"/>
  <xs:element name="LabroatoryEquipmentOfficeEquipmentAndSoftwareMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_LabroatoryEquipmentOfficeEquipmentAndSoftwareMember"/>
  <xs:element name="MundipharmaMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_MundipharmaMember"/>
  <xs:element name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
  <xs:element name="Non-employeeDirectorsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_Non-employeeDirectorsMember"/>
  <xs:element name="PerformanceBasedGrantsMadeInAugust2013Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_PerformanceBasedGrantsMadeInAugust2013Member"/>
  <xs:element name="PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember"/>
  <xs:element name="PerformancedBasedGrantsMadeinDecember2014Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_PerformancedBasedGrantsMadeinDecember2014Member"/>
  <xs:element name="PhaRMANotesMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_PhaRMANotesMember"/>
  <xs:element name="RAPIACTAMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RAPIACTAMember"/>
  <xs:element name="RAPIVABMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RAPIVABMember"/>
  <xs:element name="RetentionGrantsMadeInJanuary2013Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RetentionGrantsMadeInJanuary2013Member"/>
  <xs:element name="RoyaltyMonetizationMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RoyaltyMonetizationMember"/>
  <xs:element name="RoyaltyReceivableMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_RoyaltyReceivableMember"/>
  <xs:element name="ShionogiAndCoLtdMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_ShionogiAndCoLtdMember"/>
  <xs:element name="Shortfall2013Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_Shortfall2013Member"/>
  <xs:element name="StockOptionsAndRestrictedStockMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_StockOptionsAndRestrictedStockMember"/>
  <xs:element name="UABMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_UABMember"/>
  <xs:element name="USDepartmentOfHealthAndHumanServicesMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
  <xs:element name="UpFrontPaymentMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_UpFrontPaymentMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="bcrx_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>bcrx-20150331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Fri May 08 17:32:20 UTC 2015 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedBalanceSheet" roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedIncomeStatement" roleURI="http://www.biocryst.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedCashFlow" roleURI="http://www.biocryst.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ScheduledMaturityfortheCompanysInvestmentsTable" roleURI="http://www.biocryst.com/role/ScheduledMaturityfortheCompanysInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_InventoryTable" roleURI="http://www.biocryst.com/role/InventoryTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborationExpenseAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="bcrx_DeferredCollaborationExpenseAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_RoyaltyRevenue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RoyaltyExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense"/>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqIaiEUguwqkWGa4cpv416hMMHjZG8xE46xL+mr4cf8Tq9b70MVwJzKgr6HCfYcFXZs/8eE/WbBTxrVDMgYuQntYWFD0E/pnX5XPvNTZUuRQpNVkusoa+c494MTAEv8KuXfbHWCH1lOJcQA3ctTEoDUIdP5GHFBF0gC+D9Yie2bdDE4AXJse2llxm4kHnNODfD] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="4" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockPlans" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:href="bcrx-20150331.xsd#bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ScheduledMaturityfortheCompanysInvestmentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/InventoryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>bcrx-20150331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Fri May 08 17:32:20 UTC 2015 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedBalanceSheet" roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedIncomeStatement" roleURI="http://www.biocryst.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedCashFlow" roleURI="http://www.biocryst.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note1SignificantAccountingPolicies" roleURI="http://www.biocryst.com/role/Note1SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note2StockBasedCompensation" roleURI="http://www.biocryst.com/role/Note2StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note3CollaborativeandOtherResearchandDevelopmentContracts" roleURI="http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContracts"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note4RoyaltyMonetization" roleURI="http://www.biocryst.com/role/Note4RoyaltyMonetization"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note5StockholdersEquity" roleURI="http://www.biocryst.com/role/Note5StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_AccountingPoliciesByPolicy" roleURI="http://www.biocryst.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note1SignificantAccountingPoliciesTables" roleURI="http://www.biocryst.com/role/Note1SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note2StockBasedCompensationTables" roleURI="http://www.biocryst.com/role/Note2StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_FairValueoftheCompanysInvestmentsbyTypeTable" roleURI="http://www.biocryst.com/role/FairValueoftheCompanysInvestmentsbyTypeTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ScheduledMaturityfortheCompanysInvestmentsTable" roleURI="http://www.biocryst.com/role/ScheduledMaturityfortheCompanysInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_SummaryofReceivablesTable" roleURI="http://www.biocryst.com/role/SummaryofReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_InventoryTable" roleURI="http://www.biocryst.com/role/InventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_SummaryofRevenuesTable" roleURI="http://www.biocryst.com/role/SummaryofRevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_StockIncentivePlanActivitiesTable" roleURI="http://www.biocryst.com/role/StockIncentivePlanActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_WeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsundertheIncentivePlanTable" roleURI="http://www.biocryst.com/role/WeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsundertheIncentivePlanTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note1SignificantAccountingPoliciesDetails" roleURI="http://www.biocryst.com/role/Note1SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note2StockBasedCompensationDetails" roleURI="http://www.biocryst.com/role/Note2StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note3CollaborativeandOtherResearchandDevelopmentContractsDetails" roleURI="http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContractsDetails"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note4RoyaltyMonetizationDetails" roleURI="http://www.biocryst.com/role/Note4RoyaltyMonetizationDetails"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note5StockholdersEquityDetails" roleURI="http://www.biocryst.com/role/Note5StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#DocumentAndEntityInformation" roleURI="http://www.biocryst.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborativeRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_DeferredCollaborativeRevenueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredProductSalesMember" xlink:href="bcrx-20150331.xsd#bcrx_DeferredProductSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_DeferredProductSalesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborationReceivablesMember" xlink:href="bcrx-20150331.xsd#bcrx_CollaborationReceivablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="bcrx_CollaborationReceivablesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborationExpenseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="bcrx_DeferredCollaborationExpenseAssets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_Assets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborativeRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_DeferredCollaborativeRevenueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredProductSalesMember" xlink:href="bcrx-20150331.xsd#bcrx_DeferredProductSalesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="bcrx_DeferredProductSalesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborationReceivablesMember" xlink:href="bcrx-20150331.xsd#bcrx_CollaborationReceivablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="bcrx_CollaborationReceivablesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:to="us-gaap_SalesRevenueNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ExpensesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_ExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpensesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_CostsAndExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_OperatingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_OperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_OperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_OperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_OperatingActivitiesAbstract" xlink:to="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_OperatingActivitiesAbstract" xlink:to="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_InvestingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_InvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_InvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_InvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_InvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_InvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_InvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_FinancingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_FinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_FinancingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_FinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_FinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_FinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:href="bcrx-20150331.xsd#bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_FinancingActivitiesAbstract" xlink:to="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_FinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_FinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note1SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note2StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContracts">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note4RoyaltyMonetization">
    <loc xlink:type="locator" xlink:label="bcrx_RoyaltyMonetizationAbstract" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyMonetizationAbstract"/>
    <loc xlink:type="locator" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyMonetizationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_RoyaltyMonetizationAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note5StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_AccruedExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note1SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note2StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/FairValueoftheCompanysInvestmentsbyTypeTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NuclearFuelNetOfAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NuclearFuelNetOfAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_NuclearFuelNetOfAmortization" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SpentNuclearFuelObligationNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SpentNuclearFuelObligationNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_SpentNuclearFuelObligationNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForNuclearFuel" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForNuclearFuel"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_PaymentsForNuclearFuel" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNuclearFuel" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNuclearFuel"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ProceedsFromNuclearFuel" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ScheduledMaturityfortheCompanysInvestmentsTable">
    <loc xlink:type="locator" xlink:label="bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:href="bcrx-20150331.xsd#bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecurities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/SummaryofReceivablesTable">
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems" xlink:to="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesBillingStatusDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:href="bcrx-20150331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:href="bcrx-20150331.xsd#bcrx_ShionogiAndCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ShionogiAndCoLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BilledRevenuesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BilledRevenuesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledRevenuesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/InventoryTable">
    <loc xlink:type="locator" xlink:label="bcrx_InventoryAbstract" xlink:href="bcrx-20150331.xsd#bcrx_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_InventoryAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_InventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_InventoryAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqIaiEUguwqkWGa4cpv416hMMHjZG8xE46xL+mr4cf8Tq9b70MVwJzKgr6HCfYcFXZs/8eE/WbBTxrVDMgYuQntYWFD0E/pnX5XPvNTZUuRQpNVkusoa+c494MTAEv8KuXfbHWCH1lOJcQA3ctTEoDUIdP5GHFBF0gC+D9Yie2bdADZs5oTP+c9wYNGTpEsUhj] CSR-->
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/SummaryofRevenuesTable">
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:to="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:href="bcrx-20150331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:href="bcrx-20150331.xsd#bcrx_ShionogiAndCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ShionogiAndCoLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:to="us-gaap_Revenues" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/StockIncentivePlanActivitiesTable">
    <loc xlink:type="locator" xlink:label="bcrx_StockIncentivePlanActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_StockIncentivePlanActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/WeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsundertheIncentivePlanTable">
    <loc xlink:type="locator" xlink:label="bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:href="bcrx-20150331.xsd#bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note1SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="bcrx_Note1SignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ProductOrServiceAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductsAndServicesDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RangeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsTable" xlink:to="dei_LegalEntityAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueProductLineMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PhaRMANotesMember" xlink:href="bcrx-20150331.xsd#bcrx_PhaRMANotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_PhaRMANotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_RoyaltyReceivableMember" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollateralForCreditMember" xlink:href="bcrx-20150331.xsd#bcrx_CollateralForCreditMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:href="bcrx-20150331.xsd#bcrx_JPRRoyaltySubLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_RAPIVABMember" xlink:href="bcrx-20150331.xsd#bcrx_RAPIVABMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaximumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinimumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_SecuritiesOffered" xlink:href="bcrx-20150331.xsd#bcrx_SecuritiesOffered"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="bcrx_SecuritiesOffered" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:href="bcrx-20150331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:href="bcrx-20150331.xsd#bcrx_MaturityPeriodOfHighQualityMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketableSecurities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:href="bcrx-20150331.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_MaturityPeriodOfShortTermInvestment" xlink:href="bcrx-20150331.xsd#bcrx_MaturityPeriodOfShortTermInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="bcrx_MaturityPeriodOfShortTermInvestment" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_LongTermInvestmentMaturityMinimum" xlink:href="bcrx-20150331.xsd#bcrx_LongTermInvestmentMaturityMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="bcrx_LongTermInvestmentMaturityMinimum" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AverageMaturityForPortfolioInvestments" xlink:href="bcrx-20150331.xsd#bcrx_AverageMaturityForPortfolioInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="bcrx_AverageMaturityForPortfolioInvestments" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note2StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note2StockBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note2StockBasedCompensationDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note2StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_Note2StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note2StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note2StockBasedCompensationDetailsTable" xlink:to="us-gaap_VestingAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note2StockBasedCompensationDetailsTable" xlink:to="us-gaap_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note2StockBasedCompensationDetailsTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note2StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_Non-employeeDirectorsMember" xlink:href="bcrx-20150331.xsd#bcrx_Non-employeeDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_Non-employeeDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:href="bcrx-20150331.xsd#bcrx_StockOptionsAndRestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_StockOptionsAndRestrictedStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_IncentivePlanMember" xlink:href="bcrx-20150331.xsd#bcrx_IncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_GrantsCommencingMarch12011Member" xlink:href="bcrx-20150331.xsd#bcrx_GrantsCommencingMarch12011Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_GrantsCommencingMarch12011Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_RetentionGrantsMadeInJanuary2013Member" xlink:href="bcrx-20150331.xsd#bcrx_RetentionGrantsMadeInJanuary2013Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_RetentionGrantsMadeInJanuary2013Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PerformanceBasedGrantsMadeInAugust2013Member" xlink:href="bcrx-20150331.xsd#bcrx_PerformanceBasedGrantsMadeInAugust2013Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_PerformanceBasedGrantsMadeInAugust2013Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember" xlink:href="bcrx-20150331.xsd#bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PerformancedBasedGrantsMadeinDecember2014Member" xlink:href="bcrx-20150331.xsd#bcrx_PerformancedBasedGrantsMadeinDecember2014Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_PerformancedBasedGrantsMadeinDecember2014Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinimumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaximumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_NumberOfStockBasedCompensationPlans" xlink:href="bcrx-20150331.xsd#bcrx_NumberOfStockBasedCompensationPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_NumberOfStockBasedCompensationPlans" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_NumberOfMilestonesAchieved" xlink:href="bcrx-20150331.xsd#bcrx_NumberOfMilestonesAchieved"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_NumberOfMilestonesAchieved" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:href="bcrx-20150331.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:href="bcrx-20150331.xsd#bcrx_PercentageOfCommonStockSharesBeginning"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:href="bcrx-20150331.xsd#bcrx_PercentageOfCommonStockSharesEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContractsDetails">
    <loc xlink:type="locator" xlink:label="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_BaseContractMember" xlink:href="bcrx-20150331.xsd#bcrx_BaseContractMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:href="bcrx-20150331.xsd#bcrx_AdditionalDevelopmentOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ASPRBARDAContractMember" xlink:href="bcrx-20150331.xsd#bcrx_ASPRBARDAContractMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_GreenCrossCorporationMember" xlink:href="bcrx-20150331.xsd#bcrx_GreenCrossCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AECOMAndIRLMember" xlink:href="bcrx-20150331.xsd#bcrx_AECOMAndIRLMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:href="bcrx-20150331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="bcrx-20150331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_UABMember" xlink:href="bcrx-20150331.xsd#bcrx_UABMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementContractValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementAdditionalContractValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementAdjustedContractValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentContractReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GovernmentContractReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="us-gaap_GovernmentContractReceivable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:href="bcrx-20150331.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:href="bcrx-20150331.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAgreementPeriodOfContract" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementPeriodOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_CollaborativeAgreementPeriodOfContract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:href="bcrx-20150331.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_MilestonePaymentMinimum" xlink:href="bcrx-20150331.xsd#bcrx_MilestonePaymentMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_MilestonePaymentMinimum" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_MilestonePaymentMaximum" xlink:href="bcrx-20150331.xsd#bcrx_MilestonePaymentMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_MilestonePaymentMaximum" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:href="bcrx-20150331.xsd#bcrx_AnnualLicenseFeeMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:href="bcrx-20150331.xsd#bcrx_AnnualLicenseFeeMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:href="bcrx-20150331.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:href="bcrx-20150331.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:href="bcrx-20150331.xsd#bcrx_PaymentsForModificationOfLicenseAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:href="bcrx-20150331.xsd#bcrx_RenewablePeriodOfAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PeriodOfAgreement" xlink:href="bcrx-20150331.xsd#bcrx_PeriodOfAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_PeriodOfAgreement" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note4RoyaltyMonetizationDetails">
    <loc xlink:type="locator" xlink:label="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note4RoyaltyMonetizationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note4RoyaltyMonetizationDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note4RoyaltyMonetizationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="bcrx_Note4RoyaltyMonetizationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsTable" xlink:to="us-gaap_CurrencyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsTable" xlink:to="dei_LegalEntityAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PhaRMANotesMember" xlink:href="bcrx-20150331.xsd#bcrx_PhaRMANotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyMonetizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:href="bcrx-20150331.xsd#bcrx_JPRRoyaltySubLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_JPY" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_JPY" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:href="bcrx-20150331.xsd#bcrx_CurrencyHedgeAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:href="bcrx-20150331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:href="bcrx-20150331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_TransactionCosts" xlink:href="bcrx-20150331.xsd#bcrx_TransactionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="bcrx_TransactionCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_InterestReserve" xlink:href="bcrx-20150331.xsd#bcrx_InterestReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="bcrx_InterestReserve" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:href="bcrx-20150331.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:href="bcrx-20150331.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:href="bcrx-20150331.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note5StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:href="bcrx-20150331.xsd#bcrx_MaximumAggregateOfferingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="bcrx_MaximumAggregateOfferingPrice" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="bcrx_RemainingAggregateOfferingPrice" xlink:href="bcrx-20150331.xsd#bcrx_RemainingAggregateOfferingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="bcrx_RemainingAggregateOfferingPrice" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>bcrx-20150331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Fri May 08 17:32:20 UTC 2015 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborationReceivablesMember" xlink:href="bcrx-20150331.xsd#bcrx_CollaborationReceivablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_CollaborationReceivablesMember_lbl" xml:lang="en-US">Collaboration Receivables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationReceivablesMember" xlink:to="bcrx_CollaborationReceivablesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xml:lang="en-US">Trade Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Net inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred collaboration expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xml:lang="en-US">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Furniture and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredCollaborationExpenseAssets" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborationExpenseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_DeferredCollaborationExpenseAssets_lbl" xml:lang="en-US">Deferred collaboration expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseAssets" xlink:to="bcrx_DeferredCollaborationExpenseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredCollaborativeRevenueMember" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborativeRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_DeferredCollaborativeRevenueMember_lbl" xml:lang="en-US">Deferred Collaborative Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborativeRevenueMember" xlink:to="bcrx_DeferredCollaborativeRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredProductSalesMember" xlink:href="bcrx-20150331.xsd#bcrx_DeferredProductSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_DeferredProductSalesMember_lbl" xml:lang="en-US">Deferred Product Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredProductSalesMember" xlink:to="bcrx_DeferredProductSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Non-recourse notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl0" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred collaboration revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; shares authorized &#8212; 5,000; no shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value: shares authorized &#8212; 200,000; shares issued and outstanding &#8212; 72,474 in 2015 and 71,955 in 2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Product sales, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyRevenue_lbl" xml:lang="en-US">Royalty revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyRevenue_lbl0" xml:lang="en-US">Royalty revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl0"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment_lbl" xml:lang="en-US">Collaborative and other research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment_lbl0" xml:lang="en-US">Collaborative and other research and development revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of products sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_lbl" xml:lang="en-US">Gain (loss) on foreign currency derivative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_lbl0" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted net loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized gain (loss) on available for sale investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Financing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets_lbl" xml:lang="en-US">Change in fair value of foreign currency derivative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities_lbl" xml:lang="en-US">Deferred collaboration expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Acquisitions of furniture and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Change in restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Purchases of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Sales and maturities of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Sale of common stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US">Employee stock purchase plan sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:href="bcrx-20150331.xsd#bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral_lbl" xml:lang="en-US">Payment of foreign currency derivative collateral</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:to="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_FairValueOfTheCompanySInvestmentsByTypeAbstract" xlink:href="bcrx-20150331.xsd#bcrx_FairValueOfTheCompanySInvestmentsByTypeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_FairValueOfTheCompanySInvestmentsByTypeAbstract_lbl" xml:lang="en-US">Fair Value of the Company&#8217;s Investments by Type [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_FairValueOfTheCompanySInvestmentsByTypeAbstract" xlink:to="bcrx_FairValueOfTheCompanySInvestmentsByTypeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US">US Government Agencies Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xml:lang="en-US">Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest_lbl" xml:lang="en-US">Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains_lbl" xml:lang="en-US">Gross Unrealized Gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Gross Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US">Estimated Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecurities_lbl0" xml:lang="en-US">Total investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Paper [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:href="bcrx-20150331.xsd#bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract_lbl" xml:lang="en-US">Scheduled Maturity for the Company&#8217;s Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:to="bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US">Maturing in one year or less</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xml:lang="en-US">Maturing after one year through two years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears_lbl" xml:lang="en-US">Maturing after two years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_SummaryOfReceivablesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_SummaryOfReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_SummaryOfReceivablesAbstract_lbl" xml:lang="en-US">Summary of Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SummaryOfReceivablesAbstract" xlink:to="bcrx_SummaryOfReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:href="bcrx-20150331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember_lbl" xml:lang="en-US">U.S. Department of Health and Human Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:href="bcrx-20150331.xsd#bcrx_ShionogiAndCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_ShionogiAndCoLtdMember_lbl" xml:lang="en-US">Shionogi &amp; Co. Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_lbl" xml:lang="en-US">Billing Status, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BilledRevenuesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BilledRevenuesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BilledRevenuesMember_lbl" xml:lang="en-US">Billed Revenues [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledRevenuesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnbilledRevenuesMember_lbl" xml:lang="en-US">Unbilled Revenues [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_InventoryAbstract" xlink:href="bcrx-20150331.xsd#bcrx_InventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_InventoryAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InventoryAbstract" xlink:to="bcrx_InventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_SummaryOfRevenuesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_SummaryOfRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_SummaryOfRevenuesAbstract_lbl" xml:lang="en-US">Summary of Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SummaryOfRevenuesAbstract" xlink:to="bcrx_SummaryOfRevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_StockIncentivePlanActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_StockIncentivePlanActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_StockIncentivePlanActivitiesAbstract_lbl" xml:lang="en-US">Stock Incentive Plan Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockIncentivePlanActivitiesAbstract" xlink:to="bcrx_StockIncentivePlanActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Awards Available</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Restricted stock unit awards granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Restricted stock unit awards cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_lbl" xml:lang="en-US">Stock option awards granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Stock option awards granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Stock option awards granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock option awards exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Stock option awards exercised (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_lbl" xml:lang="en-US">Stock option awards cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Stock option awards cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Stock option awards cancelled (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:href="bcrx-20150331.xsd#bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract_lbl" xml:lang="en-US">Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:to="bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Life in Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected Dividend Yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RoyaltyMonetizationAbstract" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyMonetizationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RoyaltyMonetizationAbstract_lbl" xml:lang="en-US">Royalty Monetization [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationAbstract" xlink:to="bcrx_RoyaltyMonetizationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ExpensesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_ExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ExpensesAbstract_lbl" xml:lang="en-US">Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpensesAbstract" xlink:to="bcrx_ExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_OperatingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_OperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_OperatingActivitiesAbstract_lbl" xml:lang="en-US">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_OperatingActivitiesAbstract" xlink:to="bcrx_OperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_InvestingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_InvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_InvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InvestingActivitiesAbstract" xlink:to="bcrx_InvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_FinancingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_FinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_FinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_FinancingActivitiesAbstract" xlink:to="bcrx_FinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NuclearFuelNetOfAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NuclearFuelNetOfAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NuclearFuelNetOfAmortization_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NuclearFuelNetOfAmortization" xlink:to="us-gaap_NuclearFuelNetOfAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SpentNuclearFuelObligationNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SpentNuclearFuelObligationNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SpentNuclearFuelObligationNoncurrent_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SpentNuclearFuelObligationNoncurrent" xlink:to="us-gaap_SpentNuclearFuelObligationNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForNuclearFuel" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForNuclearFuel"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForNuclearFuel_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForNuclearFuel" xlink:to="us-gaap_PaymentsForNuclearFuel_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNuclearFuel" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNuclearFuel"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNuclearFuel_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNuclearFuel" xlink:to="us-gaap_ProceedsFromNuclearFuel_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock_lbl" xml:lang="en-US">Available for Sale Securities Debt Maturities Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock_lbl" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished Goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenues from Collaborations [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract_lbl" xml:lang="en-US">Collaborative and other research and development revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyMonetizationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RoyaltyMonetizationTextBlock_lbl" xml:lang="en-US">Royalty Monetization [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:href="bcrx-20150331.xsd#bcrx_JPRRoyaltySubLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_JPRRoyaltySubLLCMember_lbl" xml:lang="en-US">JPR Royalty Sub LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US">Certificates of Deposit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RoyaltyReceivableMember" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_RoyaltyReceivableMember_lbl" xml:lang="en-US">Royalty Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollateralForCreditMember" xlink:href="bcrx-20150331.xsd#bcrx_CollateralForCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_CollateralForCreditMember_lbl" xml:lang="en-US">Collateral for Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaximumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinimumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_PhaRMANotesMember" xlink:href="bcrx-20150331.xsd#bcrx_PhaRMANotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_PhaRMANotesMember_lbl" xml:lang="en-US">PhaRMA Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueProductLineMember_lbl" xml:lang="en-US">Sales Revenue, Product Line [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueProductLineMember" xlink:to="us-gaap_SalesRevenueProductLineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US">Products and Services [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RAPIVABMember" xlink:href="bcrx-20150331.xsd#bcrx_RAPIVABMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_RAPIVABMember_lbl" xml:lang="en-US">RAPIVAB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_IncentivePlanMember" xlink:href="bcrx-20150331.xsd#bcrx_IncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_IncentivePlanMember_lbl" xml:lang="en-US">Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_GrantsCommencingMarch12011Member" xlink:href="bcrx-20150331.xsd#bcrx_GrantsCommencingMarch12011Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_GrantsCommencingMarch12011Member_lbl" xml:lang="en-US">Grants Commencing March 1, 2011 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GrantsCommencingMarch12011Member" xlink:to="bcrx_GrantsCommencingMarch12011Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_StockOptionsAndRestrictedStockMember" xlink:href="bcrx-20150331.xsd#bcrx_StockOptionsAndRestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_StockOptionsAndRestrictedStockMember_lbl" xml:lang="en-US">Stock Options and Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockOptionsAndRestrictedStockMember" xlink:to="bcrx_StockOptionsAndRestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RetentionGrantsMadeInJanuary2013Member" xlink:href="bcrx-20150331.xsd#bcrx_RetentionGrantsMadeInJanuary2013Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_RetentionGrantsMadeInJanuary2013Member_lbl" xml:lang="en-US">Retention Grants Made in January 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RetentionGrantsMadeInJanuary2013Member" xlink:to="bcrx_RetentionGrantsMadeInJanuary2013Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_PerformanceBasedGrantsMadeInAugust2013Member" xlink:href="bcrx-20150331.xsd#bcrx_PerformanceBasedGrantsMadeInAugust2013Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_PerformanceBasedGrantsMadeInAugust2013Member_lbl" xml:lang="en-US">Performance-based Grants Made in August 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformanceBasedGrantsMadeInAugust2013Member" xlink:to="bcrx_PerformanceBasedGrantsMadeInAugust2013Member_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember" xlink:href="bcrx-20150331.xsd#bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember_lbl" xml:lang="en-US">Performance-based Grants Made in August 2013 Unvested Portion [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember" xlink:to="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_PerformancedBasedGrantsMadeinDecember2014Member" xlink:href="bcrx-20150331.xsd#bcrx_PerformancedBasedGrantsMadeinDecember2014Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_PerformancedBasedGrantsMadeinDecember2014Member_lbl" xml:lang="en-US">Performanced Based Grants Made In December 2014 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformancedBasedGrantsMadeinDecember2014Member" xlink:to="bcrx_PerformancedBasedGrantsMadeinDecember2014Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Non-employeeDirectorsMember" xlink:href="bcrx-20150331.xsd#bcrx_Non-employeeDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_Non-employeeDirectorsMember_lbl" xml:lang="en-US">Non-employee Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Non-employeeDirectorsMember" xlink:to="bcrx_Non-employeeDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_BaseContractMember" xlink:href="bcrx-20150331.xsd#bcrx_BaseContractMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_BaseContractMember_lbl" xml:lang="en-US">Base Contract [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:href="bcrx-20150331.xsd#bcrx_AdditionalDevelopmentOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_AdditionalDevelopmentOptionsMember_lbl" xml:lang="en-US">Additional Development Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ASPRBARDAContractMember" xlink:href="bcrx-20150331.xsd#bcrx_ASPRBARDAContractMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_ASPRBARDAContractMember_lbl" xml:lang="en-US">ASPR/BARDA Contract [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="bcrx-20150331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_lbl" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_GreenCrossCorporationMember" xlink:href="bcrx-20150331.xsd#bcrx_GreenCrossCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_GreenCrossCorporationMember_lbl" xml:lang="en-US">Green Cross Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AECOMAndIRLMember" xlink:href="bcrx-20150331.xsd#bcrx_AECOMAndIRLMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_AECOMAndIRLMember_lbl" xml:lang="en-US">AECOM and IRL [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_UABMember" xlink:href="bcrx-20150331.xsd#bcrx_UABMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_UABMember_lbl" xml:lang="en-US">UAB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyMonetizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_RoyaltyMonetizationMember_lbl" xml:lang="en-US">Royalty Monetization [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrencyAxis" xlink:to="us-gaap_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_JPY" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_JPY_lbl" xml:lang="en-US">Japan, Yen</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_JPY" xlink:to="currency_JPY_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:href="bcrx-20150331.xsd#bcrx_CurrencyHedgeAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bcrx_CurrencyHedgeAgreementMember_lbl" xml:lang="en-US">Currency Hedge Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCash_lbl" xml:lang="en-US">Investments and Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_SecuritiesOffered" xlink:href="bcrx-20150331.xsd#bcrx_SecuritiesOffered"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_SecuritiesOffered_lbl" xml:lang="en-US">Securities Offered</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SecuritiesOffered" xlink:to="bcrx_SecuritiesOffered_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:href="bcrx-20150331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized_lbl" xml:lang="en-US">Revenue Recognition Royalty and Milestone Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:href="bcrx-20150331.xsd#bcrx_MaturityPeriodOfHighQualityMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketableSecurities_lbl" xml:lang="en-US">Maturity Period of High Quality Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:href="bcrx-20150331.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_lbl" xml:lang="en-US">Average Maturity Period of High Quality Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_MaturityPeriodOfShortTermInvestment" xlink:href="bcrx-20150331.xsd#bcrx_MaturityPeriodOfShortTermInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_MaturityPeriodOfShortTermInvestment_lbl" xml:lang="en-US">Maturity Period of Short Term Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfShortTermInvestment" xlink:to="bcrx_MaturityPeriodOfShortTermInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_LongTermInvestmentMaturityMinimum" xlink:href="bcrx-20150331.xsd#bcrx_LongTermInvestmentMaturityMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_LongTermInvestmentMaturityMinimum_lbl" xml:lang="en-US">Long Term Investment Maturity Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongTermInvestmentMaturityMinimum" xlink:to="bcrx_LongTermInvestmentMaturityMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_lbl" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AverageMaturityForPortfolioInvestments" xlink:href="bcrx-20150331.xsd#bcrx_AverageMaturityForPortfolioInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AverageMaturityForPortfolioInvestments_lbl" xml:lang="en-US">Average Maturity for Portfolio Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AverageMaturityForPortfolioInvestments" xlink:to="bcrx_AverageMaturityForPortfolioInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_NumberOfStockBasedCompensationPlans" xlink:href="bcrx-20150331.xsd#bcrx_NumberOfStockBasedCompensationPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_NumberOfStockBasedCompensationPlans_lbl" xml:lang="en-US">Number of Stock Based Compensation Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfStockBasedCompensationPlans" xlink:to="bcrx_NumberOfStockBasedCompensationPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_lbl" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized for Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_lbl" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_lbl" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_lbl" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive_lbl" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Five</label>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqIaiEUguwqkWGa4cpv416hMMHjZG8xE46xL+mr4cf8Tq9b70MVwJzKgr6HCfYcFXZs/8eE/WbBTxrVDMgYuQntYWFD0E/pnX5XPvNTZUuRQpNVkusoa+c494MTAEv8KuXfbHWCH1lOJcQA3ctTEoDUIdP5GHFBF0gC+D9Yie2bdAyrnvHn/RU/XC/sl02YBsE] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_NumberOfMilestonesAchieved" xlink:href="bcrx-20150331.xsd#bcrx_NumberOfMilestonesAchieved"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_NumberOfMilestonesAchieved_lbl" xml:lang="en-US">Number of Milestones Achieved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfMilestonesAchieved" xlink:to="bcrx_NumberOfMilestonesAchieved_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Awards UnVested, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award First Vesting Period after Grant Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:href="bcrx-20150331.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_lbl" xml:lang="en-US">Percentage of Salary to Purchase Common Stock Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:href="bcrx-20150331.xsd#bcrx_PercentageOfCommonStockSharesBeginning"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning_lbl" xml:lang="en-US">Percentage of Common Stock Shares Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:href="bcrx-20150331.xsd#bcrx_PercentageOfCommonStockSharesEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_PercentageOfCommonStockSharesEnding_lbl" xml:lang="en-US">Percentage of Common Stock Shares Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesEnding" xlink:to="bcrx_PercentageOfCommonStockSharesEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Maximum Number of Shares per Employee Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementContractValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CollaborativeAgreementContractValue_lbl" xml:lang="en-US">Collaborative Agreement Contract Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementContractValue" xlink:to="bcrx_CollaborativeAgreementContractValue_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementAdditionalContractValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue_lbl" xml:lang="en-US">Collaborative Agreement Additional Contract Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementAdjustedContractValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue_lbl" xml:lang="en-US">Collaborative Agreement Adjusted Contract Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentContractReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GovernmentContractReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentContractReceivable_lbl" xml:lang="en-US">Government Contract Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:href="bcrx-20150331.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_lbl" xml:lang="en-US">Proceeds from Awards for Research and Development Contracts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:href="bcrx-20150331.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_lbl" xml:lang="en-US">Expected Receivable from Awards for Research and Development Contracts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborativeAgreementPeriodOfContract" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementPeriodOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CollaborativeAgreementPeriodOfContract_lbl" xml:lang="en-US">Collaborative Agreement Period of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementPeriodOfContract" xlink:to="bcrx_CollaborativeAgreementPeriodOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:href="bcrx-20150331.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived_lbl" xml:lang="en-US">Collaboration Agreement Additional Payments Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US">Proceeds from License Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_MilestonePaymentMinimum" xlink:href="bcrx-20150331.xsd#bcrx_MilestonePaymentMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_MilestonePaymentMinimum_lbl" xml:lang="en-US">Milestone Payment Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_MilestonePaymentMaximum" xlink:href="bcrx-20150331.xsd#bcrx_MilestonePaymentMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_MilestonePaymentMaximum_lbl" xml:lang="en-US">Milestone Payment Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:href="bcrx-20150331.xsd#bcrx_AnnualLicenseFeeMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AnnualLicenseFeeMinimum_lbl" xml:lang="en-US">Annual License Fee Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:href="bcrx-20150331.xsd#bcrx_AnnualLicenseFeeMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AnnualLicenseFeeMaximum_lbl" xml:lang="en-US">Annual License Fee Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:href="bcrx-20150331.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US">Advance Notice Period for Termination of Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:href="bcrx-20150331.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement_lbl" xml:lang="en-US">Stock Issued During Period Value for Modification of License Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:href="bcrx-20150331.xsd#bcrx_PaymentsForModificationOfLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement_lbl" xml:lang="en-US">Payments for Modification of License Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:href="bcrx-20150331.xsd#bcrx_RenewablePeriodOfAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RenewablePeriodOfAgreement_lbl" xml:lang="en-US">Renewable Period of Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RenewablePeriodOfAgreement" xlink:to="bcrx_RenewablePeriodOfAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_PeriodOfAgreement" xlink:href="bcrx-20150331.xsd#bcrx_PeriodOfAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_PeriodOfAgreement_lbl" xml:lang="en-US">Period of Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:href="bcrx-20150331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet_lbl" xml:lang="en-US">Revenue Recognition Royalty and Milestone Revenue Recognized Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_TransactionCosts" xlink:href="bcrx-20150331.xsd#bcrx_TransactionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_TransactionCosts_lbl" xml:lang="en-US">Transaction Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_InterestReserve" xlink:href="bcrx-20150331.xsd#bcrx_InterestReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_InterestReserve_lbl" xml:lang="en-US">Interest Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestReserve" xlink:to="bcrx_InterestReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:href="bcrx-20150331.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes_lbl" xml:lang="en-US">Private Placement of Senior Secured Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeForwardExchangeRate1_lbl" xml:lang="en-US">Derivative, Forward Exchange Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:href="bcrx-20150331.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar_lbl" xml:lang="en-US">Required Foreign Currency Hedge, Per Dollar (in Yen)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:href="bcrx-20150331.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost_lbl" xml:lang="en-US">Maximum Amount of Collateral Required to Post</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:href="bcrx-20150331.xsd#bcrx_MaximumAggregateOfferingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US">Maximum Aggregate Offering Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_RemainingAggregateOfferingPrice" xlink:href="bcrx-20150331.xsd#bcrx_RemainingAggregateOfferingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RemainingAggregateOfferingPrice_lbl" xml:lang="en-US">Remaining Aggregate Offering Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RemainingAggregateOfferingPrice" xlink:to="bcrx_RemainingAggregateOfferingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock_lbl" xml:lang="en-US">Description of Company [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Receivables, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_AccruedExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AccruedExpensesPolicyTextBlock_lbl" xml:lang="en-US">Accrued Expenses [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income Loss [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock" xlink:to="bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock_lbl" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock_lbl" xml:lang="en-US">Currency Hedge Agreement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock_lbl" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US">Deferred Revenue [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US">Investments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesBillingStatusDomain_lbl" xml:lang="en-US">Receivables Billing Status [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable_lbl" xml:lang="en-US">Note 1 - Significant Accounting Policies (Details) - Summary of Receivables [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" xlink:to="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems_lbl" xml:lang="en-US">Note 1 - Significant Accounting Policies (Details) - Summary of Receivables [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems" xlink:to="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable_lbl" xml:lang="en-US">Note 1 - Significant Accounting Policies (Details) - Summary of Revenues [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable" xlink:to="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems_lbl" xml:lang="en-US">Note 1 - Significant Accounting Policies (Details) - Summary of Revenues [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:to="bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products and Services [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Note 1 - Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsTable" xlink:to="bcrx_Note1SignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Note 1 - Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="bcrx_Note1SignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note2StockBasedCompensationDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note2StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note2StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Note 2 - Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note2StockBasedCompensationDetailsTable" xlink:to="bcrx_Note2StockBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note2StockBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note2StockBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Note 2 - Stock-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note2StockBasedCompensationDetailsLineItems" xlink:to="bcrx_Note2StockBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable_lbl" xml:lang="en-US">Note 3 - Collaborative and Other Research and Development Contracts (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" xlink:to="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems_lbl" xml:lang="en-US">Note 3 - Collaborative and Other Research and Development Contracts (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US">Other Commitments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note4RoyaltyMonetizationDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note4RoyaltyMonetizationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note4RoyaltyMonetizationDetailsTable_lbl" xml:lang="en-US">Note 4- Royalty Monetization (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsTable" xlink:to="bcrx_Note4RoyaltyMonetizationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note4RoyaltyMonetizationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Note4RoyaltyMonetizationDetailsLineItems_lbl" xml:lang="en-US">Note 4- Royalty Monetization (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Note4RoyaltyMonetizationDetailsLineItems" xlink:to="bcrx_Note4RoyaltyMonetizationDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AccruedExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Represents accrued expenses policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock_lbl0" xml:lang="en-US">Represents accumulated other comprehensive income (loss) policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock" xlink:to="bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement_lbl0" xml:lang="en-US">Represents advance notice period for termination of agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AnnualLicenseFeeMaximum_lbl0" xml:lang="en-US">Represents annual license fee maximum.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AnnualLicenseFeeMinimum_lbl0" xml:lang="en-US">Represents annual license fee minimum.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AvailableForSaleSecuritiesAccruedInterest_lbl0" xml:lang="en-US">Represents available-for-sale securities accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleSecuritiesAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl0" xml:lang="en-US">Represents available for sale securities debt maturities after one through two years fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of available for sale securities debt maturities fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears_lbl0" xml:lang="en-US">Represents debt maturities after two years.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:to="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AverageMaturityForPortfolioInvestments_lbl0" xml:lang="en-US">Represents average maturity for portfolio investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AverageMaturityForPortfolioInvestments" xlink:to="bcrx_AverageMaturityForPortfolioInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_lbl0" xml:lang="en-US">Represents average maturity period of high quality marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_CollaborationAgreementAdditionalPaymentsReceived_lbl0" xml:lang="en-US">Represents collaboration agreement additional payments received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationAgreementAdditionalPaymentsReceived" xlink:to="bcrx_CollaborationAgreementAdditionalPaymentsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_CollaborativeAgreementAdditionalContractValue_lbl0" xml:lang="en-US">Represents collaborative agreement additional contract value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementAdditionalContractValue" xlink:to="bcrx_CollaborativeAgreementAdditionalContractValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_CollaborativeAgreementAdjustedContractValue_lbl0" xml:lang="en-US">Represents collaborative agreement adjusted contract value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementAdjustedContractValue" xlink:to="bcrx_CollaborativeAgreementAdjustedContractValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_CollaborativeAgreementContractValue_lbl0" xml:lang="en-US">Represents collaborative agreement contract value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementContractValue" xlink:to="bcrx_CollaborativeAgreementContractValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_CollaborativeAgreementPeriodOfContract_lbl0" xml:lang="en-US">Represents collaborative agreement period of contract.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementPeriodOfContract" xlink:to="bcrx_CollaborativeAgreementPeriodOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopment_lbl1" xml:lang="en-US">Represents collaborative and other research and development revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopment" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock_lbl0" xml:lang="en-US">Represents concentration of market risk policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock_lbl0" xml:lang="en-US">Represents currency hedge agreement policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_DeferredCollaborationExpenseAssets_lbl0" xml:lang="en-US">Represents deferred collaboration expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseAssets" xlink:to="bcrx_DeferredCollaborationExpenseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities_lbl0" xml:lang="en-US">Represents deferred collaboration expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock_lbl0" xml:lang="en-US">The description of company policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_lbl0" xml:lang="en-US">Represents employee service share based compensation non-vested awards compensation cost expected to be recognized for remainder of fiscal year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive_lbl0" xml:lang="en-US">Represents employee service share based compensation non-vested awards compensation cost expected to be recognized year five.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_lbl0" xml:lang="en-US">Represents employee service share based compensation non-vested awards compensation cost expected to be recognized year four.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_lbl0" xml:lang="en-US">Represents employee service share based compensation non-vested awards compensation cost expected to be recognized year three.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_lbl0" xml:lang="en-US">Represents employee service share based compensation non-vested awards compensation cost expected to be recognized year two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_lbl0" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Represents interest expense and deferred financing costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_InterestReserve_lbl0" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestReserve" xlink:to="bcrx_InterestReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_LongTermInvestmentMaturityMinimum_lbl0" xml:lang="en-US">Represents long term investment maturity minimum.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongTermInvestmentMaturityMinimum" xlink:to="bcrx_LongTermInvestmentMaturityMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketableSecurities_lbl0" xml:lang="en-US">Represents maturity period of high quality marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_MaturityPeriodOfShortTermInvestment_lbl0" xml:lang="en-US">Represents maturity period of short term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfShortTermInvestment" xlink:to="bcrx_MaturityPeriodOfShortTermInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_MaximumAggregateOfferingPrice_lbl0" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_MaximumAmountOfCollateralRequiredToPost_lbl0" xml:lang="en-US">Represents maximum amount of collateral required to post.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAmountOfCollateralRequiredToPost" xlink:to="bcrx_MaximumAmountOfCollateralRequiredToPost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_MilestonePaymentMaximum_lbl0" xml:lang="en-US">Represents milestone payment maximum.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_MilestonePaymentMinimum_lbl0" xml:lang="en-US">Represents milestone payment minimum.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_NumberOfMilestonesAchieved_lbl0" xml:lang="en-US">Represents the number of milestones achieved.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfMilestonesAchieved" xlink:to="bcrx_NumberOfMilestonesAchieved_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_NumberOfStockBasedCompensationPlans_lbl0" xml:lang="en-US">Represents number of stock based compensation plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NumberOfStockBasedCompensationPlans" xlink:to="bcrx_NumberOfStockBasedCompensationPlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_PaymentsForModificationOfLicenseAgreement_lbl0" xml:lang="en-US">Represents payments for modifications of license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PaymentsForModificationOfLicenseAgreement" xlink:to="bcrx_PaymentsForModificationOfLicenseAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning_lbl0" xml:lang="en-US">Represents percentage of common stock shares beginning.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_PercentageOfCommonStockSharesEnding_lbl0" xml:lang="en-US">Represents percentage of common stock shares ending.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesEnding" xlink:to="bcrx_PercentageOfCommonStockSharesEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_lbl0" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_PeriodOfAgreement_lbl0" xml:lang="en-US">Represents period of agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes_lbl0" xml:lang="en-US">Represents private placement of senior secured notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_lbl0" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral_lbl0" xml:lang="en-US">Represents the receipt or payment of foreign currency derivatives.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:to="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RemainingAggregateOfferingPrice_lbl0" xml:lang="en-US">Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RemainingAggregateOfferingPrice" xlink:to="bcrx_RemainingAggregateOfferingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RenewablePeriodOfAgreement_lbl0" xml:lang="en-US">Represents renewable period of agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RenewablePeriodOfAgreement" xlink:to="bcrx_RenewablePeriodOfAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RequiredForeignCurrencyHedgePerDollar_lbl0" xml:lang="en-US">The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RequiredForeignCurrencyHedgePerDollar" xlink:to="bcrx_RequiredForeignCurrencyHedgePerDollar_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized_lbl0" xml:lang="en-US">Represents revenue recognition royalty and milestone revenue recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet_lbl0" xml:lang="en-US">Represents revenue recognition royalty and milestone revenue recognized net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RoyaltyMonetizationTextBlock_lbl0" xml:lang="en-US">Represents royalty monetization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of schedule of revenues from collaborations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_SecuritiesOffered_lbl0" xml:lang="en-US">Represents securities offered for sale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SecuritiesOffered" xlink:to="bcrx_SecuritiesOffered_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage_lbl0" xml:lang="en-US">Represents the percentage of performance awards that remain unvested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate_lbl0" xml:lang="en-US">Represents share based compensation arrangement by share based payment award first vesting period after grant date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_lbl0" xml:lang="en-US">Represents share based compensation arrangement by share based payment award maximum value per employee amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_lbl0" xml:lang="en-US">Represents share based compensation arrangement by share based payment award options grants in period awards available.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement_lbl0" xml:lang="en-US">Represents stock issued during period value for modification of license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:to="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_TransactionCosts_lbl0" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AECOMAndIRLMember_lbl0" xml:lang="en-US">AECOM And IRL [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AECOMAndIRLMember_lbl1" xml:lang="en-US">Albert Einstein College of Medicine of Yeshiva University and Industrial Research LTD.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ASPRBARDAContractMember_lbl0" xml:lang="en-US">ASPRBARDA Contract [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ASPRBARDAContractMember_lbl1" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_AdditionalDevelopmentOptionsMember_lbl0" xml:lang="en-US">Additional Development Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_AdditionalDevelopmentOptionsMember_lbl1" xml:lang="en-US">The additional development options that can be exercised by the Government.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_BaseContractMember_lbl0" xml:lang="en-US">Base Contract [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_BaseContractMember_lbl1" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="bcrx_ClinicalTrial2007Member" xlink:href="bcrx-20150331.xsd#bcrx_ClinicalTrial2007Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ClinicalTrial2007Member_lbl" xml:lang="en-US">Clinical Trial 2007 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ClinicalTrial2007Member" xlink:to="bcrx_ClinicalTrial2007Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ClinicalTrial2007Member_lbl0" xml:lang="en-US">Represents 2007 clinical trial.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ClinicalTrial2007Member" xlink:to="bcrx_ClinicalTrial2007Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CollaborationReceivablesMember_lbl0" xml:lang="en-US">Collaboration Receivables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationReceivablesMember" xlink:to="bcrx_CollaborationReceivablesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_CollaborationReceivablesMember_lbl1" xml:lang="en-US">Represents receivables from collaborations for reimbursable research and development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationReceivablesMember" xlink:to="bcrx_CollaborationReceivablesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CollateralForCreditMember_lbl0" xml:lang="en-US">Collateral For Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_CollateralForCreditMember_lbl1" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_CurrencyHedgeAgreementMember_lbl0" xml:lang="en-US">Currency Hedge Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_CurrencyHedgeAgreementMember_lbl1" xml:lang="en-US">Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_DeferredCollaborativeRevenueMember_lbl0" xml:lang="en-US">Deferred Collaborative Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborativeRevenueMember" xlink:to="bcrx_DeferredCollaborativeRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_DeferredCollaborativeRevenueMember_lbl1" xml:lang="en-US">Represents revenue deferred under collaborative arrangements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborativeRevenueMember" xlink:to="bcrx_DeferredCollaborativeRevenueMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_DeferredProductSalesMember_lbl0" xml:lang="en-US">Deferred Product Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredProductSalesMember" xlink:to="bcrx_DeferredProductSalesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_DeferredProductSalesMember_lbl1" xml:lang="en-US">Deferred revenue related to product sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredProductSalesMember" xlink:to="bcrx_DeferredProductSalesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_EmployeeStockPurchasePlanMember_lbl0" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_EmployeeStockPurchasePlanMember_lbl1" xml:lang="en-US">Employee stock purchase plan, (ESPP).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_GrantsCommencingMarch12011Member_lbl0" xml:lang="en-US">Grants Commencing March 12011 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GrantsCommencingMarch12011Member" xlink:to="bcrx_GrantsCommencingMarch12011Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_GrantsCommencingMarch12011Member_lbl1" xml:lang="en-US">Represents option grants commencing March 1, 2011.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GrantsCommencingMarch12011Member" xlink:to="bcrx_GrantsCommencingMarch12011Member_lbl1"/>
    <loc xlink:type="locator" xlink:label="bcrx_GrantsCommensingPriorToMarch12011Member" xlink:href="bcrx-20150331.xsd#bcrx_GrantsCommensingPriorToMarch12011Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_GrantsCommensingPriorToMarch12011Member_lbl" xml:lang="en-US">Grants Commensing Prior To March 12011 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GrantsCommensingPriorToMarch12011Member" xlink:to="bcrx_GrantsCommensingPriorToMarch12011Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_GrantsCommensingPriorToMarch12011Member_lbl0" xml:lang="en-US">Represents grants commencing prior to march 1, 2011.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GrantsCommensingPriorToMarch12011Member" xlink:to="bcrx_GrantsCommensingPriorToMarch12011Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_GreenCrossCorporationMember_lbl0" xml:lang="en-US">Green Cross Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_GreenCrossCorporationMember_lbl1" xml:lang="en-US">Represents Green Cross Corporation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_IncentivePlanMember_lbl0" xml:lang="en-US">Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_IncentivePlanMember_lbl1" xml:lang="en-US">Represents Incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="bcrx_InducementGrantMember" xlink:href="bcrx-20150331.xsd#bcrx_InducementGrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_InducementGrantMember_lbl" xml:lang="en-US">Inducement Grant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InducementGrantMember" xlink:to="bcrx_InducementGrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_InducementGrantMember_lbl0" xml:lang="en-US">Represents inducement grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InducementGrantMember" xlink:to="bcrx_InducementGrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_JPRRoyaltySubLLCMember_lbl0" xml:lang="en-US">JPR Royalty Sub LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_JPRRoyaltySubLLCMember_lbl1" xml:lang="en-US">Represents JPR Royalty Sub, LLC</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="bcrx_LabroatoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:href="bcrx-20150331.xsd#bcrx_LabroatoryEquipmentOfficeEquipmentAndSoftwareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_LabroatoryEquipmentOfficeEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Labroatory Equipment Office Equipment And Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LabroatoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="bcrx_LabroatoryEquipmentOfficeEquipmentAndSoftwareMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_LabroatoryEquipmentOfficeEquipmentAndSoftwareMember_lbl0" xml:lang="en-US">Represents laboratory equipment, office equipment and software.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LabroatoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="bcrx_LabroatoryEquipmentOfficeEquipmentAndSoftwareMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="bcrx_MundipharmaMember" xlink:href="bcrx-20150331.xsd#bcrx_MundipharmaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_MundipharmaMember_lbl" xml:lang="en-US">Mundipharma [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaMember" xlink:to="bcrx_MundipharmaMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_MundipharmaMember_lbl0" xml:lang="en-US">Represents Mundipharma.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaMember" xlink:to="bcrx_MundipharmaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_lbl0" xml:lang="en-US">National Institute Of Allergy And Infectious Diseases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_lbl1" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Non-employeeDirectorsMember_lbl0" xml:lang="en-US">Non-employee Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Non-employeeDirectorsMember" xlink:to="bcrx_Non-employeeDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_Non-employeeDirectorsMember_lbl1" xml:lang="en-US">Represents non-employee directors of the company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Non-employeeDirectorsMember" xlink:to="bcrx_Non-employeeDirectorsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_PerformanceBasedGrantsMadeInAugust2013Member_lbl0" xml:lang="en-US">Performance Based Grants Made In August 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformanceBasedGrantsMadeInAugust2013Member" xlink:to="bcrx_PerformanceBasedGrantsMadeInAugust2013Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_PerformanceBasedGrantsMadeInAugust2013Member_lbl1" xml:lang="en-US">Represents performance-based option grants made in August 2013.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformanceBasedGrantsMadeInAugust2013Member" xlink:to="bcrx_PerformanceBasedGrantsMadeInAugust2013Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember_lbl0" xml:lang="en-US">Performance Based Grants Made In August 2013 Unvested Portion [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember" xlink:to="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember_lbl1" xml:lang="en-US">Represents performance-based grants made in August 2013 that remain unvested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember" xlink:to="bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_PerformancedBasedGrantsMadeinDecember2014Member_lbl0" xml:lang="en-US">Performanced Based Grants Madein December 2014 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformancedBasedGrantsMadeinDecember2014Member" xlink:to="bcrx_PerformancedBasedGrantsMadeinDecember2014Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_PerformancedBasedGrantsMadeinDecember2014Member_lbl1" xml:lang="en-US">Represents performanced based grants made in December 2014.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformancedBasedGrantsMadeinDecember2014Member" xlink:to="bcrx_PerformancedBasedGrantsMadeinDecember2014Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_PhaRMANotesMember_lbl0" xml:lang="en-US">Pha RMA Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_PhaRMANotesMember_lbl1" xml:lang="en-US">Represents PhaRMA senior secured notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="bcrx_RAPIACTAMember" xlink:href="bcrx-20150331.xsd#bcrx_RAPIACTAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RAPIACTAMember_lbl" xml:lang="en-US">RAPIACTA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIACTAMember" xlink:to="bcrx_RAPIACTAMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RAPIACTAMember_lbl0" xml:lang="en-US">Represents RAPIACTA product.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIACTAMember" xlink:to="bcrx_RAPIACTAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RAPIVABMember_lbl0" xml:lang="en-US">RAPIVAB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RAPIVABMember_lbl1" xml:lang="en-US">Repesents RAPIVAB product.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RetentionGrantsMadeInJanuary2013Member_lbl0" xml:lang="en-US">Retention Grants Made In January 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RetentionGrantsMadeInJanuary2013Member" xlink:to="bcrx_RetentionGrantsMadeInJanuary2013Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RetentionGrantsMadeInJanuary2013Member_lbl1" xml:lang="en-US">Represents retention grants made in January 2013.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RetentionGrantsMadeInJanuary2013Member" xlink:to="bcrx_RetentionGrantsMadeInJanuary2013Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RoyaltyMonetizationMember_lbl0" xml:lang="en-US">Royalty Monetization [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RoyaltyMonetizationMember_lbl1" xml:lang="en-US">Represents the royalty monetization transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_RoyaltyReceivableMember_lbl0" xml:lang="en-US">Royalty Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_RoyaltyReceivableMember_lbl1" xml:lang="en-US">Represents royalty receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ShionogiAndCoLtdMember_lbl0" xml:lang="en-US">Shionogi And Co Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_ShionogiAndCoLtdMember_lbl1" xml:lang="en-US">Represents Shionogi &amp; Co. Ltd.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="bcrx_Shortfall2013Member" xlink:href="bcrx-20150331.xsd#bcrx_Shortfall2013Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_Shortfall2013Member_lbl" xml:lang="en-US">Shortfall 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Shortfall2013Member" xlink:to="bcrx_Shortfall2013Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_Shortfall2013Member_lbl0" xml:lang="en-US">Represents 2013 shortfall.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Shortfall2013Member" xlink:to="bcrx_Shortfall2013Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_StockOptionsAndRestrictedStockMember_lbl0" xml:lang="en-US">Stock Options And Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockOptionsAndRestrictedStockMember" xlink:to="bcrx_StockOptionsAndRestrictedStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_StockOptionsAndRestrictedStockMember_lbl1" xml:lang="en-US">Represents stock options and restricted stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_StockOptionsAndRestrictedStockMember" xlink:to="bcrx_StockOptionsAndRestrictedStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_UABMember_lbl0" xml:lang="en-US">UAB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_UABMember_lbl1" xml:lang="en-US">Represents University of Alabama - Birmingham.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember_lbl0" xml:lang="en-US">US Department Of Health And Human Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember_lbl1" xml:lang="en-US">Represents United States department of health and human services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="bcrx_UpFrontPaymentMember" xlink:href="bcrx-20150331.xsd#bcrx_UpFrontPaymentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_UpFrontPaymentMember_lbl" xml:lang="en-US">Up Front Payment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpFrontPaymentMember" xlink:to="bcrx_UpFrontPaymentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bcrx_UpFrontPaymentMember_lbl0" xml:lang="en-US">Represents up front payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpFrontPaymentMember" xlink:to="bcrx_UpFrontPaymentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="bcrx_DocumentAndEntityInformationAbstract" xlink:href="bcrx-20150331.xsd#bcrx_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DocumentAndEntityInformationAbstract" xlink:to="bcrx_DocumentAndEntityInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities_lbl1" xml:lang="en-US">DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:to="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bcrx_DeferredCollaborationExpenseAssets_lbl1" xml:lang="en-US">DeferredCollaborationExpenseAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredCollaborationExpenseAssets" xlink:to="bcrx_DeferredCollaborationExpenseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl0" xml:lang="en-US">Payments to Acquire Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Derivative Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SpentNuclearFuelObligationNoncurrent_lbl0" xml:lang="en-US">Spent Nuclear Fuel Obligation, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SpentNuclearFuelObligationNoncurrent" xlink:to="us-gaap_SpentNuclearFuelObligationNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNuclearFuel_lbl0" xml:lang="en-US">Proceeds from Nuclear Fuel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNuclearFuel" xlink:to="us-gaap_ProceedsFromNuclearFuel_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl0" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets [Standard Label]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl0" xml:lang="en-US">Payments to Acquire Available-for-sale Securities, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl0" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl0" xml:lang="en-US">Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss_lbl0" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl0" xml:lang="en-US">Revenue, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl0" xml:lang="en-US">Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl0" xml:lang="en-US">Available-for-sale Securities, Debt Securities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForNuclearFuel_lbl0" xml:lang="en-US">Payments for Nuclear Fuel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForNuclearFuel" xlink:to="us-gaap_PaymentsForNuclearFuel_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>bcrx-20150331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Fri May 08 17:32:20 UTC 2015 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedBalanceSheet" roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.biocryst.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedIncomeStatement" roleURI="http://www.biocryst.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ConsolidatedCashFlow" roleURI="http://www.biocryst.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note1SignificantAccountingPolicies" roleURI="http://www.biocryst.com/role/Note1SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note2StockBasedCompensation" roleURI="http://www.biocryst.com/role/Note2StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note3CollaborativeandOtherResearchandDevelopmentContracts" roleURI="http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContracts"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note4RoyaltyMonetization" roleURI="http://www.biocryst.com/role/Note4RoyaltyMonetization"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note5StockholdersEquity" roleURI="http://www.biocryst.com/role/Note5StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_AccountingPoliciesByPolicy" roleURI="http://www.biocryst.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note1SignificantAccountingPoliciesTables" roleURI="http://www.biocryst.com/role/Note1SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note2StockBasedCompensationTables" roleURI="http://www.biocryst.com/role/Note2StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_FairValueoftheCompanysInvestmentsbyTypeTable" roleURI="http://www.biocryst.com/role/FairValueoftheCompanysInvestmentsbyTypeTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_ScheduledMaturityfortheCompanysInvestmentsTable" roleURI="http://www.biocryst.com/role/ScheduledMaturityfortheCompanysInvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_SummaryofReceivablesTable" roleURI="http://www.biocryst.com/role/SummaryofReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_InventoryTable" roleURI="http://www.biocryst.com/role/InventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_SummaryofRevenuesTable" roleURI="http://www.biocryst.com/role/SummaryofRevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_StockIncentivePlanActivitiesTable" roleURI="http://www.biocryst.com/role/StockIncentivePlanActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_WeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsundertheIncentivePlanTable" roleURI="http://www.biocryst.com/role/WeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsundertheIncentivePlanTable"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note1SignificantAccountingPoliciesDetails" roleURI="http://www.biocryst.com/role/Note1SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note2StockBasedCompensationDetails" roleURI="http://www.biocryst.com/role/Note2StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note3CollaborativeandOtherResearchandDevelopmentContractsDetails" roleURI="http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContractsDetails"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note4RoyaltyMonetizationDetails" roleURI="http://www.biocryst.com/role/Note4RoyaltyMonetizationDetails"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#bcrx_r_Note5StockholdersEquityDetails" roleURI="http://www.biocryst.com/role/Note5StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="bcrx-20150331.xsd#DocumentAndEntityInformation" roleURI="http://www.biocryst.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="CollaborationReceivablesMember" xlink:href="bcrx-20150331.xsd#bcrx_CollaborationReceivablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="CollaborationReceivablesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_TradeAccountsReceivableMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DeferredCollaborativeRevenueMember" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborativeRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="DeferredCollaborativeRevenueMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredProductSalesMember" xlink:href="bcrx-20150331.xsd#bcrx_DeferredProductSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="DeferredProductSalesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="2.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DeferredCollaborationExpenseAssets" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborationExpenseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="DeferredCollaborationExpenseAssets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_Assets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="CollaborationReceivablesMember" xlink:href="bcrx-20150331.xsd#bcrx_CollaborationReceivablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="CollaborationReceivablesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_TradeAccountsReceivableMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DeferredCollaborativeRevenueMember" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborativeRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="DeferredCollaborativeRevenueMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredProductSalesMember" xlink:href="bcrx-20150331.xsd#bcrx_DeferredProductSalesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="DeferredProductSalesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="2.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAndOtherResearchAndDevelopment" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="CollaborativeAndOtherResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAndOtherResearchAndDevelopment" xlink:to="us-gaap_SalesRevenueNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ExpensesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_ExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_CostsAndExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="OperatingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_OperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="OperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingActivitiesAbstract" xlink:to="ChangesInOperatingAssetsAndLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" xlink:href="bcrx-20150331.xsd#bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="InvestingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_InvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="InvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="FinancingActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_FinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="FinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:href="bcrx-20150331.xsd#bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="ReceiptPaymentOfForeignCurrencyDerivativeCollateral" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReceiptPaymentOfForeignCurrencyDerivativeCollateral" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note1SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note2StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContracts">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note4RoyaltyMonetization">
    <loc xlink:type="locator" xlink:label="RoyaltyMonetizationAbstract" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyMonetizationAbstract"/>
    <loc xlink:type="locator" xlink:label="RoyaltyMonetizationTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyMonetizationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyMonetizationAbstract" xlink:to="RoyaltyMonetizationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note5StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfCompanyPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfCompanyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AccruedExpensesPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_AccruedExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AccruedExpensesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CurrencyHedgeAgreementPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CurrencyHedgeAgreementPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConcentrationOfMarketRiskPolicyTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConcentrationOfMarketRiskPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note1SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfReceivablesFromCollaborationsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenuesFromCollaborationsTableTextBlock" xlink:href="bcrx-20150331.xsd#bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfRevenuesFromCollaborationsTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note2StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/FairValueoftheCompanysInvestmentsbyTypeTable">
    <loc xlink:type="locator" xlink:label="FairValueOfTheCompanySInvestmentsByTypeAbstract" xlink:href="bcrx-20150331.xsd#bcrx_FairValueOfTheCompanySInvestmentsByTypeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueOfTheCompanySInvestmentsByTypeAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CommercialPaperMember" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AvailableForSaleSecuritiesAccruedInterest" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="AvailableForSaleSecuritiesAccruedInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NuclearFuelNetOfAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NuclearFuelNetOfAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_NuclearFuelNetOfAmortization" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SpentNuclearFuelObligationNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SpentNuclearFuelObligationNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_SpentNuclearFuelObligationNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForNuclearFuel" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForNuclearFuel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_PaymentsForNuclearFuel" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNuclearFuel" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNuclearFuel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ProceedsFromNuclearFuel" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NuclearFuelNetOfAmortization_0" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NuclearFuelNetOfAmortization"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NuclearFuelNetOfAmortization_1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NuclearFuelNetOfAmortization"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/ScheduledMaturityfortheCompanysInvestmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:href="bcrx-20150331.xsd#bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" xlink:href="bcrx-20150331.xsd#bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduledMaturityForTheCompanySInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/SummaryofReceivablesTable">
    <loc xlink:type="locator" xlink:label="SummaryOfReceivablesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_SummaryOfReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable"/>
    <loc xlink:type="locator" xlink:label="Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryOfReceivablesAbstract" xlink:to="Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="USDepartmentOfHealthAndHumanServicesMember" xlink:href="bcrx-20150331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="USDepartmentOfHealthAndHumanServicesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShionogiAndCoLtdMember" xlink:href="bcrx-20150331.xsd#bcrx_ShionogiAndCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShionogiAndCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BilledRevenuesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BilledRevenuesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledRevenuesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" order="2.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesTable" xlink:to="Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems" order="3.0"/>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqIaiEUguwqkWGa4cpv416hMMHjZG8xE46xL+mr4cf8Tq9b70MVwJzKgr6HCfYcFXZs/8eE/WbBTxrVDMgYuQntYWFD0E/pnX5XPvNTZUuRQpNVkusoa+c494MTAEv8KuXfbHWCH1lOJcQA3ctTEoDUIdP5GHFBF0gC+D9Yie2bdAcbwIwqQOxlU9lVb9ehvlg] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/InventoryTable">
    <loc xlink:type="locator" xlink:label="InventoryAbstract" xlink:href="bcrx-20150331.xsd#bcrx_InventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/SummaryofRevenuesTable">
    <loc xlink:type="locator" xlink:label="SummaryOfRevenuesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_SummaryOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable"/>
    <loc xlink:type="locator" xlink:label="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryOfRevenuesAbstract" xlink:to="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="USDepartmentOfHealthAndHumanServicesMember" xlink:href="bcrx-20150331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="USDepartmentOfHealthAndHumanServicesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShionogiAndCoLtdMember" xlink:href="bcrx-20150331.xsd#bcrx_ShionogiAndCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShionogiAndCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="2.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesTable" xlink:to="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:to="CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAndOtherResearchAndDevelopment" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract" xlink:to="CollaborativeAndOtherResearchAndDevelopment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems" xlink:to="us-gaap_Revenues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/StockIncentivePlanActivitiesTable">
    <loc xlink:type="locator" xlink:label="StockIncentivePlanActivitiesAbstract" xlink:href="bcrx-20150331.xsd#bcrx_StockIncentivePlanActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIncentivePlanActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/WeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsundertheIncentivePlanTable">
    <loc xlink:type="locator" xlink:label="WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:href="bcrx-20150331.xsd#bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note1SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="Note1SignificantAccountingPoliciesDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note1SignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="Note1SignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_CertificatesOfDepositMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RoyaltyReceivableMember" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="RoyaltyReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollateralForCreditMember" xlink:href="bcrx-20150331.xsd#bcrx_CollateralForCreditMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="CollateralForCreditMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ProductOrServiceAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="RAPIVABMember" xlink:href="bcrx-20150331.xsd#bcrx_RAPIVABMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="RAPIVABMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3.0"/>
    <loc xlink:type="locator" xlink:label="PhaRMANotesMember" xlink:href="bcrx-20150331.xsd#bcrx_PhaRMANotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="PhaRMANotesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueProductLineMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueProductLineMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RangeAxis" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaximumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinimumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="6.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsTable" xlink:to="dei_LegalEntityAxis" order="7.0"/>
    <loc xlink:type="locator" xlink:label="JPRRoyaltySubLLCMember" xlink:href="bcrx-20150331.xsd#bcrx_JPRRoyaltySubLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="JPRRoyaltySubLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsTable" xlink:to="Note1SignificantAccountingPoliciesDetailsLineItems" order="8.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsAndCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SecuritiesOffered" xlink:href="bcrx-20150331.xsd#bcrx_SecuritiesOffered"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="SecuritiesOffered" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:href="bcrx-20150331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MaturityPeriodOfHighQualityMarketableSecurities" xlink:href="bcrx-20150331.xsd#bcrx_MaturityPeriodOfHighQualityMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="MaturityPeriodOfHighQualityMarketableSecurities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:href="bcrx-20150331.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="AverageMaturityPeriodOfHighQualityMarketableSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MaturityPeriodOfShortTermInvestment" xlink:href="bcrx-20150331.xsd#bcrx_MaturityPeriodOfShortTermInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="MaturityPeriodOfShortTermInvestment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentMaturityMinimum" xlink:href="bcrx-20150331.xsd#bcrx_LongTermInvestmentMaturityMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="LongTermInvestmentMaturityMinimum" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AverageMaturityForPortfolioInvestments" xlink:href="bcrx-20150331.xsd#bcrx_AverageMaturityForPortfolioInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1SignificantAccountingPoliciesDetailsLineItems" xlink:to="AverageMaturityForPortfolioInvestments" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note2StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="Note2StockBasedCompensationDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note2StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note2StockBasedCompensationDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note2StockBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="Note2StockBasedCompensationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockOptionsAndRestrictedStockMember" xlink:href="bcrx-20150331.xsd#bcrx_StockOptionsAndRestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="StockOptionsAndRestrictedStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsTable" xlink:to="us-gaap_VestingAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="GrantsCommencingMarch12011Member" xlink:href="bcrx-20150331.xsd#bcrx_GrantsCommencingMarch12011Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="GrantsCommencingMarch12011Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetentionGrantsMadeInJanuary2013Member" xlink:href="bcrx-20150331.xsd#bcrx_RetentionGrantsMadeInJanuary2013Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="RetentionGrantsMadeInJanuary2013Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PerformanceBasedGrantsMadeInAugust2013Member" xlink:href="bcrx-20150331.xsd#bcrx_PerformanceBasedGrantsMadeInAugust2013Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="PerformanceBasedGrantsMadeInAugust2013Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember" xlink:href="bcrx-20150331.xsd#bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PerformancedBasedGrantsMadeinDecember2014Member" xlink:href="bcrx-20150331.xsd#bcrx_PerformancedBasedGrantsMadeinDecember2014Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="PerformancedBasedGrantsMadeinDecember2014Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsTable" xlink:to="us-gaap_RangeAxis" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinimumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaximumMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RangeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="4.0"/>
    <loc xlink:type="locator" xlink:label="Non-employeeDirectorsMember" xlink:href="bcrx-20150331.xsd#bcrx_Non-employeeDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="Non-employeeDirectorsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="5.0"/>
    <loc xlink:type="locator" xlink:label="IncentivePlanMember" xlink:href="bcrx-20150331.xsd#bcrx_IncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="IncentivePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeStockPurchasePlanMember" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="EmployeeStockPurchasePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="2.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsTable" xlink:to="Note2StockBasedCompensationDetailsLineItems" order="6.0"/>
    <loc xlink:type="locator" xlink:label="NumberOfStockBasedCompensationPlans" xlink:href="bcrx-20150331.xsd#bcrx_NumberOfStockBasedCompensationPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="NumberOfStockBasedCompensationPlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:href="bcrx-20150331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfMilestonesAchieved" xlink:href="bcrx-20150331.xsd#bcrx_NumberOfMilestonesAchieved"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="NumberOfMilestonesAchieved" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:href="bcrx-20150331.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="PercentageOfSalaryToPurchaseCommonStockMaximum" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCommonStockSharesBeginning" xlink:href="bcrx-20150331.xsd#bcrx_PercentageOfCommonStockSharesBeginning"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="PercentageOfCommonStockSharesBeginning" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCommonStockSharesEnding" xlink:href="bcrx-20150331.xsd#bcrx_PercentageOfCommonStockSharesEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="PercentageOfCommonStockSharesEnding" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:href="bcrx-20150331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note2StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContractsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="BaseContractMember" xlink:href="bcrx-20150331.xsd#bcrx_BaseContractMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BaseContractMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalDevelopmentOptionsMember" xlink:href="bcrx-20150331.xsd#bcrx_AdditionalDevelopmentOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AdditionalDevelopmentOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ASPRBARDAContractMember" xlink:href="bcrx-20150331.xsd#bcrx_ASPRBARDAContractMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ASPRBARDAContractMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GreenCrossCorporationMember" xlink:href="bcrx-20150331.xsd#bcrx_GreenCrossCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="GreenCrossCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AECOMAndIRLMember" xlink:href="bcrx-20150331.xsd#bcrx_AECOMAndIRLMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AECOMAndIRLMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="USDepartmentOfHealthAndHumanServicesMember" xlink:href="bcrx-20150331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="USDepartmentOfHealthAndHumanServicesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="bcrx-20150331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="NationalInstituteOfAllergyAndInfectiousDiseasesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UABMember" xlink:href="bcrx-20150331.xsd#bcrx_UABMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="UABMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsTable" xlink:to="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementContractValue" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementContractValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="CollaborativeAgreementContractValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementAdditionalContractValue" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementAdditionalContractValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="CollaborativeAgreementAdditionalContractValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementAdjustedContractValue" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementAdjustedContractValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="CollaborativeAgreementAdjustedContractValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentContractReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GovernmentContractReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="us-gaap_GovernmentContractReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:href="bcrx-20150331.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="ProceedsFromAwardsForResearchAndDevelopmentContracts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:href="bcrx-20150331.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementPeriodOfContract" xlink:href="bcrx-20150331.xsd#bcrx_CollaborativeAgreementPeriodOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="CollaborativeAgreementPeriodOfContract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CollaborationAgreementAdditionalPaymentsReceived" xlink:href="bcrx-20150331.xsd#bcrx_CollaborationAgreementAdditionalPaymentsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="CollaborationAgreementAdditionalPaymentsReceived" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentMinimum" xlink:href="bcrx-20150331.xsd#bcrx_MilestonePaymentMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="MilestonePaymentMinimum" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentMaximum" xlink:href="bcrx-20150331.xsd#bcrx_MilestonePaymentMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="MilestonePaymentMaximum" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AnnualLicenseFeeMinimum" xlink:href="bcrx-20150331.xsd#bcrx_AnnualLicenseFeeMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="AnnualLicenseFeeMinimum" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AnnualLicenseFeeMaximum" xlink:href="bcrx-20150331.xsd#bcrx_AnnualLicenseFeeMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="AnnualLicenseFeeMaximum" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AdvanceNoticePeriodForTerminationOfAgreement" xlink:href="bcrx-20150331.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="AdvanceNoticePeriodForTerminationOfAgreement" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" xlink:href="bcrx-20150331.xsd#bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="StockIssuedDuringPeriodValueForModificationOfLicenseAgreement" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentsForModificationOfLicenseAgreement" xlink:href="bcrx-20150331.xsd#bcrx_PaymentsForModificationOfLicenseAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="PaymentsForModificationOfLicenseAgreement" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RenewablePeriodOfAgreement" xlink:href="bcrx-20150331.xsd#bcrx_RenewablePeriodOfAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="RenewablePeriodOfAgreement" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PeriodOfAgreement" xlink:href="bcrx-20150331.xsd#bcrx_PeriodOfAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems" xlink:to="PeriodOfAgreement" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note4RoyaltyMonetizationDetails">
    <loc xlink:type="locator" xlink:label="RoyaltyMonetizationAbstract" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyMonetizationAbstract"/>
    <loc xlink:type="locator" xlink:label="Note4RoyaltyMonetizationDetailsTable" xlink:href="bcrx-20150331.xsd#bcrx_Note4RoyaltyMonetizationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note4RoyaltyMonetizationDetailsLineItems" xlink:href="bcrx-20150331.xsd#bcrx_Note4RoyaltyMonetizationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyMonetizationAbstract" xlink:to="Note4RoyaltyMonetizationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="RoyaltyMonetizationMember" xlink:href="bcrx-20150331.xsd#bcrx_RoyaltyMonetizationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="RoyaltyMonetizationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsTable" xlink:to="us-gaap_CurrencyAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="currency_JPY" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_JPY" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0"/>
    <loc xlink:type="locator" xlink:label="PhaRMANotesMember" xlink:href="bcrx-20150331.xsd#bcrx_PhaRMANotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PhaRMANotesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="4.0"/>
    <loc xlink:type="locator" xlink:label="CurrencyHedgeAgreementMember" xlink:href="bcrx-20150331.xsd#bcrx_CurrencyHedgeAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="CurrencyHedgeAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsTable" xlink:to="dei_LegalEntityAxis" order="5.0"/>
    <loc xlink:type="locator" xlink:label="JPRRoyaltySubLLCMember" xlink:href="bcrx-20150331.xsd#bcrx_JPRRoyaltySubLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="JPRRoyaltySubLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="6.0"/>
    <loc xlink:type="locator" xlink:label="JPRRoyaltySubLLCMember_0" xlink:href="bcrx-20150331.xsd#bcrx_JPRRoyaltySubLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="JPRRoyaltySubLLCMember_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsTable" xlink:to="Note4RoyaltyMonetizationDetailsLineItems" order="7.0"/>
    <loc xlink:type="locator" xlink:label="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:href="bcrx-20150331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" xlink:href="bcrx-20150331.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TransactionCosts" xlink:href="bcrx-20150331.xsd#bcrx_TransactionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="TransactionCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InterestReserve" xlink:href="bcrx-20150331.xsd#bcrx_InterestReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="InterestReserve" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementOfSeniorSecuredNotes" xlink:href="bcrx-20150331.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="PrivatePlacementOfSeniorSecuredNotes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RequiredForeignCurrencyHedgePerDollar" xlink:href="bcrx-20150331.xsd#bcrx_RequiredForeignCurrencyHedgePerDollar"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="RequiredForeignCurrencyHedgePerDollar" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumAmountOfCollateralRequiredToPost" xlink:href="bcrx-20150331.xsd#bcrx_MaximumAmountOfCollateralRequiredToPost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4RoyaltyMonetizationDetailsLineItems" xlink:to="MaximumAmountOfCollateralRequiredToPost" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/Note5StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="MaximumAggregateOfferingPrice" xlink:href="bcrx-20150331.xsd#bcrx_MaximumAggregateOfferingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="MaximumAggregateOfferingPrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RemainingAggregateOfferingPrice" xlink:href="bcrx-20150331.xsd#bcrx_RemainingAggregateOfferingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="RemainingAggregateOfferingPrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.biocryst.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="bcrx-20150331.xsd#bcrx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="5.0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="6.0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentDescription" order="7.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="8.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="9.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="13.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="14.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="15.0"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>timephased.jpg
<TEXT>
begin 644 timephased.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`CD"
MDP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HK)\>ZI-HG@76KVWD$-Q9V$\\4A`.QEC9@>>."._%>+^%OVB
M]0N=!MWO-<M&N6W;R1`I^\1T`],5U4<'.I3]I':]CGJ8B,)\DNUSWZBO$?\`
MAH2?_H-V?_?4/^%'_#0D_P#T&[/_`+ZA_P`*KZC5%]:@>W45XC_PT)/_`-!N
MS_[ZA_PH_P"&A)_^@W9_]]0_X4?4:H?6H'MU%>(_\-"3_P#0;L_^^H?\*Q?$
M/QJU[49;PZ?XVLM-6;3I+:W7[+;3?9KEON7/S#YMO_/,_*>]"P-6_P#7]>7_
M``!/%P2O_E_F?1%%>(_\-"3_`/0;L_\`OJ'_``H_X:$G_P"@W9_]]0_X4?4:
MH_K4#VZBO$?^&A)_^@W9_P#?4/\`A1_PT)/_`-!NS_[ZA_PH^HU0^M0/;J*\
M1_X:$G_Z#=G_`-]0_P"%'_#0D_\`T&[/_OJ'_"CZC5#ZU`]NHKPG3?VB+N6W
M8RZY9[O-D`R81\H=@O;TQ53QI\<=8UOP?JUGH_BZRT35KNSFALM1\BWN?L$[
M(1'-Y3#;)L8AMC<-C!X-$L#570%BJ;/H&BOFOX._%WQ5X,^&NE:9XN^(5EXT
M\16J,M[K0T^TT[[>Q=BK>1'E(\*57"GG;GJ:WM6_:(NX=+N7AURS$RQ,4(,)
M^;!QQBCZC5O;^OR$L9"UW^G^9[M17B/_``T)/_T&[/\`[ZA_PH_X:$G_`.@W
M9_\`?4/^%'U&J/ZU`]NHKYC^'?Q5\9>'/%GBN\\0?$NQ\2:7JUZL^B:?_9EG
M9_V#`%P8/,3YKC)YWO@CI77?\-"3_P#0;L_^^H?\*/J-47UN']6/;J*\)O/V
MB+M+BT":Y9[7E(DYA.5V.?3CD"K'_#0D_P#T&[/_`+ZA_P`*/J-4/K<#VZBO
MFOXO_%[Q3XQ^&^JZ;X3^(5EX-\174:K9:R;"TU#[`P926\B3"294%<,?XL]J
ML?#+XS>(O"_P_P!(T_Q)XZLO%&O6=LD5]J_V.UL?[0E`^:7R8\I'G^ZO`I?4
MJM]OZ_K\P^M0_K^OZMZ7^C**\1_X:$G_`.@W9_\`?4/^%5X_VB+LZI,AURS\
ME8HRHS#]XE\\X]EI_4:H?6X'NU%>(_\`#0D__0;L_P#OJ'_"N"^-_P`1O'_C
MF;PZW@OXM6/@5=-U%+G55.BV6I_VQ:C&ZVS+CR<\_O$^89H^HU;V"6,@E=?I
M_F?5=%>(_P##0D__`$&[/_OJ'_"C_AH2?_H-V?\`WU#_`(4?4:H_K4#VZBO"
M=)_:(NYM+MGFURS,S1*7),(^;`SQBK'_``T)/_T&[/\`[ZA_PH^HU1?6X'MU
M%>"V/QWU*#5;Z:;Q19W%K<,AMH/+MU^R@*`PW`9;<V6YZ9Q5S_AH2?\`Z#=G
M_P!]0_X4?4:H?6X?U8]NHKPG4OVB+N*W4Q:Y9[O-C!P83\I=0W;TS5C_`(:$
MG_Z#=G_WU#_A1]1JA];@>W45XC_PT)/_`-!NS_[ZA_PKSOX(^/\`XC>!O$'B
MJX\:?&*Q\=6.K7OGZ+:#0K'3/[!@W2'R-\63/\K1C>^#^[S_`!&CZC5_K^OZ
MMZ`\9!?TO\SZRHKQ'_AH2?\`Z#=G_P!]0_X57D_:(NQJD*#7+/R6BD+#,/W@
M4QSCW:CZC5#ZW`]VHKQ'_AH2?_H-V?\`WU#_`(4A_:$N"/\`D.6?YP_X4?4:
MH_K4#V^BOG?PY\:M>TV_\S4/&UEJ4']GVMOY7V6VA_TF,R^?<[E&?WH:,;/N
MIY7'WC6U_P`-"3_]!NS_`.^H?\*/J-7^K_Y!]:@>W45X3J7[1%W%;J8M<L]W
MFQ@X,)^4NH;MZ9JQ_P`-"3_]!NS_`.^H?\*/J-47UN![=17B/_#0D_\`T&[/
M_OJ'_"J.A_';5+!+H7OBJROVEN9)83Y5O%Y$1.4BX'S;1QN/)I?4JM[6_K^O
MR]+U]:IV/?**\1_X:$G_`.@W9_\`?4/^%<WX^_:<U;29+/[%KUK&L@D\S"P-
MG&W'53ZFO+SO%1RO`U,?B4W"%F[;ZM+2]EU[G;EM%X[$QPM'XI7M?;1-]+]N
MQ])45\F_\-9^(_\`H8[7_OU;?_$5D^.OVG?'&O>$;^ST3QU:Z#JUQ'MMM0_L
M^TNOLK9'S>4Z[6[C!]:_.(>+62RDDXU%YM1LO/2;?W)GU<N",Q2NN5_?_P#(
MGV117R;_`,-9^(_^ACM?^_5M_P#$4?\`#6?B/_H8[7_OU;?_`!%3_P`1<R7^
M2I]T?_DRO]1\Q[Q_\F_^1/K*BOFSX:_M.:QK-KJC:AKUK(T-[Y<!*0)B/R8F
MXPHS\S/S^':NE_X:$G_Z#=G_`-]0_P"%?IF3UUF6"IX[#IJ$U=7W^=KK\3Y'
M,*;P6(EA:OQ1WMMM?K;\CVZBOFWQG\8/%&MZI;RZ/\0++1+:.TFAE@^PVMSY
MTS2V[1S;FY79''.FT<-]HW'E%KI/^&A)_P#H-V?_`'U#_A7I?4:O]?U_5SC^
MM4SVZBO$?^&A)_\`H-V?_?4/^%9_A7]HR_N_#&FS7>N6C74MK$\Q/D*2Y0%L
MC''.>*/J-6UR?KE.]CWZBO$?^&A)_P#H-V?_`'U#_A7$ZC\3?'-S\>M/\06_
MQ4L;;P/;Z6UK=>%/[(LG^UW99R+K[8?WJ85D'E@;3LSW-+ZC5OM_7]:!];A_
M5CZDHKQ'_AH2?_H-V?\`WU#_`(5G^(_VC+^UT^-K77+02&ZMT./(;Y&F17[?
MW"W/;K36!JMV!XNFE<]^HKQ'_AH2?_H-V?\`WU#_`(54UWX\ZC?Z+>06/B:S
MT^\FA=(+G9!+]G<@A7V$8;!P<'@XH^HU1_6H'O-%?/6@?&W7-/U&YDOO&=EJ
M%O)O\F'[-;1>3F>5U^8#+;8GBCYZ^3NZL:U_^&A)_P#H-V?_`'U#_A1]1JB^
MMP_JQ[=17@-Q^T9?KXGLX5URT^RO:SO(/W&"X>$)SCCAGX[_`(5H?\-"3_\`
M0;L_^^H?\*/J-4/KE,]NHKP74_CQJ5U<6+6WB:SM8X+CS+A-D#_:8]CCR\D?
M+\Q1MPY^3'0FJ_@WXX:SHOAV&WU?QA9:UJ$;2&2\\BWM_-!=F4;%&!M4JO'7
M;GJ:/J-7L/ZU`^@J*\1_X:$G_P"@W9_]]0_X5GZ/^T9?S:AJJS:Y:&.&Z5(,
M^0,)Y,3'''/SE^?P[4?4:HOK=,]^HKQ'_AH2?_H-V?\`WU#_`(5PGQ7^(_C[
MQ;XU\'WWA?XL6/A'1]&O3/KVF'1K*_\`^$B@+1D0>;)AK?`60;X\G]YG^$4+
M`U;I?TO,'BX6O_D?5-%>(_\`#0D__0;L_P#OJ'_"C_AH2?\`Z#=G_P!]0_X4
M?4:H_K4#VZBO`?"O[1E_=^&--FN]<M&NI;6)YB?(4ER@+9&..<\5[AX9U$ZO
MX;T^[,BR&ZMHY2XQA]R@Y&..<]JSK8>=+XBZ5>-3X2]1117.;%/Q#$L^@7R.
MJNCV\BLK#(8%3D$5SOPZ\(Z3-X3A9]+T]F\Z<9-LA/\`KG]JZ37/^0+>?]<'
M_P#0367\-?\`D4(?^NUQ_P"CY*VC)JEIW_0RDDYZ]O\`(N?\(9H__0)TW_P%
M3_"C_A#-'_Z!.F_^`J?X5I45GSR[E\J[&;_PAFC_`/0)TW_P%3_"C_A#-'_Z
M!.F_^`J?X5I44<\NX<J[&;_PAFC_`/0)TW_P%3_"C_A#-'_Z!.F_^`J?X5I4
M4<\NX<J[&;_PAFC_`/0)TW_P%3_"C_A#-'_Z!.F_^`J?X5I44<\NX<J[&;_P
MAFC_`/0)TW_P%3_"C_A#-'_Z!.F_^`J?X5I44<\NX<J[&;_PAFC_`/0)TW_P
M%3_"C_A#-'_Z!.F_^`J?X5I44<\NX<J['A_QH^/_`(4^!7C7P?X37P3JGC#Q
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M<'_]!-73J2:3;(E"*;2/,?!'QO\`A_\`$'X[?$+X?Z;I.[5?AC9Z==:Y=S:3
MY-C&UZMP\<,4K*/-=([?<Y0%%\Q5W%PZIPMS^WG\([7]B+5?C^VAZM_P@NGR
M7T=O%_PCCC4]3-O>RV2>5:E?,7SI8LIYHCVHX:7R@'*U_"MW\6-"_:W^*'B#
M_A4]PWAO5'T[2K"\DUO3@VJ6%E9:K-YL,:S%E>2]EAC"SA,+=;C@(V/*[KPI
M\>KC_@GAXB\$2_!2XD\1>(H)_-TU/$6D_:%GU+5]2FU#+FX%N(X[=H&4A]S-
M=8Q\C8S]M.U[/^GK]_3MUN/V<5*VF_;NOTZ_A8]>_:O_`&S/"/[)WCO0-!O/
MACXH\5OJFAZAXHU*ZT*PT]H/#>E6,MI%<WEW]HN(G*H;R,[(%FE8))M0[<'T
MA_C!\(8_$%]I+>*/ANNJZ7<QV=[9'4K+[1:3R3101Q21[MR.\T\,:JP!+S1J
M`2R@_/\`^V[\#?BI\8_CQJ%EX5\&K<:#X]^'J^";OQ)<ZG:1V_A>*[OI'U,R
M0F3[1+(UJD(B\F-U,@7<54$CY\_:A_8%^)6O^![PW7AG2=&TW4-,O_$?B'Q#
M<:Y96L.A74.MZIKBB5VE#',SZ8WFC,:);2;F7:H.U.:YZ<:CM%\W,^UI.WRY
M>5^>MF[66/*^6;BKN*C9=7=1O\[\RMY+;K]C?&W]M;X1_"G]GJ\^(V@PZ/\`
M%/2[?6M.\.P6G@J?3M2N+W4+ZZM[:WMD=ID@5RUS$Q\R5`$;=G&,ZOPD_:\^
M!WQA^%O@OQ79>)/`NFVOCRTTNXTRSU.\L[6^:3483+9VK1,VX7$BJX6(99C&
M^W=M-?)_[.O[(^G_`+:W[%>GMIFE-X6\(_$CXN2^+[\>'M:MU>QTVPC>ULY+
M>ZMW>*7YM.L0'MV=&#;E+)\U<Q\;O^"2WCX^-O#ME\/_``GH^EZ/J6JZRL]^
M+^".+PE$FO:)+IUTL1?>Y.CZ.+>,1!GB>4!@@9R-Y1C&+BV^9V:_\!BW%]KR
M<HWU2:5U:X0DIRC966M^O623Z7LHIV6K4K)-V/N/0/VFO@YXE^)_B;PK:ZWX
M)DO?"=HESJ$_VRR-O&WFW,4\.X/D2V[6Q\Y6`\OS8LG)('*_%C]N+X->$]9U
M#PGX7U[X:>+/B9':7\UCX;CU>S@\^>REMX;BWFN23#;2H]S$#'*RR$%BJ-L?
M'YQ^!O\`@E?^TWIVJ^'[B'X=Z3H7VK0K+P;J+R:_8RR6MG&GA%+J^F*2GSI)
MA8:W]W<YWKD?,N?4+#_@FY\:/$/P2^"OARX^'6GZ'K'AWP=X:T'6-0_M>PE:
MQN;/Q'I5YJDT[+*6F>YAL#,K1;\KE6(=MAYJ<:CDXRDK:I._5\UGKLM(WOTD
MNJ9U5J=&$%4CKM=::*\;[/5I-[;N+Z6O^A%Q\?\`X)VCLLWC;X6QM'K#^'F#
MZQ8*5U-&17L3\_\`Q\JTD8,/WP9%!7D9[:+P;H_]LW`_LK3<>3&<?9D_O2>U
M?D5\%O\`@D3\<K>Z\&ZIX@\#Z=I@T_2=.TN;33K-G<2:=<1S>$;.[U!G64K)
M+);Z;K5T&4ERKQ*<2,4K]AX?^0U<?]<(O_0I*N2J1>K371I^=M5NKVNK]';=
M-F<HT[^[\[KKZ[/M=:73MI8K_P#"&:/_`-`G3?\`P%3_``H_X0S1_P#H$Z;_
M`.`J?X5I45'/+N3RKL9O_"&:/_T"=-_\!4_PH_X0S1_^@3IO_@*G^%:5%'/+
MN'*NQ\N?%?\`;W^&7P&^*_B[P#JWA+6+W7/`OPVB^(UPUEIMK)'J-J]S):1V
M=OND5FNWFCPJ,JH=Z_/UQW7A?]JOX)Z[\/X?$%]XF^'_`(;C71-/U_4;/6-2
ML+6ZT.VOH4EMS>(9,0[U=0"QVL?NEAS7RY^UQ^P!\4OC1_P4/\-_$KPO:V<?
MA6*S\&:?JDTMW"IOK"RN=>NK^#RV8-Q+-I3#(PVXXSL;',_"?_@G1\5-+N/#
MNEZ]X+L9(?#K:7-<ZM)J5G*NL(\^@2R6Y02%_P#04TN>+YU"N&3RRX)K#$8B
MI"IRTTVM+OSOJON:=]ERM;FM.C%IN37EZ<O7_MY6MOJGL?6=I^W!\`]4^-UK
MX!L?$_@>^UV:\ETR8PW5GY-I>JEH\=HS,P+33"]B$2QAM[)*N=T;*-&3]HCP
MK9?'KQ5X/OO`]SI>A>"[6VEU?QI?OI5KH%I/<)&\-J2]R+KS&65<-]G\O/&_
M)`/R+IG_``3W^)QDTVRD\`V<$FCVNEW2ZI_:-B1<7*Z?X5MYE4"3S`\4FDWV
M78`-O!4MNKT_XX?LF^)/&G[5/Q4U*V^%?]I+XU/ADV?C%M4L5A6RLKS3I;JP
M>%IA/D_9Y)`?*VG9C=D@'OC&\8WEJUKKHG;U[WZK9;O1\4I-.5HZ*UM/Z]-G
M\MU[AJG[4WP;T_XJ^&?",>M>"[[4O%6DOKEM):WEC)#!9?NO)N)#OW"*X,RB
M%P"LA!`/3/J__"&:/_T"=-_\!4_PK\ZO@O\`L,?%3X<?%/0I-5^$NB^(--TF
MR\UKRZUBS\I_,ATFV%EM$GF?Z.VGS7(.WRR7C"DL6`_2>E6M%+DE??\`-_I]
M^Y5&\K\\;;?DOZ\MF9O_``AFC_\`0)TW_P`!4_PH_P"$,T?_`*!.F_\`@*G^
M%:5%8<\NYMRKL9O_``AFC_\`0)TW_P`!4_PJK+X-T?\`MFW']E:;CR9#C[,G
M]Z/VK<JK-_R&K?\`ZX2_^A1TU.7<'%=CQOQ[^TCX)^%GQAUSPOXD\(WFB:;H
M7A*^\92>)KFTM/[(FM+(VXO$4K(9Q)$MU`Q+PK&P9@CLR.J^,^)?^"J?P_\`
MA'X0\47'C_X7^*-`UKP?X0T3Q5=V5KI=M=KJIU*22!+6R.]9&>.Y@GB9KB.!
M"(FE!,0\RN1_:A^'6N>)/VWY=+USP3#H6C_&9K/P%+>6]]'<IXVM8KG^TYYG
MC1C)!';Z387-LYF6,-+>A4WKM8U?BW^SK\7+CXD_&+Q-IOP9NM0T;Q_JGA?3
MI/#MEK^E(VI?V9J$UQJ&M;Y[A42*ZM/L]JD3,LV8P7C1<FHPLYRE&51VC=W3
MTT3?6_6+CKT:U7Q<M8B,8*48).22MJK:I=/)J2>JO?1K1/V;]HK]N3PY^SA\
M2?%5G?\`PRU37/"?@;2=+O\`Q!K6DVEO)_93WLTZG>DC(K);P0K-*$=I=MQ"
M(XI"6VY.D_\`!4GX+ZKXVOO#_P#PB_B&/4%\3Z/X9TH?V#'(NO\`]IWUU8V]
M]`8V;R[036-]N>Y\EMMMD*WFP>;Y_;:/\4OVA_"OP_U^R\!W7B+P)\8/B1/X
MR\9?9M0L;>2WT&U:&'0D9;B6-I(Y8;:QN95B#L5BD3:3(`<?X7_LF_%CX?6G
M@ZZF^%=[<:I<Z]X/T/6S%K>E[=/T;P[(;A;\EIQO^T7MS=3"-,RA``RAB%K:
MDTJ:<[\S:5FUI>4+WM_+>2]$W=V3,)7<GRVM9V:3U:3MOJ^9*_35I>ZG9_6W
MP8^-'@/]I%_&R>&-'9K?P#XL/A2]NKO2?LL=W=PI;2S&#>`SQ*9Q'YFT*[(Q
M3<A5V],_X0S1_P#H$Z;_`.`J?X5XK^QUI/C2UL?B;J?C?P3>>![[Q)X]DU.Q
MM9]0L[PW-EY-E;P2YM99%7]W;J"K$-D'C&"??*SC4DZ<9/1M)M=FTFUZIZ,U
M<(J4DNC:^YM?T^NYF_\`"&:/_P!`G3?_``%3_"C_`(0S1_\`H$Z;_P"`J?X5
MI44<\NX<J[&;_P`(9H__`$"=-_\``5/\*J7'@K1GUBW5M)TQE\F0X-JG]Z/V
MK=JK-_R&K?\`ZX2_^A1TI>^N66J''W7S1T93_P"$$T/_`*`ND_\`@)'_`(4?
M\()H?_0%TG_P$C_PK6HKF^JT/Y%]R-_K-;^9_>S)_P"$$T/_`*`ND_\`@)'_
M`(4?\()H?_0%TG_P$C_PK6HH^JT/Y%]R#ZS6_F?WLYGP_P"#-'&IZTO]DZ;M
M6]4`?94X_P!'A/I6I_PAFC_]`G3?_`5/\*;H'_(6US_K]7_TF@K4KJ^%*,=%
MH8/WGS2U9F_\(9H__0)TW_P%3_"C_A#-'_Z!.F_^`J?X5I44<\NXN5=C-_X0
MS1_^@3IO_@*G^%9?@OP?I,O@[26;2]-9FLH22;9"2=@]JZ:LOP1_R)>C_P#7
ME#_Z+6JYY<NXN57V'?\`"&:/_P!`G3?_``%3_"C_`(0S1_\`H$Z;_P"`J?X5
MI45//+N/E78S?^$,T?\`Z!.F_P#@*G^%9?BSP?I,>EQ%=+TU3]MM1D6R=#<1
M@]JZ:LOQ?_R"8?\`K]M/_2F.JC.7,M0E%6V'?\(9H_\`T"=-_P#`5/\`"C_A
M#-'_`.@3IO\`X"I_A6E14\\NX<J[&;_PAFC_`/0)TW_P%3_"C_A#-'_Z!.F_
M^`J?X5I44<\NX<J[',W7@_21XQL%_LO3=K65R2/LR8)#P8[>Y_.M3_A#-'_Z
M!.F_^`J?X4V[_P"1TT__`*\KG_T9;UJ54IRLM1**UT,W_A#-'_Z!.F_^`J?X
M4?\`"&:/_P!`G3?_``%3_"M*BIYY=Q\J[&;_`,(9H_\`T"=-_P#`5/\`"LO0
M?!^DOJFM`Z7II"WJ@`VR<#[/"?3W-=-67H'_`"%M<_Z_5_\`2:"JC.5GJ'*N
MP[_A#-'_`.@3IO\`X"I_A1_PAFC_`/0)TW_P%3_"M*BIYY=PY5V,W_A#-'_Z
M!.F_^`J?X4?\(9H__0)TW_P%3_"M*BCGEW#E78YGP7X/TF7P=I+-I>FLS64)
M)-LA).P>U=)#"EM"L<:+''&H554850.@`]*S?!'_`")>C_\`7E#_`.BUK4IU
M)-R=PBDEH%%%%0497CN/SO!&LJ'DCW6,XWQN4=?W;<AAR".Q'(KEO@YX5CN/
MASI[/?:NS;I@2;^7)Q,XR?FZ^]=7XU_Y$W5O^O*;_P!`-9'P5_Y)KI_^]/\`
M^CI*\5U)+.(Q3=O92T_[?B>FHIY<VU]M?^DLU/\`A#H?^?S5O_`^7_XJC_A#
MH?\`G\U;_P`#Y?\`XJM:BO<YY=SR^5&3_P`(=#_S^:M_X'R__%4?\(=#_P`_
MFK?^!\O_`,56M11SR[ARHR?^$.A_Y_-6_P#`^7_XJC_A#H?^?S5O_`^7_P"*
MK6HHYY=PY49/_"'0_P#/YJW_`('R_P#Q5'_"'0_\_FK?^!\O_P`56M11SR[A
MRHR?^$.A_P"?S5O_``/E_P#BJ/\`A#H?^?S5O_`^7_XJM:BCGEW#E1D_\(=#
M_P`_FK?^!\O_`,51_P`(=#_S^:M_X'R__%5K44<\NX<J,#2_",,ELQ^V:J/W
MTHXOI1TD8>M6?^$.A_Y_-6_\#Y?_`(JKFC_\>C_]=YO_`$8U6JJ4Y7W%&*L9
M/_"'0_\`/YJW_@?+_P#%56UCPC#'I-TWVS53MA<X-]*0>#VS6_577/\`D"WG
M_7!__032C.5]PY44_P#A#H?^?S5O_`^7_P"*H_X0Z'_G\U;_`,#Y?_BJUJ*7
M/+N/E1D_\(=#_P`_FK?^!\O_`,52-X-@88-YJQ!X(-]+S_X]6O11SR[ARHP;
MCPE#;36L<=YJJK)*4(%]+TV,?7U`JQ_PAT/_`#^:M_X'R_\`Q57-0_X^['_K
MN?\`T6]6J?/+N+E1D_\`"'0_\_FK?^!\O_Q5'_"'0_\`/YJW_@?+_P#%5K44
MN>7<?*C)_P"$.A_Y_-6_\#Y?_BJK1>$83JTR_;-5XAC.?MTN>2_?/M6_56'_
M`)#5Q_UPB_\`0I*:G+N+E13_`.$.A_Y_-6_\#Y?_`(JC_A#H?^?S5O\`P/E_
M^*K6HI<\NX^5&3_PAT/_`#^:M_X'R_\`Q5'_``AT/_/YJW_@?+_\56M11SR[
MARHP-'\(PR:3:M]LU4;H4.!?2@#@=LU9_P"$.A_Y_-6_\#Y?_BJN:'_R!;/_
M`*X)_P"@BK55*<K[BC%6,G_A#H?^?S5O_`^7_P"*H_X0Z'_G\U;_`,#Y?_BJ
MUJ*GGEW'RHP=1\*QV]NK+>ZMDRQK_P`?TO0NH/?T-6/^$.A_Y_-6_P#`^7_X
MJKFL?\>B?]=X?_1BU:I\TK;BY49/_"'0_P#/YJW_`('R_P#Q5'_"'0_\_FK?
M^!\O_P`56M12YY=Q\J,G_A#H?^?S5O\`P/E_^*JM+X1A&K0K]LU7F&0Y^W2Y
MX*=\^];]59O^0U;_`/7"7_T*.J4Y=Q.**1\&6Y(/VS5LCI_ITO'ZTO\`PAT/
M_/YJW_@?+_\`%5K45//+N/E1D#P;`HP+S5@!T'VZ7_XJE_X0Z'_G\U;_`,#Y
M?_BJUJ*.>7<.5&!JGA&&.V4_;-5/[Z(<WTIZR*/6K/\`PAT/_/YJW_@?+_\`
M%5<UC_CT3_KO#_Z,6K5/GE;<7*C)_P"$.A_Y_-6_\#Y?_BJ/^$.A_P"?S5O_
M``/E_P#BJUJ*7/+N/E1D_P#"'0_\_FK?^!\O_P`57Y:_\%\/V)](_;H_;Z_8
MI^#>L:[K&CZ/XYF\;BZOXMEW<6WV32[2\3RQ,&4;F@53QT8]\5^L%?!7_!0G
M_E-[_P`$\O\`KO\`$7_U'8ZF4FU9CBDGH?,7_$&?\)?^BO>/O_!3IO\`\:H_
MX@S_`(2_]%>\??\`@ITW_P"-5^R5%3R1[%<S/QM_X@S_`(2_]%>\??\`@ITW
M_P"-4?\`$&?\)?\`HKWC[_P4Z;_\:K]DJ*.2/8.9GY?_`/!O?^RIIO[*7CC]
MJ#X7Z;K&KZEIO@3QM;Z9:WCN+6:Y00R'<ZQ;4SSV&/S-?I5_PAT/_/YJW_@?
M+_\`%5\:?\$K-"OM)_;-_;0FNK.ZM8;WXBPR6\DL+(LZ^0_S(2,,.1R/6ON&
MJIR:5D3)*YD_\(=#_P`_FK?^!\O_`,51_P`(=#_S^:M_X'R__%5K457/+N+E
M1D_\(=#_`,_FK?\`@?+_`/%5F^#_``I#<>$M+D-WJBF2TB8A+V15&4'0`X`]
MJZBLOP1_R)>C_P#7E#_Z+6JYI<NXN57&_P#"'0_\_FK?^!\O_P`51_PAT/\`
MS^:M_P"!\O\`\56M14\\NX^5&3_PAT/_`#^:M_X'R_\`Q59OBCPI#!ID;"[U
M1LW=JN&O9&',\8]>O/!['FNHK+\7_P#()A_Z_;3_`-*8ZJ,I<RU%**L-_P"$
M.A_Y_-6_\#Y?_BJ/^$.A_P"?S5O_``/E_P#BJUJ*GGEW'RHR?^$.A_Y_-6_\
M#Y?_`(JC_A#H?^?S5O\`P/E_^*K6HHYY=PY4<O<^%(5\6V,?VO5,-:7#9-[)
MN&'@Z'.<<\CO@>E:7_"'0_\`/YJW_@?+_P#%4Z[_`.1TT_\`Z\KG_P!&6]:E
M5*4K+42BM3)_X0Z'_G\U;_P/E_\`BJ/^$.A_Y_-6_P#`^7_XJM:BIYY=Q\J,
MG_A#H?\`G\U;_P`#Y?\`XJLW1/"D,NIZPOVO5!Y=VJ@B]D!/[B$\\\GGJ>P`
M[5U%9>@?\A;7/^OU?_2:"JC*5GJ+E0W_`(0Z'_G\U;_P/E_^*H_X0Z'_`)_-
M6_\``^7_`.*K6HJ>>7<?*C)_X0Z'_G\U;_P/E_\`BJ/^$.A_Y_-6_P#`^7_X
MJM:BCGEW#E1R_@_PI#<>$M+D-WJBF2TB8A+V15&4'0`X`]JZ6WA^SP1QAG81
MJ%!=BS''J3R3[UG>"/\`D2]'_P"O*'_T6M:E.I)MNXH[!1114%&;XRM9+[PA
MJL,,B0S36<R1R.F]48H0"5R,@'MD9]17,?";2-<L?`5G#_:6EMY3S*6^P/\`
M,1,^3_KN,GMV]ZZ_7/\`D"WG_7!__037S'\3++04\:77B_7-1GAO_A/X>_M_
MP];)J9LE:YFOKY)E89VRB?[-;V^&5L"4A<,X-3'!TG66)M[_`,-]7[KU:ML]
M4O/SL5+$U%3]A?W=[:?%LM=[:]_DW8^D/L>N?]!#2_\`P`?_`./4?8]<_P"@
MAI?_`(`/_P#'J^)[_P#:V^-WAOXLS>`YO%GP]U:\\$6>L^(M?UNST&01ZW9V
M-MX>O!916_V@BUF9-8DC\PR2#:D4NSY_+7<G^-_QL^'GAK5[>\\<>#M8N_[;
MAT>UU"X\./:I;2:IXFN-'M9'07+!DM5C\S9N!F)2+='_`*RMH\TI1C%7<MMM
M7?EMK;K==M'KM=U*+IP52>D7K?RUU[]%YZK3>WUY]CUS_H(:7_X`/_\`'J/L
M>N?]!#2__`!__CU>.?!GXLZI8V/C#7/%FH6NJWGA;PU&NHW5A`T%M?26.H:W
M!+<Q0;G\KS1;!_+#/MR%W/M#'Y>_8Z_;1\;ZY\(M-\-:/KT=OJWP[TW7?$'C
M"?Q7X<O['4/$$MO%I]\]M;VUX+>>WB+ZN5-PZ,$$,86.19`RE'FJMJG9V5^B
MTUU5][)-OKY:F4K12;O=NW7\7LM;)7>K?K;]!/L>N?\`00TO_P``'_\`CU'V
M/7/^@AI?_@`__P`>KY?^)'QN^,'P1OX8;_Q9X2\3MX<T=4U6.#PR]E+KU[=0
MZC-!<VZ_:I/)A@6UC#)^\,H2=MT>S!Y7Q[^W%\3-5_:9\6>%?"^J^$+/0O`\
MFJZQ>R3::UY->V.G:1X3O9+-"LRA)97URZ7S3D(%C^1L'-TH2J*4H6:C>^G\
MMK_FG_P=#2E1=1J,=W'FWZ*WX^7D^A]E?8]<_P"@AI?_`(`/_P#'J/L>N?\`
M00TO_P``'_\`CU?(/QY\/>-?&O[)VFZ3XP74OB_K.J?$/4[*WL?#:1^';B>&
M)]2CMDW2WB(%@:%)F8S`E(MH1V`5^?N_VJOVE-#\;:WIXT&U7PK#JNE^$;+Q
M3?V-@VG0:BVLZ=I4\J>5J+7ET91/>3;)K.U6-HE3>ZL)"J,75LE:[:2T[_Y.
MR?2[5F^F=3W)6\K[^;7?JHMKR3O9Z/[>^QZY_P!!#2__```?_P"/4?8]<_Z"
M&E_^`#__`!ZOBKPKXQ^)7[-T^MWT/B[P?J5NWCE]3\16]SI$UO<>(%U/Q$^B
MP0V[-=2"W>W2V##:K+,SQ1;(B3*5N_VE/VA/$/P4\!^*]-\5?#O3)-:\%VGB
M/5()?#DUR#/<V.IZGLB/VA,+'%816W(RYG>7Y/+$3YQGS14E_=OILY)O\XM:
M=K[,N-)MV7=I:]K?HT_G;>Z/M3['KG_00TO_`,`'_P#CU'V/7/\`H(:7_P"`
M#_\`QZOB#XN?MY_%[PC\=O%OA?28;,:/KESIUKX/UG5-#MX;.UD?Q%HVC7BJ
M(K^2YO%B?5)`6GM[,;[<>7YR/O77^*/[7?QD\%?"WQ)K6F7FAZ]JG@_^S?!T
MNEVNA117.O:W>ZU_98U.W-Q>Q0Q0*?F2UEE"R2!HVN(@N^JESQC"37QMI:;M
M:6];Z?/MJ.C2=5<T-KVO?_"_RDOQ/L2VTO6K6,JNHZ9@LS\V#]68L?\`EK[U
M)]CUS_H(:7_X`/\`_'JYO]F;7_&7B?X$^&[[X@:3<:)XRFMB-3M)XK:&59%=
ME#M';7%S#&70*Y2.XF5-^W>V,UW5)R=S-+0R?L>N?]!#2_\`P`?_`./57UBT
MUH:1=;M0TUE\E\@6+@D8/?S:WJJZY_R!;S_K@_\`Z":(R=PY2G]CUS_H(:7_
M`.`#_P#QZC['KG_00TO_`,`'_P#CU:U%+F8^4R?L>N?]!#2__`!__CU'V/7/
M^@AI?_@`_P#\>K6HHYF'*8-]::T+FSW:AII/G';BQ?@^6_\`TU],U8^QZY_T
M$-+_`/`!_P#X]5S4/^/NQ_Z[G_T6]6J?,Q<ID_8]<_Z"&E_^`#__`!ZC['KG
M_00TO_P`?_X]6M12YF/E,G['KG_00TO_`,`'_P#CU5XK36O[7G_XF&F[O)CR
M?L+X(R^./-^M;U58?^0U<?\`7"+_`-"DI\S%RE/['KG_`$$-+_\``!__`(]1
M]CUS_H(:7_X`/_\`'JUJ*7,Q\ID_8]<_Z"&E_P#@`_\`\>H^QZY_T$-+_P#`
M!_\`X]6M11S,.4P='M-:.D6NW4--5?)3`-BY(&!W\VK'V/7/^@AI?_@`_P#\
M>JYH?_(%L_\`K@G_`*"*M4Y2=Q1CH9/V/7/^@AI?_@`__P`>H^QZY_T$-+_\
M`'_^/5K44N9CY3!U2TUH6R[M0TTCSHNEBXY\Q<?\M?6K'V/7/^@AI?\`X`/_
M`/'JN:Q_QZ)_UWA_]&+5JGS.PN4R?L>N?]!#2_\`P`?_`./4?8]<_P"@AI?_
M`(`/_P#'JUJ*7,Q\ID_8]<_Z"&E_^`#_`/QZJ\MIK7]KP?\`$PTW=Y,F#]A?
M`&4SQYOTK>JK-_R&K?\`ZX2_^A1TU)B<2G]CUS_H(:7_`.`#_P#QZC['KG_0
M0TO_`,`'_P#CU:U%+F8^4R?L>N?]!#2__`!__CU'V/7/^@AI?_@`_P#\>K6H
MHYF'*8.J6FM"V7=J&FD>=%TL7'/F+C_EKZU8^QZY_P!!#2__```?_P"/5<UC
M_CT3_KO#_P"C%JU3YG87*9/V/7/^@AI?_@`__P`>H^QZY_T$-+_\`'_^/5K4
M4N9CY3)^QZY_T$-+_P#`!_\`X]7P1_P66_8*_:/_`&I/C1\!?'GP!\8>$/"_
MC;X2'Q!+%J5_,;)K8:A;VELWEJ]M>))NB6=2&1=NX$9/*_H;56;_`)#5O_UP
ME_\`0HZ'[RLPVU/QV_X8O_X*[?\`1Q7P^_\`!A9__*&C_AB__@KM_P!'%?#[
M_P`&%G_\H:_9.BL^5?TR^8_&S_AB_P#X*[?]'%?#[_P86?\`\H:/^&+_`/@K
MM_T<5\/O_!A9_P#RAK]DZ*.5?TPYC\]?^"2?P/\`CW\-?VU/VQ-5^(W_``D5
MGX7\3>-%N?!\FMZB=2L[BU_M'69<V<(G)MD^SSV1VG'[MX$ZQ&OO3['KG_00
MTO\`\`'_`/CU.T#_`)"VN?\`7ZO_`*305J5I\.A&^ID_8]<_Z"&E_P#@`_\`
M\>H^QZY_T$-+_P#`!_\`X]6M11S,.4R?L>N?]!#2_P#P`?\`^/5G>#[76&\)
M:68K[34C-I$45K)V91L&`3YHR??`KIZR_!'_`")>C_\`7E#_`.BUJN9\HN74
M;]CUS_H(:7_X`/\`_'J/L>N?]!#2_P#P`?\`^/5K45/,Q\ID_8]<_P"@AI?_
M`(`/_P#'JSO%-KK"Z9%YE]IK+]LM0`MDZG/GQX/^M/`."1W'''6NGK+\7_\`
M()A_Z_;3_P!*8ZJ,GS(4HZ#?L>N?]!#2_P#P`?\`^/4?8]<_Z"&E_P#@`_\`
M\>K6HJ>9CY3)^QZY_P!!#2__```?_P"/4?8]<_Z"&E_^`#__`!ZM:BCF8<IS
M%U:ZQ_PEMB#?:;YGV2X*M]B?:!O@R"/-ZGCG/&#USQH_8]<_Z"&E_P#@`_\`
M\>IUW_R.FG_]>5S_`.C+>M2JE)V0E'<R?L>N?]!#2_\`P`?_`./4?8]<_P"@
MAI?_`(`/_P#'JUJ*GF8^4R?L>N?]!#2__`!__CU9VB6NL'4]8VWVFJPO%#DV
M3D,?(AY'[W@8P,<\@GO@=/67H'_(6US_`*_5_P#2:"JC)V8N4;]CUS_H(:7_
M`.`#_P#QZC['KG_00TO_`,`'_P#CU:U%3S,?*9/V/7/^@AI?_@`__P`>H^QZ
MY_T$-+_\`'_^/5K44<S#E.8\'VNL-X2TLQ7VFI&;2(HK63LRC8,`GS1D^^!7
M2VXD6!!*RO(%`=E7:K'N0,G`]LFLWP1_R)>C_P#7E#_Z+6M2G4E=L4=@HHHJ
M"BCXGE>#PUJ$D<33R);2,L:D*9"%.%!.`,].3BO*K#X/^'/B=<>%O$WB#P!;
MZMKWA62]_LF\N'A:73_/D9954[\<@`'.1QD>M>LZY_R!;S_K@_\`Z":R_AK_
M`,BA#_UVN/\`T?)6T7:GMU_0SU]IIV?Z'GOP_P#V6_`/PJ\-6NC^'?A;INDZ
M;8V-]IL$$'DA4MKUX7NXLER2LK6\!8$\^4G8"KM[^SYX/U'P_P"+=)N/AO9S
M:=X\>23Q!;LT)356D=G<R?/U+.S9&.6)ZUZG14RJ<WQ=K==M[;[7+UTUVU7D
M^Z.!\-?#31?!W@Q?#NE^!8K+1%TJ+0Q9QO"(_L,8D5("-_*`2R<'^^WK6-X_
M_9R\$_%/QE9^(O$/PSL-6US3[C[5;WLYA,T<OEK%NSOY_=JJX/!"CT%>KT5,
MFI/FDDWO\^X*Z5D_(\9\%?LE_#OX=:MX=O\`1?A7INGWGA+3Y])T>:-HBUA:
MS/(\L*9D/RLTTI.<_P"L;UH^&_[)?PZ^$.C?V?X9^%&E:/9_9;RQ,5OY(#07
M8MEN8R2Y)646=J&SU$">E>S457M&OZ?^?F_O8XWC\+M_7_`.%\/_``]TGPK-
M-)I_@E;1[C6)O$$A26'YK^9626Y^_P#ZQE=@3_M'UKFY?V7_``'/\6M3\=O\
M,+%O%VLFV:]U,O%YUR;>:":`M^\QE);6W<'&<Q*:]>HHC4::DMUMOI^)/+T[
M_P"=_P`VWZL\O\1_`3PCXO\`''AWQ)J?PXL[[7?"<]W<Z1>2M"9+"2Z<R7#I
M\^,NY+$G//(P:T+?X7:%:^';/2(_`<":9I]C'IEM;!H/+AM8X);=(5&_[JPS
MS(!_=D8=Z]`HI*5H\J6GS_S'K?FOJ>/G]EGX?M\1-4\6'X6::WB36IK6XOM0
M)A,UQ);3V]Q`Q._JDUI;2#&/FA0]11XN_9<\`^/=>O-4UCX6Z=J%_J&EW.BW
M,TIA+36=S.]Q-"?WGW7FD>0]]S$@BO8**4I72BUHO7KO]XXWBK1>FYQ?PR\.
MV/PJ\":;X<\+^$I-)T'1HS:V=G!-$([=%8_*N7SC.:WO[>U#_H!WG_?^'_XN
MKFC_`/'H_P#UWF_]&-5JJE+75?G_`)DQ6AD_V]J'_0#O/^_\/_Q=5M8US4'T
MBZ#:+=JIA<$F>'C@_P"W6_577/\`D"WG_7!__032C)7V_,+%/^WM0_Z`=Y_W
M_A_^+H_M[4/^@'>?]_X?_BZYG]J7Q/KG@G]F?XA:SX8N([3Q)I/AO4;O2IY(
MEE2&[CMI&A9D8$,!(%)!!!QBOG_P#_P4'\1?$3QIXCN?#/ANX\6PKHOANWT;
MPU%+#8SRZM=V]U?7P>YD&U%CM?)!#G"M;.!AF-*,E)M);:]=M=?2ZLWLFUW1
M4HN,>=O3Y=XK_P!NOZ)OH?4W]O:A_P!`.\_[_P`/_P`71_;VH?\`0#O/^_\`
M#_\`%U\L2_\`!4G4/&'AOQ5J7@KX7:SK%GH>EI+9W=]J4%C'>:D^C6NL"Q:-
M\.A6TN&9G/`:!E^\PKT']F_]K36OB)\6;SP3XJ\+WFAZE,FKWVG7<EQ#)#=)
M8W\=O<VRA.3]G^UV:&7[LA=L<HU5#WVXQ2;M?Y6;OOM97^[NKNK3G3MSIJ[M
MMY7_`"_7L[>NWVN:@;FSSHMVNV8D#SX?F_=O_M_YQ5G^WM0_Z`=Y_P!_X?\`
MXNN-_9YU_P`3>(_AO8S>,+S3[[Q%!KFJ6EW+80F*U'DW5W$J1*?FV(B*H+98
MA06)8DUA_M>_'/5/@)?_``LU"TFCCT76/&]MHVOAHE?=97%I=H&W$901W'V:
M5F&/EB8'@FE.48VYK=/35]7?;N^A$8MN7+K:^W6W;O>VG<]._M[4/^@'>?\`
M?^'_`.+H_M[4/^@'>?\`?^'_`.+KY=^"'_!0G7-8^'OA?6M6\,ZAXBTWQ)K%
MQ+J&K6C16Z>&M.OM:FLM&$D.-TQ*^7&Y3E1$\C\9-9G_``\N\9_$3X-:+XD\
M-_"J_P!*A\36#:K;W-]K%JTEGIDVDW5]9ZCY7\6Y[68&$C<!"<CYUHE[KM)6
M>B:=TU?:_;KOIH^S-J=&<[\NJ3:NM5=7ZJ]]M.NVFJ/K7^WM0_Z`=Y_W_A_^
M+JM%KFH#5YS_`&+=[O)C!'GP\<O_`+?^<5Y1X7^.NO?M%_`CQPNFS7'PG\6^
M%;_^S-0NKV."_DTA?L]M?"XV,#$6>RN8I`C@A&DVL,J:[3]E[Q7XD\=?`KP3
MK7C*R&F^+M7\+:7>:U:A-@M[V2#?.FW^'$A88[=*TY&E)M;<O?[2;7X+K;?U
MMSQES1C)=?\`@?Y[JZ^]7ZS^WM0_Z`=Y_P!_X?\`XNC^WM0_Z`=Y_P!_X?\`
MXNOC_P#;C_;`^(WP$\/?M'WFCZUI]C_PC/A>&Z\%>;8Q2M:7T%O%->LP93YN
M5O+=@KY`\MN,9KT:Z_;XU&2'Q))I?PWUK5K>TO6TOPS.-1@A'BNZAU2'2;I5
M#<VR17DZ*'E^5TRZ_*#4-I04[:-VZ[Z:>NJLNNZTL;.C-)-];VVZ6_S7H[I[
M'O7]O:A_T`[S_O\`P_\`Q=']O:A_T`[S_O\`P_\`Q=?(/Q*_X*&_$X>/?`\?
MA;X8S7VDZUKVG6T-O'JUIY^O)=>%]2U.2TW/Q;M!/;Q$RG`81$#ACGUKXR?&
MG7?^$Q^">K>&]8U33_#?C"^B^VP+HJ7-A?0W"P^6EW=LI^R'$A\G:RF:8JG(
M.*):-*V[2ZZ7;2O]S^02IM14K[IR7HFU]^C_`*O;UO1]<U!-(M0NBW;*(4`(
MGAYX'^W5G^WM0_Z`=Y_W_A_^+JYH?_(%L_\`K@G_`*"*^#S_`,%#O&WPPT?X
M-7WC+7+6:&YUCQ%<^-$M=-C::[TN'0K_`%>P2-%7*.(UMQE,,[1$<[FS4??G
MR):Z]];*[MYVZ;[]G94Z<I*ZZ)OILDW^GWV74^Y/[>U#_H!WG_?^'_XNC^WM
M0_Z`=Y_W_A_^+KPNT_;C\06VK>%=*UCX5ZOI&M:IJCV&OVKZS:RIX:B$NGQQ
MSM*ORW&_^U+-@D?S#<X/^K:N!^`G[?OQ'\<_M&6ND^*/AW+H_AW5/#F@W=P(
M=3MID\/SWVIZU9QSLZ_/,+EK2S01J28_F8XRU33M-<R2MLM]7>UE\_U[#5.3
M4G_*K_*Z7YO^KJ_U3JFN:@ULN=%NU_?1')GA_P">B_[?>K/]O:A_T`[S_O\`
MP_\`Q=>6^$_B[J/C/]J3Q=HL>LV=SX;TBTM+>VT^)8F>*[BG3[1.7'S_`#&=
M82C'"FVR`"QSM?MD>*/%GA#]F_Q'>>!;RWL/&$GV6STBXF@6>.*XGNH8%+(P
M*L/WG0BLX5H3IJHMG?OT;73TTMNB73:J.F]U;\4G^NIW']O:A_T`[S_O_#_\
M71_;VH?]`.\_[_P__%U\BZ9_P42\4/\`M.^--#T?1Y/'EKJ&C^%6\&>';.2"
MRDDO+RVUBZOVDNY!M55ATYC^\.`T(089^>O\;_\`!0K7([;Q"WA/X9W^M+8:
M=97FCSW6JP6::W--_9<DMN$;#1&.'5(6WO\`*65E'(-:25I*-KW5U:^J=M5W
M6JU6@3IRAI+I9]-+I-7[/79GT7_;VH?]`.\_[_P__%U6EUS4#J\!_L6[W>3(
M`//AYY3_`&_\YKQ#]B+]JWQ=\;]0\5:/XN\-W&F7&GZ_XEM](U0SP-%J=OI^
MO7=B85CC&5-N@M8R[?ZTDL,\FM[]A/X@:Y\1?@KI5UXHUKQ1K7BBV:XM]6_X
M2'P_'H.H65Q^XD\A[6-$"JJNC(Q7+HZ-D[LT*2YW&RT5_75K3YK7Y=T56I2I
MRE"6\79^J_X;^M3UK^WM0_Z`=Y_W_A_^+H_M[4/^@'>?]_X?_BZUJ^!3_P`%
M#O&WPPT?X-7WC+7+6:&YUCQ%<^-$M=-C::[TN'0K_5[!(T5<HXC6W&4PSM$1
MSN;)3]^7(EKKIKK97=O.W3??L[$:<I7:Z)OIT3?Z??9=3[D_M[4/^@'>?]_X
M?_BZ/[>U#_H!WG_?^'_XNO"[3]N/Q!;:MX5TK6/A7J^D:UJFJ/8:_:OK-K*G
MAJ(2Z?''.TJ_+<;_`.U+-@D?S#<X/^K:N!^`G[?OQ'\<_M&6ND^*/AW+H_AW
M5/#F@W=P(=3MID\/SWVIZU9QSLZ_/,+EK2S01J28_F8XRU%.TUS)*VRWU=[6
M7S_7L"IR:D_Y5?Y72_-_U=7^J=4US4&MESHMVO[Z(Y,\/_/1?]OO5G^WM0_Z
M`=Y_W_A_^+KQ'X8_'G4?'O[8WQ&\+W6I^*(=-\/M;V^F:7<>'EM])F$7V)KB
MY@O]@:XE$ET$>,.50%.`2:[;]LCQ1XL\(?LW^([SP+>6]AXPD^RV>D7$T"SQ
MQ7$]U#`I9&!5A^\Z$5,:D73C42T:OUV>WX:_\$GD?.X7U3M\_P#@;'<?V]J'
M_0#O/^_\/_Q=']O:A_T`[S_O_#_\77R+IG_!1+Q0_P"T[XTT/1]'D\>6NH:/
MX5;P9X=LY(+*22\O+;6+J_:2[D&U56'3F/[PX#0A!AGYZ_QO_P`%"M<CMO$+
M>$_AG?ZTMAIUE>://=:K!9IK<TW]ER2VX1L-$8X=4A;>_P`I964<@U4E:2C:
M]U=6OJG;5=UJM5H$Z<H:2Z6?32Z35^SUV9]%_P!O:A_T`[S_`+_P_P#Q=5I=
M<U`ZO`?[%N]WDR`#SX>>4_V_\YKPS]BW]J3QC\>I?&&@^*M#N=!O+/7/$UKH
MNM"6WDCO8+#7;NQV+"HX-J@M4+N,2DEN?FKJ_P!CK5/$FJ>&=87Q%XVNOB$^
MGZ_JFEVFLW.F6NGRRI:RQ6TT9BMD2/Y+N&Z0-C)"C.:+I3<;=&[]'9V=OG_P
M"JU&5-RC+[,N5^NOYV?W:V/4?[>U#_H!WG_?^'_XNC^WM0_Z`=Y_W_A_^+KR
MW]I/XO>(OAA\;/A7%87]K9^%+ZZO7\4)-"C&6VVP6T&UR,Q[;J[@8E2,A2#Q
M7@W[-7_!3;Q)=?"".\\5>';[Q;=:/>:S<>)]9LC!90Z':G7]5T[2HQ#@&9Y/
ML/E-LY0*)'^]FB-G%R26C2>^E]K^3MOM?3=,:HS<>9=TNFK=]%YZ;;[=S[+_
M`+>U#_H!WG_?^'_XNC^WM0_Z`=Y_W_A_^+KY+\4_\%)O&6IZAJVDZ7\-;S1+
MS1_#OB:^U9KK48)KK1;JPL-.OK("(<2>?#J=JQ3!*-*%/W'K<_:T_:]\2>%O
MV&U\=QR:K\+]<766TK45M;2V\07>DS1W$UOY2IM>*96GCC5W"D)%([\;,B6[
M-+EUT[W][;3?Y;^6J(<;051O1WUZ:*^^UK:I[;]CZ&T36KY-3U@KH]TQ:[4L
M!/#\A\B$8/S>@!X]?K6E_;VH?]`.\_[_`,/_`,757P!<7%W;WTMYY(NY)H7G
M$+;HPYM+<MM/=<YP?2ODGXK?MB_$32_B-^T=X9T?6M.L]0\&ZYH\/A(3643>
M3:+HMIJFI@@C]Z?+:;!;.TS)T&*VE%N;@E=I?Y+OMK?TN^A-&//3=2]DE?7S
M:7WW:5OEN?8']O:A_P!`.\_[_P`/_P`71_;VH?\`0#O/^_\`#_\`%UX/K7[>
MVJ6>K:QIVG_#+6M5U!M2-CX7AAU.W4>*462ZB>=6/%NBR6KY\W^%E?[IKSVT
M_P""FWBSQCI5UXF\/_#J;4/"=KK>GC3VBU2W2;6M+N?##:U+,Y?B!H%:-\'!
M<;4'S$UBI7CSI:::ZVU=EKZIW[6=[&D:4G)P6ZW_`*\^G?H?77]O:A_T`[S_
M`+_P_P#Q=9O@_6KZ+PEI:IH]U*JVD05Q/"`XV#G!;//O7B_Q\_::O/AM^VA\
M,_"Z^,K/2[#Q,MO#;^&7M(GF\4FX-TDTL<C*9%^QB*WD(C8#;,=^1MK/^.'[
M46L?`;]H/X'Z-]NM[7P7KOA#Q%JFO1R0H6DDLHM,%H1(1N3]Y<LN`0&,B@YP
M*T@G*%XQOJUUWBKM?=MYNV^V=-<]3DB]H\WE;5W_``?Y[:GT5_;VH?\`0#O/
M^_\`#_\`%T?V]J'_`$`[S_O_``__`!=?,7PQ_;C\5_#SP-HUC\0-!F\1:CI=
MI?+XI\26$L%M;6=]%<:@D%N+<`,QD%BPW*,+OCW??%9'BG_@I-XRU/4-6TG2
M_AK>:)>:/X=\37VK-=:C!-=:+=6%AIU]9`1#B3SX=3M6*8)1I0I^X]9\VCDE
M=*]VKM:6OKMU7K?0TC3;DH+=Z_+OMMW?39GUI_;VH?\`0#O/^_\`#_\`%UF^
M*-:OI-,C#:/=1C[7:G)GA.2)XR!PW<\?C7F_BSXT^,/&7[)MYXNTNSB\">)M
M-FN!J5C=21:D]B;2XDCGA5U!B=G:+;NP0%<D?,`:R?A[\1_%VH_'GQ#IVO:X
MNJ:%KEQ)=Z)IZV44(T%=.UI=/D02*H>;SPT4I,A8JP8+A<"KI^]5]FEKO]RN
M^O9-_+T,:DE&'.WI>WS;M^=D_4]P_M[4/^@'>?\`?^'_`.+H_M[4/^@'>?\`
M?^'_`.+KX_\`BM^V+\1-+^(W[1WAG1]:TZSU#P;KFCP^$A-91-Y-HNBVFJ:F
M""/WI\MIL%L[3,G08KTC6OV]M4L]6UC3M/\`AEK6JZ@VI&Q\+PPZG;J/%*+)
M=1/.K'BW19+5\^;_``LK_=-3+2UX[JZWNU9/1=='T[/L[;5*;A?F>R3?E=)J
M_;1_BNZO[Q_;VH?]`.\_[_P__%T?V]J'_0#O/^_\/_Q=?(MI_P`%-O%GC'2K
MKQ-X?^'4VH>$[76]/&GM%JENDVM:7<^&&UJ69R_$#0*T;X."XVH/F)KZ%^)O
MB+Q9I_Q<\%QZ+J6FPZ'K,5[;/:36^\W5S]DEFBD=_O+&AB7A""=[YSA<*I+D
M;4H[.S]?O!TY)I/2ZOK_`,-_2.CN=:OCXML6_L>Z#+:7`">?#E@7@R<[L<8'
MY_6M+^WM0_Z`=Y_W_A_^+KA_V?M?UKQ#X.\/W'B#4%U;6H;?5;6ZO%@2`7+0
MWRPA]B`*N1&.`*^6_P!F?]O_`,?>-/@3\$?&6O:G9:H;CPO>:CXWL[>SAAGU
M*\ELKFYTY(P%Q"66SE.%P&\U.U5S<T.=+1)-_._GY?>TMV@C1DXN5^J7S:T_
M)_GLF?;G]O:A_P!`.\_[_P`/_P`71_;VH?\`0#O/^_\`#_\`%U\]S_\`!1&^
MTN[T6SU'X9ZU8ZA)?6VF>(8CJEN\?ARZNM0.G6D32#Y9C-<F!08^BS;^B-6?
M^RW^W-XV^,7BKX=IXE\`MH=AX_\`">FZK<20ZE!+!H=[<#5)4C'\<PGAL@PV
MD^5@!N6HULGR[[;ZZ7T[JW5::D\KM*7\N_EZ]FMVMTM=CZ4_M[4/^@'>?]_X
M?_BZS=$UJ^34]8*Z/=,6NU+`3P_(?(A&#\WH`>/7ZUX[\;?$?Q,@TKXOQ:3X
MVM?#]UX=L[77-&G@TJ"X^R0".Y8VQ$RL',S6Z!F;)7S7V8PN/</"$LD\^K23
M1^3,]U&TD><[&-K!D9]C2IR4HMV_K[R9Q<6EZ_A_P_S^3)/[>U#_`*`=Y_W_
M`(?_`(NC^WM0_P"@'>?]_P"'_P"+K6KQ+]MJ'QVOA_P?+X'^(5YX!FN/$EAI
M=\\&CV6H_;8;JXCA.1<QN$*!F(*XR3SD41]Z48):R:2]6TEU\PDU&,IR>D4V
M_1*_Z'J_]O:A_P!`.\_[_P`/_P`71_;VH?\`0#O/^_\`#_\`%UX!K/[=7B9_
M'%MHNB_#.ZO_`+9XF@TJRN9M9MXDU733+=07&H1Y^YY4MM_JV^9UD5AP13OV
M9_V]1^U'KBV5GIMAH5]H7C"7PYK-G;:U:ZTF%TV]G`,T&4202VX!3[R[.>'%
M*,DX\Z6GSUM:]OO2];]F$M&XO=6OMUO;\F_2W='M?@_6KZ+PEI:IH]U*JVD0
M5Q/"`XV#G!;//O72V\C2P1L\;1,R@LA()0^F1QQ[5G>"/^1+T?\`Z\H?_1:U
MJ4ZCU81V"BBBH**?B"18M!OF9E55MY"23@`;36-\-=5M?^$/@_TBWYFG(_>#
M_GL];/B.".Z\/7\4J+)');R*Z,-RL"I!!'<&O"];_:-\)_!#Q1X/\*:IX0UJ
M[C\277V=M9LK"VDTW16GOS:VJW3-*LJ^;.RQKY<<@!.6VKS713CS04%NVDO6
MS,:DN5N<MDFV^VJ/>/[5M?\`GXM_^_@H_M6U_P"?BW_[^"OFW3_^"B'PNN-*
MU*_O/"_B/1]/M]+NM=TRYO=)MUC\2:9#-9PK>V165M\4KWUOY8D\N0AOF1.,
M]YI/Q_\`#.O?&6U\&6/@O7KR6:2ZCNM5CTZV_L[33!)/"IF8RB0":6VN$C*1
MMEH6W;`5)S44[-7U5UZ7M^::]323<5>7>WSM?\M3U;^U;7_GXM_^_@H_M6U_
MY^+?_OX*A_X1?3/^@=8_^`Z?X4?\(OIG_0.L?_`=/\*GW1ZDW]JVO_/Q;_\`
M?P4?VK:_\_%O_P!_!4/_``B^F?\`0.L?_`=/\*/^$7TS_H'6/_@.G^%'NAJ3
M?VK:_P#/Q;_]_!1_:MK_`,_%O_W\%0_\(OIG_0.L?_`=/\*/^$7TS_H'6/\`
MX#I_A1[H:DW]JVO_`#\6_P#W\%']JVO_`#\6_P#W\%0_\(OIG_0.L?\`P'3_
M``H_X1?3/^@=8_\`@.G^%'NAJ3?VK:_\_%O_`-_!1_:MK_S\6_\`W\%0_P#"
M+Z9_T#K'_P`!T_PH_P"$7TS_`*!UC_X#I_A1[H:C-)U2V%JW^D0?ZZ7_`):#
M_GHU6?[5M?\`GXM_^_@K/TKPSIKVK;M/L3^^E',"_P#/1O:K7_"+Z9_T#K'_
M`,!T_P`*<N6XHWL3?VK:_P#/Q;_]_!5'Q3XBT_3?#&I7%Q?6=O;V]K+)++),
MJI&H0DLQ)P``,DGI5C_A%],_Z!UC_P"`Z?X5YW^UYX,T>_\`V3?BA!/I.FS0
MS>$M5CDCDM499%-G*""",$$<8-+W0U+/Q"^*OPW^(_@/6O#]YX^\*PVNN6,U
MA-)#K5J)$25"C%<L1D!CC((KQS4O@7\)].T354\'_&:#P)K=_J<FKVVM:9K6
MF7%UIUQ+?WUW(8TNDEA9674;BW"21NJP[%4*45AZA_P[_P#@-_T1+X1_^$=I
MW_QFC_AW_P#`;_HB7PC_`/".T[_XS4K1\RWV^6]OP14M8\CVW/+_``O^S[\$
M?`W@'6O#NB_$[3["QU:Y%RC'Q#9W$UHP\.Q:`NUY2S.1;PK*6E+LTI)8LIVU
MU7@'0_A?X(\?>&_$TOQ6TC5]:\.Z;K>G^?=:QIZ"^.K7EE>7,TBQA%#B6R3:
M$"J`[C:?EQTC_L`_`6-"Q^"?PCPHR?\`BCM/_P#C-?--K\3?V3'U6QT^Y_9M
MT/3]2EU[^P]1M+GX=Z0LF@J3I_EWUYM)$=JXU73V5E+2`7(+1KLEV:1J3<GR
M[V_!+E^2L[>FO2ZU<JDK2U=OGTM\]-/G;=Z^[?L^:OX6^`WAR;2]6^/%I\1)
M=0URZU5;W6KW1K::T\\2221(+*&!"GFL[@NK,#(1NVA0-#]HD_"7]IGP!-X;
MU_X@>'8=/N(;R%S9Z_;12XN;&YLF*ONRK*ER[JRD%71#GBO"?AM\.OV;_P!J
M?4?`.J>&_@+X+T.TM_&<EA<6^K^!M-LY;^WD\.WM[;SJBJP:WFBEMY4W$,",
M,B.A4?1'_#O_`.`W_1$OA'_X1VG?_&:SJ0NN2:Z;/]?^#\R(R<9.2T=V^WW?
MI;3L>:Z_\%_A+J_BS0[JU^,5MI&@Z=?F_P!2\/V6N:<ECX@,>H-J-G%.Q4S)
M';73,R+!)'YBL8YO-C)2J\'P&^$FE_"?PKX1TWXR6VFVGA;0=,\-I<QZQIDD
M]Y965E>V6R3S$9098KZ7>R*I!52A3!SZE_P[_P#@-_T1+X1_^$=IW_QFC_AW
M_P#`;_HB7PC_`/".T[_XS6GM)/=]4_FKVOWW84Y2@G&#LGKIIKW\GZ?HCS[X
ME_#/X:^./AY\3M#TOXW1^$;GXHZS9:U?:GI>LZ8]S9M;6FG6A@B6=)(FAEAT
MZ-9$E1PZS3*?E8`>F_#_`.-'@[PKHMGIVJ?%7P[XFU"QL+>"XU:^U/3X;C49
M%WAII$MQ'"K,>2(XT4$\*!Q7@'Q@MOV8?@K\2=8\*ZG^S7X<NM4L;&.[TW[%
M\/M)DC\22O<V5M]DLF;;NF6;4+-6\T1QCS\[R$D*Z_P$_9;_`&??C;\1[SQ)
MI/P7^&:Z#X@\#^'-8L;:[\&V$<EN+B?5F.^+RB$EPJ*XZYC`).T4>]*/M&M'
M97]-%;TM^O574KZ)]%9>B2M^%ON:Z,O?M*_L^_`W]J.?5)=?^)6GVLVI1ZG'
MNLO$EK$L7V_1O[(E^7)5]L.)%$@8"55;'R@"UX*^$_PK\%^,]8U!?C+;W^DW
MFK#5])T6YUS3OL?AR5]3CU2\6W95$KI<WD22,)Y)/+`V0^4GRUZ)_P`._P#X
M#?\`1$OA'_X1VG?_`!FC_AW_`/`;_HB7PC_\([3O_C-3SRT79W^>FOKHM=[:
M%>TERJ-]%JOG_6VQYSHOPA^%.A_$GP?KT?QCLWL_!<MK=V6D-J^F?99+J#2[
M_2_M#OL\XL]M?$,HD"!K>,JJDOOW]1TOX?W+?#NUM?C9;Z?X?\!P6\-QHL.M
M::UKXC^S>2UHUTS*94:&6%)`;=XMYRLF]/DKI9OV!/@+!"TC?!/X1[4!8X\'
M:>>!_P!L:\)\,0?LU^)-7\-Z?)^R[HNEZAKVIR:9=V][X!T19/#I$D$4,U[L
M=@L4[W-N(S$9&/FC<J;7VS*HI346[RT:[Z-V_P#2G]_9#YI\GDE;\W^;;]7W
M/IK1/VA_A^NC6@/CGP?_`*E/^8S;?W1_MU\W^)OV,?V>?&&K?:M2^(UI<>=9
MVUA<Q?\`"4VZ1W$,&C:GHX`"L/*9K?59F9XMCEX8#G"`5VG[+W[!_P`#M6_9
MG^'=U=?!GX4W5U=>&--EFFE\):>\DKM:Q%F9C%DL2223R2:[K_AW_P#`;_HB
M7PC_`/".T[_XS5*<E\.G]6_)DTY2@[Q[6^3."\%_#WX;Z'H]E_;WQNA\9:_%
M.US>ZYJ>KZ7#=:G)]KT^X1I([>.*!-BZ;:P@11H"BL2"[%Z@^'/PF^%?@'Q'
MJVJ3?&*SUJXU(:3!$+O5],1;&VTS5KW4[2W3RD3<JM>O$6?<[1QIEB^YV]$_
MX=__``&_Z(E\(_\`PCM._P#C-<Y\7/V2_P!GGX-_#/7/%&H?`GX8WUKH=H]R
MUK8^"],>ZO&'W885:-5:21BJ*&9068`D#FDZO)#>R6ODM>:_WJY5/F;Y8];+
M\4[??9BZ+X7_`&?/A]\;-6^)'A^X^$^A^,O$4*V>K:GIS:;:W>J!KJ.9WGF0
M"65BR*278YV@]0#7:>/?BE\-_B#X>73;KQ]X5AA6\M+W=%K5J&W6]S%<(.6(
MP6B4'V)Q@\U\S^//AC^SK\0M9D\,:/\``'P7I\UAK7AR>/5Y?!6E16&I(^KZ
M6+F"&1`9&:);N%)5=%7]Z5!?#8^AO^'?_P`!O^B)?"/_`,([3O\`XS2@N2,5
M'9;?>WI\[F;?-)R>[W^Y?H>!V7[%OP6\(1?:O!_QPNO!_B&U,#Z9K=GXATZ[
MN]+>.ZUJ9V0722QR"2/7KV`I*CHD8AV*CQ(X]`\0?"_X0ZAX:O\`3]+^*FFZ
M#)/8R6=E=6VMV$TNEL;?3H(I8Q,)%=XO[,MW42AU9B^\,#@=Y_P[_P#@-_T1
M+X1_^$=IW_QFC_AW_P#`;_HB7PC_`/".T[_XS5<\KWOK:WRTT79:+1%5*DIN
M\]?^!W[_`#.;^$VB_"_X/V2#3_BMI%Q?1R>()Q>7&L:>9/.UG4_[2N)-J@)E
M)N$&W:%X8-UJ]\"/$G@OX+Z0]GJGQFTWQUK6ISW&H:EKNLZKID-U?RL((TS'
M:K#;QA(8HHPL42`B/)!8LQY[XF_LW_L^_#'QCX;T63]G?P#K$WB`SRS7&G^"
M](:WT6UAV>;=W;2!"L*F2-<QAWRW"D`D<!\&/@7\`?VA_B]X6U*Q_9]\%^&[
M7^PM<CN-*UOP5I<%QO6;1)8)FCB$B$-!<K(AW;@LY!"L643&2E)R6KUO\W=^
MEV_GMTT=24Y:SZN_J]W_`%Y^9]0_\-$?#_\`Z'KP=_X.K;_XNOF;Q-^QC^SS
MXPU;[5J7Q&M+CSK.VL+F+_A*;=([B&#1M3T<`!6'E,UOJLS,\6QR\,!SA`*]
MN_X=_P#P&_Z(E\(__".T[_XS1_P[_P#@-_T1+X1_^$=IW_QFJC*4?A=OZM^3
M%"<HN\?3Y,X+P7\/?AOH>CV7]O?&Z'QEK\4[7-[KFIZOI<-UJ<GVO3[A&DCM
MXXH$V+IMK"!%&@**Q(+L7J#X<_";X5^`?$>K:I-\8K/6KC4AI,$0N]7TQ%L;
M;3-6O=3M+=/*1-RJUZ\19]SM'&F6+[G;T3_AW_\``;_HB7PC_P#".T[_`.,U
MR7QN_99^`/P1^'5UX@D_9W^'_B22&:"W@TK1O!6DR7]_+-*D21Q"98H]VYP?
MGD48!Y[%>UY(VO9?K=-67KM]P1E+9?TD[_==7^19T,_#OP=\;_$'CB/XN:7>
M1ZZ8U@T.;6-/%AI4DC6HN9H2H$S--]DMRPDD=5,9*!-[[NV\>_%+X;_$'P\N
MFW7C[PK#"MY:7NZ+6K4-NM[F*X0<L1@M$H/L3C!YKY>\1>!_V<?B^8=%T#X`
M^#M/VZIX9OH-7G\$Z5#9:E%+JNE&XMXG0-(7B2\A25715S*5!?#8^C_^'?\`
M\!O^B)?"/_PCM._^,TH6C&/)MTMVZ6\NWEMH2]W??K_7Y^>^IX'9?L6_!;PA
M%]J\'_'"Z\'^(;4P/IFMV?B'3KN[TMX[K6IG9!=)+'()(]>O8"DJ.B1B'8J/
M$CCT#Q!\+_A#J'AJ_P!/TOXJ:;H,D]C)9V5U;:W832Z6QM].@BEC$PD5WB_L
MRW=1*'5F+[PP.!WG_#O_`.`W_1$OA'_X1VG?_&:/^'?_`,!O^B)?"/\`\([3
MO_C-5SRO>^MK?+31=EHM$54J2F[SU_X'?O\`,P?@KIWPK^";VLEK\3M$U.XM
M[C7KII;S6K$&:36-4_M.Y+"/:!MF^5`H`"G!R>:Z+X;?$;X9_"OPWHF@6/CW
MPK/;Z;9RQF>?6[5IKF0NC/+(0P!DD<L['`RS$UPGQ-_9O_9]^&/C'PWHLG[.
M_@'6)O$!GEFN-/\`!>D-;Z+:P[/-N[MI`A6%3)&N8P[Y;A2`2.`^#'P+^`/[
M0_Q>\+:E8_L^^"_#=K_86N1W&E:WX*TN"XWK-HDL$S1Q"1"&@N5D0[MP6<@A
M6+*!57*Z3[M_-O\`5O\`'LPJ<TI<\]W?7UU?]?YGJG[3/A[X/_M4^$;O1?$/
MQ$T6UL[W2KK29#IWB.WMIECN);:1G617WI(K6L>UE((R>^,>9W7[)?P;75;U
MM/\`C4=)TG79=1EU_2;;7-,^RZ[]HU/4-4MA(60O']CNM2N&B,#1EU"+,9E4
M+7MW_#O_`.`W_1$OA'_X1VG?_&:/^'?_`,!O^B)?"/\`\([3O_C--5))67]6
MO;[KNW9Z[E1J2BN5/2]_FNOD>;Z]\%?@_K7Q#\1^)(_BS86=WXKDO_[2BBUK
M3FCFAN]'T_2Y(!N4E5`TNSG#*0_FQD;C&S1G<^*.A?#[Q[\-)-!TGXU6?@Z^
M_MN[UR#6-,U;2YKNVDNFN//C5+E)861H[J:/YHRRA@RD.JN.L_X=_P#P&_Z(
ME\(__".T[_XS7@/CVX_9I\`ZOXLL7_9;TG5+KPQ<)!;)8>`-$D/B(`SBXDLM
MSKN2V^S7'F^=Y3?NFV"3C,RO-\KUNOP7Z)+7RO?2Y,JCY(IO2-K>5DTK?+1?
MYGT-\-OB_P##/P/I=QH^G>-/"%OINE-!9VD9UR!MD,=I;H@W-(2<!0,DDG%>
M3^+_`-GGX&^-?C/X@\=7GQ*TU=:\0-J9=8O$5HD,'V_2--TJ7:@.&VPZ9$R^
M9NVO)*>A`')_L9_L9_`WQM\:?VF)?^%3?"O4]+M?B181Z5O\*V$D5O;2>"_"
M]P%A!BPD;2322;5P"TKMC+$GWS_AW_\``;_HB7PC_P#".T[_`.,U=24W)N5[
MO1]^E[^K6OW,G#R]G"U+:W3:VZ_)6.%\!?#WX7^"OB7=>))_C%8ZT5U=]3TF
MQN]7TQ;?0(G^V,]G;^6B.86DOI7)E9W^2)=^R-5'/_#7]G'X,_"_P#'X9LOB
MY:SZ-#I=EIR0S:WIQ*O;:')HAN-P4-YDEJT6X$[`]NA55W2!_6O^'?\`\!O^
MB)?"/_PCM._^,U7U7]A+X`:)I=S>7'P4^$JV]G$TTI7P78.P502<*L)).!T`
M)/:HYFH<G16_"_\`F_F[[FM.K4C)N+U=OG:]ONOH1^)/$O@CQ+\4/"NN2?&3
M2H=&\+1NR^'8]4TS[!?W)C>..ZF<H;@O&LC;4658\X8H652.`^-OPJ^"W[6.
MC^$;KQ/\1-)M_P"Q=#.G1PV7B&VM]RRWVDZ@Q9@V\,)=)@7Y6`*22@@Y&*7@
M#X7?L^_$KQ9X7TO2_P!EWPZT/B*QFOKG4)?`NB):^'Q')/$([SYO,61Y+>15
M$22C(&XJ.:P_^"7O[#_P5\6?\$T/V=]5U7X0?"[4]4U/X9>&[N\O+OPK837%
MW-)I5LSR2.T19W9B6+,2222>:I3DE=>?KK=/SOKOOVZ&5/\`=R]S2RM\FMO2
MS_$Z?Q7\$_A3XK\8SW[_`!FMK;1[Z"^%_H<6KZ7]BO[FXDOY([IV9#*)(/[0
MF$860(=L1=7,:$2Z]\%?@_K7Q#\1^)(_BS86=WXKDO\`^THHM:TYHYH;O1]/
MTN2`;E)50-+LYPRD/YL9&XQLT9](_P"'?_P&_P"B)?"/_P`([3O_`(S1_P`.
M_P#X#?\`1$OA'_X1VG?_`!FIBW&/(MG_`)I_HONML:*K-2YT];6^6CMZ:?U=
MG+?%G3/`OQ"^"&N^"]&^.%GX*_X2#4;J_N-5TS4=(N+Q1<7$D\L*K=131;"9
M"N3&6``PP/-4_!6G_#OX4^-->\22?&#3_$L^MWEJ+2UU'5]-$.AH]ZMQ=+;^
M4J/MGN':9_,9\$*J[$14!^T!^S5^S_\`L^_#.\\47/[.?@7Q);V!#36>B>"-
M)FNA&`6DEQ*(TV1QJ[ME\[4(4,Q"GPC]KKX&?!/QI\)IH]%_9Y\*^&[?0?BQ
M\/M)CUR?PAI%O9Z_'-XTTBWNEM7A+2M%L\R*02I'N60KAE8TZ<FI.:_K^D_S
M\S&HDU:75W]7>]_-WU\M/(]<\7_L\_`WQK\9_$'CJ\^)6FKK7B!M3+K%XBM$
MA@^WZ1INE2[4!PVV'3(F7S-VUY)3T(`UO`7P]^%_@KXEW7B2?XQ6.M%=7?4]
M)L;O5],6WT")_MC/9V_EHCF%I+Z5R96=_DB7?LC51W7_``[_`/@-_P!$2^$?
M_A':=_\`&:/^'?\`\!O^B)?"/_PCM._^,U-W>_E;T5K67;3MY]V:U*DJD>6>
MJ>GX6_+\EV/)?AK^SC\&?A?X!C\,V7Q<M9]&ATNRTY(9M;TXE7MM#DT0W&X*
M&\R2U:+<"=@>W0JJ[I`_<?$^X\*^/_B3X/UZP^/UOX8M/",=P%TFPO=$FM=0
MEE@D@$TKW$,DP9%D)41R(I(&Y6KHO^'?_P`!O^B)?"/_`,([3O\`XS7G/Q<^
M"?[.?P6\;Z/I.K?L[^!Y;'5;6[NI-:M?`NE2:=IOV>WFN?+G8J)-\D=O,4$<
M;C,9W%,KERDY2O+5MW^>XZE2=1\TW=Z_C:_Y+Y>1TGP"\1>#?@7X<T?PYJ'Q
MHTSQS<6\>I7$FL:OJ.E6]U,T]U',59;1(80`SL!MC!QUS7FOPV_8_P#@+\*_
MA_=Z!I?Q0M0MY86%C)=R^([-Y5^QZ"VB02HI_=I((6\XE5`,P#8QQ7">!O@1
M\#/CE^W9\'[JS^`_@SPO97GPZ\>C5/#FL^#]+AN;2]M-8\)1)]IAA$D1D1)I
M"C!VPER<$;V%?4__``[_`/@-_P!$2^$?_A':=_\`&:=1.W(]%IY72VVZ:W_'
M<BE6:B^1Z-W^>J_#5>6QYOIGP<^%/_"'KI^L?&2T\0:I/J.CZOJ.LW6KZ9%=
MZI=:;K7]KQRR+"B1+OFQ&RQHJB)55`F`:UOA1X%^$_PHMO#,</Q5TK4AX32V
MM[`W6M:>"MO;#44MX6\L+E8XM1:,,?G801%F9B[/V7_#O_X#?]$2^$?_`(1V
MG?\`QFC_`(=__`;_`*(E\(__``CM._\`C-#J2=O+;\%^22\A\\N64.DKW\[J
MSOZH\B^,/P9\-?%[Q#XLOV_:EU/1E\2:AIE]:VUG<>&Y(-&%A))+%#&LUF_G
M1L\FYA<^<247!&*CU;_@L[^RS\#?&GB#PMXL^/W@F'Q!H]W';WGVBY!EDD6V
M@5G;RD\O)8$G8`N<X`'%5/&GA7]GWPAXJ\1:'#^R=I>M:QH=Y:6MK:6'@/0?
M,U])_M&;BS\V1`T,1M9U<RF-LI\JN"I/G?\`P2^_8P^#OB[Q[^UA'JOPF^&N
MI1Z/\=-3T^P2[\,6,PL;9=&T5U@B#1'RXPTCL$7"@NQQDFE'W862T?\`7K_7
MD9RLYW>_]?TOPW/3?^'^_P"QM_T<)\/_`/P(E_\`B*Y_XB?\%L_V*_B38:;;
MWG[17@>%=+U6SU>,PW+@M);3+,BG,9^4LH!QSCH17T'_`,.__@-_T1+X1_\`
MA':=_P#&:/\`AW_\!O\`HB7PC_\`".T[_P",T1DU)26Z::]4[K\0E%2BXO9I
MI^CT9\20?\%$/V,;76]8U"']L/3H[B[UJ#5=(YM&7PW`EW-=2V%L#9D-!,UQ
M.CF;S)0KJ$=/+B*6_P!G/_@HU^Q%^SI;:;!;_M6Z)KUOH<UNNDQ:A/$D>F65
MM9W-G:V,8AMHQY,,%RRAFS(Q16=W8L6^D/B7^SY\!/A]\0=+\-6?[,OA+Q9J
M&H6%SJ,[:+X'T9X=,BB1C'Y[3&+#3NK11!`^74[MBC=7B_CG0O@;\5/@MXPL
M=._9'C\+Z@WAK77N;S4?`_A^!?#DEM!=(AN'AGD96DE@=8S")/F7YBG6G"+<
M>6.V]NFFE_EM??5]W<J63YI;NWZV3_1/I9]$?:WP2^(^@_$;X,^$?$.AZM8Z
MEHNO:+9ZCI]W%(/+NK>:!)(Y%SSM9&4C/8UUJ.)%#*0RL,@CO7SI_P`$HO#F
MGS_\$M_V:Y)+"S=W^%?A=F9H%)8G2+7))Q7T5%$L$2QQJJ(@"JJC`4#H`*)-
M/4:TT'4445(RKKG_`"!;S_K@_P#Z":^,/VJOV<M?^,?Q?^'=]HG@/7]:N[>>
MWCM?%5KJMK:V'A(1:VL]X]U#)<++-YMH)$C$5O.=_&8<^8/LOQ/;_:_#6H1;
MY(_,MI$WQMM9<J1D'L1ZUY;H7Q.\#>`=6\*^#=<^(6FZ/XM\6278T/1;[78;
M?4-:\J5_,-O`S"28J.6V`XZFMHQ3@K]]//1KIK]S3[,S<FI>5OR:>M]+::WT
M:T9\]ZU^R]\0/VBO@-\+/"'B+P'<>#;_`,`S0^$]9NCJ5F\%_86]I'</?67D
MR.WV.:^T[3EC258I]K,7AC"`GK?AU\/OB%=>+?@OJVK?#G7=`\9RQW&J>)->
MM-7L9--T2.[N+B[O='O8Q<>9.6:2,1/;Q2J)1DR(@;S/:=!^-_PW\4R^(8],
M^*&@Z@_A&YN;+7%MO$=O*='GMF1;B*YVL?)>)I8PZO@H9%!QD58E^+7@"W^)
MVF^"9/B/I*>,M8^T?8-";Q!"-2O?LXW7'E6^[S'\H`E]JG:!SBCF;G[1N[D^
M?;=V2;]'972T^5T3*G%1Y$K)+D2N]%>]M>JOHW=[:WU/1J*R?^$3'_01U;_P
M)/\`A1_PB8_Z".K?^!)_PK.R[FFIK45D_P#")C_H(ZM_X$G_``H_X1,?]!'5
MO_`D_P"%%EW#4UJ*R?\`A$Q_T$=6_P#`D_X4?\(F/^@CJW_@2?\`"BR[AJ:U
M%9/_``B8_P"@CJW_`($G_"C_`(1,?]!'5O\`P)/^%%EW#4UJ*R?^$3'_`$$=
M6_\``D_X4?\`")C_`*".K?\`@2?\*++N&I<T?_CT?_KO-_Z,:K58.E>%@]LW
M_$PU4?OI1Q<G_GHU6/\`A$Q_T$=6_P#`D_X4Y)7W"-[&M7G_`.UE_P`FL?$S
M_L5-4_\`226NJ_X1,?\`01U;_P`"3_A7G/[8?@==1_9(^*5O_:VN0^?X0U:/
MS(;PI)'FRF&Y3CAAU![&E9=PU/7**^<?^'<D/_1</VCO_"[E_P#C='_#N2'_
M`*+A^T=_X7<O_P`;J2CZ,F<QQ,RJTC*"0JXRWL,\?G7Y[K\-_C%\:+A=4N_@
M1XD\$ZU\2KFZT_Q?)JVN:-(NCL]YI$L5Z#:WDQGMH["R>V7:!,TUM#F%(Y6E
MC]\_X=R0_P#1</VCO_"[E_\`C=4]4_8'TG0[W3K:]^/W[05G<:O<&TL8IOB"
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M#]H[_P`+N7_XW5/Q#^P+I/A'0+[5M6^/O[0>FZ7IEO)=WEY=?$%X8+6&-2SR
M2.R!515!)8D``$FI*.(_:?\`A9\1M;_:PO/&WA#X5Z]>0^#DT^>\F_MVP6/Q
M\D5_I=S%#81RS_N+BWACU%6^T?98W<PC?*&\R'U7]CSPAK'@/Q&^E>(+:WLM
M>MO`7APZC:P3>?':W#W6LO)$LF!O",Q4-@;MN<#->:^*/V?OACX(U7Q)8ZU^
MU=\6])OO!NFIK.OV]Y\54@ET2Q?.RZN58`PPM@XD?"G'!JKX#_83TOQ=\=->
MN-,^.GQ\OM-NO">A:A::C:>/7D%[%-<:J482JA#Q;5#)CC]XQ!.ZB%N3ECLF
MW?S>C\M7'7SB[6?-=RDG*[WLEZI:K[N;[I+IRV^T**^<?^'<D/\`T7#]H[_P
MNY?_`(W1_P`.Y(?^BX?M'?\`A=R__&Z!'T5=M*EI*T")),$)C5VVJS8X!.#@
M9[X-?%/P5^#/C;PGXJT.;3?A'XL\+>&_%VKPL^FZIK6FW5QX(@L]0L[YWO)$
MO)C,MU+'>M$+=[AE\R$.(E9A%Z9_P[DA_P"BX?M'?^%W+_\`&Z\\T'X._"/Q
M3?Z/:Z9^UU\4=0N?$6J76B:5%;?%J*5]2O[49N;2$+DR3PCEXURR#[P%1[.]
M13ZK9>NC^].WSTL]2N;]VX/9[_+5?=:_W]#Z1_9-_P"36/AG_P!BII?_`*21
M5Z!7QU^S-_P3UAUG]F_X?7G_``NC]H6U^U>&M.F\FW\<2QPQ;K6,[479\JC.
M`.P`KM_^'<D/_1</VCO_``NY?_C=62?1U>5_MB?"#Q=\;O@Q-HW@GQ38^$]:
MBNHKU;B\T;^U8+H1;G6!HO/@QND$;!_,&TH."*X7_AW)#_T7#]H[_P`+N7_X
MW1_P[DA_Z+A^T=_X7<O_`,;K&O1C5@Z<MG_7]7T>S31I1J.G-373^OZZKIJ>
M<^%OAGX[^'DNGZ3XH\/W4=CX=U?0V_X27S+6.SU^YO\`6_#\LBV]O'/)-$89
M+6X1Q*JKS$8WE!8I]J5\=?M!?\$]8=*\!V$O_"Z/VA;C=XET"'9/XXE=1YFL
M6:;@-GWEW;E/9E4]J[?_`(=R0_\`1</VCO\`PNY?_C=;+1)+HK?);?<M/EWU
M,5&WY_Y_?N?1U%?./_#N2'_HN'[1W_A=R_\`QNC_`(=R0_\`1</VCO\`PNY?
M_C=!1D_MU?LQZG\</C;X`OM/\+ZOJTB6MQIB:[::G':P>%-]S:RS3W,33QM/
M'-;QS1!8XYF#E<JBL9%L?LLVOBAOB_X<U#Q;X3U#P3JFJ:%K+?V1?7=K=7$"
MP)X:LR[/;2RQ;9'MG=,.3Y;QE@CED6]_P[DA_P"BX?M'?^%W+_\`&ZXC7O\`
M@GK#%^TAX3L_^%T?M"MY_AK6IO.;QQ*9H]EUI(VJVSA6\S+#N43TK.E3C3OR
M]?\`-R_.4OD_)6JI)S:<NG^27Y17W>;O]BT5\X_\.Y(?^BX?M'?^%W+_`/&Z
M/^'<D/\`T7#]H[_PNY?_`(W6A)]'5XG_`,%!OAKJ'Q=_9CU30;/PWK_BZUO+
MRS;4M'T"_M[#6+ZU2X1W6SGN)H88Y@RHV9)4!17`;<5!YW_AW)#_`-%P_:._
M\+N7_P"-T?\`#N2'_HN'[1W_`(7<O_QNLZE-5(\LMOZ_IE1DXNZ/-?!OPZ\=
M>!4TO3?$WA.^TNPT'5="D&MR7=I):ZM<:AK7A^:2&".*5I5:WDMKB.0R1QH?
MW1C,@9MGVQ7QU^T%_P`$]8=*\!V$O_"Z/VA;C=XET"'9/XXE=1YFL6:;@-GW
MEW;E/9E4]J[?_AW)#_T7#]H[_P`+N7_XW51BHQ45T27R6B^Y:?GJ3U;[N_S>
M_P")]'45\X_\.Y(?^BX?M'?^%W+_`/&Z/^'<D/\`T7#]H[_PNY?_`(W5`9/[
M=7[,>I_'#XV^`+[3_"^KZM(EK<:8FNVFIQVL'A3?<VLLT]S$T\;3QS6\<T06
M..9@Y7*HK&1;'[+-KXH;XO\`AS4/%OA/4/!.J:IH6LM_9%]=VMU<0+`GAJS+
ML]M++%MD>V=TPY/EO&6".61;W_#N2'_HN'[1W_A=R_\`QNN(U[_@GK#%^TAX
M3L_^%T?M"MY_AK6IO.;QQ*9H]EUI(VJVSA6\S+#N43TK.E3C3OR]?\W+\Y2^
M3\E:JDG-IRZ?Y)?E%?=YN_V+17SC_P`.Y(?^BX?M'?\`A=R__&Z/^'<D/_1<
M/VCO_"[E_P#C=:$GT=7PGK'P8^)7PZ_:#^)OC3P_\*_%VN_VCK+7-S"^N:6(
MO$326]]9VDVEK)=+]GA@M[I&NUN/)=W#-$DQ'S>O?\.Y(?\`HN'[1W_A=R__
M`!NC_AW)#_T7#]H[_P`+N7_XW2LKZ]FOD]Q25TO)IKU6QG_\$X/!K_#GQQ^T
M9X>DF6YDT'X@:/IS3*-JRF'P%X2C+`=L[<_C7T]7P'^RG^P/#KGQW_:8M?\`
MA<7Q\M/['^)-G9B6V\:2QRWN?!_AJ?S9VV?O)!YWEACC$<42_P`->W?\.Y(?
M^BX?M'?^%W+_`/&ZUJ5)5)NI+=N[^9%*G&G!4X[)67R/HZJ^K7LFG:5=7$-K
M<7TUO$TB6T!02W#`$A%+LJ[FZ#<RC)Y('-?//_#N2'_HN'[1W_A=R_\`QNC_
M`(=R0_\`1</VCO\`PNY?_C=9FBW.*^%7@OQ7XS^)7PGUR_\`@IX^\$>)-+U#
M5;K4-<U76=*:UTG3I;F^<V4\-GJ,WG2S"6)DV12*F_)D0J5/H?\`P2=_Y19?
MLT_]DJ\+_P#IHM:H_P##N2'_`*+A^T=_X7<O_P`;KQ'_`()G_L#P^,?^"<'[
M/VKGXQ?'S2SJOPV\.WAL]/\`&DMO9VGF:7;/Y4,80A(USM51T4`=J(V4%!;+
M_@?Y??=]6#NY<[W_`.'_`,[>B2Z'WY17SC_P[DA_Z+A^T=_X7<O_`,;H_P"'
M<D/_`$7#]H[_`,+N7_XW0!V7[;>M>,-+^`E]:^#/!&M>/K[6KB+2[_3M)N+&
M&\BT^8E;J:/[;<6\#.(MRJ&E7YG4\@$5\N_M(>!;[2O^$C\06_PY\3?#?0]:
M^)_PN6X76-3M+I?$%^OCK2&:[MXK:[N%@C6-E1MWE%V;/EX7<?</^'<D/_1<
M/VCO_"[E_P#C=>(_\%`OV!X?"OP(T&Z'QB^/FH>;\2?`5GY5]XTEFB3S_&&C
M0>:%*<21^9YD;?P2(C<[:(>ZV_ZVMMMY][^BLIKF5GM_P;W[^7IIU9]^45\X
M_P##N2'_`*+A^T=_X7<O_P`;H_X=R0_]%P_:._\`"[E_^-T#/HZOFO\`;7^$
MGB#XM_$GPW;^'?!.K7FHVNDZFD7BL:I;PZ9I\<]I<0RV4\#3"5GG9H`CI!(%
M^8L\8&'F_P"'<D/_`$7#]H[_`,+N7_XW1_P[DA_Z+A^T=_X7<O\`\;HV:DNG
M]?UWV>F@:-.+V:M_7]:;K4\\^"VF:\__``4;^'/B'Q)X<U+P?JOC3P/\1-9?
M0M0GMI[S2D.J>"+>..9[:66!G9+=9#Y<CJ/,QDD&OM&O@/Q[^P/#:_\`!1_X
M4Z1_PN+X^2"^^&WC2\^V/XTE:\@\G5/"B>5')LRL;^?N=?XFAB/\'/MW_#N2
M'_HN'[1W_A=R_P#QNJE)RMY))>B22_!$P@HK3JV_FVV_Q9]'45\X_P##N2'_
M`*+A^T=_X7<O_P`;H_X=R0_]%P_:._\`"[E_^-U)1Y_^T/I'C+XSZC\6-/\`
M$7[/?Q$\0A;JTTWPA?:9K>BV=O<10"<P7RS'4X[A-D\\LDBR1*P1D58YB&%.
M_P""/UM=V7B7]K2'4)DN;Z'X\:DES,@PLL@T'0@S`>A;)_&N^_X=R0_]%P_:
M._\`"[E_^-U\M?\`!-']AF+QCX[_`&J(C\6OCIIG]B?&[4M-#Z?XPDMVOMNC
MZ._GW!"?O)SYFTN<$JB#^&B.D>5?U_P_6UEMT2LI*\N9^?XVT^5M+^?=GZ9T
M5\X_\.Y(?^BX?M'?^%W+_P#&Z/\`AW)#_P!%P_:._P#"[E_^-T#(?V@?@9K7
MB7]M[X?^+M+\)ZS?26-O;(OB:UU6*"TT&&VDO)+NVN;=IT>8WD=Q'%$4AF"L
M'+M"`K-Y'^T%\)O%=[\'_#>LZI\-==TWQQ#X-UO6O$_B2#6;5M(T#[9:7]Q>
MZ0\:W(EN9//N-D;I;/&!AO-7!!]B_P"'<D/_`$7#]H[_`,+N7_XW7$?M,_\`
M!/6'1OV;_B#>?\+H_:%NOLOAK49O)N/'$LD,NVUD.UUV?,IQ@CN":J,N5+R=
MU^J]'977^<KS*-^;^\K?=?\`'5N_IV5O1?\`@D[_`,HLOV:?^R5>%_\`TT6M
M?0%?-O\`P2E\,BX_X)<_LVR?;]43?\+/##;4N"%7.DVO`'I7TA;Q?9X$CW.^
MQ0NYSEFQW)]:3MT*'4444@*NN?\`(%O/^N#_`/H)KX'_`&XM7%M\<?AKI]OX
MN@T[6M0O-,?2_"KVL4LGBV:+Q)&^4?:9H_L@/VDF(@83]YE`17WIXG$Q\-:A
MY#1K/]FD\LR*64-M.,@$$C/H17,_#6'7?^$.M_\`2-)SYL^[_1Y.OG/G'S],
MYK>%U%33M:5_/9K3?5;JZ:\C*5FW"2NFMGL[23L_)VL]M'N?GYXG\+>'OCW^
MS9\';'X<H8_$UMI$7PM\2P>2YN-+N%ALM4O+&][^?&-%DC=7Y!N,'_6<^R_L
M]:)JO[2WQ.\%^,-';2]/\%ZM80>-[LW4$JZG*)M6U:[L5@/W55EF`EW\E"H'
M4U]>>3KW_/QI/_@/)_\`%T>3KW_/QI/_`(#R?_%TXU&I.>E^;F5MD][)?R\W
MO)=&WO=W)TU*G['7ELHZZWU3N^\G%<M]-/N-:BLGR=>_Y^-)_P#`>3_XNCR=
M>_Y^-)_\!Y/_`(NL>7S-+FM163Y.O?\`/QI/_@/)_P#%T>3KW_/QI/\`X#R?
M_%T<OF%S6HK)\G7O^?C2?_`>3_XNCR=>_P"?C2?_``'D_P#BZ.7S"YK45D^3
MKW_/QI/_`(#R?_%T>3KW_/QI/_@/)_\`%T<OF%S6HK)\G7O^?C2?_`>3_P"+
MH\G7O^?C2?\`P'D_^+HY?,+ES1_^/1_^N\W_`*,:K58&EQ:Y]F;;<:5CSI>M
MO)U\QL_Q^M6?)U[_`)^-)_\``>3_`.+IRCKN*+T-:O/_`-K+_DUCXF?]BIJG
M_I)+75>3KW_/QI/_`(#R?_%UYS^V%!XF;]DCXI"TNM#2Z/A#5A"TUI*T:O\`
M8IMI8"0$KG&0"#CN*7+YCN>N45\X_P#"-?M<_P#0Z_LX_P#A%:S_`/+6C_A&
MOVN?^AU_9Q_\(K6?_EK4C/HZOGO]M;XA>`/AW\3_`(/S>)-5\/Z/XPU36;[2
MO#4U[(L=W+]HL)HI(8&/.'G:Q5@.K&+/.*J_\(U^US_T.O[./_A%:S_\M:/^
M$:_:Y_Z'7]G'_P`(K6?_`):U,HW5OZU*C*SOZ_E_7J>._P#!/W6?#?B?2?A]
MJ'A"Q6RT)?$NE:9($M/LR&^M/`\]O<IMP/GA,<=N_=7MV0\QD#[PKX[^*_AS
M]JY?'GPS^T^,OV>VF;Q+,+0Q>#=854E_L?4\F0'4R67R_,&`0=Q4YP"#VW_"
M-?M<_P#0Z_LX_P#A%:S_`/+6M:E1SFYO=N[]7J[=E?9=%97>Y*5DHKHDM=79
M*RN^KMN^_8^CJ\B_;UU7P?H7['?Q`OO'DFCP^&[/2GF>35`IMHKE2IM&^;C>
M+D0%#U#A".<5QW_"-?M<_P#0Z_LX_P#A%:S_`/+6C_A&OVN?^AU_9Q_\(K6?
M_EK4:[HJG+EDI'R+\:?%OA?4?VO?^$\LO%'@/Q9\+M'O-*\:^(+_`$^WDN+S
M0(KV[\,"!KZ4?NA;,FGQW49^]Y=JSD[8N/K;_@G_`&,>G:9IL5O8R:;9_P#"
MN/##6=G)"8&M;9KG66AC,9Y3;$479_#C':I/^$:_:Y_Z'7]G'_PBM9_^6M<3
MH/AS]JX_M(>+%3QE^SV+\>&M%,SMX-U@PM%]JU;RPJ_VGD,&\W<22""F`,$F
MK^[RZ[WW\HQ^Y*,4NWO7OS:3'W5RK;3\V[^KE*3?JETU^Q**^<?^$:_:Y_Z'
M7]G'_P`(K6?_`):T?\(U^US_`-#K^SC_`.$5K/\`\M:D#W[Q6+IO"VI"QW?;
M?LLOV?;U\S8=N/QQ7YW_`++'Q4L[Y?AYI.N>.+7QXVI2:3H?@[46T^WM)+U[
M&^TF[U&VCC@14\RV^=9"!NVV;%B3&V/I+_A&OVN?^AU_9Q_\(K6?_EK1_P`(
MU^US_P!#K^SC_P"$5K/_`,M:R]E^]56^UOP4E^4G\TGT:=N=X<G];Q?YQ7R;
M[W7IW[)O_)K'PS_[%32__22*O0*^._V9O#G[5S_LW_#YM/\`&7[/<=@WAK3C
M;)<>#=8DF2+[+'L#LNI@,P7&2``3G`'2NV_X1K]KG_H=?V<?_"*UG_Y:UJ0?
M1U%?./\`PC7[7/\`T.O[./\`X16L_P#RUH_X1K]KG_H=?V<?_"*UG_Y:T`>G
M?M+_`/).M-_[&OPW_P"GRQKT"OCO]H+PY^U<G@.P^W>,OV>Y(?\`A)=`"B#P
M;K",)?[8L_*))U,C:)-A88R5#`$$@CMO^$:_:Y_Z'7]G'_PBM9_^6M`'T=17
MSC_PC7[7/_0Z_LX_^$5K/_RUH_X1K]KG_H=?V<?_``BM9_\`EK0!]'5Y_P"(
M_P#DZ?P;_P!BIKW_`*5Z-7F/_"-?M<_]#K^SC_X16L__`"UKB=>\.?M7#]I#
MPFK^,OV>S?GPUK1A=?!NL"%8OM6D^8&7^T\EBWE;2"``'R#D$`'V)17SC_PC
M7[7/_0Z_LX_^$5K/_P`M:/\`A&OVN?\`H=?V<?\`PBM9_P#EK0!]'45\X_\`
M"-?M<_\`0Z_LX_\`A%:S_P#+6C_A&OVN?^AU_9Q_\(K6?_EK0!Z=^TO_`,DZ
MTW_L:_#?_I\L:]`KX[_:"\.?M7)X#L/MWC+]GN2'_A)=`"B#P;K",)?[8L_*
M))U,C:)-A88R5#`$$@CMO^$:_:Y_Z'7]G'_PBM9_^6M`'T=17SC_`,(U^US_
M`-#K^SC_`.$5K/\`\M:/^$:_:Y_Z'7]G'_PBM9_^6M`'T=7G_B/_`).G\&_]
MBIKW_I7HU>8_\(U^US_T.O[./_A%:S_\M:XG7O#G[5P_:0\)J_C+]GLWY\-:
MT877P;K`A6+[5I/F!E_M/)8MY6T@@`!\@Y!`!]B45\X_\(U^US_T.O[./_A%
M:S_\M:/^$:_:Y_Z'7]G'_P`(K6?_`):T`?1U%?./_"-?M<_]#K^SC_X16L__
M`"UH_P"$:_:Y_P"AU_9Q_P#"*UG_`.6M`%[]C?\`Y.*_:Q_[*K8_^H1X4KZ`
MKX#_`&4O#_[44GQW_:873?%WP#BO$^)-FNJM<^$=6DBFN?\`A#_#15H%74E,
M<?V<VZE7+MYBRMN"LJ+[=_PC7[7/_0Z_LX_^$5K/_P`M:`/HZBOG'_A&OVN?
M^AU_9Q_\(K6?_EK1_P`(U^US_P!#K^SC_P"$5K/_`,M:`/HZOG__`()._P#*
M++]FG_LE7A?_`--%K5'_`(1K]KG_`*'7]G'_`,(K6?\`Y:UXC_P3.\/_`+44
MW_!.#]GY_#_B[X!VV@M\-O#C:;#J'A'5I[R*V.EVWE+-(FI(CR!-H9E15+`D
M*HX`!]^45\X_\(U^US_T.O[./_A%:S_\M:/^$:_:Y_Z'7]G'_P`(K6?_`):T
M`?1U?/\`_P`%+/\`DW7PY_V57X<?^IOH54?^$:_:Y_Z'7]G'_P`(K6?_`):U
MXC_P4"\/_M11?`C06UOQ=\`[BS_X63X"6-;'PCJT,HN3XPT86S%GU)P8UN#$
MTB@!FC#JK(Q#J`??E%?./_"-?M<_]#K^SC_X16L__+6C_A&OVN?^AU_9Q_\`
M"*UG_P"6M`'T=17SC_PC7[7/_0Z_LX_^$5K/_P`M:/\`A&OVN?\`H=?V<?\`
MPBM9_P#EK0!>^(W_`"E-^#?_`&2KQY_Z=_!E?0%?`?CWP_\`M1#_`(*/_"E)
MO%WP#;7F^&WC1K.9/".K"S2V&J>$_M"R1G4B[2,YMBC*ZJJI*"K%U*>W?\(U
M^US_`-#K^SC_`.$5K/\`\M:`/HZBOG'_`(1K]KG_`*'7]G'_`,(K6?\`Y:T?
M\(U^US_T.O[./_A%:S_\M:`/HZOC_P#X)0?\E%_;"_[.`U7_`-,>AUV7_"-?
MM<_]#K^SC_X16L__`"UKY;_X)HZ#^TM-X[_:H_X1_P`5_`RVFC^-VI+K!U#P
MIJLZSWW]CZ-O>W":BAC@,9B`1R[!@Y+D$!0#],J*^<?^$:_:Y_Z'7]G'_P`(
MK6?_`):T?\(U^US_`-#K^SC_`.$5K/\`\M:`/HZO/_VLO^36/B9_V*FJ?^DD
MM>8_\(U^US_T.O[./_A%:S_\M:XG]IGPY^U<G[-_Q!;4/&7[/<E@OAK43<I;
M^#=8CF>+[+)O",VID*Q7."00#C(/2@#T3_@D[_RBR_9I_P"R5>%__31:U]`5
M\V?\$I8M:/\`P2Y_9M\J?2UB_P"%6>&-@>!RP']DVN,G?UKZ0MQ(((_-*-+M
M&\H,*3WP/2FT`^BBBD!5US_D"WG_`%P?_P!!-?&/[4O[5[?`7]H_X(V+:IJ$
M&G^??FYTVWLKJ6/5;O4+Z/3+$32QH8HXXVFN9")F4,47;DK7V5XGF:V\-ZA(
ML4D[1VTC+&F-TA"GY1N(&3TY('N*\\\/>%=,\:^#)AJO@^\OAJ>R.Y$CP_.M
MO=RSP*<2]8Y79@1_$>IXK;E;IW6MGLW:^C_76YGS6G9:73U[:KNFMO\`/<^*
M/B'I_B;X8_LZ_#_Q7X-\;>)]>U3XU>%Q_;&=7FF2\UG4'TJ\>_M4DD;[*/LE
MKJA6&+$2`?(BX8-Z=X/GU+XJ?M=>"M?\.KXRUA)Y;G6H-:@UB3^P=.TV35-4
MCD2YM_/"2FXM8X(X,0R;&CW!H^=_OG@7]FGP'\-8Q'HOPXFLHTUN7Q%%'YZ2
M);WTEO+;/)&KSD1KY,TJ"-`(U$C;5&:W_AA\.=!^#&@Z;I?A?P3>:/8:3I=O
MHMI##+$1#9VY<PQ`M,20ID<Y.2=QR351E:7-9:.\5I91T?)YQ4KV[IV>B22J
M1<J;IWO=*[M9N5U[VFSY5;KKUZG?T5D_\))>?]`+5/\`ONW_`/CM'_"27G_0
M"U3_`+[M_P#X[6/(_P"FC3F-:BLG_A)+S_H!:I_WW;__`!VC_A)+S_H!:I_W
MW;__`!VCD?\`30<QK45D_P#"27G_`$`M4_[[M_\`X[1_PDEY_P!`+5/^^[?_
M`..T<C_IH.8UJ*R?^$DO/^@%JG_?=O\`_':/^$DO/^@%JG_?=O\`_':.1_TT
M',:U%9/_``DEY_T`M4_[[M__`([1_P`))>?]`+5/^^[?_P".T<C_`*:#F+FC
M_P#'H_\`UWF_]&-5JL#2_$-TMLV-$U1OWTIR'@_YZ-Q_K.W2K/\`PDEY_P!`
M+5/^^[?_`..U3@[_`/!%&6AK5Y_^UE_R:Q\3/^Q4U3_TDEKJO^$DO/\`H!:I
M_P!]V_\`\=KSG]L+Q;?67[)'Q2FC\-ZU=R0^$-6=8(I+423$64Q"+NF"Y/0;
MB!D\D#FIY7_3'S'KE%?./_#</Q&_Z-'_`&A/_!GX-_\`E]1_PW#\1O\`HT?]
MH3_P9^#?_E]4C/HZO-?C5H5U=?%KX4ZC%KFM65O::Y=VTNG6TJ1V=^9=,NRL
MDXV;W:+RSL7>(\RLS([+&T?G?_#</Q&_Z-'_`&A/_!GX-_\`E]7"?&'XE:C\
M>_$'A?5/%G[%_P"T1JE]X+O3J&C2KXA\*VWV.<E"7Q%XB0/]Q1APPQD8PQ!`
MZ->3_(UOV>OA_-X`\2:$MGKVJZ_X/U+XK7MSX8FU+4I=1N%ME\,7<%RQFD9B
MR2:A#?3(%.P+,H0*FU%^LZ_/GP3XNF_96N/ASH/@']C?X^>%='3Q9->K8/KW
MABZ%S+_8NHQ;(C)X@DV$)\V"43;&V/F(5O>/^&X?B-_T:/\`M"?^#/P;_P#+
MZJ<KI+LDM--DE^@;MOS?]?Y]7UN]3Z.KSO\`:XT*X\1_LQ^.K:UUK6/#\RZ-
M<W`O=+E2&Z41(9&C5V5MJR!#&S*`X5V*,CA77S7_`(;A^(W_`$:/^T)_X,_!
MO_R^KF_B_P#M">)?CS\.-4\(^+/V./VA=4\/:U&L5[:#6_"5OYZJZN!OB\0*
MX&Y1G##(X.02*DJFTI)L\3_:1B\50_MXW7AK6I_B1HF@_$J[M+*YU2#7Q;Z/
M?Z*;OPY`EM:!)1-:W(FEO(I)(XXW87[XF9O)$7TA^P9?S:A!8M/JEUK;1_#K
MPS`NHW4PFGU!([G68TGDD&`[R*JN7``8L2.M>.C0]).@ZUILG[#'Q_N+3Q#I
MUEI5\+CQ'X8FD>VLQ']F1)'\1EXBABB;=&59FC1F+,H(W/AK^U3XQ\!?&C6M
M.T?]D?XZV6GZ;X1T'3K72X-0\(*UC;PSZJL777-FP@E5`8M^Z;<%&TLXZ0Y%
MW\NR5OE9ROUE.;=GO$59:_UNWYZW2MTC"*\E]J45\X_\-P_$;_HT?]H3_P`&
M?@W_`.7U'_#</Q&_Z-'_`&A/_!GX-_\`E]2&?0'BG5)-#\,ZC>Q1^9)9VLLZ
M(?XBJ%@/QQ7P#^S,FJ:]+X,_X22TU;PGX@\&7>E:GY-GX^U#7+75;S5+W2Q<
MW,DLRQ"9)+6Z51;-%Y5NT[^6,^6X]]?]M[XBR(5;]D?]H-E88(.I>#,$?^#Z
MO*/":V/@:X\+S:7^PU\?+63P9>W.HZ.W]O>%7^R3W&SS6.[Q$?,!\N/:LFY4
M\M-H7:,9*$E652^FFG_@7ZM/UBO57*2=/DM_6G^37I)]K/ZF_9-_Y-8^&?\`
MV*FE_P#I)%7H%?'7[,W[:?Q"TO\`9O\`A_:P_LI_'S4(;?PUIT275OJ/A`0W
M*K:Q@2('UQ7VL!D;E5L$9`/%=O\`\-P_$;_HT?\`:$_\&?@W_P"7U:D'T=17
MSC_PW#\1O^C1_P!H3_P9^#?_`)?4?\-P_$;_`*-'_:$_\&?@W_Y?4`>G?M+_
M`/).M-_[&OPW_P"GRQKT"OCK]H']M/XA:CX#L(Y?V4_CY8JOB70)1)/J/A`J
MS)K%FZQC9KC'<[*$7(V[G&XJN6';_P##</Q&_P"C1_VA/_!GX-_^7U`'T=17
MSC_PW#\1O^C1_P!H3_P9^#?_`)?4?\-P_$;_`*-'_:$_\&?@W_Y?4`?1U>?^
M(_\`DZ?P;_V*FO?^E>C5YC_PW#\1O^C1_P!H3_P9^#?_`)?5Q&O?MI_$*3]I
M#PG=']E/X^)-#X:UJ);5M1\(>=,K76DDR*1KFS:A10VY@V94P&&XJ`?8M%?.
M/_#</Q&_Z-'_`&A/_!GX-_\`E]1_PW#\1O\`HT?]H3_P9^#?_E]0!]'45\X_
M\-P_$;_HT?\`:$_\&?@W_P"7U'_#</Q&_P"C1_VA/_!GX-_^7U`'IW[2_P#R
M3K3?^QK\-_\`I\L:]`KXZ_:!_;3^(6H^`[".7]E/X^6*KXET"423ZCX0*LR:
MQ9NL8V:XQW.RA%R-NYQN*KEAV_\`PW#\1O\`HT?]H3_P9^#?_E]0!]'45\X_
M\-P_$;_HT?\`:$_\&?@W_P"7U'_#</Q&_P"C1_VA/_!GX-_^7U`'T=7G_B/_
M`).G\&_]BIKW_I7HU>8_\-P_$;_HT?\`:$_\&?@W_P"7U<1KW[:?Q"D_:0\)
MW1_93^/B30^&M:B6U;4?"'G3*UUI),BD:YLVH44-N8-F5,!AN*@'V+17SC_P
MW#\1O^C1_P!H3_P9^#?_`)?4?\-P_$;_`*-'_:$_\&?@W_Y?4`?1U%?./_#<
M/Q&_Z-'_`&A/_!GX-_\`E]1_PW#\1O\`HT?]H3_P9^#?_E]0!>_8W_Y.*_:Q
M_P"RJV/_`*A'A2OH"O@/]E/]L7Q]I/QW_:8N(/V7_CIJ4NJ?$FSN;BWMM0\)
MB32I!X/\-1"WG,FM*ID*1),#$TB>7<1@N)!)&GMW_#</Q&_Z-'_:$_\`!GX-
M_P#E]0!]'45\X_\`#</Q&_Z-'_:$_P#!GX-_^7U'_#</Q&_Z-'_:$_\`!GX-
M_P#E]0!]'5\__P#!)W_E%E^S3_V2KPO_`.FBUJC_`,-P_$;_`*-'_:$_\&?@
MW_Y?5XC_`,$S_P!L7Q]X8_X)P?L_:;9_LO\`QT\06>G_``V\.VT&J6&H>$UM
M-2C32[95N(1/K4<PCD`#J)8T?:PW(K94`'WY17SC_P`-P_$;_HT?]H3_`,&?
M@W_Y?4?\-P_$;_HT?]H3_P`&?@W_`.7U`'T=7S__`,%+/^3=?#G_`&57X<?^
MIOH54?\`AN'XC?\`1H_[0G_@S\&__+ZO$?\`@H%^V+X^\0_`C0;>Z_9?^.FB
M11_$GP%<K<7NH>$VCDDA\8:-*EN!#K4C>9,Z+#&2H022H9'CCWR*`??E%?./
M_#</Q&_Z-'_:$_\`!GX-_P#E]1_PW#\1O^C1_P!H3_P9^#?_`)?4`?1U%?./
M_#</Q&_Z-'_:$_\`!GX-_P#E]1_PW#\1O^C1_P!H3_P9^#?_`)?4`7OB-_RE
M-^#?_9*O'G_IW\&5]`5\!^/?VQ?'UQ_P4?\`A3J3?LO_`!TAO+3X;>-+:+2W
MU#PG]KO(Y=4\*,]Q&1K1A$<1A1'#R*Y:YBV(ZB1H_;O^&X?B-_T:/^T)_P"#
M/P;_`/+Z@#Z.HKYQ_P"&X?B-_P!&C_M"?^#/P;_\OJ/^&X?B-_T:/^T)_P"#
M/P;_`/+Z@#Z.KX__`."4'_)1?VPO^S@-5_\`3'H==E_PW#\1O^C1_P!H3_P9
M^#?_`)?5\M?\$T?VM_'7ACQW^U1)9_LU?&OQ`VK?&[4KZYCL+_PLK:1*VCZ,
MAM)_.UB,&90BN3"9(MLJ8D+!U4`_3.BOG'_AN'XC?]&C_M"?^#/P;_\`+ZC_
M`(;A^(W_`$:/^T)_X,_!O_R^H`^CJ\__`&LO^36/B9_V*FJ?^DDM>8_\-P_$
M;_HT?]H3_P`&?@W_`.7U<1^TS^VG\0M4_9O^(%K-^RG\?-/AN/#6HQ/=7&H^
M$##;*UK(#(X37&?:H.3M5FP#@$\4`>B_\$G?^467[-/_`&2KPO\`^FBUKZ`K
MYL_X)2Z_=0_\$N?V;471=2E5?A9X8`=7@VN/[)M>1F0'!]P#7TA;RM-!&[1M
M$S*"4;&Y#Z'!(R/8D53BT`^BBBI`JZY_R!;S_K@__H)KYG^*/QD\:>`OB)HN
MDZ-K$6CZ??:!K$^E6MUHCSVWB35E^V,EJ+W_`%<$\7EPRI`3ON(S<%01`Y7Z
M4\3W<=AX:U">:18X8;:221V.%10I))^@KQ5?`MI\2/%7A'7IO'TUOX;T.X>\
MG\-K#`]KJ=S'/-);7!E8>;&T;.&Q&0'V(&R`*V49.GIW_1_TEW[;K&4K2?>V
MGWK[O-]N^SWOV6?C[<?M'2^,->M&AD\'Q7UC#X<N(UXO[>72K*\DG#?Q#S;I
MX_8P-7K5>5_LQ_#7P=^RM\%-)\"^']6@DT?1'N/LGF,JM%%+<23+%QQMC601
MKWVHM=]_PG>C?]!*S_[^"IE&[O"+2[/7U_$TBVE:33\TK771VN]6M]=]C6HK
M)_X3O1O^@E9_]_!1_P`)WHW_`$$K/_OX*GDEV'S(UJ*R?^$[T;_H)6?_`'\%
M'_"=Z-_T$K/_`+^"CDEV#F1K45D_\)WHW_02L_\`OX*/^$[T;_H)6?\`W\%'
M)+L',C6HK)_X3O1O^@E9_P#?P4?\)WHW_02L_P#OX*.278.9&M163_PG>C?]
M!*S_`._@H_X3O1O^@E9_]_!1R2[!S(N:/_QZ/_UWF_\`1C5:K!TOQQH\=LP;
M4K-3YTIYD'0R,15C_A.]&_Z"5G_W\%.4)7V%&2L:U>?_`+67_)K'Q,_[%35/
M_226NJ_X3O1O^@E9_P#?P5YS^V%\2_#^D_LD?%*ZNM8T^"VM?"&K2RR/*`L:
M+93%F)]``32Y)=A\R/7**^<?^'O?[+__`$7CX9_^#N+_`!H_X>]_LO\`_1>/
MAG_X.XO\:D9[A\0/BGX9^%%EI]QXH\1:'X;M]8U&#2+"75+Z*S2]O9VVP6T9
MD8!YI&X2-<LQX`-?&7Q__;Z\=_L^CX9_\)1XH\!^']0U36]2M]1LI5VQ>*)(
MM?M=/72M/DEVLTR6UQ+*I"^;)]F4E`K.4];E_P""NG[+LZ@-\=?ABVT[AG6H
M3@]CUKYW\._M+_`272=+TGQ=^VKX1\8>'[7Q)<>([_3Y5TFQ&JL\\=W#`\D"
M*Z1Q72-+A"/,#F-\H`*F2DTU'1]'TVT];/6VSM9JUTZTM=]UIU:5[KY[=&KW
M36Z]>_9M^*GC[XE7_P`/S\1-1T;5-7_X2VWU2TETRU-O%;VM]X2O;I;8@_>,
M,LDT8D/+HL;$*Q*CZZK\X_@[^U]^S-^S.?A_IL/[3'A/QM)#XK^T7.IZGK4!
MFM+*#P]>V%K"=IP$C1(4W'YGDD9V)>1B?H[_`(>]_LO_`/1>/AG_`.#N+_&M
MJDHN3<-%T79=$][M+1N[N[N[O<B-TK/?J^C?5KLF]4NBTLMCZ.KAOVF/$?B;
MP?\``'Q;JW@]M+C\0Z9ILMU:R:B&-O"$&Z1RJ@EF6,.RH<*SA58JI+#RK_A[
MW^R__P!%X^&?_@[B_P`:X_X_?\%+_P!F_P",OP:\1>%=+_:;^'OA&\UZT:R_
MM:VU"SNY;6-R!)MCF#1L6CW)R.-^1R`:S+IVYE?8P?BG^W)XPUO]JOQK\.?#
M'B.;PQJEA=Z9X7T:"_\`!MS-IL\UPVDRW6J)J+JMO--!%J106*.2=B.Q522/
M8OV0/&^L?$?Q(VM>(6M&\07W@#PV=4>U4K;R7:W.LK,T8/(1I%8J#R`17R%X
MB^)'[-/B;Q%?:W<?MH>'UURY%GJ4%W%>Z?&MGKD`TU6U58P-A:5-*MD:W(\G
M:TP"_O7SZ?\``'_@HS^R_P#!3Q[=:':_'CP'=:3H_@OP_I-O?W>NQR27TEO/
MJOFL[D_-*?,1W/7,N>]4K<G*OGYZ+;M:7._.,H=N6.<;_:_K?SUNN5;?$I/9
MWE]T45\X_P##WO\`9?\`^B\?#/\`\'<7^-'_``][_9?_`.B\?#/_`,'<7^-2
M4?1DQ<1-Y>WS,';NZ9[9KXS^"W[37Q.\<:SH-O+XJAN(?#^MK'KPU'PE)H]_
MK%O=:C;64,#VDVV:Q>'SII`73=-&MNX&R8-7>7G_``5R_9?O+26'_A?7PWC\
MU"FZ/78E9<C&00<@^]>`^%_VE_V<]+\3^'=<U;]L3PGKFL6=^;[Q%<R76GP?
M\)6(WMGLXY5C4"%;=K.`@P[2^)-V?,?.5I^VC+[/7_AO)V;[JZ\GI[OLVNO3
M]?O5UY.WJOM#]DW_`)-8^&?_`&*FE_\`I)%7H%?'?[,W_!6/]FGP]^S?\/M/
MOOCA\-[6]L?#6G6]Q#)K,2O#(EK&K*PSP0001[5VW_#WO]E__HO'PS_\'<7^
M-:F9]'45\X_\/>_V7_\`HO'PS_\`!W%_C1_P][_9?_Z+Q\,__!W%_C0!Z=^T
MO_R3K3?^QK\-_P#I\L:]`KX[_:"_X*Q_LTZYX#L(;/XX?#>YFC\2Z!<,D>LQ
M,1'%K%G)(W7HJ(S$]@I-=M_P][_9?_Z+Q\,__!W%_C0!]'45\X_\/>_V7_\`
MHO'PS_\`!W%_C1_P][_9?_Z+Q\,__!W%_C0!]'5Y_P"(_P#DZ?P;_P!BIKW_
M`*5Z-7F/_#WO]E__`*+Q\,__``=Q?XUQ.O?\%8_V:9_VD/">H)\</ANUE:^&
MM:MY9AK,6R.22ZTED4G/5A%(0.^P^E`'V)17SC_P][_9?_Z+Q\,__!W%_C1_
MP][_`&7_`/HO'PS_`/!W%_C0!]'45\X_\/>_V7_^B\?#/_P=Q?XT?\/>_P!E
M_P#Z+Q\,_P#P=Q?XT`>G?M+_`/).M-_[&OPW_P"GRQKT"OCO]H+_`(*Q_LTZ
MYX#L(;/XX?#>YFC\2Z!<,D>LQ,1'%K%G)(W7HJ(S$]@I-=M_P][_`&7_`/HO
M'PS_`/!W%_C0!]'45\X_\/>_V7_^B\?#/_P=Q?XT?\/>_P!E_P#Z+Q\,_P#P
M=Q?XT`?1U>?^(_\`DZ?P;_V*FO?^E>C5YC_P][_9?_Z+Q\,__!W%_C7$Z]_P
M5C_9IG_:0\)Z@GQP^&[65KX:UJWEF&LQ;(Y)+K2612<]6$4A`[[#Z4`?8E%?
M./\`P][_`&7_`/HO'PS_`/!W%_C1_P`/>_V7_P#HO'PS_P#!W%_C0!]'45\X
M_P##WO\`9?\`^B\?#/\`\'<7^-'_``][_9?_`.B\?#/_`,'<7^-`%[]C?_DX
MK]K'_LJMC_ZA'A2OH"O@/]E+_@J7^SGX:^._[3%[J'QH^'EG:>(?B39ZAIDL
MNL1*M];KX/\`#5LTL9S\RB:WGCR/XHF':O;O^'O?[+__`$7CX9_^#N+_`!H`
M^CJ*^<?^'O?[+_\`T7CX9_\`@[B_QH_X>]_LO_\`1>/AG_X.XO\`&@#Z.KY_
M_P""3O\`RBR_9I_[)5X7_P#31:U1_P"'O?[+_P#T7CX9_P#@[B_QKQ'_`()G
M?\%2_P!G/X>_\$X/V?M`USXT?#S2]:T/X;>'-/U"RN=8BCFL[B+2[:.2)U)R
MK*ZLI!Z$&@#[\HKYQ_X>]_LO_P#1>/AG_P"#N+_&C_A[W^R__P!%X^&?_@[B
M_P`:`/HZOG__`(*6?\FZ^'/^RJ_#C_U-]"JC_P`/>_V7_P#HO'PS_P#!W%_C
M7B/_``4"_P""I?[.?CCX$:#9:/\`&CX>:E=P_$GP%J$D4&L1.R6]MXPT:YN)
M2`?NQPQ22,>RHQ[4`??E%?./_#WO]E__`*+Q\,__``=Q?XT?\/>_V7_^B\?#
M/_P=Q?XT`?1U%?./_#WO]E__`*+Q\,__``=Q?XT?\/>_V7_^B\?#/_P=Q?XT
M`7OB-_RE-^#?_9*O'G_IW\&5]`5\!^/?^"I?[.=[_P`%'_A3K\/QH^'DFBZ;
M\-O&FGW5ZNL1&&WN+C5/"<D$3-G`:1+:X91W$+^AKV[_`(>]_LO_`/1>/AG_
M`.#N+_&@#Z.HKYQ_X>]_LO\`_1>/AG_X.XO\:/\`A[W^R_\`]%X^&?\`X.XO
M\:`/HZOC_P#X)0?\E%_;"_[.`U7_`-,>AUV7_#WO]E__`*+Q\,__``=Q?XU\
MM_\`!-'_`(*:?L^_#[QW^U1-KGQA\`Z7#XD^-VI:QI;W.K1QB_LWT?1HUGCR
M?FC+Q2*&'&48=J`/TRHKYQ_X>]_LO_\`1>/AG_X.XO\`&C_A[W^R_P#]%X^&
M?_@[B_QH`^CJ\_\`VLO^36/B9_V*FJ?^DDM>8_\`#WO]E_\`Z+Q\,_\`P=Q?
MXUQ/[3/_``5C_9I\0_LW_$'3['XX?#>ZO;[PUJ-O;PQZS$SS2/:R*JJ,\DD@
M`>]`'HG_``2=_P"467[-/_9*O"__`*:+6OH"OFW_`()2^--)M?\`@ES^S;%)
MJ%JDD?PL\,*RF094C2;4$&OI"WN$NH$EC97CD4,K#HP/((IN+6X7'4444@*N
MN?\`(%O/^N#_`/H)KPOQ]^T[K7P7MK>TT;P+?>,+'3=/O=9U^YMK];>32(#/
M.ML5C*,9O,DBE#8*^6D;/\WW:]TUS_D"WG_7!_\`T$UXM#X7\>1_$S2+SP[I
MOA74O!_B:U.E^)IM3O)8KK2HK:\NI5:WA1"MR9TN9HB&DB$1"29E&8CM&_)I
MWZ[;/=]$9_;^7SW6WGV_)['?_"WXV6/Q:\6>,M/TR%FM?!]]:Z?)>;PT=W+/
M86U]\@QT6*[@YR<ECZ5VE>._L(?LZ:E^RU^S;H_A'6KV/5M<L9)4O-15R[ZB
MD;?9[661BHS)]CAM5;C@H1D@9/L59RY+_N[V\]_/\?P*CS6M.U_+5.W572WW
M\KV"BBBI*"BBB@`HHHH`****`"BBB@"KH_\`QZ/_`-=YO_1C5:JKH_\`QZ/_
M`-=YO_1C5:IRW%'8*\__`&LO^36/B9_V*FJ?^DDM>@5Y_P#M9?\`)K'Q,_[%
M35/_`$DEI#/0****`"D=MB%L%L#.!U-+7._$KX8Z5\4M,T^WU6/4)%TC48-6
MM%M-4NM/)N8&W1[VMY$,D>?O1/NC<<,C#BE+8#Q'P-^T/??'SQUX5M]8\*W'
M@W7O!?Q'GT6_TZ6\6[QO\+W=]#()%51\UO>0EEQ\C[UR=N3](5\M_`S1/B1H
ML?PZ?XK>%O!_AOQEJ7Q`O;^^E\.Z[+JUMJCR:%J9\XM);0/$$`6%(SYI6*"/
M,C'-?4E6[65NROZV5_O=_P#@!I=V[O\`K^OO>[****D#A_VB/B_<_!'X8S:U
MI^AS>)M8GO;33-,TJ.X%M]NN[JXCMX4:4JPC0-(&=RK;45C@XQ7&_LV?$]?C
M3\1KSQ8NGW&D-XB\!>&KZ2PN&#36$CW&L%X'(X+1MN0D=2IKH/VKO`_BCQQ\
M)X_^$*M]'O/%.AZQIFMZ?9ZK<O:V=^;6\AG>WDF1':+S(DD02!'V,RL4<`J>
M5_91^'^I?"SQG<>']:N+.[UK3/`?AR/49K1&2WDN3=:RTQB5B6$?F%MH8DA<
M9)/-$?A?>_X65K='=\U^UH[7U;_KUN[W]%RVVO=[VT]THHHH$%>8_%[]H6\^
M&GQ7\)^&['PVVN6NLR1G6+Y;Y8/[#AFN8K2WE\LH3,9+B8+M!7:J.V3C!].K
MQGXX?"?Q=XE^.WA+5O#MIHEQH5U]FM_$=Q>WSPW&FQ6=_!?P/;0K$PG:1DEB
M96>,('1P6VE'B3ESPMM?7TL[?^363\F_4K3EEWMI]ZO^%VO.QTW[)O\`R:Q\
M,_\`L5-+_P#22*O0*\__`&3?^36/AG_V*FE_^DD5>@59(4444`>?_M+_`/).
MM-_[&OPW_P"GRQKT"O/_`-I?_DG6F_\`8U^&_P#T^6->@4`%%%%`!7G_`(C_
M`.3I_!O_`&*FO?\`I7HU>@5Y_P"(_P#DZ?P;_P!BIKW_`*5Z-0!Z!1110`44
M44`>?_M+_P#).M-_[&OPW_Z?+&O0*\__`&E_^2=:;_V-?AO_`-/EC7H%`!11
M10`5Y_XC_P"3I_!O_8J:]_Z5Z-7H%>?^(_\`DZ?P;_V*FO?^E>C4`>@4444`
M%%%%`'S_`/L;_P#)Q7[6/_95;'_U"/"E?0%?/_[&_P#R<5^UC_V56Q_]0CPI
M7T!0`4444`%?/_\`P2=_Y19?LT_]DJ\+_P#IHM:^@*^?_P#@D[_RBR_9I_[)
M5X7_`/31:T`?0%%%%`!7S_\`\%+/^3=?#G_95?AQ_P"IOH5?0%?/_P#P4L_Y
M-U\.?]E5^''_`*F^A4`?0%%%%`!1110!\_\`Q&_Y2F_!O_LE7CS_`-._@ROH
M"OG_`.(W_*4WX-_]DJ\>?^G?P97T!0`4444`%?'_`/P2@_Y*+^V%_P!G`:K_
M`.F/0Z^P*^/_`/@E!_R47]L+_LX#5?\`TQZ'0!]@4444`%>?_M9?\FL?$S_L
M5-4_])):]`KS_P#:R_Y-8^)G_8J:I_Z22T`>?_\`!)W_`)19?LT_]DJ\+_\`
MIHM:^@*^?_\`@D[_`,HLOV:?^R5>%_\`TT6M?0%`!1110!1\3P&Z\-:A$))(
M3);2*)(SADRI&1G(R/I7,_#7PO)_PAUN/[6U;Y99USYB<XF<9/R=3UKJM<_Y
M`MY_UP?_`-!-9?PU_P"10A_Z[7'_`*/DK:,FJ6G?]#)K]Y\BQ_PB\G_07U;_
M`+^)_P#$4?\`"+R?]!?5O^_B?_$5K45GSLTY49/_``B\G_07U;_OXG_Q%'_"
M+R?]!?5O^_B?_$5K44<[#E1D_P#"+R?]!?5O^_B?_$4?\(O)_P!!?5O^_B?_
M`!%:U%'.PY49/_"+R?\`07U;_OXG_P`11_PB\G_07U;_`+^)_P#$5K44<[#E
M1D_\(O)_T%]6_P"_B?\`Q%'_``B\G_07U;_OXG_Q%:U%'.PY49/_``B\G_07
MU;_OXG_Q%'_"+R?]!?5O^_B?_$5K44<[#E1@Z7X9D>V;_B;:HO[Z48#I_P`]
M&_V*L?\`"+R?]!?5O^_B?_$5<T?_`(]'_P"N\W_HQJM4Y3=Q1BK&3_PB\G_0
M7U;_`+^)_P#$5SOQ@^$,?Q*^$OBCPY>:]XAM;/Q!I%WIL\UK/$D\*30O&S1L
M8R`X#$@D$`@<'I7<55US_D"WG_7!_P#T$T*3N'*CY[_X=^ZW_P!'(_M'?^#G
M2O\`Y74?\._=;_Z.1_:._P#!SI7_`,KJ^CJ*@H^<?^'?NM_]'(_M'?\`@YTK
M_P"5U'_#OW6_^CD?VCO_``<Z5_\`*ZOHZB@#Y>U__@G%J&JZKH<]S^T3^T5-
M-IMZUS:.VLZ5FWE-O/$77_B7]3')(O.>'/?!K3_X=^ZW_P!'(_M'?^#G2O\`
MY75]":A_Q]V/_7<_^BWJU3$?./\`P[]UO_HY']H[_P`'.E?_`"NH_P"'?NM_
M]'(_M'?^#G2O_E=7T=12&?./_#OW6_\`HY']H[_P<Z5_\KJS+3_@G%J$'C/4
M-13]HG]HI;^ZLK:VFG&LZ5NDBC>X:-#_`,2_&%:64CC^,^V/J&JL/_(:N/\`
MKA%_Z%)3`^>_^'?NM_\`1R/[1W_@YTK_`.5U'_#OW6_^CD?VCO\`P<Z5_P#*
MZOHZBD!\X_\`#OW6_P#HY']H[_P<Z5_\KJ/^'?NM_P#1R/[1W_@YTK_Y75]'
M44`?+W@C_@G%J'AKP9I&G:?^T3^T59V&GV4-M;01ZSI6V&)$5409T\G`4`<G
MM6G_`,._=;_Z.1_:._\`!SI7_P`KJ^A-#_Y`MG_UP3_T$5:IO<2V/G'_`(=^
MZW_T<C^T=_X.=*_^5U'_``[]UO\`Z.1_:._\'.E?_*ZOHZBD,^7O%W_!.+4-
M?TJ&"^_:)_:*NH8[VTN51]9TK"RQ7$<L3\:?U61$8>ZCJ.*T_P#AW[K?_1R/
M[1W_`(.=*_\`E=7T)K'_`!Z)_P!=X?\`T8M6J?0#YQ_X=^ZW_P!'(_M'?^#G
M2O\`Y74?\._=;_Z.1_:._P#!SI7_`,KJ^CJ*0'SC_P`._=;_`.CD?VCO_!SI
M7_RNK,N_^"<6H3^,]/U%_P!HG]HIK^ULKFVAG.LZ5NCBD>W:1!_Q+\89HHB>
M/X![Y^H:JS?\AJW_`.N$O_H4=-"9\]_\._=;_P"CD?VCO_!SI7_RNH_X=^ZW
M_P!'(_M'?^#G2O\`Y75]'44AGSC_`,._=;_Z.1_:._\`!SI7_P`KJ/\`AW[K
M?_1R/[1W_@YTK_Y75]'44`?+WB[_`()Q:AK^E0P7W[1/[15U#'>VERJ/K.E8
M66*XCEB?C3^JR(C#W4=1Q6G_`,._=;_Z.1_:._\`!SI7_P`KJ^A-8_X]$_Z[
MP_\`HQ:M4^@'SC_P[]UO_HY']H[_`,'.E?\`RNH_X=^ZW_T<C^T=_P"#G2O_
M`)75]'44@/G'_AW[K?\`T<C^T=_X.=*_^5U9EW_P3BU"?QGI^HO^T3^T4U_:
MV5S;0SG6=*W1Q2/;M(@_XE^,,T41/'\`]\_4-59O^0U;_P#7"7_T*.FA,^>_
M^'?NM_\`1R/[1W_@YTK_`.5U'_#OW6_^CD?VCO\`P<Z5_P#*ZOHZBD,^<?\`
MAW[K?_1R/[1W_@YTK_Y74?\`#OW6_P#HY']H[_P<Z5_\KJ^CJ*`/DOP#_P`$
MR)/"WBKQM?:;^T#^T-97GB36H]1U6:/6=+W7]RNG65JLKYT\C<(+:WCXP-L2
M\9R3TW_#OW6_^CD?VCO_``<Z5_\`*ZO>M`_Y"VN?]?J_^DT%:E5+<2/G'_AW
M[K?_`$<C^T=_X.=*_P#E=1_P[]UO_HY']H[_`,'.E?\`RNKZ.HJ1GSC_`,._
M=;_Z.1_:._\`!SI7_P`KJYGX)?\`!,B3X;?!CPCX=\/_`+0/[0VDZ#H&BV>G
M:;8P:SI?E65M#`D<42;M/+;41549).!R37UI67X(_P"1+T?_`*\H?_1:U707
M4\%_X=^ZW_T<C^T=_P"#G2O_`)74?\._=;_Z.1_:._\`!SI7_P`KJ^CJ*D9\
MX_\`#OW6_P#HY']H[_P<Z5_\KJYGXN?\$R)/'WA6TL=:_:!_:&U.S@UK2=1C
MAFUG2]J7-KJ-M=6THVZ>#NBGABD7MNC&01D'ZTK+\7_\@F'_`*_;3_TICJH[
MH3V/!?\`AW[K?_1R/[1W_@YTK_Y74?\`#OW6_P#HY']H[_P<Z5_\KJ^CJ*D9
M\X_\._=;_P"CD?VCO_!SI7_RNH_X=^ZW_P!'(_M'?^#G2O\`Y75]'44`?)>K
M?\$R)+[XSZ!XBF_:!_:&DU[2]%U+3K.^.LZ7YMM;7,^GR7$2_P#$OV[9'M;9
MCD$YA7!'.>F_X=^ZW_T<C^T=_P"#G2O_`)75[U=_\CII_P#UY7/_`*,MZU*J
M6R$CYQ_X=^ZW_P!'(_M'?^#G2O\`Y74?\._=;_Z.1_:._P#!SI7_`,KJ^CJ*
MD9\X_P##OW6_^CD?VCO_``<Z5_\`*ZOG/6O^#<7X4_$7XE^,O$6I?%K]I!=:
MU[5S?:E<6?C6.R^WW#V\&Z:1(;9$+D!5R%'"*.U?HU67H'_(6US_`*_5_P#2
M:"JCLQ'Y[_\`$,K\'_\`HL'[47_AQ7_^,T?\0ROP?_Z+!^U%_P"'%?\`^,U^
MCE%2,_./_B&5^#__`$6#]J+_`,.*_P#\9J.\_P"#8KX,ZA:2V]Q\7/VGIX)T
M,<D<GQ"9DD4C!4@P8((X(-?I!10!YG^S3\!]/^"'[./P_P#!>AZMKRZ+X0\-
MZ=HFGB>>-Y1;VUK'#'N;8,ML1<G`R>U>E6\7D0)'O>38H7<_WFQW/O6;X(_Y
M$O1_^O*'_P!%K6I5S>MB8[7"BBBH**/B?SO^$:U#R/+\_P"S2>7YF=N[:<9Q
MSC/I7,_#7^W/^$.M_P#D$Y\V?=Q)U\Y\X]LYKJM<_P"0+>?]<'_]!-?&/[1G
MB/5M-_:;^%,.CZEXXT[4DN[5[6:SU>ZMO#D<+ZWMOXM1MTE%O/)/8K/%;B:*
M0B8KY9C?#5TT?>4:;LN:5KOIHS&J^6]1]%^J7ZGV%C7?^H3^4E&-=_ZA/Y25
M\4?!S_@HO\8OBU\$M-\;WW@_3?`N@ZYKFGSP:OKOAF]^PZ?HMU;33#S-EYNF
M<,D,7VQ-D1>YC_<`$X]=^'O[5WC34OC3#H^MVOA=O#_B35IUT1[.">.ZLK&%
MM1B87;/*RM,TEG$P*JBA7==I*[JPYO?]FU[VNGHKO\/R9M4A[.,I2>D=_O:_
M-?BCWK&N_P#4)_*2C&N_]0G\I*^0?V7/V\?BO^U+X6\-WMC8_#W19-=FT:0M
M/9W=Q']G?P]8ZQJ)4+.I\PMJ$4,`R=HC=W\SH-#]F?\`:9^*G[=/[(7Q"U:^
M\,WG@6Z\0:2MSX/G:VGT-I8+RW=HH5NC/(7E7Y%^V0^4,S(R1H5JJZE2<XM:
MQM?YJZ^]?J:2P\HRY9=[;KS7Z?D?5V-=_P"H3^4E&-=_ZA/Y25\W^$_VG[[X
M;?#?2]*T?3-4:#2].6".'Q1?W%]JT<\<.NF2">YED:2=DDTE$\V1F=U+LQ+'
M(\[U3]OOXZ>%OB'?>$-2\/\`PS;6;JY.F:3<P)=_9_M"ZQX?M'FF4S%C&+?Q
M#$-BL&,MC*VX+,B1W1ISJSY*2ON^G3_AUM<S]F^:,.LK67W_`))-N_1,^U,:
M[_U"?RDHQKO_`%"?RDKXE\2?\%!/C9X%_9Y_X2#5M(\#W?BS?8ZE'8:+H%_J
M$=SISP7YN$$?VQ&217TZ67SBY2.)PIC=E+'U#6/VP?B!H?QBT?09-#\.7&G>
M--;N],T!HHIQ+`ECJ]I:7?VA_,VM(UG+=7"!%7'V5L[AFLJ4E4:4+.[LGLMK
MK>V]TEYZ!5BZ>D^U^^BW>G1)-OLCZ*QKO_4)_*2C&N_]0G\I*UJ*.;R)Y3)Q
MKO\`U"?RDHQKO_4)_*2M:BCF\@Y3!TO^V_LS;?[+QYTO42=?,;-6,:[_`-0G
M\I*N:/\`\>C_`/7>;_T8U6J<I:@EH9.-=_ZA/Y257UC^V_[(NMW]E[?)?.!)
MG&#6]577/^0+>?\`7!__`$$T1EJ'*4\:[_U"?RDHQKO_`%"?RDK6HI<WD'*9
M.-=_ZA/Y248UW_J$_E)6M11S>0<I@WW]M_:;/=_9>?..W`DZ^6_7]:L8UW_J
M$_E)5S4/^/NQ_P"NY_\`1;U:I\P6,G&N_P#4)_*2C&N_]0G\I*UJ*7-Y!RF3
MC7?^H3^4E5XO[;_M>?\`Y!>[R8\\28QE\?UK>JK#_P`AJX_ZX1?^A24U(.4I
MXUW_`*A/Y248UW_J$_E)6M12YO(.4R<:[_U"?RDHQKO_`%"?RDK6HHYO(.4P
M='_MO^R+7;_9>WR4QD29Q@58QKO_`%"?RDJYH?\`R!;/_K@G_H(JU3E+4$M#
M)QKO_4)_*2C&N_\`4)_*2M:BES>0<I@ZI_;?V9=W]EX\Z+H).OF+BK&-=_ZA
M/Y25<UC_`(]$_P"N\/\`Z,6K5/FT#E,G&N_]0G\I*,:[_P!0G\I*UJ*7-Y!R
MF3C7?^H3^4E5Y?[;_M>#_D%[O)DQQ)C&4S_2MZJLW_(:M_\`KA+_`.A1TU(&
MBGC7?^H3^4E&-=_ZA/Y25K44N;R#E,G&N_\`4)_*2C&N_P#4)_*2M:BCF\@Y
M3!U3^V_LR[O[+QYT702=?,7%6,:[_P!0G\I*N:Q_QZ)_UWA_]&+5JGS:!RF3
MC7?^H3^4E&-=_P"H3^4E:U%+F\@Y3)QKO_4)_*2J\O\`;?\`:\'_`""]WDR8
MXDQC*9_I6]56;_D-6_\`UPE_]"CIJ0-%/&N_]0G\I*,:[_U"?RDK6HI<WD'*
M9.-=_P"H3^4E&-=_ZA/Y25K44<WD'*<QHG]L_P!IZQL_LS=]L7?D/C/D0]/;
M&/QS6CC7?^H3^4E.T#_D+:Y_U^K_`.DT%:E5*6H1B9.-=_ZA/Y248UW_`*A/
MY25K45/-Y!RF3C7?^H3^4E9W@_\`MG_A$M+\K^S/+^R1;-X?=C8,9]ZZ>LOP
M1_R)>C_]>4/_`*+6JYO="VHW&N_]0G\I*,:[_P!0G\I*UJ*GF\@Y3)QKO_4)
M_*2L[Q3_`&S_`&9%YG]F;?MEKC:'SGSX\?AG&?:NGK+\7_\`()A_Z_;3_P!*
M8ZJ,O>02CH-QKO\`U"?RDHQKO_4)_*2M:BIYO(.4R<:[_P!0G\I*,:[_`-0G
M\I*UJ*.;R#E.8NO[9_X2VQS_`&9YGV2XVX#[<;X,Y]^GZUHXUW_J$_E)3KO_
M`)'33_\`KRN?_1EO6I52EH@2,G&N_P#4)_*2C&N_]0G\I*UJ*GF\@Y3)QKO_
M`%"?RDK.T3^V?[3UC9_9F[[8N_(?&?(AZ>V,?CFNGK+T#_D+:Y_U^K_Z3054
M9:,.4;C7?^H3^4E&-=_ZA/Y25K45/-Y!RF3C7?\`J$_E)1C7?^H3^4E:U%'-
MY!RG,>#_`.V?^$2TORO[,\O[)%LWA]V-@QGWKI;?S/(3S=OF;1OV?=SWQ[5F
M^"/^1+T?_KRA_P#1:UJ4ZCU81V"BBBH**/B><VOAK4)%CDF,=M(PCC`W/A2<
M#)`R>G)%>9Z7X"\/_$7PY:W6M>$]2OIUN(9E9B%*-::@;RW/RRC#1W"*^1U*
MX.5XKU#7/^0+>?\`7!__`$$UE_#7_D4(?^NUQ_Z/DK>,K4[^?Z,RDKSMY?JF
M>,P?L+_"VTTLZ?;^$/'=KIG]K+K*Z?;^+=5ALHYE!41)`M\(TM0I*_9%46^,
M#RL`"K^M?L<_#37[#QA;W/@OQ5Y?CK48M6U=HM>OH9'N(YGG4P.EV'M5\R21
MFCMS&CF63<I#L#[K162<5LOZT_R7W+L:RO*_,[WW_'_-_>SP^T_9"^&>E^#]
M)T&P\!Z[I.EZ'JEEK-A%IVIW-DUO<V=E%86Y#PW*N8UM8(HC$28W5?G5LDFU
MX0_9>\`^`_`7BOPOI/A#Q1:^'O&1?^T+`ZU>20P!E*[;,-='["B@_(MIY2QD
M*4"E5(]FHHE)3OS*]]_/9?DE]R[`I26S\_S_`,W][/"[3]CWX:V>K>';[_A"
M?%$USX5TR72-.:XUR]G"P2K.LAE5[HBXF(N;@>?,'F'GR8<;CG<UC]G_`,#:
M_P",H?$%YX'U*;6+>Y:[CN#.ZE96N-.N6;:)MO,VE:>V,8_T<#HSAO6**N%9
MP?-'1^3?75_B2HV:DMU_E;\FUZ-H\3^(/[)_PY^*/A.'0]8\#Z_)IL`@18[7
M5+FR<I";@I&9(;E':/\`TNX#(6*N)2'#``#<USX7Z?J7BKP7J%OH>HVD?@W6
M[W7XH_)21Y;FZMKN"0AS+\H/VV5R,'G:!@"O4**RM!1Y4M/Z_P`BG=OF>YD_
M\)1+_P!`?5O^^(__`(NC_A*)?^@/JW_?$?\`\76M15<R[",G_A*)?^@/JW_?
M$?\`\71_PE$O_0'U;_OB/_XNM:BCF78#`TOQ-*ELW_$IU5OWTIR$C[R-_MU9
M_P"$HE_Z`^K?]\1__%U<T?\`X]'_`.N\W_HQJM4Y25]A1V,G_A*)?^@/JW_?
M$?\`\75;6/$TLFDW2_V3JJ[H7&2D>!P?]NM^JNN?\@6\_P"N#_\`H)HC)7V#
M4I_\)1+_`-`?5O\`OB/_`.+H_P"$HE_Z`^K?]\1__%USO[37C76OAO\`LX>/
MO$7AM;.3Q%H7AW4-0TM;M"]NUU%;2/")%!!*;U7(!!(SR*\+\)_\%')?%OBW
MQ'=:+X7UKQEH]KH?AMM(T+0HK==;O]5U"&YO+F$-=3P6ZK%9_9G/F2Q[3%.,
MEMJE1DFVDMK?C?\`R^]KNBI1:CS/;_@Q7_MR^5WT9]+?\)1+_P!`?5O^^(__
M`(NC_A*)?^@/JW_?$?\`\77S7?\`_!5G0M:T+Q/?>#_AO\2?%]MX?TA+^&\A
MAT^RM-0NWTNVU5-/4W-W'*MQ]CN1,V^((HAE7>7"(_<?LZ?MBM\7/B7J'@W6
MO"WB3PWKD:ZG>6<M_#;):W<-I>I;S6Z-%/*S3VPN+-9FVB)FG'ER2;7"5%<S
M<8J[2O\`*S=_2RO]W=7*D)4TN=-7=MO*_P"7Z]G;U.]\32M<V?\`Q*=5&V8G
M!2/G]V_3Y_\`.*L_\)1+_P!`?5O^^(__`(NN0^`'B_Q-XW^'6GWOC"'1K?Q%
M'K6IV=W#I,DDMG!Y-S=0K'')(J/(%1%7S&1"Y!;8F[:,K]JCX^7WP!U7X7W$
M26K:-XF\:6WA[6WEC+/#;7-K=K&Z$$!2MT+4LQR!'YGU!)J-DUV6_=VWV^>Q
M*3]ZW2_X;V[[:=ST3_A*)?\`H#ZM_P!\1_\`Q='_``E$O_0'U;_OB/\`^+KY
MM^#/_!1Y=?\`!/A?5-=\,^(-4L_%VLW:_P!L:+:0G3_#FG7&L366C27PDG6<
MM<+Y,9-O'-M=9'D$48W5FS_\%39O&_PFTOQ%X1^$OQ(^S^([>2[L;S5!I4,5
MM8OI=Q?6FJ/&M\9&MI3;RJ$`\[]Q*3&/W?F)V7Q*VRUTM?O?;Y]GV9K&C.3:
M71M7Z75^WIZ[=U?ZD_X2B7_H#ZM_WQ'_`/%U6B\32C5IF_LG5>88QC9'D<O_
M`+?O^E>9>'/VA-8_:,^!/BR[\%*WP]\7>'[W^S+D^+[!)ETAO*M[H7,D$$Y#
MH]G<13I&9HVQ*BR>4X=5ZO\`9A^(&M?%CX&^"O%'B32_[#\0^(_"^EZGJ>G8
M(^PW,T/F2Q8/(VNS#!YXYYJ^1I2;C:W+_P"3)M:;[+^M;81ES1C-;/\`K^K7
M_%7ZO_A*)?\`H#ZM_P!\1_\`Q='_``E$O_0'U;_OB/\`^+KY1_;-_;>^('[/
M>@_M%7FEQ^&U7P+X8M]1\'&[MW?S;V.&.6]%P`X\Q5%U:LJKM.-^3W'H5]_P
M4)TJW7Q0UG\/_B+K4.AW7]G:3/96]@L?C&[348M,N8=/\V[0J8+V:.%WO!;1
MMNWQO)&#((?*HJ?1NW7?33UUT77IH;NC-)-]=ON3_5?CV9[9_P`)1+_T!]6_
M[XC_`/BZ/^$HE_Z`^K?]\1__`!=?*'Q._P""G/B31?'7@^W\._"'QYJVCZOK
M=A:GR#I<EUKT-YX;U'5?LUJK7R+%<P2VT(D:=EB*K)L=\@UZG\9/C_J^D^/?
M@S-X;UC3[?P_X[O56>TNM"NKDZK!*D3+B^0BWL&1'+KY^XW#[88QO.:<M&E;
M=I>EVTK]MF_344J;24NZ<EZ)M?FG_5SU/1_$TL>DVJ_V3JK;84&0D>#P/]NK
M/_"42_\`0'U;_OB/_P"+JYH?_(%L_P#K@G_H(KXGM?\`@I)XL\#:/\'+_P`;
M2>'+"SUS6?$1\9R6UE-(]OI=IHU]JUD]O&K,PD:".U+<.6(D55R1BHI2ERI:
MZOKTU=O\M_N84Z4Y+W?ZLF_R3_+JC[,_X2B7_H#ZM_WQ'_\`%T?\)1+_`-`?
M5O\`OB/_`.+KQ?3OV^[>:^\*6&H?"_XG:+K'B'4I-.U'3[V/2O-\*JLME&MQ
M>O'?/$8G.HV146KW$F)^44I($X/X$_\`!27Q#\3?VAK7P_KGPK\9>&="UCP_
MHU[').=.F_L&XO-1UFT$EY+%>-NAN&LK5(1"DDBM(QD6-<E9A:2NO^'=[67=
MW_7LP5.3C*7\JO\`*Z7YO^M#Z;U3Q-*]LO\`Q*=57]]$<E(^TB_[=6?^$HE_
MZ`^K?]\1_P#Q=>>:#\5=:\4?M)>*-!\[3V\*Z3:6<=HB0YN#>I,C7,AE#E3'
MB>*,)M#(]O+DG<`M_P#:_P#'OBKX:?LZ>(]8\#QZ;-XPB6WM](COXVDMGN9K
MF*%!(JD$KF3L141J0E351;._?HVOT8O9R]I[/KI^*3Z^IVG_``E$O_0'U;_O
MB/\`^+H_X2B7_H#ZM_WQ'_\`%U\LP_\`!274-,_:-\<:"GAO4O&VEKI'A>;P
M=H7AJ"#^VM6O-1@U6YNT:6ZN(;55C@T]I/WDD040R+N=W1#U7CG_`(*.VNCP
M>(CX;^&OQ`\6'1=.LK^RFMSIUI;Z\UQ_9SM;6QN+N.0310ZG;2-YR11G+*LC
M,K*+DK2Y+:VOUVWOZ:[[!*G*'Q::)_>DU^?Y]CWS_A*)?^@/JW_?$?\`\75:
M7Q-*=6A;^R=5XAD&-D>3RG^W[?K7C?[%_P"V/JW[1%[XKT?Q!X2US0-2T/7?
M$%I8W]Q%;)8:O;6&M7=B$@\NXEE,L"1VRS-(B(TDN8RZYVZ_[#'Q<U;XV?!#
M1=<\0>(H?$FO2"YCU"1/"5YX6>RE#1,;9[&[=YT9`P^=B!(I5U&UE)$US.*Z
M*^^CU:T^:WVV[H=:G*G)PEO%V?JO^&_K4]6_X2B7_H#ZM_WQ'_\`%T?\)1+_
M`-`?5O\`OB/_`.+K6KX=M?\`@I)XL\#:/\'+_P`;2>'+"SUS6?$1\9R6UE-(
M]OI=IHU]JUD]O&K,PD:".U+<.6(D55R1@@E)\J6NKZ]-7;_+?[F$*4Y?#Y_@
MF_R3_+JC[,_X2B7_`*`^K?\`?$?_`,71_P`)1+_T!]6_[XC_`/BZ\7T[]ONW
MFOO"EAJ'PO\`B=HNL>(=2DT[4=/O8]*\WPJJRV4:W%Z\=\\1B<ZC9%1:O<28
MGY12D@3@_@3_`,%)?$/Q-_:&M?#^N?"OQEX9T+6/#^C7L<DYTZ;^P;B\U'6;
M027DL5XVZ&X:RM4A$*22*TC&18UR5(6DKK_AW>UEW=_U[,%3DXRE_*K_`"NE
M^;_K0^F]4\32O;+_`,2G55_?1')2/M(O^W5G_A*)?^@/JW_?$?\`\77C/PW_
M`&CYOB1^UW\1O!C>($%EX2:U@M=#?PK>VTA9?LCS7:ZI(1;7*[[D1F"%2T?R
MLS9;:.R_:_\`'OBKX:?LZ>(]8\#QZ;-XPB6WM](COXVDMGN9KF*%!(JD$KF3
ML14QJ0=-5.C5^NW?]?\`@D\DN=PZWM\SM/\`A*)?^@/JW_?$?_Q='_"42_\`
M0'U;_OB/_P"+KY9A_P""DNH:9^T;XXT%/#>I>-M+72/"\W@[0O#4$']M:M>:
MC!JMS=HTMU<0VJK'!I[2?O)(@HAD7<[NB'JO'/\`P4=M='@\1'PW\-?B!XL.
MBZ=97]E-;G3K2WUYKC^SG:VMC<7<<@FBAU.VD;SDBC.659&9645)6ER6UM?K
MMO?TUWV'*G*'Q::)_>DU^?Y]CWS_`(2B7_H#ZM_WQ'_\75:7Q-*=6A;^R=5X
MAD&-D>3RG^W[?K7BW['?[8&N?M(OXPT/6/#&L^%]:T?6O$-EIFJ7=M;'3M2@
ML=:N[!1$L=R\KR6Z):K/O6-'>3]VSKDKT_[)'B?Q=XFT#5QXQ\5:#XTOM)UO
M4M)@UC2-#;1K>X2V>"&9/L[7%P0T5TES$6\P[O+S@472GR^3=[Z.SL[>C_X`
MZU&5-N,OLRY7ZZ_G9V]#TO\`X2B7_H#ZM_WQ'_\`%T?\)1+_`-`?5O\`OB/_
M`.+KS;]H+XU>(/A?\;?A9IM@NF#POKUW>+XEEN4)FA@"10V[1-N`4_:[FW#%
M@1L+=.M>)?LY_P#!4R36_A59WWC3PSKFK:G!>:S+K^I^'+*%=+\-64>MZEIV
MF?:!/<+,[W/V$Q#[.DQ$B%Y1!&RM0K.+DNC2>^E]K_Y[=-QJC-QYEMHOF[V_
M)Z;[=T?6W_"42_\`0'U;_OB/_P"+H_X2B7_H#ZM_WQ'_`/%U\M^*/^"HEQ>S
M7VGZ%\+_`!Q8WEEX>\1ZG?S:L+!7T*?3;*RO+=9[>.Z=W6Z@U"UD01DNOGQ*
MZHWFB+:_:G_;7U3P9^Q1'\2--:;X67TFJ_V9>#Q3HRZU/H<R3RP&":VL+ETD
M:2XC2'?%.R1B?S6)1&%3>VCCV[WUVTW^6^VFJ(Y;1YV]-=>FBOOM:W7;?LSW
MC1/$<D>IZPW]E:HWF7:L0$CRG[B$8/S]>,_0BM+_`(2B7_H#ZM_WQ'_\75?P
M)<W-Y'J$UY"EM>2SQ//"C^8L4AM8"RAOX@#D9[XKY9^*'[</C[0O''[1'A[1
M8_#7]I?#O6]&M/#"W4#_`+^U?2;74M2,N'_>.D+7!7;M`)B!]3K*+<W!*[2[
M^:6_;7?:VNPJ,7.#J+9*[OVNE^NVY]7?\)1+_P!`?5O^^(__`(NC_A*)?^@/
MJW_?$?\`\77B>N_\%"=+T?4->LH?AW\2=4O]/U'^S=%MK.#3F?Q>0]S$TMB6
MO%41++:RH6NC;X^5L>6P>N#_`.'ITNN076N:+\,O&NJ>$]/UVPM;>[M'TZ27
M7].N_#CZR;N!9+N,0B!"CR"8J3'@1B21O+7)23CS):::ZVU=EKM_EU+5.3DX
M]5_7X]._0^J/^$HE_P"@/JW_`'Q'_P#%UF^#_$<D'A+2XQI6J2!+2)=Z)'M;
M"#D?/T->3?&[]I^^^&_[7?P_\*KXF\)Z?H_B!;:%]"O(<ZOXB>[:ZC$MD_FK
MA;1K>)Y0L4F4N,L8@H+T/BS^U3J?P,^/GP3\,,=-C\(^*/"?B#5=;FFC/GQ-
MI\&G&W\M]P50S7+J00=Q9`"#UTBG*%XQZM?.*NU]WYVWT,Z<?:5.2+UY>;Y:
MZ_@_N['O7_"42_\`0'U;_OB/_P"+H_X2B7_H#ZM_WQ'_`/%U\X_"S]OO4O#'
M@O0;/XE^&-6F\11V5[+XDUG0H+?^P](NH)[Y([5A)<"X,DHL90FR)TR%WM'O
M7.3XH_X*B7%[-?:?H7PO\<6-Y9>'O$>IW\VK"P5]"GTVRLKRW6>WCNG=UNH-
M0M9$$9+KY\2NJ-YHBSNK-VT5[VU2MOJM/3OTN:1IMR45N]O3OZ=WTZGU)_PE
M$O\`T!]6_P"^(_\`XNLWQ1XCDFTR-?[*U2/_`$NU;+)'@XGC./O]3C`]S7G_
M`(K_`&@?$OBS]EBX\<>&-#D\)ZQ:2S?;],\4"&6ZTL6L[QW,+K:330R2DQ%!
MLG*`/OW';L;)\"?%SQ=K_P`;_$6C^(;S1KGP_J5TUUX;MK.Q:&XTN/3]86PN
M$N9FD83M*QBE0JD>P%T(;:';2G[U7V:6N_W*[_!-_(QJ248<[>FWWNWYZ>5]
M3VC_`(2B7_H#ZM_WQ'_\71_PE$O_`$!]6_[XC_\`BZ^4?BA^W#X^T+QQ^T1X
M>T6/PU_:7P[UO1K3PPMU`_[^U?2;74M2,N'_`'CI"UP5V[0"8@?4^A:[_P`%
M"=+T?4->LH?AW\2=4O\`3]1_LW1;:S@TYG\7D/<Q-+8EKQ5$2RVLJ%KHV^/E
M;'EL'J):)-K=77=JR>BW>C_/LS:I3</B>R3?DFKJ_;^NZO[9_P`)1+_T!]6_
M[XC_`/BZ/^$HE_Z`^K?]\1__`!=?*_\`P].EUR"ZUS1?AEXUU3PGI^NV%K;W
M=H^G22Z_IUWX<?63=P+)=QB$0(4>03%28\",22-Y:^\?$KQIXNT3XL>#[715
MT&70=:AO(7BNFD6XNKM;66>'YU4B&)?*`9@LC-YI^5=@WJ4E%M-;.S]0]G)-
M)]5?^OZVUV-ZY\1R'Q;8R?V5J@*VEPNPI'N;+P<CY^@QS]16E_PE$O\`T!]6
M_P"^(_\`XNN*^`WBO7/&'A/P_?>(YK"XUQ;;5+:\ELH&AMY9(+U(=R(S,5!\
ML'!8]:^;OV<_^"C'C+Q_\$O@IXT\06^ARV>N>&+_`%?QO!I]LRW*W'V6XN+"
M*TC:3"F5;.X.UV.<Q@'YLU5TX<Z6B6OSN_T?SLMV@C1DTY=+I?-[?D?8W_"4
M2_\`0'U;_OB/_P"+H_X2B7_H#ZM_WQ'_`/%UX4?^"C^BVUQH-K>?#WXDZ?J&
MIW,5CJEI/#IV[PO<S7K6%O#>NEXT1::Z\J)/L[S`^?&Q(C$CIG?LS?\`!0/5
M/CIXK\!V^K?#7Q9X8M?B%X6L-;B>:2PF@T*YG_M)Q!<RI<EI//BL2\)AC?"@
M^;Y+,JTNSMOHM]=+Z=].J)Y79O\`EW\O7L_+>VI]#?\`"42_]`?5O^^(_P#X
MNLW1/$<D>IZPW]E:HWF7:L0$CRG[B$8/S]>,_0BO)?C+\1/BMIVE?%E="U;P
M;H]YX3M;;6M(DN--FU!$LA%<N\,J^9%OEF-L!N!58?./^M\L;_:/"-P]W<:M
M+)$T$DEU&[1L06C)M8"5..,CIQ3IR3BW8F2::3_JW_#_`#Z7LR3_`(2B7_H#
MZM_WQ'_\71_PE$O_`$!]6_[XC_\`BZUJ\7_;0UCXE:!H/A.;X<^+O#7A6:^\
M0V6DZ@=7\-OK2W$=U/'""@6ZM_+9-S-R6W<#Y>M*/O2C!+6327JVDOQ82:C%
MSD]$FWZ)7?Y'J7_"42_]`?5O^^(__BZ/^$HE_P"@/JW_`'Q'_P#%UX;K?_!0
M$V_C./0])^%_Q`UFXD\30:#!,DFEPPZG:O)<PS:G;%[P%K:&:U='641S'<K)
M&ZL";/P"_;MT_P#:6UJ*STC0]2\-WVD^*Y?#>N:;JE_I5_<VY33[NX!WZ;>W
M<,;>9;[3')(LJ[&W1J&1BHR3CS):?GMMWW7])@]&XO=6O\[V^^S_``?57]7\
M'^(Y(/"6EQC2M4D"6D2[T2/:V$'(^?H:Z6WE\^".0H\9=0VQ_O+GL?<5G>"/
M^1+T?_KRA_\`1:UJ4ZEKL([!1114%%77/^0+>?\`7!__`$$UE_#7_D4(?^NU
MQ_Z/DK0\3VD=_P"&M0@FC66&:VDCD1AE74J001Z$5POPSMO"QBDT0V-DM[IM
ML;Z4-`%2."2YN(XSNZ=8'&.P`]:Z(I.D[]_T,I74[^7ZI?FSTBBN/M9/!]YX
MMDT2.VTUK^.SAOMHB78\4KRHA5NC$M!)P.1CWK23PQX;DSMM-);;)Y1PJ</_
M`'?][VZUERQ\_N_X)>M[?UM?\M3>HK)_X031?^@78_\`?D4?\()HO_0+L?\`
MOR*7N]_P_P""/4UJ*R?^$$T7_H%V/_?D4?\`"":+_P!`NQ_[\BCW>_X?\$-3
M6HK)_P"$$T7_`*!=C_WY%'_"":+_`-`NQ_[\BCW>_P"'_!#4UJ*R?^$$T7_H
M%V/_`'Y%'_"":+_T"['_`+\BCW>_X?\`!#4UJ*R?^$$T7_H%V/\`WY%'_"":
M+_T"['_OR*/=[_A_P0U+FC_\>C_]=YO_`$8U6JP=*\#Z/);,6TRR8^=*.8AT
M$C`58_X031?^@78_]^152Y;[_A_P11O8UJJZY_R!;S_K@_\`Z":I_P#"":+_
M`-`NQ_[\BO.?VP/AKX?U3]DKXI6MQH^G36]QX1U:*6-X%*R*UG*""/0@XI>[
M_2_X(:GH'Q,\%1_$GX<Z]X=DN&M8]=T^?3WF5=S1"6-D+`=R-V<5X<?^"?[>
M#=+U6;P'XTNO"/B2[U9]7LM4DTR._6QE>]OYF0PLZB1!;:A):JI(VI%&1TQ2
M?\.@OV6_^C?_`(3_`/A-VW_Q-'_#H+]EO_HW_P"$_P#X3=M_\341TES+>UOE
M=.WI=+[BI>]#DEM>_P`^XO@[_@G5I/P^^'.N^'-)\3:DD.K78NX9[BW6>6W8
M>&(?#XW'</,.V$7!)QEV*\#FNR^'G[+3>#?B9X7\67OB*;5=6\/Z9X@L)B+)
M8([Z35[ZQO9I=H8[-CV0"J,@B4\C:,\9_P`.@OV6_P#HW_X3_P#A-VW_`,37
M+^,O^"<W['/@+QUX6\,ZG\#_`(20ZWXREN8]+M1X:MV>9;>$S3R'"?+&BA07
M/`:6->KBM%4DG==K;+91<;+LN733]#256I-J3;;7^36O?2^K\SV7]G7X0^*O
M@QX9FTWQ9XVA\=7E]KUYJD-W'HD>E?9DN/,E>'8DCAL2O(P8D'#`8XR;?[3W
M[.-C^T_\.I/#FH:A=:7`Z7:B>V4&:)Y[&YM%D0D_*\9N?-4_WHU^M?'?P_\`
MV0_V-_VGK_P+JG@7X(_#MM+7QE+I%^MQX1BLS=QG0+V^A8*Z`R6\L;VMQ$XR
MKJT;J2,&O?/^'07[+?\`T;_\)_\`PF[;_P")K.K3YH\E1:-=>S_X!,92A-R6
MCN_OZEC5OV"P_B#0X])\87>B^$;6_6[UC0X-/1AK$=OJ3:E8P+-N!@2&9W5M
MJMYL;%3MZU7LO^"?G]A?!KPCX1TOQG=6B^%_#6E>%GNWTQ)FO;6RL+^Q<E2X
M"-+'?N<@G88QC.:/^'07[+?_`$;_`/"?_P`)NV_^)H_X=!?LM_\`1O\`\)__
M``F[;_XFM)59/5ZZIOS:O:_>UWH]-0ISE3BX4]$W?3OW7;Y&Q\1_V-]3\1?#
MOXLZ1X;\=W?A75/BIK=EJ\NI#3$N_P"ST@L=,L9;;RF=1)'-#IQ5LE3BY<=@
M3ZM\/-'U3P_HEE8ZYJT>NZQ::?;Q7FHQV:V:7LHWAI!"K,(PQYV@D#IFOD'X
MC_LC?L0?#";QG#??`_X8W=YX#735U6TT_P`(17=P+C4'\NSM(D1"9+F5C'MA
M7+GSX>/G7+/@C_P3C_9/^-/Q&O-<T/X(_"V^\*ZYX*\/:[I0;PW;JFR[FU1O
M,"%?E9T2(-W^10>E*\I7F_)7]%HON7ZA)-**?167HDOTL>J_M5_\$[-'_:JD
MUI]0\3:MI)U>'58BMM$K1@7VB#23O4D>8(]J3J#C]XB],9K0\"_L1W'@_P`7
MZK<3>-+S4/#_`/;!UC0=);3TC.B--J\6K7L9F#DSK-<Q+MW*OE)\HW=:S?\`
MAT%^RW_T;_\`"?\`\)NV_P#B:/\`AT%^RW_T;_\`"?\`\)NV_P#B:7.[)=G?
MYJUGZJRUWLK;![27*H]KV\K[Z[V=MMB]H/[#$FA?$SP1K*^,+B32/!%Q:7\&
MEG34#7%W!H^HZ4TK3;\A7AOD;9M(5K?J=YQTVH_LV:M+:_#72K/QE/9^%_!$
M-I'JFF'3DD.OM9F"2T<2EP;<I-`&;:&WJ2IP.:XL_P#!(/\`9:49/[/_`,)^
M/^I;MO\`XFO&_#O[./[#7BV'P3-IGP%\!7UKX^O[S3].N8?`R/#`]M=_8G>X
M<1X@C:Y*Q([X5V=`N=PHDW-IO5W7W^];UWE9?Y:/VDN6W1*WRNW^;;/NC0_^
M0+9_]<$_]!%?*_C#_@DSX9\=:JMQJ'BK77A>RM[":!$55V1:%JNC,T7/[MY(
M]3$C,,_-:1#IR,W]FC_@DY^S+XD_9Q^'^HZA\"/A;>7U_P"&].N;FXF\/6[R
M3R/:QL[L2N2Q8DDGJ37;?\.@OV6_^C?_`(3_`/A-VW_Q-.-247>.C_%:-:/=
M:-JZ[BIR<-NS3[-/=-;,W/"/['NIPZ?9W/BKQQ<>*/$_VAKK4=472TLDOG^U
MZ9/'M@5V$86/2X(L!CG<S\'BJGPS_8>D\#^*=8U34/&%QK$FH1Z):6R#34MQ
M9VNE:S?ZG;1'#G>Q%[Y+.<$B(/C+$#._X=!?LM_]&_\`PG_\)NV_^)KE/CC_
M`,$Z_P!CO]G;X4:UXT\4_`GX5V>@^'X/M%W+%X6@FD52P4!45,L2S``#DYIQ
ME))0CWT7GS*2^?-_EU",VDTNNGRNG^:3^1Z[X8_8Y\`_"WX_:Y\3O#V@V>E>
M*/%40M=6N(5;=?-)=Q3/(Y+$;BR+G`'2N_\`B-X'C^(GAE=-DN'M56^L[WS%
M7<<V]U%<!<?[1B"Y[`YKX>^*W[$7[(NI^+]0\$Z-\!?`=IX@T'7?#XN;D^#X
MX;.YBFU;34GAAN"FR5ECNHUE122HN%#8W"O</^'07[+?_1O_`,)__";MO_B:
MSIVA"*ALMOO;T\KW_(F5Y2<I;O?[DORL<EHW_!*C_A7EW'J_@SXD:QH7BO3_
M`+,VF:M=:;'J'V1HKG77;?$SJ)4:WUZ:!5)&P6\+`DC%>BZ]^Q%;R^&+ZQT7
MQ-=:3<M8O:Z=<R6:W7V&06VEP0RLI8"78=+B<J2`WF,,C&:Q_P#AT%^RW_T;
M_P#"?_PF[;_XFC_AT%^RW_T;_P#"?_PF[;_XFJYW>Z[6]%IHNRT6B*J3<WS2
MU;M?SMW[O3=ZG:?!C]EUO@W:QM!XBFOM0CF\2W0N7LE1?.UK5O[3=M@8C$4G
MR`9^8<G%:GP"^%.M?"C3;B/Q-XI_X3/Q)K5U<:CJ6K#3DTZ.X<K;PQA+=&=8
MU2&&)<!CDJ6XW8'A/CS_`()Z_L;_``U^(/A'PQJ_P+^%5OJ_CB:[ATJ,>%K=
MED-M;/<S%V"815C0G+<$X'4BN!^$/[#/[)/[1'Q6\+W_`(;^`?@6UT6;0];%
MQ9:EX.CL)6FBGT=H96AD0-@PW.^-R,-'<!APW)JY.76S^YR=WY>]?\N@5*DI
MN\NKOZMZGWU7R;XP_P""3/AGQUJJW&H>*M=>%[*WL)H$1579%H6JZ,S1<_NW
MDCU,2,PS\UI$.G(Z3_AT%^RW_P!&_P#PG_\`";MO_B:/^'07[+?_`$;_`/"?
M_P`)NV_^)HC.4=8Z/\5HUH]UHVKKN$9N+=NJ:?9I[IK9FYX1_8]U.'3[.Y\5
M>.+CQ1XG^T-=:CJBZ6EDE\_VO3)X]L"NPC"QZ7!%@,<[F?@\54^&?[#TG@?Q
M3K&J:AXPN-8DU"/1+2V0::EN+.UTK6;_`%.VB.'.]B+WR6<X)$0?&6(&=_PZ
M"_9;_P"C?_A/_P"$W;?_`!-<I\<?^"=?['?[.WPHUKQIXI^!/PKL]!\/P?:+
MN6+PM!-(JE@H"HJ98EF``')S51E))0CWT7GS*2^?-_EU",VDTNNGRNG^:3^1
M['X>_9]O/!WQY\0^,W\227FDZPR_8=$-BL8TR:9[,74GGABT@D-G"0I4!#OP
M3NX[GXC>!X_B)X9739+A[55OK.]\Q5W'-O=17`7'^T8@N>P.:^'OBM^Q%^R+
MJ?B_4/!.C?`7P':>(-!UWP^+FY/@^.&SN8IM6TU)X8;@ILE98[J-944DJ+A0
MV-PKW#_AT%^RW_T;_P#"?_PF[;_XFLZ=HQCR;+;T6B^ZUE]Q,M9-O=[G):-_
MP2H_X5Y=QZOX,^)&L:%XKT_[,VF:M=:;'J'V1HKG77;?$SJ)4:WUZ:!5)&P6
M\+`DC%>BZ]^Q%;R^&+ZQT7Q-=:3<M8O:Z=<R6:W7V&06VEP0RLI8"78=+B<J
M2`WF,,C&:Q_^'07[+?\`T;_\)_\`PF[;_P")H_X=!?LM_P#1O_PG_P#";MO_
M`(FJYW>Z[6]%IHNRT6B*J3<WS2U;M?SMW[O3=ZG=?`?]F./X)S6DS:Y-JUS!
M=>([R1VMEA$KZSJ_]J2\!CM$;_(/4<G'2NF^%'PWM_A)X5T7P_;S-=?8K:X>
M>Y=`KWD\DJRS3L!T:25W<^[&OG'QY_P3U_8W^&OQ!\(^&-7^!?PJM]7\<37<
M.E1CPM;LLAMK9[F8NP3"*L:$Y;@G`ZD5P/PA_89_9)_:(^*WA>_\-_`/P+:Z
M+-H>MBXLM2\'1V$K313Z.T,K0R(&P8;G?&Y&&CN`PX;FO:2?XO[V[O\`\";^
M>@JDG.7//=O?S>K/J3]JK]E:S_:G\(W6D7FMZEH2W.DW>EBXL`!/!Y\UI*)4
M;/RNC6JX_P![VKR=O^"7T>G7FJ6^C^/K_2_#WBB74)/$&EC2XY!J(EU;4M5L
MA')O!A^S7&IR`D!O.2-`=E=!_P`.@OV6_P#HW_X3_P#A-VW_`,31_P`.@OV6
M_P#HW_X3_P#A-VW_`,32C4DE9>7SM>U^]KMI/9Z[EQJ2BN5=[^C75=GZ;EKQ
M!^P/;ZO\3?%7B6W\575I)XP?44OH#8I(HM[S1-+TMHE)88*OI-M.'ZG+IC!W
M5T'Q>_96OO'OPFF\/Z'XL'AW4FU^\UV'49M)CU&.,W3W)EB:W=U5QLNI%5B<
MJP1\9&*Y7_AT%^RW_P!&_P#PG_\`";MO_B:\B^)7[+O[$7PNTWQ3<WGP!\"Z
MA_PB-[#I][#IG@5;V::61'<^0D<9,PC6*=I"F1&()2V-AQ$I<SM+K9?=9)?E
M^I,I2E!1>T;6\K)I?<K_`)GV-\,/#-OX*TBXT:T:9[726M[*%I7WR,D=G;HI
M9N[849/<UXMXU_X)SZ/XU^.OBCQY+XDU2WOO$C:HS6L<*^3%]NT73-).[G]Y
MY::;YBYQS<..@R?#_P!DG_@F#^S7XX^-7[24-U\%?AAJFFZ'\1;*RT9)-"MY
M(K*T?P?X:NC'"-N%C:>YGEP."TSMU8U[A_PZ"_9;_P"C?_A/_P"$W;?_`!-:
M5*DW)R>[T??I?[[:_=M<FA+V<.6GM9>:LFFON:37H;OP_P#V-[CPE\4I/$6H
M>+IM7M['5Y+[0K'^S4@71K63[<SVF\.3+F2]+>80#MAC7'&:YCX4_P#!.*U^
M%GPSA\)P^,+R\TJ#2;&P3?IZ+()K?P])H3SY#_\`+2#R'V=%:$X)WDBU_P`.
M@OV6_P#HW_X3_P#A-VW_`,34&J_\$EOV4="TNYOKSX"_".VL[.)IYYI/#MJJ
M1(H+,Q.W@``DGVJ.9J')T5OPO_FWYMW>IM3K5(R<H/5VOYVO;[K_`-61Z?XR
M^!%UXR^,G@GQ%-K5FNB^#8Y)!I;:1%)/=71C>-)1=EM\:*'),:KAF"DGBO/_
M`-H+]AW2OVNM+\%WVIZ[J6CC1?#[Z:BV:#?()K_1K]FWYRO_`""5B(QRMP_H
M`?'?#_[*G[$OB;Q5X)T>U_9^\#FY\>132V,C^!56"S\LS`)=R&/;;O(UO.L:
MR8,C0N%R0:S?^":7_!+7]G'XC_\`!./]G_Q%K_P1^&>L:[KWPW\.ZCJ-_=Z!
M;RW%]<S:9;22S2.RY9W=F8L>2235QJ224EYV?F[I_/7?=:6V1ST[4Y6AVMWT
M:M;T:OZW9[EXP_8,D\5>++R5?&EQ:^&]6COY-2T<:6C_`&N\GEU"2"X\[?E?
M)_M!AL"D.88B2,8J3Q!^P/;ZO\3?%7B6W\575I)XP?44OH#8I(HM[S1-+TMH
ME)88*OI-M.'ZG+IC!W55_P"'07[+?_1O_P`)_P#PF[;_`.)H_P"'07[+?_1O
M_P`)_P#PF[;_`.)J(MQ@Z<=G^K3_`$7W);&RK34N=/6UOD[.WWK^KL[+XM?L
MWZYXQ^`OB+P;X7\:?\(I?>(M2O+Z359-(CU#RH[JYDGDA$+.H/\`K"H;=D8S
MCM5'P-^S???#'QYKOB75/%4GB-=2O+>/2K5M/2V&BQSZ@MU=J'5F,OG7+;\D
M#8J(HR!FO-?BY_P3@_8_^"/A!M<U_P"`OPMALO/CME$'A6":61W.`%14R<#<
M[8^ZJ,QX!KY__:Z_8^_9/U7PO?:#X1^!_@C2=?\`"OQ,^'^EW]V/"*6<-];7
MGC'2K*[CMYR@6XB*&YMIMA(!9XVZD4Z<FI\T=_TM;\G^)C4BG'W]F[_-N_YZ
MKS6FQ]3>-?\`@G/H_C7XZ^*/'DOB35+>^\2-JC-:QPKY,7V[1=,TD[N?WGEI
MIOF+G'-PXZ#)W?A_^QO<>$OBE)XBU#Q=-J]O8ZO)?:%8_P!FI`NC6LGVYGM-
MX<F7,EZ6\P@';#&N.,UA?\.@OV6_^C?_`(3_`/A-VW_Q-'_#H+]EO_HW_P"$
M_P#X3=M_\34W=U+LK+R5K67;3MO=]V:5)NI%QGL]'YV5E?Y)?<NR*OPI_P""
M<5K\+/AG#X3A\87EYI4&DV-@F_3T6036_AZ30GGR'_Y:0>0^SHK0G!.\D>D?
M%+X)>+/&GQ,\$ZUHOCN+P]I/A)+AIM,;0H[PZC-);R0))YS2*8P@DSM"D-CJ
M*X'_`(=!?LM_]&__``G_`/";MO\`XFN+\?\`[`'[&?PR\86>AZQ\#/A7;WMY
MI]UJ>1X6@:*WM[>-I'>5PF(\JDA7=][RGQ]TT5)W;E/J[_,TJ5*E67-+5Z_C
M:_WV7Y'N/[//PHUSX,^&='\/^(_%2>,M4BCU2YEU1=+331-Y]W'-M\E'<+M,
MA&=W.*\C^%/_``2LT3X2_#6X\/V7B[5YY+C3].LEN9;9<6[V7A]]&BECCW84
MDN;DC./,XZ'->">"OV'OV6_CC^VM\'Y/#_P)\%Z;X7UWX>>.;F_T75/"*:?,
MM]8ZQX6MXVN;61`R31"XN0N\9"W#8X?GZ:_X=!?LM_\`1O\`\)__``F[;_XF
MJG?E]F]%HFMKVO;\_OUWL9TZK47RNZ;OWUU77U:]&T7+/]A22^\)-;Z]XRN-
M7UZ_U70]:U758],2V%_<Z;KHU<$0AR(UD(6#:"=B*",GBMCX._L<Q_"BU\)Q
MR>)+C5/^$/BL[2T+6:P[[>T74XK>-L,>5AU$(6_B-N&P-Y`YO_AT%^RW_P!&
M_P#PG_\`";MO_B:/^'07[+?_`$;_`/"?_P`)NV_^)INI)V7;;[DOR22[=`YY
M<DJ?25[^=U9_>E_3&_&G]C'XA?%?Q#XRO+3XQ1Z+:^)+[2KBQM!X3AN(].@L
M9))!;RDS+]I21I`6+;?N`8-7;[_@HI\`O@MXQ\0>&?&_Q_\`@UH?BK2+R.WU
M*TU7Q?ING7<<RVL`<O;R3AHR6!.TCCI7B_Q*_9=_8B^%VF^*;F\^`/@74/\`
MA$;V'3[V'3/`JWLTTLB.Y\A(XR9A&L4[2%,B,02EL;#CRS_@F?\`\$O_`-FK
MXP>-/VHI-<^"7PM\16N@_&K4=*T5KOP_;7"V-@NCZ--'!"64[8@\TKA1QF1C
MW-33T@^5:=_^#N3/X_>W_I;'UY_P]F_97_Z.6^`/_AP=)_\`C]<W\3O^"C_[
M*?Q,TW2;>7]J#X"VHTK6;'6%9?'VD-YC6TZ3!#_I'`8KC/;-7/\`AR_^R5_T
M;C\&O_"5M/\`XBC_`(<O_LE?]&X_!K_PE;3_`.(HC)QDI+=-->J=U^),HJ47
M%[--/T:L_P`#Q.V_:)_9OLO$&I:E%^VM\!5F36X;_P`/JWB;1670;(7D]S<6
M7_'W^^\W[1*GFMM*`1D`[.9/V6/CS^RG^S1!8Q?\-??`/6H](N[=[!5\6:+9
M^5:V]E=64$,A6Z)ED$=UEYF^:1DR0-W'<>-?^":G[%/@#QSI_AW4/V>/A&-4
MU*RN=0C2+P;;2+'#`C.Q=A'A2RI)L!Y?RWQG::\5^+_[,/[$&L?!.^CT;]F_
MP;H^O>)O#FMRZ>]S\.ELY=$NK6&[4)>,T0-G,TMK.(EDVL[0MMR12IW<?9PV
M73^NNC_'N[NI:[J3\KOTVO\`?^796_1+X1>)M-\:?"?POK&CZA9:MI&K:3:7
MMC?6<ZSVUY!)"CQRQR*2KHZD,K*2""""0:Z*OFW_`()2^"])NO\`@ES^S;+)
MIMG)))\+/##.S1`EB=)M22:^D+>!+6!(HU6..-0J*HP%`X`%5*SU01TT'444
M5(RKKG_(%O/^N#_^@FOEOXRW>KQ7/B[0[3P+K_BF'Q[X$O=*M[F+0XM4TB.6
M&75'>"\27,;>:LR*D3HZ2L^QA@FOJ#Q/`USX:U"-99(&DMI%$D>-T9*D;AD$
M9'7D$>QKA_`=Y8Z79Z3HMSXQDM]8U)KI[.QEN+1+J]6*5_,>.,Q[GV]6*C`S
MV%;63HM-[NWWIF?,U.WDOPE%K\4CX7\`?LIZQIO@[X5Z7!\,?%5UJ%C>67_"
M,:U>Z)9Z/+X)6#Q/=WCSS6UG'%;V).G.4VP1JI21K?&R=\^A?L3_`++4:W/@
MC^V/A+<>&V\,W]A/XD.JZ?'C7/$]II]Z+KQ`6.?M4DT\ML5OI,RRO$C$YC4C
M[.DT_P`G5(;%_$U^M[<1//%;E[82RQH4#NJ^7DJIDC!(X!=<]16?>:[I.G>,
M[3PW<>.%M_$6H0M<6NER7=FM[<Q+NRZ0E-[*-C9(!`VGT-3+7=[M/KNG?3IW
MNTDW:-[\JM:;2U6_^2CWL]$K7O;6UN9WZZBN/\%^(='^)-G<W'AWQTNOV]G.
MUK<2Z=>6=TD$P`)C<QH0K@$$J>1D5M?\(U=?]!S5ORM__C53RKN&O8UJ*R?^
M$:NO^@YJWY6__P`:H_X1JZ_Z#FK?E;__`!JCE7<5WV-:BLG_`(1JZ_Z#FK?E
M;_\`QJC_`(1JZ_Z#FK?E;_\`QJCE7<+OL:U%9/\`PC5U_P!!S5ORM_\`XU1_
MPC5U_P!!S5ORM_\`XU1RKN%WV-:BLG_A&KK_`*#FK?E;_P#QJC_A&KK_`*#F
MK?E;_P#QJCE7<+OL7-'_`./1_P#KO-_Z,:K58&E^'+E[9O\`B=:JO[Z48`@_
MYZ-S_J^_6K/_``C5U_T'-6_*W_\`C5.45?<$W8UJ\_\`VLO^36/B9_V*FJ?^
MDDM=5_PC5U_T'-6_*W_^-5YS^V%X0O+[]DCXI0Q^)-<M9)O"&K(L\*VOF0DV
M4P#+NA*[AU&X$9'((XI<J[A=]CURBOG'_AA3QY_T=I^T=_X#>#__`)0T?\,*
M>//^CM/VCO\`P&\'_P#RAJ2CZ.KQ;]KCQ9?:3XA^&^EV?A/QAXB75=<F2XN]
M&TW[5;Z0CV-Q:B:Z;<OEQ[[I#GGY4D/\//-?\,*>//\`H[3]H[_P&\'_`/RA
MH_X84\>?]':?M'?^`W@__P"4-3*/,N5[%1E8X+]DK3O%!/PYU#Q5X1U;P5=_
M\)+8Z0EAJ6//D-CX0O;>:88_Y9-.)E1OXTC5^-^T?9=?'7Q7_8C\<6?CSX9Q
MO^U1^T+<M=>)9HDDEM_"6ZU8:/J3^9'MT,#<0I3YPR[9&XW;67M_^&%/'G_1
MVG[1W_@-X/\`_E#6DY.4G-[MMOU>K?S=W;H9QBHQ48JR227HM%^!]'45\X_\
M,*>//^CM/VCO_`;P?_\`*&C_`(84\>?]':?M'?\`@-X/_P#E#4E'-?M3>//$
M2_'77H])^&?Q&UZ/PNGA?5OMEGI8-EJL=GJK3W4-K*7_`'LZ07>X1X&YH9%R
M,9KL_P!C#P[JGA76?L6N6+:7K"^`?#DM[9,_F-9327>M2/"6XW%"Q4G`R5KD
M]6_9FU70+S5+>^_;7^.%E<:':K>ZC%//X)C?3[=ONS3!M"!CC.#AFP#ZU@>$
M/V,_&&M?M`^)#9_M8?M`312>%M#NH]0@B\(NUW%)<ZKL&?[#,9C7:64JH)\U
MLLPVA2.L;=FW]]D_OY5]S[L)<O,VEJTD_DM/S;^:\C[+HKYQ_P"&%/'G_1VG
M[1W_`(#>#_\`Y0T?\,*>//\`H[3]H[_P&\'_`/RAH`^CB<"OA7]GZ'Q==ZCX
M?FF^&OQ`TE?%GBK4]_\`:6F"W_L:&+Q:^M1SW7SG9'-:7!"$9S+$4[Y'KG_#
M"GCS_H[3]H[_`,!O!_\`\H:YO3/V=[[6DTMK/]M[XU7:ZY/+;::8;KP1(-0E
MBSYL<.-#_>,F#N5<E<'.*6[3[._X.+^]2:*YO<<7L_TU_-)_(]R_9-_Y-8^&
M?_8J:7_Z215Z!7QU^S-^Q'XXU7]F_P"']U%^U1^T+I\5QX:TZ5+6WM_"7DVR
MM:QD1IOT-GVKG`W,S8`R2>:[?_AA3QY_T=I^T=_X#>#_`/Y0TR3Z.KQW_@H0
MFI77[$'Q4LM%T'7/$^KZMX;O-,LM,T>V^T7EU-<Q&!`J9&0&D#,<\*K'G&*Y
M/_AA3QY_T=I^T=_X#>#_`/Y0UG^*?V/_`!1X&T"XU;6OVQOC]H^EV8#7%Y?#
MP9;V\`)"@L[Z$%7)(')ZD4XR<6I+IJ..YRLJZY<^/[A;OPGXET?3+'Q+IFIQ
MZCJ-H(+>[&JZ_H%U%#'R<RP^3/'*O\#(O)W<?9%?$WQO_9:UZXT2/3;?]L#X
MXZQJ=EK_`(<:YTXMX.>:T2?5[-8IV2/1`ZXR)(RWRLR#(9<J?2_^&%/'G_1V
MG[1W_@-X/_\`E#44X*$(P6T4DO1:+[DK?(5[MR[N[]7J_P#,^CJ*^<?^&%/'
MG_1VG[1W_@-X/_\`E#1_PPIX\_Z.T_:._P#`;P?_`/*&J`D_;LTS6/%GCKX/
MZ'I?AKQ-J\5]KFI_;=2T^Q\^ST2*70]0L$ENGW#8IFOHL<'*K(?X><C]DZ^U
M?7OB[X?U;6/#.N>$I]4T/6"FG:O"(;R,01>&;1V9`3A3+;RE#GYDVMQNP-/_
M`(84\>?]':?M'?\`@-X/_P#E#7$:]^Q'XXC_`&D/"=J?VJ/VA7EF\-:U*MTU
MOX2\Z%5NM)!C7&A[-K[P6RI;,:8*C<&2W<NZ2^YMK_TI_?Y%2=TEVO\`C:_Y
M+[C[%HKYQ_X84\>?]':?M'?^`W@__P"4-'_#"GCS_H[3]H[_`,!O!_\`\H:9
M)]'5X[_P4(34KK]B#XJ66BZ#KGB?5]6\-WFF66F:/;?:+RZFN8C`@5,C(#2!
MF.>%5CSC%<G_`,,*>//^CM/VCO\`P&\'_P#RAH_X84\>?]':?M'?^`W@_P#^
M4-.,G%J2Z#B[.YPLJZY<^/[A;OPGXET?3+'Q+IFIQZCJ-H(+>[&JZ_H%U%#'
MR<RP^3/'*O\``R+R=W'V17QU^T#^Q'XXT[P'822?M4?M"WRMXET"(1SV_A+:
MK/K%F@D&S0U.Y"P=<G;N1=P9<J>W_P"&%/'G_1VG[1W_`(#>#_\`Y0U%.*A"
M,%M%)?):+\+(3U;D^K;^;U?XGT=17SC_`,,*>//^CM/VCO\`P&\'_P#RAH_X
M84\>?]':?M'?^`W@_P#^4-4!)^W9IFL>+/'7P?T/2_#7B;5XK[7-3^VZEI]C
MY]GHD4NAZA8)+=/N&Q3-?18X.560_P`/.1^R=?:OKWQ=\/ZMK'AG7/"4^J:'
MK!33M7A$-Y&((O#-H[,@)PIEMY2AS\R;6XW8&G_PPIX\_P"CM/VCO_`;P?\`
M_*&N(U[]B/QQ'^TAX3M3^U1^T*\LWAK6I5NFM_"7G0JMUI(,:XT/9M?>"V5+
M9C3!4;@R6[EW27W-M?\`I3^_R*D[I+M?\;7_`"7W'V+17SC_`,,*>//^CM/V
MCO\`P&\'_P#RAH_X84\>?]':?M'?^`W@_P#^4-,D^CJ^2/CC\1?$4?QF\::A
MIOPO^).KP>&YK"WC>#2@(]9+V.K6I>T8O^]1)+V`NV!M3<W.W!ZG_AA3QY_T
M=I^T=_X#>#__`)0T?\,*>//^CM/VCO\`P&\'_P#RAJ)TXSTEL5&3CJMS+_X)
MK>#YOAYXO_:(\/W,B37&A^/M&T^5T^Z[Q>`?",9(]B5-?45?`?[*?[&/C35_
MCO\`M,6\/[3WQ\TV32_B39VL]Q;6_A4RZJY\'^&I1//YFB,HD"RI"/*6-/+M
MXLH7\R1_;O\`AA3QY_T=I^T=_P"`W@__`.4-;U:DJDW4ENVV_F8T::IP5..R
M27W'T=5?5M0_LK2KJZ\BXNOLT32^3`F^67:"=J+W8XP!W)KYY_X84\>?]':?
MM'?^`W@__P"4-'_#"GCS_H[3]H[_`,!O!_\`\H:S-$>=_"^;Q3\1O$?@VV?X
M<^/O#]KXBU>WU*6ZUC3!;+HZ:;K6IW[+=#>?+::.X@6(<[B[=-O/J7_!)W_E
M%E^S3_V2KPO_`.FBUJC_`,,*>//^CM/VCO\`P&\'_P#RAKQ'_@F?^QCXT\4_
M\$X/V?M3M?VGOCYH%KJ7PV\.W4.EZ?;^%39Z:CZ7;,L$)FT227RXP0J^9([[
M5&YV.6+B^6FJ:V3;^;27Y11/+>HZCW:2^2;?YMGWY17SC_PPIX\_Z.T_:._\
M!O!__P`H:/\`AA3QY_T=I^T=_P"`W@__`.4-(H[K]M;Q/>>%_P!FKQ.VG^&?
M$_BR^OK8V4.G:!9?;+QVDX#;-R_*.I.>!7R?^T_IVN:UY-[J'AC7O#]AX9^)
MG@RTBNM1MQ'#JYU+XF:)J$;6YR=PBB5%DSC$CE?X<GW;_AA3QY_T=I^T=_X#
M>#__`)0UXC_P4"_8Q\:>'/@1H-Q<_M/?'S6HY/B3X"M1;WUOX5$4;S>,-&B2
M<>5HD;>9"SK-'EBGF1)O21-T;%/W)^T6]FOO33_!LFI%3AR/:Z?W--?BD??E
M%?./_#"GCS_H[3]H[_P&\'__`"AH_P"&%/'G_1VG[1W_`(#>#_\`Y0T%'T=7
MSY^VOJNL:SXA\->%M'\'^+=<FU:PUG.I6-B)--L&DTN[@C6XFW#RR\DB`?*>
MM5/^&%/'G_1VG[1W_@-X/_\`E#1_PPIX\_Z.T_:._P#`;P?_`/*&IE&^C*3L
M>;_`W^T=;_X*/?#WQ1J6AZQX9D\:>"OB)K$.E:O!Y%_90_VGX'MD$R9.UV%O
MOQDX$BU]K5\!^/?V,?&EO_P4?^%.F-^T]\?)KJ\^&WC2ZCU1[?PK]LLTBU3P
MHKP1@:((O+E,R,^^-GW6T6QT'F+)[=_PPIX\_P"CM/VCO_`;P?\`_*&M)2YK
M>227HDDOP1E"'*GYMOYMMO\`%GT=17SC_P`,*>//^CM/VCO_``&\'_\`RAH_
MX84\>?\`1VG[1W_@-X/_`/E#4EG+?''XB^(H_C-XTU#3?A?\2=7@\-S6%O&\
M&E`1ZR7L=6M2]HQ?]ZB27L!=L#:FYN=N#RG_``1`\'S?#S2?VFO#]S(DUQH?
MQIN]/E=/NN\7AW0(R1[$J:]4_P"&%/'G_1VG[1W_`(#>#_\`Y0U\M?\`!-']
MD#QCXI\=_M41VO[27QTT!M)^-VI6%Q)I\'A@MJ\BZ/HSF[N/.T:0"=@ZH1"(
MXML28C#;F8I^Y!P75IOY7M_Z4R9Q4IJ;Z)I?.U__`$E'Z9T5\X_\,*>//^CM
M/VCO_`;P?_\`*&C_`(84\>?]':?M'?\`@-X/_P#E#04='^TG\3-2\%_&'X>Q
M:?X&\;>*1:'4=2ENM)T\36=OML+E$BEE+#9)([*JC!R6%?*'Q2G\5_$S]G76
M/M?PU\<>&[KQAHTVNZQ<ZEI'V.WT>YL9]4U&Z28;V*JYN8HH"22X!)QMY^AM
M1_8E\::1I\]W=_M=_M$6MK:QM----#X.2.%%&69F.@X"@`DD\`"O)OCI\$I-
M?_9V\72Z9^VQ\7?$W]H^&]7DLK*.]\%SQZN+>TD::-?)T4.ZJ.'\M@RANJG!
MIT?<G[1:M-/[FFM/5+?MZDUXJI#DELTU]Z:?SLW]_H>V_P#!)W_E%E^S3_V2
MKPO_`.FBUKZ`KYL_X)2^'KB;_@ES^S:ZZSJD2O\`"SPPP1!!M3.DVO`S&3@>
MY)KZ0MXC#!&C2/*R*%+OC<^.YP`,GV`%#10^BBBD!5US_D"WG_7!_P#T$U\=
M_M)>(H/A[\5/#FM:+JGA>^\<WVBZAIMAX?N(5_MZ(%M0:+4M,<MDB)S(MQ$$
M*M&4=G4Q)'-]@>)S,/#6H>0L;3_9I/+$A(4MM.,D`G&?05QOP_T*]O=%T_4)
MM*\.S:A:M<I%<ON:6$-+('5'*9"G)'&,CK6\?@4NTE\]'I\_^&U,[KGL^WZK
M^K=>NA^>OQ#_`&KK?XN?ME3>*-+^,$FFZ'H<?B2Q\&:EI<]N]KKLXTOP+<Q:
M3%(R,L\=Q?/<AHXSYDC"1$=2/E^BOVU;SP?)^TA8V)DTMOBM--X+E\+06SPC
M76A77KDWCPJ3YIM%M_/-P5^01"3/.*^D(/AY':VUM#'X9\'QPV<OGV\:P!5@
MDR#O0>7A6RJ\CGY1Z5<G\/7EUKL.J2:1X;DU.V0Q0W;`M/$ASE5?9N`.3P#C
MD^M3B/WG(EHHVV>NE]4^C;>_SM??H==NG"+2;C%1U6CMW76_7774^1_^")UM
M8V/PDU2.P\2>"_$XN-*T:[N9?#5C'9QZ5.T,T;:?>+'+*LE_$(E::9F1W\Z/
M=%'M4M]N5S.@^&[KPK#-'I>C^&=-CN)#+*MJ#"LCGJS!8QEN.IYK0\W7O^>.
MD_\`?^3_`.(K*G3Y8J(JU3GJ2GW;?WFM163YNO?\\=)_[_R?_$4>;KW_`#QT
MG_O_`"?_`!%5RF=S6HK)\W7O^>.D_P#?^3_XBCS=>_YXZ3_W_D_^(HY0N:U%
M9/FZ]_SQTG_O_)_\11YNO?\`/'2?^_\`)_\`$4<H7-:BLGS=>_YXZ3_W_D_^
M(H\W7O\`GCI/_?\`D_\`B*.4+ES1_P#CT?\`Z[S?^C&JU6!I<NN?9FVPZ5CS
MI>LTG7S&S_#ZU9\W7O\`GCI/_?\`D_\`B*<HZBB]#6KS_P#:R_Y-8^)G_8J:
MI_Z22UU7FZ]_SQTG_O\`R?\`Q%><_MA3>)E_9(^*1M+?0VNAX0U;R5FN)5C+
M_8IMH8A"0N<9(!..U+E'<]<HKYQ_M_\`:Y_Z%/\`9Q_\*O6?_E=1_;_[7/\`
MT*?[./\`X5>L_P#RNJ1GT=17SC_;_P"US_T*?[./_A5ZS_\`*ZC^W_VN?^A3
M_9Q_\*O6?_E=0!Z=\9?^2B_";_L:Y_\`TQZM7H%?'?Q7UW]JX^//AG]I\+?L
M]K,OB68V@B\4ZPRO+_8^IY$A.G@A?+\PY&3N"C&"2.V_M_\`:Y_Z%/\`9Q_\
M*O6?_E=0!]'45\X_V_\`M<_]"G^SC_X5>L__`"NH_M_]KG_H4_V<?_"KUG_Y
M74`>%_MK^(?@IKW[7U]=:AXF\'V5]X#;1[#Q]IL]Y&L]_!?:OHDZR7L1;>;2
MUAM+0L[*8%6_;<P`F%>V?\$]X;>VT728[&.:'35^&WA<:?'*CHR6GVC6?LX*
MOAUQ#Y?#@,._.:S[WPQ^TQJ6HW=Y<?#;]EFXN]0C\FZGDU[56DN4X&UV.F99
M?E7@Y'RCTKGO#6K?M56O[17BA+?PG^SPEVGAG1$DB'B?5U@CA%SJWE;"-/SN
MSY@((``"8)R0*C*7LE3;V;:[:]&O*WN]KR[Z5*5W?7HO+2_XN[N_)=C['HKY
MQ_M_]KG_`*%/]G'_`,*O6?\`Y74?V_\`M<_]"G^SC_X5>L__`"NJ23Z)OGAC
MLIFN&6.!48R,S;0JXY)/;CO7Y[?![QA\*_&_C_PKKWA^\\"MI?B[7+>\\!V&
MEWMM<K9R1ZQIR726PB)V7+V,5M=7$0^>-;B4/PLAKZ`?7/VN)$*MX2_9Q96&
M"#XKUG!'_@NK'TSPU^TSHGV7['\-_P!EFS^PR/-;>3K^JQ_9W<!69,:9\K,`
M`2,$@5G[/]]&KV_6]_T:[-%\_P"[=/O^C3T^ZS[H]F_9-_Y-8^&?_8J:7_Z2
M15Z!7QW^S-KO[5R?LW_#X:?X6_9[DL!X:TX6S7'BG6$F:+[+'L+JNGD!MN,@
M$@'.":[;^W_VN?\`H4_V<?\`PJ]9_P#E=6A!]'5Y-^V^FBS_`+,_B*#7O$O@
MOP?8W/DQ#6/%U@M]HEE(9DV&YB:6%&5FPHWR*`[(>3A3Q7]O_M<_]"G^SC_X
M5>L__*ZJNM/^U9XDTR2RU'P/^S/?V<V/,@N?$VL2Q28((RK::0<$`\]Q6=6'
M/'E_/4JG+EES'B7P9O\`P_>:[I<<,%G9^-[>^T9M?LS*)M2LK636?"[::ETV
MU7*_9P1$9%7=LFP`1(!^@M?%_P`=U_:?LO"UO>3>"?V;[6:Z\1^'EEN+3Q'J
MWGSNFKV?D*Y.G`E`^T'))52Q`)P#Z%_;_P"US_T*?[./_A5ZS_\`*ZKBK0C&
M][)+[NOJ]WW=V*6LG+NV_2_3T73R/HZBOG'^W_VN?^A3_9Q_\*O6?_E=1_;_
M`.US_P!"G^SC_P"%7K/_`,KJ8CZ.KS_Q'_R=/X-_[%37O_2O1J\Q_M_]KG_H
M4_V<?_"KUG_Y75Q.O:[^U<?VD/"9?PM^SV+_`/X1K6A"J^*=8\DQ?:M)\PLW
M]GY#!O*V@`@@ODC`R`?8E%?./]O_`+7/_0I_LX_^%7K/_P`KJ/[?_:Y_Z%/]
MG'_PJ]9_^5U`'T=17SC_`&_^US_T*?[./_A5ZS_\KJ/[?_:Y_P"A3_9Q_P#"
MKUG_`.5U`'IW[2__`"3K3?\`L:_#?_I\L:]`KX[_`&@M=_:N;P'8?;O"W[/:
M0_\`"2Z`5,'BG6&8R_VQ9^4"#IX&TR;`QZA2Q`)`![;^W_VN?^A3_9Q_\*O6
M?_E=0!]'45\X_P!O_M<_]"G^SC_X5>L__*ZC^W_VN?\`H4_V<?\`PJ]9_P#E
M=0!]'5Y_XC_Y.G\&_P#8J:]_Z5Z-7F/]O_M<_P#0I_LX_P#A5ZS_`/*ZN)U[
M7?VKC^TAX3+^%OV>Q?\`_"-:T(57Q3K'DF+[5I/F%F_L_(8-Y6T`$$%\D8&0
M#[$HKYQ_M_\`:Y_Z%/\`9Q_\*O6?_E=1_;_[7/\`T*?[./\`X5>L_P#RNH`^
MCJ*^<?[?_:Y_Z%/]G'_PJ]9_^5U']O\`[7/_`$*?[./_`(5>L_\`RNH`O?L;
M_P#)Q7[6/_95;'_U"/"E?0%?`?[*6M_M1)\=_P!I@Z;X9^`<EXWQ)LSJJW/B
M;5DBBN?^$/\`#058"M@2\?V<6Y+.%;S&E7&U59O;O[?_`&N?^A3_`&<?_"KU
MG_Y74`?1U%?./]O_`+7/_0I_LX_^%7K/_P`KJ/[?_:Y_Z%/]G'_PJ]9_^5U`
M'T=7S_\`\$G?^467[-/_`&2KPO\`^FBUJC_;_P"US_T*?[./_A5ZS_\`*ZO$
M?^"9VM_M11?\$X/V?E\/^&?@'<:"OPV\.#39=0\3:M#>26W]EVWE-,B6#(LA
M3:65690V0"1S0!]^45\X_P!O_M<_]"G^SC_X5>L__*ZC^W_VN?\`H4_V<?\`
MPJ]9_P#E=0!]'5\__P#!2S_DW7PY_P!E5^''_J;Z%5'^W_VN?^A3_9Q_\*O6
M?_E=7B/_``4"UO\`:BD^!&@C6_#/P#AL_P#A9/@(QM8^)M6EE-R/&&C&V4A[
M!0(VN/*$C`[EC+LH9@%(!]^45\X_V_\`M<_]"G^SC_X5>L__`"NH_M_]KG_H
M4_V<?_"KUG_Y74`?1U%?./\`;_[7/_0I_LX_^%7K/_RNH_M_]KG_`*%/]G'_
M`,*O6?\`Y74`7OB-_P`I3?@W_P!DJ\>?^G?P97T!7P'X]UO]J(_\%'_A2TWA
MGX!KKR_#;QH+.)/$VK&S>V.J>$_M#2.;#>L@<6P154JRM*25*J&]N_M_]KG_
M`*%/]G'_`,*O6?\`Y74`?1U%?./]O_M<_P#0I_LX_P#A5ZS_`/*ZC^W_`-KG
M_H4_V<?_``J]9_\`E=0!]'5\?_\`!*#_`)*+^V%_V<!JO_ICT.NR_M_]KG_H
M4_V<?_"KUG_Y75\M_P#!-'6?VEHO'?[5'_"/^&_@9<3/\;M2;6!J'B/585AO
MO['T;>EN4L6+P"/RB'?:Q8N"H`!(!^F5%?./]O\`[7/_`$*?[./_`(5>L_\`
MRNH_M_\`:Y_Z%/\`9Q_\*O6?_E=0!]#:K9VNHZ9<6]]#!<6<\31W$4Z!HY(R
M"&5@>"I&00>"*_,_XRQ?#YO@G_:/A?3O#^CZUXVT$^*?!=I#:QV=T^EW5QK-
MQ=O;Q878/[,D@\\(.`8PW)3/U4==_:X88/A/]G$@]1_PE>L__*ZO.OVEK3]I
MI?V>O&DU]X%_9LAM].\+:E`L]MXAU5KBSMS:2+(L&[3@`=@P%RH.`#@5=*7)
M453LT_6SO9^3:7ROW5IK052E*F^J?RNK7];-_.QZG_P2=_Y19?LT_P#9*O"_
M_IHM:^@*^;/^"4LFM#_@ES^S;Y4.EF+_`(59X8V%YG#$?V3:XS\O6OI"W,A@
MC\T()=HWA#E0>^/:I:L4/HHHI`5=<_Y`MY_UP?\`]!-?+?QK\;:U\%OB#X=\
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M=3BU/6Y[&Z2:S#>5).\4@6.1E+*Z1D$8IVC_`/!-GX,Z'%I?D^%O'TEUI=_-
MJ)OKCQ/JT]]J+S)9131WEP]T9;R&2+3K*-X;AI(WCMT1E*\5Z-XT^`?@_P"(
M7QMT?X@:QHWC"\US0H(H;:V.IWJZ3(87ED@EET\3"TFFB>:1XYI(FDC;:R,I
M52(Q,'-05+2RWTWUN_.[>ST^6AT2K0=.":U44GTNT]7?=7[VNNFQX_\`\$6O
M$WBWQQ^QSI>O>)M1\?:M#KUOIVH6EYXOFGFOKF233+1KR2)IR9#:-=^>T)^X
M5;*?(5KZZKC?AAH6C_!SX;>'_"/AW0]8L=`\+Z=;Z3IML4>4P6T$:Q1)O=BS
M815&6))QDDFMS_A*_P#J&ZM_X#__`%ZJK&\VX[7T]/T\ET6@5JD)U)3CHFV_
MO?\`5_,UJ*R?^$K_`.H;JW_@/_\`7H_X2O\`ZANK?^`__P!>L^21CS(UJ*R?
M^$K_`.H;JW_@/_\`7H_X2O\`ZANK?^`__P!>CDD',C6HK)_X2O\`ZANK?^`_
M_P!>C_A*_P#J&ZM_X#__`%Z.20<R-:BLG_A*_P#J&ZM_X#__`%Z/^$K_`.H;
MJW_@/_\`7HY)!S(N:/\`\>C_`/7>;_T8U6JP=*\4[+9O^);JI_?2GBW_`.FC
M>]6/^$K_`.H;JW_@/_\`7JI0E<(R5C6KS_\`:R_Y-8^)G_8J:I_Z22UU7_"5
M_P#4-U;_`,!__KUYS^V'XW_L[]DCXI7']CZY/Y'A#5I/+AM=TDF+*8[5&>6/
M0#UJ>1AS(]<HKYQ_X>+_`/5"?VCO_"*_^W4?\/%_^J$_M'?^$5_]NJ2CZ.HK
MYQ_X>+_]4)_:._\`"*_^W4?\/%_^J$_M'?\`A%?_`&Z@#T[XR_\`)1?A-_V-
M<_\`Z8]6KT"OCKXK_P#!07[=X\^&<G_"D?VA8?L?B6:;9+X.VM/G1]33;&/.
M^9OGW8_NJQ[5V_\`P\7_`.J$_M'?^$5_]NH`^CJ*^<?^'B__`%0G]H[_`,(K
M_P"W4?\`#Q?_`*H3^T=_X17_`-NH`^CJ\_\`#G_)T_C+_L5-!_\`2O6:\Q_X
M>+_]4)_:._\`"*_^W5Q&@_\`!07ROVD/%EY_PI']H5O/\-:+#Y*^#LS1[+K5
MCN9?.X5M^%/<H_I0!]BT5\X_\/%_^J$_M'?^$5_]NH_X>+_]4)_:._\`"*_^
MW4`?1U%?./\`P\7_`.J$_M'?^$5_]NH_X>+_`/5"?VCO_"*_^W4`>G?LF_\`
M)K'PS_[%32__`$DBKT"OCK]F;_@H+_8_[-_P^L_^%(_M"W7V7PUIT/G6_@[S
M(9MMK&-R-YWS*<9![@BNW_X>+_\`5"?VCO\`PBO_`+=0!]'45\X_\/%_^J$_
MM'?^$5_]NH_X>+_]4)_:._\`"*_^W4`>G?M+_P#).M-_[&OPW_Z?+&O0*^.O
MV@O^"@O]J>`["/\`X4C^T+;[?$N@3;Y_!VQ3LUBS?:#YWWFV[5'=F4=Z[?\`
MX>+_`/5"?VCO_"*_^W4`?1U%?./_``\7_P"J$_M'?^$5_P#;J/\`AXO_`-4)
M_:._\(K_`.W4`2?MO:WX@^'GCSP'XSL[/Q==>'?#D.HK?OI7B,Z?8V]Y/]FC
MLC>V8<&^B:3<@7:PC+ES@9-8O[)6CWWAGXQ:'I-]XB\0^*/L&BZPT=[K5_)?
M79\^#PQ=R*97);9YUQ*57.$5@HPJ@5SOQ%_:0\-_%7XA>&O$FN?`O]JZYN?"
MCM+9V$>D7L&D3R'E9+FP2[%K=/&P#1M/$YC90R%6`-<;\)OVB/#?[.?Q3\(Z
M/X6^!?[3$.FVV@ZXQCU+0KG4M0G:2YT<!O.N;F25XXHX8XE!?$2"&-0$55&5
M&,HN7,]'MY:MO[[KTY4M5M=1Q:BETO?S[?=KZWZ=?OBBOG'_`(>+_P#5"?VC
MO_"*_P#MU'_#Q?\`ZH3^T=_X17_VZM2#Z.KR_P#;-L=/F_9G\77NJ:CXPTVS
MT/3Y=69_"^KW&EZI.UNIE6&*:!EDS(RA-H/S;@.<UP/_``\7_P"J$_M'?^$5
M_P#;JS/%_P"W-IWCO1?[.U7X`_M'75G]H@NC$?!I4,\$R31YQ.,@21H2#P0,
M$$$BIE!37++;RW]5Y]BHRY7S6O\`KY'!^%]+\1:-KEBVN>+/%&M7$VL:3HUW
M97^J375G&^E:[X=MHYXXW)"32&6XDED`W2-+EB=JU]NU\"_%G]H/PSH7BC4_
M'%C\"?VEK7Q%XF\0>'/MLMYH-S)9*(=5T[(M[9[EH+>29;>%7,*(TS10[RQ1
M2/;/^'B__5"?VCO_``BO_MU%/F5.*ENDD_7J_F]?*]NA,K<S:VOIZ=%\MOD?
M1U%?./\`P\7_`.J$_M'?^$5_]NH_X>+_`/5"?VCO_"*_^W50$G[;VM^(/AYX
M\\!^,[.S\777AWPY#J*W[Z5XC.GV-O>3_9H[(WMF'!OHFDW(%VL(RY<X&36+
M^R5H]]X9^,6AZ3?>(O$/BC[!HNL-'>ZU?R7UV?/@\,7<BF5R6V>=<2E5SA%8
M*,*H%<[\1?VD/#?Q5^(7AKQ)KGP+_:NN;GPH[2V=A'I%[!I$\AY62YL$NQ:W
M3QL`T;3Q.8V4,A5@#7&_";]HCPW^SG\4_".C^%O@7^TQ#IMMH.N,8]2T*YU+
M4)VDN='`;SKFYDE>.*.&.)07Q$@AC4!%51E1C*+ES/1[>6K;^^Z].5+5;74<
M6HI=+W\^WW:^M^G7[XHKYQ_X>+_]4)_:._\`"*_^W4?\/%_^J$_M'?\`A%?_
M`&ZM2#Z.KX[^._P<N;OXV^,+'2/B9\5-+M/$7V8WZ6OBZ\\O2KK[)JM_Y=H-
M^+0#[)9EHX]H:*3:1M?![;_AXO\`]4)_:._\(K_[=7EOQ'^)O@'XIZ)XHL=4
M_9X_:BC3QEK4/B#59]/T2\T^ZGO([2&R#+/!=I)&IM8(X6C1E1XS(K*RR.&6
MN\79][7WT_*[]4EUNJ7+:TE=?Y:_\#Y_)]Y_P33\6W/C[Q9^T-KUXB1WFM>/
M=&OYU0859)?`/A%V`]LL:^I*^`?V2OVZX_#'QO\`VE)(?@I\>IHM3^(]E<I;
MV?@_<^GJO@_PU`(9E$H\N3]SY@7G]W+$W\6![A_P\7_ZH3^T=_X17_VZM:TH
MRJ2E!63;LNR[&-&,HTXQF[M)7?=]SZ.HKYQ_X>+_`/5"?VCO_"*_^W4?\/%_
M^J$_M'?^$5_]NK,T/HZOG_\`X)._\HLOV:?^R5>%_P#TT6M4?^'B_P#U0G]H
M[_PBO_MU>(_\$S_V]/\`A#_^"<'[/VD_\*7^/FJ?V7\-O#MG]MT_PCY]G>>7
MI=LGFPR>:-\;8W*V!E2#B@#[\HKYQ_X>+_\`5"?VCO\`PBO_`+=1_P`/%_\`
MJA/[1W_A%?\`VZ@#Z.KY_P#^"EG_`";KX<_[*K\./_4WT*J/_#Q?_JA/[1W_
M`(17_P!NKQ'_`(*!?MZ?\)3\"-!M?^%+_'S3?*^)/@*\\V^\(^3$_D>,-&F\
MH-YIS))Y?EQK_%(Z+D9S0!]^45\X_P##Q?\`ZH3^T=_X17_VZC_AXO\`]4)_
M:._\(K_[=0!]'45\X_\`#Q?_`*H3^T=_X17_`-NH_P"'B_\`U0G]H[_PBO\`
M[=0!>^(W_*4WX-_]DJ\>?^G?P97T!7P'X]_;T^U?\%'_`(4ZM_PI?X^1_8?A
MMXTL_L3^$<7EQYVJ>%'\V./S?FCC\C:[9^5IHA@[N/;O^'B__5"?VCO_``BO
M_MU`'T=17SC_`,/%_P#JA/[1W_A%?_;J/^'B_P#U0G]H[_PBO_MU`'T=7Q__
M`,$H/^2B_MA?]G`:K_Z8]#KLO^'B_P#U0G]H[_PBO_MU?+7_``31_;B_X0_Q
MW^U1)_PI_P".FJ?VU\;M2U'9I_A3SVL-VCZ.GD7`\T>7./+W%.<*Z'/-`'Z9
MT5\X_P##Q?\`ZH3^T=_X17_VZC_AXO\`]4)_:._\(K_[=0!K?M9^(8_A;\1/
M!_CAO%&L6*^&K;5+V^T9-3DATZ\TV#3KJ:ZGGMU.R4HXM0LC@^6Q7!&\Y^1_
M%7QSE^+O[+6H>,-'^+5UXZ7PQIMWI-\^C:V\NBZO/J=WJ]M=>=&K;95BC6W:
MW#@^2J)MP":]@\:?'CPOX[^.WAWXCWGP/_:XMO%'ABU:QM&TZPU&PLIX&<R&
M.YM(;Q+>Z7<<XGC<9"^@QQ/[5'QE\&^*O`_B+Q5)\`_VEK/7=&\.:VEI/)H5
MU!IRO=073-+=0+=>3-Y;7,[1O*CF#SI#'LW'-46HRC*>MG>WE>[5^O,M'HK7
MZVURQ$9S4E!V]VWJ^C\G%[.[NE9I=/H;_@D[_P`HLOV:?^R5>%__`$T6M?0%
M?-O_``2E\3>1_P`$N?V;8_[/U1]GPL\,+N2#*MC2;7D'/2OI"WF\^!)-KIO4
M-M<89<]B/6AQ:W-;CJ***D"KKG_(%O/^N#_^@FOGOQ%^TAJWPG^,'A_1[C4/
M#^F^#X]#U36[ZWN]+N)M2UQH9+IGCLKI9D@AD@$<3M%+'(TRS_(4\IVKZ!\2
M7$=IX>OY972.*.VD=W<[50!222>P%>`>/O@FW[0H\/1WGCO0[3P';&YEO]$.
MG)->7=SNN5AG@O?/7[.,38=?)D\Q%VAD#$G:/P+33F5_2S_K_+=9Z<^O;]5_
M7^>SR?BM_P`%);/X=_M2V/@NU\-Z]K6BZ?:ZLGB.:QL$DN=-GM8/#MXET"TZ
M+]CCM-;9ICM:3<@"*=I#[WQA_:F\0_"K]K$Z`+KPOJ/A.R\*_P!KW/A^WLS_
M`,)/=2^5JDQN()WNT@%N!I\<.R2$#S+E29T&%/E.D_\`!.SQ)#XPE\47_P`>
M=#O/%&O3:C#XEN8_"Z0VVIZ??6>AV4]M;P_;6-M)Y&A0[96>7:\SL48`*?>O
MBM\"/"OQ0U?QMJDFJ>'[?6O%WA1/"L-_);133:=$K7;$[MZN\;M<@M$&0-Y7
M7G*SB8Z15'HM?-Z_YZ?\!,[.:DX0OORKF_Q7U_#\-.YQ]S_P49T?Q1\'6\3>
M%_#?B.9)?#&J>(I;R[BM9-.\.BS%RBKJ$D5R0/,FM)T7R&E!\MLL@P:]R^&7
MQ!L_BMX!TOQ)I]OJ%MI^LP"ZM5O8#!,\+$[)"AY4.N'`;#`,,A3D#YN\*?L5
M7OA[X<3>$Y/B7X';P_XD\/:KH7BJPM/"<=G:ZE]KFOIXGLXUO"MG'$^H2AHC
MYWF(JC<ARQ]]^$FFZ=\+?AQI/AUO$D.KQZ+";2WNKF=?.:W5B(5D.X[W2+8C
M/_&5+8&[`F4?>=D_+[WO^%O*]]3EC+W=>_Z*WXWOM;I=:G945G_\)7I?_02T
M_P#\"$_QH_X2O2_^@EI__@0G^-'*^Q5T:%%9_P#PE>E_]!+3_P#P(3_&C_A*
M]+_Z"6G_`/@0G^-'*^P71H45G_\`"5Z7_P!!+3__``(3_&C_`(2O2_\`H):?
M_P"!"?XT<K[!=&A16?\`\)7I?_02T_\`\"$_QH_X2O2_^@EI_P#X$)_C1ROL
M%T3:/_QZ/_UWF_\`1C5:K'TKQ3IB6K;M1L5_?2GFX3O(WO5C_A*]+_Z"6G_^
M!"?XT2B[[$Q:L:%>?_M9?\FL?$S_`+%35/\`TDEKL/\`A*]+_P"@EI__`($)
M_C7G?[7OC?1=/_9-^*%Q<:OI<$$'A+59)))+I%2-19RDL23@`#DDT<K[%71Z
MI17CO_#Q']G_`/Z+I\'?_"TTW_X]1_P\1_9__P"BZ?!W_P`+33?_`(]4@>Q4
M5X[_`,/$?V?_`/HNGP=_\+33?_CU'_#Q']G_`/Z+I\'?_"TTW_X]0!T7QE_Y
M*+\)O^QKG_\`3'JU>@5\Q_%O_@H!\![WQ_\`"^2'XV?".:.S\3S33NGC#3F6
M!#HVIH&8B;Y5WNBY/&64=2*[K_AXC^S_`/\`1=/@[_X6FF__`!Z@#V*BO'?^
M'B/[/_\`T73X._\`A::;_P#'J/\`AXC^S_\`]%T^#O\`X6FF_P#QZ@#V*O/_
M``Y_R=/XR_[%30?_`$KUFN=_X>(_L_\`_1=/@[_X6FF__'JX7P__`,%`/@/%
M^TOXNNV^-GPC6UF\,:)#',?&&G".1TNM7+J&\[!90Z$@<@.N>HH`^G**\=_X
M>(_L_P#_`$73X._^%IIO_P`>H_X>(_L__P#1=/@[_P"%IIO_`,>H`]BHKQW_
M`(>(_L__`/1=/@[_`.%IIO\`\>H_X>(_L_\`_1=/@[_X6FF__'J`.B_9-_Y-
M8^&?_8J:7_Z215Z!7S'^R_\`\%`/@/H_[-'P[M+OXV?".UNK7PQIL,T,WC#3
MDDA=;6(,K*9LA@000>017=?\/$?V?_\`HNGP=_\`"TTW_P"/4`>Q45X[_P`/
M$?V?_P#HNGP=_P#"TTW_`./4?\/$?V?_`/HNGP=_\+33?_CU`'1?M+_\DZTW
M_L:_#?\`Z?+&O0*^8_VB/^"@'P'U3P!I\=K\;/A'<2+XG\/S%(O&&G.P1-9L
MG=L";[JHK,3T`4D\"NZ_X>(_L_\`_1=/@[_X6FF__'J`/8J*\=_X>(_L_P#_
M`$73X._^%IIO_P`>H_X>(_L__P#1=/@[_P"%IIO_`,>H`]BKS_Q'_P`G3^#?
M^Q4U[_TKT:N=_P"'B/[/_P#T73X._P#A::;_`/'JX7Q!_P`%`/@/+^TOX1NU
M^-GPC:UA\,:W#),/&&G&.-WNM(**6\[`9@CD`\D(V.AH`^G**\=_X>(_L_\`
M_1=/@[_X6FF__'J/^'B/[/\`_P!%T^#O_A::;_\`'J`/8J*\=_X>(_L__P#1
M=/@[_P"%IIO_`,>H_P"'B/[/_P#T73X._P#A::;_`/'J`.B_:7_Y)UIO_8U^
M&_\`T^6->@5\Q_M$?\%`/@/JG@#3X[7XV?".XD7Q/X?F*1>,-.=@B:S9.[8$
MWW5168GH`I)X%=U_P\1_9_\`^BZ?!W_PM--_^/4`>Q45X[_P\1_9_P#^BZ?!
MW_PM--_^/4?\/$?V?_\`HNGP=_\`"TTW_P"/4`>Q5Y_XC_Y.G\&_]BIKW_I7
MHU<[_P`/$?V?_P#HNGP=_P#"TTW_`./5POB#_@H!\!Y?VE_"-VOQL^$;6L/A
MC6X9)AXPTXQQN]UI!12WG8#,$<@'DA&QT-`'TY17CO\`P\1_9_\`^BZ?!W_P
MM--_^/4?\/$?V?\`_HNGP=_\+33?_CU`'L5%>._\/$?V?_\`HNGP=_\`"TTW
M_P"/4?\`#Q']G_\`Z+I\'?\`PM--_P#CU`&#^QO_`,G%?M8_]E5L?_4(\*5]
M`5\4_LE?MW_`_1/C[^U!<WGQF^%-G;ZQ\3;*[L)9O%MA&E["/!OAB$RQ$RX=
M!+#+&67(WQ.N<J0/=/\`AXC^S_\`]%T^#O\`X6FF_P#QZ@#V*BO'?^'B/[/_
M`/T73X._^%IIO_QZC_AXC^S_`/\`1=/@[_X6FF__`!Z@#V*OG_\`X)._\HLO
MV:?^R5>%_P#TT6M;W_#Q']G_`/Z+I\'?_"TTW_X]7A?_``2__;O^!_A#_@FE
M^SOI.K?&;X4Z7JNE_#+PW:7ME=^+;""XM)H]*MDDBDC:4,CJP*E6`((((S0!
M]K45X[_P\1_9_P#^BZ?!W_PM--_^/4?\/$?V?_\`HNGP=_\`"TTW_P"/4`>Q
M5\._M0_&_6/B9X:\7Z'JWB#PU>+X3^-/PUM;+1K+P]>Z=?Z3`?'6D*KW-S/.
M\5[YP175[>.)4^96W'D?0'_#Q']G_P#Z+I\'?_"TTW_X]7R-^V;^TC\,;VPN
MO$VH_M'?!GQ=)??$;X=Q:-IFDZI8VKZ)I=MXWTF[G\]A>2FY9$#2/-MB5(X6
M)0#<:<;<VNUG_P`#^NU_1J5^73>Z_P"#^&OJDO-?HW17CO\`P\1_9_\`^BZ?
M!W_PM--_^/4?\/$?V?\`_HNGP=_\+33?_CU(9[%7C/[4?Q<\=_!;7]"UG18_
M#-[X0^SW\>IZ?<V4[:E=7$=A=W4+PW"SK'#$AM0'#0RLXE.TQE/GD_X>(_L_
M_P#1=/@[_P"%IIO_`,>KQ']H?XZ_"WXV?%O1]6T_]K+X&Z'X4MM#OM%U#0Y]
M3T^^FN3=J4>Y@N1J$:P2A,("T,HQNZ;C2ZK^OZ_SMMN'1_U_5M_P\BQ\)?'?
MBKQC_P`%%/A;9>.KCP_>>,/"_@'XB:/JMWH5A-8Z;=NNK>"I8Y(8)IIY(P8)
MH0RM*_SA\'&`/LBOSM^&W[2WPC^%?[>/PKO->_:$^#_B[4KCP#X]N/$/B.TU
MRPT^PFO[K5O"!A01?:I1`3!:LJ1M*S,MM(P)PV/K#_AXC^S_`/\`1=/@[_X6
MFF__`!ZM:G+=<O97];*]O*][>1G2YDO>[NWI=V^=K7/8J*\=_P"'B/[/_P#T
M73X._P#A::;_`/'J/^'B/[/_`/T73X._^%IIO_QZLS0X7]I;]J'Q]\(%\7;M
M6\!^#[/3=6TR.QU;4?#FH^((+"QN$N@SW4%K<02.[R6P"LC1I")AN\P(6;F?
M^"34HF\?_M@.K+(K?'[52&7[K#^P]"Y'M7/?$;X[^%?&'B7XB7&F_ME?LY:3
MI_CB*TT^UMY(;&ZFTJQB6X66(R?VLHFE<3G;+L0(5&8WSBN(_P""4O[8OP1^
M%WB/]J2SOOB]\,M+L[SXV:A<Z4]]XKL8OM]F-$T2))XV:4>9&6B==ZY4LC#.
M0<%/X/>WO_5_PV[O:VI4^-<NUO\`AK?>UKKHM[GZ-45X[_P\1_9__P"BZ?!W
M_P`+33?_`(]1_P`/$?V?_P#HNGP=_P#"TTW_`./4`>KZ]K=MX:T.]U*\D\FS
MT^![F=S_``1HI9C^`!KXJ_:`_:I^)VL_L^:E>:MIOA/1=#NO#^HVOB?2WL9Y
M-4C>^EU2RL(X)A<>7$UNUI&+@O'*)C(Y3R0H!]K\9_MQ?LV_$+P?JV@ZQ\:_
M@Y>:3KEG-87MN?&^GIY\$J%)$W+.&&58C*D$9X(-?(WQ:TG]G7X9?![Q):^"
M/VC/A-;>$X])U6_O_#3^*;;4[O6;Q1?7%AY5U+?M)%Y4MU\R;)/.,<>/+.[=
M5+E]HG/:Z^Z_O+YK9ZZ]MS.MS^S:I[V?W_9:]'NNJOUT?U=_P2=_Y19?LT_]
MDJ\+_P#IHM:^@*^<O^"4?B;38/\`@EO^S7')J%BDB?"OPPK*TZ@J1I%KD$9K
MZ+BF6>)9(V5XW`964Y#`]"#4V9H.HHHH`J:^BRZ%>JRAE:"0$$9!&TUXM!^T
MMX?^&WC8>"[S0]1FNH/"^I^+OMD,$;6QBMKIT-L#G=Y[#>RKC!6-^>*]JUS_
M`)`MY_UP?_T$U\Q_&7]GKQI\4==TG4_"XT^&!KO3;*^FN)@K-IPOM3CU-%'7
M<;6[^7L6QZ5I+F]B^3>^GK9I?CKKIWTN9NR;D^B7_I4;^NE_/MJ=!X#_`."E
M?P'\6?"*T\5:GX_\">%;H>$++QOJV@:KKEC'K'A[3KJW@GCDN[99"\8Q<P+N
MQM9I8PI;>N>ZC_:Q^#<MUK$"_$OX9M-X=LK74M5C'B&Q+:9:W2HUM/./,S%%
M,LD9C=\*X=2I((S\;_!K]ACXR>%='T'3?$&DW^H1^&_AE!X>LXU\2Q#2(I5\
M.Q69LA9A]K7`OTG<WC+@QS1J&VH0-JZ_89\5>-/CYJ&N:EX!\5PS3>(-+UV"
M_OO'$5YH4%NWB#2=4NK.'3/,(AFC2V8&14"NUJ2I/F#.W)&6)<$[0OO?HV^_
M96^YV;33.C$QIPE*--WL_6^BUZ+?33O_`'6?77_#0/P]L?'&B^%=4\3>#='\
M7>)I[R+1="N]9LEU+6%M99(Y7MH!(7E`$3,P0%D&0X5E8#<^&/BW3?BEX#TW
MQ!9V)M[74XS)''-&OF*`Q7G&1V[&OEG]HK]EGXC>._BU\-9--T_6KK1=$\9C
M7IY+/Q(EAI^GQ+XD.H2O=VN\&],MIY8B7#>4\;G@OS]+?L[>"]0^'?P6\/Z+
MJD:0ZAI\#1S(CAU4EV/!'!X(KE]ZT97WYKKTY;/YW?W&:W:_P_>T[_=H==_9
MMO\`\^\/_?`H_LVW_P"?>'_O@5-13NP(?[-M_P#GWA_[X%']FV__`#[P_P#?
M`J:BB[`A_LVW_P"?>'_O@4?V;;_\^\/_`'P*FHHNP(?[-M_^?>'_`+X%']FV
M_P#S[P_]\"IJ*+L#/TC3K<VK?Z/#_KI?X!_ST:K7]FV__/O#_P!\"H]'_P"/
M1_\`KO-_Z,:K5.3=R8[$/]FV_P#S[P_]\"O/?VM](M)_V4_B='):V[H_A/55
M96C!#`V<N01BO2*\_P#VLO\`DUCXF?\`8J:I_P"DDM3=E&K_`,*(\#_]";X4
M_P#!1;__`!%'_"B/`_\`T)OA3_P46_\`\175T4`<H?@1X'`_Y$WPK_X*+?\`
M^(KYWUO]J+X3Z):>"[Q_@[?+8>++ZZ@N9I_#%O:R>';6'4X=,6\O89@LL227
M%Q;CRMAF19&:2-%BE*?69/%?"/Q"_9>^('[5EGX3M/$GPO\`$/@+4;7QCJ%W
M<ZK!XVMC;VVDR:I;ZF8[F&UDS=I.8Q$L)#!)80[`*0:F7-;W=7TZ*_2[[7M?
MK:]M;-4DK7>UU?TU;LN]EINN:UT[V?9?##QQ\/\`]J?5/A[JEG\*D\(BS\:-
M!]CUO0[6">^M)_#5]>6MVJKN_=30S1,%;#HZNDBI)&Z+](_\*(\#_P#0F^%/
M_!1;_P#Q%?-W[,OPU\>>`G^&\GQ#T73_``]K4GBFUTR&SL[U;M'AL?"=[:_:
M-ZD@>;+',ZK]Y8S&&PVZOKRMJG*I-0VZ=VNC?9M:M65G=65K$1O;WM^O6SZI
M/JD]$^JZO<Y3_A1'@?\`Z$WPI_X*+?\`^(H_X41X'_Z$WPI_X*+?_P"(KJZ*
MS&<I_P`*(\#_`/0F^%/_``46_P#\17!>'?@?X+;]J#QA$?!_A<QIX6T)E3^R
MH-JDW>L`D#;U.!^0]*]HKS_PY_R=/XR_[%30?_2O6:`-7_A1'@?_`*$WPI_X
M*+?_`.(H_P"%$>!_^A-\*?\`@HM__B*ZNB@#E/\`A1'@?_H3?"G_`(*+?_XB
MC_A1'@?_`*$WPI_X*+?_`.(KJZ*`/%_V5?@?X+NOV7_AO++X/\+R22>%M,9W
M;2H&9B;2(DD[>2:[W_A1'@?_`*$WPI_X*+?_`.(K*_9-_P"36/AG_P!BII?_
M`*215Z!0!RG_``HCP/\`]";X4_\`!1;_`/Q%'_"B/`__`$)OA3_P46__`,17
M5T4`>+_M(?`_P7;?#W3FC\'^%XV/BGPZI*Z5`"0=;L01]WH02#Z@UWO_``HC
MP/\`]";X4_\`!1;_`/Q%97[2_P#R3K3?^QK\-_\`I\L:]`H`Y3_A1'@?_H3?
M"G_@HM__`(BC_A1'@?\`Z$WPI_X*+?\`^(KJZ*`.4_X41X'_`.A-\*?^"BW_
M`/B*X+Q%\#_!:_M0>#XAX/\`"XC?PMKK,G]E0;6(N]'`)&WJ,G\SZU[17G_B
M/_DZ?P;_`-BIKW_I7HU`&K_PHCP/_P!";X4_\%%O_P#$4?\`"B/`_P#T)OA3
M_P`%%O\`_$5U=%`'*?\`"B/`_P#T)OA3_P`%%O\`_$4?\*(\#_\`0F^%/_!1
M;_\`Q%=710!XO^TA\#_!=M\/=.:/P?X7C8^*?#JDKI4`)!UNQ!'W>A!(/J#7
M>_\`"B/`_P#T)OA3_P`%%O\`_$5E?M+_`/).M-_[&OPW_P"GRQKT"@#E/^%$
M>!_^A-\*?^"BW_\`B*/^%$>!_P#H3?"G_@HM_P#XBNKHH`Y3_A1'@?\`Z$WP
MI_X*+?\`^(K@O$7P/\%K^U!X/B'@_P`+B-_"VNLR?V5!M8B[T<`D;>HR?S/K
M7M%>?^(_^3I_!O\`V*FO?^E>C4`:O_"B/`__`$)OA3_P46__`,11_P`*(\#_
M`/0F^%/_``46_P#\175T4`<I_P`*(\#_`/0F^%/_``46_P#\11_PHCP/_P!"
M;X4_\%%O_P#$5U=%`'RU^Q_\%_!UY^T)^U5'-X3\,RQVOQ1LHH5?2X&6%#X*
M\+.54%?E&YV;`XRQ/4FO>O\`A1'@?_H3?"G_`(*+?_XBO*OV-_\`DXK]K'_L
MJMC_`.H1X4KZ`H`Y3_A1'@?_`*$WPI_X*+?_`.(H_P"%$>!_^A-\*?\`@HM_
M_B*ZNB@#E/\`A1'@?_H3?"G_`(*+?_XBO!?^"5GP7\':K_P3`_9ONKKPGX9N
M;FY^%WAF6::72X'DE=M)M2S,Q7)))))/)-?4M?/_`/P2=_Y19?LT_P#9*O"_
M_IHM:`/5?^%$>!_^A-\*?^"BW_\`B*/^%$>!_P#H3?"G_@HM_P#XBNKHH`Y3
M_A1'@?\`Z$WPI_X*+?\`^(KP7_@H_P#!?P=IO[/?AV2W\)^&;>1OBC\.XBT>
MEP*Q1_&NB(ZY"]&5F4CH02#P:^I:^?\`_@I9_P`FZ^'/^RJ_#C_U-]"H`]5_
MX41X'_Z$WPI_X*+?_P"(H_X41X'_`.A-\*?^"BW_`/B*ZNB@#E/^%$>!_P#H
M3?"G_@HM_P#XBC_A1'@?_H3?"G_@HM__`(BNKHH`^6OB'\%_!T?_``4_^#]J
MOA/PRMM-\+O',LD(TN#RW=-6\'A6*[<$J'<`GD!V]37O7_"B/`__`$)OA3_P
M46__`,17E7Q&_P"4IOP;_P"R5>//_3OX,KZ`H`Y3_A1'@?\`Z$WPI_X*+?\`
M^(H_X41X'_Z$WPI_X*+?_P"(KJZ*`.4_X41X'_Z$WPI_X*+?_P"(KY(_X)7_
M``>\(ZI\0OVNENO"WARX6S^/6JP0"7387$,8T71"$7*_*H+,<#C)/K7W%7Q_
M_P`$H/\`DHO[87_9P&J_^F/0Z`/I7_A1'@?_`*$WPI_X*+?_`.(H_P"%$>!_
M^A-\*?\`@HM__B*ZNB@#Q/XMZA\./@]XGL]/O_AK87-O<:;>ZE-J%OH%N;6V
M6V@DG\HL5&^1TBE(1-Q&P;MH="W@_P`<?CYX)\0_`[7M)NO@;/X:O]3\/ZO9
M:U+=V&E%?!U[Y%Y':073Q2L)'N9+=Q&UL95!,>YDWIGWC]J'2/%7B[XA>#])
MT_X>W'BSPF\.I'6[Y-8M;-;=9;"XMU@\N1A(YD,H&Y00N<G&*^5_&?[*/C[P
M%^S?XBLKKPWK4>E^)=)O/$?B+4=;\4IK.I:'-8OJ%U!;SS.[/=R3++;1[T+*
M@C<$@!:K#14JG[WX;I?BK_)1YGYM)=;//%2G&G^Z7O6?Y.WWRLO)-]KKZ/\`
M^"4&GV[_`/!+3]FIF@A9F^%?A<DE!S_Q*+6OH15"*%4!548`':O`/^"3O_*+
M+]FG_LE7A?\`]-%K7T!4F@4444`4?$]LM[X:U"%FD59K:1"8W*,`5(X8$$'W
M!R*\BOOB_P##OX&:=X3TGQ=XPDT'4/%FH2Z=H\%SJER&OIC<>6JC#'DLZ#<V
M`2W)S7L.N?\`(%O/^N#_`/H)KY*^/GB[1/"FMZ]HFNZ3J&H7_P`4/"1\->%O
M)TR2\2XOEO[\2PF15*P?-=64A:0HI$8.24`&T925.R[[=7H]%YO;KZ/8RE;G
MNUT^[5:^BW_-I:KUW3?VE?A-J[>.EM_'R2-\,S(/$X_M6Y4Z1Y9=7W@MSAHW
M7Y<\KCJ0#VW@:30/B5X-TOQ!H.KZAJ6BZU:QWMC=Q:E<;+B&10R.,L#@@@\C
M-?#/QL\2:?X[^*>GZMIGA_7-7L_@OKNJW'CBXAL;F$VUL_C'3;V*)4*+]K58
MK2>\_=;P$M649,NT_>OPS\5Z3X[\!:7K>A0R0Z/J\(O+/?:M:M)%(2ZR&-@&
M7?G?A@&^;D`Y%9TJDI4E4?\`6F_I+97L[QENK,TE%*?*OO\`G:WJK)O_`!+9
MW1/_`,(9:_\`/SJW_@RN/_BZ/^$,M?\`GYU;_P`&5Q_\76M11SR[BY49/_"&
M6O\`S\ZM_P"#*X_^+H_X0RU_Y^=6_P#!E<?_`!=:U%'/+N'*C)_X0RU_Y^=6
M_P#!E<?_`!='_"&6O_/SJW_@RN/_`(NM:BCGEW#E1D_\(9:_\_.K?^#*X_\`
MBZ/^$,M?^?G5O_!E<?\`Q=:U%'/+N'*C)_X0RU_Y^=6_\&5Q_P#%T?\`"&6O
M_/SJW_@RN/\`XNM:BCGEW#E1@:7X/MI+9C]HU7_72CC49QTD8?WZL_\`"&6O
M_/SJW_@RN/\`XNKFC_\`'H__`%WF_P#1C5:IRG*^X**L9/\`PAEK_P`_.K?^
M#*X_^+KSG]L+X?6>I_LD?%*VDO-<2.X\(:M$S0ZO=12*&LI@2KK(&5N>&4@@
M\@YKURO/_P!K+_DUCXF?]BIJG_I)+2YY=PY4>8_\.O?`?_0\?M'?^'R\8?\`
MRRH_X=>^`_\`H>/VCO\`P^7C#_Y95]'45)1\X_\`#KWP'_T/'[1W_A\O&'_R
MRH_X=>^`_P#H>/VCO_#Y>,/_`)95]'44`?'7Q7_X)H^!]/\`'GPSA3QK^T*Z
MWWB6:!S+\:_%LC(HT?4I,QLVHDQME`-R88J67.UF![?_`(=>^`_^AX_:._\`
M#Y>,/_EE7IWQE_Y*+\)O^QKG_P#3'JU>@4`?./\`PZ]\!_\`0\?M'?\`A\O&
M'_RRH_X=>^`_^AX_:._\/EXP_P#EE7T=10!\X_\`#KWP'_T/'[1W_A\O&'_R
MRKB-!_X)H^!YOVD/%EB?&O[0HBM_#6BSJZ_&OQ:LS,]UJRD-(-1WLH\L;5)*
MJ2Y`!=L_8M>?^'/^3I_&7_8J:#_Z5ZS0!YC_`,.O?`?_`$/'[1W_`(?+QA_\
MLJ/^'7O@/_H>/VCO_#Y>,/\`Y95]'44`?./_``Z]\!_]#Q^T=_X?+QA_\LJ/
M^'7O@/\`Z'C]H[_P^7C#_P"65?1U%`'QU^S-_P`$T?`^N?LW_#^^E\:_M"Q2
MWGAK3IW2W^-?BVWA1FM8V(2--1"(HSPJ@*!@``"NW_X=>^`_^AX_:._\/EXP
M_P#EE7IW[)O_`":Q\,_^Q4TO_P!)(J]`H`^<?^'7O@/_`*'C]H[_`,/EXP_^
M65'_``Z]\!_]#Q^T=_X?+QA_\LJ^CJ*`/CK]H'_@FCX'T?P'831^-?VA9&?Q
M+H$!$_QK\6S*%DUBSC)"OJ)`8!B58?,C!64AE!';_P##KWP'_P!#Q^T=_P"'
MR\8?_+*O3OVE_P#DG6F_]C7X;_\`3Y8UZ!0!\X_\.O?`?_0\?M'?^'R\8?\`
MRRH_X=>^`_\`H>/VCO\`P^7C#_Y95]'44`?./_#KWP'_`-#Q^T=_X?+QA_\`
M+*N(U[_@FCX'A_:0\)V(\:_M"F*X\-:U.SM\:_%K3*R76DJ`LAU'>JGS#N4$
M*Q"$@E%Q]BUY_P"(_P#DZ?P;_P!BIKW_`*5Z-0!YC_PZ]\!_]#Q^T=_X?+QA
M_P#+*C_AU[X#_P"AX_:._P##Y>,/_EE7T=10!\X_\.O?`?\`T/'[1W_A\O&'
M_P`LJ/\`AU[X#_Z'C]H[_P`/EXP_^65?1U%`'QU^T#_P31\#Z/X#L)H_&O[0
MLC/XET"`B?XU^+9E"R:Q9QDA7U$@,`Q*L/F1@K*0R@CM_P#AU[X#_P"AX_:.
M_P##Y>,/_EE7IW[2_P#R3K3?^QK\-_\`I\L:]`H`^<?^'7O@/_H>/VCO_#Y>
M,/\`Y94?\.O?`?\`T/'[1W_A\O&'_P`LJ^CJ*`/G'_AU[X#_`.AX_:._\/EX
MP_\`EE7$:]_P31\#P_M(>$[$>-?VA3%<>&M:G9V^-?BUIE9+K25`60ZCO53Y
MAW*"%8A"02BX^Q:\_P#$?_)T_@W_`+%37O\`TKT:@#S'_AU[X#_Z'C]H[_P^
M7C#_`.65'_#KWP'_`-#Q^T=_X?+QA_\`+*OHZB@#YQ_X=>^`_P#H>/VCO_#Y
M>,/_`)94?\.O?`?_`$/'[1W_`(?+QA_\LJ^CJ*`/@/\`93_X)R^"_$'QW_:8
MM)O&7Q\ACT/XDV=E`]M\9/%5O+.C>#_#5P6G>/4`T\FZ=U$DI9Q&L488)%&J
M^W?\.O?`?_0\?M'?^'R\8?\`RRJ]^QO_`,G%?M8_]E5L?_4(\*5]`4`?./\`
MPZ]\!_\`0\?M'?\`A\O&'_RRH_X=>^`_^AX_:._\/EXP_P#EE7T=10!\BZ_^
MQA\%O"_Q8T/P+J'Q4_:#MO%OB6"6ZTS3&^./C(S7<409I'7&HX``5NI'0UY[
M_P`$S_\`@G+X+\<?\$X/V?M:NO&7Q\M;K6/AMX=O9H=/^,GBJPLX7ETNV=EA
MMX=02*&,%B%CC5410%50``/H#XT>)O\`A&_VTOAO!HOBKQ1#K^M0FUU+PQ!I
MT<NCZGIB)=.;NXN&MF>*6"0DH$N4W%@&C<$%8_\`@D[_`,HLOV:?^R5>%_\`
MTT6M/[*EZK[OZ^^_9I$G:;CY)_?_`,%/3M9]2C_PZ]\!_P#0\?M'?^'R\8?_
M`"RH_P"'7O@/_H>/VCO_``^7C#_Y95]'44@/EGQY_P`$_OA3\,/#DFK^(/B5
M^T)I.FQR1PM<7'QT\8*@>1PB+_R$NI9@/QKY_P#VS_V4_@_J?@2YT/PW\3OC
M=K7B/PC\3?AYIFN:?<?&7Q7>_P!FB^\7:1$"R37[()?+9VCD7YXI$5T9)$5A
M]A?M[>-_#OP\_9=\2:IXD1FMXX3%:-'ILU_*ES(K)&42)'<,=S#<!P&.2`:^
M3?VC/$%MXQU'_B5V]]"OA?XF>#[?5VFL9;9));_XH:->V6UF4";-OODRI.SS
M@#AF8!TESU'%[6>O:R;7WVMZM$UI<D%);W6GJTG;TO?Y/U/HC_AU[X#_`.AX
M_:._\/EXP_\`EE1_PZ]\!_\`0\?M'?\`A\O&'_RRKZ.HI%'SC_PZ]\!_]#Q^
MT=_X?+QA_P#+*C_AU[X#_P"AX_:._P##Y>,/_EE7T=10!\!^/?\`@G+X+M/^
M"C_PIT5?&7Q\:UU#X;>-+V29_C)XJ>\C>#5/"B(L=P=0,L<;"X<O&C!)&2)G
M5C%&5]N_X=>^`_\`H>/VCO\`P^7C#_Y95>^(W_*4WX-_]DJ\>?\`IW\&5]`4
M`?./_#KWP'_T/'[1W_A\O&'_`,LJ/^'7O@/_`*'C]H[_`,/EXP_^65?1U%`'
MSC_PZ]\!_P#0\?M'?^'R\8?_`"RKY:_X)H_\$^O!WC?QW^U1#=>+OCI:KH/Q
MNU+2[<Z?\7?$]@T\2Z/HT@>X:&_0W$Y,C`S3%Y6544L510/TSKX__P""4'_)
M1?VPO^S@-5_],>AT`=E_PZ]\!_\`0\?M'?\`A\O&'_RRH_X=>^`_^AX_:._\
M/EXP_P#EE7T=10!\WS_\$Q/`%M"\DGCO]HR..-2S,WQS\8!5`Y))_M*O"/C]
M^S]\`[CX-ZQI^E_&#XY:AK?BKPAJ^J:!9R?&OQA<QZI%;VLYD;8]^8V0&-PR
MR##!6!!Y%??/B66Q@\.:@^J1QS::EM(UVDD/G*\(4[P4P=P*Y^7!STP:_/7Q
MS\9=%\4?"&SOO`WBSQA'=^(-!\4VEYX9&@-;Z3J6E(=7D%U.\]F)H)(&;,82
M>,/O`,;@@J1NZBA_7E?LK_KZA.T:;G_3ZZ=W:^G>W<^A?^"4OA*WN?\`@ES^
MS;(UQJBM)\+/##$)J$ZJ,Z3:]`&P![#BOI"WA%M!'&I=EC4*"[%F./4GDGW/
M->!?\$G?^467[-/_`&2KPO\`^FBUKZ`IN3>X6"BBBD!1\3I))X:U!89%BF:V
MD$;LF]4;:<$KD9`/;(SZBN9^&NGZU_PAUO\`\32QSYLX)^P'D^<^3_K.Y[=J
MZK7/^0+>?]<'_P#037P?^VKHNKV7QP^&_C+3]/TF:W\$W.G22WSZE+;ZG9&[
M\1I:K'9Q8\F;[07$,RR.K>4Q\L.Y"'>$DHI2T3>K[*S;?RL92C)MN"N[:*]K
MMM)+YMGW)_9^M?\`04L?_``__':/[/UK_H*6/_@`?_CM?F]X^\"MX+_9M^&O
MB;X>Z]=ZEJ_QL\+)!K;PW_.N:KJ)TR_EU':7^25[73]3/R\<,`,J0?;_```F
MFZQ\</A[\688;'Q-H7B#4=0M+&]AU)_MVBM?ZA?K:W20#Y);2Y@$<+G.Y#;P
MLJE!*T9RRYN32ZERNRVGT2TU335GI=NUKIV4JD5!375<R3NGR]6^S3O=:Z:W
M/K+^S]:_Z"EC_P"`!_\`CM']GZU_T%+'_P``#_\`':UJ*RYW_21KRF3_`&?K
M7_04L?\`P`/_`,=H_L_6O^@I8_\`@`?_`([6M11SO^D@Y3)_L_6O^@I8_P#@
M`?\`X[1_9^M?]!2Q_P#``_\`QVM:BCG?])!RF3_9^M?]!2Q_\`#_`/':/[/U
MK_H*6/\`X`'_`..UK44<[_I(.4R?[/UK_H*6/_@`?_CM']GZU_T%+'_P`/\`
M\=K6HHYW_20<I@Z58:P;9MNI62CSI>MB3SYC9_Y:58_L_6O^@I8_^`!_^.U<
MT?\`X]'_`.N\W_HQJM54IN__``$*,=#)_L_6O^@I8_\`@`?_`([7*_';X=>(
M/B5\$/&7AVW\1:=IEQX@T.]TV*\?26N%M&FMWC$AC\]=X4MNV[ESC&1G->@5
M5US_`)`MY_UP?_T$TE)W_P"`@L?/?_"EOVI/^B__``G_`/#07/\`\O:/^%+?
MM2?]%_\`A/\`^&@N?_E[7T=14%'SC_PI;]J3_HO_`,)__#07/_R]H_X4M^U)
M_P!%_P#A/_X:"Y_^7M?1KKN1ADKD8R.U?F!XX^%NA^`/$%UJ6C^)+A?#,.J7
M'C/X:VR:NS+)=1ZCX:TYKB,[O](^T78N2NTLKIJQ"_Z]<)25WS=(REYOE5VD
MNKM=KNTEU;6D:;E9+=M+YR=EMYM7?17>]D_I?Q7^S9^TUXAU[PS>7/Q_^%OG
M:%J3WUKL^$=PJ^8UG<VYW#^W#E?+GDX&.=ISQ@[?_"EOVI/^B_\`PG_\-!<_
M_+VN9_X);Z5HOA_X?:A:^'=8DUK3;V31=:N)VU#[=NO[WP_:7%R^_)PTVZ.X
M*]";DN``XKZTK6M3]G-P>Z;3]4[.WE?9]5K9;&,972ET=FN]FKJ_9V>JZ/J]
MSYQ_X4M^U)_T7_X3_P#AH+G_`.7M'_"EOVI/^B__``G_`/#07/\`\O:^CJ*S
M*/G'_A2W[4G_`$7_`.$__AH+G_Y>UB6'[-G[35G\2-6UQ/C_`/"W[=J&FV5C
M-GX1W'E^7!+=O'@?VYD-NN),G)R-O`P<^5?MJ>"-+7]N"SM]8O+>UT'XI06.
MA:BUEKAW:G%'K.@Q3VE]$Q7R%`N(8HO)W[UU"X5VC9X0_P!0?L-7,=U^R[X!
M-O?2:I9Q^&[&&TO7G\]KRW0.D,ID_P"6F^-4;>.&SGO512=)5.[:MVM;?U3B
MUWN^B3=2BT[=-']]U]Z<9)]K+NTN/_X4M^U)_P!%_P#A/_X:"Y_^7M'_``I;
M]J3_`*+_`/"?_P`-!<__`"]KZ.HJ23YQ_P"%+?M2?]%_^$__`(:"Y_\`E[1_
MPI;]J3_HO_PG_P##07/_`,O:^B+^6."QFDFF%O"D;,\I8*(U`Y;)X&!SGM7P
M!\'/A1;>#_B1INBZU8Z;H^H?#GQ#9W>BVVDZO-=Z;:3:AJFEK.UM+)M>826M
MS#O$B`J]Y,`-K(S9^T7M8TGU_P`F]O1.W=JQ?LW[-U.W^:7YM7[(]<^&?[-G
M[37@7X;^']#T_P"/_P`+?L.CZ;;6-MYWPCN'D\N*)43<1K@!;:HR0!D]A6W_
M`,*6_:D_Z+_\)_\`PT%S_P#+VOH30_\`D"V?_7!/_015JM7N0MCYQ_X4M^U)
M_P!%_P#A/_X:"Y_^7M'_``I;]J3_`*+_`/"?_P`-!<__`"]KZ.KPW_@HMX]M
MO`_[*VNQWVD^+]8T[7V32+]/#F@WVLW<-K+DW#-#9QR3+&85D0R*N$,BDD#F
ML,165*FZCZ?TC6C3=2:@NIQ'Q!_9L_::\8Z#;V=[\?\`X6^3#J5A?+Y7PCN%
M;S+>\AN(^3KA^7S(DR.XR,C.1M_\*6_:D_Z+_P#"?_PT%S_\O:XW]C5-/\1?
M%B+QD@OH=>\7:=<QZ@MXLUO</;6CZ(MBLMM+AXF2&X+;656!N&+#YA7V!6VC
MBI+JK_?JOPW\].AA%WO_`%_7EY'SC_PI;]J3_HO_`,)__#07/_R]H_X4M^U)
M_P!%_P#A/_X:"Y_^7M?1U%!1\X_\*6_:D_Z+_P#"?_PT%S_\O:Q+_P#9L_::
MO/B1I.N/\?\`X6_;M/TV]L8<?".X\ORYY;1Y,C^W,EMUO'@Y&!NX.1BE_P`%
M!-7\0:7\<?`.I:;X?\.Z]9>%=.NM347]_<07EE>SW=E9V]S9PQH4N)8WF`*2
M,H"R'&YF`KNOV#O!NB?#WP5J.C>''W:-:W<<\"BY-P`UQI>E7,K!B2?WDLTD
MIYP3*2."*SH554<K=/\`.4?SB_P[Z55@X6\_\D_RDOQ[:YO_``I;]J3_`*+_
M`/"?_P`-!<__`"]H_P"%+?M2?]%_^$__`(:"Y_\`E[7T=16A)\X_\*6_:D_Z
M+_\`"?\`\-!<_P#R]H_X4M^U)_T7_P"$_P#X:"Y_^7M?1U>$_P#!1W3+SQ-^
MRY?Z#IFAZ=XIUCQ!J>GV-AH.H7K6-IK<OVJ.0VTMPO,2,D;DM_L8&20#G6J<
MD>;T_%V^;\E=O9)O0J,>9V_K37^GLNIQGQ!_9L_::\8Z#;V=[\?_`(6^3#J5
MA?+Y7PCN%;S+>\AN(^3KA^7S(DR.XR,C.1M_\*6_:D_Z+_\`"?\`\-!<_P#R
M]KA?V'='TV3X@Z?XDCN+J;7/$6D36E_+/.3+=6UDVB)8[X]Q"E89RX(Z_:6;
M)#@U]D5<)*5.-1?:2?R>J_#\="7=2<7T=ONT_,^<?^%+?M2?]%_^$_\`X:"Y
M_P#E[1_PI;]J3_HO_P`)_P#PT%S_`/+VOHZBF!\X_P#"EOVI/^B__"?_`,-!
M<_\`R]K$O_V;/VFKSXD:3KC_`!_^%OV[3]-O;&''PCN/+\N>6T>3(_MS);=;
MQX.1@;N#D8I?\%!-7\0:7\<?`.I:;X?\.Z]9>%=.NM347]_<07EE>SW=E9V]
MS9PQH4N)8WF`*2,H"R'&YF`KNOV#O!NB?#WP5J.C>''W:-:W<<\"BY-P`UQI
M>E7,K!B2?WDLTDIYP3*2."*SH554<K=/\Y1_.+_#OI56#A;S_P`D_P`I+\>V
MN;_PI;]J3_HO_P`)_P#PT%S_`/+VC_A2W[4G_1?_`(3_`/AH+G_Y>U]'45H2
M?./_``I;]J3_`*+_`/"?_P`-!<__`"]H_P"%+?M2?]%_^$__`(:"Y_\`E[7T
M=7YR^,/A]I/C?]I'XH:/XST^WTOPSXXU>ZGM[R+6'!\50Z;;ZJSSW"AA]F>Q
MO(X88UR-Z0*_.&`%O;R;^Y7=EU=K_=?9-J92LEYM+[]->RO;7SMNTGZM\*?V
M0_VCOA[X[^)FK:;^T!\,_MGCKQ+#KFJ^=\);AT^TIH^FZ>OE`:V"B>18P94E
MCOWMG#!5[;_A2W[4G_1?_A/_`.&@N?\`Y>UZI^SKK6H^(_AAINH:NLBZM?V=
MC<7H="C"=]/M6DRIY!W$\'I7=5MB*3I5'3?1V(H555IQJ+JK_>?./_"EOVI/
M^B__``G_`/#07/\`\O:/^%+?M2?]%_\`A/\`^&@N?_E[7T=5?5;#^U=+N;7S
MKBV^TQ-%YT#[)8MP(W(W9AG(/8BL34^>?^%+?M2?]%_^$_\`X:"Y_P#E[7$_
MLS_LA_M'?`O]G#X?^"=`_:`^&?\`87@[PWIVAZ=]K^$MQ-<?9K:UCAB\QUUM
M0S[$7+!5!.3@=*3X<_#-?A[\6/@[XG;0=!U30K&ZU/PA8WMWJ=R-8T69KK4M
MAMX=IBFCDC`20NX9%3<`0"1]8^"/^1+T?_KRA_\`1:TX>]251?U_2:?S%+W:
MG)Y7^_\`X*:^1X+_`,*6_:D_Z+_\)_\`PT%S_P#+VC_A2W[4G_1?_A/_`.&@
MN?\`Y>U]'44AGSC_`,*6_:D_Z+_\)_\`PT%S_P#+VN)_:!_9#_:.^,7@2PTG
M6OV@/AG]CL_$N@ZY']E^$MQ$_P!IT[6+/4+;).ML-GGVT6]<99-R@J2&'LG[
M=?@_P[X^_9MUK1_$:27`U`K;Z3;1R.LEUJCY2R5`GS,PG:-P!P"FYOE5C7$_
M!'P/<?";]H;XEZ7JFC>'(]4\47FF>(H]:TV^GGN]7MFOWC47L4BA()(SE4$1
M970$[LJ0*I14Y<O7^G^5WZ?A-27+'F_I7=E][:2\^W6Q_P`*6_:D_P"B_P#P
MG_\`#07/_P`O:/\`A2W[4G_1?_A/_P"&@N?_`)>U]'45)1\X_P#"EOVI/^B_
M_"?_`,-!<_\`R]H_X4M^U)_T7_X3_P#AH+G_`.7M?1U?*7_!0O1Y=!\>^%?&
MT$.FQMH.EZM8MJ,>IR1ZIILESIMZ(1%;A?+:!V5FD=FW*;:,JI5792*;DHKK
MI\^GWO0-%%R?17^[?\#(U[]D/]H[5_VC_"GC:;]H#X9_V[X>\-ZUH=GM^$MP
M+?[-?76DS3[T_MO+/OTZVVL&`4>8"&W`KVW_``I;]J3_`*+_`/"?_P`-!<__
M`"]K6_8T\)Z;\-X]:\*:!#]G\*^%M;U:PT.(2-*D5N393.BNQ)95N);A>IVE
M2O5:]XK2I3Y>7S2?WJZ^=GJ94JG.GY-K[G9_BCYQ_P"%+?M2?]%_^$__`(:"
MY_\`E[1_PI;]J3_HO_PG_P##07/_`,O:^CJ*S-3YQ_X4M^U)_P!%_P#A/_X:
M"Y_^7M?+?_!-'X5?M#:EX[_:H70_C1\-])FM?C=J<&JO=?#*>\74+P:/HQ:X
MB`U>/R(RAB41$R$&-F\P[]J^N?M,_L_Z3XUU?XO:YX5T;PWXFL=.N--U+Q78
M:_JEU9:;JM[9QWLLRF>)6VRP6\]K@*`FY$5V4JQ%K_@C]K$?B'Q)^UIJ$*21
MPWWQWU*XC21=KJKZ#H3`$=B`>13CK#F7E?Y[??9V]/DE)VGR_P!:6O\`==7\
M_O.^_P"%+?M2?]%_^$__`(:"Y_\`E[1_PI;]J3_HO_PG_P##07/_`,O:^CJ*
M0SYQ_P"%+?M2?]%_^$__`(:"Y_\`E[7$_M,_!W]IJV_9O^(,E]\=_A9=V,?A
MK46N((OA-<PR31BUD+(KG6V"$C(#;6P3G!Z5K_M2Z6WB']MSP3_;7AOP[XE\
M(Z=IMOI4PNM4N(-1TR76)+ZU::UMT3RYE9;=%E,DBE(PS*&.<>%>+?@AX8^$
MWP;T_P`=>$?#'A6[\`:_H?B:ST&]_M:Z:_TM;V+4Y;6>RAPT4T%Q:^27+N&1
M`&"D!B+IPYK7ZMI>NFGS33^=B:DK<UOLI-^2=]?E9^>CTM9OZ0_X)2V.K/\`
M\$N?V;6CU&SCC/PL\,%%:R+%1_9-K@$^8,_7`KZ0MUD2!%D99)`H#LJ[0Q[D
M#)Q],FO`?^"3O_*++]FG_LE7A?\`]-%K7T!4N5R@HHHI`4?$]R+/PUJ$S+)(
ML5M(Y6-2S-A2<`#DGV'6O)=/^$/P]^)VL>$_&7B+P';:UXJ\(S7,FAZK>:*9
M;O22\[,?*<KE#D#..XKU[7/^0+>?]<'_`/0367\-?^10A_Z[7'_H^2MXM*G?
MJGI]QE+6=NEOU1Q_@KX,?#GX<2W4F@_#^STAKS6Y_$LYM=$,?FZG-"\$MX<+
M_KGBD="_4JY'>J^B?`7X8^&_$?@_5]/^'5A9ZI\/M.;2?#5U#H9630[1D,;0
M6Y"_NXRA*[5P,&O5J*R3BME_5K?EIZ&KN]^O_#_GJ9/_``F$7_/CJW_@#)_A
M1_PF$7_/CJW_`(`R?X5K447CV%J9/_"81?\`/CJW_@#)_A1_PF$7_/CJW_@#
M)_A6M11>/8-3)_X3"+_GQU;_`,`9/\*/^$PB_P"?'5O_``!D_P`*UJ*+Q[!J
M9/\`PF$7_/CJW_@#)_A1_P`)A%_SXZM_X`R?X5K447CV#4R?^$PB_P"?'5O_
M``!D_P`*/^$PB_Y\=6_\`9/\*UJ*+Q[!J8&E^+8H[9A]CU4_OI3Q92'K(Q]*
ML_\`"81?\^.K?^`,G^%7-'_X]'_Z[S?^C&JU3DXWV%&]C)_X3"+_`)\=6_\`
M`&3_``JMK'BV*32;I?L>JC="XR;*0`<'VK?JKKG_`"!;S_K@_P#Z":(N-]@U
M*?\`PF$7_/CJW_@#)_A1_P`)A%_SXZM_X`R?X5K44KQ[#U,>7Q7;SQ-&]AJS
M(X*L#8R8(/X5X_\`#O\`8G^!/PD31E\,_!OPWH2^'=4;6M,%EX;$0L+UHUB-
MQ'A?ED*(B[ASA1Z5[Q11[M[V[?@[K[GJO,-;6_K71_@><_#7P)X-^!FB0Z/X
M,\(+X7TJ;49M0EM-.TDV\4EQ*KF23:J@%V/)/4XKL/\`A,(O^?'5O_`&3_"K
MFH?\?=C_`-=S_P"BWJU3]U)*VRM\D+6[9D_\)A%_SXZM_P"`,G^%'_"81?\`
M/CJW_@#)_A6M12O'L/4\B\5_LY?"GQUK'C#4-9^&>EZI??$"U@L?$L]SH/F2
M:Y!"%$,=P2N9%0(N`>FT>E=IX?U+3_#*1:?I^DWUGI]C9P6MM;0V#HD$:;U5
M%4#A0N`![5U-58?^0U<?]<(O_0I*<7%*R7]?TW][[A*[=W_6B7Z+[EV*?_"8
M1?\`/CJW_@#)_A1_PF$7_/CJW_@#)_A6M12O'L&ICOXMAD4JUCJS*PP0;&3G
M]*\U\(?LQ_"/P!!X0BT7X7Z3I<?@"YNKSPVMMH'EC1)KG/VB2WPO[MI,G<1U
MKV*BCW;WM_6X];6,#1_%L4>DVJ_8]5.V%!D64A!X'M5G_A,(O^?'5O\`P!D_
MPJYH?_(%L_\`K@G_`*"*M4Y.-]B8WL9/_"81?\^.K?\`@#)_A4=WXEM;^TEM
MYM.U26&9#'(C6$A5U(P01CH16U12ERM6:*5T[IGFVD?#OP3X)\;:MXJT;P;'
MI?B3Q`EC::GJ<&D&.YOH;8JD$<CA<LL:_*H/08`KL_\`A,(O^?'5O_`&3_"K
MFL?\>B?]=X?_`$8M6JJZML38R?\`A,(O^?'5O_`&3_"C_A,(O^?'5O\`P!D_
MPK6HJ;Q[#U.#\9^"?!WQ%\7>&]>U[PA_:VM>#YY+K0[VZTEI)]*ED4([PL5R
MC,H`)'4"J_PJ\$>#_@/H5GX?\%^$1X7T&W^TSII^G:4UO"LDLBR2.$5<99B2
M3ZFO1*JS?\AJW_ZX2_\`H4=./+V_K^DA2O\`U_7K]Y3_`.$PB_Y\=6_\`9/\
M*/\`A,(O^?'5O_`&3_"M:BE>/8>ID_\`"81?\^.K?^`,G^%<[\5_"GA/XZ^`
M=0\*^,O";>)O#>J!!=Z;J.E-/;7(1U==R,N#AU5A[@5W%%#Y7HT-76J/,_#_
M`,,?`OP\\6ZEXDT'P5#H^OZW%86.H:A;:08;B\M[7:EO$[A<LL:#:H/08`KM
MO^$PB_Y\=6_\`9/\*N:Q_P`>B?\`7>'_`-&+5JJNK;$V,G_A,(O^?'5O_`&3
M_"C_`(3"+_GQU;_P!D_PK6HJ;Q[#U.#\9^"?!WQ%\7>&]>U[PA_:VM>#YY+K
M0[VZTEI)]*ED4([PL5RC,H`)'4"J_P`*O!'@_P"`^A6?A_P7X1'A?0;?[3.F
MGZ=I36\*R2R+)(X15QEF))/J:]$JK-_R&K?_`*X2_P#H4=./+V_K^DA2O_7]
M>OWE/_A,(O\`GQU;_P``9/\`"C_A,(O^?'5O_`&3_"M:BE>/8>ID_P#"81?\
M^.K?^`,G^%>7^)?V6?@_XQN?%4VJ_"O1M0E\<7=K?^('G\/[VUBXM3NMY9\K
M\[1GE2>E>S447C>]A6NK,Y?0_%,4.I:P?L>J8DNU8!;-SM_<0C!&.#QT]"/6
MM+_A,(O^?'5O_`&3_"G:!_R%M<_Z_5_])H*U*J35]@C<R?\`A,(O^?'5O_`&
M3_"J^K:W8Z]I5U8WFEZE=6=Y$\$\,EA(R2QL"K*PQR""01[UO45/NO1HI76J
M/%/AC^R7\&?@MKV@ZIX3^$^B>'=1\*P7%KH]S8>'_)DTV*X9WF2(A?D#M(Y8
M#J7/K7H?@_Q5';^$M+C-GJC&.TB4E+.1E.$'0XY'O745E^"/^1+T?_KRA_\`
M1:U?,G'4CEL]!O\`PF$7_/CJW_@#)_A1_P`)A%_SXZM_X`R?X5K45%X]BM3S
MGXW_``N\!_M*^"?^$;^('@B'QAH'VA+O^S]6T=KFW\Y,[)-K*1N7)P>V:R_"
M7P@\`?!0ZQ>>#?`]KX8O/$NHV5UJT]CI!MVU&2*9`C2,%&Y@I(&?7`ZUZU67
MXO\`^03#_P!?MI_Z4QU5.23LA25]6-_X3"+_`)\=6_\``&3_``H_X3"+_GQU
M;_P!D_PK6HJ;Q[#U,G_A,(O^?'5O_`&3_"N2\4_#?P/XW^(>F^+=8\%1ZEXF
MT>RGTZQU.XT=I+JUMIP5FB1RN51P2&`Z@FO0Z*/=>Z'JCS?X;>$_"OP2T_0?
M#7@_PN?#?AO1K&ZBL],T_3&@@M@\T3G9&HP`6+$X[M[UV7_"81?\^.K?^`,G
M^%.N_P#D=-/_`.O*Y_\`1EO6I52DG9LB*MHC)_X3"+_GQU;_`,`9/\*/^$PB
M_P"?'5O_``!D_P`*UJ*F\>Q6IX-XB_8G^!/B[Q)KVL:I\'/#M_JGBB^BU/5[
MJ?PX'EU*ZB8M'-*2OSNK,2">1FOASX8_MS_%+]@3]I#]I70;7]DG]H+XG:7X
MR^*U[XKT[6_#FB,;&2WFTW3;=4!9>6!M6;(XPZU^KE9>@?\`(6US_K]7_P!)
MH*>CC9=!=;]S\]_^'ZOQ6_Z,'_:N_P#!&/\`"C_A^K\5O^C!_P!J[_P1C_"O
MT<HJ"C\N_$W_``5J\4>-/B)H/B[5O^"<G[2^H^)_"\5Q!I&J7'AJ-[K3H[A-
MDZQ.5RHD7A@.HKB?BE_P4`UCQGX2==+_`.";?[0^F^)-)\)7?A#PWJG_``BL
M8DT*SFMI(%@B8+E(0'QM7MD5^O5%";2LOZW_`,W][[A97O\`UT_R7W(^?/\`
M@FDM]\.O^"<?[/\`X?US1->TW6M!^&_AW3K^SGT^5);6XATRVCDC=2,AE=6!
M!Z$5]`6\WVB".0*ZB10P#KM89]1V/M6=X(_Y$O1_^O*'_P!%K6I52LG9"CJK
MA1114C*?B&98-`OI)&5(TMY&9F.`H"G))K#^&NNV/_"'V_\`IEK\TTY'[U>0
M9GQWK<\0PK<>'[Z.15DCDMY%96&0P*G((KQ?Q)^T5X-^`OANVM]8T>_NIO[3
MTJP"6-C'*1_:NKS6$$G++^[A9'DF/\$*%@&(VUT0CS4^7JVE]YC+2=^EF>U?
MV[8_\_EK_P!_5_QH_MVQ_P"?RU_[^K_C7#Z#\:?A]K5];6,FI^'=,U6^:_:T
MTZ^N+:&\NX;*>6">XCBW;GA!A9MX&`A!.WD"E\)_VA?AY\:?&?BC0=`NM'N[
M_P`+WQLF"R6TBZD!96%X]Q:['8RP(FI6J,^!MD;:1@J6QCRR5UVO\EN_Q-_9
MS=]-M_P_S/1?[=L?^?RU_P"_J_XT?V[8_P#/Y:_]_5_QKY__`&;O^"@GPI_:
M&\$:+K%Y"GPUNO$US!!HND>-)M.T_4=:6XM[>YMI+5([B5)EEBNH"JHY<%]K
M(C?+787W[4?PMLOC58^`QK'ARXUB\AO6FEANK1K?3KBUN=.M397!\S='=22Z
MI:K'$5W,2PX.T-<:=Y<JO?7\-6O5=5NMGJ-TZBDXM:J_X7O^3U\CU#^W;'_G
M\M?^_J_XT?V[8_\`/Y:_]_5_QKSVU_:5^#=]X0_X2"'Q_P##.;0?[1&C_P!I
M)KEBUG]N*[A:^:'V><5((CSN(YQ6E?\`Q8\`VVE>,+FWU3PYJDG@&&2;7[73
MYH+JZTK9&TI2:-"6C<HC$*^"<5'N^?\`7_#DVE>S_K^M3L/[=L?^?RU_[^K_
M`(T?V[8_\_EK_P!_5_QKB/AQ\4="\:^`+'6M:\/S>`;R[:..;1?$ALH=0L))
M;@VT*2^1--"3+*`L9CE<.64`ELJ&>'OC]\)?%U_=6ND^-OAWJEU8PS7-Q#::
MQ9S26\4(0S2.JN2JQB2,LQX42+G&X9IQ2U9,;M71W7]NV/\`S^6O_?U?\:/[
M=L?^?RU_[^K_`(UYRO[3GP7?PK>ZZOQ"^%[:'IK6ZW>H#7;'[+:FX7=`))=^
MQ3*H)3)&\<C-=(GCGP-)KMYI:ZQX3;4]/M_MEU:"[M_/MH-H;S73.Y4VD'<0
M!@@YQ4^ZM6&IT7]NV/\`S^6O_?U?\:/[=L?^?RU_[^K_`(TW_A'[#_GQL_\`
MORO^%'_"/V'_`#XV?_?E?\*/=#4KZ3KEDMJV;RU'[Z4_ZU?^>C>]6O[=L?\`
MG\M?^_J_XU4TG0;%K5LV5H?WTHYA7_GHWM5G_A'[#_GQL_\`ORO^%.7+<%>P
M[^W;'_G\M?\`OZO^-5=:URR;1[L"\M23"X`$J\_*?>K'_"/V'_/C9_\`?E?\
M*K:UH-BFCW9%E:`B%R"(5X^4^U$>6X:EO^W;'_G\M?\`OZO^-']NV/\`S^6O
M_?U?\:;_`,(_8?\`/C9_]^5_PH_X1^P_Y\;/_ORO^%+W0U'?V[8_\_EK_P!_
M5_QH_MVQ_P"?RU_[^K_C3?\`A'[#_GQL_P#ORO\`A1_PC]A_SXV?_?E?\*/=
M#4KW^N61NK+_`$RUXF)/[U>/W;^]6O[=L?\`G\M?^_J_XU4O]!L1=67^A6GS
M3$']RO/[M_:K/_"/V'_/C9_]^5_PI^Z&H[^W;'_G\M?^_J_XT?V[8_\`/Y:_
M]_5_QIO_``C]A_SXV?\`WY7_``H_X1^P_P"?&S_[\K_A2]T-1W]NV/\`S^6O
M_?U?\:JQ:Y9?VQ<'[9:X\F,9\U?[TGO5C_A'[#_GQL_^_*_X56BT&Q.L7`^Q
M6F/)C./)7^])[4URAJ6_[=L?^?RU_P"_J_XT?V[8_P#/Y:_]_5_QIO\`PC]A
M_P`^-G_WY7_"C_A'[#_GQL_^_*_X4O=#4=_;MC_S^6O_`']7_&C^W;'_`)_+
M7_OZO^--_P"$?L/^?&S_`._*_P"%'_"/V'_/C9_]^5_PH]T-2OHNN62Z/:`W
MEJ"(4!!E7CY1[U:_MVQ_Y_+7_OZO^-5-%T&Q?1[0FRM"3"A),*\_*/:K/_"/
MV'_/C9_]^5_PIRY;@KV'?V[8_P#/Y:_]_5_QH_MVQ_Y_+7_OZO\`C3?^$?L/
M^?&S_P"_*_X4?\(_8?\`/C9_]^5_PI>Z&I7U;7+)K5<7EJ?WT1_UJ_\`/1?>
MK7]NV/\`S^6O_?U?\:J:MH-BMJN+*T'[Z(<0K_ST7VJS_P`(_8?\^-G_`-^5
M_P`*?NV#4=_;MC_S^6O_`']7_&C^W;'_`)_+7_OZO^--_P"$?L/^?&S_`._*
M_P"%'_"/V'_/C9_]^5_PI>Z&H[^W;'_G\M?^_J_XU5EURR_MBW/VRUQY,@SY
MJ_WH_>K'_"/V'_/C9_\`?E?\*K2Z#8C6+<?8K3'DR''DK_>C]J:Y0=RW_;MC
M_P`_EK_W]7_&C^W;'_G\M?\`OZO^--_X1^P_Y\;/_ORO^%'_``C]A_SXV?\`
MWY7_``I>Z&H[^W;'_G\M?^_J_P"-']NV/_/Y:_\`?U?\:;_PC]A_SXV?_?E?
M\*/^$?L/^?&S_P"_*_X4>Z&I7U;7+)K5<7EJ?WT1_P!:O_/1?>K7]NV/_/Y:
M_P#?U?\`&JFK:#8K:KBRM!^^B'$*_P#/1?:K/_"/V'_/C9_]^5_PI^[8-1W]
MNV/_`#^6O_?U?\:/[=L?^?RU_P"_J_XTW_A'[#_GQL_^_*_X4?\`"/V'_/C9
M_P#?E?\`"E[H:CO[=L?^?RU_[^K_`(U5EURR_MBW/VRUQY,@SYJ_WH_>K'_"
M/V'_`#XV?_?E?\*K2Z#8C6+<?8K3'DR''DK_`'H_:FN4'<M_V[8_\_EK_P!_
M5_QH_MVQ_P"?RU_[^K_C3?\`A'[#_GQL_P#ORO\`A1_PC]A_SXV?_?E?\*7N
MAJ._MVQ_Y_+7_OZO^-']NV/_`#^6O_?U?\:;_P`(_8?\^-G_`-^5_P`*/^$?
ML/\`GQL_^_*_X4>Z&IG:%K5FFJ:T6NK8!KQ2I,J\C[/"..?8_E6G_;MC_P`_
MEK_W]7_&LO0M#LGU36@UG:L$O%"@Q+\H^SPGCCU)_.M+_A'[#_GQL_\`ORO^
M%5+EN$;CO[=L?^?RU_[^K_C1_;MC_P`_EK_W]7_&F_\`"/V'_/C9_P#?E?\`
M"C_A'[#_`)\;/_ORO^%3[H:CO[=L?^?RU_[^K_C69X+UJSB\':2K75LK+9P@
M@RJ"#L'O6C_PC]A_SXV?_?E?\*S?!FAV4W@[26:SM69K.$DF)22=@]JKW>4-
M;FI_;MC_`,_EK_W]7_&C^W;'_G\M?^_J_P"--_X1^P_Y\;/_`+\K_A1_PC]A
M_P`^-G_WY7_"I]T-1W]NV/\`S^6O_?U?\:S/%FM6<FEQ!;JV8_;+4X$J]!<1
MD]ZT?^$?L/\`GQL_^_*_X5F^+-#LHM+B*V=JI^V6HR(E'!N(P>W<54>7F02O
M8U/[=L?^?RU_[^K_`(T?V[8_\_EK_P!_5_QIO_"/V'_/C9_]^5_PH_X1^P_Y
M\;/_`+\K_A4^Z&H[^W;'_G\M?^_J_P"-']NV/_/Y:_\`?U?\:;_PC]A_SXV?
M_?E?\*/^$?L/^?&S_P"_*_X4>Z&IG76M69\8V+?:K;:MG<@GS5P"7@QW]C^5
M:?\`;MC_`,_EK_W]7_&LNZT.R'C&Q7[':[6L[DD>4N"0\&.WN?SK2_X1^P_Y
M\;/_`+\K_A52Y;(%<=_;MC_S^6O_`']7_&C^W;'_`)_+7_OZO^--_P"$?L/^
M?&S_`._*_P"%'_"/V'_/C9_]^5_PJ?=#4=_;MC_S^6O_`']7_&LS0M:LTU36
MBUU;`->*5)E7D?9X1QS['\JT?^$?L/\`GQL_^_*_X5FZ%H=D^J:T&L[5@EXH
M4&)?E'V>$\<>I/YU4>6S#4U/[=L?^?RU_P"_J_XT?V[8_P#/Y:_]_5_QIO\`
MPC]A_P`^-G_WY7_"C_A'[#_GQL_^_*_X5/NAJ._MVQ_Y_+7_`+^K_C1_;MC_
M`,_EK_W]7_&F_P#"/V'_`#XV?_?E?\*/^$?L/^?&S_[\K_A1[H:F=X+UJSB\
M':2K75LK+9P@@RJ"#L'O6W'(LJ*RLK*PR"#D$5A^#-#LIO!VDLUG:LS6<)),
M2DD[![5N1QK#&JJJJJC``&`!3J6N[!&]AU%%%045=<_Y`MY_UP?_`-!-?+/[
M1/P!\9_%+Q)X6U3PQIMOJ&EV_A[Q/:Z@K7<<#B_VM_96`Y&1YTD_S=$)4G`R
M:^HO$]O]L\-:A"6DC$MM(A:-BK+E2,@CD'W%<S\-?",?_"'6X^W:M\LLZ_\`
M'Z_.)G'//7WK;EO2>MM6OOBT_P`&S._[RS5U;9^337XI,^4_$G[)'CYM(\,^
M&6\&MK%X_@FRAOO%:W]FJ:9?V]CJ"7-D`\JSM]IN+I2'1#'B60NR[5!]!_9E
M_9O\1_!7]MWXR>(9/"MK#X0\?2VCZ1J$5Q;XTY++2-(MO+6(-YBK<3"Z!PO!
MTX%N'B+?1/\`PB,?_/\`:M_X&O\`XT?\(C'_`,_VK?\`@:_^-"G%1E".BES:
M+;WK;:Z6LK+;3K=WTC.6\M6XJ-WY-2OI97NK_P!*WYYVG_!.'XA?#?\`99^!
MGA?3-)\5:QJUGIEO-XL\G7=/6\TS6([73XH!)<3,`^FP16]Q!Y-MO=C]F()5
M6<=K;_LS_$8_M/?"[Q)'\+'BL?A??^);74;VXU'3-GBO^T=2TH0ZHJI.9,K"
MMQ=[9E20/9%`NYHMWVO_`,(C'_S_`&K?^!K_`.-'_"(Q_P#/]JW_`(&O_C1S
M+VWMNOO>2][?9W]'>_GL=$L54E.4W]J]UTUYK_\`I3^Y>=_RH^)/@#Q9^S;H
MOA'_`(6?I>I:,GB[QM9IJ0U+4-!GAU6=()4NQIZ27<,,,<[/FU@1Y+_8,);R
M,LBI]?\`[+G[-NL?"CQ_\==3U'PGXZO-0\07%Z]I)K>OZ=<Z+XGBFNKVXCCL
MXH9#-;`+*B/]J5,>9A2RJ2/I*[\!6=^$$]QJ$PC8.HDNF;:PZ$9Z'WJ;_A$8
M_P#G^U;_`,#7_P`:YX4HJ4I-ZN_39-15OP?EJU8QJ5')6?=/YJ3?ZV[Z+4^'
M5_9V^*R^%_"FBZ3\,=<TW0]<\1^'KK[%J6OZ9+)\/M+T?Q+!J0MKATNG^T;X
M/.$(MC-M541V4\G1^$7_``3QU+P%\)].T]?`^DV.JR>'['2M0\J>WWRA?"T]
MA/&SA_F!NVC4G.&(#Y(7</M'_A$8_P#G^U;_`,#7_P`:/^$1C_Y_M6_\#7_Q
MK:LU4I*E+9.^VNW+^6_=J[UW=*M.G%Q6S=_G9+\DK=NA\>_&O]C+Q!I7@'QE
M9^%?!.HM8^(+U9+FQ\+7NFZ?J=]'_;.KW*F&6Z=8(RBW5H[%R#Y/F1H"^$'(
M?#;]D/QU\*/A)X/TG5M'AL_%WB;QIX;TW4[@W4=S-=:7%X5TZSU-3(C-D`V-
MV,$C)CWCA@3]X_\`"(Q_\_VK?^!K_P"-(?!T+%<WNJG:<C_3'X_6M*=2*A*G
M+52Y;W[1:=OGL_(QDI.?M%H[?I:]NNR>N[->BLG_`(1&/_G^U;_P-?\`QH_X
M1&/_`)_M6_\``U_\:QM'N5J7-'_X]'_Z[S?^C&JU7D_Q*^./PW^`6I>']-\<
M?$/3?"6H>+KZ>TT2VU37!:R:K*DJJR0JS`R,#+&"%R<R+ZBMZ/QCX1EU+1;-
M?&"M=>(EA;2XAJYWZ@)H;B>(Q#=\^^&TN9%QG*P2'HIJN5.[OI>WS%JDK]5?
MY=SNJJZY_P`@6\_ZX/\`^@FL+PQ_8_C73YKO2->NM2M;>[N+"26VU)I$CN+>
M9X)XB0>'CEC=&'561@>15G6/"D<>D73?;=4.V%S@WCD'@^]**C?<-3>HKF?%
MB:1X#\+:EKFM:[=Z7H^CVLM[?7MUJ+106D$:EY)7<G"JJ@DD\``FFVC:+?\`
MBFZT.'7[J76+&T@O[BR34F,\-O.\J0RLF<A':"958\$Q.!T-+W>X7?4ZBBLE
MO"42C)OM6`'))O7X_6JNE:5I^NP22V>KZA=1PS26SM%?NP22-RDB'!^\K*RD
M=B"*.5=PU-;4/^/NQ_Z[G_T6]6JY'25TGQ?;VUWI.N76I6JWUQ9O-;Z@TB)-
M`98IDR#PR2QNC#J"K`]ZGUL:/X;U'2;/4->NK.ZUZ[-CIT4VI,CWUP(99S%&
M"?F<0PS28'.V-CT!IOETU!-ZG3T5S'AC^Q_&NGS7>D:]=:E:V]W<6$DMMJ32
M)'<6\SP3Q$@\/'+&Z,.JLC`\BK.KZ18Z!I=Q?7VK:A:6=G$\\\TM^ZQQ1HI9
MF8DX`"@DGL!2M'N-7;LC>JK#_P`AJX_ZX1?^A25RWQ$\0>&?A'X#U#Q3XH\4
M/X?\-Z3#]IO=3O\`53!:VL>0-[R,0JKDCDGO5O0=-L/$BQWUAJU]>6-]9P7-
MM<0W[.D\;[V5U8'#*5P01QS[TURZJ^WZ[?D_N8N;9]_Z_5'445YSXL^*?@+P
M)#XJDUKQW:Z7'X&LX=0\0M=:UY0T6WE#M%-<9;]TCB-R&;`(4^E=@OA.)U#"
M^U8@\@_;7Y_6GRI;_D%V:U%<QK/]C^'=2TJSO]>NK.ZUR[-CIT,VI,CWMP(9
M;@Q1@G+.(8)I,#G;$YZ`UF>+_&GA#P!XR\-^'=<\8+I.O>,IIK?0M/NM7,5Q
MJ\D2>9*D"%LR,B'<0N<#FIY5W*U6Z\_D=AH?_(%L_P#K@G_H(JU6#H_A2.32
M+5OMNJ#="AP+QP!P/>N7T;XJ^`?$2^&VL?'EI>#QA>76G:&8=;W_`-K7-JLS
M7$,&&_>/$MO.75<E1$^?NFJY4WI^1*>AZ-163_PB,?\`S_:M_P"!K_XUG6O]
MCWWBF\T.'7KJ76-/M(+ZYLDU)C/!;SO,D,K+G(1VMYU4G@F)P/NFERHK7>QN
MZQ_QZ)_UWA_]&+5JN*N]2T&Y\87/AF'Q%-+XBT^"TU&YTT:D6N8+::=HXIFC
MSD([PRJK$8)C;'0U8\>:AX?^%WA"^\0>)/$DVAZ'I<?FWE_?:FT-O;)D#<[L
M0%&2!D^M-132L3JGJ=;17'Z5J_AW7/&^K>&K/Q-)=>(-!M[:[U'3HM4+7-C#
M<^:+>21`<JLGDR[21AO+;'0UM-X3B49-]JP^MZ_^-+E2W"[-:JLW_(:M_P#K
MA+_Z%'6%X:_L?QEILUYI.O76I6MO=7-C)-;ZBTB)/;S/!/$2#P\<T<D;#JK(
MP/(KGOA!\1?!7[0WAZS\2>!?&D/B[P]<?:(8]2TG5_M5N\D;HKH)$8C*G@C/
M44U%7M<)76ZZV^?8](HK)_X1&/\`Y_M6_P#`U_\`&N/T;XJ^`?$2^&VL?'EI
M>#QA>76G:&8=;W_VM<VJS-<0P8;]X\2V\Y=5R5$3Y^Z:%%/;\@NST:BLG_A$
M8_\`G^U;_P`#7_QK.M?['OO%-YH<.O74NL:?:07US9)J3&>"WG>9(967.0CM
M;SJI/!,3@?=-+E16N]C=UC_CT3_KO#_Z,6K5>>/XW\(:I\2=0\$6OB^.Z\8:
M/!;:A?:*FK;KVTMI956.9XMVY48\!B,$UK>/-0\/_"[PA?>(/$GB2;0]#TN/
MS;R_OM3:&WMDR!N=V("C)`R?6GRII6)UOJ=;17'Z5J_AW7/&^K>&K/Q-)=>(
M-!M[:[U'3HM4+7-C#<^:+>21`<JLGDR[21AO+;'0UM-X3B49-]JP^MZ_^-+E
M2W"[-:JLW_(:M_\`KA+_`.A1USNE7^@:[X>O-6L_$<]UI>GSW5M=746ILT-O
M+:RR0W*,P.`T4L4B.#]UD8'D&N;^"GQ8\`_M+:''X@^'OCJS\::"KSVC:AH^
ML_;(%F3RBT>]&(#`.I(]Q0E&[5]4.2DMUUM\UT/4**Y'7-1\/^&?$NB:+J/B
M2:QU;Q))+#I5G-J;)-J+Q1F658E)RY2-6<@9PH)Z4G@+5O#OQ3\-KK'AOQ-+
MKNE-<7%H+NQU0SPF:WF>">/<I(W1S1R1L.H9&!Y!I\JM?]!79U]%<_K.F:?X
M=TNYOK_6+^SL[.%[B>:;4'1(8T&6=B3PH')/:L+XO>._!OP`\#S^)O''C*/P
MGX>M98X9=1U75_LMM&\CA(U+NP`+,0`.Y-3[O<>IU.@?\A;7/^OU?_2:"M2N
M7T'PS%<ZAJVV]U+:MVH5ENW^8&WA.2<\]>OH!6%K7Q1\!^'!XD.H>.K6S_X0
MVXMK37?.UK9_9$URL;6\<^6_=M(LT14-@L)%QU%5/E3U8H<SV1Z+163_`,(C
M'_S_`&K?^!K_`.-5;S3-/TZ\M+>?6+^&>_F-O;1OJ#AIY!&TI11GEA&CM@=E
M)[5-H]QZG05E^"/^1+T?_KRA_P#1:US.N^-?!_ACXE:'X-U'Q@MCXL\30SW&
MDZ1-JY2\U*.!=TSQ1EMSJBD%B!P.M0Z+K7A[2IO">@7WB1K/7_$6FO=:;IK:
MD8Y[V.W2(SM%'G++'YL>[`PN]<]15+EY=_ZU%JY6L>@45R?@6^T'XG>%+/7O
M#OB.?6]%U!2UM?66IM-!<`,5)5U)!PRD<=P:N:SIFG^'=+N;Z_UB_L[.SA>X
MGFFU!T2&-!EG8D\*!R3VJ?=[E:WM8Z"LOQ?_`,@F'_K]M/\`TICK)\97.A_#
MOP_)JVO>(;C1],A>.*2ZN]2:&)&D=8T4LQQEG95`[E@*YV/QWX/\;>)?$'AO
M1/%T.K^(?!NH:?!KNFV^J^=<:0]Q(CPB>,-F-G3++N`SC(Z54.7FM<F5[79Z
M917G6M?%'P'X<'B0ZAXZM;/_`(0VXMK37?.UK9_9$URL;6\<^6_=M(LT14-@
ML)%QU%=?_P`(C'_S_:M_X&O_`(U/N]RFI+=&M17/WFF:?IUY:6\^L7\,]_,;
M>VC?4'#3R"-I2BC/+"-';`[*3VJIJEUH6B>)]-T6\\17%KK&LQS2V%G+J;+-
M=I"%,K(I.6"!E+$=-PH]U;L->QKW?_(Z:?\`]>5S_P"C+>M2N$\+7NB?$*71
MM8T'7IM8T?4K"YFMKZTU$S13*LD*Y1P<$9SG'<>U5O"OQ0\!^.(/"\NC^.K7
M5(_&UO-=>'VMM:\P:S#"`TLEOAOWBH&!8KD`$53Y;+448RUT/1**R?\`A$8_
M^?[5O_`U_P#&JMOIFGW>J36,6L7\EY;PQW$L*Z@Y>..0N(W(SPK&.0`]]C>E
M3:/<-3H*R]`_Y"VN?]?J_P#I-!7"^/OC5\./A7IVMWGB3XA:?H5KX;N;6RU6
M6^UT0IIT]SM^SQREF&QI-Z[0>6W#%=-HGA>.74]87[9J:^7=JH(NW!;]Q"<G
MGD\]?0#TJH\K3L_ZT%*Z:3.HHK)_X1&/_G^U;_P-?_&O/_CS\??AA^RY::7/
M\1_B3I?@>'7)FM]/?6]>%FM[(N"R1EV&YAN7@>HJ?=[CU/5J*QQX4A*J?[0U
M7#=/]-?G]:AO-&L=/N+6&?5=1AEOI3!;H]^X:>0(\A51GD[$=L#LI/:BT>XK
MEKP1_P`B7H__`%Y0_P#HM:U*YCP?X7CN/"6ER&\U1?,M(FVI=NJC*#H,\#VK
MI;>'[/`D89V\M0NYVW,<>I[GWIU+7=@CL.HHHJ"BKKG_`"!;S_K@_P#Z":R_
MAK_R*$/_`%VN/_1\E:'B=Y(_#6H-#&LLRVTAC1GV*[;3@$X.,GO@XKF?AKJ.
ML?\`"'6__$KL\F6<D?;CP?.?(_U?8\9[UO&-Z7S_`$,F_P!Y\CM**R?[1UG_
M`*!=G_X''_XW1_:.L_\`0+L__`X__&ZRY7_31IS&M163_:.L_P#0+L__``./
M_P`;H_M'6?\`H%V?_@<?_C='*_Z:#F-:BLG^T=9_Z!=G_P"!Q_\`C=']HZS_
M`-`NS_\``X__`!NCE?\`30<QK45D_P!HZS_T"[/_`,#C_P#&Z/[1UG_H%V?_
M`(''_P"-T<K_`*:#F-:BLG^T=9_Z!=G_`.!Q_P#C=']HZS_T"[/_`,#C_P#&
MZ.5_TT',:U%9/]HZS_T"[/\`\#C_`/&Z/[1UG_H%V?\`X''_`.-T<K_IH.8^
M6?VM/%-CX._;^_9[N=4\=77@6QOM,\4Z9NCLH+F+Q#+-J>@;-*D,L,GEB?:Q
MW1[)/W)PX&[/B3>$/$?@?X+VVHV.E:I)-^S_`.-8M#\.B.-I+C6=+\,Z3J$G
MR]V:X6:[ML_Q%L9YK]"]+U#6!;-MTRS8>=+UO2.?,;/_`"SJQ_:.L_\`0+L_
M_`X__&Z*E.4HJ-[<M[-.UGS<REYN-VDGHKMVO>^_UCW8Q:NDK-/6Z?-=>5[J
M_=*W:WE/_!/KP+J7PU_9FL=%UIA+K5GJVJG4Y@FT75V^H7#SS8_Z:2L[Y[[L
MU[%KG_(%O/\`K@__`*":I_VCK/\`T"[/_P`#C_\`&ZY7XZ_$;7OAK\$?&7B*
MW\.V.I7&@:'>ZE'9MJI@6[:&W>01F3R6V!BNW=M;&<X.,5I/WI\R22[+9>AR
MQNKW;;;;N_-M_J1_M=:%'XI_93^)6F30FXAU'PMJ5K)$%W>:KVLBE<=\@XQ7
MP[X?6^\(Z=XNU;XN>)/%OA7PW)+HWA;7/$&EZA>:1J,>G:3)J>G1R"[M62XB
M2XU.V\[=$ZEDOL'Y78'Z8_X7?^U!_P!&^?#+_P`.Y+_\IJ/^%W_M0?\`1OGP
MR_\`#N2__*:L8>[)RW35K?/1^J5TO*3-9OFI\BT=]^NZ=O1N*?>Z78^5?#?A
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M&./:H1!#)$5"C`5ABLO_`(*5P:IIWP^\$>)M%M;R\U3P!XF/BR""UC+S7*V.
MF7\\MNH'>>%98/?SL=ZQO%?[3/[2OA_7?#-I<_L^_#CSM<U)[&TV?%F5E\U;
M.YN#N/\`8XPOEP2<\\[1CG(V_P#A=_[4'_1OGPR_\.Y+_P#*:LJUYK1V>FO5
M-:W7SU,X22DVU=.^CZIWNGWWL^Y\X^%[;6/@[#\-/"^H>*O&6F?$*'7=^AV&
MCWUU;6/B:^E\2R_\)!+=6T;""Z06K>:?M"N(4EDECVO\U<WH/@6:;]E;X9ZQ
MXT\:?%74M4U;POI?B9Y=2\7ZO*)]:U3P[JZ2P-$9MAA:2VMU%LR^2IDDP@\Z
M3=]9?\+O_:@_Z-\^&7_AW)?_`)34?\+O_:@_Z-\^&7_AW)?_`)35I*49.Z5M
M4]-$K-Z+M?376W*K(THUG34DUS-MN[WUO=/NM7IIN^YP_A[XQVG[)/P!^.UQ
MXVU+6O$.@?#KQ?96VC77B*:?5)C+=Z7HUU&6DD+N(EU*^D8;?D@0;4"I$JK[
MQ^Q]X9\.^"?V</`&B^$-4_MSPMHOA/2]/TG4,G_3;:&$QQR\@'YE4'H.O2O/
M_P#A=_[4'_1OGPR_\.Y+_P#*:L2P_:9_:5N_B/JVB)^S[\./M^GZ;97TV?BS
M+Y?E3RW:1X;^Q^6W6\N1@8&WDYXJ59NZ6B:CIT]U6O\`/4YXQ481A'9+7S=E
MK]]W\V>$_P#!4S0KZWTKX\6NE^'[[4)/B3X?U/2+ZZAM3(D2:;X?M]3MBY'8
MM'=1+U^><`<FNA\*W^H?%?Q?X]\/S>./BA#XHU#Q&=+\:6-IXBU&S70+,^)[
M6WTI;$1R*NG^=I)F/FV?EO,C&61FD`<>X?\`"[_VH/\`HWSX9?\`AW)?_E-1
M_P`+O_:@_P"C?/AE_P"'<E_^4U9WCR1A;12YORNO\+LVUKJ[WZ'3*LW",7NF
M_G>RU\THI+6UNEU<^6=7^#>G_%SXZ?"W2=2\5?$VU\3>(M8T.]U4V?B[5K:Z
MM[-/!6NPI=1.DP^S2230O')/$4ED;<'8[N?HSXC>/8]=/[.<>J^(KBT\5>(#
MIM__`&"^FQ2+XIVFTDN"TQC,T36>XW>(Y(P3&-X=<K6U_P`+O_:@_P"C?/AE
M_P"'<E_^4U'_``N_]J#_`*-\^&7_`(=R7_Y345)<TE+LT_N<GIVW7S5^NDNI
M[JC;:/+][;_6WHD?0FA_\@6S_P"N"?\`H(K\I_B!'XR\&#X>Z=X)\/:Q8ZG\
M/!?Z]H5Y#I_F;[[6/!6NW#>2&!5I$O+21BK#!>YC!SNQ7US\-/VF?VE?'/PX
M\/ZWI_[/OPX^P:QIMM?6WF_%F5)/*EB5TW+_`&.<-M89&3@]S6W_`,+O_:@_
MZ-\^&7_AW)?_`)355.:C/GM=ZK79W35FNJV?35+4*-5PNGLTUZ735UNKI-[I
M[L\;^'_V;Q<O@G4O`OQ`^*?B#P#H&M37GA^\N/%NK7#:RIU#0+>7[9-+,9KZ
M%)+C5$6*Z:2-0S`*!%'MXO\`9(^%EAX=_:&.M^&O$OQ$N?\`A"]&\):1+'<>
M)]4NH+BZF\3^(K/4+>[6:4BY6!)7"1R[T@)5D"D*:^F/^%W_`+4'_1OGPR_\
M.Y+_`/*:C_A=_P"U!_T;Y\,O_#N2_P#RFHIR4(J*6SO>^_O*5GW5E;[GT%&I
M9237Q)+_`,F4OOTM\V0?"S_A/8OVXO'C>)O!5GI&A7UJLVEZY#K*71U"&.ZM
M88$,&P-"=B,Y!8@,7('S5Z+^V1X*L_B1^S]J7A_4+7[;IVM:AI=C=P%=PE@D
MU*V60$>FPMGVKR;X@?M,_M*^#M"M[N^_9]^''DS:E86*^5\696;S;B\AMXN/
M[''R^9*F3V&3@XP=O_A=_P"U!_T;Y\,O_#N2_P#RFK"E34:4:4M4K_.[;U\]
M=?OTV)E-^U=6.E[/TLDM/N_X<^+[7XA7VH?&+7O%GQ`O?&_PY\$>*K#PMIWC
M+5-*N[S1M1AM[`^+K*(F\M62XA2:_LK)MT3JS+<1(3Y<K*WJ_P`5?"6J^(/"
M7C#5/'?BKXEV]KJ6@6HUU(_$NI6%OI4-E;>&KN2:"*WE5+:822WSO-"JRL'D
M4L54*/>?^%W_`+4'_1OGPR_\.Y+_`/*:C_A=_P"U!_T;Y\,O_#N2_P#RFK>5
M1.?.U>T>77K9)<S[O1WVT95:HJCNE;1+TLDM--%IUN_,X'_@G=X63X;:MXBU
MA=;\67&B^+-9\>ZA<Q:GJUW=6%K'9^*KA;:6W@E=HX6DAN97=T56FRK.7*J1
MZ=_P3Y\8KXN^#D*V7C:]^)'AW1[JXTS0O$UW8P6<NK6<4=KR4@BBC(BF,T`9
M8U)$`SN;+'/_`.%W_M0?]&^?#+_P[DO_`,IJQ+_]IG]I6T^(^DZ(_P"S[\./
MM^H:;>WT./BS+Y?E02VB29;^Q^&W7$6!@Y&[D8YF_ON7=/S?Q.2N^MKV[[ZZ
MV'B*GM)RG:SE)O[WM_7W'U37Y._$"/QEX,'P]T[P3X>UBQU/X>"_U[0KR'3_
M`#-]]K'@K7;AO)#`JTB7EI(Q5A@O<Q@YW8K[4_X7?^U!_P!&^?#+_P`.Y+_\
MIJ/^%W_M0?\`1OGPR_\`#N2__*:G3DH2Y[7=FM=G=-6:ZK9]-4M1T:W)==&F
MOO35UNKI-[I[L\;^'_V;Q<O@G4O`OQ`^*?B#P#H&M37GA^\N/%NK7#:RIU#0
M+>7[9-+,9KZ%)+C5$6*Z:2-0S`*!%'MXO]DCX66'AW]H8ZWX:\2_$2Y_X0O1
MO"6D2QW'B?5+J"XNIO$_B*SU"WNUFE(N5@25PD<N]("59`I"FOIC_A=_[4'_
M`$;Y\,O_``[DO_RFH_X7?^U!_P!&^?#+_P`.Y+_\IJ=.2A%12V=[WW]Y2L^Z
MLK?<^A,:EE)-?$DO_)E+[]+?-F3\$/$VL6G[=OQ8T&;QEJ.IV<UTNJ77AN;3
MK:.'1#LTF*SN([A8EFD^T1?:!MDD<`VY"A=O/JG[9'@JS^)'[/VI>']0M?MN
MG:UJ&EV-W`5W"6"34K99`1Z;"V?:O)OB!^TS^TKX.T*WN[[]GWX<>3-J5A8K
MY7Q9E9O-N+R&WBX_L<?+YDJ9/89.#C!V_P#A=_[4'_1OGPR_\.Y+_P#*:L:<
M(QIQIO5))>J2M^/7^D3S/VCJ+1MW].NGIT_IGQ?:_$*^U#XQ:]XL^(%[XW^'
M/@CQ58>%M.\9:II5W>:-J,-O8'Q=91$WEJR7$*37]E9-NB=69;B)"?+E96]7
M^*OA+5?$'A+QAJGCOQ5\2[>UU+0+4:ZD?B74K"WTJ&RMO#5W)-!%;RJEM,))
M;YWFA596#R*6*J%'O/\`PN_]J#_HWSX9?^'<E_\`E-1_PN_]J#_HWSX9?^'<
ME_\`E-6TJB<^=J]H\NO6R2YGW>COMHRJU15'=*VB7I9):::+3K=^9Q/_``38
M\$R>"/%6LW]GJWBR^T[QIKWCJ[DMM2U:[NK&`6OBR=+62W@E<QPM)%=2N[HJ
MM,2K.7*J1[A^RV=2U?P<WB35O^/[QEJ&I:V@V%"EI)<(EBK*>C+8QVJMZLK'
MO7"_\+O_`&H/^C?/AE_X=R7_`.4U8E_^TS^TK:?$?2=$?]GWX<?;]0TV]OH<
M?%F7R_*@EM$DRW]C\-NN(L#!R-W(QR2DF^;KKK>[LVW;SZ*^^GFPQ%1U)RGM
MS2<K>=W^"3M;KIV1<_X*':K/X!UGPCX\L]#OM?U+X<V&I:_96MG"99Y76?3H
M9$0#^)[>:X3'4AC7QW\,M1USX->&;KPS/XF\;^'?$6@W/B)_`>EZ3?7=E8:Q
M<?\`"6>(5UF66")EBNVCLH[:11<*XA#))%M=RQ^T_P#A=_[4'_1OGPR_\.Y+
M_P#*:C_A=_[4'_1OGPR_\.Y+_P#*:B,HQBXVW:?S5]5V;NDWKHMNII"O:'(U
M?5/[KZ/NM6]+;N]UH?+/B[X8WMC\:/&&CZMXH^)&I)X6T?QCX=\.WNH^(M1N
MGNY;WPSX>U%T</(4F/F3ZE)&CADC\A5C"B&-5]7_`&IX[SX9_L#Q:;#XXUCP
MNV@^+]1TNT\4>(9;CQ!<VEJD^H1*EQ)=&66<SP9M%DD+,#<HP8,JL/3_`/A=
M_P"U!_T;Y\,O_#N2_P#RFH_X7?\`M0?]&^?#+_P[DO\`\IJB=GLDE:*\O=\M
MM==+6UL[]<923IQ@MUN[ZO1IOU;UOOHK=SV#X,2>=X11O[-DT7=':G^SY#E[
M#_0K;]RQ]4^Z?I7P7\:]$U"[_:N_:*\/S>';S4M!\>:K)J5Q<?9B\-O)HGA'
M1KBUR<8RUU=QE3S\UJ0.0:]>^%7[87[17Q!\=_$O2=-_9]^'OVSP-XDAT35?
M.^*TB(+E](TV_7RB-'.]/(OK?YB%._>N,*&/;?\`"[_VH/\`HWSX9?\`AW)?
M_E-6\J[]I*I'=KUMJG?O=6T?>SUV<X6U*DZ4M4TEVV:?XVLUV;V/&O#D%]\:
MOC#XB\*V?C[XF11:OXHDLO&R67B?4K=]$N4?5FBM+&02`V43V\$.1:F,$>2_
M^L;=7DWP<\(:E\4_A!J'B+6/$'Q'L_'/B%M`\;:DUIXDU.SG$P^'\CQ2Q>7*
MI@22]BN$D2+:)?(\J0,@"5]??\+O_:@_Z-\^&7_AW)?_`)34?\+O_:@_Z-\^
M&7_AW)?_`)35C&RIJ"6NFO5V;?YM6[)+KJ=%.M%3E.4;WMIT6][?XM+^GF97
M[0:ZEJ7[:OPFL=+\0>&K>XUXV=]JFDW&GS2:J;;3OMTPGMIE81Q1DW4D4GF*
MQ(=`NTDD^<?M^ZUKW@+XT_`[QAX?TF^U;4/#?@;Q!%#%:PF1M]]>>&]-#<?W
M!=M+CTA8]`:]<_X7?^U!_P!&^?#+_P`.Y+_\IJXG]FG]L+]HKXY?LY?#_P`;
M>'_V??AZ=!\8>&].UO33=_%:2&X-M<VL<T7F(-'8*^QURH8@'(R>M:4ZG*K6
MOK)V>SYH\MGY6MIZ[7TYL/\`NI\[;;Y>6^SV>JWUO)O[CR[5I7^#7B.'POX8
MUWQ5X=UOP[I^MQ>%/#VG:E=V^ES:6EUKHN9Y+1&%O))'Y5OLD="\96#85WMG
M`\7?#&]L?C1XPT?5O%'Q(U)/"VC^,?#OAV]U'Q%J-T]W+>^&?#VHNCAY"DQ\
MR?4I(T<,D?D*L840QJOU-_PN_P#:@_Z-\^&7_AW)?_E-1_PN_P#:@_Z-\^&7
M_AW)?_E-6<7[DHRU<KZO?5IOY:?>VWV-XU(QJ*:6B5DNE]+/U2NEY/RUYWXI
MZYX6^!?_``3^\2+XTU:^FTWPSJFJZ9I.H^);VYUB_#K>W,-L3<W!EGDE\L[!
M(S%BIQG%.^!/BO2_&G[16OQZ')N;PQ)>0:\%B:,++?>(_MEANX`<M;&653SM
M6;MO-=!_PN_]J#_HWSX9?^'<E_\`E-7$_'_]L+]HKX/>!+#5M:_9]^'HL[SQ
M)H.B1_9OBM)*_P!IU#5[.PML@Z.OR>?<Q;FSE4W,`Q&TU2J<M7VOJOO33_-O
MUL<M:'/#DZ7O]TN9)>2V]+]SR'XUZ)J%W^U=^T5X?F\.WFI:#X\U634KBX^S
M%X;>31/".C7%KDXQEKJ[C*GGYK4@<@UU_AR"^^-7QA\1>%;/Q]\3(HM7\426
M7C9++Q/J5N^B7*/JS16EC()`;*)[>"'(M3&"/)?_`%C;J]E_X7?^U!_T;Y\,
MO_#N2_\`RFH_X7?^U!_T;Y\,O_#N2_\`RFJ92YFN;91M;H]$KOOLON5[VUZL
M14]HG;1M)7OM9)*W;O\`-ZZZ?(/P<\(:E\4_A!J'B+6/$'Q'L_'/B%M`\;:D
MUIXDU.SG$P^'\CQ2Q>7*I@22]BN$D2+:)?(\J0,@"5]E?M#_`!.^'OAKX^_"
MW3/%5QHL&O>(HK_S(;FT\R2\L$TZ[\Q'.T@Q!G?Y&.,N>.35/_A=_P"U!_T;
MY\,O_#N2_P#RFH_X7?\`M0?]&^?#+_P[DO\`\IJ*K4Y-[7=_1=ONLOT"M54I
M*4%RV35ONM]UG\W<VOV*/B-X=^*?PAT'5_"M];:CHDLFO);S6Z%(]HU/@`$`
M@8(QQTQ7PQ^R/#KVD?LH>!8Y=%U;1[[X5^$+:RTK5D@>&XCAU/PM>:K>R0.,
M,'1GMTXP1);(.M?2^O?MA?M%:1^T;X5\$S?L^_#W^WO$'AO6=;LPOQ6D-O\`
M9K&ZTJ&XWO\`V/E7WZA;;5"D,/,.1M`;MO\`A=_[4'_1OGPR_P##N2__`"FH
MYK4W3CU25WNK<R=MM7>WHVNMTJ=6T'"2^TGIIM>RZZ:W]4O0^?[2ZU?6/#6A
MZ]X5\>_$[5?"&@:_X>L_#$K^)]3F.LZ;J7BHZ;<S7DCR^;>;;22=4:X9RJ^5
M+PZ1LNE^P9\+U\&7OP0U#2]:\=2+HOA;2/#=W:77B'4)[5Y-GB(WD=U%)*5N
M'ANH41#,'\@1A8MBL0?;O^%W_M0?]&^?#+_P[DO_`,IJ/^%W_M0?]&^?#+_P
M[DO_`,IJIRC:*2V=WW>B6KZO1W?GI8GF7LYQMK*]GVT5DO)/5+_ASS3]I#]J
MKX2_#+7/CAI,VH:-;W$D.EZ!J`2U98]-OM0^WPRW$Q5.H29W=ADL"03\U?7'
MP[N;6]LKR:PF^T6,TL+V\NXMYL9M+<JV3R<K@Y/->)?\+O\`VH/^C?/AE_X=
MR7_Y35\A^`?VQO\`@HC^T7\6/C!'\+_A[^RGI.A^`O&\_A2ZM/$>IZQ=WD-U
M!964S`3PO$DR>7<1?.(H\MN&P8!,4_=BT[W?W?=_P3.I>4U+HK^NMKZ^=E?0
M_4JO,?VI;>2Y\->$1'&\A7QIH3L%7.%%_$23[#UKXQ_X37_@JU_T)_[$O_@3
MK_\`\?H_X37_`(*M?]"?^Q+_`.!.O_\`Q^G3ERU(U/Y91?W-/\;$U8<].5/^
M9-?>FOU-#4]1TGQA\5=0N=:\;?$*2S\/_$&RN/%$2^*M5@M]#U;^T-0MK*TM
MPDH$-O)$\"M!%B&0-"SJQ8FM3_@F=XJUWQ9=6QU#5]8U6Q7QC'?16FH:UK&M
MW'AZ671=36?3YKK4[B>5I8'1(Y!$R0"0$I&I9BW-_P#":_\`!5K_`*$_]B7_
M`,"=?_\`C]9/CWXT?\%3OASX&UKQ#J'@[]BMK#0;"?4;D13Z\TABAC:1]H-P
M,MM4X&1S4P]VFJ?X]7MOWV^225]'>JEY3<^]M/3FV];W?G?OI^CW@C_D2]'_
M`.O*'_T6M:E>*_L+?&GQ/\>OV(_@YXZU31]'AU+QIX'T77;N.TNGCMTFNK""
M=Q&K*[*@9R`&=B!@%B>3[1;L[P(TBK'(5!90VX*>X!XS]<54M[BCM8=1114E
M%77/^0+>?]<'_P#037S'\6?BKKGP3^)7AOQ)?7WBRU\&6>D:H;6VLA;?V+JN
MIJUXYM-09@UQ%(Z)$;:2,>4&CF60[GA1_ICQ/<K9>&]0F82,L-M([!$+L0%)
MX5023[`$FO$Y_@OX9^+^J:#X@UFZ\;/;Z;'<P/HL44ZZ5J&Z2?RY+B#RCODC
M\URAW#:W4'&*WC%\B=M.97]+._S[>=KZ&=X\]GV_5?AWZVVU/*?BQ^WCX^TW
M]LR30?"OAC3]2T#P/IVO'Q#97>MFT6]MK:R\):B;Z,BVD)N(8M7N(8K<E4D8
MY>6,'*>J_$_QIKVB_&'QAXLAU[68=%^%^BQA?"\3PI9>)+FXMYY`TS-$TB$.
M;9(W5MJE)=RMD%>(T?\`X)J_#+2+FQO/[:^+5UJT-[<WE[J5Q=W#WFM+<0Z=
M!/;W;^0/,@DATJRC9`%RL6,\YKTSXI_`'PK\7/'UUX@U"]\=V<FH:'+H%[8V
M*7$-E>PNDZ)+)'Y1W31"YF\M\C:7Z'`Q&)BY**HZ66OF[/\`5Z7V]+)=7MJ;
MA!-:J*3\W>[?S_X"/.;[]OWQQX?O]+L-4^&_AV"^L=3LM&\6/!XJEFM=)N[[
M5#I=FMHYLE>[5YWMW9GC@V1-*V"Z+')Q^F_\%(/BMH?[*^B>--:\`_#J35W\
M,:1J]^J>)-6:"YN[^641P6L-GI%W=28MX6E?$)V$[?F17F7V31?V5/`NE^#+
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MG#Q[A@$YK;\3?LB?#/Q?\4]:\97VF>))->UTZ@9YQ;W`$7VW3;#3+C8/+^7-
MOIUL!UPV\_Q8'1+V2;<(NVMK[[QM\M'_`-NNV[N1AY6YE4:UC%)VZ\UVTN_+
MI?OK:WNG$Z=_P4(\8>*?'7Q!\)^'O`?AG7/$OAOQ)%H6AJFO:C::?J4<OV\K
M-<W-QI<:QLGV"3S!:"]122%D=EVGF;7_`(*Z-J&N2S6WAKPO)X;OO`,7C+2[
MMM<OTGMYI-.AOEMM3<Z;]ALU"2,6*7D\ZQ>7+]GV/\OM'@+]FWP?\/\`XBZI
MXF@N_'=_>:EJ@U6*"^2>6UTU@+W$-NGE#RX=U_=/MR3NDSGBO(_B#_P3:\(Z
M=\(-4TGP!?\`C+3=4C\-P:+I-I?/<KIHFM[&&Q2YDVV[LMP]K;P0M.%<J(T8
M1MMVMQU(RCAY.*;G96]>5W^]V?77317-:<J3F^;:ZMZ.6K?I&UO5];$.C_\`
M!5;6W\6>"=)O?A]IUU)XB\+S^(=1GT+4M3U6SMCB^-L+:[73%M);>5;(,9IY
M[9@MQ&4CE!K/\;?\%;O$_P`'I?$UKXV^$L>D7VE6UQ%IHL-=FU6/4+^/4-(M
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M_3/@-X5ATRPAU.\\=>(KJRM(;-[_`%6.>>[O5BBOHE:9Q$-S%-0N`3@9^3^[
MSV7PTAL?AE\/]'\/0W7BO5XM%M([-+S4[6>XO+E4&`TL@C&YR!R<"LU3LI+7
M?3TU_P`U]QG-^_'E>EM?73\-/O;/*OVA?CCK_P`)?C?I<>FW.[2X/AQXX\23
M6#J/*N[RPN]&^S.QQN^5;FX7`(!$ISD@8\M^)6B_$WX->*?#G@?_`(6)\9/B
M`NK^*-(U":^T$:+;ZS!%<6.K_:+=C=+';_V<DNGQ3%5#7"J[JK2'%>T?&/\`
M9Z\*_'_QMX6\1:MJ'CS3;SPJNHV2PZ2LUO;ZM97D]O)<V=VOE-YL$ALX`R`J
M<`C(S7.:9^Q1X6TCPG8Z?#XT^-(U+3]:AUF/76O9VU9O)MI;:.T:8V^#;"*>
M4>7MS\Y.:J<6XQMHUOYKF;_)KU2MV-Y5(<L4OY6GZN]GY]/3[SZ4KS_]K+_D
MUCXF?]BIJG_I)+75?\)G:_\`/#5?_!;<?_$5YS^V%\0;'3/V2/BE<R6^M-';
M^$-6E98M(NI9"%LIB=J+&68\<!023P`36?)+L9<R/7**^<?^'H_PY_Z%3]H3
M_P`,;XS_`/E91_P]'^'/_0J?M"?^&-\9_P#RLJ1GT=7F'Q^USQ%X6\;?#_4-
M,UJ.ST./4+Z/5=,%H&DU9O[-NI8`9BW[N-&A9F4(6=C&=ZA&63@/^'H_PY_Z
M%3]H3_PQOC/_`.5E>>_&S]K[X6_''Q+X.U*ZA_:VT,^#-1.I06VC?![QC:V^
MHN5"%+I#I+>;'LWIMRORRR#//$RNU:.Y4;=>S_+^O0L_LJ>(/&.I7G@&W\:>
M+[SQM?S>*[/6H;VZM8[=K07WA"\N);5%CX\E)S,8\Y98Y%1F<H9&^QZ_/'X;
M?M%?!?\`9:D^'NC>%/#G[2D]FOBZ2_GEUCX0>,)KHQIH%[9P01%M,4ND,*01
MI&@++'$6.0KL/H#_`(>C_#G_`*%3]H3_`,,;XS_^5E;5)*4G*.BZ+LNB\[+2
M_6UWN1%-*S=WU=K7?5VZ7>MNA]'45\X_\/1_AS_T*G[0G_AC?&?_`,K*/^'H
M_P`.?^A4_:$_\,;XS_\`E968R']H_6O'EIX[\6Z'8>.;C1K/Q--X4T[29=/L
M(TN/#D%WJ$UO>21M(766ZD5)-LKJ$3,(\I_+8RZ7[%OB+5_%6JK>>(-0_M;7
M&^'_`(;AU"_\H0_;YX[K68Y)R@)"&1D+[02!NQDXKP3XN_%GX-_&GQ_XD\0:
MM-^V9;R>(K2QMA8V7PG\8PV>E265Q%<VMS:I_9!,4\<\?F!R6&99."&P-WX*
M_MW_``I^#OQ,O]#T7PC\?H-!T7P9X?T>PA/P7\827$<=O/JH!=?[-W@%77#L
M`'8/@DJP#B_<MY_>K)+7I:S?GS:[#E\5[Z65M-M-?OT7_;M^I]P45\X_\/1_
MAS_T*G[0G_AC?&?_`,K*/^'H_P`.?^A4_:$_\,;XS_\`E92$?1QZ<=:^+/A)
M\1_B%XHG\(QZG\0-9FNO!_B+4(=3:"V@B@\3I)XOFTA([B,HS)'%;1L46-PP
M9D+,P0A_13_P5&^')'_(J_M"_P#AC?&?_P`JZ\#^&_C?X'?#63PNT*?MCZLW
MA?5[[65.I?";QC/_`&G+=W27CI=8T@>;&EV@N$7C;(2<D'%&O,O5-^EI+\&T
M_.UF5IR-=>GWZ_>M/G<^ROV3?^36/AG_`-BII?\`Z215Z!7QW^S-_P`%,_A[
MH?[-_P`/K&;PO\?))K/PUIT#M;_!3Q?<0LRVL:DI(FFE'7(X925(P02#FNV_
MX>C_``Y_Z%3]H3_PQOC/_P"5E!)]'5Y+^WCXB\0^#OV-/B9K7A76Y/#OB#0_
M#UWJ=GJ$<"S/`T$9F(56^7<RH5#'(4MG:V,'B_\`AZ/\.?\`H5/VA/\`PQOC
M/_Y65Q?[1'[:WPH_:5^"GB+P'K&C?M0Z3I/BBU-E>W&C_!CQE:WGDL071)#I
M3;0Z@HW!RKL.,YJH249*35[-?F.-KZECQ9XE\1:]\7-2O;SQ-JMWH>J>*K"R
MM]!E6+[%I9TWQ%H,"2PE4$F^4W$[R;V8',84+L)?ZZK\\?&/[2?PC\!:E-XF
ML--_:BU#5-4UCPW%(FL?"/Q>;6$0ZIIGGRQ!M*0">X%I"TF"3+)&@5=S!3]`
M?\/1_AS_`-"I^T)_X8WQG_\`*RLZ<7&G&,G=I)/S?5_-Z^5[=!2UDVMKZ>2Z
M+Y+3SW/HZBOG'_AZ/\.?^A4_:$_\,;XS_P#E91_P]'^'/_0J?M"?^&-\9_\`
MRLJ@-K]L'XE>)/A/X^^%>JZ1JS0:/)J6L0:MI0A7;JXCT'4;R$-(<E%22T!P
MHR2P.0%*MRO[*J:_8?&30=.\1>*M6\97NGZ)K)74]32);EUGB\,W;(?*1$V)
M)<2*@VY"!`2Q!9N+^,W[6?PC^./CWP)K^J:9^U58R?#^_GU&SLM/^#?C&&SO
MY)8&MW%U&=)/FKY,DJ`9'RS2>O')_!K]K;X4_L[?%'PGI>CZ/^TSJMG!H.MF
M:YUKX0>+[G49W>?1DB'_`""U=XXX;=(@54A%2)6.67<1O=M[62^?-)O[TUZ<
MMMF5*S4;>=_/M]VOK?R/OZBOG'_AZ/\`#G_H5/VA/_#&^,__`)64?\/1_AS_
M`-"I^T)_X8WQG_\`*R@D^CJ\E_;Q\1>(?!W[&GQ,UKPKK<GAWQ!H?AZ[U.SU
M".!9G@:",S$*K?+N94*ACD*6SM;&#Q?_``]'^'/_`$*G[0G_`(8WQG_\K*XO
M]HC]M;X4?M*_!3Q%X#UC1OVH=)TGQ1:FRO;C1_@QXRM;SR6(+HDATIMH=04;
M@Y5V'&<U4)*,E)J]FOS'&U]2QXL\2^(M>^+FI7MYXFU6[T/5/%5A96^@RK%]
MBTLZ;XBT&!)82J"3?*;B=Y-[,#F,*%V$O]=5^>/C']I/X1^`M2F\36&F_M1:
MAJFJ:QX;BD36/A'XO-K"(=4TSSY8@VE(!/<"TA:3!)EDC0*NY@I^@/\`AZ/\
M.?\`H5/VA/\`PQOC/_Y65G3BXTXQD[M))^;ZOYO7RO;H*6LFUM?3R71?):>>
MY]'45\X_\/1_AS_T*G[0G_AC?&?_`,K*/^'H_P`.?^A4_:$_\,;XS_\`E95`
M;7[8/Q*\2?"?Q]\*]5TC5F@T>34M8@U;2A"NW5Q'H.HWD(:0Y**DEH#A1DE@
M<@*5;E?V54U^P^,F@Z=XB\5:MXRO=/T362NIZFD2W+K/%X9NV0^4B)L22XD5
M!MR$"`EB"S<7\9OVL_A'\<?'O@37]4TS]JJQD^']_/J-G9:?\&_&,-G?R2P-
M;N+J,Z2?-7R9)4`R/EFD]>.3^#7[6WPI_9V^*/A/2]'T?]IG5;.#0=;,USK7
MP@\7W.HSN\^C)$/^06KO''#;I$"JD(J1*QRR[B-[MO:R7SYI-_>FO3EMLRI6
M:C;SOY]ONU];^1]_45\X_P##T?X<_P#0J?M"?^&-\9__`"LH_P"'H_PY_P"A
M4_:$_P##&^,__E902?1U?+_QY7QWJ7B_Q?X7L?B1KGA_^V;VSN;&^TRTMTFT
M2);#4[D00B59%(=K"$2,X8N'EV^7N79I?\/1_AS_`-"I^T)_X8WQG_\`*RO"
M_B'\3_@W\3?$GB[5-2N/VSUG\73VLS);_"GQC''I0@69!':#^Q_W2/'<3QN"
M6W)*PR.M9SC)_"[>?_`+C)):Z_U_7Y[H]B_X)M^,I/B+XT_:*\030K;S:]X_
MT?49(D.Y8FF\!>$I"H/<`MBOJ"OS]_9"_P""AWP[\$?&?]I';X5^.*6.I_$6
MQN+*&S^#7BR=K:%/!WAJV"2QQZ<S6[AK=B(I0CF,Q2!3')&S>Z?\/1_AS_T*
MG[0G_AC?&?\`\K*Z*THRJ2E!63;LNR[&%&,HTXQF[M)7?=]3Z.JOJT-S<:7<
MQV<\5K>21,L$TL1F2*0@[69`R[@#@E=PSC&1UKYY_P"'H_PY_P"A4_:$_P##
M&^,__E95?5O^"G'PYU;2KJU_X1O]HRU^TQ/%YT'P0\9)+%N!&Y#_`&6<,,Y!
M[$5F]C6.YS?AOQMXVTWQ=X#OKOQWKVH6OAJ_M-'O[%X[=(?$G]H:MJ6G&:Z(
MCW;X5MH)(_**#<'#!@PV]U_P2=_Y19?LT_\`9*O"_P#Z:+6OG_X9?$_X)_#/
M7_">I+'^V)KUSX3>XEC_`+8^$OC&Y74I)99Y4>Z`TA?-:&2YG:(\;#*W7C$G
M_!,[_@H]X"\#?\$X/V?M%O/#/QTN+S1_AMX<L9Y;#X-^++^TD>+2[9&:&X@T
MYX9HR5)62)V1UPRL5()J-E247O=Z^5EI]Z;^=NA#3=5RZ62MYJ^OW67ROU/O
MRBOG'_AZ/\.?^A4_:$_\,;XS_P#E91_P]'^'/_0J?M"?^&-\9_\`RLJ2CTC]
MJV?7-/\`@9K5]X?UR;P_>Z6@OFN88%EED2([S$I;Y4WD*&8JWR%P`"0R_)7[
M6GBGQ(M^T&J^)=4UO2_%7Q/\%WEGIMRL2VOA[^S?B9HNGA+;:@<K-&\;R>8S
MGS(R5VJVU>W_`&AOVU?A?^T9\+;[PG?6/[5GAVSU%E\ZZT#X-^,K.\9`>8_,
M.DM\K=",<BO!/VJ/VB/A/X-\#3:QH^E?M*76I^(/B5X`OI1K_P`*/%D5K8Q6
MWC+2;R>.U,VF(J/.XED\H,SSSNJ1JSNB%TK*HY2VL].]T[>EG9_+S)K7E!1A
MO=?@TW]ZNOGY(_3^BOG'_AZ/\.?^A4_:$_\`#&^,_P#Y64?\/1_AS_T*G[0G
M_AC?&?\`\K*11]'5XG^U;XJ\4?#[6M+UO1_$#6=C#I.L+_9@M5:*XN(].N;B
M.:5R=S!&ACVHNW&7R6W`+SO_``]'^'/_`$*G[0G_`(8WQG_\K*\S^-'[4OPC
M^.OCC0=9U>S_`&LK6WT*WN[;^R+#X/>,H--U!;F"2"0W$7]DDN?+E<`AAC-3
M.+:LBHRMJ2_`Z;6-,_X*-?#OPSK?B+6/%UYX+\%?$71UUO5?*^W:E$=4\#W*
M--Y*1Q[U6X$>5101$#@$FOM6OS5\%?M<_#+X(_MN?"&'3=)_:-U:RTOX>>.8
MKR\UKX2^+)]:U*YN]7\*S><Z'3%EG4"!U>5(RD7[A'*F6(/].?\`#T?X<_\`
M0J?M"?\`AC?&?_RLK:I)-JW97\VDDW\W=_,QI1:5I=W\DVVE\E9'T=17SC_P
M]'^'/_0J?M"?^&-\9_\`RLH_X>C_``Y_Z%3]H3_PQOC/_P"5E9FAF_'E?'>I
M>+_%_A>Q^)&N>'_[9O;.YL;[3+2W2;1(EL-3N1!")5D4AVL(1(SABX>7;Y>Y
M=GG_`/P1%\92?$73OVG/$$T*V\VO?&J[U&2)#N6)IO#N@2%0>X!;%<[\0_B?
M\&_B;XD\7:IJ5Q^V>L_BZ>UF9+?X4^,8X]*$"S(([0?V/^Z1X[B>-P2VY)6&
M1UKB?^"8'[?7P_\`AAXK_:@B;PO\:/L>K?&K4;^QBTWX1>*;[[-;G1M&B2.9
M8-/<VTP\HY@F"2JI1B@5T)=.RIM2W;5O+>_WW7W>9-2[JJ4=DG?SO:WW:_?;
M9'Z<45\X_P##T?X<_P#0J?M"?^&-\9__`"LH_P"'H_PY_P"A4_:$_P##&^,_
M_E92*/0/B['XC'QE\$IIWB:?2]*U9+_3I+&*U1E>8V<TJW#LQRWEM%'L1=H'
MSY+;@%^1OCEXH\;^&_@'K5Q-\2?$OB31?#.FWVE*MRUI(/%UIJ5YJ]C%<WLD
M<"AI(8X+=XF@$:':Q8,)!LZWXU_M3?"GXY^-=#UJ^7]KS2/[!MKNVBL=(^$/
MC*UL[C[3!)`\DJ?V02TBI*VU@1M.#SBO'OB%XR^"_@/X!WJ6G_#7FL3^$_"F
MIV-@NO\`PL\7-:W(-I<+;?:V;240K;&:4Q.Q41^8Q)/4/#^[4YI[73MO=)ZK
MRNKKY]+(G$7E3<(;V>OG:R^YV;\UUNSZ[_X)._\`*++]FG_LE7A?_P!-%K7T
M!7S;_P`$I?%EK;?\$N?V;8VAU(M'\+/#"DKI\[*2-)M>A"8(]QQ7TA;SK<P)
M(H8+(H8!E*L`?4'D'V/-#BUN5<=1112`JZY_R!;S_K@__H)KYU\<_M4:U\#?
MB#H5G)9Z&_@2W@:XUZXD:9M5C-Q<WR0M;1J-CHAM2T@;YMIR.AKZ)U]UCT*]
M9B%58'))/`&TUXD?V7_"7Q8\477B[6K'P_>ZLWAV[\-Z3J$UG%)J&BI/->K<
MM;SL"T8FCG16"$;A&,Y&,=%.R@G)72>J[JVWSVOTW(LFVKV=E9]O>C=_)7?F
M:?BS]O3X<^#?'VL>&;O4-4DUG08[V:]@M],GF\B.ST^QU"=R54C:(=1L@#T:
M2X2,9<XKC_A%_P`%(M%^(GQ+^(GA^\\+^.-.F\(L+FPB;PQ?K<WEN-%T_4F@
MDC:/*Z@3=S!;3'FLD.0IYKBO!'[`/C9M<\9^*?%GCSPC?>,O%UGJ)#Z;ITL&
MGV5Y+:^'H+1UC>1G,<;:"CNK,2YF(!`&*Z:;]C3Q-XP\(>.SXE\4^$Y/$7CS
M6I-<NSI]I-'I\<C^%8=":((\K2&,R1&4@ODQL5SGFIJQC%/V>ON+_P`#YM4M
MNFOX'5A_9./[S1V7W^[?_P!N2\CT/PU^W!X-\4S^'4@LO&4*^(+&[U&26Y\.
M7D$6@PVQF60ZD[(!8DM;S(HGV%FC8#)%<1\9/^"B^G:'^R'X@^)W@[1M2NKK
MP]X@TG0;O2/$6G7.D7=N]YJ%C;L9()565/W%XLR$C#@H>0:XGP3_`,$X]0\/
MZ)X%T16^#_AG1]"T_7++4Y?"?A^32[N*'4I+R1]-LL2F)--W7,3-;3)(#);Q
MR?ZQ$9=KX9?\$_X_#7[*=Q\.YM'^"/@IKKQGHOB2XC^'_A?^Q-+OH;#4=.NW
M\^WWG=<RI9/&9,X`:/C"D$A&'-KM=?=S*_\`Y+\_URPTHNI#VOPW5_0[#6OV
MZD^'OCWX@Q^)O#>N2>%?#.HZ=9:7J&@Z7<ZM-<1SPW!GN;A(5;R8(I[6>,RM
MA5V#)&14]W_P49\#:-K5]I^I:7XWL;RS\1WGA]8SX<NY/M"6CQI<:BA5#G3X
MC-")+K_51F5`S`L*\:\??\$L[_Q9^S-HO@.Z\2^"?&5U865G:7<_C#1_[2M+
MN2,ZJ9+PP!E4W*MJ0DA9LA)(0Q!-;GQR_P""=MS\8OBMI'B34[;X*^,;?PSK
ME_=:1IWC+PP=7M[:SOS937,N&?Y+Z.>SQ#-'M58I65E=L-6=-1<FG>W3O]FS
M^>MUT^1,KZ)VOUMMM+175WKRZV5^ROIZQ??MO>'X+G6KNUT[Q1JFEZ##>":V
MT_PW?W6IWTMK>06DKVL*1DW$*23;2T8/,<G:-\/U3]M_P[I'A@>(FTOQ3J&C
MWFFZ9=V%GINA7=YK=Q/=RWJ/;FQC0S"2(6;%TV[DV2[@-AQQGQU_8@NOBQX`
MNM)A\0:`S26%W:FUU&V>;3M2$VM6^I_9KR)7!FLY4A-O/#D>;%+(IX8BL/7/
MV!]3M/V8;7P+H=Q\+/MEO8Z?9VWVS1I8M.T-K:ZU"X2YTZ.VEC>TG@:\C-M)
M&RF!H`RX(4B8_P`*#?Q?:_\``G^:MZ"^W)=+NWIRQM^-T?7$;^9&K88;AG!&
M"*=5+3)X['3;>&6^6ZDAB5'FD90\Q``+'&!D]3@`<U/_`&C;_P#/>'_OL54E
M9V0HMN*YMR:BH?[1M_\`GO#_`-]BC^T;?_GO#_WV*DH\*_:._:6\4_!GQYX1
MTGPWX?TO6-/O+B34/$EQ>7+1/9Z=_:EG9,;=1]^8&],H#?+LMG'WF0%FO_M)
M^+/!%_<:A<:78ZEX;DN?$.R7S!'/'_9R7'E6\:CKN-E*S.__`#V0#[IQ6_:@
M^`7B#XK>+/#?B#P[XET_3-/TE;JU\0:?):"XN-7LQJ%I?+%;-D>7,SV7E;CD
M>7<R$`.(W3*U7]FSXA>(/A[\-?#J^*/!MMINEZ'>0>*Y;JSFEU*]U"\L9X)I
MK=UE$2#S;B20AT;)HESN/NV[/O=R;5O+E2U6J=T]&5'ET<O5;[)*]_/F;TZJ
MSW6D/P__`&O_`(CW'Q%T70?$V@^#+?\`L35H]!\;3:=<7#B*ZO)9H].:P#CY
MHSLB,OFX(\[C[K8]B_:R_P"36/B9_P!BIJG_`*22UX[X`_9)\;V?Q'T?7O$W
MB_P;?#5M1BUSQI!86$T(O;ZTEFDT_P"Q%I6\F%/,C$BR;V?R%P1N;=ZU^UMJ
MMK#^RI\37>YMU5?">JEF,@``^QR\FMI\G(K?%U[;1O\`^3<UO[MCFI^TYWS;
M=/OE_P"V\M_[U['I%%<U_P`+G\'_`/0V>&O_``9P?_%4?\+G\'_]#9X:_P#!
MG!_\56)N=*>E?)/C_P#X*!>-/`5MX,N+[P?H>G_;+R_F\465QJ.^XTRQ@URV
MTE5MV0E);A3=I+(<F/$,@4DLF?I$_&?P?C_D;/#7_@S@_P#BJ^0-?_9IF^/%
MAX2T[XL^*OV;_$%GX>\9W?BD7UGI._5-/5[N.]B2PFNKB46TC3J\<LBC<T)4
M*4<;ZF7-;W+7Z7VOTO;6R=FUU2M=7N4K6N^ZOWMJVELM=D^C:?0[KX%_M"^+
M?V@=2^'MWXT\/Z3X=U6W\8QW5G;Z?<M<1O87GA6^O+<NQZ3)YSQ2`?+NA++E
M64GZJKXU^!7A6']GR7X;VGB_XG^#?%FLR>+(X!>6,L-I##96GAB^LK<,F\_O
M&$7F2-T,D[!0J!$7ZE_X7/X/_P"AL\-?^#.#_P"*K:IR\SY-NGITOYV^+SO;
M0B-[+FM?K:]K];7UM?;R.EHKFO\`A<_@_P#Z&SPU_P"#.#_XJC_A<_@__H;/
M#7_@S@_^*K,9TM>?^'/^3I_&7_8J:#_Z5ZS6W_PN?P?_`-#9X:_\&<'_`,57
M!>'?C!X27]J'QA(?%'AT1MX6T)5;^TH=I(N]8R`=W49'YB@#V*BN:_X7/X/_
M`.AL\-?^#.#_`.*H_P"%S^#_`/H;/#7_`(,X/_BJ`.EHKFO^%S^#_P#H;/#7
M_@S@_P#BJ/\`A<_@_P#Z&SPU_P"#.#_XJ@#$_9-_Y-8^&?\`V*FE_P#I)%7H
M%>._LJ?&#PE;?LO?#>.3Q1X=CDC\+:8K*VI0AE(M(L@C=UKO?^%S^#_^AL\-
M?^#.#_XJ@#I:*YK_`(7/X/\`^AL\-?\`@S@_^*H_X7/X/_Z&SPU_X,X/_BJ`
M,3]I?_DG6F_]C7X;_P#3Y8UZ!7CO[2/Q@\)7'P\TY8_%'AUV'BGPZQ"ZE"2`
M-;L23][H`"?H*[W_`(7/X/\`^AL\-?\`@S@_^*H`Z6BN:_X7/X/_`.AL\-?^
M#.#_`.*H_P"%S^#_`/H;/#7_`(,X/_BJ`.EKS_Q'_P`G3^#?^Q4U[_TKT:MO
M_A<_@_\`Z&SPU_X,X/\`XJN"\1?&#PDW[4/@^0>*/#IC7PMKJLW]I0[03=Z/
M@$[NIP?R-`'L5%<U_P`+G\'_`/0V>&O_``9P?_%4?\+G\'_]#9X:_P#!G!_\
M50!TM%<U_P`+G\'_`/0V>&O_``9P?_%4?\+G\'_]#9X:_P#!G!_\50!B?M+_
M`/).M-_[&OPW_P"GRQKT"O'?VD?C!X2N/AYIRQ^*/#KL/%/AUB%U*$D`:W8D
MG[W0`$_05WO_``N?P?\`]#9X:_\`!G!_\50!TM%<U_PN?P?_`-#9X:_\&<'_
M`,51_P`+G\'_`/0V>&O_``9P?_%4`=+7G_B/_DZ?P;_V*FO?^E>C5M_\+G\'
M_P#0V>&O_!G!_P#%5P7B+XP>$F_:A\'R#Q1X=,:^%M=5F_M*':";O1\`G=U.
M#^1H`]BHKFO^%S^#_P#H;/#7_@S@_P#BJ/\`A<_@_P#Z&SPU_P"#.#_XJ@#I
M:*YK_A<_@_\`Z&SPU_X,X/\`XJC_`(7/X/\`^AL\-?\`@S@_^*H`\D_8W_Y.
M*_:Q_P"RJV/_`*A'A2OH"OE_]C[XM>%;7]H7]JJ23Q-X?CCN?BE8R0LVHPJ)
M5'@KPLNY3NY&Y6&1W4CJ#7O?_"Y_!_\`T-GAK_P9P?\`Q5`'2T5S7_"Y_!__
M`$-GAK_P9P?_`!5'_"Y_!_\`T-GAK_P9P?\`Q5`'2U\__P#!)W_E%E^S3_V2
MKPO_`.FBUKUO_A<_@_\`Z&SPU_X,X/\`XJO!/^"57Q:\*Z;_`,$OOV;[>X\3
M>'[>XM_A;X8CEBDU&%7C8:3:@JP+9!!&"#TH`^H**YK_`(7/X/\`^AL\-?\`
M@S@_^*H_X7/X/_Z&SPU_X,X/_BJ`.EKY_P#^"EG_`";KX<_[*K\./_4WT*O6
M_P#A<_@__H;/#7_@S@_^*KP3_@I#\6O"M_\`L]>'8X/$WA^:1?BE\.Y"L>HP
ML0J>-=#9FP&Z*H))[`$]!0!]045S7_"Y_!__`$-GAK_P9P?_`!5'_"Y_!_\`
MT-GAK_P9P?\`Q5`'2T5S7_"Y_!__`$-GAK_P9P?_`!5'_"Y_!_\`T-GAK_P9
MP?\`Q5`'DGQ&_P"4IOP;_P"R5>//_3OX,KZ`KY?^(GQ:\*R?\%0?@_<+XF\/
MM;Q?"WQU&\HU&'8C-JW@XJI.[`)",0.^T^AKWO\`X7/X/_Z&SPU_X,X/_BJ`
M.EHKFO\`A<_@_P#Z&SPU_P"#.#_XJC_A<_@__H;/#7_@S@_^*H`Z6OC_`/X)
M0?\`)1?VPO\`LX#5?_3'H=?3?_"Y_!__`$-GAK_P9P?_`!5?(W_!*WXJ>&--
M^(7[7C7'B30;=;KX]ZK-"9-0B431G1-$`=<MRI((R.,@^E`'V]17-?\`"Y_!
M_P#T-GAK_P`&<'_Q5'_"Y_!__0V>&O\`P9P?_%4`<=^T'\==<^"^N64L&BV5
MWX?.E:G>75U+<;93/;6<US'%&H/`*P-N9N/G7'1L?.?QP_;%^(&H_!?Q=H^O
M:/X)6'2=*U+0?&MQIMU<2>5>745[#8&Q#?>C+11F7S<,!,,?=./9/CQK-[X^
M^)W@^\\/^.OA#'X7T5+U]3LM:9KJYO99K6:W14:.=8Q%^]RZLK%@"`1FOFWQ
MK^RQH_P?_9EU33-+\6?!70?"]OX>U+4O$.@>%[*/3;62^@_M"[LUTZ))=L$*
MS77SJX=G$*<Y9RU8>WM+U?ANO7=7?_@/,EY\O8SQ7/[.U'XK/\G;_P`FY;^7
M-Y'TA_P2=_Y19?LT_P#9*O"__IHM:^@*^>_^"3]_`G_!+3]FI6FB##X5^%P0
M7''_`!*+6OH16#J&4Y4\@CO4F@4444`4O$EO'=^';^&:-)8I;:1'1UW*ZE2"
M".X/I7C6G?''P+\//%*^#-0TB0:I;^&]1\6&2/3XVMQ9VUTT;QALY\WG*IC!
M5&Y&,5[1KG_(%O/^N#_^@FOE?XW_``2\<>//%.E:IX2TNUN$N)M.TB^NI[E8
M?+TV6^U2'4]G!)=+>Z215(`=E09')&DI35%\F]]%M=V:6NRU[Z=VD9RY;N3Z
M)?\`I4;^NE]M>QZY\%/C_P#"_P"//P^T'Q!HUWX>MQK_`(>M/%"Z;>M;1:E8
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MV@Q?VXES<Z=:73VBW=]:P7$L'VN.-'8M`YA9U?\`ND;@K!E&UX1^)WPQ\?\`
MB)])T+7/!.LZE';QW9M[&YMKAS%(9%1P%)R"8I!Q_=-?%]O^Q7XVT3Q)\*=/
MTOP1K.E?\(W\/KK2O/TQ='M='L)I=/U6.6WNI1F^,S7-S;-&+?\`<#=*[DM@
M'T`^$;WP=XKT7X@>#_V:?$OA^>STW3;C^PK*VT"SU&/RYM4M);)FCO?)WA;V
M&ZXE,9BC;YO-`B/!AZTZE*$Y73:U6S6C_5+^K&%=*$II:V3:[-Z67XV^[>SM
M],WGCCX<Z?IS7EQK'@J"T3R"T\EU;+&OGC,&6)Q^\'*?WATS7&?'/]H[PC\`
MOB!HNAZIX*U_4+?5(XY[S6--TF"?3M`ADG6!);QS(KHAD;JB/@*Q.`,U\3Z)
M_P`$[?&.@_L4Z3H?BGP7X\GU6WUGP\^L6'@>YT2;6+V"T\&V.F'RGU0_96BA
MOEG&&*,,-(GS8W?5G[2.C>,K#Q@GASPUX#\2^++/QQX07PG)KWVFQ6Q\/$RN
MCW%_YDZ3L!%*7`MX92[(5.P$-795CR57&,KI;>?N<WRUL@Q,8PNJ>J[VZ<Z5
M[?X;RM^#/;+;5/!=ZUTL-QX7F:QN$L[@))`WV>=W")$^/NNSLJA3R2P`&37'
M?$OX_P#PY^'GPIU+Q=:Q:;XOL].O[;2!:>'$MK^ZN;^XGBMX;1`'"><\LT2A
M7=<;P20*^;/CS\`/&GA+2+32_#/PWOM07Q;XETK6]9U.RN+2"WT==,\7#5I9
M[LF032236C8B$,<K9AVMY8"UPW_!-K3/#GBK_@EGXGAT[X?^(/B)>3:_:+X@
MTG1(M(T>^U"ZBM=,2.YL6M]2GM3-%#';2L[WJ.T\4[,(F(B$TUST'4YK-):=
M=6E\OM6;36B>P5DH2C&.MY->22BI)^>KLTFMM/+[S\.>)_!OB+PA;ZUY>CV-
MK);I<3)>QPPRV6ZW6Y*3*?\`5NL+!V4]%YZ<UG:+\5?AOXB\:+H-G?\`A:XO
MKC3(M7M"DMLT>H6SM.N^`@_O`GV>0N5!"@J2>>/CW1O@+\4K;P]XDT+QKX&^
M('BR'Q6J>*M7UK2[[2/[2FD?PA!H;6$8FECADU(3P-([/&EH0Z$,P+(NC9_`
M+Q9XD\0>$9=;^#.JV4TGA.&-]8T2UTC39_#\%M_;9ETU8!>.MO=7,5Y:1A8)
M);<R22%Y@L2%L9U7SI1O9V[Z73YO_`6OFEINKZ2ITU&\7?2_SLG;YWMZ^CM]
M4'XY_"$3K'_PE7P]&^Q_M-9#?VOE-:^<8#,'SM*"93&2#PPQUK?M?$7@2^O]
M.M8;[PE-=:Q:&_L(4FMVDO;<#=YT2@Y>/;SO7(QSFOAK4/V;O&DWP'MK.#X+
M:E]NO/#+Z/#))HOAM=;T[2X-<6:2WEB^T&Q75;BSEDDA:,O:-<Q^;*(`PB'5
M>"/V+O%=E\.]`E_X16XB\2:;X771+2[U*>S_`+0L(C;^(T\AI;<+'&<WEB'^
MSJJ$LNU=L8"W*35K/O\`K;\E^/D902ES7Z7^=E%_>VVEZ>I]$/\`'_X=Z;\3
M/`OA-8['4KOXC6FL:GHU]900W%A)!IS1&<M,IP.+B/;M#`[6Y&.<?X"_M:^!
M/VCM?T6S\.^#O$'V76M).J_VC=:/!%:6)\Z:)+:<[RZ3O]GE=5"%=J\L&(6O
M#?VA_@)\0/BG#\)?$OPO^',W@>X\-^%]?TZ/1-0ELK,^'WO]6T2&2W=;:66(
M-]@CU)U,+.F8@"06`/I'PF^%WB'P1^U'HP@\#>)]#M87UA[_`,0VNH6;:'J6
MF27VHRVME/`9?/6Z26:&:,QP[/*<AIMW[I2I+EY=7=WNNUG*WEK96UZ/O&^L
MJ<?91E%;I-ZK?F:M;?;5W756ZV^DO^$1TG_H%Z?_`.`R?X5YU^U]X%T/4?V3
M/BA;W&CZ5/;S^$=6CEBDM(V2139R@J01@@C@@UZK7G_[67_)K'Q,_P"Q4U3_
M`-)):7,^YE9'+_\`#MW]G?\`Z()\%_\`PB-,_P#C-'_#MW]G?_H@GP7_`/"(
MTS_XS7M%%2,\7_X=N_L[_P#1!/@O_P"$1IG_`,9H_P"';O[._P#T03X+_P#A
M$:9_\9KVBB@#Y=^+7_!._P#9_L?'WPOBA^!GP=ACO/$TT-PB>#--59T&C:FX
M5P(?F7>B-@\913U`KNO^';O[._\`T03X+_\`A$:9_P#&:ZCXR_\`)1?A-_V-
M<_\`Z8]6KT"@#Q?_`(=N_L[_`/1!/@O_`.$1IG_QFC_AV[^SO_T03X+_`/A$
M:9_\9KVBB@#XE^,'AC]DOX)_$G5_"FK?LS^"9M6L;&.\T];3X<:3(GB.1KBR
MMC:V)*CS)UFU&R1@X1!]H4[\!BNQ\!OV._V;?C9\1KSQ%I/P+^$S>']>\$>'
M=9L+>Y\#Z=&T`N9]58EHO)(24JL:N.N8P"3M%1_M-W/Q`\8?M)ZMJ5K\#?&V
MN+\-7TF?POJ]M?Z2MGKUH+ZPO-4B@,EXDT=U)Y:)''-$D3-IW,Z"4%?2?V.O
M">L>!_$+:9X@M8;#7;?P#X<;4+2&;SX[2X>ZUEY(5DP-X1F*[L#=MS@9Q3BX
MNDFM[N]_PLO/5>7*K_$FZDK2TVTZK5]?/337JY/MIJ_\.W?V=_\`H@GP7_\`
M"(TS_P",T?\`#MW]G?\`Z()\%_\`PB-,_P#C->T44B3Q6;_@G'^SK!"TC?`7
MX+A4!8G_`(0C3>`/^V%>%^%_#'[*OB75_#>GM^RQX5TW4->U.32[JVO?AOHR
M2>'V#P)%+>A=WEQSM=6PB*;RWG+D+AL?;5W,UM:R2+%),T:%A&F-TA`Z#)`R
M>G)`KXM^#^C_`!*\4>)?#>OZU\)_'6B:QXZU2)_$SZM/I*KX?DM-4M=0623[
M/>S>9:M;JUI`T>Z4M:1F2.-9"ZY<TO;1C]GKY=M=K-JS[7N]-KLO9M]>GX7^
MY:^=K':?LP?\$[_V?]9_9I^'=Y>?`SX.W5W=>&=-FGGF\&:;)),[6L19F8PY
M9B222>237=?\.W?V=_\`H@GP7_\`"(TS_P",UU'[)O\`R:Q\,_\`L5-+_P#2
M2*O0*U(/%_\`AV[^SO\`]$$^"_\`X1&F?_&:Y?XR_L6_LZ?!OX<ZCXB;]FGX
M:^)/[/";=,T3P!I,]_=EG"XB1T1"1G<=SJ`%//8_2%>:?M>Z6FN_L^:]8W'@
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M_P`(C3/_`(S1_P`.W?V=_P#H@GP7_P#"(TS_`.,U[110!XO_`,.W?V=_^B"?
M!?\`\(C3/_C-<+X@_P""=_[/\7[2WA*S7X&?!U;2?PSK<TD`\&::(Y'2ZT@(
MQ7R<%E$C@$\@.V.IKZBKS_Q'_P`G3^#?^Q4U[_TKT:@#E_\`AV[^SO\`]$$^
M"_\`X1&F?_&:/^';O[.__1!/@O\`^$1IG_QFO:**`/%_^';O[.__`$03X+_^
M$1IG_P`9H_X=N_L[_P#1!/@O_P"$1IG_`,9KVBB@#Y=_:'_X)W_L_P"E>`=/
MEM?@9\';:1O$WA^%GB\&::C%)-9LD=21#]UD9E(Z$,0>":[K_AV[^SO_`-$$
M^"__`(1&F?\`QFNH_:7_`.2=:;_V-?AO_P!/EC7H%`'B_P#P[=_9W_Z()\%_
M_"(TS_XS1_P[=_9W_P"B"?!?_P`(C3/_`(S7M%%`'B__``[=_9W_`.B"?!?_
M`,(C3/\`XS7"^(/^"=_[/\7[2WA*S7X&?!U;2?PSK<TD`\&::(Y'2ZT@(Q7R
M<%E$C@$\@.V.IKZBKS_Q'_R=/X-_[%37O_2O1J`.7_X=N_L[_P#1!/@O_P"$
M1IG_`,9H_P"';O[._P#T03X+_P#A$:9_\9KVBB@#Q?\`X=N_L[_]$$^"_P#X
M1&F?_&:/^';O[.__`$03X+_^$1IG_P`9KVBB@#XD_9+_`&`O@/KGQ\_:>M;[
MX)_".\MM&^)EE9Z?#/X/T^2.Q@/@WPS.8HE,)$:&:::0JN`7E=L98D^Y_P##
MMW]G?_H@GP7_`/"(TS_XS6/^QO\`\G%?M8_]E5L?_4(\*5]`4`>+_P##MW]G
M?_H@GP7_`/"(TS_XS1_P[=_9W_Z()\%__"(TS_XS7M%%`'B__#MW]G?_`*()
M\%__``B-,_\`C->&?\$POV`O@/XR_P"":G[/.L:Q\$_A'JVK:M\,_#=Y>WMY
MX/T^>XO)Y-*MGDEDD:$L[LQ+,S$DDDDDFOMNOG__`()._P#*++]FG_LE7A?_
M`--%K0!L?\.W?V=_^B"?!?\`\(C3/_C-'_#MW]G?_H@GP7_\(C3/_C->T44`
M>+_\.W?V=_\`H@GP7_\`"(TS_P",UX9_P4-_8"^`_A3X!^'[K2_@G\(]-N9?
MB9X`LWFM?!^GPR/!/XRT6">(LL()22&22-UZ,CLI!!(/VW7S_P#\%+/^3=?#
MG_95?AQ_ZF^A4`;'_#MW]G?_`*()\%__``B-,_\`C-'_``[=_9W_`.B"?!?_
M`,(C3/\`XS7M%%`'B_\`P[=_9W_Z()\%_P#PB-,_^,T?\.W?V=_^B"?!?_PB
M-,_^,U[110!\2>/_`-@+X#VO_!2OX2Z/'\$_A''I-]\,_&UY<V2^#]/6WN)X
M=5\))#*\?D[6>-9YU5B"5$T@!`=L^Y_\.W?V=_\`H@GP7_\`"(TS_P",UC_$
M;_E*;\&_^R5>//\`T[^#*^@*`/%_^';O[.__`$03X+_^$1IG_P`9H_X=N_L[
M_P#1!/@O_P"$1IG_`,9KVBB@#Q?_`(=N_L[_`/1!/@O_`.$1IG_QFOE/_@F)
M^PI\$/&7C[]JZ+6/@W\*M5CT/XYZGING)>>$K"==/M5T;176WA#1'RX@\DC!
M%PH+L<9)S^BE?'__``2@_P"2B_MA?]G`:K_Z8]#H`]8_X=N_L[_]$$^"_P#X
M1&F?_&:/^';O[.__`$03X+_^$1IG_P`9KVBB@#POQ#_P3S_9YT'0+Z^3]GCX
M1Z@UE;R3K:VG@;2VN+DJI;RXPT2@NV,`$@9(R1UKY8^*NG?LQ^*_@MX@L8?V
M5=#\'ZQJNB:U;"?4OAUHML=`NH+>Z6'[1)$S^6TTMO,L)C+Y>(@[.,_HS,YB
MA9E5I&4$A5ZM[#-?!?[0WPZ^(FI_L\26^M>![^RG\6>$O^$E\37\%Y:S67A6
M_MGU/5;FRE_>++(7FO$@B:%)%.QV<H%7?=%)U$I?"VDWVN]7YV2;^[NKQ6YE
M2E*&Z3:7?31?-V7S?;3VC_@E'X7TRX_X);_LUR2:=8R22?"OPPS,UNA+$Z1:
MY).*^C(85MXECC58XXP%55&`H'0`5X#_`,$G?^467[-/_9*O"_\`Z:+6OH"I
MYF]RPHHHI`4?$]O]K\-:A%YDD7F6TB;XSM=,J1D'L17!>!M8T'1[&'1KSQ@M
MKJ\=I=:HUE-JD27/V.*X9)+HQGYO*5F4-)C:&8`D$BO0=<_Y`MY_UP?_`-!-
M?%?[2V?#WQ@TW6;72[O4=2UC3+7P*#;P-*8H-9U#5+=F?:,B-9X[61V/"K&2
M>!6KE*-%N*N[[+=NSLEWUMIN]EJ9R2NYRZ)?<Y13^Y.]^A]<^%AIOCGPSI^M
M:)XEGUC1M7MH[VPO[&_2XM;V"10\<L4B95XW4AE9200002#5_P#X14_]!35O
M^_X_PK\I_P!E#XO^)='\,^&]%T/Q?JN@_8O@98VHT23Q%=RW$++X5M;F'5;7
M3\_9[>W$H\I9@!(T]O<#H37NWQ+^.=]\#]+T'X>R>/\`Q.NL>(/%VB:!X;%[
MK$MQK&LV]MXV\C4B)6/F2E-/EB69^<1$;N*WE2;Q#H0?6RO;NU^EW\^S.JMA
ME2GRR:TDHM^;M_G?T7F?9_A*[T?Q_I#:AH/BI]:L%N9[-KFPU&.YA$\$KPSQ
M%TR-\<L<D;KG*NC*0""*T_\`A%3_`-!35O\`O^/\*_-/X:^,]<^!>I_!/PWX
M;\<:K#<1?#*\NO['U+Q->75_K+/8ZO="ZBL"3%,(;B.%6GD&Y=T,8/05Z/X2
M^,7PK^`GQ,TGQYI/QZUSQ%X(NM%TF:XU36O',FJV-WIYN-8M#<$R.58"_:U@
MW]I)%3J<5P8?$.M2A5CM)?H_\OS['/7BJ4IQE]E-_=;3UU^^VUT?<O\`PBI_
MZ"FK?]_Q_A7(^-/BGX%^&WCOP_X6\1?$C1]`\3>+',>AZ1J.OVUK?ZRP(4K;
M02$23$%@,(&Y(]:_-_3_`(T?$K5_V&-+\3:Y\8YO!-YJ6L>%]/U#7/%_B6]T
M:RTE/^$,LKXJ\T)#QR3ZA<NTF[`E8K&V>!7U-^VA\1?!?A_QJWA?QMJ6@S>-
M/&W@F&Q\*:<647FLZNMVQB-BA^=GCN&@DRHR@"L<`9KLJTY4ZKIMWM^/N<VG
MX+Y]1XF"I75T[=>GQJ-WMIK?Y;H^J#X3R/\`D)ZM_P!_Q_A7)^)8/`_[-'PX
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MJRLI!#`D$$$4RXAT^T\0VND2^([F/5KZWFN[:R>^1;BXAA:)994CQN9$::$,
MP!"F6,$@LN?@36X+S]F[X6>+-!\7?%CQ-X8T'PSXKL?"]G?:=J\FF06DMOX4
MMKNUL[95(VI<7\\F4'^M(BB(.0*Y'XK?%V_T3]L2V\62?$37(_%?A6PNY/'V
MG/JC?8/`VG1>+O")E&PG99PSZ1%<3R#@31;Y#D9-/#T_:5%&;459.[V5X<ZU
MZI?:?33N@HT5*I"DW\5U?;5::WVN]E=O>U['Z;?\(J?^@IJW_?\`'^%'_"*G
M_H*:M_W_`!_A7YS?';XK>'OCSH^K7/B+XM>*]`DCN],U_0=.LO%,VEQW?AU?
M%I:?5C$K#>L,2!?-(Q%'$AR`U?I?7+"LY+MJ_P`-/S3)E22U33]/1/\`5'&I
M?:/I7B#3]#N_%1L];UHWDVGZ=+J,<=U?QP./.>*(_-(L?F1ERH(7S%SC<*R_
M#/Q:\`^-?$^G:)HWQ,T75M:UC3GU>PL++Q!;7%U>V22F%[J*-&+/"LH,9D4%
M0P*DYXKYA_X*0^,M2^%G[3GPD\8:387>I7WASPSXN2&"VA:61GO=4\/:8K`*
M"?D:]$AQVC/I5O\`92'A/X+?M->'?`OAW6-`2^F75;&;PK<QA=1L+"SOM7%M
MJ=I_&;<Y-K(?]6&('W\BKG-QY6VO>OIUT<E^BZ:Z[<K*G04:<9)/5)WZ+WFK
M7[Z?+3NC[#_X14_]!35O^_X_PKSG]L+P2VH?LD?%*W_MC7+?S_"&K1^;#<A9
M(\V4PW*=O##J#ZUZY7G_`.UE_P`FL?$S_L5-4_\`226ES,QY4>8_\.[9O^B^
M_M'?^%=%_P#(U'_#NV;_`*+[^T=_X5T7_P`C5]'45)1\X_\`#NV;_HOO[1W_
M`(5T7_R-1_P[MF_Z+[^T=_X5T7_R-7T=10!\=?%?_@G]-8^//AG'_P`+U_:%
MF^V>)9H=\OBN)F@QH^I/OC/V?Y6^3;GGY78=\CM_^'=LW_1??VCO_"NB_P#D
M:O3OC+_R47X3?]C7/_Z8]6KT"@#YQ_X=VS?]%]_:._\`"NB_^1J/^'=LW_1?
M?VCO_"NB_P#D:OHZB@#YQ_X=VS?]%]_:._\`"NB_^1JXC0?^"?TTO[2'BRS_
M`.%Z_M"KY'AK19O/7Q7%YTF^ZU8;&;[/RJ[,J,<%WZYX^Q:\_P##G_)T_C+_
M`+%30?\`TKUF@#S'_AW;-_T7W]H[_P`*Z+_Y&H_X=VS?]%]_:._\*Z+_`.1J
M^CJ*`/G'_AW;-_T7W]H[_P`*Z+_Y&H_X=VS?]%]_:._\*Z+_`.1J^CJ*`/CK
M]F;_`()_3:Q^S?\`#^\_X7K^T+:?:O#6G3>1;^*XDAAW6L9V(OV<X49P!DX`
M%=O_`,.[9O\`HOO[1W_A71?_`"-7IW[)O_)K'PS_`.Q4TO\`])(J]`H`^<?^
M'=LW_1??VCO_``KHO_D:C_AW;-_T7W]H[_PKHO\`Y&KZ.HH`^.OV@?\`@G]-
MI?@.PD_X7K^T+=;O$N@0[)_%<3*-^L6:;P/LX^9=VY3V95/.,5V__#NV;_HO
MO[1W_A71?_(U>G?M+_\`).M-_P"QK\-_^GRQKT"@#YQ_X=VS?]%]_:._\*Z+
M_P"1J/\`AW;-_P!%]_:._P#"NB_^1J^CJ*`/DWQ=^RCX7^'_`(P\.^'=>_:G
M^-6B>(/%TDL.A:9?_$&SMKS6GB"M(EK$\`>=D#*6$88J&&<9%<;X5_92\._%
M_P"-7A._\(?M,?&;Q9H]QH.OH-6TGQW:W\:2V]YI4<D*S10L@P[$.O4-&H."
MI%>B_M[>,H_#_P`3_A_9Z'X^TG2/B!JT%]I>D^$)(+>:^\4PW36ZS2P%OWT7
MV58S.9(N`$.\A<UB_L->,O"WQ#^)6@ZUX*N-/O?#-YHNJQVEQ8@?9Y&AM?"M
MO,JD<9CFBEB<=5>)U/*D5E1J<[DG]G_-K\$E?LY)676ZD.51?>_R_P"'OIZ/
MY=7_`,.[9O\`HOO[1W_A71?_`"-1_P`.[9O^B^_M'?\`A71?_(U?1U%:D'SC
M_P`.[9O^B^_M'?\`A71?_(U<W\5OV4/"_P`"/!LWB/QQ^U-\:O!OAZVD2*;5
M-=^(-GIUG$[MM16FF@5`68@`$Y).!7UE7G_[4OB"^\-?L_\`BBYTF"UN->EL
M_L>C)<Q>9"=1N&$%IO7!^7[1+%GVS4RYK>XKOMW\BH\M_>=EW[>9\H_$W]G'
MP?XTT:'2_#O[4WQ<\4:M:ZOX7OKC3[7X@V=[-;6E[JME]FNVBCA+*CHWF0R$
M;6(5E+"O8/\`AW;-_P!%]_:._P#"NB_^1J\DT*/PYX4^+EWX'T^XLYO$W@?Q
M#I\6K0(0UU9VD^N^&?[-,V.0LEM`1'G@B"0#[C8^Z:*<E*$9KJD_OZ?+9^:9
M,DU)Q?1V^[K\]UY,^<?^'=LW_1??VCO_``KHO_D:C_AW;-_T7W]H[_PKHO\`
MY&KZ.HJ@/DWQ=^RCX7^'_C#P[X=U[]J?XU:)X@\722PZ%IE_\0;.VO-:>(*T
MB6L3P!YV0,I81ABH89QD5QOA7]E+P[\7_C5X3O\`PA^TQ\9O%FCW&@Z^@U;2
M?'=K?QI+;WFE1R0K-%"R##L0Z]0T:@X*D5Z+^WMXRC\/_$_X?V>A^/M)TCX@
M:M!?:7I/A"2"WFOO%,-TUNLTL!;]]%]E6,SF2+@!#O(7-8O[#7C+PM\0_B5H
M.M>"KC3[WPS>:+JL=I<6('V>1H;7PK;S*I'&8YHI8G'57B=3RI%94:G.Y)_9
M_P`VOP25^SDE9=;J0Y5%][_+_A[Z>C^75_\`#NV;_HOO[1W_`(5T7_R-1_P[
MMF_Z+[^T=_X5T7_R-7T=16I!\X_\.[9O^B^_M'?^%=%_\C5YCJW@7X/Z!J/B
M6SOOVV/B!97?@N:.W\003_%?3(Y-"EDE$,:7:M&#`S2D1J)-I+D*,DXK[<KX
MW_:G^)/@'3/B!XR\3^*5TO3_``SX-U2U\)ZO>7\`6`WDNB:A<A2Q&&\QM5L(
MEZYE(4?-@4G*VMF_3?R_%I>K12BY+3\=O/[E=_(XO]E/]@^;6_CO^TQ:_P#"
M[?CY9_V/\2;.T,UMXHCCEOL^#_#4WFSG[.=\@\[RPPQ^[BB7'RY/MW_#NV;_
M`*+[^T=_X5T7_P`C5C_\$RM.U+1_$G[0=GK/F_VQ:^.]%AOO-;<_GKX!\(B3
M<>YW`Y-?4U:UJ:A4E!.]FU?O;J8T:CJ4XS:M=)V[7Z'SC_P[MF_Z+[^T=_X5
MT7_R-1_P[MF_Z+[^T=_X5T7_`,C5]'45F:'SC_P[MF_Z+[^T=_X5T7_R-7B/
M_!,_]@^;QA_P3@_9^U8?&WX^:2-4^&WAV[%CI_BB.&SL_,TNV?RH4-N2L:9V
MJI)PH`R:^_*^?_\`@D[_`,HLOV:?^R5>%_\`TT6M`%'_`(=VS?\`1??VCO\`
MPKHO_D:C_AW;-_T7W]H[_P`*Z+_Y&KZ.HH`^<?\`AW;-_P!%]_:._P#"NB_^
M1J\1_P""@7[!\WA?X$:#='XV_'S4O,^)/@*T\F^\41RQ)Y_C#1H?-`%N,21^
M9YD;?PR1HV#C!^_*^?\`_@I9_P`FZ^'/^RJ_#C_U-]"H`H_\.[9O^B^_M'?^
M%=%_\C4?\.[9O^B^_M'?^%=%_P#(U?1U%`'SC_P[MF_Z+[^T=_X5T7_R-1_P
M[MF_Z+[^T=_X5T7_`,C5]'44`?`?CW]@^:V_X*/_``ITG_A=OQ\D-]\-O&EW
M]N?Q1&;RW\G5/"B>5&_V?"QR>?N=<'<T,1R-O/MW_#NV;_HOO[1W_A71?_(U
M7OB-_P`I3?@W_P!DJ\>?^G?P97T!0!\X_P##NV;_`*+[^T=_X5T7_P`C4?\`
M#NV;_HOO[1W_`(5T7_R-7T=10!\X_P##NV;_`*+[^T=_X5T7_P`C5\M?\$T?
MV()?%_CO]JB,?&;XZ:3_`&+\;M2TXOI_B6.%M0VZ/HS_`&BX)@.^<^9M+C`*
MH@QQD_IG7Q__`,$H/^2B_MA?]G`:K_Z8]#H`[+_AW;-_T7W]H[_PKHO_`)&H
M_P"'=LW_`$7W]H[_`,*Z+_Y&KZ.HH`^4]8_9`\/>'O'VC^%-0_:@^.%CXH\1
M13SZ5H]QX^M(M0U..$!IG@@:`22K&""Y12%!&<5YW^TM^SIX-TOX-^)M+7]J
M?XM7FN:UX=UY](T>?X@V<DNMM8V\PO(XH!"'F$+(RS!`3'A@VTBO5/VS_CKX
M7\-_'OP-X(M+_0[?XL7UC?Z_X;L[N_@LKG5I8;.[MK:TA:5AN:2>Y/`.`L<A
M;`KY4\>ZW#HGP%O/!FK^%IO`/CA]-N(O#6C:CJEMJ&I75CI][KDFHS)-"[*X
M2WE*S$')\Q=W$BYNC'VDHKN[7Z:NUT]GR_:M?1/;IEB*OLTVE>T;_-:V?;F^
MR^[2[7^M?^"4OAHS_P#!+G]FV3^T=4CW_"SPPVU)@%7.DVO`XZ5](6\7D0)'
MN>38H7<YRS8[GWKP'_@D[_RBR_9I_P"R5>%__31:U]`5+DV:V"BBBD!1\3B8
M^&M0\@QK/]FD\LR`E0VTXR!SC/I7,_#6/7/^$.M_WVDY\V?=^ZDZ^<^<?-TS
MFNJUS_D"WG_7!_\`T$U\A_M22:EX%U>Q\832:_\`V1;^'=7TFPN=+\1W%FNB
MZE.+[8]Q8H1%<Q7`V(LTF7MY;:/RQ^]D9=X?`HKJTOP=OO>GY:Z&?+>I\OU5
M_N6I]8>7KO\`SVTG_OS)_P#%4>7KO_/;2?\`OS)_\57R?9?M;^.M)@\6+XBL
M_"]SXQ^&J:[!YEFUY:Z;.4T/3=7ME>,W#!RJ7T<,DCYW-$[QB$2%!]"?LS^-
MO%'C+X>W,?C2;0;OQ1H>JW>DZA=Z)9RV>G7KPRD++##+-,\:E"H*M*Y#JXW=
MAES/VDJ;2O%)_)I/_P!N7W_=6JIPJ2NN;;[FU]Z5T=9Y>N_\]M)_[\R?_%4>
M7KO_`#VTG_OS)_\`%5K44<P^4R?+UW_GMI/_`'YD_P#BJ/+UW_GMI/\`WYD_
M^*K6HHY@Y3#O]-U?5+&:UN#H\UO<1M%+&\$A5U88((W="#BN'_9W_9FM?V7O
M!]WHOA>:XFM[^[^VW-QK.JW^L7L\@BCA7=<74TDI5(H8D1"VU%0!0`,5ZI10
MIM7MUW%RWW,GR]=_Y[:3_P!^9/\`XJCR]=_Y[:3_`-^9/_BJUJ*.8?*9/EZ[
M_P`]M)_[\R?_`!5'EZ[_`,]M)_[\R?\`Q5:U%','*8.EIK?V9MLNEX\Z7K%)
MU\QL_P`56/+UW_GMI/\`WYD_^*KYV_:N\::KX8^-^EV]IJNHZ?9S?"WX@71C
MAN7BB>[AN=$,$A`('FQJTY1OO*&DP1EJYSQ/^UCXYC\>:AX?UVS\-R>'-4@U
M"X\/K9B]MM0A.D:WIEC.]U.EP-XE-^A5(UCV^0^\R++L72HFH>TC9Z2?IR\U
M[_\`@/KKL:RH-*G;7GO\K?\``N_1,^K/+UW_`)[:3_WYD_\`BJ\Y_;"B\2']
MDCXI?9)]#6Z_X1#5O),T$K1A_L4VW<`X)7.,X(.*\Q^$/QQ^,VF_&?P?H/CG
M6/!-SX=US5M>M9=5LO"-U`E_)!=W<=IIT4QU!A;3I';F3=)#,LT:LN8I%#2^
MU?M9?\FL?$S_`+%35/\`TDEK-2O!2[_U;U,=I./;^K^FG]:GF/\`8_[7/_0Q
M?LX_^$[K/_R;1_8_[7/_`$,7[./_`(3NL_\`R;7T=14E'SC_`&/^US_T,7[.
M/_A.ZS_\FT?V/^US_P!#%^SC_P"$[K/_`,FU]'44`?'?Q7TG]JX>//AG]I\0
M?L]M,?$LPM#%X?U@*LO]CZGDR9O22OE^8,#!W%3G`(/;?V/^US_T,7[./_A.
MZS_\FUZ=\9?^2B_";_L:Y_\`TQZM7H%`'SC_`&/^US_T,7[./_A.ZS_\FT?V
M/^US_P!#%^SC_P"$[K/_`,FU]'44`?./]C_M<_\`0Q?LX_\`A.ZS_P#)M<3H
M.D_M7?\`#2'BP)X@_9[^W_\`"-:*9F;P_K'DF+[5JWEA1]MR&#>;N))!!3`&
M#G[$KS_PY_R=/XR_[%30?_2O6:`/,?['_:Y_Z&+]G'_PG=9_^3:/['_:Y_Z&
M+]G'_P`)W6?_`)-KZ.HH`^<?['_:Y_Z&+]G'_P`)W6?_`)-H_L?]KG_H8OV<
M?_"=UG_Y-KZ.HH`^._V9M)_:N;]F_P"'QT_Q!^SVE@?#6G&V6X\/ZPTRQ?98
M]@<K>@%MN,D`#.<`5VW]C_M<_P#0Q?LX_P#A.ZS_`/)M>G?LF_\`)K'PS_[%
M32__`$DBKT"@#YQ_L?\`:Y_Z&+]G'_PG=9_^3:/['_:Y_P"AB_9Q_P#"=UG_
M`.3:^CJ*`/CO]H+2?VKE\!V'V[Q!^SVT/_"2Z`%$'A_6%;S?[8L_*)S>D;1)
ML+#J5W`$'!';?V/^US_T,7[./_A.ZS_\FUZ=^TO_`,DZTW_L:_#?_I\L:]`H
M`^<?['_:Y_Z&+]G'_P`)W6?_`)-H_L?]KG_H8OV<?_"=UG_Y-KZ.HH`^<?['
M_:Y_Z&+]G'_PG=9_^3:XG7M)_:N_X:0\)A_$'[/?V_\`X1K6C"R^']8\D1?:
MM)\P,/MN2Q;RMI!``#Y!R,?8E>?^(_\`DZ?P;_V*FO?^E>C4`>8_V/\`M<_]
M#%^SC_X3NL__`";1_8_[7/\`T,7[./\`X3NL_P#R;7T=10!\X_V/^US_`-#%
M^SC_`.$[K/\`\FT?V/\`M<_]#%^SC_X3NL__`";7T=10!\=_M!:3^U<O@.P^
MW>(/V>VA_P"$ET`*(/#^L*WF_P!L6?E$YO2-HDV%AU*[@"#@CMO['_:Y_P"A
MB_9Q_P#"=UG_`.3:]._:7_Y)UIO_`&-?AO\`]/EC7H%`'SC_`&/^US_T,7[.
M/_A.ZS_\FT?V/^US_P!#%^SC_P"$[K/_`,FU]'44`?./]C_M<_\`0Q?LX_\`
MA.ZS_P#)M<3KVD_M7?\`#2'A,/X@_9[^W_\`"-:T867P_K'DB+[5I/F!A]MR
M6+>5M((``?(.1C[$KS_Q'_R=/X-_[%37O_2O1J`/,?['_:Y_Z&+]G'_PG=9_
M^3:/['_:Y_Z&+]G'_P`)W6?_`)-KZ.HH`^<?['_:Y_Z&+]G'_P`)W6?_`)-H
M_L?]KG_H8OV<?_"=UG_Y-KZ.HH`^`_V4M*_:B;X[_M,#3=>^`<=XOQ)LQJK7
M.@ZLT4ES_P`(?X:*F`+>`K']G-N"'+-Y@E.=I55]N_L?]KG_`*&+]G'_`,)W
M6?\`Y-J]^QO_`,G%?M8_]E5L?_4(\*5]`4`?./\`8_[7/_0Q?LX_^$[K/_R;
M1_8_[7/_`$,7[./_`(3NL_\`R;7T=10!\X_V/^US_P!#%^SC_P"$[K/_`,FU
MXC_P3.TK]J*3_@G!^S\WA_7O@'#H+?#;PX=-CU#0=6DO$MO[+MO*$S)>*C2!
M-H8JJJ6R0`.*^A/C+I-[X>_;,^&_B>\TG4+[P_<0OH4%]!XOO;&/2KZ5+EAY
MFE1XMKY95VKYDV6@*!E'4BO_`,$G?^467[-/_9*O"_\`Z:+6G;W>;U7W?\!I
M_,&[2Y?)/[_^#=?)E'^Q_P!KG_H8OV<?_"=UG_Y-H_L?]KG_`*&+]G'_`,)W
M6?\`Y-KZ.HI`?./]C_M<_P#0Q?LX_P#A.ZS_`/)M>(_\%`M*_:BC^!&@G6]>
M^`<MG_PLGP$(UL=!U:.47)\8:,+8DO>,/+%QY1D`&YHPX4JQ##ZP_:^T>XU;
M]GWQ!);ZMK&CR:;$-0$FG7)MI)FA^=(VD7YPF\*Q"%2VW:249E;Y!_:DCFTG
MQ!+<)JVMZC_PF7Q.\'7>IPWFISW5K9R:=\4-&L;06T#N8K4&W8HRQ*@E,*NV
MYPS,4USU/9KLW]R;_)/YDU9*$.=]TOO:7YM?+TL>^?V/^US_`-#%^SC_`.$[
MK/\`\FT?V/\`M<_]#%^SC_X3NL__`";7T=104?./]C_M<_\`0Q?LX_\`A.ZS
M_P#)M']C_M<_]#%^SC_X3NL__)M?1U%`'P'X]TK]J(?\%'_A2LVO?`,Z\?AM
MXT-G(F@ZL+-;8:IX3^T"13>;S(7-L4*L%"K*"&+*5]N_L?\`:Y_Z&+]G'_PG
M=9_^3:O?$;_E*;\&_P#LE7CS_P!._@ROH"@#YQ_L?]KG_H8OV<?_``G=9_\`
MDVC^Q_VN?^AB_9Q_\)W6?_DVOHZB@#YQ_L?]KG_H8OV<?_"=UG_Y-KY;_P""
M:.F?M+2>._VJ/^$?USX&0S+\;M276#J&AZK(LE]_8^C;VM]EVI6#R_*`5]S;
M@Y+$$`?IE7Q__P`$H/\`DHO[87_9P&J_^F/0Z`.R_L?]KG_H8OV<?_"=UG_Y
M-H_L?]KG_H8OV<?_``G=9_\`DVOHZB@#YQ_L?]KG_H8OV<?_``G=9_\`DVN)
M_:9TG]JY?V;_`(@G4/$'[/;V`\-:B;E;?P_K"S-%]EDWA"UZ0&VYP2",XR#7
MUYJMG)J.EW-O#=3V,L\31I<PA#);L00'4.K+N7J-RD9'((XKX+^-?AW4/!?P
MRT_6]0M?$&O>'[?PSXF\+6NK3^.=1CDTZZQJJQF?3@3#J/FQK&GFW!+0F,,H
M[@CK-0[_`-?G9!+2#GV_I_A=_)GM7_!*5-9/_!+G]FWRI-,$?_"K/#&P/$Y8
M#^R;7&?FZU](6_F"!/-VF3:-Y084GOCVKP'_`()._P#*++]FG_LE7A?_`--%
MK7T!3;N`4444@*/B>=K;PUJ$BQ23-';2,(X\;I"%)VC)`R>G)`]Z\=C^!7A#
MXM7FC^)O$7@G6-2UC3;:]T^!VO3'$L$[SI(CPI<"*1@LL@#.K,A8E"#S7LVN
M?\@6\_ZX/_Z":^7?'O[2^O\`PQ_:0\#^%],U_0I+;4+62X/@YH8?[8\3B2YO
MEFGM99)4\M+188Y)#M*;7^=TR">BG\"77F5ON?\`7_`,Y7BW/HE=_>E^=CTC
MXD_LX^%_B!X7\;6<?A+4-/U'QS:7EO?7X*2,9+G3X=.>4IYX!/V:VMTP"O$0
MZ$DGJOA-X,TGX'>`+#POX8\+ZUI^BZ;O\B%[H73@O(TCLTLL[R.S.[,6=B23
MUKYY\+?\%:-&^-_P?DU3X>^%=8US76M]8:]CL=5T?5++PTEA!!(]W<WMM>26
M<\7^F6G[NUGFE;S'4)NAF$?5^(?^"G/@WP?KWPI@U&RDCT;XNW$MKH6M'6M*
MCCO<7"P036]HUT+V[AG,D$B26L$RK%<1R2&-"6`Z4D^9Q^*R]=/=]5;1/;1I
M;-%2J/E2;T5_E:R:\NFG;R:O[_\`\)-<?]`/5O\`R!_\<H_X2:X_Z`>K?^0/
M_CE?'_\`P_!^'^E>'M"O?$'A?7O",_B/66L-/M-=UK1+&2ZLEM-/NVU&-I+X
M1RH(=4LB+6-FO7,C!+=C')M]0^*7[4%SX'_X*`>#?A[)XNT'2='U+P__`&K>
M:1>686:[22XELTN%O&<)&PO9-,MT@P7G:].P'RVQ#C)24)1:;Z-.^U]M]O\`
M@[.Q#WX\T'==&M4]>71K3=-?TCW#_A)KC_H!ZM_Y`_\`CE'_``DUQ_T`]6_\
M@?\`QROE7XR?MO>/O@9\>OB#9S:1:^)+73;[1K'PWX,B6'3]4U>SN[C3+:35
MK:[N98X;F)+B]GADC4@P/';;R!<*1Z1;_MU6]WXSOM#B\`^,I+G^UQIFBR+)
M8^5XCB#W,<UY;M]H_=P1-:3;O/\`*<C8RJRNA:(SBTK+>_X;[=NJW6J=FI)5
M*+2<GLNO3^O/KHU=--^Q?\)-<?\`0#U;_P`@?_'*/^$FN/\`H!ZM_P"0/_CE
M>0?L/_\`!0/P/^WSI'B34/!,D4UCX?NHD65-5L+XW=O,K-!<%+6>5K4R!'_T
M>Z$-S'M_>0ID9]UIW75?F$HN+<7NM/N,G_A)KC_H!ZM_Y`_^.4?\)-<?]`/5
MO_('_P`<K6HI<R["LS)_X2:X_P"@'JW_`)`_^.4?\)-<?]`/5O\`R!_\<K6H
MHYEV"S/*_BK\&_"W[0FB:;:>,/!NJ:Q#H^I/?VFVZ^S-%*&<$%HIT9D()#QL
M3&^,,K`"K&K_``;\)Z]J]O?WG@6^FO+5+V.*0RH"BWEW;WER.)L?O+BUMY#Z
M&(`8!(/)_'CX^Z_\+OBG9:+I9L_L5SX`\9>)W\V'>_VS3;G2EML'(^3%[/N7
M^+Y>1CG-U/\`;OL[WQ1K7AM=%\2:#=::C2V.L7-I;S6FM_9=0M+._6VC\X28
MB>\MU9Y%1?\`2`4,C1R*NDX\L.=1T:D]+[*ZE?Y1:UZ676QI[.<%3E?XMOEI
M^K^5WM<Z;3/V8O`FD?%BV\;0>"?$*^(K.\NM0AE;5YI+>.XN2QFD%LUT8-S%
MW(_=_*6RNTU8_;"\875C^R1\4ID\.ZY=/#X0U9UAA^S^9,193$*NZ8+N/09(
M&3R1UKEO@S^W3J/Q.^+FC^"=2^&/B+PWKFJ2:Q-.EWKFBN=.L+&[DM4O&B2]
M:>:.6:,1'[/'*8G=/-\M9(W?T7]K+_DUCXF?]BIJG_I)+4<UX1=M&M/3]#+E
MM)KKU_KK_3ZGF/\`PW?XV_Z-2_:._P"^_"G_`,O*/^&[_&W_`$:E^T=_WWX4
M_P#EY7T=14%'SC_PW?XV_P"C4OVCO^^_"G_R\H_X;O\`&W_1J7[1W_??A3_Y
M>5]'44`?'?Q7_;@\97GCSX9R-^R[^T);M:^)9I4CE?PMNNB='U-/+CVZT1N`
M<O\`,5&V-N=VU6[;_AN_QM_T:E^T=_WWX4_^7E>G?&7_`)*+\)O^QKG_`/3'
MJU>@4`?./_#=_C;_`*-2_:._[[\*?_+RC_AN_P`;?]&I?M'?]]^%/_EY7T=1
M0!\X_P##=_C;_HU+]H[_`+[\*?\`R\KB=!_;@\91_M(>++H?LN_M"/)-X:T6
M)K97\+>="$NM6(D;.M;=K[R%PQ.8WR%&TM]B5Y_X<_Y.G\9?]BIH/_I7K-`'
MF/\`PW?XV_Z-2_:._P"^_"G_`,O*/^&[_&W_`$:E^T=_WWX4_P#EY7T=10!\
MX_\`#=_C;_HU+]H[_OOPI_\`+RC_`(;O\;?]&I?M'?\`??A3_P"7E?1U%`'Q
MW^S-^W!XRTK]F_X?6L?[+O[0E_';>&M.B2YMW\+>3<A;6,"1-^M*VUL9&Y5.
M",@'BNV_X;O\;?\`1J7[1W_??A3_`.7E>G?LF_\`)K'PS_[%32__`$DBKT"@
M#YQ_X;O\;?\`1J7[1W_??A3_`.7E'_#=_C;_`*-2_:._[[\*?_+ROHZB@#X[
M_:"_;@\9:EX#L(Y/V7?VA+)5\2Z!*))W\+;6*:Q9N(QMUICN<J$7(QN9=Q5<
ML.V_X;O\;?\`1J7[1W_??A3_`.7E>G?M+_\`).M-_P"QK\-_^GRQKT"@#YQ_
MX;O\;?\`1J7[1W_??A3_`.7E'_#=_C;_`*-2_:._[[\*?_+ROHZB@#YQ_P"&
M[_&W_1J7[1W_`'WX4_\`EY7$Z]^W!XRD_:0\)W1_9=_:$22'PUK42VS/X6\Z
M8/=:23(N-:V[4V`-E@<R)@,-Q7[$KS_Q'_R=/X-_[%37O_2O1J`/,?\`AN_Q
MM_T:E^T=_P!]^%/_`)>4?\-W^-O^C4OVCO\`OOPI_P#+ROHZB@#YQ_X;O\;?
M]&I?M'?]]^%/_EY1_P`-W^-O^C4OVCO^^_"G_P`O*^CJ*`/CO]H+]N#QEJ7@
M.PCD_9=_:$LE7Q+H$HDG?PMM8IK%FXC&W6F.YRH1<C&YEW%5RP[;_AN_QM_T
M:E^T=_WWX4_^7E>G?M+_`/).M-_[&OPW_P"GRQKT"@#YQ_X;O\;?]&I?M'?]
M]^%/_EY1_P`-W^-O^C4OVCO^^_"G_P`O*^CJ*`/G'_AN_P`;?]&I?M'?]]^%
M/_EY7$Z]^W!XRD_:0\)W1_9=_:$22'PUK42VS/X6\Z8/=:23(N-:V[4V`-E@
M<R)@,-Q7[$KS_P`1_P#)T_@W_L5->_\`2O1J`/,?^&[_`!M_T:E^T=_WWX4_
M^7E'_#=_C;_HU+]H[_OOPI_\O*^CJ*`/G'_AN_QM_P!&I?M'?]]^%/\`Y>4?
M\-W^-O\`HU+]H[_OOPI_\O*^CJ*`/@/]E+]M'Q?I'QW_`&F+B']F?X^:C)JG
MQ)L[J:WMF\,^;I;CP?X:A$$^_6%7S"L2S#RFD3RYXLL'WHGMW_#=_C;_`*-2
M_:._[[\*?_+RKW[&_P#R<5^UC_V56Q_]0CPI7T!0!\X_\-W^-O\`HU+]H[_O
MOPI_\O*/^&[_`!M_T:E^T=_WWX4_^7E?1U%`'R#XA^.MYXK^+NA^.M0_9!_:
M3NO$WANW>VTZX;4/#@AME<.&/V<:_P"2SXD<!V0N`Q`(K@?^"9W[:/B_PM_P
M3@_9^TNU_9G^/FO6VF_#;PY:Q:GI[>&?L>HHFEVRK/#YVL1R^6X`9?,C1]K#
M<JG('WY7S_\`\$G?^467[-/_`&2KPO\`^FBUH\@\RC_PW?XV_P"C4OVCO^^_
M"G_R\H_X;O\`&W_1J7[1W_??A3_Y>5]'44`?(/QT^.MY^TE\/+GPIXR_9#_:
M6U30;R1))K:'4O#EBTA0Y7,EOX@CDQZC=@]P:\-_:X^)8\!_#635=%_91^/G
MA?4O$WQ+^'E[J5_?WN@3QWDEIXNTB2*!%&MR^7),P,:A$1&FG5I64%Y5_3"O
MAG]J#XLZQXUT3QAH>N>(+JYF\/\`QF^&JV.B7'A&ZT?^S+0^.M)6.6*\F_=Z
ME',$5O-@RL;`H3NX#C>[2"6R;[V]+W/6/^&[_&W_`$:E^T=_WWX4_P#EY1_P
MW?XV_P"C4OVCO^^_"G_R\KZ.HI`?./\`PW?XV_Z-2_:._P"^_"G_`,O*/^&[
M_&W_`$:E^T=_WWX4_P#EY7T=7BG[5OQ#\=?"/6]!\0:!J&E2>&X;?4(;_1IK
M+=/?S)IUY=1RBXW#RDB:V3*A7+B1_N[1N.M@Z7_K^OZ6I\W>/?VT?%]Q_P`%
M'_A3JC?LS_'R&YL_AMXTM8],=O#/VR[275/";-/'C6#%Y<1A17WR*^ZYBV*X
M\PQ^W?\`#=_C;_HU+]H[_OOPI_\`+RN!^#WBOQ/K?_!1;X8Z3XSU6QU[Q1X2
M\"?$31K_`%6SL/L-OJ)&K>"9XI$@WOY?[F>)2-Q^9&.<$5]F54HN/S2?R:NG
M\TR834E==VOFG9_BCYQ_X;O\;?\`1J7[1W_??A3_`.7E'_#=_C;_`*-2_:._
M[[\*?_+ROHZBI*/G'_AN_P`;?]&I?M'?]]^%/_EY7RW_`,$T?VPO%GA;QW^U
M1);?LY_'/7FU?XW:E?SQZ>WAS=I,C:/HR&TN/.U>,>>H17/E&2/;*F)"VY5^
MD/VF_CU\0/A>OC0MXBB\-Z;INIZ7+!J6E>#;SQ3)HVG3)=!WFM;<>9)N>W0O
M)@)`)6))5"QY[_@DM.EUX\_:^DCD2:.3X^ZHRNARK@Z'H1!!]#1'6/,N]@E[
MLN5]KG:_\-W^-O\`HU+]H[_OOPI_\O*/^&[_`!M_T:E^T=_WWX4_^7E?1U%`
M'S3JW[;?C#6]*NK*Y_90_:0:WO(F@E59O"T;%&!4@,NNAE.">001V-?.?Q+L
MM`^&?P*UR;1?V/?VDM'F\,^&-:@TNZU#7]&O+;3!=07)FF=)/$,N\YFE8N4>
M10S!>PK]%/$OB&U\)>'-0U6^D\NSTRVDN[A\9V1QJ78_@`:^)?V@OVA?BI=_
ML_:E?:_-HVD6":#J%EXGT);%9KF674)]5L;6..X63;&;1K6(.RAQ-ER-N!FJ
M<6YJ,=VTOF]E\W_P;$U)QC!N>R3?R6[^2^=MKGJO_!*7Q#<0?\$N?V;471]4
MD5/A9X84.GD[7QI-KR,R`X/N!7TA;RF>"-VC>-G4,4?&Y,]C@D9'L37@7_!)
MW_E%E^S3_P!DJ\+_`/IHM:^@*3:*"BBBD!1\3W<=AX:U">:1888;:221W.%1
M0I))/H!7DVB>#?"/C;3M9U"^UBQ;_A)-$ET!U\Q,PP&>\8NC9R"RW)'T5:]=
MUS_D"WG_`%P?_P!!-?/_`(X_;";X"^/O!'A>7PR=3TKQ'=B*^U5=4BADTLW.
MHFT@*VS*7N%,KC>4(\M`6/`KHI^]!06\G9?-,QJ3Y+S;LDKOY--?C8X/PU^P
M7%X>N+O4/^%WW$FM:^^HQ>(KF/2;&&#6;.\L]/M7MQ;J?+AV+IT#)(GS`M(/
MXS6M\1OV*=#\2OX?31_B-#H^E^'[R&]_LQ+2V9;Q;74CJ5E;K,?GMXH9F=?W
M?WD90?N+4W_#T"WT?PO)K>O>`M8T72=5T*Y\3^%KAKZ.4>(]-2XTZ""0`*/(
MFF;4H#Y+99.Y.>/2_#W[45_XJ^/5KX/L/",TNGAKW[?JS:E&ALT@N+BVC=8"
MN^59)K6925/[O]V3G>*4I2:BG?;3RMI;5:6:^'H[NUV[MQ4(INUD[>3V?3=/
M2[U3LE?1(^4OV$OV,?%'@SX&^$(=>U_0_A=XF\`ZG>VFEPVNEZ-=QW6D7:V,
MMU#+!`S6P>6[M=ZS*?-51S@L17N_QY_94T/XW?'[1?&W_"Q;?2[?1YM.OQI1
MLK6ZCDOK&:1X+@22'>GRRLI0?*2J/]Y!7TK12J5N>:F]T[K79]U^?KJM2XJ4
M8\J>FJ^3;=OQ^[1GS3\8?V8H/C-\1]8US4/BY,EB4BE\-Z=]DM9%\-7:3V5Q
MYZR$[IU,UBC>5)\@WN!P:U?AW^SQH?@SXGW7B*^^("ZU!!JDM[HMA)#!#'HM
MM+]M9[164YD4R7SMO;YL11KT45]`T5C&,$[I:VM^%NW;2^]M-BI.4HN#>CZ?
MUZ7]==]3Q7]D_P"%FG_LO>")O#/_``G]GXBT&Q\JUT&":SMK672+&%/+BMWE
MC^:Y94"CS9<NV,GJ:]4_X3W1/^@MI_\`W_7_`!K6HK24DW=W^_\`X`GS-W9D
M_P#">Z)_T%M/_P"_Z_XT?\)[HG_06T__`+_K_C6M14^[V_K[A:F3_P`)[HG_
M`$%M/_[_`*_XT?\`">Z)_P!!;3_^_P"O^-:U%'N]OZ^X-3P7]HOX(Z+^T&='
MO;/QS'X1UC2EU'3);VWCAN6O-*OF07MD5D.%$WD6["0?,AB4K57Q7^S!X.\5
M>*]-U5O&"V[:;!K=ND2-%M8:GJVGZD_?_EF^GI&OJLC$\@5[UH__`!Z/_P!=
MYO\`T8U6JJZ5TKZWOKW5G^%_OON7&I47*T]MO+1K]7_21\[VGP`7_A<7A_7[
MSXJ6MYX?\-Z]J/B"ST0Z79QO'/=FY(478_?!4^U2@C^-6(;BNL_;!^)GAW2O
MV2?BE=76N:7;VUMX1U:6662Y15C1;.4LQ.>``"<UZY577/\`D"WG_7!__032
M7+912_K;MY&?*[N77^G^K/GO_A\!^RM_T<1\&_\`PK++_P".4?\`#X#]E;_H
MXCX-_P#A667_`,<KZ.HJ"SYQ_P"'P'[*W_1Q'P;_`/"LLO\`XY1_P^`_96_Z
M.(^#?_A667_QROHUVV(6P3@9P.IKY,_X>B7&G^)'T;5/A=KVGZKHNOC3?$\/
M]H1R+X=L&&E-'?NP3$F4UBS9H5PR!;C)/E')%7=ET5_1=6WLK7N^RN]DVJ46
M]4OZ_P""]%W;26K2,_XK?\%9_P!F'5/'?PSFM_V@/A#/#IOB6:XNGC\4V;+;
MQG1]2B#N?,^53))&N3W=1U(KMO\`A\!^RM_T<1\&_P#PK++_`..5U7[*?[44
M_P"U)X:FU.\\):IX-N+'4(O)L[Z=9I+JSN+".[M;K*@;=\4X#(>4=)$))7->
MR54HN+M+?^M_/NMT]'J3>_\`7]:=GLUJM#YQ_P"'P'[*W_1Q'P;_`/"LLO\`
MXY1_P^`_96_Z.(^#?_A667_QROHZBI`^<?\`A\!^RM_T<1\&_P#PK++_`..5
MQ.@_\%9_V88/VC_%>H/^T!\(5L;KPUHMO#<'Q39^7+)'=:LTB*WF8+*LL9([
M"1?45WOQN_;LU#X._&/5O!L?P[U36KTV,$OA^6#48D77+N2[L;3[.X*DVR"3
M4(2)7RK+%<$#]TU>J_`SXGQ_&GX<Z#XMCL+K2AXBT:SOVL;G_76+R!V>!_\`
M;C8E#[J:J,6X>TZ/;SUL_NMKZI[-7'H[?U_7;O9]G;R/_A\!^RM_T<1\&_\`
MPK++_P".4?\`#X#]E;_HXCX-_P#A667_`,<KZ.HJ0/G'_A\!^RM_T<1\&_\`
MPK++_P".4?\`#X#]E;_HXCX-_P#A667_`,<KZ,FD\F%GVLVT$X498_05\Y^"
M?V\=7\4ZUX=T^X^'-Q9W5YJK:?KWE:Y!=1Z!$]Q!;VLX=4Q<"62YC4JF#&4E
MR3Y9J>9<ZI]7_7]>6NR*Y7RN71?U_7GH<3^S/_P5G_9A\.?LX?#_`$_4/V@/
MA#9WUCX:TZWN;>;Q39I)!(EK&K(RF3(8,""#T(KMO^'P'[*W_1Q'P;_\*RR_
M^.5]":'_`,@6S_ZX)_Z"*M51)\X_\/@/V5O^CB/@W_X5EE_\<H_X?`?LK?\`
M1Q'P;_\`"LLO_CE?1U<K\</B:?@W\)M=\3)ITFL7&EVQ>UT^.40MJ%PQ"0P!
MR"%,DC(FX@@;L]JF<U"+E+9%1BY248[L^9?V@?\`@K/^S#KO@2PALOV@/A#=
M31^)=!N&2+Q39NRQQ:Q9RR.0)/NI&C,3V"D]!7;?\/@/V5O^CB/@W_X5EE_\
M<KJOAM^U!/\`%KXHW_A]?"]S8:+#!'<Z?K37J2)J,L3V?VN'R@H:/R7NXDW$
MD.0^,;37LE7;1/O_`%_7WD)W/G'_`(?`?LK?]'$?!O\`\*RR_P#CE'_#X#]E
M;_HXCX-_^%99?_'*^CJ*0SYQ_P"'P'[*W_1Q'P;_`/"LLO\`XY7$Z]_P5G_9
MAG_:/\*:@G[0'PA:QM?#6M6\UP/%-GY<4DEUI+1HS>9@,RQ2$#N(V]#7O7QH
M_:&/PE^('A;0X]*M=076H[J^U&YFU6*R_LFQM_+\RX5'!,[;I5`C3#$!CGBH
M_P!F[XVZE\=_#O\`:FL>%[CP?J5I));RZ;->)=LB/%:W,+^8H`^>&XB8KC*L
M64Y*YI0DI-J/3_AOSNOD^SL23BDWU_K^O5=T>?\`_#X#]E;_`*.(^#?_`(5E
ME_\`'*/^'P'[*W_1Q'P;_P#"LLO_`(Y7T=13`^<?^'P'[*W_`$<1\&__``K+
M+_XY1_P^`_96_P"CB/@W_P"%99?_`!ROHZN'_:*^+EU\$/A3>>(-/T:/Q!J$
M<]M:VNGR:A'I\=Q+-.D2A[B0%(E&_)9ACC'>IE)15V-)O1'SG^T#_P`%9_V8
M==\"6$-E^T!\(;J:/Q+H-PR1>*;-V6.+6+.61R!)]U(T9B>P4GH*[;_A\!^R
MM_T<1\&__"LLO_CE=!\&?VLY_CKXV?3%\)WFDZ++8V]_I^K2WJ2"]E0V37=N
M8@H:,PO>1)N)(=EDP!M->W52UBI+9_U_7EJ+JT^G]?U]Q\X_\/@/V5O^CB/@
MW_X5EE_\<H_X?`?LK?\`1Q'P;_\`"LLO_CE?1U%`'SC_`,/@/V5O^CB/@W_X
M5EE_\<KB=>_X*S_LPS_M'^%-03]H#X0M8VOAK6K>:X'BFS\N*22ZTEHT9O,P
M&98I"!W$;>AKWKXT?M#'X2_$#PMH<>E6NH+K4=U?:C<S:K%9?V38V_E^9<*C
M@F=MTJ@1IAB`QSQ4?[-WQMU+X[^'?[4UCPO<>#]2M))+>739KQ+MD1XK6YA?
MS%`'SPW$3%<95BRG)7-*$E)M1Z?\-^=U\GV=B2<4F^O]?UZKNCS_`/X?`?LK
M?]'$?!O_`,*RR_\`CE'_``^`_96_Z.(^#?\`X5EE_P#'*^CJ*8'SC_P^`_96
M_P"CB/@W_P"%99?_`!RC_A\!^RM_T<1\&_\`PK++_P".5]'5\U^./V^=;\.>
M*?&6CZ3\,[SQ!?:#=BVT>.#7((SK:Q_:3=LX*'[*T2VD[(DF3,`NW&X4;NW]
M:?U]VH/179XS^RI_P5._9L\,?';]IB^U+X[_``HL;/Q%\2;/4=+FG\3VD<>H
MVR^$/#5LTT1+X=!/;SQ%AD;X77JI`]L_X?`?LK?]'$?!O_PK++_XY7MGPZ\1
M6GBZRO-6T^43V.J20W=M(.DD<EI;NC?BI!KHJJI!PERRW)A-2BI1V9\X_P##
MX#]E;_HXCX-_^%99?_'*/^'P'[*W_1Q'P;_\*RR_^.5]'57U74/[*TNYNO)N
M+C[-$TOE0)OEEV@G:B]V.,`=S4E+70^>?^'P'[*W_1Q'P;_\*RR_^.5XG_P3
M0_X*G?LV?#K_`()Q?L_^']>^._PHT;7=!^&WAW3M1T^\\3VD-S8W,.EVT<L,
MB,X9'1U964@$$$&OI#X;?M5:U\1_'WA+1X_!*6-OK6GW%YJ\]QKL"S:*\<US
M`L2P;=]SNDMF!9"`@8$UZMX(_P"1+T?_`*\H?_1:TTKQYA7M+E_KO^IX+_P^
M`_96_P"CB/@W_P"%99?_`!RC_A\!^RM_T<1\&_\`PK++_P".5]'44AGSC_P^
M`_96_P"CB/@W_P"%99?_`!ROE']K_P#;G^`.JZ9=^(F_:C^&/CG4-2^(OP_D
MT[38-8TZ(>'M*L_&>E7UR!Y3[I5CB226263E4@))`4FOT"_:.^+&K?!+X2ZG
MXFT;PO-XON=+0W$UA'>I9D6Z*TDTOF."!LC1B%QEFVJ,%LU@?#_XWZC\8=2\
M50R>'[?2]%T#6[.STW4%U>*ZEU4"Z"R.]NH#VVUDX#DEPV1P*JFFW=>GWZ?D
M[?>NY-2RC:77\;:_AH_+1]CBO^'P'[*W_1Q'P;_\*RR_^.4?\/@/V5O^CB/@
MW_X5EE_\<KZ.HJ2CYQ_X?`?LK?\`1Q'P;_\`"LLO_CE>+_'W]M3]FWXW?%[2
M/$$/[8WPKT/1+/0[W0KW0X]9TNXCOH[L;99%F>3?!(5"+N3G"8[FOO:O*?CK
M^TO<?`WQ]H>GW'AF;4="U*ROKJ\U2*_C22R:WM9[E46V(WS!UMW!92`A:/.=
MXI:77]=/Z_X<.C/B/X=?MX?L[_";]M_X5ZA??M+?##QAY7@+QS_PD/BF77;"
MVCN=1O-5\)R0)((W\N)WALY5C0'E+1R/NG'U)_P^`_96_P"CB/@W_P"%99?_
M`!RO0/@'\7[_`.,]I9ZAK7AZ3PEXAT_^T--U;17O4O6TZXCFM\+YR`*X:-HI
M`0!Q(*].K6HI)KF[+[NEO*UK>1G3<6O<[O[[Z_.][^9\X_\`#X#]E;_HXCX-
M_P#A667_`,<H_P"'P'[*W_1Q'P;_`/"LLO\`XY7T=169H?GO\0?VSO@CXS\2
M^/KRS_;L^%>CV?CA;2T2UBN=%D.EV42SK);I(TFYC()V_>-\RX&*XO\`X);_
M`/!2']F_X.^(_P!IRWU/XV?"W0]/U?XT:AJ&B&\\2VL2W^G_`-C:-#'<1%G'
MF1%H9$#C()C89R#7U]\3?VQO$W@'QIXBT"#X;K=:A97=C%HGVOQ);V$.N6T_
MVH/<%W0BW\MK24!'R9`4((W"O/?^"3QS\0_VPLC!_P"%_P"JY'I_Q(]"IQNH
M:;/\?UZO\>MQ2LYZ[K\+V^Z]EZJS['9?\/@/V5O^CB/@W_X5EE_\<H_X?`?L
MK?\`1Q'P;_\`"LLO_CE?1U%(9\P^+/\`@JK^R)X[\+:EH>L_'SX):EH^L6LM
MC?6EQXJLGANH)4*21NIDY5E8@CN#7R?\4?B5^QG\-?A%XBM?AS^T-\'/#_AR
M'2-6NYO!^E:SIWV?7+XK>2V+9$F]6@DN2%5/O[(\_=%??_Q1^/FK>$OC#HW@
MWP]X5A\2WU]IESJ=X\NM0Z?]B55?[,BI(I,S32QNGR_ZL*7.1Q7B'Q"_:[\:
M?%+X.^-/#VL?"^W\+R3>%?$0U:23Q7;73:;Y$-Y`GE1J@:Y#R6[J2F/+ZG-7
M3YD^>&CW[;/]'MYZHBJH\O+/5??O^5U^'DSJ_P#@E+XUT>T_X)<_LVQ2:I8Q
MR1_"SPPCJTZ@J1I-J"",U](6]Q'=P1RQLLD<BAT93D,#R"#7@7_!)W_E%E^S
M3_V2KPO_`.FBUKZ`J7;H5J%%%%(95US_`)`MY_UP?_T$U\C_`+1O[)GB'X_?
M$OP)J6E>$?!^H6EI-#'-XIO[XP:MX12#65NK@V*+"7<W4"/`X6:)<-AQ*A:,
M_6GB>`W7AK4(UDDA:2VD421XWQY4C(R",CKR#7,_#7PQ-_PAUN/[9U;Y99ES
MNBYQ,XR?DZGK6RBG3N^C_1KIKUZ6?8SYI*?N]OR::_%+?3N?-]S^QI\1/C9\
M&OASX.^(%CX6LU^'M_%H]Q?:??RRMX@TFWLB4O-FU/L\DU];:?(;;,@C6%_W
MKY`&[X&_9[^)4FL_!>?Q)X<\&_V]X?675O$?BRPU1X[_`$N[GDGGOM/@C\K-
MU9W+R(I#NBJ8UDV,Z1&/Z1_X1>;_`*#.K?\`?47_`,11_P`(O-_T&=6_[ZB_
M^(I<SYG-O5RYGYRLE?YV5UL[6M;0)4XN/+:RY>56Z1O>R_1[KH[ZFM163_PB
M\W_09U;_`+ZB_P#B*/\`A%YO^@SJW_?47_Q%1RKN7=FM163_`,(O-_T&=6_[
MZB_^(H_X1>;_`*#.K?\`?47_`,11RKN%V:U%9/\`PB\W_09U;_OJ+_XBC_A%
MYO\`H,ZM_P!]1?\`Q%'*NX79K45D_P#"+S?]!G5O^^HO_B*/^$7F_P"@SJW_
M`'U%_P#$4<J[A=FM163_`,(O-_T&=6_[ZB_^(H_X1>;_`*#.K?\`?47_`,11
MRKN%V7-'_P"/1_\`KO-_Z,:K58&E^&IGMF_XG&JK^^E&`T7:1O\`8JS_`,(O
M-_T&=6_[ZB_^(JI15]Q1;L:U5=<_Y`MY_P!<'_\`035/_A%YO^@SJW_?47_Q
M%5M8\-31Z3=-_;&JMMA<X+18/!_V*48J^X79OT5D_P#"+S?]!G5O^^HO_B*/
M^$7F_P"@SJW_`'U%_P#$4N5=QW9J3,RQ,44,X!V@G`)^M?"=G^S'\?OBE!IL
MWBGP?\.?"^J>*+FZL?&US9>(I=1W6\U]IMW]MMLV\1++#9RV:02%BBBV<RN(
MVCD^V/\`A%YO^@SJW_?47_Q%'_"+S?\`09U;_OJ+_P"(J?9Q;NWNFGV:>C3\
MFM']ZL[,:DU;39I]-UJG\GJOQNM#Q7]ASX0>/?A5X);_`(6-#X=M=>FFL=.A
MAT6>2>W-M8Z7':),6<`AYGBEEV8Q&LB1[G*&1_H"L"]\-3+<V?\`Q.-5.Z8C
M):+C]V_3Y/\`.:L_\(O-_P!!G5O^^HO_`(BM9^\^:3U>K\V]WZMZNVE]D1'1
M62T6B79+9?):=^^IK45D_P#"+S?]!G5O^^HO_B*/^$7F_P"@SJW_`'U%_P#$
M5'*NY5V?+/[2/[-/Q2\>?M*ZAXZ\)^%?`5C)X72QFTV<ZK+;W'CXQ7NFW*V^
MH!(\0?9DMKZ.&9OM!4W895C7S8YO??V;/`.I_"[X1^&]!UN:SN-:TW1K6/49
M+166W:Y/F--Y08EA'YA;:"2=N,DGFNI_X1>;_H,ZM_WU%_\`$56B\-3'5IE_
MMC5>(8SG=%D\O_L>WZTXQ2AR7TW^;M=_.ROZ)[MMN<W)WMV7R5[>>C;MZVV2
M2WZ*R?\`A%YO^@SJW_?47_Q%'_"+S?\`09U;_OJ+_P"(I<J[BNS2O!,;27[.
MT:S[#Y9D4LH;'&0""1GL"*^0/A)^RY\1?"'B?0;ZW\">`?!6D^(-5CGUW0M(
MUII++PE!:7EI>1&Q5;>-)S=307+R(%A$;W>[]X5<R_5O_"+S?]!G5O\`OJ+_
M`.(H_P"$7F_Z#.K?]]1?_$5'LH\ZJ7U6V_FG]Z;3\O.S*]H^1PZ/_@/\&D_^
M`W>YH?\`R!;/_K@G_H(JU6!H_AJ:32;5O[8U5=T*'`:+`X'^Q5G_`(1>;_H,
MZM_WU%_\16LHJ^Y$6[&M7F?[67P!U#]I#X22^']+\:>)O`FH17"7MOJ.AK9-
M,\D:OLB=;RWN(6C+,"<Q[@54@@C-=M_PB\W_`$&=6_[ZB_\`B*/^$7F_Z#.K
M?]]1?_$5C6H0JP<)O1FE*K*G)3CN>#?LU_`/QS\'O'C6>O?V??>&M#LA'I^M
M->K)J6MW-XVG/=&>".&.*'RYK.3!3*R"9<)'L(;Z/K`U3PU,ELO_`!.-5;]]
M$,%HN\B_[%6?^$7F_P"@SJW_`'U%_P#$5KRI123VT^73[EIZ(R6C_KY_?N:U
M%9/_``B\W_09U;_OJ+_XBC_A%YO^@SJW_?47_P`12Y5W*NSP3]L_]D2Z_:)^
M+W@;4H?#'A76+6SAEL;O6M1=%U+PJAN;:X-Q89B<M),D,D#J'C^60$E@"C=G
M^R5X1\9>%O"<DGCS3=%T?Q%J4IDELM+OFOK>%(;6QLT82LB%C(+7S=NT;/-V
M9;;O;TC_`(1>;_H,ZM_WU%_\15:7PU,-6A7^V-5YAD.=T61RG^Q[_I4T:,(-
M\KW]>[?YRE][\K.I.4K.73_)+\DON7G??HK)_P"$7F_Z#.K?]]1?_$4?\(O-
M_P!!G5O^^HO_`(BJY5W%=FM7C_[=7P8U#X_?LZ:EX9LO#>B>-8+R[M9;_P`-
M:O?-I]EXAMHYE=[:2Y6.1H1D+)N"-DQ!2,,:]*_X1>;_`*#.K?\`?47_`,11
M_P`(O-_T&=6_[ZB_^(J*E&$X\LGI_6_==T]&M'H.,W%W7]?\'LUJMUJ>!_LR
M_`OQ]\*?&PM_$MOHS:!H]BJV6IP:B]Q=ZI=WK:=)=B2(HHB6&:TE"MO<RK,I
M(0H=_P!)5@:IX:F2V7_B<:JW[Z(8+1=Y%_V*L_\`"+S?]!G5O^^HO_B*N,(Q
M@HIZ+3KLMON6G?374G6[??7_`#_S-:BLG_A%YO\`H,ZM_P!]1?\`Q%'_``B\
MW_09U;_OJ+_XBCE7<=V>"?MG_LB77[1/Q>\#:E#X8\*ZQ:V<,MC=ZUJ+HNI>
M%4-S;7!N+#,3EI)DAD@=0\?RR`DL`4;L_P!DKPCXR\+>$Y)/'FFZ+H_B+4I3
M)+9:7?-?6\*0VMC9HPE9$+&06OF[=HV>;LRVW>WI'_"+S?\`09U;_OJ+_P"(
MJM+X:F&K0K_;&J\PR'.Z+(Y3_8]_TJ:-&$&^5[^O=O\`.4OO?E9U)RE9RZ?Y
M)?DE]R\[[]%9/_"+S?\`09U;_OJ+_P"(H_X1>;_H,ZM_WU%_\15<J[BNS6KX
MIUS]DOXI^$?CC\1O&_@_P?X(74M=U8W;27'B"9#XS,D-Y:07-R/)86;V%I="
M)8X]XN!'\S1G:5^P/^$7F_Z#.K?]]1?_`!%'_"+S?]!G5O\`OJ+_`.(HY8WO
M?HUZI[I_UO9K5)I2U^337DUL_P"NEULVGC_!GP;'\.O"2^'X9I+B'08[73HY
M7`W2+#96T88XXR0N:ZZN7T3PY-)J>L+_`&MJB^7=JI(:/+_N(3D_)UYQQV`K
M2_X1>;_H,ZM_WU%_\16M:3G-SD]7JR*,%""A%:+1?(UJKZM/<VVE74EG;QW5
MY'$[0022^4LT@!*J7P=H)P-V#C.<'I5'_A%YO^@SJW_?47_Q%'_"+S?]!G5O
M^^HO_B*RY5W-5+R/F7X:?`SXB^(_&_PKU3Q;\+?A[X=U;POJ6IZG?>);3Q"-
M4U32HIY[QQI]LQLXG>*=9H_,8NJCYAY;$*P^G/!'_(EZ/_UY0_\`HM:;_P`(
MO-_T&=6_[ZB_^(K-\'^')I_"6ER#5M4C#VD3!$:/:N4'`RF<"JC%*GR+9>O]
M=/ZNR'=SYWO:WX_\'^K(ZBBLG_A%YO\`H,ZM_P!]1?\`Q%'_``B\W_09U;_O
MJ+_XBIY5W*NSS_\`;,TKX@^(/@C<:;\.='T;7M6U*\@MM0LM1U;^RTGTUF_T
MI$N/(G"2/&/+!,;8$C$88`CD?A5\)M>T3XX^./&6J>`O!WP_AU^32K4_V'?K
M>3^)IH[O<;V\9;>'$J*XC4'>VTME\;57V[_A%YO^@SJW_?47_P`16;XH\.30
MZ9&QU;5)/]+M5PS1X&9XQG[G49R/<55%*,^9/7^E_7GKN14O*-GM_D[_`->6
MCT.HHK)_X1>;_H,ZM_WU%_\`$4?\(O-_T&=6_P"^HO\`XBIY5W+NS6KY[_:_
M_9^\2_';XA>'X]'\->$TM[/3+^/_`(2ZXN=FKZ4TUM/"UE'&(R9+>X+P^9^]
M0#RLE7;84]N_X1>;_H,ZM_WU%_\`$4?\(O-_T&=6_P"^HO\`XBA*S4D]5_7]
M=]G=:!>Z<6M&K?U_7IKJ>;_LT>$/$WAX3:IXRT[3=%\5>++K4=9U'3=/OC?6
MNG,S6D,<4<YCC,G[J",EBBY9FP`,"O7JY>Y\.3#Q;8Q_VMJA+6EPV\M'N7#P
M<#Y,8.>?H*TO^$7F_P"@SJW_`'U%_P#$5I4]ZUWLDODM%]R5C.G'ENEW;^;U
M?XLUJ*R?^$7F_P"@SJW_`'U%_P#$4?\`"+S?]!G5O^^HO_B*SY5W-+L^6_C?
M\(_BU\79_BUI?B#X0_#'QSI/B"ZMK+PQ+K'B4>1;V,2RB&=[9K%S'/#+++."
M)69FEPKQ!%(S?^"/VFRZ-XE_:TLY[F2\FM?CQJ4,EQ)]Z=ET'0@7/N2,_C7U
MM_PB\W_09U;_`+ZB_P#B*^#_`(H_\&^GPT^.7QZ^(?C>7XM?M%^%=2\7:Z=4
MU&T\->,TTRQDN'MK<-((DMS\Q"J,DDX51G@417+#ECY7^7_#]-^NR$]9<S\[
M?.W^77;IN?H-17YQ_P#$-'\-?^C@/VNO_#D__<U'_$-'\-?^C@/VNO\`PY/_
M`-S5)1]+?'K]F75/B%^U_P"!/&ECX7\)WT.CQVQE\274@CUKP[]DDNI3!:?N
MF9H[W[2(9<21A40Y$FX!?)_VB?V<_&DWP(\/7FO>#?`LWB#PSX.UC5_$WC:&
M\_XF5C?W%C>R7UA91&#>;6>XG)+&95"<>62%8<#_`,0T?PU_Z.`_:Z_\.3_]
MS5'??\&RWPOU.RFMKGX]?M;7%O<(T4L4OQ&#I*C#!5@;;!!!((/6JC)Q2MT=
MUZ_TEIY>;O,HI\W]Y6?IK_F_O\E;Z@_X)._\HLOV:?\`LE7A?_TT6M?0%>8_
MLR_`:R^!W[-WP^\$Z)K6O_V+X/\`#6G:)8?:)87F^SVUK'#'O81@%MB+D@#)
MSP*]+MXC!!'&7>0HH4N^-S8[G'&31*-AIW'T445(R'4;=KS3[B%<!I8V0$],
MD8JGX1T:70-!CM9FC:19)7)0DKAI&8=0.S"M*BJYGR\HN76X4445(PHHHH`*
M***`"BBB@`HHHH`****`(;"W:U@96QDR._'HSEA_.IJ**`"H=1MVO-/N(5P&
MEC9`3TR1BIJ*`"BBB@`HHHH`ANK=IY[=EQB&0NV>XV,O]14U%%`!1110`5"E
MNRZA+-QMDC1`.^06)_\`0A4U%`!1110`4444`0Z=;M9Z?;PM@M%&J$CID#%3
M444`%%%%`$-_;M=0*JXR)$?GT5PQ_E4U%%`!1110`5"]NS:A%-QMCC=".^25
M(_\`034U%`!1110`4444`0W]NUU`JKC(D1^?17#'^53444`%%%%`!4+V[-J$
M4W&V.-T([Y)4C_T$U-10`4444`%%%%`%/2].DLK[4I&*E;RX$R8Z@"*-.??*
M'\,5<HHHO<`HHHH`*I^'-.DTCP]8VDA5I+6WCA<K]TE5`./;BKE%%]+`%%%%
M`!5/7=.DU2QCCC*JRW$$QW=,)*CG\<*<>]7**$[.X!1110`4444`4Y].DE\0
MVMV"OEPV\T+#^(EVB(Q[?(?TJY111<`HHHH`*IZ7ITEE?:E(Q4K>7`F3'4`1
M1IS[Y0_ABKE%%P"BBB@`HHHH`I^'-.DTCP]8VDA5I+6WCA<K]TE5`./;BKE%
M%#=W<-@HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
LB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>seal.jpg
<TEXT>
begin 644 seal.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`4D!
M1`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BFSSI
M:PM)(RHBC)8]!38[R*:W,J2*T8YW`\470:DE%4](UVVUQ)VMYHY/L\K0OM;.
MUEQD'WYK/T3QW9Z[X@OM-ADA:XL93%(JR;F!`SR,<5G[:&FN^Q7LY:Z;&Y16
M+>^-[6S\6V>C[HVN+OS./,^9-J[NF.<BKFJ^(;31;BWBN)HXI+IBL89L%R!D
MXH]M#77;1C=.2MIN7J*CFNX[>+S)'55]33T<2(K*=RL,@CN*TN0+1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%8]UXZTVR\0'3)9O+NEVDAL!>1D<YJ*E2,-9NW0J,92TBC8JCJ/B
M2RTF]CM[FYA@DF`*"215W9.!C)K@OB?X]UGPS\0-/AL8O.L9!$TW+E=I8[L8
MXS@5SWQ_\7^'].M['7-6\0:?I4=O;([QM>Q1RJPW.<(Q!SU'U&*YI5JT[QP\
M&Y)V]?0Z88>*<75=DT>@?%#XEK\/[*WF"^=YS*```V06`)ZBJ?Q3U^YU3X=R
M2Z4EX\EP`5-L"TBXD7.-OX_AFOAW]H;_`(+A_"'P9';:'IUOJ?BC6;5"B_:=
M,,D;D$<[E?\`45\H_'O_`(+@?'75O"M]/X;\*>'=#TG2=@N#:W%Y%<0>8Z!/
ME#\9;=U[$UZE'AS'8JK4H59JG&44E?1IO=KN/GA&,7"+;3^3/V$N_&4NN?"Z
MY749H=%OIHV4K?-]F9?FX.&.1QS^-<+X>_:$\$?#7PAJ&F^(?BE\/[61TE*O
M/XDMXVB+=,EW!`&#VXK\-_%G[5_Q@^)OPNMO%VO?%GXDVMK?M*@M]-UF=V'E
MML.4))'0=Z\KM_BU#=^.[/3O$6O>*-:34C&DCZHQD8J[8_B/IG\S7;+A6C"#
MQE2;FH+E;B]/.]]`IUI2BZ:M&[O:VOR/WJ\/?MQ?!7X.7%])>_&+X?7,>H>9
M-LC\6V+EG?'S*&E7CY3S7,:7_P`%%?V??"GCR;7K?XF>';B2Z+O+%#XETY]Q
M88Y7SA_.OPU_:0_L?PKXFT_25T73[AM0TQ+FQ<VP9C&[2+&21T/':K>L?L_:
M3>_LM2:QI-I)_P`)9;S6XGB6!550>9,$+OQBO7AP?DE*A1JRY[:-:K2Y'ML0
MYR\]S]P)?^"B?P`U;Q^OB63XE:);SG<4C?Q+IZ>7E-A^7SN./>NF\2?ML?!C
MXH:Y]IM?C)\-[5H<&&&?Q;8HT1P`25$IQG!/%?@[^SCX5M?&'[.WQ`U&;PUH
MFI:EI,FG+:27=L'E023L'YQD94=O2G?%CPIX1^$_Q=\-R21F)HYV.L6D,*;6
MC\H&,*N`6ZY(/2O.EPWDV(KU,)24]W)NZZ:W+E4KJ*EVT^1_0MX]^./@_P"+
MGAVVT_PS\3O`TMQ'@_Z-XB@9Y/E*_P#+-R3DD5VNI^*K[3?A98PZ7-!JU^MO
M';N]JQN/^66"^5.>N#GW%?SG^*H/$7PC^*`U.R\5>)M%T-K.&YB:QNVC50?F
M[8`(&*=\(O\`@HK\;M%^+$=CH/Q0\;:C;W%T(+:WO-:N/)?=,JH&"MT("@X[
M$U:X)A7ISQF%K>[)6NV_PZ(P^M.$XQG'8_H]\+^-9M"^&R7NK17$4UM&J.)%
MVLS;?]H^M7OA;\0E^(7AX7AC,+8!967:5R3U&3Z5^.W@W_@MM\7/A>]UH?CS
MP_X+URUT^7RIVDO;FYF.T8)*L_WN"?K7TS^SG_P7-^#/Q/\`#\VEO_;GA2^N
M-I+KI;6T`V[FX=GQT7'U;%>;5X9S/#N]->TA&/36[[W+52E55UNW]Q^A&B>*
M+'Q&TGV*Z@N?*P6,<BOC.?0GT-:%>1_!+6M#TC0M1U#2M9TW4X[A4V);W<<W
MW68'Y4/U_*M+X-_$/5_%GB75$U2`V\$$>^,X<1XWX'+'&<5X*QTZ<J='$1:G
M*^VRMW953#J\G3=TCTJBLC2O'&GZUKLVG6\IDN($+OC!4`,%/(/J16O7H0J1
MFKQ=SGE%QT844451(4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`5#]OB^T^3N_>>E8'BCXG6?A'7H;.\7RHYD#"8L<`EB,8`/I7#?&+PJM
M]K&G^*(=133K*UC=WO&B\Q55B.V>^,=.]<-;%3^'#+GE=)J]K7Z[/8Z*=%;U
M-$UHS3\7_$C6/#WQ,6RMX5FLV8_*\@4?ZL'^9KS_`/:Z^)_@+X$M_P`)EXT\
M0-HUNJABJV4MUY@5!QB,%O?I7P[_`,%#?^#A[3/"$W_"-_!^9-0U"7(3Q-#(
MCPVY'D29^SSVY#9!EC]B,^E?G=\:=)U[XDZI>:UXW1M>UV^C4VUZ%2T".`,'
MRXL*<+@<BOI\+P7*,/K&9U+0D^91;7-_VZFEIZM^AM3JNZ]FK.UFUU/NO]JK
M_@O9XD\=:A<>'_ACHZZ+9BW\NV\1)>'SG)WHO[B:`8QE'Y/48]:^&/%OCWQQ
M\=M*\0?$#XB:O<>-/['U.?38H+L1QJ)E!F5\Q@'@L_;'S5H:!JJ?%/X&26^M
MR#4-2\)S2WTE@!Y31VD,>T/O3`QR1W/UJC\&/'UCX.\-:XVI:6UIX'UQY[%R
MUP66WN9D4+*6`,C;8_X>`<=C7U>55L'3C*-"C)VM?EBG4^6OWG/4IS4KW2_Q
M;'E-E\<(8_$NDW3:3!I]].RE?+E:3:I8;N<8KZN\;:9&)_&MKI6L3ZA??$5[
M1].T^2'RHV%I@R?O#P,+EOFQDC`S7RCXAL_`_P`++NZ30]:@US]Z/)FCCFA"
MKTQA\Y_&NADO?B1^TY:>'=,\+Z3</=>'5G6RN5:W83^=\SX5@H&!&P^;/MBN
M_,LMA5Q=/$0K1II6;567*]O0TCBHQ5I)O_"KG=_!;2?$<?[/_BG3+ZQABU?2
M+<RVT?VE&^9YB?O`X'RUY/\`$W0KE;W2]4\13&VNEFCC!7$VP*"0?E_&OH[X
M??\`!(3XW?&>\.I:Q8W7AO[0`DCR0VUQD+E>BS#T'3UKW#X4_P#!MW?792[U
M[Q5'JD\S[#`-,>`JN0<Y6ZQZBN"ECLMPN$J8#%58S4V[NG*+W?2[7Y!%<\U*
MFFG_`'M#XG^-GBWPOXE^(?P_OK75IIAH_AO3[>XS:NN6CD=FZCW[58^$W[5\
M7ASXX:Q'=7<C>&+E;A%4HVT$KA#M"[N*_3+PS_P;=>$]*NC)=Q_:%EA*,<W*
M;<XR.+KZUV=G_P`&\'PKN-'CTZ?P^TL*@,\OVZ]4$KT&!=9YK.MQ-P[.$,,H
M5[026T.GS,E'%*3;E#[V?D]I'Q\\._!GX:>,;?1=<N+BXU*2S)0VCQCY)/7!
M[,:YW]I#Q5X>^)FJ?\)+I]X\VO$`B,P,O*JJ#YB`/N@U^P$__!NI\)[S=':^
M%VLQ-]Z0ZC?2=.G!NOP_&N+UO_@VV\+,5?3&6UN!_'BYDQZ<-=8]:Y\'GO#N
M&G4Q*IUW*2<=H?:5K[[+J7+ZS[/XH?>S\V?VL_'GVOX1Z#I]IKEQ>+,J+<[H
M=FT&$AEZ<X/%<Q^Q'X4C\5?$1M5MH5^R^%;<WTS$[=[6\D+MP>>0>V?QK[G\
M?_\`!N+?Z5'-_9/B))%C9I0@T]_F;G(RUS7@7C7_`())?&[X!SW\OAVSN;ZU
MN4DAEC2"V7S4;.>7E8C(11QTS7T6"S#*:V4?4,-6A3?]^48O?R?Z'-4J5?:I
MR@WZ)LXK5[C0?CU^T1J5OILQANKZXFU"Z41-P%;<XRV`>*POBY\5?#-E\;X?
M#B:7#<^%;,RI<`^8H;]V'C^3&[[_`*5QK>#?'?[/'Q!:\UC3IM+GB9DF5S"^
MW)PR<%AVQD5U/@7XP>#=!^+4GC(VJZA>3,S/I"W$L;N3$8_];C`P#NZ<XQ66
M(RK&4J=1X6JIZ+X)-I_<C?"^R<HN:<=>MD>J?"VR^+7[)7[0WB/PUX(\67WA
M^V\.K:27$L`MVP)H3(.&W`\R-T)ZU]K_`+.'_!P!>>!=47PS\9M)6UMKHBW7
M7Q<R7,DN6[P00'&%&>O-?''A@:=J_AK3[/Q#=+>ZY\3FDM+_`.5HC"+5B8R0
MF%.5"_=V^^:\1_:O^,\GB23_`(1.SL&TVR\(@:@DYE$HE.TH1@KD>O)/TKS,
MMCAL\K2I8V@Z=EORJ+[=;W-)P5/7F4O1W/Z/OV5_B1X0^)VA7GC+P=K']M:?
M=6\CY:UDML,PCEQB0!NC+SCO[5V'PO\`BEJ'C;QWJ%K/"(;6U:1%`?<#@C!Z
M>]?S>?L0OXX^#^DI\3O#/B9="NYKS^S+(-IT-S]KN3Y-RD8\P,`6*+R5P,=>
M<5^J/[$G_!<W1O%$T/@?XN[/#/C#`M/[3N9E9;^8*D98100!$WR%N,X&,=*^
M/S3A=8*M[/+I\T(MOE6K^:7Z?<;*HZD7*2OI:[Z'Z;+>1O/Y8;+^E25Y3\(_
M#R>%9;S7;JZ66QN65TNPFU9@05W`=N2!TKK_``-\4K'Q_JNH6]C\Z:?Y>9`3
M\^\$]"!C&TBOG<-CN9*-=<DY-VBWKH<]6A9OV;YDNIT]%%%>@<X4444`%%%%
M`!1110`4444`%%%%`!1110`444V2584+,RJHZDG`%`#JX7XT_$74/AW!IL]I
M&LT=U>1V[)LW,^0Q('N<5>^*JWE]X6:?29I&N+<,ZB!S\YQT^7DUX+^UG^W)
MX=_8Z^`=QJWCR32[[Q$$D?2=,C,<MP\WV>1X7:&:5'*EHF4E3DDX'/3E4:V+
MK/!X=-2LFFO,ZJ=-1BJLK/R.@_:K_:&\`_!WX;VOC#QY>Q:3/#;HUM9S7:6\
M]PY5G545B`Q+`@>I%?DA^U?_`,%%?$G[>OC9M)D\00^"?AW:EUBMYG-K=,<J
M\8>2-B"=ZX]\XKRC]J[XD_&7]NKQ;-X[NM2TF3PRMP6T_0UN+W;;P%WGCWVY
M,B*ZK)M^5L#H..:\C^+7P3\7>*/`T>J6^G:CIEK:E&N_(MYH/-DW`J8\*05X
MY).:_1LIR+!8)<U27[U[NR^+HO\`@F,I2DK=#F/VFM)?P-XP^PWFEW5G=J3]
M@=UVI/\`)&9,#^+`(^F:ZO\`9Y^/GC^QT!F@USPS"FDYFO4OK$3-+&6.T)G[
MI]Z=XM^)WAOX[?L]PMXF^V0>-M%5O)FC\M$8RW`W;F=FE/[I%`QC\153]D?]
M@GXB_M8^(8(=!M=5TO1;QQ%=7=PES;QRH"1A72)U)!'.>!7VDOJM3!7S&W/3
MZRW[^[??_,YZ;KQE[NQN^)OVD[K1OB1J%QX=6QOM4UC1Q920PP)(LCNV2`GN
MV!CWQ7<_`W_@F3\7/VU+ZWU'6[*Y\/:'<;9]\UE+!#(3L<`;1C<5E./85^F/
M["?_``1-\&_!FWM]2UO3?[:UR$*PDU.&&YAR#&PP7ME;&Y3WZ$U]W>#/A%I?
MA;3X;6.QL[..W"^7#:0I';@*`!\NT<\8^@%?F^*XHA&[RB/+?[;3C+\#JG'G
M7[W4_/7]E#_@@UX)^'%C:S:MI]]J%\%!>3SY#&3C!X9:^Y/`G[)G@WX;:(MG
M:Z39Q9'RE8U#\$GKC/\`$:].^S-'"R?)''V\GY6%-L@'0??*KWF^]^%?-XRM
M7Q?O8JHY>KN3":AI35BKIO@ZQT2V"16^5],4_5'L="TZ2XG\NWC12Q+$+T&:
MEU77$T73)+JZEACCC&<LVW^9KP3QU\0M2^)FJE86-KI]LV6W%HUF`R"!@D-D
M'I7DTZ$.;DHQU]!5*THZR9V?BK]HF'2_W.EPR73=,IM<'J/\*Y6\^-WB;4FW
MI$MN,Y&Z`5AQ::UL-R"U;O\`-UJU#&UT!YRR+CIL&!7N4^'YNU2M4E'T.&MF
M45LC6/QT\4V4GF7:QS1KVC@"_P">U=EX5_:+T?Q(JQ78:RDSR9)%7UKSN_N[
M?0=.-]J5]I-A:KC<;Z81#DX'WL#J1^8KYO\`C9_P5&^#OPVN6MG:;5)UZG1?
ML4_93_SW![_H:ZGP[B9MU,.W))=3*GF*>EC]#+"&WU*#<KV\D;#(*CM5;5_!
M&DZQ`T=Q"C=CC'O_`(U\I?L3_MSZ#\;4+6-W>W%J"3DR1L(EW*/FQ*P&,\^E
M?7%A=0ZII\=Q;R(R28VEF&#D9'3ZUX/U.G&?)7@E+T/0HXB=KQ9Y#\5OV,_"
M/Q-L)([C2[.1/NG]V-YZ]\=>:^&?VKO^"`/@WXC6\M[X?MK[2]2R"'>XE\OE
MD!X5?[H(_&OU(:)EB82COQY'7\::+"21=NV)H?\`IJ,O^/:O1P>:YKA:G)2J
MM0_Q,U]M">E17/YJ_CA_P3Q^,'[(&OV^J'3=0\56FC$R6D^GV<S1P%E7>6+C
MG)DQ]5->%W-NOQ8^-]A%K4T.@3320QW4]Y^[AVYP00/3O7]3?CWX)Z+XRTM;
M>>QM[A>?EN(4>-^GWP5.>E?GI^W7_P`$.M!^*<5]JGAVW;2?$2Q%X39A+>QW
M!3MSY=L7ZGG!K[?*^,\+7C+#XN/LYO3GBM4N]WU(J4X7YJ>GD?FKXZ_:0\.^
M`==\/Z!#:27VBZ(UM+!]E=,7>H1$HKJ>ZLJ\*>N1721^&3?Z/?\`C/Q)H]]#
M-XFO@VDVZKY4T4=QS&??:QZBO+?B?^RCXO\`V,?C):R>,M"U+6K.QNTGCG6S
MFNK(!9F(RTL:#.(G)_V3[G'=>"_VAI/B=I/B+4)FL_/TV]>+1],/W(XPNZ,B
M'><;6.!LP!VIX_!RISC4RYWC;6>TGY.W0]"C452.NB['N_[*G_!3[Q=_P3Z\
M<P>`?'$]UXB\-W^[;9@;KVV$4;$#?*PQ\SJ3["OV"^!/QZ\$^-?A;=>+O`NH
M6OB"VN5&]+*YCN'3;*\0W;>!DJ^/H:_G]^#O@>ZE.I?$WXCPMJ6OW#*]MI,B
MF:24.#$_D03C>57Y6;#<8R?2NL_9(_;Q\7?L=>,=/\1:*9KK0;]F^W>%[D32
M/"$61$_T-941=SR&3YCSPW7KYN89!A\RINOA$H5J::;LEK;5IO=O\3"52TK2
MV?3N?T+_``C\:ZAXWTN2ZO(O*3<0@*;>AKL*^;O@W^V#HO[4OP/M=<^&=Q8B
M0;C>Z?*R"]M@"5),4$CE<L#C)Y%>X^`'N;/PK"VI38N)`)&,C'Y<J#CYN>.:
M^"PU6<)?5ZMVTM6]F/$4D[U8V2OMU.@HI$D65%96#*PR"#D$4M>@<84444`%
M%%%`!1110`4444`%%%%``3BLG69[;Q%I=Q9Q7B1R2`#*R`.O(/\`2K&H^(;/
M3KA8)YMDD@.!L)SZ]!7D'Q*M=$^!L^K^/]<O/[/\*Z6L<L\@A>4;2%B^ZFY_
MOL.BGKZ<UQUY5)SC1IQYE)VEKJDUO^GS.BC33U;L^GF^QQWQO_:.M_V$/@5K
MWC#QIJLUU<0P3-9:?YAF$\B995"CYOF&,XK\/OVA?B%XY_X*D^,=8\9OK!C:
MQN)A86-S?>6EM;QN[Q*`_(QY^,?6O3_VE?C_`*Y_P4K^,6J>(KN1FLM!(_X1
M[2259'F0M'O\S;&5+KS\X(%?*/PXUS4/`_QJU+29M/6*[U%GLA&)P=LCSA>H
MR.HQUQ7Z%PUE<L-13R]_O([_`.5Y?F:U:<IO7<Z+1[_X@?`R6#1]4NM22QN=
ML7FV,KS(I/R`Y''12?I63\1OC;X\\$ZI+H,?B34]8TO4&+0PR7C2>2J]!M4_
M+R<XJ]XQ_:B\:>$M=NO`]Q=30)<2N+>(-&PQN,2C(4^F.37VI_P2L_X)$3>-
M-1MO'?CS3X[^36Q]KL;*1XRMTA1@9"\<WR[2`<,`3BO3QE3"Y93^M9M!<TG=
M+5WET=XW_'0YJEY)48;K4\M_X)Q_\$?]8^.NHQ^)O'"W%KX9FPT<`"O+.,7$
M9WQ.N>'1"/8YK]MOV<_V2_#/P-T&*STK3;/3X5'%K;0HL,?).X8'4YR?>NFT
M'PII'PET]9IF#06W_+;8W[C)(X`))R6Q4.G_`!5DU@LWAVR6^MCP"9?)VGO]
M\9ZYK\WS[B"IF%;V^/=XKX5_*NRLE?YFT83C$[UG,$:QQ*NW[OTJ59/*@!D]
M<<5Y[/XA\:))YBZ(NP_]/T53#XAZMI42R:UIBV=OD#S!<"3YO3"C/K7FQS+"
MN',Y:=[/7\"Z>%JU%[OYH[Y660=.*26,,GR].^*P?#OC^Q\5_NX&^;TVM_4"
MMN,?9(B"V15R=&M#FI/\#C?/3GRS/+/CEXN6Z#:*OWG&#^(!K@((FLM+CA55
M8J^0#T)Q6AXQ9M5^+5S(?NQ"(_\`C@%0C$EN9B=JK*1G'3%?2Y+0<*3GLUU/
M*S&M!U%R[@LFR)%:&,228&5YVYKC?C3\<]!_9Z\/2ZAK>I#(C+1Q%@WS<@#&
M0>HJU\</B?9_`KX7ZEXBOIC*$MY'BRK#GRG=?NAO[A[5^4_]D^//^"L?QVO[
M&PDD70K.YD/^LA(5%/F#AS$W2OM<KR_VD?;8N?NKR_R/+KU*O8K_`+57_!1G
MQM^U;XA71]-OI=!TF8MDVMU)$O'EN.&)'WHS^9KZ@_8]_P""0W@/5_!*>(O$
M&K2:[,VXMYRV]QTD=?3/3'Y5P/[9O_!+7PQ^SS^S'<:S9ZLT]]"L>&^Q%#S=
M1(?^6K#HY[5ZM_P1)UR^\1_LZWC7V;I85;!8A?\`EZG';Z5]1G6-HT\#&65R
MM9J]E;KKN8TZE7JCUC]EG]D_2?V==1UZUT>&.*SN(9&3;&B#YG!_A`]!7U;^
MSOXOFU.PN=.NCN:U9S$&)/RJ(U7%<)9+'!MM5XFN&V_0'I[59^&<]Q8_&J.T
MC8K&MF)'QCG]\H-?D/$%2MB*_MFK?,^FRWV2I[GT/!_J59OO$9-'VSC[I_*G
M%@R;L_+VKG_$?Q)LO#(_?'/X-[>Q]:\*KBZ=&/-69T0HU:T[4S8N)I)%VJHV
M^IIDZI/:-'(JMN&".M<1/\2M:\26OVC1M)6ZM)>(Y?M2Q[L<'A@",$$53M=5
M\9VDOFS:&NWK_P`?T5>>L=0JI2C'W+[ZZ_([J>!E%\U1ZG)_M1?L?^$_CSX)
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M6>(KC2-6T?RW$8MA<\NOE?>0`?=13T/7VK],QF61QV#A6P-5QI63V^:6MF&'
MDJE7V=7IH?3_`,*?VM]:_P""9'Q]TO6M+N3+I^LRQ'5=&MIV-J8<&3A8^2<M
MT-?M'\,/C0O[8/@'PWXS\%ZU,=/U`6UMJ%F)O+6V)19)CL/.Y?,5<FOPG\"^
M`O#?B'1]<\=:BBZ]9Z-8B=+J5'A,C1G!7:#D8]=IK;_X)5_\%)KG]B_]IMVY
M_P"%?^*-0^QWEL&(2P%Q>6YEN!B)Y7*PQD;!C/;!KYO,>'89K@Y2HQ]^.]G:
M_G>Z-,16<*UHH_HZT>ZM])TVULWNHWFAC6,YD!8D#'-:5>._"W0M/\?WNF^/
MM-O6N_#?B6P35;9C"4R)@LL;;6P_W"."H]P#7JUAKMKJ<C+!)O93@C:1C\Q7
MP."Q%62<*\.1IV2O>Z74PQ%*,=8._?3;R+E%%%>@<P4444`%%%%`!1110`57
MU+5+?2+5IKF188EX+'H*L5@^)M:T74[2XTVZU&RCDDS$4:=58,<C&,YS6=6I
MRQOI?I<J*N]3E_B%X3TOXTVT,VGW\;7%CPL@5CM#$%AC('(%?D9_P6'_`&T8
M/VBO'^J?"/P5,K>%/AWY?]IR(RRKJBWL-K<QA6*AX]DB.#\QS["OM#_@IG^U
M/:_\$YOV7K^70[ZWD\9:T8?[,@DE$C2JMQ$D[!"RLV(Y"<KG&,FOQO\`A[X*
MN'T.TUKP5XGT34/&"[C>VE[.UY-?'<R1CRQ\S;8]Q^;H`".E>]P[ERP]*>:U
M(+GEHEW:Z_).QU2DG+DB[I;'(:O\$/'?CS2(_$7A7P[?6_AW3"7>+<DNXK\K
M_.QSR?;BG?$']IBT^(WPSATGQ1H\TGC;39?L-M-]H$7E6\<92(&-%"MAR>3R
M>]=#J/Q0\52:[-K_`(NO+?1;FS4'^Q;=&LC-LX'[G.#N'/OUKN?^":W[&NK?
MMB_'VW\47EDL?AG3-36XS)`P-W)'=0N8%8*59V20_*37WT,5"EA_[3Q#]Z/P
M^;7V>U_-HQ7Q'MO_``1__P""9TWC'4;#XC>,+614E*-IENQ9&<.L$T4X9)`"
MH)/RD<U^RL36GP7\)&3;YM[<%?-P=OFMG;D`Y`QGH*K_``8^&6G_``R\&V%J
MMFL45C9)%&BH%%NBHH".,#YQBH?#-C_PL#XA7.H32))8Z2S0PPD_ZP,N<XZ'
M![U^-YIF5?'XMXBK\4NFFB?H=4O9RC>ILM?F,M_AS%XC>:]\2*9OM6TQIDQE
M,<'[IYSA:ROA)^TE:_&/QS>:3I+JT.CJCS,I#;U;(Q]T$8(J3]K_`,?M\*?@
M5KNN*WR0+"5*_P#++,\2<],9W5^?_P#P2B_:5D\'^"O&%K:VMYK>O"(O"T"B
M8L6G<@$$[CP<8KPY8VE@\5]4OIO]Q]GE/"<\QR2MG$5S<CC%=-]6]U^1^K42
M*D!C\L[)"<C/7->:?M"?%N7X*:;;:HL?F6*R)',F0-J_.2<D'H%KYV;XB_M$
M:S%)J5OIMO:Q*2\=K-I$WG.HY&`.#GI7$_M4?M0:XW[-VM6GC?3+K2=<:&6U
MB>6W^S1LYMY`"`QSR^['?BM*V>4_935]8VL<G#/"<\9CXX>DU44MTNGXH^NO
M#B:5\9]#L/$NC87^U(?M.0S-UY[X]/2NF\!>*U^WG3+Z=?M4?$2$8+<,QZ>V
M*^-?^"''QBN_&/P&NM-NKC[5/H<D%KP=V/W9)[YKZ^^*GA0O$VKZ;',NI6OW
M54==Q53D#_9S6RE.5!5XGDYQE;PV/EA*JY>5V5SRWQ#%*_Q&URSNE,<D,,+)
MGOE<]JL7T^ZUCN`^UIL6K<=`!5GXK9U'6=/\1PHT=O=N4E)':-0O)Z=:XCQ?
M\6M!\)^.K'1;S4+6U^W>45>:=55"YQDY/2OM<@E4JT'4HZN)\/F4TIN%;;H?
M)/\`P7!\2W>B?!+1]+M[=[JUO+^V:9T(4*&CNE;KST';UJQ_P3@^/?PI^`'[
M):Q:KKMEI]Y(L$KQR/*6+"/&.A[\5W?_``44^+WPAF^$M]H^O:YIVH:CL9K9
M;;4(0Q;RYU3`8Y^]GIZBOR[^$?P`\2?M#>*[C1?"NFZ]-ILESE6"22JL8P<Y
M0'C%?J^!P:Q.`4Z[Y6M3P:DM?W9[G^VK^U)X@_X*+_%.V\#^"=/FFT(&53)&
M8Y!@)'.O54;[T+=Z_2S]EOX#Q?L]?!NU\/1W"QW1\P,"IR,RNXZD_P![UK@_
MV*?V'-#_`&0?#4=SY=M?ZDRCYV_>-QYBG[R@])/TKWO4'*SK<30S&X?HJCT]
MOI7S6<9A"M36#ALCIHT=.:>Z)GCBTV,21G=-/^Z:I_`T+7/Q4LU@&Y5MT>3'
M;]Z,U5DDBLKAII&^18PX!/0]:O?"ZTGTG1M8UI@2UU-/;6QP?XE5TQ_]:OSG
MB:O&A",8:\I]'E,I5]9'HGC#QY)-?3Z;I*F3RBRW4H((MR/O`@CTYXKY`_:#
M_P""J/P7_8N^+&G^';V2'7O$5^)O->.]EM_+,:*>5,;#E9.Q[5V/[77QTC_9
MU^`>L7.J:MINDWFL1&=3=2"*1]R,OR[B#U';O7\]?B#XUZ;XH\8:AK&I1W^J
M7AD4QW+2"1>5`.TL2>P'X5R<.489E"6*K1UCY_Y6/4Q52-%61_5@VI?\)%;0
MQK.MTBDYF5=JM^'MC'X4ZZT(Z%>0S198.0#7Q+_P1S_;8T_XF?"EO!-]<2MX
MAT$%IUN)E:8>=/<2)D%B_P!P#&1T]J^R-<^*-KX1\/W=_J#*L5HC298A>!]3
M7R'LZ5.NY8G^-TZ:=-%H=JIU.2]/8\G_`&]/V]?!_P"PY\,+'7/%S1W5GJ6I
M1Z=]C\XP,ADBG?S=X1N,0N,>^>U4_P!GGXY>%?VCO`NG^/OAO>0S0SVR2W%B
MCM,R%T$A!=P!PI`X%?CS_P`%FOVR-*_:3^-*SV_VJ^TG1+Q=.:.&5'A\Z&6[
MSP&*[MLF/7!J3_@CE^VO;_"3X]2:7-J:Z'I=XDL<<6H3K'$=PC1<`L![#`KZ
MS.<'&AET<:XWGIUM_P``\[#XFA*KR-^\?NH+'3_C'X;^UVH%OJVW]X&)?[/D
M\@C@'*C\*_#_`/X*^_\`!+Z3X!7UWXV\*Z?-_8=\`;B`,[_8!&EM$"SO(2V]
MV8C`XZ5^T_@/Q'_8EY97\<MO-I&N*TSW$/\`JSM!5=K=,9K1_:(^!^F?%;PI
M=0W%O%J%O?*%N+8*':8*4P(Q@C@KD_2NGA//)8*2Q#7-"HO?6BM?1ZV[=C;&
M1YGR'\ZGA"5?CG\$=)\'>'U-BVEW4MQK,I/G"*W?Y=Q!P0,_W3FO0_#'PC;P
M)X0C\,>%]'GUK2=;;[+J^IPS;8[99D$<[%7);Y0`QVD=>*Y+]OW]DC7OV+/C
M%,;'[8F@ZM(%6Z@\Q8<D%V5GPH.WN.U4_$T?C#XLW'A[2_`+74?AZXT^UM]4
MU7;));6\Q&R?=+'D*55E8YY`YK]`S+"TW2I2I54L-+6,;=/\6^_<FC4Y8^S/
MO7_@C3^W#I_A#Q]KW[//B;4(7L(;BX?1KML1K&8OL]K#;X"[V8X)RS<]_6OU
M*^'_`(8TCX*6DJWM]&MU?,'=V##>PXZ9..HK^<NY\':'^SYJ.FII>I76I?$7
M3+F+5EU*TO/,M6\ELM&1PY9I$!QT(/-?M=^PU\<['_@H?^R]H&J3:A%#XLT.
MVA@UR%9@K6URWSLI169ERJ]&P:^5XNR&-&<<WP\5*4EIOIM_2-(R7\)NT>I]
MA6-_#J=JL\$@DADSM8=\'%35A^&?%>@W216>FZI871&=B13J['J3T/UK<KQZ
M-13CS)I^FJN<,XN+L%%%%:$A1110`4444`1W5Y#8Q>9-+'"G]YV"C\S7F_CG
MP-I6JZO)X@AU*W^SZ>C7-P%N$\LLA+DG`]/4]*[3QMI-OXC\/W-E)-''))&P
MC)8`ABI4'GZU\4_\%._C:_[%7['>K6MK>EM?\37L5I;Y?!\J=6B;YE[<'KZU
MC3P=3&8J&'44U>]^M_0Z*:2@Y)Z]C\V_^"@O[6TG[9?[:&L-I]UI-YH?AB>2
MUTF'5I2VG/'+#&7./,=/O)D%,#..IKRO_AG_`,._#[7@VO>,9=-\9WQQ9P^!
M=5B6SB*K\WF942+F)E(QU8R=JQO#7[.NJ^,3HFG-9Z7H.FVMO(+_`%:UN4\^
M9QED)!.#G&WZ&LCX@1^&?A)"=:\/R/XJU!^?MVHP^3)%C:ORD=<AF4^RBOTW
M#T8U\3&A2^"*27:ZW*I4W&%Y;E'5(O$7[5OQET'P#]AL_P"UH[M1)?Z?')NF
M1QA!++\Y.`.ZX!K]^/\`@F]^QUHO[.WP3TFQM;&%9HPEQ.TD,8?[1Y<.]@1&
MO=.IYK\Y_P#@@E^Q5/J^O#QYX@\RZGN9OW=Q(JN\>R9L8/7@<5^UNE:,NB:3
M'!;_`'1CG&">,?TKY3B3,?K6)^JTM*</_2EHWIT,^I3\63KIWAV^;&W=$^<=
MSM-<IX<U&Q\+?"J'5+J2&SMY(1+-.I6.1F&<?,<9STY-=1X]M3=>$+Q?XEB;
MG_@)KQSXO>$M4\9?LNV>DZ>,R7`@R=^TA1(,_I7QN*K6JV2]ZWW^AZ&&ITYR
MC[5VC?7T/SJ_X*#_`+?_`(L_:3U`^&?!.GZU+X=N,BZ>.VN/*<`02)DQRLAP
M\;]1UZ<YKY+\$^.O''[-GC&&]L8=:T-E</*)%N+6&Z'7;\I3?C.<&OV(\?\`
M[&^F_`7]FO5K/PQH.G2:XZ1>1-M$;Y%R">1_LNPKG?AW^SSX!_;2^`EO?:KH
M^G?;H7G3S5@$CQLKE,Y/^[7P];)\5.OSU;\WS/Z@X>\5,GRK*I8'"85O#O1N
MT6[M63OMN8W[,O[;/Q`^(7[)VN>*M0T/&K:/977V6,6=SMG\F%6C8AI"S;B>
MH(SVQ7YP?M,?M.>//VG/'VH:??+J4DRW,K'3[;[0WER"608\MG<@`OMQC(Z5
M^A"?\%%OA7^SG<2_#N6T=?+!T\JMA(5?_EESCCG97>_"#]ECX6^&=*U;XLMH
M>G74^O6L^NPM-:`&-)T6Y`!Z\'L>:Z*F'AB6E3?P[GE\,\0/A*=7'XK`RC.K
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M]2AFC6*9+N6WCRJN%WLB$[<D$U][?!=AJ!NKN-5\N0`'\&(KH/%?P\L_%5E-
M`X6*21#MD4#<A((R/IFOLLES&KED_:TE=?>?D.:485HJD?D%\*?^",?BCQ7K
MMKJ?Q)\47&K>6RL8XM6:Z4X96QB:`\<R=^_N:^W_`(2_L]^$?V>-!M[;PSHU
MC!>(BQM<-9PI(W&TY:-%/(KT;Q'\(_$7AJ9AI]Q)>0+G_62A>.>WT`_.N;.H
MWFG3-%J-O*LBY'R*9,U]5+B[ZPOW[Y5\E^I\_+):D'^[-*>5K<"*XC@E4=/)
M&[%.>&./;*TTI9>GG-TK-L9[[4ABSM&9STW@I_GO73>'_@GKOB4;]0E-O$?[
ML@;_`#TKRYYI2AS/#OFNGYG=A\O:5ZASWA[2)_B;=M#"LT<.XQLX!7O@\\BO
M1?$NEGP]9>'M"M8X]J7-M+,=OWL91B2,9SCN*[+P?X,TWP+I"P6L294EG<+@
MDGK7+_$>X?3O&NDR*W[JYEABSZ%I&KY?$2;E&I5V/<PL8J/N'XA_\%J/V@[W
MXK_M:>(/`=QJ>I6]CH$]U910I<,L)$<S[?E+E>_91^%?"/@O]G^ZO=0:UU*1
MK/3XCA948QL_!/5EP><"OZ4OCA_P2U^#OQ6\?7GB[6?"^CW6O7TKS33R62-)
M,[L69BW7)-8'BC_@E1\)]4T"RV^$=%CVJ=X%FO/S#%>M+B6EEU)NC#2VNB.7
MZK*M4U/S4_X)K2KX1_:$\2?$R#5&TOP+X'6SNM5DEN?(EU:.2.6%5'2.;9(>
MC,-H/KQ7U-XE_P""KWP]_P""@O@?Q)\-_`$VL:+XTU.VEL--EO$ALX'G?]W&
M=\<TC_>.<JN<<BO5/VM_^"9_@[QS^Q%X@\+_``OM]/\`"%SJ5N8P;=([-+C%
MRC@.S'``P^/][WK\[/\`@F5_P2(^)'A']L+P]XDUB31M)T[PWJD%U*]KJT$D
METD<PR-N<L2.<"JC'+L3A98R37.EW1TNM7@O9P6A\X?'?X<G4O#.N:1?0I8^
M+/#_`(BN+:Y$*^7'>R0K(C39(WR%Y,_.0-P'8UY/\.O#.J>"=0FUK4%\J:Q5
MQ$4W!L@9!&0#U'8U_1?\6/\`@G!\)_&OC6.X/A/1I]6NRMQ=7!M%+3,SL79F
M]2S9-1:]_P`$B_@[>Z;`MUX3T1HV"K(#9H<DUQX#C"E*FL-.'-&^KLF<2RN-
M.7UAO4\S_P""2G[0]Y\?/^">FFW6J&2>ZT&&VB,L^YI3YD\I.2SL?X?:OOVT
MMEU%+>:/:L:EB`.,=N*\0TO]F;P?^R[\`;KP_P"#=)LM)LYF@WI;0B(/LER,
M@>FX_G7N&B(UAHD*'[WS?^A&N&C[)8V<L/\``[[_`(6.VI4:@IOJ?(G_``5;
M_8<T?]HC]GW6K<6L<>K6]M-)IK0QQJS3E,#)\MF_[YYK\)O#6MZ_\(QX@^&]
M]J&H:')#<7+6C6MQ);S7%SD0(C$D;D;:>`N20/I7]2&NZ1;Z]IRK=PQRLI)0
ML,[3ZU^$'_!<O]CC_A3_`,5+'XH:;;A;6358K?RE4!1,'N[DR<<_P#GI7Z!P
MCF7-7^H8EJWV$_QWW^0J-/F7.?+NF^"O&GBRXL=/2WTFQ81*)]8U<2PLV#AL
M3D<YSGGJ<FOJ_P#X)8_M%3?L%_M8Q>']8\06>H^%?%0GDO9[*^-Q`9UA*1%F
MWI'DLPP6!/I7S+JVK^//VA?"&DVN@R6<=G]EBMKA&OQ%F0C_`%F&ZD!AS57X
M@?"NX_9_^#PT:YF&L>,&FMYH9D83/%Y4H+X=,CE3^E?08GVE:$L#B)1\[=.J
M]"HQO/G>S/Z3?`OPXTOX<ZJUQ<75A"@Q]E9I45FX(?/`Z;N,5W]O=1W<0DAD
MCE0]&1@P/XBOC']@SXN3?\%`?V/O!OB.XOFA\062W;:DH;YHR]Y/'%DMC.4@
MK[`\+:7;Z#I,=G#,LHC[Y&<GZ5^0X7#RPM>>%A3Y8+5.^[;U*Q7O)3E*\MFN
MUC2HHHKTCA"BBB@`HHJ'4+=KNQFB1MC2*5#$=#2EHKH#@?B3\);CQ-XKL=0A
M?SH5>..6#:%\L!F8R;BP)P#C:!7XH?\`!>?XB:]^TY^U9I?P]\)PM<0^";=]
M/N@)$7]]!=2#_EH$Z!AT9A[FOUU\<R:Q\&/!'Q$\4:O,6MM&T'4K^WEVA%/E
M1M*H_)">:_FR^-'QWU3Q!^U+XX\>64<VW5==N[ER2&#B28N2.,`8]J^IX`RZ
MM^_Q^&I+GMHI7:OMTUV[&^*E\,)ST7;0]$TW]EWX[:_H$FBI837>AQLHGMOM
M%BBOM.Y?F\P,,'T-<YXZ\%WGC'XPZ3\,=-TC^Q8[1Y%ETY;A9Q%OA6X'SL1G
M."W#?Q8[8JSXT\7W7QL^&*:IH>I"QNU"&XC(\PDEQ]`.`:^@_P#@A'\!U^+/
M[2\WB>XCDN++3WB82DG!W07D?7/JN*^DQ%3&8/`5,5C(0A*=U'D35FGOKJO5
M%N=)M1HR;?6[_P`C]HOV$_@=#\%O@SIMA8Q"SLTCW+"#N`<G+')9CR:]RA:2
M4GNO2LG0M(?2=!AMT^['D].U:]F/*CQW-?EL9-^]+=O<SJ>ZNA4U.W6YL+F%
MEW!U8$>O!%<?\.C+'>7>FW#;DA<+:+_SS0#)''7\37<3QA6.[^*O.?BGX>FT
MS5K77;1CYMF#'M`^\'(!]JY<3AX0JK$ROVT-::]I'E3M?OH=EJUG'=QI'<3?
M-'G*[.N<=Q7Q0WP3\:?L4?$74+[PC<2+\/+X*TFDJL*I:G[\K^8[/*V]V)QC
MCMQ7UAK/B_4O$&D*^AWT,>H=T,(D(Y'8\=`U?%G[5/P$_:2_:*NFTF36K>/1
M9,J`-%B!&0`?F4@]J\W.,5[6FO8I\W=?TS[_`((P"IU/9XNK35+[4:CU:75)
MV3?9W/S;_:/\=IXS^..H:W(?+:VOW=HOO;MLKMUP.N?2OTC^'6J^+OVI/V6?
M`'A_PBKZ3I=OINF6NIR(\4WVJ-;9%EC(DV%=R.O*GC''-<MX._X(3VLGA"Z7
M6+@S:I<1.S./.0;V4=@_][-4O@'_`,$_OCQ^R?X^NF\%:W#;Z7]H<1K)I2W'
M[K>H`S(Q_AC7FOE<'E^(I1<JJE9[VW/V[CSBGAWB##TXY96Y:M!62J.,8_*S
M;?WGZ"?L_P#P@TSX'?"_3M"L;=;'[+"D;("S9(X[LW\ZZ7Q5XIM_"?AV\NF7
M'D[,\GG+`>A]:XCX0MXXM-&6;QMJ]K)=JHW*+)8,G'HOO2W=M<>/M;9YD;[!
M&?F/][(XY'NM?8_7J<J2HTT^9_S=#^5ZF'G*M.=:2;7\KNM_,Z+X2:!-X?\`
M">V1?LZN6.<AL98GU/K71"22.[22/_2%D(0M]W`JMXMUO3_"UDUUJ=]#:6*+
MQOR,8QGFOD#]HS_@J9I?PZN;C2O"K1W%U@JDBND@#'<`<,OJ!7NY;E>(JM4*
M$92;ZM-Q^](\3&9EAL'%U*LEZ-J_R5T?:,K^02TDGEJ1R,9K.?7-/L9F83=>
M3\C?X5^1OQ3_`&^OB)\4II%>\6*+G.+6(=V]%']ZO+YOB9XJ\67)ACU"2653
M\VU!VZU]/_J%CHTO:8ZI1IIO3FDX_P#I43YRGQMA7)^QA.7HK_DS]R$U6TOK
M166;:Y[[3ZU>:1;@HJMD=QBOPNL_BYXN\+:R88=2.4.,&,'M[_6O5?A=_P`%
M&_B%X"N?^/E9%3G_`(]H??U7WJ,5P+FM"*G2]G*+5_=N_P`HDT>.L#5J>SFI
M)^:2_P#;C];Q($AD29?(@DRH7.[)_"N8^*6G>7H-O=&W\Z.QE6Y1M^W;L5B#
M^%?.G[./_!3_`,._&$6]EX@:.SNED`9GE51G(7.%4>IKZJTG5=/\;:#YUE=1
MW6FS0;1L[Y4'K_NL/SKY?,L!/V?LJJ<9_<OQU/K,OS*G4]Z#7+Y;_F<JOB.3
M6H='OVA\RUFM59SOQM8\CMFNB7Q%9P2MNN?M3,?W:>6R;!WYQS7'6<4WPNU^
M:`J;C3]3D,J`#'E*?E`R:SOVCOB#:_`SX5ZCKMK;R74C&(H%?IF5$/7(_BKY
MC#8'%UY/#1Y6_P"\W;^OD>Q.5-+F?P_B?G__`,%M/VO;OP!;V?POT"#S%N#)
M'J<HEV95DMYX\JT9_O$?*_U]*^!O`?[3NM?#GQWHNN:3XRE\3ZAHMS'=1V9T
M];/[*R\CYV0AL'CH?6O'?C#\2-;_`&GM)OM1UJ.XE\6VJJTUF,)+%G:B9"X7
MF-`:\L\%^'I=?\1VMNMG=,895^T8?_5KG!)K]#P_#N"6&=.52TWT3BE]UKGE
MUZV(HRLE>+ZJ[9_4_P#L6?&W3?CM\%-%\3;1;7T]A#%?IEI-UP8(9)&SM4?>
M?^$8]*]0U'[/=V4J+)Y^YMR+M*[/3\J_%;_@A3^VCJVC_M#7'P[DLY[WPJUB
MZ?:T*+'#<FZLH#&3C=N6/)Z_K7[*ZMJ&F>"]-N+BS;S;BX;*H')/(]Z^%S++
M:N`O!J%G_+O^AZ%.<)Q7*W?S,_Q,PU1]+T:9O/\`,1S.I&WE2&'^0:]"2*2.
M%$9MS<\XKA_A3X-DD>?6[O+7&I$2(O3R\`J1Z5WV_(Y&&':NG+5R4KR6^USG
MK5KOV;6URKJ4OV:`>9\T?\?;BOE__@IE^SM;_'#]G#Q-930"[:;2[K[("=OE
M2FUN%0_?7.-_?CUKZHN`IB'F+]\XKGO%NB_\)#X=GMY%X4M@>J[2/ZUZ^#JU
M:6(A7LM.JO<,+%IO70_E@\-:):_!_P")GB30]:O?[+DT2XN;8/Y1F\[RSM\K
M";L;BI&[)Q7L7P+\=Z#\-/"FH>.M4TI-*DN-O]G2^?)-E)`8VX4'N0/F6NB_
MX+/?LY?\*H_;`FU1K&::QU>ZEU"1$8KN+W<IZY]!6";KXB?%OP5I.D^!_!NI
M6.BPQ8^V2)%<QX#;@>>>Q%?IF>5*%:-'$X7W7/>]E>R\M_O'1C+V;@WJCZ<_
MX-S/CK>^%?C7XL\`^(EPOQ"^Q+8[F!W?9(;^:3[BG^\/O,OMGI7[%_"/X;7G
MA5YKC4&S.[':"!PNX[?NL1TK^?+X:WFM?LQ?M%^%/B/J?B*QU74/#;W+RQV]
MJ(/*\VW:`9'W>5D';M7[Z2Z)K7C#Q5;ZEIMVL>G7$$.'\H.OW1DYK\]XPPD*
M6,IXB%-RVMT5[*[[/_@FM&4I0<>:U][^1ZM14=I$T%K&CMN9$"LP'4@=:DKE
M.$****`"N=^)PUH>&I6T3R?M2JQVNC,6XXP%YS715P/QF^(6M^"8H?[+L8[J
M.5MKNT;L4&,Y^4C'XURXR<8TGS7733<VP\6ZBM;YGR3_`,%5OC3K'PS_`."?
MVL0ZLL\>I>*[ZX\."-0R2.MQIUR!@,P."5(XSSV-?AS<_!N'4]4LEN=-URQM
MX='::629#''-,O.<XP0??DU^KW_!POXXO_%'PZ^&?AJUNH;.^N/$&EZM*IF,
M8*-#>QG/.>I[CMUKX(_M[XC>`H5,WAGP%XHTOBS1F2:]G6,\#<`<!L#)'3)K
M](X>Q&.PF71IX)).3U=[,V7)5F^>)\T:SX.30O!IU;3[R[^TR%/W$,Y\DY;:
M?D'M7[6?\&_GP&C\&_LW:7K4EG);W/B(/]H5X]KKY-W>HNT%1C@\\G-?D7^T
MQKDFHZWHFB6^@V/AV2X)\V*RM#:J"'4]/\1WK^BC]@+X5VGPM^"VEZ/;<MI`
MES]W!\R>=^P'][TK'C+&XB>"H87$/WU)MZWT:.7#NG"<E31[P;O=E`K1X`'S
MC%.@N/,C+*R*R\?,>*Q=3\56^EZ5=:IJ<D=G:VBERS,$R!USN./UK\W_`/@H
M1_P6N_X0>\O/"_@-(7FV-&;R)765)")HSAXIAT(4CCKSZ5^<8S'4X)06YY>9
MX[#X"/M,1/Y'Z,>-/C'X9\"Q?\3K7-)LF4?-YMY'$`>?[S#T/Y5PVH_MJ?"7
MS56;QYX-DXPR'6;4[?J"_6OP%^)?[6GQ%^*NJO=:WXX\4JMR3)]G&L7!10Q)
MQM9STW$5Q+>,=0DDFD&N:I(L;8D9KMBP/;O7EU<TFWR6NC\]QGB9"G-*G34H
MWWU/Z)],\2^$?$^K-JW@_P`9^&[RXDY,":I%,HP"O"QD]@Y_"N@T?XFZIH4L
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M7Q^U6?3=$N)+?0[?JZ,0[`JH/S(Y'WE-?/<RB(>?Y=]?/./+>7_6>5_M$]L>
MM6+.6WC^SPVL:QPW#E9'VA20/IQU]:C\3^!O&'@3QIIK6%O#J7A_4'B6[.9)
M6AC8Y=@%&T$#UXK]1S3BK)N%L-]2FK5HJZ?*]6^C:/S*659EG=2-=6Y6]7?5
M(M>%/`.L>)KOR;"WNF\ULES&[+L.!G(!]17U5^S]^SKH?@'PA/JEY')-J1B/
MG"5@R*2G/#*"*D^#<&CZ?I^GO;VMKYAL8Q(#$H<-M3/2LK]H#X\0^"?#-_9:
M:Q6ZN)`I0_+@'@_=8&OXRS[Q)XCXZXGI9+A9RITXS3=FUHFK[Z;'ZIE^09?D
M&5SKXGWI-=5?IY'A.H^`=;^-_P`2]1M_A_;)K4FGNJSQ6T+W4B;H\KD1!L<*
MYY[#V->=^%_%-OKKW\:Y6XT]5:XC8C<@;.WC/&?>M'0_%7B_X;F>\^'NK7>@
MZS<$&^N(+N6S$S#*I\\1!;",XY/&<=S6/J/P+G\(>&[GQMX/O[_7-49<WNE7
MLOF+<A#L0>5&NY^I.">V:_N;*,=B,G_V;%>_3CHF_P"K'Y74RW"YI0E5PCY:
ME[VV.AAL9K6'S5F^QLW\<3&/`Z]1WKZ;_81_X*#ZM\'_`!);^&?$-S')H4T@
M$<TQ^89:&,?.\@&-B,>GO7S_`/`_X7R?'/1Y=4FU9;&TTE3<ZC#]J$1B1<!Q
MM8'@9Q@XZ5)\=#X<&LZ3%X96>ZM;"&&.YNH8T8^<C.'^9.,XVGGGFN7/(Y7F
M=XTHKVG=+]33)\/F.5VQ&*D_9]KW_`_:?0]4TOXN^%XKZQN+:XL;J(/YB2*[
M*&&1AER!P:Y#Q/\`#O4-"T-K*U6UUK09L%DNT:ZFX8%<$C;][G\/:OC?_@F1
M^U]-X?\`$)\+ZSJ%Q-I\V1:K/,S%%"*JC#/@?0"OT12Y:2?[.L49M>Q"\>OT
MZU^*X[+_`*OBG2NXR[I'ZQE>;4\715:*O#JCY(^)7[!OP=^(7C5M0N/">H:3
MJ#%<&SM[>UAFPBK\P$>6P!^!)KDX?^"<GPIOTFAUC0)H[A<^7_9,4,,CC^'=
MF/)X_6OMD^&+2]9IIK>%VAY0[`3Z'M6%X^U#1/A]IK7TEG9RW3*1&&A5FR!D
M>AKYG%87$4<1]?>(ERQ[^1])AZ\)+V5*-[GE?PJ^"7A?X/:!;Z3X)\"V>E3Q
ME9VU74=(BY^55.Z5%!W95'/T)KLM/UOP[X:U<W&N:]I,FJ,"&C2\06ZD]<(Q
M!'.<5X[\6?VB;K3[2>ZO-672=/`;$%G=&.5N&/W"W=01]0!7@&M?MGVMY=R1
M:?X6U/7-K$?:I]*>=F]]X;OU_&O#K<08K%57.BN9K;F=D=T<IC3?[Q[]C[[A
M^.7AVSNXR=4T]44':8[F,1+]?FKI-'^(6B^)+A39ZYH]VV?NPW2.>_H?8U^9
M-Q^UKK5D"]QX'O&M^RQZ/,Q_$;J[#X??M8Z'J3QLJZYX9NO[K0?8E_B]6ST&
M?^!>]51XFS"$U#&4HV\G<SK9;3E_"/T>NIEN(V1EDV@9W#^AIOV56A+%CC;M
MQG_/->"?"#]I2:6*%-0GCO+.X(2*;S#*V<\Y);%>[Z?>1:G8PW$,BR1R`-A6
MR!D9KZS`YQ1QEXTY--=+'DXC"U,-9SZGY1_\'$OP(F\0_"^'Q5:P2+=Z;?0P
M*R(<&/?.YSA?ZU^8T/Q"UG4OA]X<OK'4M1L]*T6V,.IK8W#Q,9';]W]T[1_P
M+!]*_>C_`(*M?"\?%#]G7Q#:>7NCM;66[`"@_,D<Q'8^M?@!\!]+U#Q1X.UG
MPFDFFP?VC<02,9I3&Z"/+$>W3TK]2RBI3Q.3T_::^SN[VUW,U4Y:S\RSXFCU
M+Q'X8\0:O8Z/XP_L/5E@^Q7=W$[)^[8))F094_,".">P-?OW^Q!\>=4^.G[$
M_@OQ%H#O=W$TMU!+LS*P\J5H^=K-_=[FOQ;^)OB[2_"/COP_X#TV\DO-`\-M
M.+V.!UDMYA.BS)N"G8V')QD#!'K7Z2?\&^OQG6?]AW6-(L1YEYX;DO+E(7!R
MOF7<[+P#GGV`K@XTI^WR>%5OELY:K>VG^1=%<E2UK_\`!/TD\#'4F\.PMJGE
M_:F`)"J5P,#@@]^M;%<5\&?'>L>.='>?5+&.S*,R*%1U+8VX/S$]<FNUKXW!
MU(SHQE%MJV[W^9SUHN,VG^`4445TF05Y[\0_C"-!UN/2DT^.\,^`PD8J,$>N
M,5Z%7`^*?B7X5U;Q%:Z3<.EY=;PRIF1-F>AX&#^=<&85'&,>6HH:K?6^NR]3
MHP\;MMQ;].A^1'_!?BY7XC?MF>#?#\>I3:2T7A?3M3!A7=Y9^UWB8YXXW?I7
MS%8_!KXD:!X7FB\+>*)Y/M%XMR9C=0POC'/!/IBO=O\`@L!H%O\`%+_@HK?6
M<<GV-H/`0AAEP9/+`OKE5.,C.-V>?2OCNV_88\7MXA2ZTG5V\G/FM(+.+][S
MG.&DXR,<5^AX>6#M3I5L7R-)>[R-_BCHIR<*7/%V8W0?#GB'Q3^UE8:1XPNG
MUB^627YI9%DP0FX\KQV%?TS_``>\+Q^'_"\*>6MO--G=LYSAWQ_.OYO?V+O`
M-Q9_\%"[/2=4D\V[!NOWA4+]VW8GA3C]:_I$LM8/A#X7P7UY+YK6(8L^W;G=
M*1T&?45Y7&M:E2QDHP5XQC%I[=-=#DA5_<\_5MW/@#_@MG^WA=^`M$_X0;P_
M)Y-Q>*T<\L;LK!7C5AVQU]Z_)OPWI>H>/_&2:?H<;ZYK5U()I!+^[VEW`/S=
M/OL/SKO_`-JGXD2?%?\`:(UCQ!>R>9;AUC08`^YE>H`_E7LO_!$+6+/PE^V+
MKEO+9_:%OM$9K=_-*[)7O;;;QSG&._%?CN/K2G%UX+5'X91PM//L[E0QRYX)
M[;=?*S.N_9+_`."(7BKXRZA'K'Q`O)/#]E<6QFM8H'@NA)N".@(WY&=S#GIB
MO)/^"I?["VF_L/>)]"M]-U!KBUUJ"2>\41HI1UD55&%8D]:_:V'Q5>3WZFXN
M/W,+B)(=B_+@\<@=J_(?_@N#\$_$7PH_:"7XD:M=-JWAW5+IIXK+R8X!&KRQ
MH!YBL6//.2HKPLCS;%5JU7GUY8MK;?[C]*XCX+R["8.A1PU-07/'JW^;.5^!
MW_!*;Q%\=_V:M-\<>`;N:ZU"^1V>RE,5JB;;EX1AG8$Y".>G;WKP'QUX.U?X
M6:Y+HOC#3DT_4H\".17\WRR1G(*\=,5^X?[#OQXTOXE_L[>'KKP?;#P[8VJ3
M%XA*UWC=<3`<R*#U5S_P+V%?"G_!=36++QSXW\*Z;(`;JUNV>27)^<-`F..`
M/SKNR7.L3BVZ=?[]/T2/`X[X0R[#87^T:<;2BTKZ[M^OZ'1?\$;_`-OK5/!7
MCS3_``/J]_-=Z1J$\<,+RN?E,DT$8^4#LH/>OV*T>\2_L/.2-%AG??&0?OJ0
M"&]LU_+UX&UB7PMXTT'5-/D\MM&U*&X8X!R(W!_B!]/0U_1C^Q/\2A\7OV7/
M!.J*V9(](L(YCUR_V2%F[#^]V%?89-5ESSISE==^QW\$9M+%X)4ZDKRCN_Z0
M_P#;/^+"?!WX):EJ&[?,S(B(<CACMZBOQK76'UG5KW4IIGN)M1*,-P_U.T;>
M/KBOT#_X+(^-/)\.Z=I*R;5N%#L,?W91[?UK\_M-TRXO]7M=*T:V-W>'<$C5
MPN[`+'EN.@)Z]J_;.#\1@<DRF?$>-G:G&_1N]GY7?_DI\WQK"MF&81RVBKO3
MJNOK;\S;\!?"V\^)%W%:V?\`H]M$V=Z,,\YSP3ZBNZ\.W^I?LY:[<7/BC4+K
M5/#WD;9H)!O58P<MA4R3\JD8KU[X$?!67X-Z&L$>EM<7-UD.?.V;/F+#^)@>
MM:'C.]\.17'D:DZM(IWR1'S!@<YY7\:_AWC?QJQ7$&:UIU8^UH0;Y'?EY6G:
M]N1-Z:69^N9+PSALLPL*2]QR2ON[Z>K.(_9JT";XA>*]2\9/<3Z;X4DGE%C`
MB;EEC+)-%E3\RYC;'(XQZUQ7[>7A*U\.>)+'6K>?R[2^B,I50/XG].M>[>*?
MVH/!OPP\$6MO<:I'+IVQ,6WERKY?R$#Y@A)PJXKYH_;#^#=_^T?H>G>-/AW=
M_P!H6_V?!LXX@OEAV+??E9<X'^SS79X/8W,LKXF_M/-=(U(ODC[KNGMK&[7S
M2.'BOV6)P7L,&KR3M?R^=CR;PQ\1=/\`$U]J%GIMY,TMBR*8C$45MP)ZD>QK
MZ"_8G^',GB3QEJ5XC_8K;3UB>.9L+YI.\'.[&,$5^?\`^SUXLUZZ_P""@'AG
MX3>)KPZ;IDQO5U!FBCDR8["2XCX0;OO!?NOWYXXKZ;_;>_;(N/VC=63X3_#/
M_B2^!;'B^U-6%TI29$D_U<T:R\2JXX?G/88%?V_C.)*^=T(993I>\[77,M/F
MTD[>I^9Y3D=/*J\LQQ4N71Z6OK;35-_D>F_M5?%;X9_L^>`_'NG^%;6%?'7B
M;1[C3SHMM;2?9LN&*W'G@%=[N.0>F:\C_9AN8=<_96E^R2&+Q&/$!N+^W<>7
MY,?V6+S5#-][#G''6J?[/WPUTW]G;Q1::WX(TG[=K`*"[O$N&CW!2&)V2LRC
MY@#P/TK1^,OP\?XKZA=^--`EV^*+.5Y+NR";FF=2\T@WL0BYD8+PO'4<<5PY
M-EW]DYC[*K]__#7/>SC&K-<HYZ6[_KK8VO#.IS>&/$]KK-NQM[BUF1<J>7!8
M$DU^RW[+_P`4/^%K?`W1KZ&1I[Z:$M*&R,'S''4^RU^''P^\9-\1=&FAF3[+
MKFEGR[ZV+;S'*HRP+`!>/;(K]3?^"07Q%_X27X,W%L(?WEB(58;_`.\9SZ#T
MI^(6%:E2K1=U)_H>9X?XJJI5,)4^ROU_KJ?6NN7L>A65Q.[>7#$`20.O3_&O
ME_XD>+]0\:ZY=WDEQ(MC9)O6('*MMR#[\U[5^T=XE.@^`IH%7?)<*0O.,X9#
MZ'UKP!K;R(/O;FF',>.N?>OY@XRS&M]?A@Y?P]+KUW\S]ZR#`I47.Q^5O[=W
M_!6SPM\!/B]J6E:AI</B;6K7S!!IEXDT<!C6695;S%4@'<A7'HQ-?*VN?\''
MOCK2[J6'P[X,TSPU;HQ5(;/4Y2H';JGI@?A7U]^U_P#L&?"K]H;XM:U'XXTN
M/0_$<\\S6^LO/=S[+<RRA!Y,4JH</([Y/)VX/!%?/.K?\&]G@OQ)<.OA_P".
M%O;JQ)5!X2G?;[9>[],5]/@Z>6*C&G..G;4\K%3JPJM0=CR=O^#B[XT-YDC2
M3,K$$1?V@VT?^.5TWAO_`(.";WQ2WD^,_`>CW3+_`,O3WLTK\Y[!/0*/PK:?
M_@W!?<RR_&:/RXSA9?\`A%#_`"^UUT_AO_@@U\+_``"TDWB#XM6WB69<?Z-_
MPCEU9[NO\271[%3_`,!]Z[HX3*7+FIQU_P"WC.GB*T97A+_AS[9_X)6_M]:-
M^V%;ZI8:0\GF6MOO%N8I$2TS)MW*649)K]*OV7/B-<PZ_-H%],TL:P&6-V/.
M[?&@7'YU^<__``2X_9B\(_`FYFD\)^&/[)7[LU\+Z:;[4HDSMV2.VW!YR*^S
M]+U==#\1Z;J2-MD75(T?_<#AC_+TKX>CF2H9RUAE:+?];JY]!6HU,1A+UM9=
M#V?]K7P]]O\`@WXC8R,OG6<\2J!G=NBDK^;_`$KP;-X0_:*URSCL;>2Y29U2
M,R!0/W7//XU_2Q\6KR/7/@S/=,?W=U8DK]6C8C^=?S)_M;WNL^!?VS_&$NC7
M9FU+[>PCB$2`@&-0>6R.A/6OZ0X']K7PN*H.7+[JZ7M=GQ]6T73E+5W=SU#2
M/`5E\#?A19S7FBZ?K7C3QL'4K<R;/LYMI2!B13@[HG'7'3%?<W_!O?K]CX4^
M(GQ:T6.&/=:Z7I\YMAG9EY)B1D>YK\E_BWXG\777B&S_`.$NO&MM4R_V`-%$
MQ!VKYG^K&/N[?O?AWK]!O^#9SQ!]H_:5\=!OWAO+"QCN6Z;U$DNWMQSZ5ZF>
M</RPF359SJ\_5>[:UVO-A]:4ZJCR_B?M3\-?C!;^+M5FTW[,+::W!(50Q7`8
M+U(QWKNZXCP'X^\-G5+K3;(K:W8N75HLR/O;<%SDC`R>V:[>OR7*ZDIT$YU%
M-]UMZ?U8TQ<5&II%Q79A1117I'*%</XI\/>%9/$5G->3Q0WPD'E@RE2Q[<5W
M%>;^(O@O9KXFLM1_M*1?)D#%;NZX.!V&WK^-<..]HU'D@I:J]^BNM5YF]&VM
MVUI]Y^$__!;;Q_<>#/V_]4B6*26TOO"YL8_+P&P][=8.?3`KX1O/$E[IFM*T
M=W>6*M\V99F((S]:^]/^"^7POD\2?M^B%;RWM5L?"<5^7,IC#QK>WG(..<YZ
M]..M?#VM_#.^TC3XKRXD@U"WE"^28F:5BIY&<C'Y5_2605<+'"4]5)\J/,E"
MORZ+0]W_`."54T=U^W3H>H3&2\DFBNV+J_\`T[2"OZ'?V@7FA_96U7RFW2B-
M<$#K_I*5_.5_P3+UMO#_`.V+H>]?LZK'<@*Z[3_J'^E?TJ7'AIO''PEELI%_
M<W2XP1Z2Y]#Z5^,^)5&4,WKU+:.$2I4YO+]-[L_FNU.Y6\UBY\U698KN5G&>
M<;C7NO\`P2KO%MOVVM&M8VVM>/:PX_V6OK<8KRW]H/P1<?"GXWZ]HMQ!)#N(
M:/<A4$L2W&0/T%=A^SMXBM?V:_C3X:\875OJ5U+;S6DS1V:AV*+-'+T)7^YZ
MXZ?6OQ6M4J/"SIQWU/QO@2C4I9U5J3[O\S]XK#P);V.H37"QR1RJS`[V)\P]
M<@5^5?\`P6\^'WB70OCQX5\5>((9M8\$Q^9&;&WC,;Q^9-&J9?IPW->T:A_P
M7-\/AHX;7PGX[-RH&6ETV$QL?7BYSC-?*G[<_P"VIK_[8OQ.\,:E/I-U9^%_
M#L4D5U9O:-&]RS.KHVSS'1L%>I(([5\EDM+%8652I-[IK8_H/&U:>(C#VJND
MT?K3\'O#'AR3X,Z6OAF%8]+=9,QJ^YDQ,V,G_>W5^5?_``6ZU2&+]LZ^T>!@
M+?3[:SECYSR]M&37T%HO_!;KP_X-MUT]?!GB*UT>WX!ATF&/(.6Z_:`OWC^M
M?'O[6/Q7TW]L/]H_6?%=GI^M6%M=6MM'"U_$L8=DC"$`JS@XQV-=.1SQ5*IS
M5_A?D?$>)&%CBLHJT*.[DG\D>!7*+%ITB1@Q%@29&.03BOWH_P"".=](_P"Q
M-H:L&^6"TC!/\7^@6W(]J_"NQT.36/'&D^'UC=WO-1CM_D4GAGV>F?TK^A_]
M@[X81_"G]E/P3IR+M:32+">0$<[OLD*GL/[O<5^D93.+KN<'9'Q7A;A:E&G5
MG5^&5K?(^/\`_@L_#-'XCT'KM^SMD_\`;45\V_L\?%73/A!XADU2ZTNXOKV,
MCR2C@!<JZMP?9OTKZ^_X+0>')+O1M-U*.%F6W0(6"'C,H]OZU\"P%[F2W\GR
MUDDW<O\`=XK]NH\&9?Q9PNLJQGPMROJUO;LTQYOF=7+L\EBH+HK;=/4^I_!G
MQ[\3_M437%OX`\O3;6$#SK^X@6YA4'([<C#*PJM\?OV;])^''P?OO$&L7S7W
MB21)8[>XAG>.(S"-F7Y.A^8'BOE_X$_M.S?\$]_B]X>O-062X\*^,+HVL]L%
MWRVZQ*S,Q5WC1=S/P><^U?3W[;7QC\.^)_A9I4GAW6+/6--U2<7#&&[BN6MV
MDA<LK;&(7;D`CG%?)<#\$Y5D>:+`8"'[N#UNV_Q=V?;9YF4\9E+E)VJM:?A\
MCXE^.NIW6A>%XK[RKB59+94GDSE$8JY8\],8S7*_LV?\%'[C]G:>1+>WDN[/
MGS)3L:)1MQT;VKZ8^$/P2_X2_0[J^2$WFGKODN&U)3+:HNU6;'RE0`IXST!-
M9?Q5^'W@'Q[X'U#PSX5M_`AUI(FCG=([<A&`.[_5@L./45'%F!PV*Q<J&"I\
MJ;M:][ONNWH>#D>35,)2]KBI[JY\:?$%[K]O+]IO5O'_`,(=!U/4O&$,H;?:
M'[0B%[<1G]VN!S%%)^1-5/V3?BK\1/@]\2!\/?&V@W5G>7C*ES--:)%N#!Y5
M_P!H8#+6Q^P7\%_&_P"PKX\U&[T>234+JZ9"LL9GFM9-L4RG!"IGB4_B/S\\
M^)/Q8^*G[4GQSU37+2W\+VNN:&L$OV"UM;B.\GW1!`%C4LS':F<9''-<?#&)
MQW#./^JXM/V5[)M+396;U;U-LSY<QPT\/1]Y)7OZ'W*+RY:]A&/W<A"B)!M8
M_C[TS2I-.TSQ#827DC:?;S:O'!<>;(1L0N-TA_V0,_E7#?LX_%*Z\?>%Y!J*
M)::WI$9DDBG4QDE<#[I);KGKBO1/%(CUQ($=;-EN+9?,**/W;G.3GL1GZBOU
MJM%9K.2H:M]3Q,OK/`Y;"5;1(S_VA=+\'_#CXX:7_P`(#JUKKK:Y9R7>H-:S
M&58I3(000>GRX/%?H;_P1<9DL?%D:S1-"LUKA0O/W)Z_.;P[X4L?"MU-);VS
M75TR,JS3()``1CY3C-?II_P1A\+R>'_A%JEW=0M]HOC;L7"'''GCJ0#WKP^-
ML&\-@,/0F]4W^1Z?!>80Q>+KS@M&E^9[!^U:]U+9Z(L;K!AYO,+KNSPF*\OM
M8?*U(S-^\D5%VD?=S]*]N_:>\/R>(/`'VJW7<]N&*E02>60=@?2O$=+?S+6W
M9OO*^'^@K^.^,*/L\QC4<NQ_0V158RPW*O/\SP?]KV&0ZS'<:QHT^H:"UNJ/
M/;*(O+?,I.7Z\)N/X@U\_?\`"LO"?B.3S-(\1V>DPR<F&XN'DD3/8D>@XK[7
M^+FE7&M^$KZ.**SO$59'%LR&29OD<9"X/!S@>YQ7QWXAL?#D.I75MKFB>)=&
MF65@'BMH[6,X]V]\_E7UF0XR-:"6YY>887EDY,R[KX'66GPNT'CK2?L^1YI+
MR-@]N:MVOA;P+X(GC>.:3Q5>S9P+&[8;<>H/L?\`QTTB>$/`+>0TFK:W)'M)
M,<=]"2?3<*[CX&^'+?Q3XTCA\/Z#/-:Q,/WMW9!^JM_$@(ZAA^5>OCL1]6HR
MFUN>?@:/M+KSN?1OP(M9[+X=6^Z%;6W1WD6%D`D&3W-=#J1CE5)-C*))`JC/
M(;L:L0VC65J+5ECB=$&40;0/PJ'[-)JWB32[&%6;=<PLP`SP6P>GUK\<H1J5
M\:FGU/KJTHTZ%^R/H*\NY!\`M-"[5*6$2-N&<_NN37\\W[1^L-I?_!43Q9]A
MM/[5F:^N!LA4-Y?^CJ.0?S_"OZ'_`(CV?]D?!%4^Y]GL`N.G(B-?S:_M2?$>
M]\(_MW^,KZQ@ADO9+Z0@^46(_<J#T(/2OZ^X(P,\3A<53C*WN1U^X_.JU11G
M"7FSVSXA^#/"]I:M9_$+4-/\5:U_RQ72V^QM;'Y2VX=]R>7C_=/K7LO_``01
M\*Z7X5_;9\5PZ+'(NGSV=EY@:0R%/FE/)^M?G1-^T-JMY#K4=^UI-<:H(09R
M"TUOL_NL6RN1@>XK[U_X-HH[C5OVE/&EQ-<F?;969D<R%O*'F2X)/;/3FOHL
M=P[4R[)JTYU%*Z73S0I8Q3J<MC]K_`GA_P`*VGB"\FTVXCDU!KAS*OG%BK;P
M3Q_O8KNJ\_\`!'P@T_3?%-UK,.H232R2LVR"Y#19WA^1MZ^O/2O0*_*<KC-4
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M2I'$C$*H+#.`N!7Z%AL'&OAZ-:-?V;V]Z5D[=CLHXM<GLI6L6/AOXMTVS_;$
MT?4K.U?1;93."JP?9P=T>!@?YZU_3!\+=1>X\*V2^8LL,6_S!NRW+MCBOYA?
MC<M[X4U_PQ>:T?)OT5M[@B0D[U!^[QZ5_1Q^PMXTC\9_"VQU7SFN&U0/ABI'
MW)IE]/:N'C*BZ=>%6=VII1N_)=#CHU%R2INUCX%_X+6?L,WEGXAD\?:#IMN;
M,*#-Y*#S,)$`>%7/7WKX7\&^.+/7Y(X;]2EU:J(5\Q<!2N`.3^-?T6>.O`.G
M^//"5[HFN0I<6]XC)\PSPWL#7Y-?\%`?^".>L_#W4-2\7>$(Q<:*5DG:WW0P
MKO`EE;[TN[H%'2OR7,\G3J/EO8_-\TRC'9;6>,P$5)2W5FW\K(^9=-T^UOK_
M`'?:%Z<!'!%:=Y8QQ6[*\D+1Y&1O!8_A7B&HOK7@6_FM;R%M'F@=HSY;B7."
M1VSZ?I5+_A.Y//6XEUJZ\V/(4>0?FS^%?&O)<1.HZ<'9>=_\CLP?BEAL)!4\
M3@ZKEUM%6_%GMM[8VLFFK^[MIH^=Z7&/7CBN6\2^/]'\,:6K^9M:`EDBM@&P
M?H#7`GQ9J_BF]2.WDEOG?.$;"=O4CV_2OK']B'_@D%XG^/GC.WUC7-/CL='M
MV62;$\,OFKEE((\P-V["O1R_(U"RJSNUV9Y>,XKQV>5TL#AI0AM[\.C]&T:?
M_!)O]C;4/VCOC-8^+-3TY?[%TZ[CN0T\>&/EW$+'AE(^ZQ[U^W'A[3+?PWHU
MOIMNJBUL8%@B``&U44*`,<=!VKC_`(%?!'2?@%X&L="T*QAAA1529E.W)VJK
M'!)_NCO7=+8B([54>6WS$^]??Y;@84X-Q3OYGW&49?#`8..'MM]YX9^WI\&V
M^+WP'OH[>&&2\@>-E,F/NAMQYP?2OR`N[1C>7%GON+-K`@2.!L9=W(VG^?UK
M]Z]3T==8M9K&:-6MYE(Y-?E%_P`%(/V;9/@M\26OK.U4Z/<,QG(8+G"0*O&X
MG[SU^J\"YO&*>"K/DOLWIJ?)<<93*HXXRDF^75I=CQ+]H[]G7_A9OPB\&^-+
M6Q@U:/3;NZDU*S,8E,,:XC4QH`268C)S47[*O[+]]XQN1I[7VM1^%UE^TW+Z
MG^Y^QJS*'VAEVA54\9[5TG[-_P"TQ<?LZ?%F.Q\2@W/A746C1(V8E5P&9^$4
MMU8=:]\_X*0:QXD\%?L;^)-5\`:?'<6/B;2;F"5EN5A,*26TCDX?DX^7C`K+
M'8K$8"O/#V5Y];='KH]SKP^'PV/P\<9S?`DK)]5IJCY8_;+_`&Y5MYT^!/P;
MTNUM9K%!!J^NPQ/;22",RV4Y$T3;')Q$XR/F//3%<Q^S]\-;/X->')[J:34M
M8U:XQ'>7-U&))#(R[258`%AWR:/V'?V<[SQ!X/MU^RK'K^KVRWLT^]=V^2.'
M</O;?OG.:]^/[*7Q(T;1+C[+'YS6DJQ$&Z@7<O<_>_2N/"U<)3:=2]TTV[J]
M_P#(]:ISXFAR76UD>*6RR6DDUFNZ/^SR%A;HT@;D[OI[5YAK_P``9+7XO+X\
M\,0PZ/>NR&>"#%O%,$C$:AMHR>YZ]37T=XL_9]US1+&ZUB^F:/<5)&4;J0O9
MO<5P\=Y-??9XA*PBW$&OTG&?V7G&!DZR25GJN5.]M[ZGY/+#X[`XV-&G+=KO
MM='G=MX?U:UN/[>T[2=-M(U?_B9!5,;R1KRY`'WB3Z]:Z[PWXHL?%$+M9LRJ
MJ&*43#84DXS@>@R.:Z20W&G"Z>Y<_9)(/+"9&#^7/2L72O!>D:!IEWJ%T%W7
MDSF)=A.=P##H?:OG.$(XC*5[2FN?#])6<G_X%HCZ3BR4<1AE@].?^[_5S1T+
M0I]:U6STV*2;SYW41F,Y!7(')K]B?V/OA>_P6_9UT>WCCC?4&A_?[\<D2OCD
M`$\-7PE_P3-_9DF^*OC2/7-0MU72[`%8<LK9&U67C<#^E?J#8VK1W`CB0)91
MY"J#QC^?6OC^,,XEF.*M3?N+O_P&SZ#@O(ZN781RJ+5^OZI#=8TF'6+"ZL6C
M1H2H`!4;>Q/M7RGK^EW'@_5KRUNXI(S(6\E@IV`D\<U]92[[==OW84Z2YY_*
MN)^*7@FS^)FE21PRYFC!Q\G4XQW(K\?XQR"GC5STOB\O^`C]0R/,%0J<LMF?
M/K*R%5*P;9H@#.AS*">V?3O]:\%_:"^&FHV&MMJ$=GI.KV<A+%=1?=U8GICT
MKZ`\0^%+_P"']Q);W5JORDLC"0'*<@'@G^[6#K'ANQ^(^FR0S*K2J.%(_KQZ
MU^99=]:RZOR5HOE\D_UL?68B$,3%ZGRG;:;=ZG=F.'P;\/X=_P!TA-IKW[X#
M>`[KP3HS33_9=/N7QA=/?Y>&?^A_4UC:)^SP+3Q'(]YIL,4,+8C(D#;@1ST;
MBO43/INDVZ6UG:1B;G&,CW_K77Q!G%?%N.%PJ=O-?Y,X\OP]&A><WL.BNY(K
M9[B9I9&CRSL_WG7T'J?:O1_V:?!#>)O%3:O-#_HL*_)YBX;<KQL."/0U4^'?
MP5U3QY<0R7Z^79V["11N5MW8C&0:^@O#>B6OAK38+6VC6,(JAL=^`#_*OK.#
M^&YPD\1C%JMNGYH\_.,TINE[*D]SSO\`:HU@Z7\'?$.Z5H/(MII4*'&%6-Z_
MFSLO%TNL_MD^(-271[7Q(][=2,G]HPM-`!Y.#ENWJ/<5_0!_P5!^(\?P[_9Z
M\132MB.XL9H`>>&:*4#H#Z5^!7[*>C:SXCTK7+BQU"2V>::/;(`N5RK#O7]`
M<)P4LOKU+^S4U92>BT?1GR=2HE*$5T9ZSXS^'G@ZVGT]-2\$Z''/?&07#Z-I
MBS1Q;<;<L!QD8Z]]U?7W_!OO\.M-B^,OQ<FT:UCLXVTK3DC)C$(!\V7/05\.
M67P9^/7P;MM0L=-U2XU2PN0@>5[NTA,>WYA\NXDY+D?A7Z2?\&_/P\U6?]D/
MQ-XMW&3Q%X@$]L7+*&+07,RJ,YQ^@K'-.?#93/GKJKS75HR;>FNAZ5:--M.%
MEL?H3\+OAUJ_A75KBXO-0FDMYBQ6`3[XQEE.<>N`17H%<3\&+/Q-9:2R^(L[
M^2A,J/Q\N/N_C7;5\+E-*$,-%0C**[2W./&2E*JW)I^FP4445Z1RA7/?$O7M
M0T#PW))IMNTUTRL%(*_NSC@X8$&NAJ'4)UM;.25D\Q8U+;<=:RK1<J;2?+Y]
MBZ<DI)M7\C\_?^"S/PYU#XZ?\$[=4U34(V_M'P??SZZ'.!M6VTV[;.%*CAG/
M4'Z&OQ)\(?MY?$CP-X-M]/\`[>6XTIK98;918VR^0NS:J9\LLV`.I/-?T<?%
M_4KC]H?X-_$[P?<Z;);0ZAH&JV,"M$%+L\#PJPQUSYGUK^;CXH_L[3_"[X@>
M,K%[RUTV/0?$<VB,MX&QD.1N&1P./KQ7Z7X=XK`5,%R8R*J<FJ<DGZO78RQU
M.I[3W=+]C@/%?BK6?&NJ-J6O7'VIG;=&_EI'@'&>$`[@=J_>[_@@9\9O^%@?
MLK^'=/:X6YN])$_VIPH79YEY>LN0%`Y`[9Z5^,?@/X.Z7:>*K71+B.XUJ;6(
MI)X[BTD)A7RU)/7GGVK[(_X-_?C]=_#GXZZMX)U=OL-Q?-;)'!*!&PVQ7LQX
M)ST8'\:VX_IX3&X"E/!N\J<FW:UDK66UPP-&5.HXUOM;'[MF)'ED>243;0"0
M!MP*E@M,C;N_=.,[,=<^]4M.U(W=I;W$8#1NV)#C(P*U#+^Y+#KVQZ5^6RA&
M5--F]3F3Y&]/,\T^*_[(/P]^-4S-XG\/-?'GY_M]Q#W8](Y%[L?SKR>Y_P""
M3'P/N=44_P#"*L`H.Q?[5ONG_?\`KZ>C>2;=N^Z*XGXE^+9D7^R]-&^\F(*%
M1N(`(S[]*\W'4Z5&UEJ_(Y*>2X>M.TJ4&EK>R_R/)_#?[,?PK^!>JO)X6\*R
M7&H6Y&Y5U2Z^3(./]8[#D.W^<5Z3;:#XK\3RH]Q??V3:QX*6KV\<I/;[XYYZ
MU\S_`/!3?]LG5/V$?A]X9FL-(N-4OM6%WY[0PK)CRI+8+]XCM.?RKV_]@O\`
M:,O/VH_@#I_BJ^MVMIKJ2:,Q,@5ODD9.@..U7_8<:5JS>_3^D%'$T*4W#"4X
MQMO9)?D=A+\,=4EN4;^VDB48RAM5.[\<T3>`-6T:Y:\@U!;S9&=MNL"H2W4'
M<3[8KKKKQ-9VE]':R7EO#,^`L#L/,?/`Q]>E8GQA\:7'@/X5^(=8L;>26XT[
M3KFZCCVAF)2)W!QZ945UUL'.=E3DX_.QV/,X7]M.S:]&4M`^)=_96DG]NV[:
M>L3JGF.RMDGV4>M6/C/\)=,_:`^'5UHUVP$>H!-LWS879(CGA64_P`=:^$O^
M">__``4/\7?MA?'[4/"/B3298]/S,Z%;1(C\D1<<@D]:^T?"6H_\(-XB_L6\
MD>UM[HXMS.W)"J6;!/N1^=.-'$X::A4G:2U33?YBYJ.-@ZM->Z]TU^A^5?[6
MO[)6I?`G6)=$U#39-4T:3[M\'\E8LJKD[=Y8\G'7M7%?!7]HGQY^SJEYI^FW
M9U[0-0A:![>.W@@\E6(S\[(S'"J!U[YK]J?BE\,]%^*%A_9^L62R0R#`D`"]
M<=\>PKX5_:7_`."35^-9FOO"9DFC8;UB02R$GYCC@8]*^_P_$&$QV'5''1M4
M6BE97T_O-W/A,1DM?+ZSGA=:<M7'IKY))'SS+^T5_P`(G>6>MW4.%N-EPZEP
M/+9CO*9VG.,'G%>\_#WXV:7\<O#8U>.'[!)9Q8`,ID\T8W%ONC'TQ7S5XX_9
MP^('P^U!['6/#>J2V<)(#"R=1@$KU(]%-<C<:/<Z7.85M]5L`O&WS"@_(5ZM
M'A++:T%)XG?^_'_(\F7%6,HS<(8?;^Y+_,]6^)?Q6TOXG7=Y:W&J10V;,NPF
M,MN'RGL`>JBO.]#T'0[:-;=[A/*4GY_G[\],U3LM'U"YBXT>_N'_`.F4==?\
M/_V7?B'\2)_^)7X<U6-3T+V;MZ^@]C7?4RO+\OA[)8EN/5<\7==NB95/,JV.
M;JU,-:3V?(U9OKJ<;XFO(]?O"'B\FUA`".6W!R./KTKUG]DW]C'6OVG/'.FS
M7%M)%H>G31MYI`*LL;Q'^%U;[DF?_KU]'_L[?\$GI(+RWOO$\AC$961XF,D9
MSD$C!&/6OMOP%\/M'^%'AF'3=-MTM[>*-0TF!SA%4\X]%!KY3..*W[)X'+O=
MHK_MU_@[?@>EE/#-:598C%N[];_FB'X>>`=)^"'@2UTBV7R;.U@6-Y2SD$JN
M,X))Z#UKG]<^(FH:O(+#PW:OJ%JO#S(ZJ!W'##/.#^5-U07GQ)\2S6L,FRST
M^4Q%^=KX.>H]17=:9H-EI=G]FM_+61."0>?6OSQ2JXEN&R[K?[S]"I_NG[RT
M/%/C=\8M(^`6@3:UXT\5VVD:.JYCMY;0MT*AOG12>K*>G>O%_A)_P5'^#OQ0
M\6IHMKXBL]+O+J016TK">;S7+8&%\H#WY-?)'_!:3Q'KGB;]J(:%<7#0:79L
MAM8R"JW!>TMF<#LV"/PKX[\7Z!'X5>WN--F6&2,@R2AO]5@9SGM@UX_MTZWL
M]79]3\AQ'BA7CFOU:-)+6VB?_P`D?T(VL?B2WT%;B&X_M[3[H?:(WCAC@!A9
M<CW^[^/S5D/\-?`_Q,=EU"S^SZJI_>(;B8D-U/W6`ZFN/_X)4>(=7\9_L@Z3
M)J[22/#)'%$[`_O(1:6VT@GJ#D\U[-XY\`+JD'FZ?MCN(SEB.^,D]*Z,5EU"
M;4JD$_DG^A^P97F3KP4Y2E&_;0Y&W_93\,K-&L<?F8!PHDE&?_'Z[#PY\#O#
MNA,K+I[+)V/GR'U_VO>G?#'Q1]LAN+&XPMU8E4YZOG)X[UUEJSY_>?>/3BNB
MADN6N2J0IJ_I'_(,1F%92]ES.WS!;58XO)C.T*.GI1).EI;JDG[O>VQ2>Y/2
MI)X-[+M;G//N*QO&FLKI&AW,DC*FZ-XXBW_/3:<?RKU*BY;4X+<Y:<7)W9^8
MW_!P]\=V\'_`LZ"ERL5U>:I!L0J"9$+3IC[IZD8ZU^2NK^&UT#X'PR:CI,EK
M<WWE20!I\^<JR#<1@X&*^GO^"T?QZN/C#^UQ;>&[9ENHM'9K6>-0&)ECNY@1
MQT;GOS7G.CQ?#_X;+_:OBV'41JFGC9;:;+>!'^;@_NVX."0:_3)0^H97A\/R
MJ2=[K=_-'7AJ$9RE-GG=QX]@TJ\U._M;Y-):#RS;JT?G>;D8;&1V]_6OW<_X
M)V?#*_\`V;?V&_!>EZ-"R7DUW>S3=&W>9.\@X<L!][M7XUZ=IFJ?MH>-/"'A
M^]CTMM0\3-=+86]A:B&2V,2;Y/-"CYMRQ`KCH,U_05;>.)/ASXHTOPW:Z;+/
MIMO#%DI$&$>5YY^M?'\98RE2P]/#\OLM=U&SN[6_)CPL9RDW:_D_(]%\!ZQ?
M:YX=BFU&T:SNONLK.K%L`?-\O'//%;-1VLHGMHY%7:LBA@/3(J2O)IJT4KW\
MSCD[N]K!1115$A2.H=2K`,IX((ZTM%`'`^-O'ND^#?$EKI\6GVZW%\Z+-+]G
M3;Y;L5/.0<Y&>>*_%'_@K7\$_#OP`_;@N]0\26&M7GAWXA)=>(8%TZ&.6(7,
MERXC4AU5,G'0;C@\$U^YOC/1M%@L9M2U#3[.X>UC:0/)&&8;06_QKX+_`."Q
M/P*L_P!JS]ED^*M!T^-]?\$W]NML%C"XMXBTKC."P'/0''%=7#^8/#8MX>JU
M:II9=CLLG!3BGIN?D/XS_;!N/##QZ%H/@[0=-FTT&%+O4M',-Y$N02&D60$$
M@D=!FN>^&OQ*U3X+?M):-\1+&9Y(7DD=WA=F1]MN81]UE!QN/\7^%7/^&>]:
M_:(\4+XCMM4T^%M2W2W=M-?)&L3$8``;GH,\U<^-GPB6#PUH'PW\(2W%UJ.C
MFX6^U7:%5O-9)X\2K\K8!9?;&.M?JD<+ESIRP."@E.HK2TM;K=7WU,74E4DI
MM']%W[*WQALOBI\,[&:UN8;Z&XC'[^V=9(PW<;@Q&0>#Z5ZP/N\?=5<5^/O_
M``0&_;3.N^%9/!>H7<UO?:)(\@@);;<%YV&.3SZ\5^OFG7+:AHZ2[8U\P9PA
MR!D?SK\CQN#E1DZ*>S=AXBG%KF6X37X@TRX<X78K<G@=*XOX;01:MK.HZI>+
M_J)0MN[`;'5AR5)Z_@:Z+QU/_9O@^[)_BA8?^.FJ/PJMUN/AUH^41HY;<,2W
MJ,XKSX1C5K<SWBMO,UH_N\*^[=BC\8/V?/"/QXT^WA\4Z79:FMGN\M9K>&;R
M]Y0G'F(V,[%_+Z5\:_%S]M;PE_P3574/#VA3Z=K2S(!IUI8-#=):RG$C&9$D
MBV*=QY49)KZ0_;W\1>*O"?[,&O:MX1FDL]<MTA*M#,8F!-S"O4<_=+?G7\_6
ML^+=7\>W\VL:]?3WFJ7$C)*9)3(0%.!R>>@K]`X1X?GFKY\1I&/3?S/D\RDZ
M$[4EOU/9_B;_`,%%OBWX_P#C-%XQAU[["MG<)+#8PWEW%`RI(74-&)CG.<$!
MNG%?:W[-/_!6&U_:C\-Z7X!\7S1^']8D6*&YOFQ9V=S"$CB>,RRSNS,[.QVE
M<,!D]Q7Y;U);>9',LT-Q):W%J?.A=&VG>O*\_6ONLZX*PCH\]%6:\CS>:=%^
MT>J?0_HK^"O[-O@/X=PVM_X9TG28KKR\+J5C;6ZM.",%O-C0%LCC.>:Z?XC^
M`E\5>'9(85C6^7'E7#<21_,I.UP"1D#!QU%?$'_!"GXT?$#XE?#'6O\`A+M0
MOKS3M'GBMK'S;AYL1F(D8!Z<^E???VEKO3(FW-'-,#TXZ'O7X/F5[/VC]Z+9
M]AEW(K.DN5/IT,3X9ZXWB?0FANF622'.74Y(^8]R3Z5T<%NRQ+Y;,ZAL-N.3
MCVKA?A4"][=21+Y%NN,J.-W)[5J?$?XIZ3\*O"=_KFN:A%I>EZ="]Q(QD"L5
M12S8!(SP":NG4C4@N=&BC-3<$:VL>$-"\2LRW^EV-PV.3<6T;;NO]X'U-<SJ
M7[-7@&_W--X3\..S9^8Z7;G]=E?F3^W/_P`'2_@/X!:_=:+X3L;?Q!=1JT:R
MW%M-C<'F3.Y'QU13_P`"K\\_BO\`\'8WQIUO69?[#TVQM+1B=@COKN/:,\<;
MZ=.HU/DC'3N:O"J,DYG]'WA7]G7P1H?"^%]!<KU\S3H"1U_V/>NLT[P]HWAR
M/=8Z78V:^MK;)'C_`+Y`]:_F2^#O_!V#\;O`]Y'_`&SI>FZU;RYWO=7]W(_`
M;'&_U(_*OTT_82_X.9OA9^U/J5OX;\0[O#VJS-L+):2)&,F0CYY&Q]U1^=:5
M8TY+EEN76PTOXD/N/U)E'G(JNQ56Z;3C.:YWXE7KKI:V%O-''-,H5<OM<Y#*
M,8YZ^U6O"7B.Q\2Z+;W%A?PZE9W"B2.X619-H(!'(..`17/?$%?M'C/2^@\M
MH=LG=B';`KFQ<8JFJ;V(C"?/=&[X)T#^PM"M8]NVZ,:F8N/F=L<GID_4UL-I
MX=O.CSN[\]>U$-X)(FD8(9(?D;)_.H[;6;>[PT$WRPCF,'KGVK6G*%.*@GIV
M(J2;G:3/C?\`X*B?LC>#?CEHL-PNO:/H_C2UWFP2YOX+:6[<B$$`>6TK[8US
MA>@/I7YO_LA_LO6'[1'CN^TWQ5KNG^&-*T.5FO;G5+Y;&.:)9-C;7D1E;CGD
M`8YKU#XE?M/ZG\4_BOKWQ@U[[4=,L$MY?#.EW`?[(9%B6WN<AN4R5#<'DUYG
M\.?VA5\;:M<>&_$_@_PYI.G^*9&M&O+-6DGB61OO*&.-P!SS7A^TI.M=02/R
M'-(9+3S6+JKEJ76B3=_F?MM\"_".B_#?X4:#H_AR:UFTBSL;>**Y@=&BN@L*
M()%>,!6W*JG<!R.>E=LS1R0;59%=QGYCC</6O@G_`()!?&KQ*=6\1?#/Q/+?
MZA8Z6+K4-$O+LNYCL$>UM[>,$_*H"[CM'3)[5]X6[6\C!1);R21+M&&!(%>Z
MJZG:-C]8C**I1]GHCC?%]LOA#Q+:7L(V1D/]I<<+DX"Y(QZ]Z[VRG6[ACFPR
M]<`C!]*X#XV7B+\/=2D4L9(Y80V1ZR+TKL=`NGO-*AD[G/\`,BN6BZ=*<D]V
M]#NKI.$7U_,NR2,+A"/NDX-?/?\`P41^/%O\'_@GK]\UQ%;R:/IUQJ<+,X43
MR1V\[+&OS+N8[>%&"?6O?+N^6VL2TS>7UY]*_%+_`(+\?MCS^(_$-K\/=)OI
M(UNKF..9XY&&%<7D#9YQW%?1Y%@Y8W'1I5%:,=VM?0BG35G)L_.WQE\8?$/C
M[X\^)/'%KI_]HW6J:E<WRQSV\DRQI)(9.`&)!&>/F./6O>]!\8/\3O!&D77B
M#P7::Q'?0&2X.F:/]HU2`AN,[R=O0$Y_A%>26'CJ7]GO3-+6W\/:?KPDMDDN
M;F\1B#V8;EX)(7..^:[KQ=^T>WBGX+3:WX'+>%=562"#R--W6X?S)`I[Y/RY
M'XU^A9A0KXG&PITJ<8I?:3UV[#PL>6&KU9]9_P#!$?\`9LT7QI^W'XB\::>^
MH7GA?X:M:-9-=LD@/VVRNX7Z(4/[Q3]UEZ#.3Q7[$?#SX@:;X]U!UETZ%;Q<
MC>;=1P#@<Y)KY*_X)0_`:S_8@_8ET'^V].B;Q'XH2;^VBT0:2?R+VY\G<0`6
MPDPQGH.E?;/A71-%%NM[IMC:P>:/OQQ!2:_*\_QU7'YMI53Y$DT]6U:R_*YL
MU&G2?,GKL_S-I5VK@#`'``[4444'GA1110`4444`4]=\/V?B;3VM;Z!;BW?.
M48D`Y!';V)KSOQ1;^$O"-M=>$X;*.WCUR&2)T!E8%I`8O?\`F*]0KE/$GPP\
M/7-Q)J5]:LTD<GVDL9G7#@[L\'U[=*X\1&49*M24>9;MZ.WK9FU.7V97L?SQ
M?M1_L@>&_P!C3]M'QIH/B-5MO#T]V)-+E\MI//C%NA;Y8W=EP[X^;GO7F/C#
MX_ZUI_@B^A^'>CKX?\(V2K]HGANUD\H,X*_)*N\YD,@X_O9Z8K]C/^"P7[+9
M_;+^`)\5>";1KKQIX-V16,*,7:1)[B'SN&94XC1C\P)],&OR;\">-?!?PV\/
M3>+)+J'Q'J7B`#R?#\$CP3V1A9HSND.5;>K;QP,`8K],R_%4<;"GFD8>TJ1L
MDKVU2WOMKYJQM&ZBXR/+_P!G3XN^(OV6OCGX>^)4,CR:2UXA=MR+YACR6&,,
MPY/]VOZ0OV&OV@M/^.WP?TS6+"[-VE\B32DQNGERM'$S)\RKG&_KC!K^;WXX
M_$GQW\9]4TWPSK%L_P!AEG/V;3!#$DB;Q_ST4`G(]37U-_P1]_;>U;]ECXNZ
M?\//&C?8=/U&^C73_-6-/LLTMQ;Q1N2JEG"JC<$X.*TXLR=YC#^TO9VKQ7O*
M][17G=+[E<QH[:G[\>.+#^V?#-['_=B<_P#CIKYX_:-_;7T/]BCX$Z/>:PWS
MM%'Y8VRG*^8%/W(W]:]O\$>,=/\`'?AR/R[A)FO(!.'4G_2%91^]'`P#GI7@
M_P"T=^R?X=_:EM[KP/XM8*UQ*LFE2%Y$`AC8.W$;*6R1U)K\IIU(QQ%YOW6O
MQ,L8JCH\M/N4_AS^WYX9_;2^&RIX=LX[I=6'W=TT?W)&_P">D:?\\F]/Y9_%
M?XX_#BX^%/Q=U;1;JR6TFA*RG$@?(<;AT)'?UK^@/]E[]E+0/V3_`(8Z?X;T
M/;':Z>K"1BSOYFZ220??9B,&5N]?%'_!3K_@EEXL_:(^-$GBCP;-Y,-TD22+
M]F\[.R)5ZLX[@]J_1N#<]6!Q#]I+W'_79L^:QF#Q,X\[_0_*NF_V<^KW=K:Q
MVXN9;B=(XT+[?F8X')]S7UAXA_X(Z?%32=:L=,-PS2731K_QXKU;C_GI7I'P
M&_X(H?$;1OBYH&I>(+D_V;H]Y!=[39!/FBE1ARLF>@-?:9YQOA/JTXX=WD[=
M_P!8G+1P]6<?>/I[]AO6]?\`V.?V3-'NM2\,QM:WUA'=NWV]/FVJ1T3>:M?L
M2_\`!8SP_P#ME_&R?PG#I,=@TS`0N)YI-F()I3PT"#_EECD]Z^Q&\'6=QX4C
MTVX3SOW!A8`E>""#_.OF_P`$?L&?#W]DCQ)J?B3PWILDGB[5FC:V5;N=CE%,
M;_*[LA_=RMV_6OQ/'5*4J$ZL]]SZ3`T9PJ*^QZIIWQ"C\">"]:\6:LWV?0M+
MB\TG!?@-M;A06ZGT-?S>_P#!<+_@M[XG_;0\?ZOX-\'7<UCX3TTO!=!&RLRK
MYT,@*RP(PR&'0GV]:_0C_@YH_;-C_9R_95T[X:Z3>1R:MKWVJ&9U`_=!E@F4
ME64_WCT(K\8?V6-,\!_M0;?"OBK;I?B#4'\FSU62>3RXY798T/E1X#8+%L$\
MXQ7DQQ,(T%7E\*/HHX.>(E:DKOI_3/DXR-]K:27YGD8G<?4FK"RBV<.TF[=U
MXZ5]>_'+_@D)\1_@UXCM39V=QXG\-ZC<)/#>V]N((WC=WVGYI"W,:AOHP[U]
M)?&O_@CRWCK]DSP+J7AFQF3Q5!IEO'<0`O(R$ME\@R;>!6=3C3*<.HNI-:^O
MY6_,]##\&9A7@VX:^J_S/SD^#'P>U;XT>,X]-T&V_M!H]P,AD2+^!VZ.R_W3
M^5<WJ%BVAWL<+MG4XV.Y?3N.>G2OVQ_88_X)XW7[*'[.%UJ%QI<UYXK\2+#)
M*`S(5,4TB_=+LOW).V/SKX%\1?\`!'7QQX*^&][XI\7:HOA_2;$-*?M%CNR-
M^T_,LF>I';O7FY7QEEV-K5(4Y];+?7\!YEPGC\)&,U#1*[U7^;/KC_@@G_P7
M;U[X$>/M(^%7Q,O9;KPWJUS';6MQ(2WE---&N`D-NS'"`]6&?K7]!FK:W'XD
M3POKUNV[0-5BM+BRDP1O,GSQ_*<,,H1]X#'?FOX@[3SO#?B21K2X#-I<QEBE
M"\/M;@X/TSS7].G_``;S_M;Q_M;?L-0Z#>W"RZUX'NO,A3@,1:6%@B\*JC[T
MAZD_C7KXZFN5-,\B$*LH2K<^OH=M_P`%5/\`@IIK'P*\;0^#_`MU)9ZQ-&[7
M3QG!$BR,C?ZR(J>,=#7R;\'_`/@J+\</A=X@.K:YJ%UKEB^2\$DUM"#\K*.5
MB)ZL#T[5T'_!6']GCQ)#\9H_&5I:320ZHLEU=D*.&>5B>IXX]!7S3H=QJOQ7
MDB\/>%[*6:9LB7:5?!'SC[V.RGO7E2Q&(YTH+\C^;<\SG/GG7LJ4WRW[0_R/
MH*.?5/VB_@[J-EXRA_X1'P;>1[?#LJ2+?BU<2_Z251,/RZ#[^/O<<"L'P5^S
M+9^$?'NFZAXT\63266DR1W.G0MIVX7KKT3,;$IE>[=*_5CX1?L4Z#J?[*NA^
M!_%^GR3+8M=>8GG20G$ERTG5&S_=[U0^&'_!)+X&?"OQ`NJ:+X?N8=0#AP[:
MM>2#.[(^5I2.M>Q4RWEDI?U^9^D8G@W#U,3'&SIWFDNKW7SM^!^<FI?ML_&/
M]F37=2LKS3Y(HM5@E_L2Z%_;$KIDK8MP%5&P`(\X?#=CBL7PE_P4J^+_`,*_
M%-KXDU36+JXTNZ<%XBT`&'(/\,9;H#VKW7_@N)^S%XB\/^,]!\;Z'8S76B6-
MC:Z20BC$90WDQ)9F[*!V_&OST34+[XFZS#X;TBTDEURZ<,Y4AO+YVL-IP.I]
M:\_$XB=*=D?F.<YGQ%A,[A2I-J%U9>YW\U<_>3X:?&^']IO]E?2_$L2[#K44
M<SC)/28CNJ_W?05[_9!-'MH8/X>?YY_K7QQ_P3F^!FI_"[X">%O#>IQ2+/\`
M92-1D(P`ZM(R\9.,Y'0U]$_$_P")UC\-K"2>[NXT:R&XR$<6>=O+#!W;MWX5
MT9:JD>:K6U<G[JVW\U^I_1]'FJ8:$JOQ6U]?EH>:?\%$?VJ+7]GSX&:QJ4C>
M6RVTI1L-P0F>R-7\YOCCXV:?\;/CQJOB+Q5<_P#$ODN)5A=HW?!\\NO"*#]U
MFZBOH_\`X*<?MA:E^V_\;+?1?#<;V'AO3;A2TY*3K$VTH[D[58C/..U>8?"3
MXJ>#/@H;KP[<1KK6M7B.%OXYFB2W=RJ`F,@@[67/OG%?L.4Y?/*LO]I2I<U6
MI\:O:WSU6W:QA1O5G?HC8\+?$;33X"N+&;PQ;^*?"+RAX_-O&M0'"XC.W&_[
MO/XUZ)_P3=_9=T_]LG]KC3=%L_"UOX?\*Z6D\UZ([O[0/,2(R1##.C]5ZC/7
MFO-_$G[2?Q6T!+?1]!N$O-'UZZCT^VE2QM]JO,?+CCRRY)((YXK]E?\`@EW^
MSY:_L*?LNZ=>>*%W>+/&44%]JBG,;),`8RN`S)P&'W<"O.S?&8;+LN^'DE+S
M>FNO<VY92K.4/D?46CZGX4^*6KO926D<\NFX\H'S!C>"3V`_AKN-*TBWT.S6
MWM8EAA4DA02<9^M8GA[X9Z#H^H1ZA8VS+,IRK^:[9X(Z$X]:Z2OSW`T)Q3J5
ME'G?6*W737R#$5(M\M-OE[/N%%%%>@<X4444`%%%%`!5/7=#A\1:<UK<&01/
MUV-M/YU<HJ914E9C3:=T>=:PGA_X(VICCAGE:_.3$65RV.#P<=,U^*/_``51
M_8#A_9E^,>I:IH\,:_#WQP8UTR]0,T6D?98+99C+-M"KYDTC`;<\\'FOW7\2
M_#_3_%5[#<7BM(UN&"@A6`SUZ@^E>+_M'_#'P3^TYX>U'X6^(-,MI+.Z58[*
MY2U@:2WSLGD,;NKJI)0`X7GOZT93CYY?B>5M1A*T8KL[-LZ]:D;QNVM6?B#X
M,2QMK5O"O@MM/U;5[=!+-K]P%O+*W$G*GS!\R[3P?3I7B?QE\#V=]XLFGT_Q
M)INJ>(=.'FRRZ==EU25&8E5`^96#XX[9%>G?&W]G/Q=^PQXL\4>`M2FOM/U+
M6(BFGZC#)+''*LC%XP)BD9+!>H53CM7*_!SX$Z7\(?"^N>-/%VL6\DEY:SVL
M=JMW').TV%E$VR10<G:PWYR3^=?J&2QCEU=5*$^:-3=;[[[F-:I%KDV9]V?\
M$:?^"GL>H:=;_#CQE?1V^M:.JV]E//*D?FPPQP1+$2[[FD9MW;GZU^IFO:1:
M?%GPW#>:?+Y.K6ZC`W_/;\Y*MMR02!TK^5>Y\;77A7XE2>(-#O+JQC^WF>">
MTE:*YP9-Z@E"/09P>M?L-_P2F_X*[V_CK08_#/BF_M[+Q!8!8;:ZO)3&M^@1
MF=[B22<L\G92!7S/&/!DL'*6-I1;IU'=K71][]O(TP]>+C[-[KKT]#](O!'C
M]=3A_L?6/,L=2MN&$I\OS<Y;@$Y.%`_.NVM29&:9D?9@!8Q]X?\`ZZY273=)
M^(D,.H6JPQS29+S(J+<>@VD9/\)!]JI?\([XD\,W2W&GW[7\*'+)=W$DF1Z`
M#%?!4<1[JC"+DNZ-Y4XU(.*>I\/_`+7'_!3Y?AM^V]X8\+QZ7?&-K^RA8^6A
M!)N'0_QCT]*_0SX?>(QX\\#:3JRQ20?VE90W.'&,!XU?M]:^>/B!^QGX>^)O
MQ#M?&6H^$?#MQK&GRQS([Z9$[;HV+@Y:,M]XG^*O7_#VF^(M0TBULO+M=)TZ
MSC2WB6S,D#J%`"@#IMQZ#L*Z\1C:,M:%*3:WUN>7A<O<%><UJ;WBKQ;:>#B%
M:9?,D^Z&<9)Z>M8OACPWJFL:])JVH&'?"1]G5D..5*MP?PK;TWX70QS+-J+M
MJ#KT^TL)MOTW+71_8ED"F-MNWHH.%KSX8>K7D_:+E7F>C6Q%.,5&"N^Y_,#_
M`,'4WCNVU?\`X*'7.C7*WB6FAQVDTML7`DQ)86YX&>,]>:Y;_@GA^P=\%?V@
M[>VU!O&$>GZQ`%E2R77$BNMX,>/E52>2V![UU?\`P=D_#Z2V_P""C=UK$,<L
M*:U'9P^?<+MB?R]/MQ]['./J<5X3_P`$YO"/@?X,:Y;^,/&'CS5M/N+&19X[
M/2-7@6.?8\<@1T<`LIP01GGBO'XIP];^SI4<%4Y96TLKW\CZ?A+$4Z>+BZZT
M;^X_:K]GCX:V>@Z39^%Y)K:_TS3H4MK=KQO/E<1JD:?,PY^4?F2:]Z\.?!?2
M],;]W"?,4$+$<%=N.<+BOC7]D']L_P`(?'-KJZ\+2:E)'I<[V[2WJQA6:,1,
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M:])J,9:V):_@F7<H89(3G[P%?<G_``9_^-M1M/VG?%'AV-O)MYM#OKSRIP><
MW&EQYQ]..E?`/[6_[4WPR_:"N'U"Q\%V7A34F&'_`+(T2WL09`K98X9FR6.2
M<YR*_0;_`(,[OAI?:S^T_P",/%<?VA]/@T34-/BDGSRPN-+E`SC&=IZ`_AWK
M^YL+3=2@KP<7V9^"YAB)0F_9M->A^[WQ-^&MM+=33W&GV^HQS.?-5X!*J9/.
M`1@"H?A;\&/AU9W@DTG0])6\DY<Q6\.Y3AO1<],UZM);(;<_:(XY/.Y92-PR
M?8UR>K?"C%PUQILTFFLW_/J_D^W\*_7\ZTC&=.7/T/-]G1JOFY+2[G;6VG0Q
M2;U+<^IXI\]FL@XPON*\_AE\7Z%IZPV@L;R*/.)+II7F;)SR1Z9P/:HH/%/C
MBX?RVM-&3MD"8?UJY9C)S490:?;]36-%WT9TGC'PYI>OZ7-8ZI9Q:C:R(V^.
M5%D"9!4OA@0,`D9]Z\;N?@_\/?!M_)%X7\/:3=:Q=2;I)([6"5H,G##Y5W+C
M@UWUUX-U[Q%<K-J5_+9JP"A=/N'0-WPX8'Y3DY^@J34/[&^%^G27$\>G1W4<
M98W+J@S@'.]^#N.*YJT54E[\;._WFT</23]I4LY='831);7X4^&5^TCSKME&
MZ)"-S<X)4''`!R:_(C_@L/\`\%,X/$VN3_#GP+?K?&;":C?VTJ31S`QVT\?E
MNCY&/G4Y'4$5TW_!5O\`X+#7'A"2;PWX#U"WFU=B5N[I9GVVS*\3`0R0S@JK
M*6!R.:_*/PC\09-"\3KJFN`ZKJ-X<98&X`VJ5'+'/W<=^U?KO"/!M:-+^TZ\
M;N.D5VNKIOH[,XL1C>>7+UZL]N\"?!<_#6R'B&_BU+Q1I^I?)JL>C,TDNFP`
M[C+*2`(U/3<3UKI]+^)W@VTT_4H_!_AJ\O--:VE%Y<W<,-U-;MC]Y^\'W=HV
MGV.37#?!KXUR_#.R-YIC:MXBNM9=K:^TK4@UU8B$-E0T2L#@]#NR#7L7[,_[
M']Q^VS^TOH>F?#U=4T;PY--;7GB]8`;2SCA:ZC2^BB\J-TWA95VK*,8'S<#F
M,9A:M3$2Q68)QGOS[1^Y'9&I2<.2F]3VS_@B_P#L#3?%KXL:C\5/$:S'P#H]
MQ++96D^\,]\AM[B%E)4QE`C$8!SGVK]C-)M_#?QVMTE>.17TT[?*#HIC+<X(
M&<?=KD_V>_!GA'X)^%]-^&.B:;;V>FZ-9QV\DOV:&-[V6%$A\V0H%5Y&5`2V
MT$^W2O5O"_@#3_"%Q<26,?E-<L&D"JJ@D#'8#UK\US#'/,\6ZL+.G=II]T5)
M>RIVG=2Z>AJV5HMA;+#'NVKG&3D]<U+1172DDK(\]N^K"BBBF`4444`%%%%`
M!1110`$9%<W?>#-#T&=M8DL+<W%KRDQ3+1Y&TX^H.*Z2HKVRBU&U>&9?,BDX
M9<XS6-:DIJZ2YELWT9<)N.WS/B[]LC]DW0O^"D7PLU2PDT^'3?&NB))-I>HI
M"/,24@I%^\<<#'ITK\!?VK?ASXX^"'Q3U'PCXT6XDN]-N'M84E??%/&DDD2N
M&QC+;&Z=J_J>^*6K'P#X*N&TR/RKF1&6'!SAL9'WLC\Z^3?V]O\`@F_9?\%&
MO@/+J%]8KH_Q`TF%WTJ_S]I>=XK>;R$VB6*)<S3;LMD#&#QT^BX1XL6!K_V=
MC$IZ)\W+HKZ:-O3S'B<)[2/MHZ*_<_"OX%?LI7GQU\+--:R-I\EM<#Y`552J
MJI."W^]^E<I\4_#DWP2^)C6NGWET-0TV1DF?&W##'1AP>#U%>Q^*?$'CK]A7
MXC:QX"\?S222:<9XK(MY`R8W,,;XA\P?>C;@L??UKPKXJ?%G4?BWJ327;M)>
MJV=YV_O!D$\!0!TK]?R>C7G7G+&-5*,D[;M+[]$<F(DO9*G#XK_@?IO_`,$S
MO^"U\MC]C\*_$+4;KS.5MM4)DGG?_CXD?/&!_P`LU]Q7ZZ?#KXKZ7XYLHVAO
M%25@&,<)W1X/0@^I[^E?RY_`[]FG4/CYXGMK2U)T./6"?LEP`MQY>Q7+_*77
M.=F.<=?:O>_V3?\`@J%XN_8E\=0Z'JE_)XH\.Z7*'D5A'9A`2S-]V&1CR<=3
MTK\^S#@ZCB*]>KD<TW%^\F[K;["BGI;\3IHSE3TEU/Z38H5^SJ4Y+<_6FPPL
MTAW2-\O\';ZU\B_L8?\`!43P5^U5I\!L]46WU-(ED^PB&=\_ZL`>8847EGQG
M\:^IM%\4P:[%]HW>5+C:J8+9Z$<X]Z_/Y8>K3BJ=6#BWW33T[FU:C*-F;B[I
M3M;^=)Y'V8;@6"CKBJG]I2P0J9X_+C[R;LY_`4'6FD4M`OG1KUYVX_,57.FN
M2^OD<<JB3V/RC_X.G?V%$^/_`.S9IOC#2-,@;6/#INKBYF4*)"I2"-,D\\`=
MJ_F3%I?S7EU9\>99EHSN?&TJ=M?W:?$KP)I?Q+\):CH>L6JWVDZU%Y%U"69`
MR@@]5(;J!T(K^7W_`(+I_P#!#;7OV./B!J7C;P98FY\&WTCW4Z*T42V61--)
M)F2Y>1\*H&`O/;THHQIPERU$]>O0ZH^UY6X.WWGRE\`_^"@6K?LX?!J;PUX=
MB%GJDVH>=<7$,CH[`PI&^2.#EHU-?:G[6G[>$MA_P30\"S6>J7=OXPUNRT^^
MGECW;W(?Y\M[U^3-O'+;WQ$#[YC\CKC&>>1DUV'C?XL:YXL\,Z1HNJ,T=MHE
MNMK:9*-Y48.<?*H)_$DUX>.X5R[%XCGJ0BW>^MM?70^CPG$^,H4/9N[^]_J?
MH)K_`/P4D7XM?\$RKWPW>WTR^)[&.V5ISO,F3J*R'YCQ]Q<5\W?"#_@H[XF\
M"?#S5O`?B2ZFU;1M0B$;+-,\@`,AE/`XZD?E7S1;W5P]K=VMJWVJ&Z*^:<!-
MVWD=?Z502">[N!']^9N-O`_6NK`\.X#`MNG&/?2VGIH<N*X@Q>+BH7:7S7ZF
MLUC-XI\:R6MK'YSZI<%+9/0NQP!^=?U/?\&S'[$)_9@_8HCUG4H5M=:\1WOV
M\#"[C!/8Z<_4<_>C/'M7YG_\$`/^"$NO?&_XDZ+\1?B#I?V?P_I-S%>VEL[Q
M2!FCFC;=NBN5<90G@J<>A-?TA>'O"]CX3T;2]*M;41V^DVD5C:D.3L2-0J+@
MDG@`=2?K7=*,JU2]/8\6LE'=FY+%'*=S<]\'M0[C[JU74B28QR+^\_O9Z^]+
M$WV>1D8[V[=JN2<I<BL<T:DW\*+$L?DV^%^:HU143?)A<<UE:[XULO#MNS7,
MV64?<V-QT[@'UKX__;F_X*P>%OV:O#Q@6\74-4N"T:6NV:'<=A(&_P`AEYQB
MDJ.)K5%3PU%RYM.91;C'SDULCMIT9L^C_CQ\?-%^%OANYNIKQ86M8FFESP/+
M5')QZGY>E?C5_P`%.O\`@L]J'CZ^O/"O@.\FAMHG:&ZN5>2%LJ[J<`C!!4BO
M*?VA/VJ_B5^W;::UX@NEDT'P#H;3O<VOF6]TLBPB1W?=LCE&89B,`'&.,D\>
M3:)^S;X'_:-^'-QJW@36%AU[0X"\]@MG,WVQ43S))?,E=53J!M`/J*_1.&LE
MP>%KJKC_`-Y/:\;.FO\`P)?$16A-(\V^$_PY_P"&AO&KV-WJ%Y]NO"7^T[`S
MR;4+$L3P.%Q6Y\?/V>(O@GI5@L<\]Y=*9/WKH`?X#U'LV/PKE?A+\=]0^#6I
M+?VL36,UQ\TD@</Y9P5Q@JV<AJ^@O#OA+XA?\%$/C=#X4\!227FELP5XU^SH
M(@82_68Q$Y:%^_\`3/V5;%8W"XWVU1J.&2>]U?M_=9G*G0JPM3?O==O^'/,?
MV,_@+XY_:(^-%GX3\(K,E]K+I;RW:R;%M58G#%B,#&.]?T!_LI?LZ>%_^"=_
MP\T/PSHNEP7&O:M+#/K=^;<++*9DC6<ET&&'F1`XZGK5#]E+]A'3?^"='P0\
MOPGIZZQXGU)"FI:H&-JQ7)=08WDD3Y"2/EZ]:^H/`LW_``FGA"WFU&'=-@+(
M"W\6T9Z8[DU^2\9\55LXQ4L+A/W<5JGRZ->>MK_D:X7!PHT_;2]Y;6OK_P`,
M36/@O1=5>WU2.PMUGG`F$FSYCGYLUT%,MX%M8$CC7;'&H51Z`4^O%ITXP5DD
MN]C*<W)ZL****T)"BBB@`HHHH`****`"BBB@`HHHH`1D5Q\RAOJ*X'XXZ!K7
MB.PL+71E9&6[1WD"!E1<,"2/;(-=_16.(H^U@X7:\UN:4ZCA+F/E']NC]@KP
M-^UW\&;/0/'#0KKUO;Q?9+P/+$8Y$5]N4C9=P\QF//7I7X;_`+4O["_C?_@G
M'\4KJ[\0:/=:OX7=W6SU..,0PS*=J`@%F/+.!S7]'_COX2OXX\9V>H2W1CM;
M6$1F-9"K,0Y;.,$=#7%?M%^&O"?C33[7P?XCTBUUC3KI"I22"*6X&U@05+@X
MYP3@5[N1\88G*W['%-^QNEOO?3^NY<L+&I:5+66[/Y_/V2?BA-XJ?6-2O56Q
ML?#GD&S5E`+>=YJO@@<X('7UKYH\+V,WB_QDMN;>26TEN&#D>A)[]:_43_@H
M)_P0.\6?""\F\2_!6ZNM0T9^9=&+W5Y>O@01J`D,.TX9YGY/W1GL:_._RX_@
M7:^(]+\1:-KVB^)FME$:7L'V=8VW9!VOM<9!["OTW+*F%IT<3C,MEK-Z+1-:
M6V6J,,56AS05G=;Z'IW[0O@9_A-X\\%ZGX)N)--O+J&PMV9F:92^"Q^4G'WE
M7\J^A/V<O^"ROC#]G?4K30O&2MK5G"4@W0QPV^PC9&&)VDX&QCCWKPVP\4:?
MK/[*6EZA=WD&H>*H=8?[*B2K(558,Q94G?\`>XX]>*P_@?\`"&'7_%-QK'B5
M+B_^V.[?8[?YIHV<JV=CCA1EA[5\_'ZK/+%4S:#4T]U&\G=]WJ=E1U:D^:E:
MWG_D?M1^S#_P6'^'/Q=2.TF\1Z99W)7FVDF#2*0,XX6OJWP-\7]#\9V?VJWO
M(6CXPX;CN/3VK^9#2O".BZO^T+XBT>&XU[1;BUO9$LA%<BV/E@9.[')/N!BO
M6/"_QJ^+'P*^(/\`9O@CQE:ZY):$A-/NKZYOIYLQD\1JPW8#NW3@+GM7S^8<
M-TU7=+`M\R2?O62L]M4OO#V2<>:HC^C2'4;36K>2WMYE:''+`YZUF^+_``)H
M_C_P=J6B:I:KJ&FWEM)#.F<%D92K`'J#@GD5^)_PV_X+Q_$7P1--H/BSP[=7
MUQ``6?2-+<-\V6ZO,#T([>M?0G@+_@X.\%WTUKI^IZ-XGT6]M]L[/J$=M;QO
MT&#NN,D=3CT%>-6R3-:,?:8B,7'O%MLEQ2ER19F_M[_\&OOP[_:9OKG7O"5Q
M'X=U*96<+-+<S?,6FDQ@2`=9%_[YK\Y/B3_P:7_&;PUJ\W]DZQ#J%KN(0QZ7
M*>,X')DK]C_"G_!=?X4>)8M__"2:%:"W_=S13:C9))O&-Q`\_ISCGN*ZRQ_X
M+)?!O585;_A.O",+.,@3:U8KM]C^_P"M>.Z%:E4MR5'?M%O]#>%XZ2M]Y^)_
MPC_X-&_C!XDUZ-=>UJ'3+,YW&72Y1_"V.5D]0/SK]*OV$O\`@V5^&?[)NNQZ
MIX@GB\0W>06\J:YB'!DQPSD=''Y5]`ZC_P`%D?A':*\(\>^#59<?O3K=EY9^
MA\_\*X_Q?_P79^%WAF7REUK2]0#<));7UG(K'@G!\_WK26'J5):0GO;5/<4:
M,[N2M;U/MO2_"UCX6TFWTZQCCL]-MXU15`_A``QGKT%6=1UZRL;=-UQ&L4(!
M!)]*_+3XD?\`!P7X0@@FAT71?%6O,H+^9IR6]S&F<]2MQP`:\"^)/_!:KXK?
M%/6X=-\*^&KZS6:-9+=KS29>A9E7=LF.?O+G'H:]6CD>92@Y)0BEO=V9S_NG
M\5V?M#XQ^.>A>$K+[7=7,3Q*,[@^W9]>*^2_VI_^"TWP]^!D4GE^+-'O[DGY
M=/C=5F^\@/)3L&W?05^1_P"T+\8?CG\1_#E]JFJ:]YD,>H);WL&BR7D?V!V.
M3'(N2(V`/(/05P?Q<_9COK7P+H/BS1]0;Q7,\4C7<0F>_DB8NJ*&`7C(R>3_
M``^U?28+A+"M1]O6M.7\K37WV'[.7_+I?>?4'QX_X*A_&C]J?3;[2_`?AG5-
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M?>QFJ5S!%X]^)FI:3\,M`UKQ1J^NB4GR[7^T/(::7:2!#EE*NT?;C=ZD5][?
M\$^O^""FM^)+"Q\9_&F\O)HX85GMM&2:XAN[<;4D6-XIX<``[E*@XSQ7M8RO
M0P$57Q%DGKRKOWL>=*M[9>[^)\6_L3_\$S?&_P"WK\1IIK.RFTGP1O+3:K+#
MYD(_=LR?=96Y9-O'K7[Q?LE?L9>#?V6_@K<^&OAJL4%P%'FW+R2W'F_OY9%X
MD8D8\QQUY_*NQ^`ND>';?PY-X5TG1HM#TRUVQP116\=O,%&6^?:!DY![=#78
M_#7X82?#W5=29+CSK.Z$7E*SEG3:&W9X`Y+=J_-<ZXHQV<3A&F_]G=UHVK6V
MLK[^?W%4\/2H<SVGH[::][B?"'3-6TO2I(-6C96#$C*``\UV2J%'`Q]***\_
M"X=4:2I)MV[[F5:HZDW-]0HHHKH,PHHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`*R;[P3I>IZO'?7-E:W%Q%D(\D*LRYZX)&:UJ*SJ4X35IJY492CK%GE
M_C.R\2:E\1_L^FEDL=W.Z1T3_5@]N.N:\'_;<_X)Q_`W]IY[K2=<\-Z;H_B"
M>(*=2TG2[&*\)*@+NE>)FX`X]*^R*Y75OA'INM^-?[;N%$DV%&PIQ\HQUS6-
M"IC<%/VV#FW)ROJ[)+K8Z8U*<[*HK)+IU9^#_P"U#_P0M^*7[+%Z=:\)WLGB
MKPG9/]NALC=2W=V0N]\>5%`J_<15X[MCO7RWX*^*>O\`P@^.$DGC/1_$VAVF
MY[80/8S0J',P`.V3''RL,^U?TN_%%->;Q[86FD-(EFR1)(JRA`!N(/Z8KS/]
MJS]DSX2?%:QM;'QKX.T2\U:[MT9[Z2T\V=7.\%@PZG<S-UZFOJ_]>J5>E+#Y
MDK*+2<[/3TV3^\CV-2$HU*;U:V1^#WP<CT7Q=^TKXJ\6->60M(FNO*6[E16.
MZ(D<'W]#7-?L8C5/&?[0[>,M0NKB"TL6S(1*PB&^VFB&=V>X'?K7Z2_M"_\`
M!MEHVMZ7)K'PY\5:A8S:@1.MHUO!!'@D<99L]*^1?'7_``2O_:,_93T_4K6+
M1[/4-"U(Q^9''JT!4>65*\*23\\F?PK[2GB,MQ*E##UN9S27O+E_,/K%5QM,
M\T^)^NP^"/V<M!\20V]O>>(/$%U>0//(F]E$4F$^<?-]WCDFF^%O"%GXC_9_
M\/\`C37+&TFU!O$#VURHB$A>W1-V#N!8CKP3BN*M-8UKP[X;MO!OBW0KR2/3
M)))(G>)WV&5MYQM&.X[U-<_'^WFNM#T!H9]%T#3=02[N8HHG9;I/NNK`C.&'
MIZ5%/)\SJ8)4<-*W+)NZ<=OO#ZU2YKS1UWQW^`&@VWB'PMXK\*6=NVBWMM:1
M:G:P0Q@).[O)*3'&N,A-H)8Y[&O'?'#:2OQ>?1;.UDCANKT;-D`41IO`V\<#
MZ8KT/X&_M-:9\(_'/BBSOV;6?#>M37EQ:QSHZK9>:ZK'M51GY$7C/K7F&M^)
M]/U7XNZAJ-I=RK:7&J"XAG$1#01[@=H![&OH,IHYC'"U(U*K<DG;;L*IBL+?
MX5^)]+^,/V</"<WBF^\/S6XLX=/94:X,$4;-E0_WBN#Z=.]3^#_@[X<UF+P?
M>0:#I]UI-Q<W"O)-91LSA<@_PX."*\Q_;(^.`\0:W'<>'=>O9(;TLT[F(QD;
M?+V\$<]#6W8_M/V/@/X)^#[?3=0N)I_#MQ>3R6OE,JW/F2$@,<<8R3Q7P]'`
MYY.I2JSJNTK-_#W.FCB,*XVY?S)_V?-#\/:CXP^(^A6%O"@ATB>2WDGB1&CD
M,N,(>V.V!FL/0M<O/!?Q2T";^U=0FMH=6M["X$4Y;8@F&_@'H`._%0:5\9/"
M?A?XC+KVBVLMU]M2,WEI]EE5)3NW.I.,X)XS5;^TM6^)7C&XM?"7@WR9]2N6
MNEV[XPCN^,@L,<%EKV*N28C$UJ\J]G#3=K_,SC6IT_@1WW[1GQ,;P)K6J:'H
MS7/V/QEK":K)+?`QJPW["5*D`C'J#]:J:K\?[?X&>*V\/;;>\T60D-L_>8VK
MN&`&"_>;TKTWP#_P2,_:(_:UNM(N=<TZTATK2K86UL\VJV^43A@0I8$8STK[
M"^!?_!N/X6T"S77OB)XHU'59;<?O+,VL,T0+!EZJV3R5/X5P.61X.A*%5KG7
M9-_CL$L15GMH?FOH_C:X/BG7-%^&GA77-=T3Q2D,,,$>E22M;>4NYCLA^5=S
M[^QSCUS7U+^R'_P0;^*GQQMHKCQ]KUWX>\'I)]I>TM]1EAO@&;YP(IH"@^4\
M9K]7_P!E[]E;X5?#C0+R+P%X.T/1=3M%4_;+6T\J8EF<C)/H&8=>AKT3X0+K
MMQXFU2WUQI&A6#:JM(&!^;`/'M7S6*X[BXQHY73Y(SO[ROT[O9:D_5W'F<NG
M?<\6_8G_`&`?@Q^SA8W&F^$?#MC?>(K.%U?5]2TVS.H"1?)!(FCC5O\`61JX
M/]XD]<5[3\,-!U_2?&^H1:M--<6+O(80\K2*J\`#G@=^!72>%_A38>$O%MUJ
MUH=CW4;H\87Y<LX<MG/7@5U%?)RIXG%2C6QDWSIWT>C'*M"-XTU=-==T9NG^
M$-/TK4WN[>UAAFD.6*1JN>,=A6E1179&$8JT58Y7)O5A1115""BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K#\2_#_3O%>IV]U>0
M^;);;=GS,N"I)'0CUK<HK.M1A5CR5%=>949.+O$X7XQ_#FX\::3;PV+>6\+*
M`<!L+N!/4CM4?Q&AU+X>?"M_['GVW%DJ@.$7G=*O9LCHQKOJ;)$LR;6564]B
M,UQU,O@W.I3?+.2M==.QM'$-<JEJD]CR_P`0^%X]4^&-QJ7B;3#JEY%&S.AG
M,.1NP.4..F.U>*WW_!/KX&?'[PUJ&M:]\-TE6.*3?G6[Y=Y4'(^25<=3VKZX
MN[2.]M7AD7,<@P1[5#:Z-;V5@UM'&%A;.1ZYZUM2^NT:L94*SBDK>;?>^Y7M
M:?(TXZW[O;L?`&F?\$4_V7?B9=7:Z=X'AT^XAB<2D:OJDVU1]Y?FN0.K#D>E
M<\__``07_9QUC6XM)TVP@L;[8QR)M2E.%Z\-=8_6OT0\)>`]/\'?;OL<6TZA
M<R7,A+%LL^,]>@X''2J/ASX:V^@^,=0U=57S+R1FX<G`..V,#IVKNP^?9_24
M/W[NW[WH3*&%;E:+VT]3\_[+_@@Q^S9I&I7&CZEIMO=7BE0S&XU.,MQNZ+=8
MZ8[UN2?\$5/V6_A;KJ6-QX!AOKML'=_;.JQ;N-PX%R1T-?<6L?#&WU3XB:;K
MNV/=9B7S`7.6WQ[!QC!_&KWBOP!I_B^\LYKN'>]DY="&*\D8[=:SQ&?9_6I3
MINOM)*/^'2_Y_@:0^JQ<=':VNO4^9[[]@/X*_L[:-;WV@_#A06QL(UN]X.W=
M_'*WI7L*>&QX/^&-GJ7AG3CILGD),\(F\[$?E;B,R$^BCIGBO2-0T6WU2R6W
MGCWQJ,`>G&*G@M8[>U2%5'EQJ$`/H!BN&K1Q-6<_:5'RM:;73[WW(C6@DO=U
M3U\SBM.TN[^)?PO1;R3RYKR))D)4':=OMCUJ;X-?#^X\#^$A97S>=,P7>VT+
MN()[`D=Z[)5"+M4!5'0`=*6IIY;156->6LXJUV]UYBEB)-.*T3=[&'X/^'VG
M^!Y+@Z?#Y*W(4,-S-TS_`'B?4UN445V4J,*4>2FDEV1C*4I.\MPHHHK0D***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
2HHHH`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#2;URCR@$``.`1```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-]*PS`4QN\%WZ'D5M8L
M];^L\V+JI0KJ`\3D;"U+DY!DNKV]IYT.D;DQ''AN&MHDW_=K*!\]9W`];TSV
M!B'6SI9,Y'V6@55.UW92LI?GN]X%RV*25DOC+)1L`9%=#P\/!L\+#S'#W3:6
MK$K)7W$>506-C+GS8'%F[$(C$]Z&"?=23>4$>-'OGW'E;`*;>JG58,/!#8SE
MS*3L=HZ/ER0!3&39:+FP]2J9]-[42B8DY6]6_W#I?3KDN+-;$ZO:QR/$8'RM
M0SOSN\'GO@<\FE!KR!YE2/>R00P^-_S=A>FK<]-\L\@:2C<>UPJT4[,&3R"/
M/H#4L0)(C<F[,6]D;;^X-_AWBR/O!K%GD/;].N$=.0HB',=$.$Z(<)P2X3@C
MPG%.A.."",<E$0[1IP)")5$%E4@55#)54`E50255!958%51R55`)5D$E60LJ
MR5I02=:"2K(65)*UH)*LQ7\E:\+Z%7AW_?MGVLEL*:!B6AB(>_[I68IN<ZYD
M`/V4`E;Z>P?XKKV%0TFC1A66O'L^A)7N)G^LPQ^#\Q$[$@%V!_AJ.;2[>QZ%
M(*0:5DV'=<7[RA&[&;L;_N@>0-LOT:#7>/.N/S/\````__\#`%!+`P04``8`
M"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^U
MC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B
M(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA
M:-&3&:AEW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[
MRW;E0V8+J<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*
M<T#KZX$NGVBI^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````
M(0#LIW/&LP$``)L0```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@
MH@0!**```0``````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````"\F,M.PS`0
M1?=(_$/D/77&?:.F78"0NH7R`5;B)E$3.[+-HW^/52"A4AE86+.)9$<97YVY
M,YEDM7EOF^1565<;G3$8I2Q1.C=%K<N,/>\>;A8L<5[J0C9&JXP=E6.;]?75
MZE$UTH>'7%5W+@E1M,M8Y7UWR[G+*]5*-S*=TN'.WMA6^K"T)>]D?I"EXB)-
M9]S^C,'69S&3;9$QNRW"^;MC%T[^.[;9[^M<W9O\I57:7SB"OQE[<)52/@25
MME0^8_V6XZ<[BU%0S/AE,3`F5@-C5`XU'$#IB%E,.CYX2`UY.BWYZ0H8$^H,
MH0D2$)-(;]6!2K_UY5Z!LID3JYECB0)!K`8$*H<:#J!TQ)28CIAB=*ASA:<J
M:I_I2^CWJH(9RB:\,TE?42)%Y2QCRLEED]]5LM8#G7X+4T'=^-"^1^T7U"Y`
MC@9E(R8Q[?*/8A(3S#?4;0_M>D"M!E`Y@GJV$?AP$W7Z=)6TJGCR-GQYN*'9
MG&UCQ@'J+@QH%X:H7?@?905+C`YUD:,U3HT&)0/4:`!E(\@G+734$E&G8N>/
M3?A_T'][?ZZ_?<O/?BFL/P```/__`P!02P,$%``&``@````A`!BYU_36`@``
MZ@@```\```!X;"]W;W)K8F]O:RYX;6R4ED]SVC`0Q>^=Z7?PZ-[8EB'_)I`)
M23K-H6FFI,E1(VR!-9$E5Y)#R*?OV@QF`<.4$ZR-?WG[]JV<J^N/0@7OPCII
M](#$)Q$)A$Y-)O5L0/X\?_]V3@+GN<ZX,EH,R$(X<CW\^N5J;NS;Q)BW``#:
M#4CN?7D9AB[-1<'=B2F%ACM38PONH;2ST)56\,SE0OA"A32*3L."2TV6A$O[
M/PPSG<I4W)FT*H3V2X@5BGN0[W)9.C*\FDHE7I8=!;PL'WD!NC\4"11W_CZ3
M7F0#TH?2S,7&!5N5HTHJN'N11`D)AVV33S;(Q)17RC]#>RLZ^$5[E)[6OZRM
M>)%B[M8/U67P\2IU9N;U3\':15LE(&#>W'J5F<_A?A1%[;4?0LYRO[H(^!#Q
M&P?A[S2?@6[:6SG";G3&[K67?L$>]-)]:6"$M>L/T%E,`GLIX8M]R.):.*;<
M@HE&R8R#16S$%=>I8./Z4<=N*T2!GM<8>AP&%+1JZ!GB-([OE3/VH*H>NF-F
MRFY-@3`]1.D=5+-%X0Y1P/W6FOXVY=%XP6(VEC,M(8)<>W:3IJ8"J_6,(0J%
MA6DQ331P2PV&LK$WZ=N(.[`9.H%5<4V",>8"8<XZU23PK%)\8BP\_"X8+"G[
MY7-A$2:!T+5JSCLQ/?;;++B"P/R$#??R<UM*@C-ST<GH+SO*C<I@\=C]WPH"
MB&50)"..MAG(R2?(7RJ%8Y,%:[XOL+E)@CD[^3T\)!R\!$<FWDGPX3%M@'!J
MXIT('U8$KK2K$&\HVDGQ81#8L@9M*#HRR""B!25XR>/N*._="!"Q!N$MC[O#
MO!<$(M8@O%MQ=YSW@D!$"XKQ=D&Q=0X>'C^>6GVHM_L%Q5$@/#6*EPR*HT!X
M:A2O&A1=H+TG!TXVQ;L&11>H^^Q@=P)YG6"O:7>P.\\/P'C$Z6U8W>0Z;`8*
MK\*4JQ3>T?5'\Y+K]4^7'H:K?U.&_P```/__`P!02P,$%``&``@````A`-&&
M>P]S!```71```!@```!X;"]W;W)K<VAE971S+W-H965T-"YX;6R46%UOJT80
M?:_4_X!XMV'Y,-BR?74A2GNE5JJJWO89X[6-`JP%.$[^?6=WUH8=;G+Q2Q*8
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MVVI/XOI;4^S_*&H.:D.?9`=V0KQ(Z+>]O`4/.Z.GGU4'_FJL/3]DE[+[6UQ_
MY\7QU$&[0ZA(%K;:OS_Q-@=%(<W<"V6F7)1``'Y:52%'`Q3)WM3O:['O3AO;
M7\S#R/49P*T=;[OG0J:TK?S2=J+Z#T%,I\(DGD[B`WL=]Z8F<9"0JN\IZ[+M
MNA%7"X8&EFS/F1Q!MH+$M\*0QKW4CRJ%$F62KS*+R@5%M-">UVWDKIU74#37
MD`0AD6W=(<Q$I#>$;`2PNU.$NBE%'SKX8^UOC.1#)J,%62\90SS":(R(^B0&
M1Y!NR/%S;A(,$S"0(B(K)P@)5/^EPNG@AK%P\,C"$KRQH:I[#R+?+#E!2*QZ
M&/J1&4TQJF@9+&"(IY<OP81%8*Z3("14+%C(8C.<&N'8^Z`G"Y.4'.V?SXU\
MB)`+S=43A""Y(!I,A-H+Z3#,%@,)#<5@(TQ73(()J04AA1`DM8@]$DZ'83\(
M>T$-4O)U-3"#SZ=8@LD4DW%)$#*8XL$-8^'E(PM+,%&CKT?U($%(H.?'E"J]
M!:G/,#"5Z>4K-*&Q-%=*-$;/<<0\8HJI`5BRN-^-ACR,N/3GC5%HDUE,%DXT
M1@^Q2[TQ->(LC'N!36+2(2=/#$,_'?I/W.]=[)S&8.L6A'9J1`?>99*27CF=
M%#JK08JZ,4,,JN7!.YMN+P/`W#CH#<VD]I!=L[%?#R9$ZX48I#9C0>"/-#,0
MD1_WY$UN#YFX_/HANS#NB];<$*.W(2/ND.H4.MQ'35;$Q7\R^F/[CJE]LZ%!
MSYC/""`E`"_HQ\&D1CQ\V@N&C<U\T!$M'&)0F6!!=$UUBEO/PX';FP0?\G.&
MYFQLA+XIFAAB[BNS,3<3X;*/7H",>/Y$]<;F/_`F31(Q2^7^,_@B)QZ3JJ4W
M]ATPF$Q#/X^\$*915$\1^Z4O!HU!'2//#RA%`Q`NP[C/8%(D;X:)%/%3>]CJ
M);&-Q$.,WIT!":=&>/;!#H$CV0-.K-"F<$NB2Z(Q^'TZ8Z'KT<U!$#"`5#H\
MY>$IJ.+-D:>\+%LK%Q=Y@F,P-O>[>+I,X'2ICF+./0"'NW-VY']FS;&H6ZOD
M!WC4G4?@>`T>#_&B$V=U"MF)#HYUZL\3'.,Y?-*[<P`?A.AN%_)[Y/Z/@>W_
M````__\#`%!+`P04``8`"````"$`$4'IF<L(``#B+0``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6R<FEMSXCH6A=^G:OX#Q?L!;#"75))3#9)UJ9FJ
MJ:FY/!-P$JH!IS#I=/_[D2S92'LQ7+H?FL[76]O>RUOR$M'CGS]WV\Z/XE!M
MROU3-^D-NIUBORK7F_W;4_??_\K_F'8[U7&Y7R^WY;YXZOXJJNZ?SW_]R^-7
M>?A>O1?%L6,R[*NG[OOQ^/'0[U>K]V*WK'KE1[$W__-:'G;+H_GQ\-:O/@[%
M<ET/VFW[Z6`P[N^6FWW797@XW)*C?'W=K`I6KCYWQ?[HDAR*[?)H[K]ZWWQ4
M3;;=ZI9TN^7A^^?''ZMR]V%2O&RVF^.O.FFWLUL]J+=]>5B^;$W=/Y/1<M7D
MKG^`]+O-ZE!6Y>NQ9]+UW8UBS;/^K&\R/3^N-Z8"*WOG4+P^=;\E#WHX[?:?
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MI6L3VZ"^!6Y7IN^:KNYAMCPNGQ\/Y5?'+`RFK:J/I5UFD@=[#=N]0_/I>JWM
MY__7SJ:/;99O-LU3U\AMAE=F#OYX'DTFC_T?9MZL?,S<Q9B_@YAI'+,XEV<6
MQ[`FQDXE>W&.B9-X2-X,"2]-THHFIDDK*5!XG=%T$%])GXF9G*[4-ZJWTIM)
M$4E_?L%H%+;15N'F]N8.F.N=Y)R2NA<N9CQR3V0P3$^W4DO'SB5)XY(XQI"(
M'"-&TV&<19R+&<4Q\EQ,%L>H<S'D6OI<S+C-$ST$L]3=\1!L]%/7I`\TIVWN
M8D;M@UI0P"C@%.04"`HD!8H"'8"H8K,L1Q7;&3\RR]GE]K.CS,H054XF[]S%
M!)53P"C@%.04"`HD!8H"'8"H<E-D5/GEBFTT?=9D^LQ=3%`Q!8P"[L"TGI%)
MF@Q'@_I/VYWUO,SI,$&!I$!1H`,0R6!>CI$,S9)_60X[BL@Q(XO?W,4$<E#`
M*.`4Y!0("B0%B@(=@*AR\WZ"RJ^WOAUUK?5=3%`Y!8P"3D%.@:!`4J`HT`&(
M*K>;C?`U?_E9VVCRK*>T]5U,4#$%C`+N0%:W?FIL97:V]>DP08&D0%&@`Q#)
M8#S8'3+8:"+#C+QAYRXFD($"1@&G(*=`4"`I4!3H`$056T\7E7S;<E\/N];T
M/B@H'@@#PH'D0`00"40!T2&)1;"N[/;V3YR)BU_SM/]]4%B\&W8B#&*X)VX.
M#$>SZ>SL'("!`H@$HH#HD,2*6(MTAR+.446*S(@+G"<NZ%3_`@@#PH'D0`00
M"40!T2&)B[?6*"S^QCGA'-5E#Y2XH%`$2AC$<"`Y$`%$`E%`=$AB$:Q+"D6X
M_$I(G*F*.X#X[KD/\BM\O;S'OF;A(T[R,"`<2`Y$`)%`%!`=DE@,ZY7N$,-9
MJU@,LIF9V^^`S.OC5.H""`/"@>1`!!`)1`'1(8F+MW8I+/[&Z>!<UI7I$%BQ
MVMDN$DH8$`XD!R*`2"`*B`Y)+()U3J$(5Z:#,UIQ!Y"MZCP)W)@OGA(&,=P3
M-XD2MSV(9U$.@P00"40!T2&)U;`&Z@XUG-^*U3AMN.O:YTE@RKP:E#"(X9XX
M-<[OE6"0`"*!*"`Z)+$:UES=H8;S8K$:]%N")#!L7@U*&,1P3WQOG%E@<Q@C
M@$@@"H@.221&2@WEY8E2AU,33;\X\$'!4@F$`>&>.#'<7H+,$Q@C@$@@"H@.
M22P&-9:W[:73,P9S1@VF#PI%`8/9QIR^D#)"Q"KP-JCYZC`'(H!((`J(#DFL
MBVG^:,;<J(L=%C=+-J`[KM0%A;HXXAMAEB3&4\<:,!C$@>1`!!`)1`'1(8E5
ML4XP7$=N5,492%-D^ZUC-J#F.Z4N<^&)4Z7>9E!-Z!`.27(@`H@$HH#HD,2:
M4!MZHR9G[&A"'5CJ@L).H81!#`>2`Q%`)!`%1(<D%H':3RO"]2^F[._DS'0Q
MC[%MC-$4UE:PH7[8218&A`/)@0@@$H@"HD,2BW#.AMI?15UYP3@_&<\.NC%)
MJ>E<`&%`.)`<B``B/?'OZ$$Z'N-ZI&"8#DFL"W6F-\X0=*C9`&8(]:.+E!(&
MA`/)/?$KL'L7DR581#&323)#621D5D!T2&*AJ&F]42@TK]F`6OF46M4%$`:$
M`\F!""`2B/+$R9L.1]/,G/$@^NIP6*P+M:\WZH(V-AM04Y]2T[H`PH!P(#D0
M`40"44!T2"(1[$("[][K2VP][-H2ZX-."^H""`/"@>1`!!`)1`'1(8E%^#V[
M.D2[F@WHAL8'A2*`7848#B0'(H!((`J(]L0O2>1;UE@5:Q_OMV5#YSKC%P]]
M^_J@4!4W[$08Q'!/_'R?):,)3/<<1@D@$H@"HD,2RV+MX6_(XEQE+`O=VPRI
M]5P`84!X2P*_,R**YVU0L]L10"00!42')-;E]QSK$!UKEI`U?.Z#3LVQ`,*`
M<$_<[Y13LS?`-VL.HP00"40!T2&)9:$>]K)M&SI;&K5)0K=Z/BB4@[I9!C$<
M2`Y$`)%`%!`=DKCX<][UAK>+LZ67#?P0O"L0!H0#R8$((!*(`J)#$HM`C>J5
M#CAC4!.ZK1U2.[H`PH#PEEQ<*&AJT0YKE@X)1`'1(8GUH'[TBAYG?&A"-S+F
M("OYI0(0!H2WY*1'1G?+>1O45"^`2"`*B#UKV]ZBT\,=G77'#G?%X:U8%-MM
MU5F5G_98[-"<!VAI>V3W6VH/4!&^2![,Z3_D>?)@3NL9WF\'F!.V'\NWXN_+
MP]MF7W6VQ:NYU*!GSVT>W!E=]\.Q_*@/0;Z41W.VMO[GNSE+79ASA8.>"7XM
MRV/S@[U`>SK[^7\```#__P,`4$L#!!0`!@`(````(0"?S4F2U`(``*`'```9
M````>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;)256V_:,!B&[R?M/UB^;PZ0
M`T6$JJ3K-FF3IFF':Y,XB=4XCFQ3VG^_SS%)D["RC@L@]NO7SW?@8W/SQ&OT
M2*5BHDFP[W@8T283.6O*!/_\<7^UPDAITN2D%@U-\#-5^&;[_MWF*.2#JBC5
M"!P:E>!*ZW;MNBJK*"?*$2UM8*<0DA,-C[)T52LIR;M#O'87GA>YG+`&6X>U
M?(N'*`J6T3N1'3AMM#61M"8:^%7%6M6[\>PM=IS(AT-[E0G>@L6>U4P_=Z88
M\6S]N6R$)/L:XG[R`Y+UWMW#F3UGF11*%-H!.]>"GL=\[5Z[X+3=Y`PB,&E'
MDA8)OO77:8S=[:;+SR]&CVKT':E*'#]*EG]A#85D0YE,`?9"/!CIY]PLP6'W
M[/1]5X!O$N6T((=:?Q?'3Y25E89JAQ"0B6N=/]]1E4%"P<99A,8I$S4`P#OB
MS'0&)(0\=9]'ENLJP<O("6-OZ8,<[:G2]\Q88I0=E!;\MQ7Y)RMKLCB9+('^
MM!\ZJS`,HE7\3Q?7$G4!WA%-MALIC@B:!NY4+3$MZ*_!V40607XLQQ#K:Z%"
MC,;DUK@D.,8(CBLHS^,VB(.-^P@YS4Z:W;G&GRK27F%*`7@#(T0^9OQ[UGL4
M(S8HI@J&;6<7P'M@6\SN/5?$+V@3$LC0F*3/UF4B<P@J/@((XG"*L+.:8*!.
M1PL3@F!*</EF(TXPA/<2^FHYN]EJX'W0!'$TU:27-1,^Z,1QAB[S&?&<;]XV
M5A,MNZ[RG#E_.M^/!_8)5_0_7$8\YYKE9&<U/==P:==SZ2N;$R+XM;P]4T8\
M)WJ)U#:ZU9R(?">XGKX^7,W[?G8@&BLLJIV(=F!P*DN:TKI6*!,',^T64)-A
M=1C$MPO3Q;/U'0SH;IRYPP8,R):4]"N1)6L4JFD!EIYC9IFT(]8^:-%V8VHO
M-(S&[FL%_X04?MN>`^)""-T_F,DQ_+=N_P```/__`P!02P,$%``&``@````A
M`.O>_Q*B`P``?PP``!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&ULG%==
M;YLP%'V?M/^`>"]@/I,HR;10=9NT2=.TCV<'G,0J8(3=IOWWN[8AP:9KD_6A
MA-SCP[GG7E^<Y8>GNG(>2<<I:U8N\@+7(4W!2MKL5^ZOGW<W,]?A`C<EKEA#
M5NXSX>Z']?MWRR/K[OF!$.$`0\-7[D&(=N'[O#B0&G./M:2!R(YU-19PV^U]
MWG8$EVI17?EA$*1^C6GC:H9%=PD'V^UH06Y9\5"31FB2CE18@'Y^H"T?V.KB
M$KH:=_</[4W!ZA8HMK2BXEF1NDY=++[L&];A;05Y/Z$8%P.WNIG0U[3H&&<[
MX0&=KX5.<Y[[<Q^8ULN20@;2=J<CNY7[$2URE+K^>JD,^DW)D8\^._S`CI\Z
M6GZE#0&WH4ZR`EO&[B7T2RF_@L7^9/6=JL#WSBG)#C]4X@<[?B9T?Q!0[@0R
MDHDMRN=;P@MP%&B\,)%,!:M``/QW:BI;`QS!3^IZI*4XK-PH]9(LB!#`G2WA
MXHY*2M<I'KA@]1\-0CV5)@E[$KCV)"CQXC#)9M>P1#T+7`>6T`MG"4K2M[7X
M.B]ETRT6>+WLV-&!W@/EO,6RD]$"F*4_\3_]`6/DFH]RD5H*:`Y%?5S':;KT
M'Z$018_93#'(1.0#0M8/U)PD@4VVI`@*_W+)!DERD2DIM9ZWF4)"2]$+B'-:
MAD:PZGJ-<A$TD.N,;,M,"1N-B57_2*_ST1>&@MA4\+H[$KQR(;W1DV?6DS4F
M4>5$46RYEX_#892>K3-40>N,?7E=E03;JN:6*HWI505A$IOQ?!R?IT%R"ANR
M4E.6[/*W6THNLN1EP8E?[82-QLR5::F769[F9C@\>VJHRTQUKYLFP::J<*)*
M8V*EZ@9%D2DZ'\+VQI,OO=$L>%V'!-LZSDVAW=$8K>.<NXKE0\P6,;]&A`3;
M(JQL-QK3FS%'UH;+A["M`\'(N=P-A7Y+20_24J9*3N&)E!>&]-OMB_1\-39]
M9E5ATX-T`R/DS2SW\AZ@!I+1M$@.RXN[1:%M?\Z;5;=+#^I+%<;69LM/\8E!
M<DB.M%RVOY$>K:9!=@OW(&U0Y`5V^_3Q%_RY:D"CZ80.,^M9FQZD_0GM67.*
M3MRY:BC+T]%D3TV4:-!0J8F4(3R1\E^#&`Z(MJ0XLQIUTX-TH>9>D`3C/RL!
M>>:4E*.RZ2.D/ANU>$^^X6Y/&^Y49`=OB\#+(*=.'R#UC6"M.G!LF8"#G_IX
M@(,^@9=VX`%XQY@8;J0/IY\.Z[\```#__P,`4$L#!!0`!@`(````(0!W.,:<
M%`@``$XG```9````>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;)Q:VV[;.!!]
M7V#_P=![8^N:.(A35"2ZN\`NL%CLY5FQY5BH;1F2TK1_OR2'DF:&;"2G#VTR
M/#,]G!G.H64]?/QV.BZ^EDU;U>=-$-ZL@D5YWM:[ZOR\"?[Y^_.'NV#1=L5Y
M5QSK<[D)OI=M\/'QYY\>7NOF2WLHRVZA(IS;37#HNLO]<MEN#^6I:&_J2WE6
M*_NZ.16=^K5Y7K:7IBQVQNET7$:K5;8\%=4Y@`CWS9P8]7Y?;4M9;U].Y;F#
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M-E@,F)`B1(_05=!A91]6%UCQ'4BK?'+2L>H,?TU[CMJ)<TPI@]S%1!0A7,0M
MVX9T(5$V1"'[4/UP_3ZTD^I"E,<$Q3>)RP&3F";4F13<()&!4%(]<#TE[;0)
MU+Z'TB;1[;!EH`28Q#0'3VJ_-A0>&0@[=>2N9Z>=.+L[Q@XP=\`N2M>KU8HB
M!$:$6:@`#"$!89).2&<NZ41AW^Y6[<1)KRFE'#"I(1TF6:1)48@`R-@($AD(
M274N>69O)TEJ)T8R9@QRP`#)1&F?RQ$0B",R$(Y:D]FLRB:/O7;B'-F)S0%C
M.:;1G<L1$(@C,A".Z_=PU$Z<(SLC.6#Z/&8JE2S3`A"((S(0CJ%*VO6)-%Z<
M94S[+;<@VY-K?8XX30M!/+&%$M4"<'7%0Y`-,HYB1XT`!/,H9ML0-@3FV..Y
M%H5ZW%_/$42"<N1J9$)O`IO,.&%M*^PZ9@EAP2.*L[&):%[U]&><IT=2")I!
M.8_*!F/>@D9.PK%(;*&\]-QGO*:%/02U4.R0_#B\D*08IL*ZC4PEME!>>K0S
M7M.31U\SG6/-9=&"LMA,<7T)I2=*6`"F"7&-A=+4PYW1G%%6D`1:5JZ/8:\;
M*,<QTR,Q@`8=QQ9*5<]X1G5&1D$9"-6$S9<\1/)A*\TM$F,H+SW7&:\9'0AJ
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M-1O),\XJ3'@RDA/GK`+(GE56<Q$AD8"!C"V4HY[4UW.$^4XY\@M5A$3`CF!N
MD1A#>.GZ<5[3-35>DX\^=.A-@&IJW4:+Q!;*BTF#?APV?09BGT1PF;4@-37&
M6VK"KEEB`/4'16(+I:JG\]6EC6&FT]*R>UQN06/"A&.1V$)Y><1A1FFUUV1I
M`81Y<8N,D87R\HC#C-+"E*?Y<DK;2P$JK3.)XQXTEA99*%6/7DQ/EMBC%RF;
M';D%X12"VVB1&$-Y>11B1FEA^*NZC(WO/K!T%"+F%HDME)='(6:4%A2"E#;E
M%[L80*I2(_F4C6LQ@,;2]F[*0JEZ1&,&58]HI/SJ%'-9$(Y%8@OEY1&*&:6%
MB3]16BX+(N86B2V$5^(1BNE\&2]VU70^]UC0#R_$=AT=#&RA+#VR,7U@$X]L
MQ$P1<@NB#<CN5V(`#0V(+92J%@`D&V]_^$DTFB4RY3<!"QH3)1R+Q!;*1\]K
MQ$<K[G3C)3#EWVX\"\*\P&VT2(RAO/1POIX7C'0R4R*GI`"R#^G"+'6?D288
M$J:I^T1:6HC9"V7N48_I1_FZ79U*<Z&SH+5Y5G5W$S)U$6P]NEWC/VQ@28OV
M[.!=.I.`8)#<IT[NN:H(ZX9[`F%H9CTZ,Z-700LF>A4)!MRF$VZ1V$)Y>41E
M!B^/J+B]VHN*_DYWS2HH$EB%3D[5FPWLXZ>T`$^)/7HS8ZZ#<-`2\]MK`B#[
MD3BY=8:EHS[6PV69ODM]C!<;FC%CD5L0/#%*0[8),2P/$QU;2/53C_A,5]]X
M,9(9*U]N08-$AFP7P@+0X<$62E-+R=4#-=5>G"8;.[D%#33O')H0!=-$%DI3
M2\3U-$%85-#QFHB^?#$G.D\!]`9-`&":R$)I>N1I^ORD'GG*V&TVMR#[S1C[
M-F)8'/L28GH.CT>'9E#TZ%#&YDZ>`LA^7>_13PO`F007#TV/V&AE>OMBI%Y9
M<ON2M5UN0?:I,#M<8E@=4^D(#[S6!"_LG,KFN13E\=@NMO6+?F4I5#H\6.%U
MJCR\%^;=H^6PH-YFNA3/Y1]%\UR=V\6QW"O7U8V^$C3P/A3\TM47\WK,4]VI
M]YC,CP?UWEJI7A]9W2CPOJZ[_A=%>3F\"??X/P```/__`P!02P,$%``&``@`
M```A`/YAJ6C,`P``G`P``!@```!X;"]W;W)K<VAE971S+W-H965T,2YX;6R4
M5]N.HS@0?1]I_P'Y/0&3D)M"1AU:O3O2C#3:Z[,#)D$-F,5.I_OOIPH#C4VK
M15X(E\.IXU-5IK+_^EKDS@NO92;*D-"Y1QQ>QB+)RG-(_OG[:;8ACE2L3%@N
M2AZ2-R[)U\-O7_8W43_+"^?*`892AN2B5+5S71E?>,'D7%2\A">IJ`NFX+(^
MN[*J.4N:EXK<]3UOY18L*XEFV-53.$2:9C%_%/&UX*72)#7/F0+]\I)5LF,K
MXBET!:N?K]4L%D4%%*<LS]1;0TJ<(MY].Y>B9J<<UOU*ERSNN)N+$7V1Q;60
M(E5SH'.UT/&:M^[6!:;#/LE@!6B[4_,T)`]T%]$5<0_[QJ!_,WZ3@W-'7L3M
M]SI+OF<E![<A3XJ=_N(YCQ5/('/$P8R<A'C&5[_!+0^"R`:`0>3_79@''Z.X
M?9CA>1?RJ4G;S]I)>,JNN?I3W/[@V?FB(%(`-J`;N^3MD<L8T@"QYGZ`K+'(
M@0*.3I%A/8&-[%6KRQ)U"<EB-0_6WH("W#EQJ9XRI"1.?)5*%/]I$&VI-(G?
MDL#OK26A<W\3T&!U!\NB98'?EH7Z<[KT)G"X>E6-88],L<.^%C<'RA5TRXIA
M\=,=\'[L"MB!V`<$AV0->0N)A-2\'+R]^P+FQRWBJ!%P[!'41$0=`O,'&GHA
M8,UT(0A&(9@N5';4-X9Q?2ON&+'H$880<&$H!.ME`:7ZN3/X$N`&ZU[V[%JA
M1BQ[R='@AA%_:<;_/"Z"0P)KZ_T.K+@:`<<>L3(148>P,P+E/33B<R$(-H6L
MS3!'C1@*V9B(J$/80E;W"$&P*61KACEJQ!+J-SW,9M2?+:!&4ZSF&;6P48>U
M)4$/#+V95B3XDBF-VOVC(8,JT3>"IMG6?N![P?(]PT;=X%=N<B<CV))B->I1
M0W2^3A\U>]0A;'.V]RA!L*7$:MVCAF#"7@Z;C;_>VA7<`6PA%/IVNB<-VI+R
MOD?H+FXQPRJF5J='/68D!_>^R2FB>J<<]C9]3WTK1V,,.;8Y+4]34T;!4-P2
MI\O1&Z@AQV[QAC$DAAR[R7O,R!W<$*?+T=NG(<=JWB/MMMCWO6^<K`XSD@.K
MN$,.HLW:\>W>IAJS:NIXZ7O;4>%HP`>9NFLKQNG&UF(W=XO1/>5[=F%%_?.1
M+7=MQC`-CJ38W=UB8.W]%\JWV@ZG2N09.*-G/SW*%+P^\XCGN71B<<59CH+'
M_=U^.&VGQOX!C'D5._,?K#YGI71RGL*KWGP-_M5Z4-072E3-H'02"@:\YO0"
M_P(X#![>',"I$*J[0+_Z_Q6'7P```/__`P!02P,$%``&``@````A`'M^P@"T
M!@``MA\``!D```!X;"]W;W)K<VAE971S+W-H965T,C0N>&ULG)E;;^(Z$,??
MCW2^0Y3W!9(0"JATM9#[13HZ.I?G%`)$"P0EZ7;WV^\XSL6>84O8/K3EQ]\3
M^S]V,HZ?/W\_GY1O:5%F^66E:J.)JJ27;;[++H>5^N\_SJ>YJI15<MDEI_R2
MKM0?::E^?OGSC^?WO/A:'M.T4B#"I5RIQZJZ+L?C<GM,STDYRJ_I!;[9Y\4Y
MJ>!C<1B7UR)-=G6C\VFL3R:S\3G)+BJ/L"R&Q,CW^VR;6OGV[9Q>*AZD2$])
M!?TOC]FU;*.=MT/"G9/BZ]OUTS8_7R'$:W;*JA]U4%4Y;Y?^X9(7R>L)QOU=
MFR;;-G;]@80_9]LB+_-]-8)P8]Y1.N;%>#&&2"_/NPQ&P&Q7BG2_4K]HRUA;
MJ..7Y]J@_[+TO13^5\IC_NX6V2[*+BFX#7EB&7C-\Z],ZN\8@L9CTMJI,_!7
MH>S2??)VJO[.W[TT.QPK2+<)(V(#6^Y^6&FY!4<AS$@W6:1M?H(.P&_EG+&I
M`8XDW^N_[]FN.JY48S8RGR:&!G+E-2TK)V,A567[5E;Y^7\NTII0/(C>!#&@
M]\WW^L-!IDT0^-L'T>>F9LX>Z`ITNAX/_&W'`R-_-,JL=87EH['%',U-<SJ;
M/PWW1>O<[9W1YR-M.ADPI#'/5)UX*ZF2E^<B?U=@-4'0\IJPM:DM-0C<IIPG
MJ)L$OYH#D'P6Y0L+LU*?5`726\+$_?8"5C^/O\%DVS::-=5HLF+3*MC,8F$M
M#OC\8,!N07\=8S:3HSBMIHWBMJ!OA"[L<878?6.QD,/ZK:8-&[1A6Q!B$+6@
MOS#I;=QJ(,H8<M(E!I:!E)C;:[#UGZF9_VU?UAQ`\"XANCR>#54\(5LL*M&1
MV3:5&+.Y?"6':E!?W+L*[X8"=<6_+PGN2\(;$GDX$560(<<?:Z1$PZ)[(-%,
M+26:`S'1IH:<V0S06`,T]BW-D^R.<TN#)H1+-<9\*L?Q!FC\`9I@@"8<H(D&
M:.(;FD6?"RGK\&!Z(.M,+66=@_[&N,'`PL!N07]',(3.U?=;YX8&)\:E&E-#
M]TIO@,8?H`D&:$*J(>.*!FABJA$7DI0\>&@_D#RFEI+'@9`\#"P,[!;TR1,[
MQY-W2X,2XU(-,<L;H/&IAO0GN*'1)_(J#V]H\-TK&J")6PU^BD+M]4"FF%K*
M%`="IC"P,+`Q<#!P6_!!+KT!&K_5M,_\`(,0@PB#6`#2#(=22/*-E84&U*\?
M5R&L%>B$HL/444VQYIII5ZEL,+`PL#%P,'`Q\##P,0@P"#&(,(@%()G%MK^X
MAKYO%FNU4J%0Z"HT8X$>IFNN$<S"P,+`YF!>U^#&A/_(B\[!;5P,/`Q\#`(,
M0@PB#&(.?M$SR=#%;QG*6LF&FCHJ--=<(QB*@86!S8%9&ZKKLX4&GB)#<1L7
M`P\#'X,`@Q"#"(-8`))]&BQ4:4)^O&IK.3;.D(>X;D2"<X18A-@-X>9-C<F"
M>D<:N81XA/B$!(2$A$2$Q"*1/63[,G%1W_&0;^/$U6SJJ*1=LQT\S%#10TPL
MHK$;PCUL5K2<'(<T<@GQ"/$)"0@)"8D(B44B>\AV0:*'PYXB&M\\R5Z2EPE<
M)'J)B=4$ZC4V(0XA+B$>(3XA`2$A(5%#I$RB6TDLMI+-9)N+WS"3[TED,_L]
M25TYKMF+'S0Q,;&(QB;$(<0EQ"/$)R0@)"0D:LC,J&_,$_8>3/I!=4<L1I"-
M986_:.R=E<[W";*A^+FM<=%'F=XTFGYV6@-:V:250XA+B$>(3TA`2-B0CT81
MD5:Q2&2C69'^@-&\II>-1F\2UNSM-)JYF%A$8Q/B=(2]NH0GO'R#=;NOVUK;
M(\0G)"`D)"0B)!:)[!\KUD7_!MY.>8TO^XCVA6N-B_K)N"'$(L0FQ"'$)<0C
MQ&\(GVC:PF0+6<Y`0!J%A$2$Q"*1O62U_&]XR;<`DI<&ZNI:$_8)]?UU0XA%
MB$V(0XA+B$>(3TC0D9MS.^R^;N=V1$@L$ME'5M1C'Z>P!._<1/E>0/31>")/
M)2[BLV(Z8_=W>5)L-%'Q23/U&=%8C::?V38A#B&N%/G6M3U)<?/2/@D;$!(2
M$A$2BT1VG^T`L/OW=YYPA$AV2@9Z7JX;4>_;AA"+$)L0AQ"W(7PCJ&E/;+6C
MS'JDE4](0$A(2$0(.S_MGAC<3'X<RD_%SFEQ2#?IZ50JV_R-'76R^J*CW3'L
MEQE[@8'X6EO"$1;EGK:$TR/@XZX!G)I>DT,:)\4ANY3**=W#I28C=AQ8\'-7
M_J'*K_49W6M>P7EI_>\1SL=3.`N;C$"\S_.J_<`NT)VXO_P$``#__P,`4$L#
M!!0`!@`(````(0`YR6SIB0(``$`&```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;)1476_;(!1]G[3_@'BO\4?2M%:<JDW5K=(J3=,^G@G&-JHQ%I"F
M_?>[0.+:R32E>7#,];F'<^Z]L+QYE2UZX=H(U14XB6*,>,=4*;JZP+]^/EQ<
M860L[4K:JHX7^(T;?+/Z_&FY4_K9-)Q;!`R=*7!C;9\38EC#)361ZGD'7RJE
M);6PU#4QO>:T]$FR)6D<7Q))18<#0Z[/X5!5)1B_5VPK>6<#B>8MM:#?-*(W
M!S;)SJ&35#]O^PNF9`\4&]$*^^9),9(L?ZP[I>FF!=^OR8RR`[=?G-!+P;0R
MJK(1T)$@]-3S-;DFP+1:E@(<N+(CS:L"WR;Y>H[):NGK\UOPG1F](].HW1<M
MRF^BXU!L:)-KP$:I9P=]+%T(DLE)]H-OP'>-2E[1;6M_J-U7+NK&0K?G8,CY
MRLNW>VX8%!1HHM3+8*H%`?!$4KC)@(+05_^_$Z5M"IQ=1O-%G"4`1QMN[(-P
ME!BQK;%*_@F@Q(D:2-(]20;J]]_3<TE($.3]W5-+5TNM=@AF!K8T/743F.1`
M[(QE4)Y_&P,Q+N?6)?E40!MHQLMJGJ5+\@(59'O,7<`L,!IALBEF?8K)+A<#
MAH#$02>8_[A.ES35F<X'>F_E+D`6OM#.VWH4F`B`XHP%_+]`#@R%')G/TG=C
M8>>`F;WO/`I,=IY]9&<'+C"8&)5]=N0Y8*Y\XY)Y#+\I8#T!I`XQ`";*8';/
MKXD#'RL[[D;`C&H2`GNI$Z5!2#BQ8:(EUS5?\[8UB*FM.XTI6!RBX:*X2W+H
M.1RKH_@:+A`?)\,'.,`]K?D3U;7H#&IY!91QM`!-.EP!86%5[X=LHRP<7?_:
MP$W-89KB","54O:P<)?,</>O_@(``/__`P!02P,$%``&``@````A`/MBI6V4
M!@``IQL``!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M
M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMT
MGR9;AZT#^A7V2$JR&,M+T@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZ
MB,0^'],X:'MWAOU+&QZ2"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*
M)9N5BO1A&,O+/"$QS$VXB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^
M04--TMO*B/<8O,9*Z@&?B8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8
ME@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`
MU#*NU^MU>[6<G@%@WP=-K2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.
MI]%*9;%$#<@^UI?P&]5F?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&
M%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`
MAA6-D9HG9()]B.(NCD:"8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY_
M_^KY4_3J^9/CA\^.'_YT_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7
MY7A9Q/_ZPR>__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD
M"!WP"'0SAG$E)R-QOA7#$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_=
M=V0=A&*F:`GG&V'D`/<X9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]
M60)5,PM*Q_;=D#AB[C,<*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-
M,J0C)Y`6BW9I!'Z9E^D,KG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5
MD1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'
M+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=
M?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JV
MY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77
MY44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29
M#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<
M8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AF
MBJ+#+5=9F]B<R\'DN6HPF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MT
MD0SQF*0^TGHO^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[
M$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.O
MA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,
M>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q
M@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I
M2+D,YJT@'NA6*KM1[ORJF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A
M0@Y5*`FIWQ?0.)C:`=$"5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I
M4!"R#V7)1-\IQ&KIWF5)LI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,
M[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9
MGNV]147TQ*+-JF=9`<P*6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1
MA/0?V/^H\)G]X*$WU"$_@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QI
MT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*
M0Y/L(&,<8[Z4%3]F\=%]</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````
M__\#`%!+`P04``8`"````"$`6@1(/GX&``!%'```&````'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;)Q9VV[C-A!]+]!_$/2>R"1U->(L5EILNT`+%$4OSXHL
MV\):EB$IF]V_[Y!#F^3(=JSF(;8YA\/#&?(,)3Y]^-[NO6]U/S3=8>6SQX7O
MU8>J6S>'[<K_^Z_/#ZGO#6-Y6)?[[E"O_!_UX']X_OFGI[>N_SKLZGKTP,-A
M6/F[<3PN@V"H=G5;#H_=L3Z`9=/U;3G"SWX;#,>^+M>J4[L/^&(1!VW9''ST
ML.SO\=%M-DU5?^JJU[8^C.BDK_?E"/R'77,<3M[:ZAYW;=E_?3T^5%U[!!<O
MS;X9?RBGOM=6RR_;0]>7+WN8]W<6EM7)M_HQ<=\V5=\-W69\!'<!$IW..0NR
M`#P]/ZT;F($,N]?7FY7_D2V+4/C!\Y,*T#]-_398W[UAU[W]TC?KWYI##=&&
M/,D,O'3=5PG]LI9-T#F8]/ZL,O!'[ZWK3?FZ'__LWGZMF^UNA'1',",YL>7Z
MQZ=ZJ""BX.:11])3U>V!`/SWVD8N#8A(^5U]OC7K<;?R1?P8)0O!`.Z]U,/X
MN9$N?:]Z'<:N_1=!3+M")UP[@4_MA/'93H1V`I_&"4\C%L7O4PEP6BI*G\JQ
M?'[JNS</EAX0'XZE7,AL"9YE>`0$^7)X("ZRST?9274%]``Y_?;,PZ?@&Z2A
MTI`<(8GO&8B+*"X@XC,D`'IGCA"V^1QE)\(Q.KM7T\@1DJA4R7D55H-#``)C
M$[@='`F&(-HS3\C`"`G-P%:#,W`X9V`)7ODP!Q/RE`R,D%2E+$Q%3(@5MCT*
MHW!Q[N_0@I5_?SPDF-#*SFXQ$0B)<"7%@K)"<ZC,++K"*9[#28)=3L*X14X(
M04XL8S&Q%XX]Y8*?Y^2$"G;`_:&28$*+G=TB+81H6IQ15FC&4,6I.'=V.,G:
M-GO/RTZ$FYDR<D,(<@L%)^;"-L<L,6:'7.:2N[W7))B0,G-&4@C!B"1&8)2Q
MN&)T"#&00SM<MQDI-*$TT4;I<>5CH%(F8DI+.]&`3(1F4BXUHM[O4$/%M05B
MLNH98G0.&6,3:M<!+C6II=8B>X<:*J]#C:HU0XS.)*<BX9CYPIA=6E)I[Z>%
MNNS0,JG`]<5.VBW+((N)N7#-R35:LX2>395>D#SE&H.)C,.,1+-P[7"<N2P5
M\J@T(UY3K:=BGBN/I\7/>)9.BI"+$'&:F`WD)G.6YC-4;$C7N3X*6A\UQJK,
M=HL[^"QE9Q>DG59!C<&41<):PBA6CIVGH>GO$B/R_L[.F^JZ5?7U$K>5FW&>
MF<6BF3D`)O@U:K/$G4W5/20CYQJ#,4LXM1>./5Y<(\9G:;Q"NQH?FFJ&,=,8
M)"86\'?>8!BS&P`GG7R6QBLTH48D*=<8+0TLC0GWP@%$"<^,!Y>:5.2[Q92C
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M8\>A2`C_P@$D42S,HG2I$=V_+[$"C^?VIHB,>FN*]A'^X@E,>\%)P//)U1.8
MD'I]=P50:!(_(Y6:'%8`2]%T+]7B1FB6R@M4>5M.Z3-$KC'VX-CKPN"SM%Q,
M3^R1R;N>.6(PZ%%D%1%E+[0/M(NKQS\A!??^E$SUG1;=7'F$8F&]KCJ)NGSS
M:K^I$T3);Q<7A7[O51FJO#VXU>(./DNGQ52GIRE!C#VXH]RQ==YTJ?PO51:H
MN,[FI<568VQ*)YV>)&.6]@H437M_3!Z/-,8>''NI%B<"X2QE56BB#*0DYAJC
M12G,3+7&_4'LJ1%>EQC1U=M+-+R@I^;A!C>NQEA1L5O<P6?I98A:>#,E&F,/
M;BFH.[C4LKN5`2YEZ,DOFJ0$,?@^.8H$J33R8D?ZT/9X820/B>&M#=Y'M'6_
MK8MZOQ^\JGN5-S(<7OB>6_&V*&?+G$L=(NT%W"*I]N!L@$N<8[FM?R_[;7,8
MO'V]`9>+QP2DJ\=K(/PQ=D=U3?#2C7!]H[[NX+JNAON`Q2.`-UTWGG[('7:^
M`'S^#P``__\#`%!+`P04``8`"````"$`F>0OL1D#``">"0``&````'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;)266V_:,!3'WR?M.UA^;VX0+A%0E73=*FW2
M-.WR;!*'6$WBR#:E_?8[MB$EYM+R0HC]]Y^?SSGV87;[4E?HF0K)>#/'H1=@
M1)N,YZQ9S_&?WP\W$XRD(DU.*M[0.7ZE$M\N/G^:;;EXDB6E"H%#(^>X5*I-
M?%]F):V)]'A+&Y@IN*B)@E>Q]F4K*,G-HKKRHR`8^35A#;8.B?B(!R\*EM%[
MGFUJVBAK(FA%%/#+DK5R[U9G'[&KB7C:M#<9KUNP6+&*J5=CBE&=)8_KA@NR
MJF#?+^&09'MO\W)D7[-,<,D+Y8&=;T&/]SSUISXX+68Y@QWHL"-!BSF^"Y,T
M#+"_F)D`_65T*P^^(UGR[5?!\N^LH1!MR)/.P(KS)RU]S/40+/:/5C^8#/P4
M**<%V53J%]]^HVQ=*DAW##O2&TORUWLJ,X@HV'A1K)TR7@$`?**:Z=*`B)`7
M\]RR7)5S/!AY\3@8A"!'*RK5`].6&&4;J7C]SXK"G94UB78F\-R9A-'5)H.=
M"3S?3*))',:C]U%\NRT3I7NBR&(F^!9!Z0&X;(DNY#`!9QV>X=GP0%STFCN]
MR"P%M82</B]&P<Q_AC1D.\G22L88=9*HKTA/*$:=Q`>\CA'"YC(.H!!.IW#/
MJ!<YC&%G;[:QM)*Q297>5WHPT`.`P%P/H!?-,5AV$1@Y(5A:R=1$,/QR,^CS
MI6>G>W##/MSEJ&BQ`^7\ZM)*8@,5!X&3V/3L=`\*2N@P8I>AM-B!&O9#L;22
MH8%RB4[/]7!&U^!HL8,3.SA6<AKG]%P/!X[%873TH7N_H/4B!^OMO-B"MA);
M3X$7./6>GIWNP>G.=W`C7$Z=%CM08R=65F+K"9K?<45=$/3`IM>`:;$#-G'`
MK,2"C:/AV*FYM#<?3N.W(NAA0?>Z(F!&[8!-';"=YCQ97W`"S;9#>]'75*QI
M2JM*HHQO=*N+X!AUH[8-+\,$KD-H?\YX"NW9C/O=!'3'EJSI#R+6K)&HH@58
M!MX8CJ&P_=6^*-Z:^W?%%?1%\[6$_T$4+MK``W'!N=J_Z`[>_;-:_`<``/__
M`P!02P,$%``&``@````A``@$#905:0``OT<!`!0```!X;"]S:&%R9613=')I
M;F=S+GAM;-R=VVX<2;:>[PWX'1)"VU`#)"7JT(?IPP9%2=.<K0,W2<UX,/!%
MLBI)UJA.4UDIB7/5,/P&]LT&/(`PUWX*^4WZ2?S]:T5$1F9645)[O`T8V-BC
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MJ4?EM/AC5:[$G^)QN1Z\'\@]7,QFBWEQNEZ,7N\4IU?EJJJ+E\W:Y`$!Z4]Q
MP!Z-;9^>3LO!KW%0B%A!P!%[\Z[XY^JZ/TI\+M![4BT7JS6S04>Y;NK^XW^L
M!G\*(_Q^,6WFZW)US9JG2'C_S1>+_E_"B_9X<0AC+A>K`7W/RM5E51R,1A6#
M\LS8A]\RUA^JZ73W]7SQ%CY698T.C8NCNFZJ5?^%M*/'U6JRD(!MWIST7+Z3
M3]&0P0+[3X:!-S[[+_M]>@X7\WHQG8QMB8_*:3D?50@!*EP7MZ,TA2%?S<MF
M/($77Q:W7YT^+K[XLC_:T;PXNUHT-:I3[Z#ITZJNB\7ZJEJ]G=1542^KT>1B
M,M36Q]4H:>N#_J`'=0TU_;\>EO55(14=Z1_57YK)FW):S8</GE0HXV2D+=2C
M_7&.YF]X0/(\F$(_S=<;A.-X52W+R;BHW@&"->HB.FR9Q2@(=+F1Z,?5186"
M0LEB.BW/%T@6R!;'Z9-VMEBC0C>/^+19S2?K9E49#6+#4FO9*>;5NC_>2VU$
ML9DRGVOS;\\FY?ED.EE/PDH-*JX6TS'J]K_^_LM_^9^__->_%T^8>CU0(Q1(
M0%\7R_*Z/)\.,(C?5PW\B)SLDWPT7U?@T7K;^R\6\]U5Q1PKQ&N^6$/AEIFZ
MS)RV2^I/N66/5A7"T`P6D)X6[/:'VL@H[='Z^C?]9Y&I(!NU(_$7=_?NWMUG
M.:L"R6ZJ[XK:L;ELUE>+U>2OL,VY__/?BH<[=^_>_0X.Q(<F0I^Q"^9V+`_8
MG\V83?B;.-:F";'N/F4@:O-\+8%?W]MY\/6#8C(W@VQT?;V_\^W#A^%/0ZT?
M`S4H!QH@7=OES5&YG*`1?<XA0\VLF1J"!25<S'!%KM#-R9N*"4:+657<GB[J
M>H!8^<OCZF(RF@QVT27'>-07>M_+/D'^0B9BMMS/&."P@PXGU:@"W-">NOC3
M\VIV7JT&KD?VS(":53DV2^:*V#ZY=;`DTQD=\/'$->#CKWU,58Y7BW$S6A>G
M`/;V)?U:RW2,`X-?6*TG>$#U)YJJZMVH6JX+#!W&CP$*#&+Y.1:LI[ZMVA:W
MD=S'VM`5V,3XIC`#.>R]OS/4O?Z^;GMCL5W=M[WBRMN?H`L."8<^<4'=MP?0
M=?-D'5#YI$=O6'5'D.1>5F;MB\5%`9'+%BB>`1!X-A_U<O+88H!;04L&SD04
M^EI"O]$\GRRNRRDQSQ;UZ2ICZW%@'O'R1^X,C='1Z<)<@#[;')7"X`/RG@17
MIO_6X0+C"Z>6KK-U46/W^P_A8GT2";^MYCC34X/#<CR;S"U.6@/2@Q&=%_T_
M^QH(/>4X$2QL<QML)R]6BUD1GL7+[8^57(N6E6XIMCX89NO__EMBW&!="IPY
M`M9J<HFU,D]P=%W@)@'?FU;YHEH7LDK]$1^5]61D7!I/IHT\5[PY>](0!'.F
MB,V4Y!.U\0^0=*6!2K(`)9%-T+!,;6RD4W,Q!NCT:DYD/S67X[*[VO)-.<&3
MG59:=R'AQMYN]:B[^K9IZ3<IJQS]I]/%VT]2TI=)2`C5)V_,>^WS^6#\YR;X
M_L5Z@>*-%O,1463+;OXJUEN,T=3PCZUNQ:\=>>#./:X`EM'$_7M)6#E3@/M7
M^T.?CE-Y?+OGI29@<Q54^(M;).X@&TO*.:[.UX5`W**W$2H[$*G#JW+.MD/^
M13D)'J5>_0QI]2'J'@LLSC%9S1R>`3N.MT=,FV..?N#@F/&1:$'Z]-&MZC/?
M`T"A2;N=_6<.1CCMM?FCQ+-P;7/4U7^M9;IBF!N"T.,&`&?[;?`;],<])HD3
M2;=FY2$9]-SPRH`G_NS-ZWTZF2-*-S\C6L2+B$8>M:`M?2X\>5>M1@K_>=B<
M8#1(GOU`1I_,EM/%=04X::QB&9A2+,E*&+0,WC@NKRT3I2W9#KL>;1-(#F.'
MQ!WLVYO)&/T[ORXN/F'U9"R`1!:%1IG(:5/L'XH)MJ0B#H5@FQXLRG5Q3MIP
M/A?/60W@17:HS\D;WR<KM_W-%X3&Q7ZQ6YQBFDC!C)2=##JF*8_)`8V([_LS
M;GCDA@3H1P8O_G16O5L7CZ;L[B"""13^\O-__UP:SZXJ<^3*^2#]\&BR.%Q=
MX\$<8]=FY:AJ/"K8(3%)QNDV84+QR\__0V:)MW_Y^6]?`J-%69Q/X-?H:KZ8
M+BZO#9+YN5A?L4WCJH:%>'`2XADFT;,_P?&J"<'QP(IZ5DZGQ6PQK48-:C)>
M-9>UOW^NU1>OJVLR\']%>H6G;Q;3-VY;1-"R)+Z_Q%6JH059&*,[PH8]<FMI
MI<@[N4`!QIQQJV*--%H62V^L+(()KTE"WUY-<!!%>-S[9CX#+&?56%$2-JX:
MUWA3^&,.M%-Y,&\GZZMB0O*&P+N;`9)=PIK559>FMZ56,UJL2.9:.,[4CZMI
M^5;T\._];[_YRL;7H%?4"O[2E"OTDK=JW)M1>J=9796SG>(%)O.*%.T*Z9R7
MW;DF9(8N-8OX"H=)>$^6/":67&@#M74[Q4C;SUXL>'9YQ1]LR8Q&8HU"AAS0
M:U=)9`!7:\6FC2O&N91'H%'93Y)F*%?8XO[>+KNB!36K17-Y952!*B.E0#TU
M#'>8CLB7=-WN96-P(\D(,K57)''%%HB1\B#'YO>Q*I$PKR[-D72DN3!?J.?F
MLLM*X>K_&<KN]54:YY)!$1O;V9"N;'T:@2W2+9X&M3`O>\2.3=:%"*N;"^5)
M"+*+*:6<"7D:^)J$Q:1(_$NPF%DG[<T7^_O[._>^H?P"A_&X\.0;"&8"S:W4
M>>NT=[@YFXS';G,HZGS5$8=??OY7)"A2X_*\8RQSP45Y%T4Y'F.')2\+90LE
M\Z(;124XOZRFUV`P>X$0$)I`!J9`;*@;J@#*8V-G163(7@"A8\N;^]9(H[/H
MR^9>59?*2Y%!+I0[$0M=6R\:R<`>*%0L5F/DJ\^)C`-U0[T)N)X@Q:+P>H$@
MB*XN.[0[MA:MB_%^4]S>__+#^T#\1:.7:]`(3<111SS<?+W:.]TK?BL9!Q#8
MT8N&5;D-"HM%<6;PB3>F9/_Y24+-,/:XMD^UL/J[XO8]IB.>V,62*"M>K!1R
MP&TV&;!0V-#E(!Q=;>#FC@R_7-FU7G7DRJ7Q[:*9CN6KDQ2K7,AF^.SX#.@^
M9-R'C%4I?X/]CBG$D#I,XN2).Q%@OG.R^$:3:Q1S$M"066;S&?:!5G=NRQA(
M`-2DC2Z7_(S]EV@9ZCJ]PG.A%8]:'MGDPS1$6LSX#T5V15[,RB1A$V#9W/8+
MAU^O;@ZSQ43;I>\TZAT6=?LK&RVA3:91';5A2*W((333E,4%N>@VHK,UO9O@
M<TI)OMA_:+E?;:=)E+FAN81T7<)E/[-M+,_?'%/]P[M6$:^V`-2X@]50$;4N
M;#\DC15D*9A3^%I-+XK3W?NLP*NM5DA!43R[$YF/4EP@'&.')XG1J73`'6<A
MZI-W.-Z*C``[K($*Y,)&4CP8S/M>(=[[\/[#^X,D3%/0+A?(7\?#_^]9^`)0
M4:[ZP_NOC(WWNY)G6)70'TT'8)I5%%1@1MF!&\Q>`R).V7W3III_E&Q864R5
M`,M-%"/7S7*))\&^7BX,VSPU0`2RR3BZTW4L9:.N++'J6]`SQ`C*R82%NFF`
MCY*)HP":_08P\<QXNHQE,%0F%QU)H`3[+86%Z?4N]6-$58"/444;=HK?'9\4
M,2]XVIP7SYX=%K?Q6+._R6O=ZSPD-XQP"$]']@9*Y](:I-IL=%E\0>L#Y:(/
M[Q/LX3YB]17_\E1.()J\G&(1S6$PI?CP_EO;SOT]5*G"10/3'NRD^>G)(//N
M:8X=0Y!2T3)C"FKKT6IB7HFP8WT%J[.)]XH#3+'\NI6F-8^[)<NM[+E7J/$>
M261A#"N*IU/<\#EZ/Q[LYAFL1Z\UE#D(']^T=MBE,A9ROV"AMF\UMN2*L]"W
MTXTA<HOCB:0ZQ,O.\CS.E[\K;KZB1,M_G4HX2%ZQ?VYV#PZ.+>90ZLS6/9G%
MX!-9@H#0$R$QT3@@M?F/[)+9U:=L<J$V$,/+,;FJ!7D@,]3(',P,XC9INVCL
MR8O%8LVCT+*2(=0J\7423;9M<><S@EKA9N\;U&VCW(/V1#W$$<Q?Y@DV14]P
M5(:"],6<+*1<"-N8Q9)<\&*NM+A<+1D"])8MD`Y:QDJ@JYU@4)FA%=X0Q*NA
M8%UWX/BFC38K8_/P:C-%\6!0ZVJYPYB,L@=<V-VW%?^/TFJ^&B\T$A'.^870
M4M2`7RO)1/;<)I'$,]G(N)K."3R;<QGZ,JKNGYMYIKL2@HWO2H+TX[4:?L@$
ML*-D*`+^AC:H![;W>LKWGG]AN@QX!50VHW[--09'^P']6/.&!9Z8/,HZ1KG[
M9WFPVHR49V?UD;6*^22/<4LG*,8$OX8H3Q:\Y7SV3ER&W%5;B]N,H/6R^@2M
MH!LO;UB>@A.#!#QJIAB[XZ`EA;Z53T?MC<R8J18BQQ.9O($GW_<:U4ZJT90D
MIT7>`MA!DN4PN,>]9<Z\8-M=;NQI>Y`A("2%"5@S&PK,P<B9_JG%JP,NZI+9
MLX%0IKR2_>/)]@3662L>&=P)5@EF">--=[($F$A`GJ6U]A->6Q#LV4Q)0:2*
M*'STVK0FV$A"=&S(-6J^>JW=3J93&)DJ"P(#3WL;)@I),*-*6'0SHT3C6"E&
M5*<@2@)08TD(+5@)^1N3PYAH=&$;X79>BR#KNI"H&>G"X,'R,L<8D]LFUL<$
MM('[:/5JO8N2S`J,E(5?Y@.``AB%V=`%.6E3Q8<;^I6RGYTNTX9@FF/#(U)J
M(%R;LVZ+#5JM3$L"?4A4@Z8%-0)7<@*QW^8<(!$3%+JYY!JK@J>NQ=75"C5&
M.D<J;K-`-E/Z6_*'D``B^T*"23GYU3@&*3N0M'/WFZ^U@:MNQ=,:/62)3J]0
MD\7EY,/[_UC.EM^!2'L[Q;/UF(P=MC/^:J83GX)4E:R_39[H#W[,\55)CZ5Y
M*1A>-7C(PV+J%^:W?&F0"$$/[M[])"YM6B[^$:LW0?'EHNP+E7Z8R212LC:U
M9''U#B-A3I;$Z;R93,>[A,QZ5V[@O'I+#DC9ATOR7T)2+ZM>E%2E+&89J&ZN
MD:X>EF2X(O:.W"?)QLL"WX[V])T:$=`^4BR5$<;H>A"+U#BG'6%4NE7NTWB&
M5:TGUB!VK87(;W=-6IS_.81K_%E,R"W+8"I))F)%ZD!*HL?K\J*";K%J*5ZL
M5$5E8\4M6XLVG7Q%C>%&^>G!U/]&B9;TMAFA+&DEJ9<=,?51]!T5PD#$28_:
M0D8*A\0V1RTB8(>]9=NZB<>M<9:O1F.>`3YI2*++"'CFD))K=W?CLLV]X!'A
M2VHZUAC30O)N':ZH(#98GB`K0;7(Q"[$,,LE;=K2N(\9_RW'K9(MG'!&:D;'
M6ROE]@)T-@/$G)7*A(/T&$%HZ">.M$O]M82,4\@/=&&=QV=DP00:;&&@PW8`
M`T"/.$XUOQGJ)CAQO\54AR08#,S8NBR)ZNQY*R@*ZU4EO82I5%9'KY&5/.4`
M,Y$/\^*"M-XLG`$S)0IB6S09A81@-VI8QL)VKAAUS4HR*,V,E8XI1X^U\F"J
M3&W<4,E_\T@G30@JQZ*]XH$+]%*P;>4_>Q//U-)#YHSN?Q.,'2ZZNMZ"YF7D
M=`3!U,@$3MMKT4^PNZM)_5JZ@%;.*H)#%P+`/162T4D5_Z5G"78](6^B4C:8
M.$VVQ)"$W4P2K+]G"`!'+Z8-B7%`DTE94`LP,EC0TG'R"YU"&%-9<=5L1QKZ
M`":[(^+^$2Z*[X6J%ZD?F(E!@)`,7E\U</_-@O";58G(D$T%(L95-4.^<K)9
MF?QNM`CL3%LRMD4<6,S(,/UTT7@!U7*,SXE<R59(HN2YEAK!`YNHU*Z@_!&7
M@**.LH=P@B"*6C3TI;Q8MGZ2N=YDTYO6PJ+L.45B1D5KO=7>T44_D25*B4>\
M^4,Q>5Y%"CF:C81\WW.#S^!FT+$B^:LL&]0.D-8A3_L06DMV<2MVU5JR1R2=
M:%$C"@^!'8$*+$-G!!:(9[R@YJ5661`.M$!F8UNHWDH=?NQKTPZMGP22T;%U
MHX<CFT5]^&ZHHR5I&-JM)+;!17[36"0V+WV@-N+LLMN+OBK($2JA7).*5I>N
M6;;$SD8RL,\C+W]!3N:*(F7(MWI""AI,6)0X]A8F('J$BEZ60(I=KPT*1I,5
M';5$^]20]`>+V;2PX#<G#[FU2`(I=8(@P]=!N(WYS"&+TEUG$'Q!BE`@P6&/
M:\Q-"D2&7Z6`R.YVG6@?6*6PDF>(YEN5B$ZLJ4Q8&"FR*,4#R9$N!(_9)27A
MF9CEFPZ`"$]AKJ@^Q!"F])_E=3P"09(EXZV4/9,H:13-D=66&M-@#14.18P*
M\(F<IFKSYN50G[WB@(A[D'D>3$*-=P!A,!VCMEY/O1@CX/%-EC?0.GLV!!WC
M]!>T1L>:^2EGZQVH3@8M%9BRN,E%1B5D`SF\?ER`$$NYU;D70RR#`BVK&\S:
M-&)!TGPX@H)Y^7$#N8:&#8GZ5/+:_Y5S<*+MTN(O\HMK3^Q_>!\#I:Y5R00S
MBKIZJ3;BDXF,%8?-94(N-N:F-CKLV'"4TDR,7E9)=291#@YUIKW!?`?<'(`X
ML=*:DV&N7A@)*]'@%+>1Z(8!+B;O3,J#/+=R,MR?9Y9-OQ>E/AOW:H)F4R/!
M/5=HD.*JE$0TFH!#1=$FT*@!//,F-SGQY^;0RPT=DX$<$>FC)4(#^X_)G&H\
M^-PJ^5\:0C9%`I07;4MJ/&,*MSO$4629E/DT!0(^E2I4IM1U4EM##@U+ZZZ-
MY0&ZHREN36]+M,/8_7'B``:%6HZF]<'C>EL>^8*]9@CA;B1)S='>)T)M)9(!
M\<'6Y$:$D$'&MFAY+TX,Y$@UJ;Z)?:X=:86[_W-H&QP>OU*3[^!A[[7K__DH
M8&O_[[]=`73]/[;6NO^+>F8'CPLKARU(3Z)8]\=XBI1_>/][G8WI__3RG`:6
M('5HP*98178U!ES]U[_H_^'VO?Y?J*\.^7^8(I5>!-5_^_;^_?Z?#MM$BTEW
MR+3T'[N]/R#%FZ(SUV?PSKVO^W\:9D_[3]"(U?_3[7L#JF'#X*D'@]EN?S5X
M$0X,_G:&V>A!8XN,[BU$OY_@,49`TETWR6VA)V.&;%5/+PQIAAP8J-ASF\+"
M&VQM2*X'N]=?=7JVO+!D4'P\=0.]75A"N_[(B^MMSYV0=XZG@`Q*#I5VBT<(
M!\,.'C<_/SUN6`S0NB-A:;N0;LY2E\'JX!I-\1+&BD9H;9^=TYYA-D^NV::3
M!^9MAK*]=L;4[['*::E#[2=\,7*U@OR?&HI!U!(#",+?-BW86W+,_&5Y04\+
M(CF8&M:36"1P)CR5[7'*D^]53"Z8UYQ&RV`R(99[\=;*>VT-!FO*(B>4'/!4
MUH65E]N*7(CQ@FC%I/S#+9+5]3*N*.Z(+:VH9X0/A/`1_4E#Q'XU)^&VX>^&
M!7T1^QS^]]_=QO+^<_%T2=J!_@//E8*W$A#AM2RX=HA2-]FML$.?+2J_3B[=
M68JRK8!H6BOM2+9.C2((N54++*QP87?O&CN2O!-KL6]]&<]Z8*>6X1ABB!)(
M;%6KJ143""6M4:HSN]<JRRD]HJVQ\H`ON$$6M_GP@5]*J8I(*VG%%K6>@1L(
MT0`-CO,C>-VM6NDNAL$+M!C9F3V%X;YW".WGHH>_#"-/#HZ/?G_PR"=F0OW?
M,?^O_JO\Q1]N?;WW]:T[/WX/9CFXS[B38E]_63V%C_[,&=6;NGA!ROQD`8+H
MUXL2C_#:?[;'[]BHZQ_/GF^=:O_N/W0FV]__!UB4UI?=D!'#G<WP%/]*\X8T
MKQ]BV,%WSX#44M!VUU2!=ER\7"S&2A`HB:`F1XL3%ZO7_`GOUEI?/;3SG]$U
M:R$P0-6<H&XHG."`[G3"8VF.H^1D5:]W)W.:2>Q?*I>H"O3TZ.E+JP!YG$P_
M-@E?*QEV5"P=$0M&*<,,41#$.JLJB%2+C95]V&+?E$"T<_]!SSUQPZHMGAV3
M2E)O$JV7=`&KQDB&C[6'Z%+@CT'Q%M`")9HO9ISV.B<C<^$/IOPD:GZ>)[%B
M-:;M-&%85C11LV2S)*HR2\)!5G9K0T\B^3-_:-"MV)$!<@XDY4++I$(1=211
MU570XLCWJ5P<`-%C0GH<*K456#\'J^\T)VE/GCX^*&(7929V71+/Z836R8NE
M3H1/_JI!G;1-Q;?N+@?P27++;@_H//LTC1"YK1G_9$]S<#SJ#UVEZ0+R^L>G
M4>%^*X7K_ZHS+%$'64O_YV,\(!7'I9S/O#5W\$RV7,+1ZK5N4=!;TH\U!L?T
MPS,<EAHCCP3.AG9GP"$HNRP#LP1VU][0%4:*(A-V2>Z9:Y&9W"#1]GKW9&A\
M3$UR='LE'2/M(`MD"4851ZT48BIGXU)VIBH&.-5HX\@;+`:[3([>;I]X$O2Y
MS[J<+:W.P1<[L@!2"!_-K*N:4UZ2,O.40RC[3E;C77F]F"1B_@65'1K]Q!X=
M-8+\S?!"_:N<-]1\5>*97WJ9T).0*540@`<#3$X/Y`TW8*#VY\HL4JCLU'\P
M2)%2-]YH='0D4O-T.("(*.&@2:&TEVE&N1]DC&(WH)+'*"#G>93-8,^I7)"M
MA``A7A>"W5-0?[ZW&`M>S342P&>DB8E,@4<8N&@;KB,W,)R*D(D7B:,8VUO9
MQ!I^HE3L"/5H-K`N#]&"?D*/%A/^RU=G!"(:06ZE/CJ"(Y%2UMV>!^)SIDFN
MZ06G)$*^5,59DE,B5J5*G#=FL$T'N*B;6W@4+*I84POFIE;.4>IG<J'*:`AX
MS!ID?8?5BG!,O9NJ9Z"WY]552:^S-B-D^#295N:]KBPLC*69PKMZ6H]D:&BN
M9&24-4OH@?BJ*9?^$*F.M9]KT"7PV!QWZ*+7@2?]2I_Y0BEK]P\DL;:%]=H%
M8%;^&6,:5-/7&Z5?9WY,T+Q@$F>-KC?R31N.%4,5G"9FI15V)6Q6OF;S8@+4
M\B?4PCLWRRA/":LLCMN0FV9",;NMWYNGXG*8<I;BC_328:Y3)NG2X]H0*CEH
M'J[+S!,8D-5P8,+02A.V-`?,:+<DX$2H!_L2L]9"Q;&QM^YZCT9V6F7DFVN1
M,66F[JDN%Q``-?L-+-`O/_^]CWX7%:/9/4<`W2&U):VG.(FH]7*%!0Z=OM[4
M>GCRLC:7#&:RZ(YA7P("<0@3SL6[B=Q[CM?5:\Z5,)7^G)[AM"QQV7<WTH0`
M::7A2!0'"!ADP]2?-6:$R0R#'>P'*Y(P!$L7W$?.BE"E?:O4%&AH1T#L>)?<
M)RNFV1+M3^'%^KL/[UEV?Y7\>@&$,RP,US8,+-=9IJD23Q8N88I^:32VLE"1
MZ\[1B"I11$Q>M)2D8N9"JGM2^\&)"WH.PLB&\TU[-B?R*A;=58-#!%O#EO?`
MV'"2$'`)1XEW+9[4)-X,O(E2$1:@P6)EQT+7M59591WB.D#GS`[W8F:.SP%7
M%FKO$"5B-RV3%M<A?$[_=L)B;5%RU:AD2F`3SAS;Z;N](AQ!CA:M;ILN,LNF
M$HG2_N*^`$2N@/DJ@)(QWX^8T?9*(H+3CE,!CS09YTD'[5PY].3(37"0N.[F
MTC4!`-@YJ-@.M&ID+"+(2Y2Z;G0K!AK<@A7'KD*>52AK)]&PN("()*&P;:K>
M3*;(!<8E4?("WPQR?53(<J,<3$77-H=A+1'76C5VUB/!_AQLH&`C51SC6KHK
M-)H=-MTB"A%1*Y#1O"?Z,_!337PL31S#XFXN+_XU!,NI`JX,H]5/!T#;:0V%
M15RZT):&BC;+RM^S%M&VFCM0^2,O0)^5[X8^_IFV('A7=,YZY5BN;[BR0EN4
MZY$6W^"'(!LRKQ@%B>U:0ZO'`N\&7O%^C*TI\%5V%I5'Y%-402+CG`;?.(C)
M4Z.Y$50R>1]/=)B,SC;VZKQ:O]69C59WVY2J%$[#.YRQ_]OFX3GI-5U):GPC
MVDZE]&J.7/$7#1.29CS,^>,`.GI-&.D/67`M^;1391Y>B%$YP?TW=-Z(J^8&
MFW.0W4'VDD%6QNZV#>"V:EM?4I47H_MPG[_L?KZT/'M9_2B<3`\=".I+X6=.
M.,+?"V#ITUMBWO0[:DR!V6@==&861@21U%1`V((5LYDH?3@8V;4,X0HTX-@N
M75Q+>T+I0":>37-_T-02.;OQ:C:_DRVN3,SV6,'IV-Z%`8RZ2']&%\9>$9(/
M>K/3%NX13%?[%4F$IB=O%X'37WSC1T$ZZPSMNY^UTCW:C[72P"UO^`""2&U)
M[C^+:78X)7%M[/F5FY:8ZL,/!E)\(@,'GIT06-,VI;"_+ZMG+9+87EEWE<5-
M>C.@<59K4HNX[!X4X1Q%WU%_ZAR6UDE//P_DIB[X1W[KAZMFV@\`R_]M49:&
M(DZ@K5L=/DX_`OW1IWU0]6S`<O&KS>-P2,T<N``S:XY23RAT8IXXEFQ7"A(E
M$L>-'/DM5(GD@R\TR.K`\$3OZ"H!$$.ME>RO?'\A5A[1M)$?&`GP5F-[5R^+
MJIJNYFIESH]U/LA'T=_/FVL8RD*]FX,1(_:**W80&!+>,(HV`\2+IWN=-S6N
MY3DI'-15&#J0A,.VN!AVT%$M>?]B^V/8'2X;*P[Z.^@G%#$,?0F*FV0`$<^*
MNV<2"W_!Q<)7T8:NH\O%?VO:K5)D`4L$D=#V!]N%V9+J%.)*7#!]6?COD*J#
MCLFC.01C52;T.#B=891_R'T%LIP==R4E)9*[D@\@P/9CE-J[;2\V*>F=>[2M
M/[M7/%5(AK+KZ+O2S#+4SD(1E#F^J4$EBP1"QCF?7<Q*MMUYFQHFS0%4BB<%
MD[RI'$\4-"@XUS&=>)*O-?E:Y.8E)/;&`"B0+^T]<E#W+><DK^<JVU5AC.RH
M"FY)C#2">DGD^XYMJ/U:VA!ZW(7,GS?M3H8.!6*3SNUX""D=_!M'XN`F&;;0
M=4O;GS0PBA1O*58C;1^Y!'S)@"*CT*@QLKY*L24^)S%VL0Q<[<DMP]KA1C8:
M![6O0Q_>O[*]'X638\RCX'/`LAY3@N0@0N'@352TL'560L@&J@CG_Y4DPSK@
ML)8CL6#GX_YU\QZR0]$B=,_VQ/2MCEVH3"'/$?R)[`C14'`D)(F_"K9.0GM"
M2,,F39&3&RJJ&-G=Q<7NDEMX6->FB'DKOK2I:ZW36C`S>,&3U`8??E9G*$Z6
MRR9,"8*CL%CAG3S3$,^3W>G@H(ENXK7Y;%&:;`M%!\?AU5T>`\ET]79L^25[
M9!>$F%#:Z%B&D*FP9CGF#P?6M!T;AFS?U('SN?>)]PQ+0:BOY_!=_3J::&T3
M5ADBV-TA>BY!^-PN=M;1$"FW/:0_^:D7_0FW$W1VL$ABG#8<6\F6HZDU`71]
M825XQE=(GAOW?!\3#@96MH%0-W82"MF5)Z$U%ZH?3?#J_2:E@_$;Q:]C?)$L
MN]^QE'Y],UE19?R"U'1/B']JKPQUT+\].CAY?'#GIY].+?,6M^J%)3E*7<`/
M?',,R5R5`_D29-ST%%]6L,).4Q>/XTU1JJN^.#HX>AS'DQ?L*&5N0[(-)O99
M)]"F#LY66]A\\WMZ,&:-!K%_+&L"F%#)CXT`_^#J_/&P[8&)LY+Y&;L9#7=2
ML-:%L%RT=4``A;&.Z'Z%ND>,L4F'K$8F!U."K8,;[MJN*BXV&9M]T7T/J_IJ
MLL3+P,VRNQ"(E86OP<WCCJ\ULD63JS>'ME4H<R89Q5$GMG%K,%-Y\ZX$Y:;X
M=J\L,1XY0)IER3YQ\,':3.4VB+Q3W,S=LW!S5=SSP("L&]T2MN2\-C:#!(\K
MNEFX%@@-UFW@-+MSLLEM)G5C?)33M53\/_9DCKN^=J^%-2]+@*,;(C!PQ_"3
M3,;-Q,O6L;71+`&ML34,EBE(MC/9.\$><GR>BR#Y!2//X0X=,XM[?$[T3"[E
MR+>GH][=_)0<_#K)DA"+_`3)8_"ANV$J'0HMF)'Y==B1A[G2C*MBJ?]#-2<'
MY`5QN945Q9V2"\XM<3*7-]:*Y\4X_)QX%I$[V-2&1SI+1:TLG\^5-WV?X]3D
MGIR>VZ=P.H9C)?!+@TNNE"ZUE1OTVHS/#1@G;*3_BYE$A`>$_0.#L0S@C4*)
MW[J:-MX^A9*,E:,)6V&#)4;);N;)3BY&0:-!_8SLZ&BU]CNMR)0F2K_]1]3Q
M`-,UWW.12,L-1D1-L4-SI)-L19PH/:;CP>MV=3-4AICL>@+2;##.2BLR]Z0T
M%5=ZPM)Q(%ZHX9?(]?S)F$TVG9H0LM`=9IEE>3$<T+ZY=!!ZS<G_<-VY9U)5
MT5VI[A"NOM).<FQ_28$AJ45QJ6[OW?5BM_4-\\J4LT;",)70!2S+X02927S&
M4$<VUUPNK5*6DX!_Z$2@[*+/A4`RKHY_P$4^AYV/-4:IH02`IOHB,>CVW6]6
M*K?@<$HIP4`F^5C5E;QCR5+.KDCLM5*UPLG4TTNY(.`S-+'H>`0YI\/$"#N?
M6@%T&Q$'_Z@`P`3O6((7P5FP=09^+3L7"T+5F,E6PV``"4\VB]R1(52L[R+Z
M09=:O466]5CG0IO@D\`Z[)"N)O0DO#QUM__YYAG"XP;9I0_.;3;CDE?GB@C+
MT.T@AG)>-'!H`Z+DA`OQR8/I6SQV7,\1OL9;.V=S[7RKWV$GG6M3-?EAQ/Y"
MV1+/[H0C[%[C3T+LV_KG9GQI5=YH835^]`#B&BWF.W??T30UL%G6,RE[3$[8
MA3JJQVG]#1LPD(:^BFU@S4F`4;'AL#4N`TP&8C^"N\3/($H$UA:#P>&4HF_A
MN\55B`]::<DG";XE/73\!H(/;(6*Y=;4WFD^TVK)JN1W;?BNH=XY!W@,3B).
MGL-`4T,MB*\&<0T;.A'!`#F-QF.CR0"CB$+#]83YML4;`.2W.0B:.OAI13D6
MUQ93I'0+>Q0'X@T@R[RBM'[7H)[SNOXQVQ:=:J/KQ?(A6Y!&5B?Q6\3&*H/N
M=6P+(]#A9='VPFEHDV&';+XXA'KIY6V3("W>4YD9UABOV#BVA6$@8O#+B8*K
MJ*(RZ1[=.VN"[P`,VP%W:_.(C!JPXPRRVO.@(C(PWW@?W0+S/UIY%H@GKJ2L
MCA^G=RS2"_PW23=$7>`4#)[`/KD$3):94;T"F>IO8DMRP^MPCHO4VMP0.EJH
M[;;7O#F2T=9+T&J&59$TM%4EEKKT3W8&%&EQ/[):]45,F*[-C!NJ313S;Y_C
M^6"X[,JHCE(Y'K43HC>Q7LTR7`B^[!`'$0+(I=F[,5_ET\)+7482#D;G:T>Q
MM"D!VD)"V84MVK-E0Q9SA'IZ)ZIN8Y5=8U2]&6QA1T&CG0SN4<</DZ-"TU,W
M051*KB&;]62TYW2:!?S'&\W.W<G-DEFTP:3Y$G[;0I4/GQE#^44W"D9G#R;(
M!"IP4U8X-=[DEWT)`C5D$'S<_]-T.->L_38MX`QGZ!6RJ"XF!G(X-8XLN<;`
M_6U\<1CKI0#KP5M'&-TVA^--6RW/!2'Q@-U.UURF9>"DV,VXZ=H@)#,NT7Z+
M=R08K@,@%K95)#?(NB(N;G[]&M3@H5H^0(E]=Z6CD@1G8X,]?-SQ]T\M%#G"
M4087\''[9K'[M(<:[AT`&N$=:13>E\X+F)GW0.8HN7[/V[SV06SLM,;SH^<'
MEFI1+IY0F#7F:I_R6J"";J/JZ]QFY.Z&A+!#]25)6L%L2HJU*%F*:5I$L)9,
M@%\:6Q--S((!=<V+`ZB<RXB8(:KWPF2(0VVSX_=Q&:SJK$4*9244UCK_D'`F
MQ&`F55<K2U]3<(_H.F,VO/-8=\H-JYC2S,V@+2'$W'6#)P:V#*"\2+SDF+;K
M<-@7`B$6YD31,?(V",YQ,*@G'JKW)25?:+J8PQ4=ZN/@'N>WN0!A/OY=>L&O
MR]6JXFHA+[SD9R3XK@@_%N>4W2[4^YOR-/)[K;T2GOF=D>9!;Q23#<LCW:AS
MH^J`N&EIU5SWX)A%X_GK%#2E7=06".@]D<<G]>HEMDUQ:!K?ZV>P9$8/%98L
M2ME-\SHG,5_B3>NU!SVG>`F4Z*=MY?A4JWYHU.G8P*!S<5BJ=(471&T\G1AG
M'XQT&JX=*V[_C@OOYX.OX/@9-V69PKG+4!K]Q/GZC#K)"<PSQ$]"VK__0B:L
M9K^WKK!-O6*$XZTCH9C@VP@.>DJVZ%"1U^1C\2$X6L@"T=2F1&_^DL_L<3^[
M[@8J?V"3&Y)N->+'J'+M[>HD^CVG+L?=0C43FZ!766^PI4!BBUJC7A8S5%Y4
MMW="+F8KWXA$PI>"#"A314":D8Z:J%1YJJ,],9Z(":6VXMQAM>0[,L2)U@NA
M$NE$YH^$])5#-5"OC(;W-FP1Y_X^8</;NZV`*>X8Q`W%*GL/NNU0[CV#G-Y(
MIU4&WX\W\";;,P@`,$T-.)^AF=3Z['5HD91?\!"S?M[8V9ZH5]BBUD^-BG=J
M$8]F"ZD0_J[_4NRACT(8SL:>F&";!3A(AUK^^+PLL*0+HLB&M$$"<4&X(R]Q
MVXC>*YY#NUX6EW.OI[M"V^/8*ZO_6`)>\;]3BS([UUE5GMC1"O>803>&"-CB
M2YT7K`-6`N`V,D5T,>5@57=1&M.8O$VV$?NKM+"%8,'93N;:F)=<.)/<F#YD
MGY5H\SM^29M93UXJ$>;,H+;FEV.#CIR`B/Q*/9>M6%J3/UY36M8@%-Q^5;JL
MW;!('3TE<F3H..9,*;[8'GLPY0[Q=?%$O<052Q?<5YXHL.R`4@YL[A\K3.J;
M4E<M(T;T@E^;LW;PY/#E<[EK^N*+Y<\0OH1Y.WYZ7&6OHY-G_IBV7OS/!F+X
M`R"_G)4J9V87-.K%5P>/_$5W<P.SW8V):F_.BF(K^RY"YB(B)9:LH'%1#H)\
MGZ[SE92;JE)\/\&@O)#VR*&=>8%R7"?$*YLZVCN6!?EMOU&$-X%!<-+3!59I
M7L>J"R]*B3<RZ0'IDJS&R<),\1ES[%Q^MZPJ7_RF90U$ZW%L1,VL,*Y+(K>]
M,`J&I2]1Q*'!0>4^@EG*Q;\<4570,4S)GXIR@^.4!D1C:BFV*@O'(AJ-VH)*
M?#T@&MMAX4&6*8T4J#8WG%6XP0=HVEN@H#5]4"4*0"M`QE;<M+B5+2,\W)J3
M(&\W/`F+(A,U&[*7%>D#Z8\[T]'`]J@(;7U2BYQI&]9M6"29.4=7T_<9K0T<
MRQZ=_;`!?;'Q=UH!ZPK-.?DJDM&AE=?:D[,T;/O](VN\)KC#TH!2&!RN"@P'
M&'1.(D5EA/KQEM8@MP-I.[7O\CTRU-3"45_;_KYC=H!G5.-IZ:9)^1VMO,'R
M\-44\I3JXQ>K[>MF_@VT0M]&`MU=LU2?M:25/]+0AQ0>0)Y,J9/N!2.0;\?A
M9W6>I+0;NTH`V?:F!P1J_["-9G)WT>KD3=B/N#+U]>[IB$9AV!V6&=-?]G$E
MW]?N!/AD6Q??R1)*"(V7?G69NI8E:98?$Z7Z78()*A@7<=9L%WV]_))VT9P:
MC=U*G`*[@"6JK-,(C8NAS]@`)=@9QN#Q#/8PK#IVU#/6D0S;6ZL!QZP*1092
ME:KUHWZD^KCM2K2[ER<3$`0H%Q%W)MRZ<-5G9P61UNXB&K(B4WW7+!L8&\7$
M$!]Z4`>R?A0OS7OBT8>)9();3B!#GH@U_Z:O`.GE2-"O".P*E?>YBOD^MY5+
M'?CGO0?WY&G*]5&>1U=:NJ),+9D18"1]^#+L_O%'[GR./IK',F!$A@0)'6X<
MM(74+"HPTJ2EKO/``#KJH6%,=ZFC01C@30$=?7WD'[;@ZFNN)G85!-?-@S75
M=VS$L\<]TG66K-T2T:A-*[%X/B;_RCU'(>QP(SLJD3ZEDX918B6<^+">?LWD
MU@[&)@L3CFX@"4Y<OMHT5!0#W]+]N^8/6Y8H[-%G!/P#23U4Y#KG".5/U1A'
M,&7GAD()B=U3B`*'M+,$)=ZDS(7C?%IE@_1TTW+DW*SUD56JL+F-C(W7C/,&
M%PE![2AT;(9^H-8&F>0I9Q[R-"(UG2[2?UA.0JFW:\JL9CI5#@DZ8!?`C)69
M6`6KN85);=+*:SH<@</8.VV;S.EW$B@Z$/C^E**WU6M5_?6_)!$[)?]_K'E"
M1_W@B-9XP[2_!F<`%'IS73_+0J<[M/=?//CJ@:NPW2=K?]K?>7B/CQ?E"$0X
M>3,38EL2XULFSR)$<RL)F4(1R*R@N^/D*6H*7/G5AM#C#`ZNCC!%CIQE)^33
M6`O,V(C5^MTTY)5POSS1<&-PS2+O\TZ\R4B0FGQFP?LS7*QI<4_8):'+C/3&
M&Q]9HM\]Q*=LNNX:)LDN5HK1IR25J\KI_Y64HDG$84RR24-OV._,:V%7=!:I
M<_ND2-ZFEV`:T'MQXV5PV3$_3&W0V)9>P9G6P-ZFXG';GSX`*EW,H7-?5B0X
ME7_8AR@]H<-=<@'<@VQ]G12FO^U_NWO>Z+M:6DMT=#0VB\M\BNP@4(S`'H=O
MB0\G;+_8H5V2ES.RKN_>DQ(V)0%]0*_A"13'<&JEV/R\&MFMWX&L;%CSCD,8
MP3G:=[H+7YYRQ]'A#I]L!3C&YC*[S>^N5/;%'&61ZY#>V9-#/[QA65(N#M[^
M56$[/:7J\NY8W`%M7(I'[:5<XK/]R`SMR9&T7[\&@5+A(!A//C3WX.$WIM`/
M=^[=[4$.;(GQ&3`!K6A.AQUPR'K1U+KD'6`>_<&9[M+ZXO<*:\+83V@15F)N
M4$<[0YV6P(/.`H8B37MR4Y7JT&?O>@PGN+K#VYI;5`!>0LG7E-,W1F*F"PU2
M`.$14%Y]]291/YJI-V.VU0^,LA<1H=PSA2<M0:BZ9:F$W$"]^AKT9:5N"53?
M`(WQR[!+[C3[5NYA@YC2,NE$OH2:57&B?MX^/\6O('I,3;@J'8E51O/ZN"%F
M6_.&\#%>,"(OUY*CWNZ1WZ,1RRZAL=$=J24`T'[>>-L,P;[#.PDM14W!L,S0
MO/CV[G^0)$B[PP10GM_X!G6JF;N%]":S,`X",N8&*^*#M7QI1F"@;*]-"7/%
MMJS#&[7@!$#HS.3Z9\C#.+IV$UJMD\B'9=<V%L?8'/XO];*$+8\?S(6RH!JB
M3-HC!-(!SR39D;$W;&KHFM".QM9$+3:FO4)^36+B]B%<_:>O?MM7!H@F*[[K
M@FD4%4"FW:69SFB`JUQ@]P8UUOX_.OQ/#Q[<OXOGW9ZR"WYU'9O59)"$26R%
M&R3YY+O+:5/OVKG`796.,;&JX:(&YF.F`P,V2VKW[[LY&V09"=[RLO0Y+4>0
ML5DB\J5X]"!!5,O$YJ4C&-;>)7U.I_5%:(]Q<%/*',IF_`X%-4@I@<C]HIA_
MVB"@63[Q\ZIZP5Z`:QSP`R0-C%,8^3N,7<'G%NW&LXQ[[7J[//&=`O'12[OS
M*(FG)"9ME@M(//F11"7RZTZV&C;-T6^S*N26,I3'.G'I:8OR<$U/M^?2G\ES
MD:@>2L*?TGE&X'I$VB3TD'3#I^`-;CL@UG:FM#W%S"BM/#@\._B.OO:W:`(G
M(<0)D_:^>H6N(<G"X(#;I;ZZD2)^82U-+1HIQJSN9O`7=WS!;?]H"7L1PW4[
M$&H8X*>3X"N]+O+-!?3>59@N!(DH&,<W1AGIW)(B:RLQ#5>)L,XT7W@OC1L+
MFC+\V!3B-:W=@HM8SNP?YAM3,M+Y4./'1FZZT.9[;[?2Y++8JX4BL++O/K'Z
M.C#U_`>-X+1^FC[%ZDVZ[`Q9P*+0+&4_:U=H%QO;+6BXBVRA=6%J*WQL;0?8
M%RM-VFB0TH4WT^(NE.=KR)HO1JZ/;"\@<,/:!CZ[V77GW)F:MKG?1?>WT0V4
M54,E\_08^6D:.4:HC%IRW$VZP8"PY^85\(JREO1>ULC02"%N'%]NAE`1N3>1
MP>'RRS:CE6P?5;P65.3W!X\`R=2[U?OX2YS60@I!HDV=1Z;:A7`M'7YW177`
MLJI::*=')&Z.D1@M)@?!I^6U=9=(P%L"S79WWH=<241<BV^N-9G0"[G%1D.]
M]Z"+FB#S#$!2S2VGQ1!+_Q!1QH[^-AQBE<BG:X,'/PF_VFC%0<UOE_*&`X7@
MK>>K4F3\N(`'W\OHF+,&"D]^M1ZL"-(I\X@5;D5$VZ8,D'X0RT(+GQ+1\<L>
M^G,'B3=D"-/XX;)X):]I%58G/0LR(V2N8X_V^%FRZ$)W3B?M%6$B?=&(`Y8,
MB)Z+&O?`13H,:(C-D-L@-!3OD6@U141*.@A#C!9J-VR`LM#XW2A_N$26TP;\
MK-O]S!NP2[WL#)MF0GWS-:$_6$3/>XWY7RJ]Z8,I$@^`M>&`ISQO\\9B*SCM
M:^E;<NFC<-#8^=*4N1#V-;5X/T^03+5K74`)(4>"<V5+\<-\F_RJ@#B9W`ZY
M&C0\\:DNXQ=UJWBIH;H"<1#C-[T"Q8:2V9U!"%+ZE)>\`55W]PJ//<QCCRJD
MQC<T)-V[+7VEH5O!-5U*;\C:B<0\@LA(-F.6OVPFH^,]L!B$7_<51?/:_YP"
M-_-"H"L"8_,TL$WZQ*(YR`A?JI.\#^$6PND#E7O78.``M.,5%^(VR)9I7E=3
M=6*T>#>;_J9>\EF^'VXMY>9QR.G6CW@=!YA0,E=\[-27_#0%AMGHN#.<*%;%
M[=&"__&;A`].K81OF6'HW?CX*VL9]IZ"TU>J^'.'RYY-MWOW_D[AA/[;G&(]
M)929<H>DV*7-/'9O-[F*CZOS=7%$)[.IZ*$:4@;D_5\Z8"NU9_=1;V,SF(')
MEPIC+45N.EH$\,56"2W!=C)\;ET:8]_/2)GZ6&FPU9Z'2@DW\RL'+67#'VJH
M$(%!24;3#5TM:FD>PP_VV,9OFU.MN83.(V;6:*'=@6P\S7.X,6M)M%\3)>R1
MN-/;KBY_ST9H93@QUJ?#Q<23N:X7*?Q+$/$[$X7D4M+)^;:22^'QDD-ME+%Y
MV>_![\)FRA-YOHOE\^S!Z2N@G3#;JE#95^-"@`L7A)K8FSI]H:JU7>Q,R-H$
M7<S//]^H7\^Q!GYOLQCY%*5)"@-%^F7W[K=4'?_;OZDNG`3?P#8>>YE'NBEO
M\V\D_9NAJ8C!>K"5$ECWP.BGZ\13T<^1&T"+C0FTEPI,XMAR-C5?8#JXXV*#
M\R!-"H&+A#D)#')C]A##HT`"CS9\Z2+,Q27?<78[W8>=9J)YC28@G?3\6K9V
M0\]E=@12YE&&S3_R:-.ESQ!+9"21F/J02P0`DLF(-+F80ZIE=8U0?9*!<?$!
M_+N3X@3-*P03`V("]D@_\LH#_$Y^L1E'<DNXCK*.#:N$,+_F@@#0*,=Z^(W!
M\B=DB%;Z/C(<@Y^11_K)?"R[!!(+:1W8CCYQ4]K-ZG1;9GG%=/80MC%>6_OK
M_A"JQFFG0F`701$_&,]6//,CK_(6."IY(8C0MYA=8C+F;,.R@&`>")N?PW?=
M(ZS)F60?G/4!_-(+'\.\KS9AWIR25L(]YP#:P)6R^&YVKE#RYTK`VFR?Z$M,
MEL4R`/9G^U@\W?;MC3FABFU9%/;7&ZK@T::'NH@+;XR?ELL,WX^)9C8E$`<@
M_'\`N>L?7Q`[4'#[W]R=V6X=1YKG7^5<R#T40,DD)<K6=,,`K<56M42Q2<J%
M@C$7AXLDMBF2X&*5"G,UF$>8R[D0&IB[?@KUF_23].__+1&1F2</#V6YJC!`
M=U6))S,RXHMO7^]$GLKWUV8;87DJZT4X#$K*Q,B\I,FVU&,.:C)_>;*CN%"D
ME&QE;M?/&W2CE3_P?SA;O#BBW0;_?_G=;UUX%S-F\OTQG74&2\<A&2JU\#$W
M9D7KN@JW3=)A8))9@''.$NX1;RV`B5HV8=&.I5\],VM,TGR+,C<O[.G\R50\
MT:7>>9(Q)']Y*_WTY=TG.UM;G@9J]7W.V3RX)`V(*]%2Z&D2O\;1""-C+DEL
MVD^F^LMI0T157PS+T11T.U[T710S3$D\)[4I?*%"D%MKRVOK#R=+_/?J@W7]
M)7],92C(JP<2;?C6P_MS7M"A;UO:3L.;FL"C#>S@-`IZ6&-ONU'I0"82L5O(
M\7E`=L@2_[U.`.QF>UM?F_/"9^]MV!5QUVP:N=J[]MDM9E@\6%O5)BY/F4*!
ML&C@T$$_\6INWXD3<,M_*).0^[;+S32Y!;,!/0%N@"Q2AMF,85:MG!&#LX;+
M;$&LOQLZ;7;,VUZB<_'?R8987EEY@-FG"02&D#A;$(.(;WW"[Y"'UM>^%4;R
M;X*6>HDD"O_W-_Q[=?GAPY7XMX<W;]V[%_]^.,=5;(EJ32@8,8'<QZ_T5TR0
M,ZH4)=J=X+K$BL+%YAH#&H(Q7_T5`+DB5YA-TE>Z;BN,!_;O+&;49\O@7[(#
MOWC95S#9FR(->&?NE.!E."_<'V[M@$P#04$C7$H@+[M9Z_Q=MM!VQ>K^0LK^
MK%TAI2Q=$VPUAY0TT`C_2U?%AX3C#>())J3<#\PZ_T6450]?>6%V%;.()`_9
M!Y361UC/LQ2#!E;-Y.(_9VTMM\674VC0Q8+B9U)3L,]TMY.U]:^\NE&#V2%P
M)59Z'XH@7S?R7BN;VV:W&U;_`6^N0H20Q;VNQ'JGYC6H(=)MT1IL"T:TLS:8
M(F.0%`PB@A3HP,$O;*OK*PMMM0P8M)UN7+VYTC'9J"%\L5;Y2_2Z#DF4QM[J
M\LJ]-7N6_,SU%:EP\VAS1EBQMV]S2N,[E.,2T**Q9BA-G";*7O:QRFL8M.US
MOE%Y7F;O(%X$C,">]H@!;[.<XP(]H\@]X_N=EGF"5/T236!7;\O'.7N?PM.7
M6U<[=U9+D106E%(U9+&X/J`OBIUF#JXXH=Z[P-Y#V$(&YP3]@K\"?=T_G?'&
M!B(ML++P$G=C;V5ASQ7D/U-<C,)N>-$!36US=:4"O(-#,_`C7G.!`DTE);',
M6'ZS!()5R596:J<'>F"3?*U0DR&"X'F&F:8R,8A8+B0XS]C>0X/J<5+;(&^%
MH$[F4-EEHE:21H]IY!`32Q3/P:'(#@RR661NV)AV6FD=H6^L:PNK*Y\^!FO9
MY7")1`T3I5K<.Y/RBO(O@BOD,:JEU&78YM@MT0K\M:`V_0'=C1BH*>^*U8>$
M&>P'<%WT3M%9S56@@"&78+'KDKL6J([@UGDP1]V*9W4[\"F;'23P=7<Y$)EI
MXT2`\@,8)*U$%]]]4]H.JZ=.TQ>K&U9Y,?CKK]$BO?_#2^\*,?AS55/Z/_TQ
M\O;Z?]\@;$$U=O_/3T(J]O^^)2'9_V,&@Y+6BKIWO__D-DQG($!Z*-)_!S/M
MTXSQQG.7PF0'?6:,)-V9H14$:O:_N_1P=3`[>-;KB?N#P2E+:_=7^HO.6F!T
MLTMKW_;?3U#WU.K^8T]A\[.H^UHJ;'3L<8/)9$&5R4U:KJ4`(5>44F!A.!%"
M1S&*`0E33//K*G/L,UJ@S<0[P4%A)JM^4-Q.U5TD>Y@20D&+ZF-X(`-:=F#?
M0;--.'`DN(98[C&IFT'!:T6^O;NZ:CN^]>W=M6]G:!IM^G)\=M85B4^TA16I
MOY="G^2Y',)\_!$<Y[[;ZJ!\C0X\UF93"IX/T'!(U?X'#D0ZS:#M4LWAZ6"_
MJ'*S:3]SI1!>UQL@<>`U`;J*64=);+L9.'U_Q3(DMF0QO";9&HQPKI6BK^X4
MSHMY:7E_E1?.W%S:0X5\I<>;]RX!+%6BBWZ_<74M]N[HH#3.T;_#P><HND2!
M]/28M+P#U_@/#V[+;=C?F!Z##M#QF3X+1]5CN5D[05]^]T#ZZ^DQ<M7&%#;9
M:=H-(9WL_]@\!.KHQU`PS/+Q[DSH-"#=`:B!GMP4N>W6IRW";O?#4VA4Y5X)
MF.-_!\0?C@Z/:<@IT1M_NO!HDB8<G;NFE76J@66HI=YG*OU0.KU=J,"RA]*E
MREKINMHW_XUB=FB\PC,V'!X#9J&@\)W7<A!U`NL2W5K'`IV<PC:<%Z?864II
MY1W\Y?#\]`[QXS,95*+9$X6.7?6+G$<U9)?[PIP9*H[JV)P%0&C?[P;Z1HKQ
M2<AMR@AJCR@=>,<$G.L'$]<J)C\H=9V-7Y[VY42Z$N$Y0/`Q.5W[W/^XP3UX
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MM?(LN?R,TPLB>(P\CRR5IEMKZQ(!MG$,E=P9)2$``"^0C#%G9X\L8%6LS+65
M/.%BXK<:+D(6\U_5B(68DCHP"3DNO+XGC]='L]:SK#O-YRS:J;R:(JJH"3X^
M/?V%4,G^+ZH(#IYN@8JF<"WUF^L5Q@&WW%0TZQ[1K$<JF]H[E3E)D$6\+@HG
M(+'2ENEQX]1YE+'M+B>Y_*X=-+G,NIG7(/U*ZVZ):IO<D9KXLW,)JD@87$S&
MHU[=C39S;)3BF8&VGZ^+;=TC\^'_?+%#&_M48=VGCS>8!?!_2W:^0E%Q-0WS
M_7UR?D:R'IZ=4+&:;M`5H@%E<VY\2C@VW'=*M&!E;?G!`YRU\EK=$965Z'51
M+$C(DYVI!)[J#H3GH9E'Z83H10O7AA#\3`-:YO2=_&5:AH"MK:P\M+9(\5II
M]=,N;&E_)L79`'%]:1MPMW-T87+4Y+B(Z4Y"P\%'LQ&[U6N?00="1!B'.M>=
MR6?%*^@YMC+*V&1'_=^LLD^;JV?W\+4W1#+#QTPGWY8ECOJWC^[^>K>!`TD;
M&`/OG/15+$X:'J%E]&WGXE@6M[[Y9GGUX2IIA2=,%MIC+.+YAT\?U_`\8FER
M#YW[.?&L/'T+YEDO4S'8W!!9(]SC^CJQHY79^U<J!,YOZ:]()NU%>FR43J1M
ML86[3TRDO0I=8O>`,R\ZP5RZX!OP+?#0X$`$Q#PS(M(#`KY[)+1CS_IMF@J0
MFKV?TG,\ZO$YQ:VU>_>7OR4:*2R()!\E*CN<>:!>-^`O><K3R2:#[O4S`]=A
MX6^N,!'40M_=:N$Y[ATZW')6<PN%I?LG(@W?'YT^.O^`/Q^OGN>3L2?[3'Q6
M,.NMR`9TST_92V*Q]E7"G=*&^&K[I?LN_2H0"H@06BBTYH;H5K[@6R2SV=1O
MCT))U<ZJNZY.!C*:`M1X\]]+@'3P3UOFM-0C=(<2ZPBM4-F8.6P%QLI39[C;
MS5(`MWX\M$$(>OW'*P*-$*./Y\;TFKRTT0J)G:C_F&RH]SP#35U*RQ)<$4.L
M>'B@X>L&2MQEF"1@LMI$;>QL;7M*@=R.@*C<5<W1*5Q.\&3(&$_U2"!KPK#<
ME&*<U:"5UVDC)`"+TI5%<Q4^A.W-#0PTDG?P5..AA1E$5QKP`N_Q.<]=(&L^
M?=P51YIQL?Z&U"YK(E:)&]C=6B6SX-Y]0^5@;+E/J[RH]0#<OUF=V2?_UMH:
MA+,N_&ISM%K6'KUXC>DH*PAMN[H/X&%"A&KTT>),`6O#,WZH$'*MC\WJ^8*N
M(EYH]^&W#WMZC,G?+S1#YV\OAUO!HH!D+2-+2(!IQB,%G51JD[_.0\$NXD&V
M>U?G;R:&4(F&&`$Y44CMMY!Z<0M#\)IYY92H7A-$2KEPC':K>#89HW=ON7@)
MOA6[=8[D-EMR7ABPQ07`Z#RG7!XLT>4O_*KJ8##+S:A;:P^75^^CL9AKJ"9=
MAK8,#6#1=)"P.:'Y#+$XI/2:"N,^0]_?FU.L(C]_LZF6'BU?VC16"$6&$T*2
MH<Z39YN/K2,NW,Y#7<;)&U7$N+K8U]'==Y1P1.UHWF&])S_]\)J0]E:CXMWG
M*]A=%J].WAI7+%J2AS9-8"#`&.#^H7S3>%/]H+;P9`\O1!\M-F9<A=2@8GAC
MARVOD%]3@G^I9OC%UAMP*\9=/2$@\\(K*`"XL/M8#2:E<F`7%:=V()&YV;[?
MV?@):1Q&2FA1E89[LZ+R._-K:^TJE0-T9ZPT5_B!6G4$<VYID$VC-&HDDNE+
M^(HT-8'MM06P@K#<K[V$4#%5D[I6!5#(N^[85)48:6@N7/"MR5'2/GJT7[5L
MW7PBF<[$O?D@4@J.+0+(XHQ%!/RE2%6O%$)QUZ&U`'`"H>,$+DM$IYMKH*F!
M/F6I-J.=(Q6-`)*)Y&GD,.RXJ]LKY0O`R-*''+Q*W[&*(_;-KJP3CB?XAD8O
MQR57H1]/^;3:HYF7+LFX.!F%F^<*@*0#+^.D96.,AI!T%7E)YZ$H!0.9-=$+
M\ID+6[;]@].^/V[QEKZ@DWM$C@E+1!("[*'=DT_(_])-*[/9I/\LN;83;8X_
M??R'Z;NS?X3AWVT:8>:O?Q\F9)HE*+BR(84&<;,B#&J-1,.`%D%!BCB(*/(8
M]$ETX98GTU4$8ML-PPU*-P!TAF))0D#6<ZFH996I@9[2L>CF?6Q+%$4#W[2B
M)QH1I.X*YG!VUMF8'Z]*P-JTX,3ETM91B;LX-T[?'-4I1H%D;/WH1.6%[EH'
MJV4U*.ZN589[=X1-D,6I`5I]TIEI';=JA10T-;5SF8.?NFL9%`G5*%IVC'Y[
M2*,Q]Y%%96;)F%%%M!,S9/0UB.DUV4KO#CXV"&_9M_/LEI_T$K)3KQNNGP!?
M>_VBS7S4RXS$(\7A^VU6==\8)GI!OP-S*@1E:.6TDU`C"_SU0BB\D]WIT7N0
MRUZN-;)Q&R*\L@=>"D8#,S2Q25"^GPP$3OUXBD_RG_D/DD_RFL5&*AH*B:94
M'M!_:'!1.D%]DM(%$A%5AZL:>3;M&#M#7)E&^P->>XJ5-;P+,CK'!^',5`9*
M\]O?!^F;`<F]DUC:WGN?[.NMF8AKCG$#.O]GG-3XAJXGS';Y#&>B+,C.LU$Z
M*8L;P:FX=-KV+E+J_67[D13=X(5M9+?A<X58IE`:G$6IIXGC:N\!W:,IK3BE
MYP]6`&,"_D"R1^*]!:)MW;S*PAF7U3:WA/1/&4^EC,ZJ2_N<Q3;9:JU:>O@D
M!*$?[.E.9$Y`NE#0+(JV\5?354NMCY\J70VQ!Q26B:%5;+4-PU`ZI\`$)I9R
M=`4+4MC2J][P?O#A:)Y3V9R^V5R*$;0$:'(M"P[HZ)W#`ADIQ%;YZU<SC"(9
M9;V`C1Z=61<>#XLAYN'*B(<?Z5'&NA>3Y]$R0<36//[W06RMG+V&X(J<!;&C
M\\0>OEK!SMBB@;;@X1LNT9PL1IW-N8M4[=_*D#JX$J[O%$RF2EPFPI;2TFF'
M<K5_?$C[5PS%+3E;W\+4C^4Z%(BW-JT@`_Q^>[0G?N]ERNAB0GF*\6V6Z61)
M*,KC+]D[NMEQ;2=I%S/&$@;G8ULHDYP4WPZC+AMT*(,(WY^>'Q^\UVZK,*_G
M*L,]6F^8X=;G=T"7U)K?]CS[H]NE`09O@P['JCU7_QX"">JB@RB@CXZNZU&$
MW>(2\#^K:8@4"Q&O><7JM=L?00;G:79>.RPG79XL@07':%-HC=DR`R`\-PV"
MH+RCP"Z?-+,QN(&JTPZ8D*@H9#!*L^9+O$L*$;94O5O[X-5Q8'!7)Y/HGX$B
MA<H:9`E*B=4\Y0M=`7^?)QR%76'VET4MQ4MQND0CKV;;)A#>R6YAI[@+_1S%
MZN4`O&J4$L3C)DJ!O#:MFXCX(0RW4;`V"LWS]]2CW(SRR9JFKD*$6H&)!OA>
MS-D3:ICWW3AZ(V<XH#DO(5Z[2;U3[J<+2=,$T/%\ZF)E(X`(H2IE7:849=R$
M7DQ[37CZ6>6KY)C/N+R9_8MTYOH)R:*T]6:HO'S#ZP8*CN8M+'DN./DA;XP3
MZ4#3-X",`\<]4#=SGP`*!YD>OU/ED%7CD`:,.`.@<GE+N-PV%AH"K.6B4($?
MJ?`^;%DO.099WA"EJ:HX5]WI$"2\`0]"#\A-M_<3U.>J#'MT-:);&J6DYR;I
M//98#(*BTACY.&H0"RLC4L]P$ZH)O[O@3C[<Z%:B.#4`;S,5L@);#F0'O'WX
MUBKU"YS@UKIS%MG4T*WWJS!DF;Z9JC6`6J]:M;_).S$:<5;?=SF46F2PV`!!
MX0V&-B8%(_6A>`(&)E!KUT,0#%658'W`Y1^HQ4[$/Y6+IM(9L"SH")^Y)VHK
M#]3J#C`@*!'E`R`_GH&@KDH[0TWF4FTTHKBPQVI#LMGI`K)"VQ3NF+L*FS45
MW<FCOQAK$V(F.MZ(D[7"07*@)8HF$%(4C#ZS'C,*).MUIRZ3"EP;'H'[C9`N
MTHEK0(N$9"6@I,2_G1XK*&W@A*C5`R7&N<TGE99(,,G3#G#))\R+NR$IHG-2
M/@1BO5.ISQXNCF8(1MFW>"FH6K=:FD]`VK!04'OIZ/:GC[J'&0Q/'\\[%Y*G
MJS(.&<="+0I%/3;:X)`$ZD$3A[;:+6H0!XJC:&_I2'NI;*S+460)=,'#-O"V
M,;71;L&6U([3:"E@"PR#\XB#UP8%3"5V]3#('38"MS:K)-*Y^()W"'&A9+]S
MVZDB%S;19Q'5;?EY?!A(*[-1_D<OKCCH^?R,JCE\TWM!9^/X"/@VM\"L'"+_
M/=*/$IK!OB,IB3.ZX56S4?W*X+55KI7X&]&;AY&U[6C(+10<I-[8RD756J'?
MSJQKP7HM(!,F4@414G#EWGF+2$:T60^!;;FAP(`&8%(^)+N*Z6>]_`8M])R9
M)['`/-41H\?=F\J3(3H'IS?)&;,PA82<3)9SIG3-@)ZI;SRAN/"[/?F+@W%8
MPPD[IZ6##:[Y):%^#&%ED'SZN(JW=)C%\=KMZS14[.8*%X\8ANBBW@C=0)@H
MZG9W_6N`%8!\#H_;)`UOBP9N-!:[F"RA5M%Q!WN.E.I"QO'%Y"B5;VRXB65,
M>IM$;&,:&T40#9B%,;[TU"3C,RO@:RR`63"4WPGXD1T$_)@_T7*V1>!7%H=]
M5-A)I;'.%AJV9F.\M*X=W'M<@`GZB^O#=HPPPH1V#3<7,@@)ZF?J952CH=J:
MB9FLGP$;%BS9!V(%(@;R&5`UJ'S5R/(!6#8(38FG_C4)KH4[.Z[G=630SWFV
M@L(8$C:J]GJJ:U8W7@*ME6SZWT*!F?.&$P7T(97*/D1@_/3MAP,3"H_PF<MB
M8_H$'-A2(7?5%=A4TD<$\J9OE"W[C(277YWVRW.M"^E1F5C&%1*_0$3/,/73
MZ\0^U$[E-;YON<E/)S\Q:`BAUAF8!HK\T<>\7X)D<J+\].J/LH'U@FC-6O;9
MB9[*B8XH+UM[AIJLOH+1/UU97F992VU&J*+D$&`+OX<%&:76LBP:C3D>'1"7
M`"(,"ZX7ALVNY7[KOH$HF+V^M'<XIT#.-_<5/.1,>S:*JG_^5W\T[9G%WU/2
M`/1.WZN-,C($07D$D2H`6/5#K5GWP\9=-RAT)"W?TALP5I[0,Q&]STC+%C3(
M!!</1N"((3O`C8DJG+3E[M=T+*4#9\?[T#C&!+XYC7;9[PU'V`75\[K^;XO_
M^*LFC&K'R>]K#YYB=4O5#@FEZ)2`6T)JF+!7RO\\P2N#4B/V"#V35:B7>*PZ
M,5[-#+WIG10AW+K6!V&-KL`('[RX#Q(&N>K;NJ'<+2A''MC5.>WG^*4\5E0^
M[2=9E8_XTQ=TLBS7:E=+U:4Z"<6?<?)8N$HRQ%%<FY9?0Q]LW?;E^^$2D`G(
ME`Z^R.;^51/$0?;Z6]&%XS1=GTH!OS$-3C3'CR!EV@A.^ZV;@A(CJ<36*%&'
M^9;.N%-@N$&_:UD/@F,Y?Y43.GR]8%L`Z*F^O_Z5^R!TG-E&:^N>@&P$"D>"
M`JFV.,6XCD'M3"`Z?)]!6*3VKX?-"^S#[.%L,&8%=4'6.*@O811*W3-$U=+Z
M"HI>$^E/U(I":NQL5/63R[=JK&F6OW`JKM7/F6BS?W2^?_5."8KP/T):A*9R
M?5,DK3]1,"%IH4H<4;I@5(D*@NG8,(U%"9!BX#!$2W5TXCK1%&M4!K@[5*CD
M"EM</Z8#`D+28MU/)?[!;!T7>5V>"VGE!@Y=E>]*&$2HRZKKQ)O/+]X>6:MI
M;5F/!4E9SJU%:>QB)0((IJHIFF$Z-2*E4GSO\/*]8DHMN6G+1ASVYQXGV"./
MPOKAM6_$=^4!Y4N7A_MO3RR6@(_-Q@(G@4K9!YC.S4NH5]_[H8EL50PTM0-<
MKLD(UGK/`U#=Q!S6Y4Z4WQU03GPQ3;<7L!?+$>U7:UDJI/6Z8ZOJ2V191;.S
M<3=5SW'_3IF4]0+W1<X%<P]2[1^V'594^\R<PHO9CU]7:''?"BUFO=O?SDN"
M@IIE._A[)!A_^N@Z?B_3O7(3<MEIW4_8X=-'[!,(RG06Z5'"*-&5RIL,'B@'
M87$&6W-@2Z^&(LC@(]Z)3[2(A,J;"F)LI`3"8W]UKN:ME_J`ZQGEJ8+T$7FH
M4D@H6F5&5#L-4@.T(7>KGH%!UB4>U*A89RZ1Y8FG/719;3'.Y*C@9;??P&^E
M\3YXN`J4:!1IQ&7*5@#).^2T?_%HMUZ\OWQOY:%\2LZZBXYI<IL'=`-^`5+X
MX`C"U@N5Z%ENVQ4@@@DF,NQ<[<&J2VDHP'M[>'S&X2PZG`O0^)+6S#"10J=^
M9=Z@(\AU]',2B'OB(>)+])Y04:_F\14QVDFV78.]Q;[CZH>F%43>9,4V<`K;
M(8)=<#,`D.E.M<9+L#,W5F$D5MA\T*:Z%DSW;7;@U1JIR45ZNG+G>1B'HN1@
MFY0@*`(.9(Y!&8@5_P)9"EE<0P^&.07)%9,2K<VG$IW<_8`%]44P^>4>K4T[
M`_2^?K7#)#QL+5+[2#:@*6>(#,8*QC`\39]ZXQKD$I>>IC]1Z'W*^Z55J0F"
M7Q*FTB.3.,.IA&8_G2%'P`0RA&C!0/N$;AX#^ASJ_\`YV:#"W8+CY50=GP8+
M%N"Q6F=4H,`T@P/9^^80X85F?"`ZPRZ<)%`A;.,VM&F87KZF.I$3*L"].290
MX=]R>$LE==DG&5EYY@#_-VF%MTT#)%@>$7VD#>/2?)3&`GR[P<S0^*4%*B^$
M6>`(+@.W,1-@KTA.M+XWM45U_!9BA!$YG^>1QF?)(CX")(2ECB,D)[=K^\7&
M9(?L/E@G12!7HLO5^W=7OHH#*!2TMD(Y:&87Q"MVO!I4;O]*'PW37*Q=49>G
M!1F83T!*%Y^C=9LYO@`VF[)T]DKC^5'<`?ZTODAEA`NCU(%:T`E%#`6^GY[\
M,MDT70X04>EB$Y(1=?#5B\DN=2*7AUCX6Q4RO%E8G"0BJ-,Y5GB/I>6"NJXP
M(R7<R-=?:7YE\-O[X*34L)!0)T80>!YSZ'@[>M0&)O3/GD3E@O&$G9@#J?=D
M_>`8K3OI=,ZOU)@*(3P7J_>_\D"NXI3`(:'B84M$BG`0Y96B?D)%H->9%P7B
MDD3Z<=L6S;/2@KQHZ,5P_#$X4;$KF7G&!\"%02*Y66J=H.8,3M&HGL7$PSR.
MPLF6]=0.)YW9-GVD&/"`YCZ,X9SB:"(<;D:!F"9F9T.,UZ&<L*I=05Y+^7=>
M#^Y=3XJ=R4Y#;#@/XH,"2QA!F!W"_JXC*$"[K)QC>7IX16>,*1Y\2/]J.2BN
M"`U_Y1<Q$$T:P1N6=&-Z2`,"84"6#,9:+4IU^+,<GI"VQ(OSX3@X#.GR5&C,
MC+V842P94QK36/X#$8;IV9':'.#%MSIQ#Q.Z#Q4_L!8!,`>D<)EQ`CYZB8QT
M65I[,2B2/^EZ!+$\#_9;:%@@L!-U9_\S^'J+Y>DX;2$B*=/,"^*#@K"9AF[(
M&&@;5<L8C6[RUU/:DL`Z2WP<E_L4V82VER6)F?G3;I)7#CCYL7/9_?US%>.5
M`YJKP+1`LOLI!S1_/EN$D\GJQ#+U441RU@13W&NG%O#QOI0$>S*"'SMLM)]V
M9P[0[,(R`S^$$FY!F))<6[K->%888M6+ARITYTZ=@RLKBI,K&F#LV>R>/F<7
MA`SKN]@L[&VO3H]EJ4X0%1R)NDU@T]'56>M=<^8BO;0@^H3<G[IE?;*%A^6&
MF.%M`'3P)._3Z4[03F"G4M/MY3T\-Y2F:*V>K08BBX_*L(=1>WJ4L8'W2I&"
M1L`"400O+\CI#(UXO+_6'LL=8)78T*.I#;D\/%!MNJVO(UI4,ED2,4!DY*S3
MBS/Y+23VB!+/2F4HFVX0P)7=Z&G@D(*O8BI"O#XX-#A9PJ_,$=66P!!3-\:@
MUM/AN?=CDIJR+@DZ,64".C(-$H_I$6I$3#!I1K;/2?;1=<*)KV2PTHX7G:2[
MID_V07#$LDG`8_(Z\X+\F'B*CK%ML&NXGC*VN`]?F0L%@NA_%`GV43(<:L"2
MA9`M<L8I!]C(?O"PA)#^6$66+KI/0AU\Z-Z27^2`?<R@E102;3#!>)DF4C!Q
M0J.48%^!"\$,6CF65V_JO2&#(CLAJ>5'(+QMHR[3F52=0[L<L=)T22Z14")]
MP01(.%D,94!GMA+&2'W/Y3"LPZ<L"'-+/ZW8AA@.-=:8'!9P[<(2O9-B;G-7
MRH?`HSD6$92*;_;`OSQY(MJRTSYVX=&1#LG-7*654R6Z<2JE+VK>.?L!K@*)
M`T>74*5%O@>'[QSRYE+J_ZXMNBJ"7Q66#'/Z<"8?=$1`0L5'/$I<`T@BB^0:
MF4I=G%;Q65EB'\YF1'?M][`B[EG>30Y1JAD<UD.GI'$,L+C;AM!1OYL3N+[R
ME4XO!:@,YRGKA0'FN@UV6;0SO.:C'*@K@&\XO1QPF=GS@Z:79[>J+LJVH@:]
M7(Q!ZI#I%P@)(UQOC-9%M$Z!'@]:$AC-BNR28;IX`3H]R!HVT>BZJ34$5G0V
MXV%-WPY7[U68H:D(:ZY.PKH/!U3FZ&G+>BOV(D,RY?Z<]0<Z^]-PFW1Y:U^W
M>S;;M5$F.V$]M)QNQCF[`AU"/&3S(#HH-AV=]2XI'=/;PRVK1G-#@;%?9ZX(
M+`4=]8^.$\4DB6H+@_4V#I.V;*@+C%I+T#V$?(AV"Y:`S8JU89,4+VA<]X=N
M<$P).:S1L,>NB6YD)`;KC[#=QH$57F(MFJ);LA+Q4^28/L.?:LT,R%]-29/=
M)"RLLS%/Y93_PG+'U3/0-;VQT_$13T'3DJ;,(.GTM73C:A#`.E[T]%F531V]
MQJZPG%/,6YO_8'!!9:'-C[HM3LE?UY\:>$N(D=Y"6^N$!8)'X_'DHFB:6+$9
MF37G!]WZY[%##!!\5\`<<>H!>GBY-$NK'7YM.G0Z#MV6,AT$O=-:C/RC#L$P
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M)V.]R_O5S4/DH=H#:Y/%&$-RP=$5E1-F*BPJ7"%K&G,17)_LW+GG5I.`OO/D
MD0@(V,Y]=^]P7\7!=6RAY1)$(RBCT6--[#;*3PSEWDSLN-4OA;5U?>UW<N3`
MP=>'EDZ&&WW_%US2AR"O5U9;D@?OVB]5O)D'2@E=&%ZNH;NHNZ+'"W_S\*'J
M6]F'$03$8;J2/R:#Q!*F^!EL:W@]SPDR]@Z$+3?E`-6XEYH>Z^EY]\;N1IU'
M$+1SX<MN/OMNQ$0.,"/A]WA'3&1*N8#+Y1:5/7C/6>G_W]?41ILFTHSH`VC`
MKRPM6=E,C!_<L_QZ5]A^\,(M).6^(3%ZIOWCPV0I_WB[SUX>6V3/-720*&GB
MYWAQ3F)"%<H6*HD7%GB1P%<X$+VD:SEWN<"[CV1KBX[M?X@7H;[*4/U"BVQC
MAL7@@"_RJ6=EL/---@B$:'DCB7:C<^ECF`CG.,<7OXUGN")H'J8T+$)?AX+D
M4R6$'=YY#G62-K'X4B"AN8R?>!=7^H]>CT7/J$F&]^U._WS#+[F2!R=Y"1,\
M-\2MBF"L^ESJV`*;V)8?"3<D<,\9I#?9#4CCF;Q"S,>L=7QZ9@IJ`.(F:^TT
MTPM%C#E?:WD2O;;U#8['18MY:A8?P5F1_(=%3LIMHY*C9L;6C)9P\+A,X^(C
MX>>1N1H7`-VHL;#`NT^FY^H5P_ZY0#OX32#U2J[[UY,GX3>Y$:7`NP3!4#U<
M*Y99HC;?BX"Q^[[>HD<O8@VOM_]C\1O99+YGR[T[D\!O`@_3*E>E539>S7;E
MD`N3I5WC+`-1L)%)1'>PC>Y8>HW%^2G5P.[[V=Z:S!$(Y7WSTNW`ESU/P-]_
MK/G<+^JD^J=J3_W3E`ZU"RR]LX\F?J7")YS$E3E&^8#4<V^ZK(3*ZS?:KM;P
M3$?ERQLN$+PCJN(?W70O=FOS!J&.7E=[BG&NL4'2WJ\*O-X,+.V"6^'3V$!]
M11Z801#<"*+3%;H&C_BX<O_:(I>P.+H^)@?WZ/CB]F3IU<[CR:T!WMI>E1LR
ME2ZY2V#[`B;)UJY.S$-2HUF1U7XX:.^_,B%]4XG&3^0`Z.M(J*=W)VK)(_6T
M_R/V-#\^M!]7^S]^QB%_?JXN'\]P<5P,!LI6;<)M`ZDH_4\V)$L+5_D-^T\L
MIN,$-0Q?[BIO3H*PF07D,3PR8L4P?&;*$,,W[Y"D?_\[?4'5_WV#=CF9DBNN
MT!-=_<=_D*]F2?K`;?G>L&$L_:U(K\=L2(5'B%05]9R3A*WHQR9^"S1D&"K&
M*1;L!3US#ZS3:O-4_UL;B.:#HV-"'ZS67`<5,C2@91DS^23<K[!YE4P@,39#
M%G+&*QR"2VS=</QB@/J/</1:`$L99*Q"?U]9HY.?7UA%Y`"!TNU<>>CHH\;)
M4!:F'G0)Z3:Z\`)Z<Q].2M/]B93V7'/R/R<2&A=P>%/'$'Y116$DT3SVZ`H;
MFXQQM+Y6CKOT'CGZ\%'6+U7H_;UU@@+YY?Y#+\(Q-?X[(2GQ7D=W7="/>+\G
M_T)]F/X,ZT#I,,=519/^1^Z90W@PZR3GLH1$_6W?P`M-@BO\K__Q&:OO*,\%
M-0`'365'_?=6UT86'&P;50/UE=QDM)/39L7A5C!*Y`4<`_:]D2\^5^9N;[NI
MAW`%OFI__W_8VNZ$:)X_?S3ZX1G&0WE7ROJ+D@C?>Y(,ZOYW-^497$B'*T+Q
MSJ31I,"PQD/Y'__VG__KW__S?__;10M7I43N$A`=DZ9<W3Q9V&H=1>&;K3#.
M$63!O>&%,C3Z4$@[,F5`__<?K)??*P9/6X(+I253TERO?4K<_W#P6-H/=&$H
M&FE_J5<[DQ^43^\SEC;H)RX'"]P6E;92[BB&9-?!PQN\D04QY`6?P>C&L'[S
M<Q`F[U"1CN!0(L-K,6=,_PKE_*;+C4\G^;Q3V60Y3WEL3(2137_)3\Q3V2R&
MMV#;_7++2,)7)WM$#R"08E^,H<!G?:&/X26U_1^R.^[D^27)6?E1=O3]@ONY
M;JG^IQ===W&(?-;=%D-PC#'6!WY/Q#7-AP81LTV=SSK93DL8L?X\E&UL6!18
MB3#/Q<%O5-U<;>NM<]?7!JS5=CO?MBUB;.3`H[9=)"&C6;EN;/;?34R^FVQN
M'K0VKVQZ#9+7#>/OI\I):EUW[J3[IZ\OO_NGII'Z!A$._-\\V]K:G??"1]=_
M\TE._]KQ<1VC"S#TX#0'39OQCDW<^8"$K]DXFO`8SL\96LGL#TYFG+3_O1F?
MTZ&RII]X5OVJ>8VV+:GB@%L%H$\I_\;\^!-8MQ@,OOB6].G)[OO1>89(?YN8
M$CCXI2'BGU>"PM_R_$\I$?B;?A\[NO_]49II1YFAZ;;/]?Q8#>'ZI+FBSAHF
MVC#+>;9WI8IV%&8C,&T%]9RV<7L*S7GNA><:KK:RM>O0+[_\#J<V/C#Y"7-=
M&]JV+O[S#.$6@!W>L3B@NY]T6[A_LONSK=QK8<QJJ*XVY8#Y?N*\`?47TP,+
M+6]<O<%9X('EYF[^>@#WL`V<-S:&,\=!H+\H/C7'O5-1M!B1%P0+WAXA<`>V
MXT(W]?U<DG`A@>XI_+#8WZB#Y,O>S*L44W(%R"-V\ZNZR888XS'`E6>]<5^_
MQQ;"V_`92R]TN?/Y74'$)W_F5H\NY'=:IO>16`!TDYX9E\!B#GC,B)!Y$U`Y
M4/HTN_Z9--MWFV%;+$B.JTH#G37XMVA$(ZP8O>3.83Y4QP_?',OL'F:I&;/8
M83S7D3LH->?PHV3`S@K(S[]$Y7&1\QBEL`_J53MW_Z^=2(PIZHUKWW]L3KA]
M>*F@,<358Y'9O<N2;YH7%KR4M=EWLN#;7Q*QAQQV@-T5Q(V[QUCP8T7NR$(^
MXR(NI!`,G.T]#D,_]GU2=SP&7TAZ<$<C\?S)+(0)$=9!&)3X:F&$HI(CD-4*
M8#0V`&HU+5;QK*MNA"2RLF\I)F"#(TH097_[W44Z;]C-,3<OYR;?_%6";?"9
M_GM?`".2PPP@QW$FY1KGP,[V\)O(?'0+PJ^R!8_P#"!@7.P9X53X\F-""#!C
M=FX1,X<ZY3G)S?SZRJ5Z0LB<HVW*8[B@44XN@6^EDV^"!F(Q9;E`Q\SV:UX;
M]Z"$"E)T\3YL0HI-7M8*L_XC`Z(/@0>E6@F*@',]M?O)3STS;JK0=^U<]ODK
M9%&H4^[G[8)R->H;Y1M<;!\WN_$!]-JPOMS$#AB_ATE<E[%5-@1[2<3T"'65
MM9G/J`!KF[UT[>W]SM^?DT8="L[DP4AHR0#[V\9^3Y:N\X`]F!N.69W[*YW>
MY\5R:/IZ=T(3$*RCE0?]>VA_7.G_R.24NY.<F=S_D;KVLNS#_H\H&_SH;:Z_
MZ?_8O#E,M)#*7G3247F[*?;VQ>YDGN.OB0BEIBQO5B1N]H^V$>,5\&>U&8+)
MSE+M&KS&!-VO;9S@]4=O&ZQER*FUI?IK$UWW;E:6C_`\)H@]5>,T/\?0QK1^
MM*9ITHAU]`Z*L:JF-I8(.1)FG?&@A]3[6]V@;0B0:_8X%KF=]>3(FCY57?Y/
M%2:Z@#77CXR=I@7U1O8HZ^_JP0I>YP\#MW?(S!GBVY*E:.$`%WUQ>N")&Y'_
MD4<;_5B`4J/3/^/MKD^_?*0BE67B]0\X]E:#S`7U;[B`RK\0&/-?+TUYE&UC
MC7;E%L9S?GC^QAO[/#MYC3?Y2'/I*6U12T=RST8R0+KX'I)+T,1JPJID7(1B
M'2UUYNX&5UR<V)7@(Q'*%87/6W4,W(&:'#TW-.>BT.CK]3875?!GC+;5#W(,
M=-NE\6?=2_E*?S,+/+(VXCO8%/<>:;Q8167_@XJ5+0WS`C/9"1%(VX6_>*K5
MV`FM\'696,-)?_62(Z;4+Y+DDQN,`NL/6W^:+'WZ?P/[<;'#3>;)G%X&B5GS
M><SK<DTFFX>#3(O=VJ,,W**[1/_PF8)A-$('PO[O:-36<PRS8[\49>YTFX3I
MW(.%+7>B)M$MHQ7B`L'M.-G&_Z$L4XN-@4MAQ/:_;*MFUS2+=.U[<F'_P<<E
MM8_*AM-S$:B:55L1M'VL_T*A%%'Q4H=KW+;\/[;GJ4\RS*HQU%]GFUKW(]4Z
M\=5NMJ%ADGG=PQ`Q31[<&^!,FI$;G@IH+*"TJ2D?D%4_(X]&(!JM,ZSD-&;$
M>6;K/2_HZQ^N;*Q,<;)L4S-5967UGZ]NQ8UKW_CZXN+RN_\2````__\#`%!+
M`P04``8`"````"$`</L[`N4+```$:P``#0```'AL+W-T>6QE<RYX;6SL76UO
MX[@1_EZ@_T'0MD4/:&);EF,[%^>P=J)V@6UZN$W1`KVBD&TYT44OKBSO)E?T
MOW>&>AM&+Z0CV=P#>L9M;-F<>6:>X7!(4=+5=\^^IWUVHIT;!C-]<-[7-2=8
MA6LW>)CI?[VWSB:ZMHOM8&U[8>#,]!=GIW]W_>M?7>WB%\_Y].@XL08B@MU,
M?XSC[66OMUL].KZ].P^W3@#?;,+(MV/X&#WT=MO(L=<[;.1[/:/?O^CYMAOH
MB81+?R4CQ+>CI_WV;!7Z6SMVEZ[GQB],EJ[YJ\L/#T$8V4L/H#X/3'N5R68?
M2N)]=Q6%NW`3GX.X7KC9N"NGC'+:F_9`TO55L/<M/]YIJW`?Q#/=R`]IR3<?
MUC/]0M<2DQ?A&D#\[M_[,/[V-\F?=W]X]Z[_KV^^_<</SOJ?/_Z^_-V/W^B]
M3`V1"1PTRSSO-XJ%KQ/)O=2"ZZM-&!!#AN`F]-;E4Q!^"2S\#H(!S,.?75_M
M?M8^VQX<&2"\5>B%D18#RV`?.Q+8OI/\8F%[[C)R\6<;VW>]E^2P@0=88*2_
M\UV@"0_V$@VGU;-$-)E-$X3!V33$(]0F'TRR\6"S3?9/%39QND9B76W\Q^EB
M5C3;U9FN<ER4?-A&5\X5T1,]+&>Z94$.&?3[Z%9*V)&431=]T'<R91>CDUDV
MM(;6N%/+N%@L\X8*AU:7KA0HM-Z/;T[FSNZ5U5F7IN%3]0#L<-UZT86NV]"_
MQQ:^3A$G)Q[0.F6,BPXFF4O\K/L5^?'>]9V==N=\T7X(?3M`Y]*!C?V:&Y=1
M/,=3]RKR$#B>Z/'Y&$WMU#-'\PKS_PZ(<3TO+SB')I9D<.3Z"FK?V(D""SYH
MZ?O[ERT49`&4Z6AF+_F=X-</D?TR,%A9(M=@%WKN&E$\+%@9F`[#BXM;:W'+
M]!)DLBAJA%K68GP$H;?SZ:)[I(OIM&NAA@6OCH6^'^&K8Z$6_+?HS*=I(C:[
M`IG+TV(7IVW]\_%T.IT,+B:3R=0<#DR3.7F91K0;K)UG!V=RG;FIC&`$"*;#
MR?3"`"!]<\)4G13!$`",1Z/):#`U3/B?9?WC(^C:IR-=-:L$@2)6"0)%K+*9
M0Z^#S)_V%%A$4=Q7"0)%K!($BEAEY5*'K(Z5LTH0*&*5(%#$*EOOZI!56)Q4
MW%<)`D6L$@2*6.VL^$PS\%0YJP2!(E8)@E.SFDVK%K>W%EO]*%=F]?4QF\G!
MW'$91FLXLY.=KAB,8-Z6'+N^\IQ-#+/$R'UXQ+]QN(5_EV$<PWF0ZZNU:S^$
M@>W!VU[6(OO;T!+.%,%)H9D>/[JK)U#&3;43O(F*8VG(,Y&)%;XY-OMC<V1<
M)).HCE3[SMK=^V7K<MV5L0)N1-^*#2<^#'(E:3@4BV$]9"&E3[(%HYHQ+=D`
M8B(+"<D67=A8+`S+VDA:R-E(&DC:2%K(V@A=IZIS99Y<AWLX2?F:8,N:]/O)
M^INLGF:!!'A%Q%2#(&W*_A0VJ?"HL,VAMD)^*?6-N8$OMF908:F@1=E.08,*
M*P4M9&WDXR9CEQ.>+R=@>JY`\LK?W,_?!@,4)0TS/*^28)J?\-Q`<G9`.MWQ
MYI;TO#*E*SW29A#O`K;#AL6W*)%N\S8>,_%"MQ*[LS:M*$^K""A*5H[G?<(R
MX>^;O#*!!;CKJ^<-V?$`VU!P2P!NJ,"WL,J=ODVJD.0#,%+7R*AMI-G;K?=R
MM_>73F2QO2E,!3N*J^G%ISDKGXK/[SWW(?`=MH2H)V*^C\+86<5L[PP[<5&'
M!S985!HQ2`7)X&FCWZS1#WZ2]D<;_;!$56D_^$6I?@@N:?U=Q@/N$DJ#&BB@
M0=V$ITL$L!"1(0`25"#`74VI#R`\52"`"5Z&``*T0`!P&J*B33\8D&P&,5"H
M!/W'4@DY)K.24WE$*^O2+^AOL-+BTF\K-Y-\"X%>N!D^-`!HI;(NQ:I*,81V
MZ&F%"^!#@PLL&'6[&?)@N2&/._!!`4"90TC2Y0!!&FCR2'=127(NZ)3UR+S#
M.H0$!:8BU1``CA((A(B!HO%W0#$H&H%I-"@:@BD$;@QNSA*=]@G*!#="*L(`
M>)3TBB)?#[@1XX1N(!!494@2#8:J%$DQJ,J1!16&JA1)(*C*D)0)52F28E"5
M(PD5JE(D@0`>49(A*1.J4B3%H"I'%E0,5:5(`D%5AB1,#(^<(GMTV3191"7K
MI[!3L7XI%`C*IO^ON7K>"!=2!W63)I"5-4]F3\G,$;A@<RDRE<;KR.QL[51[
M#"/W9YADXO5D*UA,=2(=KS^,W14]\B6RM_?.,TQ%D[-ASYM6!@HP%?IAW5O7
M#E'>N7]:8)%@6N`(H>6XKB)<EW\5&/S:MC!`A!C8PH)J$.CK%$/G(=!1%\&>
MJ]I-,$@JQT"I0CSIFC,<YFJ(UMD,3SL?ECQP?O$5P1E`.7%".!KNM$^NHX8S
M>;VF%%_K*%S$:B(N6R<09AW:Y]H1.7P]56G"9['%Q9;HWNC(TP.MI)D,*91F
M`;KJ0<6"?(<E0UJ1'.Y<MA'D[9U8`%HUO!.D/%$LUK#=C$R&;*F"LR6]S2AY
M=D^!AP\W42[D<\TQ,V,-R2*X,C1W8$3+(!!9P8>!>KR=!*VP*`<MF[38K,_B
M</^0QM&Z`V=)CMUR$5J"^XN,T)(57T.$XAF&354E+LIB;\I;Z4)#9?U1$[F=
M=)MV566MCP!;4U$I-?1(NJ06`YXW;0)Q3)Z0,KG8*5`T;1:LE7<,&R4S%&*J
M2*AP>,GV`^#*W5'Z2H?X`&QUB$B2<9*A]I"AK;XWU)J:3$6*.!2LP-&,D2V/
M"A'6C&:"6)$9S-Z$NV6!)8#-CUXJ`/)A*6">KVEJ4[.08U`CS@>"H?Y-SI+,
M!U(Q6,+W-<5@?><&VZKSV"DZMPSQ@A@\<M0)M$M'W=?;![K,:`)OU7)%1X:D
M3[8X581;.BI+J.[0439%JT*@59C<CHPLN3&)["+T,8:`,L&5+A0#16]6E<<E
M#];&&E4LFC2UU]8BCFMS=LE6OFRHM;R9!)$O3GP&Y2N#<T@O_W_^238W_`)\
MEERXWY09C]H+I6=!F(@$Y[O+$^;C%">GC6YA&JA=:X,=C>H*6R1#1%@IC5=/
M&&K3N7`@HYM)Y#=R5*-XPQ"3!7<Q!&9'JI"S76"P[XM<1<M?0YOO$M/P;I]P
MA_+^;[4S[?T*A>9S+QRDEGO7@[OVX"(2[N!;[7=P<XIY<C#=<]4D*U\7,V!J
M1&5!0!TJ*Y]<&;BKD^""J#U45A[/0["6R((+C`^6!3MMD[XQQ#VW!2X3]M4<
MB@N:I+)XWX\D?6]6\8CG60@N-%D&%Y55\`B>H[+`Y$-E%3P"<506F'RHK()'
M0$ADF:#D4%D%C\`"E07A=JBLG$>3]_U(TO<7E3SRL8I;265P45D%CWRL#B5C
ME<HJ>.1C%4T^%%?!(TBEOH<O#I55\,CG"5,R3U`;"QYYWX\D??\ZH_(1;TA&
M?"*EX`[>$1_A%%/&1XF4@C4^RH>249Y(*?CBX]N4C.]$2L$4R",6F?"%O$4Y
M1T/>NZ:D=^?V.LNZ?,#@.",#`YYEL=I[\(R1$)]0PK9*XPEL8A"NHDA)>G16
M3]H"[GR1"^+[`PZC,H)NG[>>'=AQ&+UHN#TZ%\>3/I(4]\<PS'W$2S#@HPR@
M/\'S7.!1,1KX)?$0'\-841TB)N\+O'OP6LE#Q$#K!`T??SA-.40,M$[$\$D5
MZR<9,1^"[3YGB,^E.'3+B/CH!D_.FH\<WL,&@)21=.?LX\C.XX_O4H:D8^[P
M?BFY##Y%)/=MSV[NDM:?=W![E,R)6&F3OH/5OPSPO^QCXD9L1808DGGIWHWA
M9EM9)^9$("P9'/<A7+*0BWB5421E_,V.`NPM7-=]%:,U%A47@$#UOWXN[IW#
M_![C$X_8777R^0`X:NUL[+T7W^=?SO3B_9_9;>P@F-)??>]^#F,F8J87[S_B
M_0&A%\,4$]+-QQW<<P[^:OO(G>G_N9V/IS>WEG$VZ<\G9^;0&9U-1_.;LY&Y
MF-_<6-.^T5_\%UR&CX>ZA.<+M7C\$GM,%%P",C`O=QX\I"E*C4W!?RJ.S73R
M(8'/;@H&L&&3<69$;Y<_ONKZ?P```/__`P!02P,$%``&``@````A`(M-P\"S
M`@``$0<``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULE%5=;YLP%'V?
MM/]@^;T82"`I"JG:5-TJK=(T[>/9,0:L`D:VT[3_?M=V2@BMMN8E8/O<XW//
MO;FLKI[;!CUQI87L<AP%(4:\8[(0797C7S_O+I88:4.[@C:RXSE^X1I?K3]_
M6NVE>M0UYP8!0Z=S7!O39X1H5O.6ZD#VO(.34JJ6&EBJBNA><5JXH+8A<1BF
MI*6BPYXA4Q_AD&4I&+^5;-?RSG@2Q1MJ0+^N1:]?V5KV$;J6JL==?\%DVP/%
M5C3"O#A2C%J6W5>=5'3;0-[/T9RR5VZW>$/?"J:DEJ4)@(YXH6]SOB27!)C6
MJT)`!M9VI'B9X^LHVZ28K%?.G]^"[_7H'>E:[K\H47P3'0>SH4RV`%LI'RWT
MOK!;$$S>1-^Y`GQ7J.`EW37FA]Q_Y:*J#50[@81L7EGQ<LLU`T.!)H@3R\1D
M`P+@%[7"=@880I_=<R\*4^=XE@;)(IQ%`$=;KLV=L)08L9TVLOWC0=&!RI/$
M!Q)X'DBB^&R2V8$$GD>2>)E$2?I_*<2GY5RZI8:N5TKN$70>"-<]M7T<9<!L
M[9F!R>_;`[[8F&L;Y$(!K:&D3^MY=+DB3U`'=L#<>,P"HP$3GR(V[R#2`4)`
MWR`2?#M?I`TZ%1DG`[W+X\9#%JY6-K'-:.-$`#@S%O!O=RP87!QE/H_#R<T>
M,S_>/-HXN7E^SLT6G&-(8O`\6DYS]IC1S7YCZ<H8IXM!Z(D,Z/6/&V#!4QG'
MRGKK/29QMT9Q-/%GXX_GA]XZ!I^(2L\19<%34<=DO2B/\5:\(VI\G"YG$Z?\
M"/)_KI:KBF]XTVC$Y,Z.EQA2&7;]Y+N),NA`&#F3_0U,1+=/A@.82#VM^`-5
ME>@T:G@)E&&P`)N4GVE^863O6GXK#<PB]UK#IX=#;X<!@$LIS>O"3LWA8[;^
M"P``__\#`%!+`P04``8`"````"$`&L;?.WP#``!+"P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6R,5MMNHS`0?5]I_P'QWA!S"4F4I&JHNKO2KK1:
M[>79`1.L`D:VT[1_OV,[H39)6UY(\)PYG+DPS.KVN:F])\(%9>W:1Y.I[Y$V
M9P5M]VO_S^^'F[GO"8G;`M>L)6O_A0C_=O/YT^K(^*.H")$>,+1B[5=2=LL@
M$'E%&BPFK",M6$K&&RSAEN\#T7&""^W4U$$XG<Z"!M/6-PQ+/H:#E27-R3W+
M#PUII2'AI,82](N*=N+,UN1CZ!K,'P_=3<Z:#BAVM*;R19/Z7I,OO^U;QO&N
MAKB?48SS,[>^N:!O:,Z98*6<`%U@A%[&O`@6`3!M5@6%"%3:/4[*M7^'EAF*
M_6"ST@GZ2\E16/\]4;'C%TZ+[[0ED&VHDZK`CK%'!?U6J"-P#BZ\'W0%?G*O
M("4^U/(7.WXE=%])*'<"$:G`EL7+/1$Y9!1H)F&BF')6@P"X>@U5K0$9P<_Z
M]T@+6:W]:#9)TFF$`.[MB)`/5%'Z7GX0DC7_#`B=J`Q)>"*)0/W)'HXE"8P@
M'=\]EGBSXNSH0=/`(T6'50NB)1"?`S,R^E#?BA1"5"1WBD5S01`"RO.TB4.T
M"IX@I?D)LS68U/=ZS`"1G1&J$B"OUPB!#S5&4,+KR3]+4DZNI#`9*+H"<1'9
M)2)]%>UHA-P--<9O-LA9HW*"5K!2$H>A*V%K,+JW=:XSZ\!1$+L*WL^.`J]]
M"*\O1AH-'FP@<UW-)$I=:V:L6I:C`F*V\_"^"@4>J(C=YVP-)-$J4(+FKCES
MS'.KYQQ1,U>4:O*/&T@YN<4)+SK(8*SB6`>.`FA[.RWC%"@G-SUQ.*R2P9C\
MQ*G5G:99;#.:655TU*G/E#4$WB^:`KNJTIE;E:V!&%&S>3@P9[8YBI/7FCJB
M%JZH<2E33JZX&`U;RF"LHED'C@($0\;.RS@)VNNCQCF!+!'VB:OBRHC^N'N1
M&:;V&W[9/"?0J7OB=#`@,\>.HOB-V8?4F!S=/QH]K-&@1;8GD)T?,XOUB9L?
M-1"MIX^LDAFC<.TGX.7KC:Q9:]XG^\15,1B_(U5<SN$K5;(G<;@8I$KM/:KG
MS:"VS4:?V6G,-[\A?$\R4M?"R]E![2L(!FM_:G:IK=JE]#;4&V"5Z?">_,!\
M3UOAU:0$U^DDA>G+S3)D;B3K]"=WQR0L,?IO!4LK@15A.@%PR9@\WZB/?+\&
M;_X#``#__P,`4$L#!!0`!@`(````(0!Y/-DIY@(``-`'```9````>&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;)1576^;,!1]G[3_8/F]`1,@"0JIFE3=*JW2
M-.WCV0$#5@$CVVG:?[]K.R&!=%W[$K!][LFYYUY?EM?/38V>F%1<M"DF$Q\C
MUF8BYVV9XE\_[Z[F&"E-VYS6HF4I?F$*7Z\^?UKNA7Q4%6,:`4.K4EQIW26>
MI[**-51-1,=:."F$;*B&I2P]U4E&<QO4U%[@^['74-YBQY#(]W"(HN`9NQ79
MKF&M=B22U52#?E7Q3AW9FNP]=`V5C[ON*A--!Q1;7G/]8DDQ:K+DOFR%I-L:
M\GXF(<V.W'9Q0=_P3`HE"CT!.L\)O<QYX2T\8%HM<PX9&-N19$6*;TBRF6%O
MM;3^_.9LK\[>D:K$_HOD^3?>,C`;RF0*L!7BT4#O<[,%P=Y%])TMP'>)<E;0
M7:U_B/U7QLM*0[4C2,CDE>0OMTQE8"C03(+(,&6B!@'PBQIN.@,,H<_VN>>Y
MKE(\C2?1S)\2@*,M4_J.&TJ,LIW2HOGC0.1`Y4B"`PD\#R0D^##)]$`"SQ-)
M,(](%/]?BN?2LB[=4DU72RGV"#H/A*N.FCXF"3`;>\)_V@.^F)@;$V1#`:V@
MI$^KT%\LO2>H0W;`K!UFAE&/"8:(S2N(N(=XH*\7";Z-14ZA$UZOX5&D"1J*
M#**>WN:Q=A#;?79C<[8Q$`#.?%R`"8)V.7,@)/Y(@<.$MEN,M9NSC8&"<*C@
M[=0-.,603.\]B>>C?W:8N:T>69!XI&PS.)\'TU/U!KJ@5S[NC`D:ZQOWC\-$
M5E^PB*-3:[A2#<ZC,#K%#_3%0WUO^V;`(UVSD2]KAW&Z"`DO?!N<1W$TZWT?
MZ(*+<>[;V[H,>*0K&M?385P]8S^8C?TZ/X\6T_`4[W2Y">IF0\-DR3:LKA7*
MQ,Y,QP#JT.^ZP;TF"5P@F)BC_0T,=+OO]0<P4#M:L@<J2]XJ5+,"*/W)#&HH
MW4AV"RTZ>V.W0L,HM:\5?#D97`Q_`N!""'U<F*'??XM7?P$``/__`P!02P,$
M%``&``@````A`,J83N!-!```R1$``!@```!X;"]W;W)K<VAE971S+W-H965T
M."YX;6R46$V/HS@0O8^T_P%QGX`-29HH9-2]K=X9:59:K?;C3,!)4`..L-/I
M_O=3MA."C=V!2Q0JY7KUJLH/.^MO[W7EO9&6E;1)?30+?8\T.2W*9I_Z__[S
M\O7!]QC/FB*K:$-2_X,P_]OFMR_K,VU?V8$0[D&$AJ7^@?/C*@A8?B!UQF;T
M2!KX94?;.N/PV.X#=FQ)5LA%=17@,%P$=58VOHJP:L?$H+M=F9-GFI]JTG`5
MI"55QB%_=BB/[!JMSL>$J[/V]73\FM/Z""&V957R#QG4]^I\]6/?T#;;5L#[
M'<59?HTM'P;AZS)O*:,[/H-P@4ITR#D)D@`B;=9%"0Q$V;V6[%+_$:V>HKD?
M;-:R0/^5Y,QZWSUVH.<_VK+X638$J@U]$AW84OHJ7'\4P@2+@\'J%]F!OUJO
M(+OL5/&_Z?D[*?<'#NV>`R-!;%5\/!.60T4AS`S+-'):00+PZ=6E&`VH2/:>
M^AB`RX(?4C]:S.;+,$+@[FT)XR^E".E[^8EQ6O^OG)!,2L62J3UG/-NL6WKV
MH-_@S8Z9F!ZT@L#7G%2$+DM7DI"="/(HHJ3^TO<`GT%EWS8X"=?!&U0CO_@\
M*1_X['Q0YQ%`-EU*D$8_)7MYKLC"62!#X64J3\K0A\%VF$B'$<QC9S>N<&(1
MU+U'`B<W&BH#Y1/+LO=YQ4-`O!"M=DS`%5.L2_TY$.LJAY,;*06JG!`,9<\I
MLC,'Q/$%%LX2O:NPL@SY+?2PHJ#1?#E;WB4H%NH0RK+0NIC$=C8P=>/9"&<=
M2EF&;(3J&AL#A_$(-F*A#J$L2&<SM[-)=-C/AU\XZU#*,F0C!F-`YP&-F#ZY
M4@>YF(SV+.R$!.T^\N>,I+>!)@+`WASL)V0(A1@XC):SN_,F%QH@%]G0>[1T
M4#*DXPXEI0>P?[L=A%P2@:P:\3""4B<2-Q!E,KKTX*`D-G5OW.]04A*@45(F
M2Y<LLC"N2T-90%9=2!R4)@D#&BK#Q62A9-$&%,/HW*G:4!F0,FD]BL+;FU-[
M+Z))VB"]C2%WJ0.VJ$,<)C,H]^>4Y$(=Y&(R*-W>D1HE/$D<I+>!YA(';!.'
M!+;$'4)*!_J3+2/!\:@O#5%X>__JA"9)`QY*P\4T'#ILD8810R>7&353PF`0
M<IP5Q/%DO#!(;P/-)0S8(@PHQ"/>L'*E@:*4P>#D.#'@2<H@O0TTUZ$!6Y0A
M@<UU9^B&PB`##8;.<6;`DX1!>AM\7,(0683A/A^Y2D>XF(S^.(X,T215D-X&
MFDL5(HLJH`2,GS=(+C,@E%`8A!P'AFB2*DAO`\UU8(@LJC!*N>5"`T3I@J'<
MC@,#7)0GZ(+T-M`&NJ`NSNIV6I-V3WXG5<6\G)[$I1C#M;*S=A?V1WFJ,NWQ
MZE%=Y(/N%[A('[,]^3-K]V7#O(KL(&8HQ:955W'UP.E17HJWE,,56GX]P%\F
M!&ZYH3B&[2CEUP<X:@7=GS";7P```/__`P!02P,$%``&``@````A`()Y>*^Z
M#0``<$@``!@```!X;"]W;W)K<VAE971S+W-H965T-RYX;6RLG-MR(CD2AN\W
M8M^!X'Z`*DXVT>Z)-G4^Q<;&[.XUC7&;:&,<0$_/O/VF2DHDY5_&9F+F8NS^
ME`=5*J52"IE/O_ZQ>^[]OCD<M_N7NWXP&/5[FY?U_F'[\NVN_Y_?DE]N^KWC
M:?7RL'K>OVSN^G]NCOU?/__S'Y]^[@_?CT^;S:E'%EZ.=_VGT^EU,1P>UT^;
MW>HXV+]N7JCE<7_8K4[TS\.WX?'UL%D]M$J[YV$X&LV&N]7VI:\M+`X?L;%_
M?-RN-]%^_6.W>3EI(X?-\^I$_3\^;5^/;&VW_HBYW>KP_<?K+^O][I5,?-T^
M;T]_MD;[O=UZD7][V1]67Y_IN?\()JLUVV[_`>9WV_5A?]P_G@9D;J@[BL]\
M.[P=DJ7/GQZV]`0J[+W#YO&N_R58-)-)?_CY4QN@_VXW/X_.[[WCT_YG>M@^
M5-N7#46;QDF-P-?]_KL2S1\4(N4A:"?M"/SKT'O8/*Y^/)_^O?^9;;;?GDXT
MW%-Z(O5@BX<_H\UQ31$E,X-PJBRM]\_4`?I_;[=5J4$16?UQUP_)\?;A]'37
M'\\&T_EH')!X[^OF>$JVRF2_M_YQ/.UW_]-"@3&EC8R-$?IIC,P&-]/I9'8S
M)R,7%"=&D7ZR]\E@$D[G-ZW["YIDM^TW_32:P<T@O)D&TYGJ^`7-F=&DGT;S
MUC[P!;VYT:.9<V5?;XTF_32:8?"QIPPH']K'5+]<U=N`!U;]<F5_`TH&[=5F
MQ0<'-.!44+\8M\'MQY(AX&Q0OQC=RVZ'.IG;N1&M3JO/GP[[GSU:<.B9CZ\K
MM7P%"V6-9X4>WO,\>6N:T/Q05KXH,W=]&GB:`4>:V[]_#J?AI^'O-!_71N8>
M90)?8LD2:O(ILY$$L02)!*D$F02Y!(4$I025!+4$C0.&%-IS?"DO_H[X*C,J
MOAR9>P9.P$4P68)5(@EB"1()4@DR"7()"@E*"2H):@D:!WC!I)D"P9S0&M:]
MA'-N*BU:K+W<'/O!NM<R4[U8J]1;`HF`Q$`2("F0#$@.I`!2`JF`U$`:EWBA
MI*GNA?)R")7T77]*X^+,[XF(H1$BEX[0U!=:GH7.:0DD!I(`28%D0'(@!9`2
M2`6D!M*XQ`LK)>,58572;5@Y&/>&.'D()`(2`TF`I$`R(#F0`D@)I`)2`VE<
MX@6,]A9>P-3[)YP.2/[*-Y`RY,=2DY#V$DX^SD0^GH5X""(@,9`$2`HD`Y(#
M*8"40"H@-9#&)5YXZ8WLA??R-%?2?@P-<?(12`0D!I(`28%D0'(@!9`22`6D
M!M*XQ`N8JO;D?N@OY:,RY,=2$Y&/<Y&/9Z%S/@*)@21`4B`9D!Q(`:0$4@&I
M@30N\<)+D]$+[^5\5-)^#`UQ\A%(!"0&D@!)@61`<B`%D!)(!:0&TKC$"Y@J
M9ZZ(6"ONAXP1O;.<=?!&Y)V5.B<>HAA1@BA%E"'*$16(2D05HAI1XR$_I&JO
M[L[QRTFHRD*1A8R<-$04(8H1)8A21!FB'%&!J$14(:H1-1[RXZ>VYV[\U#M[
M3F<A5[^S5?DL0ZN16"5O9;:>I6RV`HJ->;+%4@FB%%&&*$=4("H158AJ1(V'
M_&BK+;P;[7>RU>SXP_,SWZL#!A5E-UL!12@5(TH0I8@R1#FB`E&)J$)4(VH\
MY,=/[=6OB)_9VKOQT\A/R=E(IN19BI,M4N<I%'@G_V)$":(4488H1U0@*A%5
MB&I$C8?\D*K=_!4A-9M_-Z0&N2D)*%*GLW[BQH@21"FB#%&.J$!4(JH0U8@:
M#_GQ4]OU*^*G=_=4?7-FW0?NAK\]*EM:9%_SP5B\YB,C-:7]AMT,S,0Y7&RE
MV&-BS3-*$656T34O#EMR*\6V"K15(JJLHFM>'#'45HK--YXM?RQ4)7#%6)C"
MP1T+C9Q9O@P`10:)P(LCTMA*<=<3M)4BRJRB&QEQ0I-;*39?H*T246457?.B
MEJZM%)MO/%M^X%6-<$7@=4GA30*WRC"3`%`4&$6[U,2($H.<04P19:B8(RI0
ML414L:(_$T4Y6%LI&U+W&?V0JBK"#:D^S!^HCY9.3]OU]_L]37K:SG9L(<9T
M:&^.\DTMXJ:X1DYTE@&@R*!9^S%<:RM&E!@T;C_I:Z52M)6A8HZH0%LEVJI8
MBB:EL^:)E;&V4C;2^AEU5[U(A]=59:VX7Y49I%ZR3J?D/I>EU`#R!RNXJ%LI
M[GK,:*8_BQG/Q$J3L,!%RZF58LL9HIR1=G8[&XD5N6"!B\Y**\7.*HN<YY^*
MUU7-4O/V86>#4`@T+/"6?W]LKRL/0RP/#9I0^IQ'+9S+#:.14G766:IC;+5Y
MDN*@Q$91/915G(G%..DT/Q.OXM1*L?D,4=[E,9R+*!=6T>F7W(&45HH]5HCJ
M#WELK&*W1W]<58$H5\>0LH6RHF-!),PK8JA+2_?=P\@=@W`N)MG22*F=H!TI
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MFMAJ8FG0>Q-6VW(48[256%L\V"FB#!5S1`4JEH@J5*P1-1[RYQ!-_K]A#BDK
MHA312)6:YRP.YU"*&*EWMJM::F(S+PX-"MLY%(PGL)TYZUC_L!%.C1GGK9JQ
M9>LL9V2<C<*I>,D6+''Q.4KT5EGD=!-K$?TP9E+-!G(&-YUFWIQ&JM9W7X5R
MW?QM__I614_S];R!-6<@3DD?&F1CMT04(8H1)8A21!FB'%&!J$14(:H1-1[R
MYY*J[&5<9^/VI.3*>R=T*`(32B/58B?4#=1_9RE>@2)CRSEGB1$EB%)$&:(<
M48&H1%0AJA$U'O+"/;[NN*05]]<H1DZZ(HH0Q8@21"FB#%&.J$!4(JH0U8@:
M#_GQ4X<`;KI>WA&/]9F!NR-FY*>D6(F75NJ<DHAB1`FB%%&&*$=4("H158AJ
M1(V'_)#*TX!W0HI'`&.#W)0$%*%4C"A!E"+*$.6("D0EH@I1C:CQD!\_585>
MD9*Z:/52TB`_)>41RO@L95,24(Q2":(4488H1U0@*A%5B&I$C8?\D%Y7]]*Q
MM'SQ,')3TDA9%*%4C"A!E"+*$.6("D0EH@I1C:CQD!^_OZ7('&.1:9"S]5Q:
M9%_QL&>-C-18%]'A*!!'$+$5X.Q.V+(M#5-&=@PSJ]C^K<4H$-O<W`JPY8+-
MM);]R%U7K8VQ6C/(_SA#'@,M68I"?-X8=41-FZ<RC[L>LZ(.)%T/]B]?)-Q^
MT7!JI=APABAG](:O@MO?\N5'5I4#5RR3NGKPEDF-_.KL1@SWDE),+0;OG'!8
M*0Y`;)"I5^2()5;#CAC][9@?_M1*L=T,42Y<B?.%PFITN_+C*@NC=U[?6`"-
M-1(9*X[4EBSUUF"WAWB1E>+GCQGI+!)[_X1;7;,=835=M!,ALXKL*6?4Z:G@
MUK<\^5%5)<D5V:HK&"];-1+9*H9Z2>=I'\G6LQ0_:VP43;8&N`Z<5;IS2)^Y
M6O=L.$.42U\B-0JKTNW+BRR=1ET3V5;<KX`8V9?`$E&$*$:4($H198AR1`6B
M$E&%J$;4>,B/WW45$)T_R;V10:I(/;][PAMQOKJT4IP:$:(848(H190ARA$5
MB$I$%:(:4>,A/Z3754`3K(`8N2F)%1!*Q8@21"FB#%&.J$!4(JH0U8@:#_GQ
M4V6(NUBJL[DQ_6DU+;57GB%-3$7CG,\9)-)5'LI:*9NNVA8I,HI1*D&4(LH0
MY8@*1"6B"E&-J/&0'^[KJB/Z)@%8`:`46K*4S>`(48PH090BRA#EB`I$):(*
M48U(?8%"^]CM`^GXZ2]$T'_TO=L<OFV6F^?G8V^]_Z&^[&"J/B`^8_U-#/<3
M]54,K0EH":FE35-H&5-+6UI`RX2_V$&VC$<+=>I%B0HMU`,ZO.EJH1[0L417
M"_6`JNNN%NH!U8T=+1/J`;UU.EH"\D.W\KM:R(_^D%#V.B`_M*'LTIE22[N/
MDSKAS4(=5'?HA+?4TDYCJ3-;T%_\=6C,%_2';1V<7'1Z(`>=]@.*"OW]3(>E
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MB;[II?T$[HF^V6=#5YY&ZN^@'O?[$_^#NCL\?U?0Y_\#``#__P,`4$L#!!0`
M!@`(````(0!=)*%5&4P``'#N`0`8````>&PO=V]R:W-H965T<R]S:&5E=#8N
M>&ULK-W9DMM&UJ[A\QVQ[T&A\]\JUEP.VW^T2<P#"4[[6"V7VXJV)(<D]W#W
M^P.1R1Q>%$BJ^Z2M?FHA`6*MQ+"`8OWPO__Z\/NK?SQ__O+^T\<?7\^^NWK]
MZOGCNT^_O/_XMQ]?[[;I_SR^?O7EZ]N/O[S]_=/'YQ]?__OYR^O__>G__I\?
M_OGI\]^__/;\_/651OCXY<?7OWW]^L?W;]Y\>??;\X>W7[[[],?S1_WDUT^?
M/[S]JO_[^6]OOOSQ^?GM+X>%/OS^YOKJZO[-A[?O/[X>1OC^\SEC?/KUU_?O
MGA>?WOWYX?GCUV&0S\^_O_VJ[?_RV_L_OMC1/KP[9[@/;S___<\__N?=IP]_
M:(B_OO_]_==_'P9]_>K#N^^+OWW\]/GM7W_7Y_[7[/;M.SOVX?]@^`_OWWW^
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M[-JIU6D_#LOJ(Y[WT68/=A']PRQR_73FZK0#A]5Y>_+AN]GMU7U?`U,;:O?H
M=5^WIC*F,W]]+#C]P^X7K^(FUG:MG7_8SOX?DVM[,Q3Y8<XLWGY]^],/GS_]
M\Y6.1%KGES_>]L>UV??]*':V#&L]SI^7IH_F33_*7_IA?GRM/:V9\463_A\_
MS6://[SYA^;I.Q/S\TA,&#&W$?VD[(==Q)#$D,:0Q9#'4,10QE#%4,?0Q-#&
ML(QA%4,7PSJ&30S;&'8Q[#UXHQ0?\ZS4_C?RW`_3Y]EFZ&<++O'745)MA%UD
M$4,20QI#%D,>0Q%#&4,50QU#$T,;PS*&50Q=#.L8-C%L8]C%L/<@2*H.+$%2
MQT]Q=H[VT3J9!7/T*4S6ST/,W7`RZZ?@'+*`))`4DD%R2`$I(16DAC20%K*$
MK"`=9`W90+:0'63O2Y!2G>@N2&D?_>/K.]6'.^Y>7T4Y-4%:I1<T"X/FQZ#C
M-(4DD!2207)(`2DA%:2&-)`6LH2L(!UD#=E`MI`=9.]+D&9=15R0YC[ZD&:;
MG)^->/,4LH`DD!2207)(`2DA%:2&-)`6LH2L(!UD#=E`MI`=9.]+D$!=AUZ0
MP#XZ3*`1%8@W*>-3YS'(YGT!22`I)(/DD`)20BI(#6D@+60)64$ZR!JR@6PA
M.\C>ER"GNGR](*=]=)A3(]ZDA"P@"22%9)`<4D!*2`6I(0VDA2PA*T@'64,V
MD"UD!]G[$B2P[^'$-S/7=]]I$E]X.],/%.9VD&O=WGGS]28ZB1Z#CO,5DD!2
M2`;)(06DA%20&M)`6L@2LH)TD#5D`]E"=I"]+T&ZE8P@W=.7OWUTF%,CWGR%
M+"`))(5DD!Q20$I(!:DA#:2%+"$K2`=90S:0+60'V?L2)+#O(@49[+L/NOFX
M=+H>Q@ES:RB:L+?1A'51QQE+2D@I*2/EI()4DBI236I(+6E)6I$ZTIJT(6U)
M.](^H+`&^HZ%?]">GL6SH<&A6QZ;L9\M>?.8M"`EI)24D7)202I)%:DF-:26
MM"2M2!UI3=J0MJ0=:1]0F->^:7%!7H<>1Y!70SI]>^?<NW@*'Z-L02SZGG1_
MJ!^Z^WT7(R&EI(R4DPI22:I(-:DAM:0E:47J2&O2AK0E[4C[@,)4]]V,"U)M
MFA_^%/;[(8?6[[Q_7-`GT<WJ!2DAI:2,E),*4DFJ2#6I(;6D)6E%ZDAKTH:T
M)>U(^X#"O/;MBPOR:KH=?EX'BL["]_$4/D:Y*0Q*9J"4E)%R4D$J216I)C6D
MEK0DK4@=:4W:D+:D'6D?4)CJOM%Q0:I-7\1/M2$W7^?]4]=X"H,21J6DC)23
M"E))JD@UJ2&UI"5I1>I(:]*&M"7M2/N`PKSVS0X_K_T5]C?=$L],V\1/^4#1
M['Z(9_<QRLUN4&*&UU@V*B5EI)Q4D$I21:I)#:DE+4DK4D=:DS:D+6E'V@<4
M5D'?,?&KX,0UMFFP^*GV>R[F!`U:],_<PPF?D%)21LI)!:DD5:2:U)!:TI*T
M(G6D-6E#VI)VI'U`85[[UL@%>1TZ*<$U]K&YXE]C1T_NY[-CE)V<"U)"2DD9
M*2<5I))4D6I20VI)2]**U)'6I`UI2]J1]@&%J>Z;*!>DVO1<_"GLMV',%`8M
M9J"$E)(R4DXJ2"6I(M6DAM22EJ05J2.M21O2EK0C[0,*\MJ_)W1!7@_A8:?+
MDJZLO-ODZ,'^W$4=IS`I(:6DC)23"E))JD@UJ2&UI"5I1>I(:]*&M"7M2/N`
MPE1?UNGJWPOK3Z;>%+;D76.3%J2$E)(R4DXJ2"6I(M6DAM22EJ05J2.M21O2
MEK0C[0,*\]JWF\X_-/=OV<5Y'2B\D+Z)WN.8FP6]2^0%*2&EI(R4DPI22:I(
M-:DAM:0E:47J2&O2AK0E[4C[@,)47];INF:GRY(_A=GI8E1"2DD9*2<5I))4
MD6I20VI)2]**U)'6I`UI2]J1]-KY,/,.^S[,:]];NF`*#ZVHX-!L*#@+W\1O
M65T?H]Q9&)0P*B5EI)Q4D$I21:I)#:DE+4DK4D=:DS:D+6E'V@<4IKKO0%V0
M:M.P\L_"AOPI#%KT+XI']\*DE)21<E)!*DD5J28UI):T)*U('6E-VI"VI!UI
M'U"8U[ZG=$%>AQ94,(6/72GO0OHF?B?K^ACEIC`H851*RD@YJ2"5I(I4DQI2
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M6]*.M`\H3/5E[:P;MK,L>1?2I`4I(:6DC)23"E))JD@UJ2&UI"5I1>I(:]*&
MM"7M2/N`PKQ>ULZZ83O+DG\61C?+!;D9;(;R3L*,2DD9*2<5I))4D6I20VI)
M2]**U)'6I`UI2]J1]@&%F;ZLFW7#;I8E?P;[39;AMW@9E9!24D;*206I)%6D
MFM206M*2M")UI#5I0]J2=J1]0&%>^Y:2?W'UC:]5WYC6E'?592@Z.\?O9+HH
M-[>'L;2@I811*2DCY:2"5)(J4DUJ2"UI25J1.M*:M"%M23O2/J"P!OKVDU\#
MTZ]\W)ANE9]J0_[<!BWL@BXJ(:6DC)23"E))JD@UJ2&UI"5I1>I(:]*&M"7M
M2/N`PKSVO28_K_W<OGGLO\KDTM^:N!G:5GX+S%`TO>/W-5V4G<L+4D)*21DI
M)Q6DDE21:E)#:DE+THK4D=:D#6E+VI'V`85E<%D+[(8M,$MNXLY)"U)"2DD9
M*2<5I))4D6I20VI)2]**U)'6I`UI2]J1]@&%>8U;8-_\ON8-NV.&HMD=OZ_I
MHMSL'L8*3MZ@E`MFI)Q4D$I21:I)#:DE+4DK4D=:DS:D+6E'V@<45D'?R/(/
M\B=.WJ;OY9^\T0J;ZSNWXNX8*2&EI(R4DPI22:I(-:DAM:0E:47J2&O2AK0E
M[4C[@(*\WL;=L7YVS^Z^>]#)^^MO[]_]_>=//8Q^V=*-OE7I<#OUE\,H8=/,
MD'X;R\[9N2._CQ:]V;DP47VCUNNV12^/)2[*#I^2,E).*D@EJ2+5I(;4DI:D
M%:DCK4D;TI:T(^T-Z9=MM`O#HKBLCW;+/IHA[_`\=^3G%=D?QNI[02[[M]%[
M1XD92U$N^V;!PZ<Y5&5FHW3[[\:ZB=:8VZAPC=$SUL)%V366EMP:*T<3:ZQM
M5+C&J)_<N"B[QM:26^/2T<0:5S9J<HV=B[)K7%MR:]PXFECCUD:%:XSV_<Y%
MV37N+1W6&%;E95W`6W8!#055.41YM#!1?9O9E<UM]-Y,XJ+LIJ<</B/E;D%_
M^.B!8.&B[/`EQZI(M5O0'SYJAS0NR@[?<JPE:>46G!B^<U%V^#7'VI"V;D%_
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M<NCLK*C<1=D-*`SIUS(.WTI[&WVRTBTR\<FJLZ)J%V57WX2KOXZ.R:U;8F+M
MR[.B5B[*KKUS:_>&OXLJ;NT6]*,P"TRA3.9IZ\:R&[&S9$O@^BG:"WL;\=+0
M8<F/=<`OOXEF\_MVH.C,$IVDYS9*>V-J)@QCZ9=&[&Y(S(+ZY8+AZY'U5=+A
M;TJG-N*EW6!NM,QF3FY`[L:R&U!8ZCL)^G[F:.VE_?'DVBL3U?_&^<L?OW9C
MV;4WEH:U1WNUM3^=7/GRK)6OW%AVY9VEX.;T+BK#M8T*-H)G@W/V_]:-93=B
M9^E8`#?1L6AO(X(-\(ZRX3RX[!'`+1\!&-*[\G8;YX9.'>>'L;P%$XZ5NK'L
M\)FCB>K).59!*MU8=OC*T<3P-<=J2*T;RPZ_=#0Q_(IC=:2U&\L.OW$T,?R6
M8^U(>S>6A@_+1B?ZX(KAV^[0^E&B"XF!HL-GU(28WYJHR>/'PD3U#S7=42:^
MEDILU'`M=:^_LQ$=5E(;$8SC32AS1#UGF_+1L>)M*FS4<!U\?17=3)3VYY-;
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MZ0L798=/+)D'0P^S^/EL:B,FA\[.BLI=E-V`PI!]-A@GI'2+>,>5^)-59T75
M+LJNO@E7'UTAM&Z!B94OSXI:N2B[\LZMW!O^/KH&7KL%O2ATX4:CXOVT=5%V
M(W:6;`5<QT>'O8UXJ0+"BN^?2_@5'[?<SGJ_]JX?)3K!#!2=8*+9.3<+GCK!
M#&/YCP;-@L='@X_QODMMQ$N[P9Q-S&:^='@8VG1N+)N'PM+HP[G2_M0]S*P,
M37_4F@LVEH(G<7'66QLU^7&79VW$RHUE/VYG*=R(:`*N;52P$3P!G+//MVXL
MNQ$[2_9QH/X*<O@\>&\C@@WP2B.L_;X3[M?^B9NSH7$>'.T'"OJ#`YUH*]]A
MP824&O+Z49DC[^CB?4!3KQB^X/"E&\ONX<K1Q/`UQVI(K1O+#K]T-#'\BF-U
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MFK0A;4D[TCZ@,*_]PXKSKZCOAV<;_A6U(?^*FK0@):24E)%R4D$J`PH_<]\_
M]S]S?)HZZW+P?NC"![MB(._J?VZB3MQ<F"C]ROSPVQ?Q>ZN)"[!'P-2.[!Z:
M999>NI<:;C7<6&9E43^D<`%V9:4=F<_+[G5E$.S,Z5NR0WAT#NA'B!O;]]&%
MR-PL.'TSOAB-BB_'$ALU7/;,GF;Q@__41KQTV3.T(LZ*RD>CXFTJ;)39IL?K
M^$MY2QOQTC:%-1[W1<]^]'#/%JFAL$5Z'UWFSVW49/4M7)0MKL22:9`]W=]%
M3:?41DP.G9T5E;LHNP&%);,!=[=WT6<K;<1+&Q#N^[Y;\I\?7X:>2W!\,6V8
MX&KI(7II97YOHEZJDT/M+DR4OGW%[H;$T+%#=\MI,0S=_YD(=[D6WWMD9VU`
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MI'U`8:HONZU^X&VU)7\*\[::40DI)66DG%202E)%JDD-J24M22M21UJ3-J0M
M:4?:!Q3F];+;Z@?>5AO22U[>A<!#]/[&W$79*X@%*2&EI(R4DPI22:I(-:DA
MM:0E:47J2&O2AK0E[4C[@,)4Q]V$Z:O,![8-+/E3V$0Y6C`J(:6DC)23"E))
MJD@UJ2&UI"5I1>I(:]*&M"7M2/N`PKSJY!F<A;^I2]1_ZUE\<A[([Q*9J!,W
M%2:J_V)%[^XKNE5-7)0])*2DC)23"E))JD@UJ2&UAD9^-^!AK'UQ\>NTAU&B
M*Z.ANQ'L_"/YNS7J/RW,6/T7P+B=_Q"]*9>X*+?SS?!>G\Y$3:<[=V/Y:XR;
M=2[*KK&TP[LU5I9>NF\^]`1J-Y:_QNCQ:>.B[!I;.SS;@P]]Q\"_!S^[#W58
M,DJ>Z6R$_8^H630W"Y[H%(Y&Q7=RB8T*IES\)D]JHX++;>]N;N@6GA65CT;%
MVU78J.$.\_;J,7ID5MJ`R4VJSHJJ1Z/B36ILU$N;U-J`ES8I//KV#92X;BX_
M``QM&+^E\V#Z-_J/-X^CW3>W49/S96&CW$1+#.EK3X?OG\`KTVX9;_VL%;.5
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M*ALUN1&UC7(;T=B-,#><V`FM6V9\_6$IQ#VKZ1O.QZ$K%>1\(.\F<6ZB3ATD
ML&!B%O3&2MU8]H"8.1K_@,,-)\<J2*4;RPY?.9H8ON98#:EU8VGX<,?W78_X
MV'UQT^=QZ)T$^3#M%/W'%6E\")N;!4^=EX>Q3MUPFBASPXF*3,W*PF'B&9&=
MM4GYZ%CQ\;*P4<,FC1W"QSY9O$G569M4VY4%4SG>I,9&#9MT\W@;/<QH;4`P
MC+=)8?GTW9JI\CGSAG-H^@3U8\B_B`,M'D$)*25EI)Q4D$I21:I)#:DE+4DK
M4D=:DS:D+6E'V@<4Y/LI[D]-'Z</X>'UG:'H(7M4A',798^'"U)"2DD9*2<5
MI))4D6I20VI)2]**U)'6I`UI2]J1]@&%J=8!()C:)U+=AT>I-N1-X2?0@I20
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M_?0A?W[_M\,CK=&_N^M]%?_3T`3RNQ^&HO-S_"JZBW*S>QA+"UI*&)62,E).
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M8_0ZARI@6-1_<V[$5`&(4P7`5`$P50!,%0!3!<!4`3!5`$P5`%,%P%0!,%4`
M3!4`4P7`5`$P50!,%0!3!?@65<!E[;+9%?ME1PLF/#MF(W%*-^*4;IC2#5.Z
M84HW3.F&*=TPI1NF=,.4;IC2#5.Z84HW3.F&*=TPI1NF=,.4;M^B=,==M&]Z
M_VQVQ>Z:-?\--,_<_?K,>ZYZ>%U@8<->_EXB+\)>+JA,AHT8WK(;7D4ZF@YY
MQP8!5JC*&19U*XP.5ZJC8X1=H>K(7V&T7_M6TOF7Q+,KTWKRKHFMA6^!/49O
MJ>E`.BQZX@V/\;#XR;CFGQE-]]9NA\7OU6A?G[-2S=)SPK3[Q\+B;5,.CMMV
M^`:I^^AE)B5D;!ROO*(<Q>VG;ZQ]MJ5F5X.%+U\]QK\Q=@R;K$Y-AV$T_25?
M6WO*TV#V_:OK6?3H22DRVZ#)[S+I[0P[0TS8Y#8H1=@&Y<-LP_#]1;>SZ/,I
M'R<V(<K'94VBV16[1-:\MY8T08:XDQ-D"/,6U5Z&:;\>A[/94)T?;6)?:R=B
M..U$F/;;<3BM(MI)8QV7B]]5FEVQW6(M*MIHDFEW#HN>>%W)AH4O&L5S6GMX
M&.W6O+`T5L<F8K)`E8)S-DLI&!LMWBQEQ80-+WG>/T;WJTK1V#C>[(JR%G=(
MXD/->:\(S:[8.CE:<+6%?HJ.(C#M?9CJ&Z:="].>A&FWP;2G8+K:@NEJ"Z:K
M+9BNMF"ZVH+I:@NFJRV8KK9@NMJ"Z6H+MANQ?6AA&<PN[*<<XJ-^BC6=ZMQA
M_3'^);:9"[-'J<6()2.6CE@V8OF(%2-6CE@U8O6(-2/6CMARQ%8CUHW8>L0V
M([8=L=V([4.+*D!'L4NN"_NC;/0L<V;-G_`TI=LLZ^*4;IC2#5.Z84HW3.F&
M*=TPI1NF=,.4;IC2#5.Z84HWK!LQI1MQ2C=,Z88IW3"EV[<HW?V-]@6W`;/A
MQMQ_"C(S%C50XY<%O3!OP@_#^0]"1N)4`8A3!<!4`3!5`$P5`%,%P%0!,%4`
M3!4`4P7`5`&P;L14`8A3!<!4`3!5`$P5X%M4`?V]]R458.[5_1M!W=$>#@)N
M(L]G-$UXQ&G"PY1NF-(-4[IA2C=,Z88IW3"E&Z9TPY1NF-(-4[IA2C=,Z88I
MW3"E&Z9TPY1NWZ)T]RV!2](]M!#""6\L.,,_1?=WJH!CF#?A8:H`F"H`I@J`
MJ0)@J@"8*@"F"H"I`F"J`)@J`*8*@*D"8*H`F"H`I@J`J0)@J@"8*L"WJ`+Z
M'L0E%3#T+,(*,!9,>)@F/$SIABG=,*4;IG3#E&Z8T@U3NF%*-TSIABG=,*4;
MIG3#E&Z8T@U3NF%*-TSIABG=OD7I[EL<?KK[.[N;Q^_ZKX^]\!6(V6QHEX2E
M,%AX]G^*7W&RBWIG>E7'<5%[@%!UP%0=,%4'3-4!4W7`5!TP50=,U0%3=<!4
M'3!5!TS5`5-UP%0=,%4'3-4!4W7`5!V^1=71-W+\ZIA^,V(V&QH_8048"PX&
M,*4;IG3#E&Z8T@U3NF%*-TSIABG=,*4;IG3#E&Z8T@U3NF%*-TSIABG=,*4;
MIG3#E&[?HG3W32$_W=[!X%3FAWY2F/G!=']A)_!\UG?G=$-XJXUPM_]/T4M1
M*H9CF%U4Q7`T?U'7V8H^2]_N\#_+J0]@VB/!A2M:)OH`,&TM3%L+4^G"5+HP
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M!ND>+*S7P4[6ZS',J]>C^?7J'NM&'Z"_*[KD`YB[J.`#^'=6MEYAJE>8ZA6F
M>H6I7F&J5YCJ%:9ZA:E>8:I7F.H5IGJ%J5YAJE>8ZA6F>H6I7F&J5YCJ%:9Z
M]2U*=W^;XZ?;72%<>J.KOYK",^[Q+LJO/3Q]-HL&-[HT%<=Q.%O>*@Z8B@.F
MXH"I.&`J#IB*`Z;B@*DX8"H.F(H#IN*`J3A@*@Z8B@.FXH"I.&`J#M^BXNAO
MBOSB.'7N,C=1P;'`O[&RQP*8C@4PI1NF=,.4;IC2#5.Z84HW3.F&*=TPI1NF
M=,.4;IC2#5.Z84HW3.F&*=TPI1NF=/L6I;N_E;PDW<.M9WBM94Q''.].%@^R
MKX]A=B*K`F"J`)@J`*8*@*D"8*H`F"H`I@J`J0)@J@"8*@"F"H"I`F"J`)@J
M`*8*@*D"8*H`F"K`MZ@"^EO)2RK`W'H&$]Z_';43'J9TPY1NF-(-4[IA2C=,
MZ88IW3"E&Z9TPY1NF-(-4[IA2C=,Z88IW3"E&Z9TPY1NF-+M6YCNF[@]<.+X
M?HB/F@+&^K5X$QX/LEV8F_"T9$9+1RP;L7S$BA$K1ZP:L7K$FA%K1VPY8JL1
MZT9L/6*;$=N.V&[$]J%%%7!A5^5FI*MBS>^JT!8SFM)MQG/+*MTPI1NF=,.4
M;IC2#5.Z84HW3.F&*=TPI1NF=,.4;IC2#5.Z84HW3.F&*=V^1>GN6Q<7'-]O
MAE9'<(:WYI_AKZ_P(-N%>1/>#.>_\LPX50#B5`$P50!,%0!3!<!4`3!5`$P5
M`%,%P%0!,%4`3!4`4P7`5`$P50!,%0!3!?@654#?NKBD`DRKPS_#W_CM#W.&
MIVG"(TX3'J9TPY1NF-(-4[IA2C=,Z88IW3"E&Z9TPY1NF-(-4[IA2C=,Z88I
MW3"E&Z9T^Q:EN^_]^.G^]MO[FZ&-%!X+!@M._M=7>(YM%E68=RPX+FI-Q0%3
M<<!4'#`5!TS%`5-QP%0<,!4'3,4!4W'`5!PP%0=,Q0%3<<!4'#`5!TS%`5-Q
M^!851]\6\HOCU.6?:2,%QP)C[@0^G]W`="R`*=TPI1NF=,.4;IC2#5.Z84HW
M3.F&*=TPI1NF=,.4;IC2#5.Z84HW3.F&*=TPI=NW*-U]H^>2=`^-H7#"&]-:
MCE?[UU?1@VI5P#',3FY5`$P5`%,%P%0!,%4`3!4`4P7`5`$P50!,%0!3!<!4
M`3!5`$P5`%,%P%0!,%4`3!4`4P7X%E5`W_NYI`),KRB8\'[_R)[\84HW3.F&
M*=TPI1NF=,.4;IC2#5.Z84HW3.F&*=TPI1NF=,.4;IC2#5.Z84HW3.F&*=V^
M1>GN&SV7I-LTAH)T#Q:=X=WK);8"CF'>A(>I`F"J`)@J`*8*@*D"8*H`F"H`
MI@J`J0)@J@"8*@"F"H"I`F"J`)@J`*8*@*D"8*H`WZ(*Z'L_EU2`Z14%%>#W
MCVRZ89KP,*4;IG3#E&Z8T@U3NF%*-TSIABG=,*4;IG3#E&Z8T@U3NF%*-TSI
MABG=,*4;IG3[%J9;O^5Z4;H/\5$_SYK.(MX9WKV58RK`A;D)3TMFM'3$LA'+
M1ZP8L7+$JA&K1ZP9L7;$EB.V&K%NQ-8CMAFQ[8CM1FP?6E0!?>_G@@G?_R)O
M_):4-?^2GK:8T91NO_=T*!6E&Z9TPY1NF-(-4[IA2C=,Z88IW3"E&Z9TPY1N
MF-(-4[IA2C=,Z88IW3"EV[<HW7VCQT_WM]_>ZW>U60F#12=_]Z:3/18<P[QC
M`4S%`5-QP%0<,!4'3,4!4W'`5!PP%0=,Q0%3<<!4'#`5!TS%`5-QP%0<,!4'
M3,4!4W'X%A5'WQ;RB^/$[7W_Q\%P+/!;2S;=,!T+8$HW3.F&*=TPI1NF=,.4
M;IC2#5.Z84HW3.F&*=TPI1NF=,.4;IC2#5.Z84HW3.GV+4IWW^BY)-U#8RBX
MO>^_WDLE$$UX]ZJ8K8!CF#?A8:H`F"H`I@J`J0)@J@"8*@"F"H"I`F"J`)@J
M`*8*@*D"8*H`F"H`I@J`J0)@J@"8*L"WJ`+ZWL\E%6!Z1?[5OKZ.YG`0"$[^
M,$UXF-(-4[IA2C=,Z88IW3"E&Z9TPY1NF-(-4[IA2C=,Z88IW3"E&Z9TPY1N
MF-(-4[I]B]+=-WK\=/\')W_3,PHJ8;#H6(!7]VZ/8=ZQ`*;B@*DX8"H.F(H#
MIN*`J3A@*@Z8B@.FXH"I.&`J#IB*`Z;B@*DX8"H.F(H#IN*`J3A\BXJC;POY
MQ?&OV>W;=]__\N_%\Y=WSQ]U:W?5_S;C3S\<#NE_F?4O%N/D[[>6[*$?IF,!
M3.F&*=TPI1NF=,.4;IC2#5.Z84HW3.F&*=TPI1NF=,.4;IC2#5.Z84HW3.F&
M*=V^1>GN>T"7I'OH&84G?V-:BW?GCU?W;H]AWH2'J0)@J@"8*@"F"H"I`F"J
M`)@J`*8*@*D"8*H`F"H`I@J`J0)@J@"8*@"F"H"I`F"J`-^B"NC;0I=4@&DC
M!8=\O[5D)SQ,$QZF=,.4;IC2#5.Z84HW3.F&*=TPI1NF=,.4;IC2#5.Z84HW
M3.F&*=TPI1NF=,.4;M_"=-_%K;YO/_D?AHJZ@,:BDS_>ZG-A[EA`2V:T=,2R
M$<M'K!BQ<L2J$:M'K!FQ=L26([8:L6[$UB.V&;'MB.U&;!]:5!Q]Q^B"8T'_
M>W7QR=^:?R-`6\QH2K??L3H<1Y1NF-(-4[IA2C=,Z88IW3"E&Z9TPY1NF-(-
M4[IA2C=,Z88IW3"E&Z9TPY1NWZ)T]SV@2](]](R"D[_^#^_\XZ\?G<]<F#?A
MCXM:4P7`5`$P50!,%0!3!<!4`3!5`$P5`%,%P%0!,%4`3!4`4P7`5`$P50!,
M%0!3!<!4`;Y%%="WA2ZI`--&\D_^=WYKR9S\:9KPB%.Z84HW3.F&*=TPI1NF
M=,.4;IC2#5.Z84HW3.F&*=TPI1NF=,.4;IC2#5.Z84JW;U&Z^Q[0)>D>>D8J
M(#M#?Y[='?M(WM7^#*_NN3"[J"K@N*@U50!,%0!3!<!4`3!5`$P5`%,%P%0!
M,%4`3!4`4P7`5`$P50!,%0!3!<!4`3!5`$P5X%M4`7U;Z)(*,&VDH`+\UI*=
M\#"E&Z9TPY1NF-(-4[IA2C=,Z88IW3"E&Z9TPY1NF-(-4[IA2C=,Z88IW3"E
M&Z9TPY1NWZ)T]XV>2](]-(;""7]L%OD3'J_NW1W#[.16!<!4`3!5`$P5`%,%
MP%0!,%4`3!4`4P7`5`$P50!,%0!3!<!4`3!5`$P5`%,%P%0!,%6`;U$%]+V?
M2RK`](J"">_WC^R$ARG=,*4;IG3#E&Z8T@U3NF%*-TSIABG=,*4;IG3_?]+.
M=#EN(UN#K^*8!["))KN;5'@487'?=_WW]967&,]H0M+,??V;I[%T5>61*,A_
MY'`6"@U6?E4`#L&&&+K%T"V&;C%TBZ%;#-UBZ!9#=\D:W5'HF:-[*`Q5NGM6
MW\-W>G1O.6U63'@Q$B!&`L1(@!@)$",!8B1`C`2(D0`Q$B!&`L1(@!@)$",!
M8B1`C`2(D0`Q$B!&`DK6)"!J/W,2,-2*J@24]:-QPHLQX<70+89N,72+H5L,
MW6+H%D.W&+K%T"V&;C%TBZ%;#-UBZ!9#MQBZQ=`MANZ2U;I7;3WOA=_7;+9O
MBG8CXRRR+>!W>G1ON]EVPIL==V8G"3M-V%G"SA-VD;#+A%TE[#IA-PF[3=A=
MPNX3]I"PQX0])>PY86]KUB0@"CPS)OQJ*`B5$WYD9='.[*@S0W=98-HL%N@6
M0[<8NL70+89N,72+H5L,W6+H%D.W&+K%T"V&;C%TBZ%;#-UBZ"Y9HSNJ.7-T
M]]6?ZI)^-56$R@FOY_.VFQ43?NHZ,A(@1@+$2(`8"1`C`6(D0(P$B)$`,1(@
M1@+$2(`8"1`C`6(D0(P$B)$`,1(@1@)*UB0@"CQS$C`4A*H)7Q:)AC/\2HP)
M+X9N,72+H5L,W6+H%D.W&+K%T"V&;C%TBZ%;#-UBZ!9#MQBZQ=`MAFXQ=)>L
MT1W5G#FZ^^I//>&GBE`YX?5\WFK:;)S<)$",!(B1`#$2($8"Q$B`&`D0(P%B
M)$",!(B1`#$2($8"Q$B`&`D0(P%B)$",!(B1@)(U"8@"SYP$#`6A:L*71:)Q
MPHNA6PS=8N@60[<8NL70+89N,72+H5L,W6+H%D.W&+K%T"V&;C%TBZ%;#-UB
MZ"Y9HSNJ.:7N^!7]-WZ)_*JO#-6+P50M*A<#/:`W=*4,4"P&4]>1D0XQTB%&
M.L1(AQCI$",=8J1#C'2(D0XQTB%&.L1(AQCI$",=8J1#C'2(D0XQTE&R)AU1
M_"G3\=(-WU`LJA:#LH`T+@9B+`9BZ!9#MQBZQ=`MAFXQ=(NA6PS=8N@60[<8
MNL70+89N,72+H5L,W6+H%D-WR1K=4>F9H[NO#-43?F"$JKB_UP-ZJVFS<7*3
M`#$2($8"Q$B`&`D0(P%B)$",!(B1`#$2($8"Q$B`&`D0(P%B)$",!(B1`#$2
M($8"2M8D((H_<Q(P%(NJ"5\6D,8)+X9N,72+H5L,W6+H%D.W&+K%T"V&;C%T
MBZ%;#-UBZ!9#MQBZQ=`MAFXQ=(NANV2U[O7,@MYF^Z:@-["F@J^G\+:;;2>\
MV7%G=I*PTX2=)>P\81<)NTS85<*N$W:3L-N$W27L/F$/"7M,V%/"GA/VMF9-
M`J+X,V/"KX=B43GA1U86],R..C-TE\6GS6*!;C%TBZ%;#-UBZ!9#MQBZQ=`M
MAFXQ=(NA6PS=8N@60[<8NL70+8;NDC6ZH](S1W=?&:K.\.N!56?XA;Y;;[M9
M,>&GKB,C`6(D0(P$B)$`,1(@1@+$2(`8"1`C`6(D0(P$B)$`,1(@1@+$2(`8
M"1`C`6(DH&1-`J+X,R<!0[&HFO!E`6DXPZ_%F/!BZ!9#MQBZQ=`MAFXQ=(NA
M6PS=8N@60[<8NL70+89N,72+H5L,W6+H%D-WR1K=4>F9H[NO#-43?JH6%9?T
M"SV%MYXV&R<W"1`C`6(D0(P$B)$`,1(@1@+$2(`8"1`C`6(D0(P$B)$`,1(@
M1@+$2(`8"1`C`6(DH&1-`J+X,R<!0[&HFO!E`6F<\&+H%D.W&+K%T"V&;C%T
MBZ%;#-UBZ!9#MQBZQ=`MAFXQ=(NA6PS=8N@60[<8NDO6Z(YJSAS=??6GGO`#
MJ\_P>@IO/6U63'@Q$B!&`L1(@!@)$",!8B1`C`2(D0`Q$B!&`L1(@!@)$",!
M8B1`C`2(D0`Q$B!&`DK6)"`*/',2,!2$J@E?%HG&"2_&A!=#MQBZQ=`MAFXQ
M=(NA6PS=8N@60[<8NL70+89N,72+H5L,W6+H%D.W&+I+UNB.:LX<W4/UI]+=
ML_H>?J&G\-;39L6$%R,!8B1`C`2(D0`Q$B!&`L1(@!@)$",!8B1`C`2(D0`Q
M$B!&`L1(@!@)$",!8B2@9$T"HL`S)P%#0:A*0%DD&B>\&!->#-UBZ!9#MQBZ
MQ=`MAFXQ=(NA6PS=8N@60[<8NL70+89N,72+H5L,W6+H+EFM>W]FT6ZS?5.T
M&U@SX?44WG:S[80W.^[,3A)VFK"SA)TG[")AEPF[2MAUPFX2=INPNX3=)^PA
M88\)>TK8<\+>UJQ)0!1X9DSX_:$@5$[XD95%.[.CS@S=98%ILUB@6PS=8N@6
M0[<8NL70+89N,72+H5L,W6+H%D.W&+K%T"V&;C%TBZ&[9(WNJ.:4NN-W]-WR
M^[@+^/3['[_\X\W[`.EK1W>WWYZR/Q2%JA3TK'J+X[`=;'N[S_>W_OC#?U__
M^,,OPY>Q$(R^*U_M^_K'_[[F"_6;1_J(R;3%N'H0D^$#=Z=?]!.3Z2"^\($D
M9]K=\('-<D6.IBW&#R1'Y0<VXQIEDW)<7_CM]OY09JD&L&<=]]_3KSO7NG`:
M>O(]H^.!,7Y#SY#X][]]W(PB?T!=#S.#.&S6#_-RMWET@A'M-RCVS8B*,7Q?
M\WF,X?1YQ6&MFL-B6,M/:(8U:A%SAK6O751WH/L]B_>&3X.S;GP?=N-6+R6U
MW]EB;QI]AG7X@(-QW)M\,Z[#%E_<.4/]-9LQ^CH&AKH^AOVVI,8HO[#S9N"C
M*E`._.;K-E;Q%4HOO9%X/[JVUP@]JZ*]6#2S'`G#9OQG4I4M%_UF14R1(,:P
MBS'&/>OXS^<_@C%65\98C%$M63.$<5O]C4,XW)%7JT//XBM2M@>^UJ.0^_UF
M+ZZXTV;C*L(0#JS/\=[>NO'#@$Z]BF-HEW/&^&LV8XRGS<9C8(RK8^!E'EXM
MIE[Y,302XF:WE?`-Y[OAGKD2,C`NH2<ABX6%])M].7`LX?UFO(E]'`R$#"Q.
MO)P6#YI]XV/JM#T$S1=\?,TAX&/:VW@(^/CR(3`!ID[Y(30ZXLZSU1%OZ)QS
M[='?O=9K?,^JU"\6S?F-]:7?K%B]&?B>\;V#XT_-P/>,+YJ/@=];KYL4,O+J
MQ3!K[XRIMF-,J[WS"'5SG`QJV:L9P;B9*T?PI0N-X>:O2F[/BO63H>G9BS%5
M5T9+C/&9=C>.*N,SL3PJFZM_ADR[8\C$&*1I=WQ$/4@'[6WMMUWE;G;3G,D&
M5E]--!/SL!NW^N()_VC<++[P>EI"DNNV86]\]7'$<;7?+C(G^8Z\,'_589WE
M>VLO)\^GS?K#VMU;-M<]%],6U<]7'%9CC<VJ:+?6GM[_^W/W)N57.Q[$?EIM
M`]LNKT@2PXC8<<(8<&UWFC"&4MLQ;F*,E-AEPJX2=IVPFX3=)NPN8?<)>TC8
M8\*>$O:<L+<U:V(0=UDS5KB#_JZL.A^,K+S*6RR:?)*`H>MV[2<!8B1`C`2(
MD0`Q$B!&`L1(@!@)$",!8B1`C`2(D0`Q$B!&`L1(@!@)$",!8B1`C`24K$E`
MW!#.24!_`UDG8&#5A!=#MQBZQ=`MAFXQ=(NA6PS=8N@60[<8NL70+89N,72+
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MQ`B'&.$0(QQBA$.,<(@1#C'"(48XQ`B'&.$0(QQBA$.,<(@1CI(UX8AB0QF.
ME]:"OCA1)V!@U5H@QEH@QEH@AFXQ=(NA6PS=8N@60[<8NL70+89N,72+H5L,
MW6+H%D.W&+K%T"V&[I(UNJ,,4NK^"VM!7U&ID]"S9BUH2CV'W<&TV3CO"8<8
MX1`C'&*$0XQPB!$.,<(A1CC$"(<8X1`C'&*$0XQPB!$.,<(A1CC$"(<8X1`C
M'"5KPA'EGS(<+ZT%?;FH3L#`JK5`#-UBZ!9#MQBZQ=`MAFXQ=(NA6PS=8N@6
M0[<8NL70+89N,72+H5L,W6+H%D-WR2K=BYVVI/=EW?WV=1%H8EQ+3.6VQ6[[
M+&JQV33A$W:<L).$G2;L+&'G";M(V&7"KA)VG;";A-TF["YA]PE[2-ACPIX2
M]IRPMS5K$A`ELJ^?\#Q%P/9M`E1F.YRVVRX"1PE#M_JB6PS=8N@60[<8NL70
M+89N,72+H5L,W6+H%D.W&+K%T"V&;C%TBZ&[9(WNJ`^5NK_YY,_[VI,D]*PY
M^;=/6XQ=RQN!A!&.:7?CFD$XQ`B'&.$0(QQBA$.,<(@1#C'"(48XQ`B'&.$0
M(QQBA$.,<(@1#C'"(48X2M:$(ZI)93A>.AL,U:?BMV"+G;(BU3^FFC#6`FV'
M;C%TBZ%;#-UBZ!9#MQBZQ=`MAFXQ=(NA6PS=8N@60[<8NL70+89N,727K-$=
MY:$YNOMR4GFMM]@96'WR;Y\#*C8;)S()F+J.C`2(D0`Q$B!&`L1(@!@)$",!
M8B1`C`2(D0`Q$B!&`L1(@!@)$",!8B1`C`2(D8"2-0F(BM&<!,3V[<E_8-L3
M_>%B1PS=8N@60[<8NL70+89N,72+H5L,W6+H%D.W&+K%T"V&;C%TBZ%;#-UB
MZ!9#=\D:W5$#*G7_A9-_7TZJUX*IQ%3>"#2/.Q&.:;-QWA,.,<(A1CC$"(<8
MX1`C'&*$0XQPB!$.,<(A1CC$"(<8X1`C'&*$0XQPB!$.,<(A1CA*UH0C*D9E
M.%XZ^0\5INKD7U:=QI._&+K%T"V&;C%TBZ%;#-UBZ!9#MQBZQ=`MAFXQ=(NA
M6PS=8N@60[<8NL70+8;NDC6ZHP8T1W=?,ZHG_,!8<8H[__:QG<7.M%DQX<5(
M@!@)$",!8B1`C`2(D0`Q$B!&`L1(@!@)$",!8B1`C`2(D0`Q$B!&`L1(@!@)
M*%F3@"@+S4G`4$:J)GQ96AHGO!@37@S=8N@60[<8NL70+89N,72+H5L,W6+H
M%D.W&+K%T"V&;C%TBZ%;#-UBZ"Y9K;MK2WUQ\O^VYP$6FWTUUX$#:V[]FX<P
M#\>NU:W_MNNX0!PGVYTD[#1A9PD[3]A%PBX3=I6PZX3=).PV87<)NT_80\(>
M$_:4L.>$O:U9DXXH&<U8#.*9X/9.8&3EG8#9T<(,W67):K.0H%L,W6+H%D.W
M&+K%T"V&;C%TBZ%;#-UBZ!9#MQBZQ=`MAFXQ=(NANV2-[B@"S='=%XVJLW\W
ML/KLWSX-N-AN-DYN$C!U'1D)$",!8B1`C`2(D0`Q$B!&`L1(@!@)$",!8B1`
MC`2(D0`Q$B!&`L1(@!@)$",!)6L2$'6A.0D8ZDCEV;\K:TO#V=\,W=H.W6+H
M%D.W&+K%T"V&;C%TBZ%;#-UBZ!9#MQBZQ=`MAFXQ=(NA6PS=8N@N6:,[BD"E
M[F^_]8\_-]/2W[/FY-\^#+@8NM8G_ZEKL1:($0XQPB%&.,0(AQCA$",<8H1#
MC'"($0XQPB%&.,0(AQCA$",<8H1#C'"($8Z2->&(DE$9CA=N_>//692`@54G
M?S'6`C'6`C%TBZ%;#-UBZ!9#MQBZQ=`MAFXQ=(NA6PS=8N@60[<8NL70+89N
M,727K-$=1:`YNONB47WR'QB?LKWUWVN?^%MTTV;CY"8!8B1`C`2(D0`Q$B!&
M`L1(@!@)$",!8B1`C`2(D0`Q$B!&`L1(@!@)$",!8B1`C`24K$E`U(7F)&"H
M(U4G_[*V-)[\Q=`MAFXQ=(NA6PS=8N@60[<8NL70+89N,72+H5L,W6+H%D.W
M&+K%T"V&;C%TEZS1'46@.;J'HE&ENV?U&;[].^+#1?P%'Z>&^@PO1@+$2(`8
M"1`C`6(D0(P$B)$`,1(@1@+$2(`8"1`C`6(D0(P$B)$`,1(@1@+$2$#)F@1$
M76A.`H8Z4I6`LK8T3G@Q)KP8NL70+89N,72+H5L,W6+H%D.W&+K%T"V&;C%T
MBZ%;#-UBZ!9#MQBZQ=!=LEKWHJWUO7!!M]F^J>>-C,O&X@ROQ_JVFVW/\&;'
M"[.3A)TF["QAYPF[2-AEPJX2=IVPFX3=)NPN8?<)>TC88\*>$O:<L+<U:Q(0
MM9\9$YYO2-`E_<C*2WJSHX49NLO:TU#/,T.WMD.W&+K%T"V&;C%TBZ%;#-UB
MZ!9#MQBZQ=`MAFXQ=(NA6PS=)6MT1Z%GCNZA,%2N[XN>-6=X/;NWW:R8\%/7
MD9$`,2:\&`D0(P%B)$",!(B1`#$2($8"Q$B`&`D0(P%B)$#L(6$D0-N1`#$2
M($8"2M8D(&H_<Q(PU(JJ!)3UH^$,OQ!CPHNA6PS=8N@60[<8NL70+89N,72+
MH5L,W6+H%D.W&+K%'A*&;FV';C%TBZ&[9(WNJ.:4NO_";_/XXA:O_5.UJ#S[
MZ[F^H6MUN6]&.J;=C0L$Z1`C'6*D0XQTB)$.,=(A1CK$2(<8Z1`C'6*D0XQT
MB)$.,=(A1CK$2(<8Z2A9DXXH_I3I>.GZ;R@658M!64`:%P,Q%@,Q=(NA6PS=
M8N@60[<8NL70+89N,72+H5L,W6+H%D.W&+K%T"V&;C%TBZ&[9(WNJ/3,T3U4
MABK=`^,>LKC<U\-[BVFS<2*3`#$2($8"Q$B`&`D0(P%B)$",!(B1`#$2($8"
MQ$B`&`D0(P%B)$",!(B1`#$2($8"2M8D((H_<Q(P%(NJ!)0%I''"BZ%;#-UB
MZ!9#MQBZQ=`MAFXQ=(NA6PS=8N@60[<8NL70+89N,72+H5L,W6+H+EFC.RH]
M<W3WE:&J@K_HV1YGD6+"Z^&][6;%A)^ZCHP$B)$`,1(@1@+$2(`8"1`C`6(D
M0(P$B)$`,1(@1@+$2(`8"1`C`6(D0(P$B)&`DC4)B.+/G`0,Q:)JPI<%I''"
MBS'AQ=`MAFXQ=(NA6PS=8N@60[<8NL70+89N,72+H5L,W6+H%D.W&+K%T"V&
M[I+5NG=G%O0VVS<%O9%Q'5%,>#V@M]ULG-Q'"[/CA)TD[#1A9PD[3]A%PBX3
M=I6PZX3=).PV87<)NT_80\(>$_:4L.>$O:U9DX`H_LR8\+M#L:B<\",K"WIF
MZ"X+39N%`=UBZ!9#MQBZQ=`MAFXQ=(NA6PS=8N@60[<8NL70+89N,72+H5L,
MW6+H+EFC.RH]I>YO?UYGMR\:52?_@<6*4ZP%>G9ONUFQ%I0UJ#$<8H1#C'"(
M$0XQPB%&.,0(AQCA$",<8H1#C'"($0XQPB%&.,0(AQCA$",<8H2C9$TXHBY4
MAN.%V_O=H8Y4K05E;6DX^8_;;=<'U@)MQUH@AFXQ=(NA6PS=8N@60[<8NL70
M+89N,72+H5L,W6+H%D.W&+K%T"V&[I(UNJ/0,T=W7QBJ)_S`^)1BPNL!O=UI
MLV+"BY$`,1(@1@+$2(`8"1`C`6(D0(P$B)$`,1(@1@+$2(`8"1`C`6(D0(P$
MB)$`,1)0LB8!4?N9DX"A5E1-^+)^-$YX,2:\&+K%T"V&;C%TBZ%;#-UBZ!9#
MMQBZQ=`MAFXQ=(NA6PS=8N@60[<8NL707;)&=Q1Z2MU_X>0_U(RJ)/2L/ODO
M]>S>[K19L1:($0XQPB%&.,0(AQCA$",<8H1#C'"($0XQPB%&.,0(AQCA$",<
M8H1#C'"($0XQPE&R)AQ1%BK#\=+)?R@C50DH2TOC6B#&6B"&;C%TBZ%;#-UB
MZ!9#MQBZQ=`MAFXQ=(NA6PS=8N@60[<8NL70+89N,727K-$=-:!2]U_X11]O
M7M`O^@;6+`;MU_4MMIL5BT&_.[J.C'2(D0XQTB%&.L1(AQCI$",=8J1#C'2(
MD0XQTB%&.L1(AQCI$",=8J1#C'2(D8Z2->F(DE&9CI<6@Z'$5"T&9=EI7`S$
M6`S$T"V&;C%TBZ%;#-UBZ!9#MQBZQ=`MAFXQ=(NA6PS=8N@60[<8NL70+8;N
MDO6Z?_CX^[MWGXY^_O3SZQ__^>[#;^\.W_WYY\?O?GG_GW]Q-;]8QJML)O[=
MAW>__OUO;XC-JTUVF)QN.XBVS<1UVR+:-@EQVVZT;5X-Y[:]:-N\PLMMRVC;
MO!#`;:MH6\4BXK9UM*W3MD7TXW=B6;]%].,7*&E;C`NE];0MQJ5?T'PL.[11
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MC_4J^JWR?JOHM_I,O_"PRCVLPL,J][`*#ZO<PRH\K'(/R^BWS/LMH]_R,_W"
MPS+WL`H/J]S#*CRL<@^K\+#*/2RCWS+OMXQ^?>&P/8]UR_#`I4:6I65X6.8>
MEN%AF7M8AH=E[F$O^O4OD-.Q[$6_O<_T"P][N8>]\+"7>]@+#[P(,OWYPL,R
M][`;_?)KJ6XO^O5OA///$!YX25GV>7OA@3>3I6WA82_WL!<>>*0CZ[<;_?)K
M-]X(&6V?Z1<>\FNW;C<\Y-=NW6YXR*_=>)MBM.4>XMJMRZ_=ND7TRZ_=ND5X
MR*_=NMWPD%^[=7'MQC_YF(6'_%JXZ^(X\VN;KHMCR:]?NKCFXY_T\Q;A*+^N
MZQ;A(;]VZ^):F'_2?7;Q>?FU3=?%SY=?VW1='$M^;=/%M2+_Y)\7QYE?*W9=
M'&=^K=C%=0'_I/N,ZX+N,]<%<9W5Y==9W4[\#/EU5K<3CO)KQ2ZN%?DG.Y8#
M?O3\JN"`'SR_)HA+K/P**RZP\NNK`Z*>7UT=<.#YM56<?O.S;YQ\\W-OG'KS
M,^\^>^/EW,E:LL\1\*+(I.6`@>-]B$E++)/Y*ADGN?P<%Z>X_`P7)[C\_!:7
M+OF52URXY-<ML33F*V,LC/FZN(OM?%6,13%?$V-)S%?$6!#S]7!S*YN>S6(Q
MS-?"6`KSE3`6PGP=C&4P7P5W&>M\#=S<OJ8KV8(^G[EW9:SS%6[!6'_FOI6Q
MSE>^31$@7_=B&<JO.F(1ROO$DIZ.=1<GGOQ\Q5CG*_WFQC^="W1)9\]FV4E[
M](MX-J\V2W@Z2S<+^&>N$SCF;/7^J7OU4[XO.F2?'IHS'A,JX3_ML?]\%4!^
M=D1OT)A:1&+J$(6I001F_H[V]UX=\Q9WKUAGM)RG+5>T7*<M1]T.N^.?;'_1
M=IZW\<+D!?W2U99W]R[HE[:]B1O?_+[W`#7Y7>\!<M)[WB-N7:_3.]>C]>K5
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MVG)!GXNTY9*6R[3EBI;K]*BO..KK]*BO.(+K=&]'%`2>\WH`G_,F[7-(RV':
M<D3+<7IL1QS;<7IL1QS;<;JW$_9VDK:<TG*:MIS1<IX>P1E'<-X?P0]3Z>/C
MZQ___?-O[ZY__O#;'__Z^-V?[W[EUU<[WW/*^>Y#__[)_G\^#:\D_Y_WGW@W
MY>;MY+^_^_E_WWV(K=GXU_?O/XW_PXG[A_][_^$?FU^1O?Y_`0```/__`P!0
M2P,$%``&``@````A`/E2=Q6;!0``N18``!@```!X;"]W;W)K<VAE971S+W-H
M965T-2YX;6R<6$V/HS@0O:^T_P%Q3\`&$A(E&0VT>G>D'6FUVH\S39P$=<`1
MT)WN?[]EEP.V23)A+C,=ZE%^?E5^-EY]^2B/SCNKFX)7:Y=,?==A5<ZW1;5?
MN__\_3R)7:=ILVJ;'7G%UNXG:]POFU]_69UY_=H<&&L=R%`U:_?0MJ>EYS7Y
M@959,^4G5D%DQ^LR:^%GO?>:4\VRK7RI/'K4]V=>F165BQF6]2,Y^&Y7Y.R)
MYV\EJUI,4K-CU@+_YE"<FDNV,G\D79G5KV^G2<[+$Z1X*8Y%^RF3NDZ9+[_M
M*UYG+T>8]P<)L_R26_X8I"^+O.8-W[532.<AT>&<%]["@TR;U;:`&0C9G9KM
MUNY7LDR#P/4V*RG0OP4[-]K?3G/@Y]_J8OM'43%0&^HD*O#"^:N`?MN*1_"R
M-WC[65;@S]K9LEWV=FS_XN??6;$_M%#N"&8D)K;<?CZQ)@=%(<V41B)3SH]`
M`/YURD*T!BB2?<C_S\6V/:S=8#:-YGY``.Z\L*9]+D1*U\G?FI:7_R&(J%28
MA*HD`;!7<?IH$@\)R?D]96VV6=7\[$#3P)#-*1,M2):0^#(QI-%-]=9,88HB
MR5>11>:"2310GO?-@JZ\=U`T5Y`$(7/7Z2#$1*07A"@$L.LHPKQMB@%4\+KV
M%T;B)9,1C<SQDBL0$Y$.$?.>M,$1I-,YWN<FP-`!FA2+P!PY04@HZR\43K4'
MQL#AF($%>.W"K+H:Q'-K8(3$LH83$I%9:`)2$^"3H,]@$(.^UA41C?7CJHF7
M+&6L\1.$:,IH#PP",Y/`_9((L*G,PFX7A(12F=`*IGHPZHMI$(+>UQ6Y3TB`
M+4(SLQ()0B))B-)H8893/4QFQ._"!BFQ0VGK_SXI`;9(]=673I`@!%4BVJ`R
MFMZ*&I06)J7'.D>\9%&+NQDC-80@M4DX:&P,HYPDHKW:!CD"SJ,+]A@[^9;5
MV%:]$H71.EM_8I*P7/M^U0@:J[[L(ZM_$X7!V0?QHI\]%LZ(3PB9]0E,9L(R
M'^XG@@:K,PMZ@\6J*8PJ6T2MADN[N+UM$&&9CU-!@]6I$+]?,XH+@E2/Q*'5
M8:D<<NTBUUC;`DV-1GDV&9IVT!N,XH48M>HLQTQ5!A6]5;B?\FMQ!K*6'?$'
M%420ZJW0'_#3XQ-PLO[H8.HVRM')T-+#`3/$J'I2T@^LNEZW]5E\2[I1QDZ&
MSAY9?90HC.KY8&#M9IQJJ]44;)2YDZ&[$]]2)%$@5&P2S#6;5))A%@6(%QIW
MDYOE\C^P,#1G6'[=R87X@U5P,7AQ_I:')J(],4:G/^7B\BUSDR%V-R<*I&H7
M:4:)G,QX[V8FOU$&3X<&3_R^6>6XB0*IPM#0/OFE"J!LHML[35ZC[)T.[9WX
MULZ2*-"EHX*YM1A2$[`(9K<T&^7W])K?]YF59KK?@V36:DA5$N0>!U&_7YBJ
MC3)\.C1\XENB)`IT46TQV(I,`"SD?K68W"S?O[\.Q=<J^+VY#NV#C`)I!QG]
MB3GZ*$NG0TL?'#$3!4)E")E;ZR!5<<G.Y#+*QNG0Q@FQ]Q<%NNR\`RJ8`ZD&
ML68E)K%1-DZOV+B]L24*I(AI'[7*HS"'"M.^^4Q>EH4_=A2FZ,G&08OTS:D6
MGF;<BA(^40U/HN#&6A/?F/JI[S%2\BW+V8EU3DD42'569)]S4B-.0VWO-&0+
M1GF[1-O,K$9*%$B),R-S2\_4!,RC^)9ZEK\_J-X5GR>VSP<(0HY1&(4]!:RP
M`:#PB='K;^IG^?R#'*_X/;']'JX0A;WA[4<8ZUN-XJ@#2!#%-D>\0<0;MI+5
M>Y:RX[%Q<OXF;@<)?*MW3_'F,H&;2WG-YW4!N#@\97OV/:OW1=4X1[:#5_WI
M'+RWQJM'_-'RD[SA>N$M7!G*/P]P1<S@NLB?`GC'>7OY(3Z.NDOGS?\```#_
M_P,`4$L#!!0`!@`(````(0!L-!\3#@0``+`/```9````>&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;)Q776^K.!!]7VG_`^*]`1/(EY)<-:FZ>Z6]TFIU/YX=
M<!)4P`@[3?OO=^RAQ`82FOO2)/:9Z9DY]K&]_/*69\XKJT3*BY5+1K[KL"+F
M25H<5NZ/[\\/,]<1DA8)S7C!5NX[$^Z7]9]_+,^\>A%'QJ0#&0JQ<H]2E@O/
M$_&1Y52,>,D*F-GS*J<2?E8'3Y05HXD.RC,O\/V)E].T<#'#HOI,#K[?IS%[
MXO$I9X7$)!7+J`3^XIB6XB-;'G\F74ZKEU/Y$/.\A!2[-$OENT[J.GF\^'HH
M>$5W&=3]1D(:?^36/SKI\S2NN.![.8)T'A+MUCSWYAYD6B^3%"I0;7<JME^Y
MCV2Q#0+76R]U@WZF["R,[XXX\O-?59K\DQ8,N@TZ*05VG+\HZ-=$#4&PUXE^
MU@K\6SD)V]-3)O_CY[]9>CA*D#N"BE1AB^3]B8D8.@II1D&D,L4\`P+PU\E3
MM32@(_1-?Y[31!Y7[G@RBJ;^F`#<V3$AGU.5TG7BDY`\_X4@4J?")$&=!#[K
M)"2X.\FX3@*?ER3!+"+19)B*AV7I+CU12=?+BI\=6'I`7)14+62R@,RJ/>'5
M]D!?5,RC"M*A@!:@Z>LZ)&3IO8(.<8W9(&;J.@TFL!';'L2D@7C`KR$)?6N3
M',-*Z-?P@Z0*LDD&49->U[%!R%1KI0K;&@,6`>A,F\!PEU00+!>C`R%I]6"#
MF/#"P!BP&(0V@]NE*_#*A6*:WD?MTA$RT^)%T3RT.[,UI\>S<-Y,6Z1@H=S?
M%A5DDPO)N,F/PB#&:(LQ8#&8_`X#%30D#&(,!L:`Q0!6N-F#V\(HL%U[1QB$
M1+BK_-G4[LS6G`ZFTUDS;9%2IU=K5P]O&!5DDPM):UUL$&.TQ1BP&,R[#(9W
MC`H:$@8Q!@-CP&)`P"',)MQ61J/MZCO2U)BKVECSU\4A/9X[K(Z.L@F&I+VK
M:Y#1'7/$;H_RNM8:&5:(H$/>-K4:9++`,#UBLU!^9[`8$`G=\::Q$<2@2"3R
MVQO(GO>GEW/+)G:7X9*NXX;D<IBAJ=4@LRT8UM.6WW)6=:\9W#\UR&1QS5Q)
MRUT'Q$&'O"T.8JZ+8\U?%^<NTR5=UPU):UEL:I#9%@SK$:?'73^Q<]`I!W:.
M8:=ZT6R),6(OT);##HB#+GE;',1<%\>:ORI.<)?O:G3;UBZG6GU/4RGA8GJY
M)M5A77&"'G,=%D='#9T\-<AD@5?8'A;*[SYM:_#^:9^\G;.GQN"%+>S>"ZSY
MGK,''TAX]<]9=6!;EF7"B?E)/7X"N&XTH_@PVY#%1K_+6N-;]6!30GC-!+R7
M2GI@WVAU2`OA9&P/*?W1%'REPA<7_I"\U!?R'9?P4M)?C_`R9G#S]D<`WG,N
M/WZH?]"\M=?_`P``__\#`%!+`P04``8`"````"$`H\YXJP@$```H$```&```
M`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;)1776^C.!1]7VG^`_+[`#;D4R%5
MNU5W1]J11JN=F6<"3H(*&&&G:?_]7MN48@,-O"3AYOH<G^OK@[V[>RURYX76
M/&-EA+#K(X>6"4NS\A2AG_\]?5TCAXNX3..<E31";Y2CN_V7/W975C_S,Z7"
M`8221^@L1+7U/)Z<:1%SEU6TA'^.K"YB`8_UR>-53>-4#2IRC_C^TBOBK$0:
M85M/P6#'8Y;01Y9<"EH*#5+3/!8P?W[.*OZ.5B13X(JX?KY47Q-65`!QR/),
MO"E0Y!3)]MNI9'5\R$'W*P[CY!U;/?3@BRRI&6='X0*<IR?:U[SQ-AX@[7=I
M!@IDV9V:'B-TC[</`4;>?J<*]"NC5][Y[?`SN_Y59^D_64FAVK!.<@4.C#W+
MU&^I#,%@KS?Z2:W`C]I)Z3&^Y.)?=OV;9J>S@.5>@"(I;)N^/5*>0$4!QB4+
MB92P'"8`GTZ1R=:`BL2OZON:I>(<H0"[(5FLUACRG0/EXBF3F,A)+ERPXK?.
M4I):%-*@P/<[RM)=K/Q@`HBG9Z0$/L8BWN]J=G6@:X"25['L0;P%X&%%($7F
MWLOD"*V0`W/EL`PO^\#?[+P7*%W2Y#SH'/AL<W";X0%IRPQLTYEELF26M953
M>="!+@T9I@GFT,AD6)S.Y`/LM[B:6>>$JF&Z>L(Y1#(Y0@M0T98IP!^%TDPZ
M"4.[=I)&9$(;3:^F3%;L;3EUI"]J.0=6)INP.A*"#W84!&U!C7Z`MIJN0":;
M5#K25R`]N-/@<NL2/W17H/CS9I<#30H=P=VF"W`XK&9CTGY.)9--*AWIJY'-
MT),3*-NY(4>--$F:D"5H,2Q(9G69/U>DLBTV"1"A`4VSG`#KG0];IVW>)K0T
M%V8YHF.6(6"]VPVV,0/`E@/(5@O\Y8164R.M:C6;W]2T&M$T:_?+-Y?5;DUH
M8&TL`]!OOF"*IKX;8!VR^FT]HFF6'^"^(32A`4T#EA#Z&Q=F=Z.I^Y:`!SWA
MXYUH.!R>90HJVVJ*,5L@`[:`R5J>1FYH4B--EB9D+A/Y>`T:FL@L6U#9%MN8
M+1#+%F3KK593)/4=0F'!$<?83>3C?6M*FN40I.\03:C?>63`(3:P=)^WG1IE
M%6W('<C(T4`VP73G5MD6FS:,`3V6.]S0T7<$HD.F<Y.1`P*9Y0@JV](Q=D8@
M`XY`\,J]O7OZCJ"P>JTV<DH@LQQ!95N2QAPA&'`$LES?EJ0&FB1-R-H](^<$
MN(?-Z#:5;;'U#$'?R_2UI:#UB?Y)\YP[";O(.Q>!BT@;;>^#]^I\8,?#[;V^
M)WKM/W!/J^(3_1[7IZSD3DZ/@.FK%URM;WKZ0;!*W98.3,`%3?T\PXV<PF7$
MEU4],B;>'^!DXK5W_/W_````__\#`%!+`P04``8`"````"$`<P#C@VA)```@
MU`$`&0```'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RLW=F2VT:VMN'S/^*_
M!X7.MU2LN1RV=[0X8.`\XE@MRVU%6Y9#4D]WOS\0N9C#FT:1:I^TW(\6$B#Q
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M__'KU\VG?Y7O/_SMEZ_:WW?Z2.TG^^ZG_XS>?WFGKU3#O+H^;L:[3[]J`_2_
M+SY^:+.AK^3MOW]X>:T5?_CIZR\_O+RY?W7W<'4S4/F+O[[_\G7RH1WRY8MW
M__CR]=/'IBL:M!MU&N3&#7)[&F0@ZEE`0Q_7JC^_?:WW;A!EV0WRS%J?W`+Z
M,[/6GLT=:+<<MW?@OZ9GUM7^=;>(_L/6=OOJ]OKNX?'XU?:M3M]CMZP^XGD?
M;?!@B^@_W"+73V>N3E]@M[K@FWQX-;B]NF\ST+>A]HU>M[EUR>C?\]>GP.D_
M['L)$M>SMFM]^<?M;/_CS+797K@.]D*PMOY\O^Z.E>.A-WK[]>V/WW_^]*\7
MFM"TZ5]^?]M.CX/OVI'MH.LV_G08_M%1J".G'>4O[3`_O-0.TP'V17/'/W^\
MN;G^_O4_=;B_<S5O6#.(*X96T1Z0[;"C%,8I3%(H4BA3J%*H4YBF,$MAGL(B
MA64*JQ36*6Q2V*:P2V&?PB&%)H#7VN>G':_@_1D[OAVFW?&VR]X8^"0D.1A:
MA2TR2F&<PB2%(H4RA2J%.H5I"K,4YBDL4EBFL$IAG<(FA6T*NQ3V*1Q2:#K0
MOCX=?P_^X(KVNX[Q:+_GSZYV7+?5.H\&XPX&3_%1^Z:KN>O.H^UA.X2,(&/(
M!%)`2D@%J2%3R`PRARP@2\@*LH9L(%O(#K*''"!-)[?'JZKPV-9)]X)]W%;_
M\/).$3J%Y^;F)MG)KDA_G(H&U^F1?2HZ'=J0,60"*2`EI(+4D"ED!IE#%I`E
M9`590S:0+60'V4,.D,;)\8B+#FY=XURPX]OJXXZWW?7&27`H0T:0,60"*2`E
MI(+4D"ED!IE#%I`E9`590S:0+60'V4,.D":4:)?JNCG:I>T%VO7=*]5?>(G6
M#A3O[4ZN=>4;'-/)@3\\%5E(1I`Q9`(I("6D@M20*60&F4,6D"5D!5E#-I`M
M9`?90PZ0II/N+!H%0!?540#Z3]AM=;R7G03'-&0$&4,FD`)20BI(#9E"9I`Y
M9`%90E:0-60#V4)VD#WD`&E"B79IV[)*;[JTYR\]HMMAXGW=27)$W\:G\N&I
MZ'1$0\:0":2`E)`*4D.FD!ED#EE`EI`59`W90+:0'60/.4":3C)'M";<:/?W
M']%M]7$O^UGZYB;9IV]<D<X*P51^E^SX4]%IQT/&D`FD@)20"E)#II`99`Y9
M0):0%60-V4"VD!UD#SE`&B>\/&N;;Q?L^6-Y?(`;!;,Y:40:DR:D@E22*E)-
MFI)FI#EI05J25J0U:4/:DG:D/>E`:B**IOA!VW<)Y_C^@_Q8GNSJKG.33.;W
MR3'M%E35Z:`FC4D34D$J216I)DU),]*<M"`M22O2FK0A;4D[TIYT(#6.,C-\
MVUR_9.]W[1O=@MM.?',<08$(#W17Y6G$JC%I0BI():DBU:0I:4::DQ:D)6E%
M6I,VI"UI1]J3#J0FHOA`;YLPX8'^S3=H[7.6Y'K.43('/*1S0+=@-`>`QGXL
M"]F$5)!*4D6J25/2C#0G+4A+THJT)FU(6]*.M"<=2(VCW!S0=FG"8#QS!G!-
MG7`."/L\QP<BPP%H1!J3)J2"5)(J4DV:DF:D.6E!6I)6I#5I0]J2=J0]Z4!J
M(HKG@+9[<\&N=LV><%=WE!SHC^F!?JJR0WC4/B#7I!$<^V/2A%202E)%JDE3
MTHPT)RU(2]**M"9M2%O2CK0G'4B-H]R!WK9N+MC[KM,3]]N3>[4W`U>EW1O<
MT26/7H:^R@?BM*#1F%434D$J216I)DU),]*<M"`M22O2FK0A;4D[TIYT(#5&
MF=N\MO%S02!<GRB<#L+6D9OY0:/V38GV@L%?$(Y)$U)!*DD5J29-23/2G+0@
M+4DKTIJT(6U).]*>="`U$<4S?]ODN6!7NYY0N*M/C:/@0+^Y2F?^4Y4=U:,!
M:$R:D`I22:I(-6E*FI'FI`5I25J1UJ0-:4O:D?:D`ZEQE)OYVT[/!7O?-8;B
MF3^YHW\S.#64PD#XI_EN.CA5^4"`QGXLJYJ0"E))JD@U:4J:D>:D!6E)6I'6
MI`UI2]J1]J0#J3'BS-^^/'9!(([E<=?'R,_I0]*(-"9-2`6I)%6DFC0ES4AS
MTH*T)*U(:]*&M"7M2'O2@=1$%,W\[=M_E^SJKIL7MGB.(QPOW<,#/7VGPE?9
M(3PBC4D34D$J216I)DU),]*<M"`M22O2FK0A;4D[TIYT(.EU9^UCN\"*]W[;
MBPMG_F]\;[)]_[/K^?@,W-PD#9XW5A7=#*2OZ`Q]E4^*&[Y[7;I]-VO,J@FI
M()6DBE23IJ09:4Y:D):D%6E-VI"VI!UI3SJ0&J/,*2'M#_:W@=IW<+M`V$Y\
M8Q2>$ER5IQ&KQJ0)J2"5I(I4DZ:D&6E.6I"6I!5I3=J0MJ0=:4\ZD)J(XDGA
MLH[?-3M^CN(V4/JP=^BK+",CTI@T(16DDE21:M*4-"/-20O2DK0BK4D;TI:T
M(^U)!U+C*',ST/Z`071*>.9`[QIWR6N72<?OS7%0G8'"F1\WA[[(Y\&-'D[\
MH`D7+$@EJ2+5I"EI1IJ3%J0E:45:DS:D+6E'VI,.I,8H,_%?UA:\/K4%;2>^
M,?*S_)`T(HU)$U)!*DD5J29-23/2G+0@+4DKTIJT(6U).]*>="`U$<43?]N(
M2Z\&-45<^D+7M6OH!>TA1\D9(>D6#WV5A6=$&I,FI()4DBI239J29J0Y:4%:
MDE:D-6E#VI)VI#WI0&H<Y<X(;8<NC,4S9X2NH1?=(CH*9P#0Z!HT)DU(!:DD
M5:2:-"7-2'/2@K0DK4AKTH:T)>U(>]*!U$04SP!M[RW<U>W]X,UC^X.J%T\"
MKHT73@(=)9-`TC@<MG^M6P?]X2<!T)A5$U)!*DD5J29-23/2G+0@+4DKTIJT
M(6U).]*>="`UCC*3P,UE+<%C>=P2-`HF`=*(-"9-2`6I)%6DFC0ES4ASTH*T
M)*U(:]*&M"7M2'O2@=1$%$T"-VE+\)M?!3J.E*2@ZT6U0?,/A--.T=`MJ*K3
M'$`:DR:D@E22*E)-FI)FI#EI05J25J0U:4/:DG:D/>E`:ASEYH"T6]A_(7!S
M:@K:3GQC%,X!KLK3B%5CTH14D$I21:I)4]*,-"<M2$O2BK0F;4A;THZT)QU(
M343Q')"V^[K&\*N']@[^EP_O_O[FDPY?'<N9"-SH!^>/3_?^<L,NH".]<VJA
M&'H*IX2DA3!R5>VU2S!Q)&^2C'V5#3\A%:225)%JTI0T(\U)"]*2M"*M21O2
MEK0C[4D'1WHCT+["QE%N2KBL5WC#7J&C8*H?>@IW-0+1C=5.5SX0M\D;!V,W
MEJKLTTR,_`<L/`5CW21K+*TJ7F/RI*OR5;;&VLBO<>JI9XTSJXK7F/S4S-Q7
MV1H71GZ-2T\]:UQ95>\:U[[*UK@Q\FO<>NI9X\ZJXC4FW_W>5]D:#T9^C8VC
M7%#;MF%X9Y.9N'27<YJY7)<QN'NYZ2@**FCDJMJKJR"5R6L/8U]EGV;"X0M2
MZ1<,AT]^V+7R539\S;&FI)E?,!P^:=/,?94-O^!82]+*+]@S_-I7V?`;CK4E
M[?R"X?#)*6+OJVSX`\=J'.62E#9$O^W4R#[I34=1P$`C5Z53MVW^F#0Q.OY2
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M=]D<Z-<<QF^.3ZRB]YLISMJ`TH]E&U`9M;T+'1S)VFO[Z]ZU3\]:^\R/96N?
M&W5K3[[5A?UM[\J79ZU\Y<>RE:^-U*L)YKTDF1NKBC:"YPP7D]X`[/Q8MA%[
MHU,`TK>%#E81;4`Z/36N*G-HW%[V`.-8'I\@'.G5&=OLH:/V)ZC]=Y=NU(@+
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M]%PB:._=\M&4HVAV[ZJ>F]V[JF#!,<>:.`J>>Q2>@D,T_2Y*CE61:C^636!3
M3SW#SSC6G+3P8]GP2T\]PZ\XUIJT\6/9\%M//</O.-:>=/!CV?"-HUS"TB=?
M_;V:6S[B<A0$8NA(347;@A%I3)J0"E))JD@U:4J:D>:D!6E)6I'6I`UI2]J1
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MQ,@W9`H.7UJ5?[17D6HC/]:48\V,HF<$>,CIJ^S+7W#XI57YIY`KHWCXI!6W
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MGS;6]K?^Z>STK#7-N.#<*'JTF`9A856]'W=YUD:L_%CV<==&\48DQ^3&JJ*-
MP&GBK(W8^;%L(_9&MM/U3P[&#[@/5A%M0!J-QE7E#@<M&%V)]9\3-$+:I'`4
M]BT=/=,!YX)CTL2/9=]*X2F8@]+/7'*LBE3[L6SXJ:>>X6<<:TY:^+%L^*6G
MGN%7'&M-VOBQ;/BMIY[A=QQK3SKXL6SXQI'^$$4_^Z%+\CA)WS:Q\A'+<6`]
MG8E?8DR:($.K>F9B=4]=HJKT-#]V8[GGFW=/>.-F8A71.&D$B[.VJ<R.E6Y3
M957=]?W@(;EUK^WO>[=H>M86S;)CI5LTMZINBY*9<6%_V[L]R[.V9Y4=*]V>
MM57%%_;)"7AC5=%VX0+FK.W:Y<=*INB]5747]G=/-[=)=@]6$6U3FJ;&5>4.
MO?3A4WKHG?=X\XX/I8S\:7U(&I'&I`FI()6DBE23IJ09:4Y:D):D%6E-VI"V
MI!UI3SJ0FHCBV3=]*/7,>9Q/G^XZ:I]G^'N[^Z2Q,?15=DH8D<:D":D@E:2*
M5).FI!EI3EJ0EJ05:4W:D+:D'6E/.I`:1[D)0#/')5=Q;7ER]^(H/-!!H_8W
M,;4+^JHQ:4(J2"6I(M6D*6E&FI,6I"5I15J3-J0M:4?:DPZD)J+X0+_L8<T=
M']8XBB[8W?,;W[P=L6I,FI`*4DFJ2#6I<91+?-O]3SO(@[L+?]+XKATE.1`Z
M"A_"NZKG;F>Z!?6S!NU+<7H!+;DB&KMA5&!3Y\1&]H_I"J/>&[K2C^56EO1I
M*E]@*ZMM9+^RQE'N^VU[C>'W^\SYI&M-ZA+%5O?FSG4KX_-)<NDSM"I-+/ZL
MDU[ZC+)5Z07@V*JZ"ZW!TR!]!6)B%;UK*\ZJ*K-5Z3955N6VZ?$Z_8?A:ZOH
MW:;&5>7V5-K5;2_^SGJ6<L<&KZ/XIUGNDWN-H57U9G3DJRP38R/7WGNZOTLN
MSR=6T3MT<595Z:ML`RHCMP%WMW?)9ZNMHG<#&E>5V1WW?TI_\3A*/#$YBF^#
M']+'7%;5FZ:1J])/(=HW,W:D7^5Z_%&&P2T.'JOH_6:*LS:@Y`94-KS;@+O[
MN^3:L[:*W@UH7%5NUVC!"^:T^[8\V0<=A:=.5_7,R<%5!0N.21,_ENV6PE//
M_%ARK(I4^[%L^,91[LOZ4]HY]VSG.(IS?)>>%ZSJF1R?U<YQ8YU>5\?[Q1.K
MZ%U;<=8VE=FQ<%ZPJC]L"M16T;M-C:O*[<`_IREP?VH*^`#>I#^$^,:JHHU]
M2#HA0U]E`1R1QJ0)J2"5I(I4DZ:D&6E.6I"6I!5I3=J0MJ0=:4\ZD!HC-F[O
MVQO_\R_UCN7)M-BU#KH0=O]"AU7Y.\41:4R:D`I22:I(-6E*FI'FI`5I25J1
MUJ0-:4O:D?:D`ZF)*+IYO-?Q><FN;LN37=V1WKKRT\'@(7E[8GA<3_S+&$EC
MTH14D$I21:I)4]*,-"<M2$O2BK0F;4A;THZT)QU(C:/<&>&RUL$]6P=&_J@>
MDD:D,6E"*D@EJ2+5I"EI1IJ3%J0E:45:DS:D+6E'VI,.I":B^$#_4]HC]VR/
M.`K;(YZ"*0&W\*ZJ_54,P8U^<O<U]E5VA3`A%:225)%JTI0T(\U)"T?ASP(X
MRAUZ:3LE?4)SUL^,W+/+XBC:'Z[QTGN;-'(+MC_FXO?'0_*"V]A7^?WAAO=M
MI,)O1#!6FH#2CQ54/:2-*U]E:ZQM>+_&J5'O9YSYL<(U)GVYN:^R-2YL>+_&
MQE%NWWYS`^:>#1A'\=U1^O.00ZN*+K?3+WR4K4KO1,96%1V8Z=LV$ZOJ76-Q
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M=F"]E1HFX$3!=)M.2B,W5GPCG#YL&_LJ.T`GI()4DBI239J29J0Y:>$HO!%V
ME#OTTA[4M^T/MJ8>.HKVQXEZ]T=7]<R-L!M>57Y_N.$]%7XC>M98^K&"*MP(
M^RI;8VW#^S5.C7K/.C,_5KC&]$;85]D:%S:\7V/C*+=O<TVGL]Y$>&"CR=$S
M-\)6U7O#-<I6I6?XL57UWPA;5>\:B[.JRFQ5NEV5575WG=</#\G%8&T%O9LT
M/:MJEJU*-VEN57^T20LKZ-VDQE7EHO2G],L>V"]SE%Q>XT;XK!::C>4/CK$C
MNQ&^2A^!3OPRP9&8GB,*J^H]JDNK\NNO;/W/W`B?6G@]&S&UX7LW8F95?B/F
MMA'N1AA?PL(OT[/^QE7ETM%V?LY_8OG0-8K"E],<!?>S0T?/W0AW8P4+CCG6
MQ(]E,VGAJ><SEQRK(M5^+!M^ZJEG^!G'FI,6?BP;OG&4V1>/?TK+ZCA*?('E
M*#E2D[EO:%6](1VYJO@.-IW5QE;E;H21VXD5]*ZL.&N3RNQ8Z2955M5M4F;N
MMX+>39J>M4FS[%CI)LVMJMNDF\?;Y!G.P@IZ-ZEQ5;E$:<'HZ$XO$<_[:9;'
M=I@D4HZ":W:K\C0BC4D34D$J216I)DU),]*<M"`M22O2FK0A;4D[TIYT(#41
M17=MCVEWK?_MXV-YLJN[;E3RGD(2U:%;,/P=,J0Q:4(J2"6I(M6D*6E&FI,6
MI"5I15J3-J0M:4?:DPZDQE%N`D@[8<_L?7:\'AWYHWI(&I'&I`FI()6DBE23
MIJ09:4Y:D):D%6E-VI"VI!UI3SJ0FHCB`_VR3MPC.W%&T9W&8_I:M*^R2YH1
M:4R:D`I22:I(-6E*FI'FI`5I25J1UJ0-:4O:D?:D`ZDQ.AZ,\=[73HO.],\<
MZ&UY,LT["@]TT.@1-"9-2`6I)%6DFC0ES4ASTH*T)*U(:]*&M"7M2'O2@=1$
M%._JMEEV_BW;8]=;"V_9',5G]/3W80Q]E3_0N[&"D_R851-202I)%:DF34DS
MTIRT("U)*]*:M"%M23O2GG0@-8YR9_2T,_C,@7YJ!_J;V9OTWVA\\^BJ='"?
MGF[>I*^<^R*?A]-R1F-634@%J215I)HT)<U(<]*"M"2M2&O2AK0E[4A[TH'4
M&&4F_K2]]TP>V,=[=!1._*`1J\:D":D@E:2*5).FI!EI3EJ0EJ05:4W:D+:D
M'6E/.I":B.*)/^W5M7?SUW>O=-2^^\>7KY\^EN\__.UXAY_]5X&#W[[_R#:>
MH^2<D+Z-[JOL@!^1QJ0)J2"5I(I4DZ:D&6E.6I"6I!5I3=J0MJ0=:4\ZD!I'
MF7/"4]HX[)\#CN7QQ9]1,`>01J0Q:4(J2"6I(M6D*6E&FI,6I"5I15J3-J0M
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MKLJJW"]F2G^E76U_W[M%C:O*[:NVG_3?'PNN*Q4>"QW%;T`\)K\Q9_CDJGH3
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M(M"N2\OZ.D4`I@C`%`&8(@!3!&"*`$P1@"D",$4`I@C`%`&8(@!3!&"*`$P1
M@"D",$4`I@C`%('0D@A<UJ<97+%18Y8TY-/7KH*R8&+HA@L?TV;JE`K4*14P
MI0*F5,"4"IA2`5,J8$H%3*F`*14PI0*F5,"4"IA2`5,J8$H%3*F`*16=9<\L
M;5\EO+I];F+H^C!JWX5GD.21S)O!E2N+SB!/R17H,"@+@G):U$S3!TQ!@2DH
M,`4%IJ#`%!28@@)34&`*"DQ!@2DH,`4%IJ#`%!28@@)34&`*"DQ!@2DHSG)G
MD,NZ/X,KMG].YL\,BH"K\Z8S"$P1@"D",$4`I@C`%`&8(@!3!&"*`$P1@"D"
M,$4`I@C`%`&8(@!3!&"*`$P1@"D",$4@M.0,HJ,YFBO:J]";QU=ZB'OIP][!
M53M6>H'167QV>4JN3I684YE-$$H,3(F!*3$P)0:FQ,"4&)@2`U-B8$H,3(F!
M*3$P)0:FQ,"4&)@2`U-B8$H,3(F!*3$P)::S[-GELC[7X(J-KI/Y"4(1<'7>
M%`&8(@!3!&"*`$P1@"D",$4`I@C`%`&8(@!3!&"*`$P1@"D",$4`I@C`%`&8
M(@!3!&"*0&C)I)%KG[E)X[EK#?;,!E>G=I@=_$I#9^V_1^H;64_)-8D"<BJS
M1160DX6+)@^>]?FZLFS$+VM##:[8ASJ9C[,^E*OSID\`TR>`*>(P11RFB,,4
M<9@B#E/$88HX3!&'*>(P11RFB,,4<9@B#E/$88HX3!&'*>(P12"T).)M^R>\
MAF[/B]T[4,\EO&L<A0_#!U>GQI3%5&%P#:;G$GXJLT65CY.%"4^>N.KC=66Y
MA`_2YM,S'^I8GYS:S7R:AP/:*&/CC$TR5F2LS%B5L3ICTXS-,C;/V")CRXRM
M,K;.V"9CVXSM,K;/V"%C36QQPMLN*1*NK+QX+@JN'1$\]1@<QXI_LX;9<S.X
M6U1E/M_>PGPG#\+TX?ZX,3)H[X[#P_>Y#^7NIJ,/%=YA=[\B>7`<-^J#*=^H
M4[YARC=,^88IWS#E&Z9\PY1OF/(-4[YARC=,^88IWS#E&Z9\PY1OF/(-4[YA
MRC=,$0@MR7=[WWM)!-Q]<A2!SA0T"Z>FN,Z>S?6IS!95*DX6YCIYB*8/U95E
MY^WV3NZ2#^7N_*(/%=X-6JYARC5,GP"F7,.4:YAR#5.N8<HU3+F&*=<PY1JF
M7,.4:YAR#5.N8<HU3+F&*=<PY1JF7,,4@="27+>W9F$$_)7)A6]G#]I'HND-
MN[/DACU]^&>+!JU?!08WD@H,3(&!*3`P!0:FP,`4&)@"`U-@8`H,3(&!*3`P
M!0:FP,`4&)@"`U-@8`H,3(&!*3"=9>>,]D8N#,QSYT)WXZ>I]73K=7.;W#^]
M&0Q<F59\*AL\X8&B+[-Y4$$Y+6JFH,`4%)B"`E-08`H*3$&!*2@P!06FH,`4
M%)B"`E-08`H*3$&!*2@P!06FH,`4%)B"XNQX2DMFEO:.^)*@N#OHZ.02WE7;
MR06F",`4`9@B`%,$8(H`3!&`*0(P10"F",`4`9@B`%,$8(H`3!&`*0(P10"F
M",`4`9@B`%,$0DLBT-X17Q(!=P<=1:"SY`R"!XKMZR4Z^<1G$)A2`5,J8$H%
M3*F`*14PI0*F5,"4"IA2`5,J8$H%3*F`*14PI0*F5,"4"IA2`5,J8$I%9]DS
M2-M(N"05KO$0GT&2_H3.(*XL/(-<7^&!HB^SLX6FC].B9@H*3$&!*2@P!06F
MH,`4%)B"`E-08`H*3$&!*2@P!06FH,`4%)B"`E-08`H*3$&!*2C.,F>0ZPO;
M2L?ZI*UD%MYST48#VCACDXP5&2LS5F6LSM@T8[.,S3.VR-@R8ZN,K3.VR=@V
M8[N,[3-VR%@36WP&N<ZUE;[IAT<'QZ'2='0]G^CDHG^X]?O7__SQ^]?O?OS>
M77*X1:.3"TV!.0UG\X@"`U-@8`H,3(&!*3`P!0:FP,`4&)@"`U-@8`H,3(&!
M*3`P!0:FP,`4&)@"`U-@.LN=7/3/5UYT<CG6'U/A[SMN;I/FX)N!E<4GE^0!
MTC`HLP!H9G%-I>#%ZXPI**A34&`*"DQ!@2DH,`4%IJ#`%!28@@)34&`*"DQ!
M@2DH,`4%IJ#`%!28@@)34)SE3BYM6^R"JY!KUT8+KTW-HI-+V&X[SA^*`$QS
M!4P1@"D",$4`I@C`%`&8(@!3!&"*`$P1@"D",$4`I@C`%`&8(@!3!&"*`$P1
M@"D"H24GE[8M=DD$7!LMBD!GR1DD:6]H8CB5!1,#3*F`*14PI0*F5,"4"IA2
M`5,J8$H%3*F`*14PI0*F5,"4"IA2`5,J8$H%3*F`*14PI:*S[!FD[7U=DHJV
M/KVN<!9-##!-##!%`*8(P!0!F"(`4P1@B@!,$8`I`C!%`*8(P!0!F"(`4P1@
MB@!,$8`I`C!%`*8(P!2!T)*)H>UJ71(!UP6+)@9G^N/4T+R^2NY:-3&<RH*)
M`:94P)0*F%(!4RI@2@5,J8`I%3"E`J94P)0*F%(!4RI@2@5,J8`I%3"E`J94
MP)0*F%+A+'?%T#:Z+DF%:XQ%J0B;979W`=/$`%,$8(H`3!&`*0(P10"F",`4
M`9@B`%,$8(H`3!&`*0(P10"F",`4`9@B`%,$8(H`3!$(+9D8VJY6&(%O?UIV
M[1ID43I.C;1PSDAN1C1GG,J".0.FP,`4&)@"`U-@8`H,3(&!*3`P!0:FP,`4
M&)@"`U-@8`H,3(&!*3`P!0:FP,`4&)@"TUGV8J+M;H6!>>9I67L=B8N)L$-F
M<P9,<P9,$8`I`C!%`*8(P!0!F"(`4P1@B@!,$8`I`C!%`*8(P!0!F"(`4P1@
MB@!,$8`I`C!%(+1XSKBYL(MYK$^N)YVU:PDN)I)7/88#7^8G!MHX4S?)6)&Q
M,F-5QNJ,33,VR]@\8XN,+3.VRM@Z8YN,;3.VR]@^8X>,-6:YB>&F;6%=,#$<
MZ]-4A&TP-S%8G;_S&`UHB@"6501@B@!,$8`I`C!%`*8(P!0!F"(`4P1@B@!,
M$8`I`C!%`*8(P!0!F"(`4P1@BD!HR<30-J?""'S[Q<2-ZW.%%Q/.DCD#K][X
MLF#.Z(;3HF8*#$R!@2DP,`4&IL#`%!B8`@-38&`*#$R!@2DP,`4&IL#`%!B8
M`@-38&`*#$R!@2DPG67GC+:5%0;FF8N)&]?ZBE(1ML-LSH!ISH`I`C!%`*8(
MP!0!F"(`4P1@B@!,$8`I`C!%`*8(P!0!F"(`4P1@B@!,$8`I`C!%`*8(A);,
M&6W?ZI((N#Y7%`%GNLT)+B;PJM7-J<PF`:4"IE3`E`J84@%3*F!*!4RI@"D5
M,*4"IE3`E`J84@%3*F!*!4RI@"D5,*4"IE3`E`J84N$LTYFX:5M9EZ3"M;ZB
M5(3M,)L88(H`3!&`*0(P10"F",`4`9@B`%,$8(H`3!&`*0(P10"F",`4`9@B
M`%,$8(H`3!&`*0(P12"T9&)H^U9A!/Z+BPG7`HO2T5ER,8&WL&Y.9<&<`5-@
M8`H,3(&!*3`P!0:FP,`4&)@"`U-@8`H,3(&!*3`P!0:FP,`4&)@"`U-@8`H,
M3('I+'LQT7:YPL`\=S'ANF)1*L).F<T9,,T9,$4`I@C`%`&8(@!3!&"*`$P1
M@"D",$4`I@C`%`&8(@!3!&"*`$P1@"D",$4`I@C`%('0DCFC[5M=$@'7YXHB
M<.J'!1<3Z2^2&^HW"FI5R>N9-*4"=4H%3*F`*14PI0*F5,"4"IA2`5,J8$H%
M3*F`*14PI0*F5,"4"IA2`5,J8$H%3*GH+#LQM*VL2U+A6E]1*L)VF$T,,$T,
M,$4`I@C`%`&8(@!3!&"*`$P1@"D",$4`I@C`%`&8(@!3!&"*`$P1@"D",$4`
MI@C`%('0XHE!O^_PH@@<ZY/FE+/XBF&`5^M\F;]BH(T'M$G&BHR5&:LR5F=L
MFK%9QN896V1LF;%5QM89VV1LF[%=QO89.V2L,<M-#.VO2[QD8CC6IZD(VV%N
M8K"ZL&5)4P2PK"(`4P1@B@!,$8`I`C!%`*8(P!0!F"(`4P1@B@!,$8`I`C!%
M`*8(P!0!F"(`4P1"2R:&MCEUP;GAUC6SPG.#LV1BP*N4OBR8&-`O4RI@2@5,
MJ8`I%3"E`J94P)0*F%(!4RI@2@5,J8`I%3"E`J94P)0*F%(!4RI@2@5,J>@L
M.S&T_:I+4N'Z6U$JPIZ730RPT>`6I@C`%`&8(@!3!&"*`$P1@"D",$4`I@C`
M%`&8(@!3!&"*`$P1@"D",$4`I@C`%`&8(A!:,C&TS:E+(N":65$$.DLF!KQ*
MV?[+$.FM!$VI0)U2`5,J8$H%3*F`*14PI0*F5,"4"IA2`5,J8$H%3*F`*14P
MI0*F5,"4"IA2`5,J.LM.#&V_ZI)4N/Y6E(JPYV43`TP3`TP1@"D",$4`I@C`
M%`&8(@!3!&"*`$P1@"D",$4`I@C`%`&8(@!3!&"*`$P1@"D",$4@M&1B:#M0
MET3`=:RB"#C3'_Z!Q0"O4MZ>RH(K!IA2`5,J8$H%3*F`*14PI0*F5,"4"IA2
M`5,J8$H%3*F`*14PI0*F5,"4"IA2`5,J8$J%L\P#B_;7G5R4"M?$BE(1-K9L
M8H!I8H`I`C!%`*8(P!0!F"(`4P1@B@!,$8`I`C!%`*8(P!0!F"(`4P1@B@!,
M$8`I`C!%`*8(A)9,#&T'ZI*)P76LH@B<.EOAQ(#W)6]/9<'$`%,J8$H%3*F`
M*14PI0*F5,"4"IA2`5,J8$H%3*F`*14PI0*F5,"4"IA2`5,J8$H%3*GH+'O%
MT#:E+DF%:V)%J0@;6S8QP#0QP!0!F"(`4P1@B@!,$8`I`C!%`*8(P!0!V/^1
M=J;+<1S7&GP5AQ_`QLQ@(\-6!`8`"9``5X#XK2O3DL(+'2)]E[>_>7J;ZL[/
M!$?ZPPAF55?75.6<JC[3Z$8!,1000P$Q%!!#`3$4$$,!,1000P$Q%&C9/#`<
M[9E\[.HOTDP#6UQ*Z'[)7;5=8#"[7)D]"^QY8%>!70?V(K"7@=T$=AO8J\!>
M!_8FL+>!O0OL?6!W@=T']B&PAY&EP`#;*S!T]9=6M(FM(3",]=KDHQD*Z%@4
M$$,!,1000P$Q%!!#`3$4$$,!,1000P$Q%!!#`3$4$$,!,1000P$Q%!!#@98M
M`D-EH-JUH6YQ^)4/%Z^W$RSOLQ_8(FCHALE=M29H*&&&,6(8(X8Q8A@CAC%B
M&".&,6(8(X8Q8A@CAC%B&".&,6(8(X8Q8A@CAC%B&".&,3U#'.9C84PEK%IC
M_G=U^/T/3__R?Q<?/__P\9_H<U"/IA^>\W"V.AH27.UN8F2[`'$^U=NQB\!0
MH$V8=0$'!<100`P%Q%!`#`7$4$`,!<100`P%Q%!`#`7$4$`,!<100`P%Q%!`
M#`7$4*!E"P4J.[6/`D,V:Z;`P+B>;?(/NF'R:*K6!`8QK!##"C&L$,,*,:P0
MPPHQK!##"C&L$,,*,:P0PPHQK!##"C&L$,,*,:P0PPHQK!A8"@R5L-K'BB'!
M-;.B37J-NPDQ`H,8"HBA@!@*B*&`&`J(H8`8"HBA@!@*B*&`&`J(H8`8"HBA
M@!@*B*&`&`J(H8`8"K1L$1@J.[6/`D,V:Z9`SQ8[!MT5>315:P*#&%:(8848
M5HAAA1A6B&&%&%:(88485HAAA1A6B&&%&%:(88485HAAA1A6B&&%&%;T+.X8
M*F&UCQ5#@FMF19OT&@.#&(%!#`7$4$`,!<100`P%Q%!`#`7$4$`,!<100`P%
MQ%!`#`7$4$`,!<100`P%Q%!`#`5:M@@,E9W:1X$AFS538&"(MMLQK/4LPJ.I
M6A,8Q+!"#"O$L$(,*\2P0@PKQ+!"#"O$L$(,*\2P0@PKQ+!"#"O$L$(,*\2P
M0@PKQ+!B8&G'4`FK?:P8$EPS*]JDUQ@8Q`@,8B@@A@)B*""&`F(H((8"8B@@
MA@)B*""&`F(H((8"8B@@A@)B*""&`F(H((8"8BC0LGE@.-XS,=G57Z2@!C;?
M,:QU5^2NVBXPF%VNS)X%]CRPJ\"N`WL1V,O`;@*[#>Q58*\#>Q/8V\#>!?8^
ML+O`[@/[$-C#R-*.X;@25GL$AJ[^THHVZ34$AK%>FV,P0P$=BP)B*""&`F(H
M((8"8B@@A@)B*""&`F(H((8"8B@@A@)B*""&`F(H((8"8BC0LD5@J`S4/@H,
M&:MV;3@>V'S'H+LB=]6:P#`=.C*L$,,*,:P0PPHQK!##"C&L$,,*,:P0PPHQ
MK!##"C&L$,,*,:P0PPHQK!##"C&L&%C8,1Q74FH?*X8DULR*-K$U!@:QBU5W
M+H+*+EB@@.JA@!@*B*&`&`J(H8`8"HBA@!@*B*&`&`J(H8`8"HBA@!@*B*&`
M&`J(H8`8"K1L$1@J`[6/`D/&:J9`SQ8[!MT5>3Q5&X,`5HAAA1A6B&&%&%:(
M88485HAAA1A6B&&%&%:(88485HAAA1A6B&&%&%:(88485HAA1<_BCJ&24OM8
M,22Q9E:TB:TQ,(BA@!@*B*&`&`J(H8`8"HBA@!@*B*&`&`J(H8`8"HBA@!@*
MB*&`&`J(H8`8"HBA@!@*M&P1&"H#M8\"0\9JID#/%H%!=T4>3]6:P""&%6)8
M(8858E@AAA5B6"&&%6)8(8858E@AAA5B6"&&%6)8(8858E@AAA5B6"&&%3V+
M@:&24OM8,22Q9E:TB:TQ,(@1&,100`P%Q%!`#`7$4$`,!<100`P%Q%!`#`7$
M4$`,!<100`P%Q%!`#`7$4$`,!<10H&6+P%`9J%:!NL=A=?2'$V+)EY]^_N%O
MVT\%XFLU-[L?LH^'1-;,C)[-WCXXU*M77TYY2OXV>/[^`V3I#^5/R;_[TW]_
MQPL2%K=8HLY48XPRJ#.<<#,]10IUIDY\Y838-#4WG'`1UG!KJC&>$+=T0L:Z
M9_'K5JF>=JP?N3O@>$@-S0:U9_6"O6D`3[PYZVOQ-ZQC9QG3X<B:V#___G,W
MLMS],A]Z!G:HU@_]T69Q.PJCK+8993&&]%O.Q[A.YVNZ=;SH%D.M,S#4/4M#
M?;)GZJRKOTB2#*Q>+#0-V,G"B_/56.L1HX=J/`9\G)'+Z=`GXUPLO@?/IAI?
M;?SYMU6[&JLU?;@>&2_%*?%7I\O4X(NIQE?[\#!6BY/!H3/ONT?%'->=,(^]
MK?>D#EW.2\]F7X'U>A$AF)BAVLQWAYJA6O-586+Z0QO&5(@Q[M]R"L9=AS+N
M8HRT&,/:LSBLE0IHP\D>PSID$=K(<M*SNE%VTGUUHEM8AVJ/1?!=M<;W_@R#
M:X>')XLY8Y"'&GSH71^6<\:X?TLUQGVJ-O:!<9_U@6=<*=*,-;[:!R:F;RA.
M3%V@+R=F_S7U9+C.GTW2P`AOTP"MUYZDOEJ]57.J%I;9X0R\W68<(-SO#^4M
M%MU*^&31-G,T5/CJ^#!'W](%YFAJ;>P"<_3U+O!%F0[ZRL=CBOIJ<8KJ:GDY
M1?4<[CWV/"?#%?=L?GHV^W:LUXLUE-C45VLB\<7(^-.V<228C+X>#T^IR3@\
M.5G8RFST-9JC&'JUSCBK'N,\:YV\TJ*?#+2.8E1[%D<5WV:C^L@&IS:9BNX]
M:V(OP]6S1W76H8R@&&,V-3>.-&,VL:\HQ3"J.891C(&;FAM/P<#U+`Y<7:,M
M=?P5$6.XU)L9V;/Y+F;QI6:$AUI?_5+C:%^M'MBPBRO>0X[5UIVVQZ?+`,44
MI(9"H/^6;C$KJ;5EMYBHH5K?+5ZZM=AO,6VIH66WF,F^6IS)NM3ZVDS>??K7
M?[J>:N\,/ADNV5AEII'>'"[F;;L:JZ'65&V]7GPNIG=H;1=;F$LQOBUB3)48
MWQ8Q)D&,$1=CC,5>!G83V&U@KP)['=B;P-X&]BZP]X'=!78?V(?`$&@8@_`K
MSDE=/[8"/19#A^O-V7>^O08=<C)=N[-?;%!`]5!`#`7$4$`,!<100`P%Q%!`
M#`7$4$`,!<100`P%Q%!`#`7$4$`,!<100`P%Q%"@9?.<S$E=U[8*_(:_.^G:
M6EY`]=?-BT2N[B(=#J7:N(9AS'3HR#!&#&/$,$8,8\0P1@QCQ#!&#&/$,$8,
M8\0P1@QCQ#!&#&/$,$8,8\0P1@QCQ#"F9VG5.=TSW='57U@QLMW%P/G*["*P
MR\">!?8\L*O`K@-[$=C+P&X"NPWL56"O`WL3V-O`W@7V/K"[P.X#^Q#8PYS-
M@\8I>S(%C5_WXMJNJ:4=U7SW/,UFH['1#:;#H;.8888P4W-C'$$8,8010Q@Q
MA!%#&#&$$4,8,8010Q@QA!%#&#&$$4,8,8010Q@QA!%#&#&$Z5F,&97`:%>9
M1S8:IT/"H]UHC&P6,]K$2+?Y(&:(H8`8"HBA@!@*B*&`&`J(H8`8"HBA@!@*
MB*&`&`J(H8`8"HBA@!@*B*&`&`J(H4#+%C&C$B2M`ET&\>@/7$W\\._/7S[]
MX^KCSS\6PZ+'[!AR+3,[AC0-Z];NXF2S2&&PR$S5QEB`,&(((X8P8@@CAC!B
M"".&,&(((X8P8@@CAC!B"".&,&(((X8P8@@CAC!B"".&,&((T[,8,RKWTPKS
MF!5#K@@%)P,VAXLTTW9U.E2;7<5N="_BKEHCRG3HR!!%#%'$$$4,4<0010Q1
MQ!!%#%'$$$4,4<0010Q1Q!!%#%'$$$4,4<0010Q1Q!!E8.$J]K1R7?N(4O67
M6XZ!S187,6*%&`J(H8`8"HBA@!@*B*&`&`J(H8`8"HBA@!@*B*&`&`J(H8`8
M"HBA@!@*B*&`&`JT;+&X5)*L5>`W+"Y#OFVVN/1L?A&[T2_AIU.U,3X@C!C"
MB"&,&,*((8P8PH@AC!C"B"&,&,*((8P8PH@AC!C"B"&,&,*((8P8PH@AC!C"
M]"PN+I44:X5Y;'$9DFCSQ661^V1QF?*-NS5HO='O^+MJC2C3H2-#%#%$$4,4
M,4010Q0Q1!%#%#%$$4,4,4010Q0Q1!%#%#%$$4,4,4010Q0Q1!%#E(&EQ:52
M9_N(,J3:9N&C3;\-*=)3,6*%&`J(H8`8"HBA@!@*B*&`&`J(H8`8"HBA@!@*
MB*&`&`J(H8`8"HBA@!@*B*&`&`JT;+&X5"ZL5>`W+"Y#6FUF1\\6B\OB=H7S
MU>E4;8P/"".&,&(((X8P8@@CAC!B"".&,&(((X8P8@@CAC!B"".&,&(((X8P
M8@@CAC!B"".&,#U+B\N3/3.D7?UN0[I;-3:'BQSY=C56:_>H9A>AWF5@SP)[
M'MA58->!O0CL96`W@=T&]BJPUX&]">QM8.\">Q_876#W@7T([&%DJW:?L-[L
M?DJ=1Y8GE3%K(\LCNY"N_N+*960S*]I,W)`6<SVL4#VL$,,*,:P0PPHQK!##
M"C&L$,,*,:P0PPHQK!##"C&L$,,*,:P0PPHQK!##BIYU]V,N#*B$66M`K2V;
MHY/NGNC';*ACES8,;&:#&#%"#!O$L$$,&\2P00P;Q+!!#!O$L$$,&\2P00P;
MQ+!!#!O$L$$,&\2P00P;Q+!!#!MZ-K]OJ[D?:F%(9<A:0QZS8LBH<9)=&NQH
M\>,)B\E0C6OJJ=IZ>??)>5-MM^O8'3HRW)F:&QGNB.&.&.Z(X8X8[HCACACN
MB.&.&.Z(X8X8[HCACACNB.&.&.Z(X8X8[HCASL#"E<J3RI#M(\J046OWHET;
MA)19^&@S;^-B(H8"8B@@A@)B*""&`F(H((8"8B@@A@)B*""&`F(H((8"8B@@
MA@)B*""&`F(H((8"+5O$BLJ0M0K\^BN5)T.R;69'SQ97*HM]*C%CJC;&`M8;
M,8010Q@QA!%#&#&$$4,8,8010Q@QA!%#&#&$$4,8,8010Q@QA!%#&#&$$4,8
M,83I6;Q2J0Q9*\QCB\N049LO+HM?V5A<AFJ<>+>X'"[6($29JC6BB"&*&**(
M(8H8HH@ABABBB"&*&**((8H8HH@ABABBB"&*&**((8H8HH@ABABBB"'*P-+B
M4AFR?409,FJS\-%FV88TV!,Q8H48"HBA@!@*B*&`&`J(H8`8"HBA@!@*B*&`
M&`J(H8`8"HBA@!@*B*&`&`J(H8`8"K1LL;A4AFP?!8:,VDR!GLU7D.6?Q1`8
MIFI-8!##"C&L$,,*,:P0PPHQK!##"C&L$,,*,:P0PPHQK!##"C&L$,,*,:P0
MPPHQK!##BI[%%:328/M8,:3-YBO(XN=W5I"A&GN=9@595$.4J5HCBABBB"&*
M&**((8H8HH@ABABBB"&*&**((8H8HH@ABABBB"&*&**((8H8HH@ABABB#,PK
MR/I@OZ1H7W^>W9A8<WD2V$5@EX$]"^QY8%>!70?V(K"7@=T$=AO8J\!>!_8F
ML+>!O0OL?6!W@=T']B&PASF;K2#\:?U>L:*OOU2@3Z4M5I#E3_'CH52;`D-@
M6#$U-];#"C&L$,,*,:P0PPHQK!##"C&L$,,*,:P0PPHQK!##"C&L$,,*,:P0
MPPHQK.A96$'6!Y4.^_85I*^_M*+:F.<MIGJ[8$%@4#T4$$,!,1000P$Q%!!#
M`3$4$$,!,1000P$Q%!!#`3$4$$,!,1000P$Q%!!#`3$4:-DB,%16JU6@RX*?
M=G^TO^?-H>N#(4/6;#M'M@@:R]LRFFIC,,"8OKDFD&",&,:(88P8QHAAC!C&
MB&&,&,:(88P8QHAAC!C&B&&,&,:(88P8QHAAC!C&B&%,SV+0J"18:\S7$Q?K
M@R%I-K.B3:3UUZ-3O5G04#T4$$,!,1000P$Q%!!#`3$4$$,!,1000P$Q%!!#
M`3$4$$,!,1000P$Q%!!#`3$4:-DB:%1::Q\%AC383(&!<7W37&8L[[U8'TS5
MFL`@AA5B6"&&%6)8(8858E@AAA5B6"&&%6)8(8858E@AAA5B6"&&%6)8(885
M8E@AAA4#2Y<9E</:QXHAYS6SHLV#C8%!C+5!#`7$4$`,!<100`P%Q%!`#`7$
M4$`,!<100`P%Q%!`#`7$4$`,!<100`P%Q%!`#`5:M@@,E</:1X$AYS53H&?U
M^N\F,.SNXQBMF*HU@4$,*\2P0@PKQ+!"#"O$L$(,*\2P0@PKQ+!"#"O$L$(,
M*\2P0@PKQ+!"#"O$L$(,*WH6=PR5P]K'BB'GQ:YU,F!SM+C0W*X/AFI$I*G:
M>OE7)^=-M4:4Z="1(8H8HH@ABABBB"&*&**((8H8HH@ABABBB"&*&**((8H8
MHH@ABABBB"&*&**((<K`T@I2.:Q]1!ER7K/PT>;!QE@AQ@HBA@)B*""&`F(H
M((8"8B@@A@)B*""&`F(H((8"8B@@A@)B*""&`F(H((8"8B@@A@(MFZ\@JV6N
M\E?_CK[NFEID*P:VN!Q=_#'!^7AH<^EY$=AE8,\">Q[856#7@;T([&5@-X'=
M!O8JL->!O0GL;6#O`GL?V%U@]X%]".QA9&EQJ7NY]HD97?W.BMVJL3E:)"2V
MZ[$:U\'-XK*\X:*I-BXDB#(DW';/)T44,4010Q0Q1!%#%#%$$4,4,4010Q0Q
M1!%#%#%$$4,4,4010Q0Q1!%#%#%$$4.4@87%I6X,WDN4(6G6+BY=&XMDIQD*
MM`FW;A%"`3$4$$,!,1000P$Q%!!#`3$4$$,!,1000P$Q%!!#`3$4$$,!,100
M0P$Q%!!#@98M%I?*:K7[B]^PN`P)LID=/9LO+LO[/UE<IFI-S!!#&#&$$4,8
M,8010Q@QA!%#&#&$$4,8,8010Q@QA!%#&#&$$4,8,8010Q@QA!%#F)[%Q:5R
M8*TPC^0ZZV&UB_O"UR/;Y351H,VM=?&!F"&&`F(H((8"8B@@A@)B*""&`F(H
M((8"8B@@A@)B*""&`F(H((8"8B@@A@)B*""&`BU;Q(Q*>+4*_(8?2.K)EM*C
M9XN@L;BO#V.F:DW0$,,8,8P1PQ@QC!'#&#&,$<,8,8P1PQ@QC!'#&#&,$<,8
M,8P1PQ@QC!'#&#&,$<.8GK5!XX^??_KX\<O%]U^^_^Y/__CXRX\?SS_^_>^?
M?_?#IW_7&^'7/,:\X;_[Y>-?__Q[VED][1IC5J=C^K*S*N.?[F&.B[)ME=&Q
M+J:X;%UEW<KDLDV5=5M3EQU66?>G,BX[JK+4E[KUA,]`_B=]AH/3^@S=`^K5
M)F5=BL#'D=QY4F7=/00Z;G50?4EM5G:AQC.5G54_SW(_ZZZGI]U]-;$O=3YN
MHHEE-0_\Q![+:A[X[366U3SP*ULLJWG@YY=85O-`$CZ6'5?9<2X[J;(T1\S?
MYBG_I#89L^.G_'.:VJPRQBR>C[L9JRR=C[%FWG.;=..X^I+.1S<.JB]Q/*N,
M-E,9AVSJN/3YZ`OS4'_:$<:3V_VK+,X#S559:O.,!Z9P/IZ`D-JDC#]JS6V>
M5IL\:B,>5V,=V^3O80\9LUA&-TZJ+_%[5&6TF>?HM.:(O\R.?:GO2FR3;IQ4
M7]+Y'E;K-64\5-=MGO&HU.IGG@?*>%1B[N=)]9.';+I-GII;_>1QBJGLM'SA
MN8>Q;%5E\3O-8[:J+'G&(RC*I?@9^-C=N.3/=UQM\L:_U)?C:I-7P<6R<HD7
M@L6R<HDW1<6R<HGW!<6R&FM>))/*CNHX7G(>R^HXWGX=RVJ.>`=R+*LYXN6X
MJ>RXYHA7T<:RFB/>G9G*CNJXHWS<41W7K]K+=65U5/-PE.?AJ.;A*,_#4<W#
M49Z'HYJ'HSP/AW4<OW.ESW!8Q_6/>U<_#VL>#O,\'-8\'.9Y.*QY.,SS<%CS
MP$LA4E\V=1P/IX]E==PF'W=8\]`_X=V?H>:!!XRG-@]K'@[S/!S6/!SF>=C4
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MYFN9U:KZF:]7^-A5EC[[0VU1N%O>,\2(U0XS[]BKC$^0K3XHJ_-5`,U56;(3
MDPZ8O5S&PO^0]W2UI8O]W]:&+N_G:CN7=W.G?)'C?FU;6VH><N)QVC[AX_)@
MA53"AXV[\&UMM/,^N[;9<9?]P)?P(>Z+SAB=LS@ZV]HPY?W2,>?)NZ5C9,E[
MI6.4SCNE$UKC'2EA#$X9G;Q[K,UCWCO6UC'N'+<5V'-<K[">HWH%]1C3M[5$
MYA6R-CAY?U/;F[B[.:N@G.,G)1]R1*Z`G./QFO/$UA[JPB&6G&'(631D6P$\
MQN]M+;]Y]:W%-Z^]:[X_<>4]ZP)^CFL5#G.TKV"?8WV%R=0:K\$C5*02+FTK
MQ9),[!;I%.G(K_!YXG>[%NC8&I?EE5H)YWG@^C/VK/8/*01O<3IVJUL)8K<J
MWY737=T*D<+K=H5J.=75K1SQR]NM&ZG/#[4Y205GE:4+H[(ELY=&:UM?C52?
MWJ;U^(QL0AK=+5^7^!$0/_5S6Z$LG1<9HXNU9(3Z%R?'3R_C3NR*DNM8<D/)
M;2RY()%R&?,H5Y1<QY)Z<>C3[MV@CK[UCL^GW6L\7;:MY$O.O53J)6=>3AFV
MN-)<')\\O8U7RA?5/5X0ZAY<5>=BR0TEM['D_&3S]!7O.'-K%R='C&J:Z_=<
M/KZ/5X%WE-S'Z\H[+BOOXU7E'1>5][&U#W69&DLNCDZ>7L9\P!4EU[%D6Q?+
M\5KY%>=Y%<_SFI+7L>0-)6_C)WW#)WT;/^D;/NG;V-H[6GL72ZXXYCJ6O."8
M%['D)24O8\D-);>QUS?T^C;V^H8>W,;6+D@QW.<,`^?9QF/.*3F/)1>47,:^
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MNA\QO_M_`0```/__`P!02P,$%``&``@````A`&4HK(\S!0``!A8``!D```!X
M;"]W;W)K<VAE971S+W-H965T,34N>&ULG%C;CJLV%'VOU']`O$_`0*Y*<G3"
M:-HCM5)5]?),"$G0!!P!,YGY^VY[&VQO,DGHRV2PE[?7OBV#E]\^BI/SGE5U
MSLN5RT:^ZV1ERG=Y>5BY?__U\C1SG;I)REURXF6V<C^SVOVV_OFGY857K_4Q
MRQH'+)3URCTVS7GA>75ZS(JD'O%S5L+,GE=%TL!C=?#J<Y4E.[FH.'F![T^\
M(LE+%RTLJD=L\/T^3[-GGKX56=F@D2H[)0WPKX_YN6ZM%>DCYHJD>GT[/Z6\
M.(.);7[*FT]IU'6*=/'C4/(JV9[`[P\6)6EK6S[TS!=Y6O&:[YL1F/.0:-_G
MN3?WP-)ZN<O!`Q%VI\KV*_<[6\1AZ'KKI0S0/WEVJ8W_G?K(+[]4^>ZWO,P@
MVI`GD8$MYZ\"^F,GAF"QUUO](C/P1^7LLGWR=FK^Y)=?L_QP;"#=8_!(.+;8
M?3YG=0H1!3.C8"PLI?P$!."O4^2B-"`BR8?\O>2[YKARP\EH//5#!G!GF]7-
M2RY,ND[Z5C>\^!=!3)E"(X$R`K_*"!N/HF`\G0VQ$BHK\-M:F3QLQ4._9)B>
MDR99+RM^<:#V@'E]3D0ELP58%O&90)2OQP<"(]9\%XOD4D#7D-3W=3B?+;UW
M2$2J,)L^AMF(N(\(Y_,.XP'!CB5$CK(,[[(4BVR6P;@S+QW97('8B/@*8M)!
M+(X0O>$<Q2*H*=?I(AGY?F<?22(FDB4EPA\;`Q:#R&9P.X<"O'+!/6-GDJ$-
M8F8RPQ,0+NVY9!:;\^-Y,)]VS"U>T"EF9&[S$F#**^CL8D00$TE>@4]8Q^8L
MFWY149,AG`28<@H))\0@IY`&RIS4-6@%:3J$D`!30A$AA!@D]!3HU&#JK%D6
M:F\L4N(8--3A=N8$F)+2SF+F$#-6%15,::#,^?$\C+2J6+SF0W@)L.`EU%WT
MSP8'H'B[TF>AW@CCTV+$X6(J$0/9>3PD$FWMK49N;]Z!>KL3N;Z=$(8*:WBN
M1N[LCLNDX-B^"S%\N!P82J>Y.X[<V;T%]7P7LF?L+HZJ^X<`0[$$HUVR(Y]4
MW4:!#(DU1^P8`/O_P4*LNJ?S#$$F"V/$9C%(4L4+3Z\SB6IN%`A;,_!#GXAN
MW`-H2;&Y#9)6=DU;R=8;!4(MB\AL;,T&>M9F-4A?V36!U1J),J)`2O)M]8V[
MR5X9#])4=DU4J=(K4"OUE`F::&>U%W9\!DDJ:S75["JJ]0K4551$`+$-"$.C
M+RUNP2#-E6AZ#NE:Q=PID-%KYHB].]'<QW0G0!$%]3%TA[[9*9#)XBOM#80L
M&NIW6_DEFL:`=KP"J?S,6*A?E?`,M`%3-OZBMP*BS'>X75-D;5GE!T%8M"PB
M%1_+'5>NFAYKS^S,$:V^PPO%UCXI=+<H7JTBBX^>WDM58,[J:K=)#9)N\979
MDVX2C8T"J0YGA'-L3T>Z%6Q>@V0[N";;VF,5+`2U!69^'Z@"LP#38/)5(@>)
M=W!-O,G[W4:!S-;#97+$C@Q1[`<%`&7WC@"TV@RGA`J),6*S&"30P36!UM%5
M^4$0YH>Q"?T\CI65%C`SWI(M;N(U['%QDF@J3E0`%*CM<'*F6;/Z;<XF173[
M=O>'*+RWNU^!D)3>%C/73=(3/QPDW1)-HT,[7H':CB?!B^WIB18$.T"#9!MN
MZ?I*1#M>@?#&`"HJ),3%79^PT@+@!JS++'+#FSR\HCHGA^SWI#KD9>V<LCT<
MI/YH"H)8X3T>/C3\+"]YMKR!^S?Y[Q'N6S/XT/-'`-YSWK0/(C/=#>[Z/P``
M`/__`P!02P,$%``&``@````A`,H.#JXX!P``D2(``!D```!X;"]W;W)K<VAE
M971S+W-H965T,30N>&ULG%K;;N)($'U?:?\!\3Z`;:Y1DM'@[MX=:5=:K?;R
M[(`)U@!&MC.9^?NM=K?MNK!@)@\A'$X5=;JK^[AC/W[\=CP,OJ9%F>6GIV$P
MF@P'Z6F3;[/3Z]/P[[_,A^5P4%;):9L<\E/Z-/R>EL./SS__]/B>%U_*?9I6
M`\AP*I^&^ZHZ/XS'Y6:?'I-RE)_3$WRRRXMC4L';XG5<GHLTV=9!Q\,XG$SF
MXV.2G88NPT/1)T>^VV6;5.6;MV-ZJER2(CTD%=1?[K-SV60[;OJD.R;%E[?S
MATU^/$.*E^R05=_KI,/!<?/P^?64%\G+`71_"Z;)ILE=OQ'IC]FFR,M\5XT@
MW=@5*C6OQJLQ9'I^W&:@P`[[H$AW3\-/P8.)5L/Q\V,]0/]DZ7N)_AZ4^_S]
MER+;_I:=4AAMF"<[`R]Y_L52/V\M!,%C$6WJ&?BC&&S37?)VJ/[,WW]-L]=]
M!=,]`T56V,/VNTK+#8PHI!F%,YMIDQ^@`/@].&:V-6!$DF_UZWNVK?9/PV@^
MFBTF40#TP4M:5B:S*8>#S5M9Y<=_'2GPJ5R2T">!5Y\DF(VFX6RQO"=+Y+-,
MNRSAW:5`T;4>>&U*"4?A<A;,YG<(FOLL\-IEZ3DJ8S?"]82II$J>'XO\?0"K
M`,:P/"=V304/D+B9*3>N[=S]W]3!G-DDGVR6.A?,2@G]]O4YFD\?QU^A1S:>
ML[[$F5-.[#B+X:#-$U"&:ABV:>Q7ZR9M`Q@$C$%DJQ3Z@"N-H+,O]V0CS`9Q
M83-:TOH29T$YL>2$E*$D8\&T:TD)V0`:28GFR_:;R'A`9]\_'C8(5B.:H&B^
M:O/7,[)VG&F]&.T4Q1Q0'-`<,`@@1<,RQ$5?GSQ+?AK"D+3=%"TFK%C'0<4Z
M8%DW<1`$X7("/S1(\2#-`8,`4C_L`/WKMV1>/^N)M>/,7+FV5/BAU<:$,G,4
MQE&.TPV#YH!!`%$$FP969#>0V\O*!G%E;$&L':<K*7:`DQK.82JY4L5#-`X)
M:NET;`R*(*I@"^*JIC`"U_O-!G%5$?W"M>,@50YPJFRO4;YJ^'9/99_IYK-V
MZT,`46.OJ]`F?UV%)7,5?"]W'*3"`;X-HWJHF1#""*=P1<;E\*0&`43.ZAXY
MELSE\!W<<9`<!W@Y@5TR3,TM@N8I#0*(F``\"$^.74"W6ZV.XK*8&:P]">GR
MB!,VG4^E,,+X$,S"N>!HD==@A*JS;HQ:KZ<ZY^%TYV:6N@X<":MSB%,736>=
M\=7&I'R$^WP63MAX:9'18(3JLD:+=%U?4H&S9:J'5;?V)*S'A76($APM$(,1
M6K,U551SOZTZ<%8,OSL7%9;O25VEL4"40+1`#$9H[=90[Z_=V3`==^XS`?+J
MND]BC_CE?\$VE(C1`C$8H5JLE2(M-WK'&2_5P"^Y[.$*=CD\_AQ1@J,%8C!"
M:[9&B6KNV3O.7F_T#O)@/_X<40%'M$`,1FCMUA;OK]V9*1UWT3O(<7WM#O&]
M,UE>N$H)>)`6B,$(%6--$8FYT3S.0HF()?.R=8!\UHO@B!(<+1"#$5JS]3Y4
M<\_F<8YYHWF0K?K:.:("CFB!&(R0VD-FS]?'NV8S6U[R2W9/0HO5([YIK"N+
M"PX1I`5B,$)%_)`+AQ=<>,E7@"=A,=R7E>!H@1B,T-JA>>]OGM!&W3JH>A*N
MW85UB!(<+1"#$5J[]4[4^#>:Q[)Y\_#S0^A(786Q1^91?0:<C)@W*!&A!6(P
M0A4PW[VAX(+?+OG9(11^*Q`E$"T0@Q%:,_/7?MN-_4?<[8[AKAK[L&X^E$"T
M0`Q&:.W6Z/IWC+-%LKTOQ'AS[XQ#A_CMYN)IC5(N'M<\I5-N,$)56<?KK\KY
M(U&UY$>VD)MH+!`E$"T0@Q%:,S/:GEWDG/.Z:87<7F.!*(%H@1B,T-JMXZ'Q
M[EF[\TDZ[NR,M`ZYF<8M@@X(2W984RVI^5^%%HC!")%C_Y]TOYPZBF^G_-#E
M25T3QRV"Y?`]M26U<@1B,$+E7'!C2[Z^MT87W'C%+^4\"<MIW!C)6;$K$B7"
MM$`,1J@<ZYEW-UMDH]CLK/C%A2=A.2X,+*0[C2[%[#2D;G8X8G!J*N<NSXXN
M>/:*>[8G81G<Q97@:($8C-":F4OW6^^1,^+K>Y4GX=JY?RO!T0(Q&*&U_Y!;
M1\Z(85J[/I"K0;BU#R/MLV*&J5I2USX\D<$<*H<9>,^IN&#D*VYYD3#R%L&C
M(!8W#]-M6"/08(3*N<NYHPO.O>(.XDFXH[B7*\'1`C$8H37_D'-'?9S;DW#M
MW,N5X&B!&(S0VG_(N>%>OMQ,F06O/0G7SKU<"8X6B'UPP'Z9NT,6U6=5=%IU
M:MR3`>Y&\S$M7M,X/1S*P29_LW?]`SBIM*A[(B$.'N#6+O3CN/T`'@@X)Z_I
M[TGQFIW*P2'=0>ADM("U6+A'"MR;*C_7=VA?\@H>!:C_W,.C'RG<>9R,@+S+
M\ZIY8[^@?9CD^3\```#__P,`4$L#!!0`!@`(````(0")AN;1GP(``/`&```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;)15RV[;,!"\%^@_$+Q'U,./
M6+`<.`W2!FB`HNCC3%.41$04!9*.D[_ODFP$*78;YR*(J^',SG*Y6E\]R18]
M<FV$Z@J<1#%&O&.J%%U=X)\_;B\N,3*6=B5M5<<+_,P-OMI\_+`^*/U@&LXM
M`H;.%+BQML\),:SADII(];R#+Y72DEI8ZIJ87G-:^DVR)6D<+XBDHL.!(=?G
M<*BJ$HS?*+:7O+.!1/.66LC?-*(W+VR2G4,GJ7[8]Q=,R1XH=J(5]MF38B19
M?E=W2M-="[Z?DAEE+]Q^<40O!=/*J,I&0$="HL>>5V1%@&FS+@4X<&5'FE<%
MWB;Y]0J3S=K7YY?@!S-Z1Z91A\]:E%]%QZ'8<$SN`'9*/3CH7>E"L)D<[;[U
M!_!-HY)7=-_:[^KPA8NZL7#:<S#D?.7E\PTW#`H*-%$Z=TQ,M9``/)$4KC.@
M(/2IP"D(B](V!<X6T7P99PG`T8X;>RL<)49L;ZR2OP,H\4D%+I_:#;5TL];J
M@."X`6UZZIHGR8'X="Z0A,-N';C`2XQ`QD#]'C=9NEB31S#-_F*N`P:>`R89
M$`1$!V50.U_9@9VRJXI+Y3H$QC+I:9GL/3(.#&4=)9^ERX$W*`?,S%=U[&?V
M'B$'+O`<7`QERM++5TH!E$"CC4"K`32I)G3`^=5T8*\^E#-$CDTMIK2^9=-+
MUY]OM(K;.)4(D61\9%D6GW8#+7:^&P>>2H7(L1LW2$?-'BY@%BW?=.,V3B5"
MY)6;?W3Z:BK[_SOFP%.I$!FY"1,F7&/)=<T_\;8UB*F]FQXI7,PA.@RV;>H:
M]G5\EF_]P"/#!Q@X/:WY/=6UZ`QJ>064L2^1#B,K+*SJ_?#8*0NCQK\V\&?A
M<#?C".I9*65?%B!,AG_5Y@\```#__P,`4$L#!!0`!@`(````(0#O@Q(3[0@`
M`#TF```9````>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*Q:6V_BR!)^/]+Y
M#XCW!6P,)%:250!?N6BUVG/VF1`G00,XPLYDYM]OM;NK+U6&)*/=AR7S^:NO
MVG7IB^V;WW\<]IWOQ:G:E<?;KM<;=#O%<5L^[H[/M]W__17_=M7M5/7F^+C9
ME\?BMONSJ+J_W_WW/S?OY>E;]5(4=0<4CM5M]Z6N7\-^O]J^%(=-U2M?BR-<
M>2I/ATT-_SP]]ZO74[%Y;(P.^[X_&(S[A\WNV)4*X>DS&N73TVY;S,OMVZ$X
MUE+D5.PW-8R_>MF]5JAVV'Y&[K`Y?7M[_6U;'EY!XF&WW]4_&]%NY[`-L^=C
M>=H\[.&^?WC!9HO:S3^8_&&W/955^53W0*XO!\KO^;I_W0>ENYO''=R!"'OG
M5#S==N^]<.T/NOV[FR9`_]\5[Y7U=Z=Z*=^3T^YQN3L6$&W(D\C`0UE^$]3L
M44!@W&?6<9.!/TZ=Q^)I\[:O_RS?TV+W_%)#ND=P1^+&PL>?\Z+:0D1!IN>/
MA-*VW,,`X/^=PTZ4!D1D\^.VZX/CW6/]<ML=CGNCR6#H`;WS4%1UO!.2W<[V
MK:K+P]^2Y"DI*3)4(O"K1+S>U6@4C*\FGQ<!9C,2^%4BP==%QDH$?I6(_^6[
MN58:\*LT1KV)-[@>?N%F/$AD<S?BCU\>B0=9D2HF/7[/"P9CD9P+"?$P(^(/
MY7[\*<,`/<(?RO#SN>S+XFIJ=;ZI-W<WI_*]`Q,`E$_UNA'3B1=ZH(Q5*F]!
MU^VYLH5Z%2KW0N:V.^EVH"(KZ+7O=\.Q=]/_#OVQ59PIYQ#&#!FB&83LG`(1
M!6(*)!1(*9!1(*?`@@)+"JPHL+:`/H16QQ?*X]^(KY`1\<7(3!$P`??=<,^0
M@29S"D04B"F04""E0$:!G`(+"BPIL*+`V@*<8$++L&`&T&_M4RK6IK""R=.J
M37\T=(,UE9R1G#Q%Z<T8,F=(Q)"8(0E#4H9D#,D9LF#(DB$KAJQMQ`DEM+H3
MRLLA%.S;[@CR8O4W*;BI)/G7NDAG&C%FWO#*#?U<:<.<KK5].G=$FH35'&MM
M1!*&I-K*EB:ISS0)A7(FM&#(4EO9TB/WUE::A-)K6\C)!U3Q%_(AV$T^4'@J
M$3OX#)DK*S?2)(N1)J%TS(02AJ3:R@Y'X(8CTR24SIG0@B%+;65+CUWIE2:A
M]-H6<B(-&Y`O1%JPW4A+Q(XT0^;*RDPG$4-B9I4P)&56&4-R9K5@R%)9N9F?
MD!AJDHZA+>3$$!9Z)X9RU]`3V[#Z9;?]-BWESK1E5AG"[D#N&82(&UJ)V*%E
MR%PBXV;OW>A$#(DE,@ST3)0PG91990S)F<Z"Z2P5!WZLZ8O,<2M-TJ%52#-$
M)[3B^&=OR%I""%M,C*%@NS&4B-C*6>.Y=E,]4R21+MRO\8E9DW#0D4+&S0;/
M'X[)W!%KBPNRB2:A;,J0S'%T/1Z0B377%A<<+30)'2TU8IF-R"9TI4B3YB;'
M/9]<7[>)6(N:DTQHN"\D4[#=9$HD</IV,B#)E"0/=J`7DJE)&(Q((G`"MLS&
M9%Z-M9E-(BMHHDFHG3(D:_'F3TAH<VUF>;-"V[3[0I/0VY(AJ\]X6VNS=F].
M(L5AT<FDF/%\J`YHH<L=VEBZ647(#KT_(<TT4RSQR.!"7@T+PQ$A)"N8Q#C&
MJQ=E$\-"V91#&4+.Y,>RBJR+'A>&A1Z7'%HA=-'C&EGG/+JI%4>WS\^XHL](
MERJ(M"GIDIEB?="GAH5AB!3D=*H_(9NKV!A:Y3(F@T@,"^53#F7&HSC)7WMD
MIY`;$\L7:U3#0E]+#JU<7QX\TB!C7ANC=F]N-L79\0O9E$=-.-G@&*?BT8Y(
ML-N=9`6:*=9'W2FU@(7R$1I>K.`86><JN)D*$\-"^91#&4*N1S+3Y\AR/-+Z
M61@6>EQR:(60G(&&O0$IH#42'&=6`;DI%8=8.Z6_M-L4S]MHWTJ(]"T9ZTP9
MBBJ\-`]++2!C8")E.+R6VR6R)XQ1%PS/ZR;(,D>)%"'C*C.NC)8_(1YS8VA8
M'GT4LD"6\;CDT$I!,"DU4T1O,!K8_Y$@KHV"Y?ILPL4IV4[X!RNL.F;;/2RA
MP)P29F)'#/G_J&&98:0,+:W8:&&R$PZEW##C4,X-%QQ:<L,5A]8.Y/80=)H3
MTE_K(:%"]C(2\F!7K*O8G]#SAHBZ"/X'/219@:F\2!D&?E-FWC!@VQEM8_RS
MHTQB_&/"4E0VSC*$E+.!/R*+;(Z,B_>QX-Z6!K*&R8X>BJ6::MRC';QNE3G;
M1N+X;K=1DW-XAP2I$H?TO\K7YOG_YT_LGGI$`*N:3O:0KA%3Q8)D8[!G!C*&
M+$MSQ1K+^/L#CRRZD2&@<HS*9C),$#+^4V,H9BM0)HG-#`&5<Y1IE-UF@I74
M!!;V"1_,3X).ND9"HE]U('VZ\9EYBB42=OZ8;E@X]`@AN?Z.>B2.,5Z_*)P8
M%@JG',H0.N,KQ^OG?+F1%8=K7;(?1U:>Q9W=FSJ>._/1%4GW3$Q7GYB/-`L#
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MPR<D+3K380AOWEKT@_`>EO"6"S"D>X@0OY('(3R&YO@B".%A-,>700BOG5KP
M40@O25KP<;AJ"\5R$L)3:\Z/@Q`>KW,\"4)XR,[Q-`CA#5L+/@KA?5`+#KEI
M&T\Z">$!/>=/@W#:AL^"<-:&SX,07B9RG?DHA%=?+3A44=MXYI,07CP`OZ]K
M`C[>>=T\%ZO-Z7EWK#K[X@E*=M"\%#G)SW_D/VJU[WHH:_ALI]F"O<!G6@6\
M=1Z(S=E36=;X#^%`?_AU]P\```#__P,`4$L#!!0`!@`(````(0"F?'!VNA<`
M`%!]```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*Q=75,;N=*^/U7G
M/U#<'V!LCPU324XM]GSZV]A^KPEQ$FH!IX!L=O_]:8W4TU*W+`_DO5FRCQX]
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MV7]]/0.Y<^VH?.:K\ZMS4/KTX<L]/(%J]I/GW=>/IW]$R38>G)Y_^E`WT/9^
M]^O%^O?)R_?]K_SY_LOD_FD'K0W]I'K@\W[_IZ*67Q0$E<]%[:SN@<7SR9?=
MU]N?#Z^K_:]B=__M^RMT=PQ/I!XL^?+/:/=R!RT*,F>=6"G=[1_``?COR>.]
M"@UHD=N_/YYVP/#]E]?O'T^[_;-X<-&-@'[R>??RFMTKR=.3NY\OK_O'_].D
MR$AID:X1@;]&)#J[C.->_W+07J1G1."O$>F<1;V+OO(C8!M*ZP>`OZ9:_VP0
M75QUE>E`O;ZI!P/A_3Y?&1'X:T1B,MZR\2+H\_H)(FCD][L200]J&>K*SEFO
M$P\NZZX,-$6$_:?^\:9&C+#35,C]AN_8&1'\P\ATK`@*^3[`QX9_-+YW+N,H
M/A8Y$72];C&*`;O%VO8?!D%$4?".\.]@&*A_-&W08@!TFB%,\=-OUW@=C!GU
MCS=WW[E.)75F&MV^WG[Z\+S_=0+I'OQX^7&K)H\H4<J8DW0W-EGJ4)*"[*14
M_E`R'T^A6R'_O$!F_>M3-XX_G/\%V?#.<*XE)W(90V2HU*=D1QQ(.9!Q(.=`
MP8&2`Q4'QAR8<&#*@1D'YAQ8<&#)@14';CBPYL"&`UL+.(<N;OH9NO;_HY^5
MC.IG[*%K!*CC.ZQ3D8%51AQ(.9!Q(.=`P8&2`Q4'QAR8<&#*@1D'YAQ8<&#)
M@14';CBPYL"&`UL+<#H5I@"G4_T+"1RCB@U+!FN,1M&5VUG7FA/K)8,:@D.!
MC`22"B032"Z00B"E0"J!C`4R$<A4(#.!S`6R$,A2("N!W`AD+9"-0+8VXG0I
M3-).E^I\?*862*_?[^_^O-[K%9ZGJ[N0=W4V5B(?3V,(&RL=]UE7:Q(L9'!@
M#AN$JD7=2[?:2),Z,`TWVE&7A5':D%`[$T@ND$(@I4`J@8P%,A'(5"`S@<P%
MLA#(4B`K@=P(9"V0C4"V&H%%';28$Q#0\4Y`>#H>5MW8\XI=]SPV_+5&.E?4
MS0UB]R#O9DWJPG1"W=R[<&,A;4AH+3-(_1AU+.8-8@GQH"H:(8O48Q-)V9#0
M6M5H(S)N$$N(6YLT0A:IUW.?;=J04'O6:",R;Q!+B%M;-$(6B5M;-B347C7:
MB-PTB"7$K:T;(8O48YV[:4BHO6VT`7'"#Q;Y;P@_Q7;#3R-V^`EDI)$NK*6M
M6&-KP[0AH<^9$,H%4C2U;.FNV]5E0T+I2@B-!3)I:MG2;,T[;4@H/1-"<X$L
MFEH!Z65#0NF5$+H1R+JI94NS]+UI2"B]M86<^(`EOQ,?[YJOE(@;-AJQPT8@
M(XUT.TUF2P62&:37<'*A4XA:I4`JH3,6.A.#.#-CC\VZTX:$33L3TG,AO6AJ
MV;TV<,-XV9!0>B6D;X3TVG"H%3<"V=HZ3N_#LXK>[_35Z=6!0RV<IU1%M\<U
MH@XI*`G$;,(9&A+($XFGP)&/%/-T8DC]>J_:N>A>L-DF\ZEP4WD;4N$C<7]*
M0QK4_O"IK_))<&?&;4@3'XD[,W6<8=ERYE/@OLS;D!8^$O=EV?AB=7G,.FOE
M56*.W_A(W/&UC\1]VAA2$SP]EO:W/A7+E#.&X"3*&4/A!9YBNP-'(^J`C,9$
MS%8S0T-REG.60_JTI2%A`DD-<J5'R:58Z&=-%<LXU\W;D(J&A,9+C<`1FSI.
MBOB2J6HJ!$R/VY`F#0E-3QW3'99H9PT_8'G>AK1H2&AYV5BVM/E)VJJI9I-X
MN/M(O&O6#0D=V!@$N[QSQ9Y^VU2QC%NZ3FRK\W(GN-^U/*A5W*`W$)LNV&0[
M1%9XOC`L.)O%1D@1ZNC8B^!XVIUL,V0$1U3>RH&"M-"!$B&UIX?@9]8K+`Y:
M'[>R/B$MM#Y%2%MGK3K#TJ#Q>2OC"])"XTN$X(C$2F@L"E?(<IR(^1AHY<2:
MM-")#4)-`'191MTBPW'@X#@`EC,.PDE>W2ZQ+&^@#JUDAP92?ZBA+`_,$;K6
MLBJF4BLC+6R"G*"`?"&U2@E5I(7R8X("\A.I-970C+10?DY00'XAM9826I$6
MRM\0%)!?2ZV-A+:D!?)N^E0'O_)VYHVG@>JVD4>3AECZ9,<$0U-1W1>&`DQK
MJ34_L?B2*35:';UFZL,'#UA:R9#AZ/!PSEOY5'BUN$\ELO2BNW/!]@@5E@<]
M&K?R:.+5XAY-D:4]ZK(FFF%QT*%Y*X<67BWNT!)9L`.T.I>=%ZR0Y?@ED[$)
M.H?%.WCMUV)=LT$6AE-GP-IJBXQ#UMR!IL[C0P-MO?]1WY4>R=OF6)\VT]?J
MFAX&GY5^AP92PY[:E+?#2%9,)921%J:FG*"`?"&U2@E5I(7R8X("\A.I-970
MC+10?DY00'XAM9826I$6RM\0%)!?2ZV-A+:D!?)N.*G3?#N<CH2-/OR'^QKT
M\UIE9AXV&NKJ3P;IZW$!I::BQ<HDE$NHD%`IH4I"8PE-)#25T$Q"<PDM)+24
MT$I"-Q):2V@CH:T#N?T*R<3IU_=M9Y0*V\YH"%("1L!0S;K`.I8E-,N]CNNS
M8[/4:`$+Y3,)Y1(J)%1*J)+06$(3"4TE-)/07$(+"2TEM)+0C836$MI(:&L@
M&/-BL*NS\3<,=GV4[@QV^W2]7K4/U8>KU/B'S79HCM"L([=T1@M8U/NFHG5/
MARQGV\5GI0)9SMS%CRM+8J'%"B&R."8H\(P39+D6V6YL2BRT.$.(+,X)"EA<
M("MH<4DLM+A"B"S>$!2PN$:6:Y$MQS?$0HM;A&J+;JI29_9OB$I]Q.]$I8;L
M.YA(0",#';F\(Q:ZGDFM7$(%5;3:K\>V^26Q4+Z26F,)3:BB+<].6Z;$0OF9
MU)I+:$$5`_)+8J'\2FK=2&A-%6UYMCC?$`OEMXZ6&S;JY-H.F_?-</K\VXDF
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M.T,LO&.LZ>X6PD!J%%,'BGM`9#DK#<LI?69,+,PT*4+F7F@0\3O8#!E!Z;P5
MJR`6.E`:"/[H&Q$6FA55L9Z?/]FX%6M"+#0_-1#\4>;9"F%&%0+&YZU8"V*A
M\:6!U!_JVSY;`Z^HHL42IW!>%F^G-;'0B0U"&`$=GAVVR#@4`6[$`\N)^'>M
M-.#2CD\P!E*[>&JLF(W.(;(.C4XS$+2\?35H*L)W)>HXC"YYVV7(.-0,M73>
MRH&"M+`?2H2\EW,5EM)F;]S*TD16G"+D;`EYK\^0%7S<>2LG%J2%C[M$R'6"
M#<`5LAPGQ`30RHDU::$3&X2PT^%[6NY]\!89C@-6:+BQKT["[075D6RO#\[M
MY;3ZJHXZ'Z!EZ]!`1PZ,9,540AEI81/D!%G#RGK`.JH+J55*J"(ME!\3%)"?
M2*VIA&:DA?)S@@+R"ZFUE-"*M%#^AJ"`_%IJ;22T)2V0=\-&W2788?.^E*E4
MV-I!0RQELO.'8<>PCJ1,S3IR'6BTS'5@?"4^9I(A(V@M;^53X=7B2[H267I-
M'@W81KK"\J!'XU8>3;Q:W*,ILK1'+.?-L#3HS[R5/PNO%O=GB2QW,<ZFUA6R
M'+_D.J1--*W]6BSY;I"E%^/Q59=_XGV+#,<G*WNYXTQ=JX3&6;O;0$C.9J!1
M4NC&;.]Y;5A.)M<5+6@D6:F$,@GE$BHD5$JH<B"W>:`1@\W3ZCM**D'P-*0A
M^Q;$L(Y-:KIBU^RF+_CGI5(C`P1,V1DJTV%MCM"A.=Q,<=P86X>7TEB%RO*<
M%C*@VYA'E@+ZX-Y9"FC(3=Y]D;P-"YRG5;$U`,QZU\?B:2"M?8:K*3W<HJN(
M7SAER`A:RUNQ"B^+^U0BR_ATV>FR,X(*&8=\<F-<G73S%-#JR*NC:K+I54/N
MUKS/II>AJ7@LU(T6K>]3K&@V9E=]OMG)D!$,[+P5JR`6#J42(>-`W(O9LU7(
M..2`V_;J$)BW?00O:U`]U_H[D.I*E/>#AMR1,F"7I4-3\<C1HV%U^TU&20T$
MZS>],^S)8:$=4'N%PX,P;^5`(1THF0-QGT\V%3(..>#V`S_V/9*:Y%FONKZ$
M/H"I!&-E:*!C42XJIE(K(RV4SPD*M'`AM4H)5:0%\D[+J-NNWX_06L7-%`9R
M(S3FN1Q9AS*9SN6&I:8>"C:>-U-DZ;S9OQ`?I,J0X>CPF2-OY5/AU>(^E<@Z
MN)RKD''()[>W(-IE;\&;<TPZP=5<^]RB+MQU;J&F[?)NNC8L>SE#$%647[$V
M+%BMV"R64U-B8?1G$LHE5$BHE%`EH;&$)A*:2FAF(,^')^"FS],W;\WUM0H;
M2?J`Q&G\!K*;E0VND='JP?:$ALV`726DQ*+&-_+6@M*PPLFN("W;(E]5$@LM
M5BA/%L<('4KP=6J8D)9MD>TOI\1"BS.4E^O8KMK.X:2M\I<ZFVBU8*IKLLXS
M>T.0L?J`[3.'IN*1B=K+XBDG198SY/A19X:L0VFG;MV\%:OPLKA?);)T*NQ=
M7++M8X6$H$OC5JR)E\5=FB+KD$LS)!QRR4W.:J_+X^;-B[VNWC';VR(#N8ON
M`6N^(;*"XV6$+!IHJ8&ZE^8Z2MPI4QTKAN6TJ1T_EB$,B^R7:!\62C1$>,!6
MK9P8(RO8"!-DD1-3=.)0(\RHCN6EU0AN*$#`.*$07F_"1USY`M]`O?HU?/5@
M'!KH6)+06E;%5&IEI(4),2?(_X"U$X74*B54D1;*CPD*R$^DUE1",](">;?A
MU:[_]\>@/CMPQJ`Y3H!M#P7I@,VX0]A#J8X,CX&18?6<(.7)*466V8/%<EAJ
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M6F(@-B;B&6<H7UMT1A',Z;(C6VU,ZIKNQL1`[OD,_^K9$%F'%L"Z/[TL,:$A
MRQUR[`(L0U;08MZ*57A9W*\267H7T!GP6;U"0M"E<2O6Q,OB+DV1=<BE&1(.
MN>3&#43J[R<`M<[0)T4X.*X-=&1C@JS@>!DABP9::B#(;/4I],5`Q(IV27U[
MC9(XSS8Y*@?M%\@B^R7:AS%*\F)C0A4M%G=BC*R@$Q-DD1-3=.)0(\RHCM^^
M&PKV(94:^^&%3$\?!-E)WT`0@!@&0P,=V9C(BJF$,M)"^9P@_P/6.:B06J6$
M*M)"^3%!`?F)U)I*:$9:(.\VO.]0Z<V'`VK&Y&/0'#"%-R:F8GB6'!F6BB@*
M>)Z<4F29C8EG6&J77!D^(O)6+A5H+.A2B2SMDB^%MW%IW,JE"1H+NC1%EG:I
M>]ECA]XS)#@R5BNYX:..3<0:[G<._F';84*)^KK+;SNO#<M>XA%$%>7!OV'U
M38_(SS$0`4=BALJ4_7*$#C62&?OZ6<@87]A)8Q4JU\;<MH9)U6GK(SE2T=G:
M2D/NVNJ2K?V&/<."/S3:K``P:RL?2XY)PSJRMO)I<8MY*[\*+XO[52++?)RE
MSPXM*RP_U`9NQZC3!3$(WGK#TM-G%,Z<9LY(G!QZR0_I3<5C.=0<@=!WVU-3
M$=<QG8C=TV>H#$GJ<"3DR#HR%H3]$NWK#S7T(O9@%0H?,N]V@CJUL#OAR.A0
M=#8Z-.2L(#1T;`4A*J8]`64&`BU,+#E!@?8MI%8IH8JTQ!2OSB+LEGG79UI[
M^D3#"4\-N<ML?GTR-!6/A:?6<N=F/FQ3HP7+F7KE[8E8GXS,),;Q(Q'KT^(N
ME>B2WA+U+]DU9H7EAVRY0:RVW4U7P;:Z[JK?FD[U1AZZC4*LR\^3KGN:Y4RG
M#405/=.I9M$,QR:3U"@#`:,^0V/V=-K&6$%:JO?A94)B.FV\06.58\QIZ]@Y
MM8#_"2>,FNXF#`,YTRF_QAX:DI551EC/F5QX8*7(,I],[K(I*I/"N80*5`G:
M*I$%68L2O=A1.O)N6T)T.W%[I"T5G;6EAIQ<,F#].X0?35#UCJ02P[*.M%.L
MJ&>:*([8!4F&!#!`#2#R1BM6(>V76-'8O^RP$X,*"8?LNZWM;)9-EFAUWJ;2
M`&]X#3E!W.'O8AR:BD<F0L.R8CV54":AO)5\(2N6$JH<R&TWM=GBV;5=N^EM
M&DAC8KF.-:3R"T6,.*<TK&,1J[6L])MB1;,VZO$3V@P)AR*F7J7GK5@%L?#Q
M2H1,Q'9[(F(;GZWGMT:,V_+.-A'GM;>ND.-F:XAN7B,$DDTO=#IL(3DTK&/1
MJ^7AHZ,HGYJ*\-6&>L:Y8L(9EA_I!"T<-E^0%IHO$3I@OL+R0^;=/E";+!']
M*N.W_L!OK"18WM:0$^`=_CK?H:EHI>21@6"CA8^;&LCL1WH#<:XJZ^12N9"L
MTE6.^GPRK9PZ;K.I?8O=;$>F-KW-<3*%V?E8)Y.QAL(1,3(L)YT*K8RTL"%S
M@FA4B+5;(>5+"56D!?)NRZ@]CMTR[]I7P*]!BIC2D+L68$-O:.HY@2>><618
M1[85R-+;BOXE3R`9$@X--)-LC=]!5N'5XJN_$EGFF*['/_I:(>&0,=U5^H<R
M]<_1/>Z>O^V&NX>'EY.[_4_U(Y@#E=T;V/Q"9S=*_H`S0.AM7M+K04G]@C-1
M<I7\`0YYZH!8/6FR&M?P.Z!UGN5X)]EZ^=T$?M#)HP\N07;V%'2@!#[#+$O@
MEC=)X3)3EL!M;*+N6F4)W)HF4V_)"!HEA3,[6:>`DM);,NJ!![!P\-4!#[PE
M(^@6];E?60<^3@O/XVLT^-@K/(^O!#Z>"FJ^DF%WD*@/3/CL7$(=7_?#*[@2
M]5(<60=>NY6HEVKY2@90XK,#[]*!$I\:O(L+HL97,NK$B?H&FK130(GZNI@L
M@;>7)>KE0;($7F*6J'<(R1)X<5FB7DOF*QE`B>]YX-5#4.)3@[>9)>K]0E(-
MWJR4J%<IR1)XRUNBWJ@D2^!E;XEZL9(L@1>\)>KU;;Z2`93XO(;W,4&)3VT4
MQ=`_OA:]!CO7WCKPLKUDZ"T904GJ]0W>>P8E/M_@'590XO,M`S7U[BKYI#F4
MJ%=8R1)XX1ZTM:]UX-5H4.+SX"9.;GSX&IK&US)K&`8^"VL8!#Z=;9S`+\)(
M7X=1#T:`+]O,X@1^YD;6F,<)_-B-Q!=QLO1YNH``]WFZ@/#VZ:SB9.7#"V@Z
M'U[%"?S2C_1G'"?P>S\2G\0)_$Z8!X>0]ODY@8#VZ8QZR<;7;M=Q<NWC#^-D
MZ,-'D&A\_HP@C'W^C""(?3I9G,`O)\GGRN,$?C])X@6D,9_=`H*WMGO>S*3P
M>]8_;K_MIK?/W^Z?7DX>=E]AJK^HO]OWK'\16__/JWGA\N?]*_R2-1RKP'$C
M_'+Y#GZ2\D)]<^?K?O^*_P,.G3>_A?[I?P(```#__P,`4$L#!!0`!@`(````
M(0#*!_>3,P$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````"<D5%/PR`4A=]-_`\-[RUE
M<V:2EB5J]N02$V=F?$.X6XF%$D"[_7M9U]89?3+AA9QS/\X]%(N]KI-/<%XU
MID0DRU$"1C12F5V)GM?+=(X2'[B1O&X,E.@`'BW8Y44A+!6-@T?76'!!@4\B
MR7@J;(FJ$"S%V(L*-/=9=)@H;ANG>8A7M\.6BW>^`SS)\VNL(7#)`\='8&I'
M(NJ14HQ(^^'J#B`%AAHTF.`QR0C^]@9PVO\YT"EG3JW"P<:=^KCG;"E.XNC>
M>S4:V[;-VFD7(^8G^&7U\-2MFBIS[$H`8L=^:N[#*E:Y52!O#VS_YNK$^ZK`
MO[5"BBX=%0YX`)G$]^@IW:!LIG?WZR5BDYS,TCR>^9K<4#*GLZO7`@^N?IZ-
M0-T'^#=Q`+`N]\\_9U\```#__P,`4$L#!!0`!@`(````(0!ON$4-?P(``.8'
M```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````)Q5WT_;,!!^G[3_(<H[I"V%3<@-@L+$I&U42V&/
MEG$NC85K9_:UHOSUNR1K2;<D;'VS??>=O_O-+IZ7.EB#\\J:23@\'H0!&&E3
M91:3\'[^Z>AC&'@4)A7:&IB$&_#A1?S^'9LY6X!#!3X@$\9/PARQ.(\B+W-8
M"G],8D.2S+JE0+JZ162S3$FXMG*U!(/1:#`XB^`9P:20'A4[@V%M\7R-AQI-
MK2SY^8?YIB#",;LL"JVD0/(R_JJDL]YF&-P\2]`L:@H9L4M`KIS"33Q@4?/*
M$BDT3,EPG`GM@46O#^P61!FTF5#.QVR-YVN0:%W@U0N%;10&C\)#26<2KH53
MPB#1*M7J2W76A4<7_[#NR><`Z%E$"O5C=6SJ-L]J'(].*PTZ[6N6%FHF)-CG
M.%>HP=]E,^&PC?)IDW/%HF9<$]IFD5^:E-\8I'CQSZ;.MK)-YCL?IM9XJU4J
M$%)^);0P$GA2><JGJP,@P[<Q"=)O9;5Y;C,^M<O_AHB]-.R<^681^)`G:F$4
M537EDU]*:5<4";/@K;]4D!%/T,JG*ZJ&M.1#7>*KNNR&G)">UN+1.E)<`Z=N
MY'>8@^N&C/EWNQ&:<O*5VA;5RQM?G-:L<JM3F@7\YN>*\MEJON'DC)(I:0#P
MQPVOSIL>OSM#U9[$_ECU8#K_&;6ZTY_&DP,PXP,P=?/^[O1_++&S`_[YT(WI
MK,N>N'5B>N+6B>F)6V<#]-1!>P?P:YK:NP"7\[<.>E4&K4U`"&Q"]@;J'R/T
MBS)/_KZ8VVL:.ML=L?_(DEPX2&EZ;N6O#^R6UH/3I9%I+LP"TJW.WX)RHSW4
M:SL>CH\')P-:5HTW%KTNZ/@7````__\#`%!+`P04``8`"````"$`'(0:_I4`
M``"I````$````'AL+V-A;&-#:&%I;BYX;6P\CD$*`C$0!.^"?PAS=V?UL(@D
M65#P!?J`D!U-()DLF2#Z>^/%2T/14-UZ?N>D7E0E%C:P'T90Q+XLD9\&[K?K
M[@A*FN/%I<)DX$,"L]UNM'?)7X*+K+J!Q4!H;3TAB@^4G0QE)>[-H]3L6L?Z
M1%DKN44"4<L)#^,X8>X"L-JK:N`\@8K]`ZCT2[0:_R/V"P``__\#`%!+`0(M
M`!0`!@`(````(0#2;URCR@$``.`1```3``````````````````````!;0V]N
M=&5N=%]4>7!E<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L`
M`````````````````P0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`.RG
M<\:S`0``FQ```!H`````````````````*0<``'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L!`BT`%``&``@````A`!BYU_36`@``Z@@```\`````````
M````````'`H``'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(````(0#1AGL/
M<P0``%T0```8`````````````````!\-``!X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"+0`4``8`"````"$`$4'IF<L(``#B+0``&0``````````````
M``#($0``>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M`!0`!@`(````
M(0"?S4F2U`(``*`'```9`````````````````,H:``!X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L!`BT`%``&``@````A`.O>_Q*B`P``?PP``!D`````
M````````````U1T``'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4
M``8`"````"$`=SC&G!0(``!.)P``&0````````````````"N(0``>&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+`0(M`!0`!@`(````(0#^8:EHS`,``)P,
M```8`````````````````/DI``!X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"+0`4``8`"````"$`>W["`+0&``"V'P``&0````````````````#[+0``
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0`YR6SI
MB0(``$`&```9`````````````````.8T``!X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L!`BT`%``&``@````A`/MBI6V4!@``IQL``!,`````````````
M````IC<``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`6@1(
M/GX&``!%'```&`````````````````!K/@``>&PO=V]R:W-H965T<R]S:&5E
M=#(N>&UL4$L!`BT`%``&``@````A`)GD+[$9`P``G@D``!@`````````````
M````'T4``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````
M(0`(!`V4%6D``+]'`0`4`````````````````&Y(``!X;"]S:&%R9613=')I
M;F=S+GAM;%!+`0(M`!0`!@`(````(0!P^SL"Y0L```1K```-````````````
M`````+6Q``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`(M-P\"S`@``
M$0<``!D`````````````````Q;T``'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"+0`4``8`"````"$`&L;?.WP#``!+"P``&0````````````````"O
MP```>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+`0(M`!0`!@`(````(0!Y
M/-DIY@(``-`'```9`````````````````&+$``!X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L!`BT`%``&``@````A`,J83N!-!```R1$``!@`````````
M````````?\<``'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+`0(M`!0`!@`(
M````(0"">7BON@T``'!(```8``````````````````+,``!X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"+0`4``8`"````"$`722A51E,``!P[@$`&```
M``````````````#RV0``>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`
M%``&``@````A`/E2=Q6;!0``N18``!@`````````````````028!`'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+`0(M`!0`!@`(````(0!L-!\3#@0``+`/
M```9`````````````````!(L`0!X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L!`BT`%``&``@````A`*/.>*L(!```*!```!@`````````````````5S`!
M`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0!S`..#
M:$D``"#4`0`9`````````````````)4T`0!X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L!`BT`%``&``@````A`&4HK(\S!0``!A8``!D`````````````
M````-'X!`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4``8`"```
M`"$`R@X.KC@'``"1(@``&0````````````````">@P$`>&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(````(0")AN;1GP(``/`&```9````
M``````````````V+`0!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`BT`
M%``&``@````A`.^#$A/M"```/28``!D`````````````````XXT!`'AL+W=O
M<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"+0`4``8`"````"$`IGQP=KH7``!0
M?0``&0`````````````````'EP$`>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;%!+`0(M`!0`!@`(````(0#*!_>3,P$``$`"```1`````````````````/BN
M`0!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(````(0!ON$4-?P(``.8'
M```0`````````````````&*Q`0!D;V-0<F]P<R]A<'`N>&UL4$L!`BT`%``&
M``@````A`!R$&OZ5````J0```!``````````````````%[4!`'AL+V-A;&-#
>:&%I;BYX;6Q02P4&`````",`(P!>"0``VK4!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 03, 2015</div>
        </th>
        <th class="th">
          <div>Nov. 06, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum Aggregate Offering Price</a></td>
        <td class="nump"><a title="bcrx_MaximumAggregateOfferingPrice" onclick="toggleNextSibling(this);">$ 150,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_MaximumAggregateOfferingPrice</span><span></span></td>
        <td class="nump"><a title="bcrx_MaximumAggregateOfferingPrice" onclick="toggleNextSibling(this);">$ 125,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_MaximumAggregateOfferingPrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RemainingAggregateOfferingPrice', window );">Remaining Aggregate Offering Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_RemainingAggregateOfferingPrice" onclick="toggleNextSibling(this);">$ 10,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_RemainingAggregateOfferingPrice</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RemainingAggregateOfferingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the remaining aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_RemainingAggregateOfferingPrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001171843-15-002688-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-15-002688-xbrl.zip
M4$L#!!0````(``9ZJ$:04;P!G0(!`!98$0`1`!P`8F-R>"TR,#$U,#,S,2YX
M;6Q55`D``WP+355\"TU5=7@+``$$)0X```0Y`0``[%WK;]NXEO^^P/X/VBPP
MN!=8-WK8LIVV!APGZ7@F#U\[G;G=+X4BT3:WLN0AI32>OWY)/6*)DBS)8A++
M43&8NGKP_'A>/#P\I#[]5ZLE?`$60)H##.%A(\#1/YS5/X66,+)7ZYD.A;'E
MD+NZ`Q\!N68]`D3^3>XO'6=]=GKZ\^?/#SIY%.L0`6R[2`>87A!:K8%`__SG
M?WRB1$8(4!)GPA6"PHVV$<2>('7/%/E,%H6O]R-!%J6._Q)YX^D!F<+3RK3P
MYY,((7KY@XT6I[(H*J?0PHYFZ>#$?_*,WH4EGS>V+T0?5D_]F^&C+FXM-&W]
M_.Q<PP_>L\$-\H[4;HE22Y'"5PS`-(V!_F%A/YZ2&RF/F]#ZL0,[O?V@X2UV
M<\?#_[XF3T>@.YLUP*G8O3LI:!YT]!0C\`!M'6VP0T5+G^^(RO9IW44(6/HF
MO;_AW10R$-MM6>KNDIG_Q#,E7].>7TC3O"V+6);^5+R&I7Z_?^K=?7X4ISU'
M`$BG_[ZYGNE+L-):S^KCJ:@@?*(MG&'OYA3,!:_%,\K1SR<8KM8F%99W;8G`
M_/,)Y6DK9-V')VR<G`[\AG2;V-B3(T#C\XDN?A_BN[DBW6B(/GPR\(V(_O\3
ML!SH;`;/%\@E:-"+<TALTH,"8CT)93`:_WXR$,F?7D_N]M5/I]O7HNV?;@F$
ME]8`0=N(D_08X0PHO):H$'E^.@VO/;>T?<_OXVG0R;"E>*>EH-,70*=:<MB=
M;K<DF4>GY;BDOX]LT]0>;.**H6U-@0[@H_9@`GP#5@\`G83N]#680IK#8+$"
MV\YYUWRG>`:>UB;4H>,#$PQ('L0$\^>3P!V>#77==BT'W]H.P->V9N&A95Q!
MB]@/M!;;OIUOMK_OB>4,GR`^&5!+.=O-C4^GJ5@&D0Z</O?@S=5;B:MW(^F#
MDS0OFVXSDKY'F@%"'FW[%A7T>Y!SV,I.=F1+^C!EW6'\]P68`Q+J&!%]?@13
M\`@LMX8"#WL3=&"(D&8M`&V/,=_\;N\2[$'Z:Y6QXD:R;RU97C;;S;#9";(-
M5W=F6G04/E)Q)OM:KVBJEV&=C0SK$R?UOU\A>R7]IEE4,>[M0Y[ODHXBYT)S
M0*#$$OF/\/+Y:MS9`<N(/.LK?'AMW]FQ&.56>\NM]JM.%?9A5[L$N]J\V!7/
M)BB'R*2(22F<3$J*YQ,.4C=BGH13ZBB87(O#=<2!'&RWB4]HMQ2Q>K?;OD^X
MM1^I#MW;:O#KT!TH4??"'L%_5JWN$?RI6M^W#.G[;Y/IU-YHIK.9N0_7UZ-M
M#'_8X8(!X-DU6&CFI8<O$A>D]^C5PG.)&K/8KZ[5*IL3!8AR3R?")]<OP-K&
M82].MF`.55YA>#<%V$%0=\A42L/+H>7]=?F7"Q])_&8Y./UJ/'6R@Q.UFU]+
M[#0LT-TZ)\BJR-@SX0P>[!#N08JVE[:J09>0S2L;C<C4)6*_[T2RF2RHG^%F
MSMN^WVA/<.6N:FBX=*H=][6QOKS@Q/K-9Y:RF"U/:!V//*-].6IY2IGRG"RU
MZ<W06[ZI7?QT;5L+XC]7%^"!38@ENO6BJTAO+V`Y*Q74")B[@-\B>24KF1;L
M)7N##'&0_[V&5A`F?A^YV+%7`(UL2R==#5;3(?X1W)\.)^,_AN<UB[T2O3G?
MG`-+7ZXT]"/NXW=R)U-G.&%*KG3GB*-`5%\&4M#A.S0#Z!'J4?N)R?UE`\ZW
M]XYM9O+Q=?;%?@3(HKT9+HCB0("ICYD!W470@;5;*!I;CV0V$E\8"N\5[6S-
M9I1R)],C-N)]9?&^O84G$H0V6M/*!)`A]TA_:BS[G;VLU^J]W,TTYT:6QSTY
M3:8&5R1"TJ%F3C325%U688H).:5KKU7@R,U4L[-]C>B.*:N@B$Q)51-8O5W<
MS*O$2I$2J:)&O(<0-Y=+*P7*4-7"Y<06E";6JE7%I*)DFG,CRU>+F]_$=ME-
M14WP==@;@Y3.#E-M1'<(BS6<+%/-$O0A5J&^/;O8LJ^OU@,TS>=M#X$O)^'I
M!5@35%0G[N:_`LUT:('-K^Y*LX(%CKH%J$6W3^+SS3EA";DV<S3'Q2GA;"K/
MN"YP4:)W\\@FE,AR4G'9U*ZX26'S4Z7TL"XN_+T*M\\(]SS-\\R6A%?V`M)R
M/OO:,>I7_<3/T:0QJ,APSDL9TV51.\5K,P>Z[-*Q>JC8>Q":5,!;O,/@8U^?
M<%"R9<_=28^H:F20;QY<'I1XV<-VFDE&,\DXG-Q0FTWF-9.,(Q)NAQ%N,\EH
M)AFOHGCLB47-)*,&0NL6\!;O,/AXRTD&-]FRAQ0UDXQ#F&1P$V]V95P3S[U1
M//?F572=S&.:&J4X"*5XB_U\G>P=N4V,=G0>('MW;B/LH[/L[)VZ8V_/)WP$
M$U.S:EB&1V'?:JOH-M*4+AWU1K-..U.ZEZNU:6\`F#FV_F/B(GVI84;2M15S
M3M^.W7\G"_="_]V8=/T==K):+Y1N8])'.TIG;S>-,>9N30]H"#+T*9;Q_0L)
M?!SL%;EZ&0_2BKZ4Z-F'-<S?_]20D4S,9#*$]VD5O'Q1&:)_`.P0L45HYDGT
MV`>[7O;,=*L`-,NW/0#/N['#2*;`H==LR^?MC6:`L44(N!K:D):5NN6TXW;B
MSW4*\(;K0OF!6$LQT;Y<%O?M[24[YUMN))D`-+?1BGY+[IP,Q4:4H4-WX6*G
M_J;R3H>4,J(]YJ,>U.QS)5_"5KYZVY*`,;'1MKW&=([0=%(E?=26E+U^L+<E
M&0R#H74!=.\I.O%JIC.U-Z`B`C[RV8TJ<[*;6]MJ@>"-"XB`[M@(-S92!QNY
MAXX)[N9CRX"/T'`U,T)]AUB/W3*RUZW*64;*">&-,1RL,;SG8]'5@HMY^2J?
M_,A!H_*U4OGW\F4'E?TZ<;/$59_MIVITI5+L4G\5_#S.2L(IP(`NOI".7(!'
M8-IKK\!H6VLTLND1ZKIS;P>SG"L;W3E+@'#T['5^E8=<[5_L%K=__UD>]A^L
M>\[`FK3:)RHD!C\;%:JA"O5;]+]B*N0]2S\Q656%@@7"*_!`%T7O;;D=_&Q4
MJ'XJ1+_1*!>-0KQGY79U%>HS`UFC0C56H3(#&3<5ZK+GI]#<9LC&^N7A=I51
M)WM6JY,7NNRA*4/#@'1&J9D18PA*)VHXA=XENORNUNLK#5WVD)3A;#(]'TXO
MAL=I>AG=JY?]*9&0GWX2/`CY)>7[K>8KYYA0@([K4#Z8)D"+#1E1QM8<Z.2^
MBR\@&;XPJ.'R!L^!=R]FO=Y!ITKQJ8#_+(>I0#<[@=JHUO&HUELD*KO1/1>B
M2KW6;Z[W\_L7!(`U0C;&X=G?T>*>NNC/KF%G1P]?;Q525$ODI\BS*A>/HF9Z
ME.'EZ.Z&VL/T^JB$G>C7D2\T=\.M%YXYBUO+%AL1OX`5BRW/D`M9L<C+BH,4
MX8U&:\!%WXJ]GXV(7\"*B=@Z1:W8>Y:'%>\XZB3R.>%(+PY<N%QS=._DP[H]
M/PG7]R4O??]M,IW:&\UT-C/WX?IZ%)1'!-=N;`LX\.]ZAFLESCFZ!@O-O/2Z
M<S<?T;<`HAE;5DO2N55(9<H@]W24;F>#7LX81S?O9`GF=;)2$E5#L5\YP]&3
MPN$&^2M2C4(V"KF?%_55LO!2AJ^^5;VH7%)])TMM>C/T!%_#@;:^BDN_,$93
M-,AE@K^$0(Y:795"@WZCI.]825]BD&\S2T^)_F1H8FTV_/&47!&Z!H!G$>7E
MHZJ'M/+58XM=?YM\2U&;D8L0L/3-K\!8@.$"`6^Z5S/E"3OA2U$/_D4D^8WK
MJ0.OK:-;NH@X7%H6OJ4^A?A'!,$N,;[2-YJY*6[F!P3+JV]-]+=1K,/[,&./
M/8F\4;YWHWPO<#IV+_MDH:)SB%Q]$^JB<LT$XXB,Y>T3\?W,@*$QK<:TCL6T
MWB((ZK.%YHU!-0958X-Z@>EJ/ZCP#RSD-:LX]^RTJ%3OM%\*K][:C[2B]K`[
MK;1H'E;=I].N!?T>N]B(+H^N@(9=!`80VVU9ZM)]29].PXO"MCWZ?N3?T>8F
M`.&EA@".S!2],UE`K!_TE5MB0DAS;,8@<T%LS85M)=[^!;#L%?%HP;TT&M0D
MX9D/.*6G6RIL6\^\WO8MAS?/7&%XG0%A=V-K\DQ,.^.MT=M)GF4W]W_KS2XU
M\!*.!=0@3%MJF%;<T+\N_W*)SS2]%6%GI"&T(8/+'YKI`H&^/`5S7P>%0$.]
M"SHS.I\(!M#A2C/QYY,6,<IV3U&[Q)X(@#(4!_R!2O%<"@NTT^ZT11Y`MR?/
MOC1O956)L[8DZ<$+0L_AMM01*R*/`1\^:M"D$="5C6;DC1G0700="#`-0+;_
M\L=\IP+/I;ZDQJ&7I)U4&([@\[C>DQ69,_@@--T&H;?`*8"4W<<VLDV"(ZBT
MCT2T0;3.&FNGWX[W8P>,`1_$[/>KRR%6>NW^:R-F/VE\CS0#)!O+8+':EDH`
M3BC&V'HD-VRT(4]5L3=9BIM;M-V$`RM*-,=.U)ZRBV:,Y`2!M0:-RZ<UF8,`
MXKF\ZJHAQL#AX&[:BAPWV`+DDD9:$6,>MZ0N!XP78`[(+6-D8QZ,ZZHQ2&FM
MLY(LBR"'+7L@X*4U/4E1X]09YN]'-:?#O;[25HI3+3CRW-J67MV,)$E2]QKX
MMN13?!S?/N2P]X7Z,$$VF8(Z&WHLET-LE09=7N5]-;_=E;N,3\@FD^:P]@.5
MPT)9W`>4ERW:FF]DU`\]G*?F508YU;>;@I0B4N2`+2]F[';WQ!8K-_;O<C%F
MM=WOQ,282F!0$43>H"<J4FD0U15%[O>8Z?26[25)Y<E=47O==B%206`XT3;4
M&54?OCH*8Z?I%#@`R?,764%[/A#D`N,::@_0Y#7QE.5^(B!/IY(V4NV#*$]#
M)$5.L*<PHC%=F2"S?FY:TY69"4LZA90Y0UD@N:Z!84M!(*%S#;Z_7@`(6UZ9
MXIX?0=!<^BQ/\A0\)4R-@^"`564FH_M@[4FO@[6;P5<2+QBN[M!8*S,QH2@%
M,59&V<O@:`&4JMC9#^6U;2WN`5IY"W>!/E>P6<JKN/ZE$>"`(\=D]\?!T\6K
M4D^-SZ33/&D%^GDI\*[<5\K19Q2'2WRGR)WTJ7."2'86H12>/.7H=.3J>"QG
M1/Z&#A\6=7L9B))D^('*XQ.3DRT':H*"Q[W#HJLNC<2S46S#@TJD<]A0BC3=
MA6E;7+K<E>,^G6TZ;?&O!/6\;)<LEJ6^/9MOHD%C;(VT-70T,_)FE3E$6U7[
M<2/)IY>RO%$)8^Z2H]QG,V;[8-1U=^6:F@.,<&?O&H$E+8FAY2^ZO0+7-L:W
MP+F;WVM/5>8@(AONER&<7-7@!3N'SRU)J0@\L4[J:-`"QJ6&+&@M<*0]XO1H
MO5`%)K?:/45DXH!\@BGV50UE'D_;:K?'&-A>*#VE7MJF`1"F^3=G4RDUI'3C
M<X1D\X,J]/.\8$=5.N7H1T*LH65PY49*MBB/VNX0MS3`\CFF/0#&1]F)AN[0
MS*%*YPT\$X!FM%XG!G-;^%28H71D_R#2VM=R='?&&I7`[F#NBX#UGL!#UUG:
M"/X-C"W(LKST!C]VQK6;6,JRZ_[0\L9E_M#N7(?6_1G$+59C6PZJ")W$J%4-
MU[Y1[WZXQAB[534L!Y)/@A^::@S*0!,)_%[*L<F>KY!20_=L/_%20'=PD3M0
MO@Y-%A-)I!VT=DF:KS?CC8N':7;E-C/N9Y`I(#\>QMF5^IW,V7-)/-Q<?0$F
M,6Z5&[+J[-J)S$M-!]FS+[9MX)QE_<RC#I,KA_%P-XU0<C;G[X,)'N."0^I(
MS-0H1H.-&(HCD,3$/D,?0EJMI[0;0J2"(+8($Q9LI1_(R(4_[6XP32M+G:G*
MX(2[!%?#DNN]@&=;`2\#4'NRFFD!J:4V)5`49Y/2[O1R8;#>"CMW<\](9V3"
MQ\D,&2<5(Y&PPE3!!=4M?/!T)29-NI-F6GW^?@B+2ZXO,;6OY1!^`19`FDD>
M'AHK:$'L^,;!DXMM48U[MARB`VX02_B)3J]7#F/JB,"3;<RVA3B%M/1A80C%
MV=)5=F)(.`2:`PKN[JQE*LP$66(7%UDRK"3*P"BA'V*OS<9V"1Q,!=N:;ITC
M\=0V0<V%)2VIW6;RXRFDD@-'23S%>=/J*CVU/)ZPRB8<A_UG^?AM*1Y6II-B
M-:<\H!+Z4P40UR%-8099ADBVG/CZ6[DMY\)@Q@$-6E23[JPK&P&XL,(-X6E[
MQ^G6^PN`R5,TQ3#$=-.XIX_/#_`9VM2X4^",D1T)7X\#):Q?ZC`A+'<FL)I`
M`E+N/K4C,:*,$6$MLS"",GP4)68VS$*(8PA7[<+4V;F&H4ZC/FBZ#H@'Y%G9
MNT(,D@DX\8,<2>3ED&:YQ0-I,4;Z4*5N&:AQK'\2A5U237PD0]@"W+JT'N]N
M[KT;R9%D=F%_-OLI)(4IBMT/S^`5.E5<M3O]3J_/I5<I>P12:@&^6@AH)LV.
M_DJFC:2=K4?:;K(9(HC)K0OR3VLQ\0YU*%*Z4'R@97:GOQ38E$#O#=A2PL_)
M;\26%")<!4[&$%%.Y'^S2*97=^T#L.00TR^.D"E")`_JT-M!1'Z;@/Z@T^.5
MC<)/#_")J=A2YWRZ:263U="6<&YL_7A!N$Q6+QB;:'W]BD;`_/@IRYVXS--I
M)4;"\I#*I&69TK1L3$P16H2-=_/G([6\R3BGJ2-3>K:#(#]X)3A7%A\[F=,1
M_23F!?#_'EO;H#Q_"]K>\Z)\L@.>.*O,7HI`S>=JY'P)/H.+TNOGX8S03-DT
MM2?",IJILIF%:@C#4QP@)QYV9#8)LX-BKCX&AR:$1?.IAR=PBBMZ[5X.\")@
M"G"\:I]*V%VOS^9_*O4I=[?S:$D_2X?'UG-NTF^!M!<I8>25H"VV`[L8IA(;
MVZMWLI3GY-[+//UDMO/2L"JQ@Y6+")6VF#>`%<&23.CR[E&9>9?<R3.Y@GTJ
MX+EC&VAY+99+LI37@R3E7$=>#FQQAJN]O.%P#[#,5C9.L46'W?^<0[9@8%D8
M:ADMS@V#$EC9S"T]JFZ";'JTI'&^^4KF'%'?I)-`S]]`21!"RR77@INVQ2N6
MZS(Q9S50J0GR%^IDJ1&>42L.O61*?[6-MT)P;P_UOUR(0+"3FN]<IL.$M;E4
M4_9*5@%:8K6^/,[<24+TF$<^Z8AV+R\,CU/E"K-4LJPDRMTBWWWX$Y^HA=UF
M7!)$LK:>7R=*5#2Q!]#NT8O$Z50Z``:F`.CS)*ZYT1SZRN9NGMT8+W5G#]O;
M"\RK]*JXD'H*<R!LE6X5&KSHW!R_V@C=9Z;<U4`5'J$Y=+*4AY,5WKW,UE%:
MD*]9.J"?.2BT&[M,N4\G4QE3R>9`]9ZY6WN]NGP"2(<8\*IPS4::2C7'[LL"
M+5$2W&.FP`6@[L9)3^WCE*1G-@VGDTKN\RL+J$P]4Z\8HD@FQ\N&KIU@>+N;
M9U;+>%D5AY:C<DO=!`6$^^)(J8=)<QS/RQ&OX+.ECB@5<68%,25BH9?K8G'!
MR6U1YMQ'9@DZ]3!W?V6=C8#YC+2JQ-08EX&0W/S&"7^9XE=OYT2%#A3I09F#
M_.-[P91D135;Z5;\NPF\H<8/E4\Y;J#3JP:5?K'YTOOTRQ0LO!I^R[G55J"H
MM@[.QW>CZ;?9O3#Y=3B]&8XNO]Z/1\/KF3"^'7TZS6I^$`-P8>M>)2/]HE-A
MPI+8^I=/(/IZO.'@B*\KB'7-_`8T=.E_N:LPD5;XR:]=K0U85E;9IQ@<RB\.
MUPEW,+Z]\@Y%DL5.NQ/E;>Y>Q2W`(6&409EU96J+PFR8$_K`IQAK8)#0HA&Y
M0X:_L66`I]_!IC`%ZB'"+Q1EMC9(:FT@DRE8TU5^:T%W3+NX,-EO]*LW>:VE
MFLL?MNE:CH8V5]`$J#C%6SM*D&DEE9)W:T3T;&&CX@R]UM`""$-=!R8=S4C0
MZ[43)1YK."G*/X%I_F[9/ZT9<<2V189-NF$8[<O;C.8&*7Y@:V%7Y$IQWM+_
MQUT"T](@BY8_^)2C]B\IC5:DI4&:C_/OE_5#]/_AI]4R6TL6*)$@%<ZA3L\"
M]Q>N:!6@3;__!O`]H7MNTAEF41"_F,Y'`SX*V-F8X/,O?[FV\_'^\M_WK?'M
MQ>7M_9D@KIV/PL5X-KD>?CL3'FCC'X6;X?3+^+9U?7D5/A%<F8Z__.I?\IL2
M-)/@#=HUP3RX_,N"W/([1O]0$',".(;BF2:T3&B!C\+5W>U]ZVIX,[XF%^_A
M"F#A%OP4IO9*LX*[L_'_7IX)DH?(N_#GI0_HP3:-+6EZ7*8@";]HJ_7'_^[)
MDOQ1B+!5V/)5"!E+$9Y2B#YR'[AWD3"/7J._']!I^//-6)K#5)]+]]^N"9OH
MD6U0CR#AS^C[)1!H:9MF;1@.5F2AW'TQ'KZ@4FZIG$-[A#;8$29D;%]I.G`=
MHGLF_A^!!,L?A'\XA'&A>LKBQY"'X17IXS\%B`5->(!$E?6E99OV@HXCWF."
ML]0<$F/0_26D17OMP!7\FR`CT0.Y[&V/Q8)EDQ\")F&(*:QL$^BN"00#N0OL
MO^_Q5/A!QGM@_;VA'8/6HVT^DE$'6@(%N-:<I;T`%B&$!7LN&!#3\!Y_$")R
M%^;4;9*W;?\EATP!'&^K.WD#T0-7PM=HLS^74%\*.&*,KO7_[+T)<^-&LB[Z
M5W#[>"+:<2F9I':WIR/4F]US>KN2VCZ^-UXXBD"1A`T"-!:IZ5__,K.JL!&D
M2(H+0.:),S,MDBA4Y?+E4EE9(QE;(^D@?2P?TPN6_`9N)ZV&^&@]N/$0Q!E@
M7HRS`@+\7G[#JQ/@!<4Y/0A\FQV$XT#947CU&^F)!YP/_+MS=7E.S^.@0RF<
MOQ,1QN@2P$J!+NDS23@4HY;U"5R+H07^.,"%+XKO<@&(!_B6B-8/J[7=,0H/
MT0P8B*QK63:*`_`B@-^.A_`!+1E&\RR\"!+][`E-"9F<P%R`:8[T$*3B@$8%
M?H9Y%I=Y.RZ*&LPF#)+!4+$2,S=19/V%QMP"ZN!!)#M.0GDT2##()LG0,G5L
MI>([5(1$%\L!PD21IKLO!Y0\`8Y$0ZOO!0^1U0<;9`59<B""!Y':MJ24VG$1
M(0X<'[`H&%6&I%HWO0W,GK$UQKQ:BSAGQ`PEW88?NXHI4=+'7H;XF.="T.B`
MM];*%(4T"$<B_I"D4[I;'9$#N?RNT^FTNI?M%DJ7K=(HDA[%=_LXN8R3>4D:
MN8X#P@9#@(-Q7E"%U-Y>O(BR62F=;BEU)N6=X#N%XX0HD0`QD32_>7!!H#WT
M@KV)U0-EDJ`((^SF:/4F]/HHL4F0X?TT6;7["\N$P,DA)<3W(*HYN:X;^%DH
M!]@%$OUQK*&((P-S_03UX!B0V0I"!W2L3)&\3"<]NCG5!<W#&4X"&'F:+,@E
M6@NN"\;[T7K>^5Z1IW/>?J$7T4]PD`BWC>#)$%5%Y7"^'M\>6S^COOLT_7ZB
MPM!LT0`B(Z`7/.$E]!4J.`Q#/\?)AP*$Y87UO)M[;9#$1^`1T'G7$(\J1;14
M`%`!I"A2-,()35.W98V3$+<>8GQ4H7E>2A^"Q$-28T6L!H<11"Q1#,$#3N<D
M-YU0`&ZC'.A>LXCNZ+.DXB959T>8B(/[L'V3_Z.Y*;3!HDDK"I+0IN%/\ZOM
MT;*FUI`7!#&&K^_)+JNUJ/D/J$T"_#3G;H6ZX(<@VH`>O/(LOR()KP(9'4O-
M+Z"J3ZP=!2&^6#6QR(,X,<PP]`5^\P/\_/EY8=04K'.B6#1"(34]518HIV1!
MOP_TZ<.(D0#II.5^<T>P-!"\[SIG[1:$\,CY*-V[S`N533D*`$!`5^!\J&N0
MS`?$E?R3#L3@D8NAL:42);12,+J80M(&@M`)ID4E&_`SZ?6MVZ,3Y(IN1T%O
MA"DB:0Q?7&2_!Z\FA,-5YO9^\25OO]E4D8D4`6.*]W`C^3\2O4]:J)5GQQE-
MLW]EO8Z]21%Q5Z/IWI/T$^`2'FS,2'A.Y#TIN6`(?RF,`MW(C<C9N$>\"0S0
M/*-U$?Q#H.)8GB2O-K-^,'*4C#'W`Y,;!*1VF9*4HY+-AW:=RTWX'5N.Z_"(
M*MG8+XA9?DS4;%R$MV$?;J.#HRJ!]D00<#@4C6CK!^8QU>1(XXI4$*7+G)%M
M>1@S8<[#,`"(.P+_'^$&_!CPS@!66M9_OMQ8N@>.=9OTK`\?7EO/<\%I[KM\
M@'I<>`@C+L#$D8J;8.8^PE&@8S=A?7="P)B!1FK-+=Q@B(3Z=7[B&`AY,E9^
M,@%Y]O0504[G&#!+6I3N.6VE\_D(1M><'FL14@MPH4+R%2#"L4.7`A)%*)#S
MW`2.K6N`+0SIPC38SKY5:-43'I9>0.`H`+)Z4OH6Q&ETU;MTBHA3F5:JI<YL
M-%E7G3#*1PN/BWI&[#$>H0F5H*'0APZR0PM:EMH;AZ`=$(G#S)0_A\XV?`_1
M:);B^.J[^!?U;(T*4J]\\.OK+X6D3)_<=)`.=Y2;9FCV'D@^<%S75SZ;"I\"
MZQVHAH6[7\KW"RP_B%/MQ2A>*ZWKHQ(IBXV_[`=![./E/_`.JA*D0"B=&\W'
MZ$DEW4!#$C"<E20%Y\,#+:7W"^?/Q(2'E!X""J/?8@$_Q8`>*#`L&+L^J1?H
M.80RZ)_`,L?*7%A]X8;H3B&',$6!]16*4!%%L05':Q%!(">(W@=#))Y"N<S.
MMXINN7*.P5U^P/_R@\+J5,P`:_3A&Z`US@HC<&)?]CM.5Q35-JJ6+W`W*63J
M87@C#/C_F?@Y]*<@N^I9E%[\<@)AD04Q$[#\#8A3T;L\Z1#6GZ:ZI?0!N2B5
M6XE*E&ITE5#1X]>^G\#KU3XAFA2CD_^-H;]2Z<P[-6(F2(#B5,Q=#S-^F*PD
MAS63PMPS9ED8W]/:E&>L[08ZZ#+&'!P\/&>YF.4AO'.P5`FU`7U]LO002J!Z
M+.P?S"7.*(ABBMAQ9V0VC=;K_1V('WTC;4]`Y-0G>0%V3<4CAXTKKW7NJ:0:
M(^7(%E7$RFF&<07"E+Z49D.-0/N)_T1QQZ#?V"2Q]AST@<CP:Y-!IG_D"I36
MNF?:=$G.ISXR=Q,1VG6HU`2))S/BH8CVE.M'7PVEIXWG:(25QVI;R/Z+O!(=
MV;4`JWTY`7<J_`O5)`WXPD)VW_55&LG--<4C.SQ21Q=<J6/$$&(G&#$>TA`>
MIM7!\:--/%@W_F:<0-0ES.Z:K>O1K'NJ@8/OT]V%J>7ETF(1N8/Z(4<E@RB5
M/P0C<X0)?LL7*KM)3G"$67<YFD[>L+HN9'+,`2Y26%;2N)(V2G))$4JI!6UF
MSDQX%%&BO)"9<'/A&`CS"$P8F3$,=WP5'\*;0+\%116XPZ)<`!)QG=*ES*4,
MP90)#'O28GB5KTCWKBV;+JU$Y7/,1D$+IM1J7U[@"T.=]##[$]A=`F/$VR'8
MNV#@EG+>^!]8QW'+^A`[QX6(M_B$#GB=M(ME%OOBVG2NYLM0W'R\I@P,A,^.
M[-->G>OKG,SW!`XPV=/V8A2L(@7$MK@=CG"C2`$6/\!F5/G<M4<;9_(;A')I
M\-Q+7,\Y"I+8[&WY(".O7-Q0'`S%*-N/Z0M;%Q5PPG@UU'F?V9_&I8FWYA<H
M(TT&>N@.AD:<_X:0"_>62C:\G-IRZ6/S$VN,E6N3=#,GTIJJ]<GUJ21(U7X$
MX"'K_2M0!-QW4?8\Z/VI]XR**>-">#CU2GP7O$+Z$9IL,N2B+V.5:"9G.[P7
M)K^JGD;P2'PJ`@!71&*Z*4IUGO:"TF*!XL[.",.!-*UC($,GMO*D'7L",[*J
M]($*!.@I(EP5K;-H&;TD-TYT&BGO?M'0M`F'*QMDV_$"'#PL&D0NI14#F`%6
MSI,*7PSFZ!?+;\`&4V90Q5K#SQ)*TI7BE.9`0JJ$''I_]'EIMU`E[D9"^YT1
MS:%<2U"UEDEAR['H9,+/1TF,60%D85Y(X9>)#[P:PW>J<,F8+)6A(0@.B.TY
MLH[%6)<Q"3ROKS?'XP%,Y*@G[+]P<R(W&2`F[NAAMB>:76PR+:1:5*A>!A.3
MVI$E83@R4I#+>N>HFB.HWKP8"?!DDQ$E?NY=!XFA?>E)YDECHB?2E2;ZW>`,
M"-4+UL*$2A^F%A2>]`-5&4#9R,ZE]L:/K=M@E"IE@;^58((<IYA8\RQTH[^0
M5B`^(RE\D]"U]'8N%45(/+R,JI=:=%7"1M(CDDA#A\JA(X-3H59IZI3>0-R^
MA]4)\#B\M(`]:.5A+D6ACB"N<1)/:VL>],I!"DW;#G`*CM84504E<[E>4SH4
M#Q,@^'W@TC8[Y0E5[0VPPY%RI#RS3$Q"-R"]Q4FD+'%H$=>DGC!,N2+`"61$
MV<">]%SPMTPQEL@RW$;/E<[F2$N4L(3J[9KMV^?6#VIJ`L?9^?$\O4QN,O.8
ML+-L$1AQ>O@;TW?6(A;DZB_U-GSEA#A;-=.6IWFGR&S?E*49Y<)T"#@"3_8(
MRT6.K:P%L#6@\A)$#,V$P)_B;RCM`)CUC]E7S36VI:=:5N*KR!V;F*9#XU=H
M/DP"0FE"3^9W/R#&1KP.U3Z-\B-LH36_:JPA%N;10+/*D,9TM`'+3SV*2%SY
M,*WFZ-5730-/3:FZ69A.+F4`R@9J;F.:ND=U"50!`T206!"K:_EP'TRU9",Z
MN:&=C+!2C[P"E:^7"E#B?"8C@S7$:C)(B(!*QXGXB-\]KU1?K/4_TF"86H42
MU6C;SNR)5:P30&BDMA34UD&&#`7DT`L[MFYF2HX2%8I7E:2D(^"/%+5==?-'
MNA60VSRXS;8,@!2%]LD6709`]CHL%&0FD0%:W--#.+%`TOPX37:#\8F'@8G1
M\KOH2-?041O[`@Q<''NJ<I'J\XC)Z">5+$,0N@.JE\Z9B)P%%_KQ7-HJ*]#,
MI;J4]*"PCU362<1I^DO9X:[Y:;KC4LQ/TVN0&KGDLTC+>"MF+C(+HV>TZCL\
M\(8H9096*IZ5N2@:K9RL&NFGQKU5D!469'[F]BT;AFG#`,X=P!2IA&H_&R4C
M5&X=A.7P;*%@*Z*"Y\E8`P]V*AFI+,Q"`_7=;X0#6N.++"Z*U`>JJ.NFU=#9
M^$,7Y``D;((_R^5VTO(#FANH&?Y<%TCC^#U3W![T*!BD4`4<8CO6E>CZ#]<?
M)QA&9#"(%)481;JV2E)'X$IZ(FQ9O216-1,$,6!@6H7\-L7+%,HJ'Y@,0G$T
M2E^9I_%K/79Y'#.`J8*@UZK!S7HS&JD%JU)CLT4+ZY-8`:S=3*IQ0CK0+!3R
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MOZHZL[T6.7B2*B_#[<:@G/HXK*`FFPDV$P=M)KH[L!);,1)+V(A=FPA]0XUT
MYJKF(VQG0L8O\$Z?I]"0+2L;!C8,;!CJ@F?Z;I$9)[\68#D3$<N)U.X%1UQL
M%]@NL%W8`TC[.0RBZ>,_;!B6HV)6/<&D?*I`8@W!DZC()I9-+)M8-K&U030V
ML6QBZT3*#U2<MS$$8OO*]I7M*]O7;<'96U.$R'M>3R/D.^'F.K[0]2Z\!5:G
MXI+"E/%4VB`,$M\Y`DP*PA^M_WK]^NW;=^]>S%[]JI3/UV6>F;+,65L(<Y7H
M2)TK7O[H\8*&9SMJE+WQ<P\FHXN,9QQKQ')V<S:S3CL'A6+;/$_9D=B&(\'\
M>C*_OEM].W,9[E!3\J78<_$4B%PK?W)SKX2<#7.HVVZ=M+O;81,K$8,>\XOY
M53-^L9&JNY$Z+1LHUJ!::1`C'O.+^<46ZG`MU`E'4#76'\8[YA?SB^W3X=JG
MYQQ!U5J#GCYX-M;W!58SEC9,$IA?C>(7V[ZZVS[<XCHM-V%A):J3$FT#]-3'
MVVD,P^4XLSC].FWV76I"SC;NL-5S*_RJ:5DA6_PU6_S+5N?DBBT^0PKSB_FU
M?0JQ"=BY">B<GLYE0XTEE!&E68C"_&H6O]@"'(0%Z%[PEA?C"?.+^;4#"C'^
M[QS_GW?*17EL`6J&*%STP)+`MH5M2^-L2_>RU;TJQQ<-$5&&E*V5%-2K'<C<
M7E7=\;?B-`Z^4$&&^DI2=:.@(\=!Y-;KRHDJK5^.RPP/C?$X%NBN=%S97^E0
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M4\:R`K/5W35?=]WNK-V9&R*SSC959QN.S6QT]Y2QK,!L='?-UQT;W9-RF,L:
MNQ<:VW!D9I.[IXQE!6:3NVN^[OJP^O2=0:RS>Z&S3Q\\&VNO#ZRS.6=S?EA\
M9G.^K^;\O-WJ7O!F\3XJ+1^O;T[A)Y==[UR4N>R:RZZ7U+Y]6#LC#R,/(P\C
M#R,/(P\C#R,/(P\C#R,/(P\CSR;6SLC#R,/(P\BSEK5O(OD^:P.HIB1(%V0'
M7C069D7=MF:R'SR$8JP_57\\!LL'(P-+VZMY-1&=<7P``+)&<K!%7[]%+X)`
MYW)U$%B@F7MED_[M<+IS,8/5MO1C&<Z=T4;XK3_X[:V:7R_P<F1Y(VTYZL&T
M4@$XZ;2L;KMSNC%!>)(N+\/NQL`<VPFV$VPGJIW%'9B)K5B))8S$KFW$]2@(
M8_<?Z<Q5S4?8SH2,7[P.HO@I-&3+RH:!#0,;AKK@V;5MA\F466"CL!01W^.4
MY+1A8+O`=H'MP@(L9+M0-TC[.0RBJ9:S;!B6I.)7/Y0PQZJXBTFYI$`*UW^:
M0+*)91/+)I9-;&T0C4TLF]@ZD?(#R*.,-H9`;%_9OK)]9?NZ+3A[&\'C(N8]
MKZ<2\IUP<\4EOPHOD;P%5J?BDL*4=W[/TZPMA(.ZONES#R8C8C?P(ROH6U^/
M;X^MGX-[&?IXF9,E?,=RX\@2`^G;;MGIVJTZ\;&)YK?A.FQ^U;Z=UDH0N4]M
ML;KMUDF[W.B2E:A.2L2@Q_QB?K&1.F`CU66WO,X:Q(C'_&)^L84Z7`NE].BR
MV^F6\XJL2772)$8^YA?SBRW5X5JJY]V36NT9L@Z5.?3]TT>O!-`\UQE#Z\M_
MMGG-XA?;O+K;O.Y)ZZ1=][M?#EN):GZ'"Q?DK(W3KX-P'(0BEI8C>_`*:2>A
M&T^5WK!Z'IIZ;H5?-2TL9(N_9HM_T>J<E7<-&R*B#"G-@A3F5[/XQ2;@($Q`
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M-NALT!D:V*#OO4$_NVJ=G#:_*S0K;;V.UZO/!3)#>Q:]\`?SS[GT[UZLQ(!*
M\O^91+';GU1JUPJDOR/2?P+2WSQ6'#>45C_PO.#!]0<6T<&*DM%(A.X_,$0,
M7T?V4#J))QUK).(D=.,)/!'25Z^#T5CXD[2SX<6+*%]H9XG8^BA">YBQ]:33
MLKKMSIDE?,=Z(VTYZLEPZNO3XUFN>Y[U)6:IR=O2\\;"<6`YFE1M36_\)AH+
M>_J;@B:W*ZLLEY+L61\\ZHQ.%YY688,&K`7M3O.[/AQB=?EB]=5[O,SN?HGM
M@?"3M?,PELG:6>]ESO)V%W`KEHZ#YB6@.N-Y$6.-";@K<G#$M_YTG!V@WV_6
MW5V*@]7M\7;6]K`S@YDVA%L01\W!Y(TP5'_PVULUNU[@Y4B"8=Y<U=MVPF9%
MOC)H,6@Q:!T.:)TR:-7)5:W%T>M2%FU)K5G]1#7N%3P.@UM%P8^4!/8',(X5
M^-*:2!%:06AY,IHZ65V[_9D9*,T&K*:;X(?-K]IN9I?S/P>\+=VY:G7.G_Z&
M;,!V@>FLGO553X93YA?SB\W?09N_RU;WI+L=1K$:U1;VMKG?Q''Y_+A<]&,9
M9J%Y/`R#9#"TXH>`/B@'Z:RLAZ:L6^%73;.-[`&LFQ_=J];YV3F#"H,*\XOY
MM7T*L1&H@Q$X:YV>E=M*-41(&52V%@;6:R]W;M7+U%W/'%QFP>6L6+*22C4Z
MD<<7>M?"Y=C2=<4-*H)9MT>R5IH=C!?3Z;1.#W8O=V618<QL3)C&QK!^C&5C
MR,:PEL;PK'5^UOS+&=AHU2\-,">R/YBF!IS1:H0HKVBF9V:$ZRZ6JV6^&[C0
M1?1OSRXY9.QA[*FS6#+V["_V[-'.T`XO6*WASA#?KLH&KH:,Y=Z;>W/(8G6^
M'G#V[KS=ZE[4O2J3-?8`D9E-[IXREA683>XAFUQN4+^W&MO,!O6/T[\RR[`0
M^4L3G**\(N7=[Q^`EFX,(]FYJ:S4LWYNVRZ<P_\Z.GK[[@O(L!S"=S(\.L)O
M;J0MW7LD7V3U@<_6Z\#S1"\(1>P&_JR.17D&+D/R==X),".KLX*@+WX=P!2U
M[`*U+!%**Y1V$#K2H5L`Q"A(L-._DT@K#O*7`L#O/!'#S^#C4+JC7A)&U*$_
ME)'$2P'H"@!'WDLO&&/F"-X5Q?JU.,[7X]MCZXT<BY`22U;0MWZ1PHO5@[\D
ML!+K5H;WK@V3A:F$P02^Q?>6UG`[A+D'`[>DQ?@?F.RQ]2%VCJV[(4RK\"RN
M50*Z)F85CHQE.`+R6F[?4BN,X/T27R[P"@7AV]**AD'B.58/'HY0;=UH"(^+
MV)("UAS*<1#&6$GMP+#'UK6^(<%:\&*$5H'$0^'0W]D-#KD%3-^A\*AL[]D5
M"H5Z@VF$WG2CS-T9J<=,D[$^529]-U39G2,Q/9^=.Q/5),H<BN4Y6NPFVFDO
MQ=&%VTYNA[%7B[83W0I?Y[HE,RZ_F0+FM?/[21K\)'[7%]X*#C8;"382;"2*
M'-U2R^EM\7;AMM.[MQ.O7,^3SJ;YRT:!X8SAC.%LXW#VU>]5`AI#&D,:0QI#
M6@,AC<H<Y^[M,9CM(&A?OFQX/93/I[O/SN86I->@('CKV+C,UDW=E&KA(Q5L
M\;9@\9A]&RL[VBRSGMY.;]<,FRXGVI'&778[W?F';M;-/-8T!DIF'[.OD>QC
M.]<X.W?::E^66\VPBM57Q1@AF7W,/C9P;.#8P.VEBFT1(1_)<&\Z:;U,2U!.
M;"]RE*`9F9HE^,Y8T$QO:6U]3^N^2;ANOV55PAV\F]-IG;6;X>:L63<8#AO&
M<K9X>\]BMGAL\;;$R0;MT++A.VQ49,.W]RQFP\>&;^.<Y%"/X7![6?`UU7FO
M4M"]!_C(FT%-48,E);6SR$9K`X1UE7WEABYU$;U<K/=_8[G-T,30U!AA96AB
M:&)H8FBJH;`R-!T`-#T2&,^.=;=0'G;*Y6%5ER'E>K!.[0DU($4VG\MLU?9U
MAV"QEOX'Q_'&5-NOSN%=^ZJ\G<&*O'D6[P=TLW7>>Q:S4K-U9NO<S.-SK,@'
M#=ULG?>>Q:S4;)W9.A<N/FR=79VR(N^S(M>G$G#VAL=,49B'/?7=^$G75;J[
MZ=&NS[,W8^J[V!E,5Q_/N/MR+RZK*RTVN_]S2O(WW,]]FE5;EY9*F5CC?;A/
M(P=?=;O^2\BW<RW=EMBY\+UT4_/9"$OGMK.??<'HQGC])'5]&J]KBF0%HV>Q
M*6!3P*9`+V%C5YML@YD+7VLR-9_M&X*JF^<8]!FS&+,68"%CUJ88.A>S9ETO
MQ[C%N,6XM0`+&;<VQ="YN%5UAUPEF1BVMA9C+]]8H.*]:[Y!;DF]V?0IBJWB
MX!-NCMNQ*LT\<<0V;1LVC?FU]FJ-#7'GZ1<*[))#T_46.]"IJGZ#K$MUTB7&
M/N87\XMMU2';JF[KXN*2E:B^2L2@Q_QB?K&18B/%2E1;)=H&Z#V6)=YXXG?N
M)EGI%K;E]76O,L0K7,%6-X5>CMNL^8UQ=Q;83ZMN-=Z8_;1U.R`K4^R@G99.
MJWW1.1A58+AK`H_9CNTI8]F.L1T[^-U,-F<'AGILSO:4L6S.V)QQ6,9VK$YP
M]UC^>5U5RBN5(S<=!GG?I;9ROZ1@SKW(H0EBN=KN;`,7NHC^+79?QWZNG;&'
ML8>QA[&'L8>QA[&'L:?!V/-8[#HG'-U"[=0IUT[EWO;H_62U3E<]RENV67N4
MDI_=</MP^5S_@O+5^<K[!JRO^Z:O#<=E-KA[REA68#:XAVQP&W#HB_7U`'&9
M#>Z>,I85F`WN(1O<D];EZ17KZ_[IZRZKX]3G,VZ'FDO_[L5*#%CP;K;"!)>D
M_!U1_A-0_N81RG^$@8?>!(:Y#[`;IB5":45);^3&L72L.+#BH;26Z:=IA=(3
M^ME0NJ->$D9TQU8H(RE"6SWCR'OI!6,:S0ZB.#JV[N!%KX/16/@P'9B(%P46
M?.W&GAILI*=J!I5F*J[ON*&T]4!63T3P0.!;(4PC`JJYXT3-R/5I-8GOR-";
MN/X`GO#C4-AQX>WI>9*+%Y%E"\_&Q]W`C^AE\(;""_5K--W^Q(]ALB)QW-CJ
M33+R_1S<R]#'.1]7B79>I)<1PL=!H')?:9E-I4H!5!)U]_L'$"DWAE'LW#16
M$LJY78]OLMTFJP]P8GT)`R<!6M^*Z0VHIU%T@VI=1*.-*?5&!Y_BQ%AS(D).
MD!Z`;@2A`PK7#T)+C(+$!Z5Q$FG@Q&AY#BG4PZ!?-]=?WO]Z_6J)):A)7K3_
M]<+Z]>W-W?O7UQ^.KC^\__D36"#Y+3Z*@W$V^[N/!5DAO8]D?C.35B#!ZB=F
M;HZ,93B"%UINWU+SC@#LI(6K\[S@0?@V*/\P2#S'ZL'#$9H3-QK"XR*VI`#,
M"^4X"&.$'`>&+2)`M:6K(2`\8I.V#`GO_7L`TR"<K`-.M<#@@E]8ZX2#QY%T
M78IY'5L?R;[J2]C.R-":.]K,IZ>MO`H63)UK"(IF,7(C%/],(ZV^ZRN9'@2!
MD_\UON8A"/]"^PI@`#X`6/.4.VC+02%BI0SX;M`8F`^,C.:SE:F7HRPS_:;O
MAE%\Y/HM_:\@B:WG9K;=]HMW[]]]3O_LO/C>&LEX&#@MU,F1"/^219-NR6]C
MZ4=`2>4CY)`'WZ8A#&R\\B?4U%T$@VBVWY*.J?V*L0S=`+T,.PE#6DWL>N`4
MP*/H"H-.("UZTG-A$'CW$.C13^($\08H'HQ<&[[U95_]$(>W]21["E0'OON/
MA$4^#%T8=`"_#0&`B,2P(E?`I)(Q>CX(9V-RCD(Y0/>%^#2&=0*P'5M?U8^F
MOBG(!L0WG@?^SYAT^1]R;R+Y=Y*Z;`M3L=Q)QUK51.^!EKY)0K0"2A-!<(#Q
MOE1$>W#!H49"OGMSG;(DIX%%[O3D`+SNE#W*FT6NB"@*;)<8DXY89(W1Z$VP
M*,^0&0'-ABD\RY.?`6^$-@&:<22AT"`Z=:5E$4VG;[S\<6;5VQP*[L?EPQLM
MUIN7V.8K)_D:I)VG^?D:I$TQ=*[WCY`\5_6VG0U>D:\,6@Q:#%J'`UJG#%IU
M.E>RKIX(3]H\O&C_:S;L/*HU>W6VY+=B'JG>F[T[WX\_'(/%_#J`HI@:N(#<
MRI!UB;&/^<7\8EO%MFK^\8?SBUK%LJQ%=2JKW,1>4&7,O%R_W8,.KM^9"HZ?
ML8)CUHYO?;276RG71LU3QFZI46R#4HS;/QK"79.KNA]T.^UZN_3<-;G6R,8F
M:T\9RR:+358=3=9IY[SV`33;K#I"V[9VM5?:OFXZ#G*RJ;9ROZ))GYFKK;M8
M<L?;_>UXR]C#V%-GL63LV5_LJ?>F#7?;SG/ZDXSS!_4:G/[B/F0[L5?<UVAG
M?*Y_&0OW(3O4O2;6U[W#93:X>\I85F`VN(=L<,\O3_9@IXP5MEZ[9>KS53I_
M;K3'6G&"N^ZR]D7$$MOW8?>;#ZY-#:\J03;/F65HN85VBRM(\$KMAJQ(RK\B
M:TPDPR.LL>[L!/\O/`_>%,O0IXY=NH^8=,Q)5ZE(K!LU1<?6-3R@1S)]MG1_
M)^P7IEJ/4>LMW0:,'A?."&M\XU#$[KW,.I0]#*6?-2:CIF8V]B,5/==SXPGV
M0:(^9?2`XV)/L@B[BB6^+<-8N/YT?ZBG<?U`VI9>VW:8`,7?:D:4J<BJ8U0G
M:V9'?1NP71?(MNG/FZ!\#T))/7\CT]?,#9TC[$D\L>Y!:H,0Y3Q`%;IWG=G]
MAEL6S"KIXZC8BJU%WP?Q4(969'H8ZXY^0>BXOJ".8=AP&-6DET2P9.QP>!N,
MI&X@!E^9F4YU`AZYGHSBP)='JC&QZK1,O<;@O>D;\2D;:.%)ZDL&N@G?@SX"
M`&`G5=U;$%\'Y"WV-E3M5B/+<Y4Z8]_"M)-B;FI(1'C%R(TU%0D4XJP!(T*0
M%?1`*JC?L344V*XPAQPM;!HH0@=6%)G>:3`?7(S^2_>1Q@D"?&ALHT^]>^H-
M?>]*:K0&V.?GB8;8EP"W1$1D!PEHT603W[4%-4XEIHOQ&'26VJ:9Y0-I(FRB
MYR&U@?%^[/8G&6&IS>)0`!K24N#7_2`<J0[1V,RY)X?"Z],$@$_N2+V,^E2B
MS!`TJK%RS^*O\2>Y7GO4"SJ%6.Q\BS\PCQ*M\^W[D+9^$%L3&1L:$^4<[&!)
MTOC@`BG@)V[?59WJ4A9&NKGE2/P9A`:^S1R5](>1&;#P5M-#&^1;P#P%_`QG
MFA(K\SW2M19E;23^@I]I0JF.O4)C7&IL!'U,;6][PM/-<26L$UO?XJN1['U0
M+!](YZGFH$HBT];=U)0O%0S;#>UD!+^#H4J-PI5>@$0@<H`X]=UP%"G6V,`*
M84],T^YLSFE7Q&F:X=O4$H7S9Q)I17'[X,NB(`,4'`.6"U13M4@]J#--!1`%
M+W'DK+Z`<S!_+[H"KGE+<>8&[%DC-V"76GO:P+JP\!H=1*U!!'G9[9[ON&5"
M-9L:7P>R^M(O+Q^M#3D0&>U+B6&A2_'::Q@*#99U8QS4S^%`^.X_^I*)?)OK
MUS>?HT*;ZXJ.P6/P_\R0Y)<$WUPL]!V`$Q0GCJLCR_0W<0A6-YHO%%M,M.R#
MM6-CMV$H86/'QJ[>$LK&KM+88>4:Q$@#E8^,W%@E5\HVC(T3&Z?&JCX;)S9.
M]990-DZ5QLFDGW,;`BIQ6GDK2_$.E2`)K5`\6)C](YO5LIPP&=`E.92H5-L.
M^)'9T\O)`7S')HY-7&,`A$T<F[AZ2RB;./,Z,#=]&45@IR">0GLWJW;C*<*Z
M_IJJ?;A-.;\SB7N9D=IY-%N"N?OR2@&OV8PN;*SFMB@C?4.IWGJ6_7X0FI&I
M/"`)HP2O_\MY-7JC<Y1XL3O.W[_L^O"6.%'99AP.L\QJGQR>I;M<U3ZH+P:R
M:J:S+I!46^EJ@S;;W\7B@B@KE,B5<90J)7PY"&*7LN`M4/EPHNZ73;VTO,>F
M)DA7L<+ZT&5+?'F/^_MB0I<S]KW@(3JVOJ@_34%$-*-FPY%(2%P;NH%824+E
M4$)M)<._<?>WGWB6],/`\\S-TV.8;%H=A[_4%1S:1RR2+JL$H>LQU8XQUAJ8
M;6C4U>(=?YDXZ$J+])))*A!1UT"F(D+W-?:JRA322@8E.)G<`-UHGUZ-"M/J
MZ[USJC0HEG;H8<FWS0H.(DM7.I3?`0QTS17!^+U92\4=DVJOW>S:AU3L8]M4
M?#/P)L?6-8G/XI>;VB(,Z7IOO,67)IM'@.EZ!;QJ\5M&:#<$*8#_4D]G]Q;#
M1]$0EG:$$@WKCV-/5MSGS95QB]W>:Z,NWHEOTU5Q7!:7UG)-],6V5(P997?8
M5\$OZ@S>.0N"CT4]KJ)PC!0^MK[J@C`8QUR5Z\B^I&(E^`E6,DD-9/DZ,H3H
MW`6]:8&.X_;A88D%.0`Y\0-6,&60G]UV30@$PRMKB-5",]Z#Q:OPKI$444*7
MYT:F#$OZ0EV#"\.$I*/TL'C0-LO4P^;NRD58@_F!G4CKKO(3+C\1`G2%D5S[
M':@'HLK7MIV,$N7:?*8Z2I3.4`+I(\SZ/_\01-'WEM+XM6)ETS4]3SE5@6H7
M*><1Y;0FNY'ZVHU4/6#BAU+@S<R.-1"N]N7P":G\2=IZT9[6O7`]],J/`!F.
M(N&I]!2,Z+B1#<^HJG`!5FTL4,GH3>"J*#\'O!;[KR$P'=0D!SF6_#L!B`(#
M/4+@(2?5`P57%8MD^<52*T3%5-6L:CY4,`^+R)7HZE^F7JA/G>=H_-NLD!#F
M7)1!%,%C2U^^3,[4$-Q050\)?C0Y0T4'`VM="]2%,;^[M!ZDFF.V3KR:7)5!
M+K[28^M3D!O%UJ4?JPR5SDA1S7E\B=.7%[,'LP+LW6"\`<[AC;J8'3E8).-A
M8UNY0IWNKJ<*<*1:9&([#V`IT,=5,BV?5;N/5<O"'YCX,3LP8R&FZ9+V5&^#
M4/^;4MP4.(O0QY)FPSLW>OS7:E`\OS-U6[@=NI3]UZY+_*/UW/T^4R^L3$\$
MJ:S$`F,=.0D_OPSP1-PHCE[`H_EG'>G!<Z$J%`]L75:>K]7.:MI#5&[XFL;(
M#Z(R")YG+BS7CB*8$-L$-58OF2"L8D7V-_4&X^\A'5X0(9Z[][E1D6G@.QD'
M5=$P"O#W$_3OT'_C\T*/:\CK*>%7WM--7OC?Y(3_NBS\-\%$>/%45Z!#=ZN,
M=A/$>.K0HLZNA$2QB4D3P2?XVSCW-])U)OS0]J'Q4@C1]&DZ]<(TVD#D`(#(
MG8")TM,]:5:F>!3$ZB>AMO48PU%FJ)!R2<_EI"F7_`#9V:&I7$WNP?184"$K
ME^7DCJUW,I]L5+]7)*1P+DO>I;%7+JO93W`+M?!V%4#J0%/1-J5<>LHI/46A
MLUOYB'.B$Y%$_\(!D>HEI.0UVZY&`AS*NA%WB.4B%8WL6:0].7MIUE3C,&)A
M.3F'^2%UH&0HB7,49^9^KQ*<QJ,.R(WKT:H2WXW-X1D=LY-1<B-BDXY)4:3@
M*4SHNW$N&4B>NLY\8IIQB*B0'EK+J&G&T%0MR2T,&V$,#-/U)E-X?=@(DAD[
ME3?1IV#-QO^4X)1$0^M/-`4W6H"3,2:(LX%D(:KRI7%GD+FH)#)_,'B68Z5?
ME3I8YGB?+=!#P&2+EV64=7Y;QVU4'[Z*53]L*;F1[JB'!T,5;U/4Q.R;XX:8
M?X*([BCH'XUA93*NW`F::6NRT][YD-CHM+M"`(SI,X53Z((J$#$E+9@RT[,[
MMMX6;.(<@T>"K/+V0Q<^,QLC""PJ.B:LI2-TSSLESU3!L!N9FAER@V`>OB`K
MDIZQ+`Z=/?F@CU!.RZDE8GT:U99CLQLS;26>=TLS2LV['_A'H>R#^4N#`?S(
MAK%=VMT\MJ[)!!3HE`H`.-AHH@-0X]B-^A,=D>.64SYBR/,UM9&:M%G&MCK9
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MN_T/`IL4H`?UX,LP&KICE<(`&/,CLQ.E<A)V$L6`96%+;W%GS2$H$Y(6(="!
M<C0W,)B*SS#B0\>*#!#Y0PZV0W%[">[JMZPD!O?F'Y,AO96>=W0W#(-D,$Q7
M&V;Y/+U51H?ICJTOA513R2B:T"\D$*K*_*B`J2KWT])TQ#ANC!MD3DM',-0Z
M0)C<C/(0LN1,:W'';?[DT>,LGF;'#!<=MV_1#@&YB2W]<"C!/OO8GV$HPH'$
M^T4,CWMH.-(XJV!.BAXR9J6B5);04LY@&';T0.L$;VS14_CC\7`2N?!SM.M]
MEV8YA&`&X4#-I"\=%)B6:BZ@R30"B:+MR:$R9392(<B?O3R>4\9VX!"QT<$)
MGD&TM3-*WDT$8J#VGL`=!%F8&/$B:2&V?B1OQP5M4?\*\RGD`09.OO+U`#]L
ML\NL9#@5:NNY:M1`D!`*1^:^(GTSTHAPD*_4^9XBL4CFISWMK*=?$3*%^<24
M$7[M>T4BJ^[1=4<F2M"Y;?3S"@5B.MVB,$VU;`&Q5R$(OF$(<P<?#QU"].U#
MEW!(5=N8X*./V&']Y0,HEQ,)IA2*@,L%O47XP+`10Y;POEQ8N'5G:1WE@$W6
MFKS55C*`@BUBH;B/O8.PVY@5@4&TE=X,I3>V<KDD:Q!"7'@4!T=9TB'?^40)
MXD1+HC'/>0L)8IAW$XQ00U#J8*N4M.&9FH2CYJ=[HP!L@V*AQ<(PSG-'KA++
M%OR`$HCJ#3U,O1B9KK832CE`+L>ZEE"5:YF^^1-5G9;6Z6$E%YK^6)M^K"S4
M+@=F@&$X-#2T`9W-0U>R94VGH@2;$>&)$2#"2(08X:?1/*U3TVL,=G($OBTP
M"741(@YX63AY1'V*-;7U,CD[J*?5F=+(M%:*I('R#&1=7Q<.4NI9-8S2<:[:
M9!DDKOHN\"O]/?+BR/B@_Z`2(Y$U<+&RM`=ST(W&D+$B%1GV&A9B(.U2`(H,
M@!W_I-YL9(,.PU^C`"Q9/T&H*.ZQ1K`"*I'PXRF&M\RVK`H3=)NQ?*8<WO%G
MX@QTCE;]+.^'&EY'NG(,\S.JDT963)<.9S:'_DY<ZH](2)-$<AHFRM@[1T0X
MI?"T$/]&>X54R)X%)`MAZZ&JY>WC/G71:<[\:_A/N@F7N>:9SPP#:1^@D*Y$
M<TL[FAC2YK3A.C);%+'X"_/)=!``UF;JE@!L%31016NF9DI=TXPK=EA51>M)
MA*<6<HD*,`K9HBK"`WAF'`:#4(Q*,>H(W`ZU&V@<7IJ%V309BPEE%?.M%LU`
MRF&BF"+(?")$+]Y"*=9`Y%((MB?<D=KRG>'E%:0O7]4;T]$44XAL:H*$#4@=
M*<M.@J>/_O:4C9GU$JJB?"B&D.G!$QR'!%D/)(&`+IV@-0YDNF6G!$.G(L"N
M_0WBJ39%C)BP,$QY"TJ[S'Z-5CS2NS`']/G,DYOK&YENVQ.MXZRRYF\\'64^
MT(%MR\J%_O"R7+BL*\O^5"7B^0!;!1*M_(_-D:,LQF[E0^D,):EF7>TY@'LP
M#F6LRS)R$4>^62L5.+12<3:B][P'$`8A$T"A5P16G>%(7PA4,X>JU*X4_.3[
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M5A'<R*;969U_TT#3//%-5BB^*:1"59;V/>`;;=5ST>$<6NE^XD0Q-Z480C`@
MCNM-\AGN]RGV?<PJW:[32H7\]O?[C]>%C76LUCNVONBJP=F=TJL5<]:>2]X)
MUKV1J34XO!U3WYFY%:ABN#CM<JO4FNGCG0=X!9IF`'V,BZKC8C3N\9#Z0OL@
M(:ZCFESK\H8BVN)G@#J*K@JF(UETW\I0JXY[1E3N9_;(\MXY+C;QR9VC0VNI
MG=,UHY3W`8MABC@*E`[3X`GSXH5:]-DA?S-QICX1O]G*O%'[D+RMOTCVS0FD
MJ99"UP-5-S6+2,9LRY?RWG'V0$`6GJJGM/K0QA$]-`@"W-.GIZP>V/4^WKR0
M;L>G%PB`$LIQK&([48T[K"^;TI=K![RFV,4"[KE9,5:6M+3;'P@=(-$9'+,U
M50A*U.XPEHX=X<930`7!&:G57@(HV2@@4V,,(2/4G,(CVC@OYO^S`V/ZU,/"
MQQI5CP@\WUB^A.%1HN]#4[1U=T4KW(`W[]K1]O%9GL=6^9W[TXIJS20YD`95
M6[V,U0Y04<VZNTMQL?(6Q\YQ9QQ;5'2_`X9V9C#4IENSBA/:`E/G'I!&")ZK
M@EOHD[<.WC)V,78Q=AT<=ITR=FT1N]3'TPTEC?-:F#+N/0S"(/&=([SI)OS1
M^J_7K]^^???NQ6PI6I7P>8?^HOVOV<CSJ-(<J43#\KD(NC=Z\8AM*]PNG"=H
MX0F"3:K+<E=QETH4:R_[ZQ'.SOSFU`=BH+^K#/77(H3Y-8;N8+@D>VK40SLW
M^\K9;)A'9R<7#!9/!HL#629C(F/B`6!BNC'?W>#-`OL-&8^%$!P5;)R!-\4F
M-!O+C+!1:%8F:[^!AZWANOG1:9UU+AD]&#V87PWD%Z,]H_UR:`]Q#Z/'8:,'
M;P`U*]2;[E[]2.MV4\A7+L;;[;XJ*SN["K7)U7<?O<-R3Q;:='XRS##,U%`L
M&6;V@I_[NY%Q<MX0[_;K\>WQH@VPIUC,#NWA6II-\JNF<,4)L77SX[1U>G'6
M2!%E2&%^,;_8!+`)>/*>R,DI[XD<.*0T:T]DN5.$AQQ=W@[=P`\&KO7\/V(L
M_.]+D%LW15^*L0P(C?$Q5CXP>K!^R1..V!ZP+].].J_]GN\:=8'QK@EXQW9L
M/_G*=HSM&-LQMF.UPKN=[^C.-7W=\;>BCF])&!:+S+<L#G=!3/V'5ZQNW"1`
MK-';*;*\>79P2Z#(+@*["$ONW%Y<;"YMSU+/V,A2PMC83&SLM,[+C7\8&_>@
MI=Y*Q:4-HB/OFC<KV%X1$F;6G-1=+`^FZG\1_1NYCN/)Y?5O'];.V,/8P]C#
MV+,E_W&W2>O3IR:M]^HTOLI:STQ"UWN;ZE'6LLG:H[WX+NF/Y01)SX#EP?.Y
M_AU:5^?K`6>\SEN7W7/6U_W3UX;C,AO</64L*S`;W$,VN">MT[.:]XUE?:TK
M+L_*=ZC/\498FHE7B[NGRQ.<HKPBY=PKHDO<>.S:7OU!]85I-_G"N#>YPKBW
MW\;2CV;G)/*<6H2VUQ_>__SI1PO)\<):YV7(!2E:09A7NO4XO?;AXD4TN[C0
M#J(XLD0H+7LHP@'>D1Q84A%6W3/M^G82AM(YMFYF#:)_C[=:VU[B2+SQ75]@
M3;]U??W'])M#Z8E8O15O8,[_(.C31U7+&0=AW`\\-\`?F=OF;7B5Z\!HT;%U
M[=S3A?-C,<&QU!7/^DKYT(IT>QT87\0`I3#;GK22".818"&F[TA8,#W33^($
MB#.3?L*.W7LW=J4BHB/[$HE%O[/%F-3C'R3>;8)/CX+$U_3&2ZD'/GYIB:A(
M<ERV(8R:M!K;<^]I8OJZ:O.3=#GXJ[$,8=ZCI?C5PHGY`UV(ZL9R%+5PH"CP
M?>DI3K7TC_'B[$AX(J0EP\`]Z<N^BS\`T4SZ0)`DQ!_IIVR09]<67@NF.TA@
MPD$X:=&#<?#-Q8*`P21;03I[JS>Q7M]\IE%C&;K"4V^+DO'8<_%>.*J<!7H,
MI4#["2HI\/+T"%[L1VY$-Z.#=-S#3(,$'G9&,)$HSM7=PEQ=3_'.D)(F?6Q]
MA/^9)W_%E1*O]3+ICS'PUOP=Q4`SS9L\LA96&@_=T#G"EE!JU<?PUDA+K1E@
MBC0TI+#M,#&#9#>>(V'H`TU9?-I%08K&TG;[KD2EI!\`M8`F=JS(*X%N2'`]
MN/-G$@%9@/=](-'?"6@Q_-$3J"G)./!G$BCPCP:!OF/=!=S2M/10"/&/3&2!
MB,"\24YN*_WG`\3R:\=Q4:*1/*T"=X<`&&!U"3#$()128=R#&P^5*%DH2J0E
M$<%.9%U[/1F"R71]8"BP'GOLRH%$7GR4CFO#1/'?O\MHZ-X+ZZN/4!.Y((_/
M#6.[[1?7;U]__IC^W7GQ?<MZ[SL@(ZB@*=ZTK`\QP$_^P?<W'XJ/$0#`DG(O
M@M=?>Z(G1L("5'[EAJ"P@Z$8%0;Z>OVJ.-##T(45:N&T^E(6;$H$CNXTH4"K
M1L+U8^F3D<"'CJV<Z<P`,O=\:DI$E-I$*_$]&:$=D1,-ZNFKS8Z),C)#`:#3
MDP#NQD0@H.K9VZ!01(WTO5.V)&<M4MTV+]-O,K]!F='Z/F-5^<57+:NL@H>K
M@V\,#W*G-H"Z*25#.4;7`-^>]([*H@)&5+BI;U.%D\(6CARY-BFL#XJ@8!4X
M*=TQF2"R9N"/J!?W(9I)39H=C$8RM%'US..MW(&2XI-F)D$25KP5#<TH<,`R
M*"NJO$!M1:<UB.0JRHEH2I"'(/$<RP_R$I]J"P)4D,3YY1$^I3)8FD6DUCN+
M>!7KI^6C\O0DSEQ/BXP=N(GH-NK%5>F/>B;3M*+V],#]@A]J?0:81>[9Z,_A
M4W$HA>KG*,;X)@#$6()9`V-J`ZER!%(@#=2,HL!V\Q.84KM5%6\+06*=`L3;
M&!9V](J\$N06$)K$IRJ*7Y643T2LQ7;S-PIEF_55((2*(("41\HYS!`PBQH&
MH2`=!Z5'AEG!F)11/(C0B;210T_"IIB&?I*`-=,_:)6#)G>V]_D:H`.KJTFY
M;F/X'PTO??IY*"'(BC`*^!"`\58S5LZL"Q&?@/^Z%UYBG(+L@UES!R@PCC.X
M!!'A`3SX"G-N1[?V,``GP3P"R&#C#P#GI%?U@GE$P#?EIZMH:N%"(0()Z,WX
M`FD<;H1(^"D-!#$H*8H:P,XI"H4].'9U3(H+M3!RP@SL$<H)3@)^GO-$P/T"
M)ZX<;YAIT.R/P5>$D$(YM>"X264BP"!$,8;N.'<5!*!CHJ>9)[<R4\IE\H/B
M"LQ<BXM`</:LG/N8>T'.C22'.K"KG)\9R?P:(G*]DG;OP<%$239).IV\T^["
M.Q>=3^0XQ;EKB?@8J1<:/&6,T9B^SB;%0_#N`);\>`BJ[SO`IH\8S659\9-.
MR^JV.V?$2_C'J?4`>O-=IW6B/X-_=D^[F.G!-`/F63R=ZU&N5F0\+S>*$HH^
M-#Y\&8J;C]?6IP!_\QR\2E@A(3Q^8IU^;_(A*HT(;E7.>4H=JKF#9MYH+BN7
M>HLZ#T:OU,XS8@%Z<U$DT7(88Y,S+*^$1Z^['4J9N<190E6YDV*$3N<_*B9T
MR\1/$10^'U5./#,GLM]71,V&"1'X1Q*\:D#7:_4FA8<P5.J<]U-M4Y/+KW9J
M1HJEG3;)A10`M7I6*\@'0^DZH/0UB:(]L7Z1SD!:UR8*:YA[NV%4PW#71_T`
MX9^&A-[$,A<(WR:]*D4K9M@DJ05J"&BML&:QH`JK4,^']#-;AK&`+T(W^BN:
M@BQ[*/P!Y>#IS:G_AW]0[T9$DXGT%7:BVFOPI`L$',Q'A#I"G34[)\`]4(C%
M_TZ`0?T)Z;2:6U7H^@*'#R7\2&+:/?SK*`Z.\']EK%/!.E.T&4<<0#X9)7JM
M<U[_%(,%4)=XL9JTL`;('9C+=Z?GI\H66!Y&!/A1IW76/2^:LF,<?QY1'(DP
M3O(``B=RN=A)T>]7.80$\P$HPA@PA90.A_FHL76:`4=%!@H]!6"6<+3ARISA
M")2/DB;`<]<?)WHZ00^]<=Q=S@PG/&-VX]`VI_DKG-H'RLYW#4-S8<G0E2&2
M%@VO940>EDBB^//U]9=BJ@13(UX49#!J]@Y0A,<8:U`Z#8@E/'Q;E>K.$8!<
M!`23A^C*R29EA'&&2H"5)/;.$Y0WTI:C'MAE_>EI"Z,-K=+9O-%0XEHHS'"T
M&4]39&M*H1Y8)N<3<)IB\B]`SUO,)ZP[)=9T0X<4(HR"2%9E7+*<0+HC]R`Q
M4D>8`/=2@-CZ"0DTI9-50@"?C`JQMZ,V,_%YLWGPQO42'&;ZA:C/``UH9$"E
M,1M@6_[TU!"BL!;`[#YJL($AT="`KO:D+9(HS5/DAM4SI`1PXLMOF.B=2@BT
M"BMX$"&EF%3(45PINK>VWIGI*<>@H+A5UDN.QEXP`1NCWCE.`#-PIV8,?C_0
M&#=(`3B/'*02H+/"0%MX-ADQ[81K$DH1^C#',G%6M6.I93<5%U2>1M^?M;KM
M\W(,EF;:P=C`G*D-58X\+<1UE?YR@0YVK//XO?(2UQJI'PBH?8W(KWMKMM;7
M:QF:#FBH,P`+X"2E.J/C52J>2%U&Y29@\@[WBLE-2+T/XU]$!1\>-'TD_I+Y
MF@9T\4#S1SJ=J%PL"JN5]=;E.3`="*4S;Z)J0N!)4.F"=BEQ-PHUQG%AN-#L
M6P51[O5K=@D6.&.X$<:O7WM6RGS-V`K*><*OP6$,1F93\#.E=6XP%)N7E3C<
MK>Z\`Q_B7B>::Y#<T,6PP==FBNJ'*(YVL)C*[25Q$%)>+S6/:9G61#OR?P:A
MKN^XN?[R_M?K5R97IH8<@PD:"5N"A:&"J>HWZ(!5E^4-,&8ETPVF^*K]+QP<
M'0W]@K0F,!*>RCK2%@GI?V$<0!XG&*%Z4U;1\^95?>5]#=K"IMA*^RB%-RI7
MP,22`=;6X,YV:`+\:"8AP0X+R]:2JS'%EP.APS]MG<W6CMK]SN7\#(&GW&86
MZW()*<GVQ(H"D%N]\:;*`'2]#L*&<A"]">5.132T^E[P@%MA4HS0#59[7^ZH
MEX21-$6KX.&)D7L/OA3*VZO7_W-Z>M*NK+\TU4L82J*#F'JDF*<]&GM)=-1W
MOTGGJ"_SA7ID_%Y=W[RY_N&77V[I+9_>7[]_@W^5,Q856@V2,N-A5;:DES-;
M-Z:K>%&5W#B:L710C0%\3B;3#D+4'Y5[*!%.*<9T;0VJ1#[%8<HXYJCJRDU6
MM1,/0WI2[5.*7,W&?R`2L4[:*BV0HV*V[B)M%,=:5+!+F2&1GWA&=Z)6.EJ9
M;C\4BX_F@4(5+70)\W*;XCBCURCQ[T#BH]+6;=[+HD1/F@T$KNDTJ]&FM(('
MPT,%QQJGKE_?7>?V`8;!`SP2JM$K]<X,!4)BWI)6#@TP($JS7&B.A#(_9H,C
M+3E4+AVH/WAT8ZQ+GE/&Z@?^$:Z-],&G_1@8%U'_V/JB7FV8F6ZDF,I&<`K)
M[T,YSGZ:OC<3>#6NJ4+'\"Q$KO83"@5[D[0&O;QF(!'PRU%TJ21O0?\+*W/"
M9#"OD+U0;2PLSP6W&ZO1PR`9JZEGJ4U@M`.V"X0$C+`_R5:FOU"Q<N)3)A)9
MH\;6`:<I!6ZIFBHEW3EU?US`10_+N(GK6G$EH=&<-6X[D%7FLJXQV*I^?NZ,
M#FUQD"#>D61\(<GX.%4G_\8X.XAD`$FV].-PNEIK3?[+)H)DS$.[_4GUZ;EM
M>^B8P4%S*HT?DYU,,&6=``5JNP"//PQIJT%YJL5##'GO?';EN7XM91J%>74>
M"U"]P^#>=7`G&6Q*H/:OR=SF69\>`,`IIB]^(STQ2;?$<FM!"UIX/E!0DY[]
M(=00#M:2S_234YM$Y%"@"@/8\+\$#Y3F&P.6%,G!F?Q5-JW!>71CBK<YWY57
M8G*JLCQWI`_(W<O\1F*6<,+S&F&BSW=0L)"F<$',HZ3WIRQ:1F4%<[A*H0VP
MP6P?RV^Q<GC1%<\J"1\K;4G'=^0XB-"\RF\VGGT@_XP\9(KT2W-WXT3EVK1.
M?_7=U/^$@?6+\$C"A`:43BX3AU.'09)0G510N$(SIF2VF<F,.FU717%`6'`\
M%/0-$A=/T?D:=S*RTYM*:\KONSOJE$I:'H],`^<.H),\)@H9Z50%[BA'HB\!
M"O$WG@N<!D7`2"RP\`3:"+QD<]8CB!""G(1>H<'+BH9N7^4["V4^I0(%\S*,
MC0JG(?.B1%R!*-9L`^D9DX=&9>K?R$,%0>I<F@T((`L>:3G6"3-*L.1S&X7,
M!T"RG42X+0/AR;UL325\9KEL4^F30HBC=]/ST8/*]6*YE(]K:^5VOZEH`:-Q
M/U#97:QN5?"#<K^#JOI5`6C#GL0CIZP1,BA"UW4A7\+`AW_;*DZLL4>VEU6:
MUC6$BAYM^RFU>OK[LN'?I1B=X_<MYC:IROQ5`/]39'C^#-Z[Z]O"(3RSFUHY
MUM<QI5X+IPAOOQ8>_Q0<TSJ/VB>M19V7?,H?0CYPR,WF]1>5-$IMWQO9BZWW
MIA!LNMX8K0>`1Z1G#*8'HM8H._V$-H,>I>28.F:H,@C%]SCXGK3@S%1:TD][
MVIQ&:$Y5BA?L6&)G1[K(415A.-$EHTF66#"GE&A\SS7!+AWD%%1A+[)23W6(
M'R)Q*N?/*D9I(][WU7X5Y<]4M3WMRO?DP/5]>G,?D^II`0R*'C+FV'HK0LP!
M.OH0@TNIOI$;QWA*:IV26?`TS":WVKQ7^0$0'I4KH8I>D1X/-RX_SBY6A\!3
M=Z9R_VYVO%E56%E+I"NW&&DLUGT$[T]56J'$([ZDF`+LQF^.VE?I.8Y.Y\7*
M,4[>X.42E*^+R?5TZ[`H"B9?KSW1*`V!6Y1XRE*H52=R5>&?J8@I9?/-CD^:
M?PYE.56H9=\UV]8^I0H!":(A!;]I#C9]NVK?$6/-H!_U,1\`$Q]1%4U%*XP@
MFP151_H&A^AUH>Q[THXCTS,@=[(4GDP=,3,GI;&1KK:A#SVUGPX>-A6^ZO(7
MW"&?FHR&9%RN3B_K[7V1)B;(]?24`PU^8Z)B(!\=7-7.(D$G,79')ON`C@R5
MXRK'-)\*2#/,Z'>ZE*]0/FFV#:>956B"D=N1^#-Q!J,TFLM5]A:_T(<)<K6S
MVO?55?GJE"P>TNU1($']1[P^HIU()Y$CSBR(U\"N4MXYC*"`PAVEP(^B1R8J
MH&W;XK./687S*JN`:)U:!E.&!6".01)02HFBFS^$BRV:4MN;U6/!NM%4Q6%@
M=K/T.0?3_$2=$Z;#L],_FBI'U<<Y8+82*UI%;+R%-%$T95K68$@>/>3PTP])
M=#008OQCKG`A<Z.^P(MM(-T=Q.ROT&Z\-([W3ST[_/;C&QG9H4O$_]S7JZ5G
M)ND3)#;PQXWL__N9??7'.Q"XSG^$CV;]+CCI?!0A_O/9R]V%/75(5^6W23A=
ME7O+*S=X'4ZB&,]*Y*HT(FS\81];SRDRR5S[4JROHP-`KYX;Q-(>^JK?CVUR
M56A:P)#"&K&6<QQ3>B3*[\XBIF!9>C1"LSD*P`HE6-`>)@-M"8FFUE\23VW\
M,QD1\-X'WGU6OS46``H#Z4LZM(I%F9$44;GI1S^PJ2)?)\2R$_UH+B@AH1_+
M&G?D;4#B`_8`_CA4Q>)+:8((!?W(1V7K"57$6#GRIHL2&DSPRB-9G-.#ZLH1
MA&-,C:@589+\09U:LSI7E^<J@PB#8B>DOQ,1QF3"(XM:(NEGDG`H1BT(M4)T
M;T0(*.&+$DP"4`Q"=4QO2*L%[T,ERX`"P$!D'7@Z*`[8;PE^.Q["!R/5/P9K
M2H=RA$GZ28K\"5H.\GP(<`,:E0Z]Y5A<YFVQ(`AG$P;)8*BCKH`R='_YP8./
MH12F1VF+X(B2>X[9]4/6'%NI^`[S75NP,$?3W6RCYYT`,LK!6)ID%'@$-IT1
ME`2UQU7QP<'B@SF+05*M#TUJVF&("8%O^6B5=@UU>C9*^GTT<GZ<)4M;F:*D
M83CQIYPKIX,ZG4ZK>]ENZ<0W_#A1V[_X;BRIR7$R+TGJ2@T<0CDSLW;*TUDI
MG59.56[+&7S24/4`0B]*_X;<"`]C<0\STJ630?CZ*+%)D'7B>;J)';T'4:VP
M@TUG:4T?-0N=V"S-H+:TJ%8#4_OA%$7R,IWTT.O2^P@].0ETV4*1+,@E6HM/
MF?G@1^MYY_NL,%TO`ITU;.)FZYTZ4)40D;*<M:6:!KV[IA=-!2YYMSJ_(9?Z
MW2^LY]W<:\'=3WOM4%M8%;[HXW9%BE)@,4W=%M8K8JXF+L8O*?":F$JFX#!R
M/1"\`/`0IG.2FTXH7/2?L]A$'S%.Q0W#EYC.7E$2)SV/2W-3:$/)=K6'B\.?
MYE>K@H&I->0%@;+Y]V27=4D9S1]M'IT1MO)GL2HB'WCE67Y%F)VB&D7-+[]0
MQ#BSBLHP]`5^\P/\_/EY8=04K'.B6*Y14[L:M`F4*5F@JJHQ1L0]B.+FQ7>=
MLW:KW6ZKQG*VWI3)"U6^#48+,W<Z7:8_(*[DG]0[2U0?J,Z/X$K-^1+%,D*G
M-/J*AM+K6[=')\@5W6:0WJC#!,,7%]GOY8^MWZ;OI9>\-?$Q4`2,:43915^=
M"+%.=#ZNJF?MO$W[56BZ]R3]!+B$`6U&PG,B[TG)!7-UNH9@E`[QP^@Y&_>(
M-Z%ZD*3=X$(Z4R]T*\2<]:-N=6/,S<+D5//$G)),!YG:V?CIAT5#P9?I_M)/
M)NI\G]G2:]^AK6GL-D/!8A(YSXK18_N/Z^AS/XL9@:<VR(L7_?O9T<FSEV"(
MP0[#_V51[?3X+_/Q:\:GSRB+5/XZ\^VS8]?R/,[:ZO\T::;>4HJBEYI%YU1-
M`X0'1>4N.-?_FIK%`I,H\"+;@`<>[C"*7[7\I`YA_"NA([S\)E`#CY`V.9U_
MIQ/$<Y-FZ;E%LDDJX165"@;2N/9A&(!-.X*`#^T+.*[@C@OL(OR?+S>%M@X?
M/KPN;#3FOLMG)(X+#V&(K4M=*XZB"^N[$[*$F97(VJE0-E.H7^<G;JI0G=1R
M9T]?D8WI'(.1DKIE1"N=ST?PLDP+%U7B(,!G#LDY=#*$3S<$<A,XMK`'&V5X
MT^Q*]JUNU6RJ;;)N.!(K>WWDTT:;M6QE$VPGYT@>%_6,V.J<H^X^04<A:%M8
M"5JV>:XW?K`V1CGP&%W!]W*<.Y-8**0JML@UQR(+63A5[Z3R_]DTL\U@4[:N
M"LZTT(!/\@XKM3OMH_^CG/V@<.HX=RC$I;.96754/PAB5=F>-G_(-XR@^:35
MVM4'+*EE>B5)]6X4O3_?&<+TS&BI1AJ^&*A..8537&/7)_4"/8?8%1U2*EI5
M;5RQZ07ZS\@AS$F9W65]JJ:8RUA$$,CKI?>9@Z)X(BQU[%JE'2CR/4.I2N:Q
MH"FWNB"KR/*1UC@K3+D0^[+?<7ZJJ+91M7R9?=,>QK/"@/^?B5]J1%+YK#F[
M/X$X6)_9-_MC4\?V3U/=4OI`]6HJCDC;<,T2*GK\6NW,W4@='*0Z^=^8ZU$J
MG84C1LQ,ZQ@CYGB,$UN_V"I"R:0P]XQ9%NV^X=I4*#15OT)E-3.7BVD]W>HZ
M=T"%+#W$CJK-_H+^P5SBC+"33*CKUF;3:$[HM(CO78H6=-G`3;:SKXTW!#@?
M38:H^*-_'@DISBBNNE).?.</\&KTD.">@$OSD>A<CB].BO'%:M.J"`F_A&X0
M?J%-8/B=)Z*LZO4ZQ9A<M,FAR<+UE05B1HS2N:)XG;HM`8VY+:4`.%8.9XQC
M%:;$5?43NE.$J3&@WBGY>KU%,&%917A9CN?!INNDQ]NLW)\#^]6.DYC='_I'
MCIZ\6S_KA%@6.IAR+7VN(7_X1-5G44$:?C64GG:$TC-3]E#:?Y&'J:/T%IX4
MD!/+-&9+@_?\>0K:DU(5L?D#+.J42'IL@D*'7/,C??;`$JJ:"^]PHS.SNK.$
M:;"DRV33CHGIUN#4\G(Y[2C?STX?N:!]N"$X#$?4?E55CV7'5^DBI(7<AT54
M?3KA5_G43=K^>]ZHC!L+WQUGFJDC'=GF5I)&*=#<QHAI_2=NMA6276XNPJ>6
M2_H4E*HA3<\P]2":H'TC+',A0RI5U3P%R+3[(4.LZ([R3195"BRM?S'G>FPL
M%M2;C2WLU=F^O,`7EIL/T*4GO8EU.P0#'0S<TKX9_@?6<5QQ85'Q"9U#454E
MPC2/2=>FTW^/=;$V/;)/VXM1L(H4GHQCW<E/D:*J$[9'F^_RF[23-!_32US/
M.<)"6;T_CH67N4N6TCW=[%:TU:%O,1";0L3''KN.7VOP_Y5@?%Y0=5[<K/KC
M=29W\/D;)7;5H97:0,K6N.2T7FYN41>E1>D8[R8]33=C0:`>3UO1DHR:NXC+
M,F=2&8>879T;GK&,T_9RC#'A[4__Z^C(^G^_??SU]/_[?_]CCY-OO_MG5\X_
M%_>#WR?^US?)P\\7X=7%?W?__'HWB;R+>_N?MO>?^/+KZP]?G-__KW=RYO]/
M[_/K-^\G/]_]_5ZX;[\.DH>___KM9W%JC^]/.^?#CQ]_^?/__GSY[>WI^;</
M_WL4GMK]R[N_KWH7[8^_/OSGG_\>A.>_O.[_;K_[G_\;_7`IW_[P6^_5W;?P
MUS<?![\G_\>/?__MW9OVVQ_&_O^<_<^7^T]W__=K<O-_QI]^_2N)`O&_[=.K
MTX]WUV_O+_\[^9]^[Y??7O_2\3[_Q_X_UR=V?/<V>//UO?/E[.=?WKUZUQZ\
M_M]OKGYW9;?GO#F)_OO/J_<W__L_7R=_)Y/^F\G?_TGB_\]Z?7MS=%2.5K*=
M6HY05KSP(O5]U]I;I.EN1K'"%&E$L<'0'0R-":/NY/&D'#Z4=TA<^C@]L3TF
M.4V+0")MG;4-S9^T!JB/7%WW`L;/HU[C.*^`3L_K;.BL+./4*^D(3F!)GPZ?
M4`R1'?BF+$-XGYX*5$^CPY#XCNJS^B!QUR)*[;RZ8LT4&18K0D:8!\DZ(&DW
M(;N#+27MV!/4/[SJ7'X5K:M/Z;<*D9\YN:'V*`99&9^`V!+/)5ANKM*06@25
M#^]C4:AZL3GNKEI)5;#6\+/D&9FF08J068-TU=:\6&5DSN%/S!VP.(=R#6+5
M6B:%4J5B?(LG_1/J](DLS`LI_!+LG#JBI0J>C9NJ$OWD=@7$]L)5=6-=_DS'
M@71173R`B1SUA/T7[G'G)I.[F3>:7:0Z+:3IF2GE7*?=&5$8CHP4Y#9/<U3-
M$53O@8\$!-')B/8/[ET'B9'O):"">-PO,/=XF?-:6>^!K$E!_DD_4!6%M*F5
M-B$XMFZ#4:J4!?Y6@@ERG)*!FF=T[%\=DQI)D39ZU0>S+"JFE/="=7HI=EE0
MTD,]J0MMPDJ'<G/T!N+V/:QJA,?+71[0LX>Y%(4ZLH?223RMK5/]&LIM)>P`
MI^!H34G[6&>@H$N.XR'><GP?N(XYVZ1K=H$=CI0C%8UE8H+I35*L.,I8XM`B
M"FWZ\E-/3^3J)ANFB#MW##=M:Y&_[H:4@IJ0%`[8E=8/:FIR5K.W6<NM4G`V
M690T?6TC3@]_$\KTSI])X=R&+M^KG%#SFAYLS9:G"??(5`&4I1GE`I4,,>4(
MHM<C+#,]MK[Z*2L&JH&)GY[("/PI_A8O&BD>L\6G6N8.7NK6F0Y-O5?=*,U]
MIIW?<YOHL1PA7H>3JJMXJ\:BP_7J@.:,\F5U>A*/K7@3???UM)IC)%\U#0QW
MU'D;F$XN6PG*!FI.=_2I>_>H<A:(@/T2S1D`+*?(SIW:;F@G(ZSP5[>*."KA
MHJ\NK>PU@%A-!@D14.DX$1_QFQH>5C;946"86H42U?)=/*O6F3485CO0&3(4
MD$,O#&^TGR4Y2E0H1U6ZV"IK_HD'J48RVU%>MA]FZ8J7[&8N?:FZ;8&D^7'6
M)4B?6%5YF7PQ5K[YD@`#%\>>OK$'ETM,1C^I9!F"T!W0.:N<B<A9<*$?SV7,
MLX,=N2R[DAX4]I%*>(LXS;PK.]PU/TTW[HL;<ZJ9<BBMW*Z;2(__5,Q<9!9&
MSVC5=WC@#5&V'JQ4/"M;631:Y8M[37..*L@*"S(_LPJ(#<.T80#G#F"*5$+U
M=8J2$2JW#L**EYPN8MWQH-1DK($GNU]UL8&H;W*F\446%T5JR6N/X&?%:X\B
M=7E7KG-5>D'1U`U,^@2;_D/=U=3*P2!2-+L-"@]?@"OIB;!E]9)8E=X1Q-C8
MN#:_M4;Q<GISEE0&H3@:I:S-T]1N08U='F?.!51FO;D[<O5-4QC(FDH?6)_$
MDT/:S:12V;3/A$(>"#<1R'.T1THLW955Q2LV!-1C/'[E#[1<M[5>X#?16-C3
MWSRX3CS4GW7:[7_ICZ<22$878M(%S)F'\W)#4Q_,>#Y?OUHL^H[#<D_1]!MG
MAIXC)[+/>T$<!Z.*]7RY?O/F_:>?CUY]OKO[_!%F.:XNHUT9+QZC42YAE^W#
M5`-IKMHX=LIDVA4Y-M`>X?ARH1+GXERVQYP9;)HFC=%/:UD60N@&"FK6W;G4
MQ/"#AU",]:?JCZ68^^KSS9NW-REO>W@3-W+8(I>OP.?M<+IS,8/56+THP[DS
MV@B_YR:S9_A5U<4V:Y&#)ZGR,MQN#,JIC\,*:K*98#-QT&:BNP,KL14CL82-
MV+6)N#;WFL]5S4?8SH2,7V!'TJ?0D"TK&P8V#&P8ZH)GU[8=)E-F@8W"DM5$
M:O>"(RZV"VP7V"[L`:3]'`;1]"T2;!B6O$P\W6!G4CY5(+&&X$E49!/+)I9-
M+)O8VB`:FU@VL74BY0<JSML8`K%]9?O*]I7MZ[;@[*TI0N0]KZ<1\IUP<XW#
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M28FV`7KJX^TTAN%RG%F<?ITV^RXU(6<;=]CJN15^U;2LD"W^FBW^9:MS<L46
MGR&%^<7\VCZ%V`3LW`1T3D_GLJ'&$LJ(TBQ$87XUBU]L`0["`G0O>,N+\83Y
MQ?S:`848_W>._\\[Y:(\M@`U0Q0N>F!)8-O"MJ5QMJ5[V>I>E>.+AH@H0\K6
M2@KJU0YD;J^J[OA;<1H'7Z@@0WTEJ;I1T)'C('+K=>5$E=8OQV6&A\9X'`MT
M5SJN[*]TJ%[*R@0[9,^FTVF==^M>++E&56"X:P+<L1W;4\:R'6,[MAD[5JM;
M5]F(,=:Q$=M7QK(18R.V$0Z><QS&2%<G'K,)VU/&L@EC$[:A*IRISB/[K`F'
M@G9<N<,&D@TD&T@VD.O8<#LIGU7;8U5@N*M#1Y.56I<T'=FXDJZVHKRD8':*
M<MD\L5REWK:!RUQ$^T:NXWAR>>W;A[4S\C#R,/(P\C#R,/(P\C#R,/(P\C#R
M,/(P\FQB[8P\C#R,/(P\:UG[8\GW!IW]/>6SOT7)N`MBX<$@]S**1]*/H[*`
MU'I_[E'VLH7;HQJ$[O'%V3BVG"#I&70]>#[7_DZ6)['UD*LESMNM]GGSR^)9
M:?<.G-GJ[BEC68'9ZNZ:K[MN=];NS`V166>;JK,-QV8VNGO*6%9@-KJ[YNN.
MC>Y).<QEC=T+C6TX,K/)W5/&L@*SR=TU7W=]6'WZSB#6V;W0V:</GHVUUP?6
MV9RS.3\L/K,YWU=S?MYN=2]XLW@?E9:/US>G\)/+KG<NREQVS6772VK?/JR=
MD8>1AY&'D8>1AY&'D8>1AY&'D8>1AY&'D6<3:V?D8>1AY&'D6<O:-Y%\G[4!
M5%,2I`NR`R\:"[.B;ELSV0\>0C'6GZH_'H/E@Y&!I>W5O)J(SC@^``!9(SG8
MHJ_?HA=!H'.Y.@@LT,R]LDG_=CC=N9C!:EOZL0SGSF@C_-8?_/96S:\7>#FR
MO)&V'/5@6JD`G'1:5K?=.=V8(#Q)EY=A=V-@CNT$VPFV$]7.X@[,Q%:LQ!)&
M8M<VXGH4A+'[CW3FJN8C;&="QB]>!U'\%!JR967#P(:!#4-=\.S:ML-DRBRP
M45B*B.]Q2G+:,+!=8+O`=F$!%K)=J!ND_1P&T53+638,2U+QJQ]*F&-5W,6D
M7%(@A>L_32#9Q+*)91/+)K8VB,8FEDULG4CY`>111AM#(+:O;%_9OK)]W1:<
MO8W@<1'SGM=3"?E.N+GBDE^%ETC>`JM3<4EARCN_YVG6%L)!7=_TN0>3$;$;
M^)$5]*VOQ[?'UL_!O0Q]O,S)$KYCN7%DB8'T;;?L=.U6G?C81//;<!TVOVK?
M3FLEB-RGMEC==NND76YTR4I4)R5BT&-^,;_82!VPD>JR6UYG#6+$8WXQO]A"
M':Z%4GITV>UTRWE%UJ0Z:1(C'_.+^<66ZG`MU?/N2:WV#%F'RASZ_NFC5P)H
MGNN,H?7E/]N\9O&+;5[=;5[WI'72KOO=+X>M1#6_PX4+<M;&Z==!.`Y"$4O+
MD3UXA;23T(VG2F]8/0]-/;?"KYH6%K+%7[/%OVAUSLJ[A@T148:49D$*\ZM9
M_&(3<!`FH'/6X40G(PKSB_FU"PJQ!=BY!3AC_Y_1A/G%_-H^A1C]=X[^ST_+
MQYK8`M0,4=98Y_!]L;QA7[#J4"1A7_C%MN4@;$OWHM4]+Z>7&B*B#"E;*RBH
M5SN0N;VJNN-OQ6D<?)F"#&.W[]HBEM0XQ)'C('+K=>5$E=8OQV6&A\9X'`MT
M5SJN[*]TJ%[*R@0[9,^FTVE=GES6W+-9HRHPW#4![MB.[2ECV8ZQ'=L(!^M>
M[7^@6L#F@,T!*P*;@ZG9;(6#3>C/P;'-@6$>&[,]92P;,S9FFZEL.:]_"P\V
M8]SV@\TBFT4VBVP6M\3!3J=U<5GWHARVBW6$N\<*>>;4YJS4`J3IR,8U:;45
MY24%LU.4R^:)Y2J5JPU<YB+:-W(=QY/+:]\^K)V1AY&'D8>1AY&'D8>1AY&'
MD8>1AY&'D8>19Q-K9^1AY&'D8>19R]H?2[XWZ!3M*9^B+4K&71`+#P:YEU$\
MDGX<E06DUOMSC[*7+=P>U2!TCR_.QK'E!$G/H.O!\[GV=YL\B:V'7"UQ=M7J
M7I4[9+'2[H/2-AR<V>KN*6-9@=GJ[IJONZY1O+B:&R*SSC959QN.S6QT]Y2Q
MK,!L='?-UUV'NASE[J&^-AR7V>#N*6-9@=G@[IJONSZ@WCF9/J'.6KL76OOT
MP;.QFGYI`QMT-N@,#6S0]]Z@GUVU3DZ;WQ6:E;9>Q^O5YP*9H3V+7OB#^>=<
M^G<O5F)`)?G_3*+8[4\JM6L%TM\1Z3\!Z6\>*XX;2JL?>%[PX/H#B^A@1<EH
M)$+W'Q@BAJ\C>RB=Q)..-1)Q$KKQ!)X(Z:O7P6@L_$G:V?#B190OM+-$;'T4
MH3W,V'K2:5G==N?,$KYCO9&V'/5D./7UZ?$LUSW/^A*SU.1MZ7ECX3BP'$VJ
MMJ8W?A.-A3W]34&3VY55EDM)]JP/'G5&IPM/J[!!`]:"=J?Y71\.L;I\L?KJ
M/5YF=[_$]D#XR=IY&,MD[:SW,F=YNPNX%4O'0?,24)WQO(BQQ@3<%3DXXEM_
M.LX.T.\WZ^XNQ<'J]G@[:WO8F<%,&\(MB*/F8/)&&*H_^.VMFETO\'(DP3!O
MKNIM.V&S(E\9M!BT&+0.![1.&;3JY*K6XNAU*8NVI-:L?J(:]PH>A\&MHN!'
M2@+[`QC'"GQI3:0(K2"T/!E-G:RNW?[,#)1F`U;33?##YE=M-[/+^9\#WI;N
M7+4ZYT]_0S9@N\!T5L_ZJB?#*?.+^<7F[Z#-WV6K>]+=#J-8C6H+>]O<;^*X
M?'Y<+OJQ#+/0/!Z&03(86O%#0!^4@W16UD-3UJWPJZ;91O8`ULV/[E7K_.R<
M085!A?G%_-H^A=@(U,$(G+5.S\IMI1HBI`PJ6PL#Z[67.[?J9>JN9PXNL^!R
M5BQ92:4:G<CC"[UKX7)LZ;KB!A7!K-LC62O-#L:+Z71:IP>[E[NRR#!F-B9,
M8V-8/\:R,61C6$MC>-8Z/VO^Y0QLM.J7!I@3V1],4P/.:#5"E%<TTS,SPG47
MR]4RWPU<Z"+ZMV>7'#+V,/;462P9>_87>_9H9VB'%ZS6<&>(;U=E`U=#QG+O
MS;TY9+$Z7P\X>W?>;G4OZEZ5R1I[@,C,)G=/&<L*S";WD$TN-ZC?6XVM3X/Z
MGWY(HJ.!$.,?WZ<A]Y?`<^W)G?P6OT(:OU3/_M2SPV\_?M0MV[_(T`V<S_U?
M0$?^3P*$C2<?1?B7I(%OI8T_<H$:-BP(!KJ1_7\_LSM7?[P#TG3^(WQLYG<7
MG'3@(?SG'Q_%-W>4C#Y2__9G+[^<_/[3#ZN\\&6Z5C7?ZWL9BH'<UK0[EQ_U
MO%=[<7GZY<=OAT$8W\EPE'&K.-=N>_9<7;](XH\S2%SQDI=/F=,R].LN-:G<
MK#X$_J#XM1E!KWME.F5S>O0=+PWSC%+=2%NZ]\CCJ*15Q>G,I-"SEVN`Q<KD
MWP*H6(F!"M3N?O\`J.;&\+"=>_M*MT?,;:"7HZ#5!QI9KP//$[T@%+$;^#.R
M@WF\Q'_OX@J.&4G4%>S*XK=O3!'++A#+$J&T0FD'H2,=NG1#C(($+]9P$FG%
M0?X.#OB=)V+X&7P<2G?42\*(+L0(923Q#@ZZ<<.1]](+QEKGHUB_%L?Y>GQ[
M;+V18Q$J2`CZUB]2>+%Z\)<$5F+=RO#>M6&R,)4PF,"W^-[2&FZ',/=@X):,
M)OX')GML?8B=8^MN"-,J/(MKE>#,)&85CHQ!=X&\EMNWU`HC>+_$EPN\L43X
MMK2B89!XCM6#AR,$9S<:PN,BMJ2`-8=R##"$!Q<<&/;8NM87DE@+WD/2*I!X
M*!SZ.[LP);>`Z2M+'I7M/;NQI%#>,^T0;;HO[>Y\PL<\0>/L57G0NZ'*[OSV
MZ?GLW'>O)E'FOR_/T6+SWDY[*8XNW.5U.XR]6K1[[U;X.M?WF''7U!0PKYW?
M3]+@)_&[OO!6B&?92+"18"-1Y.B6.KQOB[<+=WG?O9UXY7J>=#;-7S8*#&<,
M9PQG&X>SKWZO$M`8TAC2&-(8TAH(:515/'<KG<%L!T'[\E7ZZZ%\/MU]=C;W
M_$<-ZN^WCHW+;-W43:D6/L'$%F\+%H_9M[$JO\TRZ^G=*W?-L.GJO1UIW&6W
MTYU_QFW=S&--8Z!D]C'[&LD^MG.-LW.GK?9EN;,3JUA]58P1DMG'[&,#QP:.
M#=Q>JM@6$?*1#/>FD];+=.#EQ/8B1PF:D:E9@N^,!<WTEM;69KCNFX3K]EM6
M)=S!NSF=UEF[&6[.FG6#X;!A+&>+M_<L9HO'%F]+G&S0#BT;OL-&139\>\]B
M-GQL^#;.20[U&`ZWEP5?4YWW*@7=>X"/O!G4%#584E([BVRT-D!85]E7;NA2
M%]'+Q:[::"RW&9H8FAHCK`Q-#$T,30Q--116AJ8#@*9'`N/9L>X6RL-.N3RL
MZNZQ7`_6J3VA!J3(YG.9K=J^[A`L=H/&P7&\,=7VJW-XU[XJ;V>P(F^>Q?L!
MW6R=]Y[%K-1LG=DZ-_/X'"OR04,W6^>]9S$K-5MGMLZ%>T9;9U>GK,C[K,CU
MJ02<O>$Q4Q3F84]]-W[2=97N;GJTZ_/LS9CZ+G8&T]7'YJI9_&O?+JLK+3:[
M;G=*\C?<SWV:55N7EDJ96./UTT\C!]\LO;:;I6=!VX:NI=L2.Q>^EVYJ/AMA
MZ=QV]K,O&-T8KY^DKD_C=4V1K&#T+#8%;`K8%.@E;.QJDVTP<^%K3:;FLWU#
M4'7S'(,^8Q9CU@(L9,S:%$/G8M:LZ^48MQBW&+<68"'CUJ88.A>WJNZ0JR03
MP];68NSE&PM4O'?--\@MJ3>;/D6Q51Q\PLUQ.U:EF2>.V*9MPZ8QO]9>K;$A
M[CS]0H%=<FBZWF('.E75;Y!UJ4ZZQ-C'_&)^L:TZ9%O5;5U<7+(2U5>)&/28
M7\PO-E)LI%B):JM$VP"]Q[+$&T_\SMTD*]W"MKR^[E6&>(4KV.JFT,MQFS6_
M,>[.`OMIU:W&&[.?MFX'9&6*';33TFFU+SH'HPH,=TW@,=NQ/64LVS&V8P>_
MF\GF[,!0C\W9GC*6S1F;,P[+V([5">X>RS^OJTIYI7+DIL,@[[O45NZ7%,RY
M%SDT02Q7VYUMX$(7T;_%[NO8S[4S]C#V,/8P]C#V,/8P]C#V-!A['HM=YX2C
M6ZB=.N7:J=S;'KV?K-;IJD=YRS9KCU+RLQMN'RZ?ZU]0OCI?>=^`]77?]+7A
MN,P&=T\9RPK,!O>0#6X##GVQOAX@+K/!W5/&L@*SP3UD@WO2NCR]8GW=/WW=
M976<^GS&[5!SZ=^]6(D!"][-5IC@DI2_(\I_`LK?/$+YCS#PT)O`,/<!=L.T
M1"BM*.F-W#B6CA4'5CR4UC+]-*U0>D(_&TIWU$O"B.[8"F4D16BK9QQY+[U@
M3*/9011'Q]8=O.AU,!H+'Z8#$_&BP(*OW=A3@XWT5,V@TDS%]1TWE+8>R.J)
M"!X(?"N$:41`-7><J!FY/JTF\1T9>A/7'\`3?AP*.RZ\/3U/<O$BLFSAV?BX
M&_@1O0S>4'BA?HVFVY_X,4Q6)(X;6[U)1KZ?@WL9^CCGXRK1SHOT,D+X.`A4
M[BLMLZE4*8!*HNY^_P`BY<8PBIV;QDI".;?K\4VVVV3U`4ZL+V'@)$#K6S&]
M`?4TBFY0K8MHM#&EWNC@4YP8:TY$R`G2`]"-('1`X?I!:(E1D/B@-$XB#9P8
M+<\AA7H8].OF^LO[7Z]?+;$$-<F+]K]>6+^^O;E[__KZP]'UA_<_?P(+)+_%
M1W$PSF9_][$@*Z3WD<QO9M(*)%C]Q,S-D;$,1_!"R^U;:MX1@)VT<'6>%SP(
MWP;E'P:)YU@]>#A"<^)&0WA<Q)84@'FA'`=AC)#CP+!%!)C^0TOM3S\DT=%`
MB/&/.:)_"4#7)G>PLE<HF2]36_&3^?%[_QY0)@@GI9\2VL$?-[+_[V?VU1_O
M@'N=_PB_V^Z<W04GG8\BQ'\^>[E#T*D#UJ3TFU'(L"RP:&'$A;ZPU@DUCZ/T
MNI3^.K8^DNW6%[R=D1$W][^93T];>?4NF%'7T!2%,'(C5*U,VZV^ZRM]&02!
MD_\UON8A"/]"VPU``_X%>`HI@]!/`&6+E:+ANT$;83XP,IKF5J:ZCK+Z])N^
M&T;QD>NW]+^")+:>F]EVVR_>O7_W.?VS\^)[:R3C8>"T4-]'(OQ+%MT%2WX;
M2S\"2BK_(X=J^#8-C^`_*%]%3=U%H(EF^T3IF-IG&<O0#="#L9,PI-7$K@<.
M!SR*;C:H!=*B)ST7!H%W#X$>_21.$,N`XL'(M>%;7_;5#W%X6T^RIP![X+O_
M2%CDP]"%00?PVQ#`C4@,*W(%3"H9HU>%4#0FQRN4`W2-B$]C6">`YK'U5?UH
MZIN";$#LY'G@6XU)G?\AURF2?R>I.[@P%<M=>@Y92]\D(5H8I8D@.,!X7RJB
M/;C@K",AW[VY3EF2T\`B=WIR`!Y]RA[E*2-71!0%MDN,24<LLL9H]"98E&?(
MC&!IPQ2>%27,@#="FP!=!"2AT"`Z=5UF$4VG;]/\<69%W1P*[L?%QALM!)R7
M-.?K+/F*I9UO(?`52YMBZ-P``"%YKNIM.].\(E\9M!BT&+0.![1.&;3J=&9E
M7?T6GK0Q>='^UVS8>51K]NK<RF_%/%*]-Y)WOM=_.`:+^74`!3<U<`&Y32+K
M$F,?\XOYQ;:*;=7\HQ7G%[6*95F+ZE2RN8F]H,J8>;E>O@<=7+\S%1P_8P7'
MK!W?^F@OMVFNC9JGC-U2$]H&I1BW?^R$.S)7=5;H=MKU=NFY(W.MD8U-UIXR
MEDT6FZPZFJS3SGGM`VBV676$MFWM:J^T?=UT'.1D4VWE?D63/C-76W>QY&ZZ
M^]M-E[&'L:?.8LG8L[_84^]-&^[DG>?T)QGG#^HU./W%/<YV8J^X9]+.^%S_
M,A;N<7:H>TVLKWN'RVQP]Y2QK,!L<`_9X)Y?GNS!3ADK;+UVR]3GIJMHULAM
M5F^VE_1DKH5;+/R!"X]?1Y&,(ZRNC.4']UXZZD'NY;;8J>@O(I;8?1`;['QP
M;>JI-4/=\^S'?]>H7^0*:K)23R,KDO*OR!H3T?"<;*S;1\'_"\^#-\4R]*DM
MF&Y6)AUSG%8J(NMN4-&Q=0T/Z)%,,R_=1`J;DJG^9M3?2_<:H\>%,\)"XC@4
M,0A[U@;M82C]K/L9=4ZSL:&JZ+F>&T^PV1(U0Z,''!<;GT78NBSQ;1G&PO4K
M6BY.=5E\5.MRS19[=OCMQVO;#A/IO-6SY'Z+*^FHIJ)ER,CZ.5,_L[9\U($"
M&X^!`IDNQ@DJT2"4U!DY,AW:W-`YPL[-$PM,CQ.$J$P!ZNF]Z\SNRMRR8%9)
M'T?%IG(M^CZ(AS*T(M/I6?<F#$+']07U/L.VS*B+O22")6.OQMM@)'4K-/C*
MS'2J7_+(]604![X\4NV;53]JZIH&[TW?B$_90`M/4H<U``#X'I0>4`;[S>HN
MB?@Z(&^Q2Z-J2AM9GJLP`SLPICTA<U-#(L(K1FZLJ4C($V>M)!'GK*`'4D%=
MH:VAP,:+.7AJ8?M#$3JPHLAT@8/YX&+T7[K;-DX0,$H#*'WJW5,'[7M74LLX
M`%@_3S0$V`2X)2(B.TA`BR:;^*XMJ+TL,5V,QZ"TU`#.+!]($V$[0`^I#8SW
M8[<_R0A+#2.'`B"7E@*_[@?A2/71QI;7/3D47I\F`'QR1^IEU'$398;P5XV5
M>Q9_C3_)=0VDCMDICF-_8/R!>91HG6]$B+3U@]B:R-C0F"CG8"].DL8'%T@!
M/W'[KNJYE[(PTFTZ1^+/(#0VPLQ127\8F0$+;S6=QD&^!<Q3P,]PIBFQ,C<O
M76M1UD;B+_B9)I3J:RPTR*463=#'U!RX)SS=0EC".K%!,+X:R=X'Q?*!=)YJ
M<ZHD,FUP3NT%4\&PW=!.1O`[&*K43EWI!4@$(@>(4]\-1Y%BC0VL$/;$M#;/
MYISV=YRF&;Y-+5$X?R:15A2W#UXY"C)`P3&`N4`U58O4@SK35`!1\!)'SNIP
M.`?S]Z*_X9HW1V=N)9\U<BMYJ;6G;;X+"Z_1D=H:Q,*7W>[YCIL_5+.I\14M
MJR_]\O+1*I<#D=&^E!A[NA04OH:AT&!9-\9!_1P.A._^HZ_BR#?L?GWS.2HT
M[*[H?3P&_\\,27Y)\,W%DN4!.$%QXK@Z?$U_$X=@=:/Y0K')E-$>6CLV=AN&
M$C9V;.SJ+:%L["J-'=;@08PT4$G/R(U5<J5LP]@XL7%JK.JS<6+C5&\)9>-4
M:9Q,^CFW(:`2IY7WRQ1O@PF2T`K%@X79/[)9+<L)DP%=]T.)2K7M@!^9C<.<
M',!W;.+8Q#4&0-C$L8FKMX2RB3.O`W/3EU$$=@KB*;1WT[>4[<C4[/V=T_F=
M2=S+C-3.H]D2S-W\5PIXS69T86,UMT49Z7M<]=:S[/>#T(Q,Y0%)&"5XD6'.
MJ]$;G:/$B]UQ_I9JUX>WQ(G*-N-PF&56^^3P+-UXJ_9!?3&053.==16FVDI7
M&[39_BX6%T19H42NC*-4*>'+01"[E`5O@<J'$W4+;^JEY3TV-4&ZL!;6ARY;
MXLM[W-\7$[IFLN\%#]&Q]47]:0HBHADU&XY$0N+:T`W$2A*JN1)J*QG^C;N_
M_<2SI!\&GF?NYQ[#9-,B//REKN#0/F*1=%DE"%WTJ7:,L=;`;$.CKA9O*\S$
M05=:I-=E4H&(NM`R%1&Z>;)75::05C(HP<GD!NA&^_1J5)A67^^=4Z5!L;1#
M#TN^;59P$%FZTJ'\#F"@:RY2QN_-6BINRU1[[6;7/J1B']NFXIN!-SFVKDE\
M%K^FU19A2)>@XUW'--D\`DS7*^"ED=\R0KLA2`'\EWHZN]T9/HJ&L+0CE&A8
M?QQ[<OK6\V(!W@+%="^M<H4L2)&\$]^XZ&[%2XZ1?A80L'G7IV_<.ID:L8F^
M^I<J2559VDQ81UW$6WE!H;!8R%7TC9&^Q]9776@&XYC+A!W9EU0$!3_!"BFI
M`3)?GX;0G[O"."W\<=P^/"RQT`>@+'[`RJC,E&1WC1.RP?#*RF(5THSW8.4M
MO&LD1930]<*1*>^2OE`7!<,P(>D^/2P>M"TTQ;RYVX01+F%^8'_2>J[\A,M/
MA`")851U)WI%@6ZUTAMP,#B2C!+R(3YCA1@R*Y0PDP@\`S7"AR#B8MV5BW4-
M=2TBKU6@K_4<:?N]I>C,P!)74TX5TMI%RGE$.0T<;J2^=B-5UICXH11X5;9C
M#82K75)\0BJWF':0M,-X+UP/@XLC`**C2'@JRP8C.FYDPS.J@EZ`<1X+U&EZ
M$WA<RET#Y\O^:PA,!ZW,(9PE_TX`$<'/&"'.D:_M`9ZHPDMR8,12*T0<4$6Y
M:CYTN``6D:LTUK],G6F?6@'2^+=9/23,N2B#*(+'EKX-FWS"(7C3JJP3P@'R
MZ8I^$I;L%J@+8WYW:3U(-<=LG7A7O*KF7'REQ]:G(#>*K2M85ADJG9&BFO/X
M$J=ODU[$$5L!0$LGF&Y*ZT4\76#@UU@8[,=?R--^)4&`$>Y!^EV%S$GD/%L4
MJL%TVN"O>M&_GQV=/'MYV6ZW,U.RUOGESH5L??V==IX`IQD!3O,$:#][N<'%
MEU8.$68BX1W!`*8-P[.I7<G4:D):.4J6<U2';5'+QSN`2/^HXQ-(M\@D1CPP
MAH$^4);9EED'7[#D7_@#DWS)CK19:$GU>9#46@2A_C?M#U'6280^G@<PW'.C
MQW^M!L43=CJ+T(=)!W0"Q`Y=VCK3_GG\H_7<_3X#=3S6D0@R%!*K\W7:0?CY
M98"[[49Q]`(>S3_K2`^>"]4IB\#69S+R!QVR`R$AFA3XFL;(#Z+2;YXGPT(T
M!(Z+;3("5B^9H#''XPS?U!M,4(-T>$&$>.[>YT9%ID&`8*(P1<,HP-]/,(C!
M(&56PG95;=@<F,S7AO6C2O;FUU/"KWSVF[SPO\D)_W59^&^"B?#BJ>9@APX]
M1KL)8CQUL%BG)D.BV,3D6.$3_&V<^QOI.A-^:._=^,:$:/J\JWIA&E(C<@!`
MY(Z/1>G1N#2E63Q'9?634'N8F*B@M&HA7YD>:DOSE?D!LH-W4XG.W(/IF;I"
M2CM+:!];[V0^4Z]^KTA(.8LL\YTF&');`OT$ZP\*;U=9$IU-4;1-*9<>$4R/
M(.G4<#ZM,M%9?*)_X715]1)2\IJ:!2,!#J6LB3O$<I&*1O8LTIY"C'3+0>,P
M8F$YLXW)574::RB)<Y1,R?U>[0Z8."Z@X*%'JT*7T9P\TXDI,DIN1&S2B1<4
M*7@*=\/<.)=)I_A0;QM@CGZ(J)">^,RH:<;05"W)+0P;8:('INM-IO#ZL!$D
M,W8J.:C/J9NJF2G!*8F&UI]H"FZT`"=CW%W)!I*%6-Z7QIU!YJ*2R/S1_5F.
ME7Y5ZF"9L[&V0`\!,XI>MAVC-X=TMH`.5ZQBU0];2FZD.^KAJ6K%VQ0U,<7L
MN"$F68,D/@KZ1V-8F8PKMU%GVIJL'T,^$6-TVETA[8(Y8H53Z((J$#'U8)@7
MUK,[MMX6;.(<@T>"K#:]ABY\9G85$5A43H:PELZ?/N^4/%,%PVYD"L[(#8)Y
M^(*L2'I`N3AT]N2#/G\\+:>6B/51;EN.S5;FM)5XWBW-*#7O?N`?A;(/YB\-
M!O`C&\9VJ33@V+HF$U"@4RH`X&"CB0Y`C6,WZD]T'@CW:_,10YZOJ8W4I,VV
M):IW-$I;Y/BS5VXPDG20V+IV[M'Z.G-\R20>JI/7^+R6IJ_84D/+400_Q\X$
MANZ_0&P4JW%^24`OK%L3B#S/'>]Z=7WSYOJ'7WZY+1SY,JS\1&X(S.^]WK^G
M>.@:`Y3!A'[UWN]3T6("KW=AZI$LGB;[]/[Z_9OR^*U,*Z(I054J2FS,-E"U
M=E+FU==_9/IFCL#O2Q"S-JNX^.!+%%CA'__KZ.CMNR^>L*7*;1\=/27/D[WR
MB\X.W*(YG4ZM\N['(KD:U5_!."0WUU_>_WK]2L<Z;JSA,<5P:F.`V1)4^-"-
M_HJTV_\@L,,'>E`/O@RCH3M6*0R`,3\RVZTJ)V$G40Q8%K9T?4C6684R(6D%
M#W5C0',#@ZGX#",^=*S(`)$_Y&##(K>78$E,RTIB<&_^,7GY6^EY1W?#,$@&
MPW2U89;1T_O!=!+UV/I22#65C*()_4("H:K,CPJ8JG(_+4U'C./&N`OLM'0$
M0WTWA,G-*`\A2\ZT%G?<YD\>/<YB*PC,<%&OBA;M2Y&;V-(/AQ+LLX_-388B
M'$B\9LCPN(>&(XVS"N:DZ"%C5BI*90DMY0R&83L<M$[PQA8]A3\>#R>1"S]'
MN]YW:99#"&80#M1,^M)!@6FISAR:3".0*-J#'RI39B,5@OS!Y>,Y-:`'#A$;
M'9S@&41;.Z/DW40@!FK'$]Q!;,IGQ(NDA=CZD;P=%[1%_2O,IY`'&#CYRM<#
M_+!-*862X52HK>>JRPE!0B@<F?N*],U((\)!OLSM>XK$(IF?]K2SGGY%R!3F
M$U-&^+7O%8FL-$X7[9DH0>>VT<\K5%?J=(O"--7O",1>A2#XAB','7P\=`C1
MMP]=PB%5JF:"CSYBA_67#Z!<3B28.D("+A?T%N$#PT8,6<+[<E7NUIVE==32
M-EEK\E9;R0`*MHB%XCXVWL)^@%8$!M%6>C.4WMC*Y9*L00AQX5$<'&5)AWS;
M("6($RV)QCSG+22(8=Y-,$(-0:F#?8;2EH1J$HZ:GVXL!+`-BH46"\,XSQVY
M2BQ;\`-*(*HW]##U8F2ZVDXHY0"Y'.M"7%7K:*[/F*C2SK3(%<L@T?3'VO1C
M6:YV.3`##,.AH:&RAVP>N@PTZ]@6)=C)"X];`1%&(L0(/XWF:9V:7F.PDR/P
M;8%)J(L0<<#+PLDCZE,L2*^7R=E!,;K.E$:F+UDD#91G(.OZNNJ64L^JVYJ.
M<]4FRR!QU7>!7^GOD1='Q@?]!Y48B:R!BV79/9B#[M*'C!6IR+#7L!`#:9<"
M4&0`[/@G]68C&W08_AH%8,GZ"4)%<8\U@A50+80?3S&\9;9E59B@>_3E,^7P
MCC\39Z!SM.IG>3_4\#K2Y9&8GU%M:+**T70XLSGT=^)2!U-"FB22TS!1QMXY
M(L(IA:>%^#?:*Z13(%E`LA"V'JI:WC[N4Q>=YLR_AO^DFW"9:Y[YS#"0]@$*
MZ4HTM[2CB2%M3ANN([-%$8N_,)],IVA@;:9:#L!600.5;6=JIM0US;AB#V1U
MXB.)\,A/+E$!1B%;5$5X`,^,PV`0BE$I1AV!VZ%V`XW#2[,PFR9C,:&L8KY/
MJ1E(.4P44P293X3HQ5LHQ1J(7`K!]H0[4EN^,[R\@O3E2]=C.M=EJNU-39"P
M`:DC9=E)\/2Y^9ZR,;->0K6[#\40,CVUA>.0(.N!)!#0I>/GQH%,M^R48.A4
M!-BUOT$\U::($1,6ABEO06F7V:_1BD=Z%^:`/I]Y<G--5]-M>Z)UG%76_(U'
M"\T'.K!M6;G0'UZ6"Y=U9=F?ZAQ$/L!6@40K_V-S7B^+L5OY4#I#23J8H?8<
MP#T8AS+691FYB"/?Z9@*'%JI.!O1>]X#"(.0":#0*P*KSG"D+P2JF1.):E<*
M?O)]87(P"?3`QCIY,**%BQB]%S58?NV:*57;46:.)J(:)STPVZ"1OL3:A;$G
M?.T^I0?MHB)(FTC--9J=R[O@A'WI%?>^2;O1#RNLH9`,26/AM89MA5DD8X>D
MLGCTE<[L1%$R&BL&YTXHID4PF`W'$=*^O(7(&QM/Q9GE.;9NT\-ZD0JZJ[4A
MGHQU*V%*E9O=O;Q))8J,`U=OU0K<S;Q32Z9FW;$QI>8=N7"O_#H%P-D1R2K9
MR/O/CN/J+<#4IN(96#+EQ$Y=AYG[SI?IX25]&LEI6=(E*YZZ_@]!XCDF266K
M4FA#<".;9F=U_H4C3?/$-UFA^*:0"E59VO>`;[15ST6'<VBEF_$3Q=R48@C!
M@#BN-\EGN--K9ZR/6:7;=5JID-_^?O_QNK"QCM5ZQ]87734X^YJ!:L6<M>>2
M=X)U8W'JJP]OQ]1W9FX%JA@N3KO<*K5FFN#G`5Z!IAE`GU6DZK@8C7L\I*;J
M/DB(ZZ@.\;J\H8BV^!F@CJ*K@NE(%MVW,M2JL](1E?N9/;*\=XZ+37QRY^AD
M9FKG=,THY7W`8I@BC@*EPS1XPKQXH19]=LC?3)RI3\1OMC)OU#XD;^LODGUS
M`FFJI=#U0-5-S2*2,=ORI;QWG#T0D(6GZBFM/K1Q1`\-@@#W].DIJP=VO8_7
MEJ3;\>GM&Z"$<ARKV$Y4XP[KRZ;TY=H!KREVL8![;E:,E24M[?8'0@=(=`;'
M;$T5@A*U.XRE8T>X\11007!&:K67`$HV"LC4&$/("#6G\(@VSHOY_^S`F#[U
ML/!A6M5@!0];EF\P>93H^]!1<-TM!0L78<Z[?;A]?);GL55^Y_[T<5LS20ZD
MN]M6[V2V`U14L^[N4ERLO,RU<]P9QQ85W>^`H9T9#+7IRKGBA+;`U+E'I!&"
MYZK@%II,KH.WC%V,78Q=!X==IXQ=6\0N]?%T-U;CO!:FC'L/@S!(?.<(KXD*
M?[3^Z_7KMV_?O7LQ6XI6)7S>H;]H_VLV\CRJ-$<JT;!\+H*NCU\\8ML*MPOG
M"5IX@F"3ZK(8>PZB=_1BJS]8`_U=9:B_%B',KS%T!\,EV5.C!O2YV5?.9L,\
M.CNY8+!X,E@<R#(9$QD3#P`3TXWY[@:OY=AOR'@LA."H8.,,O"DVH=E89H2-
M0K,R6?L-/&P-U\V/3NNL<\GHP>C!_&H@OQCM&>V70WN(>Q@]#AL]>`.H6:'>
M=/?J1UJWFT*^<C'>;O=56=G95:A-KK[[Z`6P>[+0IO.3889AIH9BR3"S%_S<
MWXV,D_.&>+=?CV^/%VV`/<5B=F@/U])LDE\UA2M.B*V;'Z>MTXNS1HHH0PKS
MB_G%)H!-P)/W1$Y.>4_DP"&E67LBRYTB/.3H\G;H!GXP<*WG_Q%CX7]?@MRZ
M*?I2C&5`:(R/L?*!T8/U2YYPQ/:`?9GNU7GM]WS7J`N,=TW`.[9C^\E7MF-L
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MCC?"XE<__9!$1P,AQC_>J&C[1MK!P'?Q3N`O@>?:DSOY+7Z%M'Z9#O-3]HRJ
M'[OVG3=9]=C;;V/I1U(]3A?,PQ`WLO_O9_;5'^^`-IW_"!^O4[P+3CH?18C_
M?/9R#>Q?]>KK2EXKYLV]E+K$_\<N"M8?5%_1=I,OQ<L1T]+4G%6*EQ<-_/=C
M=RU??WC_\Z<?+23`"VN=MR\7Q'8%[5GIFN7TGHF+%]'L:D8[B.+($J&T[*$(
M!W@I<V!)15=UL;7KVTD82N?8NIDUB/X]7J-M>XDC\8IY?6,V_=;U]1_3;PZE
M)V+U5KSR.?^#H$\?52UG'(1Q'W0HP!^9Z^UM>)7KP&C1L77MW-,-]V,QP;'4
MG=+Z#OO0BG0_'QA?Q(#=,-N>M)((YA%@Y:?O2%@P/=-/X@2(,Y-^PH[=>X`$
MJ8CHR+Y$8M'O;#$F[?@'B7>;X-.C(/$UO4.%)O_@CZ,BR7'9AC!JTFILS[VG
MB>G[L<U/TN7@K\8RA'F/EN)7"R?F#W3EJQO+4=3"@:+`]Z6G.-72/\:;NB/A
MB9"6#`/WI"_[+OX`1#/I`T&2$'^DG[)!GEU;>"V8[B"!"0?AI$4/QL$W%RL0
M!I-L!>GLK=[$>GWSF4:-9>@*3[TM2L9CS\6+Z*A4%^@QE`(--JBD0&2.$%4C
M-Z*KV$$Z[F&F00(/.R.82!3G"GUAKJZG>&=(29,^MC["_\R3O^)*B==ZF?3'
M&'AK_HYBH)GF3=[6%%8:#]W0.<(>5&K5Q_#62$NM&6"*-#2DL.TP,8-D5ZPC
M8>@#35E\VD5!BL;2=ONN1*6D'Z`-"F$IBKP2Z(8$UX,[?R81D`5XWP<2_9V`
M%L,?/8&:DHP#?R:!`O]H$.A+W5W`+4U+#X40_\A$%H@(S)ODY+;283]`++]V
M'/(UD#RM`G>'`!A@=`DPQ""44F'<@QL/E2A9*$JD)1'!3F1=>ST9@L5T?6`H
ML!Z;^LJ!1%Y\E(YKPT3QW[_+:.C>"^NKCU`3N2"/SPUCN^T7UV]??_Z8_MUY
M\7W+>N\[(".HH"G>M*P/,<!/_L'W-Q^*CQ$`P))R+X+77WNB)T;"`E1^Y8:@
ML(.A&!4&^GK]JCC0P]"%%6KAM/I2%FQ*!)[U-*%`JT;"!=_+)R.!#QU;.=.9
M`63N^=24B"BUB5;B>S)".R(G&M335YLM&F5DA@)`IR<!W(V)0$#5L[=!H8@:
MZ7NG;$G.6J2Z;5ZFWV1^@S*C]7W&JO*+KUI6604/5P??&![DCHD`=5-*AG*,
MK@&^/>D=E44%C*AP4]^F"B>%+1PY<FU26!\40<$J<%*Z8S)!9,W`'U$O[D.(
MD)HT.QB-9&BCZIG'6[D3+,4GS4R")*QX*QJ:4>"`95!65'F!VHI.:Q#)5903
MT90@#T'B.98?Y"4^U18$J"")\\LC?$IEL#2+2*UW%O$JUD_+1^7I29RYGA89
M.W`3T6W4BZO2'_5,IFE%[>F!^P4_U/H,,(O<L]&?PZ?B4`K50%*,\4T`B+$$
MLP;&U`92Y0BD0!JH&46![>8G4%2[O+;E0]%'P\J7Y5#T%CQ[^0J--JX%?DC$
M_3S&_X9QWOMX+S?`\!=/^!&'ILN$IK<QK.>(:&OEB5N5L5@6/M<$EHM5+FP4
M13?K)D'T%J&$'RF_-`/?+&`9A(+@!?`&&68%)/N6>!"A$VG[BDZ,3>$4_20!
M0ZI_T"K':^YLQ_<UH!96DI->W\;P/QK9^O3S4$)\%V$`\B$`OT'-6/G1+@2;
M`O[K7GB)\4>R#V;-'5#(^.S@C40$1?#@*\PO'MW:PP#\$_,(@)*-/P"(E5[5
M"^81`=^4GZZBJ84+A>`GH#?C"Z3Q]1&=X:<T$(2_I"AJ`#NG*!1QX=C5X3`N
MU,*@#;/-1R@G.`GX><X)`L\/_,=RJ&.F0;,_!C<5HAGE3X//*)5U`EL4Q9@U
MP+FK^`-](CW-/+F5A53>FA\45V#F6EP$V@7/RGFNN1?D/%CRY0.[RN]:P!JL
M@.POE6WHV>&W']\#QB//M?D@FZ(,^CL7O4.@"\6AI6PG&X?%C(,AK\E3ZORE
M=IE2$JM8?STN-]N,A09/.6-TMZ]3:O$07%P`2#\>`@CY#O#I([I;V5[$2:=E
MH703,^$?I]8#:/!WG=:)_@S^V3WM8KH+<RVH?9Y.>"E_,S+NIQM%"85@&JF^
M#,7-QVOK4X"_>0ZN-:R0;`U^8IU^;Y)"*I<*OF7.@TR]RKF#9BYY+C69NLPZ
M&4BOU!$$HA*ZM%$DT889LY<S<:^$1Z^['4J9Q0595EGYU&*$GO<_*C!VR\1/
ML1P^'U5./#-LLM]71,V&"=$$C22$%H#SU^I-"IEAJ#1"Z:?JIB:77^W4C!1+
M.VV2"RD`]/6L5I"/A4']*9#\LN3REX8A0TYPG43.LR)^=SNS`/P/Q0-BP4<Y
MZLGP&=#3!F?#B_[][.CDV<L."'V[W<X,4NF]4Z'(,O/JYN=UFLWK=(%Y@08N
M-"^B^6L2<WORBW0&\MH$N7.-7J<]:W(';_4,-2TBIY72<U:I<HU-W(9M$(J4
MCV@&4#4-X+V)92[9ODUZ5;!83`I+$G'$,\!88<UB0Y5E050>TL]L&<8"O@C=
MZ*]HRL#80^$/:-N(WIS&#?@']3=%[)](7UDZ!&EMZNB2#0=3:*%.JLR:G1-@
MG4`06W\GP*#^A!!8S:TJV_("AP\E_$CB3E'XUU$<'.'_RECO7NCDYF8".##)
MR2C1:YWS^J>X%P!;B1>K20MK@-R!N7QW>GZJ++?E822)'W5:9]WSHN-QC.//
M(XHCT>B2/(#`B=SVP:08+ZJT5X(I+!1A#+1#VL&!^:BQ=68,1T4&"CT%8)9P
MM)N1!5$1*!_E^8#GKC].]'2"'D9Q6(&1N3GPC-E`1D\J3;GBU#[0AE+7,#07
MS@Y=&2)IT4VRC,C#$DD4?[Z^_E+,[F$VSXN";'_.;'>A"(\Q1J4,,!!+>/BV
M*M6=(P"YR!DF#U&YDTW*".,,E0"?AM@[3U#>2)OLH*4_/6UAE*I5.ILWNC6X
M%@I/'>UTI5G=>>G'Q>UD12G,6Q'ZP*SHBPPI8.5P<B7#^@EDBK)&0$>+",DF
MM6A2D4*$AF.@$.4$LZQ5NEW](#&7A(`$88<`!?$34AW::U$I*WPR*F2''+73
MC\^;G;4WKI?@,-,O1.0`$$)S!N"!^2K;\J>GAF"(A3)F:U[#&@R))@U0H2=M
MD41I)BTWK)XA[8XDOOR&NR!3*:M6804/(J0DJ`I%BRO%L,?6VY8]Y8(4(*+*
M3LK1V`LF8,W4.\<)H!-N8XXA'@0:8_4`0/21@U0".Z#0UA:>3>92!V>:A%(#
M1(DXJUK,U(<PY4A4+$K?G[6Z[?-R;)YN0X%9@SE34[@<>5IH052"U@4ZV+'>
MY.J5E[A`PNX1*'Q9!,YK&-Z,?BLA&J=BE;??5.2*.(F<26*5]>N7![^F:J,L
MQE++>;8HWI9BJA.@82&F6LOL*LS%-E8])WXK+?L,!&83RRXL^6LDX9=I[0T;
MQ(4,XM>(HH^4;@W;=-MX(2@8%'#D4[35&3"J24O#&N7*XL8$EN"0*YMZR,8'
MC@IQ)MB(D?A+YDO%,`P!FS'26R4J#*!$G?(P==4C3"<(X\SCK9H0>+M4$:;#
M'M0%Q%K'A>%"4PX01+G7+P*[1?W*88[R:P/:)PFUQGXD]_T&(N"-.:H+'$A?
M4;JVI)<KY>EG;*'G(L'7$#`%(U/'\9F2T,B(:)K'7.Y=+/?&G`N5B88@Y*&+
M<;.OO2>J^:1$DH,%L&XOB8.0MB%2KRTMK9WH2/;/(-0U>3?77][_>OW*I/;5
MD&,P92-A2[""5.1:_0:=L=&EU`-,VI!'"1[B5?M?.#CZO_H%:1UW)#RU24)[
MRP0NA7$`UIQ@A-A!FR">-Z]2-^\"4]D1)1>TZUQXH_)033(EP'I(K$8*388K
MFDE(<`^%96O1U8#ERX'0^0_M-)H]<56QE-NB,`1FL7[L%(.2[8D5!2"WNF)!
ME6[I&DO$#16W>!/:ZA'1T.I[P0/6$$@QPNA,%0VXHUX21M(<-(#`0XS<>W#Q
M4=Y>O?Z?T].3=F7-O*DXQ5P*QBUIH(3;2D=C#TQ.W_TFG:.^S!=7DV5]=7WS
MYOJ'7WZYI;=\>G_]_@W^54[956@U2,J,AU6IJ5[.;-V8/GF!JN3&T8RE@VH,
MX'.RQW80HOZHY%N)<$HQINLA427R.3Y3>C='55?NQ*UC2QC2DZK`0^3J[/X#
M`;)UTE9YL1P5LW47::,XUJ)#%I0:%?F)9W0G:J6CE>GV0[%@=!XH5-%"'SM9
MKIH(9_0:)?X=2'Q4JGG)NW"4Z4S3X<`UO<]@M"FMNL2LA8)CC5/7K^^N<T?I
MAL$#/!*JT2OUS@P%0F+>DE9[#C!.3].\:(Z$,C]F/S8M$U?^(J@_N(MC/$LR
MY^B!'_A'N#;2!Y^VCV%<1/UCZXMZM6%FNN]KJM'!XR07$>4X^VGZWDS@U;CF
MY!!F#4+D:C^A#$5ODIX;*J\92`3\<A1=*LE;T/_"RIPP&<P[?%0X(2(LSP6?
M'D\0A4$R5E//<OO`:`=L%P@)&&%_DJU,?Z%2.(E/J7ADC1I;YT',\8V6JH-5
MTIU3]\<%7/3PZ`UQ72NN)#2:L\;U'`Q9/#16YK*N`=ZJCG[N6"7M\9$@WI%D
M?"')^#AUMNF-<780R0K!TB;<\DU$X+@1X_8GU4>LM^VA8V(1S:DT?DQVFLR4
MX@,4J/TR/+(VI+TVY:D6#Y[EO?/9IX7T:RD!+LRK\UB`ZAT&]ZZ#A2]@4P)5
M;D/F-L_Z]-`63C%]\1OIB4FZ)YQ;"UK0PO.!@IKTO":AAG#P_,],/SFU240.
M!:HP@`W_2_!`V><Q8$F1'(]N92T8\D\5L!0>I`=@GO"!&,A.EG.$N$J6RUE.
M9I;9W*()T&?,ORCB?`"94Z4M?YB8>.K-^GN]Y.E"F.ZSE^WCJUSF<M[<7TZE
M8:=^_1I\2Y>(Q`G*!4MAB&*4P:@Q..[">I&;FFUH1?J8^+W,UR9D^4$\M1@F
M^I0CA5_I7@T`1Y3T_I1%7T/Y%3D!IF`115=7I(#TJA`"@YNLJ/VQVL9T?$>.
M@P@=%OG-QA.`Y/%2S$&YD]+<W3A1J5&-DE]]-_7H86#](CR8-Z$!I9-+G.+4
M89`D5.?U%%+3C&G7RLQDQFDE5\7%0%APY90Q&20NGB7W-9)G9*<WE=:4+^5Q
MU%G-])`8,@W<9;T%HH)P.EN(12J1Z$LP+O@;SP5.@R9@;!M8>`Y[!'&'.?$8
M1`CJ3D*OT.;`BH9N7Z6G"W6>I9HG\S*,-@L]`?*B1%P1?KK?JV=,/B\=UOI&
M/C\(4N?2[#0"6?!@Y['.05+**I\M*N22P,C9283[KQ#PW<O65`IMEA,\E9`J
M!(VZ0"<?CZG4/-;+^KBV5JZ@ANJ@,+_A!RH9CP<M%/Z@W"^2)9^#^.64^;6B
MY4=-RG=!^,60_WV.],4]MYF&XH^/`GB0C+0->_FE<_E1&^K%7C1EI@&#KM-R
M,;"I/OS35L&SLO`[K$%99V9_HUU74!BLC(Q6D8X-+#YI]I$%ZWH<NA[5.BB(
M>?K[LN'?I?8JQ_!;S)S3X:]7`?Q/D>/Y4_GOKF\+Q_)-"4GE6%_'E-@O]!6X
M_5IX_%-P3.L\:I^TJI<Y[<GE=Y1&8ZP=-14[7U1*,O4#WLA>;+TW=;;3IV_0
MD@*01GK&8(:E[T39>6BTG_0HI5Y5XP&5GRJ^Q\'WI/6\YM@!_;2G78L(70NU
M@0`V/;&S0]X4!HDPG.CS$TF6MC+GEFE\SS6I%&KM(.C@F\C./:BV/L?6>SIE
MEQV?H.HCWU=;K92=58?@J!2I)P>N[].;^[AED]87HN@A8XZMMR+$#+.CSQ:Z
ME$@>N7&,YZ;7*9D%K\M4]JB*)95]`N%1F3@ZWB+2AC$FH,39*5N4N7:56\^/
M'-28:D!60Z0K=SEK+-9]!$]8%;*BQ".^I)@"[,9OCMI7Z?'*3N?%HC`Q+R&6
M3W^_+F[=I#O315$PNT':*X_2!$N+TII9@KZJ1X>JJS9E@*6](K.?F.YNA+*<
MB-:R[YJ*"Y\2T8`$T9!2*VF&/WV[:N@58TFV'_4QVP03'U'I8$5SK"";!!6?
M^P:'Z'6A['O2CB/312C7:P*>3)U2,R>EL9$N,:0//54*`M$&G2O0-7]8W#$U
M&0W)N%R]>:$K4T2:]B(WW%/!!/C0B8H'?70<58.K!!WFV!V9W!9Z,G3:03GI
M^413NG^!/KA+V3#EGV>;O)I9A;98N?VN/Q-G,$HCV]S!B>(7^F1=[FB"C@/T
M$375-P/;=O0HJ**.9%X?T4ZDD\@19Q;$:V!7&RHYC*#@RAVEP(^B1R8JH**`
MXK./687S*JN`:)U:!E-["F".`2-02HFBFV_+@5TB4]N;%:'"NM%4Q6%@]DKU
MH3_3#DUU#J%V&M,_FJKVUV<;8;82#PR(V'@+:1IRRK2LRY!,!5[+1BM3X<[U
MO7`]C",A/L)L8E:7N%J$0STP+5MZWA@5S!]H.&UK"X3?1$"FZ6\*C5#;E?=[
M+-48=-8',Y[/F\)-WF(RK\=V9SS+(J]HE6MY!<X:R<&=;=??P=@.4$'-NCN7
MFAA^\!"*L?Y4_;$4<ZLOT*R^/G,KG.Y<S&"U3><AY\YH(_R>FU.9<72ANO?#
M6N3@2:J\#+<;@W+JX^U<=L5F@LU$@\Q$=P=68BM&8@D;L6L3<6U:I<Q5S4?8
MSH2,7V!>]RDT9,O*AH$-`QN&NN#9M>KT7ED$NQ#+F8A9XS>.N-@NL%U@N[`'
MD/9S&$1/NP>:J1B_^.J'4O7#9%(^52"Q(/-)5&03RR:632R;V-H@&IM8-K%U
M(B4>]Z[N=[00"=F^LGUE^\KVM2YP9CIS\9[7$PGY3KAAID&_8B-DW@*K4W%)
M8<H]6#$VY_"=([P'-_S1^J_7K]^^???NQ>S5KTKY?%WFF2G+G+6%,%>)CA9H
M7E=Y:'M!P[,=-<K>^+D'D]$'+H-^^8BE.IB,U=H#Z=ON]%WCNU2G0K%MGJ?L
M2&S#D6!^/9E?WZV^G;D,=T)L^;T4>RZ>`I%KY4]N[I60LV$.==NMDW9W.VQB
M)6+08WXQOVK&+S92=3=2IV4#Q1I4*PUBQ&-^,;_80AVNA3KA"*K&^L-XQ_QB
M?K%].ES[])PCJ%IKT-,'S\;ZOL!JQM*&20+SJU'\8MM7=]N'6URGY28LK$1U
M4J)M@)[Z>#N-8;@<9Q:G7P?A&!N@2]7>-DH[V;&-.VSUW`J_:EI6R!9_S1;_
MLM4YN6*+SY#"_&)^;9]";`)V;@(ZIZ=SV5!C"65$:1:B,+^:Q2^V``=A`;H7
MO.7%>,+\8G[M@$*,_SO'_^>=<E$>6X":(0H7/;`DL&UAV](XV]*];'6ORO%%
M0T24(65K)07U:@<RMU=5=_RM.(V#+U2084RW/<8R4K?]CH/(K=>5$U5:OQR7
M&1X:XW$LT%WIN+*_TJ%Z*2L3[)`]FTZG==ZM>['D&E6!X:X)<,=V;$\9RW:,
M[=AF[%BM;EUE(\98QT9L7QG+1HR-V$8X>,YQ&"-=G7C,)FQ/&<LFC$W8AJIP
MICJ/[+,F'`K:<>4.&T@VD&P@V4"N8\/MI'Q6;8]5@>&N#AU-5FI=TG1DXTJZ
MVHKRDH+9*<IE\\1RE7K;!BYS$>T;N8[CR>6U;Q_6SLC#R,/(P\C#R,/(P\C#
MR,/(P\C#R,/(P\BSB;4S\C#R,/(P\JQE[8\EWQMT]O>4S_X6)>,NB(4'@]S+
M*!Y)/X[*`E+K_;E'V<L6;H]J$+K'%V?CV'*"I&?0]>#Y7/L[69[$UD.NECAO
MM]KGS2^+9Z7=.W!FJ[NGC&4%9JN[:[[NNMU9NS,W1&:=;:K.-AR;V>CN*6-9
M@=GH[IJO.S:Z)^4PES5V+S2VX<C,)G=/&<L*S"9WUWS=]6'UZ3N#6&?W0F>?
M/G@VUEX?6&=SSN;\L/C,YGQ?S?EYN]6]X,WB?51:/E[?G,)/+KO>N2ASV367
M72^I??NP=D8>1AY&'D8>1AY&'D8>1AY&'D8>1AY&'D:>3:R=D8>1AY&'D6<M
M:]]$\GW6!E!-29`NR`Z\:"S,BKIMS60_>`C%6'^J_G@,E@]&!I:V5_-J(CKC
M^```9(WD8(N^?HM>!('.Y>H@L$`S]\HF_=OA=.=B!JMMZ<<RG#NCC?!;?_#;
M6S6_7N#ER/)&VG+4@VFE`G#2:5G==N=T8X+P)%U>AMV-@3FV$VPGV$Y4.XL[
M,!-;L1)+&(E=VXCK41#&[C_2F:N:C["="1F_>!U$\5-HR):5#0,;!C8,=<&S
M:]L.DRFSP$9A*2*^QRG):</`=H'M`MN%!5C(=J%ND/9S&$13+6?9,"Q)Q:]^
M*&&.57$7DW))@12N_S2!9!/+)I9-+)O8VB`:FU@VL74BY0>01QEM#('8OK)]
M9?O*]G5;</8V@L=%S'M>3R7D.^'FBDM^%5XB>0NL3L4EA2GO_)ZG65L(!W5]
MT^<>3$;$;N!'5M"WOA[?'EL_!_<R]/$R)TOXCN7&D24&TK?=LM.U6W7B8Q/-
M;\-UV/RJ?3NME2!RG]IB==NMDW:YT24K49V4B$&/^<7\8B-UP$:JRVYYG36(
M$8_YQ?QB"W6X%DKIT66WTRWG%5F3ZJ1)C'S,+^876ZK#M53/NR>UVC-D'2IS
MZ/NGCUX)H'FN,X;6E_]L\YK%+[9Y=;=YW9/62;ON=[\<MA+5_`X7+LA9&Z=?
M!^$X"$4L+4?VX!723D(WGBJ]8?4\-/7<"K]J6EC(%G_-%O^BU3DK[QHV1$09
M4IH%*<RO9O&+3<!!F(#.68<3G8PHS"_FURXHQ!9@YQ;@C/U_1A/F%_-K^Q1B
M]-\Y^C\_+1]K8@M0,T198YW#]\7RAGW!JD.1A'WA%]N6@[`MW8M6][R<7FJ(
MB#*D;*V@H%[M0.;VJNJ.OQ6G<?!E"C*,W;YKBUA2XQ!'CH/(K=>5$U5:OQR7
M&1X:XW$LT%WIN+*_TJ%Z*2L3[)`]FTZG=7ER67//9HVJP'#7!+AC.[:GC&4[
MQG9L(QRL>[7_@6H!FP,V!ZP(;`ZF9K,5#C:A/P?'-@>&>6S,]I2Q;,S8F&VF
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M.FOM7FCMTP?/QFKZI0ULT-F@,S2P0=][@WYVU3HY;7Y7:%;:>AVO5Y\+9`9\
M]=,/270T$&+\X_6]<#W\^%T0W@I/WDH["=W8E=&=_!:_0FJ_5*/\]/@CUZ,@
MC-U_I/,ZB&(K\=WX1O;__2R)G&>6#6N$$>D#NWOZQW7TN7_2^2C";KMS]L?7
MVY^#>QGZ6+AV/9"^#:.]D;TX&_NC'/5D^,QRI.V.A!?]^]G1R;.7W?9)N]MN
MMQ=94&%V+U/J_-2SPV_S'K/M,)'.>YA^*+>TK%.UIN5FEEO2X\3X.0RBZ*L?
M2M`.(,G/PO6CN4L[^^,=R'?G/\+'E=T%3U_DR8)\JYKJ4];Z`?[:\E(7%=&*
MF;Y<?)W;TKC3LP67\W())BV.'>>EE;P.PG$0BE@N-/W+SLG5RH"Q;KQXTE(Z
MIZ>U0XF+F:JS')<NZHH-:UI@9T7P6R<B/%&/NE>+,FF)"2^.`I=3LQ^-9&B[
MPOLBQC*<0?;.>7=1\"II_[I5?[7YGZVD\9O2]JLYRK#`:LZ?I.0;4O`GKJGS
M1%._'M5>53E.3I>Q[&M7ZG9QVA7R<KZHS$S9[C7K[R-3A<]6M<T;4M:9<CWE
MEC]-+3=F>A=>P*K.@U;!->C?HW+<O5B4R.4)?4IL3XKP72*]3S+^W-=R+F(W
M\)>:TK?H1]_U_OTL!@%\]D.%/M^.(3+(O>YSSW,'])Y/@0_3"^'K)[ZQ\+XO
M8D+'UH`$N;>N*!$5JRN^+`QL*9T(!]C(V]:.C2>&GF^D#6\]?5+*9%$-V7S*
M9'W+VG;*Y#&\.NGD!>84!>;):WQBU+`.;%L?PTY.VDN@X`8TJEM:R9(A:N=L
M]<SCNK7H24OIG*WLK&S*6SDYF:D\2RUMT6!OR[[,NI9W^C179RUX\$0MZIYW
M=IA&.#F=FOU"D=+ER64MT@BKS?^\;J;R;(XZ++*>I]K%M2C"BJ)T<;F,`JQ?
M!3K%:4\AZ-7BB;Y-!]V/3+5S<56SH/OD?)9@-\50+;R`SDD-G--'9?GD=%'<
M?KF8]**1^RAB_=<[X8:_"B^1=_CC=`=]T4#R)=5HX*.6+3UO+!S']0>Z"J&M
MRQGPFV@L[.EO"I4:[<HN.DM5+LSZX-%BPW)!PAJZ^E\TOZO_(78/6ZQ_UAXO
ML[M?8GL@_&3M/(QELG;6>YFSJAD7<"N6KG.==\"@,YY7$5QC`NZ*'%S1N_[C
M%G:`?K]9=W<I#E9??[:S:^TZ,YAI2PS*YV'R1ABJ/_CMK9I=+_!R),'(;*[J
M;;L@?T6^,F@Q:#%H'0YHG3)HU<E5K45K[5(6;4FM6;UC-IX%>QP&MXJ"*FGK
M#V`<*_"E-9$BM(+0\F0TU3F[=N?O9J`T&[":'G(^;'[5]K!R.?^S2P[MNEOF
M5:MS_O0W9`.V"TQG]:RO>C*<,K^87VS^#MK\7;:Z)]WM,(K5J+:PM\W])H[+
MY\?EHA_+,`O-XV$8)(.A%3\$]$$Y2&=E/31EW0J_:IIM9`]@W?SH7K7.S\X9
M5!A4F%_,K^U3B(U`'8S`6>OTK'QM4$.$E$%E:V%@O?9RYU:]='=W37+]@\M9
ML60EE6K4<?51)C,Z;,/E6'?/W,YQTXM@UNV1K)5F!^/%=#JMTX/=RUU99!@S
M&Q.FL3&L'V/9&+(QK*4Q/&N=GUW4/*1GHU5';'O";O#!-#7@C%8C1'E%,STS
M(UQWL5PM\]W`A2ZB?XL="]_/M3/V,/8P]C#VK&GM>[0S-'5IYD'O#-T%L?!@
MD'L9Q=2&O"P=M0X9^4+46ABX+>4"^&[%)AZR6)VO!YR].V^WNA=UK\IDC3U`
M9&:3NZ>,905FDWO()I<O(-];C:W3!>3KZ*N^^&UMQ>%^<^.AZW_VY>]X[Y<9
M^PDWNG6N.GBGQD*-Y1>9RC+]\)^ZM,<N5;CLGBQZS]%R2UM*`JZQ8!?&NE/'
M0.\>`APU6@?SNE?G9PO=B++<C!:]_V)]ZWR$D]VST[.%+LC8QCI-)3:-;L9\
MB@9V3K4&/GT:B]W2\\3U/*9V9^=G%QM8SZT]E$[BR<_]&VE+]Q['I%L07P<>
MO``O;G(#/^+[*TI^2SC#/&ZZ2^GN/(3'_`)C^JO\J=U097=>W/1\=N[)59,H
M\^:6YVBQE6NGO11'%^[YN1W&7BW:RW4K?)W;RA7`U1YF7#[IM*S*EM1KY_=V
M>KPV"]X*T0T;"382;"2*'-U2O^]M\7;AGM^[MQ.O7,^3SJ;YRT:!X8SAC.%L
MXW#VU>]5`AI#&D,:0QI#6@,AC6I,YVZL,ICM(&A?OF9[/93/I[O/SN:>!JA!
M-?;6L?'K\>VQ]4:.14@%V5;0MWZ1PHN'EO`=ZY<$GK9N97COVG)^+]@=*-7"
MYUG8XFW!XC'[-E;SM5EF/;V7X:X9-EW+M2.-N^QVNO-//*V;>:QI#)3,/F9?
M(]G'=JYQ=NZTU;XL]_EA%:NOBC%",ON8?6S@V,"Q@=M+%=LB0CZ2X=YTTGJ9
M?JR<V+X=NH$?#-R2?.!_K-?!L?4A=HZ;D:E9@N^,!<WTEM;6=+;NFX3K]EM6
M)=S!NSF=UEF[&6[.FG6#X;!A+&>+M_<L9HO'%F]+G&S0#BT;OL-&139\>\]B
M-GQL^#;.20[U&`ZWEP5?4YWW*@7=>X"/O!G4%#584E([BVRT-D!85]E7;NA2
M%]'+Q2Y>:"RW&9H8FAHCK`Q-#$T,30Q--116AJ8#@*9'`N/9L>X6RL-.N3RL
MZB:J,.O..K4GU(`4V7PNLU7;UQV"Q>Y3.#B.-Z;:?G4.[]I7Y>T,5N3-LW@_
MH)NM\]ZSF)6:K3-;YV8>GV-%/FCH9NN\]RQFI6;KS-:Y<.MDZ^SJE!5YGQ6Y
M/I6`LS<\9HK"/.RI[\9/NJ[2W4V/=GV>O1E3W\7.8+KZV%P\2O38KQOJ<C)=
M09%-]W"?9L_6):12#M9X`?'3R,%W"Z__UO?M7$6W)78N?!?=U'PVPM*Y+>S?
M2%N.>C"K\GUTIQOC]9/4]6F\KBF2%0R=Q::`30&;`KV$C5UGL@UF+GR5R=1\
MMF\(JFZ;8]!GS&+,6H"%C%F;8NA<S)IUI1SC%N,6X]8"+&3<VA1#Y^)6U;UQ
ME61BV-I:C+U\,X&*]Z[YUK@E]6;3)R>VBH-/N"UNQZHT\Y01V[1MV#3FU]HK
M-#;$G:=?(K!+#DW76.Q`IZIZ#+(NU4F7&/N87\POME6';*NZK8N+2U:B^BH1
M@Q[SB_G%1HJ-%"M1;95H&Z#W6)9XXXG?N9MDI9O7EM?7O<H0KW#M6MT4>CEN
ML^8WQMU98#^MNKUX8_;3UNV`K$RQ@W9:.JWV1>=@5('AK@D\9CNVIXQE.\9V
M[.!W,]F<'1CJL3G;4\:R.6-SQF$9V[$ZP=UC^>=U52FO5([<=!CD?9?:ROV2
M@CGW\H8FB.5JN[,-7.@B^K?8'1W[N7;&'L8>QA[&'L8>QA[&'L:>!F//8['K
MG'!T"[53IUP[E7O;HW>2U3I=]2AOV6;M44I^=I/MP^5S_0O*5^<K[QNPONZ;
MOC8<E]G@[BEC68'9X!ZRP6W`H2_6UP/$93:X>\I85F`VN(=L<$]:EZ=7K*_[
MIZ^[K(Y3GYL;H7[ZH6>'WWZ\M8?223SYN7^3I;G?P3)>!YXG>D$H8C?PHSO\
M_$Y^BU\A\5^J07]*HJ.!$.,?<X]^DO'K)`RQ%V7BN_&-[/_[61(YSRP;%@C/
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MHB\M8YF[]=Z'5<9!.-$_+'I8Q9E<_8$>6><_PD=TO`LRH'Q)+CU?[#D_?GG:
ME1HU+23:%3DX4N,;1O;DAA&$T+FJM^U$RXI\9=!BT&+0.AS0.F70JE/)]KJ.
M&S\I+W_1_M=LV#FLLNW?@O`O&,,:AX$MHVAC`,BGAYIEL)A?![#?7`,7D+N$
ML2XQ]C&_F%]LJ]A6S:\L/K^H52S+6E2GBJ5-[`55QLS+M;(\Z.#ZG>N[T5`Z
MUL]!X#3@3F'N4EH;-4\9NZ4>C`U*,6Z_ZIH;DE8=+.YVVO5VZ;DA::V1C4W6
MGC*631:;K#J:K-/.>>T#:+99=82V;>UJK[1]W70<Y&13;>5^19,^,U=;=['D
M9I+[VTR2L8>QI\YBR=BSO]A3[TT;;F2;Y_0G&<,0ZL"96VYC6^MPD5O\U,)>
M<<N0G?&Y_F4LW.+G4/>:6%_W#I?9X.XI8UF!V>`>LL$]OSS9@YTR5MAZ[9:I
MS[.F>LLV>BFWTDM_C8<8W_M?U!%&B-^Q05\DPWN@R>H]:[KGQ89>"[QMJM%/
M^HRI!*5"T(5G^$BKKTX7FP]537'VZUY::Y[C(U0\!0%;88HTPZFFBZK7T6,=
M%P^O']!F$XKS/-[V\=FX:*?V-2.]9I*PN6E"DXU9151;86C#&FTTK3M0)6\9
MNQB[&+L.#KN:UB2HV=CUV&XX]PAZ%`FW"H00ZCJ)#6,+3T8M>"3>I+H<2+D/
M5Z$=0/)YIG0>3";Y[&2C30L.!"P.9)F,B8R)!X")6VDZMM^0\5@(P5'!QAEX
M$TR$%T^L4&W+U+NZX["-`A_7J.U);K:&G=99I^87)C-Z-*N6C_G%:,]H7U.T
MA[B'T>.PT8,W@)H5ZN6J[>ZE)7S'"N*A#"'TBZ0([2%]Y$`<Z`5CO#;3Q(31
MC[7:5V5E9U>A-KGZYI_C/Q!^,LPPS-10+!EF]H*?^[N1<7+>$._VZ_'ML97=
M^6X%?4O=^DYN+=W[;IF+WZ=8S`[MX5J:3?*KIG#%";&U-Z5MG5Z<-5)$&5*8
M7\PO-@%L`IZ\)W)RRGLB!PXIS=H36>X4X2%'E[=#-_"#@6L]_X\8"__[$N36
M3=&78BP#0F-\C#7>*W$@?LD3CM@>L"_3O>([5ACO:L9CMF/[R5>V8VS'V(ZQ
M':L5WNU\1W>NZ7OR!=TK"L-BD?F6Q>$NB(6'K7=6JV[<)$!L[!;4YME!ODZ4
M780ZN@BGK8N+S:7M6>H9&UE*&!N;B8V=UGFY\0]CXQZTU.,+BGG7O$[!]HJ0
M,+/FI.YB>3!5_XOHWYY=$LK8P]A39[%D[-E?[*EWTIHO*)[.6L],0M=[FXJO
M3*R%R=K2_B/?P-;$#JVK\_6`,U[GK<ON.>OK_NEKPW&9#>Z>,I85F`WN(1O<
MD];I6<W[QK*^UA679^4[U.?9%<4K7D&;W;)+`Q3ZYUW[SF>L+[O1Y67P]YM<
M<=F<JW9/9]YE^\?7VZR!R>>^:E\"`U/S$M.[Y*,<]60X=4'OZ<49W="[[$Q?
M;F*)9^W\$D^S)9X^88F=D]-.C9;8F<E%<U80!GL=?(B=ZN5TK\Y77<WZ%].=
MR:_M+,;<*VTT<]YD9U\%79K4.81RA5NKS>@O4[!8ZL6=F5)=?O,)V+09;RZ\
M]8T;V5X0)2&`TNM@-)9^1#AT(ST12R!X%$>W0Q'*5R*2SA<Q09I%JUV1O0&S
MLUPM\`K6YHZLS2>P-C?+7PCY*8BEU;5RU[18MS$L[(B(:>7I/2O[FK=)^.]>
M^(/YYUQR=B\V1L\-4C-[RW6$[;,^HKYFQONDT[)0G%H6Z#.13_@3:R@<*WX(
M8!I(VAZ15H[&7C"1$N0SH[$U]H0?J8>)#]9['^\1Q6KM+_"5]=QPJMM^4?PJ
M_:+SXGLJX\8QWIJ7J,&^)#!9>/OT6&]OOWS)C]`".8F'UL/0M>&_92@M`6KE
MP+QQZ%!&,>H>D%`1`-=\2E^)\3@,[N&KWB1/@E3`+EY$B@Q#D$,91FJ("0UP
MK&5/$:A`%_D-_RV1XM]U6]VS*^LY_&_G_`P_,5^&"A&L.*!7ETB'L_ONZG3.
M`TB$[ZT'$<$7=C#PW7_@.R<)77]`W_?=,(KA7R$0=`1B-20)4.P&2GG2^J[3
M.N^T86Z=UMG9Y9)S.^MN8FZGQS,VR0Y5;^^&*,Y(29+5;V"28NE-@'>GK?-N
M!\D6T[93XN=(79!&&VQ.GD%^X!_=@T[`7R3;5C"FWXD'$3I1JC*A:V<_01MJ
M?C`(A1]/Z8PEYB',L74W%+&:BAN1V-AZ.CV9%Q(8I0_.1O`0_6A]=]IJM\_S
M<A/*D7!!L<-,E.%'9]U+5$SX^YS^;I^?ZK\O6BCD5U=M_?>EDMV3$_WWU3'(
MMB4<QT4*E&$0%I3$@!V^@^\?R[`?A,`M6VJ=SU,/IQUJ!/*#:CAP"^J0@$9Y
M5@[5<B_(@9N:AVTG8:CQ#"=)K+"0B]&Q=1W39QC((5WP4YAPJWH2#Z[G%6D^
MK7)/U+E-NAZ/.!]*C^Y^_P"*Y():N'9N)NMW2*JL7F52ZX#A*U4HPHUH-<P!
MG'#A6>.&@-/AN"#!<1#"/_%I\)NCQ(OI#0DAQ+3A.K:^SOBF53TK0%X#=@\N
MM1T%-9*A[8(>C6&NTI)_)X"]VNJ-1/B7C/4W",SS/`I+**UU`);QQ_2B8_P]
MN"XV`DX)2A62=JJG:J8),TEI9`VD+T/A@;5`2+"Z9_^RI`!\FD#8IN&GGYBO
M$5SZ,5"G'R0A_20B<(3@(Q$AN3PG18`<"0=A)$8ZPDPT>V$I2W$X0M,`D:3Y
M(4WUK+W05-%+S69ZG0P27"9,E%[W1MH4V9)?49RZ&T4)C-)IM4^Z]-L.>&GM
MQR"^A2M`PP5BXTVJYIV,8<518MLRBF"^A,">)#H@7>!9M^_:A3.+(_#$X"V^
M1"#/3*B5^>9(#"U-^25J>@\%R+"FBIHS30*(Y\);3-]<I%3VIA^MYYWO<U`Z
M<\;XSL]?DMNCCF4##K@V"GOHPG]GUDZ;F\Q&@6G%YR(P,$!94)`P3@WVJ=+6
MY]WOK7=OKK7_#</!MS?77][_>OUJ@9%10D$;2R,C/Q)$@_F1S@QJ3K->TY>D
MHYT]5)"JV8\I3P5$UP@L##/++T`+WY/2SWL'2(68Y&L<A,K!T!,8A_+>#9+(
M2\5XUB1TA#(;*M`33".[%%!+T%6&$?+7X0^(FX#VOB0-!-D%MZ)*\4D^,:L1
M"CLFL)3AB-YQAE/HM#,F:55&FV%8GX/;X-Z-#!U@-N7ES`)]0O$HZ?T)B\,7
M"A!U3ZKDL!$H3.60FM@RC)%MN9CO*(T1807`.5M#`?"'%`V?UP+J*]@7%H2M
M_D#BZ+3PP$.A=&0?+&DJQ"73Q&%/P6_0Z3(+R7WOQI/9[`6G.A<S+$]&VE,`
MQGO>&.,`?Z!7TM:4P&^BL;"GOREL++4KZR67VFB9]<&,YZNW@=9?%3JO9J$S
MGK?/6..RVEV1@W<*U[\C;`>HH&;=W:4X6'WJL/+,X3:8V9G!3$0\&<[;AMX(
M0^?&OM=D?U?F*I,02'@O7(_VM.=!V+8+)E;4#P;_IMM"!M*=H,!GE5U8O1B.
MB0A$S#+U]2D]8R1E)&4DW1X(_":Q\E4Z9=XQEB[IELI0#,I.*1-Q*2*^U9E+
MEL4GD?$+;J;-VJ!>B(ILU>O:L^A)I?QG9WP+O'[;*^'AWD^Z-36U[75:+P7B
MKBC-/_$V8U(U1;1UGPNK07Y_UVW86R?GW4:**$-*L_C5)$@YY+4SG#Z!'U>M
M\S9?-LQPRI#"LGH`?148\,^/NYTI/6D*AAR('NWSI42;3Y\UYB+@FP4.NVT'
M45E/:ZNG[)NQ]5\?/YYW3D[8^M<;5;Z?J30-X5.3T.20U\Y(^F1^4"^8Q]V`
MIFCN@2`L^VV,M(RTC+2,M%O4I9UEL@ZD:FP_TEXV%I1YWG0I-2OVP2DVNQ'L
M1JSQ`EIV%!A/&$]X[8RE')(QTC+2,M(RTC+2,M(V&FD?2WYQ/FOC;)[3Z[*,
MH:R?AZ:?[`VP-[#&\JVKSL44)YHBI0>"*ER^Q7$5(VG=D;0*2!NBGP>"H^R=
M,9XRGC8%3SN=X\N31JHGPRE78BTN$'N?N3(7GTP78+%"'YQ"LX_`/@+O93':
M,-IP-,9(VQRD?=X];;/_5F]$Y7T"1E)&TKHCZ<EQFW=<:XZD=4AM;3Q;-??B
MFN[X6T%%.*U53FO-/E=8.V5>CM.L]8V)2!>XP..X\@J/@_4_5J;80?LLW<LR
M[_98$QCMFH!V*YBQ)D%<'12A2?1BD[#UA."43:@W8+!16$0SGSQX-M;W!?E@
M<U-G^&0B;='&S"?3`=N4J^/RS3'50M-L7#@44U*#'.JZR@-7J@-L.MSQWD%M
MY7Y)P>P\MOE6=[%<;9.Q@0M=1/]&KN-X<GG]VX>U[^ON.NLQZ_&^R#+K,>OQ
MONCQ?O.SWB4HI]LH05$_:4`)RBOA8<&)]5&$]C!C^TFG977;G7+:I%$YDRE&
M<^S8S"1YY19+E[3)<H*D9[R=YMJ#K6TYSJ+:`6>'.ZV3T\Y!:0.C7A/XO((Y
M:Q+,U449FD0S-@U;-@WM5O?LM$D^,!L'-@Y[`'0<$&Z69=]M!],V5=ERRI4M
MZGWGQQ?3Y9)[AUP'HI2[K&Q1GPOT#P:J7+,7_F#^.9?^W8N5&+`0^4L37)+R
M=T3Y3T#YFT<H_R[`DIZ9S=&MQ'=D:,5#:;WW;>G'[KVTOGC"MYPD=/T!?=-W
MPRB&?X526B.8Z#"R@C[E4"WA._B/TY;ZH7!#5*!$6@\BLF0$$B+P+?!>_-Z!
M/_!1>KF51/@"8;U"3^[HUAX&'BQ*3W,<NC9^/0H<Z=%K<``11<F(?@!R%^#(
MKAJ9^&OUI!<\'%MW\,&#1/B"'XA[&8J!U.^D&>2F.8;%1T,1TK3H#47R+$<%
M6O5WE\>=#GT$_^I>MJQ01F-I(V6]B9I<;@+ZM54L<B-+C((P=O^!B<2!);^-
MI1_!(_>:8_=(8)@=+,(-X`%#T"@.!:[^""4G?4S$<>CV$GK#2,;#P-&3"3R@
M&JV2B`@4'HD07AK12_Z2DP+9DPAFTYO0=Z^#T5CX$YR<6LVLI:Q&3C4_G#]=
M5.FY?8E$Z8DH$RG#7L.^=*;PIXA!!3TK2.(HAC'QS563>W#A1SV9=5T#4EG]
M!#XT!)X6OZ>,GE-]$=.X(]<9!RZ(IUZ%G82A--+ZW.W#BT(IG`E-2#K?6Z#4
MY3GBST`EK(F,TY^9>=,/;2!R*.PX$9X5RW!4HNY]X(G8]=QX`@([!IF%"2@)
M&+JP+E!'>"[W(TU_+0)I6ZF+%Y$UAF#,M3V0BU`X,+0=C(##BCKJK49PAJ`O
M1%3XE1]DDP%8=AT)LY^XTG-:\)OTHP@>`HSR)6I!3TJ`"N&2?FCJAX8!@">`
M;1%1@;B`Y`%.T._[@=(A^%]8JB3)[R=Q$LH9^!&ZT5]'?9168)2$AV(K1/:X
MBDCN:.RY4D_8,!!((.Z%Z]'H,*-_9!@<V4$RAG\/4(W]$;+9!0I(E)1X"-H;
MRI%P?5(3X)(E_R:&!?26E$#$0#0<_^OHZ.T[`&Q;JN4>'1G35N4XY>WJ,I9P
M-4^DTA"BD9%AE2>R`3NH/_CMK9I1#TB4O?DWP^)KS>+K',RA?*@S[)^5-%TK
M=?Y9(UD<,(T7H/%;4(M@(J72PC=N".(;@$[.<CM6(*JR6MA88"P<A&&]JK8F
M#'X3C84]_4W!H6^WJUSZI?S=61\\>NYGLW4$\T*4SGA>B+>7N96GD8,#MO7G
M$.T`%=2LN[L4!ZO/*%:>/=T&,SLSF#F-R%MAZ%QLKBB"V6V"946^,F@U'<,9
M`'8%`.4=0`:`G9:/KNOTW9-RVQ?M0G'N(9>0OC7Q]@?*/?G6[U*$49GS==N4
MV/G6T>&XKH=\<H/[FZZ)'V?']?+#&5,84VJ`*8>\=L93QE/&TR?QZ[%8B\.G
MC;,Y#9]^3?>-ZU_2Q9K)G@Y;^^98^_*5IXPH]4*4?Y78TQ#N-`D_#GGMC)U/
MP<ZI>W4:HIV,G2MRAW>@&AI"O3$EL;]CA2GG-VJMMQQ%L2?0+$^@?3Q]66E#
M9/1`,(7C*(ZC&#T9/1D]ZX&>O+^T\^#H!L_DO<,S>>_-F;P;$4M6Q5JK(@='
M;-Z;9=X[7%!2<TSAX(B#(T;/NJ+G.:/G@:'GK.!(?;Y*,Z8UMD>8[L64G][&
M6C$M,?@2L%8YJAKD[O</,(H;P]KM'.T*;YK?MD&WP/B2A/901!4M&J846Y,R
M+S/+<'F#+;>VPN-R<QML+A/>8QL9*PZ`$=CAI],ZO3A37:>HYU&^/0XV>L$6
M-9K@^?Y<;V^_?&GA[Q^&KCVTSCI79@S5,2;7:@:;EY@AL%'0C!L0CJVW0"X7
MGY!IGXZ1F%@BB8<!MH"RDC'.J'/V+]V:R`VM2'@BI)Y/Z2L**]`]C;S@`28.
M3UVF#\/*!JY/K6U@@KG/I6J?A#V_I.D1%;G?CJ@O5/8::KP#N!X=6Y\":Q2$
MV'!*^-:)(03.O4"]'JS%QUY%V0K-_"K&QW9+JE$)]B(RO\=!TY^H)0[%O>JT
M18V\1B+\"YLN40<L/3I21/JV'*5MG&"IWW7/<.$T<>27GIDM/""`"*V)%&&Q
M/Q)U!L)F6&:%BS70*@K-,0TG_4A0(QO3#PR%1(\Z2]Q`LCRANMW09QFEW,@.
M$EB:Z3!E^C]UVR^\(/CK""L'TL\Z+TQ+)A`)>%AB]R+0,F>)%G#'51F"&2CS
MTP])=#008OSC&YBG%T1)*#_W\T2X4>MZ'41Q=(LT>(6K_R(FR*_H3GZ+7R'R
MO%1P]E//#K_]^"D9]63XN4^02+_/CXC(B&UMW/A&]O_]#"@EGU'++1B+/K&O
M_G@'=KCS'^$CC^Z"DPZH)?[S&5#$=D<@U_]^UG[VLOO3#XN^S\S/+/?:@UGC
MPK(UY9]YJSF?SC*)G%4F>70"L^R>7;7;[8S4B[W[96HCUCCILY-9L_XC[2Z$
M]/HHD:)3*^F<GZVTDG6OXG3F*HPY)E$PQKAZ12!`5Z<K<&7-B^FT\XLYS19S
M6B9_Y[S3K@7YSV;->!$AZIR=7=9B%><S5[&$$.&*SKI/7T_Z2C#;8-JK'_T4
M^*I?H>JP=H=N4OY[!.E/0?R[A"7:P<"G=IAS2-#^XSKZW)\)7)W3\VZGL+2-
MS?*EE;<?J[RF_`93#787O)+9>]X%X0VY@`[:BW=@\X2'C0J>0*73=ON<B+2C
MJ;_<"N'P37</P5/H=-:]W`:=]$Q?;D>@Z&WD6#Y%@LY/MT89G.OV1.9=D#Q%
MMSI75^UM40:G^M+:$@[1"[&3XVJT`=?EY&0[5(%)OBS[H?2.7OD=UV$H_`'%
M<:\FV4]TJ$`OIO_Z5;7AO<%4:_1%AN@Q8$_1>1'!V<5B'I_J0*K,=)4S\@<U
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M7T;7]M"5]_G`OXZTJLC>3B\A'Z<\#96C5%6:)DN;67PIT-DN<<\[ZR>N4Z*N
MZ[^1-OT*,WJ5].T<MS=)WS50]QWN6Q4<BNM^+$-:Y1O<*2N2M;LFLD*P>&3V
M]-)["%)7J?/[4XGVV++6Z.1KD_56W2B#.[[F*@M]D\6-N4+D=7;GRYT,1R7G
M]'SVOLERM/T(+QLEHY2:9V7'<[NK7%]HOS9*+[BW\SBEQ;<"I3OMW9-ZD_YI
M:1ZI-KT3;O@K;;CG<TWP3'6\L/(&(2`J7N>U*3_ST>65=^9J2=V5=\Z(NMW+
MYE,WW:LG^ER;\AGGL<CJK)@-77:/KG-Z<;:>*&C6`C9%(5.J]"Y0%G+#A#KK
M7&V$3N5EY$)&\B8RWPD>H;JIN\#,]C453:EDCT+U^<[[6LH#R`/OG&EG9[GI
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M?3.V_NOCQ_/.R0E;_WJCRO<SE:8A?&H2FASRVAE)G\R/RVZGNX`;T!3-/1"$
M9;^-D9:1EI&6D7:+NK2S3-:!5(WM1]K+QH(RSYLNI6;%/CC%9C>"W8@UWE+)
MC@+C">,)KYVQE$,R1EI&6D9:1EI&6D;:1B/M8\DOSF=MG,WJ"G5]I_'<ZBW6
MSX/33_8&V!M88_G65>=BBA--D=(#014NW^*XBI&T[DA:!:0-T<\#P5'VSAA/
M&4^;@J>=SO'E22/5D^&4*[$6%XB]SUQ)W3YPN@"+%?K@%)I]!/81>"^+T8;1
MAJ,Q1MKF(.WS[FF;_;=Z(RKO$S"2,I+6'4E/CMN\XUIS)*U#:FOCV:JY%]=T
MQ]\**L)IK7)::_:YPMHI\W*<9JUO3$2ZP`4>QY57>!RL_[$RQ0[:9^E>EGFW
MQYK`:-<$M%O!C#4)XNJ@"$VB%YN$K2<$IVQ"O0&#C<(BFOGDP;.QOB_(!YN;
M.L,G$VF+-F8^F0[8IEP=EV^.J1::9N/"H9B2&N10UU4>N%(=8-/ACO<.:BOW
M2PIFY['-M[J+Y6J;C`U<Z"+Z-W(=QY/+Z]\^K'U?=]=9CUF/]T6668]9C_=%
MC_>;G_4N03G=1@F*^DD#2E!>"0\+3JR/(K2'&=M/.BVKV^Z4TR:-RIE,,9IC
MQV8FR2NW6+JD3983)#WC[337'FQMRW$6U0XX.]QIG9QV#DH;&/6:P.<5S%F3
M8*XNRM`DFK%IV+)I:+>Z9Z=-\H'9.+!QV`.@XX!PLRS[;CN8MJG*EE.N;%'O
M.S^^F"Z7W#OD.A"EW&5EB_I<H'\`7_WT0Q(=#808_WAK#Z63>/)S_W8H0OE*
M1-)Y'8S&TH\$GEJ[MF/WWHTG=_CHG?P6OT(&O*1Q?TH'J7XT#(4_D"/IQZ\F
MV4^^B`E^=(VGX3XEHYX,];NCZWOA>OB>=T'X,[8MI_OX;F3_W\\B^L$SRP9*
MP23H,[OSQW7TN7_2>2/M;KMS^LQRI.V.A!?]^]G1R;.7W9/S;KO=SJUU0]-\
MJ>G\='I\II."T><DCF+A.ZX_4*]^&B&NSMMGZR'$K/F]M#9(@M\D8K!TKN]E
M*`;RK6X+]B5T;9D1)HF<+S)<ECS=9R_/C[N=C9!FWKQ?6NNCV-N_$U#0]WX4
MAPE^&'V.AS*\&PI?SXF$-'KO`WW<P'E$EJ[^>`<XUOF/\'%[X"XXZ7P4(?ZS
M+%6=DY/U"-62\U^CK#WZ9M#POG2!AVLGWI9(-[6`%*MZ=OCMR=)>Y`Q]D\'C
MNFAUU;D@:FU^QNLR:QO5.T..S<SRY;*Z%2TU_).Q?"$R`:I3%]@EB+2^953@
M$W8!>!]%B73>)"%8!C6(\B;H2_T2,\[:9*5[VB[*RM(S658E'J.C&7C[$H']
M4]8H$$LM)).)M8"81O4DE)O&WN[E^J#W\5FOTRN:?NFU[[S]-G9#&F'ML*PI
MM;5YK]_E?O256U-5/,^S15(NB>:["7;;.HB9Z8V?KLFGK'NP^Q@AVMVSTRU$
MN_4-=^<0B,+=B\M:A+L5B:?\"_+>R*_"2]3$P'49J<^*":E%<>8EI3W)0F(3
MIK%P<.HZS]?6"4/\)AH+>_J;0O*SW:Y*?RZ5&YSUP:-GI$OIP/677<[+Z';&
M\S+B>[D5]31R<'Y[_5NN=H`Z:M;=78J#U2T=*EMU;(.9G1G,M`$+93AO\V0C
M#-4?_/96S:X7>#F25-0,[W8_:D6^,F@U'<,9`'8%`.6"*0:`G9ZVJ<5=1A?M
MPEFF0SYQ\_;;6-H0"%D?W+Z$P:S?I0BC,N?K5L.Q\TJ;PW%=#_F@*[>#7Q,_
MSH[KY8<SIC"FU`!3#GGMC*>,IXRG3^+78[$6AT\;9W,:/OT:>")V/3>>U+\"
MGC63/1VV]LVQ]N4;XAE1ZH4H_RJQIR'<:1)^'/+:&3N?@IU3UQ`V1#L9.U?D
M#N]`-32$>N/>NX[T'>MW5WK3%PZRWM9);SF*8D^@69Y`^WCZ;O>&R.B!8`K'
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ME*7..AIZ+3KI3<K2TD1:1I8ZYUNE4I%,KP//$[T`FZ/=R]Q[WKB1[041K&RU
M=DL;\(<7\H8+_N.2;O`=N<&?P`V^6;Y%PJ<`1.+$4B'E9;?3?6$5:&L)W[&H
M4Z]U(R.)%S/21V_DO?2",=(<'O#C4-CQU+EQO:J\?XW_[H4_F'_.I7?W8F,$
M+SKR:R9X+E*O&ES]^N[W#_!S-X9)VKE%JA=F(WP]OCW.XOTW<BS"F(@>]*U?
MI/!BQ8Y?$IB(=2O#>]>&N3TW_.RV7[RZOGES_<,OO]RFGW5>?']<9-5[WP*-
M2$0XL;KM]D7+2A^R!*JI="P0`0N56_@32UC?==K=UOEYIV7U@R0\FH!@D)ZA
M&,!'(?U<./=XG:<#T)$)"\Q[+$,Q`D,1IK^,0RG29;E^'P#!_T<<6ZKQ*\[I
MJI5[S`8:N;;P"@-'0[>/=61Q`,/:260%/@P%,[J7?@!_.M(#>885(KVF7CH,
MHC$QXQ\88@RBCVU5CZV[P(J2\3@(8WC$C=3(+2#`K1S'DCH`XN2RM8\"Q^W#
MW!#)K`<19?0++``AJ=_M'M\?YQ8T#H,!_%M-+8!IVS"W2%K]A-K56;V)]=W%
M1:MSU3FV/OO6.]D+D5F98'1/Z8I4X$>!3SZLG#@0#T6<8^I0..G$W!CY>7;6
M`N^@>ATMI"/,7!,7Y@2_&XT]28L$XN$[OPQQPB=E7I<66LEP0^XB$QY<D.V<
M+-SA$JKIW`N#9#",U<@!#)#]CE9I]0'S<\N'57S7/3EM79YUB>1`?G1;G)3>
M^4@_SHL`L`3<9?@%3%M8G]Y<T]=2_F6%<I"`,QV@@(UQ0)@%KK9$`->G45"M
M4>O>2-M(4><$U,X-7H>3"(0YZ8W<&,49U!I?HU];,2),`$=\!S\RDHT/D.S1
M1)#'Q3>=(C5ECB`IN21V'(4'@*C_27S@9YODZM02MAV$1!N43^`5V.91=#PC
MKU)#Q-^HB<W>`]I)MQ=;YM+BEO4@RXJ(/`)6CZ1#*#;3L%XG\3`((3HC9<B+
MSH*&(#7K%R^LS_T^=N74Z@K^EHO=,&/X+8!-C-"/PO4EQ)&EX\LHH@%A<F-P
MRF3!IES??KG)FY,43%(!%M/F`#]P_63:'KQZ_3^GIR=M"R76&H-#`K\#LF08
M@2,X;H20&%FV2+#K.$#BS:=KQ(YA,`"/$T'*]A(245`64.@0?A<=5VW&WB&4
M5TB_&D'B-#`KDWT!D_RNTVUU3D[S<&#F[83)P`*R)WWX+5FL%J[E07H>_N]W
MW2X@S1DJ(;;P1,0JF:Y`.;Y*.&S@7T^")IK^ZK!2)-\`-#GT\?<M`#QX"2DC
M?)%1[!X]:</A=/*(=@!V5Y=7976MOW]6<^_LD]#<Q&LMW#B)B?K7GB?#@7(T
MWOM]"(Q==$#>&`G.:]*G]]?OWSSNG>7=#304Z6,IFXW%S-M_HWGS]*VH98!=
MO20<6*0]1N>.L]>!%P:X8T1L>OE1!D<M4`D'H0^HYI)X*EN,NJ2<#6VY]&R5
M35+FV]AA^!\9*L\KL^CTCB+(PK>)YZ#:)&-EW:]:G5/P8UTPTU[.'3":!A!7
MU+#<"E'/@#!]C'[(L1U3YVTUOT$`(;!:?VY2>?`10$R'NO*WZ#7H,KF>M$!K
MT"![VFF)E"W/.:ADUU%FW./1<<JD2H^IDDTM?!7,R$F02AG9E6?6L89D&E+?
M.0Z))\KCC.+$F<P3C+<0-HJR6%Q7L`*=8\5$9'07.-V%5\.(/2G]U$XHQF8<
M,'S)V3E#VXP40'"#"_@#3PKEB.+Y'>-8:6'*&3Y`^MOK7\$_TT96^]K5KLNA
M0N%=CN"*"_D0$,B;`0[*M!U$\='82Z*COOM-.D=]F7M<N^IN5`Q&@'MHIF)/
MA1$A^*.H8:%T1R#+D4Q%32EL!/,`I4K"4/FOR@'%>#+#N6S&Y,%'F1'%2882
M_''UL@H0S!QH7)X1,5P3Z?XWC`8DZ%1`T5G?13F<09$'%V8\$G])C12N#1H$
M0!\1"M#+4.:,1Y7SA40^@LK<D(C<#_+"9\DTO`EH-4)Z*#+C9BB*@'[)WXG`
MM#Z.K0-?W$!$2((O`\KGH+<2A)'!->-=D++2CGJDU=2682R`!>D$;0]]L(@H
M"V&`ZV->$<:,2E)0^$"!H?HY]C2?<FLLY!L("JZ$!*$'"`0*"_]"C@=)K'P_
M]F+6[,7<#D$*@X%;<I7Q/R![QRWK0PS6+^^U%)^8Y;28-(7.*>7!@)K%DF*#
M#(%5DM_`?$:(!S!5B>&&`(51F$#J;MZ(,J<UF409\'^$1H22!L4X^S\"7E5M
M/]%^D>-"T;_QG[T)O+TOC^(A_E;Z:,V5T<RE(;YJET3)<F24-YUN*YMJT$.U
M@55J;:+,SI_@#I+\H_IBQH!`JP!(9NY*,PW)]*HQ/97^4NFG2(E&>8ZOUZ]H
M701+`42?4=(S/QBKW'ND07&$$$.>8H)WCE@C<%2B./!S/X21?@`2AL$$G#H7
M9%(#=QJ7I,XFOMNLG9(;GP%?=(;LLIR8<C(RD<.D,XS3W*>\V3C-V<D0XF%,
MLMB(&]DL"@_H.,ZZ$^Z#\(V/H[,\AALH&'FITH@*U"2'*5.&D[+/!/SY)0#9
M^&_XK^-L#,3-3!Q1F`3$_,,*AN&$\T4CV5.6#]2P;JZ_O+]^?7>=24+S,NLU
MQ[R?0W1'7X<!V,O703@.U#T[!93+_>:1W#FFRD#*S^>#7`G2\E-8'-7^.P!P
M6@2&\L,3%/30):)DCJOQAURMG%_4RF4Q6U,3400RGIF92!ZB4F@0@"N`HVC(
M4VB24D<$;?50JNI>E.IFE.7'S)@T=;H[!E^J7#$$H2@!.,)<#\(./A`)3T[A
M*$TR'YU5_U*[B/1K/^^2()$B+,T:J_SK.`%1P;22]2X)T8L:P2,5M`;X+.V8
MC$,Y<I.1BBYQ"4A(DTT"L"CFR//.*O(AC]$B_$O&.@==V$+`P"_'&G:3U@L9
M'S$I,09)'`EU',<WZ8]?`@^%*[(^N".\P+2`(KG'%G>7'D&2U%UJ:<,\`>T6
MM%=&UHUD9H8GE5]&58*H6NU!UN#'`:@HT`1C_"^8Z)36I\3V9!"A7?V"VS=#
M@`Y/E-+%7SY]*62+77_H]M",MV@&X-.CU`8^]N`83*SG.*7<XY]A32[2^=JL
MI$#(65@XM7[*RFIOHU6@0^JI/02AYSSDO`3:333K/EY"0I<HW)XR[JRJ3U35
M:P_\SMAZZ_I1+$&TL*1!#@CT/^*F"THN_/MW&0W=>P$"A`%RA/&RRMDZ2:1<
M/;,U4Q$#7;]]_?EC3A#IT=SW[V\^Y+]%TXN98%"TR1P7HEU4?"W#:%$C&;HJ
MOZH"EDR+Z$/0,64+:5YJ'3<?6M9S&]>N7ZP&STWR`XT/0Q0UZLZDU[15P4T)
MQW4$)GBUP:7L9UHH@F%$*'.J0A-(/*,X!3<!'>4*C<MBP$SW\DX1&OP13`&,
MI>,B?WJ)23M0F@:'ILQ&JVK:Y%B,%#B&KHF5TJR@2K40$!FJ3D\:B:<RE:6P
MY+HJ^E!9%M>_Q^@2@SR=HNQC?QN5'-?!"_XFBMV!4,P,+3D:>\%$RA3+4CX5
M)T701L%-0JF67/`1JA`7/3W9![X4Z:G6BAM7$85J9F.J*'VXYNP5Z-.85%!%
MH(A(3OF:+*Y)I=?PX_G#T(5?4+F6(8<8P!L&F$$BCGS7:9VJO0'AC=!%^NX4
M-PLRZ!P341V=1O^>WJM=HU**K\S0E@6R.`"".&!/XEQ("_ST94Q^(5%<^;+&
MPS23SW-,4ZB5YL_)0:7]]F]&2)$Z?X-!!Z-$YE/-,:57ZBS3LI6P@%J%SA%N
ML4QHH\67.&N79K04GX3O)P!?.><;QE'$Q_U%Q0!-[S.B]G=G"GMT\M0&=\-5
MB0HQ$(BC%FYNPI@9V;)48KHH)Y'&F2Z(K!OEW)"10'<E2QU.I1+RB4#X:@`.
M+O#A/"<$CIA$IK[(\H.8=K;3Z@IYKR4`.4$XGF`F&5^D4HKZ?=D4>3,@]Y;W
M6,.`;FBG9(TJ,C6%S,N0ZG"TG.4?7!O:XV`K@7O>?J*IS*-"KG!@IOV:%6^;
MS;Y64:!RZBAL6XZQ(`+D+[&-,XWQ\5!X?2.R@&IX@Y903LI\K,BC1)3T4E:4
M/5^GM%)-)O!M4/W&PG5FZ6HV52?`(U9!3%N7$_S]<_?[3`^1'Q6V(,][U':S
MV6,LH%J>2H9A+#P=JCB$"].%;K3+V#Z?#F607\_=_-PJ4I9$/GQAD6QJ;\.7
M:LGI]I+)$Y3-6*3"EDS,`Q.@:`(`OL92)0(@ZD=["?\/5ECB;B;:;_H>1C;!
M6RDMFY.C=",H,U`&`Y8Q5'H>N*-C#Q'\'4X/E#'/QLP82*1R9W5H#$*9+S4D
M69D&1C>*$CFM3<HM(+54&9_1"$:F?)*2,DH*&O<GK=[Y[JQUU>FHO0E2TL*8
MWUVU26!%-#RVKM."(G3NBZFSPGYA%'BI[XH#@P+@3@25#&B?3D-6,J8LGZ\&
MIAW#-/?D!_[1E,QJFV\@!03/C:=)D66^IY5=.P0DM]+5;C.M$,%Y#A5;VNAC
MM=FHY_IIK@*?5>ND9]F^EVH4/P7W5$Z4`]:+J@KBOLIRII8?&9#R+<J@,N/S
M`_Q<EOVK)YK#3X!]7\+`AB$BZ[G`6NX^NA/?S]R,RDS+M9ZYKF6,R:Y<STZ)
MD8TT^7)C(RFF_@'B:=Z(F1(ES%SDQ.B*Q*B[O!BE-"Z($'HY:,)M#QP[B)P=
MG:_L4W535CRA@FH:2&=:D&\Y_\<`7_::3"8S7S3S3PU*Y>KEX)=I?6M?)QP$
MQ/;W;H@A1D5EPH%+QW6LG*UMVIZ\V.4U=ST&:)9Y78=1:H*X["+SNTZLTH><
MSM6I!@U2(NP%PXE#3OGKH1QAN#G)JO+OI!BIR.$UN%EB`/ZS]=[W@WO%V/1W
M59L_KXM9X.\I<AC)$$*IBBRS&0+F%0H_ZDLJ?@,I_M7%4BVWD*D&@?I->K@K
M&9?VK7_]^EMANP41+L)<CALI:_T.JRCR)_K2^ET5GN!Q'TH:8[X'H@JPQO!"
M':=369T^"!*K8%&/$@.A6H42-U7X57P"2P,KQ]=;O(3Z:.PCTKB>I"=+]/CZ
M&RD9VHYA@.G.X`'3"X`LX,*[`B/]\JYO-A\80,5N*9J[=/(``^ICZ^TW<E`(
MX&E`HHQ686V.6KE,@-HO,Y!5+N8SI<:ZR3D5/E)$.",0FX4)M42%+9VI>?I^
M$`IU476N/=$3F#:(00HP#PEJ/2IHT=?K5W/V:_-9>"I2]6,OEXC-^358CJ5*
MO74-&83R">[:^ZZ#&Z4B/4XW*N[JS$HZY2T72"*.KVN74`-`T#!:S;32[/&F
ML:H/WX%%52%N5A:=*_@JY(V/Z0VXL@$H85PZ"FH,>);$HUHU-Z+Z+%>:70^<
M-&Y)E"LWTO=GY6U@Q/&-,+D_`Y?(FGU7/N(PO4=3S(//3O@_DNPOY/5A":MF
M[Z<GJ(].:CJFZ\_<$ZK?2QELZFCCAR`O6D-!Z315X=\]4R=P24K4J0.1Q*!5
M,5:MT6:0+Q],U2&=;,@]8/*V6&"KW*-^>HC($X".8Q&G=2B5-;QIU(7N6U:B
MCWU+P2N*AY%)T>,0FKVETF(WM),1'DBS2>)P(+,_0"<\@<)I+`!,P1)Q.B&;
M1`;?S4X$_29_\`T-#$@B'7'38-W')A6QJN6C,NK4-S4[!AKBBZ\T\@C&1OT[
MO[N'3^/"U$]1HK",.:$:3)2$H3LF<8,/\&=3245B-`I;E`,4'P-FC#"HPB-^
MP#*C<B$E*8M?@0P]8"C$4L4G]'LC9;MC:0]]JKIH@:W#(XCI-J4MHE0,LEI-
M>%^^V"G_NB`LUJU%64U2L10_DN801NF(0%7%:I_RVF%1><4H2%`+4*F5(E9X
MTW.=Z:QWQ1*M)$P7BIX=?BL]9^A@>B%04XNLUT82.:56&^?GN4X4[0OL1*'_
M^<?7V^QXY^>^.DUU[3MTM-.<[/Q(Z9M\5XZCDV<O.^WN^7F'VKPL.L>L0=*<
M)[(TX^+KNU#KNY5C/"$/ZVOK?SYA?1<7G:M'ES=CLB\WM,Y+M<YWLH?IL[N@
M>ZK_^81UGIVUZ?\VM\X_(?;`;BV+KO*J)*WK6&7WY/3RK/OX,BOF6M&JZN>T
M:M/\\H:@@0S5G*5=M/^XCC[WTT8P?V"3&C-$Q<3/0<VZG9-3PZ%%WC_=A6SE
MV79*L\VD('=R7#<2K)Y]MWN9R=?"LU_3]+OEZ=]^N:%S5?,I?G)Z=?G_MW=M
M2VTD2?17M!'VFV!TQ=;.!!$:8\_:`4:!/0_[1+2D$NJ=IIM52V#\]9.WNG9U
M(T`,XUW>;"1U9]VRLC+/.35Z6(_3U-+98YS$)#Q4?BA6^O@+L]7I.Z-FT]B.
MON/=NGWCW;K]<TV*-6?JTX40@N$]E@ZLV<`U#L!;_P^QWMNKM#R7[9^==<2@
M3E!I-QW1&W4';VQ//*XAV[C&"5'X3A?Z1T_<7%2-;'1_H3UU,4B11S8&D=HJ
MS_1IY3E'<MCIQ??NK4R/."%W67"I27V`:'&KQ@[=_>P`U^^G#?WSG,);BFX=
M7DAMDSR'=(=!@4\ZT;@):>H)'.<N-Y>-9A_4CA$ENG$XSHYK8L.!ZU)J7G[8
M;&'R[2DM''0:+>27^Q:.">=F^_JI^W#H&%CS[L-&^YZV!X>=)OM,!SKV,83N
M,QW/V=6`&_UJ3]ZPTDV5Q#=3XGM>-AV[@CH1,P\G!YTC;=8]7AFL&!))_DA8
M"U8&XY]31`C/.'&`&J<+:;@UOZG/)8@_26X1W,%]3O_<HL]'7<>M/<K$,&@1
M%_AL31NY,<BVQGCSZTPGGO0V5C>;:G49SW\?_UK=*^N?&_;A3M[;,R^.O<]I
M+M<G3\!KK84Y\X/I4#ZS$N7`4Z*4[FRY_>FG>1Y7,+V[(Z,W13VZOKY%[>+A
M5<YK/'.KFUWVTX^.0]"B;!:F,HJ!G6QF/FF]ZG=\VL$"=J=\9FJ1R4S30"YY
M<BJ3RY92@<8J4%:Y"I&U^7Z37#4^I8T\TW*3,)^$:Y7F6R9Q;)BO!NZP=,'4
MS!.M<LG1(.84:'7`A9>YI<I(6[CS-?Q>!*->:4`6L7I[[8-1U^DM;9O;6<D"
MJ1#N7YA,C`\8M/N=D8LKYO*(J5MK3@>.C#\PJ;X9#4LI*U2LG<TP.TP*<3(&
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MQQKPOC-E]LT8F59Z`$]XH.DY[26EY74C(23_E*2I2)&3^\>O]P80,9<MZ8O:
MH%@KDBQ2^-E,IFDB56DC-N>V:+?@_6<,*)\R%/I<Y'MG"KSS"@83P\NR!:<8
MNIMG-SC-\?''WS[_LX5M_KFU2__[MPB-',?FA497J_0:H7*T&BWIU>"DJ*J.
MA%9A)DLH19!(0W:`AT`T=8423%3+U>C^R3(Y.QG#7IFGJ,^CF+;7'>QW7LL0
M(N2SU^EU*C(!\E/Z5I7.['[:NN%".Y$V_#!!^S^$^"%&8(/R'EML':$QYM<^
M^F_*OEV7\MT74RD?/<FO2?Z'E=8<EV4!81EO?6#"UQ56PR`FF=@>)/E#B29$
M,\YKKK0T80`+XT!@*VD;2$<I_3P5AKBS0ST\BO4VRBHR-VR[?J;FNXI^:/!-
M^\*ZK2,RW*B-87LH6<-\>NT3BI$O>]DVO</TV8PV%]C:X.<$.S`1G(-W+VGJ
M$JN4(#6562F4L".\M[<R*T-ZEHHH)-+G'NG6^M3(D#A8"X-QLC(Q[EZW@!VI
MN"'1$*69:U;-W73?2V#JWLALYZ*WNQ=P2KD0BIA@SZZV7Z"X!MTG(&(^(YQB
MN$KPFUH-<:7W-D'="0)*K4K6['?1KX:PKAC>*OPLNI)@W81L![<_9Q8.NF?U
MWPU"D71CZ*#DFHA@>5''CLTD;\Y?)K>,44HY^)$.H*G;9CW-64+W`3":%AG`
MNG\3\Y$^?C&WE7'\)!!.*V@./H&02=#K+`V,:Z68S1(4"Q6J_&WD"-C2)XV&
ME?`#X/6?.G:(>42-K7?G!0:XFUP?OK4Z%J'CG/W?.1'KKR;714J7(!A._UPM
M$@B+X5"NKR30NB;^DH+%HETAS)'51CEKD-"3=%B?94E9,K$H,<"[5I8F4[P6
M3>!F^/!IDI'80+E4:DW2QWZ`KBH6.GN5:QG;NBPR^+",K1*:Q90`HN2"RC0E
M-?+=-GT9#V6(55/:6#IK0%LQFX-;N_8"E1XBN_TU'2YI_)H6:A87`[N5FM-F
MY*94UJ@G:=ML(B!&'#,G*^H4/N:,/:0.],_WV#KT#;`%DQ0>C83*U2)=.SSY
M*HW:Z@&0Q3=H.\\"OK]BV[V/77?U65.ZW08&$-UT0LQN-<?[:HS\!=&5M(/.
M$[(S.H"A9@5)'!A)?W\"K,Q04US*5(GT$I&M?'3$M]OHP,-6:H5T@O463*ZH
MZ[\@T8"(<`C;M2QS(B&I,H2[=1J=8@V2)3BP).]<\\PLA5DY%]K(THHYUT5]
M6MV$FYD7T,3\`F8BB1["HT1%VNMIKR\1H1\9?T89,\4,]EQ$**/+(0<0W<8)
MBFRV\M@6[LT,7P._'7<DL8DIFZ;++"&OEK1*V!6H/I?KA$*3D+2>`N3*:%(@
M'4?+TJZ8M+:`M?(2!X:"Z=;#&94,#%2(SXB\1:X8T+*!$4TTF-_SC'+AR`P.
M=06M8W!'F%F&QUA8^0VEU]8B7^(G'!>+E/#K<E5;CL=K2BGJ=U9^\OY:R9^/
M9'ZY>Z7V[6U[,Q+KJN/!?67BR?E&FX/_DT,I.K.YNLSMS4SAYU8R"&Q>XP:X
MOKTB:5VFR$C'E!S"832Y7FWP4A4L4^@*C+U_`7[\(@=>R9Q7LQ3V<@8<#4=Q
M*X$CH7=KC)\F@9`(A<DN]8%R&FI<#3NOC2X#3-);G!Y6QX(3/SSI[7/N>&E:
M!D'9,2+Y6CU3D[$_7Z;@J:"AMRVK"6`2LK^-QQ/W]I^761*XK\K6Q<<E3H`P
M%4A(V^$FYLAS)2+EH/CR3@Q'9A12HEHV[VW.MNF<B74\'9L"S/ED<Y`A0Y<R
M2`Q/NDRYI-XE8M7"4QPH&%OFI+(3.6[[S]^M.,C_:"[]@]1]_/CK!V2P_P4J
M0I5:%.9?:;('N>;H>:"AO%D7_')!&_]DZ9CE']6@FAG'IKKM^6"OZL6,[6L3
MGCH5+I>56A^,NXW0RIFFYFBJM%(SXVHMWI9&%3?R*"*0U>UTZ(^8H[45R(C"
MG&1^3*RO=1"-[C8J<)DD+9UOZ.(H[3JPHM"V%T$VM<XD:QU1KW'+.42^ZK9'
M0P>A8-77]4%DT4:_=)*XPF9O]4A`YZMK#-[1U';8_[@_WA0K&$W=-]`?&5W[
M@GL@DR;KK\RIS9J_*"0%VV/M\)M@G^[86?`U:U(&YV0DHX3DOI&?L=]7:D%"
M\0C*V5L7>P+.28C;)+QKVH%G!1S>OJO&^ZS>03A>9"E7I;Z@HI&>>?CME5JJ
MG,1LCN&4OP_MX&M&KE73V\TU*2YKE\5Z:F))6K5T-RB?'67.M5`ME"$]!P-.
M69MT`RR,8>^@[6DA^SEA%&+`^P"\=8PJL$Y&JZ;@W]`X(Z*G8T1L98DIN#)^
MB9G<Q#D+4IM]D]O,"]<BC)/12G.QV=WU*8_RBI/)]0]N@!7I`$SA*W,2NQ1(
MN79T3B$(W11%79)/W<:X^)UN[HMLPE;V'&O971ZY8*V-5]WN_ANL764Q+,.=
MS-T[H;8!!O@,$RH;=<:+"[\I/Q[G<\,R\+_TO9D^\I8Y@R/&[';//TW.Y)&P
MK1\?OV/@\'G$QCC0NM_QJ`\/,_CPT4U&G;6F5G<UE'S%5->=M;_7.W!YO0^V
MW@-C?[5XF7>48WR6I@WZG9%M66A3,%,_RHGF3+"%SV)QWYN+@4F'/JN2D"`3
M#00Y73!N0V`;?-AJ:D/OGFW@2)F>N]5"VL;`PX!5=J2F:R2ZK3;X"]-\>`QM
MM?.)E28T38.(5H5MZV_E(AI;!`WJ['<'#L-L>^/"9AT7^062;.A5$[,AU(_-
M(&#J5BRM:5+]D#294AT%&CH($>#DB?3.]]_X]()M[3;W_#"P_-/DWQ'K]19(
M.Z#9`*MMZ*"L@C<$39:%[7!H,RX[D%[ZD67_\XLQ2WRD=ZP6CQ@V0,X(A"CX
MST>TCEAMHY#'>#^C_8V'MWO)%WAFP.0\XC.,:>5_KF[#5KZ1T7M\V_3(;6]8
MC.D.,10&TJ=Y\$L[#^R"+,',(X4%&%R,XQ*?#EWE?*%Q@-_6DI&V]1[W&G<(
MT'T^_6Z;&BZ%O[(G1[5+Y4EZL@O'FB?N2I>6RX'XF.)P9(;K^%O/\:_%!"/M
MA@X:A:(7N^^6(71+]XW'Z-W.[L-P"1*G4@`3[PFL@`9%]'E^!(K=L]+KAAZ]
MSNU75S"+^_BEVEM%2;?Z[H'8J!NG&7/&ND-&.I=+E2VP8(I*HEP(+6V:)F]]
MP'M&O^SU'6[0^W=R]4+C;Z=JAO>#<M81,SJDN+;@NPDIUX*H%O_^!<2!8FZ5
M@4#K0!G3%ZZ]6BG!Z\H?Y@K.['SA*HO6MD6^WN1PC=!E6Y>I2ZG1I'11`A'!
M))&A*T94))+[8W(M0D?512>!*24H^@U>V9MD$7WEEWE957)G<=M^W1SM#9]V
MCMY0'AKUNN&%=J:FUE0R[_]ANE:T'U]UV4'8U)Q.R45[E>;[/_;VWG^@$RR[
MZKV]J$[LEFIW6^^E3BCL;=X:.W`*(TOZ!E3P;0HU1+%*;[Y128UJD!!]3SP.
MNK])K$)U`!,2IV+%I-[PH2:=Z8'=O5%ABK#Q17@D^^6G;]-5QO;]"5!+`P04
M````"``&>JA&;OWQ(!T*``!D:P``%0`<`&)C<G@M,C`Q-3`S,S%?8V%L+GAM
M;%54"0`#?`M-57P+355U>`L``00E#@``!#D!``#E76MSVKH6_7YGSG_PS?ER
M[W0HD)#F,6UG*(\D;1+2A+QZYDQ'R`)T8B0BR03ZZX]D[`0#QL9(F*3]$C"R
MUO9:TM;6EJQ^_&\N9QTA@A@0R+9:(PM7_B=Z_[=R5H7V^E<06R=$R%^AP`,D
MKY$!8O*[_+TK1/\PGW]Z>GH/95$.,4.<N@PBKBY8N=QG2_W[XS\?%4B%(05Q
M:-49ML[`R"KL6\6]PYWMP^V"==VL6-N%XN[X)GF'@\E#"W!D#7L.X9^V)L"&
M+>:\IZR3WRX4=O)!P:UQR<.ANA`J_[3CE2X>'!SDO5^?BW(\KZ"LMIB_.SN]
M@EW4`SE,N``$*@".#[EW\91"(#`E">RR(DNH;[F@6$Y=RA6W<SO%]T-N;WT>
M,V=9'QEUT"5J6Y[IAV+41Y^V..[U'661=ZW+4/O35@NR84YQ6-@9U_&GNO*3
M_92:<>I@6['_!3CJ6:ZZ"(DM2U5]?7D2>HH6II"-N%`2YE6!?.3]^4!?W5:>
M$`F.KH3\W$,DE:'354A;]=M9`;Q;=^A3&@.?[\U_UD6A:K"VZR#[#`B783%J
M4R:Z2/5C0$;\1'9=+A0;O`E:JM9D5B];K3:J5<U$4#9:RMRINR8;*00.=!VO
MYYY*_)!E:"@0L9$=V*;J2MLQGCNOQ'0H#.$XRG50%L`XH(6<3ULNSW4`Z/\L
M<XX$#_/CV^`YCS;@+<^#^#=(3U(LY9$C>'!%,5G*%8J^(_ESJF9?G)2&55S&
MO`YIRKX`8$*UL&YE%K8:,!A8(S_.B!;VN'Z)/'=[/:^V');N(;B_S6@O2@E!
M(ZF@S$;LTU9QRWI"N-,5ZF/8_"69'@#LJ*9;I^P*..@*0=7K,.)5U!(OW\XI
M@0;E6-Z*_.?-E2P%I[ZNV].ZIA+U@M&^C)M&%])+B#*Q:X\N[BN?>8Z,R+<0
M;Y,[UV*B?$UV5NUKW@!316TDM;8KU)&7*?.,K@W[B'`TSP]'C%,)JIEH-IO!
M=N+G]PDOS1">JA<T9-C`QE6;]5[S@5[&OLU0(886G_M=/=Q?"0H?NM21=7+5
MJ<3(!/%S4%89"R^8WT:]>F^`XR(SWG(6)N,^&RU7V%O.X2<R($DE@0SS>Y28
MY7\&(]N>FHS[66*B(H;4D:!M8V4J<"X`EC/:"NAC`9P)8".17SSJJ^@;2=B+
MC"?2Z06AVU-D(-MSZ6J&S%!7CJ=X@,8)B5/*N8QD&NTF&!H1;TD3)A]V@Z5<
MEMB(L"65JI=(`$R070.,8-+A$\;("`I#;"2"28#Z*GIA$O;T!CJG&+2PXTWG
MY/QA/6%/+*:6QS&8?9F#DOTL,:F2D^UM'ET1`5$J.8))TR4:(.(BL].8:+#,
M<RUIM%G`763HM*)(1%3D7RS6I=,<O-?9CQ93&!$WO;)GG%=J0>3P,3^U?O#9
M^*K"]"I6VO2CRGGRH-N9R3A.0^33+X),5G5$J<W78/(S3N:>-4*K4,.=2Y#.
M8>Z2CH`C1CZ&D0`WC)!U,!M/^C0ENF;[7BYV(@<[0-*!>=.<2\21?(BN_%Z5
MJ`[M]V8&L(BD]#+U93]`+6!_>786CTW+)K^X4..)GQ4WLC`[@[&*L8VVYP^N
MY*!FRM9)B,R=991`X43=%"]1"=*4Z8%YS="WQTQF8!%@QGXTB1XQC$7XU53B
MC#>V.1*I;/<PP5R,?8A!>>(@LPV3D^@32YK>K*D_KIKL,6&$U]!%ICC1F<^4
M`^Q+RM0$W6&`519`&GVU+163CEF#Y\%DW$CFBA1:,YY'C=Z5/V_?+^(B"+C&
M2"8$B$#*>G$B5H0HAK0.80`3A=\@=<ID;62<UH2C*F)XX#GF$R)=M.OMP#RG
MHHJX+*6R!V5^C.R.UT:>"Q@9\C2;N.E]3[LD>@?4H%4:'%&G(8)Y@+?1_Z_;
MLYO2WW_=P;X[O">[!_:OO4'G?D2NJ^[3T1X[V/NV_<]U<\2=O0'\57"^BOWK
MRNF%??_#V=DE=ZU&I7HR.FH^G@!<N^ZX3X\/MT>@!/N#4O%#]^SL^)\?1_O#
M6NG#\/1=CY5@>[_Y>-#:*YS=/'W]]:W#/AQ7VO>P?O>#Y_=1+7_;^M(<LIOJ
M6>?>_4[$_6V]6JCE^^1N]^YB<-[\<>U>?N^?WSRXG()WL'10.FN6:X/];^Y=
MNW5\6SDN.HVO\'MY!XIFC5:O3^R+W:/C^I=ZH5-Y5SVXQVB[95=KI?+=5XZV
M'6?8*ST<D_-&M5W]VZI<7?JO,VQN6YYI++.A1BZ4U\@@"_J\57Z%4$(2H:JY
M8'2`I25?1M=<I5>?A]&R>K]EO&Q$B;S@RFO^C](20V'2*A:E]P^9!H`9=0(-
MVD_VFBD*]2XP]AF"V,.6GQWD427G8CW*!/[E73>SAI4`-]O)JWX=DY$=G>E-
MM[S1!0Q]`5SMO.TIKVM,TPBD#8BK->L81:FN_>+/&Y$FVD6C7<<$$"B-\Z;T
M1K9S+<)[BXYU,<$ZTR#2?S,D6TP5C?^>D#*$U)7Q^`48J5=%E!N`D+G(GEA;
M-A-,I[(D^UF29NW3*A*U?4Q3LP@B9-\(0VO1B7#?VO";C&Q?WP^:AM]9T*E]
M2>N1=QKT+7KS!%3[XNZ9<>DO"1ES+]8F0/T-7/4LT[ZR^[.)!$WB7B*()*9T
M$VO2=1+P-Y`TQ*^OYH$Q-8/7]M<69$T"_@9JAO@-$A:%.5D^37I>,-0'V`X<
M?O!>J;]2LDYWG,B2WZ`%)%,D:!K%59M&[#O&E2X@'<0GG]*S05H4.>-*\0YV
M0IBW$EMKHSUH"-N:7'[$(XZ/C]FD#'Q2B])3(1$A0C:ORS:@]CY*ZH.S=1KM
MZ+,J3'"0UI3,=_[I:4Y31T^D4T7OM@LY]1T?ID3+\-'%#$F[;!>:G<3$@V[L
M_'05Q>.IGLW]Y[1FERZE[0Q#?Y5S7?.8$.:&+@>LH&L\S;,+`[GT>8>99K3X
MN*&U]-\8$]Z>YDN+$+7106=P\[R`L3'!35*+]`0W)YR[ZEB\1MOPH17QH!L[
M?BW91J(BE@BJ=6Y-"`5(JOI&WS.M-D0,8HZ,O'(2#_K6E8V@6N<FTQDX=?R:
M^?G&"]*&CD<Z%?0IU7J$G9>B[0M_[&NT(_>C>HD`=8RSDRB?DJ;>C4R@I!`P
M/;$ZMR>HAY$34/5'O9H^D`&,6@B7N-2>#F]-]-.E\+-^HR8%5U.[^59*OL6\
M3_B&*$D<G\<<GOJ&*$GL8:(<_QHW52][DG?:-,=Z4YB+LY0&SF#VV9/?;K'H
M8M(@Z!X!5@>8&3LB<46+LHZOXEM$\N.:X^F//I)[^1`KJ2WEMHP"I"G-+J-N
MI]M\HLHH'M$H(N(N;6"O0V_-!.N8$2UETOB3=/W*M,`@K4+/1\CX(&/]VD80
M&3-76M.H.?4?2JRR2<*OR-@>THGZ5]F;XU=S2]F#VC8@)[+^X9KJZ`8V,+5#
M)QXV\U7'>1*&5QX2<*?[-6T?LJ[.:I`!7G`BU)KD6@#[>N1:Q-W"LPGG^J"/
MS__[DQ=!_PM02P,$%`````@`!GJH1H9%>L$#,0``^@4#`!4`'`!B8W)X+3(P
M,34P,S,Q7V1E9BYX;6Q55`D``WP+355\"TU5=7@+``$$)0X```0Y`0``[7U;
M<^.VLN[[J3K_P7OVR]FURO%<5S*I9%?)DC7CQ+=ERYG,VK4K19.0Q`Q%.`"I
ML>;7'X`7B91($`#1A.@H#QE;%M'-_AJ-!M#X\--_'!\??4`A(DZ$O*.'U9$_
M_'_1XK^.CH^&>/%XY_I'YV'$_NI&_A*QS\(E(NQW]O=Y%#W^>'+R]>O7[USV
M5>KZ!%$<$Q=1_L'1\?%_'_'__N__^8D+&1+$1?QX-";^T:6S.GKYP]&K[W]\
M\_K'UR^/[B?#H]<O7[U+'V)/!'[XY<&AZ.AI$83TYQ<%84\/)/@.D]G)ZY<O
MWYSD7WR1?O/')_Y!Z?M?WR3??O7^_?N3Y*_KKU*_ZHNLV5<GOU]>W+ESM'".
M_9!&3NAR`=3_D28?7F#7B7P<2NAU5/L-_MMQ_K5C_M'QJ]?';UY]]T2]M8KL
M.UZT%E-LX-U)^L<7B<&.CGXB.$"W:'J4O../T>H1_?R"^HO'@*N>?#8G:/KS
MBP>7/!US8[]\DPK[3_[)'^0/!B[%@>]QF$Z=@+_TW1RAZ,41;_K^]KSTN@\^
M=LF*1ASK$_Z%D]KG3W)'@-3RCQN'H#":H\AWG8"V57J[.;!W.`^9+N@N8C\O
MF$`=O;>;8+J:UW/HT/DXP%]U%%P_>V+,6:]PA%[=^;/0GS*`PFC@NC@.(S^<
MW3"IKH^D/4"B):/@<WFO[R+L?CEE'=_C81:%-(DG*BK7-6$,?"[DS1`'@?.`
MV>C`PK\3>M>L1Y!;1)%#W#G[?826*,"/W.T8X!$?)Y0,KR?`Z#N^O<4K)XA6
MESADG?V;,A"5SQOWF'<)W',<>(C0L[]B/UJI*%GU>**C&0UW^\SI*OE)6DE!
M"ZDMNPH;$^<A,!D\LO;,1KZ:SJ^NN[@A@QXR=GSRFQ/$"$]9#^>RG'!%SUDZ
M22/>N>G#:L):303+OH!2FT9[),\-O3A`WJ43Q81UIBDFU2HHO9!JL\;BX%V\
M6#ADA:>WR$7^,D%?3?/:!LPY/G_],,)DI:39UE-FW6#SUDQ(K&^SXM/F0.5=
MF^6&[/79V'K#<ML!G\7YD:^J:&-#!@/%)^3/YBQG'+")IC-#`TKCQ2./291U
MAD23Z^37P5>'>/0#84$7>1$^8R+P"B'*<P8V$W49Y#0.V7#'.E!)=Z57[T@;
MHPF->#P:H<CQY>='\@V:'J9KAB8-_1M:,IZK:26U&N_52H[QMZ[*@S5>2M2,
M:1>KR(HU-!:T8F#P&V$WY@`.0N^,];MH=1ZRT+-0FJ8(V\AC#_,962UKUK3R
M)2F^F/4N4=[SF5C*I!Q[:.K$0?3B*!-35'K=AA]&)^R1D^P[)[N/=Z0L7CA^
MJ*UK^G3!62&TG;,FB!L_H..U9#6%JQHH!@40$R>F.5Z@Q0,BBO8M/;I)."#4
M=()`33G^P$8EYJQ^Z//.=<&$E]1"3Q%B:8"7*\:?UEU6S>4QB0%V2V("OD"-
M22Z%#1(H^/E%3(]GCO/XQWJED*F'SMF/M-).R=M.'?J0O'+V,#/8J[<G*(AH
M_@D/5V^/7[[*EJ[_4R"EX%[Z2F?Y&Z#"Y8E+"=`!*>O,'"!7)?,%.6?)GID2
MO)#!)<+UAL"$C3L_OWC)OINX\8\N&^J9GYT%R;=85T"S=&4Y_WN`62;T\XN(
MQ*6W5,,C2P0I'P'I!79"RD:7L1\R_V3)X68:>+K:_,QGXX,G'\3=6NFSB=7&
MT:Z,TT+T2PY>1+Z=R7?]9-L/]!RA+&N4#9WF`:Z4`PC<;CI0A9J);E#$N-J:
MC=@90^Z/EUUB!PU<GG3:0HY;,\/NE:#?Z<$W0E-$"/*RY:,!(4XX2R,(8)R5
MD`HV<AJ,I3+&:T8.`#>X`"HEMX-.*8BF\BXMCR5L#)61#1-39>&$'QY%418.
M49#8FBP.Y=)+RVN9*I?9U%5BC4FB&;!(N3715D>F'(8X-M*FD4@TVZ!R0[`7
MN]&=$R"J@4;%XV`Q#QB$*DL8'K,2>06P<5C8X%.P?D,3D&E\,PBB&<S:Z$U&
M,._UN7H3XG@HSU8WDJNL;V9D$0NT&;.:D)(T&5!B-Z`4173P0).=%I!%CK($
MFU#(+59MFT1FP-8S/J\Q9!,X_@_?@UFRH,BP'T1#AY`5F]`EA2(0F,@)!DS$
MFK&J=LPB3I+6DPERFDL13#??S6I%K>"HJL*>(ZIL4;!UBL'2\0,>?L>8\%SE
M#KF\N"DI'7B(-K\-8T+2=6KS<5-1A3W'5MFB&;:OS6.[,\9>H0@22)&\\O"Q
MC[@)K96!],;\V+BN@;M"(*B4VM_SOE.V16;SM\8[Q@U!CX[OG3WQ<B,TR&IS
M4O4`^X>,6+N3K6:$I$R7`?<.:&UVB"DH3I5R]AV8:N-D2/P39#(%.914=`KK
MZT!5?K<[G]JVO>$U;=GTX@J'KOV<K:#%OG<@'<-F$']ON'O=$/R(2+3B-<A)
M72";&22%HD`I@E#>WB=N8FME$/T`M.!=6GG,1\5$9=UMB.UF;*XCU1M?V@B9
M_=^;KFPIY!VPH:Y:D,5MB>8>46.;?!'!_`I1E<>;3`1LFEOH:+O#/^1FPX7O
M//A!,@JQ.+=;V0ZYNBTMV^XX+[?R+6_(QL695BLS-\Z*9QP=K,EL2;*Z#J#J
MQE6K--N6@^MT3")KPBLH#0M7C3"[W:HE9'4&E%C6UEQ3BQ!!-(+O7S62>MN_
MZBPGLTAMI$BK@W6=+4F]Q:K.<G!KU1<XG$T0621EN9F+@"0;57+Z&P&KS2:Q
MO-TV2P3L3+5#E#V$!,Y9D_P!K]5M=5#8>6J]L/YV'($!F_<8VF(61D/VKQ]U
M!5N%/-L]R@AT579LW)?0/(;8Y8Q8/`?N(V82$V'!4K?^9FSJ*8ETL`JB*C%V
M2_14D*DT$M2AP2%>+'`("\>.#(M=1@V*7>O`U4T./"\QA!/<.+YW'@Z=1S]R
M@H(*((L0S5)M]IQ6:Q$2!FW>,=)=1XH7<<"9`I(E9<YV0]"<G]-9HI0E]`)3
M>H6BZ^G$>0):75)2H;<S8V5;2^Q2:1?/1NQ-D7?FD-`/9[2@&DN1?-<'R4TD
MI/:U"\L85&:GRU"&V4UF:7LF(._%XGS2YNZ8C5TQNR%4#[5F.\I6H_]T4F;;
M*1`8=4/#LTT4?F#E.;#R'%AYC.AS8.4YL/(<6'D.K#P'5IX#*\^!E>?`RF,6
MS`,KSX&5Y\#*<V#E,0W"@96G&ZZ7`RO/@95'??/_QB'7)$E$O61K]0:1N[E#
M.J@'J)5L>=U=;GU+UHI@\ZJR`HDT.HBC.2;^M\U"+AQ\.Q+[<`BER6@P1T^J
MI%['$;]'U6.3^*ZP*HJT6OJABU3)9LT5U\:P.J<T[JY+9=)ZB5!NJ>8ZZ[95
M4EV.6S)B^Q#]I,S76.3;%KDNABJ1.*O;P\I`U8Y1`GX10Q#!A;TZ4;W(_&KM
M!%:NNR,1.'D0RNLG1E6I@Y"?PEHMQ?;EY=IU^8?JB4/U1,M\:ZW&G8M"A_@8
M:KNN6A!4"FQP@Z[&0F"\L+F8^Y`^(M>?^LB#VXJK%V:]H$'HF26`Z@W6#))9
MB&`VV(0@V=Q3:P^1[-Z9;EU)>LLTY'FU'1E[/ZO?M0K0,G2R'Y1)^X"Q1X&(
MUBKEV-[)J?:\4J>H-`\<WWAZR7`F$*0KE"78W9]IMO^V04S3IFSOUBW7Q*[Y
M?=6#TGW5JON7C>U9/]U0CX&Z;<#XO(O=L(,`92\VZ?IC7<R2#5?JG28C.ZP9
MMVMZQLY#>SL0U[PCF(=SAMWK:3+$W.$`:+FO+,*BA]<Y3WGQ:,LB4'7-5?TJ
M4Q`F&14)M#$@2T/28"NX2<('%"+B!$SNP%LPHW`5>7`$A*E)I(7()8U3H[F:
MPUB;]!6R\Y0E['=OV;(&'#E90L_.^9\SK:!&CY(,BT-WM9]M#QYEBT"=:+I^
M1+QSA;/-X7H(\U>)V6OOK[2+S+TF[7@O\W0YE0J!1(TD*_O9TFC4F0>*2RR7
M!S@4;(O8\W1VQR(P1&`?F**\KUV'8TR0/PM3HC]W-4+$7R99P'G(M(QYYL:/
MLXT09=_B6YX#^A%YLZ3'KK\`DED95G&OPZ!Q/&3*&_1<YPI%L&-868"EE2]I
MY+;,(5NMH&SVG*(BK_TZ=:CO\AF6'\013.%/D\A]GMLTFJN9T$@+ID^L\\YY
MKURRO&:&KF+^#M?31(="64L'Z&EJLM=A4M>ZS71'^E>L5%!GW8<$.0$O`/R(
M`Z[0)KQOKDD:$)^R/XW8K^&,N:F//4AJ,S!=]SU`PX&4>Q7$?="[^D(ZATC<
M?L]8A(;*`6I<A[=2.\BO-!X'^.N+%AM>A[K!0]W@H6[P4#=XJ!L\U`T>Z@8+
M."4)Q'IQ>>!&_C)-Z%3J$$3/[_'!I.9WA]N"_1NM#DEX5_-"D6E&DX'W9TRC
M9!%P@F\1RR!</^`I,9<ZP>P'GG;>4WYTI6WW,"7+UCJ2)(!F[0K7]4:(S81<
M/R$383\'*+%CZ`T6F$3^M^1SB!XI)=<6QH;[0YE02L;>4/E'MJC):9,6?)H,
M!F^-)'O+`H"0UED5ZAK&HJM<3]=$D4E9`@260GDVQU)`3,4V!JO49&,]0<R3
M1BC]]SS<;.7!W08M(=7:`C\@QC+&-E]7E59ASSF[&BVJG%X_'A8O=%7*JQ2;
M[$/ZI&HEN-M4=UVE0+S639<L"K36&_7\5MSI2I:$(Z_;%7P>+EE8P<3O"L*B
MP&<%8<F2<'.57<$W!#TZOI?S4&9[/WDA6I<CII0FSPIT.=N;C\EU]*\XS%20
M>UFI0=6`&%L#K3[DQ@PLDSP9"@0YQ69V03&?4+LNDU*/.%0@D-+D604".=M#
MEF?OCD=I/6RF$="I3BFY_>O^:F9M+O(V-A$N$51W-0\N"[6YV@&!Z(Y1)9CG
MM+=X^$3]AN"E[R'O=%4[91_BD'T0L\^R/^(0:D^HC4;VEC+;.T);,"3JQ-53
M.CZ)H"TVED3/[_N^J_#=X98U6"#/5M8&[E^Q3U!&Y`^ZVM@LU&:4E?#"$D-N
MLP6[7-*X9;H3W\WJ!+M:F"K)M!<7%:%KMAX<L?NVUPR6CA_PG&J,":?8V-02
MC]`#2/*JJD)O8%6V+=AF#@L%+D(>';-WX8+9^'SI1%SVZGI:KQ4(VIJJ6#SW
MJ`J[KK&!2.9K4JR*M[*<[\IJ9#6%:MF5)')?:6"`2K#66\R:V:_H^7W/?H7O
M#L=L470J3O#-[[>^GA9XI:$C<;50F]FOA!?6!=T:"\)EOZ68P(5=/R9=].P)
M$=>G4+=Y-`GM*7PU%H3;S-L1?A,X,`-?C21[&6U;F#)+&4]<$^62[?C'*$NC
MKZ>UU`+)SE#$N:"D!BB==FTMGDL"I&\ON$&M)KVI>"/+>:>L1O:Z:8N>()%P
M2B,"12[%E6)Y-/_GC$V4ERQSYIMXR7'E[;41"+]0DF]MPU0Q5JL9M7%/U""P
M`^:%A*S8FR2W076'Z+;@WHR[DG:4H+GJ]KCX%8[0JSL6J?RI[SIAE.W/<RX"
M'/@NGQ?KUY[OM`7)K2^0IMLYA':9,&N?!D`S/TG)EDF[FP$N'7V0M*;<>99.
M>\CK))7>/;:AZ5<CG_)WBDDZ`5ZW=XN"A+:!'QQ(#HH\<(GY(C5DYVFID7YB
M(2WXM"@8M.^U5<ERIS3C7*5C:&TQDLQ*.^W2;TKD]LX6N;U3(I;FN38W#M7M
M\-=DYH39":$-04MZF.^&,)EA5#X]Y`3KI5#0?F]&,>V-C_(%`X3P6A7>],;C
M0'NZBGC+O=JH!Y7IC10@D%Z@[;0KO\UHF"]QB-;'8O7JBBI:4MI9$3VO6>I4
MT61-IY#7R;I;RQI[LW(FM,(>IHSODI1QC@.F&>53PFCU0I\_:;LI+@%R7&B0
MV(9YJ++EC@*^O'"K]\'(H%UFCY*VJ2RC5&=]97<J>+I*?EJ]:+&RW=NEA^P\
M#76)_YB.YSSC=L+,)FJ17Z8=NU??R:T@R!L%YFJ>4L(E!,)47BJ0UZLU'['E
M@*Z2O"$^)NDR^BUR`X?29-DI,=*:(:#@3C#[R(HZ]`I6=0L#7?13LX7201>5
M$FRUF$JQI\I9LG$SVB",Y1+K.N6Z0U=2GSZ,J&8,+W-,4_.P`B^PY$&D@ZY<
M+ZQ/2`I,)KOIJ`Q3@8VC`YP$TBS.UM10$EE,YCBE?G?BE!OB282YWE0IRT95
MAGY7JC:7Z;.,&XF1$\Y\?B`^.0@VYN9!%_X2>7"#7+/07N6D$C9LOCI'@PXU
MI2_(;Q+0F:8W--&'44C*%(T7XN@>;,0+-'&>.@EN-;+Z%-SJS-5\A8W6_@53
M+U[$R4YQW44IG)Y/L^/H-+W_8+4R7/.E,9K)7D+[P&D59ZG).LGYFH3V:HR2
ML*',C3*:^`GNS(;+,F3$]F&$4S)C#B)`S7XU@7!Z&(?IQ.("4X<%B.3<!QRL
M.FKT9I:F9>,<<T,%VMFYYM)=K8G/I20\999AG<%3M^T^=-9VQLN1-,53E1+Q
M9"=!^%6J:#`C"#4N;]61]TJUU(.E9Q6[Y)B8)YO:OL>S@ZRF261O`F6C[7+8
MZE=,M#"[I^AZ>D8C?\&R8Y"#:%L2]G_*4&>:'`%S]P6GW18G@R#)B@XO'?(%
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M*8T7CXU1&<YO6FCX[&@23",H>25L9\/$>I:`I]$<92>PZ*;NF#ZL)JSMY#7T
M28,V5JR?O5QLL\/"N+F,`D9ZO&#"G1C3TENFPJ$VHYP@J.Z96AY0W1$;#;L;
MSG$8L;YQ%B2K@S^_H&C&?S"[?;7I,[S##)Y\H.O&=J1`QMPY>Y*X\0,Z9I_R
M(K7-P3IU?$M^7WW,86,Z*-+#LJPA&Q9FF&3D`Y>EH04.MDJI<*E8CMQQ.H)6
M`UCOOO5(55O/'G)_O+2('3QZ:.K$000+'S=A8XZBM[U_]P$O$0F3U&F&0C=;
ML=S$![CN)RW;[@*%?&PJ%0=(&U:.445C5YH\\D41U!6<8H$VY[1Z"#88$*8_
M<I)^SO+N!#<.&^0AT:H29+$<2A>D2GM)+,,;WO8<+#")_&_I=+;;K<^R:)L=
MK?5\0MJ^AODL&O;PLN-6>9EKR[W/[=9L$B#I`J9JL,8.:;@[?B"8TON0("?@
M3O.!&0)DYJ>H01^AUC4VV#7CTHKP,UM604\4L)N]=@=[:FT)H@K#H'>+\#/M
MPH#4%5>Q&R"'C&,47*&(Z9Z.Y`X4'Y10GN6MD-8(BHW9R&NAMWK^R)+R@N#K
MA\"?)1*O<.BF-1,@"^<R<OO<'>4,*\&$H4G>ENVT,:4+2D`@62/)[@6(;=&K
M,U\S]84V8(4;QZ`1JQ'5]_A9:T(IQHS.-H#S]UQ?ISIE8;YR)SC?`]8O0%O+
M8):<K&7<%60H\7)K-`LR%RC7W7[RH[D?7H?H,T<\WU[O-G64TLC>-4SZ_B"7
M8LH!8G@U7*DX>S"-$&$J3>8$Q[/YY"OFRM$:=VE9\]XHK*^>8-CD,(7QLOJE
M/X6S1,]<.Z-^4"W!UA6;'4)?8]KNE^Z?_P)")_%=DK&VNQPJ7BP<LL+%`QR;
MBCF-F-%\+G"$(F8=6B5Y)RL5!@]#HG2C8ROQ%85T$&_9<<D<@`>L(Z8)<[<N
MK]-.P?EV+9N/;>XS@JJRJQ8$Y0&-17:&>THQR-:8%*J&JR"(#D+O"H?.YI,)
M^XFRP8#73<.5(ZBJ`)@<2Q7F"9V^-%ZJVA;LV(.B)C!E>UHXVRWB@X):JJBO
M%;T`Y=&)7F`FF>FSIN(J1*#3U:D?L!9F_`:[F$+62+?6":RPQ6:D;X\43!U:
M47)1[J@4$X$XYZLD=E/,*XCXIOI4#4=]I96E+X$TC"],[&]&V&:8[QY?N0%`
M8_IV?S="CPY))O/7TX_("2).HOHQ7CCA'2)+WZVN`ZZ9IBDT9Y=_2B^-74_#
M5,P&P\ER-V?JX9G/[X'!%Y&G`%+-H[T&I,X<QI>$<X5Y)T5>3BX`-]NIE&.W
M3DQNP"\&MVIC0<U1[\.'CL"ID62U)ZFC4V<OF;[3.J6X0M$0KBZH6I"M977S
M:X(-!I5*^#M;95^3YV@>1L_XH[-&E"H-=I]J=XPQ:>L3)E_.PZ1,A-*DQ([3
MT),ES#:1C%@[XX(8E\H[G$2F`SKDMI;-KR"B<^1]P-CK$#:!V-[`)C(=T/K4
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M\F$;^;"-?-A&_OMN(Q\V$0Z;"(=-!-T`R:MB:38ZYW-JB!A8*<?BJH/A;%9L
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M;FW2V;E?*J,JPT&Y;Y[)$H@I\B/.GMI'Y]Q5WR*1R=XY:`6XIADSLU7O=J&_
MW)&2OVQ27,F]!$@-^C0<=P%((WNGE;QPCP?9^J&T+VX%!5(CB2C8D$F5--V[
MF89!]9_AD&D27`E*5#T/35Z>TAAYHX2;*E4F7>$I7BJ8ZP,3T]2UL+CMJ^TP
M&K9NI%:U$Y=R#?L;FM3>H(_>UC'&4G2RW:;TV=0C)LAJ7B^A1I^RL,Z@R9=^
M31^A,JC[(/3.GA[][";V?4[[FY5^AAE8>R!S'P0HFH-6?N^&9-`7>HXC-*P'
MY*XMV,/HM)AB2]O"Y>533`KI<3I.)),GY$7X;/$8X!5"U`F]D4^0R[H<C9EL
M3A]?0D7_O%J]:N-ZU28;U08%U>ZY:I,MU92J.KK3IFUX>VAV[H=MYUX381?>
MB_DV4Y>]!"*+5V"Q"T9;BX&I<[?=B6Y`#@!WHDL[)HNT_@T'K)G`CU:W3K1?
M8Z^"VM8V7>V[,;1#P)W,@-!^Q'(;CXWNO7+FDM+VICK/SY?+WM!<%V/?CV]]
M^F5,$,KO:NV%'U<J??!C*&]H+J/I=&XD75O_0B/W4:O>OX!AX+CH[@H'`(*-
MO;Z:80<Q=>H,ZU<NW+*>27P^W@P=R@_M\']X[='2"?A>1O6G4'P:+;2!7.DW
M3+Q1R[/1!@Q(@F<=K>"8.5KI8YW\NWV':^\QX,P>;=2"8@QOYS0V^3[VQV4`
M+YJX(=B+W>B:9-064$-,I1S`J-#5V%%M/UBP^&PC9R*!N\ZA7ICU8"YRV@IP
MJNS5&(/-`@037840V0R=K0&2O%E!#Z4+',[8Y'C!;[.$O#"G4LXSB'G5]@-:
M*ML6!A?P:B399I@3>:L(%84K:`P"`Q/H1-#8)85KAXY4F--"9XB3U<>T@H*O
M"9ZN3E'HSA<.^0(5[QIEPG6EKD)?LUEE#BP:0C07#!<2&V7:#HZR;B[&<-N0
M<(LZ3;)APJ<<C'8#*022$/=SK>?S?',&;$%VW7A?[DRL7US=V*GQG*P^$(#+
MGH7F.YA5B98PMSUNQ\S2"XQM#0VT6%@VM=UX)&MMT)EJ15"$G+"*Q#W+W&UG
M]EI__-H8A+"36)&X/4S61%,FH>4Z3-&@)[>-D.U=8J:)&D0ZYB'_CPLT<X(S
M%@NBE3@R4N1^-\/+$_90"@_[81N5J@9[FX156D>"'D`9@K3]IK`F:_]2:W:2
M+H%?Y88MO[/Y@+0M0Q1]="UK)[0H&A=R&E<D)\]V(R[\$'`^(19HHRA==8&I
MCMN]PGPP]R/<S)W;RT%RS;?"U0B[3UF]%4&\K[$N::MX5[#RD2$B43+$,&'7
MTQ%ZQ-2/X'J"2)SENWK;5UZ54B*17<V/&XG?K&G\\QMH%7I*W;.63O6;AD5L
M'],#S8:RG?5V)QAC,B3(J^Y7(I+[RJ=MWSAN$!"!B63(235`^>7F-O."N_CA
MXF*H@$C-HU:B5EWZO;9LW7M"19[!S?EO@U.5>%-ZPG*4::RQVH20\HM"[;-?
M.D_^(E[`C<-E`;:#_.YJ?G$HW3(&T*74E^R=84U>$K#G)B\;`ZBT<1C3""\0
MV9F$`.:?#2(ML-4K+!J7$LPFX\%L"/&+KVER3Q[-AGD(F"JD].):F`O1+3!5
MI@/)/.^0&Y.$NN5Z.D5DF^^PCB)LYRE[1S,-G`NK,()QPOLT)4A70MBL`L]2
M"V69%P/YT@\8Y#A$Y2]]DX1$L^G]O\^L'C9=:S:68($<KAE$0X>0%7O!Y$@N
MR`:YH@I][;3:)F]F8@>!W@;6SQY<F3UY]0A]Z41\*%BEC&+7TX_^;/ZOV.'<
M)9<.^<+T?@C09KR0"LVJ;?85.3T#&F<C3]3(B!H@X-1LNL\CK:XU&VF\VW?0
MNSDF$>?)VJ3,6IVRJIT^W+4LWQ,K+=5(N*T!$=^Z*LO)5<G6"J0`:FZEO],\
M63,UDDQK[^6Q?#AP*$VWG9C-QNS5V#O$BYBOLJ=WQG*V&8+F?*=^R=EJ\`(-
M8T*8HJE+G:(I)FCB/,'D-R85[.N0"@27!-6T[I)/RBK$V;)""C+)V1;1VR!=
M:[-F$F8M;`8+%O_];XG_7$_'?NB$+E-UB"G,#$4HK[^Q6\Z<$FS#FEWL`WNW
M"TSI=3AFW9F]1=K)W=6(]?)E<NEWX7HR]JXC1-FW>)@8T(_(FS$E"U^`0-ZT
MBCU-G<$0RYT+X-;#`7L[SP]BKM0FDS][<H/80QX?=O@P$T>9VY\Y)&3:43;"
M)!1TK%/$,%=:FU&LYYYD")W<?YJOEF]?'<]D\P_8[!&$R5HHK_^#C-B<.8[F
M3J54S?99T+IA0]V4J8T+^U(Z:R5U3?47*"6#Y7C5KW5USK+Y.B$OW2$7+=)K
MZE%3BAO>L64C+Z5L>]IU2<U"U(@T9=H"&X[J*305<2EQ9TJ9IS5IIE[>POEN
M(<\^E@7L!ZVE@KN6LHBRK:`*T_1O9-LH&'J<'/G*60`>B031$R[1E#I*6=D=
MS%R7)P*G3ZX$<U@3S)GL'O*TXD]P[$>_L9R,)7A08T6Q>:@J0?!1HF0C4!C@
M0GM90$>'I05AN<+O*DP.?X:])`@F$.Z:WF;\4C'\@17(8M39I0,ROX)^8`3:
ML<*!$>B9,`)-_"A`U]/ST./W%,5.`!5LJ@7U-MNIL1M,J?".L$]^-+]%07J=
MZ=Q_G&`YP@R#\#6H8)L;2.C70B";;`MV7%Y1$Y@(J86SW3@*!37D+0G9O!7L
M=H1B^_O`M*899<MV`JK&AU\QW*^UOBKGJS*Z?,`S8':@"PWV;5U,S?:RF9_6
M[E5XC++;!M<W#2J<L1<];Y5L13-7*NQ;"0P#-O;G%S\6KH:$FW#6"[/+_P&Y
M`53L9`)C&XYUZ6G1C1A^.'=S3BGY@T*?DVK(XBES:/P4K`D4-4M7L"H@5_6<
M36JV!AM7OJ;IO;I$4JDKWL3$G3/74#1N4QL6>T2#G1O?'LB-D_N&*>NDK`/R
M&N1+]DKS5\RRKQ3,WMB(U32@<JMH;?AF`T"1&:&(]RP<IAI<.AXZ#W]QPM@A
M*R;^C0K+D5Q3ELE@Q#C(FL/L=F)*A(C(%).%PT)=,AP5-1C$LYA&BG@H-6@S
M^(LA4;.+X4NZ%#2X3PHE61K!3U549\NM@*INO^^XU5A-[CIW;1B]+8W\<(3<
M1#2?H>A!)]7F'@]!RN9I7OW2G7P>Z,D:Z<F,,\(=2/B:2/A,K;FGJSHQ;_MZ
M6KT,S5-NR<IRB78L'S#5+MB6,9'Y"<FZ8C!(_L[F\96K"(`'A"4EVSYSHH&K
MJFT;L[EV:YLI_6FU#E<XRTR2I2`ZP9$3%/_.C\DR*WQ&41W/F>&U4>/*6CU*
MV,)Y`.&#2#MUU-W6E'<(OJ0XP:<%(K@Q)K>(F]KC87+L4]<)/B-'<9&J.[7Z
MYG#6X)/)K/?)$;G6DZ_8LM_E6MBE2MD_/UNC`T$W!ZPV<R6Y`XM=Z'&(7W4`
MP5#@P:H^QK'MD7*M1@]3^<X0:J3@VT/7\I?[$+42-0ZN58]0,W=@B].>#X*Z
M@ZSLX*&R["!;IKWU9_.(;N@R(":7,(KV;[T)&#@)%D284\7"\I9,W91;#X3;
MQJA^%JHFC+F4,8QD>`^[=J:L]BG=+CH/4UT_$$Q!*LDAU.SA&`F*6C-_8XL=
MC_7%!G3@SGVTE+P>0O!XSR)#HS4DJ!<UBCY;Q2&ZWJ>OR4?J*D2-2^TCV`"V
MEV!0[-!'QCZA46FL&DPC1)+@,G(B8%]IE-[+A1M`,`#I$[4SZ&P\.GMB3NY3
M?O[J$^*)-)O;I>1TZ5IY0E#+^03=*'8"SCX.E[EV_!I_PVE3&]#-<T?"Y%1;
M;[3NAF/')V`7*77]"CT;E:TAW4R@V;W7KNML^%_I(([FF$!5,YA7\N_F>?5H
MY;XE6BFW[%M+9A<>Y<<X34?VV<5V=/T[KA(TXI<[G='[=S83'2;9"1RRFN#\
M-!(_(X/#]&Q=6J8I6ZBMTF3/HHJ6U7+H!,O2[:`K"$W]YQ3-_)!G<\J0"9KJ
M8;=4LE1>`VGNC'>S^+/0,X)2UD[_9C;R)LKA,<PLJ1VQL^Y=#MSL3?+]U+T:
M<AN5[=O*30?PY0XGHA7L<.FO2>&J"U5,+P!*ZM#3,`0.3>Y1ADGBDM<]IS1&
MWB@FZ\7(+'S6G32'V3345*5_'M/:^+DS-!8?=WK+QYLA#IA[87Z/S!(Y87IA
MX"VBB!^49[^/T!(%^)'[?KY4F%][TN(.D#9B=^!IO'##C+16]X>T44'M=I'V
MDBS</6+4'THWDQ@PO)U[2SA)SO6T,!J!\;56"K+/UVJLRY28(:NM"L-R7"1$
M&H3>%0Z=S2<3]A-E*O/E;KC3P:HJ6&=S%7E]Z:2CJFW!&-T4-8'A/]3"V3*;
M*Q#4@&RN>?`9E()/0;\\#DUPQOHPQB0)6_1TM7U)BMD[L4THM@>7`X`$?4.P
M@5&SM]"/:P='9VM&,<LLN$8[K2&W*L(&-C`9T0_H>@9CCF7Y9H>]]BV`D3`)
MU*?)QE<J7X'3J>(QRW0UF@GZ>H)990@@/L&!YR66<8*"/V35,@H82#1CD_FL
M+2`R5@*@&!S<W=R>#FY'`XU>4?=LS[M&K4ED+F_28CI%*!SR8Q9#3!YQ>B^V
M$LEI_?-6R>7:`B$T3#,OBU:L.AM>7S)=SV\O5#K"SE.]MGN%$6#H1^[O1NC1
M(<E5XM?3C\@)(IXV?(P73I@=\E49(12:LXJ/T4G3&C458YI=-$RGP$XZ>IV'
M-/*C..(+)$&`R&S%/2F<(NYR,1WY[-VI$JQZ+=NF$P3!6-/($)GT_>!4I6NN
MOVTS1P/J>!M+2&0(ZI8NK2L-9FQ0+*I:<5Z@!@.9=BSO;L-LIDD9$(C&OEKV
M)MDW!6-=BW\C0&N-"I2WUVGQ9\Q/9IH#MJH]VQ6NW>)::5&)"8#6VN,'O$0D
M+"I^BUSD+W=+&<PL*`KE/3N<Y:S<.-W0*&XFV$7(HV/V@ND9ZH1LL2HA6+^(
M5+?5:M@N(2%,[]6S,`@#84;RM'$IXZBW%/$<\6]K]6;&0%-C=%KXR"OX4^$M
MAN>=IIY=Q%:R(P@S7T$XL^-NNI<5.-/4\23)8Y0;??;`2MH6BB&O.'Q<^"YG
M>Q\C5`.JH:M7&T3://('EGDUVEF"FDZC$Z]9C3*/RNXPD>JK=<\^SRY9:RDI
MIC<#R"B<H:U[]F^"S/:Y67,%5NE&3!C&3K#II"I]IN[9YXE,K:4DB-.,(*/0
M9^J>_9L@L]UG3._@>DM^7QE[(28R35#9Y(,3!/EADN1<3]=ICF3=B4*#5@^G
M`@&H9%``'K'TQ&/UX;5D+9"I<XD]?^J[F3Z9MZGAW$["LTH535A<@HM+8Q$O
MFXV805R^M>>'KH(E)0BJ="X9#M%7OD:4KR&H02=X_/EA);*5!,.3%A&(!B:5
M4#R[X5"`0=.22*?'H]_>XI431*M+-EV)_&_%4^(OVAP'%K2[8[3&$[]2C>EF
M@@T"U,XF-S8$%7;J3QZK(%$Z6-QLE-;GAI41RU>GDC[*F77\**U?!#IV5BD'
ML%A"_AR9K,L6U_2JK09T+_"V,+A#7#62;)_T%?FH"!6%8U,&@8$Y!B6"QN[!
MIG;H2!T\TD)G&!."0G<%%=%*[<-U$=A`5C:2\6.K;M8\OVTX$^6CQ@!&D?O=
M#"]/\J=33/+?MO$0RNBH?PB"5Y4;<@3$IC$=LD321`'+,!0VXY0.$'#1:80>
M(EY53N)D_Q<H1E5(@>P1L+&JRF3F2TVKI5TY"\##\[6R+)^'KW?2>ER*EH)*
MO.HDPJ1>0G3LQK1V`$%&-^(ODV6@C=Q;GWZ!BW,">7V.>"(SRIS(;`O?^H`.
M*'F(4)[]%$[&FZMAJS(?T"J!2"A47&Q`S6YD-(>9'#F&:F?SD/_'!9HYP5D8
M^5'#-#7/P]E#*4#LAVU<JAK<`YXFE<!7:1.)L]#*AD_;EYV(-EF]U!K8?I@P
M5@F\*3=L^9W-DX]LRY"95ZI:UDY0432N9+S0HQ!T7<X837G/HA?8"3GCP-@/
M'39K#6>;HP#T=%70F)>,LZ<0X0?60>GEC.IGGUE4)VLS"U'S>1T]1RJ(3ND5
MB^+A4CT9L=W,JP0)'T0G*WJ(E.V!\D0)V3#IHB3R-I/&/<`=)M=,*RGFSNWE
M('DW!2:)W:>L<KDT+<MMZD9VWQ:`A:5B>%"P;?W3=F@$Y':<-W52]2]O.'@E
MXGZYN<TDWL4/%Q=#!4/7/&K5DQ4&X+7%ZTP@;>[.WK)NDF7@5;3WOGZY^6Q\
MIXNW:<6-9+962]M;R=M#],M\8^TC\F:;.E:%WBELP#*OE,Q2Z.9PI]`2$,,/
M6J(P1BPSP;/4+%F?8GG+^O!4^4L[M\K65OQJ-6WU0(96A9ZN#0'(0?54N4*R
M-=RZK=NM*^X0U<24,GO*ZM@6>""'F$JR7NP\9+/87@N'W=<VS2.4B#GGF1,#
ME5>;DZ5<F?'V,Y:IN[3,N_/>S8OE.E0^?`CDMY.YR8!V/;U#H8_)'6+)!>LT
M?(XE-Y>4::AW+BYG'JAUO/*$>.T/3*&[B/W/V]R@"E\;(93>KT%$Q[R&"776
M$T4<SOCQS\21;IP5%#%:I9R>!46QS238<EKOOH\QX0Q,9T_\R-,,<4]Y!;O[
M7BFQI[@UV5&"#$>7#F=S0+/(V)),Y<[#)>OT?C@;L$1FR0RY/=X9HL=15*&?
M$579T,W\.#HSK;]BGPW.3`GDS\+2Q)V%]!$_R2BYABO54K^@4C&1%$F.)C,H
M>[$+3.EUN*5#57$/W[09(<J^Q8?E`>5Z,D<J?`&BRYI6L5?+)V`X2='[Z#`O
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M/38TF(HW0AD]@4;&6LW;;9H@W<0/@>^.`^P(,F`U3(I-]B`N5=A!YMX^=8,/
MF$8>UVH<.`8Z0+DY*TM3JJ;>LD#C9IJ^B4>(NL1/[H$U:.EBJWU(;:K-T;S!
MI1WQ$2^N"LY92O[T*UH9"_);S=K9%=$,Z]LFD=F]TC5_.L;?HD=,^/([W]N,
M#<Q!A*WW(O"([=.X':6)QV\XB,/((:NQ'["YM"D@MIOM4W?8,8GQ:Q,VLA(1
M0Y;CSC`Q%HO*C?8JP]RRA\R6CZ;E/Z$@^#7$7\,[Y%`<(B\A1":F,*AKOE=H
MU-I(9MM$>^DAY6$U-BNN;K8?`:G&)%)7'^@#L)F`C]DG!A<(MQONQ;A<:Q6)
M:PY:0I!S\@.`4&RZ#],$@6&D+B80K=__=,)%/3@4)8;X_U!+`P04````"``&
M>JA&$5;74F-?```IV`0`%0`<`&)C<G@M,C`Q-3`S,S%?;&%B+GAM;%54"0`#
M?`M-57P+355U>`L``00E#@``!#D!``#EO6MSY#:2-OK]1)S_@'?VQ(0=*[F[
M[?9Z[)G=B-*M+8_4TNABN]<Q,4&1J"J.66299*F[_.M?7'@!B[B3!"B?C=BQ
M6B(2B<P'0"*1R/S;_SD^!N]@"O.@A!%XVH/X]+-R\SDX!J?99GL?QN`R+=%?
MPS)^ANAWZ3/,T;_1W]=EN?WNU:N/'S]^$:)/BS#.89'M\A`6^!?@^/A_`/Z_
M__?_^1ONY#2'N(OOP$4>@^M@#U[_!;SYYKNOOOSNR]?@\>$4?/GZS=>T$6J1
MQ.FO3T$!P:=-DA;__2>FLT]/>?)%EJ]>??GZ]5>OZ@__1+_\[A/^1>?[CU^1
MK]]\^^VWK\A?FT^+F/<A(OOFU<_75_?A&FZ"XS@MRB`-<0=%_%U!?GF5A4$9
M9ZD&7T#X!?[7<?W9,?[5\9LOC[]Z\\6G(OK3_U#)`?"W/$O@'5P"POIWY7X+
M__M/1;S9)I@C\KMU#I=\3I(\?X7;OTKA"@L?]_(M[N7-?^%>_J/Z]57P!),_
M`?SEX]VE<%#?=FC11J^<,OH`\P):<<NT9%A.\"^N$&L=IN&G$J81C&JV,1V)
MIDDW!%<-84PZ"SM$$PR9+*]IDI[_^T^[XG@5!-M_W9>(R0U,RYOE19PBN,5!
M<IL5,0;9XJDH\?SC2I&PL@R*)\)/10[Q]>;M*YB41?V;8_R;X]=O*GC]AU&_
M2&#UH##7G6'54]Y(5E2!UH+X5_*4D#F,&J<KI*_T^/'^3__3-`79$C2-0=T:
M_%*W_^??*`O_PV@+_WN1=U46Y&'-)?I1,;+JBU=AAM:*;7G<&>0RSS9VRBXS
M"]F\L@?B:5"L%VF$_W/^VRY^#A+47[$H3X,\W\?IZL<@V?'G\T`DZG7\ZE!G
MDX)1BR<!&G$C$*01"/$/L&W>@L\']HSTRX)/7Q9C+Q=;F,=9A,"?EU=C*.NU
MB;9`4((GN(K3%)'`"POEYH^NQ-=DIDV@QO,T&D6);TR5B'9TGOK^J`I\TU&@
MT19P!]%6$H?(:/*V&9BRX'9;,.1.L$&T5`A>_:XHECIGH6DCE;&WBI(Y'XRE
M.MYVP>BN673(#PRI(W"ZRW/TDV=KTX]J7]NO/XOG($:_2N!%EM^C#NYAN,N1
MD0N+,_A4MO^JQ#O%^F/*@MOUQY`[P?ISF3XCM6ZZ)JD7A%HJG$6HC4B8Q<<,
MGV&8[9#4WF<E+*ZR("W0C*@.9.GJ#H80S0O$RLF^_?D!T5U\BHM)P#J$GU<]
M&VA:Z`[@5;B/UA\"_"4ZYJ-O_^EW.QT#(AUX#Q6;\6+\%.:?_G6:)>B?64Y\
MG2WEXAINGF#>Q3)N@!'Z]>NO*GSJD)@`?D(;0(,?T5F>;0285N`7VJZ%FTNT
M&>@(@TEW_$/7Q9;J>UA.N4G+^GM5WSTX7MAXS"@7KL+W>51'=;SU2#C:CD%D
MA**'/(A@GSYOR1D'1O(.1W>#R$`D946`(M(&U(V8Q:F_-OG!EI9"67"II7`P
MN8WPA<W>%/UYCQ`[!9PZ]-V>"]BN)48_^<3+AB73`8N`WD!&]Q-D99#(_`2'
M'/"<`.A/(*Z^BZ'O0Y2I3`<<T&]SN`WBZ/S3%J8%1);H3;F&^:(H8#GEH5RG
M6\?'&0V6!!.Q:@D@;5H0%U*&6X.0-@0!(>-UHAIHFL6:KEBL$7@&EQ"1B4ZS
M8E+(<?MQC#$>#P)0U9^"L'-@J3#&&IE>T"33&@L?X8CM78I3KTV\5<CAX4-C
MP7G`6YYH;?%TZE"M(_P58UJO\GO$MW_',L.%2Q>)/9L&3N8YNYC[VK?Q,A^(
M98"AE6UA7NYOD4Q+M(WB*Y<M%N9$9Q=I?ZX7-1DS`K1=[/(T+G<Y)-84K!L<
M@126GNTHM2*[!I1B[.;K(/'^M3LK8Q_49AI9;+6<NAID1O>;R-VZ:HZ&F4S.
MW;KZFFI<NYHR&!`<R)CQTVZ3_(Y<QJ%R.1!@B'P[#Y-*JB%VA1&/;P`^>$O(
MF/:U>S^0=.V@)O4L]-Y?$C@C&*+9RAU[&^RQ_>/@5N>@)\<1%EPF!#!H?.];
M^K5O*$A5Q;O%X8QRP!U@OH/151P\Q<GD43K"SMQ'-?`9$2,&?]\X__P>C50J
M.X",9*36!QWRQ`P=%*=?7@0]N;ZHX3$A/$+3CV>RO,A5U;UQ$([2=GFI3=P[
M^`S3'5SD.9(4>1(S98"51J].KXG5_*@..U5+P#3E!T_Y=12KU<QS&RO$8G-Y
M+#I?/<.J,X.(*`TR_@_/!QRI\-1IV:"+$X#@%D^&:I.=I'D"&6!/'V#5P176
M04_C;WA*IS*?$Q6T<OJUYUU/KB_)*C1DU^M@\3;/HEU88K>S2?REI+FSQQ<*
M1E0(J%H`TH2[J'A;4\1*Z:TE@G';7VA=9>GJ`>8;$A-<V5A3+"#<?GQ<2O$8
M$6#G?98>YQ"=;A%)D.+O>]:SCU5$IC)V#1&.U*F9*>*"&PM%9%Q]=`1:E^*+
MEO?K(=/3B0M$Z/MP"!-=KT<W`B%IFWG>V_4\'Q*7QR@FX+07*N+./$4S]1@Q
MNY_K6X6SL`OE=R[RL0\.AKM#E$[1?^/2%98X_;E>?63,J(\6GO<G'<WQ`208
MK/UJ=)M7M._++/QULH?]O&Z<&C4<!L01NA5."OSI$?C_7G_Q^O4;9$CFX!FW
M^RLHUD&.0W=WY3K+X]_1IW_^C[]\^>;+OX*OCUZ_?OU79'K6W\1%@3W^),IW
M5^*,8E&<KGP[VB1:/XCGY0IMR#N,+LW;(+_)27ZCB)"_A?D]%MST&!3V[#[>
M28<M/;"V(`6?Q2DXPWMG7N#D)Q2/G_N.*C=0O1B(4AF-M102BL6BF>+3([+7
MH_M'#1)N=%?+WMHXK[5.I%8QVKB"&/*&ID?[IMT87*&,[=)E>)6"%T.0\7;4
MN4",HU05Q@X%,>">@4?^DI@BKA!6]>8;7)0-0UQ1HVUVD.HJ4(4F9N1#\D)F
MFTV63GLXZ/7A$C2'G0M30>#/V",!<R+X3G(B0%S0,X'T0-!\_LV71V^_>0N0
M\4;2(N//OGES].W77U>_>NO9:2;"0R=9'4^DXV#0Y7E!IUO')IH&2UKXG?4Q
MP4#=`M0I#PA#8>CB<"#KSG$Z7#$G6FB3'0D\`TSG.*`:OFU06X_N=`::J"O7
MO@X!'R8H.K#-?)TJ%<J3XN?0,AL'/1.?(J7]><>1^@S)!9/`)3L/1"E.D$H9
M#'@S'44DN7R0W`9Q=)F>!MNX#!*FQRD0IM&KTRL#-3^B,/^F(<#I,(Z1B172
MMMY!IJ_93O2_GB2&7`LLPG"WV2789"-/U'`1FARN85K$S_`R#;,-O,J*XCTL
M;Y8/P:=)\&?(@O.G22;<B5^@U%3JK#,L'73(Q(3`9PDBU9X"?+U/L4'$P:L5
M8YG96G-WL`SB%$;G08Y+!A1,WV=P&8?Q)'?R&KTZ73/5_&@`,Z)?>L^?K:O0
M;LIL+0$,62K)@KO.D@CF!4X04.ZG0!:GERFL/.5+W#X?TC"S@OF<^-2^^2M)
M"%'NO>^]8KUUB_UPQSM*0.(BC=R`1]GG!,\05$!2\22%%1.U2'RR,X:9KKX%
M08YBV=CNC'2C;8I835G63-25Z_.I@`_A2T]B=+5US+@5RWP]^Y0JK_ON4SQH
M^^6+/)RH(B??95E43)0#B=N/8_<^CP?AU25]'%/@)MU$1YYV-XF>.ON;:(SV
M=8NR?9"4^XKF)%9VMP>W%G6G;U%*<?H1+SS:B^G,U4C'3.Z/:A+K4ED7J,<'
MM^R/6+PO1KZO[9XA=I["UAE=[V`!$;NX(M`9ZB')2(ZR[LQ3UX50TG.U:YLR
MIJX6\0R9O+YY183\*FK)>%JP;=7**R6A)2G'K]H-V>-6A3349+TP^'K1Y%JE
M0]['L?N_`U-N(BM.[;;H\B`]7'+0X]V$T[#>!AMN.,_SS9(8@??HM#G-K66W
M"^?Q.IWNA1M'06I7;ZE-7X`"?>LY!(>KF>[U8W]H0TJ/<I::*H?E-'YS68>.
M7>825L0U1.=D4ABI\:#`I&+L0QSE[V`*\R!!Q!?1)DYC[(_`&]R$N%)UZ3*R
M5<&+`%I5*X*LH-/.[W6@IC)9=.D(8$!8:G7&FG*5ZO;@P^^@6(?H1U[W*KX:
M.(?AL9854IX")^>NLCA.9;=T^G">`?>0`ZD%B[.6HZF5KOJI+7T9LR(M'=HP
MO3$.R9-=BZ&-+9@"'+QNG*X-'`8$\,!_`E@Q-42RU/LQ1Z*E3J9LP2"'%:&C
MJ3'K(S8E/<U-&+<G/_E.NTRH\IVV_A8:C>37[I"KC)?WE#-:^ZM32G)"&^.P
MBS%/R-]2B*1PA>-?9+O-`1<JB/0K6_F$AL3TX(W+Z5+-88#G\6PD>WXHV9<C
MV"%>R7=!G.(5_B:]R'(8KU*:ZRG<G\$\?B:GALL4G1]VI*31^ZP\@P7Z"L-Z
M47P/HQ79)YH/)CE:CLRB4QB.S+SH[(IZJ6)709:")>VJ2CT6[D'4=.;UQ#(1
MV#I'WPGD[>6"=H*!\-8_BIRK&CE57Z#N#+2]`88:0/V!MD,0%*#JDOW*L]_D
M18+-_+:Z9N8]+*<]?74[\!(3VV%!E`H5E@"OA%Y7.JXR6.CT1^+VA-+K7U3P
MN2/*%R++UT-\&74`>_UV^B0HXA#[Z>-D5T[S2E75I4OGN8(7P:0C7]%+&?H=
M#LPCV"&/Z\/J#2(FJ'IY[P5CFDIG4:<CJ`$P_`GM)VN\43S#/%C!]SN<0?MF
M2;IB'CPZ0*<E)T[-;#L>!6"NB8&`4N,\FB4@IJ]/_>:,&`83%L\#1#C$,RAZ
MG_:8YC!(<*Z![[,$=]P:6VW=V44>%^A/9^B?Z0I-Q#B+IGPH.1FOKL/TIQJ(
M8$*U9,&J>U(-Z@+#^,Q*8KI!S*F@[,MA/C$V>_4IIU+)H&P+AQQ-.<-DW3G/
M_2+B1)QH@7E0W+6;O=T%*K5WD%E!.F;;HVGS-.9F>1H4ZXLD^UA,^1I*VI_K
MM5;&C`!)[8.H;`EP(T!:<9]'^7G0J=9G]VFG0@1#B@H@Q(8QN6!%/R<0_X`#
M7S997L:_D]]/`3&M?EV>VW08$N:';YO2\">FC?<US$3#W=SQF@(9<$BK#WZX
M<MH&W\=,AC=!3V[W1#X3PD4L"W\]?L)?DUP;]>><.TP_BYA4=YWE2SQLZ[+!
M#`AOEA=Q&J0A,MU(7,X4\)'VYWI'E#$CRI+!-,&;8@2?2I(1#36%"%Z%_X+D
M&AKMI&A1"<%#P4(53SP?\:%FFE;@]$`K?PR]#/(M(YL:G>8*>`;I?R_3]J:H
M6]%^Y.0`JE['<]:9A+ZHV!(=M-:XSBW."[P,XCJ?*X*>SK6WKUP"FFH_2"N@
M(Y]A87F'7=S!$*(^GI)IPGOE'4Z%P@?5PB=E2_@4I?EB;NCB*%$.K,/1CHNI
MR_09G?VR/':%*;;#>:QL#$?"$#_ZA?\\.EH*E./I<+CCXNDVASB]9%T<K(J$
MJZ-/7>ZC6IS,`X$ZK(JK1>"FS1,')E`Y(.U\'^6&040.96VYV6!<5'P]2ZM^
MJ*E37*9-4#[M$?7/I*[J@EU1&'M`-Z/YLS2WYY'X-JNTR7%/N,]I,!XF>G6Y
M!\K1WE7;GUN+,,QV:5E7(,;.N3#,=U",[:D6<BU.',>OV_`H3C)*FM9%P:F7
ME[;NOUR;QQ)N`@[Y$JXMN+'-7AJI7W4[4<X/K7Y'?T1I?J#J<Z5ZZW)8P'XF
MN!2K5643<P4PLC>I4W#9E3.IVZF7<'DE6^K:R+/((*>M4Y6GJ#]X^YT;817?
MV][FV7,<P>AD_UC`B#46PC)^II7BLQ3]8H=^=],\>YT"A0,Y\I"%=QC'DECW
M$,<'[/`M6YPR[]&#AIYO2(^#GH.`[Z&RM+VX0ZLW"4U[R!;A;[LXAU4^TDD=
M^.I.1UUS]=T,2L:$]BCZNB"E-0KBN=_E:5SN<FJ8XGS2AUE]O"!76]F=DI1:
M,AGS&'6'K(H\#I&N\*QPY;;O]#GB@CK$R=7E2GE]E#>?DU74-]QT-:ORY?=D
M,-IBMZC#=2^R'&?$:R-0S^#3),<;4Q:\`-&029&;%7&V#K!_%:V(_"CH62R"
M>B"0+HD:\K'&;)Z%$$;%!1H$)HU.^]=!B:GO;Y;B?B?!KB4KCG,U6K(I"OO"
MB3+)-KZA1&(9H#U!>AA&N@6H[85GG3528/]>$A'/Z3RFR]%\SF.:'.N>Q^*:
MW/S/8X;HT3B/F<ARC.7^LHH'O%E.7+!1W:GKD$HE1Y+5&J_.8:=(J/^B&MIJ
M%:W%8B'8G[PZ:SVF=[,E`#[_!/,P+J9Y?:ONU"?6N!P)L%;_'>.-``UDV\.\
M>+ZQ)E6K<-\7"F%$K-TB64YOI;8]N7U9P&="!*3--LGV$%8HVE;G)K!%7]&Z
M0%ZO,N6JDX*H';55S1(2QK<MJ^/6S5*8E8;$`)0X1[!6Z(@-71=OGVR9$QW`
M*0E%*#$-%R%T_%Q-#E5U$Q%B*[G1+Y*:*/O9'%QT.9K/P4638]7!95N1!4][
ML&R><G`/+S,ZNQ@"2./L8B).V[,+[G>1$C<MKC;YC'8N'*5"GN\?^G6GP+Y1
M_^,7,U(FXC9@3WB[3_\,2"7Z@I:-(#_`EJ+?@B,6&.@\V3<5TL!:]3B0"N>8
MR)(XQ(DG)GS%+^G-Y<-J,1OR8#N\;M8M>"_WO3R&4RKPH(J\;.06D4O$[+@(
MXOQ'_&;K9OFPAOA);9#N[R];__#)_@'1X$-+8*&:TG1SNK%A30`J3`7\6+]T
M*]<05)2J(LP%8"CBS1O3Y-?3=6ZK6BJ\L5-M)#@LE+.F3,A^BB<*0N[UXKY:
M\R$+DL=)],,:5^C;.=1H%BFJ>T7.':7]*>;Q_EWV#/.4%'M>H:-2=6_97N]<
M0YP\;0K4:/?M^!)1ER]1AK![T+8'-0&`*8"6!/B%$O&<_L94_RP8C>1D?4$H
MOGBLGK?C9R#%-%:;9M=.'U-H,B5//H$.Q?@CWWDFS%3;L><,I&#]FDW2"7UT
M4<?!:]EU^M2<^1NU61(?#\BSF_HS7]?!=MIJC#(S,=AOMN)^WN594;3I$7%>
MQ&ERYYAQX/1L:L2:J'@$_A0P.3K)Q[-=YF1JUUOMA+(9\!9'N[>ILO.;,>"G
MV)$1C[IHQ=_.H.R>%0"L\-JI&#`R6-TB<R9KI>B:N2CC#2EOTCI?_'KOC"(3
M-8(/77OTY2SQLHO1*ILS2@D]I@Y>#_)2G6;Y%K_BAZY<#_(.G9[GI*P(TS-7
M;32\"IZ2-6LHM)NN626%8?C:;'`L4Y#<!EN83XDK7D<NMP8N!^(LW]6W@'S<
M1X^G1-]B91VD^!8,U?8ZYSY<PVB7P";N':UU?#>]T8V.!5E'+D]+]D01N#4A
M4%,BI1!4-SR^4X$/5'WC1K"4HW7>7>G#H^OFQ<I/<;F.TYL4?H!!WMP_N;6.
MM3AR&Z8YC%G!#*#-TA5YOYY"L$=M`)H""9Q!!85Q`*-G$VK+T"HX5+??Q;*$
M.>KV89UGN]7ZX6.&&2@$D\#8;VO8F<.+^K%X5L$\P.U;I)>4#"@_9N07_C`_
M"4PT',86XIW@>J++1:TMPDW-PZC0Y_<P@VL,#3;U(,Y!]&SA+-6W,8;%0C._
M"*%FTFZS"?+]S9+)U&MF3LL(N(H[47(BLI%I$QSYQ#2:2723CFI:<U<U>&N?
M+HYMN5DN\APGMR#1!1/%+?$[<GE<YW(@@`X)5T*X8;XF0<#OL_0X8'[W@'XL
M<)@[SD@SD_`FJ4I9DU(L$-M#_>/]&=P&>4D?AGP/@Z3$8<;?[S9!>@_SYSCD
M>QH%JX\!.8=E+PQ9$X4N?7'_!6AI8+!1*@1GA`ZH"7D.8+)4;;-Z&<IJB/>1
M61_Q"PWR)&F2>"5^1\X39G+9F'OE`:F2V`5*/#IKK^,:K=39*L9O'[*K,C)8
MC`1-72\\?#9$%E#U,?ASL-G^%9QF7P#4Y`N_SF<-1;2&CWBT([Q(*=YG)2RN
M,K2'HPZ:MUL,[$[V)W&"**QP+<)=,65@]V">W(9&#N165!">?@OHQT?<L'&/
M+V`&`X;S3F:8"(?,`DRUR?4ZX0TPMQ_'@>8\'B08A!&HO^7=\WK!H$Q=+*Z$
M0[4^)#ZF3XZ@(NC)[74%GPEAD?(G-5Z\/#>0*JWSN$`\7JLK@Z8FD9&KJ=_*
MH1._U[FJW!+?B^3>CA+*NC&A^$.S]H0SKBB*%EM_XD%KI[?P(BYT'(GU+)_%
M3;I*&3P/(F?(MO?B-;%I3M@5;=?/&^N.1:Y!$EM8Y?WW?I+NRK][>&:&,:!2
M>ER$25;L<IH3K:EC?`=Q;A?R\J<@E8Y)R>8Z9>N4#_P'<N36EAC&K"@_14,4
M+TDL65#1I55TCP`A7573KHD+MBXO`!X'79WZ[<,%;F7TD$1<EVC`*4Y]A#-R
MM2E@S+9('4+.[GMUN)%5<@=-6X`;@[;U'&!HK+EV/]65B_W*RZ\?SUS7G.S;
M3RH@+SX&>?1^A^WWFR7Y:\%>/K]#;2=9DR?C=8K-?TO2W)RGTD='4XU(]+P3
M-RU`\[GGP^/4V&-7[$DE[7:WGW(HO'<N[/;>,0/8>^NG/<\,`*3?(T![QG8$
M[;N%(`DH)MV#S^*T^O/GOKU@?Q1DOK:YPQK,6)5N]F97%F601G&ZHJS.:D\0
M,CFVU3/M1B`:AF`'J#X'S/<O=JZI8#;*))/*=QZ3ZR<8K];HU+%XAGFP@G66
MY]L\#B=Y%>"*]9=GE9D-4#!%ZR:@:@.:W.2D%=DFSW#2V[P`^(U7@5GYW.O%
MI6,P3S2QE;KR<,K">3/+_66*SGH[XD,@E=T?UD%:\4^V^N(RI5DU9S7=37D?
M+[1`LX2[ZQ$*0Z::2F\T:?PNC4L0T+/:"E.`D5\/L&OXCC+!;90S)-!A.D:1
M1;^$<8G3%KW$:=YGWV$XFX?AV4SS$->#P=?CWIWE'F#L9KKS]63GAA]H='17
M'NJ5:\[OFG&B4W(P8<5>X68\_;"D-PBTW(]PU_5Q8^`"9$P,[-22MPX,&Y>U
M6>V=8D/XY6R0)J:NYEQ[61O?]*:LPF"=9E851MS,S@DU(OMS-%?'&Y[Y5%6Y
MH.8Y?<?'L]'<'EEAML%T-*2@*'8P.B//P&E_]`[)6>%("RZFRPJJ]@\9<VLP
MIV#=QJ\'UQH6G4E@)ZCI+$/5I*OY>+G;F-D(IDBL.?E69C1$FYGWQ]S/K+`]
MZI9FKCCCE6"4LVOE&=KET*M/1H,-IR=#1X,RF+%<+^F+<\SHPVTT[XRF%KRY
M:!C^%FET_FD;5S4LY^RU43,]XL'1U96F[M@&SMI9[JAC@71,GX^>(JQ/@U-S
M-SM[>M(!S=*\GG+$-JO`R[2V74P$I^O&1+;X`=E%4>PV#4>,"X":'^^H0_$A
M.]]LDVP/";-G<0Y#1+YX3"-\@PN[+V!,GCFYX\;ERV)GH]*-4&0X(/'\=/Y3
M)D#UZ*1B`Y09:!@A6<@:5L`.\T*RBQ^\YYK+(R[GX&X.`&Y5/LB<>%(O6D^'
MBU:30)<9&%JS8$AMW<V;R6R%:;AUG'=FNI&(R@]5WX"K>$D*V'_PETK7'?AZ
M^_-T(G=_$I?Q]6.6(#))7.[OT.ES5G:[`=M.4Y<Y&)!J;K9?O]2#MSDF1S&A
M#57@)6A8QN-9_!Q',(U>U&3M,/U"'M3JCD<U4^MOP8<8)B\X$LH4E)//UIX2
MG#O*>-S=Q<6O%SF$=17B%S%/N4R_X'G*&X\H<A]]>HR_;>IB`_SU'VN>RD`Y
MV3P5*L%VGM[DJR"-?R<\G:(.LB2.*(-I=(MZ0,R0?]XLJQRH08+SG=+K["GS
M28W#F%,3=A261>_0&=I'H$.=.(58^CAM1-,#:+OP7V-C$M2QDVT\%5BG8KS+
M]D%2[J^S%)85)T8N6%E[A[DW)6R(5GW:`K!-9N.)U-!*XSM4#7W0^06['M=9
M$L&\H"^P<*+I*1=218^N/6]2;F378U6C/P?;K/@KH&T!;LS#F+>04*5J>^&?
M<F'8EX4O"CCM#GW0@]M$]YV^1=F[R$?>K4Z^)CHYY_NC&;+&7,7!$_:XQ.0:
MHP^R*4&AW;?C=4>7+P&4F.;$W.JL2+2D;[4D^?7IFZJ>1:&1B.S][4[A*`>@
MQUW/9,>K\`5)P^]\^Z:-,*6!(NN:4K)$Y^,FN_:"&<TLZ'>]E-=^DU[+T"#*
M<FYUSL(NR[0P3./;:^0L9>]ASQ(7-_[,7PTHD5R;XQ%W)):E4&^V$(=9I2O+
MM,RR]@X/RQ(VA'D%JQ8@:)IX#=+7T$2#`-5P[0LZ1__>%:0B8?&0W4',<YS`
M]["\R@KT&UQN+BC6CP7.23(4.F/UY:[(\S@,BPY++74<<I;7]$$*2Y"@'O!O
M\<\AZ@3L\"NP.`49!\:^+)0I$-06BQY1^)9KY>D:WQ@4+'UZ;DPCUG0WF0.&
M))U!W8PO`:(K(@<P)73(&2YI*7WGY]0V0*T-,"U$98D_7+*H&+#@RMH[+BHE
M8$-27JJ8TUZMH8E.H2G9<*WWZJ8FHB4<9.T=PD'"A@`.38NYP$%#$PT<5,,=
M=+<1K])X&8=!6E95-'%&@RR)0]3+`_Q4GJ#VOT[BYM'KV77-*CVV1"Z@MC%H
M6X.Z.?@%$P"$@J=B9W9Z[[B']`5DG[B)3?1_'R3P'H:[G"!_4DSJ=.O8":[!
MDNAT4+<\7F;Y<8':@K8Q@B*I3,$%I)\K%WV5=^YA-.5C[?Q^OPL3&.07.YB@
M$\/-<K')\OJ*>0H,2OMSO1K*F!'`SC.,=-3%XD<YP@'9Y[;HZ,G0OWE*XA4A
M_!Z-8Y?G<*(24CK]CGTN5+_AU>!*!2DO.Z6!%CO[I.YX!URHU$7WT-K']#0%
MI@0]><@:R.=$N1CY@(Y</2Q8)(.RC1*]S;,0PJBX0"Q-#0Y!5UYRO`J8F>=N
MI5!2!R*2<5EZA\2VTQE\*J^#LOI7$]5,;$:!!2YRV0_LPY7%,P:S*D.<OAL_
M,,0Q9="2!I@V(,3E-KH/1_TX>&D=]".(VS*;6KB&T2Z!N(IW".-G3)?,K%.<
ML^,IJ_)(6.#=CK)3E%NQ*/)X5+1H1?>&&L"H`5UZ4CB[3W`V!`%MSC)K4=H'
M8S5=8C=QBC[<GU)K4H;6D4X6NGV[CE#6Y$L#Q`V!(U"14"S#7LXDAACHG$M,
M9&6-TH;V3UG^ZV5*C)>B("?L.UC`_!D64P!4IUO'V-1@292"!C7`-Z%;VL1[
M4+2!3EG`Z0I@.-8NXC0N$+K?95GD$&N2;GUA3<R2^(*,-`"DA>_US4"C7*0I
MAC_<9J0QD:,;C)ID7>;A,F=/RU*DI$S-1*]6HIG.N2:B@0"M:G8Q5)_A(HU(
M>3`,?33>-4Z/A3A(LBUV-<ECL46Q1P/H.WEK-)1+45@22Y$$(F68)L@KHN17
M44L6_8'2_<YKD,$(<&ACE@8*=8"7^RPNPB0K=CF:0^Q[_#N8X#S!IUE1%KWG
M^-->%`]ER?4]WD!^!=.BI8H7=98NJ`@#0OD($-K')$\8J*D+HB&\&!PC08PU
M1L80^8"[QV;7$>2RH*%$>Y<^`R-.W"8RL^)1P]!A<<\2/`(UR5E[%VRPP_<U
M&,MU4%`;IULV2PM;I0?[E2DO;<86/Y-B`(?.@^1&9=]P'E4=T9R[1YT\O&BG
M:;KK).R=B^MY6H2JIMY`%=GO1EWCL4VCU.Z1D\XVD^Y=3R4#WK0.)PP)P-AG
M\XD\M<`"BVM3>5E>C7/RR9BY=:0$G%[WR3@Q2@ODWUS75HTL+]!8]W#<1#".
M5C3]SOVF3!!P99<S2+F<^;*739&@SB<D7<W,\!K!^%]7<!4DYVF)<SE\BB6W
M(04,OUAESZ]0(PI&],,A!GD$G9S6.!V+4K_@KP#]#/R"/_2'$HG\,0Y$@[)-
ML?##[5VUYMWOGJZN3J_AY@GF6EN6H*G#&$\)&P)-HX]!O5NASP'Z'OQ"6_B,
M+I%KH=F=)$,=<OZ]@T69QS@W,'[@O$C)?_#B\APDV,G$_ZU\91B2D<6:&]?&
MN#VKPDPO-4&`&Y%[`O(#T_QP@?*3"68H8KHY8P:)<<`Y$^8E>9M6PN)F>0:1
M"1&7O!5PI'.EI#NW6:,EG(A.C4P+[&&IVG`63T_'1+4J.\="A0"LKE.KM;D-
M[3/83$5MW5>W%7"B./JUG\]A/U5HXO"XQQVK7=0'\3<@`0?)19:?YC#B+RBR
M"W-N:Y=E%.6LR-Q*Y'L2MDY;S`$+2HUT[ZR%0[9]6'.'74Z3&4L-<:<78$VW
MHE4!_WT6ALJA\#MV1V<40RSHZ^!3O-EMIC,=NAVXMG,[O0M47GTS&X.`JQ)6
M^_U!V1N2UW$ZL?X['3C7/]N[2/_TF_GHGZ>2COY[@[+7_U66KM#&L<'OD![0
M]U,M]]Q^7*=9YO`@\JNA3X_QM^35VA'`G_?\:UYR*$OTU<F7+!JKG7%XNP[N
MKA?885L8&(7]5JY=;#T.!/JFWQ'O>\%="-Q;?T*1-U8??W!#K('3C%21I<&Z
MN)S/R?X$IN%Z$^2_3K4R*/MT[&!0L",\1##-`&X'FF:S6#AT5=N]@M:0A741
MMB"!115!>YMGT2XLK^*4ZWD8Z2I1VJ';,#P9*Z([0]RF?E!P!*IF`+?SOV(9
M*;5S*ZB4Q,CKV91&CJP[[ZN8PN+A+&"S,7HTU*A8M@Y-(#LT[8HRV\"\1W]"
MQ[NB2Y=!#PI>1+BJ6@$.P/SZV`S5VD&8ABB&9#NB"^%-?@_SYSB<;+WB]N/X
M4,;C062DTT^K(C?T\]ZEHK?T-D*-'>2VX8_6[EAVM[B]_'%Q8G);TVGAX8Z&
M[5_D@Z7?])<'][<Q//FV=S"]L5C'V-TB`;P/-M/-=):^6U.$[5HTL=&_`/YF
M)I.9HXS.)#X<D=6=ZR79.N)GB,D9S&!>N]$/+_))S&%!F)V\^A(0'?MVL:H$
MSR0FYX_0NA[09IMD>PA)$.0MTL8Z*$P5KZ+A+-&E#C>B"D)5J^HQ2]U.C`[W
M\-!455MQ2$,0`_)#XR<L4YY9NQVXOI_I]"[**H>_X1]&/6T07*5T<C7WAF6/
M@`Z^Z#NFZ<Z;XLX<'PN$C.@M++2%_Q5%6XDL>N1CM[8Q?ZQ*;4RTD+#D7;HE
MF'X%V*B^F,OJP=$#J_W#\=B:'._R`$>@9IL-)#4UKG'^BC=(>6\,;`XE$=<7
M>BJ&!!"@S4#;#I"&X,T1P&WG89CJ:JPQ/;2$85U#AWTXNTBC-M:9_,$`1%J$
MW%JO.BS)WF[5S[")*XJ)?:=_].^X,-%=F\!)5RBV3TUAB0]564IQ>QU$\#+]
M(4AW0;Y'J/G*Q(VE1\J#?TN+,>$CBJHQJ-8KW!PG1JP(X+7JJQF@RTR1K;],
M7S:642HP7V;Y)D#<DS0`;#^+W6I7E(8P,R+HV`ECPIO([]:2J%).'.".TA'`
MSL<6::/A-E[&5&*VII=>1X^D^!V,;G$=%OZA;A`L^?1GB5(NJV.`MB8,*LHS
M6#Q'`(<AHL72'0'@T4''<7H&0](#/B?:@5J+IO-00C/^U.B-P$D/OI<IJ$EA
M`+_U[\$8HF\>3K5E-R3NYR$N:=[O*'Z.HUV03.7TX'?DTOW!Y4``/O(MS?U>
M?SV+^!ZINEC?B'BPMBO9^RP]AI6_[2S.88B^,PEQEK5WO4))>!$`@FT!FB8S
M670T5-,L,*JA#TPRP,G]RF1D.LU2DO[U(:O6N8LL)UECBVG##<=AS.WSNS%8
M%J<@:',4,]393&%'H.X`E!FHNB#//FDG@I<>GCS%HR+O(&_!2&JP]BYB,Z#N
MQ6"]Y31S[^3I,R&`)/ZP1=P,GA2+I=XLI8+!V7ED%E$4XS-'D#`XJUR,!EK7
M(./X7*OF2'2;W33LK%&U/WD>6Z^^VMH29WH"L;73%O>W=R>+N[.%Q9HA:NM^
MX1!P(H(*^OH5^5RVAGA`AUP7+20DH[5;3MX'%&*7:5'&Y:Y$9X%%DL!\M4<[
MV66Z1'9?G.V*LQAM;X714T4[RNX19,6GR/JO:(&&&#X;5N2(%=42!#7%.>QB
M@V#0GAFL16D'WG<YA.EIGA7%:99OJXHH1G?QXO;NK^&%O`AOX%$+0)H`ILT,
M'+(:>F%NW.7CMC:'%^>G-]<8=W=7)CM;KY5K(/0X$.UE^#NZIMQ=S4#I0GFW
MNQ=W9-8*?C1ZIO'8>:+A4)^/BK<9C[QW&1ZV@)XX&[T]]EYDV(;>AF&V2\N"
M/+"_R@(2%'$1IP&)M6'*H)[LF;RFN`8*:@7S;9"7D[I_1N7/I<MZ3,9U\N*2
MDCUMTQEE\Y@"8ITXY+$E/6`Z$?<1CE6+R\V465BY_3B.7N;Q($`J^10PWW*<
MCSZ@*5,7"S'A4"U?-/;3V)N$A0E;.\]"*&3%J!*!=SM)J0]9`8+N/FRU:N#\
M1?B`EN^(AWJB-8/3B_/"=3T61+7HT(>@_7(N=Q5B175JQ?%'.2`1,JGH'2JR
M_0])P,#0=YS#@^E:F%R!?C(+8X:GBF[2A(/QF*X)847@7S_<?A#KNJ[L4']-
M=5W_ZU#/'9IN],MV*4KV'VR#]`A\@*DO,X`G:ZS,'O-#;M;/8([L3_S,MET3
M<!:-Z99Y27_N%WPQ,\*EOVXBV0#\+/YJ17:W`<78+5\8U$O,]S!:P<4JA^0R
MV\"`E!)P[^V7L:/:$D@;T#2:A==&1S]M4FO5X*U?0EZ2@%AZ7*'5&:98;3B]
MN%YC^BP(\S0T'S:E.SQGX1`KB5U)!".T7#_N(=K?XC+&I166,(>1UJ+1;^7&
MD.!W+GJVUGP'J@\]7N`)Y=R^1>,.R]K[7F48O(-AMDI)G$)U7$6@N8X3!"%T
M;.U^]+NF]BU).PF[&\"@,,B.?`<8:DU9*KQP-`3!P9>_,X#S\&!MB/J9!VS6
MDAS@.%45&9IB[U+VZ?8HK&)G0%$JS[N<KG)-JD[9YZ2Z#DJ\ZNYOD7V>13?+
M[^/5^A^[($&_N@[R7V&)+PO:I5EK?32EZ7#O-&1-6#^"4@&4#+YNPH1`10FT
MI$!+R^/F:ZGD9A6TD9I]7,0SS(,5G`*8EJ3=;=QV#(H","@Q\-+0.@P`;32'
MO2QM0U8/^[I?9WGY`/-->V:Q6D!Y=!S=;^KRH[]2DL8`MP9M\QDMCA*E"1=$
MD4"LMF1<R*-+J^ZN*@.CA2$U%:>5VI7L2,JR'(*E7=&JMA[1HZVL!CMZDK#V
M=*%32!(4!2T8B<XK%XC711CN-CM<+RZJ+^^W.5S#M"#^V##;0.IZ*RF@3^`R
MR^%#\&F:@\:8#+H^E8S(N_`(T^T#8+0!IA?0!)"T_0#:T1&HNJK6VR/P1'H#
MJ#OO]\63(+-[2AI;.[8Q#(NTC*,XV>'[CM:V./\4)KL(1I@OS,>N)&S>+,^#
M/(W358%8N%\'.5QL<#36%)-O',:</B`=A661B<S09HQ?4%.G<X^ACPV8N@<\
MQP#IXPC07L!G<4I_4WSN?;J-BL%.B.%H"AFUT`NBCW^!3/XWDX2%R/IS?<LC
M8T:[VLL1:%MY]HGI*%-:[^5P_):W00=GQHLLQQETEED29\RUDXVO043*J1&N
MQY.N.P&_H6_:,^;YC'P'"@6*?`4RP5@^8]SA.VQT4,1Y%4D^'+Q&(BN$(!CG
M#M=#E0X=EYX!#7Y$3Q%)2^(0(!DT:68DMC5)$>\33`9*:Y\8:@K$VK),R-]A
M1/;27@?GG_"/<!+34:]GY_GDM=@2K6EU8VJU5=GE.B"L"/@WYXP4W['7]"4T
M0LYZ6N6(W]7[K,I+1[+E%P]9&23LWT^SHGR?E1]@*;J1'SGG_>C,.CT9338,
M9<9]VJ%PTAR!IE=`NSWJ3BK<*2Z]"_:P]!TNX`S!W(3_DZC.^N[-AJU#CO!Z
M@F^J'[(3)B0"F51W<!/$:81WQXNX"(/D`PP,Z^"X8\O=G9_[P1E-;YYA=CB[
M.9.[Y@@GW7IB0X+(L:%A"]M_E#&`.?-H[/F#?K^ND%LD#*YP-3J[F+6'CYGG
MM:'FPF%XRN2#\3OU,1,`<3&3<E]3X];!Q&;5.L-=G["'IB^<PU0F?/P1]O5F
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M?W=\_`=<XI@I[6J)J^%N';5(&'HZ9(A)3WZR;S^Y#?8DEPCFDOQ/54#S+EZM
MRZ(-!9CBZF`:1ATGJYID$*)7J**+-:8[\+3OW"547=)U[XC^!]0U76F_@N`5
M+S<'DX*7O3683F_#)FYO)>FS=")CB89>3A*V-2I_+E,FCLFXJZE)N_,<2S8%
M(GN3<$S%#'@H;,U+E::?%N6Z3"D[[W"6XUE-0@F;KN-,)AC#=-.RZO.HKC07
MI\V#`-*S*%#Y1<U7-89'F;8*_5E&FM9Q8DT2@6(1KF/XK)F"0M+<Q2:EX$$9
M\M<V`76;&<3YB771"^\3C-DV"<V@+:5HJGT*3CZB)#:C]^H,>J.S/F0I/E%;
M2`5X3'\D7?+/+>[3\4R%N#:=SR0J<CW!+N*\*#LVVV)9PIQL!F=!.?%$4_;N
M[C9SLC'(9A[/*\HS@JKO.C,/D(X/CB8@P'U3JPC@WKW>7$Z.RN&344M[0P\P
M-AZ-RBH[_X36A[C`.1Q^@MBQ`:/J+0>-=T)LUZ6H=D&"GUU/YV5P/(R7XC.T
M'Z*#\Q'#U1&H^0+U4Z>&,\"P1K(1^,V[[''6C.*.'`@)]\Y*[AGP@.=F3;P(
MXOS'(-E-=__@<`@OPN5I-S8O[I?>&M/:(@!S!@AKQ#]SEB5)D!=@BRR6`G?V
MN=?W$9XFSW0^'#V`^/#.-H\(B8=NL2O763[56ZCQF7P12X:(^^D6!>;!*^D3
MM)WRW;$O:I*K(#O*-)8JS396LO4P(,(!6G'W#]DMPN@ZP%6Q-YLL)6]YKX-/
MVKFW#$DZ<YN9\268"BT1@F5"!L<?U80`I50]ZZYH^4L$;*?>YN1L(3)+'Q7;
M$T.98OT$KN(4&\3&^).0<AIPI\>3%N8Z`*L6TX:"SV('9BKD8DPA&KL84FD'
MYVDT"JXJ.BZS3VCP8PTHVMRCB]Y`:7I(8@1BFWW">N>NUL?N!HZXK>,29V79
M*IEU^LI_LF%,9^I6/?=-7IPQK0F`GE.RM,F!/8K]JZ51ZV>`D['%2V<X]E69
M)@\N=Z>)QS+9Q9EP]F[9V4N9>(E7V&9P'7Z'9J!.ZWT9[_*71;&#T=DN;^[J
MJGV_COW'']5G%T[*L9%V74M67%]GV;$IFG3$<J3D`*77>'PIR:-VYM"/F^,R
MH3LC#]`P*'7VN0$RMCOHG&*7^5.&\T(^MP7DZDLDSJ6,J"B@!AV76XD&/\*T
MGTQ+IC9@W9;>-_A-R&"@M;94H*9$K#+P\XDOHHA4@,))F,8!E(BB?V@).#,$
M64M%A+>98$VA6@7J9,(:%7__WN&0N/'0QZ/GU"EHP)@Q]"@-X4(W&^1)E*K$
MG4A.UA$2[[)GF*?L4GH'0Q@_XQB-*:Q%:7^NGWC(F!'`KVW2`JUMY/DEE(XR
M67M-.7[;FXT\"R&,"E*/@43WDGQD!41CP<7LSN`S3+(MV[%>-F0KP@[3>=GP
M)W)85Z2J:B`TJ)RFTJ/D2*E#AF"#1U_U#@>KOO5JVXK1/B-6]=2]Q?_HV!W8
MA<ND=(,X%:7!J#-7M%2'0=M#&H=10-*F:!@N9FN\\^V+NKI9W<D`6[-':@9F
MYB%/AA9F6]&N)C`[XU*D0(5=R17,8(=,EG(.3)6?M*"@UWS\:$S4%]BTN%/#
M#COO>6?JFA*H2<T#@$:*YD%17VS6YQS6I+B*0Y@6\`)"`0S'.>JHNG09-JG@
M1<L&K=H!W+"/0!_G'4VELD<>'4%85X.MWPA7T#6IWBEJZW0E$S`A*O5:?]U<
M)_:J<_JPTA1::$NZ2@9KM_?U*!I$D(K:^M6_-"Z4H_^#V,]YZ%\0Z"D;K)W^
M%VFZ"Y)V53&9_Z*V;LN%\9D0UE+$7[/;0F\!<%\.3*Z"MOZ79*0C*=]@\HO:
M^E6^=/+SE.\[\ENA`K'RA\_\Z#E`O+W/2D24GJ;0"1X_8(Q38M_>+!L+5P\1
M)@3=)04P84L$'$H"4!KUH1I[?Q@R^)#=$/((*`NUMB@SE96MV2F(NB"70ZC'
MZRQJ"B3?+"O4FZ%Q6`_NDL0,8=,XT*=ZN(F1RU+&T*U7Q3Z$?83-C0&/-BAN
ML(QM[Y0J=\`XB-:GYNZMEBY+HL-Z[1PR1:2'2R)37;8W0T9"LH3:'4SA1^R/
MK_VB9MB2-'<&)C$/`O0T#1@W-P<LSJ&BUD6##<68[5_I66"`JWJ'KZ2T="[5
MM)?W3PH-2Q1K-\^?8;JK4YOC=>0NVP=)N5^D4>,=Z'[T.XS>0]UEP):Z0ZA8
M,RE<1LBG@"$(*HKD4K?U&1U\B1_%([(^\3<8#LQ*-$2JUGA^R(.T",(Z?;]>
M6$*OD;,]ZK!G`:28ST@-C,*O>U$DY$;YW&%9;CZ7:0F1S$L<"Y!K%FXY;.,R
MMOB@;X%&ZZ]`]9G/22^0<*--WHBL0GQO\_@Y*/&#AY!L73?+>YC&67X/PUV.
M)G]60MT8.`U"[DXM&MP(;Q=)4]"T)2_/2&M0-0>DO=^SBH'>F``V3:G8UU\_
M@T_E95J4^0YWT,`4]7I?!I+<P./<;1OT[L::,6=,@$I,`+04CD"[6J'V1X"2
MX27U]7$#;HX"]C+<4%BVCQ6[W5P'Y2Z/RWT_F^X4T.STYC+B0LR&+O#J-MV\
MM?Y1QE.@&%6]D0_(KW8&R;H:/V-7(XZ3//\4KO%K7`S92?*\*GIT_(95SHT0
M5W6C(U`U`W4[LJ9Y?K2@I]0NP)1BL(\3:QV,;*C0]S!:P4N2HCQ.5PMDW3^C
M<]VAQ392W)@A"VXW6$/N=)S5GW7BS#X'A!;>>"MJH"7G&:N6Z.@$H%G(S^K`
M<0=_V\7(V$0=P7B5GN[R'*;AGG2$-G::;%33DZ5#R:G72H,AH8>*M@558U"W
MKF&'4]90"N2-_@>8^DG#:JY$QO^D*Q]K7U,5,T%36>#(<402F8]!4O?]D-UF
MA9ZG5)>6NS@'38Y$@7%5/A7:G#X8J`F`!G\X@R*BX0];ABIL`^<,A&,=2EOU
ML5KE<(6HWRR7D-PVYW&HYP:34W`/)2X?*@#5C4#="I!F/AUF6IKI844\>EN$
M-!GC!V!$1</A=:V4$>%65E<K4`/%P\ZEI1]FSU*+P-*+?@:+,(^W-%``YW(*
MTOUMEL3A_@%^*D]0RU^UX*)#QZ6W78,?X9FP:5FEP\1MP2^T-<#-`6G_3Z^^
M5P/%-3C2%8JM,^LT2PM$+B)Q)U(4C7,:E/;G.F&"C!GALS:F";*N*<)FA#03
MQ;('.:4L['W[:,5#IT,2['`'PR0HBB;2B:8`P2=(!NB3>"%,>7"-15,&A9MH
MMZT>1/V\=K-#1??YFX70[(%\&A3X_3K^SSDZ&SP'"79]N%@UM3IVZSG3XDFT
MBJ)&)("&_,`TUUU1_2RI)NKOK*W:HK+>QKD]W,&B1-8F3K$DX<`=8#7Y<7P-
M,817<WRW=,&P63"?&6`&,_7$,!"]]<4(]4V3;!'3+]_BSAQ#7<B(,+2I_EYS
M8?8!2J4J6<3))6`-IS;IC0MS0-*;RY@`,1MBX[1N,.N-7JU-%E(*,0P($,!@
M3=&?Y>Z=\=8H;E].BT6(N)"L3^3SV>Z8*A4>KDW"P=M<;;6$2R2U&"%T412P
M+"[B-"[A%<X0,IT)J.[4]1%;R9$XP+=J!VC#(T";'I.V\SUB:^N]BT(=*5GZ
MKA=AF.]@A'/%I85BKQ2])9>3<.FQEK,B>C%.&X&ZU8PL*@,5M>_"U3*P/=1>
MIF&V@0_!)R?;GZ`OQ]L?GPOAPH0_!^C[.:]!<B5VEQ[)\*UC.Q!"=YL=OM2/
M;LHUS/$M2@[7"*YH3:-=7F6%[5ID0]IAA@LK!L4K5TT,$&J@0PY4<,0$YW0C
M,@((V-7.5IX#S@']!WA.#IFJ3EW;;TJ.]%]QSOSXJ:GN[BE41SCV=Q_\_+W5
MMC_=*4*G6\=.-`V6A$`4)(2N&L\<E=H`Z.)23UK6KC=^7;,;<M^'.D6+,NH/
MK<ZD-M-T0+5APW^E>2E_A@4VCP"E1M#=T*OJ@\T8V`,`I*Z*J1:P;<1@_;ZM
MFDID?BUACN.DXS1(PSA=D0?;-G:M+6T?C[,->50]XJ[(54LT)0@:BO3)_GQ.
M66,@H?<XW$:B=G6BV$C^-GV[!6#U*#E\TZ'%D.CVN/.$@\F=/C-/D9'ZVD3I
MVI(9XO(^#W(<?8OKE)*%V<&!2=6ER]U>P8NHJ$G5BCP:(NWFZU?25#"[0^L(
M9<`I_;&`-\OSHHPW02_YQ3@(.^C!J6NRV[<`0.@C'(#=?#;CJ`&^MEBX<$8\
MH$`-,?_R*KW?=9#_"LN[N/C5:K/3)>:V#J<>4^*XZK8YQA`E`#"%69T:K-3)
M5`DQD-*`F/ZV$TS\%)EP,>EFDE@_27>.0U+%G&C!#G]X!&BCZA\S#2O04/%!
M<+]4,+9(>P\_+L(0/YPD#YNR%/U(4P15AP0'9I<Q#Z[=UJ8,"J"*R("6#N@2
MFK7GT!8E+(*MA#C$VUW'=#V@K\\R_)AOVD@^IA_G_NP^#\H`/O`+_=#[.R>9
MIOA1>@>CM'8\U\Z1ZN9ED><X:0N&Y+28T>K7;6XH-4/"EYN5AZV^H^O!RD\.
M'WW-=C/Y:`IB8$PH#6#&-$_1T625Y?'O9&>_AILGF$^!.8U>G<>)ROE11K07
MLUG"]%7*CV27BF"($^T^7,-HEZ!C\.(YB!-2TS7+[X,$DLR/)*//PU2EU?4[
M=WJ-ILN5Z/*L:D_2E-<4CI=9?EP@&J`E`GXA9/Q;;\8@Z%R*&8EKP+*HT]%5
MG,++$FXF\<V9,>#8Q#-B;CAR,2E`:'E?6ZUP88K@KNBL#4K&7B@6:?0^2P/&
M@FCS<!?3[?.F++CU[QAR)PIC9*B0:UY$YY@A!%A*\S!(+9'!XMA&=K9N(>9%
MU$F<H"]6.`'OKG!QCN;VZ.U$S>-&_3@.5*T`;<8U5'T_C),H5O`X3B0*NQJ%
M..GXF_MXE9*,#VG)>(>P)PBMRF>P1`MV<;_;;()\GRT95CA&J^"N981NG*7=
M&LZKR/6("(,WX!@PQ#N^R(H\^*SJX'/\+>T$FPLLM`_-6N=W-^,!I[G5&4GP
MEF^J!O4NL(FGF`W.K=\1678Q,016\PN;(5QC>FQ-6$6;V?1/_'@3;Q=L'TY+
M)`]D=K(Y0?OP[@`9$S2#)L&AS-T93+3GZ?>(PWX<!FJ.P.[D$V$&_I2Q(33"
MA.A[7>QO>^4)A_B_G<X+,X@?]Z^AK'DUS9XUFQN;,0!S\$AJF!#M"X3D6;0+
MB4OH'N;/<0@G]-*(.W,,6B$CPMIN]'N"RKK%?-PR2B5V<V;*QFX-I*LL794P
MW^!R2=/&/PAZ<NN*YC,A@`_^^!A_#?#G1P`WF(=C6:XU%C:2`8\6IWH"TW"-
M-OE?IP./LD_/$:L'[&B'K8*FX6PV25WU2@-5>?*POI;`UQT36FT,>:=I^-I^
M15<+I#C:;+8KCAXZQM#!>`9$!?3@-.W.).O.\[JBW*,X2PI_FYK+:B+?KE0"
M,%U#(AC_ZQP=2\N]"CX%#+]89<^O4`N*'/3#(6!ZU%RL%X>=BAX!DD]X>G>I
M=I&\L8ZY`YGZ\F0"'_!<KP=']NZ^G!N_@2Y;=S=Y$WED9WY#-X'#]05>NHW@
M2AUVF29/>,+&&9WLVV^J0J$+7."6_`_>D!=IA-.AO`\V$UIED_#I--I]BA&(
M=O_?=GCW)^WF<V*8$FKJ'#XC"'K([<2/M(CN=!.DVX'KYY&=W@6HK+Z9S6&$
MJQ(62/U!V;]%?(A+''Y\F4;Q<QSM@N2GN%S?P81@LUC'VX=,[V1BCQ!3%MP>
M=@VY$\9?M@UP-=MYG(,&@H#%I(V8;&V#Z7=UG_NQUDZ*/P+X*PZ$O%P2*7>_
MD?:MQA;]\K[,PE][VZG5@5J'EKNTRIH<R<XI7^)S"J9P?-++I"@Y//LYF!AH
MLG,:T961;0Y$=1_F)V5=>LY#]309&P-TO%/Q#($G/PJ;R&M`X2=>>EOFQ'":
M82]T6#YDMS!?9OGF(LM)ZO!BZLP28S#F=%L=A673U,L,^2-0=X#MOZH+@/Z'
M9KLO1!?W,TK';`D\=<)F&RT,,AZ^.LT2]+L,W^`\0Z0UTD7-7-!AKN;(SE<_
MO">WAL=@?F4[Q%=HA^C0)Q.&5GL0SJ&FE[EY_4<#46=C&4<!0VR>(1R86T3C
M].;<7AJ%;3=S95:W$*.":[2),Y*]5E=MV<0T"<QT!IB@)[>N,3X3`E`W-7WJ
MK^?B_)(KC35>).,U=66%59[J?RV2I,I9':N#H^OHC[HUQ4O]KT.L2/MPM6#*
MF!"E4$@2T'[J&R8ZFL(@40YT0"JXI_(R+<I\AU$WK>-3V)?3LYJ("V&>MZ<2
MM-\?B1RC?M87E?JZ.=XD`Q]RS7<&\_B9;(S-`6OB-(*2_EQ?`LJ8$4*J;M(>
MVV<14Z^CR"ZB%&.WOSJ\@JL@H9<ZF.;-\A0'A,!\&^137A?J=.OXQ8\&2Z+'
M&[AE?1M('$#9$K"M9^(0,M!UYUV'IF#L'QV_O<OV05+NK[,4EE6"0BM'C9*0
MTU!*%3>RD^/;8U"U!FQSV;V/I\.@KO(ZYSPMT0R(D930-_=N:!%S'0^IP]1`
M@/%]#G,#F=RAH"VFL5>&*`N)_4=ZY"E171;[-?>68HNXH8GIJC+AL"X3OB4D
MOO#G4!V],/CK\8\L.GJQ+."KUE=3'#DCCI2P4QPYIL61/TL0]<][RO0Q\[R7
M1'X]R3%##8'H.4"20>M'',);9'QGT466/\!\$Z=579:F+)F.XBDYD!)Z8$L(
MDEO#LB6);<:@)OJ%QV@.D\'W56TL.3\*3M-=D%PA'M'"<P'A=?`IWNPV.KHD
M+4%"FX(EA&!#&WO5&7\\??7(QCV^W]E<#W$Z0`^T\:ST0%E2ZX$=MP\]"!,7
M5WMT7?A31S/]S,]%F_FY-EKBBN`7?F^SM`?>5Z&9R"8X'@S0*G917@=ES?`2
M<7J3PH=UGNU6ZX>/V0<8Y,5%$.<_!LD.FBB=;&N'2H^P;W?3]`<"W"%`%CDH
M:9>@_)B!/>X4+%&OX!EWZ]GV&4EX!L"QT8K[8XLF^PV?Y#ROM)/15\A"S$$4
M%R$R@'<Y<:*9P8H/G=DB1R`A:\!()3ZK3:7+-_TI71'`US#76'/XJTJSDLQV
M9]$8O34&)++TLP/!/%C!BK\]8OXVR\LE.NAE3)D=K?V%$*K5O2?KP;:FA:R)
MAICGJ:\S7HYV]<7D92)WV*/'NIOE]_%J_0]DQJ)?T2JE&)\M,&VT6AV-T<J_
M1L3!;Y0ZV#3DF>5_3HK6%(E*\4:2]7)P9L*SLK0YR2^B*,:_")+JP6M!\S+#
M2`,$(4NR=8&`H"$*MA55D%=DO>K>5`8]K=L)T</$[P3C<1BM;Z-U3PEA-Q22
MI^JPOJ@_M.-\JED]>)F.=47GWM4M8O+?NP(G&AU-NY2>6+?S42YGY-JJ%4IM
M-C-W+(V*%#D3-=JH;\;SL;8*:A8'**ZUKVH5SG`6'HY74X-\,7F?>P<A[-TW
M4YC'-T:J3.N[PYQ]/A`QSP?R*OGYC#0KE8%"O1KR\Z)C)GG@S9):Z3B)H/FU
M<-A)JXBF)CWM@!PG6.S?`GM0I=Y0.7HTD9&'U;8*]OX>1BMF&3%78$4'K#$A
M=K7U'8^A-<*^WO3EXMS[7-?/[ARAJ@"215%`+6=25)<4[QX]JS@:GV<.]?!Z
MVM*5B!=W@8RYTS5^+EQ<IC?(*@EP+B3*+EKAK^+@*4YTO4C:ZIR90O4$8*1P
M$YGZ\`>?P2+,XRW=$'`84)#N-1?<AS5$FFZ:4QN6$."%2OG0M')H'%5JBL/]
MYGB^V2;9'L*J``0_[=W[C'BG(<UM5[!_.LV*$H,25RQYR$[@'0RS51K_#G$\
MT!W$0>,1S&^6%W$1!@F^IM"8Z;!B"A24*U!@ML`3R502LIE*TBP]IJR!@/#6
M_7.(N",+!&8/IW)X@MBW6'%(+A?RFD>,M"7ADMPK^5U/W*NE!UI?R/"R@4TW
M6#RP"W3`F1'L,;P1U)\][YG3R]PAIKMJ]G!2G7AHB.'9(1CQ](=&,!J?:P0W
M:O[#(?AAC0ZX<X-PB9GRZ#AP('+'"&;4_`<T)!X^9K.#\,?,IR=E<GF[QF^M
M8><NMYJGMM3V!1(SY9]8[#S'?).;1P>6-9#RI@>`-5E#CY[&!+<=]3V6[W"_
M85+J@VD$H3M'2AWQ7GL?,7/45W41IT$:QND*@]SBZ5S]6J!VZE4PJ/Q^RYHZ
M69C\7GQ9RJ`'@$&R=.\NJMG%P,RU#K6-2G/:!*"?$<[C8HTWG0+@[`+8]5*N
MT=Y2/53>,(]X?6XN!Z,5*J\C#?=*P04Y\=.[-H:T#C34?V>5(!KDF2(38]O&
M:_:?7+E7AG*4/?5HRL7#46?\$-N7%UH[-*;6-IC6KZ;OUUE>=D%II]T"$SJ<
ML1[72HV!*E4H%([[-;5Z,;M8K7*X"DIXLT2[,JZ?E2.;7T-C>#NK'@R#H":"
M]$:I@"TF4]UMH=T.%#A!^1'Z=6WK5+^(X#8KXC++]_005QS1OX#M#N?)1!92
M8Q@?`60UYD%:U2;?I3%K(GG`@T2`'"0HQ>WE.%_SM<&ID/#=78+3&^1!<@=_
MV\4Y/L'=9EK/91LP$%)4]34Q9!M1:OB,C13N-2^`YI"%*M02E1]EQ@E:59!M
M607>ZV<#V-0MZR<*_60`[O7$'TU?+[)1^[!]#OG1ME$Y6CBT2_UK06"+2D?M
M00OO=[BJ]LVRX:M8A.L8ZCWEP9M;2@B0.,:&!`@J&C[7+_'(>DI1"<%'Z$S-
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MA`T$#9C&64Z<I3#"Z51U;,PM)8,-24J'3"E"B?J8D<698EJ>KVQUAMO7E;:,
MO$R7/`LAC(J1;^BW%=FAU_(>5&PN#X[*;87J?`:3<(%M6=G0-TO$*(Q7:?VB
MBZTC4'OA-(_U.:4,<-J=RLF"X^(I_?8)7-3TX/<2R4(0/;U;"]/'S*>!\_C!
MSY";B;RF,HN["2]+AD*0')1H"-X/(E+X$=]UVMA0>=V89TUYGMFB87%4(Y>`
M'ZW02X^#Q82\M45LGN&E1!A1C]_`5<_$0%QT;H<P"$OT_R#H+\KT73)2)(@(
M>33/\+LF/.$;G19@E3W#G,Q]_(?;=7!WO0#O#^TT#_K6$!A']=IB]K!)DP0-
M57PG_JJJ48!LB<;CW/WH=RWW>Y7YH0[%)=[<.G0*+Z_M/<G!E[_[]<S;"82C
M<WNY>KEWM&/X/=1;P.VQ`%)8^K7;K24S$B@:&;M?'/KE2DP"9>61DN[U*!E-
M7U7*H7OP$=^':/?<)<BH:T.QR4FP\_R^L$YRG->ZPQMO&P!?';4[&0W\[L-6
M@NCI>(`X/2N?)E4:4?/8*5;1QS_7:9M4BO>K>3TI2-5N(DCW-PMM8"@YQFG9
M74Q*\HPV:M*5^S2K>D/IJX4_6.>;'O^MU`)[!E;D='*R;S^I_#'$$T?=<8_5
MFZKV4D/3W=&]]4'_0FK;D%(]E8^S7`=EY11!AR;:B\?M='0Y]1$QC29\G+2M
MAW(1YT7Y(QH']N$0SP')IOX.^ZG.@E('7,*'E4';/7C:=[ZKW:H$>F")F0#/
ME(O:"4,SW*\P(R!"G'AVE4TFX?%@J:=++Z<_ZS%5E[)-S!/QL:+!U0]0::2M
M$Y36P<LD#RSQ,#5OC&D\L]?];UH!CP=2$X5ZL(ALAW5#$EOAR[(EC$MD\A:7
M:34'R6;1U+000?5^,#XSR@(VQVH>`-K*Z^64;O)-D9D7"59M*8^'5T/%^CBX
M#1P:V1],X3KJREHC=T5OQ[1`^_)0*Y7SZ(#5T*H/K.*[T<NBV,'HC-3NH>R1
M1.1C!`W3N]>8=`"B7<[8DW3;/@PF5L02>\'9$!GU<31<XCX.-`\(OD40UKE"
M=`)WRK8)S8T`@J+(PIC4(/X8EVO5TWKWJCX<94][?#&X++^^.#^]N5ZDT>7=
MU37$-IM($^1#@+X$Z%/P"_WXGQZMC![G/>D*QN:^S""/#UZJ_$6"_EB"\S@M
M2HBV2>Q4A-2A<PVC.,0U[-'/'V"QCI\#\)C&SS`OXNH:[#*-=D69QT$"ZH@N
M</5PYKGTI)V6WHRN)?$,N+^].UG<G2WJ@#?%/*@_!_7WG,G@0<[\4?2E+1NM
MCWIL8GYX,P1'C6RS$M\Q(9C3/;]*K((IO>IJQJ-[<P1]3%$,0CP+FFI.3`AH
M96LJ)D1;\(II"JJV_<GA7A7*H?6UHBD-/P7?M9@3S1ZF/AD;Y%R?T<@M01BD
M.`T>_`3S,,;G.72\PU/L'0FKZIG0?R"5OIE$I<)9=T*>J.AL._C+>>TX?=Y[
M,A<-S\,^PV=%-$F>V,A>O,$PFTN9@6*WQ?5:P<GISV_??O4:1/EN!39!NENB
MS\DIS*_19:V:@RTGZ_**_AV46<X3[RGZ#3IF)@_8_$2\?M/M=IW#)?WR^,O7
M;[Y^_=57;[[X5$3_(6WK="8*F,!"X6"D_AJ0SP'^?A9S4J&&MBR.9+0>BA>)
MN5'X!(C@PUH9Y.SC>6<:00-3K(]BW+-Q*TP<DUP%G5:`:38'QX!\2'U-:$C`
M:_E$`5>*6GN*^+OJR5N\>=KE!7D<(7G_UDU$^O(5^F9\A<HG&'E0=9'EISE$
M5JC&W*(ILU`+0)O,8W<1#86O`O&@/4TG$4/\F81=:225<Q@4=%*0'_!CC.<@
MJ>88[]%*P68]P],L``DL2YJJ)B1]^RXS.UR)3J<0MXB?8A;5#X9((]"TXDVD
MN10S%.E!.7P?14,53"EV)^Q-$*H(S2;ZS"N$.9E2N'QH_[HGI`7B\'TR)M=Q
M!OX0;(,4]07V$#6'"7G;B@GC/SY^<?]%]7S,Z[8V)@B<.@LY9?N>ZX<G\FE9
MMP2=IJ!J.P-GH7IH/=7H2F,N52LYS"EM2:J>)DL]?71Y4,ZYC5WPF9-U,@4Z
M=@W63-WF6;0+R_M`>2AKYE;5!)`VW`W/GUKZPQ&J0S1R/\4^93SQID^CC?9-
M8A)4)6:VE8+PJPK/#V)&T\L;IV$+38$:'/Y2)WO"N1'E4Z1N!D@[4#<$N.4,
M-A_%J'H:T9*"C^FBP1AOSC3J.<BQ@=-X'H'/SN]O;S^?236\\33D=N+0N$&<
M%@V2PBO7V.7SYLO7;][(9PYM!]J&@+0$I.DLO!.JD?5THR<*Y]%".FPI[#5Z
MF5O'VX8]G1T!3,YK:-PDVNI$#>E?7K&D"YKL)LL?,A%+TLLL75KNO">:'`EN
MNCKS'C<'I#UXR&:]`&BHD8LLE8!\;*8&_"FNR_H+PI8HD[@O^2O#'U&+TQS%
M)1,0PO0TSPK$7;ZM[B54NRUJ`D@;P#2:P^V:9#0<G2A&[F%SE7*DV%<%:O&\
MD8ZF#X=!MY<I?E,=/VN<V9I/!:<T+^<`#O\]:0O'Z,41*.!&@?A6^-U2"B])
MX#W'G;YEB$/J:6Y<LKT8V('\E@[G%Z=[@8G7?@O(Q[,PYJ229S0N&J:'*S$A
M,\KJH8W\B8'F.8)IH.3=/E_ZX?:N2K5UOWNZNCJ5"QU]#:K/`?H>H`:S`#M_
M%#V9RP;KW)(2,Z/84@Z4<(2UX-6G-UCZEFZ'J^`IS_`?]^>_[6(:C[Y<QB%L
M_KE(H_ML67X,<FBP]=C0=;8Q63`GV+9:2J!I"R@MYA?XP6)-;@['IP%*;VO^
M6LK0PYYHR:JJD#.]I<6JAS6=(YRO#.N^^0V)V2HJVIXW58]J/]R0]1>HZUT:
MQ=MUD&\"@^6GW\IA9$JO<\'BP7PWCX@PH:S;ZHK<H?DI,LIC13%GF38^2UG:
MB7E\^TJ(X/<!?:5VF19E7.YP"OY%DL!\A;/\7J9+B+,%[(JSN(!!H0H)J8F!
MAAK:(4%%CS[F;RB"FN0L3&(K,?24.4"8/NJ5VG*KL+@Y*,A:%`1\%/B]9_>L
M?J?1E.^S]+A.-7<6YXBI+%?-:Z8):-K,(()%,I:^=E3C=GZF57"DF&8IJY2H
M44H5D1S26A=>J]&.IQR'5P6W;2I;D@R+7O1=!Q&\3!>[U:XHD0WZE7R^,#0`
M(0*J>VU,!JU^@!+"EY]?S>2&P638/>V9R\R+'6G*IF(",DF/CVD>NFX@S`8K
M.^XHVW<A4W<J=AR^K,=>DV,YR]67XD:3N*8,*M)S\/T,D(FE^B7RG?&$%W)M
M//_%$U^1#OW_U^#PMU1$!^S&Z1D,"5^(X;?:RT/47Q^0EFM26/]OY[?+ZXQ=
MIFE]V;DOQFO.I?Y4CP!WKG>T/9.)[4K%+JUS4EN/E-933,]U`)HJ?+/8C0\Y
M[TN>/S;WTX?'AV*"5#4/%:6J7XK0+6]8[Q:WEXO3AX7![<5!$W=AVMV.!=<6
M]4>S<-'RI=N60.L/R$N1TAX;BHN*1L;5*SV_%4--9>PXMADS\./B1"%<^M$<
M%OT.OUQQ'HS&PS5`CPO!4L_@%4N7`]?Y"]BIH_T.DL2Q6<J>AWX(TEV0[]4^
MQ*;UH=NAHB!R'KI7@=8P^[HQD(Z/6:'-GC*90:W'@Q,#JT?/9:(G5J#;6=<O
MA:J8:%5P(-MB%O-*-)"^)N1#=I_^2LJ01JH>7F4%MB"#YPK+XRC&94JKBI$V
M.YW>E&B_G\<)@#\*D=CYH_6QEXCY46T>E2+:[(JS@/X0#3C=#.[72"79*EZD
MT6EV549RV-=?DTBETPR@!K/`/7\4/:'+!NNA+JV(&07D&R7\.=AL_XK4\`76
M@]_Z<@/%;^E.NE]G>;D,DJ1OA$E]2KQV[K8:3N\"[U+SI3@.PH.NA3)G%,T?
MH9]*O5Q>E'FLD;R+NJG7JLS6XG;L>2(9=:KZ#6B&M_E:R1\4^PI)+U17*,&;
M"Y/NE?YQ!N<-G1'VE:,M%B^S0Y,[Q99$TT/5)4MP`&O>ZH_\T6\ER2D5YS9=
MU*/*M_O(]>MZ$/JCT.GXR/'HN@;^HX8_MT8W4]:-A&D'3\$F`,?@),XW<;I:
M!QN/&X2FF!V'D#S>G\%MD)?T3=3W$)UUUF@2?;_;!.D]S)_C4'4]_7@/6A+X
MD00E0C8'0@;4=&809:T_W+Z6#"7E_)QBQJ!Z*M$M/<!!!U&K8#2QUE3!>/=8
M$P47%76O>X<SU5J>@1ZW%WF6EE5%8H-#$+>ATZV,PX#@(/2X!>1;4'T\!VM0
M)O@6`J(QNI_&`DX4!Z'=%A<K01*O*HC[]:X-DGG7SZ\_P\XJT:*I>YZ6R`JX
M3$G\%Y;TXJD@%;NT9IP6(6>!8CK<"*9CW92LU;0Q8%J#7^KVOG-<&VBNS:JL
M*Q>G7MJ)B]/SMNU)._7LPYIP9!SWS.3*>T%0O,CR)8S+'6+*,1[5/;]H4*J'
M-SHR=77IMQ)*EIY_PH.#I[0^S65ZLX7X#^EJ412PQ-Z=JSAXBI.XC&&AJA]@
M3WD>!1_L^>]OE2,)V^6I0\8SY=`&`+3EK(JL'/!FI#Q6$*[\1KOB>!4$VW^=
M!@4^)>/_G+>EW>CJ<IF&.<X,<`;I?X7%QNH*<>0'ALP1H(1`30E\5M/ZW).7
MP6;<K#+MY>;BJ%%S5^T>Q4.V"$F-OJIH2?S,@(W[3*5JB'-B5TU!VQ9XG'C:
M0^-I2U,>CE;&FJM#G%RF9P@_SX%:39SY1!]]U<T/->5Z#]0?(D]=NH)Q.:64
MUEMA=+#X"<:K=0FCQ3/:KU?P_!/,P[A`N(Q#X3I+R%=/>UDF`,L%>-H#]L/:
MAT=8.:IO?8_J*&Z$&LK0$:A9`A5/H&8*$*Y\F>L>%,##I'/].PF1:4:'1E2^
MWX4)#/*+'4QNGI)X14;X'FF&%%\LA;#$;4'5&.#6H&U^!%H"GK=\G3%R-:\M
M&]?&&]K%0@BCX@*-DV%0N+E7G]."V*S"O.\3@I%P]W+9H"UR/48P_A=U/>+J
M&5E*`@[(3"YN=F51(L,6':>Z+N=JR&2X!0R_6&7/KQ"=5_@=,OX!NZ/?'K]^
M<UPYI#7[<(4?/78$[NC*`TU;TG"A([KC%(!I[6N[,%,G!I:!-)RNR7TKZ#(M
M(0[U0;L+=O>\A\(U66`@U@1`10&MSK#T:L[K#%+/1!0)Q_6B++?<Z5_!+_<8
M5L@X`%>XM;^;FR[7/$GW#TBVZ^M/,$G^GF8?TWNDL2R%T651[`[OS^V75A%Y
M]ZNJ@!/Y@HH;'?^*6X&Z&:#M/-E-VHKK+J*RP3M=/WN'_L9/?I'EN'SK/4X+
M01RC9_!)N)3R7"(-I>-EEA_C.K:@)78$,#G/QJ[AX+6<)CKR,[[T;X%S!U<Q
MOO!%QG:P@6.M"@=4G2!0U+M\`6B_!?AC[[.>KX_N9.>,S[$3;?"YO#YZS\<U
MTW!DZ9UYF>X9(SU,XJ&Q0$+GKM5PO?LQ2W9I&>3[BSB!>3'6@G=(UM%\%#(@
M7_2:CP']VAN.E7KI+GR\09I&E+;4")'3H(2K+-^/!80N4?=6<*=_.0K(IZ#^
MULN!5*&,KO;[0QM@]]SNGI(XO$BRH!Q+]2Q)%Y<DW)[E*J<?`O*EG[ABJ0:Z
M^CX<E=VR7\<Z7L1%&"1TB[E`OQMAZ1>3=F;P"EE0A;72!G6H`&GBTWFHU%(-
M#?F`+3W1I_0^@=+\`(/\/(W.T$(S'")"RBYW!A$3`HQ4G]<0P0T`:@%P$X_G
M(Y62:H1(1^O9E]R^L,0Q+(9^9.:],&X],P]R=VAZWF.>.-S>P(X:MSSDG&H?
M0?`>DJ=E3*"J5V2,*U*K(Z>%TAS[3TZS@H2)5K&(PHL+\AU]@E)]Z=WE<,@Z
M3T/\X;F^$T(3`R\KMWGV'$<P.MD_(CRPP;HX%(UX4D\S9'"F._2[ZH\()<(R
M2&BZD9#+FBZ>N9]ATFA2?@X:ZJ`E?P3:#D#;@Q\#?!SI\+0^AKR]W_4^H\4B
MRV/QE!1>\C8M?<=L28>E>ZU[(`<;+\L"+;P1L=638(10CBXY-^\M>OT*3.;F
M&X`_\F@D<V5>6\;]D;A>DNN`_#N(\+6#I_(8M_IK4'V.UM%9Q+3Q1\&;6;+Q
M>E[J#E@S#GKNJL:S1I3#TUOVN#)Q;!H*=M%+4CAG*JNEH?Y"K19-Z1A8+4;R
M=CJ5!0Q?Q&F0AE,!I*'^0@&B*1T#@!C)^T4Y-9CXRZENY76]'0PK+_^IQ#AB
MG\(C8J1Q2Q][[;BG7I?1'.Q\L@ZOW[D,J&Y?JFN7GE?=U[4+5RF'5R[]$<[J
M*9@^QM_OY`F@)UJ_:+=^M\?1I3CQ<L2JRO5AE3Q)('&TT=DN1\S0"4`?*;"I
M,^M%TLD%`"=.S:^_WUA*7,A8RMJ-&ZB)RA?&XK[+LZ)X3-$Y,HE_A]$5^I?P
M,8(\C)E0`BTI@&EY/EX;C9NG7@O!N=4L9JJHCOV2%SZ-(XI]P>-I)>]RS)U4
MO$&YE6M;_*'`YRBYOX_YF$B8X^_S(6GN&'CRE@S6^=XU7MHC>H\75^=9EW?=
M#!/U'6C-QEPVOZG%/(5YI:E;S_[IVQQN@SBJ7;)UUIXTNBG7,+?*U%&1K._2
M":8(M?DF[M"1@IYO6U^>+D]UO)B@9A$UCH]J6OKV!4F'I1L;=2`'^T#W4[0`
MY$%RF4;PT]_A:*'NAV2=OWDX8$#Q=)Y^#,C7`'WN.>!=H)2#M_&<$0[``;5(
M[N`VR_'5!DY1/D8<M)2ZNXMZ&1L*;%01KTTC0%O-X%V,7&<':!$/W?8->3?<
M&D?33A([WQ)V!Q<!!YJ!\R0JNA<V[SENOJ<??M1\=ZRNCR9,:DQD?1#?SCI+
M(I@7.*=?N1?M^DP[>AH@7WNWV53#X>WV>B)X&9>&E./+M"AS`K&"V),/ZR#M
M'C?PG>GD1T?*#&"XJ0S\$O'3.UB2N^W#8^0+\\N;BW_4(Z6M]IUB6YY"H?V7
M.NN:1@J*SB^X:=AFYL(5R<#,CRN7I&-G[F1H=O;>0W,A.WP-\D(O%PWE[G8%
M$SP7L0^'/H-%F,=;MHK-"%'1+%5GST]YO2M#I)EO_;U!EFFC%R]].+J!(3`/
MZ+OQ3E"$FJOWYFRGJI,2_L9[9`LKZ\/34#,(Q]N3]I&'_?+/P38K_EIO#(NR
MS..G78GW8IPCZS;P?T^F=_:1G78\Y"E#AHQ.$M<Z'1DR^T0Y7'TF'.N.@B=V
MV7A?QD%3]_;*=\RJUJVE033KB[+DQE"2ESO/*;).M4M>4!(F']@21?V=?QD4
M3T1=54.Z_<.D+.K?'-H!@A[<3NA.WP*CH/D(_$(^\U/(5JZ0[B[5&Y2-"[U'
M[BI.X27Z4>)!'P$%;2_N8R8/65`#`G\*R+?^,_**%<5%1W>4(ZP0]R%,`[0>
M+3[%TT*DTY'3.&X>!R*05)^`7_!',UDS>"KB@J,WP-;$K4:"X/-KC77T*_0O
M;%J0Q?O_`E!+`P04````"``&>JA&12E"Q6@P``#S^@(`%0`<`&)C<G@M,C`Q
M-3`S,S%?<')E+GAM;%54"0`#?`M-57P+355U>`L``00E#@``!#D!``#M?6ES
MX[:6]O>IFO_@Z?GR3MURW%N63B6W2K9LMQ/;<FQU=_I.3:5H$I)PFR(<@%1;
M^?4OP$7B3JP$Z3A?XK8EG(.SX>#@X,%/_W5X>'`.`H"=$'@']]L#>/+_PO7_
M'!P>G*#UPYT+#RZ"D/[5#>$&T-\%&X#IO^G?5V'X\./1T=>O7[]QZ4>)"S$@
M*,(N(.P7!X>'_SQ@__WG?_S$B)Q@P$C\>'"&X<&5LSUX^</!J^]_?//ZQ]<O
M#S[,3PY>OWSU;?(E^@T?!E_N'0(.'M=^0'Y^D2/V>(_];Q!>'KU^^?+-4?;!
M%\DG?WQDORA\_NN;^-.OWKU[=Q3_=?=1`NL^2(=]=?3[U>6=NP)KYQ`&)'0"
MEQ$@\$<2__(2N4X(4<#!UT'C)]B_#K./';)?';YZ??CFU3>/Q'OQST1R!P<_
M8>2#6[`XB%G_,=P^@)]?$+A^\!E'\>]6&"Q^?G'OXL=#)L.7;Y(Q_IO]Y@_\
M!]4903[TF/2/'9_-Y6X%0/CB@`W]X?:B,(M[B%R\)2%3X1'[P%'C]X\R_9KD
M\H\;!X,@7($0NHY/5)DN#V=L#A<!Y07<A?3G-24HPW=Y",JK?CY/'+(Z\]%7
M&09WWSWZIRX17J,0O+J#RP`NJ(*"<.*Z*`I"&"QO*%47`FX+X!A)J_(9O==W
M(7*_'%-_]ECT!`&)PX0(RTU#:%,^(_+F!/F^<X]HT*=1W0F\&?4(?`L(<+"[
MHO^>@@WPT0,S.ZKPD(5_(<'+$=`ZQ[>W:.OXX?8*!=39_Q)61.WWM5O,M[&Z
M5\CW`":G?T8PW(HP6??UF$<]'%9]YG@;_\3-9,L(1QK7N&YGGSOWOL[@D8ZG
M-_(U.+\X[^T#:;20,P?BCXX?`;2@'LYH.<&67-`LD83,N<G]=DY'C0GS3D!H
M3*T>R5(^+_*!=^6$$:;.M$"XG@6A"8D.JRT.WD7KM8.W:'$+7``WL?;%.&\<
M0)_AL^D'(<);(<Y*W])K!OM94R*1O,SRW]:G5.;:-#>DTZ=KZPW-;2=L<P9#
M*,IHYT`:`\4G`)<KFC-.Z/[168()(='Z@<4D0ITAYF06_W/RU<$>.<<TZ`(O
M1*>4!-H"0%C.0#>8+E4YB0*ZW%$'*O`N-/6>N-&:T+2O1U,0.I!_?\0_H.YE
MNF%IDN"_8R3MN9I44BLQ+R4ZVF==EP=+3*IM&-TF5I,52W#<,HJ&Q6^*W(@I
M<!)XI]3OPNU%0$//6FB;TCI&%GL>,#6<((Q_>4DY*O`*'D-`PY>7<<N&E2T'
M[0V/4O616R#DLXH9PAD=:M[`__E%1`Z7CO/PQZ[&,5N<P8`."1W_!A$8A^![
M$EMX4:`IBW%%;>&0^[BLE@YW1`7]]@CX(<E^PT3_]O#EJ[2Z]M]"=%-!RD\J
M79D,LE],R>0YI?8!+NB/Q"BW>RI'!9O)6^H$%R=`(U_&$_VQ8J;%RFKZB:.'
MN-9WZ*Z@O[/P!49K.<,+4;-N$:9!XN<7K[YY*6TNZ0I,6.@AE\@)"'7KE*E@
MN<^_C[?[G]DV:/((C:A+B9]]1+>LUX+OY36H)NZBOH7C7FZ!1T%N:W4%UO<`
M<ZUT'4/85H`.:V;JZI)4JHB75!$'=)H+@#'P+A,I-TXCGD-(5W40?U+:9>?8
M\4`VTSUS=5K4XY/M!'/Q?\0:YQ2NH@=F5(J\3-':@8$)S=72>2I.VB[,5%.O
M%=;&:>K8:45E@NF&?)G$=X,K(`=5NR[7O<KQ"*ZH'U%'RB@4]JPI.8'EC&,8
MN[+F-T$F?QZIZ%JZ9#5V@Y$7N>&=(Y9XM'Q][]ZC45"=$')+2_\Y1?LTS"U0
M7'1'I&`Q>=:N48.,Z'5[]93[-UD$E]M_$@)"8K+:4J(PD+6S4O,H[!)+0I&/
MV;Y25&"=-C0W8_]CE<@-#5<T;YN$)P[&6YJKQ<>E)G3&1SAO=3;RV%K3S>N1
M4WX:U*NP$Z'L0S=MJ[*B;%$6!J]V89G*+_WJ!C#9.-!G8?\,89:/W`&7-0O$
M1W'WX?Y?)Q'&<4>A@0@MR,+@#4!8IKE$H'\#J!0[KD%H4MMM]*R7YCF4VRJO
M7%+4ZU*]:TRY!D:T5AA_\`Y8E$:JD[<VO.L&@P<'>J>/K%$`3-)3]60&!IV,
MAZSU.F"G&KF$EVKW6R7M*FV:3Q`QJLQ:.L/77KUX4G5]U[^ZC#M=G7L-H')1
M9Y[5W69904J[$:.9Z#4*7/O):(Z+X;NBC&A3._A>O5`LN7"B!X##+6MKC%N-
MZ/XI[CTSE."TTK/NRSQK99N\4F7^T%=:6G,2@8)L'8_G(GL^4Q[&\O%SHUYX
M))!JY5W?9S$9][ETRFQ0K2=DM>;=[5$-TLF*-5;*=76^HS-YL:N35GNLIBQ*
MAYDH='RU,[-+Z-Q#/UXW:;RMMNV:/-3@IFT[-^$[\.`7I8Y2J5*9[,;9LD2J
MAP)9B9+EHHNHM=>5S,JRLW6N1?G!$:6TGY)9=380L^V;BBIM$J&>TPS)*BA-
MC``)S3MI`Z41.VF3[#2<3>AH2>FAOE:B-&)=-LE._G1"0X_1)0J6<X#7<=]G
M:F5&<J,Z.F..M?6"DS_5T+-Y[&?U;%PV;>JRQ9`;LEK[U=522#"[WV\F-F8_
M;!&AED,H5<4&X0G]/PS[TFT-/?N^J46_=9+4<7`E>4^RS\I">RUAG(KE*"A(
M''-H:0Y(Z,4,&FNPJR-CNPU61'VU8M+3-"G7%HO6:Q28U5F%AN4&<1%]5>6C
MH20@5^CQO/A2M>/?.-"["$Z<!Q@Z?HY!(Q6?;JIVW4^I\,,A4@VGC?)5VF@=
M^0PE(CY,8`@M&*Q`0.`&),B6EXB0:Q#.%G/GT5"]3XB%$9<9A*4M?^"I%@=N
M&8)*`+Q3!P<P6)(<XS3I@RXTDDIQ4!UO'.`1J::C4DU9<S_9LOTM$+^QM^?(
M`S]>M7&L:CM8RZFV6Y(*=T\+BLX,_Z>C,OY3!EW5%RY4&7'[&2;J&2:*B]O+
M9YBH^KSZ&2;J&2;J&2;J&2;J&2:J6[C/,%'#4]DS3-305KEGF*AGF*AGF*AG
MF*AGF*AGF"BAD_(;!\]P3,N+#QAO`+Y;4?;-'YXW4AY.L:!2)FD^2F^6HTU(
MHB*/,4-D$H4KA.%?^]J@.1U7*-K.A&546Q6;M9LS=8S-HI"];^G13+XOA>9)
M#B.,"JNS(#4MF$':%'I!2-2?<Z;41JK&3%8:L(+4.YCZ7$MYR(XCV'()4`?N
MD*IZ^U@^V\A9/C`5UF;CNFFCM;O"E[DHVT1J)'EMHZ2TP`WI4I_AK*>5WE@5
M69?SZ&C6MM.B4'Y<6WH%+PUDL@^AB92*:SRW'PR__:##Q/@[#E0E?^>"P,$0
MF3I*J2<TC,U%=ZFM*!T-O1[9@!\"\@!<N(#`,U?9;28VF(U`G?D5--$LKUP9
M;>B'<2VEV]=*;IR]1VQRB:K0&(;SMF8Z5;EH*;K*N3P[84H9.D?((X9`]FKI
MV';T)@,M>$>M@*P"]R</VZ8\&7&J(@6[`8Q'26616`"B*1RI3TIO*$\*;RB+
M-M)UCF<]86S3D9!@;,+AYSV]ARAH,P!*&&M33%0,AY5;!$*J2U$U&S*,!L^J
M?&G`*4-U@C9?#&%XTK-%O`K>(=]0-;)(PI:'-%E6L6)5$H<UB)=ZUTWG8";M
M;B-H)V'@45F'H&S=5C\'`<".3[F:>&L80#8!%IH-:K"+I)6@R*/"3EG9.QY/
MTU"3?E>D,&!'*XG"UNLX\1,(#!0]Y=G4FE6@836AJ#?"\KI5E(FM_"WC:/8`
MF!,'RSUT@`E%U9$9K@O5"D5#9X$2OFJV64AX,G/H5$O)4CL!CZ*:9&.Q?R!C
MR>!25"8QY$R](@Z)YH!WB6H"L&3'N<HA[]R!`7/I67"&,(#+(`&*=+=3@.$F
MSF@N`CJCB"6H["K4%!#Z*49[0MX#;QD'AMT'C*2(FED<;JC5K@P-[0I25G4-
M0K-+:)&`M<(CCU)+LI"'IJI'NA#630;=D;4)'CL$NFPC"OTH--/;U45RL)N\
M3EEIP).25.,G&A]6S/$W-#U;@NN(W<Z:+6(V<RU+/6A7DI/AAF%9T6I!FY)_
M1ZD&_.Q#@('CLS;2]\AG/.]7F/V;:Q,,"?W3E/XS6%)+A\@S"4]GC-=!KP+F
M-)197>_5PIK9F+2;-G(#WI6U2BG3G8Z#1CO]I.QE^3,??7VA"@,U6V1#&6W4
M::7WW%#ZM!M*>8SMN:MT&%V`SUVESUVE0^PJW97#)VX(-TEZ)M+VT?;]0=]5
M:YVXK8?T_BZ%)@ZKZZXY]::=B??OB(1Q#7*.;H&+`A?Z+.UE[,P1_8$MOQ\(
MNXZDZD^Z:%E9%SG5JDV>MAI+IH!2<V$L4OJS#V+9!MYDC7`(_XI_;\)[N>A:
MT;QF%REB^O`(VV*O?UI)9?A?:[:!-J;^!DJ6EEF#*F\2J<674//6MH,/#I9Q
MTX<)7;?2L[9N&]1YNX!M=K#3U`,#:HQ3D/S_(MB?7YI[/YZ#JIW-BD$;X)&T
M1,M;8X^!V%64%<.2(_E)Q2S1I2C_((!(LB<XY)!S.E'IV'H%N6IB.9SI?OPX
M3]"."\N9<KNG%L0HD8T5G71>`CW5I.N+8$-%@C#L2]=Y@D]'UP4Q2B1E>@)R
M,W\W&#PXT,O00--SK:R1L,\UFXN3IV,8?(*7B/UZ+*8&J!D%*9-\XN!:UC60
ML;+4RUN$#L$J)W:E-4-3+,E@\]-WR5GAP75Q!)JMPE0LX>+DZ<02/L';Z]RO
M+HI)-W3*KZ&[SEQT1Q8]Q&0JW_]?1M+75@TH@([W50PH$K56$C*A]HI$Y5$'
M*Z\G2!_,L:K&#48;Z`'O>-M8WSA!`?U%1'^7_A$%ID[R5#BR5#16MQ953<C?
M(5"[E,?V3$3A8+#M^X,^:&^=N*T3/+J@I!7,B?MG!#%(GP8Q6M+M)FHMBG-8
M9P&%NUM\RB4@_0OU+9TBAF[:YME7L:]`TY*G"JJW6W0:BSYZ_'>R<:#/<L0S
MA!F0SK[;?`KNC63BHBR,0_7"@M58S)%\/`&Y`'CDC,Z6\4<SB2LG9"QN9XMF
MYHU8A"0KMGHH14U#5M+VWF5H2!9K)FXY;>?ER'*FI^AL''D\MVIT@6L(V=6N
M+4$RB6_[_J"3^-:)VSK+S5LC>Y^`/58_6^00[TT'^7JBUI)X#NMLBN<-XK/5
M!UV(,XR5V4/L]J>/`+N0F'H8J8OH&#7;(#YK&^\R:S>^8V:E;:!D*<RJ:C`5
MDXT^N+BSXR%,=P:S12.81WSZ%S(8.:[%4&9<*R<;G+J3DI,M!+>&]*MFJI8S
M8UZ.+/FU@G-P9,/<ZK`--<>8IYL!]K_3/R,Z99\5$9*[_>5JD@GC$:)OYXQ<
M<`40DZC\,7A)_QJU/Z$FC?&6SCA^QZ\_M9<)CV/)YQ2B_/'W0VP[=)^'0[G=
MKQ"G?[RTK/#A;J:%Y2B?)"0Z/PT*R'H]XVM<HQ"\NJ.+(EQ`UPG"M+&'8;\@
M'[JL/J1P,E\=S23>1@LUZ8O\;9*94WD?^X9*&9R4K7M3MXH+E\<XY:GMQF"_
MGO0ZW@Y6+\=)U\BGD+@^(A%.BC^[$6^!'R/BL`M8\86\>T8S.Q\RZ62*',D?
M%W`3/LX3-NJCJBQ9=UX]YE6X$*RJ)3W/3/7O^F\*#\PXI0=FG,+C"VR;R`1(
MY`/##"^=(+V1N<?(2BY?W^2FM[NMZ?B[O,=H?-##F/QNI_#,#\:LHXT-O;=+
MHQ%!A+QU[]=J0T4<.@$E:#K&Z-?;WZ9/#ERA`.QP#F3*M]5AA,XLV[XOOM36
MC-;@+?SL#,#>.80<EXA;9S_2C/3;."-=(9]R3]A&-MR^D*\D5@=C-,QB*+92
M5*B*UH_<TSK!3]PRAAZ/OHL8:-Q2U?B@:'\^5=VU'F_CGV*W^GL52::`N!@^
M)"D"2_:=()6%V*K!,XYM*$.^,@>71*P]F5?(\5H5I2L9;J%G/?L5*URURTX+
M]I%DRP9$.#EXN@6N[Q`2E]=B.>ZP8')F:::90Y"'D>E>7,;VWN-K.)GLP=FY
M"%ONHQ3T>3Y9ZNB@UJCKXFV0)O[[,P%.?L:QP.L1O89[\=+;GJ2'FT6L'H)"
M,[%QJ;M%:'I>O)/390[6J0=EME"SNDD54V6;S.1OLJOB52203>V[)WTN64O+
M+KJZN#_6"TS#*W3RD35T@B5D<"CQ-=LS&,`07,(-\,RMN=U$1Y9L<TA1_ED[
MV>PZ!;?)WN"1*7)T##&.];!+#CJ>J).]3X[68.X\]A)!&VB-*X(V"4S+RW(2
M#A:MH[A%H.GU,H9@*^EX,D./09FR4M/QC)MLQAJ#!C%DXB6-Z_W4(;N)CFR-
MY)"BIM?>))6<-+U,"DTOZ:)A+A7B(3N.959(D)FF>[^E5/\00'*;D7),XP]E
ME@:B^':<.;7+L#&B_:J4E#.;4*HP"2)H%9Z;CRTVH5I\+4!F!9<=>QS.+BVY
M3,EJI2<QF/WTYAQ[_QU,EAB`SD)B$[H^UTBC."[@%$JF+I7JDO227'Y<O(>L
MJXODB&)PI_0RW2J5G:04^X&`V>*4A'!-=P%&KOZ6*(QA7]0DG$Q-:I4CT9B)
MXB4:IZVT5P[^`L);2+Y(A4W>P<:Q]O'+)E.=4FE)NFUFSR1C[H12AC&;AKIF
M&LF-8CWDDEO6(6'A3;AK\#4W$8P"^J.;-+4G9M?#XBC,P\@J%.(RS@Q"P_MQ
M0[H].T\>W9'<8H^V-70W9"/LG%'WXB$[CA522)`:.ZKY*_>M$*0I`"']UYD#
M<7QG/O8(P1*^(HV1!$]E4>IY@E-,_W?N"GB13Q/M7&<%0\8J/#=#)+0N-_)(
M="TI-IM/;>Y9WK5?)*6/L$VYFHJ\O+3'%=7Y1:H%IE?!M>,#)_U^S3GL.+0J
M(R\=K:"#P;G8);NR(>89[J(F--2?`*6X5=L^8Z\0)W8+A?J1+6058B,I;^,Y
MG>ODJX.]//XLRRB3B1`2K1\ZH[LYXU+@T'KVUX_=J>A0SR:AWS5GM^-!BW`%
MTHN59-^53^ZW<SIV/%49&(;=^+/%?#?^76[\XWA\,3AYP3%U+!4M58)8-$8=
MN(NX=)\)!X7+,I1?WU/<,V`K5Y6TX?I0TVE(N2BB<NLA82WFZQ$:>JJU0L7Z
M(B'LL/5WD?9B*VI#.EWX<'>.-@`'\=JR!(&;EI[V7%V!]3W`)O3$3=OV7K#9
M;`M'S]RBS.6'*AC/"#^P/2;H2U_M!.TF_WPJZA!9V:<DU;)>LV<='/_&>0#8
MI#KJ"%GML>'50JV$<H5./;==&0\G5-E+A%-P)W/*X*`Z!@?A$5ZN+FG[C225
M154PQRQ9I^:CT<D:X1#^E>P6^ST>+9*V:Z12>3_?F6E)PMJPW32<FJ97[+*N
M8,7ST?)H=M'$9!4J("T=U0W-[GR.$2$?`@P<GYG<N0/-O-$BR,$X34%6W#8/
M3KEY99?UK%I&S(#M#59_MI'(6^)HM>&17,W6T:\I/-F`8!=OYSIR?>#@LPCX
MUR"DTTM2#\<4&%LKO5%4OEK5W"Y.'6`\<C7J!SKQ'&^S>Q\N8Z:N4>`F+1U&
M2M,\=,?MV'RBE8?NH9DC`9?*?IX=Y=')Y9@UH?,&2B/8?K?JN4F`\H@^1<U*
MPFONG_HTK=8&4N./V8U"E`?R*3FM]I79S`-IG6NS_GF\LC:/_KH#,@/=/7>_
MH.S4M@GL&P2D&B%W!*C]UY^Q"G4(2`RK<$+$VUW^"88K&,P"\)FI.#M4[G<O
MPL61I05/WACXMBM\VAA2R;+(\61!@S-E>+["*%JNYE\18YTT6)+BC8].8J,T
M$GVBMG$CA)?[Y*=@&<\BXUVK==13L+(=ZL<@&D2JI_CY7-T:W%JA<B^DYFWI
M'E.V:+UV\!;E;S]ER9E8:I8,5+A&)9:$M0T@$_ZZ[P1/04@52IIEP,.W!C*B
MFV(EDI4=HKG975KOQ>2Q2N;A.FRETOLG%:=9AP?=R.W?ZC/5CUE/R$ITUN>I
M^6C=($G%%LT/=U-`9Q(O%K/%>^#X(8,%?!^MG>`.X`UTZYO]&OQ+8#C+=<56
MPV1R%Y&,_*ZI4B466Z565&!H"=F3$.@R]`0TU?#5H6NE:<;R&Q(U#>QRJ3W+
MA/)VC0)G_YLY_8G0$,VNS9CK#A1E8>BJEA9MI<=3!2.%L&A.+A$E0XGOH!-S
M$?MX>PQ].L*2/6(;$9.7#I1YLM-Y9V9!5%=0V5"D[(2-#;SL9K8Y]ZZE8[NG
M1I>3Y/5:+]#*=0;)JRC!?4_Z:J`T#*@UK0IKDFDI-55]BJC`SQ2M'6BDT:6#
MXE/TN"XA-UZ:&.T:HJOD4+RF\)__\=-_'1X>_.^GJX]O_^]_?W<?HL?/P;?O
MO+^^WRP_;X,/T^CK^??XW?>_OO[WA_F6^-]OW+]>^K^$/WPXN;SQ/O_+?_-M
M\/O][&1ZL3V?_WGAP-,/R^CKGU\^G3MOW8?-VU??K:ZNWO_[7^<_/)Z^_>[Q
M\A]K_-9=_##_\]W]]R^O/G[]Y:]?E_B[]R>+S^[9[_\B1S^`TZ-/]\?S1_QQ
M>K7\'/T6A)\_G4U?GAX]!+]_^_O-YGK^KP_1[6\/UQ^_1`0Y_W#?OGM[-9^<
M;G[X-?I]<?_^T\G[5_[L%_>WR1LWG)^BZ8<+[^;;\_=GQV<OER?_F+[[#,'K
M>V_BWG^]^/KG;[-'_\,[_^/].[#:^,O_.SBYNST\U.#YUR`\,=?K5$]H?)6#
M2B6LP<7STM2V<>VWS+M#-9*^F;\;0:BH6_V6?-ZX&^L3PE\N@KB9A9"X[X&]
MSX`W9HXR>,C:6N,:E5+[1EN;W/H_QJZPQQX8(RO@G2/D]:C6%K+C4&N;W.R]
MA[UCCW)D5']L?$M[!#$]Q8*0/P$N'1,>6#PI3'8MLCU<^R.99!S94\+2MR4J
M5S+90W[NI@[0\C3Z.OE,:)H_'"S3L=47U&6%LIN>@GUH@2YX/A&4]DSQX\#G
ML\#GL\#GL\#GL\#GL\"7UK8_&H._EDQ($P0.ZQ@DZ?#97LV$*=?2&9\N6ZMS
M];*T5\2X15NZQ&U3CHP478L4QG,NS:'-LO2TK4>"[X/M\,$W[/7'^"7G^I=?
MI;:N*N,_"74K"=A"Z[P`O[H-P-ZQH08O$-2UUAV`[-%9,A,SIV7IV*,Z">:)
MVCNA:7@3H^=:)H/J+KS8G(+&PWQ94W`[V3*F6(F39R!I#.=ZR/S]GN!X6X]N
M?AVQ_4&*?4[R-V'.Z7?-)+*F>+7FB2(VTOWVN`ZMR8?>!X`A\DX#3WG[+SV[
M%&Q_%H4D=`*/!K1DOH,RQD8F[5R$Z]L"FW4DG^77F)YMP_L$X'(5`F^R`=A9
M@M-'!J5+P`V&KAFT_YY8__N$2E&=RF](!A`Y3_^,8+B]"*@<H[@V&.?G\Y43
MI&*(EP=R$=S$O`[*@D5YM[-W[MU^A56J#+<X+VV^!F;"-,E9`!@R4-HQ6G&5
M?5M'Y8.SY!K-RB-+JAXBJBTW1:>,_[)/TSG/(DUR,)KUW[`B)``MVX.EG8QU
MP,MZ\^(]"OLSI2'K>)J=$R)",QK<1DDC^T]M@=:I65WHH=)F'`N)D`AXTQB:
M*6$Z*8SEGV[,^#83'<6YL`:=(FM5$H*6P!^ULKIV.40VI?%&.[$9C,XV>U9P
M:M?O^FUD4$U!TNU5A('5C0D'&Z/)#OM0259/UW",;F5ODIOC)/!.'Q\@CD<8
M]':EF^FGEA2J:S$S5)&3G];E?ICF.KBUW^B$GEPJ8%;]F0_(7`2L"=;]M<Z4
MII5[WWZ!<"Z]3Y:G>(<(O!"=KA]\M`6`.($WA1BXU#%)1&DS@/B"^B2O%3;S
M==;,UWS/UR3'UP?&U[S$EU`/3W_<J&YW[KM=X+[L`CM<Z]R\J`=0=N/0O#;R
MUH%!;FW%KMYMMA(`#6E?0R-^OVMZVYP^(I\.X\-P>TMSCT&MW`)LVSD%MV_A
MIJW!!K"_T0E.:?+DT:Q@5,9>8-K2CNOIV7K1%+3<P+!OY[>0?#G#`&1/%8_"
MSFN9?K9S(Z:@X39#WYLR[AL>+Z1?U:Z,6+\?T@K;6T?-V%L)!B!=#+_N<&D&
MK.72^JL-_$8G=,>[Z9T&V3MCE!7(ELD3A[`K;>Q_K'5MX_CL)*G^MZ:P6Q2X
M&?Z]M$9,%Q4=Z`#;/0$XC)D/`9DMIN`!$1B:`ZEH(V<9D$+=&_)Z;95K$=A:
M2&^[B^89MJ<`YDO3=ZT_"ZM'](VBL7@9GP[@^#2I/*$4Z_VJ[:9U[;=M+VEZ
ME-4B'06`02T]-'(3-!<SE?AY&M:B1S5%Y&Y9\[C!R(O<<(93%#!3^5`MG<&#
MX#0F.O5B4WNWY79R<_%Q<BRR!!:^87WA:[.E>$DK3M`6SER)75;_R"#PS#W*
MT$S,=DSKTAJ'N(JINY0R+E&PI&I=LV=;33Y`5$MGO'&H7FQJ2\/-RKF]FL3/
M<PC$HNJW+.^`VBR*B;!FFOHBDA8?,!>-&B@-7&-=<M*"[GN"XM)WTCS$"M+'
MVV,0N*NU@[^8"DJ=-"TI1CT^=4LS=U%4NLL@!SZ8KE*L9FIN#]-.T,[)OJC]
M-J$WU@BP]'*9)K?*F#(7Y3II6HYW,JKJEJ.N<CH[P#-6'=\-/G`@Q>9*]UX\
MN:O(\LO.E?,(U]':7,PJ$K"^5ZR85UZX)6&47TZ4$S`,#`NX0&#@`BX*0TOB
M%!,T6#?,#6\%J8M+L`4A%,M!NK)1D[OC-G)/*0>M;)6_4]%11$*T!KA"Q^#!
M8P=)JP["8;,%]72)K_)PKAY/,KO#;B,WO+2S53]M@E-,-CT`_[@$2\<_I1X=
M;MO#&@'N-TNT.:)?2O1`?RB+OV[`L:68M4+)P37("/J7F]OT0/DNNK^\/!$H
M[#5\U9(1MU@,DUW3/&V=-3!V$TZ[0@VO=1=&LQ+G.U10G7)CD!B%.\JT_^7P
M,V2S"O9,(0FS=V+8&;")9:J&RO!5=-F&@EXG-RWOD`AB/@`WPO&EU]F"TBNC
MUS1!-%2^-?2LNU87-9.W<2TGK6C>`A?1B<3I2[(V4,.X@CXU$Q2`XH?^XE24
MY-`#3T5JE2DK11W74XQT/$W"$P?C+9U^?/_`1I-3F851>KFTO.4O=&@Y9NWB
MUX9!/&T+4(&#E;VK=N6$;`W:)N`/L\5[N%S]%CGLHNB5@[_06=$\;[]0<45]
MT3%'J51AP4E`L2HO[>E=-Q-*EAQZC$N[K!3E,5`EE_8RAW<KA$.&;;#/]J4<
MN&Z<P3>#<7EMK83D,3]EHS!KU2ERD3&:'D%QJ:U[E)%N6CG$(P'%J06Z@Z;R
MOD-(<NN'RO&,3I=.+EI'[*9#\GX<N_*+P0H$!&[8E6&T!B<19J)*S/`8+!`&
M<^?13$JED\%1+M6&="6/DJD*+)!=_&:`!P$QLC4KDQAGN&\4F`+HI.*V>[*F
M*P[\*Y;=;'$&`R=PZ6Q.$#&SI6JE-]+U@$^6,GB->C'HSQT87")"9L$9#1IT
MMDDH<;=3&DLV3AB'F-US(50F4T#HIU@PFI#WP%O2R>0^8,(\=+,XQOS>F+JT
MH27*11HJ``_Z$>-[ORTY?73]R`,>6_S88A>%J?N<.CB@$R!TG8NA2*AS168>
MR-3#V)@M39-J,OM2?<%6O4N$<L9^07?)1D`46^F-?!%KEV6F8K62H%K9B$;#
M&[K0+NBD4.[<4*9,U#342'7(*ZA,BTK%O_ZQF5['L%@5V*H<*)-L9C2%Q/41
MB3"8+?)#WX)X*Q9G<!483Z/838H<B6_FN@4L!NW$,Y;PKJ5[X(I?*#)Z68)Q
MLM@!J,=(L^88+EU7>H#D,C^&'&>R`;I(P&KP%G"A0@96%)&FVT`96&`.3M!<
M=W,S,=MWY6OM+R_]%CFIM3'G'VJ:!-[^Q#7^@T`[)]=`5OO'&X7,)P-M^$BR
MOB+_J-%^YH''@#>OG;7!%G4C?-J]_-KIGV9T4\9]D3*;C]2<:79N:F7+#V_%
MO176M()HE(2=O)!(:5.]LHKJ%>5[]8J*[)5`".T<Q/(%CQI+8M+LGKNM+OE;
M0'=Q3$`)BU>.!RZ"7YP@<O"6\O=&!!*);RCK*7B#CG@E86V1NP%X@?#:"=PD
M1.;YG$3+B(2""A,:T.[JTJ`S,9'HP@,TH+4/<66'+GOL\*D^P5=28OWX(]9I
M@\!T];?*JM@KL0SI`NO&O+'<0$ZM7&,.<]T3EHQ\LZH>8+IT'N8R_R*!H:Z%
M#>(HPVT\XYMHS;6KP"9O%&ZQ/:-N=*)N*,*:/./&=.'&/,.:#`[69`Y#'\P6
M%X''7C2*'-]4(*XG-+;Z1X.XBM!YP@=@P2%(J]6[YW\$<L.V[UO.`UNM*SFU
M:IF[;5CB"O>?8+B*3^98W7L%'^:(#U%`H]=TL#!T?4N+5L^I958N-H:MGA_?
M8B.[9'0KBJ>2W@N)O/!NF4`TJ_N>W<)$G=$PJ=7.4%O,$A)VX;#S)L+NBJI>
M4/!=8UC-B9ITT#EQC>59I8AC$,]^2,=^37IJ$D?I"&D4T5*H8:F(:B>8&$;,
MAF>+>EI,E)P=41SCV+Q\(]C]%>N`1S2VWMJ>^/'?@5=_QFWP2A4GY0%W4]5J
M6U2P.B!NU)JSDF<YZMFD>Y[DL")Y!G:.0L?/_YTU_5%!?09A$Q2.YN8N[<P.
M-92W&I=!W?7_/K3,9,KSR-ZZGJ/C')S0&<*W@"W>'HN_9Y"XCO\9.((Y9G]L
MC<H6;:A-RZ/.@S%/-J?Y5V39&C,N!EL"Z-GZ=EKI'WW(\*2H@?'=G^B#C^=8
M5U:,#40DLQ,[0Y'MM7;'QMCV$7UH1@<BT[`,#FZ&$.%B-IX-KJH9+5!2"O<K
M[EMZ^-,6_OSEM7T+?]I-=`N7JY#L;R2;V.J:871D-3/#6M,`CZ5DAVUW25JO
MDJ0S2L"7C&`+:.5OH"T3W2:G34%:4+'Z-K7TMES2\7H1)),YQX@8.8@VP>;8
M%E^C*M."[B5W'+2#^B83*BRPX01*;_GZF$)*FQ04X+ADE:(6V<CNWD)#^M-T
M=5@[U3&9@`&9*\!H]6XY9Q"3L+`F3A8AP'&8FCJA80OJI#ZJ(I1!)5A#SI+.
M[]/U[O21.@8DK.WA$V!I/MV9)B!$R0E"#'\8Q``DD>,ST%QS27//T_B[[>A4
M-&X%-LQ,3E>:],Z)SQR(C;U,TO<4QK3"6U.S#A2U?@UZUPG%_DHF4;A"V%3'
MB'XF_U9&V:RJS.Q43@VLFMV&2HTM'V<H28&&;'T57O]VA8U.Y67VV./[%/O=
M&.7+\1V\G:.LH9LAI:`@P99*+A9R[7$$AQQ3+!*55J90M>J\M$)S+"4V=PR6
M,&!YI;`B6X8:FQ_S2BA37J\%[U;F3@-/B^[2<4:V[>(23=;SV?_S#]++0AHM
MBJL#G6QVBCVH1;V3V5'5H7K076:0B@^_]E/C[)I.W<L!NBN=G#R,+'@95TEF
M9_T_-QL+XX*0"'C3".\*LVE<;KHI:.;\59*5D1F3LN0S8]'1?=XO</V;$^13
M%A![5&$#G"!YV^N6$G+8#`-O"C;`1P_,?[+B:0;TKP)K/\-+)T@?)*+C$N1#
M+[&0P+O)S7/W6)'CW]'?`./H]GH8DX*/5]&%&`*^.J7>)UAQ7*.3O!P.MKY6
M3\DN_FHPM2*4A1PR"?W,;)%;M(VA]M02LE8IT>;H!2R2>F$J858=QW68A`$!
M#(::KUEWHU9;8W*LFZM&Z![!=X4\#S+A.'[.%-+3(`%%<`QC%VBA4RL\@M`%
MCB&FH;N;V^/)[70BX1]-WQV^DS3.6A<*L;"GG&,`@A/6S7B"\`-*'@<3PEYO
M_KYM&*HN;;3.71=HL'#H.CV97='<Y.+V4L0E*M\:NO!KYFD;YS?_[`3E[)J&
MS?UOYO0G0CVV:0G1!-TAR,+0M2PM6C78L1U.9IH33@HY88Z9+`[/48I*?89P
MG$V2XVWYW1*]CZ7K8,Q><=M("JY)6PIXJ!_NIH!./'Y-<;9X#QP_9-R\C]9.
MD-[>$\D?!8:S[,A:'87I5$22=M#RKITD,68/*<,P"ED@\WV`EUNV*@4+P`)2
M1*:02H8(J5UN9.O9JW8;D)2P/K`^,=^?'(NX]N[3=G>`^AUW+P:-FY*^5V\V
M,W-@BWH8>V*&HUEKQ<<.K!V':4UT-!;Q2^(1\J\"!Y,EW07GB=6TNC?$0)YQ
MQJJ[VH-.+L'UC3=9S]2^\*=+KTTC_@TTW"A,#1"36G3][XC$[T3KTG3=>%;[
M*GM3=*TDM2`WRN5`YV@#<)"?UBUP`=Q4SZOUI#:M])Z6"?")6`<PHEC++48N
M`!XYHS-/KBK'J(UU2=5NFGP]N#(#6\0NU*YP.<E:`"M,L9[V9JC=%A1)/"6K
M4)6V%G!!#5E`TFS'>M&#FNXNH02@,M33"OR\\K,`XI=CC<JVFG^FK;@D,59.
MS!?A09^LNCEE:A%,+[]&74*7(=F?`="@;TU/AW20'&6?5VO&URED/2AV8A:P
M@S)*[3%]G9++PYN^^[0<N5%">J#@U+0E<".UZ;M/7%OE6ZAJH&FB;35!$#G^
MWME%O*OINT]+7XT2TH.GIJHO`?]J^NX3UU?9OQ3+5:(=MQOVH#N=*64H2:7I
MYHF!!,$@[:_?I5Z<O;<"`XZS$:9>K4*"[!U>K.&.5UPHI7Q>(0\NH)LRFAJG
MF.+5*#R=9%51TGJ`N<0JE^E&2H\=\(_V='0N($$=&%6"^KT%`?C*"F19J41,
MH2U??SH:;).1#GPG<?P."4W5*NC)K+`MFM%0\>GW_O';6[1U_'![1?=987K+
M,7>]6,R]JT/5WQ1N\N^6[TO@7+?/3NS";N=`HFE0QZ`5NU/A\+)TF;9_-^2P
MC*R]J5ME2C<J=[=Z60Q@J#LP3.X4&.K3KZ5CL^.%UR7RY<YZ897UH!PL!+IG
MF[]M2[8\AA6O[\WSUM7&KL4AS#6_-E"R?(&A2V]=<M(2E4XBJO+`W9J*1H7Q
M+:9D,D&H*!N%.SIN.M`?O]Q\;A8R`>XW2[0YRCZ="#G[5UG`A3$M6W*=$3%!
M%N>="S;"'4:[D2:^GU*#H#-B2$JTCH;UJRZ=,JZ5C)88,07W(;L0@R.3B!TU
M5*Q6OV4B1IVD5-K>;U;.[=6$<2-RF:OZ+<OQH=F`XLUM=9)6\Y(BM]?.VN"U
MG$9:=F_:M"NL6U":P@Z&F[B"LB=R"\D7<P&HA=X(0U&;]'(=HN)W<=(5YSWP
MEOORKD!\:AW`^D++8W9QCU:K&.Q<$*[.87=SS>CMPE9ZH]$HG_1*L4U(/QZ`
M?UR"I>.?!B$,.S9=6?9*OY1H@OY05D#=@/9.ED7B5*TH*A`:8N+]Y>8VY>`N
MNK^\/!&(20U?M90XM=@)DUW3/#6"EPF;=<(I[XZLRZ8+HUDY:NM0077*E>*D
M)**/ZS(X8A+GPY?("1CX3(KS&"SW'?_D>)MCC_6`TV\!S``LC,+`:.7/VB&J
M3$:E5S.Y3GU]H>Z/E\K!SN9";<+VF^,E$Y;5C69N#@DJ57X>YI(U'K*VSS1,
M68*0Z.LSO0%'*OXCWMQU$5'KO04;$$2`Z@`M@_@^2DJ1:FC70%W\4.55M\9V
M&ZFA!ZF<R_I6&SG9:0!HZ$/)UX"WK4IV]&&>(&G4=2Q"#1@-P@E%#M'P!!'.
M.[F5+PTQH:O53G6Z%A`3+MB20PV!=8;A#5]O4/D[`^WLJ!5Z9;XZD`I$H0I8
M:8>]XN&"!.CO#@00X3O@1I1VG&_P';+P##0:=^`3BQ9<`1V',CM#HCS'3Q]X
M^Z?-S!_3M%(?T0HE(]O^H0-V*3L*ENQ.26R+-\[6%)Q,+9TQ1=EV@6E`"%`\
MDCA#F"%5G#ZR5N@E8';VRNRA1"W%,:JT2X@:4`#D(`#VET#R%]7CH[&+8$.C
M"=VU3VBVM:&)<'F!U00)(,C""..TL)2U8`(([AO_C"`E0ED$<!D4SDCI,C)E
M]R(X^VVY1AJ1%CE%HP<80!*YS8'!)2)D%I28K#M!9;6Y*2#T4RQ'F!`V$6I_
MN0^8<'/=+(ZG=F1,20K@!@I%\/3N=_+X)JN_4O.GPSE^YB=S=$,WYERQ@G>L
M\2B;6SIZD`[ZOP7V;7Q7>(5\RCXYI7,*M_M+8%+!JSH@HV/RX<@.BC(0+:G:
METL,E@Y#GZ?Z9/>H,73YRD/M(]CM*N334-[\&^2@HQPNGMFP0R&68,DKIVL,
M*^4B<>UTBD)'_;K?D#1%;M+J&GC)J>!%P&#>X_%?B/MQVW!"%U2Y!A)=>O>]
M*[=@"=D@2?>NKK:=TJAV@HZ("HH-/66A*#;VL($S9MA9L[J4"Z-9B1DRPBW*
MH'B;2ERB2=(;GD'B.OYGX.#3P)O22*0NW<:1K;7'R$B[63Y-KU2(Q@YV(Q$%
M\:J1/)<^BT(2.H%'UP%=D:25QJCTP2.S4E.^M&9NHGL?NF<^<EK27C%%Y(<<
M3<2ID4:IP5A8P!/*@\?X./,=#59>',Y2,4M&M"4YE)L9Y>4Z!<3%,'[M5Z-X
M\Z..)QVI%TJQ=4LE@`-VN<&_H*GRXZ]@JRUFEX:U=<ZB$*7+@LG5T>5S[71%
MO@4/"+-"/3M;C31<_V@=?40AI5U*N;*X7(1)AO^(_(B*`&_/H$_WN;JD7QYV
M?#9?$4R^*BRU5";CQL.=T,1SB;"V$%,<=(1Y8$DJ^2*N6DS_!'S_UP!]#>Z`
M0U``O!B-L>7=9S'!-PT_0A4T2BJ/1:NZWT]PV[1M3>N''5.P:1!,'A-6*MAD
MX^[WNV?T-QKB>]/`(UI8&V63QUN5W'`6Q\ZP?PU(/C_T>#+X%O'DP5#3I+*A
MW/W3$1OSWB$@_N?_!U!+`P04````"``&>JA&:;(RV-@1``";M@``$0`<`&)C
M<G@M,C`Q-3`S,S$N>'-D550)``-\"TU5?`M-575X"P`!!"4.```$.0$``.U=
M^W/:.A;^?6?V?_!F9W;OSETN@23-8]O.$`@)O:'D$M(VW=FY(VP!NC42E602
M^M>O)#^PP9;-(ZER2WX*MA[?=XYT='3T\.N_E4K6)<20`@X=JS^S4/TG/OZ7
M5;+J9#RYM9'5PER\M3F:0O$,3R$5O\7[$>>3LW+YX>'A%ULD93:BD!&/VI#)
M!U:I]-:2?W_]RVM929U"6<69U:3(:H.9M7]B58[/#JIGU7WKKE>WJON5(S^3
MR/'(SI@]@F-@/8Y=S,X>^]1%;_9B=<HGOQ`Z+%?W]P_*"#,.L`WW@O38&Z>G
M=C@M\]D$ED4*2)&]9W%`AY"_!V/()L"&B6Q]1&PZ8UP2*DN`^P<'E;".1Y9(
M^W`0PJF4/[6O;Q7\"`_!!2`17(I@^?D\5I*OYC4-`.NK7.$;">NPM%\IQ8"Y
M"'])PU8Y/3TMJ[=ATJ642;'*UWW`A%BA"\<0\R:AXP8<`,_E;_:^>L!%`P2=
ML+2^31]7D)^HRN%1^GC-1V7_Y=Y;U8`L2S8(@#'A@"."PZ?!\\D$X0%Y&SX3
M3R7NLQ!\%PXL1?I,"NS-'D/CB2M;BGHVHG#P9D\B+X4`?W=!_Q>!,4P"J$V)
M"_42+4\HF8B^@81*YF+S"UC*G92R?%T6=4+W>@YYK_QV:WPF%#X['U$G$PU&
MZ6N!UO84Y<#!LQ,3=2*,4FAMBY0-W&<G)>JT/3=564E:,G5/$+'D/W?=5G9W
M5^6*`8,1%SG2])\#5YKHVQ&$?,]"CL_[=_I[9J)X4PD!S,7_5EA:,0[=BC:F
M;),:L^8E64%1EBJ+63_5/4IELAMA8(ECW6'@.4@D_-?K\F+)2[5Z##H=_%;]
MO]BR@^Q!DF7$\;S)QK.8,X5N//."DA9R1WHJ)Q2UW-VVI,+?;X`4YPAR)("Q
M0AI=S).KX.I6%&S]E*PW3>-ZT?_`.F]A\1A&2LC4\V*ZMVG4$LH]T"DW>L$L
M,E#.*(4CB)ET0Z\)$^K6=N"=/K/T60=LU'3)0Z8BHP3I;!(J/%Q!A:)82Y:;
MI[J=WB*]O2<<5F[1$`LWVP:8UVR;>)@C/+P14K;%:)_08H'DN197S,&L!F*V
M2YA'H?@A"[740#LOV)J7;(5%[VQJOBZKMYS87\Z%=^5(BR;,F4*QI,2L=/DV
M]56J^OQA5!194F5:\4)W/3!/:P=UXHKI&:%`!D$`=CK"DZ!=(0?AFX_$[P:<
M0I=,I*D3!I#+:,ERQUROE'R-'Z=J_$`9XUB%EJC!4E5:89WJ4:Q6*ZHV?4#=
MM8MDNSCLDAEP^:Q-L'`LOZ5WY=1$N5;X)%6IAR4K*,V*%[?KP7F:.E+&;T1<
M!U)V\=5#?+:DJ+0TRX),:.DT54M'H;$-ROJGY9>6UJEV>HKTM.RLG,_4?TE5
M:9*ER"2NKLK^HKI2O)A_RQBX7YZ8-08/=Q.,S1W5'NB[*[NK0:;\B4BELJ[;
M:OWD5Y*JXYV&B[BO&:K5I]:;UDIU93]6J\A=;UVMMS8@!\A=M;N&N?(,\<'Z
MG36H8A?!RU%Q$R#Z`;@>)`/A\\M^`O",M?`4,JY",OV9+$UUF8265\J8Y\=6
M#C?7M$@K,5D*E`PD"5A6@.L??S^I5H[_PZP8/CF`2X2[,3NGB<@5:L=SH=,&
MW*/"01T0FJ[RY5:R:M[<:6QE[;A3HJ5$N*P0F"60Y369W8B1VU:\\1C0&1ET
MH0W15`VT*:TB,U4!#RX]<K5R`_`A2#L1`[$;+?3JE7T!<T)GRSI=>)5K\=/#
M4:NJ,:IUUS57Z)I"9EY.OXPGR3?*Z6&HC?JD#V"GU@WF6UG.>4[RW*Z;'L[2
MS[DT_OA.F?,^*N77PK:@C*;PQ@6X)C=4(HY2NVMN:OWDN;H4Z%I!D6$B*P)@
M2036',*N[^:I^R-$PQ&'3FT**1C"&F/>>"(Q,.&,*NEVU,_:`Z`.NZ3"B$*'
MDXOQQ"4S")E<#$(4VF(`9!YVH'2M$^UAN<T\4Y6Y0T8U/1!7N.V%/*R`B!5C
MHEQYOW'Z9"R?C170L3BQ(D+^XE9(R5*<U#P@V:YW=NM)5C^SAJB-"LL;P*KI
M0</-ED)S0DX[NU=@432K->C2YL00J^DQQ(P5TA_*3U''+?[[L?WA\'___61/
MO,=[?'3J?#N>#N]G^*[A/5P>T]/C7ZM_W/5FS#V>VM_VW7?\Y*Y^?>/<?W8/
MCO"G?J?>:,TN>U];`%W<#;V'KU\^7H)#>S(]K+P:M=M7?WR^/'F\.'SU>/WS
MF![:@Y/>U]/^\7[[P\.[;[\.Z:NK^N#>;G[ZS,HG\*+\L7_>>Z0?&NWAO?<;
MYO<?FXW]B_($?SKZ=#-]W_M\YW5_F[S_\,5C!/QL'YX>MGNUB^G)K]ZG0?_J
M8_VJXG;>V;_5#FS>NR"-NY9S<W1YU3QO[@_K/S=.[Q&L]IW:YV;O_J2&;SYV
MWWUQ^`2P\\-WE_^SZK?=X%#)A@T[97TXJUUKDN8'0JKI,=.L566]??JSM>T-
M=-@@MB=->PT[%V+\Y[,6%O[$.+9K0YLB?R/.DM<=EF>)`BV_1"M6Y(\3H'Y=
M3AS344_]9XDC/?YS\1B-)X1R"Z>>R<HZ^.6?%[LFMBI/DT7^*H7Y2O)1J5(M
M'51^>61.=.)A11B2N'_F8C488;ZU8.C/@F4`42#B.8<`3%3&,G0YB\HJS<N*
M$*THF>6S=D6$LYA+BN94BJ;R:G,@\1-VJX$A^+T&3P%$J>?;BC:7,(.L_&A9
M#,'I/%7KF[UH":\SZ$5K,K>Q]8YSM817ZS/EXNY9_LDD=<;R3#Q#>-CB<"S3
M[%D@2/5FCU-/GBE2J2;JB$5/Y7,\&AA1C*27+4\;^6F9)S(C[LFWEY1XD[`2
M)(J/C9JK`M9P7UJ8:A*:7J8Y]-?`7$[8RP41^.'63GP5QB"R.G0+?2G)*UH3
M,(?,,B1=TYPS]X/@YO#(AJ9M:)HXI4'<BJ`,CF\N<\R.JS6SXVJ]>5RM%HNK
MW<D85&\AKF:.H)Z/JJY1I80$S!&1#IRFYU\\RF"G29UB"5%F!^A,Y-T0`J")
M?5L'3J./FO.'%VY/(6(<(MA&+GP/N3Q8V"/B'WE8[8[)0XU&\]\6D4SMUT<`
M#R&+YV8,<MG7KQ'H(]<P@:R(-Y.W[W,9JG4=.-VT`&$QXS64DPZ<AE,BKE];
M6$ZH)983S/.Z-@$?#Q`D1=*``TBIW`(0E4YP8._]SI!D/I:#F7#^TK@/@,M2
MR?OA$QZ^ZOLG\8508!_Q]252`'NVJ2HNS2T(8*[]!0G8`OXF(EB%1J8L='(L
M9B)-%M$6V&5W'S4MG?`;,),/.P/A^PJ_&/MW2]BSAB`X5;I1M<NKL=RGE-6&
M'6H=-IFM*L7[[<%'?NZ*J4$H`_^BJS,>/E]3"EMTT.<0M=&%!F0V16J"TQD$
MH1?_')AI'(L@U<VP:K8MZG/"*8"9)'-`YO#SQG*U`OK&,W%WB']+B72/C>6]
M#OAL>Z:N[Q/N8CB*RA'$-Y^1RU4GC!LJCG71Z]I':/RNH#.$M2&%ZJ69_(MA
MU3K(*@+CX^@,VH!^@;R+V!=#^1:%JS4`4X!4[3)N!5QX"VT95E<'U/H\"+*+
M7]&R@]K;9IHH-F6A'>W")8=$&+Y)R3CA4S$C!;,>]L+B\"=:+U`6!8&OUW."
M\3BTQ^9.(8M3T+:(HKVO-A"E=3#LC02FX:CW0.[%3&W>*5^BH%9DF.U[%*W"
M_T],U615804O7W+IM+3-KO`9:\V!O&<.:SG\;"1R4MOKPU924%M@DSD9W:CL
M:X055O;]@X!;XJ&SZNM4D3A*]K);5)S*UCN?7_@+;T^+)'2;&$:`PJ4C9C5*
M9=A-ICN?S9,$82>U8.RO'?O+QJR%_3M:_:7DR)XN2$^6PY[;H7I2?IG6;--J
MQ4@T@(*>%-B?5K8%2&X^7+Q<D[>M`?,E&K-B`^'<4>L,!F(2X&PU<K]VMUA"
ME1V!]TVU7.D?^INY@X!W#3MM)!P"+B@D$WW;"LLL3WK3I9PU"65/.<(ME+YY
MZ`RNT'#TF_Q.!9_YP22)<B[QI&A"73YS`U@5<V;S"'9NO409K`E=Z\\M%G8[
M(I3W(!W/=]0:P;T(SNP6?TWP,)DX+*^-,!I[8R,XYJ/4[==*-@[A!]P("0W$
M$$!BFZ.-X%D0JH9L_DT.1KHH12!G-^+\$@SS2HJ"U4\XO7$?4M'A4\N26V87
MV"+,X1#29V[316!FCDGA]N!;2*=(?@8D;0[PGJB^`0-_/OY*+N_)U3];;38^
MCWD!HF]UX1@@N=6X,V@B9@-7AMC,#1Q^!UE\![W(>GL/Y$=40T@]V]`]<=TC
M"@U><G@.\M^IP3>)]T,:GHB[;M[]Q-6CZ0_;YA5W;>P_&+NCR32KV2,D)M2.
M29Y%"KJGB$'[TKT+9"VF6W*OB?#6H\5\;RP)RJ<O)32:26G[H>8FHHQ_\$\>
M!-%7N;"I(MX-P*$1\Z^G8Z?UY.>"%VZRL!QTUB,WGKS2B,ESO,(@*>>Y#1[C
M,_+OU]Y6Q)O9F.+EQ/(I$;-S.$08"WF:Q5>#L[".E\JXP([Y1`.0VA#YNOTG
M:"K17%%5*-"$XU]M+"/WVQRGG]U$%*2H78'9Y`(T(^,^FQ/21X4V*=^PF-%V
MJ&AM5/+T4+A?."QL6SO2GNJT2A'TVIW=J?EKCJ-6EH#[LN60Q6,=B<ACP]+^
MO6QYI+'0#^&4V!`Z:I.L[SFKP%G:X;K8A_R,E<M:='+N*9#SS/D.LS^)H#8D
M5O@`<G1`(UC)"XLP8FI4$&HQLL)A6K9+@;/$?#%O>7O%EG<>K,PETZV+@A=!
MEM1E5Z.Z0Q9B_6KZ8J;D7/8ET)S/9C4;_S'V@'N-;'G>K`FA^=K,0KP:3>.U
MF8583].9RLJ%]RWR^:9.7JX&Z1CAX(Q9U/>-,-(K`=:?:5+W7C'F0:>ACB'X
MI2DO2139)H[:5.>7&8@U0Q9F6>[-B&7/-D.+_UV%LZE'6)B#9H\AA@^R[M`S
M,*N#:.#I)D)FDDGED!T+T=R7;F1L*!?ONFP-"^P40JJ]]&ZM;;#OH<FF:'U.
MFAE(CP+,!)]@8=3D.><25,UE8_Z)5#D-I5M9RWXJ3HM(M19772TC+WZTU>/.
MX!9B1*C:O2L4+?J-R>HK!%\SB'[U$%7[LN+W[:AK'(31;\C)YU;WBZS?2XL`
MS=EFK1QQ?_5#!A+"FX3"LGODACSID?%-/<JB#'3'#OP2AF(@'XJ\ZB2'=$TI
MLI]R<\JVF*?CUMV2)3<;RK/-+XUQ'O+LPQ47]4Y;C%VM[G4;RA7`A2L@'"(+
M?N[IXA(H_73X]J9[7NLV:F&TSR`F&=`TMPM$L;I8T#8X*F@0KWR4NE'T7&W(
M,$U9*:BR]51W17^S@=NC"+C5_?UC<WAD0=.0B8>-8R?Q#>*D1ZB_/U.->L(7
MJ"LK:QBI5'#9?%*OSC*(D@[?2M>[3L-IE#GD"J#46;TP^PTECF=S><F*03U,
M@TZWN!IN!);ARW"OG3P\8PZQ/(@:=OZ]!W+'&52W\K7E>FJENE^IF$,O%Z/6
M=XKG9KZ[2&B/F$Y4!U77!2^%0<)U2I@HATZ"X<0DBMGP<KXB$_LBA3E\TF#I
MU-/"PO2H!TK9)A%)`Z:Q'.]NND%@\-;K7U_7S:&2@4S;O*Y!GQ(@/PDD/\_H
M._N#@9A81C_%;.V6#/@#H`:-U^O`UNBT[6$'34:`CH$Y')=!Z0_G`G_:UL)^
MZ;`SJ+DNI$,9P&[A`92A78\U$(-BE#3(/5D/N&X7+B[!P#.(/O!C$%T-O+S]
M_.I;G,+RJJW>_JC9!@YLX9HW]!@70^6!.417PINS%EJ@H.A,$:%F#?V;P"\H
M%F>A8(0;8B(M2Y!?Q312%(4@Z_O#"'3;-;6P81##)5!:#MW:3:M6[]7,(;"`
M2+L*+))^J)V;A7T.2+<:P*7S*@N;=\5W`'N`SLRRH061:J@NK_0;Q"X37-XW
M/>9Q0N/8+$'+5L[M2!1)ADCX.75RS1USN&0@TV_@D]=`"4RN65TH#5;N5T*#
M!0]!OPOE+AVY&=\_86H.KR(X-7.>.Y,L]UW":F="OFW`":#<G^Y=0='=Y!F(
M*T]X%,%]!0:Y`BN@U?:KNTF3$AQ^$\D@?FFXLC_Q16POF)=?B!&-S\3,3KJ"
MLA9S/G%7"*7B^+HL*/I?0_?[V/\!4$L!`AX#%`````@`!GJH1I!1O`&=`@$`
M%E@1`!$`&````````0```*2!`````&)C<G@M,C`Q-3`S,S$N>&UL550%``-\
M"TU5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`!GJH1F[]\2`="@``9&L`
M`!4`&````````0```*2!Z`(!`&)C<G@M,C`Q-3`S,S%?8V%L+GAM;%54!0`#
M?`M-575X"P`!!"4.```$.0$``%!+`0(>`Q0````(``9ZJ$:&17K!`S$``/H%
M`P`5`!@```````$```"D@50-`0!B8W)X+3(P,34P,S,Q7V1E9BYX;6Q55`4`
M`WP+355U>`L``00E#@``!#D!``!02P$"'@,4````"``&>JA&$5;74F-?```I
MV`0`%0`8```````!````I(&F/@$`8F-R>"TR,#$U,#,S,5]L86(N>&UL550%
M``-\"TU5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`!GJH1D4I0L5H,```
M\_H"`!4`&````````0```*2!6)X!`&)C<G@M,C`Q-3`S,S%?<')E+GAM;%54
M!0`#?`M-575X"P`!!"4.```$.0$``%!+`0(>`Q0````(``9ZJ$9ILC+8V!$`
M`)NV```1`!@```````$```"D@0_/`0!B8W)X+3(P,34P,S,Q+GAS9%54!0`#
I?`M-575X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"```RX0$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4- Royalty Monetization<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationAbstract', window );"><strong>Royalty Monetization [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetization [Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 4 &#8212; Royalty Monetization</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Overview</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March&#160;9, 2011, the Company completed a $30,000&#160;financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and, if approved for commercial sale, Taiwan. The Company received net proceeds of $22,691&#160;from the transaction after transaction costs of $4,309&#160;and the establishment of a $3,000&#160;interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As part of the transaction, the Company entered into a purchase and sale agreement dated as of March&#160;9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i)&#160;its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii)&#160;the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen and milestone payments will paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was not impacted as a result of this transaction.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Non-Recourse Notes Payable</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March&#160;9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#8220;PhaRMA Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March&#160;9, 2011 (the &#8220;Indenture&#8221;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14%&#160;per annum, payable annually in arrears on September&#160;1st of each year (the &#8220;Payment Date&#8221;). The Company remains entitled to receive any royalties and
      milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Royalty Sub&#8217;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September&#160;1, 2014, Royalty Sub was unable to pay the full amount of interest payable to avoid an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the balance sheet. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to
      the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related Currency Hedge Agreement, which would no longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is not expected to have a significant impact on the Company&#8217;s future results of operations or cash flows.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March&#160;31, 2015, the aggregate fair value of the PhaRMA Notes was estimated to be approximately 50% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Foreign Currency Hedge</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar for which the Company may be required to pay a premium in each year from 2015 through 2020, provided the Currency Hedge Agreement remains in effect. A payment of $1,950&#160;will be required if, on May&#160;18 of the relevant year, the U.S. dollar is worth 100 yen or less as determined in accordance with the Currency Hedge Agreement.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#8217;s Consolidated Statement of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&#160;31, 2015 and 2014 resulted in a gain of $464 and a loss of $1,526, respectively. The Company is also required to post collateral in connection with the mark-to-market adjustments based on defined thresholds. As of March 31, 2015 and December&#160;31, 2014, no collateral was posted under the Currency Hedge Agreement. The Company will not be required at any time to post collateral exceeding the maximum premium payments remaining payable under the Currency Hedge Agreement. As of March 31, 2015, the maximum amount of hedge collateral the Company may be required to post is $11.7 million.</font>
    </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_RoyaltyMonetizationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents royalty monetization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>20
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q
M.&-B,38S,#DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P
M,V(Q.&-B,38S,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-A
M-F0S,F)?-V-E,E\T,30U7V(S8F-?,#-B,3AC8C$V,S`Y+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S7T-U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7T-U,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED
M871E9%]3=&%T96UE;G1S7V]F7T-O;3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?
M,5]3:6=N:69I8V%N=%]!8V-O=6YT:6YG7SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?,E]3=&]C:T)A<V5D7T-O;7!E;G-A
M=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO
M=&5?,U]#;VQL86)O<F%T:79E7V%N9%]/=&AE<CPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?-%]2;WEA;'1Y7TUO;F5T:7IA
M=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO
M=&5?-5]3=&]C:VAO;&1E<G-?17%U:71Y/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^06-C;W5N=&EN9U]0;VQI8VEE<U]B>5]0;VQI
M8WE?/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T
M95\Q7U-I9VYI9FEC86YT7T%C8V]U;G1I;F=?,3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?,E]3=&]C:T)A<V5D7T-O;7!E
M;G-A=&EO;C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y.;W1E7S%?4VEG;FEF:6-A;G1?06-C;W5N=&EN9U\R/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\Q7U-I9VYI9FEC86YT
M7T%C8V]U;G1I;F=?,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DYO=&5?,5]3:6=N:69I8V%N=%]!8V-O=6YT:6YG7S0\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7S%?4VEG;FEF
M:6-A;G1?06-C;W5N=&EN9U\U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^3F]T95\Q7U-I9VYI9FEC86YT7T%C8V]U;G1I;F=?-CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?,5]3
M:6=N:69I8V%N=%]!8V-O=6YT:6YG7S<\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y.;W1E7S)?4W1O8VM"87-E9%]#;VUP96YS871I
M;VXR/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T
M95\R7U-T;V-K0F%S961?0V]M<&5N<V%T:6]N,SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?,E]3=&]C:T)A<V5D7T-O;7!E
M;G-A=&EO;C0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y.;W1E7S-?0V]L;&%B;W)A=&EV95]A;F1?3W1H97(Q/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\T7U)O>6%L='E?36]N
M971I>F%T:6]N7T1E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^3F]T95\U7U-T;V-K:&]L9&5R<U]%<75I='E?1&5T/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X
M.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O
M<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X
M.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X
M.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E
M/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X
M;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI
M<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@
M6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8V-A-F0S,F)?-V-E,E\T,30U7V(S8F-?,#-B,3AC8C$V
M,S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-C839D,S)B7S=C
M93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.2]7;W)K<VAE971S+U-H965T,#$N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5.1T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O
M8W5M96YT($%N9"!%;G1I='D@26YF;W)M871I;VX\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$U/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT(&%N9"!%
M;G1I='D@26YF;W)M871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.
M86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y"24]#4EE35"!0
M2$%234%#155424-!3%,@24Y#/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U1/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R
M($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XM+3$R
M+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R+#4R,"PU-#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M
M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF
M86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XP,#`P.#@R-SDV/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0W5R<F5N="!2
M97!O<G1I;F<@4W1A='5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y997,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!6;VQU;G1A<GD@1FEL97)S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y,87)G92!!8V-E;&5R871E
M9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YT:71Y(%=E;&PM:VYO=VX@4V5A<V]N960@27-S=65R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y997,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E
M<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M36%R(#,Q+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^43$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V-C839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.0T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8V$V9#,R8E\W8V4R7S0Q-#5?
M8C-B8U\P,V(Q.&-B,38S,#DO5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%44E"1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS;VQI9&%T
M960@0F%L86YC92!3:&5E=',@*$-U<G)E;G0@4&5R:6]D(%5N875D:71E9"D@
M*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0X+#,V-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-30L
M-30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3DL,38P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L,C,R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C$P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C@S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X
M<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PS,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#$W,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@8V]L;&%B
M;W)A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#$L,S8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#DL,S0S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L,3$V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L,3$V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=7)N
M:71U<F4@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&-O;&QA8F]R871I;VX@97AP
M96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M-#DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-BPP,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R.2PX-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,S8L.#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI86)I;&ET:65S
M(&%N9"!3=&]C:VAO;&1E<G/B@)D@17%U:71Y/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,S`W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX-#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U
M960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M+#(Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Q+#,R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YT97)E<W0@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPR-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV+#`R.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+7)E8V]U<G-E(&YO=&5S
M('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C$L.#8R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L,CDS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!C
M;VQL86)O<F%T:6]N(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,C4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPU-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E
M<G/B@)D@97%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL("0P+C`P,2!P87(@=F%L=64[
M('-H87)E<R!A=71H;W)I>F5D(.*`E"`U+#`P,#L@;F\@<VAA<F5S(&ES<W5E
M9"!A;F0@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0P+C`Q('!A<B!V86QU93H@<VAA<F5S
M(&%U=&AO<FEZ960@XH"4(#(P,"PP,#`[('-H87)E<R!I<W-U960@86YD(&]U
M='-T86YD:6YG(.*`E"`W,BPT-S0@:6X@,C`Q-2!A;F0@-S$L.34U(&EN(#(P
M,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D
M:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4T-BPV.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU-#(L.30S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!O=&AE<B!C
M;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#@S+#`V,BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-C<L.#DX*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L('-T;V-K:&]L9&5R<^*`F2!E<75I='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8T+#,W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<U+#8S-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET
M:65S(&%N9"!S=&]C:VAO;&1E<G/B@)D@97%U:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,CDL.#8W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,V+#@W-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO
M;B!296-E:79A8FQE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PU.30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@T.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&4@06-C;W5N
M=',@4F5C96EV86)L92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV-#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D($-O;&QA8F]R
M871I=F4@4F5V96YU92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DQI86)I;&ET:65S(&%N9"!3=&]C:VAO;&1E
M<G/B@)D@17%U:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-#DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PT.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(%!R;V1U8W0@4V%L
M97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY,:6%B:6QI=&EE<R!A;F0@4W1O8VMH;VQD97)SXH"9($5Q=6ET
M>3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#4L-3,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`U+#8P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8V-A-F0S,F)?-V-E,E\T,30U7V(S8F-?,#-B,3AC8C$V
M,S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-C839D,S)B7S=C
M93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.2]7;W)K<VAE971S+U-H965T,#,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5#34%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O
M;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H0W5R<F5N="!097)I;V0@56YA
M=61I=&5D*2`H4&%R96YT:&5T:6-A;',I("A54T0@)"D\8G(^26X@5&AO=7-A
M;F1S+"!E>&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@
M<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VL@<&%R('9A;'5E("AI;B!$;VQL
M87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H
M;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C
M:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E("AI;B!$;VQL87)S('!E
M<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S(L-#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S$L.34U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E
M<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S(L-#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S$L.34U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B,38S,#D-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-A-F0S,F)?-V-E,E\T
M,30U7V(S8F-?,#-B,3AC8C$V,S`Y+U=O<FMS:&5E=',O4VAE970P-"YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P13)5044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N<V]L
M:61A=&5D(%-T871E;65N=',@;V8@0V]M<')E:&5N<VEV92!,;W-S("A5;F%U
M9&ET960I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4&5R(%-H
M87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N=65S
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V1U8W0@<V%L97,L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`U,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)O>6%L='D@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#@R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EV92!A;F0@;W1H
M97(@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#<W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<F5V96YU97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#(V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT-3@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^17AP96YS97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]S="!O9B!P<F]D=6-T<R!S;VQD/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPQ,C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#$X,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L,#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PU.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O<&5R871I;F<@97AP
M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#(U-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M+#@T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$T+#0S,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@W+#,X-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&%N9"!O=&AE
M<B!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q+#,Q-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q+#(T,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@*&QO<W,I(&]N(&9O<F5I9VX@8W5R
M<F5N8WD@9&5R:79A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,2PU,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$U+#$V-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,"PQ,S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!N
M970@;&]S<R!P97(@8V]M;6]N('-H87)E("AI;B!$;VQL87)S('!E<B!S:&%R
M92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XR,2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N
M,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!A=F5R86=E('-H87)E<R!O=71S=&%N9&EN9R`H:6X@
M4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S(L,S0Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3DL-3@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5;G)E86QI>F5D(&=A:6X@*&QO<W,I(&]N(&%V86EL86)L92!F
M;W(@<V%L92!I;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;7!R96AE;G-I=F4@;&]S<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@Q-2PP,C0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,"PQ,SDI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8V$V9#,R8E\W8V4R
M7S0Q-#5?8C-B8U\P,V(Q.&-B,38S,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO8V-A-F0S,F)?-V-E,E\T,30U7V(S8F-?,#-B,3AC8C$V,S`Y
M+U=O<FMS:&5E=',O4VAE970P-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14-*04<^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@
M0V%S:"!&;&]W<R`H56YA=61I=&5D*2`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG(&%C=&EV
M:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,34L,38T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,3`L,3,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O
M;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@
M86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O
M;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#(U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5B="!I<W-U86YC
M92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!F;W)E:6=N(&-U<G)E;F-Y(&1E
M<FEV871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0V-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#4R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD
M(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y296-E:79A8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPX.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q+#$V-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-3(W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@
M;W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#@T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F97)R960@8V]L;&%B;W)A=&EO;B!E>'!E;G-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA
M8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#0P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(L,C4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@<&%Y86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D
M(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,U.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPW,C8I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PY-3DI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DEN=F5S=&EN9R!A8W1I=FET:65S/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C<75I<VET:6]N<R!O9B!F=7)N
M:71U<F4@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-38U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@<F5S=')I8W1E9"!C87-H/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#0X-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@
M;V8@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#,L,S<X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#DL,S8W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4V%L97,@86YD(&UA='5R:71I97,@;V8@:6YV97-T
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#@R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PS
M-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8V%S:"!U<V5D(&EN(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#DT."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`R,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1FEN86YC:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!C;VUM;VX@<W1O8VLL
M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-S4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-E(&]F('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L.#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!S=&]C:R!P=7)C:&%S92!P
M;&%N('-A;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!A>6UE;G0@;V8@9F]R96EG;B!C=7)R96YC>2!D97)I=F%T:79E(&-O
M;&QA=&5R86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-3,P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#`R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5C<F5A<V4@:6X@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPQ-S,I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPU.#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N
M9"!C87-H(&5Q=6EV86QE;G1S(&%T(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T+#4T,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#$V-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!E;F0@;V8@<&5R:6]D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0X+#,V-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3,L-3@T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8V$V9#,R
M8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B,38S,#D-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO8V-A-F0S,F)?-V-E,E\T,30U7V(S8F-?,#-B,3AC
M8C$V,S`Y+U=O<FMS:&5E=',O4VAE970P-BYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@,2`M(%-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^("`@
M#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/DYO=&4@,2`F(S@R,3([(%-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,\+V9O;G0^("`-"B`@("`\+V1I=CX\8G(O/CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z
M(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SY4:&4@0V]M<&%N>3PO9F]N=#X@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY":6]#<GES="!0:&%R;6%C975T:6-A;',L($EN8RX@*'1H92`F(S@R,C`[
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M('-I;F-E(&EN8V5P=&EO;BX\+V9O;G0^(`T*("`@(#PO9&EV/CQB<B\^/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M<F]U9V@@=&AE(&UI9&1L92!O9B`R,#$V+B!4:&4@0V]M<&%N>28C.#(Q-SMS
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M.B`H,2DF(S$V,#MS=6-C97-S9G5L;'D@<V5C=7)E(&]R(&EN8W)E87-E(%4N
M4RX@1V]V97)N;65N="!F=6YD:6YG(&]F(&ET<R!P<F]G<F%M<RP@:6YC;'5D
M:6YG('!R;V-U<F5M96YT(&-O;G1R86-T<SL@*#(I)B,Q-C`[;W5T+6QI8V5N
M<V4@<FEG:'1S('1O(&-E<G1A:6X@;V8@:71S('!R;V1U8W1S(&]R('!R;V1U
M8W0@8V%N9&ED871E<RP@<'5R<W5A;G0@=&\@=VAI8V@@=&AE($-O;7!A;GD@
M=V]U;&0@<F5C96EV92!C87-H(&UI;&5S=&]N97,[("@S*28C,38P.W)A:7-E
M(&%D9&ET:6]N86P@8V%P:71A;"!T:')O=6=H(&5Q=6ET>2!O<B!D96)T(&9I
M;F%N8VEN9W,@;W(@9G)O;2!O=&AE<B!S;W5R8V5S.R`H-"DF(S$V,#MO8G1A
M:6X@<')O9'5C="!C86YD:61A=&4@<F5G=6QA=&]R>2!A<'!R;W9A;',L('=H
M:6-H('=O=6QD(&=E;F5R871E("`@(`T*("`@("`@<F5V96YU92!A;F0@8V%S
M:"!F;&]W.R`H-2DF(S$V,#MR961U8V4@<W!E;F1I;F<@;VX@;VYE(&]R(&UO
M<F4@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT('!R;V=R86US.R!A;F0O;W(@
M*#8I)B,Q-C`[<F5S=')U8W1U<F4@;W!E<F%T:6]N<RX@5&AE($-O;7!A;GD@
M<F5T86EN<R!T:&4@86)I;&ET>2!T;R!O9F9E<B!F;W(@<V%L92!A<'!R;WAI
M;6%T96QY("0Q-3`L,#`P(&]F('-E8W5R:71I97,L(&EN8VQU9&EN9R!C;VUM
M;VX@<W1O8VLL('!R969E<G)E9"!S=&]C:RP@9&5B="!S96-U<FET:65S+"!D
M97!O<VET87)Y('-H87)E<R!A;F0@=V%R<F%N=',@9G)O;2!I=',@969F96-T
M:79E('-H96QF(%,M,R!R96=I<W1R871I;VX@<W1A=&5M96YT+"!W:&EC:"!I
M="!F:6QE9"!W:71H('1H92!396-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM
M:7-S:6]N(&]N($UA<F-H(#,L(#(P,34N)B,Q-C`[)B,Q-C`[061D:71I;VYA
M;&QY+"!T:&4@0V]M<&%N>2!R971A:6YS('1H92!A8FEL:71Y('1O(&]F9F5R
M(&9O<B!S86QE(&%P<')O>&EM871E;'D@)#$P+#`P,"!O9B!S96-U<FET:65S
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M:6YG(&]P97)A=&EO;G,N/"]F;VYT/B`@("`@#0H@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I
M=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]F;VYT/B`@(`T*("`@(#PO9&EV/CQB
M<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/E1H92!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@:6YC;'5D
M92!T:&4@86-C;W5N=',@;V8@=&AE($-O;7!A;GD@86YD(&ET<R!W:&]L;'DM
M;W=N960@<W5B<VED:6%R>2P@2E!2(%)O>6%L='D@4W5B($Q,0R`H)B,X,C(P
M.U)O>6%L='D@4W5B)B,X,C(Q.RDN(%)O>6%L='D@4W5B('=A<R!F;W)M960@
M:6X@8V]N;F5C=&EO;B!W:71H(&$@)#,P+#`P,"8C,38P.V9I;F%N8VEN9R!T
M<F%N<V%C=&EO;B!T:&4@0V]M<&%N>2!C;VUP;&5T960@;VX@36%R8V@F(S$V
M,#LY+"`R,#$Q+B!3964@3F]T92`T+"!2;WEA;'1Y($UO;F5T:7IA=&EO;BP@
M9F]R(&$@9G5R=&AE<B!D97-C<FEP=&EO;B!O9B!T:&ES('1R86YS86-T:6]N
M+B!!;&P@:6YT97)C;VUP86YY('1R86YS86-T:6]N<R!A;F0@8F%L86YC97,@
M:&%V92!B965N(&5L:6UI;F%T960N/"]F;VYT/CPO9F]N=#X@(`T*("`@("`@
M/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4:&4@0V]M<&%N>28C.#(Q-SMS(&-O;G-O
M;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!H879E(&)E96X@<')E<&%R
M960@:6X@86-C;W)D86YC92!W:71H(&%C8V]U;G1I;F<@<')I;F-I<&QE<R!G
M96YE<F%L;'D@86-C97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@*"8C.#(R
M,#M5+E,N($=!05`F(S@R,C$[*2!F;W(@:6YT97)I;2!F:6YA;F-I86P@<F5P
M;W)T:6YG(&%N9"!T:&4@:6YS=')U8W1I;VYS('1O($9O<FT@,3`M42!A;F0@
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M<W1M96YT<RX\+V9O;G0^(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H97-E
M(&9I;F%N8VEA;"!S=&%T96UE;G1S('-H;W5L9"!B92!R96%D(&EN(&-O;FIU
M;F-T:6]N('=I=&@@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S(&9O<B!T:&4@
M>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$T(&%N9"!T:&4@;F]T
M97,@=&AE<F5T;R!I;F-L=61E9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS(#(P
M,30@06YN=6%L(%)E<&]R="!O;B!&;W)M(#$P+4LN($EN=&5R:6T@;W!E<F%T
M:6YG(')E<W5L=',@87)E(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F
M(&]P97)A=&EN9R!R97-U;'1S(&9O<B!T:&4@9G5L;"!Y96%R+B!4:&4@8F%L
M86YC92!S:&5E="!A<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$T(&AA<R!B
M965N(&1E<FEV960@9G)O;2!T:&4@875D:71E9"!C;VYS;VQI9&%T960@9FEN
M86YC:6%L('-T871E;65N=',@:6YC;'5D960@:6X@=&AE($-O;7!A;GDF(S@R
M,3<[<R!M;W-T(')E8V5N="!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M2RX\
M+V9O;G0^("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\
M9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^4F5C;&%S<VEF:6-A=&EO;G,\
M+V9O;G0^("`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D-E<G1A:6X@8F%L
M86YC92!S:&5E="!A;6]U;G1S(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T(&AA
M=F4@8F5E;B!R96-L87-S:69I960@=&\@8V]N9F]R;2!T;R!T:&4@,C`Q-2!P
M<F5S96YT871I;VXN/"]F;VYT/B`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY#87-H(&%N
M9"!#87-H($5Q=6EV86QE;G1S/"]F;VYT/B`@#0H@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
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M;W)T+71E<FT@;F%T=7)E(&]F('1H97-E(&ET96US+CPO9F]N=#X@("`-"B`@
M("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SY297-T<FEC=&5D($-A<V@\+V9O;G0^("`-"B`@("`\
M+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY297-T<FEC=&5D(&-A<V@@87,@;V8@36%R8V@F
M(S$V,#LS,2P@,C`Q-2!R969L96-T<R`D,34P('1H92!#;VUP86YY(&ES(')E
M<75I<F5D('1O(&UA:6YT86EN(&EN(&%N(&EN=&5R97-T(&)E87)I;F<@8V5R
M=&EF:6-A=&4@;V8@9&5P;W-I="!T;R!S97)V92!A<R!C;VQL871E<F%L(&9O
M<B!A(&-O<G!O<F%T92!C<F5D:70@8V%R9"!P<F]G<F%M+"`D,2PP.#<@:6X@
M<F]Y86QT>2!R979E;G5E('!A:60@8GD@4VAI;VYO9VDF(S$V,#LF86UP.R!#
M;RXL($QT9"X@*"8C.#(R,#M3:&EO;F]G:28C.#(R,3LI(&1E<VEG;F%T960@
M9F]R(&EN=&5R97-T(&]N('1H92!0:&%234$@3F]T97,@*&1E9FEN960@:6X@
M3F]T92`T*2!A;F0@)#$L-#`P('1H92!#;VUP86YY(&ES(')E<75I<F5D('1O
M(&UA:6YT86EN(&%S(&-O;&QA=&5R86P@9F]R(&$@;&5T=&5R(&]F(&-R961I
M="!A<W-O8VEA=&5D('=I=&@@=&AE(&QE87-E(&5X96-U=&EO;B!A;F0@8G5I
M;&0M;W5T(&]F(&ET<R!N97<@0FER;6EN9VAA;2!R97-E87)C:"!F86-I;&ET
M:65S+CPO9F]N=#X@("`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*
M("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/DEN=F5S=&UE;G1S
M/"]F;VYT/B`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@
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M86QI='D@("`@#0H@("`@("!M87)K971A8FQE('-E8W5R:71I97,@=VET:"!A
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M("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S
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M<VES+B!);G9E<W1M96YT<R!W:71H(&]R:6=I;F%L(&UA='5R:71I97,@("`@
M#0H@("`@("!A="!D871E(&]F('!U<F-H87-E(&)E>6]N9"!T:')E92!M;VYT
M:',@86YD('=H:6-H(&UA='5R92!A="!O<B!L97-S('1H86X@,3(@;6]N=&AS
M(&9R;VT@=&AE(&)A;&%N8V4@<VAE970@9&%T92!A<F4@8VQA<W-I9FEE9"!A
M<R!C=7)R96YT+B!);G9E<W1M96YT<R!W:71H(&$@;6%T=7)I='D@8F5Y;VYD
M(#$R(&UO;G1H<R!F<F]M('1H92!B86QA;F-E('-H965T(&1A=&4@87)E(&-L
M87-S:69I960@87,@;&]N9RUT97)M+B!!="!-87)C:"8C,38P.S,Q+"`R,#$U
M+"!T:&4@0V]M<&%N>2!B96QI979E<R!T:&%T('1H92!C;W-T<R!O9B!I=',@
M:6YV97-T;65N=',@87)E(')E8V]V97)A8FQE(&EN(&%L;"!M871E<FEA;"!R
M97-P96-T<RX\+V9O;G0^("`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
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M979E;"`R(&EN('1H92!F86ER('9A;'5E(&AI97)A<F-H>2!A<R!D969I;F5D
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M:6-E<R!W:&EC:"!U=&EL:7IE($QE=F5L(#(@:6YP=71S+CPO9F]N=#X@(`T*
M("`@(#PO9&EV/CQB<B\^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A
M8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX@(`T*("`@("`@
M("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&-O;'-P86X],T0Q."!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,3<N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/DUA<F-H)B,Q-C`[,S$L(#(P,34\+V9O;G0^("`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^06UO<G1I>F5D/"]F;VYT/B`@
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS
M1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^0V]S=#PO9F]N
M=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G
M/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/D%C8W)U960\+V9O;G0^("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^26YT97)E<W0\+V9O;G0^("`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q
M+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/D=R;W-S/"]F;VYT/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/E5N<F5A;&EZ960\+V9O;G0^("`@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^1V%I;G,\+V9O;G0^("`@("`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O;'-P
M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N
M.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^1W)O<W,\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^56YR96%L:7IE9#PO9F]N=#X@("`@(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SY,;W-S97,\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G
M(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY%
M<W1I;6%T960\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SY&86ER)B,Q-C`[5F%L=64\+V9O;G0^("`@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@
M("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0U,"4^("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$;&5F=#X@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^3V)L:6=A=&EO;G,@;V8@52Y3+B!';W9E<FYM
M96YT(&%N9"!I=',@86=E;F-I97,\+V9O;G0^("`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD
M/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H
M=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C(P+#,P,CPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C0R/"]F;VYT/B`@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C,\+V9O;G0^("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-R4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,CPO9F]N
M=#X@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`L,S0U/"]F;VYT/B`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT
M<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0U,"4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^0V]R<&]R871E(&1E8G0@<V5C=7)I=&EE<SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C@L,3,Y/"]F;VYT/B`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-#0\+V9O;G0^
M("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M,C<\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-R4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXH,3,\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#XF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(X
M+#(Y-SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@
M("`@(`T*("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CLG/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#4P)2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY#97)T:69I8V%T97,@;V8@9&5P;W-I=#PO9F]N=#X@("`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ
M<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,2XQ<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C$Q+#8R-3PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S
M;VQI9"<^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M+C%P="!S;VQI9"<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^,34\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O
M;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV/"]F
M;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,3(\+V9O;G0^("`@
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P
M="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXI/"]F;VYT/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ
M<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,2XQ<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C$Q+#8S-#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4P)3X@("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@
M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0W)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L
M92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-R4^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4P)2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;"!I;G9E<W1M96YT<SPO
M9F]N=#X@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-C`L,#8V/"]F;VYT/B`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D
M;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`Q/"]F;VYT
M/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O
M=6)L92<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS
M-CPO9F]N=#X@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G
M/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW
M-7!T(&1O=6)L92<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXH,C<\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#XF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@-'!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^
M("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV,"PR-S8\
M+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@
M("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-3`E/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI
M9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-R4^("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,C`@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-
M"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M)SX@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!C;VQS<&%N/3-$,3@@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#$W+CAP="<@86QI9VX],T1C96YT97(^("`@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^
M("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M="<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C
M,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$
M8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY!;6]R=&EZ960\
M+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G
M(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY#
M;W-T/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^06-C<G5E9#PO9F]N=#X@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R
M/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY);G1E<F5S=#PO9F]N=#X@
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^1W)O<W,\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^56YR96%L:7IE9#PO9F]N=#X@("`@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R
M/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY'86EN<SPO9F]N=#X@("`@
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@
M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SY'<F]S<SPO9F]N=#X@("`@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SY5;G)E86QI>F5D/"]F;VYT/B`@("`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^
M("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/DQO<W-E<SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/D5S=&EM871E9#PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/D9A:7(F(S$V,#M686QU93PO9F]N=#X@("`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M/"]T<CX@("`@(`T*("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CLG/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4P)3X@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/8FQI9V%T:6]N<R!O9B!5+E,N
M($=O=F5R;FUE;G0@86YD(&ET<R!A9V5N8VEE<SPO9F]N=#X@("`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^,C`L,S`W/"]F;VYT/B`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C(\+V9O;G0^("`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,X,C$R
M.SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F
M;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B@R,SPO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^*3QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F
M;VYT/CPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(S+#,P-CPO
M9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*
M("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3`E/B`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D-O<G!O<F%T92!D96)T('-E8W5R:71I
M97,\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(W+#$U,CPO9F]N
M=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M,34Q/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H
M=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C4\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B@T-SPO9F]N=#X@("`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI
M/"]F;VYT/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#<E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^,C<L,C8Q/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3`E('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D-E<G1I9FEC871E<R!O9B!D97!O<VET/"]F;VYT
M/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^
M("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^,3$L.#,X/"]F;VYT/B`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#$N,7!T('-O;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG
M:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXV/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,X,C$R.SPO
M9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#8S/"]F;VYT/B`@
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ
M<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O
M;&ED)SX@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N
M,7!T('-O;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXQ,2PW.#$\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T
M<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0U,"4^("`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^
M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,"4@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@("`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^5&]T86P@:6YV97-T;65N=',\+V9O;G0^
M("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C4Y+#(Y-SPO9F]N=#X@(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE
M)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C
M,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`T<'@G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$W.3PO9F]N=#X@("`@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P
M="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#1P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G
M/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-3PO9F]N
M=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`T<'@G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0W)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U
M8FQE)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@Q
M,S,\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-3DL,S0X/"]F;VYT
M/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@
M("`@("`\+W1A8FQE/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^("`@#0H@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE(&9O;&QO=VEN9R!T
M86)L92!S=6UM87)I>F5S('1H92!S8VAE9'5L960@;6%T=7)I='D@9F]R('1H
M92!#;VUP86YY)B,X,C$W.W,@:6YV97-T;65N=',@870@36%R8V@F(S$V,#LS
M,2P@,C`Q-2!A;F0@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"X\+V9O;G0^("`@
M("`-"B`@("`\+V1I=CX\8G(O/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^("`-"B`@
M("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-S`E/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&UI9&1L92!W:61T:#TS
M1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q,B4^
M("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1M:61D;&4@=VED=&@],T0Q,B4^("`@(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI
M9VX],T1M:61D;&4@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@
M("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI
M9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/C(P,34\
M+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N
M.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^,C`Q-#PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<P)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP
M=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY-
M871U<FEN9R!I;B!O;F4@>65A<B!O<B!L97-S/"]F;VYT/B`@("`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXQ.2PQ-CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,#PO
M9F]N=#X\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD
M/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I
M9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,3@L,C,R/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M,"4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!
M4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^36%T=7)I
M;F<@869T97(@;VYE('EE87(@=&AR;W5G:"!T=V\@>65A<G,\+V9O;G0^("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(Y+#8U-CPO9F]N=#X@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C
M,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR-2PT-3D\
M+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-
M"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[)SX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W,"4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X
M<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M36%T=7)I;F<@869T97(@='=O('EE87)S/"]F;VYT/B`@("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^
M("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$Q+#0V/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N)SXP/"]F;VYT/CPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G
M/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ
M<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXQ-2PV-3<\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T
M<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0W,"4^("`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-S`E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z
M(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1O=&%L(&EN=F5S=&UE;G1S
M/"]F;VYT/B`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M-'!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV,"PR-S8\+V9O;G0^("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O
M=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@-'!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU.2PS-#@\+V9O;G0^
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW
M-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@
M("`@(#PO=&%B;&4^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@("`@(`T*("`@("`@/&9O;G0@
M<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/CPA+2U%1E!L86-E:&]L9&5R+2T^4F5C
M96EV86)L97,@9G)O;2!#;VQL86)O<F%T:6]N<SPO9F]N=#X@("`@#0H@("`@
M/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$
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M8V@@<F5P;W)T:6YG(&1A=&4N($%T($UA<F-H(#,Q+"`R,#$U(&%N9"!$96-E
M;6)E<B8C,38P.S,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!H860@=&AE(&9O;&QO
M=VEN9R!R96-E:79A8FQE<RX\+V9O;G0^("`@(`T*("`@(#PO9&EV/CQB<B\^
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@]
M,T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SX@(`T*("`@("`@("`@(#QT<CX@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P="<^("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@
M("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@
M("`@("`\=&0@8V]L<W!A;CTS1#$P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Y+CAP
M="<@86QI9VX],T1C96YT97(^(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M36%R8V@F(S$V,#LS,2P@,C`Q-3PO9F]N=#X@("`@(`T*("`@("`@("`@("`@
M("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`\+W1R
M/B`@#0H@("`@("`@("`@/'1R/B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`@
M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@
M("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED)SX@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E
M<CX@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY":6QL960\+V9O;G0^("`@
M#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@
M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*
M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@("`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T
M9#X@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9"<^("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^(`T*("`@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^56YB:6QL960\+V9O;G0^("`@("`-"B`@("`@
M("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`@(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@
M("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-
M"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@
M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@#0H@("`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SY4;W1A;#PO9F]N=#X@(`T*("`@("`@("`@("`@("`\+V1I
M=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`\+W1R/B`@#0H@
M("`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[)SX@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4U)3X@("`@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG
M;CTS1&QE9G0^("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/E4N4RX@1&5P87)T;65N="!O9B!(96%L=&@@
M86YD($AU;6%N(%-E<G9I8V5S/"]F;VYT/B`@#0H@("`@("`@("`@("`@(#PO
M9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@
M#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C
M,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@
M("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@("`@#0H@("`@("`@
M("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@("`@
M#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C.#(Q,CL\+V9O;G0^("`@(`T*("`@("`@("`@("`@("`\+V1I
M=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*
M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@
M("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-
M"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@
M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)#PO9F]N=#X@("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@
M#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`@(`T*
M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@("`@#0H@("`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C0L,#@W/"]F
M;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@
M/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@("`@
M("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@
M("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D
M:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-
M"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@
M("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D
M/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)3X@("`@(`T*("`@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/B`@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C0L,#@W/"]F;VYT/B`@(`T*("`@("`@("`@
M("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@
M#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`\+W1R/B`@#0H@
M("`@("`@("`@/'1R/B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-34E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G/B`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^
M("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/E-H:6]N;V=I)B,Q-C`[)F%M<#L@0V\N($QT9"X\+V9O;G0^
M("`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T
M9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G/B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*
M("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@
M("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G
M/B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`@(`T*("`@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#4P
M-SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@
M("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@
M("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-
M"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^(`T*
M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@
M("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^(`T*("`@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@("`@#0H@("`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#(Q,CL\+V9O
M;G0^("`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@
M/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@
M("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@#0H@("`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@
M(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@#0H@("`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$<FEG:'0^("`@("`-"B`@("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PU,#<\+V9O;G0^("`@
M#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@
M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@
M("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@
M/"]T<CX@(`T*("`@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.R<^(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4U)3X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@
M#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]T9#X@
M("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI
M9&1L92!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@
M(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@
M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+W1D
M/B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^
M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1M
M:61D;&4@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]T
M9#X@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+W1D
M/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M;6ED9&QE('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@/"]T<CX@(`T*("`@("`@
M("`@(#QT<CX@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4U)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X)SX@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q
M.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY4;W1A;"!R96-E:79A8FQE<SPO9F]N=#X@("`@(`T*("`@("`@("`@
M("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T
M9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)#PO9F]N=#X@("`@#0H@("`@("`@("`@("`@(#PO9&EV
M/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`-
M"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`@(`T*("`@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#4P-SPO
M9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@
M(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@
M("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX@#0H@("`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@
M(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`@(`T*("`@("`@("`@("`@("`\
M+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^
M("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@("`-"B`@("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-"PP
M.#<\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@
M("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@
M("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-
M"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^(`T*
M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@
M("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@("`-"B`@("`@("`@("`@
M("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B
M;&4G/B`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@("`@#0H@("`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C4L-3DT/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@
M("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@
M(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@
M("`@#0H@("`@("`@("`@/"]T<CX@(`T*("`@("`@("`@(#QT<CX@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B`@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT
M9"!C;VQS<&%N/3-$,3(@=F%L:6=N/3-$8F]T=&]M/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@/"]T
M<CX@(`T*("`@("`@("`\+W1A8FQE/CQB<B\^/'1A8FQE(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SX@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,3`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`Y+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/D1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^
M("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SY":6QL960\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^56YB:6QL960\+V9O;G0^("`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY4;W1A;#PO9F]N=#X@("`@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO
M='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24^("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T
M)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^52Y3+B!$97!A<G1M96YT(&]F($AE86QT
M:"!A;F0@2'5M86X@4V5R=FEC97,\+V9O;G0^("`@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/B`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+#<W.#PO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+#<W
M.#PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@
M#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE
M9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^4VAI;VYO9VDF(S$V,#LF86UP.R!#;RX@3'1D+CPO9F]N=#X@
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R
M:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C$L,#<Q/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ
M<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT
M/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,X,C$R.SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P
M="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXQ+#`W,3PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4U)3X@("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@
M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)3X@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@
M("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4U)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY4;W1A;"!R96-E:79A8FQE<SPO9F]N=#X@("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U
M<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M,2PP-S$\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L
M92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT
M/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXW-7!T(&1O=6)L92<^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C(L-S<X/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D
M;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO
M9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXS+#@T.3PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`\+W1R/B`@("`@#0H@("`@("`\+W1A8FQE/CQB<B\^/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
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M1V]V97)N;65N="X\+V9O;G0^(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/E)E8V5I=F%B
M;&5S(&9R;VT@4')O9'5C="!386QE<SPO9F]N=#X@(`T*("`@(#PO9&EV/CQB
M<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
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M1D].5"U325I%.B`W,"4[(%9%4E1)0T%,+4%,24=..B!T97AT+71O<"<^5$T\
M+V9O;G0^+B!4:&5S92!R96-E:79A8FQE<R!A<F4@979A;'5A=&5D('1O(&1E
M=&5R;6EN92!I9B!A;GD@<F5S97)V92!O<B!A;&QO=V%N8V4@<VAO=6QD(&)E
M(&5S=&%B;&ES:&5D(&%T(&5A8V@@<F5P;W)T:6YG(&1A=&4N/"]F;VYT/CPO
M9F]N=#X@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`@(`T*("`@("`@
M/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/DEN=F5N=&]R>3PO9F]N=#X@
M#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/B`-"B`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!="!-87)C:"`S,2P@,C`Q
M-2!A;F0@1&5C96UB97(@,S$L(#(P,30L('1H92!#;VUP86YY)B,X,C$W.W,@
M:6YV96YT;W)Y(&-O;G-I<W1E9"!O9B!205!)5D%"(&9I;FES:&5D(&=O;V1S
M(&EN=F5N=&]R>2!A;F0@=V]R:R!I;B!P<F]C97-S+B!);G9E;G1O<GD@:7,@
M<W1A=&5D(&%T('1H92!L;W=E<B!O9B!C;W-T+"!D971E<FUI;F5D('5N9&5R
M('1H92!F:7)S="UI;BP@9FER<W0M;W5T("@F(S@R,C`[1DE&3R8C.#(R,3LI
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M96YT;W)I97,N/"]F;VYT/B`@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`R-W!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY$=7)I;F<@,C`Q-"P@:6X@8V]N;F5C=&EO;B!W:71H('1H92!&1$$@
M87!P<F]V86P@;V8@4D%0259!0BP@=&AE($-O;7!A;GD@8F5G86X@8V%P:71A
M;&EZ:6YG(&-O<W1S(&%S<V]C:6%T960@=VET:"!T:&4@<')O9'5C=&EO;B!O
M9B!205!)5D%"(&EN=F5N=&]R:65S+CPO9F]N=#X@("`@(`T*("`@(#PO9&EV
M/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P="<^("`@("`-
M"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H
M92!#;VUP86YY)B,X,C$W.W,@:6YV96YT;W)Y(&-O;G-I<W1E9"!O9B!T:&4@
M9F]L;&]W:6YG(&%T($UA<F-H)B,Q-C`[,S$L(#(P,34@86YD($1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,30Z/"]F;VYT/B`@("`-"B`@("`@(#PO9&EV/CQB<B\^
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@]
M,T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SX@("`@#0H@("`@("`@(#QT<CX@("`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9"<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q-3PO9F]N=#X@("`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N
M=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXR,#$T/"]F;VYT/B`@
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/B`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z
M(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E=O<FL@:6X@<')O8V5S<SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,X,C$R.SPO9F]N
M=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^,C8W/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO
M='(^("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L
M:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY&:6YI<VAE9"!';V]D<SPO9F]N=#X@("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@
M<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ
M+#(Q,#PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT,38\+V9O;G0^("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S
M;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^("`@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED
M9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@
M#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#1P>"<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE
M9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^3F5T(&EN=F5N=&]R:65S/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE
M)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^,2PR,3`\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O
M=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F
M;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXW-7!T(&1O=6)L92<^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C8X,SPO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`\+W1R/B`@("`@#0H@("`@("`\+W1A8FQE/CQB<B\^/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI
M8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY0871E
M;G1S(&%N9"!,:6-E;G-E<SPO9F]N=#X@(`T*("`@(#PO9&EV/CQB<B\^/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M=6YC97)T86EN+CPO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[
M($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^06-C<G5E
M9"!%>'!E;G-E<SPO9F]N=#X@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4
M:&4@0V]M<&%N>2!G96YE<F%L;'D@96YT97)S(&EN=&\@8V]N=')A8W1U86P@
M86=R965M96YT<R!W:71H('1H:7)D+7!A<G1Y('9E;F1O<G,@=VAO('!R;W9I
M9&4@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT+"!M86YU9F%C='5R:6YG+"!A
M;F0@;W1H97(@<V5R=FEC97,@:6X@=&AE(&]R9&EN87)Y(&-O=7)S92!O9B!B
M=7-I;F5S<RX@4V]M92!O9B!T:&5S92!C;VYT<F%C=',@87)E('-U8FIE8W0@
M=&\@;6EL97-T;VYE+6)A<V5D(&EN=F]I8VEN9R!A;F0@<V5R=FEC97,@87)E
M(&-O;7!L971E9"!O=F5R(&%N(&5X=&5N9&5D('!E<FEO9"!O9B!T:6UE+B!4
M:&4@0V]M<&%N>2!R96-O<F1S(&QI86)I;&ET:65S('5N9&5R('1H97-E(&-O
M;G1R86-T=6%L(&-O;6UI=&UE;G1S('=H96X@:70@9&5T97)M:6YE<R!A;B!O
M8FQI9V%T:6]N(&AA<R!B965N(&EN8W5R<F5D+"!R96=A<F1L97-S(&]F('1H
M92!T:6UI;F<@;V8@=&AE(&EN=F]I8V4N(%1H:7,@<')O8V5S<R!I;G9O;'9E
M<R!R979I97=I;F<@;W!E;B!C;VYT<F%C=',@86YD('!U<F-H87-E(&]R9&5R
M<RP@8V]M;75N:6-A=&EN9R!W:71H(&%P<&QI8V%B;&4@0V]M<&%N>2!P97)S
M;VYN96P@=&\@:61E;G1I9GD@<V5R=FEC97,@=&AA="!H879E(&)E96X@<&5R
M9F]R;65D(&]N(&ET<R!B96AA;&8@86YD(&5S=&EM871I;F<@=&AE(&QE=F5L
M(&]F('-E<G9I8V4@<&5R9F]R;65D(&%N9"!T:&4@87-S;V-I871E9"!C;W-T
M(&EN8W5R<F5D(&9O<B!T:&4@<V5R=FEC92!W:&5N('1H92!#;VUP86YY(&AA
M<R!N;W0@>65T(&)E96X@:6YV;VEC960@;W(@;W1H97)W:7-E(&YO=&EF:65D
M(&]F(&%C='5A;"!C;W-T+B!4:&4@;6%J;W)I='D@;V8@<V5R=FEC92!P<F]V
M:61E<G,@:6YV;VEC92!T:&4@0V]M<&%N>2!M;VYT:&QY(&EN(&%R<F5A<G,@
M9F]R('-E<G9I8V5S("`@#0H@("`@("!P97)F;W)M960N(%1H92!#;VUP86YY
M(&UA:V5S(&5S=&EM871E<R!O9B!A8V-R=65D(&5X<&5N<V5S(&%S(&]F(&5A
M8V@@8F%L86YC92!S:&5E="!D871E(&EN(&ET<R!F:6YA;F-I86P@<W1A=&5M
M96YT<R!B87-E9"!O;B!T:&4@9F%C=',@86YD(&-I<F-U;7-T86YC97,N(%1H
M92!#;VUP86YY('!E<FEO9&EC86QL>2!C;VYF:7)M<R!T:&4@86-C=7)A8WD@
M;V8@:71S(&5S=&EM871E<R!W:71H('1H92!S97)V:6-E('!R;W9I9&5R<R!A
M;F0@;6%K97,@861J=7-T;65N=',@:68@;F5C97-S87)Y+B!%>&%M<&QE<R!O
M9B!E<W1I;6%T960@86-C<G5E9"!E>'!E;G-E<R!I;F-L=61E.CPO9F]N=#X@
M("`@#0H@("`@/"]D:78^/&)R+SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E
M;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B`@#0H@
M("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1M:61D;&4@=VED=&@],T0U)3X@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0R)3X@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,X,C(V.SPO9F]N=#X@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!W:61T:#TS1#@X
M)3X@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/F9E97,@<&%I
M9"!T;R!#;&EN:6-A;"!297-E87)C:"!/<F=A;FEZ871I;VYS("@F(S@R,C`[
M0U)/<R8C.#(R,3LI(&EN(&-O;FYE8W1I;VX@=VET:"!P<F5C;&EN:6-A;"!A
M;F0@=&]X:6-O;&]G>2!S='5D:65S(&%N9"!C;&EN:6-A;"!T<FEA;',[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`\+W1A8FQE/CQB
M<B\^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED
M=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SX@#0H@("`@("`@(#QT<CX@("`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED
M=&@],T0U)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@
M=VED=&@],T0R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,X,C(V.SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1'1O<"!W:61T:#TS1#@X)3X@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/F9E97,@<&%I9"!T;R!I;G9E<W1I9V%T:79E
M('-I=&5S(&EN(&-O;FYE8W1I;VX@=VET:"!C;&EN:6-A;"!T<FEA;',[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`\+W1A8FQE/CQB
M<B\^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED
M=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SX@#0H@("`@("`@(#QT<CX@("`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED
M=&@],T0U)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@
M=VED=&@],T0R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,X,C(V.SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1'1O<"!W:61T:#TS1#@X)3X@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/F9E97,@<&%I9"!T;R!C;VYT<F%C="!M86YU
M9F%C='5R97)S(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@<')O9'5C=&EO;B!O
M9B!O=7(@<F%W(&UA=&5R:6%L<RP@9')U9R!S=6)S=&%N8V4@86YD(&1R=6<@
M<')O9'5C=',[)B,Q-C`[86YD/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@
M("`@#0H@("`@("`\+W1A8FQE/CQB<B\^/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX@
M#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1M:61D;&4@=VED=&@],T0U)3X@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0R)3X@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,X,C(V.SPO9F]N=#X@(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#@X)3X@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/G!R;V9E
M<W-I;VYA;"!F965S+CPO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*
M("`@("`@/"]T86)L93X\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`@("`@#0H@("`@("`\9F]N
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M('1H92!A8V-R=6%L(&%C8V]R9&EN9VQY+B!!<R!O9B!-87)C:"`S,2P@,C`Q
M-2!A;F0@1&5C96UB97(@,S$L(#(P,30L('1H92!C87)R>6EN9R!V86QU92!O
M9B`@("`@#0H@("`@("!A8V-R=65D(&5X<&5N<V5S(&%P<')O>&EM871E<R!T
M:&5I<B!F86ER('9A;'5E(&1U92!T;R!T:&5I<B!S:&]R="UT97)M('-E='1L
M96UE;G0N/"]F;VYT/B`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@
M("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^26YC;VUE(%1A>&5S
M/"]F;VYT/B`@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4@;&EA8FEL
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M<V4N/"]F;VYT/B`@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@
M("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^06-C=6UU;&%T960@
M3W1H97(@0V]M<')E:&5N<VEV92`H3&]S<RD@26YC;VUE/"]F;VYT/B`@#0H@
M("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^06-C=6UU;&%T960@;W1H97(@8V]M<')E
M:&5N<VEV92`H;&]S<RD@:6YC;VUE(&ES(&-O;7!R:7-E9"!O9B!U;G)E86QI
M>F5D(&=A:6YS(&%N9"!L;W-S97,@;VX@:6YV97-T;65N=',@879A:6QA8FQE
M+69O<BUS86QE(&%N9"!I<R!D:7-C;&]S960@87,@82!S97!A<F%T92!C;VUP
M;VYE;G0@;V8@<W1O8VMH;VQD97)S)B,X,C$W.R!E<75I='DN($%M;W5N=',@
M<F5C;&%S<VEF:65D(&9R;VT@86-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N
M<VEV92`H;&]S<RD@:6YC;VUE(&%R92!R96-O<F1E9"!A<R!I;G1E<F5S="!A
M;F0@;W1H97(@:6YC;VUE(&]N('1H92!#;VYS;VQI9&%T960@4W1A=&5M96YT
M<R!O9B!#;VUP<F5H96YS:79E($QO<W,N($1U<FEN9R!T:&4@=&AR964@;6]N
M=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$U+"!R96%L:7IE9"!G86EN<R!O9B`D
M."!W97)E(')E8VQA<W-I9FEE9"!O=70@;V8@86-C=6UU;&%T960@;W1H97(@
M8V]M<')E:&5N<VEV92`H;&]S<RD@:6YC;VUE+B!.;R!R96-L87-S:69I8V%T
M:6]N<R!O=70@;V8@86-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N<VEV92`H
M;&]S<RD@:6YC;VUE('=E<F4@<F5C;W)D960@9'5R:6YG('1H92!T:')E92!M
M;VYT:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q-"X\+V9O;G0^("`-"B`@
M("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SY2979E;G5E(%)E8V]G;FET:6]N/"]F;VYT/B`-"B`@
M("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!R96-O9VYI>F5S(')E
M=F5N=65S(&9R;VT@8V]L;&%B;W)A=&EV92!A;F0@;W1H97(@<F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT(&%R<F%N9V5M96YT<R!A;F0@<')O9'5C="!S86QE
M<R!W:&5N(')E86QI>F5D(&]R(')E86QI>F%B;&4@86YD(&5A<FYE9"X@4F5V
M96YU92!I<R!R96%L:7IE9"!O<B!R96%L:7IA8FQE(&%N9"!E87)N960@=VAE
M;B!A;&P@;V8@=&AE(&9O;&QO=VEN9R!C<FET97)I82!A<F4@;65T.B`H:2DF
M(S$V,#MP97)S=6%S:79E(&5V:61E;F-E(&]F(&%N(&%R<F%N9V5M96YT(&5X
M:7-T<SL@*&EI*28C,38P.V1E;&EV97)Y(&AA<R!O8V-U<G)E9"!O<B!S97)V
M:6-E<R!H879E(&)E96X@<F5N9&5R960[("AI:6DI)B,Q-C`[=&AE('-E;&QE
M<B8C.#(Q-SMS('!R:6-E('1O('1H92!B=7EE<B!I<R!F:7AE9"!O<B!D971E
M<FUI;F%B;&4[(&%N9"`H:78I)B,Q-C`[8V]L;&5C=&%B:6QI='D@:7,@<F5A
M<V]N86)L>2!A<W-U<F5D+CPO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I
M=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#;VQL86)O<F%T:79E(&%N9"!/
M=&AE<B!297-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G1S(&%N
M9"!2;WEA;'1I97,\+V9O;G0^("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
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M<&5C=&EV96QY+CPO9F]N=#X@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
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M+CPO9F]N=#X@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY296EM8G5R<V5M
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M8V5P=&EO;B!O9B!T:&4@86=R965M96YT(&%N9"`H,BDF(S$V,#MT:&4@9F5E
M<R!A<F4@;F]N+7)E9G5N9&%B;&4@86YD(&YO;BUC<F5D:71A8FQE+B!!;GD@
M979E;G0@<&%Y;65N=',@<F5C96EV960@<')I;W(@=&\@<V%T:7-F>6EN9R!T
M:&5S92!C<FET97)I82!A<F4@<F5C;W)D960@87,@9&5F97)R960@<F5V96YU
M92X@56YD97(@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VYT<F%C=',@=VET:"!T
M:&4@0FEO;65D:6-A;"!!9'9A;F-E9"!297-E87)C:"!A;F0@1&5V96QO<&UE
M;G0@075T:&]R:71Y('=I=&AI;B!T:&4@56YI=&5D(%-T871E<R!$97!A<G1M
M96YT(&]F($AE86QT:"!A;F0@2'5M86X@4V5R=FEC97,@*"8C.#(R,3M"05)$
M02](2%,F(S@R,C$[*2!A;F0@=&AE($YA=&EO;F%L($EN<W1I='5T92!O9B!!
M;&QE<F=Y(&%N9"!);F9E8W1I;W5S($1I<V5A<V5S("@F(S@R,C`[3DE!240O
M2$A3)B,X,C(Q.RDL(')E=F5N=64@:7,@<F5C;V=N:7IE9"!A<R!R96EM8G5R
M<V%B;&4@("`-"B`@("`@(&1I<F5C="!A;F0@:6YD:7)E8W0@8V]S=',@87)E
M(&EN8W5R<F5D+CPO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X\(2TM1490;&%C96AO;&1E<BTM/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SY0
M<F]D=6-T(%-A;&5S/"]F;VYT/CPO9F]N=#X@(`T*("`@(#PO9&EV/CQB<B\^
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
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M8V%R92!O<F=A;FEZ871I;VYS+B8C,38P.SPO9F]N=#X@("`@(`T*("`@(#PO
M9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY386QE<R!D961U8W1I;VYS(&-O;G-I<W0@;V8@<W1A='5T;W)Y(')E
M8F%T97,@=&\@<W1A=&4@365D:6-A:60L($UE9&EC87)E(&%N9"!O=&AE<B!G
M;W9E<FYM96YT(&%G96YC:65S(&%N9"!S86QE<R!D:7-C;W5N=',@*&EN8VQU
M9&EN9R!T<F%D92!D:7-C;W5N=',@86YD(&1I<W1R:6)U=&EO;B!S97)V:6-E
M(&9E97,I+B!4:&5S92!D961U8W1I;VYS(&%R92!R96-O<F1E9"!A<R!R961U
M8W1I;VYS(&9R;VT@<F5V96YU92!F<F]M(%)!4$E604(@:6X@=&AE('-A;64@
M<&5R:6]D(&%S('1H92!R96QA=&5D('-A;&5S('=I=&@@97-T:6UA=&5S(&]F
M(&9U='5R92!U=&EL:7IA=&EO;B!D97)I=F5D(&9R;VT@:&ES=&]R:6-A;"!E
M>'!E<FEE;F-E(&%D:G5S=&5D('1O(')E9FQE8W0@:VYO=VX@8VAA;F=E<R!I
M;B!T:&4@9F%C=&]R<R!T:&%T(&EM<&%C="!S=6-H(')E<V5R=F5S+CPO9F]N
M=#X\+V9O;G0^("`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@("`@(`T*
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!#;VUP86YY('5T
M:6QI>F5S(&1A=&$@9G)O;2!E>'1E<FYA;"!S;W5R8V5S('1O(&AE;'`@:70@
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M("`@(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@("`-"B`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!A
M8V-O=6YT<R!F;W(@=&AE<V4@<V%L97,@9&5D=6-T:6]N<R!I;B!A8V-O<F1A
M;F-E('=I=&@@875T:&]R:71A=&EV92!G=6ED86YC92!O;B!R979E;G5E(')E
M8V]G;FET:6]N('=H96X@8V]N<VED97)A=&EO;B!I<R!G:79E;B!B>2!A('9E
M;F1O<B!T;R!A(&-U<W1O;65R+B8C,38P.SPO9F]N=#X@("`@(`T*("`@(#PO
M9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
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M86P@<V]U<F-E<RXF(S$V,#L\+V9O;G0^("`@#0H@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-0
M3$%9.B!I;FQI;F4G/E)E8F%T97,@86YD($-H87)G96)A8VMS/"]F;VYT/CPO
M9F]N=#X@("`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@
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M+CPO9F]N=#X@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#:&%R9V5B86-K
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M('%U86QI9FEE9"!P<F]G<F%M<RX\+V9O;G0^("`@#0H@("`@/"]D:78^/&)R
M+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M:&4@97AT96YT(&%C='5A;"!R96)A=&5S("`@(`T*("`@("`@86YD(&-H87)G
M96)A8VMS(&1I9F9E<B!F<F]M('1H92!#;VUP86YY)B,X,C$W.W,@97-T:6UA
M=&5S+"!A9&1I=&EO;F%L(')E<V5R=F5S(&UA>2!B92!R97%U:7)E9"!O<B!R
M97-E<G9E<R!M87D@;F5E9"!T;R!B92!R979E<G-E9"P@96ET:&5R(&]F('=H
M:6-H('=O=6QD(&EM<&%C="!C=7)R96YT('!E<FEO9"!P<F]D=6-T(')E=F5N
M=64N)B,Q-C`[/"]F;VYT/B`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-
M"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D1I<V-O=6YT<R!A;F0@4V%L97,@26YC96YT:79E
M<SPO9F]N=#X@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$:7-C;W5N=',@
M86YD(&]T:&5R('-A;&5S(&EN8V5N=&EV97,@<')I;6%R:6QY(&-O;G-I<W0@
M;V8@26YV96YT;W)Y($UA;F%G96UE;G0@06=R965M96YT("@F(S@R,C`[24U!
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M;V1U8W0@<V%L97,N)B,Q-C`[/"]F;VYT/B`@#0H@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-0
M3$%9.B!I;FQI;F4G/E!R;V1U8W0@4F5T=7)N<SPO9F]N=#X\+V9O;G0^("`-
M"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!D;V5S(&YO="!R
M96-O<F0@82!P<F]D=6-T(')E='5R;B!A;&QO=V%N8V4@87,@:70@9&]E<R!N
M;W0@;V9F97(@=&AE(&%B:6QI='D@=&\@<F5T=7)N(&=O;V1S(&]N8V4@82!B
M;VYA9FED92!S:&EP;65N="!H87,@8F5E;B!A8V-E<'1E9"!B>2!A('-P96-I
M86QT>2!D:7-T<FEB=71O<BXF(S$V,#L\+V9O;G0^("`-"B`@("`\+V1I=CX\
M8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[
M($1)4U!,05DZ(&EN;&EN92<^061V97)T:7-I;F<\+V9O;G0^/"]F;VYT/B`@
M(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!#;VUP86YY(&5N9V%G97,@
M:6X@=F5R>2!L:6UI=&5D(&1I<W1R:6)U=&EO;B!A;F0@9&ER96-T+7)E<W!O
M;G-E(&%D=F5R=&ES:6YG('=H96X@<')O;6]T:6YG(%)!4$E604(N/"]F;VYT
M/B`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@<F5C;W)D
M960@=&AE(&9O;&QO=VEN9R!R979E;G5E<R!F;W(@=&AE('1H<F5E(&UO;G1H
M<R!E;F1E9"!-87)C:"8C,38P.S,Q+"`R,#$U(&%N9"`R,#$T.CPO9F]N=#X@
M(`T*("`@(#PO9&EV/CQB<B\^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX@(`T*("`@
M("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P+C5P="<^
M("`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XU<'0G/B`@("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/C(P,34\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,2XQ<'0@<V]L:60G/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XU<'0G
M/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C
M,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T
M('-O;&ED)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/C(P,30\+V9O;G0^("`@(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@
M("`@(`T*("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CLG/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L
M:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY0<F]D=6-T('-A;&5S+"!N970\+V9O;G0^("`@
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT
M/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^-3,W/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/B`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^
M("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P
M+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY2;WEA;'1Y(')E=F5N=64\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C$L-3$X/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C$L.#(Q/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)
M3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^0V]L;&%B;W)A
M=&EV92!A;F0@;W1H97(@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(')E=F5N
M=65S.CPO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@
M("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^("`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A
M;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^52Y3+B!$97!A<G1M96YT(&]F($AE86QT:"!A
M;F0@2'5M86X@4V5R=FEC97,\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H
M=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C0L-#<U/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C
M,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,2PS-#$\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XU<'0G/B`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`S-G!T.R!-05)'24XM4DE'2%0Z(#`N
M-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E-H:6]N;V=I("A*87!A;BD\+V9O
M;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#`N-7!T
M)SX@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C(Y-CPO9F]N=#X@("`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XU<'0G/B`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I
M9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,CDV/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P
M="<@86QI9VX],T1L969T/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^5&]T86P@8V]L;&%B;W)A=&EV92!A
M;F0@;W1H97(@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(')E=F5N=65S/"]F
M;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-"PW-S$\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@
M<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXQ+#8S-SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-
M"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/B`@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI
M9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@
M(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`T<'@G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L
M969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/E1O=&%L(')E=F5N=65S/"]F;VYT/B`@("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O
M=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F
M;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXW-7!T(&1O=6)L92<^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C8L.#(V/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P
M="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG
M:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXS+#0U.#PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`\+W1R/B`@("`@#0H@("`@("`\+W1A8FQE/CQB<B\^/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET
M86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY2
M97-E87)C:"!A;F0@1&5V96QO<&UE;G0@17AP96YS97,\+V9O;G0^("`@("`-
M"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^(`T*("`@("`@/&9O;G0@
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M(&%N9"!C;&EN:6-A;"!A;F0@<')E8VQI;FEC86P@<W1U9&EE<R!A<F4@("`@
M(`T*("`@("`@<&5R9F]R;65D(&)Y('1H:7)D+7!A<G1Y($-23W,N($-O<W1S
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M='5A;&QY('!E<F9O<FUE9"X\+V9O;G0^("`-"B`@("`\+V1I=CX\8G(O/CQD
M:78@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#(W
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/D%D9&ET:6]N86QL>2P@=&AE($-O;7!A;GD@:&%S(&QI8V5N
M<V4@86=R965M96YT<R!W:71H('1H:7)D('!A<G1I97,L('-U8V@@87,@06QB
M97)T($5I;G-T96EN($-O;&QE9V4@;V8@365D:6-I;F4@;V8@665S:&EV82!5
M;FEV97)S:71Y("@F(S@R,C`[045#3TTF(S@R,C$[*2P@26YD=7-T<FEA;"!2
M97-E87)C:"P@3'1D+B`H)B,X,C(P.TE23"8C.#(R,3LI+"!A;F0@=&AE(%5N
M:79E<G-I='D@;V8@06QA8F%M82!A="!":7)M:6YG:&%M("@F(S@R,C`[54%"
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M97,@;6%I;G1E;F%N8V4@<&%Y;65N=',@87,@:6YC=7)R960N/"]F;VYT/B`@
M(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX@#0H@("`@("`\9F]N
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M:6%T960@<F5V96YU92X\+V9O;G0^("`@("`-"B`@("`\+V1I=CX\8G(O/CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET
M86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY3
M=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V9O;G0^(`T*("`@(#PO9&EV/CQB
M<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
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M(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@("`-"B`@("`@(#QF;VYT
M('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY);G1E<F5S="!%>'!E;G-E(&%N9"!$
M969E<G)E9"!&:6YA;F-I;F<@0V]S=',\+V9O;G0^("`-"B`@("`\+V1I=CX\
M8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY);G1E<F5S="!E>'!E;G-E(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H)B,Q-C`[,S$L(#(P,34@86YD(#(P,30@=V%S("0Q+#,Q-2!A;F0@
M)#$L,C0R+"!R97-P96-T:79E;'DL(&%N9"!R96QA=&5S('1O('1H92!I<W-U
M86YC92!O9B!T:&4@4&AA4DU!($YO=&5S("AD969I;F5D(&EN($YO=&4@-"DN
M($-O<W1S(&1I<F5C=&QY(&%S<V]C:6%T960@=VET:"!T:&4@:7-S=6%N8V4@
M;V8@=&AE(%!H85)-02!.;W1E<R!H879E(&)E96X@8V%P:71A;&EZ960@86YD
M(&%R92!I;F-L=61E9"!I;B!O=&AE<B!C=7)R96YT(&%S<V5T<R!O;B!T:&4@
M0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S+B!4:&5S92!C;W-T<R!A<F4@
M8F5I;F<@86UO<G1I>F5D('1O(&EN=&5R97-T(&5X<&5N<V4@;W9E<B!T:&4@
M=&5R;2!O9B!T:&4@4&AA4DU!($YO=&5S('5S:6YG('1H92!E9F9E8W1I=F4@
M:6YT97)E<W0@<F%T92!M971H;V0N($%M;W)T:7IA=&EO;B!O9B!D969E<G)E
M9"!F:6YA;F-I;F<@8V]S=',@:6YC;'5D960@:6X@:6YT97)E<W0@97AP96YS
M92!W87,@)#$Q,"!F;W(@96%C:"!O9B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H)B,Q-C`[,S$L(#(P,34@86YD(#(P,30N/"]F;VYT/CPO9F]N=#X@
M(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@("`-"B`@("`@(#QF;VYT
M('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY#=7)R96YC>2!(961G92!!9W)E96UE
M;G0\+V9O;G0^(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@
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M:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q-2!A;F0@,C`Q-"!R97-U;'1E
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M<V5N=&EN9R!,979E;"`R(&EN('1H92!F86ER('9A;'5E(&AI97)A<F-H>2!A
M<R!D969I;F5D(&)Y(%4N4RX@1T%!4"X@5&AE($-O;7!A;GD@:7,@86QS;R`@
M#0H@("`@("!R97%U:7)E9"!T;R!P;W-T(&-O;&QA=&5R86P@:6X@8V]N;F5C
M=&EO;B!W:71H('1H92!M87)K+71O+6UA<FME="!A9&IU<W1M96YT<R!B87-E
M9"!O;B!T:')E<VAO;&1S(&1E9FEN960@:6X@=&AE($-U<G)E;F-Y($AE9&=E
M($%G<F5E;65N="X@07,@;V8@36%R8V@F(S$V,#LS,2P@,C`Q-2!A;F0@1&5C
M96UB97(@,S$L(#(P,30L(&YO(&AE9&=E(&-O;&QA=&5R86P@=V%S('!O<W1E
M9"!U;F1E<B!T:&4@86=R965M96YT+CPO9F]N=#X@("`-"B`@("`\+V1I=CX\
M8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U19
M3$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SY.970@3&]S<R!097(@4VAA<F4\+V9O;G0^("`@("`-"B`@("`\+V1I
M=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY.970@;&]S<R!P97(@<VAA<F4@:7,@8F%S960@=7!O
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M($UA<F-H)B,Q-C`[,S$L(#(P,34@86YD(#(P,30@9&]E<R!N;W0@:6YC;'5D
M92`S+#0U."!A;F0@-2PR,#8L(')E<W!E8W1I=F5L>2P@;V8@<W5C:"!P;W1E
M;G1I86P@8V]M;6]N('-H87)E<RP@87,@=&AE:7(@:6UP86-T('=O=6QD(&)E
M(&%N=&DM9&EL=71I=F4N/"]F;VYT/B`@#0H@("`@/"]D:78^/&)R+SX\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L
M:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^57-E
M(&]F($5S=&EM871E<SPO9F]N=#X@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY4:&4@<')E<&%R871I;VX@;V8@9FEN86YC:6%L('-T871E;65N=',@:6X@
M8V]N9F]R;6ET>2!W:71H(%4N4RX@1T%!4"!R97%U:7)E<R!T:&4@0V]M<&%N
M>2!T;R!M86ME(&5S=&EM871E<R!A;F0@87-S=6UP=&EO;G,@=&AA="!A9F9E
M8W0@=&AE(&%M;W5N=',@<F5P;W)T960@:6X@=&AE(&9I;F%N8VEA;"!S=&%T
M96UE;G1S+B!!8W1U86P@<F5S=6QT<R!C;W5L9"!D:69F97(@9G)O;2!T:&]S
M92!E<W1I;6%T97,N/"]F;VYT/B`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC
M.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9"<^4VEG;FEF:6-A;G0@0W5S=&]M
M97)S(&%N9"!/=&AE<B!2:7-K<SPO9F]N=#X\+V9O;G0^("`@#0H@("`@/"]D
M:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M
M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!R96QI97,@<')I;6%R
M:6QY(&]N('1H<F5E('-P96-I86QT>2!D:7-T<FEB=71O<G,@=&\@<'5R8VAA
M<V4@86YD('-U<'!L>2!T:&4@;6%J;W)I='D@;V8@4D%0259!0BX@5&AE<V4@
M=&AR964@<&AA<FUA8V5U=&EC86P@<W!E8VEA;'1Y(&1I<W1R:6)U=&]R<R!A
M8V-O=6YT960@9F]R(&=R96%T97(@=&AA;B`Y,"4@;V8@86QL(%)!4$E604(@
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M;6UE<F-I86QI>F%T:6]N(&]F(%)!4$E604(N/"]F;VYT/B`@("`-"B`@("`\
M+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$58
M5"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^(`T*("`@("`@/&9O;G0@<W1Y;&4]
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M96QO<&UE;G0@8V]S=',@9F]R(&ET<R!P97)A;6EV:7(@86YD($)#6#0T,S`@
M<')O9W)A;7,N($%C8V]R9&EN9VQY+"!R96EM8G5R<V5M96YT(&]F('1H97-E
M(&5X<&5N<V5S(')E<')E<V5N=',@82!S:6=N:69I8V%N="!P;W)T:6]N(&]F
M('1H92!#;VUP86YY)B,X,C$W.W,@8V]L;&%B;W)A=&EV92!A;F0@;W1H97(@
M<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(')E=F5N=65S+B!4:&4@8V]M<&QE
M=&EO;BP@87,@=VET:"!T:&4@2G5N92`S,"P@,C`Q-"!"05)$02](2%,@<&5R
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M=F5N=64@9G)O;2!T:&4@;F5T('-A;&5S(&]F(%)!4$E!0U1!.R`@#0H@("`@
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M<G5G(&1E=F5L;W!M96YT(&%C=&EV:71I97,N/"]F;VYT/B`@#0H@("`@/"]D
M:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,C=P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A
M;&EC.R!$25-03$%9.B!I;FQI;F4G/E)I<VMS(&9R;VT@5&AI<F0@4&%R='D@
M36%N=69A8W1U<FEN9R!A;F0@1&ES=')I8G5T:6]N($-O;F-E;G1R871I;VX\
M+V9O;G0^/"]F;VYT/B`@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y
M/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
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M:6QI;F<@;V8@4D%0259!0BX\+V9O;G0^("`@#0H@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I
M=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M0W)E9&ET(%)I<VL\+V9O;G0^("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
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M97)A9V4@;6%T=7)I='D@;V8@87!P<F]X:6UA=&5L>2`Q."!M;VYT:',@;W(@
M;&5S<RX@3W1H97(@=&AA;B!P<F]D=6-T('-A;&4@<F5C96EV86)L97,@9&ES
M8W5S<V5D(&%B;W9E+"!T:&4@;6%J;W)I='D@;V8@=&AE($-O;7!A;GDF(S@R
M,3<[<R!R96-E:79A8FQE<R!F<F]M(&-O;&QA8F]R871I;VYS(&%R92!D=64@
M9G)O;2!T:&4@52Y3+B!';W9E<FYM96YT+"!F;W(@=VAI8V@@=&AE<F4@:7,@
M;F\@87-S=6UE9"!C<F5D:70@<FES:RX\+V9O;G0^("`@("`-"B`@("`\+V1I
M=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^4F5C96YT($%C
M8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+V9O;G0^("`@(`T*("`@(#PO9&EV
M/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/DEN($%P<FEL(#(P,34L('1H92`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/D9I;F%N
M8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9#PO9F]N=#X@*"8C.#(R
M,#M&05-")B,X,C(Q.RD@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P
M9&%T92`H)B,X,C(P.T%3528C.#(R,3LI($YO+B`R,#$U+3`S+"`\9F]N="!S
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M9F]N=#X\+V9O;G0^(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@("`-
M"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);B!-87D@,C`Q-"P@
M=&AE($9!4T(@:7-S=65D($%352`R,#$T+3`Y("8C.#(Q,3L@/&9O;G0@<W1Y
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M86P@<&5R:6]D<RP@86YD("`-"B`@("`@("`@:6YT97)I;2!P97)I;V1S('=I
M=&AI;B!T:&]S92!A;FYU86P@<&5R:6]D<RP@8F5G:6YN:6YG(&%F=&5R($1E
M8V5M8F5R(#$U+"`R,#$V+B!%87)L>2!A9&]P=&EO;B!I<R!N;W0@<&5R;6ET
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M871E;65N=',N/"]F;VYT/CPO9F]N=#X@(`T*("`@("`@/"]D:78^/&)R+SX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-C839D
M,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.0T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q
M.&-B,38S,#DO5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`R("T@4W1O8VLM0F%S960@
M0V]M<&5N<V%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!O9B!#;VUP96YS871I;VX@4F5L
M871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N=',@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C
M;&]S=7)E(&]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S+"!3:&%R92UB
M87-E9"!087EM96YT<R!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^("`@#0H@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/DYO=&4@
M,B`F(S@R,3([(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO9F]N=#X@("`@
M(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%S(&]F($UA<F-H)B,Q-C`[,S$L
M(#(P,34L('1H92!#;VUP86YY(&AA9"!T=V\@<W1O8VLM8F%S960@96UP;&]Y
M964@8V]M<&5N<V%T:6]N('!L86YS+"!T:&4@4W1O8VL@26YC96YT:79E(%!L
M86X@*"8C.#(R,#M);F-E;G1I=F4@4&QA;B8C.#(R,3LI(&%N9"!T:&4@16UP
M;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;B`H)B,X,C(P.T534%`F(S@R,C$[
M*2P@8F]T:"!W:&EC:"!W97)E(&%M96YD960@86YD(')E<W1A=&5D(&EN($UA
M<F-H(#(P,30@86YD(&%P<')O=F5D(&)Y('1H92!#;VUP86YY)B,X,C$W.W,@
M<W1O8VMH;VQD97)S(&EN($UA>2`R,#$T+B!3=&]C:RUB87-E9"!C;VUP96YS
M871I;VX@97AP96YS92!O9B`D,BPR-3D@*"0R+#$V-2!O9B!E>'!E;G-E(')E
M;&%T960@=&\@=&AE($EN8V5N=&EV92!0;&%N(&%N9"`D.30@;V8@97AP96YS
M92!R96QA=&5D('1O('1H92!%4U!0*2!W87,@<F5C;V=N:7IE9"!D=7)I;F<@
M=&AE(&9I<G-T('1H<F5E(&UO;G1H<R!O9B`R,#$U+"!W:&EL92`D,2PV,3`@
M*"0Q+#4U."!O9B!E>'!E;G-E(')E;&%T960@=&\@=&AE($EN8V5N=&EV92!0
M;&%N(&%N9"`D-3(@;V8@97AP96YS92!R96QA=&5D('1O('1H92!%4U!0*2!W
M87,@<F5C;V=N:7IE9"!D=7)I;F<@=&AE(&9I<G-T('1H<F5E(&UO;G1H<R!O
M9B`R,#$T+CPO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@
M#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
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M,38P.S,Q+"`R,#$U+B!4:&%T(&-O<W0@:7,@97AP96-T960@=&\@8F4@<F5C
M;V=N:7IE9"!A<R!F;VQL;W=S.B`D-"PP,#8@9'5R:6YG('1H92!R96UA:6YD
M97(@;V8@,C`Q-2P@)#0L-3(X(&EN(#(P,38L("0T+#`V-"!I;B`R,#$W+"`D
M,2PY.3`@:6X@,C`Q."!A;F0@)#,S(&EN(#(P,3DN($EN(&%D9&ET:6]N+"!T
M:&4@0V]M<&%N>2!H87,@;W5T<W1A;F1I;F<@<&5R9F]R;6%N8V4M8F%S960@
M<W1O8VL@;W!T:6]N<R!F;W(@=VAI8V@@;F\@8V]M<&5N<V%T:6]N(&5X<&5N
M<V4@:7,@<F5C;V=N:7IE9"!U;G1I;"`F(S@R,C`[<&5R9F]R;6%N8V4F(S@R
M,C$[(&AA<R!O8V-U<G)E9"!A;F0@=&AE(&%W87)D('9E<W1S+B!!="!T:&4@
M=&EM92!O9B!V97-T:6YG+"!C;VUP96YS871I;VX@97AP96YS92!W:6QL(&)E
M(')E8V]G;FEZ960N/"]F;VYT/B`@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I
M=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M4W1O8VL@26YC96YT:79E(%!L86X\+V9O;G0^("`-"B`@("`\+V1I=CX\8G(O
M/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY4:&4@0V]M<&%N>2!G<F%N=',@<W1O8VL@;W!T:6]N(&%W87)D
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M2F%N=6%R>2`R,#$S+"!T:&4@0V]M<&%N>2!M861E(')E=&5N=&EO;B!G<F%N
M=',@;V8@<W1O8VL@;W!T:6]N(&%W87)D<R!A;F0@<F5S=')I8W1E9"!S=&]C
M:R!U;FET<RX@5&AE<V4@87=A<F1S('9E<W0@-3`E(&5A8V@@>65A<B!U;G1I
M;"!F=6QL>2!V97-T960@869T97(@='=O('EE87)S+B!);B!!=6=U<W0@,C`Q
M,R!A;F0@1&5C96UB97(@,C`Q-"P@=&AE($-O;7!A;GD@:7-S=65D(#$L,#,R
M(&%N9"`Q+#(U,"!P97)F;W)M86YC92UB87-E9"!S=&]C:R!O<'1I;VYS+"!R
M97-P96-T:79E;'DN(%1H97-E(&%W87)D<R!V97-T('5P;VX@<W5C8V5S<V9U
M;"!C;VUP;&5T:6]N(&]F('-P96-I9FEC(&1E=F5L;W!M96YT(&UI;&5S=&]N
M97,N($%S(&]F($UA<F-H(#,Q+"`R,#$U+"`U,"4@;V8@=&AE($%U9W5S="`R
M,#$S(&=R86YT<R!H879E('9E<W1E9"!B87-E9"!U<&]N(&%C:&EE=F5M96YT
M(&]F('1W;R!M:6QE<W1O;F5S.B`H,2D@("`-"B`@("`@('-U8V-E<W-F=6P@
M8V]M<&QE=&EO;B!O9B!T:&4@3U!U4RTQ(&-L:6YI8V%L('1R:6%L(&9O<B!W
M:&EC:"!V97-T:6YG(&]C8W5R<F5D(&EN('1H92!S96-O;F0@<75A<G1E<B!O
M9B`R,#$T+"!A;F0@*#(I($9$02!A<'!R;W9A;"!O9B!205!)5D%"(&9O<B!W
M:&EC:"!V97-T:6YG(&]C8W5R<F5D(&EN('1H92!F;W5R=&@@<75A<G1E<B!O
M9B`R,#$T+B!4:'5S+"!A<R!O9B!-87)C:"8C,38P.S,Q+"`R,#$U+"`U,"4@
M;V8@=&AE($%U9W5S="`R,#$S('!E<F9O<FUA;F-E+6)A<V5D(&=R86YT<R!A
M;F0@,3`P)2!O9B!T:&4@1&5C96UB97(@,C`Q-"!P97)F;W)M86YC92UB87-E
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M<F1S(&AA=F4@8V]N=')A8W1U86P@=&5R;7,@;V8@-2!T;R`Q,"8C,38P.WEE
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M960@:6X@=&AE($EN8V5N=&EV92!0;&%N+CPO9F]N=#X@("`@#0H@("`@/"]D
M:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^4F5L871E9"!A8W1I=FET>2!U;F1E<B!T:&4@26YC
M96YT:79E(%!L86X@:7,@87,@9F]L;&]W<SH\+V9O;G0^("`@(`T*("`@(#PO
M9&EV/CQB<B\^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX@(`T*("`@("`@("`\='(^
M("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O;'-P
M86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT
M97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/D%W87)D<SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C
M96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/D%V86EL86)L93PO
M9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS
M1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^3W!T:6]N<SPO
M9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L
M:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY/=71S
M=&%N9&EN9SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A
M;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^5V5I
M9VAT960\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q
M+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/D%V97)A9V4\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^17AE<F-I<V4\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/E!R:6-E/"]F;VYT/B`@("`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@
M(`T*("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CLG/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4U)3X@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY"86QA;F-E($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30\
M+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(L,S8R/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CDL-C`U/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV+C(Q/"]F
M;VYT/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@
M#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24^("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)3BU224=(5#H@,"XW-7!T
M)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^4F5S=')I8W1E9"!S=&]C:R!U;FET(&%W
M87)D<R!G<F%N=&5D/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXH,3,S/"]F;VYT/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^*28C,38P.SPO9F]N=#X@(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@
M/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@("`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0U-24^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#,V<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^4F5S=')I8W1E9"!S=&]C:R!U;FET(&%W87)D<R!C86YC96QL960\+V9O
M;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3PO9F]N=#X@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,X,C$R.R8C,38P.R8C
M,38P.SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-34E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`S-G!T.R!-
M05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E-T;V-K
M(&]P=&EO;B!A=V%R9',@9W)A;G1E9#PO9F]N=#X@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R
M:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B@Y,3<\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI)B,Q-C`[/"]F;VYT/B`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I
M9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^.3$W/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R
M:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C$Q+C@S/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24^("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)3BU224=(
M5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^4W1O8VL@;W!T:6]N(&%W
M87)D<R!E>&5R8VES960\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@R-#`\+V9O;G0^("`@("`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI)B,Q-C`[/"]F
M;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,RXP-SPO9F]N=#X@("`@(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-34E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`S-G!T.R!-05)'
M24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E-T;V-K(&]P
M=&EO;B!A=V%R9',@8V%N8V5L;&5D/"]F;VYT/B`@("`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G
M/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T
M('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M,C@\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,C@\+V9O;G0^("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S
M;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N)SXI/"]F;VYT/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R
M:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/CDN,#4\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO
M='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4U)3X@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@
M("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4U)2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@-'!X)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L:6=N/3-$
M;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY"86QA;F-E($UA<F-H)B,Q-C`[,S$L(#(P,34\+V9O;G0^
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXQ+#,T,3PO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^
M("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T
M(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT
M/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,3`L,C4T/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C8N-S@\+V9O;G0^("`@("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@(#PO='(^("`@("`-"B`@("`@(#PO=&%B;&4^/&)R+SX\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@
M("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/D9O<B!S=&]C:R!O<'1I;VX@87=A<F1S(&=R86YT960@=6YD97(@=&AE($EN
M8V5N=&EV92!0;&%N(&1U<FEN9R!T:&4@9FER<W0@=&AR964@;6]N=&AS(&]F
M(#(P,34@86YD(#(P,30L('1H92!F86ER('9A;'5E('=A<R!E<W1I;6%T960@
M;VX@=&AE(&1A=&4@;V8@9W)A;G0@=7-I;F<@82!";&%C:RU38VAO;&5S(&]P
M=&EO;B!P<FEC:6YG(&UO9&5L(&%N9"!T:&4@87-S=6UP=&EO;G,@;F]T960@
M:6X@=&AE('1A8FQE(&)E;&]W+B!4:&4@=V5I9VAT960@879E<F%G92!G<F%N
M="!D871E(&9A:7(@=F%L=64@<&5R('-H87)E(&]F('1H92!A=V%R9',@9W)A
M;G1E9"!D=7)I;F<@=&AE(&9I<G-T('1H<F5E(&UO;G1H<R!O9B`R,#$U(&%N
M9"`R,#$T('=A<R`D."XQ,2!A;F0@)#@N,C@L(')E<W!E8W1I=F5L>2X@5&AE
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M;&P@8F4@97AE<F-I<V5D("`@(`T*("`@("`@870@=&AE(&UI9'!O:6YT(&]F
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M<&5C=&5D('1E<FTN/"$M+45&4&QA8V5H;VQD97(M+3X\+V9O;G0^("`@("`-
M"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX@(`T*("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY7
M96EG:'1E9"!!=F5R86=E($%S<W5M<'1I;VYS(&9O<B!3=&]C:R!/<'1I;VX@
M07=A<F1S($=R86YT960@=&\\+V9O;G0^("`@("`-"B`@("`\+V1I=CX\8G(O
M/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY%;7!L;WEE97,@86YD($1I
M<F5C=&]R<R!U;F1E<B!T:&4@26YC96YT:79E(%!L86X\+V9O;G0^("`@("`-
M"B`@("`\+V1I=CX\8G(O/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^("`-"B`@("`@
M("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N
M/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXR,#$U/"]F
M;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$
M8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXR,#$T/"]F;VYT
M/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^
M("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/B`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'
M2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5X<&5C=&5D($QI9F4@
M:6X@665A<G,\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU
M+C4\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M-2XU/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^
M("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P
M+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>'!E8W1E9"!6;VQA=&EL:71Y
M/"]F;VYT/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXX,SPO9F]N
M=#X@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXE/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^.#<\+V9O;G0^("`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)3PO9F]N=#X@
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU2
M24=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^17AP96-T960@1&EV
M:61E;F0@66EE;&0\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^,"XP/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXE/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,"XP/"]F
M;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXE/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\
M='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-S`E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L
M969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/E)I<VLM1G)E92!);G1E<F5S="!2871E/"]F;VYT/B`@("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$N-3PO9F]N=#X@("`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)3PO9F]N=#X@
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C$N-CPO9F]N=#X@("`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)3PO9F]N=#X@(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M(#PO='(^("`@("`-"B`@("`@(#PO=&%B;&4^/&)R+SX\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`@("`-
M"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI
M8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9"<^16UP;&]Y
M964@4W1O8VL@4'5R8VAA<V4@4&QA;CPO9F]N=#X\+V9O;G0^("`@("`-"B`@
M("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!H87,@<F5S97)V960@
M82!T;W1A;"!O9B`Q+#0W-2!S:&%R97,@;V8@8V]M;6]N('-T;V-K('1O(&)E
M('!U<F-H87-E9"!U;F1E<B!T:&4@15-04"P@;V8@=VAI8V@@-3$Y('-H87)E
M<R!R96UA:6X@879A:6QA8FQE(&9O<B!P=7)C:&%S92!A="!-87)C:"8C,38P
M.S,Q+"`R,#$U+B!%;&EG:6)L92!E;7!L;WEE97,@;6%Y(&%U=&AO<FEZ92!U
M<"!T;R`Q-24@;V8@=&AE:7(@<V%L87)Y('1O('!U<F-H87-E(&-O;6UO;B!S
M=&]C:R!A="!T:&4@;&]W97(@;V8@.#4E(&]F('1H92!B96=I;FYI;F<@;W(@
M.#4E(&]F('1H92!E;F1I;F<@<')I8V4@9'5R:6YG('-I>"UM;VYT:"!P=7)C
M:&%S92!I;G1E<G9A;',N($YO(&UO<F4@=&AA;B`S('-H87)E<R!M87D@8F4@
M<'5R8VAA<V5D(&)Y(&%N>2!O;F4@96UP;&]Y964@870@=&AE('-I>"UM;VYT
M:"!P=7)C:&%S92!D871E<R!A;F0@;F\@96UP;&]Y964@;6%Y('!U<F-H87-E
M('-T;V-K(&AA=FEN9R!A(&9A:7(@;6%R:V5T('9A;'5E(&%T('1H92!C;VUM
M96YC96UE;G0@9&%T92!O9B`D,C4@;W(@;6]R92!I;B!A;GD@;VYE(&-A;&5N
M9&%R('EE87(N(%1H92!#;VUP86YY(&ES<W5E9"`R,"!S:&%R97,@9'5R:6YG
M('1H92!F:7)S="!T:')E92!M;VYT:',@;V8@,C`Q-2!U;F1E<B!T:&4@15-0
M4"X@0V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R('-H87)E<R!P=7)C:&%S960@
M=6YD97(@=&AE($534%`@<F5L871E9"!T;R!T:&4@<'5R8VAA<V4@9&ES8V]U
M;G0@86YD('1H92`F(S@R,C`[;&]O:RUB86-K)B,X,C(Q.R!O<'1I;VX@=V5R
M92!D971E<FUI;F5D('5S:6YG(&$@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I
M8VEN9R!M;V1E;"X\+V9O;G0^(`T*("`@(#PO9&EV/CQB<B\^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8V$V9#,R8E\W8V4R
M7S0Q-#5?8C-B8U\P,V(Q.&-B,38S,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO8V-A-F0S,F)?-V-E,E\T,30U7V(S8F-?,#-B,3AC8C$V,S`Y
M+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DYO=&4@,R`M($-O;&QA8F]R871I=F4@86YD($]T
M:&5R(%)E<V5A<F-H(&%N9"!$979E;&]P;65N="!#;VYT<F%C=',\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A
M;FEZ871I;VXL($-O;G-O;&ED871I;VX@86YD(%!R97-E;G1A=&EO;B!O9B!&
M:6YA;F-I86P@4W1A=&5M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I=F4@07)R
M86YG96UE;G0@1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^("`@#0H@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/DYO=&4@,R`F(S@R,3([($-O;&QA8F]R871I=F4@86YD($]T:&5R(%)E<V5A
M<F-H(&%N9"!$979E;&]P;65N="!#;VYT<F%C=',\+V9O;G0^("`@(`T*("`@
M(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,
M13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/E4N4RXF(S$V,#M$97!A<G1M
M96YT(&]F($AE86QT:"!A;F0@2'5M86X@4V5R=FEC97,@*"8C.#(R,#M"05)$
M02](2%,F(S@R,C$[*2X\+V9O;G0^($EN($IA;G5A<GD@,C`P-RP@0D%21$$O
M2$A3(&%W87)D960@=&AE($-O;7!A;GD@82`D,3`R+#8V,2P@9F]U<BUY96%R
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M:&ES(&9O8W5S+"!A(%-E<'1E;6)E<B`R,#`Y(&-O;G1R86-T(&UO9&EF:6-A
M=&EO;B!W87,@87=A<F1E9"!T;R!E>'1E;F0@=&AE(&DN=BX@<&5R86UI=FER
M('!R;V=R86T@86YD('1O(&EN8W)E87-E(&9U;F1I;F<@8GD@)#<W+#$Y,2X@
M3VX@1F5B<G5A<GDF(S$V,#LR-"P@,C`Q,2P@=&AE($-O;7!A;GD@86YN;W5N
M8V5D('1H870@0D%21$$O2$A3(&AA9"!A=V%R9&5D(&ET(&$@)#4U+#`P,"!C
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M2$A3('1O("0R,S0L.#4R(&%N9"!P<F]V:61E9"!F=6YD:6YG("`@#0H@("`@
M("`@('1O('-U<'!O<G0@=&AE(&9I;&EN9R!O9B!A($Y$02!T;R!S965K(')E
M9W5L871O<GD@87!P<F]V86P@9F]R(&DN=BX@<&5R86UI=FER(&EN('1H92!5
M+E,N($EN($1E8V5M8F5R(#(P,3,L($)I;T-R>7-T('-U8FUI='1E9"!A;B!.
M1$$@9FEL:6YG(&9O<B!I+G8N('!E<F%M:79I<B!T;R!T:&4@1D1!(&%N9"!T
M:&4@3D1!('=A<R!A<'!R;W9E9"!I;B!$96-E;6)E<B`R,#$T+B!4:&4@0D%2
M1$$O2$A3(&-O;G1R86-T(&5X<&ER960@;VX@2G5N92`S,"P@,C`Q-"!A8V-O
M<F1I;F<@=&\@:71S('1E<FUS+CPO9F]N=#X@(`T*("`@("`@/"]D:78^/&)R
M+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY/;B!-87)C:"`S,2P@,C`Q-2P@=V4@86YN;W5N8V5D('1H
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M86-T(&9O<B!T:&4@8V]N=&EN=65D(&1E=F5L;W!M96YT(&]F($)#6#0T,S`@
M87,@82!P;W1E;G1I86P@=')E871M96YT(&9O<B!D:7-E87-E<R!C875S960@
M8GD@4DY!('!A=&AO9V5N<RP@:6YC;'5D:6YG(&9I;&]V:7)U<V5S+B8C,38P
M.R8C,38P.U1H:7,@0D%21$$O2$A3(&-O;G1R86-T(&EN8VQU9&5S(&$@8F%S
M92!C;VYT<F%C="!O9B`D,3(L,3,T('1O('-U<'!O<G0@0D-8-#0S,"!D<G5G
M(&UA;G5F86-T=7)I;F<L(&%S('=E;&P@87,@)#(R+#@U-2!I;B!A9&1I=&EO
M;F%L(&1E=F5L;W!M96YT(&]P=&EO;G,@=&AA="!C86X@8F4@97AE<F-I<V5D
M(&)Y('1H92!G;W9E<FYM96YT+"!B<FEN9VEN9R!T:&4@<&]T96YT:6%L('9A
M;'5E(&]F('1H92!C;VYT<F%C="!T;R`D,S0L.3@Y+CPO9F]N=#X@("`-"B`@
M("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%
M.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^3F%T:6]N86P@26YS=&ET=71E
M(&]F($%L;&5R9WD@86YD($EN9F5C=&EO=7,@1&ES96%S97,@*"8C.#(R,#M.
M24%)1"](2%,F(S@R,C$[*2X\+V9O;G0^($EN(%-E<'1E;6)E<B`R,#$S+"!.
M24%)1"](2%,@8V]N=')A8W1E9"!W:71H('1H92!#;VUP86YY(&9O<B!T:&4@
M9&5V96QO<&UE;G0@;V8@0D-8-#0S,"!A<R!A('1R96%T;65N="!F;W(@36%R
M8G5R9R!V:7)U<R!D:7-E87-E+B!.24%)1"](2%,L('!A<G0@;V8@=&AE($YA
M=&EO;F%L($EN<W1I='5T97,@;V8@2&5A;'1H+"!M861E(&%N(&EN:71I86P@
M87=A<F0@;V8@)#4L,#`P('1O('1H92!#;VUP86YY+B!4:&4@=&]T86P@9G5N
M9&EN9R!U;F1E<B!T:&ES(&-O;G1R86-T(&%S(&]F($UA<F-H(#,Q+"`R,#$U
M(&-O=6QD(&)E('5P('1O("0R.2PQ-#<L(&EF(&%L;"!C;VYT<F%C="!O<'1I
M;VYS(&%R92!E>&5R8VES960@8GD@3DE!240O2$A3+"!O=F5R(&$@9FEV92!Y
M96%R('!E<FEO9"X@5&AE(&=O86QS(&]F('1H:7,@8V]N=')A8W0L(&EN8VQU
M9&EN9R!A;65N9&UE;G1S+"!A<F4@=&\@9FEL92!)3D0@87!P;&EC871I;VYS
M(&9O<B!I;G1R879E;F]U<R!I+G8N(&%N9"!I+FTN($)#6#0T,S`@9F]R('1H
M92!T<F5A=&UE;G0@;V8@36%R8G5R9R!V:7)U<R!D:7-E87-E+"!T;R!C;VYD
M=6-T(&%N(&EN:71I86P@4&AA<V4@,2!H=6UA;B!C;&EN:6-A;"!T<FEA;"!A
M;F0@=&\@<W1U9'D@0D-8-#0S,"!A<R!A('1R96%T;65N="!F;W(@16)O;&$@
M=FER=7,@9&ES96%S92X@07,@;V8@36%R8V@@,S$L(#(P,34L(&$@=&]T86P@
M;V8@)#(U+#`R,2!H87,@8F5E;B!A=V%R9&5D('5N9&5R(&5X97)C:7-E9"!O
M<'1I;VYS('=I=&AI;B!T:&4@8V]N=')A8W0N($)#6#0T,S`@:7,@#0H@("`@
M("!T:&4@;&5A9"!C;VUP;W5N9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS($)3
M058@<F5S96%R8V@@<')O9W)A;2X\+V9O;G0^("`-"B`@("`\+V1I=CX\8G(O
M/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY4:&4@8V]N=')A8W1S('=I=&@@0D%21$$O2$A3(&%N9"!.24%)
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M=VET:&]U="!C875S92X\+V9O;G0^("`@#0H@("`@/"]D:78^/&)R+SX\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9
M.B!I;FQI;F4G/E-H:6]N;V=I)B,Q-C`[)F%M<#L@0V\N+"!,=&0N("@F(S@R
M,C`[4VAI;VYO9VDF(S@R,C$[*2X\+V9O;G0^($EN($9E8G)U87)Y(#(P,#<L
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M26X@3V-T;V)E<B`R,#`X+"!T:&4@0V]M<&%N>2!A;F0@4VAI;VYO9VD@86UE
M;F1E9"!T:&4@;&EC96YS92!A9W)E96UE;G0@=&\@97AP86YD('1H92!T97)R
M:71O<GD@8V]V97)E9"!B>2!T:&4@86=R965M96YT('1O(&EN8VQU9&4@5&%I
M=V%N(&%N9"!T;R!P<F]V:61E(')I9VAT<R!F;W(@4VAI;VYO9VD@=&\@<&5R
M9F]R;2!A(%!H87-E)B,Q-C`[,R!C;&EN:6-A;"!T<FEA;"!I;B!(;VYG($MO
M;F<N(%-H:6]N;V=I(&AA<R!C;VUM97)C:6%L;'D@;&%U;F-H960@<&5R86UI
M=FER('5N9&5R('1H92`@("`@#0H@("`@("!C;VUM97)C:6%L(&YA;64@4D%0
M24%#5$$@:6X@2F%P86XN/"]F;VYT/B`@("`-"B`@("`\+V1I=CX\8G(O/CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,
M05DZ(&EN;&EN92<^1W)E96X@0W)O<W,@0V]R<&]R871I;VX@*"8C.#(R,#M'
M<F5E;B!#<F]S<R8C.#(R,3LI+CPO9F]N=#X@26X@2G5N92`R,#`V+"!T:&4@
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M:6-E;G-E(&9E92!O9B`D,C4P+B!4:&4@;&EC96YS92!A;'-O('!R;W9I9&5S
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M<F]D=6-T<R!I;B!+;W)E82X\+V9O;G0^("`@#0H@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-0
M3$%9.B!I;FQI;F4G/DUU;F1I<&AA<FUA($EN=&5R;F%T:6]N86P@2&]L9&EN
M9W,@3&EM:71E9"`H)B,X,C(P.TUU;F1I<&AA<FUA)B,X,C(Q.RDN/"]F;VYT
M/B!);B!&96)R=6%R>2`R,#`V+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M86X@97AC;'5S:79E+"!R;WEA;'1Y(&)E87)I;F<@<FEG:'0@86YD(&QI8V5N
M<V4@86=R965M96YT('=I=&@@375N9&EP:&%R;6$@9F]R('1H92!D979E;&]P
M;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@;V8@9F]R;V1E<VEN92P@82!0
M=7)I;F4@3G5C;&5O<VED92!0:&]S<&AO<GEL87-E("@F(S@R,C`[4$Y0)B,X
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M(#$P<'0G/B8C,38P.SPO9F]N=#X\+V9O;G0^("`@("`-"B`@("`\+V1I=CX\
M8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[
M($1)4U!,05DZ(&EN;&EN92<^06QB97)T($5I;G-T96EN($-O;&QE9V4@;V8@
M365D:6-I;F4@;V8@665S:&EV82!5;FEV97)S:71Y(&%N9"!);F1U<W1R:6%L
M(%)E<V5A<F-H+"!,=&0N("@F(S@R,C`[045#3TTF(S@R,C$[(&%N9"`F(S@R
M,C`[25),)B,X,C(Q.R!R97-P96-T:79E;'DI+CPO9F]N=#X@26X@2G5N92`R
M,#`P+"!T:&4@0V]M<&%N>2!L:6-E;G-E9"!A('-E<FEE<R!O9B!P;W1E;G0@
M:6YH:6)I=&]R<R!O9B!03E`@9G)O;2!!14-/32!A;F0@25),+"`H8V]L;&5C
M=&EV96QY+"!T:&4@)B,X,C(P.TQI8V5N<V]R<R8C.#(R,3LI+B!4:&4@;&5A
M9"!P<F]D=6-T(&-A;F1I9&%T97,@9G)O;2!T:&ES(&-O;&QA8F]R871I;VX@
M87)E(&9O<F]D97-I;F4@86YD('5L;V1E<VEN92X@5&AE($-O;7!A;GD@:&%S
M(&]B=&%I;F5D('=O<FQD=VED92!E>&-L=7-I=F4@<FEG:'1S('1O(&1E=F5L
M;W`@86YD('5L=&EM871E;'D@9&ES=')I8G5T92!T:&5S92P@;W(@86YY(&]T
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M86)L92!E9F9O<G1S('1O(&1E=F5L;W`@=&AE<V4@9')U9W,N($EN(&%D9&ET
M:6]N+"!T:&4@0V]M<&%N>2!H87,@86=R965D('1O('!A>2!C97)T86EN(&UI
M;&5S=&]N92!P87EM96YT<R!F;W(@96%C:"`@(`T*("`@("`@;&EC96YS960@
M<')O9'5C="`H=VAI8V@@<F%N9V4@:6X@=&AE(&%G9W)E9V%T92!F<F]M("0Q
M+#0P,"!T;R!A;&UO<W0@)#0L,#`P)B,Q-C`[<&5R(&EN9&EC871I;VXI(&9O
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M;2`D,34P('1O("0U,#`L('1H870@87)E(&-R961I=&%B;&4@86=A:6YS="!A
M8W1U86P@<F]Y86QT:65S(&%N9"!O=&AE<B!P87EM96YT<R!D=64@=&\@=&AE
M($QI8V5N<V]R<RX@5&AI<R!A9W)E96UE;G0@;6%Y(&)E('1E<FUI;F%T960@
M8GD@=&AE($-O;7!A;GD@870@86YY('1I;64@8GD@9VEV:6YG(#8P)B,Q-C`[
M9&%Y<R!A9'9A;F-E(&YO=&EC92!O<B!I;B!T:&4@979E;G0@;V8@;6%T97)I
M86P@=6YC=7)E9"!B<F5A8V@@8GD@=&AE($QI8V5N<V]R<RX\+V9O;G0^("`-
M"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);B!-87D@,C`Q,"P@=&AE($-O;7!A
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M<GDF(S$V,#LQ+"`R,#`V('=I=&@@375N9&EP:&%R;6$@86YD("AI:2DF(S$V
M,#MR;WEA;'1I97,@<F5C96EV960@9G)O;2!I=',@<W5B(&QI8V5N<V5E<R!I
M;B!C;VYN96-T:6]N('=I=&@@=&AE('-A;&4@;V8@;&EC96YS960@<')O9'5C
M=',L(&9O<B!W:&EC:"!T:&4@;W)I9VEN86P@<&%Y;65N="!R871E('=I;&P@
M<F5M86EN(&EN(&5F9F5C="X@5&AE(')A=&4@;V8@<F]Y86QT>2!P87EM96YT
M<R!T;R!T:&4@3&EC96YS;W)S(&)A<V5D(&]N(&YE="!S86QE<R`-"B`@("`@
M(&]F(&%N>2!R97-U;'1I;F<@<')O9'5C="!M861E(&)Y('1H92!#;VUP86YY
M(')E;6%I;G,@=6YC:&%N9V5D+CPO9F]N=#X@("`-"B`@("`\+V1I=CX\8G(O
M/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY);B!C;VYS:61E<F%T:6]N(&9O<B!T:&5S92!M;V1I9FEC871I
M;VYS(&EN(#(P,3`L('1H92!#;VUP86YY(&ES<W5E9"!T;R!T:&4@3&EC96YS
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M82!C;VUB:6YA=&EO;B!O9B!C87-H(&%N9"!S:&%R97,N/"]F;VYT/B`@#0H@
M("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^3VX@3F]V96UB97(F(S$V,#LQ-RP@,C`Q
M,2P@=&AE($-O;7!A;GD@9G5R=&AE<B!A;65N9&5D(&ET<R!A9W)E96UE;G1S
M('=I=&@@=&AE($QI8V5N<V]R<R!W:&5R96)Y('1H92!,:6-E;G-O<G,@86=R
M965D('1O(&%C8V5P="!A(')E9'5C=&EO;B!O9B!O;F4M:&%L9B!I;B!T:&4@
M<&5R8V5N=&%G92!O9B!.970@4')O8V5E9',@*&%S(&1E9FEN960I(')E8V5I
M=F5D(&)Y('1H92!#;VUP86YY('5N9&5R(&ET<R!!;65N9&5D(&%N9"!297-T
M871E9"!!9W)E96UE;G0@=VET:"!-=6YD:7!H87)M82!T:&%T('=I;&P@8F4@
M<&%I9"!T;R!!14-/32])4DPN/"]F;VYT/B`@("`-"B`@("`\+V1I=CX\8G(O
M/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY/;B!*=6YE)B,Q-C`[,3DL(#(P,3(L('1H92!#;VUP86YY(&9U
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M('5S92X\+V9O;G0^("`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
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M('-H87)E<RX\+V9O;G0^("`@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;B!*86YU87)Y
M(#8L(#(P,30L('1H92!#87)B;VAY9')A=&4@0VAE;6ES=')Y(%)E<V5A<F-H
M(%1E86T@9G)O;2!#86QL86=H86X@26YN;W9A=&EO;B!297-E87)C:"!,:6UI
M=&5D("@F(S@R,C`[0TE23"8C.#(R,3LI+"!F;W)M97)L>2!);F1U<W1R:6%L
M(%)E<V5A<F-H($QI;6ET960L('1R86YS9F5R<F5D('1O(%9I8W1O<FEA(%5N
M:79E<G-I='D@;V8@5V5L;&EN9W1O;B`H)B,X,C(P.U955R8C.#(R,3LI('1O
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M8VAA;F=E9"X\+V9O;G0^/"]F;VYT/B`@("`@#0H@("`@("`\+V1I=CX\8G(O
M/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/B`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M8FQE(&)Y('1H92!#;VUP86YY('5P;VX@#0H@("`@("!T:')E92!M;VYT:',@
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M;B!A;6]U;G1S(&ET(')E8V5I=F5S+CPO9F]N=#X@("`@#0H@("`@/"]D:78^
M/&)R+SX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V-C839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B
M8U\P,V(Q.&-B,38S,#DO5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`T+2!2;WEA;'1Y
M($UO;F5T:7IA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E)O>6%L='D@36]N971I>F%T:6]N(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F]Y86QT>2!-;VYE=&EZ871I;VX@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`@("`@#0H@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/DYO=&4@-"`F(S@R,3([(%)O>6%L='D@36]N971I>F%T:6]N/"]F;VYT
M/B`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/D]V97)V:65W/"]F;VYT/B`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-
M"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;B!-
M87)C:"8C,38P.SDL(#(P,3$L('1H92!#;VUP86YY(&-O;7!L971E9"!A("0S
M,"PP,#`F(S$V,#MF:6YA;F-I;F<@=')A;G-A8W1I;VX@=&\@;6]N971I>F4@
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M(')E8V5I=F5D(&YE="!P<F]C965D<R!O9B`D,C(L-CDQ)B,Q-C`[9G)O;2!T
M:&4@=')A;G-A8W1I;VX@869T97(@=')A;G-A8W1I;VX@8V]S=',@;V8@)#0L
M,S`Y)B,Q-C`[86YD('1H92!E<W1A8FQI<VAM96YT(&]F(&$@)#,L,#`P)B,Q
M-C`[:6YT97)E<W0@<F5S97)V92!A8V-O=6YT(&)Y(%)O>6%L='D@4W5B+"!A
M=F%I;&%B;&4@=&\@:&5L<"!C;W9E<B!I;G1E<F5S="!S:&]R=&9A;&QS(&EN
M('1H92!F=71U<F4N($%L;"!O9B!T:&4@:6YT97)E<W0@<F5S97)V92!A8V-O
M=6YT(&AA<R!B965N(&9U;&QY('5T:6QI>F5D('=I=&@@=&AE(%-E<'1E;6)E
M<B`R,#$R(&EN=&5R97-T('!A>6UE;G0N/"]F;VYT/B`-"B`@("`\+V1I=CX\
M8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY!<R!P87)T(&]F('1H92!T<F%N<V%C=&EO;BP@=&AE($-O
M;7!A;GD@96YT97)E9"!I;G1O(&$@<'5R8VAA<V4@86YD('-A;&4@86=R965M
M96YT(&1A=&5D(&%S(&]F($UA<F-H)B,Q-C`[.2P@,C`Q,2!W:71H(%)O>6%L
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M87(@9F]R96EG;B!C=7)R96YC>2!H961G92!A<G)A;F=E;65N="`H87,@9G5R
M=&AE<B!D97-C<FEB960@8F5L;W<L('1H92`F(S@R,C`[0W5R<F5N8WD@2&5D
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M="!O9B!T:&ES('1R86YS86-T:6]N+CPO9F]N=#X@("`-"B`@("`\+V1I=CX\
M8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M
M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DYO;BU296-O=7)S
M92!.;W1E<R!087EA8FQE/"]F;VYT/B`@("`-"B`@("`\+V1I=CX\8G(O/CQD
M:78@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#(W
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/D]N($UA<F-H)B,Q-C`[.2P@,C`Q,2P@4F]Y86QT>2!3=6(@
M8V]M<&QE=&5D(&$@<')I=F%T92!P;&%C96UE;G0@=&\@:6YS=&ET=71I;VYA
M;"!I;G9E<W1O<G,@;V8@)#,P+#`P,"!I;B!A9V=R96=A=&4@<')I;F-I<&%L
M(&%M;W5N="!O9B!I=',@4&AA4DU!(%-E;FEO<B!396-U<F5D(#$T+C`E($YO
M=&5S(&1U92`R,#(P("AT:&4@)B,X,C(P.U!H85)-02!.;W1E<R8C.#(R,3LI
M+B!4:&4@4&AA4DU!($YO=&5S('=E<F4@:7-S=65D(&)Y(%)O>6%L='D@4W5B
M('5N9&5R(&%N($EN9&5N='5R92P@9&%T960@87,@;V8@36%R8V@F(S$V,#LY
M+"`R,#$Q("AT:&4@)B,X,C(P.TEN9&5N='5R928C.#(R,3LI+"!B>2!A;F0@
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M($YO=&5S(&)E87(@:6YT97)E<W0@870@,30E)B,Q-C`[<&5R(&%N;G5M+"!P
M87EA8FQE(&%N;G5A;&QY(&EN(&%R<F5A<G,@;VX@4V5P=&5M8F5R)B,Q-C`[
M,7-T(&]F(&5A8V@@>65A<B`H=&AE("8C.#(R,#M087EM96YT($1A=&4F(S@R
M,C$[*2X@5&AE($-O;7!A;GD@<F5M86EN<R!E;G1I=&QE9"!T;R!R96-E:79E
M(&%N>2!R;WEA;'1I97,@86YD("`@#0H@("`@("!M:6QE<W1O;F4@<&%Y;65N
M=',@<F5L871E9"!T;R!S86QE<R!O9B!P97)A;6EV:7(@8GD@4VAI;VYO9VD@
M9F]L;&]W:6YG(')E<&%Y;65N="!O9B!T:&4@4&AA4DU!($YO=&5S+CPO9F]N
M=#X@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S
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M9&5E;2P@;W(@;VX@=7`@=&\@;VYE(&]C8V%S:6]N('!A>2!A;GD@:6YT97)E
M<W0@<VAO<G1F86QL(&]N+"!T:&4@4&AA4DU!($YO=&5S+CPO9F]N=#X@("`-
M"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;B!397!T96UB97(F(S$V,#LQ+"`R
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M;W(@9F]R96-L;W-U<F4L('1H92!P<FEM87)Y(&EM<&%C="!T;R`@(`T*("`@
M("`@=&AE($-O;7!A;GD@=V]U;&0@8F4@=&AE(&QO<W,@;V8@9G5T=7)E(')O
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M;&]W<RX\+V9O;G0^(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
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M960@9FEN86YC:6YG<R!O9B!T:&ES('1Y<&4N/"]F;VYT/B`@(`T*("`@(#PO
M9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D%S(&]F($UA<F-H)B,Q-C`[,S$L(#(P,34L('1H
M92!A9V=R96=A=&4@9F%I<B!V86QU92!O9B!T:&4@4&AA4DU!($YO=&5S('=A
M<R!E<W1I;6%T960@=&\@8F4@87!P<F]X:6UA=&5L>2`U,"4@;V8@:71S(&-A
M<G)Y:6YG('9A;'5E(&]F("0S,"PP,#`N(%1H92!E<W1I;6%T960@9F%I<B!V
M86QU92!O9B!T:&4@4&AA4DU!($YO=&5S(&ES(&-L87-S:69I960@87,@3&5V
M96P@,B!I;B!T:&4@9F%I<B!V86QU92!H:65R87)C:'D@87,@9&5F:6YE9"!I
M;B!5+E,N($=!05`N)B,Q-C`[/"]F;VYT/B`@(`T*("`@(#PO9&EV/CQB<B\^
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
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M965M960N/"]F;VYT/B`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`@("`@
M#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY&;W)E:6=N($-U<G)E;F-Y($AE9&=E/"]F;VYT
M/B`@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N
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M96%R(&9R;VT@,C`Q-2!T:')O=6=H(#(P,C`L('!R;W9I9&5D('1H92!#=7)R
M96YC>2!(961G92!!9W)E96UE;G0@<F5M86EN<R!I;B!E9F9E8W0N($$@<&%Y
M;65N="!O9B`D,2PY-3`F(S$V,#MW:6QL(&)E(')E<75I<F5D(&EF+"!O;B!-
M87DF(S$V,#LQ."!O9B!T:&4@<F5L979A;G0@>65A<BP@=&AE(%4N4RX@9&]L
M;&%R(&ES('=O<G1H(#$P,"!Y96X@;W(@;&5S<R!A<R!D971E<FUI;F5D(&EN
M(&%C8V]R9&%N8V4@=VET:"!T:&4@0W5R<F5N8WD@2&5D9V4@06=R965M96YT
M+CPO9F]N=#X@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@
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M<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q+"`R
M,#$U(&%N9"`R,#$T(')E<W5L=&5D(&EN(&$@9V%I;B!O9B`D-#8T(&%N9"!A
M(&QO<W,@;V8@)#$L-3(V+"!R97-P96-T:79E;'DN(%1H92!#;VUP86YY(&ES
M(&%L<V\@<F5Q=6ER960@=&\@<&]S="!C;VQL871E<F%L(&EN(&-O;FYE8W1I
M;VX@=VET:"!T:&4@;6%R:RUT;RUM87)K970@861J=7-T;65N=',@8F%S960@
M;VX@9&5F:6YE9"!T:')E<VAO;&1S+B!!<R!O9B!-87)C:"`S,2P@,C`Q-2!A
M;F0@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"P@;F\@8V]L;&%T97)A;"!W87,@
M<&]S=&5D('5N9&5R('1H92!#=7)R96YC>2!(961G92!!9W)E96UE;G0N(%1H
M92!#;VUP86YY('=I;&P@;F]T(&)E(')E<75I<F5D(&%T(&%N>2!T:6UE('1O
M('!O<W0@8V]L;&%T97)A;"!E>&-E961I;F<@=&AE(&UA>&EM=6T@<')E;6EU
M;2!P87EM96YT<R!R96UA:6YI;F<@<&%Y86)L92!U;F1E<B!T:&4@0W5R<F5N
M8WD@2&5D9V4@06=R965M96YT+B!!<R!O9B!-87)C:"`S,2P@,C`Q-2P@=&AE
M(&UA>&EM=6T@86UO=6YT(&]F(&AE9&=E(&-O;&QA=&5R86P@=&AE($-O;7!A
M;GD@;6%Y(&)E(')E<75I<F5D('1O('!O<W0@:7,@)#$Q+C<@;6EL;&EO;BX\
M+V9O;G0^("`@("`-"B`@("`\+V1I=CX\8G(O/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V-A-F0S,F)?-V-E,E\T,30U7V(S
M8F-?,#-B,3AC8C$V,S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V-C839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.2]7;W)K<VAE
M971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY.;W1E(#4@+2!3=&]C:VAO;&1E<G,G($5Q=6ET>3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K
M:&]L9&5R<R<@17%U:71Y($YO=&4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:VAO;&1E<G,G($5Q
M=6ET>2!.;W1E($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M3F]T92`U("8C.#(Q,CL@4W1O8VMH;VQD97)S)B,X,C$W.R!%<75I='D\+V9O
M;G0^(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]N($UA<F-H(#,L(#(P,34L
M('1H92!#;VUP86YY(&9I;&5D(&$@)#$U,"PP,#`@<VAE;&8@<F5G:7-T<F%T
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M92!T:6UE(&]F('-A;&4N/"]F;VYT/B`@("`@#0H@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^3VX@3F]V96UB97(F(S$V,#LV+"`R,#$S+"!T:&4@0V]M<&%N>2!F
M:6QE9"!A("0Q,C4L,#`P('-H96QF(')E9VES=')A=&EO;B!S=&%T96UE;G0@
M;VX@1F]R;2!3+3,@=VET:"!T:&4@4T5#+B!4:&ES('-H96QF(')E9VES=')A
M=&EO;B!S=&%T96UE;G0@=V%S(&1E8VQA<F5D(&5F9F5C=&EV92!I;B!.;W9E
M;6)E<B`R,#$S(&%N9"!A;&QO=W,@=&AE($-O;7!A;GD@=&\@<V5L;"!S96-U
M<FET:65S+"!I;F-L=61I;F<@8V]M;6]N('-T;V-K+"!P<F5F97)R960@<W1O
M8VLL(&1E<&]S:71O<GD@<VAA<F5S+"!S=&]C:R!P=7)C:&%S92!C;VYT<F%C
M=',L('=A<G)A;G1S(&%N9"!U;FET<RP@9G)O;2!T:6UE('1O('1I;64@870@
M<')I8V5S(&%N9"!O;B!T97)M<R!T;R!B92!D971E<FUI;F5D(&%T('1H92!T
M:6UE(&]F('-A;&4N(%1H92!#;VUP86YY(&AA<R`D,3`L,#`P(')E;6%I;FEN
M9R!U;F1E<B!T:&ES('-H96QF(')E9VES=')A=&EO;BX\(2TM1490;&%C96AO
M;&1E<BTM/CPO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-C839D,S)B7S=C93)?
M-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B,38S,#DO
M5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%55E!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S+"!B>2!0;VQI
M8WD@*%!O;&EC:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E<V-R:7!T:6]N(&]F($-O;7!A;GD@6U!O;&EC>2!497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^5&AE($-O;7!A;GD\+V9O;G0^("`@#0H@
M("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS
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M<&]R871E9"!I;B!$96QA=V%R92!I;B`Q.3@V(&%N9"!I=',@:&5A9'%U87)T
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M;W=S(&9R;VT@;W!E<F%T:6]N<R!S:6YC92!I;F-E<'1I;VXN/"]F;VYT/B`-
M"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY"87-E9"!O;B!I=',@8W5R<F5N="!O
M<&5R871I;F<@<&QA;G,L('1H92!#;VUP86YY(&5X<&5C=',@:70@:&%S('-U
M9F9I8VEE;G0@;&EQ=6ED:71Y+"!W:71H(&ET<R!E>&ES=&EN9R!C87-H(&%N
M9"!I;G9E<W1M96YT<R!O9B`D,3$Q+#(X,"P@=&\@8V]N=&EN=64@:71S('!L
M86YN960@;W!E<F%T:6]N<R!T:')O=6=H('1H92!M:61D;&4@;V8@,C`Q-BX@
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M97)A=&EO;G,@<W5B<W1A;G1I86QL>2!B97EO;F0@=&AE(&UI9&1L92!O9B`R
M,#$V(&ET('=I;&P@;F5E9"!T;SH@*#$I)B,Q-C`[<W5C8V5S<V9U;&QY('-E
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M;F5S.R`H,RDF(S$V,#MR86ES92!A9&1I=&EO;F%L(&-A<&ET86P@=&AR;W5G
M:"!E<75I='D@;W(@9&5B="!F:6YA;F-I;F=S(&]R(&9R;VT@;W1H97(@<V]U
M<F-E<SL@*#0I)B,Q-C`[;V)T86EN('!R;V1U8W0@8V%N9&ED871E(')E9W5L
M871O<GD@87!P<F]V86QS+"!W:&EC:"!W;W5L9"!G96YE<F%T92`@("`-"B`@
M("`@(')E=F5N=64@86YD(&-A<V@@9FQO=SL@*#4I)B,Q-C`[<F5D=6-E('-P
M96YD:6YG(&]N(&]N92!O<B!M;W)E(')E<V5A<F-H(&%N9"!D979E;&]P;65N
M="!P<F]G<F%M<SL@86YD+V]R("@V*28C,38P.W)E<W1R=6-T=7)E(&]P97)A
M=&EO;G,N(%1H92!#;VUP86YY(')E=&%I;G,@=&AE(&%B:6QI='D@=&\@;V9F
M97(@9F]R('-A;&4@87!P<F]X:6UA=&5L>2`D,34P+#`P,"!O9B!S96-U<FET
M:65S+"!I;F-L=61I;F<@8V]M;6]N('-T;V-K+"!P<F5F97)R960@<W1O8VLL
M(&1E8G0@<V5C=7)I=&EE<RP@9&5P;W-I=&%R>2!S:&%R97,@86YD('=A<G)A
M;G1S(&9R;VT@:71S(&5F9F5C=&EV92!S:&5L9B!3+3,@<F5G:7-T<F%T:6]N
M('-T871E;65N="P@=VAI8V@@:70@9FEL960@=VET:"!T:&4@4V5C=7)I=&EE
M<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B!O;B!-87)C:"`S+"`R,#$U+B8C
M,38P.R8C,38P.T%D9&ET:6]N86QL>2P@=&AE($-O;7!A;GD@<F5T86EN<R!T
M:&4@86)I;&ET>2!T;R!O9F9E<B!F;W(@<V%L92!A<'!R;WAI;6%T96QY("0Q
M,"PP,#`@;V8@<V5C=7)I=&EE<RP@:6YC;'5D:6YG(&-O;6UO;B!S=&]C:RP@
M<')E9F5R<F5D('-T;V-K+"!D96)T('-E8W5R:71I97,L(&1E<&]S:71A<GD@
M<VAA<F5S(&%N9"!W87)R86YT<R!F<F]M(&ET<R!E9F9E8W1I=F4@<VAE;&8@
M4RTS(')E9VES=')A=&EO;B!S=&%T96UE;G0L('=H:6-H(&ET(&9I;&5D('=I
M=&@@=&AE(%-E8W5R:71I97,@86YD($5X8VAA;F=E($-O;6UI<W-I;VX@;VX@
M3F]V96UB97(F(S$V,#LV+"`R,#$S+B!4:&4@0V]M<&%N>2!W:6QL(&-O;G1I
M;G5E('1O(&EN8W5R(&]P97)A=&EN9R!L;W-S97,@86YD(&YE9V%T:79E(&-A
M<V@@9FQO=W,@=6YT:6P@<F5V96YU97,@<F5A8V@@82!L979E;"!S=69F:6-I
M96YT('1O('-U<'!O<G0@;VYG;VEN9R!O<&5R871I;VYS+CPO9F]N=#X\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;G-O;&ED871I;VXL(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^0F%S:7,@;V8@4')E<V5N=&%T:6]N
M/"]F;VYT/B`@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE(&-O;G-O;&ED871E9"!F
M:6YA;F-I86P@<W1A=&5M96YT<R!I;F-L=61E('1H92!A8V-O=6YT<R!O9B!T
M:&4@0V]M<&%N>2!A;F0@:71S('=H;VQL>2UO=VYE9"!S=6)S:61I87)Y+"!*
M4%(@4F]Y86QT>2!3=6(@3$Q#("@F(S@R,C`[4F]Y86QT>2!3=6(F(S@R,C$[
M*2X@4F]Y86QT>2!3=6(@=V%S(&9O<FUE9"!I;B!C;VYN96-T:6]N('=I=&@@
M82`D,S`L,#`P)B,Q-C`[9FEN86YC:6YG('1R86YS86-T:6]N('1H92!#;VUP
M86YY(&-O;7!L971E9"!O;B!-87)C:"8C,38P.SDL(#(P,3$N(%-E92!.;W1E
M(#0L(%)O>6%L='D@36]N971I>F%T:6]N+"!F;W(@82!F=7)T:&5R(&1E<V-R
M:7!T:6]N(&]F('1H:7,@=')A;G-A8W1I;VXN($%L;"!I;G1E<F-O;7!A;GD@
M=')A;G-A8W1I;VYS(&%N9"!B86QA;F-E<R!H879E(&)E96X@96QI;6EN871E
M9"X\+V9O;G0^/"]F;VYT/B`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/B`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/E1H92!#;VUP86YY)B,X,C$W.W,@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S
M=&%T96UE;G1S(&AA=F4@8F5E;B!P<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I
M=&@@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&=E;F5R86QL>2!A8V-E<'1E9"!I
M;B!T:&4@56YI=&5D(%-T871E<R`H)B,X,C(P.U4N4RX@1T%!4"8C.#(R,3LI
M(&9O<B!I;G1E<FEM(&9I;F%N8VEA;"!R97!O<G1I;F<@86YD('1H92!I;G-T
M<G5C=&EO;G,@=&\@1F]R;2`Q,"U1(&%N9"!D;R!N;W0@:6YC;'5D92!A;&P@
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M("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^5&AE<V4@9FEN86YC:6%L('-T871E;65N
M=',@<VAO=6QD(&)E(')E860@:6X@8V]N:G5N8W1I;VX@=VET:"!T:&4@9FEN
M86YC:6%L('-T871E;65N=',@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,30@86YD('1H92!N;W1E<R!T:&5R971O(&EN8VQU9&5D
M(&EN('1H92!#;VUP86YY)B,X,C$W.W,@,C`Q-"!!;FYU86P@4F5P;W)T(&]N
M($9O<FT@,3`M2RX@26YT97)I;2!O<&5R871I;F<@<F5S=6QT<R!A<F4@;F]T
M(&YE8V5S<V%R:6QY(&EN9&EC871I=F4@;V8@;W!E<F%T:6YG(')E<W5L=',@
M9F]R('1H92!F=6QL('EE87(N(%1H92!B86QA;F-E('-H965T(&%S(&]F($1E
M8V5M8F5R)B,Q-C`[,S$L(#(P,30@:&%S(&)E96X@9&5R:79E9"!F<F]M('1H
M92!A=61I=&5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!I
M;F-L=61E9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS(&UO<W0@<F5C96YT($%N
M;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U++CPO9F]N=#X\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8VQA
M<W-I9FEC871I;VXL(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^4F5C;&%S<VEF:6-A=&EO;G,\+V9O;G0^(`T*
M("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D-E<G1A:6X@8F%L86YC92!S:&5E="!A
M;6]U;G1S(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T(&AA=F4@8F5E;B!R96-L
M87-S:69I960@=&\@8V]N9F]R;2!T;R!T:&4@,C`Q-2!P<F5S96YT871I;VXN
M/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<RP@4&]L
M:6-Y(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z
M(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]F;VYT/B`@(`T*("`@(#PO
M9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
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M;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S+"!297-T<FEC
M=&5D($-A<V@@86YD($-A<V@@17%U:79A;&5N=',L(%!O;&EC>2!;4&]L:6-Y
M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^4F5S=')I8W1E
M9"!#87-H/"]F;VYT/B`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY297-T<FEC
M=&5D(&-A<V@@87,@;V8@36%R8V@F(S$V,#LS,2P@,C`Q-2!R969L96-T<R`D
M,34P('1H92!#;VUP86YY(&ES(')E<75I<F5D('1O(&UA:6YT86EN(&EN(&%N
M(&EN=&5R97-T(&)E87)I;F<@8V5R=&EF:6-A=&4@;V8@9&5P;W-I="!T;R!S
M97)V92!A<R!C;VQL871E<F%L(&9O<B!A(&-O<G!O<F%T92!C<F5D:70@8V%R
M9"!P<F]G<F%M+"`D,2PP.#<@:6X@<F]Y86QT>2!R979E;G5E('!A:60@8GD@
M4VAI;VYO9VDF(S$V,#LF86UP.R!#;RXL($QT9"X@*"8C.#(R,#M3:&EO;F]G
M:28C.#(R,3LI(&1E<VEG;F%T960@9F]R(&EN=&5R97-T(&]N('1H92!0:&%2
M34$@3F]T97,@*&1E9FEN960@:6X@3F]T92`T*2!A;F0@)#$L-#`P('1H92!#
M;VUP86YY(&ES(')E<75I<F5D('1O(&UA:6YT86EN(&%S(&-O;&QA=&5R86P@
M9F]R(&$@;&5T=&5R(&]F(&-R961I="!A<W-O8VEA=&5D('=I=&@@=&AE(&QE
M87-E(&5X96-U=&EO;B!A;F0@8G5I;&0M;W5T(&]F(&ET<R!N97<@0FER;6EN
M9VAA;2!R97-E87)C:"!F86-I;&ET:65S+CPO9F]N=#X\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S
M=&UE;G0L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&
M3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^26YV97-T;65N=',\+V9O;G0^("`-"B`@("`\+V1I=CX\
M8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!I;G9E<W1S(&EN(&AI9V@@8W)E9&ET
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M:70@=&\@<'5R8VAA<V4@:&EG:"UQ=6%L:71Y("`@(`T*("`@("`@;6%R:V5T
M86)L92!S96-U<FET:65S('=I=&@@82!M87AI;75M(&EN9&EV:61U86P@;6%T
M=7)I='D@;V8@=&AR964@>65A<G,@86YD(')E<75I<F5S(&%N(&%V97)A9V4@
M<&]R=&9O;&EO(&UA='5R:71Y(&]F(&YO(&UO<F4@=&AA;B`Q."!M;VYT:',N
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M<R!I;G9E<W1M96YT<RX\+V9O;G0^("`@(`T*("`@(#PO9&EV/CQB<B\^/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M<FEG:6YA;"!M871U<FET:65S("`@(`T*("`@("`@870@9&%T92!O9B!P=7)C
M:&%S92!B97EO;F0@=&AR964@;6]N=&AS(&%N9"!W:&EC:"!M871U<F4@870@
M;W(@;&5S<R!T:&%N(#$R(&UO;G1H<R!F<F]M('1H92!B86QA;F-E('-H965T
M(&1A=&4@87)E(&-L87-S:69I960@87,@8W5R<F5N="X@26YV97-T;65N=',@
M=VET:"!A(&UA='5R:71Y(&)E>6]N9"`Q,B!M;VYT:',@9G)O;2!T:&4@8F%L
M86YC92!S:&5E="!D871E(&%R92!C;&%S<VEF:65D(&%S(&QO;F<M=&5R;2X@
M070@36%R8V@F(S$V,#LS,2P@,C`Q-2P@=&AE($-O;7!A;GD@8F5L:65V97,@
M=&AA="!T:&4@8V]S=',@;V8@:71S(&EN=F5S=&UE;G1S(&%R92!R96-O=F5R
M86)L92!I;B!A;&P@;6%T97)I86P@<F5S<&5C=',N/"]F;VYT/B`@("`-"B`@
M("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4:&4@9F]L;&]W:6YG('1A8FQE<R!S=6UM
M87)I>F4@=&AE(&9A:7(@=F%L=64@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!I
M;G9E<W1M96YT<R!B>2!T>7!E+B!4:&4@97-T:6UA=&5D(&9A:7(@=F%L=64@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!F:7AE9"!I;F-O;64@:6YV97-T;65N
M=',@87)E(&-L87-S:69I960@87,@3&5V96P@,B!I;B!T:&4@9F%I<B!V86QU
M92!H:65R87)C:'D@87,@9&5F:6YE9"!I;B!5+E,N($=!05`N(%1H97-E('9A
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M;"`R(&EN<'5T<RX\+V9O;G0^("`-"B`@("`\+V1I=CX\8G(O/CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;B<^("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,3@@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$W+CAP="<@86QI9VX],T1C
M96YT97(^("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY-87)C:"8C,38P
M.S,Q+"`R,#$U/"]F;VYT/B`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R
M/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q
M+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/D%M;W)T:7IE9#PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/D-O<W0\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P="<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N
M/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY!8V-R=65D
M/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@
M86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/DEN
M=&5R97-T/"]F;VYT/B`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY'<F]S<SPO9F]N=#X@("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N
M=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY5;G)E86QI>F5D/"]F
M;VYT/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@
M86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/D=A
M:6YS/"]F;VYT/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/D=R;W-S/"]F;VYT/B`@("`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT
M97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/E5N<F5A;&EZ960\+V9O
M;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A
M;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^3&]S
M<V5S/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^17-T:6UA=&5D/"]F;VYT/B`@("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E
M<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^1F%I<B8C,38P.U9A;'5E
M/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3`E
M/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]B;&EG
M871I;VYS(&]F(%4N4RX@1V]V97)N;65N="!A;F0@:71S(&%G96YC:65S/"]F
M;VYT/B`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,"PS,#(\+V9O;G0^
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-R4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT
M,CPO9F]N=#X@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO
M9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-R4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXS/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^*#(\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI/"]F
M;VYT/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT
M/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C(P+#,T-3PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3`E/B`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D-O<G!O<F%T92!D
M96)T('-E8W5R:71I97,\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C(X+#$S.3PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I
M9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,30T/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(W/"]F;VYT/B`@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#$S/"]F;VYT/B`@("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/BD\+V9O;G0^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXR."PR.3<\+V9O;G0^("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U
M,"4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^("`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^0V5R=&EF:6-A=&5S(&]F
M(&1E<&]S:70\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,2PV,C4\+V9O;G0^("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@
M<V]L:60G/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$U/"]F;VYT/B`@(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^-CPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q+C%P="!S;VQI9"<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT
M/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^*#$R/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#XF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,2PV,S0\+V9O;G0^("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@
M<V]L:60G/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\
M='(^("`@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0U,"4^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0W)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI
M9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-R4^("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-
M"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[)SX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0U,"4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^5&]T86P@:6YV97-T;65N=',\+V9O;G0^("`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@("`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^
M("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U
M<'0@9&]U8FQE)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C8P+#`V-CPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T
M(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD
M/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R
M:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C(P,3PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,S8\+V9O;G0^("`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#(W/"]F;VYT/B`@("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O
M=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/BD\+V9O;G0^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U
M<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^-C`L,C<V/"]F;VYT/B`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4P)3X@("`@
M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C
M,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0W)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\
M='(^("`@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@8V]L<W!A;CTS1#(P(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P="<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#$X(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q-RXX<'0G(&%L
M:6=N/3-$8V5N=&5R/B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^1&5C
M96UB97(F(S$V,#LS,2P@,C`Q-#PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@
M("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^06UO<G1I>F5D/"]F;VYT/B`@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^0V]S=#PO9F]N=#X@("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP
M="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/D%C8W)U960\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^26YT97)E<W0\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C
M96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/D=R;W-S/"]F;VYT
M/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI
M9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/E5N<F5A
M;&EZ960\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^1V%I;G,\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E
M;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^1W)O<W,\+V9O;G0^
M("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG
M;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^56YR96%L
M:7IE9#PO9F]N=#X@("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SY,;W-S97,\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R
M/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY%<W1I;6%T960\+V9O;G0^
M("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N
M/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY&86ER)B,Q
M-C`[5F%L=64\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0U,"4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^3V)L:6=A=&EO;G,@;V8@52Y3+B!';W9E<FYM96YT(&%N9"!I=',@86=E
M;F-I97,\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(P+#,P
M-SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F
M;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C(R/"]F;VYT/B`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C.#(Q,CL\+V9O;G0^("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,C,\+V9O;G0^("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXR,RPS,#8\+V9O;G0^("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4P)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#
M;W)P;W)A=&4@9&5B="!S96-U<FET:65S/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-R4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG
M:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXR-RPQ-3(\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$U,3PO9F]N=#X@("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU/"]F;VYT/B`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-R4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-#<\+V9O
M;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#XF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(W+#(V,3PO9F]N=#X@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4P)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#97)T:69I
M8V%T97,@;V8@9&5P;W-I=#PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G
M/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$Q+#@S.#PO
M9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-CPO9F]N=#X@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S
M;VQI9"<^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R
M:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C.#(Q,CL\+V9O;G0^("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,2XQ<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H
M=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B@V,SPO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXI/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\
M+V9O;G0^/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3$L-S@Q/"]F;VYT/B`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED
M)SX@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R/B`@
M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3`E
M/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-R4^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1M
M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-R4^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#<E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@
M("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^
M("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-3`E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
M/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1O
M=&%L(&EN=F5S=&UE;G1S/"]F;VYT/B`@(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O
M=6)L92<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU
M.2PR.3<\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B
M;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N
M=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXW-7!T(&1O=6)L92<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXQ-SD\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW
M-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C4\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXH,3,S/"]F;VYT/B`@("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G
M/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXI/"]F;VYT/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O
M=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F
M;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C<U<'0@9&]U8FQE)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H
M=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C4Y+#,T.#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@/"]T86)L93X\8G(O/CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J
M=7-T:69Y/B`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!T:&4@<V-H
M961U;&5D(&UA='5R:71Y(&9O<B!T:&4@0V]M<&%N>28C.#(Q-SMS(&EN=F5S
M=&UE;G1S(&%T($UA<F-H)B,Q-C`[,S$L(#(P,34@86YD($1E8V5M8F5R)B,Q
M-C`[,S$L(#(P,30N/"]F;VYT/B`@("`@#0H@("`@/"]D:78^/&)R+SX\=&%B
M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P
M,"4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/B`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X@("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N
M/3-$;6ED9&QE('=I9'1H/3-$,3(E/B`@("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$
M;6ED9&QE('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1M:61D;&4@=VED
M=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$
M,3(E/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^
M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SXR,#$U/"]F;VYT/B`@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/C(P,30\+V9O;G0^("`@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO
M='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T
M)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^36%T=7)I;F<@:6X@;VYE('EE87(@;W(@
M;&5S<SPO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3DL
M,38\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86XG/C`\+V9O;G0^/"]F;VYT/B`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$X+#(S,CPO9F]N
M=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@
M("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/B`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI
M9VX],T1L969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/DUA='5R:6YG(&%F=&5R(&]N92!Y96%R('1H<F]U
M9V@@='=O('EE87)S/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXR.2PV-38\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^,C4L-#4Y/"]F;VYT/B`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P
M="<@86QI9VX],T1L969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DUA='5R:6YG(&%F=&5R('1W;R!Y96%R
M<SPO9F]N=#X@("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXQ,2PT-CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,#PO9F]N=#X\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,34L-C4W/"]F;VYT/B`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED
M)SX@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R/B`@
M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E
M/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@
M("`@(`T*("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CLG/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@-'!X)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY4;W1A;"!I;G9E<W1M96YT<SPO9F]N=#X@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE
M)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^-C`L,C<V/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@
M9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\
M+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT
M/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^-3DL,S0X/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`\+W1R/B`@("`@#0H@("`@("`\+W1A8FQE/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96EV86)L
M97,L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4
M+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^4F5C96EV86)L97,@9G)O;2!#;VQL86)O<F%T:6]N<SPO9F]N
M=#X@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY296-E:79A8FQE<R!F<F]M
M(&-O;&QA8F]R871I;VYS(&%R92!R96-O<F1E9"!F;W(@86UO=6YT<R!D=64@
M=&\@=&AE($-O;7!A;GD@<F5L871E9"!T;R!R96EM8G5R<V%B;&4@<F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S(&9R;VT@=&AE(%4N4RX@1&5P87)T
M;65N="!O9B!(96%L=&@@86YD($AU;6%N(%-E<G9I8V5S(&]R(')O>6%L='D@
M<F5C96EV86)L97,@9G)O;2!3:&EO;F]G:28C,38P.R9A;7`[($-O+B!,=&0N
M(%1H97-E(')E8V5I=F%B;&5S(&%R92!E=F%L=6%T960@=&\@9&5T97)M:6YE
M(&EF(&%N>2!R97-E<G9E(&]R(&%L;&]W86YC92!S:&]U;&0@8F4@97-T86)L
M:7-H960@870@96%C:"!R97!O<G1I;F<@9&%T92X@070@36%R8V@@,S$L(#(P
M,34@86YD($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30L('1H92!#;VUP86YY(&AA
M9"!T:&4@9F]L;&]W:6YG(')E8V5I=F%B;&5S+CPO9F]N=#X@("`@#0H@("`@
M/"]D:78^/&)R+SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG
M/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B`@#0H@("`@("`@("`@
M/'1R/B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`@(`T*("`@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@
M#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@
M("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,3`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^
M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#DN.'!T)R!A;&EG;CTS1&-E;G1E<CX@#0H@("`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SY-87)C:"8C,38P.S,Q+"`R,#$U/"]F;VYT/B`@("`@#0H@
M("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-
M"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@
M("`@("`@(#PO='(^("`-"B`@("`@("`@("`\='(^(`T*("`@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P="<^("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B`@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@
M("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D
M:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`@#0H@("`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L
M:6=N/3-$8V5N=&5R/B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/D)I;&QE
M9#PO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@
M("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED)SX@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`@
M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@
M("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED)SX@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E
M<CX@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY5;F)I;&QE9#PO9F]N=#X@
M("`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T
M9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60G/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+W1D/B`@
M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@("`@#0H@("`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@
M(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60G/B`@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`-"B`@
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/E1O=&%L/"]F;VYT/B`@#0H@("`@("`@
M("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@
M(#PO='(^("`-"B`@("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CLG/B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-34E/B`@("`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P
M+C<U<'0G(&%L:6=N/3-$;&5F=#X@("`-"B`@("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^52Y3+B!$97!A<G1M96YT
M(&]F($AE86QT:"!A;F0@2'5M86X@4V5R=FEC97,\+V9O;G0^("`-"B`@("`@
M("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I
M=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*
M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@
M("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^
M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/B`@("`@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M<FEG:'0^("`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,X,C$R.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^
M("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@
M("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@("`-"B`@("`@("`@("`@
M("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/B`@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@("`-"B`@
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^-"PP.#<\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@
M("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO
M=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@
M("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXD/"]F;VYT/B`@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@
M("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@("`@#0H@("`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$<FEG:'0^("`@("`-"B`@("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-"PP.#<\+V9O;G0^("`@
M#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@
M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@
M("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@
M(#PO='(^("`-"B`@("`@("`@("`\='(^(`T*("`@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^("`-"B`@("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L
M:6=N/3-$;&5F=#X@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^4VAI;VYO9VDF(S$V,#LF86UP.R!#;RX@
M3'1D+CPO9F]N=#X@("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@
M("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<^(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@
M(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@
M(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+W1D/B`@("`-
M"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M+C%P="!S;VQI9"<^(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@("`@
M#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C$L-3`W/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@
M(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@
M(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)SX@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^
M("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O
M;&ED)SX@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@("`-"B`@("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,X,C$R.SPO9F]N=#X@("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@
M("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T
M9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G/B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*
M("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@
M("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G
M/B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`@(`T*("`@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#4P
M-SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@
M("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@
M("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-
M"B`@("`@("`@("`\+W1R/B`@#0H@("`@("`@("`@/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-34E/B`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@
M("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@
M("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*
M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@
M("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-
M"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@
M("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`\+W1R
M/B`@#0H@("`@("`@("`@/'1R/B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-34E('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`T<'@G/B`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS
M1&QE9G0^("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/E1O=&%L(')E8V5I=F%B;&5S/"]F;VYT/B`@("`@
M#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@
M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^
M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@
M("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^(`T*("`@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@("`-"B`@("`@("`@
M("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D
M;W5B;&4G/B`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@("`@#0H@
M("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C$L-3`W/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*
M("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T
M9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G/B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*
M("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@("`@#0H@("`@
M("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U
M<'0@9&]U8FQE)SX@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`@
M(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXT+#`X-SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^
M("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@
M(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X)SX@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^
M("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`@(`T*
M("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@
M#0H@("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXW-7!T(&1O=6)L92<^("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^
M("`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^-2PU.30\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO
M9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^(`T*
M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@
M("`@("`\+W1D/B`@("`-"B`@("`@("`@("`\+W1R/B`@#0H@("`@("`@("`@
M/'1R/B`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@
M("`@("`@("`@/'1D(&-O;'-P86X],T0Q,B!V86QI9VX],T1B;W1T;VT^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@
M("`@("`@("`\+W1R/B`@#0H@("`@("`@(#PO=&%B;&4^/&)R+SX\=&%B;&4@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/B`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0Q,"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#DN.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^1&5C96UB97(F(S$V,#LS,2P@,C`Q-#PO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/D)I;&QE9#PO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY5;F)I;&QE9#PO9F]N=#X@("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C
M96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/E1O=&%L/"]F;VYT
M/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G
M/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4U)3X@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))
M1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY5+E,N($1E<&%R=&UE
M;G0@;V8@2&5A;'1H(&%N9"!(=6UA;B!397)V:6-E<SPO9F]N=#X@("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#(Q,CL\+V9O;G0^("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(L-S<X
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N
M=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C(L-S<X/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M(#PO='(^("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4U)2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G
M(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY3:&EO;F]G:28C,38P.R9A;7`[($-O+B!,
M=&0N/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PP-S$\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/B`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C
M,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C$L,#<Q/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-"B`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-34E/B`@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS
M1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@
M("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-34E('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`T<'@G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX]
M,T1L969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/E1O=&%L(')E8V5I=F%B;&5S/"]F;VYT/B`@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P
M="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG
M:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXQ+#`W,3PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^,BPW-S@\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C,L.#0Y/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@(#PO=&%B;&4^/&)R
M+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X@("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
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M>2!T:&4@52Y3+B!';W9E<FYM96YT+CPO9F]N=#X@#0H@("`@/"]D:78^/&)R
M+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%
M.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^4F5C96EV86)L97,@9G)O;2!0<F]D=6-T(%-A;&5S/"]F;VYT/B`@#0H@
M("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9
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M92X\+V9O;G0^/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)Y+"!0;VQI8WD@6U!O
M;&EC>2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
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M=&]R>3PO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!
M="!-87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L(#(P,30L('1H92!#
M;VUP86YY)B,X,C$W.W,@:6YV96YT;W)Y(&-O;G-I<W1E9"!O9B!205!)5D%"
M(&9I;FES:&5D(&=O;V1S(&EN=F5N=&]R>2!A;F0@=V]R:R!I;B!P<F]C97-S
M+B!);G9E;G1O<GD@:7,@<W1A=&5D(&%T('1H92!L;W=E<B!O9B!C;W-T+"!D
M971E<FUI;F5D('5N9&5R('1H92!F:7)S="UI;BP@9FER<W0M;W5T("@F(S@R
M,C`[1DE&3R8C.#(R,3LI(&UE=&AO9"P@;W(@;6%R:V5T+B!4:&4@0V]M<&%N
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M;V1U8W1I;VX@;V8@:6YV96YT;W)I97,N/"]F;VYT/B`@("`@#0H@("`@/"]D
M:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M
M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY$=7)I;F<@,C`Q-"P@:6X@8V]N;F5C=&EO
M;B!W:71H('1H92!&1$$@87!P<F]V86P@;V8@4D%0259!0BP@=&AE($-O;7!A
M;GD@8F5G86X@8V%P:71A;&EZ:6YG(&-O<W1S(&%S<V]C:6%T960@=VET:"!T
M:&4@<')O9'5C=&EO;B!O9B!205!)5D%"(&EN=F5N=&]R:65S+CPO9F]N=#X@
M("`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,C=P="<^("`@("`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/E1H92!#;VUP86YY)B,X,C$W.W,@:6YV96YT;W)Y(&-O
M;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG(&%T($UA<F-H)B,Q-C`[,S$L(#(P
M,34@86YD($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30Z/"]F;VYT/B`@("`-"B`@
M("`@(#PO9&EV/CQB<B\^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A
M8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX@("`@#0H@("`@
M("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@
M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG
M;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q-3PO
M9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX
M<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SXR,#$T/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-S`E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T
M.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E=O
M<FL@:6X@<')O8V5S<SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,X,C$R.SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^,C8W/"]F;VYT/B`@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<P)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))
M1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY&:6YI<VAE9"!';V]D
M<SPO9F]N=#X@("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXQ+#(Q,#PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@
M<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT
M,38\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@
M("`@#0H@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.R<^("`@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W,"4^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW
M-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^3F5T(&EN=F5N=&]R:65S/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^,2PR,3`\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
M/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C8X,SPO9F]N=#X@("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G
M/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`\+W1A8FQE
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YT86YG:6)L92!!<W-E=',L($9I;FET92U,:79E9"P@4&]L:6-Y(%M0
M;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI
M8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY0871E
M;G1S(&%N9"!,:6-E;G-E<SPO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^5&AE($-O;7!A;GD@<V5E:W,@<&%T96YT('!R;W1E8W1I;VX@;VX@
M86QL(&EN=&5R;F%L;'D@9&5V96QO<&5D('!R;V-E<W-E<R!A;F0@<')O9'5C
M=',N($%L;"!P871E;G0@<F5L871E9"!C;W-T<R!A<F4@97AP96YS960@=&\@
M9V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@97AP96YS97,@=VAE;B!I;F-U
M<G)E9"!A<R!R96-O=F5R86)I;&ET>2!O9B!S=6-H(&5X<&5N9&ET=7)E<R!I
M<R!U;F-E<G1A:6XN/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!%>'!E;G-E<R!;
M4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L
M:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^06-C
M<G5E9"!%>'!E;G-E<SPO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
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M87)S(&9O<B!S97)V:6-E<R`@(`T*("`@("`@<&5R9F]R;65D+B!4:&4@0V]M
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M;G0^("`@(`T*("`@(#PO9&EV/CQB<B\^/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX@
M(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$-24^(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4^("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#(R-CL\+V9O;G0^("`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^
M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@]
M,T0X."4^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SYF965S
M('!A:60@=&\@0VQI;FEC86P@4F5S96%R8V@@3W)G86YI>F%T:6]N<R`H)B,X
M,C(P.T-23W,F(S@R,C$[*2!I;B!C;VYN96-T:6]N('=I=&@@<')E8VQI;FEC
M86P@86YD('1O>&EC;VQO9WD@<W1U9&EE<R!A;F0@8VQI;FEC86P@=')I86QS
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@/"]T86)L
M93X\8G(O/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^(`T*("`@("`@("`\='(^("`@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE
M('=I9'1H/3-$-24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C.#(R-CL\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0X."4^("`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SYF965S('!A:60@=&\@:6YV97-T:6=A
M=&EV92!S:71E<R!I;B!C;VYN96-T:6]N('=I=&@@8VQI;FEC86P@=')I86QS
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@/"]T86)L
M93X\8G(O/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^(`T*("`@("`@("`\='(^("`@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE
M('=I9'1H/3-$-24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C.#(R-CL\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0X."4^("`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SYF965S('!A:60@=&\@8V]N=')A8W0@
M;6%N=69A8W1U<F5R<R!I;B!C;VYN96-T:6]N('=I=&@@=&AE('!R;V1U8W1I
M;VX@;V8@;W5R(')A=R!M871E<FEA;',L(&1R=6<@<W5B<W1A;F-E(&%N9"!D
M<G5G('!R;V1U8W1S.R8C,38P.V%N9#PO9F]N=#X@("`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T
M<CX@("`@(`T*("`@("`@/"]T86)L93X\8G(O/CQT86)L92!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;B<^(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$-24^(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4^("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#(R-CL\+V9O;G0^("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED
M=&@],T0X."4^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SYP
M<F]F97-S:6]N86P@9F5E<RX\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@
M("`-"B`@("`@(#PO=&%B;&4^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@("`@(`T*("`@("`@
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M(#(P,34@86YD($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@8V%R<GEI;F<@=F%L
M=64@;V8@("`@(`T*("`@("`@86-C<G5E9"!E>'!E;G-E<R!A<'!R;WAI;6%T
M97,@=&AE:7(@9F%I<B!V86QU92!D=64@=&\@=&AE:7(@<VAO<G0M=&5R;2!S
M971T;&5M96YT+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!487@L(%!O;&EC>2!;
M4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L
M:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^26YC
M;VUE(%1A>&5S/"]F;VYT/B`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@
M#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
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M;R!R979E<G-E+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D($]T:&5R($-O
M;7!R96AE;G-I=F4@26YC;VUE($QO<W,@6U!O;&EC>2!497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=4
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M96AE;G-I=F4@*$QO<W,I($EN8V]M93PO9F]N=#X@(`T*("`@(#PO9&EV/CQB
M<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M87)C:"`S,2P@,C`Q-2P@<F5A;&EZ960@9V%I;G,@;V8@)#@@=V5R92!R96-L
M87-S:69I960@;W5T(&]F(&%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I
M=F4@*&QO<W,I(&EN8V]M92X@3F\@<F5C;&%S<VEF:6-A=&EO;G,@;W5T(&]F
M(&%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@*&QO<W,I(&EN8V]M
M92!W97)E(')E8V]R9&5D(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H)B,Q-C`[,S$L(#(P,30N/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!2
M96-O9VYI=&EO;BP@4&]L:6-Y(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SY2979E;G5E(%)E8V]G;FET:6]N/"]F;VYT/B`@
M(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y
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M;G0@97AI<W1S.R`H:6DI)B,Q-C`[9&5L:79E<GD@:&%S(&]C8W5R<F5D(&]R
M('-E<G9I8V5S(&AA=F4@8F5E;B!R96YD97)E9#L@*&EI:2DF(S$V,#MT:&4@
M<V5L;&5R)B,X,C$W.W,@<')I8V4@=&\@=&AE(&)U>65R(&ES(&9I>&5D(&]R
M(&1E=&5R;6EN86)L93L@86YD("AI=BDF(S$V,#MC;VQL96-T86)I;&ET>2!I
M<R!R96%S;VYA8FQY(&%S<W5R960N/"]F;VYT/B`@("`-"B`@("`\+V1I=CX\
M8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U19
M3$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D-O;&QA8F]R871I=F4@
M86YD($]T:&5R(%)E<V5A<F-H(&%N9"!$979E;&]P;65N="!!<G)A;F=E;65N
M=',@86YD(%)O>6%L=&EE<SPO9F]N=#X@("`-"B`@("`\+V1I=CX\8G(O/CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
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M('!R;W-P96-T:79E;'DN/"]F;VYT/B`@(`T*("`@(#PO9&EV/CQB<B\^/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M<W5R960N/"]F;VYT/B`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
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M96YT(&]F('-P96-I9FEE9"!E=F5N=',@:68@*#$I)B,Q-C`[=&AE(&5V96YT
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M<&%R=&UE;G0@;V8@2&5A;'1H(&%N9"!(=6UA;B!397)V:6-E<R`H)B,X,C(Q
M.T)!4D1!+TA(4R8C.#(R,3LI(&%N9"!T:&4@3F%T:6]N86P@26YS=&ET=71E
M(&]F($%L;&5R9WD@86YD($EN9F5C=&EO=7,@1&ES96%S97,@*"8C.#(R,#M.
M24%)1"](2%,F(S@R,C$[*2P@<F5V96YU92!I<R!R96-O9VYI>F5D(&%S(')E
M:6UB=7)S86)L92`@(`T*("`@("`@9&ER96-T(&%N9"!I;F1I<F5C="!C;W-T
M<R!A<F4@:6YC=7)R960N/"]F;VYT/B`@("`-"B`@("`\+V1I=CX\8G(O/CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPA+2U%1E!L86-E:&]L9&5R+2T^/&9O
M;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI
M;F4G/E!R;V1U8W0@4V%L97,\+V9O;G0^/"]F;VYT/B`@#0H@("`@/"]D:78^
M/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!R979E;G5E(&9O
M<B!S86QE<R!O9B!205!)5D%"('=H96X@=&ET;&4@86YD('-U8G-T86YT:6%L
M;'D@86QL('1H92!R:7-K<R!A;F0@<F5W87)D<R!O9B!O=VYE<G-H:7`@:&%V
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M86QT:"!C87)E(&]R9V%N:7IA=&EO;G,N)B,Q-C`[/"]F;VYT/B`@("`@#0H@
M("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS
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M:&5R(&=O=F5R;FUE;G0@86=E;F-I97,@86YD('-A;&5S(&1I<V-O=6YT<R`H
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M/"]F;VYT/CPO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`@
M("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
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M;VYT/B`@("`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`@(`T*("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!#;VUP
M86YY(&%C8V]U;G1S(&9O<B!T:&5S92!S86QE<R!D961U8W1I;VYS(&EN(&%C
M8V]R9&%N8V4@=VET:"!A=71H;W)I=&%T:79E(&=U:61A;F-E(&]N(')E=F5N
M=64@<F5C;V=N:71I;VX@=VAE;B!C;VYS:61E<F%T:6]N(&ES(&=I=F5N(&)Y
M(&$@=F5N9&]R('1O(&$@8W5S=&]M97(N)B,Q-C`[/"]F;VYT/B`@("`@#0H@
M("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS
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M>'1E<FYA;"!S;W5R8V5S+B8C,38P.SPO9F]N=#X@("`-"B`@("`\+V1I=CX\
M8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[
M($1)4U!,05DZ(&EN;&EN92<^4F5B871E<R!A;F0@0VAA<F=E8F%C:W,\+V9O
M;G0^/"]F;VYT/B`@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
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M<V%L97,N/"]F;VYT/B`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
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M<F%L;'D@<75A;&EF:65D('!R;V=R86US+CPO9F]N=#X@("`-"B`@("`\+V1I
M=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY4:&4@86UO=6YT(&]F('1H92!R97-E<G9E(&9O<B!R
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M(%1O('1H92!E>'1E;G0@86-T=6%L(')E8F%T97,@("`@#0H@("`@("!A;F0@
M8VAA<F=E8F%C:W,@9&EF9F5R(&9R;VT@=&AE($-O;7!A;GDF(S@R,3<[<R!E
M<W1I;6%T97,L(&%D9&ET:6]N86P@<F5S97)V97,@;6%Y(&)E(')E<75I<F5D
M(&]R(')E<V5R=F5S(&UA>2!N965D('1O(&)E(')E=F5R<V5D+"!E:71H97(@
M;V8@=VAI8V@@=V]U;&0@:6UP86-T(&-U<G)E;G0@<&5R:6]D('!R;V1U8W0@
M<F5V96YU92XF(S$V,#L\+V9O;G0^(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC
M.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^1&ES8V]U;G1S(&%N9"!386QE<R!);F-E
M;G1I=F5S/"]F;VYT/B`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
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M8V@@<')O9'5C="!S86QE<RXF(S$V,#L\+V9O;G0^("`-"B`@("`\+V1I=CX\
M8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[
M($1)4U!,05DZ(&EN;&EN92<^4')O9'5C="!2971U<FYS/"]F;VYT/CPO9F]N
M=#X@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@
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M<W!E8VEA;'1Y(&1I<W1R:6)U=&]R+B8C,38P.SPO9F]N=#X@(`T*("`@(#PO
M9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET
M86QI8SL@1$E34$Q!63H@:6YL:6YE)SY!9'9E<G1I<VEN9SPO9F]N=#X\+V9O
M;G0^("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@96YG
M86=E<R!I;B!V97)Y(&QI;6ET960@9&ES=')I8G5T:6]N(&%N9"!D:7)E8W0M
M<F5S<&]N<V4@861V97)T:7-I;F<@=VAE;B!P<F]M;W1I;F<@4D%0259!0BX\
M+V9O;G0^("`-"B`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#(W<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!R
M96-O<F1E9"!T:&4@9F]L;&]W:6YG(')E=F5N=65S(&9O<B!T:&4@=&AR964@
M;6]N=&AS(&5N9&5D($UA<F-H)B,Q-C`[,S$L(#(P,34@86YD(#(P,30Z/"]F
M;VYT/B`@#0H@("`@/"]D:78^/&)R+SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/B`@
M#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#`N
M-7!T)SX@("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P+C5P="<^("`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^,C`Q-3PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M+C5P="<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,2XQ<'0@<V]L:60G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q-#PO9F]N=#X@("`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\
M+W1R/B`@("`@#0H@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.R<^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/B`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P
M="<@86QI9VX],T1L969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E!R;V1U8W0@<V%L97,L(&YE=#PO9F]N
M=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\
M+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG
M:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXU,S<\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#(Q,CL\+V9O;G0^("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/B`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'
M2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E)O>6%L='D@<F5V96YU
M93PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PU,3@\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PX,C$\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<P)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@
M34%21TE.+5))1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#;VQL
M86)O<F%T:79E(&%N9"!O=&AE<B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M<F5V96YU97,Z/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@
M("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,S9P=#L@34%21TE.+5))1TA4.B`P+C<U
M<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY5+E,N($1E<&%R=&UE;G0@;V8@2&5A
M;'1H(&%N9"!(=6UA;B!397)V:6-E<SPO9F]N=#X@("`@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^-"PT-S4\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#,T,3PO9F]N=#X@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-S`E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P+C5P="<^("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)3BU224=(
M5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^4VAI;VYO9VD@*$IA<&%N
M*3PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,"XU<'0G/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,CDV/"]F;VYT/B`@("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P+C5P
M="<^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXR.38\+V9O;G0^("`@(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0W,"4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^("`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XW-7!T)R!A;&EG;CTS1&QE9G0^("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;"!C;VQL86)O<F%T
M:79E(&%N9"!O=&AE<B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@<F5V96YU
M97,\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT+#<W,3PO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R
M:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C$L-C,W/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@
M("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^
M("`@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M,"4^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R
M/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG
M;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^5&]T86P@<F5V96YU97,\+V9O;G0^("`@("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U
M<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I
M9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^-BPX,C8\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C,L-#4X/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@(#PO=&%B;&4^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E
M87)C:"!A;F0@1&5V96QO<&UE;G0@17AP96YS92P@4&]L:6-Y(%M0;VQI8WD@
M5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY297-E87)C:"!A
M;F0@1&5V96QO<&UE;G0@17AP96YS97,\+V9O;G0^("`@(`T*("`@(#PO9&EV
M/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.
M1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)SX@#0H@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GDF(S@R,3<[<R!R97-E87)C
M:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@87)E(&-H87)G960@=&\@97AP96YS
M92!W:&5N(&EN8W5R<F5D+B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP
M96YS97,@:6YC;'5D92!A;&P@9&ER96-T(&%N9"!I;F1I<F5C="!D979E;&]P
M;65N="!C;W-T<R!R96QA=&5D('1O('1H92!D979E;&]P;65N="!O9B!T:&4@
M0V]M<&%N>28C.#(Q-SMS('!O<G1F;VQI;R!O9B!P<F]D=6-T(&-A;F1I9&%T
M97,N($%D=F%N8V4@<&%Y;65N=',@9F]R(&=O;V1S(&]R('-E<G9I8V5S('1H
M870@=VEL;"!B92!U<V5D(&]R(')E;F1E<F5D(&9O<B!F=71U<F4@<F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT(&%C=&EV:71I97,@87)E(&1E9F5R<F5D(&%N
M9"!C87!I=&%L:7IE9"X@4W5C:"!A;6]U;G1S(&%R92!R96-O9VYI>F5D(&%S
M(&5X<&5N<V4@=VAE;B!T:&4@<F5L871E9"!G;V]D<R!A<F4@9&5L:79E<F5D
M(&]R('1H92!R96QA=&5D('-E<G9I8V5S(&%R92!P97)F;W)M960N(%)E<V5A
M<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E<R!I;F-L=61E+"!A;6]N9R!O
M=&AE<B!I=&5M<RP@<&5R<V]N;F5L(&-O<W1S+"!I;F-L=61I;F<@<V%L87)I
M97,@86YD(&)E;F5F:71S+"!M86YU9F%C='5R:6YG(&-O<W1S+"!C;&EN:6-A
M;"P@<F5G=6QA=&]R>2P@86YD('1O>&EC;VQO9WD@<V5R=FEC97,@<&5R9F]R
M;65D(&)Y($-23W,L(&UA=&5R:6%L<R!A;F0@<W5P<&QI97,L(&%N9"!O=F5R
M:&5A9"!A;&QO8V%T:6]N<R!C;VYS:7-T:6YG(&]F('9A<FEO=7,@861M:6YI
M<W1R871I=F4@86YD(&9A8VEL:71I97,@<F5L871E9"!C;W-T<RX@36]S="!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&UA;G5F86-T=7)I;F<@86YD(&-L:6YI
M8V%L(&%N9"!P<F5C;&EN:6-A;"!S='5D:65S(&%R92`@("`@#0H@("`@("!P
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M9F]R;65D+CPO9F]N=#X@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)SX@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
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M=&0N("@F(S@R,C`[25),)B,X,C(Q.RDL(&%N9"!T:&4@56YI=F5R<VET>2!O
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M86YC92!P87EM96YT<R!A<R!I;F-U<G)E9"X\+V9O;G0^("`@#0H@("`@/"]D
M:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M
M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY$969E<G)E9"!C;VQL86)O<F%T:6]N(&5X
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M;G5E+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@
M3W!T:6]N(&%N9"!);F-E;G1I=F4@4&QA;G,@4&]L:6-Y(%M0;VQI8WD@5&5X
M="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX\+V9O;G0^(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
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M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R
M97-T($5X<&5N<V4@86YD($1E9F5R<F5D($9I;F%N8VEN9R!#;W-T<R!;4&]L
M:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[
M($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^26YT97)E
M<W0@17AP96YS92!A;F0@1&5F97)R960@1FEN86YC:6YG($-O<W1S/"]F;VYT
M/B`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/DEN=&5R97-T(&5X<&5N<V4@9F]R('1H92!T
M:')E92!M;VYT:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q-2!A;F0@,C`Q
M-"!W87,@)#$L,S$U(&%N9"`D,2PR-#(L(')E<W!E8W1I=F5L>2P@86YD(')E
M;&%T97,@=&\@=&AE(&ES<W5A;F-E(&]F('1H92!0:&%234$@3F]T97,@*&1E
M9FEN960@:6X@3F]T92`T*2X@0V]S=',@9&ER96-T;'D@87-S;V-I871E9"!W
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M;B!I;G1E<F5S="!E>'!E;G-E('=A<R`D,3$P(&9O<B!E86-H(&]F('1H92!T
M:')E92!M;VYT:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q-2!A;F0@,C`Q
M-"X\+V9O;G0^/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N8WD@2&5D9V4@06=R965M
M96YT(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z
M(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SY#=7)R96YC>2!(961G92!!9W)E96UE;G0\+V9O;G0^("`@("`-"B`@("`\
M+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(W<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/B`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY);B!C;VYN96-T:6]N('=I=&@@=&AE(&ES<W5A
M;F-E(&)Y(%)O>6%L='D@4W5B(&]F('1H92!0:&%234$@3F]T97,L('1H92!#
M;VUP86YY(&5N=&5R960@:6YT;R!A($-U<G)E;F-Y($AE9&=E($%G<F5E;65N
M="`H9&5F:6YE9"!I;B!.;W1E(#0I('1O(&AE9&=E(&-E<G1A:6X@<FES:W,@
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M-C`[,S$L(#(P,34@86YD(#(P,30@<F5S=6QT960@:6X@82!G86EN(&]F("0T
M-C0@86YD(&$@;&]S<R!O9B`D,2PU,C8L(')E<W!E8W1I=F5L>2X@36%R:RUT
M;RUM87)K970@861J=7-T;65N=',@87)E(&1E=&5R;6EN960@8GD@82!T:&ER
M9"!P87)T>2!P<FEC:6YG(&UO9&5L('1H870@=7-E<R!Q=6]T960@<')I8V5S
M(&EN(&UA<FME=',@=&AA="!A<F4@;F]T(&%C=&EV96QY('1R861E9"!A;F0@
M9F]R('=H:6-H('-I9VYI9FEC86YT(&EN<'5T<R!A<F4@;V)S97)V86)L92!D
M:7)E8W1L>2!O<B!I;F1I<F5C=&QY+"!R97!R97-E;G1I;F<@3&5V96P@,B!I
M;B!T:&4@9F%I<B!V86QU92!H:65R87)C:'D@87,@9&5F:6YE9"!B>2!5+E,N
M($=!05`N(%1H92!#;VUP86YY(&ES(&%L<V\@(`T*("`@("`@<F5Q=6ER960@
M=&\@<&]S="!C;VQL871E<F%L(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@;6%R
M:RUT;RUM87)K970@861J=7-T;65N=',@8F%S960@;VX@=&AR97-H;VQD<R!D
M969I;F5D(&EN('1H92!#=7)R96YC>2!(961G92!!9W)E96UE;G0N($%S(&]F
M($UA<F-H)B,Q-C`[,S$L(#(P,34@86YD($1E8V5M8F5R(#,Q+"`R,#$T+"!N
M;R!H961G92!C;VQL871E<F%L('=A<R!P;W-T960@=6YD97(@=&AE(&%G<F5E
M;65N="X\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%87)N:6YG<R!097(@4VAA<F4L(%!O;&EC
M>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I
M=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M3F5T($QO<W,@4&5R(%-H87)E/"]F;VYT/B`@("`@#0H@("`@/"]D:78^/&)R
M+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M:"8C,38P.S,Q+"`R,#$U(&%N9"`R,#$T(&1O97,@;F]T(&EN8VQU9&4@,RPT
M-3@@86YD(#4L,C`V+"!R97-P96-T:79E;'DL(&]F('-U8V@@<&]T96YT:6%L
M(&-O;6UO;B!S:&%R97,L(&%S('1H96ER(&EM<&%C="!W;W5L9"!B92!A;G1I
M+61I;'5T:79E+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5S92!O9B!%<W1I;6%T97,L(%!O
M;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+5-464Q%
M.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^57-E(&]F($5S=&EM871E<SPO9F]N=#X@#0H@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^5&AE('!R97!A<F%T:6]N(&]F(&9I;F%N8VEA;"!S=&%T96UE;G1S
M(&EN(&-O;F9O<FUI='D@=VET:"!5+E,N($=!05`@<F5Q=6ER97,@=&AE($-O
M;7!A;GD@=&\@;6%K92!E<W1I;6%T97,@86YD(&%S<W5M<'1I;VYS('1H870@
M869F96-T('1H92!A;6]U;G1S(')E<&]R=&5D(&EN('1H92!F:6YA;F-I86P@
M<W1A=&5M96YT<RX@06-T=6%L(')E<W5L=',@8V]U;&0@9&EF9F5R(&9R;VT@
M=&AO<V4@97-T:6UA=&5S+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;F-E;G1R871I;VX@
M;V8@36%R:V5T(%)I<VL@6U!O;&EC>2!497AT($)L;V-K73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M+V9O;G0^("`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX@#0H@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
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M.3`E(&]F(&%L;"!205!)5D%"('!R;V1U8W0@<V%L97,@=&\@9&%T92!A;F0@
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M+CPO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/B`-
M"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4@
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M979E;G5E<RX@5&AE(&-O;7!L971I;VXL(&%S('=I=&@@=&AE($IU;F4@,S`L
M(#(P,30@0D%21$$O2$A3('!E<F%M:79I<B!D979E;&]P;65N="!C;VYT<F%C
M="P@;W(@=&5R;6EN871I;VX@;V8@=&AE($Y)04E$+TA(4R!A;F0@0D%21$$O
M2$A3($)#6#0T,S`@<')O9W)A;7,O8V]L;&%B;W)A=&EO;B!C;W5L9"!N96=A
M=&EV96QY(&EM<&%C="!T:&4@0V]M<&%N>28C.#(Q-SMS(&9U='5R92!#;VYS
M;VQI9&%T960@4W1A=&5M96YT<R!O9B!#;VUP<F5H96YS:79E($QO<W,@86YD
M($-A<V@@1FQO=W,N($EN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!A;'-O(')E
M8V]G;FEZ97,@<F]Y86QT>2!R979E;G5E(&9R;VT@=&AE(&YE="!S86QE<R!O
M9B!205!)04-403L@(`T*("`@("`@:&]W979E<BP@=&AE('5N9&5R;'EI;F<@
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M+CPO9F]N=#X@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#(W
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SY2:7-K
M<R!F<F]M(%1H:7)D(%!A<G1Y($UA;G5F86-T=7)I;F<@86YD($1I<W1R:6)U
M=&EO;B!#;VYC96YT<F%T:6]N/"]F;VYT/CPO9F]N=#X@("`@#0H@("`@/"]D
M:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$:G5S=&EF>3X@("`@#0H@("`@("`\9F]N="!S='EL93TS
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N8V5N=')A=&EO;B!2:7-K+"!#<F5D:70@4FES:RP@4&]L:6-Y
M(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET
M86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY#
M<F5D:70@4FES:SPO9F]N=#X@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M0V%S:"!E<75I=F%L96YT<R!A;F0@:6YV97-T;65N=',@87)E(&9I;F%N8VEA
M;"!I;G-T<G5M96YT<R!W:&EC:"!P;W1E;G1I86QL>2!S=6)J96-T('1H92!#
M;VUP86YY('1O(&-O;F-E;G1R871I;VX@;V8@<FES:R!T;R!T:&4@97AT96YT
M(')E8V]R9&5D(&]N('1H92!#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',N
M(%1H92!#;VUP86YY(&1E<&]S:71S(&5X8V5S<R!C87-H('=I=&@@;6%J;W(@
M9FEN86YC:6%L(&EN<W1I='5T:6]N<R!I;B!T:&4@56YI=&5D(%-T871E<RX@
M0F%L86YC97,@;6%Y(&5X8V5E9"!T:&4@86UO=6YT(&]F(&EN<W5R86YC92!P
M<F]V:61E9"!O;B!S=6-H(&1E<&]S:71S+B!4:&4@0V]M<&%N>2!B96QI979E
M<R!I="!H87,@97-T86)L:7-H960@9W5I9&5L:6YE<R!F;W(@:6YV97-T;65N
M="!O9B!I=',@97AC97-S(&-A<V@@<F5L871I=F4@=&\@9&EV97)S:69I8V%T
M:6]N(&%N9"!M871U<FET:65S('1H870@;6%I;G1A:6X@<V%F971Y(&%N9"!L
M:7%U:61I='DN(%1O(&UI;FEM:7IE('1H92!E>'!O<W5R92!D=64@=&\@861V
M97)S92!S:&EF=',@:6X@:6YT97)E<W0@<F%T97,L('1H92!#;VUP86YY(&UA
M:6YT86EN<R!A('!O<G1F;VQI;R!O9B!I;G9E<W1M96YT<R!W:71H(&%N(&%V
M97)A9V4@;6%T=7)I='D@;V8@87!P<F]X:6UA=&5L>2`Q."!M;VYT:',@;W(@
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M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.97<@06-C
M;W5N=&EN9R!0<F]N;W5N8V5M96YT<RP@4&]L:6-Y(%M0;VQI8WD@5&5X="!"
M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SY296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO9F]N
M=#X@("`@(`T*("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,C=P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DEN($%P<FEL(#(P,34L('1H92`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/D9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!"
M;V%R9#PO9F]N=#X@*"8C.#(R,#M&05-")B,X,C(Q.RD@:7-S=65D($%C8V]U
M;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`H)B,X,C(P.T%3528C.#(R,3LI($YO
M+B`R,#$U+3`S+"`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,G
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M871E;65N=',N/"]F;VYT/CPO9F]N=#X\+V9O;G0^(`T*("`@("`@/"]D:78^
M/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R-W!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X@("`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY);B!-87D@,C`Q-"P@=&AE($9!4T(@:7-S=65D($%352`R,#$T+3`Y
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M969F96-T:79E(&9O<B!A;FYU86P@<&5R:6]D<RP@86YD("`-"B`@("`@("`@
M:6YT97)I;2!P97)I;V1S('=I=&AI;B!T:&]S92!A;FYU86P@<&5R:6]D<RP@
M8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$V+B!%87)L>2!A9&]P
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M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-C
M839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P
M,V(Q.&-B,38S,#DO5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M2D-!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#$@+2!3:6=N:69I
M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A486)L97,I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN
M9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%V86EL86)L92UF;W(M<V%L92!396-U<FET
M:65S(%M486)L92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX@(`T*("`@("`@("`\='(^
M("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O;'-P
M86X],T0Q."!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,3<N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/DUA<F-H)B,Q-C`[,S$L(#(P,34\+V9O;G0^("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@
M("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^06UO<G1I>F5D/"]F;VYT/B`@("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E
M<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^0V]S=#PO9F]N=#X@("`@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/D%C8W)U960\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^26YT97)E<W0\+V9O;G0^("`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@
M86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/D=R
M;W-S/"]F;VYT/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q
M+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/E5N<F5A;&EZ960\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^1V%I;G,\+V9O;G0^("`@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A
M;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^1W)O
M<W,\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N
M.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^56YR96%L:7IE9#PO9F]N=#X@("`@(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SY,;W-S97,\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P="<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N
M/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY%<W1I;6%T
M960\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX
M<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SY&86ER)B,Q-C`[5F%L=64\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@
M("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M)SX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0U,"4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^3V)L:6=A=&EO;G,@;V8@52Y3+B!';W9E<FYM96YT(&%N
M9"!I=',@86=E;F-I97,\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT
M/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C(P+#,P,CPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C0R/"]F;VYT/B`@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C,\+V9O;G0^("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,CPO9F]N=#X@("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86XG/BD\+V9O;G0^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,C`L,S0U/"]F;VYT/B`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0U,"4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#$X<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^0V]R<&]R871E(&1E8G0@<V5C=7)I=&EE<SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^,C@L,3,Y/"]F;VYT/B`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-#0\+V9O;G0^("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C<\+V9O
M;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXH,3,\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#XF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(X+#(Y-SPO
M9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*
M("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CLG/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4P)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY#97)T:69I8V%T97,@;V8@9&5P;W-I=#PO9F]N=#X@("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L
M:60G/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ
M<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C$Q+#8R-3PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S
M;VQI9"<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,34\
M+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV/"]F;VYT/B`@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T
M('-O;&ED)SX@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,3(\+V9O;G0^("`@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI
M9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N)SXI/"]F;VYT/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L
M:60G/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ
M<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C$Q+#8S-#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R
M/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4P)3X@("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-R4^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4P)2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;"!I;G9E<W1M96YT<SPO9F]N=#X@
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^-C`L,#8V/"]F;VYT/B`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G
M/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`Q/"]F;VYT/B`@("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T
M(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@-'!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^
M("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS-CPO9F]N
M=#X@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-R4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O
M=6)L92<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH
M,C<\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^*3PO9F]N=#XF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@-'!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV,"PR-S8\+V9O;G0^
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW
M-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@
M("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-3`E/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-R4^("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L92!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-R4^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R
M/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,C`@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@
M("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!C;VQS<&%N/3-$,3@@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#$W+CAP="<@86QI9VX],T1C96YT97(^("`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SY$96-E;6)E<B8C,38P.S,Q+"`R,#$T/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R
M/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY!;6]R=&EZ960\+V9O;G0^
M("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N
M/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY#;W-T/"]F
M;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^06-C<G5E9#PO9F]N=#X@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY);G1E<F5S=#PO9F]N=#X@("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^1W)O<W,\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^56YR96%L:7IE9#PO9F]N=#X@("`@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY'86EN<SPO9F]N=#X@("`@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SY'<F]S<SPO9F]N=#X@("`@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SY5;G)E86QI>F5D/"]F;VYT/B`@("`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/DQO<W-E<SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP
M="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/D5S=&EM871E9#PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/D9A:7(F(S$V,#M686QU93PO9F]N=#X@("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@
M("`@(`T*("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CLG/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#4P)3X@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY/8FQI9V%T:6]N<R!O9B!5+E,N($=O=F5R
M;FUE;G0@86YD(&ET<R!A9V5N8VEE<SPO9F]N=#X@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I
M9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,C`L,S`W/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C(\+V9O;G0^("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/B`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,X,C$R.SPO9F]N
M=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B@R,SPO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^*3QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(S+#,P-CPO9F]N=#X@
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@
M("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-3`E/B`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D-O<G!O<F%T92!D96)T('-E8W5R:71I97,\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(W+#$U,CPO9F]N=#X@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,34Q/"]F
M;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C4\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H
M=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B@T-SPO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI/"]F;VYT
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M,C<L,C8Q/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R
M/B`@("`@#0H@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.R<^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3`E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/D-E<G1I9FEC871E<R!O9B!D97!O<VET/"]F;VYT/B`@("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q+C%P="!S;VQI9"<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT
M/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,3$L.#,X/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T
M('-O;&ED)SX@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#<E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#$N,7!T('-O;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXV/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,X,C$R.SPO9F]N=#X@
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P
M="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#8S/"]F;VYT/B`@("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L
M:60G/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O
M;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,2PW
M.#$\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@
M(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0U,"4^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0W)3X@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED
M9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^("`@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,"4@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#1P>"<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^5&]T86P@:6YV97-T;65N=',\+V9O;G0^("`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW
M-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C4Y+#(Y-SPO9F]N=#X@(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
M/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$W.3PO9F]N=#X@("`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B
M;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#1P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-3PO9F]N=#X@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@
M9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`T<'@G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W)2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@
M("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@Q,S,\+V9O
M;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/BD\+V9O;G0^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-3DL,S0X/"]F;VYT/B`@#0H@
M("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D
M;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`\
M+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^079A:6QA8FQE(&9O<B!386QE(%-E8W5R:71I97,@1&5B="!-
M871U<FET:65S($9A:7(@5F%L=64@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8V5L;'!A9&1I;F<]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG
M/B`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#<P)3X@("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1M:61D;&4@
M=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$;6ED9&QE('=I9'1H
M/3-$,3(E/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$
M,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,3(E/B`@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@
M("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T)SX@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX
M<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SXR,#$U/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/C(P,30\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@
M("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@
M("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0W,"4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^36%T=7)I;F<@:6X@;VYE('EE87(@;W(@;&5S<SPO9F]N=#X@("`@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3DL,38\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/C`\+V9O;G0^/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C$X+#(S,CPO9F]N=#X@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-S`E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q
M.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/DUA='5R:6YG(&%F=&5R(&]N92!Y96%R('1H<F]U9V@@='=O('EE87)S/"]F
M;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR.2PV-38\+V9O;G0^
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M,C4L-#4Y/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R
M/B`@("`@#0H@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.R<^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T
M/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/DUA='5R:6YG(&%F=&5R('1W;R!Y96%R<SPO9F]N=#X@("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@
M<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ
M,2PT-CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^,#PO9F]N=#X\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T
M('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT
M/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,34L-C4W/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/B`@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS
M1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&UI9&1L92!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<P)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.
M+5))1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;"!I;G9E
M<W1M96YT<SPO9F]N=#X@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-C`L,C<V/"]F;VYT
M/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U
M8FQE)SX@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-3DL,S0X
M/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@
M("`@#0H@("`@("`\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@4F5C96EV86)L97,@
M9G)O;2!#;VQL86)O<F%T:6]N<R!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!C96QL<&%D9&EN9STS
M1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^
M("`-"B`@("`@("`@("`\='(^(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P="<^("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@("`@
M#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C
M,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@
M("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0Q
M,"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED)SX@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@.2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`-
M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/DUA<F-H)B,Q-C`[,S$L(#(P,34\
M+V9O;G0^("`@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@
M("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED)SX@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]T9#X@("`@#0H@("`@("`@("`@/"]T<CX@(`T*("`@("`@("`@(#QT<CX@
M#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P="<^("`@("`-"B`@("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@
M("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@
M("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@("`-
M"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^0FEL;&5D/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I
M=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B`@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@
M#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@
M/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@
M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`@#0H@("`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX<'0G
M(&%L:6=N/3-$8V5N=&5R/B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/E5N
M8FEL;&5D/"]F;VYT/B`@("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@
M("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9"<^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M="<^("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@
M(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9"<^("`@("`-"B`@("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX]
M,T1C96YT97(^(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^5&]T86P\+V9O
M;G0^("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO
M=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED)SX@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]T9#X@
M("`@#0H@("`@("`@("`@/"]T<CX@(`T*("`@("`@("`@(#QT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^(`T*("`@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24^
M("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-
M05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`@(`T*("`@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY5
M+E,N($1E<&%R=&UE;G0@;V8@2&5A;'1H(&%N9"!(=6UA;B!397)V:6-E<SPO
M9F]N=#X@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@
M/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@("`@
M("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@
M("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B0\+V9O;G0^("`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@
M("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1R:6=H=#X@("`@(`T*("`@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT
M/B`@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO
M=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@
M("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV
M/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@
M("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`@
M(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@
M("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4^("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R
M:6=H=#X@("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXT+#`X-SPO9F]N=#X@("`-"B`@("`@("`@("`@
M("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*
M("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\
M+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`@(`T*("`@("`@("`@("`@("`\
M+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^
M("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`@(`T*("`@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT
M+#`X-SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@
M("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@
M(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@
M("`@#0H@("`@("`@("`@/"]T<CX@(`T*("`@("`@("`@(#QT<CX@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#4U)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@(`T*("`@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'
M2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`@(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY3:&EO;F]G:28C
M,38P.R9A;7`[($-O+B!,=&0N/"]F;VYT/B`@("`-"B`@("`@("`@("`@("`@
M/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@#0H@("`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-
M"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@
M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@
M("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@#0H@("`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$<FEG:'0^("`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,2PU,#<\+V9O;G0^("`@#0H@("`@("`@
M("`@("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L
M:60G/B`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@
M(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`-"B`@("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@
M("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O
M;&ED)SX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]T
M9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,2XQ<'0@<V]L:60G/B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H
M=#X@("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/B`@("`-"B`@("`@("`@("`@
M("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^
M("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@
M("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<^(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@
M("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G
M/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+W1D/B`@
M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q+C%P="!S;VQI9"<^(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@
M("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C$L-3`W/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I
M=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@
M("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@
M("`@(#PO=&0^("`@(`T*("`@("`@("`@(#PO='(^("`-"B`@("`@("`@("`\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24^(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I
M=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@
M("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D
M:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@
M("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO
M9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*
M("`@("`@("`@(#PO='(^("`-"B`@("`@("`@("`\='(^(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U
M-24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P
M+C<U<'0G(&%L:6=N/3-$;&5F=#X@("`-"B`@("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^5&]T86P@<F5C96EV86)L
M97,\+V9O;G0^("`@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@
M("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@-'!X)SX@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@
M#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@
M/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@
M#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@("`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^
M("`@(`T*("`@("`@("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T
M9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M<FEG:'0^("`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^,2PU,#<\+V9O;G0^("`@#0H@("`@("`@("`@
M("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L
M92<^(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@
M("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#1P>"<^(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^("`@#0H@("`@("`@("`@
M("`@(#PO9&EV/B`@#0H@("`@("`@("`@("`\+W1D/B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L
M92<^(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`@(`T*("`@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F
M;VYT/B`@("`-"B`@("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@
M(#PO=&0^("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1')I9VAT/B`@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C0L,#@W/"]F;VYT/B`@(`T*("`@("`@
M("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D
M;W5B;&4G/B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@("`@("`@("`\+V1I=CX@
M(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`-"B`@("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`@(`T*("`@("`@
M("`@("`@("`\+V1I=CX@(`T*("`@("`@("`@("`@/"]T9#X@("`@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D
M;W5B;&4G/B`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@("`-"B`@("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)#PO9F]N=#X@("`@#0H@("`@("`@("`@("`@(#PO9&EV/B`@#0H@("`@("`@
M("`@("`\+W1D/B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`-"B`@("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1R:6=H=#X@("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU+#4Y-#PO9F]N=#X@("`-"B`@
M("`@("`@("`@("`@/"]D:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*
M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U
M<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@("`@#0H@
M("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@("`-"B`@("`@("`@("`@("`@/"]D
M:78^("`-"B`@("`@("`@("`@(#PO=&0^("`@(`T*("`@("`@("`@(#PO='(^
M("`-"B`@("`@("`@("`\='(^(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]T9#X@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#$R('9A;&EG
M;CTS1&)O='1O;3X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO=&0^("`@(`T*("`@("`@("`@(#PO='(^("`-"B`@("`@("`@/"]T86)L
M93X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T
M:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86XG/B`@#0H@("`@("`@(#QT<CX@("`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#$P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@.2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY$96-E;6)E<B8C,38P.S,Q+"`R
M,#$T/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9"<^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^0FEL;&5D/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O;'-P
M86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT
M97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/E5N8FEL;&5D/"]F;VYT
M/B`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@
M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A
M;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^5&]T
M86P\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-34E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-
M05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E4N4RX@
M1&5P87)T;65N="!O9B!(96%L=&@@86YD($AU;6%N(%-E<G9I8V5S/"]F;VYT
M/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,X,C$R.SPO9F]N
M=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^,BPW-S@\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^,BPW-S@\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-34E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z
M(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E-H:6]N;V=I)B,Q-C`[)F%M
M<#L@0V\N($QT9"X\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#`W,3PO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T
M('-O;&ED)SX@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#(Q,CL\+V9O;G0^("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@
M<V]L:60G/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PP-S$\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI
M9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24^("`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^
M("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T
M)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^5&]T86P@<F5C96EV86)L97,\+V9O;G0^
M("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/B`@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C$L,#<Q/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C
M,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+#<W.#PO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G
M/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,RPX-#D\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U
M8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@/"]T
M86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-C:&5D=6QE(&]F($EN=F5N=&]R>2P@0W5R<F5N="!;5&%B;&4@
M5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQT
M86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$
M,3`P)2!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;B<^("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED)SX@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SXR,#$U/"]F;VYT/B`@("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^
M("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/C(P,30\+V9O;G0^("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SX@("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4^("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW
M-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^5V]R:R!I;B!P<F]C97-S/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/B`@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR
M-C<\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@
M("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX]
M,T1L969T/B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/D9I;FES:&5D($=O;V1S/"]F;VYT/B`@("`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI
M9"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$L,C$P
M/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F
M=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C0Q-CPO9F]N=#X@("`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED
M)SX@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X@("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@
M("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@-'!X)SX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY.970@:6YV96YT;W)I97,\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P
M="!D;W5B;&4G/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ
M+#(Q,#PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE
M)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^
M("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^-C@S/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M(#PO='(^("`@("`-"B`@("`@(#PO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!2979E
M;G5E<R!F<F]M($-O;&QA8F]R871I;VYS(%M486)L92!497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N)SX@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#`N-7!T)SX@("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P+C5P="<^
M("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@
M<V]L:60G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q-3PO9F]N=#X@("`@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P+C5P="<^("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS
M1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q-#PO9F]N
M=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI
M9"<^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S`E/B`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3AP=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-05)'24XM4DE'
M2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E!R;V1U8W0@<V%L97,L
M(&YE=#PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXU,S<\+V9O;G0^("`@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X@(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#(Q,CL\+V9O
M;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-S`E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Q.'!T.R!-
M05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E)O>6%L
M='D@<F5V96YU93PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PU,3@\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N
M/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PX,C$\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@
M("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<P)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY#;VQL86)O<F%T:79E(&%N9"!O=&AE<B!R97-E87)C:"!A;F0@9&5V
M96QO<&UE;G0@<F5V96YU97,Z/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M(#PO='(^("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,S9P=#L@34%21TE.+5))
M1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY5+E,N($1E<&%R=&UE
M;G0@;V8@2&5A;'1H(&%N9"!(=6UA;B!397)V:6-E<SPO9F]N=#X@("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R
M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T
M)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^-"PT-S4\+V9O;G0^(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#,T,3PO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@
M("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^
M("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-S`E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P+C5P
M="<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!
M4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^4VAI;VYO
M9VD@*$IA<&%N*3PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,"XU<'0G/B`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,CDV/"]F;VYT/B`@("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@
M<V]L:60G/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P+C5P="<^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR.38\+V9O;G0^("`@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI
M9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@
M("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0W,"4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^
M("`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;"!C
M;VQL86)O<F%T:79E(&%N9"!O=&AE<B!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0@<F5V96YU97,\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L
M:60G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT+#<W
M,3PO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L
M:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$L-C,W/"]F;VYT/B`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`@(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@
M("`@#0H@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.R<^("`@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W,"4^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@("`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW
M-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^5&]T86P@<F5V96YU97,\+V9O;G0^
M("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^
M("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@
M#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^-BPX,C8\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P
M.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L92<^(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C,L-#4X/"]F;VYT/B`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXW-7!T(&1O=6)L
M92<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@(#PO=&%B
M;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C
M8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B,38S,#D-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-A-F0S,F)?-V-E,E\T,30U7V(S8F-?
M,#-B,3AC8C$V,S`Y+U=O<FMS:&5E=',O4VAE970Q,RYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M13)&/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@,B`M(%-T;V-K+4)A
M<V5D($-O;7!E;G-A=&EO;B`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@;V8@0V]M
M<&5N<V%T:6]N(%)E;&%T960@0V]S=',L(%-H87)E+6)A<V5D(%!A>6UE;G1S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V-H961U;&4@;V8@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M+"!!8W1I=FET>2!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^(`T*("`@("`@
M("`\='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L
M969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX]
M,T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/D%W87)D<SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI
M9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/D%V86EL
M86)L93PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N.'!T)R!A
M;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^3W!T
M:6]N<SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,2XX
M<'0G(&%L:6=N/3-$8V5N=&5R/B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SY/=71S=&%N9&EN9SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#$N
M.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^5V5I9VAT960\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/D%V97)A9V4\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV
M/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^17AE<F-I<V4\+V9O;G0^("`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/E!R:6-E/"]F;VYT/B`@("`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T
M<CX@("`@(`T*("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CLG/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4U)3X@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G
M(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY"86QA;F-E($1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,30\+V9O;G0^("`@("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(L
M,S8R/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CDL
M-C`U/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T
M/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV
M+C(Q/"]F;VYT/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R
M/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24^("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)3BU224=(5#H@
M,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^4F5S=')I8W1E9"!S=&]C:R!U
M;FET(&%W87)D<R!G<F%N=&5D/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I
M=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXH,3,S/"]F;VYT/B`@("`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^*28C,38P.SPO9F]N=#X@(`T*("`@("`@
M("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\
M+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O
M;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@
M("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M)SX@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0U-24^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#,V<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE
M9G0^(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^4F5S=')I8W1E9"!S=&]C:R!U;FET(&%W87)D<R!C86YC96QL
M960\+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE
M9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3PO9F]N
M=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^
M("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,X,C$R.R8C
M,38P.R8C,38P.SPO9F]N=#X@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\='(^("`@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-34E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`S
M-G!T.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/E-T;V-K(&]P=&EO;B!A=V%R9',@9W)A;G1E9#PO9F]N=#X@("`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B@Y,3<\+V9O;G0^("`@("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI)B,Q-C`[/"]F;VYT
M/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@
M(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG
M;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^.3$W/"]F;VYT/B`@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C$Q+C@S/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U-24^
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)
M3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^4W1O8VL@;W!T
M:6]N(&%W87)D<R!E>&5R8VES960\+V9O;G0^("`@("`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R
M:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-
M"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@R-#`\+V9O;G0^("`@("`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI)B,Q
M-C`[/"]F;VYT/B`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,RXP-SPO9F]N=#X@("`@(`T*
M("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.R8C,38P.SPO9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\
M='(^("`@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-34E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G/B`@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`S-G!T
M.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E-T
M;V-K(&]P=&EO;B!A=V%R9',@8V%N8V5L;&5D/"]F;VYT/B`@("`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX
M<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-
M"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@
M<V]L:60G/B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#$N,7!T('-O;&ED)SX@("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT/B`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^,C@\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#$N,7!T('-O;&ED)SX@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX@("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q+C%P="!S;VQI9"<^("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,2XQ<'0@<V]L:60G/B`@
M("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,C@\+V9O;G0^
M("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D
M/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M+C%P="!S;VQI9"<^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SXI/"]F;VYT/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/B`@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CDN,#4\+V9O;G0^("`@("`-"B`@("`@("`@
M("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^("`@(`T*("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@
M86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@(#PO='(^("`@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[)SX@("`@#0H@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4U)3X@("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A
M;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1M:61D;&4@=VED=&@],T0Q)3X@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,24^
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^("`@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO
M='(^("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4U)2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)SX@("`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L
M:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY"86QA;F-E($UA<F-H)B,Q-C`[,S$L(#(P,34\
M+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<^("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF
M(S$V,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@
M("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#,T,3PO9F]N=#X@#0H@("`@("`@
M("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G
M/B`@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q
M-C`[/"]F;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@
M("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#1P>"<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXW-7!T(&1O=6)L92<^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@
M("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C<U<'0@9&]U8FQE)SX@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^,3`L,C4T/"]F;VYT/B`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-S5P="!D;W5B;&4G/B`@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F
M;VYT/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T
M9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^
M("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/B`@#0H@("`@
M("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@
M("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP
M="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C8N-S@\+V9O;G0^("`@("`-"B`@
M("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^("`@(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@(#PO='(^("`@("`-"B`@("`@(#PO=&%B;&4^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L
M92!O9B!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!3=&]C:R!/<'1I;VYS
M+"!686QU871I;VX@07-S=6UP=&EO;G,@6U1A8FQE(%1E>'0@0FQO8VM=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8V5L;'!A9&1I
M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86XG/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P="<^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N
M=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^
M("`-"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^,C`Q-3PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*
M("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M)SX@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^("`@#0H@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#$N.'!T)R!A;&EG;CTS1&-E;G1E<CX@("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^,C`Q-#PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60G/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@/"]T<CX@("`@(`T*("`@("`@("`\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/B`@("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<P)3X@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,3AP=#L@34%21TE.+5))1TA4.B`P+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY%>'!E8W1E9"!,:69E(&EN(%EE87)S/"]F;VYT/B`@(`T*("`@("`@("`@
M("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO
M9F]N=#X@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@
M("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS
M1')I9VAT/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^-2XU/"]F;VYT/B`@("`-"B`@("`@("`@("`@(#PO
M9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@
M("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX]
M,T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C4N-3PO9F]N=#X@("`@#0H@("`@("`@("`@("`\
M+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/B`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@
M(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@(#QT<CX@("`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0W,"4^("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[
M($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^17AP
M96-T960@5F]L871I;&ET>3PO9F]N=#X@("`@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N
M.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.R8C,38P.SPO9F]N=#X@
M#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-
M"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^("`@(`T*("`@("`@("`@(#PO
M=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4^("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1')I9VAT
M/B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^.#,\+V9O;G0^("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@
M(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L
M:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)3PO9F]N=#X@(`T*("`@("`@("`@("`@/"]D
M:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@
M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H=#X@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C@W
M/"]F;VYT/B`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B4\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`@
M(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^("`@
M(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-S`E/B`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`Q.'!T.R!-05)'24XM4DE'2%0Z(#`N-S5P="<@86QI9VX],T1L969T/B`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/D5X<&5C=&5D($1I=FED96YD(%EI96QD/"]F;VYT/B`@("`-"B`@("`@
M("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LF(S$V
M,#L\+V9O;G0^(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI
M9VX],T1R:6=H=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C`N,#PO9F]N=#X@("`@#0H@("`@("`@("`@
M("`\+V1I=CX@("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)3PO9F]N=#X@(`T*("`@
M("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/B`@("`-"B`@("`@("`@("`\
M+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1R:6=H
M=#X@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C`N,#PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@
M("`@(`T*("`@("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G
M(&%L:6=N/3-$;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)3PO9F]N=#X@(`T*("`@("`@("`@("`@
M/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@#0H@("`@("`@(#PO='(^
M("`@("`-"B`@("`@("`@/'1R/B`@("`-"B`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<P)3X@(`T*("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P
M+C<U<'0G(&%L:6=N/3-$;&5F=#X@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY2:7-K+49R964@26YT97)E<W0@
M4F%T93PO9F]N=#X@("`@#0H@("`@("`@("`@("`\+V1I=CX@("`@(`T*("`@
M("`@("`@(#PO=&0^("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`-"B`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$
M;&5F=#X@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/B`-"B`@("`@("`@("`@
M(#PO9&EV/B`@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X@("`-"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+C4\
M+V9O;G0^("`@(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@
M("`\+W1D/B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B4\+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@
M("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X@("`@#0H@("`@("`@("`@/"]T9#X@(`T*("`@("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@("`-
M"B`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,"XX<'0G(&%L:6=N/3-$<FEG:'0^("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+C8\+V9O;G0^("`@
M(`T*("`@("`@("`@("`@/"]D:78^("`@("`-"B`@("`@("`@("`\+W1D/B`@
M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#`N.'!T)R!A;&EG;CTS1&QE9G0^("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B4\
M+V9O;G0^("`-"B`@("`@("`@("`@(#PO9&EV/B`@("`@#0H@("`@("`@("`@
M/"]T9#X@(`T*("`@("`@("`\+W1R/B`@("`@#0H@("`@("`\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V-A-F0S
M,F)?-V-E,E\T,30U7V(S8F-?,#-B,3AC8C$V,S`Y#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V-C839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X
M8V(Q-C,P.2]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5#3D))
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@,2`M(%-I9VYI9FEC86YT
M($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E=&%I;',I("A54T0@)"D\8G(^4VAA
M<F4@9&%T82!I;B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#`V
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,#DL(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3F]T92`Q("T@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<R`H1&5T86EL<RD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G1S(&%N
M9"!#87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q,2PR
M.#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y396-U<FET:65S($]F9F5R960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E
M9"!#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S+"!#=7)R96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8S-RPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-L
M87-S:69I8V%T:6]N(&9R;VT@06-C=6UU;&%T960@3W1H97(@0V]M<')E:&5N
M<VEV92!);F-O;64L($-U<G)E;G0@4&5R:6]D+"!B969O<F4@5&%X/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T($5X
M<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S$U+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,C0R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F($9I;F%N8VEN9R!#;W-T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=A:6X@*$QO<W,I(&]N($9O<F5I9VX@0W5R<F5N8WD@1&5R:79A=&EV92!)
M;G-T<G5M96YT<R!.;W0@1&5S:6=N871E9"!A<R!(961G:6YG($EN<W1R=6UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-C0L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU
M,C8L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O
M;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4L($%M;W5N="`H
M:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT
M-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU+#(P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V5R=&EF:6-A=&5S(&]F($1E<&]S:70@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E(#$@
M+2!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS*2!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5S=')I8W1E9"!#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S
M+"!#=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y2;WEA;'1Y(%)E8V5I=F%B;&4@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E(#$@+2!3:6=N:69I
M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS*2!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S=')I8W1E9"!#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S+"!#=7)R96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X-RPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;&QA=&5R86P@9F]R($-R961I="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@,2`M(%-I9VYI9FEC86YT
M($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E=&%I;',I(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T
M<FEC=&5D($-A<V@@86YD($-A<V@@17%U:79A;&5N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4D%0259!0B!;365M8F5R
M72!\(%-A;&5S(%)E=F5N=64L(%!R;V1U8W0@3&EN92!;365M8F5R72!\($-U
M<W1O;65R($-O;F-E;G1R871I;VX@4FES:R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@,2`M(%-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E=&%I;',I(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VYC96YT<F%T:6]N(%)I<VLL(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&AA4DU!($YO=&5S(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3F]T92`Q("T@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T
M86EL<RD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T($5X<&5N<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,S$U+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C0R+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU
M;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DYO=&4@,2`M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@*$1E=&%I;',I(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-871U<FET>2!097)I;V0@;V8@2&EG
M:"!1=6%L:71Y($UA<FME=&%B;&4@4V5C=7)I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^079E<F%G92!-871U<FET>2!0
M97)I;V0@;V8@2&EG:"!1=6%L:71Y($UA<FME=&%B;&4@4V5C=7)I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3@@;6]N=&AS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-871U
M<FET>2!097)I;V0@;V8@4VAO<G0@5&5R;2!);G9E<W1M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,B!M;VYT:',\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%V97)A9V4@36%T
M=7)I='D@9F]R(%!O<G1F;VQI;R!);G9E<W1M96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^,3@@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T
M92`Q("T@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL
M<RD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUA='5R:71Y(%!E<FEO9"!O9B!3:&]R="!497)M($EN
M=F5S=&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@;6]N
M=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,;VYG(%1E<FT@26YV97-T;65N="!-871U<FET>2!-:6YI;75M/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,B!M;VYT:',\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DI04B!2
M;WEA;'1Y(%-U8B!,3$,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E(#$@+2!3:6=N:69I8V%N="!!8V-O
M=6YT:6YG(%!O;&EC:65S("A$971A:6QS*2!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!2
M96-O9VYI=&EO;B!2;WEA;'1Y(&%N9"!-:6QE<W1O;F4@4F5V96YU92!296-O
M9VYI>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V-C839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B
M8U\P,V(Q.&-B,38S,#DO5V]R:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%25-!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#$@+2!3:6=N
M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS*2`M($9A:7(@
M5F%L=64@;V8@=&AE($-O;7!A;GGB@)ES($EN=F5S=&UE;G1S(&)Y(%1Y<&4@
M*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E
M8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L92UF;W(M
M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ960@0V]S=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V,"PP-C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4Y+#(Y-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C<G5E9"!);G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'<F]S<R!5;G)E86QI>F5D($=A:6YS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@3&]S
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M<W1I;6%T960@1F%I<B!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C`L,C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3DL,S0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X-"B`@("`@("`@/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/@T*("`@("`@("`\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^#0H@
M("`@("`@(#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X-"B`@("`@("`@/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E53($=O=F5R;FUE;G0@06=E;F-I97,@1&5B
M="!396-U<FET:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS
M86QE(%-E8W5R:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IE9"!#;W-T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PS,#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PS,#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U
M960@26YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=R;W-S(%5N<F5A;&EZ960@1V%I;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@3&]S<V5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D($9A
M:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#,T
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(S+#,P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]R<&]R871E($1E8G0@4V5C=7)I=&EE<R!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D
M=6QE(&]F($%V86EL86)L92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!;6]R=&EZ960@0V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C@L,3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C<L,34R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D($EN=&5R97-T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@
M1V%I;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O
M<W,@56YR96%L:7IE9"!,;W-S97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17-T:6UA=&5D($9A:7(@5F%L=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(X+#(Y-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W+#(V,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;65R8VEA
M;"!087!E<B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L92UF;W(M<V%L92!3
M96-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ960@0V]S=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L-C(U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L.#,X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D($EN
M=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R
M;W-S(%5N<F5A;&EZ960@1V%I;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@3&]S<V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!&86ER(%9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q+#8S-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3$L-S@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B,38S,#D-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-A-F0S,F)?-V-E,E\T,30U7V(S
M8F-?,#-B,3AC8C$V,S`Y+U=O<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P139%04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^3F]T92`Q("T@4VEG
M;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL<RD@+2!38VAE
M9'5L960@36%T=7)I='D@9F]R('1H92!#;VUP86YYXH"9<R!);G9E<W1M96YT
M<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&5D($UA='5R:71Y(&9O<B!T:&4@
M0V]M<&%N>>*`F7,@26YV97-T;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-871U<FEN9R!I;B!O
M;F4@>65A<B!O<B!L97-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$Y+#$V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,3@L,C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-871U<FEN9R!A9G1E<B!O;F4@>65A<B!T
M:')O=6=H('1W;R!Y96%R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,CDL-C4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4L-#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-871U<FEN9R!A9G1E<B!T=V\@>65A<G,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#0V,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#8U-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8P+#(W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-3DL,S0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B
M,38S,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-A-F0S,F)?
M-V-E,E\T,30U7V(S8F-?,#-B,3AC8C$V,S`Y+U=O<FMS:&5E=',O4VAE970Q
M-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P15!%04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M3F]T92`Q("T@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T
M86EL<RD@+2!3=6UM87)Y(&]F(%)E8V5I=F%B;&5S("A54T0@)"D\8G(^26X@
M5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY.;W1E(#$@+2!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$
M971A:6QS*2`M(%-U;6UA<GD@;V8@4F5C96EV86)L97,@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L
M-3DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`S+#@T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^52Y3+B!$97!A<G1M96YT(&]F($AE86QT:"!A;F0@2'5M
M86X@4V5R=FEC97,@6TUE;6)E<ET@?"!5;F)I;&QE9"!2979E;G5E<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DYO=&4@,2`M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E
M=&%I;',I("T@4W5M;6%R>2!O9B!296-E:79A8FQE<R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C
M96EV86)L97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#@W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPW-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E4N4RX@1&5P87)T;65N="!O9B!(96%L=&@@86YD($AU;6%N(%-E
M<G9I8V5S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3F]T92`Q("T@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0
M;VQI8VEE<R`H1&5T86EL<RD@+2!3=6UM87)Y(&]F(%)E8V5I=F%B;&5S(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y296-E:79A8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PP.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#<W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAI;VYO9VD@)F%M<#L@0V\N($QT9"X@6TUE
M;6)E<ET@?"!":6QL960@4F5V96YU97,@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E(#$@+2!3:6=N:69I
M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS*2`M(%-U;6UA<GD@
M;V8@4F5C96EV86)L97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5I=F%B;&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#<Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&EO;F]G:2`F
M86UP.R!#;RX@3'1D+B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@,2`M(%-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,@*$1E=&%I;',I("T@4W5M;6%R>2!O9B!296-E:79A
M8FQE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5C96EV86)L97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PP-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)I;&QE9"!2979E;G5E<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DYO=&4@,2`M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E
M=&%I;',I("T@4W5M;6%R>2!O9B!296-E:79A8FQE<R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C
M96EV86)L97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3`W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E5N8FEL;&5D(%)E=F5N=65S(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T92`Q("T@4VEG;FEF
M:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL<RD@+2!3=6UM87)Y
M(&]F(%)E8V5I=F%B;&5S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#`X-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPW-S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-C839D,S)B7S=C
M93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.0T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B,38S
M,#DO5V]R:W-H965T<R]3:&5E=#$X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-D-!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY.;W1E(#$@+2!3:6=N:69I8V%N="!!8V-O
M=6YT:6YG(%!O;&EC:65S("A$971A:6QS*2`M($EN=F5N=&]R>2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^26YV96YT;W)Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V]R:R!I;B!P<F]C97-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1FEN:7-H960@
M1V]O9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C$P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&EN=F5N=&]R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$L,C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V-C839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q
M-C,P.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8V$V9#,R8E\W
M8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B,38S,#DO5V]R:W-H965T<R]3:&5E=#$Y
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%64I!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.
M;W1E(#$@+2!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A
M:6QS*2`M(%-U;6UA<GD@;V8@4F5V96YU97,@*%531"`D*3QB<CY);B!4:&]U
M<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@,2`M(%-I
M9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E=&%I;',I("T@4W5M
M;6%R>2!O9B!2979E;G5E<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O9'5C="!S86QE<RP@;F5T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4S-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F]Y86QT
M>2!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4Q
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L.#(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;&QA8F]R871I=F4@86YD(&]T:&5R(')E<V5A
M<F-H(&%N9"!D979E;&]P;65N="!R979E;G5E<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EV92!A;F0@
M;W1H97(@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(')E=F5N=65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<W,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C,W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R
M979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPX,C8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#0U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^52Y3+B!$97!A<G1M96YT(&]F($AE86QT:"!A;F0@2'5M86X@4V5R
M=FEC97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;VQL86)O<F%T:79E(&%N9"!O=&AE<B!R97-E87)C:"!A
M;F0@9&5V96QO<&UE;G0@<F5V96YU97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I=F4@86YD(&]T:&5R
M(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!R979E;G5E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PT-S4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,T,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAI;VYO9VD@)F%M
M<#L@0V\N($QT9"X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#;VQL86)O<F%T:79E(&%N9"!O=&AE<B!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@<F5V96YU97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I=F4@86YD
M(&]T:&5R(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!R979E;G5E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R.38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V-A-F0S,F)?-V-E
M,E\T,30U7V(S8F-?,#-B,3AC8C$V,S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V-C839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P
M.2]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5%,T))/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@,B`M(%-T;V-K+4)A<V5D($-O;7!E
M;G-A=&EO;B`H1&5T86EL<RD@*%531"`D*3QB<CY3:&%R92!D871A(&EN(%1H
M;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/DYO=&4@,B`M(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO
M;B`H1&5T86EL<RD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!3=&]C:R!"87-E9"!#
M;VUP96YS871I;VX@4&QA;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%L;&]C871E9"!3:&%R92UB87-E9"!#;VUP96YS871I;VX@17AP
M96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#(U.2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L-C$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#
M;VUP96YS871I;VXL($YO;G9E<W1E9"!!=V%R9',L($-O;7!E;G-A=&EO;B!#
M;W-T($YO="!Y970@4F5C;V=N:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,30L-C(Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@4V5R=FEC92!3:&%R92!"
M87-E9"!#;VUP96YS871I;VX@3F]N=F5S=&5D($%W87)D<R!#;VUP96YS871I
M;VX@0V]S="!%>'!E8W1E9"!T;R!B92!296-O9VYI>F5D(&9O<B!296UA:6YD
M97(@;V8@1FES8V%L(%EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,#`V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16UP;&]Y964@4V5R=FEC92!3:&%R92!"87-E9"!#
M;VUP96YS871I;VX@3F]N=F5S=&5D($%W87)D<R!#;VUP96YS871I;VX@0V]S
M="!%>'!E8W1E9"!T;R!B92!296-O9VYI>F5D(%EE87(@5'=O/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#4R."PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-E
M<G9I8V4@4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N($YO;G9E<W1E9"!!=V%R
M9',@0V]M<&5N<V%T:6]N($-O<W0@17AP96-T960@=&\@8F4@4F5C;V=N:7IE
M9"!996%R(%1H<F5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#`V-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5M<&QO>65E(%-E<G9I8V4@4VAA<F4@0F%S960@0V]M<&5N
M<V%T:6]N($YO;G9E<W1E9"!!=V%R9',@0V]M<&5N<V%T:6]N($-O<W0@17AP
M96-T960@=&\@8F4@4F5C;V=N:7IE9"!996%R($9O=7(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L.3DP+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@4V5R=FEC
M92!3:&%R92!"87-E9"!#;VUP96YS871I;VX@3F]N=F5S=&5D($%W87)D<R!#
M;VUP96YS871I;VX@0V]S="!%>'!E8W1E9"!T;R!B92!296-O9VYI>F5D(%EE
M87(@1FEV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB
M87-E9"!087EM96YT($%W87)D+"!.=6UB97(@;V8@4VAA<F5S($%V86EL86)L
M92!F;W(@1W)A;G0@*&EN(%-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,S0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPS-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-T;V-K($]P=&EO;B!;
M365M8F5R72!\($=R86YT<R!#;VUM96YC:6YG($UA<F-H(#$L(#(P,3$@6TUE
M;6)E<ET@?"!);F-E;G1I=F4@4&QA;B!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@,B`M(%-T;V-K+4)A
M<V5D($-O;7!E;G-A=&EO;B`H1&5T86EL<RD@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!0
M87EM96YT($%W87)D+"!!=V%R9"!697-T:6YG(%)I9VAT<RP@4&5R8V5N=&%G
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S
M960@4&%Y;65N="!!=V%R9"P@07=A<F0@5F5S=&EN9R!097)I;V0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C0@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-T
M;V-K($]P=&EO;B!;365M8F5R72!\(%!E<F9O<FUA;F-E+6)A<V5D($=R86YT
M<R!-861E(&EN($%U9W5S="`R,#$S(%M-96UB97)=('P@26YC96YT:79E(%!L
M86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY.;W1E(#(@+2!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$1E
M=&%I;',I(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@07=A<F0@
M5F5S=&EN9R!2:6=H=',L(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P
M=&EO;G,L($=R86YT<R!I;B!097)I;V0L($=R;W-S("AI;B!3:&%R97,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`S,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M($UI;&5S=&]N97,@06-H:65V960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N
M="!">2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!!=V%R9',@56Y697-T
M960L(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16UP;&]Y964@4W1O8VL@3W!T:6]N(%M-96UB97)=('P@4&5R
M9F]R;6%N8V4M8F%S960@1W)A;G1S($UA9&4@:6X@075G=7-T(#(P,3,@56YV
M97-T960@4&]R=&EO;B!;365M8F5R72!\($EN8V5N=&EV92!0;&%N(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3F]T92`R("T@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A$971A:6QS*2!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($=R86YT
M<R!I;B!097)I;V0L($=R;W-S("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#(U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@4W1O8VL@3W!T:6]N
M(%M-96UB97)=('P@4&5R9F]R;6%N8V5D($)A<V5D($=R86YT<R!-861E($EN
M($1E8V5M8F5R(#(P,30@6TUE;6)E<ET@?"!);F-E;G1I=F4@4&QA;B!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DYO=&4@,B`M(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H1&5T86EL<RD@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N
M="!">2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!!=V%R9',@56Y697-T
M960L(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5M<&QO>65E(%-T;V-K($]P=&EO;B!;365M8F5R72!\($UI
M;FEM=6T@6TUE;6)E<ET@?"!);F-E;G1I=F4@4&QA;B!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@,B`M
M(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H1&5T86EL<RD@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R
M92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!%>&5R8VES86)L92P@
M5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y
M964@4W1O8VL@3W!T:6]N(%M-96UB97)=('P@36%X:6UU;2!;365M8F5R72!\
M($EN8V5N=&EV92!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T92`R("T@4W1O8VLM0F%S960@0V]M
M<&5N<V%T:6]N("A$971A:6QS*2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M
M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@
M07=A<F0L($]P=&EO;G,L($5X97)C:7-A8FQE+"!796EG:'1E9"!!=F5R86=E
M(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!497)M/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XQ,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@4W1O8VL@3W!T:6]N
M(%M-96UB97)=('P@3F]N+65M<&QO>65E($1I<F5C=&]R<R!;365M8F5R72!\
M($EN8V5N=&EV92!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T92`R("T@4W1O8VLM0F%S960@0V]M
M<&5N<V%T:6]N("A$971A:6QS*2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@0F%S960@0V]M
M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E($)A<V5D(%!A>6UE;G0@
M07=A<F0@1FER<W0@5F5S=&EN9R!097)I;V0@869T97(@1W)A;G0@1&%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,2!Y96%R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!/
M<'1I;VYS(&%N9"!297-T<FEC=&5D(%-T;V-K(%M-96UB97)=('P@4F5T96YT
M:6]N($=R86YT<R!-861E(&EN($IA;G5A<GD@,C`Q,R!;365M8F5R72!\($EN
M8V5N=&EV92!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3F]T92`R("T@4W1O8VLM0F%S960@0V]M<&5N
M<V%T:6]N("A$971A:6QS*2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A
M<F0L($%W87)D(%9E<W1I;F<@4FEG:'1S+"!097)C96YT86=E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O
M;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT
M($%W87)D+"!!=V%R9"!697-T:6YG(%!E<FEO9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^,B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC96YT:79E(%!L86X@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.
M;W1E(#(@+2!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$1E=&%I;',I(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;&QO8V%T960@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($5X
M<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,38U+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-34X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($=R
M86YT<R!I;B!097)I;V0L(%=E:6=H=&5D($%V97)A9V4@1W)A;G0@1&%T92!&
M86ER(%9A;'5E("AI;B!$;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@."XQ,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."XR.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@4W1O
M8VL@4'5R8VAA<V4@4&QA;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@,B`M(%-T;V-K+4)A<V5D($-O
M;7!E;G-A=&EO;B`H1&5T86EL<RD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%L;&]C871E9"!3:&%R
M92UB87-E9"!#;VUP96YS871I;VX@17AP96YS93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D
M+"!.=6UB97(@;V8@4VAA<F5S($%U=&AO<FEZ960@*&EN(%-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#<U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E
M9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y
M;65N="!!=V%R9"P@3G5M8F5R(&]F(%-H87)E<R!!=F%I;&%B;&4@9F]R($=R
M86YT("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!E<F-E;G1A9V4@;V8@4V%L87)Y('1O(%!U<F-H87-E($-O;6UO
M;B!3=&]C:R!-87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@0V]M;6]N(%-T;V-K(%-H87)E<R!"
M96=I;FYI;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&5R8V5N=&%G92!O9B!#;VUM;VX@4W1O8VL@4VAA<F5S($5N9&EN9SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB
M87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@
M4&%Y;65N="!!=V%R9"P@36%X:6UU;2!.=6UB97(@;V8@4VAA<F5S(%!E<B!%
M;7!L;WEE92`H:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M(&)Y(%-H87)E($)A<V5D(%!A>6UE;G0@07=A<F0@36%X:6UU;2!.=6UB97(@
M;V8@4VAA<F5S('!E<B!%;7!L;WEE92!!;6]U;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!)<W-U960@1'5R:6YG
M(%!E<FEO9"P@4VAA<F5S+"!%;7!L;WEE92!3=&]C:R!0=7)C:&%S92!0;&%N
M<R`H:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-C
M839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P
M,V(Q.&-B,38S,#DO5V]R:W-H965T<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M14E!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#(@+2!3=&]C:RU"
M87-E9"!#;VUP96YS871I;VX@*$1E=&%I;',I("T@4W1O8VL@26YC96YT:79E
M(%!L86X@06-T:79I=&EE<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC
M97!T(%!E<B!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M=&]C:R!);F-E;G1I=F4@4&QA;B!!8W1I=FET:65S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07=A<F1S
M($%V86EL86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS
M-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#,V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`L,C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.2PV,#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M17AE<F-I<V4@4')I8V4@*&EN($1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+C<X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+C(Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC
M=&5D('-T;V-K('5N:70@87=A<F1S(&=R86YT960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@=6YI="!A
M=V%R9',@8V%N8V5L;&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:R!O<'1I;VX@87=A<F1S(&=R86YT960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#DQ-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;B!A=V%R9',@
M9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:R!O<'1I;VX@87=A<F1S(&=R86YT960@*&EN($1O;&QA<G,@<&5R('-H
M87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2XX,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VL@;W!T:6]N(&%W87)D<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(T,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;B!A=V%R9',@97AE
M<F-I<V5D("AI;B!$;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,RXP-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N(&%W87)D<R!C
M86YC96QL960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:R!O<'1I;VX@87=A<F1S(&-A;F-E;&QE9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VX@87=A<F1S(&-A;F-E
M;&QE9"`H:6X@1&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#DN,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V-C839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X
M8V(Q-C,P.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8V$V9#,R
M8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B,38S,#DO5V]R:W-H965T<R]3:&5E
M=#(R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%2$9!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
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M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V5I9VAT960@079E<F%G
M92!!<W-U;7!T:6]N<R!F;W(@4W1O8VL@3W!T:6]N($%W87)D<R!'<F%N=&5D
M('1O($5M<&QO>65E<R!A;F0@1&ER96-T;W)S('5N9&5R('1H92!);F-E;G1I
M=F4@4&QA;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D($QI9F4@:6X@665A<G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,@-B!M;VYT:',\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE
M87)S(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!6;VQA=&EL:71Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-RXP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D($1I
M=FED96YD(%EI96QD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2:7-K+49R964@26YT97)E<W0@4F%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2XU,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C8P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V-A-F0S,F)?-V-E,E\T,30U
M7V(S8F-?,#-B,3AC8C$V,S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V-C839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.2]7;W)K
M<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4U,D1)/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/DYO=&4@,R`M($-O;&QA8F]R871I=F4@86YD($]T:&5R
M(%)E<V5A<F-H(&%N9"!$979E;&]P;65N="!#;VYT<F%C=',@*$1E=&%I;',I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#,^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XU,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#`V/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA>2`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#`P/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1F5B+B`R-"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#`Y/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P,#<\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R-"P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-E($-O;G1R86-T(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3F]T92`S("T@0V]L;&%B;W)A=&EV92!A;F0@3W1H97(@4F5S96%R8V@@
M86YD($1E=F5L;W!M96YT($-O;G1R86-T<R`H1&5T86EL<RD@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=O=F5R;FUE;G0@0V]N=')A8W0@4F5C96EV86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPQ,S0L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA
M;"!$979E;&]P;65N="!/<'1I;VYS(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T92`S("T@0V]L;&%B;W)A
M=&EV92!A;F0@3W1H97(@4F5S96%R8V@@86YD($1E=F5L;W!M96YT($-O;G1R
M86-T<R`H1&5T86EL<RD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O=F5R;FUE;G0@0V]N=')A8W0@
M4F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(L
M.#4U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%34%(O0D%21$$@0V]N=')A8W0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E(#,@
M+2!#;VQL86)O<F%T:79E(&%N9"!/=&AE<B!297-E87)C:"!A;F0@1&5V96QO
M<&UE;G0@0V]N=')A8W1S("A$971A:6QS*2!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V]V97)N;65N
M="!#;VYT<F%C="!296-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-"PY.#DL,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)E96X@0W)O<W,@0V]R<&]R871I
M;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY.;W1E(#,@+2!#;VQL86)O<F%T:79E(&%N9"!/=&AE<B!297-E
M87)C:"!A;F0@1&5V96QO<&UE;G0@0V]N=')A8W1S("A$971A:6QS*2!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O8V5E9',@9G)O;2!,:6-E;G-E($9E97,@4F5C96EV960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%%0T]-(&%N
M9"!)4DP@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.;W1E(#,@+2!#;VQL86)O<F%T:79E(&%N9"!/=&AE<B!2
M97-E87)C:"!A;F0@1&5V96QO<&UE;G0@0V]N=')A8W1S("A$971A:6QS*2!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36EL97-T;VYE(%!A>6UE;G0@36EN:6UU;3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@4&%Y
M;65N="!-87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%N;G5A;"!,:6-E;G-E($9E92!-:6YI;75M/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;FYU86P@3&EC96YS
M92!&964@36%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^061V86YC92!.;W1I8V4@4&5R:6]D(&9O<B!497)M:6YA=&EO
M;B!O9B!!9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C8P(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K($ES<W5E9"!$=7)I;F<@4&5R:6]D(%9A;'5E(&9O
M<B!-;V1I9FEC871I;VX@;V8@3&EC96YS92!!9W)E96UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L.3$Q+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N=',@9F]R
M($UO9&EF:6-A=&EO;B!O9B!,:6-E;G-E($%G<F5E;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5+E,N($1E<&%R=&UE;G0@
M;V8@2&5A;'1H(&%N9"!(=6UA;B!397)V:6-E<R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@,R`M($-O
M;&QA8F]R871I=F4@86YD($]T:&5R(%)E<V5A<F-H(&%N9"!$979E;&]P;65N
M="!#;VYT<F%C=',@*$1E=&%I;',I(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VQL86)O<F%T:79E
M($%G<F5E;65N="!#;VYT<F%C="!686QU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`R+#8V,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I=F4@06=R965M
M96YT($%D9&ET:6]N86P@0V]N=')A8W0@5F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-RPQ.3$L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VQL86)O
M<F%T:79E($%G<F5E;65N="!!9&IU<W1E9"!#;VYT<F%C="!686QU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,T+#@U,BPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYA=&EO
M;F%L($EN<W1I='5T92!O9B!!;&QE<F=Y(&%N9"!);F9E8W1I;W5S($1I<V5A
M<V5S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3F]T92`S("T@0V]L;&%B;W)A=&EV92!A;F0@3W1H97(@4F5S
M96%R8V@@86YD($1E=F5L;W!M96YT($-O;G1R86-T<R`H1&5T86EL<RD@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;V-E961S(&9R;VT@07=A<F1S(&9O<B!297-E87)C:"!A;F0@
M1&5V96QO<&UE;G0@0V]N=')A8W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(%)E8V5I=F%B;&4@9G)O;2!!
M=V%R9',@9F]R(%)E<V5A<F-H(&%N9"!$979E;&]P;65N="!#;VYT<F%C=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y+#$T-RPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;&QA8F]R871I=F4@06=R965M96YT(%!E<FEO9"!O9B!#;VYT<F%C=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A
M=&EO;B!!9W)E96UE;G0@061D:71I;VYA;"!087EM96YT<R!296-E:79E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-2PP,C$L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5
M04(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY.;W1E(#,@+2!#;VQL86)O<F%T:79E(&%N9"!/=&AE<B!297-E
M87)C:"!A;F0@1&5V96QO<&UE;G0@0V]N=')A8W1S("A$971A:6QS*2!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5N97=A8FQE(%!E<FEO9"!O9B!!9W)E96UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<FEO9"!O9B!!9W)E
M96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(U('EE87)S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8V$V
M9#,R8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B,38S,#D-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO8V-A-F0S,F)?-V-E,E\T,30U7V(S8F-?,#-B
M,3AC8C$V,S`Y+U=O<FMS:&5E=',O4VAE970R-"YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14]%
M04D^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`T+2!2;WEA;'1Y($UO
M;F5T:7IA=&EO;B`H1&5T86EL<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-3QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/E531"`H)"D\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`P.2P@,C`Q
M,3QB<CY2;WEA;'1Y($UO;F5T:7IA=&EO;B!;365M8F5R73QB<CY*4%(@4F]Y
M86QT>2!3=6(@3$Q#(%M-96UB97)=/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CY*87!A;BP@
M665N/&)R/E!H85)-02!.;W1E<R!;365M8F5R73QB<CY#=7)R96YC>2!(961G
M92!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CY0:&%234$@3F]T97,@6TUE;6)E
M<ET\8G(^0W5R<F5N8WD@2&5D9V4@06=R965M96YT(%M-96UB97)=/&)R/DI0
M4B!2;WEA;'1Y(%-U8B!,3$,@6TUE;6)E<ET\8G(^55-$("@D*3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/E!H
M85)-02!.;W1E<R!;365M8F5R73QB<CY#=7)R96YC>2!(961G92!!9W)E96UE
M;G0@6TUE;6)E<ET\8G(^2E!2(%)O>6%L='D@4W5B($Q,0R!;365M8F5R73QB
M<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^4&AA4DU!($YO=&5S(%M-96UB97)=/&)R/D-U<G)E
M;F-Y($AE9&=E($%G<F5E;65N="!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M4&AA4DU!($YO=&5S(%M-96UB97)=/&)R/D-U<G)E;F-Y($AE9&=E($%G<F5E
M;65N="!;365M8F5R73QB<CY*4%D@*"8C>&$U.RD\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CY0:&%234$@3F]T
M97,@6TUE;6)E<ET\8G(^2E!2(%)O>6%L='D@4W5B($Q,0R!;365M8F5R73QB
M<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,#DL(#(P,3$\8G(^4&AA4DU!($YO=&5S(%M-96UB97)=/&)R/DI04B!2
M;WEA;'1Y(%-U8B!,3$,@6TUE;6)E<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#`Y+"`R,#$Q/&)R/DI04B!2
M;WEA;'1Y(%-U8B!,3$,@6TUE;6)E<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E(#0M(%)O
M>6%L='D@36]N971I>F%T:6]N("A$971A:6QS*2!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU
M92!296-O9VYI=&EO;B!2;WEA;'1Y(&%N9"!-:6QE<W1O;F4@4F5V96YU92!2
M96-O9VYI>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,P
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@4F5C;V=N:71I;VX@4F]Y
M86QT>2!A;F0@36EL97-T;VYE(%)E=F5N=64@4F5C;V=N:7IE9"!.970\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R+#8Y,2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS
M86-T:6]N($-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#,P.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN=&5R97-T(%)E<V5R=F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I=F%T92!0;&%C96UE;G0@;V8@
M4V5N:6]R(%-E8W5R960@3F]T97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@26YS=')U;65N="P@26YT97)E<W0@
M4F%T92P@4W1A=&5D(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F]T97,@4&%Y86)L92P@3F]N8W5R<F5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E+"!&;W)W87)D($5X8VAA;F=E
M(%)A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y
M;65N=',@9F]R("A0<F]C965D<R!F<F]M*2!(961G92P@26YV97-T:6YG($%C
M=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.34P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5Q=6ER960@1F]R96EG;B!#=7)R96YC>2!(961G92P@4&5R($1O
M;&QA<B`H:6X@665N*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y'86EN("A,;W-S*2!O;B!&;W)E:6=N($-U<G)E;F-Y($1E<FEV871I
M=F4@26YS=')U;65N=',@3F]T($1E<VEG;F%T960@87,@2&5D9VEN9R!);G-T
M<G5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8T+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$L-3(V+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-C0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PU,C8L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M($%M;W5N="!O
M9B!#;VQL871E<F%L(%)E<75I<F5D('1O(%!O<W0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,3$L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V-A-F0S,F)?-V-E,E\T,30U7V(S
M8F-?,#-B,3AC8C$V,S`Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V-C839D,S)B7S=C93)?-#$T-5]B,V)C7S`S8C$X8V(Q-C,P.2]7;W)K<VAE
M971S+U-H965T,C4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V04%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/DYO=&4@-2`M(%-T;V-K:&]L9&5R<R<@17%U:71Y("A$971A
M:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#`S+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DYO=BX@,#8L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@3F]T
M92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUA>&EM=6T@06=G<F5G871E($]F9F5R:6YG(%!R:6-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R-2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E;6%I;FEN9R!!9V=R96=A=&4@3V9F97)I;F<@4')I8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8V$V9#,R8E\W8V4R7S0Q
M-#5?8C-B8U\P,V(Q.&-B,38S,#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO8V-A-F0S,F)?-V-E,E\T,30U7V(S8F-?,#-B,3AC8C$V,S`Y+U=O
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M2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM
M/5].97AT4&%R=%]C8V$V9#,R8E\W8V4R7S0Q-#5?8C-B8U\P,V(Q.&-B,38S
&,#DM+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 3 &#8212; Collaborative and Other Research and Development Contracts</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">U.S.&#160;Department of Health and Human Services (&#8220;BARDA/HHS&#8221;).</font> In January 2007, BARDA/HHS awarded the Company a $102,661, four-year contract for the advanced development of peramivir for the treatment of influenza. During 2009, peramivir clinical development shifted to focus on intravenous delivery and the treatment of hospitalized patients. To support this focus, a September 2009 contract modification was awarded to extend the i.v. peramivir program and to increase funding by $77,191. On February&#160;24, 2011, the Company announced that BARDA/HHS had awarded it a $55,000 contract modification, intended to fund completion of the Phase 3 development of i.v. peramivir for the treatment of patients hospitalized with influenza. That contract modification brought the total contract award from BARDA/HHS to $234,852 and provided funding
        to support the filing of a NDA to seek regulatory approval for i.v. peramivir in the U.S. In December 2013, BioCryst submitted an NDA filing for i.v. peramivir to the FDA and the NDA was approved in December 2014. The BARDA/HHS contract expired on June 30, 2014 according to its terms.</font>
      </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 31, 2015, we announced that the Biomedical Research and Development Authority within the U.S. Department of Health and Human Services&#8217; Office of the Assistant Secretary for Preparedness and Response (&#8220;ASPR&#8221;) awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses.&#160;&#160;This BARDA/HHS contract includes a base contract of $12,134 to support BCX4430 drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $34,989.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;).</font> In September 2013, NIAID/HHS contracted with the Company for the development of BCX4430 as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The total funding under this contract as of March 31, 2015 could be up to $29,147, if all contract options are exercised by NIAID/HHS, over a five year period. The goals of this contract, including amendments, are to file IND applications for intravenous i.v. and i.m. BCX4430 for the treatment of Marburg virus disease, to conduct an initial Phase 1 human clinical trial and to study BCX4430 as a treatment for Ebola virus disease. As of March 31, 2015, a total of $25,021 has been awarded under exercised options within the contract. BCX4430 is
      the lead compound in the Company&#8217;s BSAV research program.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and BCX4430 plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on the Company&#8217;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Shionogi&#160;&amp; Co., Ltd. (&#8220;Shionogi&#8221;).</font> In February 2007, the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from Shionogi. In October 2008, the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan and to provide rights for Shionogi to perform a Phase&#160;3 clinical trial in Hong Kong. Shionogi has commercially launched peramivir under the
      commercial name RAPIACTA in Japan.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Green Cross Corporation (&#8220;Green Cross&#8221;).</font> In June 2006, the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a one-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;).</font> In February 2006, the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and commercialization of forodesine, a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor, for use in oncology (the &#8220;Original Agreement&#8221;). Under the terms of the license agreement, as amended, Mundipharma obtained worldwide rights to forodesine.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively).</font> In June 2000, the Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the Agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each
      licensed product (which range in the aggregate from $1,400 to almost $4,000&#160;per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately one quarter of future payments received from other third-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement may be terminated by the Company at any time by giving 60&#160;days advance notice or in the event of material uncured breach by the Licensors.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2010, the Company amended the licensee agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of one-half in the percentage of future payments received from third-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does not apply to (i)&#160;any milestone payments the Company may receive in the future under its license agreement dated February&#160;1, 2006 with Mundipharma and (ii)&#160;royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales
      of any resulting product made by the Company remains unchanged.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In consideration for these modifications in 2010, the Company issued to the Licensors shares of its common stock with an aggregate value of $5,911 and paid the Licensors $90 in cash. Additionally, at the Company&#8217;s sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by it to the Licensors under the license agreement may be made either in cash, in shares of its common stock, or in a combination of cash and shares.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On November&#160;17, 2011, the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of one-half in the percentage of Net Proceeds (as defined) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On June&#160;19, 2012, the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of BCX4430 to BioCryst for any antiviral use.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement may be made either in cash, in shares of the Company&#8217;s common stock, or in a combination of cash and shares.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 6, 2014, the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited (&#8220;CIRL&#8221;), formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#8220;VUW&#8221;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property are in the process of being transferred to VUW or its wholly owned subsidiaries, including the contracts to which BioCryst is a party. Except for a substitution of parties, the terms and conditions of the contracts are expected to remain unchanged.</font></font>
      </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">The University of Alabama at Birmingham (&#8220;UAB&#8221;).</font> The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable by the Company upon
      three months notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross agreements, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</font>
    </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQIBG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 48,367</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 54,540</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">2,637</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">150</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" onclick="toggleNextSibling(this);">19,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" onclick="toggleNextSibling(this);">18,232</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">1,210</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">683</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">4,322</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">6,172</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred collaboration expense</a></td>
        <td class="nump"><a title="us-gaap_DeferredCostsCurrent" onclick="toggleNextSibling(this);">76</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredCostsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredCostsCurrent" onclick="toggleNextSibling(this);">76</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredCostsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">81,366</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">89,343</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" onclick="toggleNextSibling(this);">41,116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" onclick="toggleNextSibling(this);">41,116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">727</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">207</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseAssets', window );">Deferred collaboration expense</a></td>
        <td class="nump"><a title="bcrx_DeferredCollaborationExpenseAssets" onclick="toggleNextSibling(this);">163</a><span style="display:none;white-space:normal;text-align:left;">bcrx_DeferredCollaborationExpenseAssets</span><span></span></td>
        <td class="nump"><a title="bcrx_DeferredCollaborationExpenseAssets" onclick="toggleNextSibling(this);">177</a><span style="display:none;white-space:normal;text-align:left;">bcrx_DeferredCollaborationExpenseAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">6,495</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">6,031</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">129,867</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">136,874</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#x2019; Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">5,307</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">2,849</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">12,291</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">11,329</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
        <td class="nump"><a title="us-gaap_InterestPayableCurrent" onclick="toggleNextSibling(this);">7,241</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPayableCurrent" onclick="toggleNextSibling(this);">6,029</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-recourse notes payable</a></td>
        <td class="nump"><a title="us-gaap_LongTermNotesPayable" onclick="toggleNextSibling(this);">30,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermNotesPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermNotesPayable" onclick="toggleNextSibling(this);">30,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermNotesPayable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">61,862</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">57,293</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred collaboration revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">3,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueNoncurrent" onclick="toggleNextSibling(this);">3,552</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">378</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">394</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#x2019; equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; shares authorized &#x2014; 5,000; no shares issued and outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: shares authorized &#x2014; 200,000; shares issued and outstanding &#x2014; 72,474 in 2015 and 71,955 in 2014</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">725</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">720</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">546,698</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">542,943</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
        <td class="nump"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(130)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(483,062)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(467,898)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#x2019; equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">64,371</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">75,635</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#x2019; equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">129,867</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">136,874</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember', window );">Collaboration Receivables [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember]" onclick="toggleNextSibling(this);">5,594</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis<br>= bcrx_CollaborationReceivablesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember]" onclick="toggleNextSibling(this);">3,849</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis<br>= bcrx_CollaborationReceivablesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Accounts Receivable [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember]" onclick="toggleNextSibling(this);">5,641</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis<br>= us-gaap_TradeAccountsReceivableMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember', window );">Deferred Collaborative Revenue [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#x2019; Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember]" onclick="toggleNextSibling(this);">1,490</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_DeferredRevenueArrangementTypeAxis<br>= bcrx_DeferredCollaborativeRevenueMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember]" onclick="toggleNextSibling(this);">1,481</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_DeferredRevenueArrangementTypeAxis<br>= bcrx_DeferredCollaborativeRevenueMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember', window );">Deferred Product Sales [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#x2019; Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember]" onclick="toggleNextSibling(this);">$ 5,533</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_DeferredRevenueArrangementTypeAxis<br>= bcrx_DeferredProductSalesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRevenueCurrent[us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember]" onclick="toggleNextSibling(this);">$ 5,605</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRevenueCurrent<br>/ us-gaap_DeferredRevenueArrangementTypeAxis<br>= bcrx_DeferredProductSalesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents deferred collaboration expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredCollaborativeRevenueMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=bcrx_DeferredProductSalesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 1 &#8212; Significant Accounting Policies</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Company</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $111,280, to continue its planned operations through the middle of 2016. The Company&#8217;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond the middle of 2016 it will need to: (1)&#160;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&#160;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&#160;raise additional capital through equity or debt financings or from other sources; (4)&#160;obtain product candidate regulatory approvals, which would generate
      revenue and cash flow; (5)&#160;reduce spending on one or more research and development programs; and/or (6)&#160;restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.&#160;&#160;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November&#160;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basis of Presentation</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;). Royalty Sub was formed in connection with a $30,000&#160;financing transaction the Company completed on March&#160;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</font></font>
      </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These financial statements should be read in conjunction with the financial statements for the year ended December&#160;31, 2014 and the notes thereto included in the Company&#8217;s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&#160;31, 2014 has been derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form 10-K.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reclassifications</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and Cash Equivalents</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Restricted Cash</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Restricted cash as of March&#160;31, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $1,087 in royalty revenue paid by Shionogi&#160;&amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,400 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investments</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s investment policy requires it to purchase high-quality
      marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company has not realized any significant losses from its investments.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities
      at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At March&#160;31, 2015, the Company believes that the costs of its investments are recoverable in all material respects.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair value of the Company&#8217;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="18" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amortized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gains</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Losses</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair&#160;Value</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obligations of U.S. Government and its agencies</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,302</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,345</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Corporate debt securities</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,139</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">144</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,297</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificates of deposit</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,625</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,634</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="50%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,066</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">201</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(27</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,276</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="50%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td valign="bottom">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td colspan="20" nowrap="nowrap" valign="bottom">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="18" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, 2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amortized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gains</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Losses</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair&#160;Value</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obligations of U.S. Government and its agencies</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,307</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,306</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Corporate debt securities</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,152</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">151</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,261</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificates of deposit</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,838</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(63</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,781</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="50%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,297</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">179</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(133</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,348</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes the scheduled maturity for the Company&#8217;s investments at March&#160;31, 2015 and December&#160;31, 2014.</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing in one year or less</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,16<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,232</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing after one year through two years</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,656</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,459</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing after two years</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,46<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,657</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,276</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,348</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><!--EFPlaceholder-->Receivables from Collaborations</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services or royalty receivables from Shionogi&#160;&amp; Co. Ltd. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At March 31, 2015 and December&#160;31, 2014, the Company had the following receivables.</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
          <tr>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2015</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Billed</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unbilled</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
          <tr style="background-color: #CCEEFF;">
            <td align="left" valign="bottom" width="55%">
              <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi&#160;&amp; Co. Ltd.</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
          </tr>
          <tr style="background-color: #CCEEFF;">
            <td valign="bottom" width="55%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td valign="bottom" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td valign="bottom" width="12%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="middle" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td valign="bottom" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td valign="bottom" width="12%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="middle" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td valign="bottom" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td valign="bottom" width="12%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="middle" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total receivables</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,594</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
          </tr>
          <tr>
            <td valign="bottom">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td colspan="12" valign="bottom">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
        </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, 2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Billed</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unbilled</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi&#160;&amp; Co. Ltd.</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="55%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total receivables</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,849</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Receivables from Product Sales</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font>. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</font></font>
      </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventory</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At March 31, 2015 and December 31, 2014, the Company&#8217;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#8220;FIFO&#8221;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2014, in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</font>
    </div><br/><div style="TEXT-INDENT: 27pt">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s inventory consisted of the following at March&#160;31, 2015 and December&#160;31, 2014:</font>
      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Work in process</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">267</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Finished Goods</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,210</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">416</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net inventories</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,210</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">683</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Patents and Licenses</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued Expenses</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services
      performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="middle" width="5%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="2%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font>
            </div>
          </td>
          <td align="left" valign="top" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="88%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font>
            </div>
          </td>
        </tr>
      </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="middle" width="5%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="2%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font>
            </div>
          </td>
          <td align="left" valign="top" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="88%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to investigative sites in connection with clinical trials;</font>
            </div>
          </td>
        </tr>
      </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="middle" width="5%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="2%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font>
            </div>
          </td>
          <td align="left" valign="top" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="88%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&#160;and</font>
            </div>
          </td>
        </tr>
      </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="middle" width="5%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="2%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font>
            </div>
          </td>
          <td align="left" valign="top" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="88%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">professional fees.</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of March 31, 2015 and December 31, 2014, the carrying value of
      accrued expenses approximates their fair value due to their short-term settlement.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accumulated Other Comprehensive (Loss) Income</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accumulated other comprehensive (loss) income is comprised of unrealized gains and losses on investments available-for-sale and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified from accumulated other comprehensive (loss) income are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the three months ended March 31, 2015, realized gains of $8 were reclassified out of accumulated other comprehensive (loss) income. No reclassifications out of accumulated other comprehensive (loss) income were recorded during the three months ended March&#160;31, 2014.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue Recognition</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recognizes revenues from collaborative and other research and development arrangements and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&#160;persuasive evidence of an arrangement exists; (ii)&#160;delivery has occurred or services have been rendered; (iii)&#160;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&#160;collectability is reasonably assured.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Collaborative and Other Research and Development Arrangements and Royalties</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables, the Company evaluates whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Under certain of our license agreements, the Company receives royalty payments based upon our licensees&#8217; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Event payments are recognized as revenue upon the achievement of specified events if (1)&#160;the event is substantive in nature and the achievement of the event was not reasonably assured at the inception of the agreement and (2)&#160;the fees are non-refundable and non-creditable. Any event payments received prior to satisfying these criteria are recorded as deferred revenue. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable
      direct and indirect costs are incurred.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><!--EFPlaceholder--><font style="FONT-STYLE: italic; DISPLAY: inline">Product Sales</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</font></font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</font></font>
      </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and requires it to use information from external sources.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Rebates and Chargebacks</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#8217;s selling price.&#160;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#8217;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates
      and chargebacks differ from the Company&#8217;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Discounts and Sales Incentives</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with the Company&#8217;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Product Returns</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Advertising</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recorded the following revenues for the three months ended March&#160;31, 2015 and 2014:</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product sales, net</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">537</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Royalty revenue</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,518</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,821</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Collaborative and other research and development revenues:</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,475</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,341</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi (Japan)</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">296</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">296</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total collaborative and other research and development revenues</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,771</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,637</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total revenues</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,826</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,458</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expenses</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are
      performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s on-going review of the level of services actually performed.</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deferred collaboration expenses represent sub-license payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-Based Compensation</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; has occurred.</font></font>
      </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest Expense and Deferred Financing Costs</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interest expense for the three months ended March&#160;31, 2015 and 2014 was $1,315 and $1,242, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended March&#160;31, 2015 and 2014.</font></font>
      </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Currency Hedge Agreement</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&#160;31, 2015 and 2014 resulted in a gain of $464 and a loss of $1,526, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also
      required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of March&#160;31, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss Per Share</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#8217;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended March&#160;31, 2015 and 2014 does not include 3,458 and 5,206, respectively, of such potential common shares, as their impact would be anti-dilutive.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Use of Estimates</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</font>
    </div><br/><div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Significant Customers and Other Risks</font></font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#8217;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB.</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s primary source of revenue that has an underlying cash flow stream is the reimbursement of peramivir and BCX4430 development expenses, which was earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its peramivir and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#8217;s collaborative and other research and development revenues. The completion, as with the June 30, 2014 BARDA/HHS peramivir development contract, or termination of the NIAID/HHS and BARDA/HHS BCX4430 programs/collaboration could negatively impact the Company&#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA;
      however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. The Company&#8217;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Risks from Third Party Manufacturing and Distribution Concentration</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company relies on single source manufacturers for API and finished product manufacturing of RAPIVAB. Additionally, the Company relies upon a single third party to provide warehousing and distribution services for RAPIVAB. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Credit Risk</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale receivables discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Accounting Pronouncements</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In April 2015, the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">Financial Accounting Standards Board</font> (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2015-03, <font style="FONT-STYLE: italic">Simplifying the Presentation of Debt Issuance Costs</font>. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">The Company does not expect this ASU will have a material impact on its consolidated financial statements.</font></font></font>
      </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2014, the FASB issued ASU 2014-09 &#8211; <font style="FONT-STYLE: italic; DISPLAY: inline">Revenue from Contracts with Customers</font> , which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This ASU is effective for annual periods, and
        interim periods within those annual periods, beginning after December 15, 2016. Early adoption is not permitted and companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.</font></font>
      </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation (Details) - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract', window );"><strong>Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life in Years</a></td>
        <td class="text">5 years 6 months<span></span></td>
        <td class="text">5 years 6 months<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="toggleNextSibling(this);">83.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="toggleNextSibling(this);">87.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">1.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">1.60%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_WeightedAverageAssumptionsForStockOptionAwardsGrantedToEmployeesAndDirectorsUnderTheIncentivePlanAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOEAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4- Royalty Monetization (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 09, 2011

</div>
          <div>Royalty Monetization [Member]

</div>
          <div>JPR Royalty Sub LLC [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015

</div>
          <div>Japan, Yen

</div>
          <div>PhaRMA Notes [Member]

</div>
          <div>Currency Hedge Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015

</div>
          <div>PhaRMA Notes [Member]

</div>
          <div>Currency Hedge Agreement [Member]

</div>
          <div>JPR Royalty Sub LLC [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>PhaRMA Notes [Member]

</div>
          <div>Currency Hedge Agreement [Member]

</div>
          <div>JPR Royalty Sub LLC [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>PhaRMA Notes [Member]

</div>
          <div>Currency Hedge Agreement [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>PhaRMA Notes [Member]

</div>
          <div>Currency Hedge Agreement [Member]

</div>
          <div>JPY (&#xA5;)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015

</div>
          <div>PhaRMA Notes [Member]

</div>
          <div>JPR Royalty Sub LLC [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 09, 2011

</div>
          <div>PhaRMA Notes [Member]

</div>
          <div>JPR Royalty Sub LLC [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 09, 2011

</div>
          <div>JPR Royalty Sub LLC [Member]

</div>
          <div>USD ($)</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note4RoyaltyMonetizationDetailsLineItems', window );"><strong>Note 4- Royalty Monetization (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized[us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember;us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember]" onclick="toggleNextSibling(this);">$ 30,000,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis<br>= bcrx_JPRRoyaltySubLLCMember<br>/ us-gaap_OtherCommitmentsAxis<br>= bcrx_RoyaltyMonetizationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized[dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember]" onclick="toggleNextSibling(this);">$ 30,000,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized<br>/ dei_LegalEntityAxis<br>= bcrx_JPRRoyaltySubLLCMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet', window );">Revenue Recognition Royalty and Milestone Revenue Recognized Net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet[us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember;us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember]" onclick="toggleNextSibling(this);">22,691,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis<br>= bcrx_JPRRoyaltySubLLCMember<br>/ us-gaap_OtherCommitmentsAxis<br>= bcrx_RoyaltyMonetizationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_TransactionCosts[us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember;us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember]" onclick="toggleNextSibling(this);">4,309,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_TransactionCosts<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis<br>= bcrx_JPRRoyaltySubLLCMember<br>/ us-gaap_OtherCommitmentsAxis<br>= bcrx_RoyaltyMonetizationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestReserve', window );">Interest Reserve</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_InterestReserve[us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember;us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember]" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_InterestReserve<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis<br>= bcrx_JPRRoyaltySubLLCMember<br>/ us-gaap_OtherCommitmentsAxis<br>= bcrx_RoyaltyMonetizationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private Placement of Senior Secured Notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_PrivatePlacementOfSeniorSecuredNotes[us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember;us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember]" onclick="toggleNextSibling(this);">30,000,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_PrivatePlacementOfSeniorSecuredNotes<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis<br>= bcrx_JPRRoyaltySubLLCMember<br>/ us-gaap_DebtInstrumentAxis<br>= bcrx_PhaRMANotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember;us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember]" onclick="toggleNextSibling(this);">14.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis<br>= bcrx_JPRRoyaltySubLLCMember<br>/ us-gaap_DebtInstrumentAxis<br>= bcrx_PhaRMANotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes Payable, Noncurrent</a></td>
        <td class="nump"><a title="us-gaap_LongTermNotesPayable" onclick="toggleNextSibling(this);">30,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermNotesPayable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LongTermNotesPayable" onclick="toggleNextSibling(this);">30,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermNotesPayable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LongTermNotesPayable[us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember;dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember]" onclick="toggleNextSibling(this);">30,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermNotesPayable<br>/ us-gaap_DebtInstrumentAxis<br>= bcrx_PhaRMANotesMember<br>/ dei_LegalEntityAxis<br>= bcrx_JPRRoyaltySubLLCMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DerivativeForwardExchangeRate1[us-gaap_CurrencyAxis=currency_JPY;us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember;us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember]" onclick="toggleNextSibling(this);">100</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DerivativeForwardExchangeRate1<br>/ us-gaap_CurrencyAxis<br>= currency_JPY<br>/ us-gaap_DebtInstrumentAxis<br>= bcrx_PhaRMANotesMember<br>/ us-gaap_DerivativeInstrumentRiskAxis<br>= bcrx_CurrencyHedgeAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments for (Proceeds from) Hedge, Investing Activities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsForProceedsFromHedgeInvestingActivities[us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember;us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember]" onclick="toggleNextSibling(this);">1,950,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities<br>/ us-gaap_DebtInstrumentAxis<br>= bcrx_PhaRMANotesMember<br>/ us-gaap_DerivativeInstrumentRiskAxis<br>= bcrx_CurrencyHedgeAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RequiredForeignCurrencyHedgePerDollar', window );">Required Foreign Currency Hedge, Per Dollar (in Yen)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_RequiredForeignCurrencyHedgePerDollar[us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember;us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember]" onclick="toggleNextSibling(this);">100</a><span style="display:none;white-space:normal;text-align:left;">bcrx_RequiredForeignCurrencyHedgePerDollar<br>/ us-gaap_DebtInstrumentAxis<br>= bcrx_PhaRMANotesMember<br>/ us-gaap_DerivativeInstrumentRiskAxis<br>= bcrx_CurrencyHedgeAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</a></td>
        <td class="nump"><a title="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" onclick="toggleNextSibling(this);">464,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</span><span></span></td>
        <td class="num"><a title="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" onclick="toggleNextSibling(this);">(1,526,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments[us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember;us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember;us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember]" onclick="toggleNextSibling(this);">464,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis<br>= bcrx_JPRRoyaltySubLLCMember<br>/ us-gaap_DebtInstrumentAxis<br>= bcrx_PhaRMANotesMember<br>/ us-gaap_DerivativeInstrumentRiskAxis<br>= bcrx_CurrencyHedgeAgreementMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments[us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember;us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember;us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember]" onclick="toggleNextSibling(this);">1,526,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis<br>= bcrx_JPRRoyaltySubLLCMember<br>/ us-gaap_DebtInstrumentAxis<br>= bcrx_PhaRMANotesMember<br>/ us-gaap_DerivativeInstrumentRiskAxis<br>= bcrx_CurrencyHedgeAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAmountOfCollateralRequiredToPost', window );">Maximum Amount of Collateral Required to Post</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_MaximumAmountOfCollateralRequiredToPost[us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_JPRRoyaltySubLLCMember;us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember;us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember]" onclick="toggleNextSibling(this);">$ 11,700,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_MaximumAmountOfCollateralRequiredToPost<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis<br>= bcrx_JPRRoyaltySubLLCMember<br>/ us-gaap_DebtInstrumentAxis<br>= bcrx_PhaRMANotesMember<br>/ us-gaap_DerivativeInstrumentRiskAxis<br>= bcrx_CurrencyHedgeAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestReserve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents interest reserve established as part of the royalty monetization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_InterestReserve</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAmountOfCollateralRequiredToPost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents maximum amount of collateral required to post.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_MaximumAmountOfCollateralRequiredToPost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Note4RoyaltyMonetizationDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_Note4RoyaltyMonetizationDetailsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents private placement of senior secured notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RequiredForeignCurrencyHedgePerDollar">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company is required to maintain a foreign currency hedge per dollar under the agreements governing the PhaRMA Notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_RequiredForeignCurrencyHedgePerDollar</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents revenue recognition royalty and milestone revenue recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents revenue recognition royalty and milestone revenue recognized net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognizedNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents transaction costs associated with royalty monetization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_TransactionCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual rate at which a foreign currency can be purchased or sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3095-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3098-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 27<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3581-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 2 &#8212; Stock-Based Compensation</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March&#160;31, 2015, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (&#8220;Incentive Plan&#8221;) and the Employee Stock Purchase Plan (&#8220;ESPP&#8221;), both which were amended and restated in March 2014 and approved by the Company&#8217;s stockholders in May 2014. Stock-based compensation expense of $2,259 ($2,165 of expense related to the Incentive Plan and $94 of expense related to the ESPP) was recognized during the first three months of 2015, while $1,610 ($1,558 of expense related to the Incentive Plan and $52 of expense related to the ESPP) was recognized during the first three months of 2014.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There was approximately $14,621 of total unrecognized compensation cost related to non-vested stock option awards and restricted stock unit awards granted by the Company as of March&#160;31, 2015. That cost is expected to be recognized as follows: $4,006 during the remainder of 2015, $4,528 in 2016, $4,064 in 2017, $1,990 in 2018 and $33 in 2019. In addition, the Company has outstanding performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; has occurred and the award vests. At the time of vesting, compensation expense will be recognized.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock Incentive Plan</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Commencing March&#160;1, 2011, stock option awards granted to employees generally vest 25% each year until fully vested after four years. In January 2013, the Company made retention grants of stock option awards and restricted stock units. These awards vest 50% each year until fully vested after two years. In August 2013 and December 2014, the Company issued 1,032 and 1,250 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of March 31, 2015, 50% of the August 2013 grants have vested based upon achievement of two milestones: (1)
      successful completion of the OPuS-1 clinical trial for which vesting occurred in the second quarter of 2014, and (2) FDA approval of RAPIVAB for which vesting occurred in the fourth quarter of 2014. Thus, as of March&#160;31, 2015, 50% of the August 2013 performance-based grants and 100% of the December 2014 performance-based grants remain unvested and no compensation expense has been recognized for these portions of the previously issued performance-based grants. Stock option awards granted to non-employee directors of the Company generally vest monthly over one year. All stock option awards have contractual terms of 5 to 10&#160;years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Related activity under the Incentive Plan is as follows:</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Awards</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Available</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Price</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance December&#160;31, 2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,362</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,605</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.21</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted stock unit awards granted</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(133</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted stock unit awards cancelled</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock option awards granted</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(917</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">917</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11.83</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock option awards exercised</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(240</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.07</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock option awards cancelled</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(28</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9.05</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="55%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance March&#160;31, 2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,341</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,254</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.78</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For stock option awards granted under the Incentive Plan during the first three months of 2015 and 2014, the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the first three months of 2015 and 2014 was $8.11 and $8.28, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. The following table summarizes the key assumptions used by the Company to value the stock option awards granted during the first three months of 2015 and 2014. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised
      at the midpoint of the current date (if already vested) or at full vesting (if not yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#8217;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on zero-coupon government issues with a remaining term equal to the expected term.<!--EFPlaceholder--></font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted Average Assumptions for Stock Option Awards Granted to</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employees and Directors under the Incentive Plan</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected Life in Years</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected Volatility</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">87</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected Dividend Yield</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk-Free Interest Rate</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.6</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Employee Stock Purchase Plan</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has reserved a total of 1,475 shares of common stock to be purchased under the ESPP, of which 519 shares remain available for purchase at March&#160;31, 2015. Eligible employees may authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during six-month purchase intervals. No more than 3 shares may be purchased by any one employee at the six-month purchase dates and no employee may purchase stock having a fair market value at the commencement date of $25 or more in any one calendar year. The Company issued 20 shares during the first three months of 2015 under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing model.</font>
    </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">72,474</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">71,955</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">72,474</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">71,955</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPEAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Details) - Summary of Receivables (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) - Summary of Receivables [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent" onclick="toggleNextSibling(this);">$ 5,594</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent" onclick="toggleNextSibling(this);">$ 3,849</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">U.S. Department of Health and Human Services [Member] | Unbilled Revenues [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) - Summary of Receivables [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember;us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember]" onclick="toggleNextSibling(this);">4,087</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis<br>= us-gaap_UnbilledRevenuesMember<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_USDepartmentOfHealthAndHumanServicesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember;us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember]" onclick="toggleNextSibling(this);">2,778</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis<br>= us-gaap_UnbilledRevenuesMember<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_USDepartmentOfHealthAndHumanServicesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">U.S. Department of Health and Human Services [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) - Summary of Receivables [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember]" onclick="toggleNextSibling(this);">4,087</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_USDepartmentOfHealthAndHumanServicesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember]" onclick="toggleNextSibling(this);">2,778</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_USDepartmentOfHealthAndHumanServicesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi &amp; Co. Ltd. [Member] | Billed Revenues [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) - Summary of Receivables [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember;us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember]" onclick="toggleNextSibling(this);">1,507</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis<br>= us-gaap_BilledRevenuesMember<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_ShionogiAndCoLtdMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember;us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember]" onclick="toggleNextSibling(this);">1,071</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis<br>= us-gaap_BilledRevenuesMember<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_ShionogiAndCoLtdMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi &amp; Co. Ltd. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) - Summary of Receivables [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember]" onclick="toggleNextSibling(this);">1,507</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_ShionogiAndCoLtdMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember]" onclick="toggleNextSibling(this);">1,071</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_ShionogiAndCoLtdMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) - Summary of Receivables [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember]" onclick="toggleNextSibling(this);">1,507</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis<br>= us-gaap_BilledRevenuesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember]" onclick="toggleNextSibling(this);">1,071</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis<br>= us-gaap_BilledRevenuesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) - Summary of Receivables [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember]" onclick="toggleNextSibling(this);">$ 4,087</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis<br>= us-gaap_UnbilledRevenuesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent[us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember]" onclick="toggleNextSibling(this);">$ 2,778</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent<br>/ us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis<br>= us-gaap_UnbilledRevenuesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofReceivablesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3,4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">BIOCRYST PHARMACEUTICALS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">72,520,545</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000882796<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Large Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6CAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Details) - Inventory (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InventoryWorkInProcessNetOfReserves" onclick="toggleNextSibling(this);">$ 267</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryWorkInProcessNetOfReserves</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished Goods</a></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoodsNetOfReserves" onclick="toggleNextSibling(this);">1,210</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoodsNetOfReserves</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoodsNetOfReserves" onclick="toggleNextSibling(this);">416</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoodsNetOfReserves</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Net inventories</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">$ 1,210</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">$ 683</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InventoryAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_InventoryAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2UAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 537</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue" onclick="toggleNextSibling(this);">1,518</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue" onclick="toggleNextSibling(this);">1,821</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopment', window );">Collaborative and other research and development</a></td>
        <td class="nump"><a title="bcrx_CollaborativeAndOtherResearchAndDevelopment" onclick="toggleNextSibling(this);">4,771</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAndOtherResearchAndDevelopment</span><span></span></td>
        <td class="nump"><a title="bcrx_CollaborativeAndOtherResearchAndDevelopment" onclick="toggleNextSibling(this);">1,637</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAndOtherResearchAndDevelopment</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">6,826</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">3,458</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpensesAbstract', window );"><strong>Expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of products sold</a></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">15</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">17,120</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">9,183</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">4,061</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">1,588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyExpense" onclick="toggleNextSibling(this);">60</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyExpense" onclick="toggleNextSibling(this);">73</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
        <td class="nump"><a title="us-gaap_CostsAndExpenses" onclick="toggleNextSibling(this);">21,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostsAndExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostsAndExpenses" onclick="toggleNextSibling(this);">10,844</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostsAndExpenses</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(14,430)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(7,386)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
        <td class="nump"><a title="us-gaap_InterestAndOtherIncome" onclick="toggleNextSibling(this);">117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndOtherIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestAndOtherIncome" onclick="toggleNextSibling(this);">17</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestAndOtherIncome</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(1,315)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(1,242)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative</a></td>
        <td class="nump"><a title="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" onclick="toggleNextSibling(this);">464</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</span><span></span></td>
        <td class="num"><a title="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" onclick="toggleNextSibling(this);">(1,526)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(15,164)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(10,137)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in Dollars per share)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.21)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.17)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding (in Shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">72,341</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">59,589</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available for sale investments</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">140</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (15,024)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (10,139)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents collaborative and other research and development revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Securities [Table Text Block]</a></td>
        <td class="text"><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="18" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amortized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gains</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Losses</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair&#160;Value</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obligations of U.S. Government and its agencies</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,302</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,345</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Corporate debt securities</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,139</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">144</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,297</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificates of deposit</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,625</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,634</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="50%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,066</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">201</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(27</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,276</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="50%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td valign="bottom">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td colspan="20" nowrap="nowrap" valign="bottom">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="18" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, 2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amortized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gains</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Losses</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair&#160;Value</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obligations of U.S. Government and its agencies</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,307</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,306</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Corporate debt securities</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,152</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">151</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,261</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificates of deposit</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,838</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(63</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,781</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="50%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,297</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">179</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(133</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,348</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock', window );">Available for Sale Securities Debt Maturities Fair Value [Table Text Block]</a></td>
        <td class="text"><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing in one year or less</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,16<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,232</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing after one year through two years</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,656</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,459</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing after two years</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,46<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,657</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,276</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,348</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Schedule of Receivables from Collaborations [Table Text Block]</a></td>
        <td class="text"><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
          <tr>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2015</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Billed</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unbilled</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
          <tr style="background-color: #CCEEFF;">
            <td align="left" valign="bottom" width="55%">
              <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi&#160;&amp; Co. Ltd.</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
          </tr>
          <tr style="background-color: #CCEEFF;">
            <td valign="bottom" width="55%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td valign="bottom" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td valign="bottom" width="12%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="middle" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td valign="bottom" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td valign="bottom" width="12%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="middle" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td valign="bottom" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td valign="bottom" width="12%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="middle" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total receivables</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,594</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
          </tr>
          <tr>
            <td valign="bottom">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td colspan="12" valign="bottom">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
        </table><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, 2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Billed</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unbilled</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi&#160;&amp; Co. Ltd.</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="55%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total receivables</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,849</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
        <td class="text"><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Work in process</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">267</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Finished Goods</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,210</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">416</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net inventories</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,210</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">683</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock', window );">Schedule of Revenues from Collaborations [Table Text Block]</a></td>
        <td class="text"><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product sales, net</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">537</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Royalty revenue</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,518</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,821</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Collaborative and other research and development revenues:</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,475</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,341</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi (Japan)</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">296</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">296</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total collaborative and other research and development revenues</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,771</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,637</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total revenues</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,826</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,458</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of available for sale securities debt maturities fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesFairValueTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure representing receivables from collaborations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of schedule of revenues from collaborations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ScheduleOfRevenuesFromCollaborationsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">Description of Company [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Company</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with its capabilities and expertise. The Company was incorporated in Delaware in 1986 and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on its current operating plans, the Company expects it has sufficient liquidity, with its existing cash and investments of $111,280, to continue its planned operations through the middle of 2016. The Company&#8217;s liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events in the future. In order to continue its operations substantially beyond the middle of 2016 it will need to: (1)&#160;successfully secure or increase U.S. Government funding of its programs, including procurement contracts; (2)&#160;out-license rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (3)&#160;raise additional capital through equity or debt financings or from other sources; (4)&#160;obtain product candidate regulatory approvals, which would generate
      revenue and cash flow; (5)&#160;reduce spending on one or more research and development programs; and/or (6)&#160;restructure operations. The Company retains the ability to offer for sale approximately $150,000 of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on March 3, 2015.&#160;&#160;Additionally, the Company retains the ability to offer for sale approximately $10,000 of securities, including common stock, preferred stock, debt securities, depositary shares and warrants from its effective shelf S-3 registration statement, which it filed with the Securities and Exchange Commission on November&#160;6, 2013. The Company will continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basis of Presentation</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;). Royalty Sub was formed in connection with a $30,000&#160;financing transaction the Company completed on March&#160;9, 2011. See Note 4, Royalty Monetization, for a further description of this transaction. All intercompany transactions and balances have been eliminated.</font></font>
      </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These financial statements should be read in conjunction with the financial statements for the year ended December&#160;31, 2014 and the notes thereto included in the Company&#8217;s 2014 Annual Report on Form 10-K. Interim operating results are not necessarily indicative of operating results for the full year. The balance sheet as of December&#160;31, 2014 has been derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form 10-K.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reclassifications</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain balance sheet amounts as of December 31, 2014 have been reclassified to conform to the 2015 presentation.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and Cash Equivalents</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Restricted Cash</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Restricted cash as of March&#160;31, 2015 reflects $150 the Company is required to maintain in an interest bearing certificate of deposit to serve as collateral for a corporate credit card program, $1,087 in royalty revenue paid by Shionogi&#160;&amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in Note 4) and $1,400 the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investments</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s investment policy requires it to purchase high-quality
      marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 18 months. Some of the securities the Company invests in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are not collateralized. The Company has not realized any significant losses from its investments.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities
      at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At March&#160;31, 2015, the Company believes that the costs of its investments are recoverable in all material respects.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair value of the Company&#8217;s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="18" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amortized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gains</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Losses</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair&#160;Value</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obligations of U.S. Government and its agencies</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,302</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,345</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Corporate debt securities</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,139</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">144</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,297</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificates of deposit</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,625</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,634</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="50%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,066</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">201</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(27</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,276</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="50%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td valign="bottom">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td colspan="20" nowrap="nowrap" valign="bottom">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="18" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 17.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, 2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amortized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gains</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unrealized</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Losses</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Estimated</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair&#160;Value</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obligations of U.S. Government and its agencies</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,307</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(23</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,306</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="50%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Corporate debt securities</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,152</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">151</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(47</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,261</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certificates of deposit</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,838</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(63</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,781</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="50%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="7%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,297</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">179</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(133</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="7%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,348</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes the scheduled maturity for the Company&#8217;s investments at March&#160;31, 2015 and December&#160;31, 2014.</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing in one year or less</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,16<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,232</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing after one year through two years</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,656</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,459</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Maturing after two years</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,46<font style="DISPLAY: inline; FONT-FAMILY: times new roman">0</font></font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,657</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total investments</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,276</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,348</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Receivables from Collaborations</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services or royalty receivables from Shionogi&#160;&amp; Co. Ltd. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. At March 31, 2015 and December&#160;31, 2014, the Company had the following receivables.</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
          <tr>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31, 2015</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Billed</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unbilled</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font>
              </div>
            </td>
            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
          <tr style="background-color: #CCEEFF;">
            <td align="left" valign="bottom" width="55%">
              <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi&#160;&amp; Co. Ltd.</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
          </tr>
          <tr style="background-color: #CCEEFF;">
            <td valign="bottom" width="55%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td valign="bottom" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td valign="bottom" width="12%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="middle" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td valign="bottom" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td valign="bottom" width="12%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="middle" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="bottom" width="1%">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td valign="bottom" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td valign="bottom" width="12%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td align="left" valign="middle" width="1%">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
          <tr>
            <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total receivables</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,507</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,087</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
              </div>
            </td>
            <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,594</font>
              </div>
            </td>
            <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
              <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
              </div>
            </td>
          </tr>
          <tr>
            <td valign="bottom">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
            <td colspan="12" valign="bottom">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
            </td>
          </tr>
        </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="10" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 9.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31, 2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Billed</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unbilled</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi&#160;&amp; Co. Ltd.</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="55%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total receivables</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,778</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,849</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Receivables from Product Sales</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font>. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</font></font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventory</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At March 31, 2015 and December 31, 2014, the Company&#8217;s inventory consisted of RAPIVAB finished goods inventory and work in process. Inventory is stated at the lower of cost, determined under the first-in, first-out (&#8220;FIFO&#8221;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2014, in connection with the FDA approval of RAPIVAB, the Company began capitalizing costs associated with the production of RAPIVAB inventories.</font>
    </div><br/><div style="TEXT-INDENT: 27pt">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s inventory consisted of the following at March&#160;31, 2015 and December&#160;31, 2014:</font>
      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Work in process</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">267</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Finished Goods</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,210</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">416</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net inventories</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,210</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">683</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Patents and Licenses</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accrued Expenses</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services
      performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="middle" width="5%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="2%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font>
            </div>
          </td>
          <td align="left" valign="top" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="88%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</font>
            </div>
          </td>
        </tr>
      </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="middle" width="5%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="2%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font>
            </div>
          </td>
          <td align="left" valign="top" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="88%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to investigative sites in connection with clinical trials;</font>
            </div>
          </td>
        </tr>
      </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="middle" width="5%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="2%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font>
            </div>
          </td>
          <td align="left" valign="top" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="88%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products;&#160;and</font>
            </div>
          </td>
        </tr>
      </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="middle" width="5%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="2%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;</font>
            </div>
          </td>
          <td align="left" valign="top" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="top" width="88%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">professional fees.</font>
            </div>
          </td>
        </tr>
      </table><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of March 31, 2015 and December 31, 2014, the carrying value of
      accrued expenses approximates their fair value due to their short-term settlement.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock', window );">Accumulated Other Comprehensive Income Loss [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accumulated Other Comprehensive (Loss) Income</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accumulated other comprehensive (loss) income is comprised of unrealized gains and losses on investments available-for-sale and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified from accumulated other comprehensive (loss) income are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the three months ended March 31, 2015, realized gains of $8 were reclassified out of accumulated other comprehensive (loss) income. No reclassifications out of accumulated other comprehensive (loss) income were recorded during the three months ended March&#160;31, 2014.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue Recognition</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recognizes revenues from collaborative and other research and development arrangements and product sales when realized or realizable and earned. Revenue is realized or realizable and earned when all of the following criteria are met: (i)&#160;persuasive evidence of an arrangement exists; (ii)&#160;delivery has occurred or services have been rendered; (iii)&#160;the seller&#8217;s price to the buyer is fixed or determinable; and (iv)&#160;collectability is reasonably assured.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Collaborative and Other Research and Development Arrangements and Royalties</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revenue from license fees, royalty payments, event payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management based on the terms of the agreement and the products licensed. In the event a license agreement contains multiple deliverables, the Company evaluates whether the deliverables are separate or combined units of accounting. Revisions to revenue or profit estimates as a result of changes in the estimated revenue period are recognized prospectively.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Under certain of our license agreements, the Company receives royalty payments based upon our licensees&#8217; net sales of covered products. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Event payments are recognized as revenue upon the achievement of specified events if (1)&#160;the event is substantive in nature and the achievement of the event was not reasonably assured at the inception of the agreement and (2)&#160;the fees are non-refundable and non-creditable. Any event payments received prior to satisfying these criteria are recorded as deferred revenue. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable
      direct and indirect costs are incurred.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><!--EFPlaceholder--><font style="FONT-STYLE: italic; DISPLAY: inline">Product Sales</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recognizes revenue for sales of RAPIVAB when title and substantially all the risks and rewards of ownership have transferred to the customer, which generally occurs on the date of shipment from our specialty distributors, utilizing the Sell-Through revenue recognition methodology. Product sales are recognized when there is persuasive evidence that an arrangement exists, title has passed, the price was fixed and determinable, and collectability is reasonably assured. Product sales are recognized net of estimated allowances, discounts, sales returns, chargebacks and rebates. In the United States, the Company sells RAPIVAB to specialty distributors, who in turn, sell to physician offices, hospitals and federal, state and commercial health care organizations.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sales deductions consist of statutory rebates to state Medicaid, Medicare and other government agencies and sales discounts (including trade discounts and distribution service fees). These deductions are recorded as reductions from revenue from RAPIVAB in the same period as the related sales with estimates of future utilization derived from historical experience adjusted to reflect known changes in the factors that impact such reserves.</font></font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company utilizes data from external sources to help it estimate gross-to-net sales adjustments as they relate to the recognition of revenue for RAPIVAB sold. Externally sourced data includes, but is not limited to, information obtained from specialty distributors with respect to their inventory levels and their sell-through to customers, as well as information from third-party suppliers of market research data to the pharmaceutical industry.</font></font>
      </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company accounts for these sales deductions in accordance with authoritative guidance on revenue recognition when consideration is given by a vendor to a customer.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has categorized and described more fully the following significant sales deductions, all of which involve estimates and judgments, which the Company considers to be critical accounting estimates, and requires it to use information from external sources.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Rebates and Chargebacks</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Statutory rebates to state Medicaid agencies and Medicare are based on statutory discounts to RAPIVAB&#8217;s selling price.&#160;As it can take up to nine months or more for information to be received on actual usage of RAPIVAB in Medicaid and other governmental programs, the Company maintains reserves for amounts payable under these programs relating to RAPIVAB sales.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chargebacks claimed by specialty distributors are based on the differentials between product acquisition prices paid by the specialty distributors and lower government contract pricing paid by eligible customers covered under federally qualified programs.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amount of the reserve for rebates and chargebacks is based on multiple qualitative and quantitative factors, including the historical and projected utilization levels, historical payment experience, changes in statutory laws and interpretations as well as contractual terms, product pricing (both normal selling prices and statutory or negotiated prices), changes in prescription demand patterns and utilization of the Company&#8217;s product through public benefit plans, and the levels of RAPIVAB inventory in the distribution channel. The Company acquires prescription utilization data from third-party suppliers of market research data to the pharmaceutical industry. The Company updates its estimates and assumptions each period and records any necessary adjustments to its reserves. Settlements of rebates and chargebacks typically occur within nine months from point of sale. To the extent actual rebates
      and chargebacks differ from the Company&#8217;s estimates, additional reserves may be required or reserves may need to be reversed, either of which would impact current period product revenue.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Discounts and Sales Incentives</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Discounts and other sales incentives primarily consist of Inventory Management Agreement (&#8220;IMA&#8221;) Fees. Per contractual agreements with the Company&#8217;s specialty distributors, the Company provides an IMA fee based on a percentage of their purchases of RAPIVAB. The IMA fee rates are set forth in individual contracts. The Company tracks sales to these distributors each period and accrues a liability relating to the unpaid portion of these fees by applying the contractual rates to such product sales.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Product Returns</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company does not record a product return allowance as it does not offer the ability to return goods once a bonafide shipment has been accepted by a specialty distributor.&#160;</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Advertising</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recorded the following revenues for the three months ended March&#160;31, 2015 and 2014:</font>
    </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product sales, net</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">537</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Royalty revenue</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,518</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,821</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Collaborative and other research and development revenues:</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. Department of Health and Human Services</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,475</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,341</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shionogi (Japan)</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">296</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 0.5pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">296</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total collaborative and other research and development revenues</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,771</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,637</font>
            </div>
          </td>
          <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="70%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total revenues</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,826</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,458</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expenses</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are
      performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s on-going review of the level of services actually performed.</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deferred collaboration expenses represent sub-license payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock-Based Compensation</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#8220;performance&#8221; has occurred.</font></font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest Expense and Deferred Financing Costs</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interest expense for the three months ended March&#160;31, 2015 and 2014 was $1,315 and $1,242, respectively, and relates to the issuance of the PhaRMA Notes (defined in Note 4). Costs directly associated with the issuance of the PhaRMA Notes have been capitalized and are included in other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the term of the PhaRMA Notes using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $110 for each of the three months ended March&#160;31, 2015 and 2014.</font></font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock', window );">Currency Hedge Agreement [Policy Text Block]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Currency Hedge Agreement</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement (defined in Note 4) to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the three months ended March&#160;31, 2015 and 2014 resulted in a gain of $464 and a loss of $1,526, respectively. Mark-to-market adjustments are determined by a third party pricing model that uses quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by U.S. GAAP. The Company is also
      required to post collateral in connection with the mark-to-market adjustments based on thresholds defined in the Currency Hedge Agreement. As of March&#160;31, 2015 and December 31, 2014, no hedge collateral was posted under the agreement.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss Per Share</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#8217;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the three months ended March&#160;31, 2015 and 2014 does not include 3,458 and 5,206, respectively, of such potential common shares, as their impact would be anti-dilutive.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Use of Estimates</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Concentration of Market Risk [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Significant Customers and Other Risks</font></font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company relies primarily on three specialty distributors to purchase and supply the majority of RAPIVAB. These three pharmaceutical specialty distributors accounted for greater than 90% of all RAPIVAB product sales to date and accounted for predominantly all of the Company&#8217;s outstanding receivables from product sales. The loss of one or more of these specialty distributors as a customer could negatively impact the commercialization of RAPIVAB.</font>
    </div><br/><div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s primary source of revenue that has an underlying cash flow stream is the reimbursement of peramivir and BCX4430 development expenses, which was earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS, respectively. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its peramivir and BCX4430 programs. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#8217;s collaborative and other research and development revenues. The completion, as with the June 30, 2014 BARDA/HHS peramivir development contract, or termination of the NIAID/HHS and BARDA/HHS BCX4430 programs/collaboration could negatively impact the Company&#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. In addition, the Company also recognizes royalty revenue from the net sales of RAPIACTA;
      however, the underlying cash flow from these royalty payments goes directly to pay the interest, and then the principal, on the Company&#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. The Company&#8217;s drug development activities are performed by a limited group of third party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</font>
    </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Risks from Third Party Manufacturing and Distribution Concentration</font></font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company relies on single source manufacturers for API and finished product manufacturing of RAPIVAB. Additionally, the Company relies upon a single third party to provide warehousing and distribution services for RAPIVAB. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of RAPIVAB.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Credit Risk</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale receivables discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.</font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Accounting Pronouncements</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In April 2015, the <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">Financial Accounting Standards Board</font> (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2015-03, <font style="FONT-STYLE: italic">Simplifying the Presentation of Debt Issuance Costs</font>. This standard amends existing guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability instead of a deferred charge. It is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">The Company does not expect this ASU will have a material impact on its consolidated financial statements.</font></font></font>
      </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2014, the FASB issued ASU 2014-09 &#8211; <font style="FONT-STYLE: italic; DISPLAY: inline">Revenue from Contracts with Customers</font> , which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This ASU is effective for annual periods, and
        interim periods within those annual periods, beginning after December 15, 2016. Early adoption is not permitted and companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.</font></font></div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents accrued expenses policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents accumulated other comprehensive income (loss) policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AccumulatedOtherComprehensiveIncomeLossPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents concentration of market risk policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents currency hedge agreement policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_CurrencyHedgeAgreementPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The description of company policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents interest expense and deferred financing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section M<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2,12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 2, 12<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3-5<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e4975-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E52DI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">50 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2006</div>
        </th>
        <th class="th">
          <div>May 31, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2000</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Feb. 24, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2009</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2007</div>
        </th>
        <th class="th">
          <div>Feb. 24, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems', window );"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_GovernmentContractReceivable[us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember]" onclick="toggleNextSibling(this);">$ 12,134,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GovernmentContractReceivable<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_BaseContractMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems', window );"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_GovernmentContractReceivable[us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember]" onclick="toggleNextSibling(this);">22,855,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GovernmentContractReceivable<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_AdditionalDevelopmentOptionsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPR/BARDA Contract [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems', window );"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_GovernmentContractReceivable[us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember]" onclick="toggleNextSibling(this);">34,989,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GovernmentContractReceivable<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_ASPRBARDAContractMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems', window );"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromLicenseFeesReceived[us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember]" onclick="toggleNextSibling(this);">250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromLicenseFeesReceived<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_GreenCrossCorporationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems', window );"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone Payment Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_MilestonePaymentMinimum[us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember]" onclick="toggleNextSibling(this);">1,400,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_MilestonePaymentMinimum<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_AECOMAndIRLMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_MilestonePaymentMaximum[us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember]" onclick="toggleNextSibling(this);">4,000,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_MilestonePaymentMaximum<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_AECOMAndIRLMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual License Fee Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_AnnualLicenseFeeMinimum[us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember]" onclick="toggleNextSibling(this);">150,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AnnualLicenseFeeMinimum<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_AECOMAndIRLMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual License Fee Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_AnnualLicenseFeeMaximum[us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember]" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AnnualLicenseFeeMaximum<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_AECOMAndIRLMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement', window );">Advance Notice Period for Termination of Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">60 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement', window );">Stock Issued During Period Value for Modification of License Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement[us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember]" onclick="toggleNextSibling(this);">5,911,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_AECOMAndIRLMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PaymentsForModificationOfLicenseAgreement', window );">Payments for Modification of License Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_PaymentsForModificationOfLicenseAgreement[us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember]" onclick="toggleNextSibling(this);">90,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_PaymentsForModificationOfLicenseAgreement<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_AECOMAndIRLMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">U.S. Department of Health and Human Services [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems', window );"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative Agreement Contract Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_CollaborativeAgreementContractValue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember]" onclick="toggleNextSibling(this);">102,661,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAgreementContractValue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= bcrx_USDepartmentOfHealthAndHumanServicesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementAdditionalContractValue', window );">Collaborative Agreement Additional Contract Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_CollaborativeAgreementAdditionalContractValue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember]" onclick="toggleNextSibling(this);">55,000,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAgreementAdditionalContractValue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= bcrx_USDepartmentOfHealthAndHumanServicesMember</span><span></span></td>
        <td class="nump"><a title="bcrx_CollaborativeAgreementAdditionalContractValue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember]" onclick="toggleNextSibling(this);">77,191,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAgreementAdditionalContractValue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= bcrx_USDepartmentOfHealthAndHumanServicesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementAdjustedContractValue', window );">Collaborative Agreement Adjusted Contract Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_CollaborativeAgreementAdjustedContractValue[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember]" onclick="toggleNextSibling(this);">234,852,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAgreementAdjustedContractValue<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= bcrx_USDepartmentOfHealthAndHumanServicesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems', window );"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from Awards for Research and Development Contracts</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected Receivable from Awards for Research and Development Contracts</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember]" onclick="toggleNextSibling(this);">29,147,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementPeriodOfContract', window );">Collaborative Agreement Period of Contract</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborationAgreementAdditionalPaymentsReceived', window );">Collaboration Agreement Additional Payments Received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_CollaborationAgreementAdditionalPaymentsReceived[us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember]" onclick="toggleNextSibling(this);">$ 25,021,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborationAgreementAdditionalPaymentsReceived<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems', window );"><strong>Note 3 - Collaborative and Other Research and Development Contracts (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RenewablePeriodOfAgreement', window );">Renewable Period of Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">25 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents advance notice period for termination of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents annual license fee maximum.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents annual license fee minimum.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborationAgreementAdditionalPaymentsReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents collaboration agreement additional payments received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_CollaborationAgreementAdditionalPaymentsReceived</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementAdditionalContractValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents collaborative agreement additional contract value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_CollaborativeAgreementAdditionalContractValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementAdjustedContractValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents collaborative agreement adjusted contract value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_CollaborativeAgreementAdjustedContractValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents collaborative agreement contract value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementPeriodOfContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents collaborative agreement period of contract.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_CollaborativeAgreementPeriodOfContract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents expected receivable from awards for research and development contracts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents milestone payment maximum.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents milestone payment minimum.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_Note3CollaborativeandOtherResearchandDevelopmentContractsDetailsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PaymentsForModificationOfLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents payments for modifications of license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_PaymentsForModificationOfLicenseAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents period of agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents proceeds from awards for research and development contracts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RenewablePeriodOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents renewable period of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_RenewablePeriodOfAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents stock issued during period value for modification of license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_StockIssuedDuringPeriodValueForModificationOfLicenseAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of receivables that are derived from government contracts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 912<br><br> -SubTopic 310<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6471842&amp;loc=d3e55295-109406<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from licensees for license fees during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYJAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Details) - Summary of Revenues (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) - Summary of Revenues [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 537</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue" onclick="toggleNextSibling(this);">1,518</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_RoyaltyRevenue" onclick="toggleNextSibling(this);">1,821</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RoyaltyRevenue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopment', window );">Collaborative and other research and development revenues</a></td>
        <td class="nump"><a title="bcrx_CollaborativeAndOtherResearchAndDevelopment" onclick="toggleNextSibling(this);">4,771</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAndOtherResearchAndDevelopment</span><span></span></td>
        <td class="nump"><a title="bcrx_CollaborativeAndOtherResearchAndDevelopment" onclick="toggleNextSibling(this);">1,637</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAndOtherResearchAndDevelopment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">6,826</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">3,458</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">U.S. Department of Health and Human Services [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopment', window );">Collaborative and other research and development revenues</a></td>
        <td class="nump"><a title="bcrx_CollaborativeAndOtherResearchAndDevelopment[us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember]" onclick="toggleNextSibling(this);">4,475</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAndOtherResearchAndDevelopment<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_USDepartmentOfHealthAndHumanServicesMember</span><span></span></td>
        <td class="nump"><a title="bcrx_CollaborativeAndOtherResearchAndDevelopment[us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember]" onclick="toggleNextSibling(this);">1,341</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAndOtherResearchAndDevelopment<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_USDepartmentOfHealthAndHumanServicesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi &amp; Co. Ltd. [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract', window );"><strong>Collaborative and other research and development revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAndOtherResearchAndDevelopment', window );">Collaborative and other research and development revenues</a></td>
        <td class="nump"><a title="bcrx_CollaborativeAndOtherResearchAndDevelopment[us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember]" onclick="toggleNextSibling(this);">$ 296</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAndOtherResearchAndDevelopment<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_ShionogiAndCoLtdMember</span><span></span></td>
        <td class="nump"><a title="bcrx_CollaborativeAndOtherResearchAndDevelopment[us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember]" onclick="toggleNextSibling(this);">$ 296</a><span style="display:none;white-space:normal;text-align:left;">bcrx_CollaborativeAndOtherResearchAndDevelopment<br>/ us-gaap_TypeOfArrangementAxis<br>= bcrx_ShionogiAndCoLtdMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents collaborative and other research and development revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_CollaborativeAndOtherResearchAndDevelopmentRevenuesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_Note1SignificantAccountingPoliciesDetailsSummaryofRevenuesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ShionogiAndCoLtdMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EISAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Details) - Fair Value of the Company&#x2019;s Investments by Type (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost" onclick="toggleNextSibling(this);">$ 60,066</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost" onclick="toggleNextSibling(this);">$ 59,297</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesAccruedInterest" onclick="toggleNextSibling(this);">201</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesAccruedInterest</span><span></span></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesAccruedInterest" onclick="toggleNextSibling(this);">179</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesAccruedInterest</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" onclick="toggleNextSibling(this);">36</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" onclick="toggleNextSibling(this);">(27)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" onclick="toggleNextSibling(this);">(133)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">60,276</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">59,348</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NuclearFuelNetOfAmortization', window );"></a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SpentNuclearFuelObligationNoncurrent', window );"></a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForNuclearFuel', window );"></a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNuclearFuel', window );"></a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">20,302</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_USGovernmentAgenciesDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">20,307</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_USGovernmentAgenciesDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesAccruedInterest[us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">42</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesAccruedInterest<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_USGovernmentAgenciesDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesAccruedInterest[us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">22</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesAccruedInterest<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_USGovernmentAgenciesDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains[us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_USGovernmentAgenciesDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss[us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_USGovernmentAgenciesDebtSecuritiesMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss[us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(23)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_USGovernmentAgenciesDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">20,345</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_USGovernmentAgenciesDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember]" onclick="toggleNextSibling(this);">23,306</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_USGovernmentAgenciesDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">28,139</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">27,152</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesAccruedInterest[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">144</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesAccruedInterest<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesAccruedInterest[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">151</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesAccruedInterest<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">27</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(13)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">(47)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">28,297</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember]" onclick="toggleNextSibling(this);">27,261</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CorporateDebtSecuritiesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">11,625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesAmortizedCost[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">11,838</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesAmortizedCost<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesAccruedInterest[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">15</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesAccruedInterest<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesAccruedInterest[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">6</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesAccruedInterest<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">6</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">(12)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">(63)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Estimated Fair Value</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">$ 11,634</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities[us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember]" onclick="toggleNextSibling(this);">$ 11,781</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities<br>/ us-gaap_InvestmentTypeAxis<br>= us-gaap_CommercialPaperMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents available-for-sale securities accrued interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesAccruedInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrealized loss before deducting unrealized gain on investments in available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NuclearFuelNetOfAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount as of the balance sheet of nuclear fuel held as property plant and equipment. This amount is net of amortization based on the energy produced over the life of the fuel.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NuclearFuelNetOfAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForNuclearFuel">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash outflow associated with the purchase of any material that is commonly used in the generation of nuclear energy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForNuclearFuel</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNuclearFuel">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash inflow resulting from the sale of any material that is commonly used in the generation of nuclear energy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromNuclearFuel</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SpentNuclearFuelObligationNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Provision for the disposal costs of spent nuclear fuel from generating stations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.Y.Q2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SpentNuclearFuelObligationNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-based Compensation, Activity [Table Text Block]</a></td>
        <td class="text"><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Awards</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Available</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise</font>
            </div>
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Price</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance December&#160;31, 2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,362</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,605</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.21</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted stock unit awards granted</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(133</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted stock unit awards cancelled</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock option awards granted</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(917</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">917</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11.83</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="55%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock option awards exercised</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(240</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.07</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock option awards cancelled</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(28</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 1.1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">)</font>&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9.05</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td valign="bottom" width="55%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="middle" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="12%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance March&#160;31, 2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,341</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,254</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2.75pt double">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>
            </div>
          </td>
          <td align="right" valign="bottom" width="12%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.78</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
      </table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
        <td class="text"><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
        <tr>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" style="PADDING-BOTTOM: 1pt">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2014</font>
            </div>
          </td>
          <td align="left" valign="bottom" style="BORDER-BOTTOM: black 1pt solid">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected Life in Years</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected Volatility</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">87</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
        </tr>
        <tr style="background-color: #CCEEFF;">
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected Dividend Yield</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
        </tr>
        <tr>
          <td align="left" valign="bottom" width="70%">
            <div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk-Free Interest Rate</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.5</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="left" valign="bottom" width="1%">
            <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>
          </td>
          <td align="right" valign="bottom" width="12%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="right">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.6</font>
            </div>
          </td>
          <td align="left" valign="bottom" width="1%">
            <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left">
              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>
            </div>
          </td>
        </tr>
      </table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECNBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Details) (USD $)<br>Share data in Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Nov. 06, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 09, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Investments and Cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InvestmentsAndCash" onclick="toggleNextSibling(this);">$ 111,280,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentsAndCash</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SecuritiesOffered', window );">Securities Offered</a></td>
        <td class="nump"><a title="bcrx_SecuritiesOffered" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_SecuritiesOffered</span><span></span></td>
        <td class="nump"><a title="bcrx_SecuritiesOffered" onclick="toggleNextSibling(this);">150,000,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_SecuritiesOffered</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">2,637,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">150,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" onclick="toggleNextSibling(this);">8,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</span><span></span></td>
        <td class="nump"><a title="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">1,315,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">1,242,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Financing Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCosts" onclick="toggleNextSibling(this);">110,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCosts</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCosts" onclick="toggleNextSibling(this);">110,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCosts</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" onclick="toggleNextSibling(this);">464,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</span><span></span></td>
        <td class="num"><a title="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" onclick="toggleNextSibling(this);">(1,526,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">3,458</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">5,206</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue[us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember]" onclick="toggleNextSibling(this);">150,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue<br>/ us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis<br>= us-gaap_CertificatesOfDepositMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue[us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember]" onclick="toggleNextSibling(this);">1,087,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue<br>/ us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis<br>= bcrx_RoyaltyReceivableMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash and Cash Equivalents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalents[us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember]" onclick="toggleNextSibling(this);">1,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalents<br>/ us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis<br>= bcrx_CollateralForCreditMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVAB [Member] | Sales Revenue, Product Line [Member] | Customer Concentration Risk [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1[us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember;us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember;us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember]" onclick="toggleNextSibling(this);">90.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1<br>/ us-gaap_ConcentrationRiskByBenchmarkAxis<br>= us-gaap_SalesRevenueProductLineMember<br>/ us-gaap_ConcentrationRiskByTypeAxis<br>= us-gaap_CustomerConcentrationRiskMember<br>/ us-gaap_ProductOrServiceAxis<br>= bcrx_RAPIVABMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense[us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember]" onclick="toggleNextSibling(this);">1,315,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense<br>/ us-gaap_LongtermDebtTypeAxis<br>= bcrx_PhaRMANotesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpense[us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember]" onclick="toggleNextSibling(this);">1,242,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense<br>/ us-gaap_LongtermDebtTypeAxis<br>= bcrx_PhaRMANotesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketableSecurities', window );">Maturity Period of High Quality Marketable Securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities', window );">Average Maturity Period of High Quality Marketable Securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">18 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">12 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AverageMaturityForPortfolioInvestments', window );">Average Maturity for Portfolio Investments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">18 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfShortTermInvestment', window );">Maturity Period of Short Term Investment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LongTermInvestmentMaturityMinimum', window );">Long Term Investment Maturity Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">12 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note1SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Note 1 - Significant Accounting Policies (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized[dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember]" onclick="toggleNextSibling(this);">$ 30,000,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized<br>/ dei_LegalEntityAxis<br>= bcrx_JPRRoyaltySubLLCMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AverageMaturityForPortfolioInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents average maturity for portfolio investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AverageMaturityForPortfolioInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents average maturity period of high quality marketable securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongTermInvestmentMaturityMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents long term investment maturity minimum.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_LongTermInvestmentMaturityMinimum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents maturity period of high quality marketable securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketableSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfShortTermInvestment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents maturity period of short term investment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_MaturityPeriodOfShortTermInvestment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Note1SignificantAccountingPoliciesDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_Note1SignificantAccountingPoliciesDetailsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents revenue recognition royalty and milestone revenue recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SecuritiesOffered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents securities offered for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_SecuritiesOffered</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of investments and unrestricted cash as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_PhaRMANotesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Details) - Scheduled Maturity for the Company&#x2019;s Investments (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract', window );"><strong>Scheduled Maturity for the Company&#x2019;s Investments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" onclick="toggleNextSibling(this);">$ 19,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" onclick="toggleNextSibling(this);">$ 18,232</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Maturing after one year through two years</a></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" onclick="toggleNextSibling(this);">29,656</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</span><span></span></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" onclick="toggleNextSibling(this);">25,459</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears', window );">Maturing after two years</a></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" onclick="toggleNextSibling(this);">11,460</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears</span><span></span></td>
        <td class="nump"><a title="bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears" onclick="toggleNextSibling(this);">15,657</a><span style="display:none;white-space:normal;text-align:left;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total investments</a></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">$ 60,276</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_AvailableForSaleSecurities" onclick="toggleNextSibling(this);">$ 59,348</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AvailableForSaleSecurities</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents available for sale securities debt maturities after one through two years fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents debt maturities after two years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ScheduledMaturityForTheCompanySInvestmentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EEIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation (Details) - Stock Incentive Plan Activities (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_StockIncentivePlanActivitiesAbstract', window );"><strong>Stock Incentive Plan Activities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards Available</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">1,341</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">2,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">10,254</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">9,605</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in Dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.78</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock unit awards granted</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" onclick="toggleNextSibling(this);">(133)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock unit awards cancelled</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Stock option awards granted</a></td>
        <td class="num"><a title="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" onclick="toggleNextSibling(this);">(917)</a><span style="display:none;white-space:normal;text-align:left;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option awards granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" onclick="toggleNextSibling(this);">917</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option awards granted (in Dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 11.83</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option awards exercised</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">(240)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock option awards exercised (in Dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 3.07</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Stock option awards cancelled</a></td>
        <td class="nump"><a title="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" onclick="toggleNextSibling(this);">28</a><span style="display:none;white-space:normal;text-align:left;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock option awards cancelled</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="toggleNextSibling(this);">(28)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Stock option awards cancelled (in Dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 9.05</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents share based compensation arrangement by share based payment award options grants in period awards available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_StockIncentivePlanActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_StockIncentivePlanActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECJAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_OperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (15,164)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (10,137)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">45</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">53</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">2,259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">1,610</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCosts" onclick="toggleNextSibling(this);">110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCosts</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCosts" onclick="toggleNextSibling(this);">110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Change in fair value of foreign currency derivative</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDerivativeAssets" onclick="toggleNextSibling(this);">(464)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDerivativeAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDerivativeAssets" onclick="toggleNextSibling(this);">1,526</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDerivativeAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInReceivables" onclick="toggleNextSibling(this);">3,896</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInReceivables</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInReceivables" onclick="toggleNextSibling(this);">(1,165)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInReceivables</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">(527)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">1,848</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">892</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities', window );">Deferred collaboration expense</a></td>
        <td class="nump"><a title="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" onclick="toggleNextSibling(this);">14</a><span style="display:none;white-space:normal;text-align:left;">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</span><span></span></td>
        <td class="nump"><a title="bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities" onclick="toggleNextSibling(this);">15</a><span style="display:none;white-space:normal;text-align:left;">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">3,404</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">(2,252)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInInterestPayableNet" onclick="toggleNextSibling(this);">1,212</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInterestPayableNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInInterestPayableNet" onclick="toggleNextSibling(this);">685</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInterestPayableNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(359)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDeferredRevenue" onclick="toggleNextSibling(this);">(296)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDeferredRevenue</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(3,726)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(8,959)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisitions of furniture and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireProductiveAssets" onclick="toggleNextSibling(this);">(565)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireProductiveAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireProductiveAssets" onclick="toggleNextSibling(this);">(7)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireProductiveAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted cash</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInRestrictedCash" onclick="toggleNextSibling(this);">(2,487)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCash</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInRestrictedCash" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInRestrictedCash</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" onclick="toggleNextSibling(this);">(3,378)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" onclick="toggleNextSibling(this);">(9,367)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">2,482</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" onclick="toggleNextSibling(this);">8,350</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(3,948)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(1,023)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock, net</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">1,175</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">155</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">3,804</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Employee stock purchase plan sales</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockPlans" onclick="toggleNextSibling(this);">171</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockPlans</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockPlans" onclick="toggleNextSibling(this);">128</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockPlans</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral', window );">Payment of foreign currency derivative collateral</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral" onclick="toggleNextSibling(this);">(1,530)</a><span style="display:none;white-space:normal;text-align:left;">bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">1,501</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">2,402</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Decrease in cash and cash equivalents</a></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(6,173)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(7,580)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">54,540</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">21,164</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 48,367</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 13,584</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ChangesInOperatingAssetsAndLiabilitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents deferred collaboration expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_FinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_FinancingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_InvestingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_OperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_OperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the receipt or payment of foreign currency derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ReceiptPaymentOfForeignCurrencyDerivativeCollateral</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from the stock plan during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 5 &#8212; Stockholders&#8217; Equity</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 3, 2015, the Company filed a $150,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective upon filing and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.</font>
    </div><br/><div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
      <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On November&#160;6, 2013, the Company filed a $125,000 shelf registration statement on Form S-3 with the SEC. This shelf registration statement was declared effective in November 2013 and allows the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale. The Company has $10,000 remaining under this shelf registration.<!--EFPlaceholder--></font>
    </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>93</ContextCount>
  <ElementCount>221</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Disclosure - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Note 1 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note1SignificantAccountingPolicies</Role>
      <ShortName>Note 1 - Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 2 - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note2StockBasedCompensation</Role>
      <ShortName>Note 2 - Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContracts</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 4- Royalty Monetization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note4RoyaltyMonetization</Role>
      <ShortName>Note 4- Royalty Monetization</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 5 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note5StockholdersEquity</Role>
      <ShortName>Note 5 - Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 1 - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note1SignificantAccountingPoliciesTables</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 2 - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note2StockBasedCompensationTables</Role>
      <ShortName>Note 2 - Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 1 - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note1SignificantAccountingPoliciesDetails</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 1 - Significant Accounting Policies (Details) - Fair Value of the Company’s Investments by Type</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/FairValueoftheCompanysInvestmentsbyTypeTable</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Details) - Fair Value of the Company’s Investments by Type</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 1 - Significant Accounting Policies (Details) - Scheduled Maturity for the Company’s Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/ScheduledMaturityfortheCompanysInvestmentsTable</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Details) - Scheduled Maturity for the Company’s Investments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 1 - Significant Accounting Policies (Details) - Summary of Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SummaryofReceivablesTable</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Details) - Summary of Receivables</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 1 - Significant Accounting Policies (Details) - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/InventoryTable</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Details) - Inventory</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 1 - Significant Accounting Policies (Details) - Summary of Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/SummaryofRevenuesTable</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Details) - Summary of Revenues</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 2 - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note2StockBasedCompensationDetails</Role>
      <ShortName>Note 2 - Stock-Based Compensation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 2 - Stock-Based Compensation (Details) - Stock Incentive Plan Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/StockIncentivePlanActivitiesTable</Role>
      <ShortName>Note 2 - Stock-Based Compensation (Details) - Stock Incentive Plan Activities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 2 - Stock-Based Compensation (Details) - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/WeightedAverageAssumptionsforStockOptionAwardsGrantedtoEmployeesandDirectorsundertheIncentivePlanTable</Role>
      <ShortName>Note 2 - Stock-Based Compensation (Details) - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Incentive Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note3CollaborativeandOtherResearchandDevelopmentContractsDetails</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 4- Royalty Monetization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note4RoyaltyMonetizationDetails</Role>
      <ShortName>Note 4- Royalty Monetization (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 5 - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/role/Note5StockholdersEquityDetails</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_AllocatedShareBasedCompensationExpense had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">'Monetary' elements on report '013 - Disclosure - Note 1 - Significant Accounting Policies (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '022 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '023 - Disclosure - Note 4- Royalty Monetization (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>bcrx-20150331.xml</File>
    <File>bcrx-20150331.xsd</File>
    <File>bcrx-20150331_cal.xml</File>
    <File>bcrx-20150331_def.xml</File>
    <File>bcrx-20150331_lab.xml</File>
    <File>bcrx-20150331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EE3BI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 2 - Stock-Based Compensation (Details) (USD $)<br>Share data in Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfStockBasedCompensationPlans', window );">Number of Stock Based Compensation Plans</a></td>
        <td class="nump"><a title="bcrx_NumberOfStockBasedCompensationPlans" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">bcrx_NumberOfStockBasedCompensationPlans</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 2,259,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 1,610,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" onclick="toggleNextSibling(this);">14,621,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear', window );">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized for Remainder of Fiscal Year</a></td>
        <td class="nump"><a title="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" onclick="toggleNextSibling(this);">4,006,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Two</a></td>
        <td class="nump"><a title="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" onclick="toggleNextSibling(this);">4,528,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Three</a></td>
        <td class="nump"><a title="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" onclick="toggleNextSibling(this);">4,064,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Four</a></td>
        <td class="nump"><a title="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" onclick="toggleNextSibling(this);">1,990,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive', window );">Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected to be Recognized Year Five</a></td>
        <td class="nump"><a title="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" onclick="toggleNextSibling(this);">33</a><span style="display:none;white-space:normal;text-align:left;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">1,341</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" onclick="toggleNextSibling(this);">2,362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Grants Commencing March 1, 2011 [Member] | Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_PlanNameAxis=bcrx_IncentivePlanMember;us-gaap_VestingAxis=bcrx_GrantsCommencingMarch12011Member]" onclick="toggleNextSibling(this);">25.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember<br>/ us-gaap_VestingAxis<br>= bcrx_GrantsCommencingMarch12011Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Performance-based Grants Made in August 2013 [Member] | Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_PlanNameAxis=bcrx_IncentivePlanMember;us-gaap_VestingAxis=bcrx_PerformanceBasedGrantsMadeInAugust2013Member]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember<br>/ us-gaap_VestingAxis<br>= bcrx_PerformanceBasedGrantsMadeInAugust2013Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_PlanNameAxis=bcrx_IncentivePlanMember;us-gaap_VestingAxis=bcrx_PerformanceBasedGrantsMadeInAugust2013Member]" onclick="toggleNextSibling(this);">1,032</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember<br>/ us-gaap_VestingAxis<br>= bcrx_PerformanceBasedGrantsMadeInAugust2013Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NumberOfMilestonesAchieved', window );">Number of Milestones Achieved</a></td>
        <td class="nump"><a title="bcrx_NumberOfMilestonesAchieved[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_PlanNameAxis=bcrx_IncentivePlanMember;us-gaap_VestingAxis=bcrx_PerformanceBasedGrantsMadeInAugust2013Member]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">bcrx_NumberOfMilestonesAchieved<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember<br>/ us-gaap_VestingAxis<br>= bcrx_PerformanceBasedGrantsMadeInAugust2013Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement By Share-based Payment Award, Awards UnVested, Percentage</a></td>
        <td class="nump"><a title="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_PlanNameAxis=bcrx_IncentivePlanMember;us-gaap_VestingAxis=bcrx_PerformanceBasedGrantsMadeInAugust2013Member]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember<br>/ us-gaap_VestingAxis<br>= bcrx_PerformanceBasedGrantsMadeInAugust2013Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Performance-based Grants Made in August 2013 Unvested Portion [Member] | Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_PlanNameAxis=bcrx_IncentivePlanMember;us-gaap_VestingAxis=bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember]" onclick="toggleNextSibling(this);">1,250</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember<br>/ us-gaap_VestingAxis<br>= bcrx_PerformanceBasedGrantsMadeInAugust2013UnvestedPortionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Performanced Based Grants Made In December 2014 [Member] | Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage', window );">Share-based Compensation Arrangement By Share-based Payment Award, Awards UnVested, Percentage</a></td>
        <td class="nump"><a title="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember;us-gaap_PlanNameAxis=bcrx_IncentivePlanMember;us-gaap_VestingAxis=bcrx_PerformancedBasedGrantsMadeinDecember2014Member]" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember<br>/ us-gaap_VestingAxis<br>= bcrx_PerformancedBasedGrantsMadeinDecember2014Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Minimum [Member] | Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Maximum [Member] | Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Non-employee Directors [Member] | Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate', window );">Share Based Compensation Arrangement by Share Based Payment Award First Vesting Period after Grant Date</a></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember', window );">Stock Options and Restricted Stock [Member] | Retention Grants Made in January 2013 [Member] | Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage[us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember;us-gaap_PlanNameAxis=bcrx_IncentivePlanMember;us-gaap_VestingAxis=bcrx_RetentionGrantsMadeInJanuary2013Member]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage<br>/ us-gaap_AwardTypeAxis<br>= bcrx_StockOptionsAndRestrictedStockMember<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember<br>/ us-gaap_VestingAxis<br>= bcrx_RetentionGrantsMadeInJanuary2013Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_PlanNameAxis=bcrx_IncentivePlanMember]" onclick="toggleNextSibling(this);">2,165,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_PlanNameAxis=bcrx_IncentivePlanMember]" onclick="toggleNextSibling(this);">1,558,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_PlanNameAxis=bcrx_IncentivePlanMember]" onclick="toggleNextSibling(this);">$ 8.11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_PlanNameAxis=bcrx_IncentivePlanMember]" onclick="toggleNextSibling(this);">$ 8.28</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_PlanNameAxis<br>= bcrx_IncentivePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_Note2StockBasedCompensationDetailsLineItems', window );"><strong>Note 2 - Stock-Based Compensation (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">94</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_PlanNameAxis<br>= bcrx_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">52,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_PlanNameAxis<br>= bcrx_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized[us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">1,475</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized<br>/ us-gaap_PlanNameAxis<br>= bcrx_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant[us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">519</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant<br>/ us-gaap_PlanNameAxis<br>= bcrx_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of Salary to Purchase Common Stock Maximum</a></td>
        <td class="nump"><a title="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum[us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">15.00%</a><span style="display:none;white-space:normal;text-align:left;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum<br>/ us-gaap_PlanNameAxis<br>= bcrx_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of Common Stock Shares Beginning</a></td>
        <td class="nump"><a title="bcrx_PercentageOfCommonStockSharesBeginning[us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">85.00%</a><span style="display:none;white-space:normal;text-align:left;">bcrx_PercentageOfCommonStockSharesBeginning<br>/ us-gaap_PlanNameAxis<br>= bcrx_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesEnding', window );">Percentage of Common Stock Shares Ending</a></td>
        <td class="nump"><a title="bcrx_PercentageOfCommonStockSharesEnding[us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">85.00%</a><span style="display:none;white-space:normal;text-align:left;">bcrx_PercentageOfCommonStockSharesEnding<br>/ us-gaap_PlanNameAxis<br>= bcrx_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in Shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee[us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee<br>/ us-gaap_PlanNameAxis<br>= bcrx_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Share Based Compensation Arrangement by Share Based Payment Award Maximum Number of Shares per Employee Amount</a></td>
        <td class="nump"><a title="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount[us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">$ 25,000</a><span style="display:none;white-space:normal;text-align:left;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount<br>/ us-gaap_PlanNameAxis<br>= bcrx_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans[us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember]" onclick="toggleNextSibling(this);">20</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans<br>/ us-gaap_PlanNameAxis<br>= bcrx_EmployeeStockPurchasePlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents employee service share based compensation non-vested awards compensation cost expected to be recognized for remainder of fiscal year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents employee service share based compensation non-vested awards compensation cost expected to be recognized year five.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents employee service share based compensation non-vested awards compensation cost expected to be recognized year four.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents employee service share based compensation non-vested awards compensation cost expected to be recognized year three.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents employee service share based compensation non-vested awards compensation cost expected to be recognized year two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_Note2StockBasedCompensationDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_Note2StockBasedCompensationDetailsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfMilestonesAchieved">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of milestones achieved.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_NumberOfMilestonesAchieved</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NumberOfStockBasedCompensationPlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents number of stock based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_NumberOfStockBasedCompensationPlans</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents percentage of common stock shares beginning.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesEnding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents percentage of common stock shares ending.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesEnding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents percentage of salary to purchase common stock maximum.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the percentage of performance awards that remain unvested.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsUnvestedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents share based compensation arrangement by share based payment award first vesting period after grant date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFirstVestingPeriodAfterGrantDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents share based compensation arrangement by share based payment award maximum value per employee amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>bcrx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of vesting of share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The highest quantity of shares an employee can purchase under the plan per period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of an employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcrx_StockOptionsAndRestrictedStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
